<SEC-DOCUMENT>0001437749-22-020091.txt : 20220811
<SEC-HEADER>0001437749-22-020091.hdr.sgml : 20220811
<ACCEPTANCE-DATETIME>20220811160146
ACCESSION NUMBER:		0001437749-22-020091
CONFORMED SUBMISSION TYPE:	10-Q
PUBLIC DOCUMENT COUNT:		50
CONFORMED PERIOD OF REPORT:	20220630
FILED AS OF DATE:		20220811
DATE AS OF CHANGE:		20220811

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			WINDTREE THERAPEUTICS INC /DE/
		CENTRAL INDEX KEY:			0000946486
		STANDARD INDUSTRIAL CLASSIFICATION:	BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
		IRS NUMBER:				943171943
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		10-Q
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-39290
		FILM NUMBER:		221155547

	BUSINESS ADDRESS:	
		STREET 1:		2600 KELLY ROAD
		STREET 2:		SUITE 100
		CITY:			WARRINGTON
		STATE:			PA
		ZIP:			18976
		BUSINESS PHONE:		2154889300

	MAIL ADDRESS:	
		STREET 1:		2600 KELLY ROAD
		STREET 2:		SUITE 100
		CITY:			WARRINGTON
		STATE:			PA
		ZIP:			18976

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	DISCOVERY LABORATORIES INC /DE/
		DATE OF NAME CHANGE:	19971201

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	ANSAN PHARMACEUTICALS INC
		DATE OF NAME CHANGE:	19961121

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	ANSAN INC
		DATE OF NAME CHANGE:	19950609
</SEC-HEADER>
<DOCUMENT>
<TYPE>10-Q
<SEQUENCE>1
<FILENAME>wint20220630_10q.htm
<DESCRIPTION>FORM 10-Q
<TEXT>
<XBRL>
<html xmlns="http://www.w3.org/1999/xhtml" xmlns:ref="http://www.xbrl.org/2006/ref" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:naics="http://xbrl.sec.gov/naics/2022" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xsd="http://www.w3.org/2001/XMLSchema" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2015-02-26" xmlns:us-types="http://fasb.org/us-types/2017-01-31" xmlns:srt-types="http://fasb.org/srt-types/2017-01-31" xmlns:utreg="http://www.xbrl.org/2009/utr" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:us-roles="http://fasb.org/us-roles/2017-01-31" xmlns:stpr="http://xbrl.sec.gov/stpr/2022" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:thunderdome="http://www.RDGFilings.com" xmlns:utr="http://www.xbrl.org/2009/utr" xmlns:xs="http://www.w3.org/2001/XMLSchema-instance" xmlns:dei="http://xbrl.sec.gov/dei/2022" xmlns:wint="http://www.windtreetx.com/20220630" xmlns:srt="http://fasb.org/srt/2022" xmlns:currency="http://xbrl.sec.gov/currency/2022" xmlns:sic="http://xbrl.sec.gov/sic/2022" xmlns:exch="http://xbrl.sec.gov/exch/2022" xmlns:country="http://xbrl.sec.gov/country/2022" xmlns:us-gaap="http://fasb.org/us-gaap/2022" xmlns:rr="http://xbrl.sec.gov/rr/2022" xmlns:dtr-types="http://www.xbrl.org/dtr/type/2020-01-21">
 <head>
  <title>wint20220630_10q.htm</title>
  <!-- Generated by ThunderDome Portal - 8/11/2022 4:21:23 AM -->
  <meta http-equiv="Content-Type" content="text/html" /></head>
 <body style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0in 0.1in; cursor: auto;"><div style="display: none;"><ix:header><ix:hidden>
<ix:nonNumeric contextRef="d_2022-01-01_2022-06-30" name="dei:EntityCentralIndexKey" id="thunderdome-EntityCentralIndexKey">0000946486</ix:nonNumeric>
<ix:nonNumeric contextRef="d_2022-01-01_2022-06-30" name="dei:EntityRegistrantName" id="thunderdome-EntityRegistrantName">WINDTREE THERAPEUTICS INC /DE/</ix:nonNumeric>
<ix:nonNumeric contextRef="d_2022-01-01_2022-06-30" name="dei:AmendmentFlag" format="ixt:booleanfalse">false</ix:nonNumeric>
<ix:nonNumeric contextRef="d_2022-01-01_2022-06-30" name="dei:CurrentFiscalYearEndDate">--12-31</ix:nonNumeric>
<ix:nonNumeric contextRef="d_2022-01-01_2022-06-30" name="dei:DocumentFiscalPeriodFocus">Q2</ix:nonNumeric>
<ix:nonNumeric contextRef="d_2022-01-01_2022-06-30" name="dei:DocumentFiscalYearFocus">2022</ix:nonNumeric>
<ix:nonFraction id="c86424713" contextRef="i_2022-06-30" unitRef="USDPerShare" name="us-gaap:PreferredStockParOrStatedValuePerShare" scale="0" format="ixt:numdotdecimal" decimals="INF">0.001</ix:nonFraction>
<ix:nonFraction id="c86424714" contextRef="i_2021-12-31" unitRef="USDPerShare" name="us-gaap:PreferredStockParOrStatedValuePerShare" scale="0" format="ixt:numdotdecimal" decimals="INF">0.001</ix:nonFraction>
<ix:nonFraction id="c86424715" contextRef="i_2022-06-30" unitRef="Share" name="us-gaap:PreferredStockSharesAuthorized" scale="0" format="ixt:numdotdecimal" decimals="INF">5,000,000</ix:nonFraction>
<ix:nonFraction id="c86424716" contextRef="i_2021-12-31" unitRef="Share" name="us-gaap:PreferredStockSharesAuthorized" scale="0" format="ixt:numdotdecimal" decimals="INF">5,000,000</ix:nonFraction>
<ix:nonFraction id="c86424717" contextRef="i_2022-06-30" unitRef="Share" name="us-gaap:PreferredStockSharesIssued" scale="0" format="ixt:numdotdecimal" decimals="-3">0</ix:nonFraction>
<ix:nonFraction id="c86424719" contextRef="i_2022-06-30" unitRef="Share" name="us-gaap:PreferredStockSharesOutstanding" scale="0" format="ixt:numdotdecimal" decimals="-3">0</ix:nonFraction>
<ix:nonFraction id="c86424718" contextRef="i_2021-12-31" unitRef="Share" name="us-gaap:PreferredStockSharesIssued" scale="0" format="ixt:numdotdecimal" decimals="-3">0</ix:nonFraction>
<ix:nonFraction id="c86424720" contextRef="i_2021-12-31" unitRef="Share" name="us-gaap:PreferredStockSharesOutstanding" scale="0" format="ixt:numdotdecimal" decimals="-3">0</ix:nonFraction>
<ix:nonFraction id="c86424723" contextRef="i_2022-06-30" unitRef="USDPerShare" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" format="ixt:numdotdecimal" decimals="INF">0.001</ix:nonFraction>
<ix:nonFraction id="c86424724" contextRef="i_2021-12-31" unitRef="USDPerShare" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" format="ixt:numdotdecimal" decimals="INF">0.001</ix:nonFraction>
<ix:nonFraction id="c86424725" contextRef="i_2022-06-30" unitRef="Share" name="us-gaap:CommonStockSharesAuthorized" scale="0" format="ixt:numdotdecimal" decimals="INF">120,000,000</ix:nonFraction>
<ix:nonFraction id="c86424726" contextRef="i_2021-12-31" unitRef="Share" name="us-gaap:CommonStockSharesAuthorized" scale="0" format="ixt:numdotdecimal" decimals="INF">120,000,000</ix:nonFraction>
<ix:nonFraction id="c86424727" contextRef="i_2022-06-30" unitRef="Share" name="us-gaap:CommonStockSharesIssued" scale="0" format="ixt:numdotdecimal" decimals="INF">29,406,196</ix:nonFraction>
<ix:nonFraction id="c86424728" contextRef="i_2021-12-31" unitRef="Share" name="us-gaap:CommonStockSharesIssued" scale="0" format="ixt:numdotdecimal" decimals="INF">28,268,950</ix:nonFraction>
<ix:nonFraction id="c86424729" contextRef="i_2022-06-30" unitRef="Share" name="us-gaap:CommonStockSharesOutstanding" scale="0" format="ixt:numdotdecimal" decimals="INF">29,406,172</ix:nonFraction>
<ix:nonFraction id="c86424730" contextRef="i_2021-12-31" unitRef="Share" name="us-gaap:CommonStockSharesOutstanding" scale="0" format="ixt:numdotdecimal" decimals="INF">28,268,926</ix:nonFraction>
<ix:nonFraction id="c86424737" contextRef="i_2022-06-30" unitRef="Share" name="us-gaap:TreasuryStockShares" scale="0" format="ixt:numdotdecimal" decimals="INF">24</ix:nonFraction>
<ix:nonFraction id="c86424738" contextRef="i_2021-12-31" unitRef="Share" name="us-gaap:TreasuryStockShares" scale="0" format="ixt:numdotdecimal" decimals="INF">24</ix:nonFraction>
<ix:nonFraction id="c86425101" contextRef="d_2022-01-01_2022-06-30" unitRef="USD" name="us-gaap:GoodwillImpairmentLoss" scale="6" format="ixt:numdotdecimal" decimals="-5">11.6</ix:nonFraction>
<ix:nonFraction id="c86425106" contextRef="d_2021-01-01_2021-06-30" unitRef="USD" name="us-gaap:ImpairmentOfIntangibleAssetsExcludingGoodwill" scale="6" format="ixt:numdotdecimal" decimals="-5">37.8</ix:nonFraction>
<ix:nonFraction id="c86425108" contextRef="d_2021-01-01_2021-06-30" unitRef="USD" name="us-gaap:DeferredIncomeTaxExpenseBenefit" scale="6" format="ixt:numdotdecimal" decimals="-5" sign="-">8.3</ix:nonFraction>
<ix:nonFraction id="c86425173" contextRef="d_2021-01-01_2021-06-30" unitRef="USD" name="us-gaap:ImpairmentOfIntangibleAssetsExcludingGoodwill" scale="6" format="ixt:numdotdecimal" decimals="-5">37.8</ix:nonFraction>
<ix:nonFraction id="c86425190" contextRef="d_2022-01-01_2022-06-30" unitRef="USD" name="us-gaap:GoodwillImpairmentLoss" scale="6" format="ixt:numdotdecimal" decimals="-5">11.6</ix:nonFraction>
<ix:nonFraction id="c86425218" contextRef="d_2022-01-01_2022-06-30" unitRef="USD" name="wint:PaymentsForSeveranceCosts" scale="6" format="ixt:numdotdecimal" decimals="-5">0.2</ix:nonFraction>
<ix:nonFraction id="c86425244" contextRef="d_2021-04-01_2021-06-30" unitRef="USD" name="us-gaap:DeferredIncomeTaxExpenseBenefit" scale="6" format="ixt:numdotdecimal" decimals="-5" sign="-">8.3</ix:nonFraction>
<ix:nonFraction id="c86425374" contextRef="i_2021-12-31_CounterpartyNameAxis-DeerfieldManagementLPMember_LongtermDebtTypeAxis-DeerfieldLoanMember_TypeOfArrangementAxis-ExchangeAndTerminationAgreementMember" unitRef="USD" name="wint:LiabilityforContingentMilestonePaymentNoncurrent" scale="6" format="ixt:numdotdecimal" decimals="-6">15.0</ix:nonFraction>
<ix:nonFraction id="c86425407" contextRef="i_2021-03-23_SubsidiarySaleOfStockAxis-March2021PublicOfferingMember" unitRef="Share" name="wint:UnitsNumberOfSecuritiesCalledByEachUnit" scale="0" format="ixt:numdotdecimal" decimals="INF">1</ix:nonFraction>
<ix:nonNumeric contextRef="i_2021-03-23_ClassOfWarrantOrRightAxis-March2021WarrantsMember" name="us-gaap:WarrantsAndRightsOutstandingTerm" id="c86425409" format="ixt-sec:duryear">5</ix:nonNumeric>
<ix:nonNumeric contextRef="d_2022-01-01_2022-06-30_PlanNameAxis-The2020EquityIncentivePlanMember" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1" id="c86425425" format="ixt-sec:duryear">3</ix:nonNumeric>
<ix:nonNumeric contextRef="d_2022-01-01_2022-06-30_AwardTypeAxis-RestrictedStockUnitsRSUMember_RangeAxis-MinimumMember" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1" id="c86425426" format="ixt-sec:duryear">1</ix:nonNumeric>
<ix:nonNumeric contextRef="d_2022-01-01_2022-06-30_PlanNameAxis-NonplanStockOptionsMember_TitleOfIndividualAxis-ExecutiveOfficersAndEmployeesMember" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1" id="c86425427" format="ixt-sec:duryear">3</ix:nonNumeric></ix:hidden>
<ix:references>
<link:schemaRef xlink:href="wint-20220630.xsd" xlink:type="simple"></link:schemaRef></ix:references>
<ix:resources>
<xbrli:context id="d_2022-01-01_2022-06-30"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000946486</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:unit id="Share"><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unit>
<xbrli:context id="i_2022-08-11"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000946486</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2022-08-11</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:unit id="NonApplicable"><xbrli:measure>thunderdome:item</xbrli:measure></xbrli:unit>
<xbrli:unit id="USD"><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unit>
<xbrli:context id="i_2022-06-30"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000946486</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2021-12-31"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000946486</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:unit id="USDPerShare"><xbrli:divide><xbrli:unitNumerator><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unitNumerator><xbrli:unitDenominator><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unitDenominator></xbrli:divide></xbrli:unit>
<xbrli:context id="d_2022-04-01_2022-06-30"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000946486</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2021-04-01_2021-06-30"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000946486</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2021-01-01_2021-06-30"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000946486</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="i_2020-12-31_StatementEquityComponentsAxis-CommonStockMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000946486</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2020-12-31_StatementEquityComponentsAxis-AdditionalPaidInCapitalMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000946486</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2020-12-31_StatementEquityComponentsAxis-RetainedEarningsMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000946486</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2020-12-31_StatementEquityComponentsAxis-TreasuryStockMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000946486</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2020-12-31"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000946486</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="d_2021-01-01_2021-03-31_StatementEquityComponentsAxis-RetainedEarningsMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000946486</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2021-01-01_2021-03-31"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000946486</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2021-01-01_2021-03-31_StatementEquityComponentsAxis-CommonStockMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000946486</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2021-01-01_2021-03-31_StatementEquityComponentsAxis-AdditionalPaidInCapitalMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000946486</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2021-01-01_2021-03-31_StatementClassOfStockAxis-ATMProgramMember_StatementEquityComponentsAxis-CommonStockMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000946486</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">wint:ATMProgramMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2021-01-01_2021-03-31_StatementClassOfStockAxis-ATMProgramMember_StatementEquityComponentsAxis-AdditionalPaidInCapitalMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000946486</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">wint:ATMProgramMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2021-01-01_2021-03-31_StatementClassOfStockAxis-ATMProgramMember_StatementEquityComponentsAxis-RetainedEarningsMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000946486</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">wint:ATMProgramMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2021-01-01_2021-03-31_StatementClassOfStockAxis-ATMProgramMember_StatementEquityComponentsAxis-TreasuryStockMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000946486</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">wint:ATMProgramMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2021-01-01_2021-03-31_StatementClassOfStockAxis-ATMProgramMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000946486</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">wint:ATMProgramMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2021-01-01_2021-03-31_StatementEquityComponentsAxis-CommonStockMember_SubsidiarySaleOfStockAxis-SharePurchaseAgreementDecember2019Member"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000946486</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">wint:SharePurchaseAgreementDecember2019Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2021-01-01_2021-03-31_StatementEquityComponentsAxis-AdditionalPaidInCapitalMember_SubsidiarySaleOfStockAxis-SharePurchaseAgreementDecember2019Member"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000946486</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">wint:SharePurchaseAgreementDecember2019Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2021-01-01_2021-03-31_StatementEquityComponentsAxis-RetainedEarningsMember_SubsidiarySaleOfStockAxis-SharePurchaseAgreementDecember2019Member"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000946486</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">wint:SharePurchaseAgreementDecember2019Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2021-01-01_2021-03-31_StatementEquityComponentsAxis-TreasuryStockMember_SubsidiarySaleOfStockAxis-SharePurchaseAgreementDecember2019Member"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000946486</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">wint:SharePurchaseAgreementDecember2019Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2021-01-01_2021-03-31_SubsidiarySaleOfStockAxis-SharePurchaseAgreementDecember2019Member"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000946486</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">wint:SharePurchaseAgreementDecember2019Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="i_2021-03-31_StatementEquityComponentsAxis-CommonStockMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000946486</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2021-03-31_StatementEquityComponentsAxis-AdditionalPaidInCapitalMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000946486</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2021-03-31_StatementEquityComponentsAxis-RetainedEarningsMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000946486</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2021-03-31_StatementEquityComponentsAxis-TreasuryStockMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000946486</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2021-03-31"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000946486</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="d_2021-04-01_2021-06-30_StatementEquityComponentsAxis-CommonStockMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000946486</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2021-04-01_2021-06-30_StatementEquityComponentsAxis-AdditionalPaidInCapitalMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000946486</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2021-04-01_2021-06-30_StatementEquityComponentsAxis-RetainedEarningsMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000946486</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2021-04-01_2021-06-30_StatementEquityComponentsAxis-TreasuryStockMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000946486</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="i_2021-06-30_StatementEquityComponentsAxis-CommonStockMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000946486</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2021-06-30_StatementEquityComponentsAxis-AdditionalPaidInCapitalMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000946486</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2021-06-30_StatementEquityComponentsAxis-RetainedEarningsMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000946486</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2021-06-30_StatementEquityComponentsAxis-TreasuryStockMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000946486</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2021-06-30"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000946486</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2021-12-31_StatementEquityComponentsAxis-CommonStockMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000946486</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2021-12-31_StatementEquityComponentsAxis-AdditionalPaidInCapitalMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000946486</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2021-12-31_StatementEquityComponentsAxis-RetainedEarningsMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000946486</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2021-12-31_StatementEquityComponentsAxis-TreasuryStockMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000946486</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="d_2022-01-01_2022-03-31_StatementEquityComponentsAxis-RetainedEarningsMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000946486</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2022-01-01_2022-03-31"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000946486</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2022-01-01_2022-03-31_StatementEquityComponentsAxis-AdditionalPaidInCapitalMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000946486</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2022-01-01_2022-03-31_StatementClassOfStockAxis-ATMProgramMember_StatementEquityComponentsAxis-CommonStockMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000946486</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">wint:ATMProgramMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2022-01-01_2022-03-31_StatementClassOfStockAxis-ATMProgramMember_StatementEquityComponentsAxis-AdditionalPaidInCapitalMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000946486</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">wint:ATMProgramMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2022-01-01_2022-03-31_StatementClassOfStockAxis-ATMProgramMember_StatementEquityComponentsAxis-RetainedEarningsMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000946486</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">wint:ATMProgramMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2022-01-01_2022-03-31_StatementClassOfStockAxis-ATMProgramMember_StatementEquityComponentsAxis-TreasuryStockMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000946486</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">wint:ATMProgramMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2022-01-01_2022-03-31_StatementClassOfStockAxis-ATMProgramMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000946486</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">wint:ATMProgramMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="i_2022-03-31_StatementEquityComponentsAxis-CommonStockMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000946486</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2022-03-31_StatementEquityComponentsAxis-AdditionalPaidInCapitalMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000946486</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2022-03-31_StatementEquityComponentsAxis-RetainedEarningsMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000946486</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2022-03-31_StatementEquityComponentsAxis-TreasuryStockMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000946486</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2022-03-31"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000946486</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="d_2022-04-01_2022-06-30_StatementEquityComponentsAxis-CommonStockMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000946486</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2022-04-01_2022-06-30_StatementEquityComponentsAxis-AdditionalPaidInCapitalMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000946486</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2022-04-01_2022-06-30_StatementEquityComponentsAxis-RetainedEarningsMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000946486</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2022-04-01_2022-06-30_StatementEquityComponentsAxis-TreasuryStockMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000946486</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="i_2022-06-30_StatementEquityComponentsAxis-CommonStockMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000946486</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2022-06-30_StatementEquityComponentsAxis-AdditionalPaidInCapitalMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000946486</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2022-06-30_StatementEquityComponentsAxis-RetainedEarningsMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000946486</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2022-06-30_StatementEquityComponentsAxis-TreasuryStockMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000946486</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2020-09-17_SubsidiarySaleOfStockAxis-ATMProgramMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000946486</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">wint:ATMProgramMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-09-17</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="d_2022-01-01_2022-06-30_SubsidiarySaleOfStockAxis-ATMProgramMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000946486</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">wint:ATMProgramMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2022-07-01_2022-08-31_SubsequentEventTypeAxis-SubsequentEventMember_SubsidiarySaleOfStockAxis-ATMProgramMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000946486</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">wint:ATMProgramMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2022-08-31</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="i_2022-06-30_SubsidiarySaleOfStockAxis-ATMProgramMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000946486</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">wint:ATMProgramMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:unit id="Pure"><xbrli:measure>xbrli:pure</xbrli:measure></xbrli:unit>
<xbrli:context id="i_2022-06-30_IndefiniteLivedIntangibleAssetsByMajorClassAxis-IstaroximeDrugCandidateMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000946486</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis">wint:IstaroximeDrugCandidateMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2021-12-31_IndefiniteLivedIntangibleAssetsByMajorClassAxis-IstaroximeDrugCandidateMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000946486</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis">wint:IstaroximeDrugCandidateMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2022-06-30_IndefiniteLivedIntangibleAssetsByMajorClassAxis-RostafuroxinDrugCandidateMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000946486</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis">wint:RostafuroxinDrugCandidateMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2021-12-31_IndefiniteLivedIntangibleAssetsByMajorClassAxis-RostafuroxinDrugCandidateMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000946486</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis">wint:RostafuroxinDrugCandidateMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="d_2022-01-01_2022-03-31_PropertyPlantAndEquipmentByTypeAxis-ManufacturingAndLaboratoryEquipmentMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000946486</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">wint:ManufacturingAndLaboratoryEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="i_2017-11-01_LineOfCreditFacilityAxis-DeerfieldManagementLPMember_LongtermDebtTypeAxis-DeerfieldLoanMember_TypeOfArrangementAxis-ExchangeAndTerminationAgreementMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000946486</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">wint:DeerfieldManagementLPMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">wint:DeerfieldLoanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">wint:ExchangeAndTerminationAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2017-11-01</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2022-06-30_CashAndCashEquivalentsAxis-MoneyMarketFundsMember_FairValueByMeasurementFrequencyAxis-FairValueMeasurementsRecurringMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000946486</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2022-06-30_CashAndCashEquivalentsAxis-MoneyMarketFundsMember_FairValueByFairValueHierarchyLevelAxis-FairValueInputsLevel1Member_FairValueByMeasurementFrequencyAxis-FairValueMeasurementsRecurringMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000946486</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2022-06-30_FairValueByMeasurementFrequencyAxis-FairValueMeasurementsRecurringMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000946486</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2022-06-30_FairValueByFairValueHierarchyLevelAxis-FairValueInputsLevel1Member_FairValueByMeasurementFrequencyAxis-FairValueMeasurementsRecurringMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000946486</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2021-12-31_CashAndCashEquivalentsAxis-MoneyMarketFundsMember_FairValueByMeasurementFrequencyAxis-FairValueMeasurementsRecurringMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000946486</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2021-12-31_CashAndCashEquivalentsAxis-MoneyMarketFundsMember_FairValueByFairValueHierarchyLevelAxis-FairValueInputsLevel1Member_FairValueByMeasurementFrequencyAxis-FairValueMeasurementsRecurringMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000946486</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2021-12-31_FairValueByMeasurementFrequencyAxis-FairValueMeasurementsRecurringMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000946486</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2021-12-31_FairValueByFairValueHierarchyLevelAxis-FairValueInputsLevel1Member_FairValueByMeasurementFrequencyAxis-FairValueMeasurementsRecurringMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000946486</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2022-06-30_DebtInstrumentAxis-LoanPayableToBankDirectCapitalFinanceMember_ShortTermDebtTypeAxis-LoansPayableMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000946486</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">wint:LoanPayableToBankDirectCapitalFinanceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">us-gaap:LoansPayableMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="d_2022-06-30_2022-06-30_DebtInstrumentAxis-LoanPayableToBankDirectCapitalFinanceMember_ShortTermDebtTypeAxis-LoansPayableMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000946486</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">wint:LoanPayableToBankDirectCapitalFinanceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">us-gaap:LoansPayableMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-06-30</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="i_2021-06-30_DebtInstrumentAxis-LoanPayableToBankDirectCapitalFinanceMember_ShortTermDebtTypeAxis-LoansPayableMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000946486</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">wint:LoanPayableToBankDirectCapitalFinanceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">us-gaap:LoansPayableMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="d_2021-06-01_2021-06-30_DebtInstrumentAxis-LoanPayableToBankDirectCapitalFinanceMember_ShortTermDebtTypeAxis-LoansPayableMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000946486</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">wint:LoanPayableToBankDirectCapitalFinanceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">us-gaap:LoansPayableMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-06-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="i_2021-12-31_DebtInstrumentAxis-LoanPayableToBankDirectCapitalFinanceMember_ShortTermDebtTypeAxis-LoansPayableMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000946486</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">wint:LoanPayableToBankDirectCapitalFinanceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">us-gaap:LoansPayableMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="d_2017-10-27_2017-10-27_CounterpartyNameAxis-DeerfieldManagementLPMember_LongtermDebtTypeAxis-DeerfieldLoanMember_TypeOfArrangementAxis-ExchangeAndTerminationAgreementMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000946486</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">wint:DeerfieldManagementLPMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">wint:DeerfieldLoanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">wint:ExchangeAndTerminationAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2017-10-27</xbrli:startDate><xbrli:endDate>2017-10-27</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="i_2017-10-27_CounterpartyNameAxis-DeerfieldManagementLPMember_LongtermDebtTypeAxis-DeerfieldLoanMember_TypeOfArrangementAxis-ExchangeAndTerminationAgreementMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000946486</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">wint:DeerfieldManagementLPMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">wint:DeerfieldLoanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">wint:ExchangeAndTerminationAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2017-10-27</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2022-03-31_CounterpartyNameAxis-DeerfieldManagementLPMember_LongtermDebtTypeAxis-DeerfieldLoanMember_TypeOfArrangementAxis-ExchangeAndTerminationAgreementMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000946486</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">wint:DeerfieldManagementLPMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">wint:DeerfieldLoanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">wint:ExchangeAndTerminationAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2021-12-31_CounterpartyNameAxis-DeerfieldManagementLPMember_LongtermDebtTypeAxis-DeerfieldLoanMember_TypeOfArrangementAxis-ExchangeAndTerminationAgreementMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000946486</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">wint:DeerfieldManagementLPMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">wint:DeerfieldLoanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">wint:ExchangeAndTerminationAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="d_2020-09-17_2020-09-17_SubsidiarySaleOfStockAxis-ATMProgramMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000946486</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">wint:ATMProgramMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-09-17</xbrli:startDate><xbrli:endDate>2020-09-17</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2021-01-01_2021-06-30_SubsidiarySaleOfStockAxis-ATMProgramMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000946486</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">wint:ATMProgramMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2022-07-01_2022-08-11_SubsequentEventTypeAxis-SubsequentEventMember_SubsidiarySaleOfStockAxis-ATMProgramMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000946486</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">wint:ATMProgramMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2022-08-11</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="i_2022-08-11_SubsequentEventTypeAxis-SubsequentEventMember_SubsidiarySaleOfStockAxis-ATMProgramMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000946486</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">wint:ATMProgramMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-08-11</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="d_2021-03-23_2021-03-23_SubsidiarySaleOfStockAxis-March2021PublicOfferingMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000946486</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">wint:March2021PublicOfferingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-03-23</xbrli:startDate><xbrli:endDate>2021-03-23</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="i_2021-03-23_SubsidiarySaleOfStockAxis-March2021PublicOfferingMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000946486</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">wint:March2021PublicOfferingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-23</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2021-03-23_ClassOfWarrantOrRightAxis-March2021WarrantsMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000946486</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">wint:March2021WarrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-23</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:unit id="Year"><xbrli:measure>utr:Y</xbrli:measure></xbrli:unit>
<xbrli:context id="i_2021-03-25_SubsidiarySaleOfStockAxis-March2021PublicOfferingMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000946486</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">wint:March2021PublicOfferingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-25</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="d_2021-03-25_2021-03-25_SubsidiarySaleOfStockAxis-March2021PublicOfferingMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000946486</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">wint:March2021PublicOfferingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-03-25</xbrli:startDate><xbrli:endDate>2021-03-25</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2022-01-01_2022-06-30_PlanNameAxis-The2020EquityIncentivePlanMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000946486</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">wint:The2020EquityIncentivePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2022-01-01_2022-06-30_AwardTypeAxis-RestrictedStockUnitsRSUMember_RangeAxis-MinimumMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000946486</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2022-01-01_2022-06-30_PlanNameAxis-NonplanStockOptionsMember_TitleOfIndividualAxis-ExecutiveOfficersAndEmployeesMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000946486</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">wint:NonplanStockOptionsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">wint:ExecutiveOfficersAndEmployeesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="i_2021-12-31_AwardTypeAxis-RestrictedStockUnitsRSUMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000946486</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="d_2022-01-01_2022-06-30_AwardTypeAxis-RestrictedStockUnitsRSUMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000946486</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="i_2022-06-30_AwardTypeAxis-RestrictedStockUnitsRSUMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000946486</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="d_2022-04-01_2022-06-30_IncomeStatementLocationAxis-ResearchAndDevelopmentExpenseMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000946486</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2021-04-01_2021-06-30_IncomeStatementLocationAxis-ResearchAndDevelopmentExpenseMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000946486</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2022-01-01_2022-06-30_IncomeStatementLocationAxis-ResearchAndDevelopmentExpenseMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000946486</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2021-01-01_2021-06-30_IncomeStatementLocationAxis-ResearchAndDevelopmentExpenseMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000946486</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2022-04-01_2022-06-30_IncomeStatementLocationAxis-SellingGeneralAndAdministrativeExpensesMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000946486</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2021-04-01_2021-06-30_IncomeStatementLocationAxis-SellingGeneralAndAdministrativeExpensesMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000946486</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2022-01-01_2022-06-30_IncomeStatementLocationAxis-SellingGeneralAndAdministrativeExpensesMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000946486</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2021-01-01_2021-06-30_IncomeStatementLocationAxis-SellingGeneralAndAdministrativeExpensesMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000946486</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2020-08-01_2020-10-31_CounterpartyNameAxis-LeesPharmaceuticalHoldingsLimitedMember_TypeOfArrangementAxis-AerosurfFundingTermSheetMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000946486</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">wint:LeesPharmaceuticalHoldingsLimitedMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">wint:AerosurfFundingTermSheetMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-08-01</xbrli:startDate><xbrli:endDate>2020-10-31</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2021-01-01_2021-12-31_TypeOfArrangementAxis-TermSheetWithLeeMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000946486</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">wint:TermSheetWithLeeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="i_2020-03-18_TypeOfArrangementAxis-TermSheetWithLeeMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000946486</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">wint:TermSheetWithLeeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-03-18</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2022-03-31_TypeOfArrangementAxis-TermSheetWithLeeMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000946486</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">wint:TermSheetWithLeeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context></ix:resources>
</ix:header></div>
  <div>
    &#xa0;
  </div>
  <div><p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><a href="#toc" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt">Table of Contents</a></p>
<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><span style="color:#333333;"><b>UNITED STATES</b></span></p>
<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><span style="color:#333333;"><b>SECURITIES AND EXCHANGE COMMISSION</b></span></p>
<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><span style="color:#333333;"><b>WASHINGTON, D.C. 20549</b></span></p>
<p style="font-family:'Times New Roman', Times, serif;font-size:18pt;margin:0pt;text-align:center;"><span style="color:#333333;"><b>FORM <ix:nonNumeric name="dei:DocumentType" contextRef="d_2022-01-01_2022-06-30">10-Q</ix:nonNumeric></b></span></p>
<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt 14.7pt;text-align:center;">&#xa0;</p>
<table style="width:100%;text-indent:0;font-family:'Times New Roman', Times, serif;font-size:10pt;" cellspacing="0" cellpadding="0" border="0"><tbody><tr><td style="vertical-align:top;width:4%;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><span style="color:#333333;"><ix:nonNumeric name="dei:DocumentQuarterlyReport" format="ixt-sec:boolballotbox" contextRef="d_2022-01-01_2022-06-30">&#x2612;</ix:nonNumeric></span></p> </td><td style="vertical-align:top;width:96%;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><span style="color:#333333;"><b>QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</b></span></p> </td></tr>
</tbody></table>
<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt 14.7pt;text-align:left;">&#xa0;</p>
<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt 14.7pt;text-align:center;"><span style="color:#333333;">For the quarterly period ended </span><ix:nonNumeric name="dei:DocumentPeriodEndDate" format="ixt:datemonthdayyearen" contextRef="d_2022-01-01_2022-06-30"><b><span style="color:#333333;">June 30, 2022</span></b></ix:nonNumeric><b></b></p>
<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt 14.7pt;text-align:center;">&#xa0;</p>
<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt 14.7pt;text-align:center;"><span style="color:#333333;">or</span></p>
<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt 14.7pt;text-align:center;">&#xa0;</p>
<table style="width:100%;text-indent:0;font-family:'Times New Roman', Times, serif;font-size:10pt;" cellspacing="0" cellpadding="0" border="0"><tbody><tr><td style="vertical-align:top;width:2.8%;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><span style="color:#333333;"><ix:nonNumeric name="dei:DocumentTransitionReport" format="ixt-sec:boolballotbox" contextRef="d_2022-01-01_2022-06-30">&#x2610;</ix:nonNumeric></span></p> </td><td style="vertical-align:top;width:97.2%;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><span style="color:#333333;"><b>TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</b></span></p> </td></tr>
</tbody></table>
<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt 14.7pt;text-align:left;">&#xa0;</p>
<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt 14.7pt;text-align:center;"><span style="color:#333333;">For the transition period&#xa0;from <b>_____ </b>to<b> _____</b></span></p>
<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt 14.7pt;text-align:left;">&#xa0;</p>
<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt 14.7pt;text-align:center;"><span style="color:#333333;">Commission file number <ix:nonNumeric name="dei:EntityFileNumber" contextRef="d_2022-01-01_2022-06-30">000-26422</ix:nonNumeric></span></p>
<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt 14.7pt;text-align:center;">&#xa0;</p>
<p style="font-family:'Times New Roman', Times, serif;font-size:24pt;margin:0pt 14.7pt;text-align:center;"><span style="color:#333333;"><b>WINDTREE THERAPEUTICS, INC.</b></span></p>
<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt 14.7pt;text-align:center;"><span style="color:#333333;">(Exact name of registrant as specified in its charter)</span></p>
<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt 14.7pt;text-align:center;">&#xa0;</p>
<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
<table style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 99.9%; margin-left: 0.05%; margin-right: 0.05%;" cellspacing="0" cellpadding="0"><tbody><tr style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><td style="vertical-align: middle; width: 46%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: center;"><span style="color:#333333;"><b><ix:nonNumeric name="dei:EntityIncorporationStateCountryCode" format="ixt-sec:stateprovnameen" contextRef="d_2022-01-01_2022-06-30">Delaware</ix:nonNumeric></b></span></p> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: center;"><span style="color:#333333;">(State or other jurisdiction of incorporation or organization)</span></p> </td><td style="vertical-align: middle; width: 54%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: center;"><span style="color:#333333;"><b><ix:nonNumeric name="dei:EntityTaxIdentificationNumber" contextRef="d_2022-01-01_2022-06-30">94-3171943</ix:nonNumeric></b></span></p> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: center;"><span style="color:#333333;">(I.R.S. Employer<br /> Identification No.)</span></p> </td></tr>
<tr style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><td style="vertical-align: middle; width: 46%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: center;"><span style="color:#333333;"><b><ix:nonNumeric name="dei:EntityAddressAddressLine1" contextRef="d_2022-01-01_2022-06-30">2600 Kelly Road, Suite 100</ix:nonNumeric></b></span></p> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: center;"><span style="color:#333333;"><b><ix:nonNumeric name="dei:EntityAddressCityOrTown" contextRef="d_2022-01-01_2022-06-30">Warrington</ix:nonNumeric>, <ix:nonNumeric name="dei:EntityAddressStateOrProvince" format="ixt-sec:stateprovnameen" contextRef="d_2022-01-01_2022-06-30">Pennsylvania</ix:nonNumeric></b></span></p> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: center;"><span style="color:#333333;">(Address of principal executive offices)</span></p> </td><td style="vertical-align: middle; width: 54%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: center;"><span style="color:#333333;"><b><ix:nonNumeric name="dei:EntityAddressPostalZipCode" contextRef="d_2022-01-01_2022-06-30">18976-3622</ix:nonNumeric></b></span></p> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: center;"><span style="color:#333333;">(Zip Code)</span></p> </td></tr>
</tbody></table>
<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 8pt; text-align: center;"><span style="color:#333333;">Registrant&#x2019;s telephone number, including area code:&#xa0;<b>(<ix:nonNumeric name="dei:CityAreaCode" contextRef="d_2022-01-01_2022-06-30">215</ix:nonNumeric>) <ix:nonNumeric name="dei:LocalPhoneNumber" contextRef="d_2022-01-01_2022-06-30">488-9300</ix:nonNumeric></b></span></p>
<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: center;">&#xa0;</p>
<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 8pt; text-align: center;"><span style="color:#333333;">Securities registered pursuant to Section 12(b) of the Act:</span></p>
<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt 14.7pt;text-align:center;">&#xa0;</p>
<table style="width: 100%; text-indent: 0px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; margin-right: 0pt;" cellspacing="0" cellpadding="2"><tbody><tr style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><td style="vertical-align: top; border-color: black black rgb(0, 0, 0); border-style: solid; border-width: 1px; width: 40%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt 0pt 0pt 9pt; text-align: center;"><span style="color:#333333;">Title of each class</span></p> </td><td style="vertical-align: top; border-bottom: 1px solid rgb(0, 0, 0); width: 20%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-top: 1px solid black;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><span style="color:#333333;">Trading symbol(s)</span></p> </td><td style="vertical-align: top; border-color: black black rgb(0, 0, 0); border-style: solid; border-width: 1px; width: 40%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt 0pt 0pt 9pt; text-align: center;"><span style="color:#333333;">Name of each exchange on which registered</span></p> </td></tr>
<tr style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><td style="vertical-align: top; border-bottom: 1px solid rgb(0, 0, 0); width: 40%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-right: 1px solid black; border-left: 1px solid black;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><span style="color:#333333;"><b><ix:nonNumeric name="dei:Security12bTitle" contextRef="d_2022-01-01_2022-06-30">Common Stock, $0.001 par value</ix:nonNumeric></b></span></p> </td><td style="vertical-align: top; border-bottom: 1px solid rgb(0, 0, 0); width: 20%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><span style="color:#333333;">&#xa0;<b><ix:nonNumeric name="dei:TradingSymbol" contextRef="d_2022-01-01_2022-06-30">WINT</ix:nonNumeric></b></span></p> </td><td style="vertical-align: top; border-bottom: 1px solid rgb(0, 0, 0); width: 40%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-right: 1px solid black; border-left: 1px solid black;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><span style="color:#333333;">&#xa0;<b>The <ix:nonNumeric name="dei:SecurityExchangeName" format="ixt-sec:exchnameen" contextRef="d_2022-01-01_2022-06-30">Nasdaq</ix:nonNumeric> Capital Market</b></span></p> </td></tr>
</tbody></table>
<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt 14.7pt;text-align:left;">&#xa0;</p>
<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><span style="color:#333333;">Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports),&#xa0;and (2) has been subject to such filing requirements for the past 90 days.&#xa0; <ix:nonNumeric name="dei:EntityCurrentReportingStatus" contextRef="d_2022-01-01_2022-06-30">Yes</ix:nonNumeric> &#x2612;&#xa0; No&#xa0;&#x2610;</span></p>
<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&#xa0;</p>
<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><span style="color:#333333;">Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule&#xa0;405 of Regulation S-T (&#xa7;232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).&#xa0; <ix:nonNumeric name="dei:EntityInteractiveDataCurrent" contextRef="d_2022-01-01_2022-06-30">Yes</ix:nonNumeric>&#xa0;&#x2612;&#xa0; No &#x2610;</span></p>
<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&#xa0;</p>
<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><span style="color:#333333;">Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, smaller reporting company, or an emerging growth company. See the definitions of &#x201c;large accelerated filer,&#x201d; &#x201c;accelerated filer,&#x201d; &#x201c;smaller reporting company,&#x201d; and &#x201c;emerging growth company&#x201d; in Rule 12b-2 of the Exchange Act.</span></p>
<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt 14.7pt;text-align:left;">&#xa0;</p>
<table style="width:100%;text-indent:0;font-family:'Times New Roman', Times, serif;font-size:10pt;" cellspacing="0" cellpadding="0" border="0"><tbody><tr><td style="vertical-align:middle;width:62.8%;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><span style="color:#333333;">Large accelerated filer&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#x2610;</span></p> </td><td style="vertical-align:middle;width:37.2%;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><span style="color:#333333;">Accelerated filer&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#x2610;</span></p> </td></tr>
<tr><td style="vertical-align:middle;width:62.8%;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&#xa0;</p> </td><td style="vertical-align:middle;width:37.2%;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&#xa0;</p> </td></tr>
<tr><td style="vertical-align:middle;width:62.8%;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><span style="color:#333333;"><ix:nonNumeric name="dei:EntityFilerCategory" format="ixt-sec:entityfilercategoryen" contextRef="d_2022-01-01_2022-06-30">Non-accelerated filer</ix:nonNumeric>&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#x2612;&#xa0;</span></p> </td><td style="vertical-align:middle;width:37.2%;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><span style="color:#333333;">Smaller reporting company&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;<ix:nonNumeric name="dei:EntitySmallBusiness" format="ixt-sec:boolballotbox" contextRef="d_2022-01-01_2022-06-30">&#x2612;</ix:nonNumeric></span></p> </td></tr>
<tr><td style="vertical-align:middle;width:62.8%;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&#xa0;</p> </td><td style="vertical-align:middle;width:37.2%;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&#xa0;</p> </td></tr>
<tr><td style="vertical-align:middle;width:62.8%;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&#xa0;</p> </td><td style="vertical-align:middle;width:37.2%;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><span style="color:#333333;">Emerging growth company&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;<ix:nonNumeric name="dei:EntityEmergingGrowthCompany" format="ixt-sec:boolballotbox" contextRef="d_2022-01-01_2022-06-30">&#x2610;</ix:nonNumeric></span></p> </td></tr>
</tbody></table>
<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt 14.7pt;text-align:left;">&#xa0;</p>
<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><span style="color:#333333;">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. &#x2610;</span></p>
<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&#xa0;</p>
<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><span style="color:#333333;">Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).&#xa0;&#xa0;Yes&#xa0;<ix:nonNumeric name="dei:EntityShellCompany" format="ixt-sec:boolballotbox" contextRef="d_2022-01-01_2022-06-30">&#x2610;</ix:nonNumeric>&#xa0; No &#x2612;</span></p>
<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&#xa0;</p>
<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><span style="color:#333333;">As of </span><span style="color:#333333;">August 11, 2022</span><span style="color:#333333;">, there were </span><ix:nonFraction name="dei:EntityCommonStockSharesOutstanding" scale="0" unitRef="Share" decimals="INF" format="ixt:numdotdecimal" contextRef="i_2022-08-11">30,627,878</ix:nonFraction><span style="color:#333333;">&#xa0;shares of the registrant&#x2019;s common stock outstanding, par value&#xa0;</span><span style="color:#333333;">$0.001</span><span style="color:#333333;">&#xa0;per share.</span></p>
<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt 14.7pt;text-align:left;">&#xa0;</p>
<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
 <div class="PGFTR" style="text-align: center; width: 100%">
  <div class="hf-row">
   <div class="hf-cell PGNUM">
    &#xa0;
   </div>
  </div>
 </div>
 <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000" />
 <div class="PGHDR" style="text-align: left; width: 100%">
  <div class="hf-row">
   <div class="hf-cell TOCLink" style="display: inline-block; text-align: left;">
    <a href="#toc" style="font-weight: initial; font-style: initial; font-variant: initial; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif;">Table of Contents</a>
   </div>
  </div>
 </div>
</div>
<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#xa0;</p></div>
  <div>
    &#xa0;
  </div>
  <div>
   <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><span style="color:#333333;"><b><a id="toc" title="toc" href="#"></a>Table of Contents</b></span></p>
   <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&#xa0;</p>
   <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><span style="color:#333333;"><b>PART I - FINANCIAL INFORMATION</b></span></p>
   <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;">&#xa0;</p>
   <table border="0" cellpadding="0" cellspacing="0" style="width:100%;text-indent:0;font-family:'Times New Roman', Times, serif;font-size:10pt;">
    <tbody>
     <tr>
      <td style="vertical-align:middle;width:8%;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&#xa0;</p> </td>
      <td style="vertical-align: middle; width: 84%;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&#xa0;</p> </td>
      <td style="vertical-align: middle; width: 8%;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:right;"><span style="text-decoration: underline; ">Page</span></p> </td>
     </tr>

     <tr>
      <td style="vertical-align:middle;width:8%;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&#xa0;</p> </td>
      <td style="vertical-align: middle; width: 84%;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&#xa0;</p> </td>
      <td style="vertical-align: middle; width: 8%;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:right;">&#xa0;</p> </td>
     </tr>

     <tr>
      <td style="vertical-align:middle;width:8%;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">Item 1.</p> </td>
      <td style="vertical-align: middle; width: 84%;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><a href="#Item1_Fin" style="-sec-extract:exhibit;">Financial Statements</a></p> </td>
      <td style="vertical-align: middle; width: 8%;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:right;"><a class="tocPGNUM" href="#Item1_Fin">4</a></p> </td>
     </tr>

     <tr>
      <td style="vertical-align:middle;width:8%;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&#xa0;</p> </td>
      <td style="vertical-align: middle; width: 84%;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&#xa0;</p> </td>
      <td style="vertical-align: middle; width: 8%;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:right;">&#xa0;</p> </td>
     </tr>

     <tr>
      <td style="vertical-align:middle;width:8%;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&#xa0;</p> </td>
      <td style="vertical-align: middle; width: 84%;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><a href="#BalSheets" style="-sec-extract:exhibit;">CONDENSED CONSOLIDATED BALANCE SHEETS</a></p> </td>
      <td style="vertical-align: middle; width: 8%;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:right;"><a class="tocPGNUM" href="#BalSheets">4</a></p> </td>
     </tr>

     <tr>
      <td style="vertical-align:middle;width:8%;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&#xa0;</p> </td>
      <td style="vertical-align: middle; width: 84%;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:54pt;"><a href="#BalSheets" style="-sec-extract:exhibit;">As of June 30, 2022&#xa0;(unaudited) and December 31, 2021</a></p> </td>
      <td style="vertical-align: middle; width: 8%;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:right;">&#xa0;</p> </td>
     </tr>

     <tr>
      <td style="vertical-align:middle;width:8%;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&#xa0;</p> </td>
      <td style="vertical-align: middle; width: 84%;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&#xa0;</p> </td>
      <td style="vertical-align: middle; width: 8%;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:right;">&#xa0;</p> </td>
     </tr>

     <tr>
      <td style="vertical-align:middle;width:8%;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&#xa0;</p> </td>
      <td style="vertical-align: middle; width: 84%;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><a href="#Operations" style="-sec-extract:exhibit;">CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (unaudited)</a></p> </td>
      <td style="vertical-align: middle; width: 8%;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:right;"><a class="tocPGNUM" href="#Operations">5</a></p> </td>
     </tr>

     <tr>
      <td style="vertical-align:middle;width:8%;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&#xa0;</p> </td>
      <td style="vertical-align: middle; width: 84%;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:54pt;"><a href="#Operations" style="-sec-extract:exhibit;">For the Three and Six Months Ended June 30, 2022&#xa0;and 2021</a></p> </td>
      <td style="vertical-align: middle; width: 8%;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:right;">&#xa0;</p> </td>
     </tr>

     <tr>
      <td style="vertical-align:middle;width:8%;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&#xa0;</p> </td>
      <td style="vertical-align: middle; width: 84%;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&#xa0;</p> </td>
      <td style="vertical-align: middle; width: 8%;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:right;">&#xa0;</p> </td>
     </tr>

     <tr>
      <td style="vertical-align:middle;width:8%;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&#xa0;</p> </td>
      <td style="vertical-align: middle; width: 84%;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><a href="#Equity" style="-sec-extract:exhibit;">CONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS&#x2019; EQUITY (unaudited)</a></p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:54pt;margin-right:0pt;margin-top:0pt;text-align:left;"><a href="#Equity" style="-sec-extract:exhibit;">For the Three and Six Months Ended June 30, 2022&#xa0;and 2021</a></p> </td>
      <td style="vertical-align: top; width: 8%;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:right;"><a class="tocPGNUM" href="#Equity">6</a></p> </td>
     </tr>

     <tr>
      <td style="vertical-align:middle;width:8%;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&#xa0;</p> </td>
      <td style="vertical-align: middle; width: 84%;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&#xa0;</p> </td>
      <td style="vertical-align: middle; width: 8%;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&#xa0;</p> </td>
     </tr>

     <tr>
      <td style="vertical-align:middle;width:8%;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&#xa0;</p> </td>
      <td style="vertical-align: middle; width: 84%;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><a href="#CashFlows" style="-sec-extract:exhibit;">CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (unaudited)</a></p> </td>
      <td style="vertical-align: middle; width: 8%;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:right;"><a class="tocPGNUM" href="#CashFlows">7</a></p> </td>
     </tr>

     <tr>
      <td style="vertical-align:middle;width:8%;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&#xa0;</p> </td>
      <td style="vertical-align: middle; width: 84%;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:54pt;"><a href="#CashFlows" style="-sec-extract:exhibit;">For the Six Months Ended June 30, 2022&#xa0;and 2021</a></p> </td>
      <td style="vertical-align: middle; width: 8%;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:right;">&#xa0;</p> </td>
     </tr>

     <tr>
      <td style="vertical-align:middle;width:8%;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&#xa0;</p> </td>
      <td style="vertical-align: middle; width: 84%;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&#xa0;</p> </td>
      <td style="vertical-align: middle; width: 8%;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:right;">&#xa0;</p> </td>
     </tr>

     <tr>
      <td style="vertical-align:middle;width:8%;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&#xa0;</p> </td>
      <td style="vertical-align: middle; width: 84%;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><a href="#Notes" style="-sec-extract:exhibit;">Notes to Condensed Consolidated Financial Statements (unaudited)</a></p> </td>
      <td style="vertical-align: middle; width: 8%;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:right;"><a class="tocPGNUM" href="#Notes">8</a></p> </td>
     </tr>

     <tr>
      <td style="vertical-align:middle;width:8%;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&#xa0;</p> </td>
      <td style="vertical-align: middle; width: 84%;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&#xa0;</p> </td>
      <td style="vertical-align: middle; width: 8%;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:right;">&#xa0;</p> </td>
     </tr>

     <tr>
      <td style="vertical-align:middle;width:8%;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">Item 2.</p> </td>
      <td style="vertical-align: middle; width: 84%;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><a href="#Item2_MDA" style="-sec-extract:exhibit;">Management</a><a href="#Item2_Unreg" style="-sec-extract:exhibit;">&#x2019;</a><a href="#Item2_MDA" style="-sec-extract:exhibit;">s Discussion and Analysis of Financial Condition and Results of Operations</a></p> </td>
      <td style="vertical-align: middle; width: 8%;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:right;"><a class="tocPGNUM" href="#Item2_MDA">16</a></p> </td>
     </tr>

     <tr>
      <td style="vertical-align:middle;width:8%;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&#xa0;</p> </td>
      <td style="vertical-align: middle; width: 84%;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&#xa0;</p> </td>
      <td style="vertical-align: middle; width: 8%;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:right;">&#xa0;</p> </td>
     </tr>

     <tr>
      <td style="vertical-align:middle;width:8%;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">Item 3.</p> </td>
      <td style="vertical-align: middle; width: 84%;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><a href="#Item3_QQ" style="-sec-extract:exhibit;">Quantitative and Qualitative Disclosures about Market Risk</a></p> </td>
      <td style="vertical-align: middle; width: 8%;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:right;"><a class="tocPGNUM" href="#Item3_QQ">25</a></p> </td>
     </tr>

     <tr>
      <td style="vertical-align:middle;width:8%;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&#xa0;</p> </td>
      <td style="vertical-align: middle; width: 84%;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&#xa0;</p> </td>
      <td style="vertical-align: middle; width: 8%;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:right;">&#xa0;</p> </td>
     </tr>

     <tr>
      <td style="vertical-align:middle;width:8%;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">Item 4.</p> </td>
      <td style="vertical-align: middle; width: 84%;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><a href="#Item4_Controls" style="-sec-extract:exhibit;">Controls and Procedures</a></p> </td>
      <td style="vertical-align: middle; width: 8%;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:right;"><a class="tocPGNUM" href="#Item4_Controls">25</a></p> </td>
     </tr>

    </tbody>
   </table>
   <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt 7.2pt;text-align:left;">&#xa0;</p>
   <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><span style="text-decoration: underline; "><b>PART II - OTHER INFORMATION</b></span></p>
   <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt 14.7pt;text-align:center;">&#xa0;</p>
   <table border="0" cellpadding="0" cellspacing="0" style="width:100%;text-indent:0;font-family:'Times New Roman', Times, serif;font-size:10pt;">
    <tbody>
     <tr>
      <td style="vertical-align:middle;width:8%;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">Item 1.</p> </td>
      <td style="vertical-align: middle; width: 84%;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><a href="#legal" style="-sec-extract:exhibit;">Legal Proceedings</a></p> </td>
      <td style="vertical-align: middle; width: 8%;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:right;"><a class="tocPGNUM" href="#legal">26</a></p> </td>
     </tr>

     <tr>
      <td style="vertical-align:middle;width:8%;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&#xa0;</p> </td>
      <td style="vertical-align: middle; width: 84%;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&#xa0;</p> </td>
      <td style="vertical-align: middle; width: 8%;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:right;">&#xa0;</p> </td>
     </tr>

     <tr>
      <td style="vertical-align:middle;width:8%;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">Item 1A.</p> </td>
      <td style="vertical-align: middle; width: 84%;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><a href="#risk" style="-sec-extract:exhibit;">Risk Factors</a></p> </td>
      <td style="vertical-align: middle; width: 8%;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:right;"><a class="tocPGNUM" href="#risk">26</a></p> </td>
     </tr>

     <tr>
      <td style="vertical-align:middle;width:8%;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&#xa0;</p> </td>
      <td style="vertical-align: middle; width: 84%;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&#xa0;</p> </td>
      <td style="vertical-align: middle; width: 8%;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&#xa0;</p> </td>
     </tr>

     <tr>
      <td style="vertical-align:middle;width:8%;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">Item 2.</p> </td>
      <td style="vertical-align: middle; width: 84%;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><a href="#unreg" style="-sec-extract:exhibit;">Unregistered Sales of Equity Securities and Use of Proceeds</a></p> </td>
      <td style="vertical-align: middle; width: 8%;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:right;"><a class="tocPGNUM" href="#unreg">27</a></p> </td>
     </tr>

     <tr>
      <td style="vertical-align:middle;width:8%;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&#xa0;</p> </td>
      <td style="vertical-align: middle; width: 84%;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&#xa0;</p> </td>
      <td style="vertical-align: middle; width: 8%;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&#xa0;</p> </td>
     </tr>

     <tr>
      <td style="vertical-align:middle;width:8%;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">Item 3.</p> </td>
      <td style="vertical-align: middle; width: 84%;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><a href="#default" style="-sec-extract:exhibit;">Defaults Upon Senior Securities</a></p> </td>
      <td style="vertical-align: middle; width: 8%;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:right;"><a class="tocPGNUM" href="#default">27</a></p> </td>
     </tr>

     <tr>
      <td style="vertical-align:middle;width:8%;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&#xa0;</p> </td>
      <td style="vertical-align: middle; width: 84%;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&#xa0;</p> </td>
      <td style="vertical-align: middle; width: 8%;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&#xa0;</p> </td>
     </tr>

     <tr>
      <td style="vertical-align:middle;width:8%;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">Item 4.</p> </td>
      <td style="vertical-align: middle; width: 84%;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><a href="#mine" style="-sec-extract:exhibit;">Mine Safety Disclosures</a></p> </td>
      <td style="vertical-align: middle; width: 8%;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:right;"><a class="tocPGNUM" href="#mine">27</a></p> </td>
     </tr>

     <tr>
      <td style="vertical-align:middle;width:8%;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&#xa0;</p> </td>
      <td style="vertical-align: middle; width: 84%;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&#xa0;</p> </td>
      <td style="vertical-align: middle; width: 8%;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&#xa0;</p> </td>
     </tr>

     <tr>
      <td style="vertical-align:middle;width:8%;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">Item 5.</p> </td>
      <td style="vertical-align: middle; width: 84%;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><a href="#other" style="-sec-extract:exhibit;">Other Information</a></p> </td>
      <td style="vertical-align: middle; width: 8%;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:right;"><a class="tocPGNUM" href="#other">27</a></p> </td>
     </tr>

     <tr>
      <td style="vertical-align:middle;width:8%;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&#xa0;</p> </td>
      <td style="vertical-align: middle; width: 84%;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&#xa0;</p> </td>
      <td style="vertical-align: middle; width: 8%;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&#xa0;</p> </td>
     </tr>

     <tr>
      <td style="vertical-align:middle;width:8%;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">Item 6.</p> </td>
      <td style="vertical-align: middle; width: 84%;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><a href="#exs" style="-sec-extract:exhibit;">Exhibits</a></p> </td>
      <td style="vertical-align: middle; width: 8%;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:right;"><a class="tocPGNUM" href="#exs">28</a></p> </td>
     </tr>

     <tr>
      <td style="vertical-align:middle;width:8%;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&#xa0;</p> </td>
      <td style="vertical-align: middle; width: 84%;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&#xa0;</p> </td>
      <td style="vertical-align: middle; width: 8%;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:right;">&#xa0;</p> </td>
     </tr>

     <tr>
      <td colspan="2" style="vertical-align: middle; width: 8%;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><a href="#Signatures" style="-sec-extract:exhibit;">Signatures</a></p> </td>
      <td style="vertical-align: middle; width: 8%;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:right;"><a class="tocPGNUM" href="#Signatures">29</a></p> </td>
     </tr>

    </tbody>
   </table>
  </div>
  <div>
    &#xa0;
  </div>
  <div>
    &#xa0;
  </div>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">&#xa0;</p>
  <div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
   <div class="PGFTR" style="text-align: center; width: 100%">
    <div class="hf-row">
     <div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">
       1
     </div>
    </div>
   </div>
   <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000" />
   <div class="PGHDR" style="text-align: left; width: 100%">
    <div class="hf-row">
     <div class="hf-cell TOCLink" style="display: inline-block; text-align: left;">
      <a href="#toc" style="font-weight: initial; font-style: initial; font-variant: initial; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif;">Table of Contents</a>
     </div>
    </div>
   </div>
  </div>
  <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#xa0;</p>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><span style="color:#333333;">Unless the context otherwise requires, all references to &#x201c;we,&#x201d; &#x201c;us,&#x201d; &#x201c;our,&#x201d; and the &#x201c;Company&#x201d; include Windtree Therapeutics, Inc., and its consolidated subsidiaries.</span></p>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&#xa0;</p>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><span style="color:#333333;"><b>FORWARD-LOOKING STATEMENTS</b></span></p>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;">&#xa0;</p>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><span style="color:#333333;">This Quarterly Report on Form 10-Q contains &#x201c;forward-looking statements&#x201d; within the meaning of Section 27A of the Securities Act of 1933, as amended, or the Securities Act, and Section 21E of the Securities Exchange Act of 1934, as amended, or the Exchange Act.&#xa0;These forward-looking statements provide our current expectations or forecasts of future events and financial performance and may be identified by the use of forward-looking terminology, including such terms as &#x201c;believes,&#x201d; &#x201c;estimates,&#x201d; &#x201c;anticipates,&#x201d; &#x201c;expects,&#x201d; &#x201c;plans,&#x201d; &#x201c;intends,&#x201d; &#x201c;may,&#x201d; &#x201c;will,&#x201d; &#x201c;should,&#x201d; &#x201c;could,&#x201d; &#x201c;targets,&#x201d; &#x201c;projects,&#x201d; &#x201c;contemplates,&#x201d; &#x201c;predicts,&#x201d; &#x201c;potential&#x201d; or &#x201c;continues&#x201d; or, in each case, their negative, or other variations or comparable terminology, though the absence of these words does not necessarily mean that a statement is not forward-looking.</span></p>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&#xa0;</p>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><span style="color:#333333;">We intend that all forward-looking statements be subject to the safe-harbor provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements are subject to many risks and uncertainties that could cause actual results to differ materially from any future results expressed or implied by the forward-looking statements. We caution you therefore against relying on any of these forward-looking statements. They are neither statements of historical fact nor guarantees or assurances of future performance. Examples of such risks and uncertainties, which potentially could have a material adverse effect on our development programs, business and/or operations, include, but are not limited to the following:</span></p>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&#xa0;</p>
  <table cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; margin-right: 0pt;">
   <tbody>
    <tr style="vertical-align: top; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
     <td style="width: 36pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td>
     <td style="width: 36pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><span style="color:#333333;">&#x25cf;</span></p> </td>
     <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><span style="color:#333333;">our estimates regarding future results of operations, financial position, research and development costs, capital requirements, and our needs for additional financing;</span></p> </td>
    </tr>

    <tr style="vertical-align: top; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
     <td style="width: 36pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td>
     <td style="width: 36pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&#xa0;</p> </td>
     <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&#xa0;</p> </td>
    </tr>

    <tr style="vertical-align: top; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
     <td style="width: 36pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td>
     <td style="width: 36pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><span style="color:#333333;">&#x25cf;</span></p> </td>
     <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><span style="color:#333333;">how long we can continue to fund our operations with our existing cash and cash equivalents;</span></p> </td>
    </tr>

    <tr style="vertical-align: top; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
     <td style="width: 36pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td>
     <td style="width: 36pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&#xa0;</p> </td>
     <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&#xa0;</p> </td>
    </tr>

    <tr>
     <td style="width: 36pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td>
     <td style="width: 36pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0pt; text-align: left; vertical-align: top;"><span style="color:#333333;">&#x25cf;</span></td>
     <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="margin: 0pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><span style="color:#333333;">we received written notice from The Nasdaq Stock Market LLC, or Nasdaq, that we have failed to comply with Nasdaq&#x2019;s continued listing standards; if we fail to regain compliance within the allowed grace periods or other processes provided under the Nasdaq listing requirements, our common stock may be delisted and the value of our common stock may decrease;</span></p> </td>
    </tr>

    <tr>
     <td style="width: 36pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td>
     <td style="width: 36pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td>
     <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td>
    </tr>

    <tr style="vertical-align: top; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
     <td style="width: 36pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td>
     <td style="width: 36pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><span style="color:#333333;">&#x25cf;</span></p> </td>
     <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><span style="color:#333333;">delays in our anticipated timelines and milestones and additional costs associated with the impact of the residual effects of the novel coronavirus, or COVID-19, pandemic&#xa0;on our clinical trial operations;</span></p> </td>
    </tr>

    <tr style="vertical-align: top; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
     <td style="width: 36pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td>
     <td style="width: 36pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&#xa0;</p> </td>
     <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&#xa0;</p> </td>
    </tr>

    <tr style="vertical-align: top; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
     <td style="width: 36pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td>
     <td style="width: 36pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><span style="color:#333333;">&#x25cf;</span></p> </td>
     <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><span style="color:#333333;">the costs, timing, and results, of our preclinical studies and clinical trials, as well as the number of required trials for regulatory approval and the criteria for success in such trials;</span></p> </td>
    </tr>

    <tr style="vertical-align: top; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
     <td style="width: 36pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td>
     <td style="width: 36pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&#xa0;</p> </td>
     <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&#xa0;</p> </td>
    </tr>

    <tr style="vertical-align: top; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
     <td style="width: 36pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td>
     <td style="width: 36pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><span style="color:#333333;">&#x25cf;</span></p> </td>
     <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><span style="color:#333333;">legal and regulatory developments in the United States, or U.S., and foreign countries, including any actions or advice that may affect the design, initiation, timing, continuation, progress or outcome of clinical trials or result in the need for additional clinical trials;</span></p> </td>
    </tr>

    <tr style="vertical-align: top; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
     <td style="width: 36pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td>
     <td style="width: 36pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&#xa0;</p> </td>
     <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&#xa0;</p> </td>
    </tr>

    <tr style="vertical-align: top; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
     <td style="width: 36pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td>
     <td style="width: 36pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><span style="color:#333333;">&#x25cf;</span></p> </td>
     <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><span style="color:#333333;">the difficulties and expenses associated with obtaining and maintaining regulatory approval of our product candidates, and the indication and labeling under any such approval;</span></p> </td>
    </tr>

    <tr style="vertical-align: top; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
     <td style="width: 36pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td>
     <td style="width: 36pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&#xa0;</p> </td>
     <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&#xa0;</p> </td>
    </tr>

    <tr style="vertical-align: top; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
     <td style="width: 36pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td>
     <td style="width: 36pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><span style="color:#333333;">&#x25cf;</span></p> </td>
     <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><span style="color:#333333;">our plans and the plans of our licensee, Lee&#x2019;s Pharmaceutical (HK) Ltd., or Lee&#x2019;s (HK),&#xa0;in Asia and our respective abilities to successfully execute necessary clinical and business development activities in a timely manner, if at all, to support development and commercialize our product candidates;</span></p> </td>
    </tr>

    <tr style="vertical-align: top; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
     <td style="width: 36pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td>
     <td style="width: 36pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&#xa0;</p> </td>
     <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&#xa0;</p> </td>
    </tr>

    <tr style="vertical-align: top; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
     <td style="width: 36pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td>
     <td style="width: 36pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: left;"><span style="color:#333333;">&#x25cf;</span></p> </td>
     <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><span style="color:#333333;">risks related to manufacturing active pharmaceutical ingredients, drug product, medical devices, and other materials we need;</span></p> </td>
    </tr>

    <tr style="vertical-align: top; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
     <td style="width: 36pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td>
     <td style="width: 36pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&#xa0;</p> </td>
     <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&#xa0;</p> </td>
    </tr>

    <tr style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
     <td style="width: 36pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td>
     <td style="width: 36pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><span style="color:#333333;">&#x25cf;</span></td>
     <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><span style="color:#333333;">delays, interruptions or failures in the manufacture and supply of our product candidates;</span></td>
    </tr>

    <tr style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
     <td style="width: 36pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td>
     <td style="width: 36pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td>
     <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td>
    </tr>

    <tr style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
     <td style="width: 36pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td>
     <td style="width: 36pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><span style="color:#333333;">&#x25cf;</span></td>
     <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><span style="color:#333333;">the performance of third parties, both foreign and domestic, upon which we depend, including contract research organizations, contract manufacturing organizations, contractor laboratories, and independent contractors;</span></td>
    </tr>

    <tr style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
     <td style="width: 36pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td>
     <td style="width: 36pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td>
     <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td>
    </tr>

    <tr style="vertical-align: top; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
     <td style="width: 36pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td>
     <td style="width: 36pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><span style="color:#333333;">&#x25cf;</span></p> </td>
     <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><span style="color:#333333;">the size and growth of the potential markets for our product candidates, the regulatory requirements in such markets, the rate and degree of market acceptance of our product candidates, and our ability to serve those markets;</span></p> </td>
    </tr>

    <tr style="vertical-align: top; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
     <td style="width: 36pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td>
     <td style="width: 36pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&#xa0;</p> </td>
     <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&#xa0;</p> </td>
    </tr>

    <tr style="vertical-align: top; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
     <td style="width: 36pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td>
     <td style="width: 36pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><span style="color:#333333;">&#x25cf;</span></p> </td>
     <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><span style="color:#333333;">the success of competing therapies and products that are or become available;</span></p> </td>
    </tr>

    <tr style="vertical-align: top; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
     <td style="width: 36pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td>
     <td style="width: 36pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&#xa0;</p> </td>
     <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&#xa0;</p> </td>
    </tr>

    <tr style="vertical-align: top; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
     <td style="width: 36pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td>
     <td style="width: 36pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><span style="color:#333333;">&#x25cf;</span></p> </td>
     <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><span style="color:#333333;">our ability to limit our exposure under product liability lawsuits;</span></p> </td>
    </tr>

    <tr style="vertical-align: top; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
     <td style="width: 36pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td>
     <td style="width: 36pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&#xa0;</p> </td>
     <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&#xa0;</p> </td>
    </tr>

    <tr style="vertical-align: top; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
     <td style="width: 36pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td>
     <td style="width: 36pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><span style="color:#333333;">&#x25cf;</span></p> </td>
     <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><span style="color:#333333;">our ability to obtain and maintain intellectual property protection for our product candidates;</span></p> </td>
    </tr>

   </tbody>
  </table>
  <p style="margin: 0pt;">&#xa0;</p>
  <div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
   <div class="PGFTR" style="text-align: center; width: 100%">
    <div class="hf-row">
     <div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">
       2
     </div>
    </div>
   </div>
   <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000" />
   <div class="PGHDR" style="text-align: left; width: 100%">
    <div class="hf-row">
     <div class="hf-cell TOCLink" style="display: inline-block; text-align: left;">
      <a href="#toc" style="font-weight: initial; font-style: initial; font-variant: initial; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif;">Table of Contents</a>
     </div>
    </div>
   </div>
  </div>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&#xa0;</p>
  <table cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; margin-right: 0pt;">
   <tbody>
    <tr style="vertical-align: top; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
     <td style="width: 36pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td>
     <td style="width: 36pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><span style="color:#333333;">&#x25cf;</span></p> </td>
     <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><span style="color:#333333;">recently enacted and future legislation regarding the healthcare system in the U.S. or the healthcare systems in foreign jurisdictions;</span></p> </td>
    </tr>

    <tr style="vertical-align: top; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
     <td style="width: 36pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td>
     <td style="width: 36pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&#xa0;</p> </td>
     <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&#xa0;</p> </td>
    </tr>

    <tr style="vertical-align: top; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
     <td style="width: 36pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td>
     <td style="width: 36pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><span style="color:#333333;">&#x25cf;</span></p> </td>
     <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><span style="color:#333333;">our ability to recruit or retain key scientific, commercial or management personnel or to retain our executive officers;</span></p> </td>
    </tr>

   </tbody>
  </table>
  <p style="margin: 0pt;">&#xa0;</p>
  <table cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; margin-right: 0pt;">
   <tbody>
    <tr style="vertical-align: top; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
     <td style="width: 36pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td>
     <td style="width: 36pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><span style="color:#333333;">&#x25cf;</span></p> </td>
     <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify;"><span style="color:#333333;">our ability to secure electronically stored work product, including clinical data, analyses, research, communications, and other materials necessary to gain regulatory approval of our product candidates, including those acquired from third parties, and assure the integrity, proper functionality, and security of our internal computer and information systems and prevent or avoid cyber-attacks, malicious intrusion, breakdown, destruction, loss of data privacy, or other significant disruption;</span></p> </td>
    </tr>

    <tr>
     <td style="width: 36pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td>
     <td style="width: 36pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td>
     <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td>
    </tr>

    <tr>
     <td style="width: 36pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td>
     <td style="width: 36pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><span style="color:#333333;">&#x25cf;</span></td>
     <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><span style="color:#333333;">the potential impairment of our intangible assets and goodwill on our condensed consolidated balance sheet, which could lead to material impairment charges in the future; and</span></td>
    </tr>

    <tr>
     <td style="width: 36pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td>
     <td style="width: 36pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td>
     <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td>
    </tr>

    <tr>
     <td style="width: 36pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td>
     <td style="width: 36pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><span style="color:#333333;">&#x25cf;</span></td>
     <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><span style="color:#333333;">economic uncertainty resulting from inflation or geopolitical instability, including the ongoing military conflict between Russia and Ukraine,&#xa0;the People&#x2019;s Republic of China and the Republic of China (Taiwan).</span></td>
    </tr>

   </tbody>
  </table>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt 7.2pt;text-align:left;">&#xa0;</p>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><span style="color:#333333;">Pharmaceutical, biotechnology, and medical technology companies have suffered significant setbacks conducting clinical trials, even after obtaining promising earlier preclinical and clinical data. In addition, data obtained from clinical trials are susceptible to varying interpretations, which could delay, limit or prevent regulatory approval. After gaining approval of a drug product, medical device or combination drug/device product, pharmaceutical and biotechnology companies face considerable challenges in marketing and distributing their products and may never become profitable.</span></p>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&#xa0;</p>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><span style="color:#333333;">The forward-looking statements contained in this Quarterly Report on Form 10-Q or the documents incorporated by reference herein speak only as of their respective dates. Factors or events that could cause our actual results to differ may emerge from time to time and it is not possible for us to predict them all. Except to the extent required by applicable laws, rules or regulations, we do not undertake any obligation to publicly update any forward-looking statements or to publicly announce revisions to any of the forward-looking statements, whether as a result of new information, future events or otherwise.</span></p>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&#xa0;</p>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><span style="color:#333333;">You should also read carefully the factors described in the &#x201c;Risk Factors&#x201d; included in Part II, Item 1A of this Quarterly Report on Form 10-Q in conjunction with Part I, Item 1A of our Annual Report on Form 10-K for the fiscal year ended </span><span style="color:#333333;">December 31, 2021</span><span style="color:#333333;">, to better understand significant risks and uncertainties inherent in our business and underlying any forward-looking statements.</span></p>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&#xa0;</p>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><span style="color:#333333;">Trademark Notice</span></p>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><span style="color:#333333;"><b>AEROSURF&#xae;</b>, <b>AFECTAIR&#xae;</b>, <b>SURFAXIN&#xae;</b>, <b>SURFAXIN LS&#x2122;</b>, <b>WINDTREE THERAPEUTICS&#xae; (logo)</b>,</span></p>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><span style="color:#333333;"><b>WINDTREE THERAPEUTICS&#x2122;</b>, and <b>WINDTREE&#x2122; </b>are registered and common law trademarks of Windtree Therapeutics, Inc. (Warrington, PA).</span></p>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&#xa0;</p>
  <div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
   <div class="PGFTR" style="text-align: center; width: 100%">
    <div class="hf-row">
     <div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">
       3
     </div>
    </div>
   </div>
   <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000" />
   <div class="PGHDR" style="text-align: left; width: 100%">
    <div class="hf-row">
     <div class="hf-cell TOCLink" style="display: inline-block; text-align: left;">
      <a href="#toc" style="font-weight: initial; font-style: initial; font-variant: initial; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif;">Table of Contents</a>
     </div>
    </div>
   </div>
  </div>
  <div>
    &#xa0;
  </div>
  <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#xa0;</p>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><span style="color:#333333;"><b><a id="Item1_Fin" title="Item1_Fin" href="#"></a>ITEM 1.&#xa0; &#xa0; &#xa0; Financial Statements</b></span></p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">&#xa0;</p>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><span style="color:#333333;"><b><a id="BalSheets" title="BalSheets" href="#"></a>WINDTREE THERAPEUTICS, INC. AND SUBSIDIARIES</b></span></p>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><span style="color:#333333;"><b>Condensed Consolidated Balance Sheets</b></span></p>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&#xa0;</p>
  <table border="0" cellpadding="0" cellspacing="0" style="width:100%;text-indent:0;font-family:'Times New Roman', Times, serif;font-size:10pt;">
   <tbody>
    <tr>
     <td style="vertical-align:bottom;width:100%;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><span style="color:#333333;"><i>(in thousands, except share and per share data)</i></span></p> </td>
    </tr>

   </tbody>
  </table>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&#xa0;</p>
  <div>
   <table class="finTable" style="width: 100%; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; text-indent: 0px; margin-left: 0pt; margin-right: 0pt;" cellspacing="0" cellpadding="0"><tbody><tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 68%;">&#xa0;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;">&#xa0;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); width: 1%;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><span style="color:#333333;"><b><em style="font: inherit;">June 30, 2022</em></b></span></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; width: 1%;">&#xa0;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;">&#xa0;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); width: 1%;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><span style="color:#333333;"><b><em style="font: inherit;">December 31, 2021</em></b></span></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; width: 1%;">&#xa0;</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 68%;">&#xa0;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;">&#xa0;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; width: 1%;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><span style="color:#333333;"><em style="font: inherit;">Unaudited</em></span></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;">&#xa0;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;">&#xa0;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;">&#xa0;</td><td style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 13%;"><em style="font: inherit;">&#xa0;</em></td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;">&#xa0;</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 68%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><span style="color:#333333;"><b>ASSETS</b></span></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;">&#xa0;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;">&#xa0;</td><td style="text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 13%;">&#xa0;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;"><span style="color:#333333;"><b>&#xa0;</b></span></td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;">&#xa0;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;">&#xa0;</td><td style="text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 13%;">&#xa0;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;"><span style="color:#333333;"><b>&#xa0;</b></span></td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 68%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><span style="color:#333333;">Current Assets:</span></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;">&#xa0;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;">&#xa0;</td><td style="text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 13%;">&#xa0;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;">&#xa0;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;">&#xa0;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;">&#xa0;</td><td style="text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 13%;">&#xa0;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;">&#xa0;</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 68%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 18pt;"><span style="color:#333333;">Cash and cash equivalents</span></p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><span style="color:#333333;">$</span></td><td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><span style="color:#333333;"><ix:nonFraction id="c86424670" contextRef="i_2022-06-30" unitRef="USD" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" scale="3" format="ixt:numdotdecimal" decimals="-3">11,378</ix:nonFraction></span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><span style="color:#333333;">$</span></td><td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><span style="color:#333333;"><ix:nonFraction id="c86424671" contextRef="i_2021-12-31" unitRef="USD" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" scale="3" format="ixt:numdotdecimal" decimals="-3">22,348</ix:nonFraction></span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#xa0;</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 68%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 18pt;"><span style="color:#333333;">Prepaid expenses and other current assets</span></p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td><td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><span style="color:#333333;"><ix:nonFraction id="c86424672" contextRef="i_2022-06-30" unitRef="USD" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" scale="3" format="ixt:numdotdecimal" decimals="-3">1,784</ix:nonFraction></span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td><td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><span style="color:#333333;"><ix:nonFraction id="c86424673" contextRef="i_2021-12-31" unitRef="USD" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" scale="3" format="ixt:numdotdecimal" decimals="-3">1,143</ix:nonFraction></span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#xa0;</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 68%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 36pt;"><span style="color:#333333;">Total current assets</span></p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><span style="color:#333333;"><ix:nonFraction id="c86424674" contextRef="i_2022-06-30" unitRef="USD" name="us-gaap:AssetsCurrent" scale="3" format="ixt:numdotdecimal" decimals="-3">13,162</ix:nonFraction></span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><span style="color:#333333;"><ix:nonFraction id="c86424675" contextRef="i_2021-12-31" unitRef="USD" name="us-gaap:AssetsCurrent" scale="3" format="ixt:numdotdecimal" decimals="-3">23,491</ix:nonFraction></span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#xa0;</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 68%;">&#xa0;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;">&#xa0;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;">&#xa0;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 13%;">&#xa0;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;">&#xa0;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;">&#xa0;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;">&#xa0;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 13%;">&#xa0;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;">&#xa0;</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 68%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><span style="color:#333333;">Property and equipment, net</span></p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><span style="color:#333333;"><ix:nonFraction id="c86424676" contextRef="i_2022-06-30" unitRef="USD" name="us-gaap:PropertyPlantAndEquipmentNet" scale="3" format="ixt:numdotdecimal" decimals="-3">307</ix:nonFraction></span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><span style="color:#333333;"><ix:nonFraction id="c86424677" contextRef="i_2021-12-31" unitRef="USD" name="us-gaap:PropertyPlantAndEquipmentNet" scale="3" format="ixt:numdotdecimal" decimals="-3">1,011</ix:nonFraction></span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#xa0;</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 68%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><span style="color:#333333;">Restricted cash</span></p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><span style="color:#333333;"><ix:nonFraction id="c86424678" contextRef="i_2022-06-30" unitRef="USD" name="us-gaap:RestrictedCashAndCashEquivalentsNoncurrent" scale="3" format="ixt:numdotdecimal" decimals="-3">154</ix:nonFraction></span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><span style="color:#333333;"><ix:nonFraction id="c86424679" contextRef="i_2021-12-31" unitRef="USD" name="us-gaap:RestrictedCashAndCashEquivalentsNoncurrent" scale="3" format="ixt:numdotdecimal" decimals="-3">154</ix:nonFraction></span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#xa0;</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 68%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><span style="color:#333333;">Operating lease right-of-use assets</span></p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><span style="color:#333333;"><ix:nonFraction id="c86424680" contextRef="i_2022-06-30" unitRef="USD" name="us-gaap:OperatingLeaseRightOfUseAsset" scale="3" format="ixt:numdotdecimal" decimals="-3">2,074</ix:nonFraction></span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><span style="color:#333333;"><ix:nonFraction id="c86424681" contextRef="i_2021-12-31" unitRef="USD" name="us-gaap:OperatingLeaseRightOfUseAsset" scale="3" format="ixt:numdotdecimal" decimals="-3">2,381</ix:nonFraction></span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#xa0;</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 68%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><span style="color:#333333;">Intangible assets</span></p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><span style="color:#333333;"><ix:nonFraction id="c86424682" contextRef="i_2022-06-30" unitRef="USD" name="us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill" scale="3" format="ixt:numdotdecimal" decimals="-4">32,070</ix:nonFraction></span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><span style="color:#333333;"><ix:nonFraction id="c86424683" contextRef="i_2021-12-31" unitRef="USD" name="us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill" scale="3" format="ixt:numdotdecimal" decimals="-4">32,070</ix:nonFraction></span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#xa0;</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 68%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><span style="color:#333333;">Goodwill</span></p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td><td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><span style="color:#333333;"><ix:nonFraction id="c86424684" contextRef="i_2022-06-30" unitRef="USD" name="us-gaap:Goodwill" scale="3" format="ixt:numdotdecimal" decimals="-3">4,046</ix:nonFraction></span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td><td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><span style="color:#333333;"><ix:nonFraction id="c86424685" contextRef="i_2021-12-31" unitRef="USD" name="us-gaap:Goodwill" scale="3" format="ixt:numdotdecimal" decimals="-3">15,682</ix:nonFraction></span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#xa0;</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 68%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 18pt;"><span style="color:#333333;">Total assets</span></p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><span style="color:#333333;">$</span></td><td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><span style="color:#333333;"><ix:nonFraction id="c86424686" contextRef="i_2022-06-30" unitRef="USD" name="us-gaap:Assets" scale="3" format="ixt:numdotdecimal" decimals="-3">51,813</ix:nonFraction></span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><span style="color:#333333;">$</span></td><td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><span style="color:#333333;"><ix:nonFraction id="c86424687" contextRef="i_2021-12-31" unitRef="USD" name="us-gaap:Assets" scale="3" format="ixt:numdotdecimal" decimals="-3">74,789</ix:nonFraction></span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&#xa0;</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 68%;">&#xa0;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;">&#xa0;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;">&#xa0;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 13%;">&#xa0;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;">&#xa0;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;">&#xa0;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;">&#xa0;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 13%;">&#xa0;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;">&#xa0;</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 68%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><span style="color:#333333;"><b>LIABILITIES &amp; STOCKHOLDERS&#x2019; EQUITY</b></span></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;">&#xa0;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;">&#xa0;</td><td style="text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 13%;">&#xa0;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;"><span style="color:#333333;"><b>&#xa0;</b></span></td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;">&#xa0;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;">&#xa0;</td><td style="text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 13%;">&#xa0;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;"><span style="color:#333333;"><b>&#xa0;</b></span></td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 68%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><span style="color:#333333;">Current Liabilities:</span></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;">&#xa0;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;">&#xa0;</td><td style="text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 13%;">&#xa0;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;">&#xa0;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;">&#xa0;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;">&#xa0;</td><td style="text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 13%;">&#xa0;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;">&#xa0;</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 68%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 18pt;"><span style="color:#333333;">Accounts payable</span></p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><span style="color:#333333;">$</span></td><td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><span style="color:#333333;"><ix:nonFraction id="c86424690" contextRef="i_2022-06-30" unitRef="USD" name="us-gaap:AccountsPayableCurrent" scale="3" format="ixt:numdotdecimal" decimals="-3">1,072</ix:nonFraction></span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><span style="color:#333333;">$</span></td><td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><span style="color:#333333;"><ix:nonFraction id="c86424691" contextRef="i_2021-12-31" unitRef="USD" name="us-gaap:AccountsPayableCurrent" scale="3" format="ixt:numdotdecimal" decimals="-3">693</ix:nonFraction></span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#xa0;</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 68%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 18pt;"><span style="color:#333333;">Accrued expenses</span></p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><span style="color:#333333;"><ix:nonFraction id="c86424692" contextRef="i_2022-06-30" unitRef="USD" name="us-gaap:AccruedLiabilitiesCurrent" scale="3" format="ixt:numdotdecimal" decimals="-3">2,823</ix:nonFraction></span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><span style="color:#333333;"><ix:nonFraction id="c86424693" contextRef="i_2021-12-31" unitRef="USD" name="us-gaap:AccruedLiabilitiesCurrent" scale="3" format="ixt:numdotdecimal" decimals="-3">3,408</ix:nonFraction></span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#xa0;</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 68%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 18pt;"><span style="color:#333333;">Operating lease liabilities - current portion</span></p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><span style="color:#333333;"><ix:nonFraction id="c86424694" contextRef="i_2022-06-30" unitRef="USD" name="us-gaap:OperatingLeaseLiabilityCurrent" scale="3" format="ixt:numdotdecimal" decimals="-3">432</ix:nonFraction></span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><span style="color:#333333;"><ix:nonFraction id="c86424695" contextRef="i_2021-12-31" unitRef="USD" name="us-gaap:OperatingLeaseLiabilityCurrent" scale="3" format="ixt:numdotdecimal" decimals="-3">528</ix:nonFraction></span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#xa0;</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 68%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 18pt;"><span style="color:#333333;">Loans payable - current portion</span></p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td><td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><span style="color:#333333;"><ix:nonFraction id="c86424696" contextRef="i_2022-06-30" unitRef="USD" name="us-gaap:LoansPayableCurrent" scale="3" format="ixt:numdotdecimal" decimals="-3">1,007</ix:nonFraction></span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td><td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><span style="color:#333333;"><ix:nonFraction id="c86424697" contextRef="i_2021-12-31" unitRef="USD" name="us-gaap:LoansPayableCurrent" scale="3" format="ixt:numdotdecimal" decimals="-3">294</ix:nonFraction></span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#xa0;</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 68%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 36pt;"><span style="color:#333333;">Total current liabilities</span></p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><span style="color:#333333;"><ix:nonFraction id="c86424698" contextRef="i_2022-06-30" unitRef="USD" name="us-gaap:LiabilitiesCurrent" scale="3" format="ixt:numdotdecimal" decimals="-3">5,334</ix:nonFraction></span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><span style="color:#333333;"><ix:nonFraction id="c86424699" contextRef="i_2021-12-31" unitRef="USD" name="us-gaap:LiabilitiesCurrent" scale="3" format="ixt:numdotdecimal" decimals="-3">4,923</ix:nonFraction></span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#xa0;</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 68%;">&#xa0;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;">&#xa0;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;">&#xa0;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 13%;">&#xa0;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;">&#xa0;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;">&#xa0;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;">&#xa0;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 13%;">&#xa0;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;">&#xa0;</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 68%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><span style="color:#333333;">Operating lease liabilities - non-current portion</span></p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><span style="color:#333333;"><ix:nonFraction id="c86424700" contextRef="i_2022-06-30" unitRef="USD" name="us-gaap:OperatingLeaseLiabilityNoncurrent" scale="3" format="ixt:numdotdecimal" decimals="-3">1,839</ix:nonFraction></span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><span style="color:#333333;"><ix:nonFraction id="c86424701" contextRef="i_2021-12-31" unitRef="USD" name="us-gaap:OperatingLeaseLiabilityNoncurrent" scale="3" format="ixt:numdotdecimal" decimals="-3">2,071</ix:nonFraction></span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#xa0;</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 68%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><span style="color:#333333;">Restructured debt liability - contingent milestone payments</span></p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><span style="color:#333333;"><ix:nonFraction id="c86424702" contextRef="i_2022-06-30" unitRef="USD" name="wint:LiabilityforContingentMilestonePaymentNoncurrent" scale="3" format="ixt:numdotdecimal" decimals="-6">15,000</ix:nonFraction></span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><span style="color:#333333;"><ix:nonFraction id="c86424703" contextRef="i_2021-12-31" unitRef="USD" name="wint:LiabilityforContingentMilestonePaymentNoncurrent" scale="3" format="ixt:numdotdecimal" decimals="-6">15,000</ix:nonFraction></span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#xa0;</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 68%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><span style="color:#333333;">Other liabilities</span></p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><span style="color:#333333;"><ix:nonFraction id="c86424704" contextRef="i_2022-06-30" unitRef="USD" name="us-gaap:OtherLiabilitiesNoncurrent" scale="3" format="ixt:numdotdecimal" decimals="-5">3,800</ix:nonFraction></span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><span style="color:#333333;"><ix:nonFraction id="c86424705" contextRef="i_2021-12-31" unitRef="USD" name="us-gaap:OtherLiabilitiesNoncurrent" scale="3" format="ixt:numdotdecimal" decimals="-5">3,800</ix:nonFraction></span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#xa0;</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 68%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><span style="color:#333333;">Deferred tax liabilities</span></p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td><td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><span style="color:#333333;"><ix:nonFraction id="c86424706" contextRef="i_2022-06-30" unitRef="USD" name="us-gaap:DeferredIncomeTaxLiabilitiesNet" scale="3" format="ixt:numdotdecimal" decimals="-3">6,643</ix:nonFraction></span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td><td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><span style="color:#333333;"><ix:nonFraction id="c86424707" contextRef="i_2021-12-31" unitRef="USD" name="us-gaap:DeferredIncomeTaxLiabilitiesNet" scale="3" format="ixt:numdotdecimal" decimals="-3">7,114</ix:nonFraction></span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#xa0;</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 68%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 36pt;"><span style="color:#333333;">Total liabilities</span></p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><span style="color:#333333;"><ix:nonFraction id="c86424708" contextRef="i_2022-06-30" unitRef="USD" name="us-gaap:Liabilities" scale="3" format="ixt:numdotdecimal" decimals="-3">32,616</ix:nonFraction></span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><span style="color:#333333;"><ix:nonFraction id="c86424709" contextRef="i_2021-12-31" unitRef="USD" name="us-gaap:Liabilities" scale="3" format="ixt:numdotdecimal" decimals="-3">32,908</ix:nonFraction></span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#xa0;</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 68%;">&#xa0;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;">&#xa0;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;">&#xa0;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 13%;">&#xa0;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;">&#xa0;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;">&#xa0;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;">&#xa0;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 13%;">&#xa0;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;">&#xa0;</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 68%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><span style="color:#333333;">Stockholders&#x2019; Equity:</span></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;">&#xa0;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;">&#xa0;</td><td style="text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 13%;">&#xa0;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;">&#xa0;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;">&#xa0;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;">&#xa0;</td><td style="text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 13%;">&#xa0;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;">&#xa0;</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 68%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; text-indent: 18pt;"><span style="color:#333333;">Preferred stock, $<span style="-sec-ix-hidden:c86424713"><span style="-sec-ix-hidden:c86424714">0.001</span></span> par value; <span style="-sec-ix-hidden:c86424715"><span style="-sec-ix-hidden:c86424716">5,000,000</span></span> shares authorized; <span style="-sec-ix-hidden:c86424717"><span style="-sec-ix-hidden:c86424719"><span style="-sec-ix-hidden:c86424718"><span style="-sec-ix-hidden:c86424720">0</span></span></span></span> shares issued and outstanding at June 30, 2022 and December 31, 2021</span></p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><span style="color:#333333;"><ix:nonFraction id="c86424711" contextRef="i_2022-06-30" unitRef="USD" name="us-gaap:PreferredStockValue" scale="3" format="ixt:zerodash" decimals="-3">-</ix:nonFraction></span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><span style="color:#333333;"><ix:nonFraction id="c86424712" contextRef="i_2021-12-31" unitRef="USD" name="us-gaap:PreferredStockValue" scale="3" format="ixt:zerodash" decimals="-3">-</ix:nonFraction></span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#xa0;</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 68%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; text-indent: 18pt;"><span style="color:#333333;">Common stock, $<span style="-sec-ix-hidden:c86424723"><span style="-sec-ix-hidden:c86424724">0.001</span></span> par value; <span style="-sec-ix-hidden:c86424725"><span style="-sec-ix-hidden:c86424726">120,000,000</span></span> shares authorized at June 30, 2022 and December 31, 2021; <span style="-sec-ix-hidden:c86424727">29,406,196</span> and <span style="-sec-ix-hidden:c86424728">28,268,950</span> shares issued at June 30, 2022 and December 31, 2021, </span></p> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; text-indent: 36pt;"><span style="color:#333333;">respectively; <span style="-sec-ix-hidden:c86424729">29,406,172</span> and <span style="-sec-ix-hidden:c86424730">28,268,926</span> shares outstanding at June 30, 2022 and December 31, 2021, respectively</span></p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><span style="color:#333333;"><ix:nonFraction id="c86424721" contextRef="i_2022-06-30" unitRef="USD" name="us-gaap:CommonStockValue" scale="3" format="ixt:numdotdecimal" decimals="-3">29</ix:nonFraction></span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><span style="color:#333333;"><ix:nonFraction id="c86424722" contextRef="i_2021-12-31" unitRef="USD" name="us-gaap:CommonStockValue" scale="3" format="ixt:numdotdecimal" decimals="-3">28</ix:nonFraction></span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#xa0;</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 68%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; text-indent: 18pt;"><span style="color:#333333;">Additional paid-in capital</span></p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><span style="color:#333333;"><ix:nonFraction id="c86424731" contextRef="i_2022-06-30" unitRef="USD" name="us-gaap:AdditionalPaidInCapital" scale="3" format="ixt:numdotdecimal" decimals="-3">833,006</ix:nonFraction></span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><span style="color:#333333;"><ix:nonFraction id="c86424732" contextRef="i_2021-12-31" unitRef="USD" name="us-gaap:AdditionalPaidInCapital" scale="3" format="ixt:numdotdecimal" decimals="-3">830,231</ix:nonFraction></span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#xa0;</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 68%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; text-indent: 18pt;"><span style="color:#333333;">Accumulated deficit</span></p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><span style="color:#333333;">(<ix:nonFraction id="c86424733" contextRef="i_2022-06-30" unitRef="USD" name="us-gaap:RetainedEarningsAccumulatedDeficit" scale="3" format="ixt:numdotdecimal" decimals="-3" sign="-">810,784</ix:nonFraction></span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><span style="color:#333333;">)</span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><span style="color:#333333;">(<ix:nonFraction id="c86424734" contextRef="i_2021-12-31" unitRef="USD" name="us-gaap:RetainedEarningsAccumulatedDeficit" scale="3" format="ixt:numdotdecimal" decimals="-3" sign="-">785,324</ix:nonFraction></span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><span style="color:#333333;">)</span></td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 68%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; text-indent: 18pt;"><span style="color:#333333;">Treasury stock (at cost); <span style="-sec-ix-hidden:c86424737"><span style="-sec-ix-hidden:c86424738">24</span></span> shares</span></p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td><td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><span style="color:#333333;">(<ix:nonFraction id="c86424735" contextRef="i_2022-06-30" unitRef="USD" name="us-gaap:TreasuryStockValue" scale="3" format="ixt:numdotdecimal" decimals="-3">3,054</ix:nonFraction></span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"><span style="color:#333333;">)</span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td><td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><span style="color:#333333;">(<ix:nonFraction id="c86424736" contextRef="i_2021-12-31" unitRef="USD" name="us-gaap:TreasuryStockValue" scale="3" format="ixt:numdotdecimal" decimals="-3">3,054</ix:nonFraction></span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"><span style="color:#333333;">)</span></td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 68%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 36pt;"><span style="color:#333333;">Total stockholders&#x2019; equity</span></p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td><td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><span style="color:#333333;"><ix:nonFraction id="c86424739" contextRef="i_2022-06-30" unitRef="USD" name="us-gaap:StockholdersEquity" scale="3" format="ixt:numdotdecimal" decimals="-3">19,197</ix:nonFraction></span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td><td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><span style="color:#333333;"><ix:nonFraction id="c86424740" contextRef="i_2021-12-31" unitRef="USD" name="us-gaap:StockholdersEquity" scale="3" format="ixt:numdotdecimal" decimals="-3">41,881</ix:nonFraction></span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#xa0;</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 68%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><span style="color:#333333;">Total liabilities &amp; stockholders&#x2019; equity</span></p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><span style="color:#333333;">$</span></td><td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><span style="color:#333333;"><ix:nonFraction id="c86424741" contextRef="i_2022-06-30" unitRef="USD" name="us-gaap:LiabilitiesAndStockholdersEquity" scale="3" format="ixt:numdotdecimal" decimals="-3">51,813</ix:nonFraction></span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><span style="color:#333333;">$</span></td><td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><span style="color:#333333;"><ix:nonFraction id="c86424742" contextRef="i_2021-12-31" unitRef="USD" name="us-gaap:LiabilitiesAndStockholdersEquity" scale="3" format="ixt:numdotdecimal" decimals="-3">74,789</ix:nonFraction></span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&#xa0;</td></tr>
</tbody></table>
  </div>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&#xa0;</p>
  <table border="0" cellpadding="0" cellspacing="0" style="width:100%;text-indent:0;font-family:'Times New Roman', Times, serif;font-size:10pt;">
   <tbody>
    <tr>
     <td style="vertical-align:bottom;width:100%;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><span style="color:#333333;"><i>See notes to condensed consolidated financial statements</i></span></p> </td>
    </tr>

   </tbody>
  </table>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&#xa0;</p>
  <div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
   <div class="PGFTR" style="text-align: center; width: 100%">
    <div class="hf-row">
     <div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">
       4
     </div>
    </div>
   </div>
   <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000" />
   <div class="PGHDR" style="text-align: left; width: 100%">
    <div class="hf-row">
     <div class="hf-cell TOCLink" style="display: inline-block; text-align: left;">
      <a href="#toc" style="font-weight: initial; font-style: initial; font-variant: initial; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif;">Table of Contents</a>
     </div>
     <div class="hf-cell TOCLink" style="display: inline-block; text-align: left;">
       &#xa0;
     </div>
     <div class="hf-cell TOCLink" style="display: inline-block; text-align: left;">
       &#xa0;
     </div>
     <div class="hf-cell TOCLink" style="display: inline-block; text-align: left;">
       &#xa0;
     </div>
     <div class="hf-cell TOCLink" style="display: inline-block; text-align: left;">
       &#xa0;
     </div>
    </div>
   </div>
  </div>
  <div>
    &#xa0;
  </div>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&#xa0;</p>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><span style="color:#333333;"><b><a id="Operations" title="Operations" href="#"></a>WINDTREE THERAPEUTICS, INC. AND SUBSIDIARIES </b></span></p>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><span style="color:#333333;"><b>Condensed Consolidated Statements of Operations</b></span></p>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><span style="color:#333333;">(Unaudited)</span></p>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&#xa0;</p>
  <table border="0" cellpadding="0" cellspacing="0" style="width:100%;text-indent:0;font-family:'Times New Roman', Times, serif;font-size:10pt;">
   <tbody>
    <tr>
     <td style="vertical-align:bottom;width:100%;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><span style="color:#333333;"><i>(in thousands, except per share data)</i></span></p> </td>
    </tr>

   </tbody>
  </table>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&#xa0;</p>
  <div>
   <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: Times New Roman; text-indent: 0px;">
    <tbody>
     <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom">
      <td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
      <td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
      <td colspan="6" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><span style="color:#333333;"><b><em style="font: inherit;"><em style="font: inherit;">Three Months Ended</em></em></b></span></p> </td>
      <td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
      <td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
      <td colspan="6" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><span style="color:#333333;"><b><em style="font: inherit;"><em style="font: inherit;">Six Months Ended</em></em></b></span></p> </td>
      <td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
     </tr>

     <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom">
      <td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
      <td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
      <td colspan="6" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><span style="color:#333333;"><b><em style="font: inherit;"><em style="font: inherit;">June 30,</em></em></b></span></p> </td>
      <td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
      <td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
      <td colspan="6" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><span style="color:#333333;"><b><em style="font: inherit;"><em style="font: inherit;">June 30,</em></em></b></span></p> </td>
      <td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
     </tr>

     <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom">
      <td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
      <td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
      <td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><span style="color:#333333;"><b><em style="font: inherit;">2022</em></b></span></p> </td>
      <td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&#xa0;</td>
      <td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
      <td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><span style="color:#333333;"><b><em style="font: inherit;">2021</em></b></span></p> </td>
      <td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&#xa0;</td>
      <td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
      <td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><span style="color:#333333;"><b><em style="font: inherit;">2022</em></b></span></p> </td>
      <td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&#xa0;</td>
      <td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
      <td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><span style="color:#333333;"><b><em style="font: inherit;">2021</em></b></span></p> </td>
      <td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&#xa0;</td>
     </tr>

     <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom">
      <td>&#xa0;</td>
      <td>&#xa0;</td>
      <td>&#xa0;</td>
      <td>&#xa0;</td>
      <td>&#xa0;</td>
      <td>&#xa0;</td>
      <td>&#xa0;</td>
      <td>&#xa0;</td>
      <td>&#xa0;</td>
      <td>&#xa0;</td>
      <td>&#xa0;</td>
      <td>&#xa0;</td>
      <td>&#xa0;</td>
      <td>&#xa0;</td>
      <td>&#xa0;</td>
      <td>&#xa0;</td>
      <td>&#xa0;</td>
     </tr>

     <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom">
      <td style="font-family: Times New Roman; font-size: 10pt; width: 52%;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;"><span style="color:#333333;">Expenses:</span></p> </td>
      <td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
      <td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
      <td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
      <td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
      <td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
      <td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
      <td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
      <td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
      <td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
      <td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
      <td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
      <td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
      <td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
      <td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
      <td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
      <td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
     </tr>

     <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom">
      <td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 18pt;"><span style="color:#333333;">Research and development</span></p> </td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><span style="color:#333333;">$</span></td>
      <td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><span style="color:#333333;"><ix:nonFraction id="c86424756" contextRef="d_2022-04-01_2022-06-30" unitRef="USD" name="us-gaap:ResearchAndDevelopmentExpense" scale="3" format="ixt:numdotdecimal" decimals="-3">2,995</ix:nonFraction></span></td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#xa0;</td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><span style="color:#333333;">$</span></td>
      <td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><span style="color:#333333;"><ix:nonFraction id="c86424757" contextRef="d_2021-04-01_2021-06-30" unitRef="USD" name="us-gaap:ResearchAndDevelopmentExpense" scale="3" format="ixt:numdotdecimal" decimals="-3">4,221</ix:nonFraction></span></td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#xa0;</td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><span style="color:#333333;">$</span></td>
      <td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><span style="color:#333333;"><ix:nonFraction id="c86424758" contextRef="d_2022-01-01_2022-06-30" unitRef="USD" name="us-gaap:ResearchAndDevelopmentExpense" scale="3" format="ixt:numdotdecimal" decimals="-4">8,340</ix:nonFraction></span></td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#xa0;</td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><span style="color:#333333;">$</span></td>
      <td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><span style="color:#333333;"><ix:nonFraction id="c86424759" contextRef="d_2021-01-01_2021-06-30" unitRef="USD" name="us-gaap:ResearchAndDevelopmentExpense" scale="3" format="ixt:numdotdecimal" decimals="-3">8,631</ix:nonFraction></span></td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#xa0;</td>
     </tr>

     <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom">
      <td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 18pt;"><span style="color:#333333;">General and administrative</span></p> </td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
      <td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><span style="color:#333333;"><ix:nonFraction id="c86424760" contextRef="d_2022-04-01_2022-06-30" unitRef="USD" name="us-gaap:SellingGeneralAndAdministrativeExpense" scale="3" format="ixt:numdotdecimal" decimals="-3">2,907</ix:nonFraction></span></td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#xa0;</td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
      <td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><span style="color:#333333;"><ix:nonFraction id="c86424761" contextRef="d_2021-04-01_2021-06-30" unitRef="USD" name="us-gaap:SellingGeneralAndAdministrativeExpense" scale="3" format="ixt:numdotdecimal" decimals="-3">3,371</ix:nonFraction></span></td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#xa0;</td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
      <td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><span style="color:#333333;"><ix:nonFraction id="c86424762" contextRef="d_2022-01-01_2022-06-30" unitRef="USD" name="us-gaap:SellingGeneralAndAdministrativeExpense" scale="3" format="ixt:numdotdecimal" decimals="-3">5,895</ix:nonFraction></span></td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#xa0;</td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
      <td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><span style="color:#333333;"><ix:nonFraction id="c86424763" contextRef="d_2021-01-01_2021-06-30" unitRef="USD" name="us-gaap:SellingGeneralAndAdministrativeExpense" scale="3" format="ixt:numdotdecimal" decimals="-4">8,040</ix:nonFraction></span></td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#xa0;</td>
     </tr>

     <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom">
      <td style="font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"> <p style="margin-top: 0pt; margin-bottom: 0pt; text-indent: 18pt;"><span style="color:#333333;">Loss on impairment of goodwill</span></p> </td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">&#xa0;</td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">&#xa0;</td>
      <td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"><span style="color:#333333;"><ix:nonFraction id="c86424764" contextRef="d_2022-04-01_2022-06-30" unitRef="USD" name="us-gaap:GoodwillImpairmentLoss" scale="3" format="ixt:numdotdecimal" decimals="-3">11,636</ix:nonFraction></span></td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">&#xa0;</td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">&#xa0;</td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">&#xa0;</td>
      <td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"><span style="color:#333333;"><ix:nonFraction id="c86424765" contextRef="d_2021-04-01_2021-06-30" unitRef="USD" name="us-gaap:GoodwillImpairmentLoss" scale="3" format="ixt:zerodash" decimals="-3">-</ix:nonFraction></span></td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">&#xa0;</td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">&#xa0;</td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">&#xa0;</td>
      <td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"><span style="color:#333333;"><ix:nonFraction id="c86424766" contextRef="d_2022-01-01_2022-06-30" unitRef="USD" name="us-gaap:GoodwillImpairmentLoss" scale="3" format="ixt:numdotdecimal" decimals="-3">11,636</ix:nonFraction></span></td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">&#xa0;</td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">&#xa0;</td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">&#xa0;</td>
      <td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"><span style="color:#333333;"><ix:nonFraction id="c86424767" contextRef="d_2021-01-01_2021-06-30" unitRef="USD" name="us-gaap:GoodwillImpairmentLoss" scale="3" format="ixt:zerodash" decimals="-3">-</ix:nonFraction></span></td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">&#xa0;</td>
     </tr>

     <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom">
      <td style="font-family: Times New Roman; font-size: 10pt; padding-top: 0px; padding-right: 0px; padding-left: 0px; margin: 0px;"> <p style="margin-top: 0pt; margin-bottom: 0pt; text-indent: 18pt;"><span style="color:#333333;">Loss on impairment of intangible assets</span></p> </td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0px 0px 1px; margin: 0px;">&#xa0;</td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-top: 0px; padding-right: 0px; padding-left: 0px; margin: 0px; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td>
      <td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; padding-top: 0px; padding-right: 0px; padding-left: 0px; margin: 0px; border-bottom: 1px solid rgb(0, 0, 0);"><span style="color:#333333;"><ix:nonFraction id="c86424768" contextRef="d_2022-04-01_2022-06-30" unitRef="USD" name="us-gaap:ImpairmentOfIntangibleAssetsExcludingGoodwill" scale="3" format="ixt:zerodash" decimals="-3">-</ix:nonFraction></span></td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0px 0px 1px; margin: 0px;">&#xa0;</td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0px 0px 1px; margin: 0px;">&#xa0;</td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-top: 0px; padding-right: 0px; padding-left: 0px; margin: 0px; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td>
      <td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; padding-top: 0px; padding-right: 0px; padding-left: 0px; margin: 0px; border-bottom: 1px solid rgb(0, 0, 0);"><span style="color:#333333;"><ix:nonFraction id="c86424769" contextRef="d_2021-04-01_2021-06-30" unitRef="USD" name="us-gaap:ImpairmentOfIntangibleAssetsExcludingGoodwill" scale="3" format="ixt:numdotdecimal" decimals="-4">37,770</ix:nonFraction></span></td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0px 0px 1px; margin: 0px;">&#xa0;</td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0px 0px 1px; margin: 0px;">&#xa0;</td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-top: 0px; padding-right: 0px; padding-left: 0px; margin: 0px; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td>
      <td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; padding-top: 0px; padding-right: 0px; padding-left: 0px; margin: 0px; border-bottom: 1px solid rgb(0, 0, 0);"><span style="color:#333333;"><ix:nonFraction id="c86424770" contextRef="d_2022-01-01_2022-06-30" unitRef="USD" name="us-gaap:ImpairmentOfIntangibleAssetsExcludingGoodwill" scale="3" format="ixt:zerodash" decimals="-3">-</ix:nonFraction></span></td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0px 0px 1px; margin: 0px;">&#xa0;</td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0px 0px 1px; margin: 0px;">&#xa0;</td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-top: 0px; padding-right: 0px; padding-left: 0px; margin: 0px; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td>
      <td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; padding-top: 0px; padding-right: 0px; padding-left: 0px; margin: 0px; border-bottom: 1px solid rgb(0, 0, 0);"><span style="color:#333333;"><ix:nonFraction id="c86424771" contextRef="d_2021-01-01_2021-06-30" unitRef="USD" name="us-gaap:ImpairmentOfIntangibleAssetsExcludingGoodwill" scale="3" format="ixt:numdotdecimal" decimals="-4">37,770</ix:nonFraction></span></td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0px 0px 1px; margin: 0px;">&#xa0;</td>
     </tr>

     <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom">
      <td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 36pt;"><span style="color:#333333;">Total operating expenses</span></p> </td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td>
      <td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><span style="color:#333333;"><ix:nonFraction id="c86424772" contextRef="d_2022-04-01_2022-06-30" unitRef="USD" name="us-gaap:OperatingExpenses" scale="3" format="ixt:numdotdecimal" decimals="-3">17,538</ix:nonFraction></span></td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#xa0;</td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td>
      <td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><span style="color:#333333;"><ix:nonFraction id="c86424773" contextRef="d_2021-04-01_2021-06-30" unitRef="USD" name="us-gaap:OperatingExpenses" scale="3" format="ixt:numdotdecimal" decimals="-3">45,362</ix:nonFraction></span></td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#xa0;</td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td>
      <td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><span style="color:#333333;"><ix:nonFraction id="c86424774" contextRef="d_2022-01-01_2022-06-30" unitRef="USD" name="us-gaap:OperatingExpenses" scale="3" format="ixt:numdotdecimal" decimals="-3">25,871</ix:nonFraction></span></td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#xa0;</td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td>
      <td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><span style="color:#333333;"><ix:nonFraction id="c86424775" contextRef="d_2021-01-01_2021-06-30" unitRef="USD" name="us-gaap:OperatingExpenses" scale="3" format="ixt:numdotdecimal" decimals="-3">54,441</ix:nonFraction></span></td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#xa0;</td>
     </tr>

     <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom">
      <td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;"><span style="color:#333333;">Operating loss</span></p> </td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
      <td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><span style="color:#333333;">(<ix:nonFraction id="c86424776" contextRef="d_2022-04-01_2022-06-30" unitRef="USD" name="us-gaap:OperatingIncomeLoss" scale="3" format="ixt:numdotdecimal" decimals="-3" sign="-">17,538</ix:nonFraction></span></td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><span style="color:#333333;">)</span></td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
      <td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><span style="color:#333333;">(<ix:nonFraction id="c86424777" contextRef="d_2021-04-01_2021-06-30" unitRef="USD" name="us-gaap:OperatingIncomeLoss" scale="3" format="ixt:numdotdecimal" decimals="-3" sign="-">45,362</ix:nonFraction></span></td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><span style="color:#333333;">)</span></td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
      <td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><span style="color:#333333;">(<ix:nonFraction id="c86424778" contextRef="d_2022-01-01_2022-06-30" unitRef="USD" name="us-gaap:OperatingIncomeLoss" scale="3" format="ixt:numdotdecimal" decimals="-3" sign="-">25,871</ix:nonFraction></span></td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><span style="color:#333333;">)</span></td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
      <td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><span style="color:#333333;">(<ix:nonFraction id="c86424779" contextRef="d_2021-01-01_2021-06-30" unitRef="USD" name="us-gaap:OperatingIncomeLoss" scale="3" format="ixt:numdotdecimal" decimals="-3" sign="-">54,441</ix:nonFraction></span></td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><span style="color:#333333;">)</span></td>
     </tr>

     <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom">
      <td>&#xa0;</td>
      <td>&#xa0;</td>
      <td>&#xa0;</td>
      <td>&#xa0;</td>
      <td>&#xa0;</td>
      <td>&#xa0;</td>
      <td>&#xa0;</td>
      <td>&#xa0;</td>
      <td>&#xa0;</td>
      <td>&#xa0;</td>
      <td>&#xa0;</td>
      <td>&#xa0;</td>
      <td>&#xa0;</td>
      <td>&#xa0;</td>
      <td>&#xa0;</td>
      <td>&#xa0;</td>
      <td>&#xa0;</td>
     </tr>

     <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom">
      <td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;"><span style="color:#333333;">Other income (expense):</span></p> </td>
      <td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
      <td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
      <td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
      <td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
      <td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
      <td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
      <td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
      <td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
      <td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
      <td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
      <td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
      <td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
      <td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
      <td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
      <td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
      <td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
     </tr>

     <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom">
      <td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 18pt;"><span style="color:#333333;">Interest income</span></p> </td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
      <td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><span style="color:#333333;"><ix:nonFraction id="c86424781" contextRef="d_2022-04-01_2022-06-30" unitRef="USD" name="us-gaap:InvestmentIncomeInterest" scale="3" format="ixt:numdotdecimal" decimals="-3">17</ix:nonFraction></span></td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#xa0;</td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
      <td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><span style="color:#333333;"><ix:nonFraction id="c86424782" contextRef="d_2021-04-01_2021-06-30" unitRef="USD" name="us-gaap:InvestmentIncomeInterest" scale="3" format="ixt:numdotdecimal" decimals="-3">39</ix:nonFraction></span></td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#xa0;</td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
      <td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><span style="color:#333333;"><ix:nonFraction id="c86424783" contextRef="d_2022-01-01_2022-06-30" unitRef="USD" name="us-gaap:InvestmentIncomeInterest" scale="3" format="ixt:numdotdecimal" decimals="-3">18</ix:nonFraction></span></td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#xa0;</td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
      <td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><span style="color:#333333;"><ix:nonFraction id="c86424784" contextRef="d_2021-01-01_2021-06-30" unitRef="USD" name="us-gaap:InvestmentIncomeInterest" scale="3" format="ixt:numdotdecimal" decimals="-3">89</ix:nonFraction></span></td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#xa0;</td>
     </tr>

     <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom">
      <td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 18pt;"><span style="color:#333333;">Interest expense</span></p> </td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
      <td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><span style="color:#333333;">(<ix:nonFraction id="c86424785" contextRef="d_2022-04-01_2022-06-30" unitRef="USD" name="us-gaap:InterestExpense" scale="3" format="ixt:numdotdecimal" decimals="-3">13</ix:nonFraction></span></td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><span style="color:#333333;">)</span></td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
      <td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><span style="color:#333333;">(<ix:nonFraction id="c86424786" contextRef="d_2021-04-01_2021-06-30" unitRef="USD" name="us-gaap:InterestExpense" scale="3" format="ixt:numdotdecimal" decimals="-3">46</ix:nonFraction></span></td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><span style="color:#333333;">)</span></td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
      <td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><span style="color:#333333;">(<ix:nonFraction id="c86424787" contextRef="d_2022-01-01_2022-06-30" unitRef="USD" name="us-gaap:InterestExpense" scale="3" format="ixt:numdotdecimal" decimals="-3">26</ix:nonFraction></span></td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><span style="color:#333333;">)</span></td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
      <td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><span style="color:#333333;">(<ix:nonFraction id="c86424788" contextRef="d_2021-01-01_2021-06-30" unitRef="USD" name="us-gaap:InterestExpense" scale="3" format="ixt:numdotdecimal" decimals="-3">87</ix:nonFraction></span></td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><span style="color:#333333;">)</span></td>
     </tr>

     <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom">
      <td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 18pt;"><span style="color:#333333;">Other income (expense), net</span></p> </td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td>
      <td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><span style="color:#333333;"><ix:nonFraction id="c86424789" contextRef="d_2022-04-01_2022-06-30" unitRef="USD" name="us-gaap:OtherNonoperatingIncomeExpense" scale="3" format="ixt:numdotdecimal" decimals="-3">201</ix:nonFraction></span></td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#xa0;</td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td>
      <td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><span style="color:#333333;">(<ix:nonFraction id="c86424790" contextRef="d_2021-04-01_2021-06-30" unitRef="USD" name="us-gaap:OtherNonoperatingIncomeExpense" scale="3" format="ixt:numdotdecimal" decimals="-3" sign="-">352</ix:nonFraction></span></td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"><span style="color:#333333;">)</span></td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td>
      <td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><span style="color:#333333;"><ix:nonFraction id="c86424791" contextRef="d_2022-01-01_2022-06-30" unitRef="USD" name="us-gaap:OtherNonoperatingIncomeExpense" scale="3" format="ixt:numdotdecimal" decimals="-3">419</ix:nonFraction></span></td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#xa0;</td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td>
      <td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><span style="color:#333333;">(<ix:nonFraction id="c86424792" contextRef="d_2021-01-01_2021-06-30" unitRef="USD" name="us-gaap:OtherNonoperatingIncomeExpense" scale="3" format="ixt:numdotdecimal" decimals="-3" sign="-">243</ix:nonFraction></span></td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"><span style="color:#333333;">)</span></td>
     </tr>

     <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom">
      <td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 36pt;"><span style="color:#333333;">Total other income (expense), net</span></p> </td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td>
      <td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><span style="color:#333333;"><ix:nonFraction id="c86424793" contextRef="d_2022-04-01_2022-06-30" unitRef="USD" name="us-gaap:NonoperatingIncomeExpense" scale="3" format="ixt:numdotdecimal" decimals="-3">205</ix:nonFraction></span></td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#xa0;</td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td>
      <td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><span style="color:#333333;">(<ix:nonFraction id="c86424794" contextRef="d_2021-04-01_2021-06-30" unitRef="USD" name="us-gaap:NonoperatingIncomeExpense" scale="3" format="ixt:numdotdecimal" decimals="-3" sign="-">359</ix:nonFraction></span></td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"><span style="color:#333333;">)</span></td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td>
      <td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><span style="color:#333333;"><ix:nonFraction id="c86424795" contextRef="d_2022-01-01_2022-06-30" unitRef="USD" name="us-gaap:NonoperatingIncomeExpense" scale="3" format="ixt:numdotdecimal" decimals="-3">411</ix:nonFraction></span></td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#xa0;</td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td>
      <td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><span style="color:#333333;">(<ix:nonFraction id="c86424796" contextRef="d_2021-01-01_2021-06-30" unitRef="USD" name="us-gaap:NonoperatingIncomeExpense" scale="3" format="ixt:numdotdecimal" decimals="-3" sign="-">241</ix:nonFraction></span></td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"><span style="color:#333333;">)</span></td>
     </tr>

     <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom">
      <td>&#xa0;</td>
      <td>&#xa0;</td>
      <td>&#xa0;</td>
      <td>&#xa0;</td>
      <td>&#xa0;</td>
      <td>&#xa0;</td>
      <td>&#xa0;</td>
      <td>&#xa0;</td>
      <td>&#xa0;</td>
      <td>&#xa0;</td>
      <td>&#xa0;</td>
      <td>&#xa0;</td>
      <td>&#xa0;</td>
      <td>&#xa0;</td>
      <td>&#xa0;</td>
      <td>&#xa0;</td>
      <td>&#xa0;</td>
     </tr>

     <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom">
      <td style="font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"> <p style="margin-top: 0pt; margin-bottom: 0pt"><span style="color:#333333;">Loss before income taxes</span></p> </td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">&#xa0;</td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">&#xa0;</td>
      <td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"><span style="color:#333333;">(<ix:nonFraction id="c86424797" contextRef="d_2022-04-01_2022-06-30" unitRef="USD" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" scale="3" format="ixt:numdotdecimal" decimals="-3" sign="-">17,333</ix:nonFraction></span></td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"><span style="color:#333333;">)</span></td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">&#xa0;</td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">&#xa0;</td>
      <td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"><span style="color:#333333;">(<ix:nonFraction id="c86424798" contextRef="d_2021-04-01_2021-06-30" unitRef="USD" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" scale="3" format="ixt:numdotdecimal" decimals="-3" sign="-">45,721</ix:nonFraction></span></td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"><span style="color:#333333;">)</span></td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">&#xa0;</td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">&#xa0;</td>
      <td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"><span style="color:#333333;">(<ix:nonFraction id="c86424799" contextRef="d_2022-01-01_2022-06-30" unitRef="USD" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" scale="3" format="ixt:numdotdecimal" decimals="-4" sign="-">25,460</ix:nonFraction></span></td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"><span style="color:#333333;">)</span></td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">&#xa0;</td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">&#xa0;</td>
      <td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"><span style="color:#333333;">(<ix:nonFraction id="c86424800" contextRef="d_2021-01-01_2021-06-30" unitRef="USD" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" scale="3" format="ixt:numdotdecimal" decimals="-3" sign="-">54,682</ix:nonFraction></span></td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"><span style="color:#333333;">)</span></td>
     </tr>

     <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom">
      <td style="font-family: Times New Roman; font-size: 10pt; padding-top: 0px; padding-right: 0px; padding-left: 0px; margin: 0px;"> <p style="margin-top: 0pt; margin-bottom: 0pt"><span style="color:#333333;">Deferred income tax benefit</span></p> </td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0px 0px 1px; margin: 0px;">&#xa0;</td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-top: 0px; padding-right: 0px; padding-left: 0px; margin: 0px; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td>
      <td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; padding-top: 0px; padding-right: 0px; padding-left: 0px; margin: 0px; border-bottom: 1px solid rgb(0, 0, 0);"><span style="color:#333333;"><ix:nonFraction id="c86424801" contextRef="d_2022-04-01_2022-06-30" unitRef="USD" name="us-gaap:IncomeTaxExpenseBenefit" scale="3" format="ixt:zerodash" decimals="-3" sign="-">-</ix:nonFraction></span></td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0px 0px 1px; margin: 0px;">&#xa0;</td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0px 0px 1px; margin: 0px;">&#xa0;</td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-top: 0px; padding-right: 0px; padding-left: 0px; margin: 0px; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td>
      <td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; padding-top: 0px; padding-right: 0px; padding-left: 0px; margin: 0px; border-bottom: 1px solid rgb(0, 0, 0);"><span style="color:#333333;"><ix:nonFraction id="c86424802" contextRef="d_2021-04-01_2021-06-30" unitRef="USD" name="us-gaap:IncomeTaxExpenseBenefit" scale="3" format="ixt:numdotdecimal" decimals="-3" sign="-">8,332</ix:nonFraction></span></td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0px 0px 1px; margin: 0px;">&#xa0;</td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0px 0px 1px; margin: 0px;">&#xa0;</td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-top: 0px; padding-right: 0px; padding-left: 0px; margin: 0px; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td>
      <td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; padding-top: 0px; padding-right: 0px; padding-left: 0px; margin: 0px; border-bottom: 1px solid rgb(0, 0, 0);"><span style="color:#333333;"><ix:nonFraction id="c86424803" contextRef="d_2022-01-01_2022-06-30" unitRef="USD" name="us-gaap:IncomeTaxExpenseBenefit" scale="3" format="ixt:zerodash" decimals="-3" sign="-">-</ix:nonFraction></span></td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0px 0px 1px; margin: 0px;">&#xa0;</td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0px 0px 1px; margin: 0px;">&#xa0;</td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-top: 0px; padding-right: 0px; padding-left: 0px; margin: 0px; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td>
      <td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; padding-top: 0px; padding-right: 0px; padding-left: 0px; margin: 0px; border-bottom: 1px solid rgb(0, 0, 0);"><span style="color:#333333;"><ix:nonFraction id="c86424804" contextRef="d_2021-01-01_2021-06-30" unitRef="USD" name="us-gaap:IncomeTaxExpenseBenefit" scale="3" format="ixt:numdotdecimal" decimals="-3" sign="-">8,332</ix:nonFraction></span></td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0px 0px 1px; margin: 0px;">&#xa0;</td>
     </tr>

     <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom">
      <td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;"><span style="color:#333333;">Net loss</span></p> </td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><span style="color:#333333;">$</span></td>
      <td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><span style="color:#333333;">(<ix:nonFraction id="c86424805" contextRef="d_2022-04-01_2022-06-30" unitRef="USD" name="us-gaap:NetIncomeLoss" scale="3" format="ixt:numdotdecimal" decimals="-3" sign="-">17,333</ix:nonFraction></span></td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;"><span style="color:#333333;">)</span></td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><span style="color:#333333;">$</span></td>
      <td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><span style="color:#333333;">(<ix:nonFraction id="c86424806" contextRef="d_2021-04-01_2021-06-30" unitRef="USD" name="us-gaap:NetIncomeLoss" scale="3" format="ixt:numdotdecimal" decimals="-3" sign="-">37,389</ix:nonFraction></span></td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;"><span style="color:#333333;">)</span></td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><span style="color:#333333;">$</span></td>
      <td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><span style="color:#333333;">(<ix:nonFraction id="c86424807" contextRef="d_2022-01-01_2022-06-30" unitRef="USD" name="us-gaap:NetIncomeLoss" scale="3" format="ixt:numdotdecimal" decimals="-4" sign="-">25,460</ix:nonFraction></span></td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"><span style="color:#333333;">)</span></td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><span style="color:#333333;">$</span></td>
      <td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><span style="color:#333333;">(<ix:nonFraction id="c86424808" contextRef="d_2021-01-01_2021-06-30" unitRef="USD" name="us-gaap:NetIncomeLoss" scale="3" format="ixt:numdotdecimal" decimals="-4" sign="-">46,350</ix:nonFraction></span></td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"><span style="color:#333333;">)</span></td>
     </tr>

     <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom">
      <td>&#xa0;</td>
      <td>&#xa0;</td>
      <td>&#xa0;</td>
      <td>&#xa0;</td>
      <td>&#xa0;</td>
      <td>&#xa0;</td>
      <td>&#xa0;</td>
      <td>&#xa0;</td>
      <td>&#xa0;</td>
      <td>&#xa0;</td>
      <td>&#xa0;</td>
      <td>&#xa0;</td>
      <td>&#xa0;</td>
      <td>&#xa0;</td>
      <td>&#xa0;</td>
      <td>&#xa0;</td>
      <td>&#xa0;</td>
     </tr>

     <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom">
      <td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;"><span style="color:#333333;">Net loss per common share</span></p> </td>
      <td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
      <td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
      <td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
      <td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
      <td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
      <td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
      <td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
      <td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
      <td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
      <td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
      <td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
      <td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
      <td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
      <td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
      <td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
      <td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
     </tr>

     <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom">
      <td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 18pt;"><span style="color:#333333;">Basic and diluted</span></p> </td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"><span style="color:#333333;">$</span></td>
      <td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><span style="color:#333333;">(<ix:nonFraction id="c86424810" contextRef="d_2022-04-01_2022-06-30" unitRef="USDPerShare" name="us-gaap:EarningsPerShareBasic" scale="0" format="ixt:numdotdecimal" decimals="INF" sign="-">0.59</ix:nonFraction></span></td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><span style="color:#333333;">)</span></td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"><span style="color:#333333;">$</span></td>
      <td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><span style="color:#333333;">(<ix:nonFraction id="c86424811" contextRef="d_2021-04-01_2021-06-30" unitRef="USDPerShare" name="us-gaap:EarningsPerShareBasic" scale="0" format="ixt:numdotdecimal" decimals="INF" sign="-">1.42</ix:nonFraction></span></td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><span style="color:#333333;">)</span></td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"><span style="color:#333333;">$</span></td>
      <td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><span style="color:#333333;">(<ix:nonFraction id="c86424812" contextRef="d_2022-01-01_2022-06-30" unitRef="USDPerShare" name="us-gaap:EarningsPerShareBasic" scale="0" format="ixt:numdotdecimal" decimals="INF" sign="-">0.87</ix:nonFraction></span></td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><span style="color:#333333;">)</span></td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"><span style="color:#333333;">$</span></td>
      <td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><span style="color:#333333;">(<ix:nonFraction id="c86424813" contextRef="d_2021-01-01_2021-06-30" unitRef="USDPerShare" name="us-gaap:EarningsPerShareBasic" scale="0" format="ixt:numdotdecimal" decimals="INF" sign="-">2.10</ix:nonFraction></span></td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><span style="color:#333333;">)</span></td>
     </tr>

     <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom">
      <td>&#xa0;</td>
      <td>&#xa0;</td>
      <td>&#xa0;</td>
      <td>&#xa0;</td>
      <td>&#xa0;</td>
      <td>&#xa0;</td>
      <td>&#xa0;</td>
      <td>&#xa0;</td>
      <td>&#xa0;</td>
      <td>&#xa0;</td>
      <td>&#xa0;</td>
      <td>&#xa0;</td>
      <td>&#xa0;</td>
      <td>&#xa0;</td>
      <td>&#xa0;</td>
      <td>&#xa0;</td>
      <td>&#xa0;</td>
     </tr>

     <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom">
      <td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;"><span style="color:#333333;">Weighted average number of common shares outstanding</span></p> </td>
      <td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
      <td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
      <td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
      <td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
      <td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
      <td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
      <td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
      <td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
      <td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
      <td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
      <td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
      <td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
      <td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
      <td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
      <td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
      <td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
     </tr>

     <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom">
      <td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 18pt;"><span style="color:#333333;">Basic and diluted</span></p> </td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#xa0;</td>
      <td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><span style="color:#333333;"><ix:nonFraction id="c86424815" contextRef="d_2022-04-01_2022-06-30" unitRef="Share" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="3" format="ixt:numdotdecimal" decimals="-5">29,200</ix:nonFraction></span></td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#xa0;</td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#xa0;</td>
      <td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><span style="color:#333333;"><ix:nonFraction id="c86424816" contextRef="d_2021-04-01_2021-06-30" unitRef="Share" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="3" format="ixt:numdotdecimal" decimals="-4">26,350</ix:nonFraction></span></td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#xa0;</td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#xa0;</td>
      <td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><span style="color:#333333;"><ix:nonFraction id="c86424817" contextRef="d_2022-01-01_2022-06-30" unitRef="Share" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="3" format="ixt:numdotdecimal" decimals="-3">29,236</ix:nonFraction></span></td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#xa0;</td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#xa0;</td>
      <td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><span style="color:#333333;"><ix:nonFraction id="c86424818" contextRef="d_2021-01-01_2021-06-30" unitRef="Share" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="3" format="ixt:numdotdecimal" decimals="-3">22,047</ix:nonFraction></span></td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#xa0;</td>
     </tr>

    </tbody>
   </table>
  </div>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&#xa0;</p>
  <table border="0" cellpadding="0" cellspacing="0" style="width:100%;text-indent:0;font-family:'Times New Roman', Times, serif;font-size:10pt;">
   <tbody>
    <tr>
     <td style="vertical-align:bottom;width:100%;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><span style="color:#333333;"><i>See notes to condensed consolidated financial statements</i></span></p> </td>
    </tr>

   </tbody>
  </table>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&#xa0;</p>
  <div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
   <div class="PGFTR" style="text-align: center; width: 100%">
    <div class="hf-row">
     <div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">
       5
     </div>
    </div>
   </div>
   <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000" />
   <div class="PGHDR" style="text-align: left; width: 100%">
    <div class="hf-row">
     <div class="hf-cell TOCLink" style="display: inline-block; text-align: left;">
      <a href="#toc" style="font-weight: initial; font-style: initial; font-variant: initial; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif;">Table of Contents</a>
     </div>
     <div class="hf-cell TOCLink" style="display: inline-block; text-align: left;">
       &#xa0;
     </div>
     <div class="hf-cell TOCLink" style="display: inline-block; text-align: left;">
       &#xa0;
     </div>
     <div class="hf-cell TOCLink" style="display: inline-block; text-align: left;">
       &#xa0;
     </div>
     <div class="hf-cell TOCLink" style="display: inline-block; text-align: left;">
       &#xa0;
     </div>
    </div>
   </div>
  </div>
  <div>
    &#xa0;
  </div>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&#xa0;</p>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><span style="color:#333333;"><b><a id="Equity" title="Equity" href="#"></a>WINDTREE THERAPEUTICS, INC. AND SUBSIDIARIES </b></span></p>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><span style="color:#333333;"><b>Condensed Consolidated Statements of Changes in Stockholders&#x2019;&#xa0;Equity</b></span></p>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><span style="color:#333333;">(Unaudited)</span></p>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&#xa0;</p>
  <table border="0" cellpadding="0" cellspacing="0" style="width:100%;text-indent:0;font-family:'Times New Roman', Times, serif;font-size:10pt;">
   <tbody>
    <tr>
     <td style="vertical-align:bottom;width:100%;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><span style="color:#333333;"><i>(in thousands)</i></span></p> </td>
    </tr>

   </tbody>
  </table>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&#xa0;</p>
  <div>
   <table cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 9pt; text-indent: 0px; margin-left: 0pt; margin-right: 0pt;">
    <tbody>
     <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom">
      <td style="font-size: 9pt;">&#xa0;</td>
      <td style="font-size: 9pt;">&#xa0;</td>
      <td colspan="6" style="text-align: center; font-size: 9pt; margin-left: 0pt; border-bottom: thin solid rgb(0, 0, 0);"> <p style="font-size: 9pt; margin: 0; font-family: &quot;Times New Roman&quot;, Times, serif"><span style="color:#333333;"><b><em style="font: inherit;"><em style="font: inherit;">Common Stock</em></em></b></span></p> </td>
      <td style="font-size: 9pt;">&#xa0;</td>
      <td style="font-size: 9pt;">&#xa0;</td>
      <td style="font-size: 9pt;">&#xa0;</td>
      <td style="text-align: center; font-size: 9pt;"><em style="font: inherit;">&#xa0;</em></td>
      <td style="font-size: 9pt;"><span style="color:#333333;"><b>&#xa0;</b></span></td>
      <td style="font-size: 9pt;">&#xa0;</td>
      <td style="font-size: 9pt;">&#xa0;</td>
      <td style="text-align: center; font-size: 9pt;"><em style="font: inherit;">&#xa0;</em></td>
      <td style="font-size: 9pt;"><span style="color:#333333;"><b>&#xa0;</b></span></td>
      <td style="font-size: 9pt;">&#xa0;</td>
      <td colspan="6" style="text-align: center; font-size: 9pt; margin-left: 0pt; border-bottom: thin solid rgb(0, 0, 0);"> <p style="font-size: 9pt; margin: 0; font-family: &quot;Times New Roman&quot;, Times, serif"><span style="color:#333333;"><b><em style="font: inherit;"><em style="font: inherit;">Treasury Stock</em></em></b></span></p> </td>
      <td style="font-size: 9pt;">&#xa0;</td>
      <td style="font-size: 9pt;">&#xa0;</td>
      <td style="font-size: 9pt;">&#xa0;</td>
      <td style="text-align: center; font-size: 9pt;"><em style="font: inherit;">&#xa0;</em></td>
      <td style="font-size: 9pt;"><span style="color:#333333;"><b>&#xa0;</b></span></td>
     </tr>

     <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom">
      <td style="font-size: 9pt;">&#xa0;</td>
      <td style="font-size: 9pt; padding-bottom: 1px;">&#xa0;</td>
      <td colspan="2" style="text-align: center; font-size: 9pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-size: 9pt; margin: 0; font-family: &quot;Times New Roman&quot;, Times, serif"><span style="color:#333333;"><b><em style="font: inherit;">Shares</em></b></span></p> </td>
      <td style="font-size: 9pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td>
      <td style="font-size: 9pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td>
      <td colspan="2" style="text-align: center; font-size: 9pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-size: 9pt; margin: 0; font-family: &quot;Times New Roman&quot;, Times, serif"><span style="color:#333333;"><b><em style="font: inherit;">Amount</em></b></span></p> </td>
      <td style="font-size: 9pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td>
      <td style="font-size: 9pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td>
      <td colspan="2" style="text-align: center; font-size: 9pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-size: 9pt; margin: 0; font-family: &quot;Times New Roman&quot;, Times, serif"><span style="color:#333333;"><b><em style="font: inherit;">Additional Paid-in Capital</em></b></span></p> </td>
      <td style="font-size: 9pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td>
      <td style="font-size: 9pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td>
      <td colspan="2" style="text-align: center; font-size: 9pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-size: 9pt; margin: 0; font-family: &quot;Times New Roman&quot;, Times, serif"><span style="color:#333333;"><b><em style="font: inherit;">Accumulated Deficit</em></b></span></p> </td>
      <td style="font-size: 9pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td>
      <td style="font-size: 9pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td>
      <td colspan="2" style="text-align: center; font-size: 9pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-size: 9pt; margin: 0; font-family: &quot;Times New Roman&quot;, Times, serif"><span style="color:#333333;"><b><em style="font: inherit;">Shares</em></b></span></p> </td>
      <td style="font-size: 9pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td>
      <td style="font-size: 9pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td>
      <td colspan="2" style="text-align: center; font-size: 9pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-size: 9pt; margin: 0; font-family: &quot;Times New Roman&quot;, Times, serif"><span style="color:#333333;"><b><em style="font: inherit;">Amount</em></b></span></p> </td>
      <td style="font-size: 9pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td>
      <td style="font-size: 9pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td>
      <td colspan="2" style="text-align: center; font-size: 9pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-size: 9pt; margin: 0; font-family: &quot;Times New Roman&quot;, Times, serif"><span style="color:#333333;"><b><em style="font: inherit;">Total</em></b></span></p> </td>
      <td style="font-size: 9pt; padding-bottom: 1px;">&#xa0;</td>
     </tr>

     <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom">
      <td style="font-size: 9pt;">&#xa0;</td>
      <td style="font-size: 9pt;">&#xa0;</td>
      <td style="font-size: 9pt;">&#xa0;</td>
      <td style="font-size: 9pt;">&#xa0;</td>
      <td style="font-size: 9pt;">&#xa0;</td>
      <td style="font-size: 9pt;">&#xa0;</td>
      <td style="font-size: 9pt;">&#xa0;</td>
      <td style="font-size: 9pt;">&#xa0;</td>
      <td style="font-size: 9pt;">&#xa0;</td>
      <td style="font-size: 9pt;">&#xa0;</td>
      <td style="font-size: 9pt;">&#xa0;</td>
      <td style="font-size: 9pt;">&#xa0;</td>
      <td style="font-size: 9pt;">&#xa0;</td>
      <td style="font-size: 9pt;">&#xa0;</td>
      <td style="font-size: 9pt;">&#xa0;</td>
      <td style="font-size: 9pt;">&#xa0;</td>
      <td style="font-size: 9pt;">&#xa0;</td>
      <td style="font-size: 9pt;">&#xa0;</td>
      <td style="font-size: 9pt;">&#xa0;</td>
      <td style="font-size: 9pt;">&#xa0;</td>
      <td style="font-size: 9pt;">&#xa0;</td>
      <td style="font-size: 9pt;">&#xa0;</td>
      <td style="font-size: 9pt;">&#xa0;</td>
      <td style="font-size: 9pt;">&#xa0;</td>
      <td style="font-size: 9pt;">&#xa0;</td>
      <td style="font-size: 9pt;">&#xa0;</td>
      <td style="font-size: 9pt;">&#xa0;</td>
      <td style="font-size: 9pt;">&#xa0;</td>
      <td style="font-size: 9pt;">&#xa0;</td>
     </tr>

     <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom">
      <td style="font-size: 9pt; width: 30%;"> <p style="font-size: 9pt; margin-top: 0; margin-bottom: 0; font-family: &quot;Times New Roman&quot;, Times, serif"><span style="color:#333333;"><b>Balance - December 31, 2020</b></span></p> </td>
      <td style="width: 1%; font-size: 9pt; padding-bottom: 1px;">&#xa0;</td>
      <td style="width: 1%; font-size: 9pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td>
      <td style="width: 7%; text-align: right; font-size: 9pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><span style="color:#333333;"><b><ix:nonFraction id="c86424833" contextRef="i_2020-12-31_StatementEquityComponentsAxis-CommonStockMember" unitRef="Share" name="us-gaap:SharesOutstanding" scale="3" format="ixt:numdotdecimal" decimals="-3">16,922</ix:nonFraction></b></span></td>
      <td style="width: 1%; font-size: 9pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td>
      <td style="width: 1%; font-size: 9pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td>
      <td style="width: 1%; font-size: 9pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><span style="color:#333333;">$</span></td>
      <td style="width: 7%; text-align: right; font-size: 9pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><span style="color:#333333;"><b><ix:nonFraction id="c86424834" contextRef="i_2020-12-31_StatementEquityComponentsAxis-CommonStockMember" unitRef="USD" name="us-gaap:StockholdersEquity" scale="3" format="ixt:numdotdecimal" decimals="-3">17</ix:nonFraction></b></span></td>
      <td style="width: 1%; font-size: 9pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td>
      <td style="width: 1%; font-size: 9pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td>
      <td style="width: 1%; font-size: 9pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><span style="color:#333333;">$</span></td>
      <td style="width: 7%; text-align: right; font-size: 9pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><span style="color:#333333;"><b><ix:nonFraction id="c86424835" contextRef="i_2020-12-31_StatementEquityComponentsAxis-AdditionalPaidInCapitalMember" unitRef="USD" name="us-gaap:StockholdersEquity" scale="3" format="ixt:numdotdecimal" decimals="-3">790,277</ix:nonFraction></b></span></td>
      <td style="width: 1%; font-size: 9pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td>
      <td style="width: 1%; font-size: 9pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td>
      <td style="width: 1%; font-size: 9pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><span style="color:#333333;">$</span></td>
      <td style="width: 7%; text-align: right; font-size: 9pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><span style="color:#333333;"><b>(<ix:nonFraction id="c86424836" contextRef="i_2020-12-31_StatementEquityComponentsAxis-RetainedEarningsMember" unitRef="USD" name="us-gaap:StockholdersEquity" scale="3" format="ixt:numdotdecimal" decimals="-3" sign="-">717,688</ix:nonFraction></b></span></td>
      <td style="width: 1%; font-size: 9pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><span style="color:#333333;"><b>)</b></span></td>
      <td style="width: 1%; font-size: 9pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td>
      <td style="width: 1%; font-size: 9pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td>
      <td style="width: 7%; text-align: right; font-size: 9pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><span style="color:#333333;"><b><em style="font: inherit;">-</em></b></span></td>
      <td style="width: 1%; font-size: 9pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td>
      <td style="width: 1%; font-size: 9pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td>
      <td style="width: 1%; font-size: 9pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><span style="color:#333333;">$</span></td>
      <td style="width: 7%; text-align: right; font-size: 9pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><span style="color:#333333;"><b>(<ix:nonFraction id="c86424838" contextRef="i_2020-12-31_StatementEquityComponentsAxis-TreasuryStockMember" unitRef="USD" name="us-gaap:StockholdersEquity" scale="3" format="ixt:numdotdecimal" decimals="-3" sign="-">3,054</ix:nonFraction></b></span></td>
      <td style="width: 1%; font-size: 9pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><span style="color:#333333;"><b>)</b></span></td>
      <td style="width: 1%; font-size: 9pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td>
      <td style="width: 1%; font-size: 9pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><span style="color:#333333;">$</span></td>
      <td style="width: 7%; text-align: right; font-size: 9pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><span style="color:#333333;"><b><ix:nonFraction id="c86424839" contextRef="i_2020-12-31" unitRef="USD" name="us-gaap:StockholdersEquity" scale="3" format="ixt:numdotdecimal" decimals="-3">69,552</ix:nonFraction></b></span></td>
      <td style="width: 1%; font-size: 9pt; margin-left: 0pt; padding-bottom: 1px;">&#xa0;</td>
     </tr>

     <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom">
      <td style="font-size: 9pt; padding: 0; margin: 0"> <p style="margin-top: 0pt; margin-bottom: 0pt"><span style="color:#333333;">Net loss</span></p> </td>
      <td style="width: 1%; font-size: 9pt; padding: 0; margin: 0">&#xa0;</td>
      <td style="width: 1%; font-size: 9pt; padding: 0; margin: 0">&#xa0;</td>
      <td style="width: 7%; text-align: right; font-size: 9pt; padding: 0; margin: 0"><span style="color:#333333;"><em style="font: inherit;">-</em></span></td>
      <td style="width: 1%; font-size: 9pt; padding: 0; margin: 0">&#xa0;</td>
      <td style="width: 1%; font-size: 9pt; padding: 0; margin: 0">&#xa0;</td>
      <td style="width: 1%; font-size: 9pt; padding: 0; margin: 0">&#xa0;</td>
      <td style="width: 7%; text-align: right; font-size: 9pt; padding: 0; margin: 0"><span style="color:#333333;"><em style="font: inherit;">-</em></span></td>
      <td style="width: 1%; font-size: 9pt; padding: 0; margin: 0">&#xa0;</td>
      <td style="width: 1%; font-size: 9pt; padding: 0; margin: 0">&#xa0;</td>
      <td style="width: 1%; font-size: 9pt; padding: 0; margin: 0">&#xa0;</td>
      <td style="width: 7%; text-align: right; font-size: 9pt; padding: 0; margin: 0"><span style="color:#333333;"><em style="font: inherit;">-</em></span></td>
      <td style="width: 1%; font-size: 9pt; padding: 0; margin: 0">&#xa0;</td>
      <td style="width: 1%; font-size: 9pt; padding: 0; margin: 0">&#xa0;</td>
      <td style="width: 1%; font-size: 9pt; padding: 0; margin: 0">&#xa0;</td>
      <td style="width: 7%; text-align: right; font-size: 9pt; padding: 0; margin: 0"><span style="color:#333333;">(<ix:nonFraction id="c86424843" contextRef="d_2021-01-01_2021-03-31_StatementEquityComponentsAxis-RetainedEarningsMember" unitRef="USD" name="us-gaap:NetIncomeLoss" scale="3" format="ixt:numdotdecimal" decimals="-3" sign="-">8,961</ix:nonFraction></span></td>
      <td style="width: 1%; font-size: 9pt; padding: 0; margin: 0"><span style="color:#333333;">)</span></td>
      <td style="width: 1%; font-size: 9pt; padding: 0; margin: 0">&#xa0;</td>
      <td style="width: 1%; font-size: 9pt; padding: 0; margin: 0">&#xa0;</td>
      <td style="width: 7%; text-align: right; font-size: 9pt; padding: 0; margin: 0"><span style="color:#333333;"><em style="font: inherit;">-</em></span></td>
      <td style="width: 1%; font-size: 9pt; padding: 0; margin: 0">&#xa0;</td>
      <td style="width: 1%; font-size: 9pt; padding: 0; margin: 0">&#xa0;</td>
      <td style="width: 1%; font-size: 9pt; padding: 0; margin: 0">&#xa0;</td>
      <td style="width: 7%; text-align: right; font-size: 9pt; padding: 0; margin: 0"><span style="color:#333333;"><em style="font: inherit;">-</em></span></td>
      <td style="width: 1%; font-size: 9pt; padding: 0; margin: 0">&#xa0;</td>
      <td style="width: 1%; font-size: 9pt; padding: 0; margin: 0">&#xa0;</td>
      <td style="width: 1%; font-size: 9pt; padding: 0; margin: 0">&#xa0;</td>
      <td style="width: 7%; text-align: right; font-size: 9pt; padding: 0; margin: 0"><span style="color:#333333;">(<ix:nonFraction id="c86424846" contextRef="d_2021-01-01_2021-03-31" unitRef="USD" name="us-gaap:NetIncomeLoss" scale="3" format="ixt:numdotdecimal" decimals="-3" sign="-">8,961</ix:nonFraction></span></td>
      <td style="width: 1%; font-size: 9pt; padding: 0; margin: 0"><span style="color:#333333;">)</span></td>
     </tr>

     <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom">
      <td style="font-size: 9pt; padding: 0; margin: 0"> <p style="margin-top: 0pt; margin-bottom: 0pt"><span style="color:#333333;">Issuance of common stock and common stock warrants, net of issuance costs</span></p> </td>
      <td style="width: 1%; font-size: 9pt; padding: 0; margin: 0">&#xa0;</td>
      <td style="width: 1%; font-size: 9pt; padding: 0; margin: 0">&#xa0;</td>
      <td style="width: 7%; text-align: right; font-size: 9pt; padding: 0; margin: 0"><span style="color:#333333;"><ix:nonFraction id="c86424847" contextRef="d_2021-01-01_2021-03-31_StatementEquityComponentsAxis-CommonStockMember" unitRef="Share" name="wint:IssuanceOfCommonStockAndCommonStockWarrantsNetOfIssuanceCostsShares" scale="3" format="ixt:numdotdecimal" decimals="-4">9,230</ix:nonFraction></span></td>
      <td style="width: 1%; font-size: 9pt; padding: 0; margin: 0">&#xa0;</td>
      <td style="width: 1%; font-size: 9pt; padding: 0; margin: 0">&#xa0;</td>
      <td style="width: 1%; font-size: 9pt; padding: 0; margin: 0">&#xa0;</td>
      <td style="width: 7%; text-align: right; font-size: 9pt; padding: 0; margin: 0"><span style="color:#333333;"><ix:nonFraction id="c86424848" contextRef="d_2021-01-01_2021-03-31_StatementEquityComponentsAxis-CommonStockMember" unitRef="USD" name="wint:IssuanceOfCommonStockAndCommonStockWarrantsNetOfIssuanceCostsValue" scale="3" format="ixt:numdotdecimal" decimals="-3">9</ix:nonFraction></span></td>
      <td style="width: 1%; font-size: 9pt; padding: 0; margin: 0">&#xa0;</td>
      <td style="width: 1%; font-size: 9pt; padding: 0; margin: 0">&#xa0;</td>
      <td style="width: 1%; font-size: 9pt; padding: 0; margin: 0">&#xa0;</td>
      <td style="width: 7%; text-align: right; font-size: 9pt; padding: 0; margin: 0"><span style="color:#333333;"><ix:nonFraction id="c86424849" contextRef="d_2021-01-01_2021-03-31_StatementEquityComponentsAxis-AdditionalPaidInCapitalMember" unitRef="USD" name="wint:IssuanceOfCommonStockAndCommonStockWarrantsNetOfIssuanceCostsValue" scale="3" format="ixt:numdotdecimal" decimals="-3">27,381</ix:nonFraction></span></td>
      <td style="width: 1%; font-size: 9pt; padding: 0; margin: 0">&#xa0;</td>
      <td style="width: 1%; font-size: 9pt; padding: 0; margin: 0">&#xa0;</td>
      <td style="width: 1%; font-size: 9pt; padding: 0; margin: 0">&#xa0;</td>
      <td style="width: 7%; text-align: right; font-size: 9pt; padding: 0; margin: 0"><span style="color:#333333;"><em style="font: inherit;">-</em></span></td>
      <td style="width: 1%; font-size: 9pt; padding: 0; margin: 0">&#xa0;</td>
      <td style="width: 1%; font-size: 9pt; padding: 0; margin: 0">&#xa0;</td>
      <td style="width: 1%; font-size: 9pt; padding: 0; margin: 0">&#xa0;</td>
      <td style="width: 7%; text-align: right; font-size: 9pt; padding: 0; margin: 0"><span style="color:#333333;"><em style="font: inherit;">-</em></span></td>
      <td style="width: 1%; font-size: 9pt; padding: 0; margin: 0">&#xa0;</td>
      <td style="width: 1%; font-size: 9pt; padding: 0; margin: 0">&#xa0;</td>
      <td style="width: 1%; font-size: 9pt; padding: 0; margin: 0">&#xa0;</td>
      <td style="width: 7%; text-align: right; font-size: 9pt; padding: 0; margin: 0"><span style="color:#333333;"><em style="font: inherit;">-</em></span></td>
      <td style="width: 1%; font-size: 9pt; padding: 0; margin: 0">&#xa0;</td>
      <td style="width: 1%; font-size: 9pt; padding: 0; margin: 0">&#xa0;</td>
      <td style="width: 1%; font-size: 9pt; padding: 0; margin: 0">&#xa0;</td>
      <td style="width: 7%; text-align: right; font-size: 9pt; padding: 0; margin: 0"><span style="color:#333333;"><ix:nonFraction id="c86424853" contextRef="d_2021-01-01_2021-03-31" unitRef="USD" name="wint:IssuanceOfCommonStockAndCommonStockWarrantsNetOfIssuanceCostsValue" scale="3" format="ixt:numdotdecimal" decimals="-4">27,390</ix:nonFraction></span></td>
      <td style="width: 1%; font-size: 9pt; padding: 0; margin: 0">&#xa0;</td>
     </tr>

     <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom">
      <td style="font-size: 9pt; padding: 0; margin: 0"> <p style="margin-top: 0pt; margin-bottom: 0pt"><span style="color:#333333;">Stock-based compensation expense</span></p> </td>
      <td style="width: 1%; font-size: 9pt; padding: 0; margin: 0">&#xa0;</td>
      <td style="width: 1%; font-size: 9pt; padding: 0; margin: 0">&#xa0;</td>
      <td style="width: 7%; text-align: right; font-size: 9pt; padding: 0; margin: 0"><span style="color:#333333;"><em style="font: inherit;">-</em></span></td>
      <td style="width: 1%; font-size: 9pt; padding: 0; margin: 0">&#xa0;</td>
      <td style="width: 1%; font-size: 9pt; padding: 0; margin: 0">&#xa0;</td>
      <td style="width: 1%; font-size: 9pt; padding: 0; margin: 0">&#xa0;</td>
      <td style="width: 7%; text-align: right; font-size: 9pt; padding: 0; margin: 0"><span style="color:#333333;"><em style="font: inherit;">-</em></span></td>
      <td style="width: 1%; font-size: 9pt; padding: 0; margin: 0">&#xa0;</td>
      <td style="width: 1%; font-size: 9pt; padding: 0; margin: 0">&#xa0;</td>
      <td style="width: 1%; font-size: 9pt; padding: 0; margin: 0">&#xa0;</td>
      <td style="width: 7%; text-align: right; font-size: 9pt; padding: 0; margin: 0"><span style="color:#333333;"><ix:nonFraction id="c86424856" contextRef="d_2021-01-01_2021-03-31_StatementEquityComponentsAxis-AdditionalPaidInCapitalMember" unitRef="USD" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="3" format="ixt:numdotdecimal" decimals="-3">2,443</ix:nonFraction></span></td>
      <td style="width: 1%; font-size: 9pt; padding: 0; margin: 0">&#xa0;</td>
      <td style="width: 1%; font-size: 9pt; padding: 0; margin: 0">&#xa0;</td>
      <td style="width: 1%; font-size: 9pt; padding: 0; margin: 0">&#xa0;</td>
      <td style="width: 7%; text-align: right; font-size: 9pt; padding: 0; margin: 0"><span style="color:#333333;"><em style="font: inherit;">-</em></span></td>
      <td style="width: 1%; font-size: 9pt; padding: 0; margin: 0">&#xa0;</td>
      <td style="width: 1%; font-size: 9pt; padding: 0; margin: 0">&#xa0;</td>
      <td style="width: 1%; font-size: 9pt; padding: 0; margin: 0">&#xa0;</td>
      <td style="width: 7%; text-align: right; font-size: 9pt; padding: 0; margin: 0"><span style="color:#333333;"><em style="font: inherit;">-</em></span></td>
      <td style="width: 1%; font-size: 9pt; padding: 0; margin: 0">&#xa0;</td>
      <td style="width: 1%; font-size: 9pt; padding: 0; margin: 0">&#xa0;</td>
      <td style="width: 1%; font-size: 9pt; padding: 0; margin: 0">&#xa0;</td>
      <td style="width: 7%; text-align: right; font-size: 9pt; padding: 0; margin: 0"><span style="color:#333333;"><em style="font: inherit;">-</em></span></td>
      <td style="width: 1%; font-size: 9pt; padding: 0; margin: 0">&#xa0;</td>
      <td style="width: 1%; font-size: 9pt; padding: 0; margin: 0">&#xa0;</td>
      <td style="width: 1%; font-size: 9pt; padding: 0; margin: 0">&#xa0;</td>
      <td style="width: 7%; text-align: right; font-size: 9pt; padding: 0; margin: 0"><span style="color:#333333;"><ix:nonFraction id="c86424860" contextRef="d_2021-01-01_2021-03-31" unitRef="USD" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="3" format="ixt:numdotdecimal" decimals="-3">2,443</ix:nonFraction></span></td>
      <td style="width: 1%; font-size: 9pt; padding: 0; margin: 0">&#xa0;</td>
     </tr>

     <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom">
      <td style="font-size: 9pt; padding: 0; margin: 0"> <p style="margin-top: 0pt; margin-bottom: 0pt"><span style="color:#333333;">Issuance of common stock, ATM Program, net of issuance costs</span></p> </td>
      <td style="width: 1%; font-size: 9pt; padding: 0; margin: 0">&#xa0;</td>
      <td style="width: 1%; font-size: 9pt; padding: 0; margin: 0">&#xa0;</td>
      <td style="width: 7%; text-align: right; font-size: 9pt; padding: 0; margin: 0"><span style="color:#333333;"><ix:nonFraction id="c86424861" contextRef="d_2021-01-01_2021-03-31_StatementClassOfStockAxis-ATMProgramMember_StatementEquityComponentsAxis-CommonStockMember" unitRef="Share" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" scale="3" format="ixt:numdotdecimal" decimals="-3">105</ix:nonFraction></span></td>
      <td style="width: 1%; font-size: 9pt; padding: 0; margin: 0">&#xa0;</td>
      <td style="width: 1%; font-size: 9pt; padding: 0; margin: 0">&#xa0;</td>
      <td style="width: 1%; font-size: 9pt; padding: 0; margin: 0">&#xa0;</td>
      <td style="width: 7%; text-align: right; font-size: 9pt; padding: 0; margin: 0"><span style="color:#333333;"><ix:nonFraction id="c86424862" contextRef="d_2021-01-01_2021-03-31_StatementClassOfStockAxis-ATMProgramMember_StatementEquityComponentsAxis-CommonStockMember" unitRef="USD" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="3" format="ixt:zerodash" decimals="-3">-</ix:nonFraction></span></td>
      <td style="width: 1%; font-size: 9pt; padding: 0; margin: 0">&#xa0;</td>
      <td style="width: 1%; font-size: 9pt; padding: 0; margin: 0">&#xa0;</td>
      <td style="width: 1%; font-size: 9pt; padding: 0; margin: 0">&#xa0;</td>
      <td style="width: 7%; text-align: right; font-size: 9pt; padding: 0; margin: 0"><span style="color:#333333;"><ix:nonFraction id="c86424863" contextRef="d_2021-01-01_2021-03-31_StatementClassOfStockAxis-ATMProgramMember_StatementEquityComponentsAxis-AdditionalPaidInCapitalMember" unitRef="USD" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="3" format="ixt:numdotdecimal" decimals="-4">570</ix:nonFraction></span></td>
      <td style="width: 1%; font-size: 9pt; padding: 0; margin: 0">&#xa0;</td>
      <td style="width: 1%; font-size: 9pt; padding: 0; margin: 0">&#xa0;</td>
      <td style="width: 1%; font-size: 9pt; padding: 0; margin: 0">&#xa0;</td>
      <td style="width: 7%; text-align: right; font-size: 9pt; padding: 0; margin: 0"><span style="color:#333333;"><ix:nonFraction id="c86424864" contextRef="d_2021-01-01_2021-03-31_StatementClassOfStockAxis-ATMProgramMember_StatementEquityComponentsAxis-RetainedEarningsMember" unitRef="USD" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="3" format="ixt:zerodash" decimals="-3">-</ix:nonFraction></span></td>
      <td style="width: 1%; font-size: 9pt; padding: 0; margin: 0">&#xa0;</td>
      <td style="width: 1%; font-size: 9pt; padding: 0; margin: 0">&#xa0;</td>
      <td style="width: 1%; font-size: 9pt; padding: 0; margin: 0">&#xa0;</td>
      <td style="width: 7%; text-align: right; font-size: 9pt; padding: 0; margin: 0"><span style="color:#333333;"><ix:nonFraction id="c86424865" contextRef="d_2021-01-01_2021-03-31_StatementClassOfStockAxis-ATMProgramMember_StatementEquityComponentsAxis-TreasuryStockMember" unitRef="Share" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" scale="3" format="ixt:zerodash" decimals="-3">-</ix:nonFraction></span></td>
      <td style="width: 1%; font-size: 9pt; padding: 0; margin: 0">&#xa0;</td>
      <td style="width: 1%; font-size: 9pt; padding: 0; margin: 0">&#xa0;</td>
      <td style="width: 1%; font-size: 9pt; padding: 0; margin: 0">&#xa0;</td>
      <td style="width: 7%; text-align: right; font-size: 9pt; padding: 0; margin: 0"><span style="color:#333333;"><ix:nonFraction id="c86424866" contextRef="d_2021-01-01_2021-03-31_StatementClassOfStockAxis-ATMProgramMember_StatementEquityComponentsAxis-TreasuryStockMember" unitRef="USD" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="3" format="ixt:zerodash" decimals="-3">-</ix:nonFraction></span></td>
      <td style="width: 1%; font-size: 9pt; padding: 0; margin: 0">&#xa0;</td>
      <td style="width: 1%; font-size: 9pt; padding: 0; margin: 0">&#xa0;</td>
      <td style="width: 1%; font-size: 9pt; padding: 0; margin: 0">&#xa0;</td>
      <td style="width: 7%; text-align: right; font-size: 9pt; padding: 0; margin: 0"><span style="color:#333333;"><ix:nonFraction id="c86424867" contextRef="d_2021-01-01_2021-03-31_StatementClassOfStockAxis-ATMProgramMember" unitRef="USD" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="3" format="ixt:numdotdecimal" decimals="-4">570</ix:nonFraction></span></td>
      <td style="width: 1%; font-size: 9pt; padding: 0; margin: 0">&#xa0;</td>
     </tr>

     <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom">
      <td style="font-size: 9pt; padding-top: 0px; padding-right: 0px; padding-left: 0px; margin: 0px;"> <p style="margin-top: 0pt; margin-bottom: 0pt"><span style="color:#333333;">Issuance of common stock warrants, equity consideration for service agreement</span></p> </td>
      <td style="width: 1%; font-size: 9pt; padding: 0px 0px 1px; margin: 0px;">&#xa0;</td>
      <td style="width: 1%; font-size: 9pt; padding-top: 0px; padding-right: 0px; padding-left: 0px; margin: 0px; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td>
      <td style="width: 7%; text-align: right; font-size: 9pt; padding-top: 0px; padding-right: 0px; padding-left: 0px; margin: 0px; border-bottom: 1px solid rgb(0, 0, 0);"><span style="color:#333333;"><em style="font: inherit;">-</em></span></td>
      <td style="width: 1%; font-size: 9pt; padding-top: 0px; padding-right: 0px; padding-left: 0px; margin: 0px; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td>
      <td style="width: 1%; font-size: 9pt; padding-top: 0px; padding-right: 0px; padding-left: 0px; margin: 0px; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td>
      <td style="width: 1%; font-size: 9pt; padding-top: 0px; padding-right: 0px; padding-left: 0px; margin: 0px; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td>
      <td style="width: 7%; text-align: right; font-size: 9pt; padding-top: 0px; padding-right: 0px; padding-left: 0px; margin: 0px; border-bottom: 1px solid rgb(0, 0, 0);"><span style="color:#333333;"><ix:nonFraction id="c86424869" contextRef="d_2021-01-01_2021-03-31_StatementEquityComponentsAxis-CommonStockMember_SubsidiarySaleOfStockAxis-SharePurchaseAgreementDecember2019Member" unitRef="USD" name="us-gaap:StockIssuedDuringPeriodValueIssuedForServices" scale="3" format="ixt:zerodash" decimals="-3">-</ix:nonFraction></span></td>
      <td style="width: 1%; font-size: 9pt; padding-top: 0px; padding-right: 0px; padding-left: 0px; margin: 0px; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td>
      <td style="width: 1%; font-size: 9pt; padding-top: 0px; padding-right: 0px; padding-left: 0px; margin: 0px; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td>
      <td style="width: 1%; font-size: 9pt; padding-top: 0px; padding-right: 0px; padding-left: 0px; margin: 0px; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td>
      <td style="width: 7%; text-align: right; font-size: 9pt; padding-top: 0px; padding-right: 0px; padding-left: 0px; margin: 0px; border-bottom: 1px solid rgb(0, 0, 0);"><span style="color:#333333;"><ix:nonFraction id="c86424870" contextRef="d_2021-01-01_2021-03-31_StatementEquityComponentsAxis-AdditionalPaidInCapitalMember_SubsidiarySaleOfStockAxis-SharePurchaseAgreementDecember2019Member" unitRef="USD" name="us-gaap:StockIssuedDuringPeriodValueIssuedForServices" scale="3" format="ixt:numdotdecimal" decimals="-3">494</ix:nonFraction></span></td>
      <td style="width: 1%; font-size: 9pt; padding-top: 0px; padding-right: 0px; padding-left: 0px; margin: 0px; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td>
      <td style="width: 1%; font-size: 9pt; padding-top: 0px; padding-right: 0px; padding-left: 0px; margin: 0px; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td>
      <td style="width: 1%; font-size: 9pt; padding-top: 0px; padding-right: 0px; padding-left: 0px; margin: 0px; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td>
      <td style="width: 7%; text-align: right; font-size: 9pt; padding-top: 0px; padding-right: 0px; padding-left: 0px; margin: 0px; border-bottom: 1px solid rgb(0, 0, 0);"><span style="color:#333333;"><ix:nonFraction id="c86424871" contextRef="d_2021-01-01_2021-03-31_StatementEquityComponentsAxis-RetainedEarningsMember_SubsidiarySaleOfStockAxis-SharePurchaseAgreementDecember2019Member" unitRef="USD" name="us-gaap:StockIssuedDuringPeriodValueIssuedForServices" scale="3" format="ixt:zerodash" decimals="-3">-</ix:nonFraction></span></td>
      <td style="width: 1%; font-size: 9pt; padding-top: 0px; padding-right: 0px; padding-left: 0px; margin: 0px; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td>
      <td style="width: 1%; font-size: 9pt; padding-top: 0px; padding-right: 0px; padding-left: 0px; margin: 0px; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td>
      <td style="width: 1%; font-size: 9pt; padding-top: 0px; padding-right: 0px; padding-left: 0px; margin: 0px; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td>
      <td style="width: 7%; text-align: right; font-size: 9pt; padding-top: 0px; padding-right: 0px; padding-left: 0px; margin: 0px; border-bottom: 1px solid rgb(0, 0, 0);"><span style="color:#333333;"><em style="font: inherit;">-</em></span></td>
      <td style="width: 1%; font-size: 9pt; padding-top: 0px; padding-right: 0px; padding-left: 0px; margin: 0px; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td>
      <td style="width: 1%; font-size: 9pt; padding-top: 0px; padding-right: 0px; padding-left: 0px; margin: 0px; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td>
      <td style="width: 1%; font-size: 9pt; padding-top: 0px; padding-right: 0px; padding-left: 0px; margin: 0px; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td>
      <td style="width: 7%; text-align: right; font-size: 9pt; padding-top: 0px; padding-right: 0px; padding-left: 0px; margin: 0px; border-bottom: 1px solid rgb(0, 0, 0);"><span style="color:#333333;"><ix:nonFraction id="c86424873" contextRef="d_2021-01-01_2021-03-31_StatementEquityComponentsAxis-TreasuryStockMember_SubsidiarySaleOfStockAxis-SharePurchaseAgreementDecember2019Member" unitRef="USD" name="us-gaap:StockIssuedDuringPeriodValueIssuedForServices" scale="3" format="ixt:zerodash" decimals="-3">-</ix:nonFraction></span></td>
      <td style="width: 1%; font-size: 9pt; padding-top: 0px; padding-right: 0px; padding-left: 0px; margin: 0px; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td>
      <td style="width: 1%; font-size: 9pt; padding-top: 0px; padding-right: 0px; padding-left: 0px; margin: 0px; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td>
      <td style="width: 1%; font-size: 9pt; padding-top: 0px; padding-right: 0px; padding-left: 0px; margin: 0px; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td>
      <td style="width: 7%; text-align: right; font-size: 9pt; padding-top: 0px; padding-right: 0px; padding-left: 0px; margin: 0px; border-bottom: 1px solid rgb(0, 0, 0);"><span style="color:#333333;"><ix:nonFraction id="c86424874" contextRef="d_2021-01-01_2021-03-31_SubsidiarySaleOfStockAxis-SharePurchaseAgreementDecember2019Member" unitRef="USD" name="us-gaap:StockIssuedDuringPeriodValueIssuedForServices" scale="3" format="ixt:numdotdecimal" decimals="-3">494</ix:nonFraction></span></td>
      <td style="width: 1%; font-size: 9pt; padding: 0px 0px 1px; margin: 0px;">&#xa0;</td>
     </tr>

     <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom">
      <td style="font-size: 9pt;"> <p style="font-size: 9pt; margin-top: 0; margin-bottom: 0; font-family: &quot;Times New Roman&quot;, Times, serif"><span style="color:#333333;"><b>Balance - March 31, 2021</b></span></p> </td>
      <td style="width: 1%; font-size: 9pt; padding-bottom: 3px;">&#xa0;</td>
      <td style="width: 1%; font-size: 9pt; border-bottom: 3px double rgb(0, 0, 0);">&#xa0;</td>
      <td style="width: 7%; text-align: right; font-size: 9pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><span style="color:#333333;"><b><ix:nonFraction id="c86424875" contextRef="i_2021-03-31_StatementEquityComponentsAxis-CommonStockMember" unitRef="Share" name="us-gaap:SharesOutstanding" scale="3" format="ixt:numdotdecimal" decimals="-3">26,257</ix:nonFraction></b></span></td>
      <td style="width: 1%; font-size: 9pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">&#xa0;</td>
      <td style="width: 1%; font-size: 9pt; border-bottom: 3px double rgb(0, 0, 0);">&#xa0;</td>
      <td style="width: 1%; font-size: 9pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><span style="color:#333333;">$</span></td>
      <td style="width: 7%; text-align: right; font-size: 9pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><span style="color:#333333;"><b><ix:nonFraction id="c86424876" contextRef="i_2021-03-31_StatementEquityComponentsAxis-CommonStockMember" unitRef="USD" name="us-gaap:StockholdersEquity" scale="3" format="ixt:numdotdecimal" decimals="-3">26</ix:nonFraction></b></span></td>
      <td style="width: 1%; font-size: 9pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">&#xa0;</td>
      <td style="width: 1%; font-size: 9pt; border-bottom: 3px double rgb(0, 0, 0);">&#xa0;</td>
      <td style="width: 1%; font-size: 9pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><span style="color:#333333;">$</span></td>
      <td style="width: 7%; text-align: right; font-size: 9pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><span style="color:#333333;"><b><ix:nonFraction id="c86424877" contextRef="i_2021-03-31_StatementEquityComponentsAxis-AdditionalPaidInCapitalMember" unitRef="USD" name="us-gaap:StockholdersEquity" scale="3" format="ixt:numdotdecimal" decimals="-3">821,165</ix:nonFraction></b></span></td>
      <td style="width: 1%; font-size: 9pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">&#xa0;</td>
      <td style="width: 1%; font-size: 9pt; border-bottom: 3px double rgb(0, 0, 0);">&#xa0;</td>
      <td style="width: 1%; font-size: 9pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><span style="color:#333333;">$</span></td>
      <td style="width: 7%; text-align: right; font-size: 9pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><span style="color:#333333;"><b>(<ix:nonFraction id="c86424878" contextRef="i_2021-03-31_StatementEquityComponentsAxis-RetainedEarningsMember" unitRef="USD" name="us-gaap:StockholdersEquity" scale="3" format="ixt:numdotdecimal" decimals="-3" sign="-">726,649</ix:nonFraction></b></span></td>
      <td style="width: 1%; font-size: 9pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><span style="color:#333333;"><b>)</b></span></td>
      <td style="width: 1%; font-size: 9pt; border-bottom: 3px double rgb(0, 0, 0);">&#xa0;</td>
      <td style="width: 1%; font-size: 9pt; border-bottom: 3px double rgb(0, 0, 0);">&#xa0;</td>
      <td style="width: 7%; text-align: right; font-size: 9pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><span style="color:#333333;"><b><em style="font: inherit;">-</em></b></span></td>
      <td style="width: 1%; font-size: 9pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">&#xa0;</td>
      <td style="width: 1%; font-size: 9pt; border-bottom: 3px double rgb(0, 0, 0);">&#xa0;</td>
      <td style="width: 1%; font-size: 9pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><span style="color:#333333;">$</span></td>
      <td style="width: 7%; text-align: right; font-size: 9pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><span style="color:#333333;"><b>(<ix:nonFraction id="c86424880" contextRef="i_2021-03-31_StatementEquityComponentsAxis-TreasuryStockMember" unitRef="USD" name="us-gaap:StockholdersEquity" scale="3" format="ixt:numdotdecimal" decimals="-3" sign="-">3,054</ix:nonFraction></b></span></td>
      <td style="width: 1%; font-size: 9pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><span style="color:#333333;"><b>)</b></span></td>
      <td style="width: 1%; font-size: 9pt; border-bottom: 3px double rgb(0, 0, 0);">&#xa0;</td>
      <td style="width: 1%; font-size: 9pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><span style="color:#333333;">$</span></td>
      <td style="width: 7%; text-align: right; font-size: 9pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><span style="color:#333333;"><b><ix:nonFraction id="c86424881" contextRef="i_2021-03-31" unitRef="USD" name="us-gaap:StockholdersEquity" scale="3" format="ixt:numdotdecimal" decimals="-3">91,488</ix:nonFraction></b></span></td>
      <td style="width: 1%; font-size: 9pt; margin-left: 0pt; padding-bottom: 3px;">&#xa0;</td>
     </tr>

     <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom">
      <td style="font-size: 9pt; padding: 0; margin: 0"> <p style="margin-top: 0pt; margin-bottom: 0pt"><span style="color:#333333;">Net loss</span></p> </td>
      <td style="width: 1%; font-size: 9pt; padding: 0; margin: 0">&#xa0;</td>
      <td style="width: 1%; font-size: 9pt; padding: 0; margin: 0">&#xa0;</td>
      <td style="width: 7%; text-align: right; font-size: 9pt; padding: 0; margin: 0"><span style="color:#333333;"><em style="font: inherit;">-</em></span></td>
      <td style="width: 1%; font-size: 9pt; padding: 0; margin: 0">&#xa0;</td>
      <td style="width: 1%; font-size: 9pt; padding: 0; margin: 0">&#xa0;</td>
      <td style="width: 1%; font-size: 9pt; padding: 0; margin: 0">&#xa0;</td>
      <td style="width: 7%; text-align: right; font-size: 9pt; padding: 0; margin: 0"><span style="color:#333333;"><ix:nonFraction id="c86424883" contextRef="d_2021-04-01_2021-06-30_StatementEquityComponentsAxis-CommonStockMember" unitRef="USD" name="us-gaap:NetIncomeLoss" scale="3" format="ixt:zerodash" decimals="-3">-</ix:nonFraction></span></td>
      <td style="width: 1%; font-size: 9pt; padding: 0; margin: 0">&#xa0;</td>
      <td style="width: 1%; font-size: 9pt; padding: 0; margin: 0">&#xa0;</td>
      <td style="width: 1%; font-size: 9pt; padding: 0; margin: 0">&#xa0;</td>
      <td style="width: 7%; text-align: right; font-size: 9pt; padding: 0; margin: 0"><span style="color:#333333;"><ix:nonFraction id="c86424884" contextRef="d_2021-04-01_2021-06-30_StatementEquityComponentsAxis-AdditionalPaidInCapitalMember" unitRef="USD" name="us-gaap:NetIncomeLoss" scale="3" format="ixt:zerodash" decimals="-3">-</ix:nonFraction></span></td>
      <td style="width: 1%; font-size: 9pt; padding: 0; margin: 0">&#xa0;</td>
      <td style="width: 1%; font-size: 9pt; padding: 0; margin: 0">&#xa0;</td>
      <td style="width: 1%; font-size: 9pt; padding: 0; margin: 0">&#xa0;</td>
      <td style="width: 7%; text-align: right; font-size: 9pt; padding: 0; margin: 0"><span style="color:#333333;">(<ix:nonFraction id="c86424885" contextRef="d_2021-04-01_2021-06-30_StatementEquityComponentsAxis-RetainedEarningsMember" unitRef="USD" name="us-gaap:NetIncomeLoss" scale="3" format="ixt:numdotdecimal" decimals="-3" sign="-">37,389</ix:nonFraction></span></td>
      <td style="width: 1%; font-size: 9pt; padding: 0; margin: 0"><span style="color:#333333;">)</span></td>
      <td style="width: 1%; font-size: 9pt; padding: 0; margin: 0">&#xa0;</td>
      <td style="width: 1%; font-size: 9pt; padding: 0; margin: 0">&#xa0;</td>
      <td style="width: 7%; text-align: right; font-size: 9pt; padding: 0; margin: 0"><span style="color:#333333;"><em style="font: inherit;">-</em></span></td>
      <td style="width: 1%; font-size: 9pt; padding: 0; margin: 0">&#xa0;</td>
      <td style="width: 1%; font-size: 9pt; padding: 0; margin: 0">&#xa0;</td>
      <td style="width: 1%; font-size: 9pt; padding: 0; margin: 0">&#xa0;</td>
      <td style="width: 7%; text-align: right; font-size: 9pt; padding: 0; margin: 0"><span style="color:#333333;"><ix:nonFraction id="c86424887" contextRef="d_2021-04-01_2021-06-30_StatementEquityComponentsAxis-TreasuryStockMember" unitRef="USD" name="us-gaap:NetIncomeLoss" scale="3" format="ixt:zerodash" decimals="-3">-</ix:nonFraction></span></td>
      <td style="width: 1%; font-size: 9pt; padding: 0; margin: 0">&#xa0;</td>
      <td style="width: 1%; font-size: 9pt; padding: 0; margin: 0">&#xa0;</td>
      <td style="width: 1%; font-size: 9pt; padding: 0; margin: 0">&#xa0;</td>
      <td style="width: 7%; text-align: right; font-size: 9pt; padding: 0; margin: 0"><span style="color:#333333;">(<ix:nonFraction id="c86424888" contextRef="d_2021-04-01_2021-06-30" unitRef="USD" name="us-gaap:NetIncomeLoss" scale="3" format="ixt:numdotdecimal" decimals="-3" sign="-">37,389</ix:nonFraction></span></td>
      <td style="width: 1%; font-size: 9pt; padding: 0; margin: 0"><span style="color:#333333;">)</span></td>
     </tr>

     <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom">
      <td style="font-size: 9pt; padding: 0; margin: 0"> <p style="margin-top: 0pt; margin-bottom: 0pt"><span style="color:#333333;">Stock-based compensation expense</span></p> </td>
      <td style="width: 1%; font-size: 9pt; padding: 0; margin: 0">&#xa0;</td>
      <td style="width: 1%; font-size: 9pt; padding: 0; margin: 0">&#xa0;</td>
      <td style="width: 7%; text-align: right; font-size: 9pt; padding: 0; margin: 0"><span style="color:#333333;"><em style="font: inherit;">-</em></span></td>
      <td style="width: 1%; font-size: 9pt; padding: 0; margin: 0">&#xa0;</td>
      <td style="width: 1%; font-size: 9pt; padding: 0; margin: 0">&#xa0;</td>
      <td style="width: 1%; font-size: 9pt; padding: 0; margin: 0">&#xa0;</td>
      <td style="width: 7%; text-align: right; font-size: 9pt; padding: 0; margin: 0"><span style="color:#333333;"><ix:nonFraction id="c86424890" contextRef="d_2021-04-01_2021-06-30_StatementEquityComponentsAxis-CommonStockMember" unitRef="USD" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="3" format="ixt:zerodash" decimals="-3">-</ix:nonFraction></span></td>
      <td style="width: 1%; font-size: 9pt; padding: 0; margin: 0">&#xa0;</td>
      <td style="width: 1%; font-size: 9pt; padding: 0; margin: 0">&#xa0;</td>
      <td style="width: 1%; font-size: 9pt; padding: 0; margin: 0">&#xa0;</td>
      <td style="width: 7%; text-align: right; font-size: 9pt; padding: 0; margin: 0"><span style="color:#333333;"><ix:nonFraction id="c86424891" contextRef="d_2021-04-01_2021-06-30_StatementEquityComponentsAxis-AdditionalPaidInCapitalMember" unitRef="USD" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="3" format="ixt:numdotdecimal" decimals="-3">1,544</ix:nonFraction></span></td>
      <td style="width: 1%; font-size: 9pt; padding: 0; margin: 0">&#xa0;</td>
      <td style="width: 1%; font-size: 9pt; padding: 0; margin: 0">&#xa0;</td>
      <td style="width: 1%; font-size: 9pt; padding: 0; margin: 0">&#xa0;</td>
      <td style="width: 7%; text-align: right; font-size: 9pt; padding: 0; margin: 0"><span style="color:#333333;"><ix:nonFraction id="c86424892" contextRef="d_2021-04-01_2021-06-30_StatementEquityComponentsAxis-RetainedEarningsMember" unitRef="USD" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="3" format="ixt:zerodash" decimals="-3">-</ix:nonFraction></span></td>
      <td style="width: 1%; font-size: 9pt; padding: 0; margin: 0">&#xa0;</td>
      <td style="width: 1%; font-size: 9pt; padding: 0; margin: 0">&#xa0;</td>
      <td style="width: 1%; font-size: 9pt; padding: 0; margin: 0">&#xa0;</td>
      <td style="width: 7%; text-align: right; font-size: 9pt; padding: 0; margin: 0"><span style="color:#333333;"><em style="font: inherit;">-</em></span></td>
      <td style="width: 1%; font-size: 9pt; padding: 0; margin: 0">&#xa0;</td>
      <td style="width: 1%; font-size: 9pt; padding: 0; margin: 0">&#xa0;</td>
      <td style="width: 1%; font-size: 9pt; padding: 0; margin: 0">&#xa0;</td>
      <td style="width: 7%; text-align: right; font-size: 9pt; padding: 0; margin: 0"><span style="color:#333333;"><ix:nonFraction id="c86424894" contextRef="d_2021-04-01_2021-06-30_StatementEquityComponentsAxis-TreasuryStockMember" unitRef="USD" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="3" format="ixt:zerodash" decimals="-3">-</ix:nonFraction></span></td>
      <td style="width: 1%; font-size: 9pt; padding: 0; margin: 0">&#xa0;</td>
      <td style="width: 1%; font-size: 9pt; padding: 0; margin: 0">&#xa0;</td>
      <td style="width: 1%; font-size: 9pt; padding: 0; margin: 0">&#xa0;</td>
      <td style="width: 7%; text-align: right; font-size: 9pt; padding: 0; margin: 0"><span style="color:#333333;"><ix:nonFraction id="c86424895" contextRef="d_2021-04-01_2021-06-30" unitRef="USD" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="3" format="ixt:numdotdecimal" decimals="-3">1,544</ix:nonFraction></span></td>
      <td style="width: 1%; font-size: 9pt; padding: 0; margin: 0">&#xa0;</td>
     </tr>

     <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom">
      <td style="font-size: 9pt; padding-top: 0px; padding-right: 0px; padding-left: 0px; margin: 0px;"> <p style="margin-top: 0pt; margin-bottom: 0pt"><span style="color:#333333;">Issuance of common stock, ATM Program, net of issuance costs</span></p> </td>
      <td style="width: 1%; font-size: 9pt; padding: 0px 0px 1px; margin: 0px;">&#xa0;</td>
      <td style="width: 1%; font-size: 9pt; padding-top: 0px; padding-right: 0px; padding-left: 0px; margin: 0px; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td>
      <td style="width: 7%; text-align: right; font-size: 9pt; padding-top: 0px; padding-right: 0px; padding-left: 0px; margin: 0px; border-bottom: 1px solid rgb(0, 0, 0);"><span style="color:#333333;"><ix:nonFraction id="c86424896" contextRef="d_2021-04-01_2021-06-30_StatementEquityComponentsAxis-CommonStockMember" unitRef="Share" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" scale="3" format="ixt:numdotdecimal" decimals="-3">447</ix:nonFraction></span></td>
      <td style="width: 1%; font-size: 9pt; padding-top: 0px; padding-right: 0px; padding-left: 0px; margin: 0px; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td>
      <td style="width: 1%; font-size: 9pt; padding-top: 0px; padding-right: 0px; padding-left: 0px; margin: 0px; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td>
      <td style="width: 1%; font-size: 9pt; padding-top: 0px; padding-right: 0px; padding-left: 0px; margin: 0px; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td>
      <td style="width: 7%; text-align: right; font-size: 9pt; padding-top: 0px; padding-right: 0px; padding-left: 0px; margin: 0px; border-bottom: 1px solid rgb(0, 0, 0);"><span style="color:#333333;"><ix:nonFraction id="c86424897" contextRef="d_2021-04-01_2021-06-30_StatementEquityComponentsAxis-CommonStockMember" unitRef="USD" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="3" format="ixt:numdotdecimal" decimals="-3">1</ix:nonFraction></span></td>
      <td style="width: 1%; font-size: 9pt; padding-top: 0px; padding-right: 0px; padding-left: 0px; margin: 0px; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td>
      <td style="width: 1%; font-size: 9pt; padding-top: 0px; padding-right: 0px; padding-left: 0px; margin: 0px; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td>
      <td style="width: 1%; font-size: 9pt; padding-top: 0px; padding-right: 0px; padding-left: 0px; margin: 0px; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td>
      <td style="width: 7%; text-align: right; font-size: 9pt; padding-top: 0px; padding-right: 0px; padding-left: 0px; margin: 0px; border-bottom: 1px solid rgb(0, 0, 0);"><span style="color:#333333;"><ix:nonFraction id="c86424898" contextRef="d_2021-04-01_2021-06-30_StatementEquityComponentsAxis-AdditionalPaidInCapitalMember" unitRef="USD" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="3" format="ixt:numdotdecimal" decimals="-3">1,119</ix:nonFraction></span></td>
      <td style="width: 1%; font-size: 9pt; padding-top: 0px; padding-right: 0px; padding-left: 0px; margin: 0px; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td>
      <td style="width: 1%; font-size: 9pt; padding-top: 0px; padding-right: 0px; padding-left: 0px; margin: 0px; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td>
      <td style="width: 1%; font-size: 9pt; padding-top: 0px; padding-right: 0px; padding-left: 0px; margin: 0px; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td>
      <td style="width: 7%; text-align: right; font-size: 9pt; padding-top: 0px; padding-right: 0px; padding-left: 0px; margin: 0px; border-bottom: 1px solid rgb(0, 0, 0);"><span style="color:#333333;"><ix:nonFraction id="c86424899" contextRef="d_2021-04-01_2021-06-30_StatementEquityComponentsAxis-RetainedEarningsMember" unitRef="USD" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="3" format="ixt:zerodash" decimals="-3">-</ix:nonFraction></span></td>
      <td style="width: 1%; font-size: 9pt; padding-top: 0px; padding-right: 0px; padding-left: 0px; margin: 0px; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td>
      <td style="width: 1%; font-size: 9pt; padding-top: 0px; padding-right: 0px; padding-left: 0px; margin: 0px; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td>
      <td style="width: 1%; font-size: 9pt; padding-top: 0px; padding-right: 0px; padding-left: 0px; margin: 0px; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td>
      <td style="width: 7%; text-align: right; font-size: 9pt; padding-top: 0px; padding-right: 0px; padding-left: 0px; margin: 0px; border-bottom: 1px solid rgb(0, 0, 0);"><span style="color:#333333;"><ix:nonFraction id="c86424900" contextRef="d_2021-04-01_2021-06-30_StatementEquityComponentsAxis-TreasuryStockMember" unitRef="Share" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" scale="3" format="ixt:zerodash" decimals="-3">-</ix:nonFraction></span></td>
      <td style="width: 1%; font-size: 9pt; padding-top: 0px; padding-right: 0px; padding-left: 0px; margin: 0px; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td>
      <td style="width: 1%; font-size: 9pt; padding-top: 0px; padding-right: 0px; padding-left: 0px; margin: 0px; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td>
      <td style="width: 1%; font-size: 9pt; padding-top: 0px; padding-right: 0px; padding-left: 0px; margin: 0px; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td>
      <td style="width: 7%; text-align: right; font-size: 9pt; padding-top: 0px; padding-right: 0px; padding-left: 0px; margin: 0px; border-bottom: 1px solid rgb(0, 0, 0);"><span style="color:#333333;"><ix:nonFraction id="c86424901" contextRef="d_2021-04-01_2021-06-30_StatementEquityComponentsAxis-TreasuryStockMember" unitRef="USD" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="3" format="ixt:zerodash" decimals="-3">-</ix:nonFraction></span></td>
      <td style="width: 1%; font-size: 9pt; padding-top: 0px; padding-right: 0px; padding-left: 0px; margin: 0px; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td>
      <td style="width: 1%; font-size: 9pt; padding-top: 0px; padding-right: 0px; padding-left: 0px; margin: 0px; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td>
      <td style="width: 1%; font-size: 9pt; padding-top: 0px; padding-right: 0px; padding-left: 0px; margin: 0px; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td>
      <td style="width: 7%; text-align: right; font-size: 9pt; padding-top: 0px; padding-right: 0px; padding-left: 0px; margin: 0px; border-bottom: 1px solid rgb(0, 0, 0);"><span style="color:#333333;"><ix:nonFraction id="c86424902" contextRef="d_2021-04-01_2021-06-30" unitRef="USD" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="3" format="ixt:numdotdecimal" decimals="-4">1,120</ix:nonFraction></span></td>
      <td style="width: 1%; font-size: 9pt; padding: 0px 0px 1px; margin: 0px;">&#xa0;</td>
     </tr>

     <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom">
      <td style="font-size: 9pt; padding-top: 0px; padding-right: 0px; padding-left: 0px; margin: 0px;"> <p style="margin-top: 0pt; margin-bottom: 0pt"><span style="color:#333333;"><b>Balance - June 30, 2021</b></span></p> </td>
      <td style="width: 1%; font-size: 9pt; padding: 0px 0px 3px; margin: 0px;">&#xa0;</td>
      <td style="width: 1%; font-size: 9pt; padding-top: 0px; padding-right: 0px; padding-left: 0px; margin: 0px; border-bottom: 3px double rgb(0, 0, 0);">&#xa0;</td>
      <td style="width: 7%; text-align: right; font-size: 9pt; padding-top: 0px; padding-right: 0px; padding-left: 0px; margin: 0px; border-bottom: 3px double rgb(0, 0, 0);"><span style="color:#333333;"><b><ix:nonFraction id="c86424903" contextRef="i_2021-06-30_StatementEquityComponentsAxis-CommonStockMember" unitRef="Share" name="us-gaap:SharesOutstanding" scale="3" format="ixt:numdotdecimal" decimals="-3">26,704</ix:nonFraction></b></span></td>
      <td style="width: 1%; font-size: 9pt; padding-top: 0px; padding-right: 0px; padding-left: 0px; margin: 0px; border-bottom: 3px double rgb(0, 0, 0);">&#xa0;</td>
      <td style="width: 1%; font-size: 9pt; padding-top: 0px; padding-right: 0px; padding-left: 0px; margin: 0px; border-bottom: 3px double rgb(0, 0, 0);">&#xa0;</td>
      <td style="width: 1%; font-size: 9pt; padding-top: 0px; padding-right: 0px; padding-left: 0px; margin: 0px; border-bottom: 3px double rgb(0, 0, 0);"><span style="color:#333333;">$</span></td>
      <td style="width: 7%; text-align: right; font-size: 9pt; padding-top: 0px; padding-right: 0px; padding-left: 0px; margin: 0px; border-bottom: 3px double rgb(0, 0, 0);"><span style="color:#333333;"><b><ix:nonFraction id="c86424904" contextRef="i_2021-06-30_StatementEquityComponentsAxis-CommonStockMember" unitRef="USD" name="us-gaap:StockholdersEquity" scale="3" format="ixt:numdotdecimal" decimals="-3">27</ix:nonFraction></b></span></td>
      <td style="width: 1%; font-size: 9pt; padding-top: 0px; padding-right: 0px; padding-left: 0px; margin: 0px; border-bottom: 3px double rgb(0, 0, 0);">&#xa0;</td>
      <td style="width: 1%; font-size: 9pt; padding-top: 0px; padding-right: 0px; padding-left: 0px; margin: 0px; border-bottom: 3px double rgb(0, 0, 0);">&#xa0;</td>
      <td style="width: 1%; font-size: 9pt; padding-top: 0px; padding-right: 0px; padding-left: 0px; margin: 0px; border-bottom: 3px double rgb(0, 0, 0);"><span style="color:#333333;">$</span></td>
      <td style="width: 7%; text-align: right; font-size: 9pt; padding-top: 0px; padding-right: 0px; padding-left: 0px; margin: 0px; border-bottom: 3px double rgb(0, 0, 0);"><span style="color:#333333;"><b><ix:nonFraction id="c86424905" contextRef="i_2021-06-30_StatementEquityComponentsAxis-AdditionalPaidInCapitalMember" unitRef="USD" name="us-gaap:StockholdersEquity" scale="3" format="ixt:numdotdecimal" decimals="-3">823,828</ix:nonFraction></b></span></td>
      <td style="width: 1%; font-size: 9pt; padding-top: 0px; padding-right: 0px; padding-left: 0px; margin: 0px; border-bottom: 3px double rgb(0, 0, 0);">&#xa0;</td>
      <td style="width: 1%; font-size: 9pt; padding-top: 0px; padding-right: 0px; padding-left: 0px; margin: 0px; border-bottom: 3px double rgb(0, 0, 0);">&#xa0;</td>
      <td style="width: 1%; font-size: 9pt; padding-top: 0px; padding-right: 0px; padding-left: 0px; margin: 0px; border-bottom: 3px double rgb(0, 0, 0);"><span style="color:#333333;">$</span></td>
      <td style="width: 7%; text-align: right; font-size: 9pt; padding-top: 0px; padding-right: 0px; padding-left: 0px; margin: 0px; border-bottom: 3px double rgb(0, 0, 0);"><span style="color:#333333;"><b>(<ix:nonFraction id="c86424906" contextRef="i_2021-06-30_StatementEquityComponentsAxis-RetainedEarningsMember" unitRef="USD" name="us-gaap:StockholdersEquity" scale="3" format="ixt:numdotdecimal" decimals="-3" sign="-">764,038</ix:nonFraction></b></span></td>
      <td style="width: 1%; font-size: 9pt; padding-top: 0px; padding-right: 0px; padding-left: 0px; margin: 0px; border-bottom: 3px double rgb(0, 0, 0);"><span style="color:#333333;"><b>)</b></span></td>
      <td style="width: 1%; font-size: 9pt; padding-top: 0px; padding-right: 0px; padding-left: 0px; margin: 0px; border-bottom: 3px double rgb(0, 0, 0);">&#xa0;</td>
      <td style="width: 1%; font-size: 9pt; padding-top: 0px; padding-right: 0px; padding-left: 0px; margin: 0px; border-bottom: 3px double rgb(0, 0, 0);">&#xa0;</td>
      <td style="width: 7%; text-align: right; font-size: 9pt; padding-top: 0px; padding-right: 0px; padding-left: 0px; margin: 0px; border-bottom: 3px double rgb(0, 0, 0);"><span style="color:#333333;"><b><ix:nonFraction id="c86424907" contextRef="i_2021-06-30_StatementEquityComponentsAxis-TreasuryStockMember" unitRef="Share" name="us-gaap:SharesOutstanding" scale="3" format="ixt:zerodash" decimals="-3">-</ix:nonFraction></b></span></td>
      <td style="width: 1%; font-size: 9pt; padding-top: 0px; padding-right: 0px; padding-left: 0px; margin: 0px; border-bottom: 3px double rgb(0, 0, 0);">&#xa0;</td>
      <td style="width: 1%; font-size: 9pt; padding-top: 0px; padding-right: 0px; padding-left: 0px; margin: 0px; border-bottom: 3px double rgb(0, 0, 0);">&#xa0;</td>
      <td style="width: 1%; font-size: 9pt; padding-top: 0px; padding-right: 0px; padding-left: 0px; margin: 0px; border-bottom: 3px double rgb(0, 0, 0);"><span style="color:#333333;">$</span></td>
      <td style="width: 7%; text-align: right; font-size: 9pt; padding-top: 0px; padding-right: 0px; padding-left: 0px; margin: 0px; border-bottom: 3px double rgb(0, 0, 0);"><span style="color:#333333;"><b>(<ix:nonFraction id="c86424908" contextRef="i_2021-06-30_StatementEquityComponentsAxis-TreasuryStockMember" unitRef="USD" name="us-gaap:StockholdersEquity" scale="3" format="ixt:numdotdecimal" decimals="-3" sign="-">3,054</ix:nonFraction></b></span></td>
      <td style="width: 1%; font-size: 9pt; padding-top: 0px; padding-right: 0px; padding-left: 0px; margin: 0px; border-bottom: 3px double rgb(0, 0, 0);"><span style="color:#333333;"><b>)</b></span></td>
      <td style="width: 1%; font-size: 9pt; padding-top: 0px; padding-right: 0px; padding-left: 0px; margin: 0px; border-bottom: 3px double rgb(0, 0, 0);">&#xa0;</td>
      <td style="width: 1%; font-size: 9pt; padding-top: 0px; padding-right: 0px; padding-left: 0px; margin: 0px; border-bottom: 3px double rgb(0, 0, 0);"><span style="color:#333333;">$</span></td>
      <td style="width: 7%; text-align: right; font-size: 9pt; padding-top: 0px; padding-right: 0px; padding-left: 0px; margin: 0px; border-bottom: 3px double rgb(0, 0, 0);"><span style="color:#333333;"><b><ix:nonFraction id="c86424909" contextRef="i_2021-06-30" unitRef="USD" name="us-gaap:StockholdersEquity" scale="3" format="ixt:numdotdecimal" decimals="-3">56,763</ix:nonFraction></b></span></td>
      <td style="width: 1%; font-size: 9pt; padding: 0px 0px 3px; margin: 0px;">&#xa0;</td>
     </tr>

    </tbody>
   </table>
  </div>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&#xa0;</p>
  <div>
   <table cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 9pt; font-family: &quot;Times New Roman&quot;, Times, serif; text-indent: 0px; margin-left: 0pt; margin-right: 0pt;">
    <tbody>
     <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom">
      <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&#xa0;</td>
      <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&#xa0;</td>
      <td colspan="6" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt; border-bottom: thin solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; font-variant: normal; text-align: center; margin: 0pt;"><span style="color:#333333;"><b><em style="font: inherit;"><em style="font: inherit;">Common Stock</em></em></b></span></p> </td>
      <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&#xa0;</td>
      <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&#xa0;</td>
      <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&#xa0;</td>
      <td style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;"><em style="font: inherit;">&#xa0;</em></td>
      <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;"><span style="color:#333333;"><b>&#xa0;</b></span></td>
      <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&#xa0;</td>
      <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&#xa0;</td>
      <td style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;"><em style="font: inherit;">&#xa0;</em></td>
      <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;"><span style="color:#333333;"><b>&#xa0;</b></span></td>
      <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&#xa0;</td>
      <td colspan="6" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt; border-bottom: thin solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; font-variant: normal; text-align: center; margin: 0pt;"><span style="color:#333333;"><b><em style="font: inherit;"><em style="font: inherit;">Treasury Stock</em></em></b></span></p> </td>
      <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&#xa0;</td>
      <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&#xa0;</td>
      <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&#xa0;</td>
      <td style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;"><em style="font: inherit;">&#xa0;</em></td>
      <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;"><span style="color:#333333;"><b>&#xa0;</b></span></td>
     </tr>

     <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom">
      <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&#xa0;</td>
      <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; padding-bottom: 1px;">&#xa0;</td>
      <td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; font-variant: normal; text-align: center; margin: 0pt;"><span style="color:#333333;"><b><em style="font: inherit;">Shares</em></b></span></p> </td>
      <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td>
      <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td>
      <td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; font-variant: normal; text-align: center; margin: 0pt;"><span style="color:#333333;"><b><em style="font: inherit;">Amount</em></b></span></p> </td>
      <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td>
      <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td>
      <td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; font-variant: normal; text-align: center; margin: 0pt;"><span style="color:#333333;"><b><em style="font: inherit;">Additional Paid-in Capital</em></b></span></p> </td>
      <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td>
      <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td>
      <td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; font-variant: normal; text-align: center; margin: 0pt;"><span style="color:#333333;"><b><em style="font: inherit;">Accumulated Deficit</em></b></span></p> </td>
      <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td>
      <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td>
      <td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; font-variant: normal; text-align: center; margin: 0pt;"><span style="color:#333333;"><b><em style="font: inherit;">Shares</em></b></span></p> </td>
      <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td>
      <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td>
      <td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; font-variant: normal; text-align: center; margin: 0pt;"><span style="color:#333333;"><b><em style="font: inherit;">Amount</em></b></span></p> </td>
      <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td>
      <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td>
      <td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; font-variant: normal; text-align: center; margin: 0pt;"><span style="color:#333333;"><b><em style="font: inherit;">Total</em></b></span></p> </td>
      <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; padding-bottom: 1px;">&#xa0;</td>
     </tr>

     <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom">
      <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&#xa0;</td>
      <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&#xa0;</td>
      <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&#xa0;</td>
      <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&#xa0;</td>
      <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&#xa0;</td>
      <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&#xa0;</td>
      <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&#xa0;</td>
      <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&#xa0;</td>
      <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&#xa0;</td>
      <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&#xa0;</td>
      <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&#xa0;</td>
      <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&#xa0;</td>
      <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&#xa0;</td>
      <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&#xa0;</td>
      <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&#xa0;</td>
      <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&#xa0;</td>
      <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&#xa0;</td>
      <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&#xa0;</td>
      <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&#xa0;</td>
      <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&#xa0;</td>
      <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&#xa0;</td>
      <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&#xa0;</td>
      <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&#xa0;</td>
      <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&#xa0;</td>
      <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&#xa0;</td>
      <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&#xa0;</td>
      <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&#xa0;</td>
      <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&#xa0;</td>
      <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&#xa0;</td>
     </tr>

     <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom">
      <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; width: 30%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;"><span style="color:#333333;"><b>Balance - December 31, 2021</b></span></p> </td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&#xa0;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td>
      <td style="width: 7%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><span style="color:#333333;"><b><ix:nonFraction id="c86424924" contextRef="i_2021-12-31_StatementEquityComponentsAxis-CommonStockMember" unitRef="Share" name="us-gaap:SharesOutstanding" scale="3" format="ixt:numdotdecimal" decimals="-3">28,269</ix:nonFraction></b></span></td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;">&#xa0;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><span style="color:#333333;">$</span></td>
      <td style="width: 7%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><span style="color:#333333;"><b><ix:nonFraction id="c86424925" contextRef="i_2021-12-31_StatementEquityComponentsAxis-CommonStockMember" unitRef="USD" name="us-gaap:StockholdersEquity" scale="3" format="ixt:numdotdecimal" decimals="-3">28</ix:nonFraction></b></span></td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;">&#xa0;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><span style="color:#333333;">$</span></td>
      <td style="width: 7%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><span style="color:#333333;"><b><ix:nonFraction id="c86424926" contextRef="i_2021-12-31_StatementEquityComponentsAxis-AdditionalPaidInCapitalMember" unitRef="USD" name="us-gaap:StockholdersEquity" scale="3" format="ixt:numdotdecimal" decimals="-3">830,231</ix:nonFraction></b></span></td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;">&#xa0;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><span style="color:#333333;">$</span></td>
      <td style="width: 7%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><span style="color:#333333;"><b>(<ix:nonFraction id="c86424927" contextRef="i_2021-12-31_StatementEquityComponentsAxis-RetainedEarningsMember" unitRef="USD" name="us-gaap:StockholdersEquity" scale="3" format="ixt:numdotdecimal" decimals="-3" sign="-">785,324</ix:nonFraction></b></span></td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><span style="color:#333333;"><b>)</b></span></td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td>
      <td style="width: 7%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><span style="color:#333333;"><b><em style="font: inherit;">-</em></b></span></td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;">&#xa0;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><span style="color:#333333;">$</span></td>
      <td style="width: 7%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><span style="color:#333333;"><b>(<ix:nonFraction id="c86424929" contextRef="i_2021-12-31_StatementEquityComponentsAxis-TreasuryStockMember" unitRef="USD" name="us-gaap:StockholdersEquity" scale="3" format="ixt:numdotdecimal" decimals="-3" sign="-">3,054</ix:nonFraction></b></span></td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><span style="color:#333333;"><b>)</b></span></td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><span style="color:#333333;">$</span></td>
      <td style="width: 7%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><span style="color:#333333;"><b><ix:nonFraction id="c86424930" contextRef="i_2021-12-31" unitRef="USD" name="us-gaap:StockholdersEquity" scale="3" format="ixt:numdotdecimal" decimals="-3">41,881</ix:nonFraction></b></span></td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; padding-bottom: 1px; margin-left: 0pt;">&#xa0;</td>
     </tr>

     <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom">
      <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; padding: 0; margin: 0"> <p style="margin-top: 0pt; margin-bottom: 0pt"><span style="color:#333333;">Net loss</span></p> </td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; padding: 0; margin: 0">&#xa0;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; padding: 0; margin: 0">&#xa0;</td>
      <td style="width: 7%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; padding: 0; margin: 0"><span style="color:#333333;"><em style="font: inherit;">-</em></span></td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; padding: 0; margin: 0">&#xa0;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; padding: 0; margin: 0">&#xa0;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; padding: 0; margin: 0">&#xa0;</td>
      <td style="width: 7%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; padding: 0; margin: 0"><span style="color:#333333;"><em style="font: inherit;">-</em></span></td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; padding: 0; margin: 0">&#xa0;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; padding: 0; margin: 0">&#xa0;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; padding: 0; margin: 0">&#xa0;</td>
      <td style="width: 7%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; padding: 0; margin: 0"><span style="color:#333333;"><em style="font: inherit;">-</em></span></td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; padding: 0; margin: 0">&#xa0;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; padding: 0; margin: 0">&#xa0;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; padding: 0; margin: 0">&#xa0;</td>
      <td style="width: 7%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; padding: 0; margin: 0"><span style="color:#333333;">(<ix:nonFraction id="c86424934" contextRef="d_2022-01-01_2022-03-31_StatementEquityComponentsAxis-RetainedEarningsMember" unitRef="USD" name="us-gaap:NetIncomeLoss" scale="3" format="ixt:numdotdecimal" decimals="-3" sign="-">8,127</ix:nonFraction></span></td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; padding: 0; margin: 0"><span style="color:#333333;">)</span></td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; padding: 0; margin: 0">&#xa0;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; padding: 0; margin: 0">&#xa0;</td>
      <td style="width: 7%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; padding: 0; margin: 0"><span style="color:#333333;"><em style="font: inherit;">-</em></span></td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; padding: 0; margin: 0">&#xa0;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; padding: 0; margin: 0">&#xa0;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; padding: 0; margin: 0">&#xa0;</td>
      <td style="width: 7%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; padding: 0; margin: 0"><span style="color:#333333;"><em style="font: inherit;">-</em></span></td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; padding: 0; margin: 0">&#xa0;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; padding: 0; margin: 0">&#xa0;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; padding: 0; margin: 0">&#xa0;</td>
      <td style="width: 7%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; padding: 0; margin: 0"><span style="color:#333333;">(<ix:nonFraction id="c86424937" contextRef="d_2022-01-01_2022-03-31" unitRef="USD" name="us-gaap:NetIncomeLoss" scale="3" format="ixt:numdotdecimal" decimals="-3" sign="-">8,127</ix:nonFraction></span></td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; padding: 0; margin: 0"><span style="color:#333333;">)</span></td>
     </tr>

     <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom">
      <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; padding: 0; margin: 0"> <p style="margin-top: 0pt; margin-bottom: 0pt"><span style="color:#333333;">Stock-based compensation expense</span></p> </td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; padding: 0; margin: 0">&#xa0;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; padding: 0; margin: 0">&#xa0;</td>
      <td style="width: 7%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; padding: 0; margin: 0"><span style="color:#333333;"><em style="font: inherit;">-</em></span></td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; padding: 0; margin: 0">&#xa0;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; padding: 0; margin: 0">&#xa0;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; padding: 0; margin: 0">&#xa0;</td>
      <td style="width: 7%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; padding: 0; margin: 0"><span style="color:#333333;"><em style="font: inherit;">-</em></span></td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; padding: 0; margin: 0">&#xa0;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; padding: 0; margin: 0">&#xa0;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; padding: 0; margin: 0">&#xa0;</td>
      <td style="width: 7%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; padding: 0; margin: 0"><span style="color:#333333;"><ix:nonFraction id="c86424940" contextRef="d_2022-01-01_2022-03-31_StatementEquityComponentsAxis-AdditionalPaidInCapitalMember" unitRef="USD" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="3" format="ixt:numdotdecimal" decimals="-4">770</ix:nonFraction></span></td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; padding: 0; margin: 0">&#xa0;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; padding: 0; margin: 0">&#xa0;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; padding: 0; margin: 0">&#xa0;</td>
      <td style="width: 7%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; padding: 0; margin: 0"><span style="color:#333333;"><em style="font: inherit;">-</em></span></td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; padding: 0; margin: 0">&#xa0;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; padding: 0; margin: 0">&#xa0;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; padding: 0; margin: 0">&#xa0;</td>
      <td style="width: 7%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; padding: 0; margin: 0"><span style="color:#333333;"><em style="font: inherit;">-</em></span></td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; padding: 0; margin: 0">&#xa0;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; padding: 0; margin: 0">&#xa0;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; padding: 0; margin: 0">&#xa0;</td>
      <td style="width: 7%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; padding: 0; margin: 0"><span style="color:#333333;"><em style="font: inherit;">-</em></span></td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; padding: 0; margin: 0">&#xa0;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; padding: 0; margin: 0">&#xa0;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; padding: 0; margin: 0">&#xa0;</td>
      <td style="width: 7%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; padding: 0; margin: 0"><span style="color:#333333;"><ix:nonFraction id="c86424944" contextRef="d_2022-01-01_2022-03-31" unitRef="USD" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="3" format="ixt:numdotdecimal" decimals="-4">770</ix:nonFraction></span></td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; padding: 0; margin: 0">&#xa0;</td>
     </tr>

     <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom">
      <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; padding-top: 0px; padding-right: 0px; padding-left: 0px; margin: 0px;"> <p style="margin-top: 0pt; margin-bottom: 0pt"><span style="color:#333333;">Issuance of common stock, ATM Program, net of issuance costs</span></p> </td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; padding: 0px 0px 1px; margin: 0px;">&#xa0;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; padding-top: 0px; padding-right: 0px; padding-left: 0px; margin: 0px; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td>
      <td style="width: 7%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; padding-top: 0px; padding-right: 0px; padding-left: 0px; margin: 0px; border-bottom: 1px solid rgb(0, 0, 0);"><span style="color:#333333;"><ix:nonFraction id="c86424945" contextRef="d_2022-01-01_2022-03-31_StatementClassOfStockAxis-ATMProgramMember_StatementEquityComponentsAxis-CommonStockMember" unitRef="Share" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" scale="3" format="ixt:numdotdecimal" decimals="-5">200</ix:nonFraction></span></td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; padding-top: 0px; padding-right: 0px; padding-left: 0px; margin: 0px; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; padding-top: 0px; padding-right: 0px; padding-left: 0px; margin: 0px; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; padding-top: 0px; padding-right: 0px; padding-left: 0px; margin: 0px; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td>
      <td style="width: 7%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; padding-top: 0px; padding-right: 0px; padding-left: 0px; margin: 0px; border-bottom: 1px solid rgb(0, 0, 0);"><span style="color:#333333;"><ix:nonFraction id="c86424946" contextRef="d_2022-01-01_2022-03-31_StatementClassOfStockAxis-ATMProgramMember_StatementEquityComponentsAxis-CommonStockMember" unitRef="USD" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="3" format="ixt:zerodash" decimals="-3">-</ix:nonFraction></span></td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; padding-top: 0px; padding-right: 0px; padding-left: 0px; margin: 0px; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; padding-top: 0px; padding-right: 0px; padding-left: 0px; margin: 0px; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; padding-top: 0px; padding-right: 0px; padding-left: 0px; margin: 0px; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td>
      <td style="width: 7%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; padding-top: 0px; padding-right: 0px; padding-left: 0px; margin: 0px; border-bottom: 1px solid rgb(0, 0, 0);"><span style="color:#333333;"><ix:nonFraction id="c86424947" contextRef="d_2022-01-01_2022-03-31_StatementClassOfStockAxis-ATMProgramMember_StatementEquityComponentsAxis-AdditionalPaidInCapitalMember" unitRef="USD" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="3" format="ixt:numdotdecimal" decimals="-3">205</ix:nonFraction></span></td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; padding-top: 0px; padding-right: 0px; padding-left: 0px; margin: 0px; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; padding-top: 0px; padding-right: 0px; padding-left: 0px; margin: 0px; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; padding-top: 0px; padding-right: 0px; padding-left: 0px; margin: 0px; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td>
      <td style="width: 7%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; padding-top: 0px; padding-right: 0px; padding-left: 0px; margin: 0px; border-bottom: 1px solid rgb(0, 0, 0);"><span style="color:#333333;"><ix:nonFraction id="c86424948" contextRef="d_2022-01-01_2022-03-31_StatementClassOfStockAxis-ATMProgramMember_StatementEquityComponentsAxis-RetainedEarningsMember" unitRef="USD" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="3" format="ixt:zerodash" decimals="-3">-</ix:nonFraction></span></td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; padding-top: 0px; padding-right: 0px; padding-left: 0px; margin: 0px; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; padding-top: 0px; padding-right: 0px; padding-left: 0px; margin: 0px; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; padding-top: 0px; padding-right: 0px; padding-left: 0px; margin: 0px; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td>
      <td style="width: 7%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; padding-top: 0px; padding-right: 0px; padding-left: 0px; margin: 0px; border-bottom: 1px solid rgb(0, 0, 0);"><span style="color:#333333;"><ix:nonFraction id="c86424949" contextRef="d_2022-01-01_2022-03-31_StatementClassOfStockAxis-ATMProgramMember_StatementEquityComponentsAxis-TreasuryStockMember" unitRef="Share" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" scale="3" format="ixt:zerodash" decimals="-3">-</ix:nonFraction></span></td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; padding-top: 0px; padding-right: 0px; padding-left: 0px; margin: 0px; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; padding-top: 0px; padding-right: 0px; padding-left: 0px; margin: 0px; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; padding-top: 0px; padding-right: 0px; padding-left: 0px; margin: 0px; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td>
      <td style="width: 7%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; padding-top: 0px; padding-right: 0px; padding-left: 0px; margin: 0px; border-bottom: 1px solid rgb(0, 0, 0);"><span style="color:#333333;"><ix:nonFraction id="c86424950" contextRef="d_2022-01-01_2022-03-31_StatementClassOfStockAxis-ATMProgramMember_StatementEquityComponentsAxis-TreasuryStockMember" unitRef="USD" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="3" format="ixt:zerodash" decimals="-3">-</ix:nonFraction></span></td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; padding-top: 0px; padding-right: 0px; padding-left: 0px; margin: 0px; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; padding-top: 0px; padding-right: 0px; padding-left: 0px; margin: 0px; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; padding-top: 0px; padding-right: 0px; padding-left: 0px; margin: 0px; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td>
      <td style="width: 7%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; padding-top: 0px; padding-right: 0px; padding-left: 0px; margin: 0px; border-bottom: 1px solid rgb(0, 0, 0);"><span style="color:#333333;"><ix:nonFraction id="c86424951" contextRef="d_2022-01-01_2022-03-31_StatementClassOfStockAxis-ATMProgramMember" unitRef="USD" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="3" format="ixt:numdotdecimal" decimals="-3">205</ix:nonFraction></span></td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; padding: 0px 0px 1px; margin: 0px;">&#xa0;</td>
     </tr>

     <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom">
      <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;"><span style="color:#333333;"><b>Balance - March 31, 2022</b></span></p> </td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&#xa0;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; border-bottom: 3px double rgb(0, 0, 0);">&#xa0;</td>
      <td style="width: 7%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><span style="color:#333333;"><b><ix:nonFraction id="c86424952" contextRef="i_2022-03-31_StatementEquityComponentsAxis-CommonStockMember" unitRef="Share" name="us-gaap:SharesOutstanding" scale="3" format="ixt:numdotdecimal" decimals="-3">28,469</ix:nonFraction></b></span></td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;">&#xa0;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; border-bottom: 3px double rgb(0, 0, 0);">&#xa0;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><span style="color:#333333;">$</span></td>
      <td style="width: 7%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><span style="color:#333333;"><b><ix:nonFraction id="c86424953" contextRef="i_2022-03-31_StatementEquityComponentsAxis-CommonStockMember" unitRef="USD" name="us-gaap:StockholdersEquity" scale="3" format="ixt:numdotdecimal" decimals="-3">28</ix:nonFraction></b></span></td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;">&#xa0;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; border-bottom: 3px double rgb(0, 0, 0);">&#xa0;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><span style="color:#333333;">$</span></td>
      <td style="width: 7%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><span style="color:#333333;"><b><ix:nonFraction id="c86424954" contextRef="i_2022-03-31_StatementEquityComponentsAxis-AdditionalPaidInCapitalMember" unitRef="USD" name="us-gaap:StockholdersEquity" scale="3" format="ixt:numdotdecimal" decimals="-3">831,206</ix:nonFraction></b></span></td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;">&#xa0;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; border-bottom: 3px double rgb(0, 0, 0);">&#xa0;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><span style="color:#333333;">$</span></td>
      <td style="width: 7%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><span style="color:#333333;"><b>(<ix:nonFraction id="c86424955" contextRef="i_2022-03-31_StatementEquityComponentsAxis-RetainedEarningsMember" unitRef="USD" name="us-gaap:StockholdersEquity" scale="3" format="ixt:numdotdecimal" decimals="-3" sign="-">793,451</ix:nonFraction></b></span></td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><span style="color:#333333;"><b>)</b></span></td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; border-bottom: 3px double rgb(0, 0, 0);">&#xa0;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; border-bottom: 3px double rgb(0, 0, 0);">&#xa0;</td>
      <td style="width: 7%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><span style="color:#333333;"><b><em style="font: inherit;">-</em></b></span></td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;">&#xa0;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; border-bottom: 3px double rgb(0, 0, 0);">&#xa0;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><span style="color:#333333;">$</span></td>
      <td style="width: 7%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><span style="color:#333333;"><b>(<ix:nonFraction id="c86424957" contextRef="i_2022-03-31_StatementEquityComponentsAxis-TreasuryStockMember" unitRef="USD" name="us-gaap:StockholdersEquity" scale="3" format="ixt:numdotdecimal" decimals="-3" sign="-">3,054</ix:nonFraction></b></span></td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><span style="color:#333333;"><b>)</b></span></td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; border-bottom: 3px double rgb(0, 0, 0);">&#xa0;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><span style="color:#333333;">$</span></td>
      <td style="width: 7%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><span style="color:#333333;"><b><ix:nonFraction id="c86424958" contextRef="i_2022-03-31" unitRef="USD" name="us-gaap:StockholdersEquity" scale="3" format="ixt:numdotdecimal" decimals="-3">34,729</ix:nonFraction></b></span></td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; padding-bottom: 3px; margin-left: 0pt;">&#xa0;</td>
     </tr>

     <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom">
      <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; padding: 0; margin: 0"> <p style="margin-top: 0pt; margin-bottom: 0pt"><span style="color:#333333;">Net loss</span></p> </td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; padding: 0; margin: 0">&#xa0;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; padding: 0; margin: 0">&#xa0;</td>
      <td style="width: 7%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; padding: 0; margin: 0"><span style="color:#333333;"><em style="font: inherit;">-</em></span></td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; padding: 0; margin: 0">&#xa0;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; padding: 0; margin: 0">&#xa0;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; padding: 0; margin: 0">&#xa0;</td>
      <td style="width: 7%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; padding: 0; margin: 0"><span style="color:#333333;"><ix:nonFraction id="c86424960" contextRef="d_2022-04-01_2022-06-30_StatementEquityComponentsAxis-CommonStockMember" unitRef="USD" name="us-gaap:NetIncomeLoss" scale="3" format="ixt:zerodash" decimals="-3">-</ix:nonFraction></span></td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; padding: 0; margin: 0">&#xa0;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; padding: 0; margin: 0">&#xa0;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; padding: 0; margin: 0">&#xa0;</td>
      <td style="width: 7%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; padding: 0; margin: 0"><span style="color:#333333;"><ix:nonFraction id="c86424961" contextRef="d_2022-04-01_2022-06-30_StatementEquityComponentsAxis-AdditionalPaidInCapitalMember" unitRef="USD" name="us-gaap:NetIncomeLoss" scale="3" format="ixt:zerodash" decimals="-3">-</ix:nonFraction></span></td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; padding: 0; margin: 0">&#xa0;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; padding: 0; margin: 0">&#xa0;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; padding: 0; margin: 0">&#xa0;</td>
      <td style="width: 7%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; padding: 0; margin: 0"><span style="color:#333333;">(<ix:nonFraction id="c86424962" contextRef="d_2022-04-01_2022-06-30_StatementEquityComponentsAxis-RetainedEarningsMember" unitRef="USD" name="us-gaap:NetIncomeLoss" scale="3" format="ixt:numdotdecimal" decimals="-3" sign="-">17,333</ix:nonFraction></span></td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; padding: 0; margin: 0"><span style="color:#333333;">)</span></td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; padding: 0; margin: 0">&#xa0;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; padding: 0; margin: 0">&#xa0;</td>
      <td style="width: 7%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; padding: 0; margin: 0"><span style="color:#333333;"><em style="font: inherit;">-</em></span></td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; padding: 0; margin: 0">&#xa0;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; padding: 0; margin: 0">&#xa0;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; padding: 0; margin: 0">&#xa0;</td>
      <td style="width: 7%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; padding: 0; margin: 0"><span style="color:#333333;"><ix:nonFraction id="c86424964" contextRef="d_2022-04-01_2022-06-30_StatementEquityComponentsAxis-TreasuryStockMember" unitRef="USD" name="us-gaap:NetIncomeLoss" scale="3" format="ixt:zerodash" decimals="-3">-</ix:nonFraction></span></td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; padding: 0; margin: 0">&#xa0;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; padding: 0; margin: 0">&#xa0;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; padding: 0; margin: 0">&#xa0;</td>
      <td style="width: 7%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; padding: 0; margin: 0"><span style="color:#333333;">(<ix:nonFraction id="c86424965" contextRef="d_2022-04-01_2022-06-30" unitRef="USD" name="us-gaap:NetIncomeLoss" scale="3" format="ixt:numdotdecimal" decimals="-3" sign="-">17,333</ix:nonFraction></span></td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; padding: 0; margin: 0"><span style="color:#333333;">)</span></td>
     </tr>

     <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom">
      <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; padding: 0; margin: 0"> <p style="margin-top: 0pt; margin-bottom: 0pt"><span style="color:#333333;">Stock-based compensation expense</span></p> </td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; padding: 0; margin: 0">&#xa0;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; padding: 0; margin: 0">&#xa0;</td>
      <td style="width: 7%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; padding: 0; margin: 0"><span style="color:#333333;"><em style="font: inherit;">-</em></span></td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; padding: 0; margin: 0">&#xa0;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; padding: 0; margin: 0">&#xa0;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; padding: 0; margin: 0">&#xa0;</td>
      <td style="width: 7%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; padding: 0; margin: 0"><span style="color:#333333;"><ix:nonFraction id="c86424967" contextRef="d_2022-04-01_2022-06-30_StatementEquityComponentsAxis-CommonStockMember" unitRef="USD" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="3" format="ixt:zerodash" decimals="-3">-</ix:nonFraction></span></td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; padding: 0; margin: 0">&#xa0;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; padding: 0; margin: 0">&#xa0;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; padding: 0; margin: 0">&#xa0;</td>
      <td style="width: 7%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; padding: 0; margin: 0"><span style="color:#333333;"><ix:nonFraction id="c86424968" contextRef="d_2022-04-01_2022-06-30_StatementEquityComponentsAxis-AdditionalPaidInCapitalMember" unitRef="USD" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="3" format="ixt:numdotdecimal" decimals="-3">781</ix:nonFraction></span></td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; padding: 0; margin: 0">&#xa0;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; padding: 0; margin: 0">&#xa0;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; padding: 0; margin: 0">&#xa0;</td>
      <td style="width: 7%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; padding: 0; margin: 0"><span style="color:#333333;"><ix:nonFraction id="c86424969" contextRef="d_2022-04-01_2022-06-30_StatementEquityComponentsAxis-RetainedEarningsMember" unitRef="USD" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="3" format="ixt:zerodash" decimals="-3">-</ix:nonFraction></span></td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; padding: 0; margin: 0">&#xa0;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; padding: 0; margin: 0">&#xa0;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; padding: 0; margin: 0">&#xa0;</td>
      <td style="width: 7%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; padding: 0; margin: 0"><span style="color:#333333;"><em style="font: inherit;">-</em></span></td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; padding: 0; margin: 0">&#xa0;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; padding: 0; margin: 0">&#xa0;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; padding: 0; margin: 0">&#xa0;</td>
      <td style="width: 7%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; padding: 0; margin: 0"><span style="color:#333333;"><ix:nonFraction id="c86424971" contextRef="d_2022-04-01_2022-06-30_StatementEquityComponentsAxis-TreasuryStockMember" unitRef="USD" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="3" format="ixt:zerodash" decimals="-3">-</ix:nonFraction></span></td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; padding: 0; margin: 0">&#xa0;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; padding: 0; margin: 0">&#xa0;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; padding: 0; margin: 0">&#xa0;</td>
      <td style="width: 7%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; padding: 0; margin: 0"><span style="color:#333333;"><ix:nonFraction id="c86424972" contextRef="d_2022-04-01_2022-06-30" unitRef="USD" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="3" format="ixt:numdotdecimal" decimals="-3">781</ix:nonFraction></span></td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; padding: 0; margin: 0">&#xa0;</td>
     </tr>

     <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom">
      <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; padding-top: 0px; padding-right: 0px; padding-left: 0px; margin: 0px;"> <p style="margin-top: 0pt; margin-bottom: 0pt"><span style="color:#333333;">Issuance of common stock, ATM Program, net of issuance costs</span></p> </td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; padding: 0px 0px 1px; margin: 0px;">&#xa0;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; padding-top: 0px; padding-right: 0px; padding-left: 0px; margin: 0px; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td>
      <td style="width: 7%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; padding-top: 0px; padding-right: 0px; padding-left: 0px; margin: 0px; border-bottom: 1px solid rgb(0, 0, 0);"><span style="color:#333333;"><ix:nonFraction id="c86424973" contextRef="d_2022-04-01_2022-06-30_StatementEquityComponentsAxis-CommonStockMember" unitRef="Share" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" scale="3" format="ixt:numdotdecimal" decimals="-3">937</ix:nonFraction></span></td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; padding-top: 0px; padding-right: 0px; padding-left: 0px; margin: 0px; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; padding-top: 0px; padding-right: 0px; padding-left: 0px; margin: 0px; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; padding-top: 0px; padding-right: 0px; padding-left: 0px; margin: 0px; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td>
      <td style="width: 7%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; padding-top: 0px; padding-right: 0px; padding-left: 0px; margin: 0px; border-bottom: 1px solid rgb(0, 0, 0);"><span style="color:#333333;"><ix:nonFraction id="c86424974" contextRef="d_2022-04-01_2022-06-30_StatementEquityComponentsAxis-CommonStockMember" unitRef="USD" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="3" format="ixt:numdotdecimal" decimals="-3">1</ix:nonFraction></span></td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; padding-top: 0px; padding-right: 0px; padding-left: 0px; margin: 0px; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; padding-top: 0px; padding-right: 0px; padding-left: 0px; margin: 0px; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; padding-top: 0px; padding-right: 0px; padding-left: 0px; margin: 0px; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td>
      <td style="width: 7%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; padding-top: 0px; padding-right: 0px; padding-left: 0px; margin: 0px; border-bottom: 1px solid rgb(0, 0, 0);"><span style="color:#333333;"><ix:nonFraction id="c86424975" contextRef="d_2022-04-01_2022-06-30_StatementEquityComponentsAxis-AdditionalPaidInCapitalMember" unitRef="USD" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="3" format="ixt:numdotdecimal" decimals="-3">1,019</ix:nonFraction></span></td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; padding-top: 0px; padding-right: 0px; padding-left: 0px; margin: 0px; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; padding-top: 0px; padding-right: 0px; padding-left: 0px; margin: 0px; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; padding-top: 0px; padding-right: 0px; padding-left: 0px; margin: 0px; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td>
      <td style="width: 7%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; padding-top: 0px; padding-right: 0px; padding-left: 0px; margin: 0px; border-bottom: 1px solid rgb(0, 0, 0);"><span style="color:#333333;"><ix:nonFraction id="c86424976" contextRef="d_2022-04-01_2022-06-30_StatementEquityComponentsAxis-RetainedEarningsMember" unitRef="USD" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="3" format="ixt:zerodash" decimals="-3">-</ix:nonFraction></span></td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; padding-top: 0px; padding-right: 0px; padding-left: 0px; margin: 0px; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; padding-top: 0px; padding-right: 0px; padding-left: 0px; margin: 0px; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; padding-top: 0px; padding-right: 0px; padding-left: 0px; margin: 0px; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td>
      <td style="width: 7%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; padding-top: 0px; padding-right: 0px; padding-left: 0px; margin: 0px; border-bottom: 1px solid rgb(0, 0, 0);"><span style="color:#333333;"><ix:nonFraction id="c86424977" contextRef="d_2022-04-01_2022-06-30_StatementEquityComponentsAxis-TreasuryStockMember" unitRef="Share" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" scale="3" format="ixt:zerodash" decimals="-3">-</ix:nonFraction></span></td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; padding-top: 0px; padding-right: 0px; padding-left: 0px; margin: 0px; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; padding-top: 0px; padding-right: 0px; padding-left: 0px; margin: 0px; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; padding-top: 0px; padding-right: 0px; padding-left: 0px; margin: 0px; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td>
      <td style="width: 7%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; padding-top: 0px; padding-right: 0px; padding-left: 0px; margin: 0px; border-bottom: 1px solid rgb(0, 0, 0);"><span style="color:#333333;"><ix:nonFraction id="c86424978" contextRef="d_2022-04-01_2022-06-30_StatementEquityComponentsAxis-TreasuryStockMember" unitRef="USD" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="3" format="ixt:zerodash" decimals="-3">-</ix:nonFraction></span></td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; padding-top: 0px; padding-right: 0px; padding-left: 0px; margin: 0px; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; padding-top: 0px; padding-right: 0px; padding-left: 0px; margin: 0px; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; padding-top: 0px; padding-right: 0px; padding-left: 0px; margin: 0px; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td>
      <td style="width: 7%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; padding-top: 0px; padding-right: 0px; padding-left: 0px; margin: 0px; border-bottom: 1px solid rgb(0, 0, 0);"><span style="color:#333333;"><ix:nonFraction id="c86424979" contextRef="d_2022-04-01_2022-06-30" unitRef="USD" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="3" format="ixt:numdotdecimal" decimals="-4">1,020</ix:nonFraction></span></td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; padding: 0px 0px 1px; margin: 0px;">&#xa0;</td>
     </tr>

     <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom">
      <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; padding-top: 0px; padding-right: 0px; padding-left: 0px; margin: 0px;"> <p style="margin-top: 0pt; margin-bottom: 0pt"><span style="color:#333333;"><b>Balance - June 30, 2022</b></span></p> </td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; padding: 0px 0px 3px; margin: 0px;">&#xa0;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; padding-top: 0px; padding-right: 0px; padding-left: 0px; margin: 0px; border-bottom: 3px double rgb(0, 0, 0);">&#xa0;</td>
      <td style="width: 7%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; padding-top: 0px; padding-right: 0px; padding-left: 0px; margin: 0px; border-bottom: 3px double rgb(0, 0, 0);"><span style="color:#333333;"><b><ix:nonFraction id="c86424980" contextRef="i_2022-06-30_StatementEquityComponentsAxis-CommonStockMember" unitRef="Share" name="us-gaap:SharesOutstanding" scale="3" format="ixt:numdotdecimal" decimals="-3">29,406</ix:nonFraction></b></span></td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; padding-top: 0px; padding-right: 0px; padding-left: 0px; margin: 0px; border-bottom: 3px double rgb(0, 0, 0);">&#xa0;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; padding-top: 0px; padding-right: 0px; padding-left: 0px; margin: 0px; border-bottom: 3px double rgb(0, 0, 0);">&#xa0;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; padding-top: 0px; padding-right: 0px; padding-left: 0px; margin: 0px; border-bottom: 3px double rgb(0, 0, 0);"><span style="color:#333333;">$</span></td>
      <td style="width: 7%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; padding-top: 0px; padding-right: 0px; padding-left: 0px; margin: 0px; border-bottom: 3px double rgb(0, 0, 0);"><span style="color:#333333;"><b><ix:nonFraction id="c86424981" contextRef="i_2022-06-30_StatementEquityComponentsAxis-CommonStockMember" unitRef="USD" name="us-gaap:StockholdersEquity" scale="3" format="ixt:numdotdecimal" decimals="-3">29</ix:nonFraction></b></span></td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; padding-top: 0px; padding-right: 0px; padding-left: 0px; margin: 0px; border-bottom: 3px double rgb(0, 0, 0);">&#xa0;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; padding-top: 0px; padding-right: 0px; padding-left: 0px; margin: 0px; border-bottom: 3px double rgb(0, 0, 0);">&#xa0;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; padding-top: 0px; padding-right: 0px; padding-left: 0px; margin: 0px; border-bottom: 3px double rgb(0, 0, 0);"><span style="color:#333333;">$</span></td>
      <td style="width: 7%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; padding-top: 0px; padding-right: 0px; padding-left: 0px; margin: 0px; border-bottom: 3px double rgb(0, 0, 0);"><span style="color:#333333;"><b><ix:nonFraction id="c86424982" contextRef="i_2022-06-30_StatementEquityComponentsAxis-AdditionalPaidInCapitalMember" unitRef="USD" name="us-gaap:StockholdersEquity" scale="3" format="ixt:numdotdecimal" decimals="-3">833,006</ix:nonFraction></b></span></td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; padding-top: 0px; padding-right: 0px; padding-left: 0px; margin: 0px; border-bottom: 3px double rgb(0, 0, 0);">&#xa0;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; padding-top: 0px; padding-right: 0px; padding-left: 0px; margin: 0px; border-bottom: 3px double rgb(0, 0, 0);">&#xa0;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; padding-top: 0px; padding-right: 0px; padding-left: 0px; margin: 0px; border-bottom: 3px double rgb(0, 0, 0);"><span style="color:#333333;">$</span></td>
      <td style="width: 7%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; padding-top: 0px; padding-right: 0px; padding-left: 0px; margin: 0px; border-bottom: 3px double rgb(0, 0, 0);"><span style="color:#333333;"><b>(<ix:nonFraction id="c86424983" contextRef="i_2022-06-30_StatementEquityComponentsAxis-RetainedEarningsMember" unitRef="USD" name="us-gaap:StockholdersEquity" scale="3" format="ixt:numdotdecimal" decimals="-3" sign="-">810,784</ix:nonFraction></b></span></td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; padding-top: 0px; padding-right: 0px; padding-left: 0px; margin: 0px; border-bottom: 3px double rgb(0, 0, 0);"><span style="color:#333333;"><b>)</b></span></td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; padding-top: 0px; padding-right: 0px; padding-left: 0px; margin: 0px; border-bottom: 3px double rgb(0, 0, 0);">&#xa0;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; padding-top: 0px; padding-right: 0px; padding-left: 0px; margin: 0px; border-bottom: 3px double rgb(0, 0, 0);">&#xa0;</td>
      <td style="width: 7%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; padding-top: 0px; padding-right: 0px; padding-left: 0px; margin: 0px; border-bottom: 3px double rgb(0, 0, 0);"><span style="color:#333333;"><b><ix:nonFraction id="c86424984" contextRef="i_2022-06-30_StatementEquityComponentsAxis-TreasuryStockMember" unitRef="Share" name="us-gaap:SharesOutstanding" scale="3" format="ixt:zerodash" decimals="-3">-</ix:nonFraction></b></span></td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; padding-top: 0px; padding-right: 0px; padding-left: 0px; margin: 0px; border-bottom: 3px double rgb(0, 0, 0);">&#xa0;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; padding-top: 0px; padding-right: 0px; padding-left: 0px; margin: 0px; border-bottom: 3px double rgb(0, 0, 0);">&#xa0;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; padding-top: 0px; padding-right: 0px; padding-left: 0px; margin: 0px; border-bottom: 3px double rgb(0, 0, 0);"><span style="color:#333333;">$</span></td>
      <td style="width: 7%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; padding-top: 0px; padding-right: 0px; padding-left: 0px; margin: 0px; border-bottom: 3px double rgb(0, 0, 0);"><span style="color:#333333;"><b>(<ix:nonFraction id="c86424985" contextRef="i_2022-06-30_StatementEquityComponentsAxis-TreasuryStockMember" unitRef="USD" name="us-gaap:StockholdersEquity" scale="3" format="ixt:numdotdecimal" decimals="-3" sign="-">3,054</ix:nonFraction></b></span></td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; padding-top: 0px; padding-right: 0px; padding-left: 0px; margin: 0px; border-bottom: 3px double rgb(0, 0, 0);"><span style="color:#333333;"><b>)</b></span></td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; padding-top: 0px; padding-right: 0px; padding-left: 0px; margin: 0px; border-bottom: 3px double rgb(0, 0, 0);">&#xa0;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; padding-top: 0px; padding-right: 0px; padding-left: 0px; margin: 0px; border-bottom: 3px double rgb(0, 0, 0);"><span style="color:#333333;">$</span></td>
      <td style="width: 7%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; padding-top: 0px; padding-right: 0px; padding-left: 0px; margin: 0px; border-bottom: 3px double rgb(0, 0, 0);"><span style="color:#333333;"><b><ix:nonFraction id="c86424986" contextRef="i_2022-06-30" unitRef="USD" name="us-gaap:StockholdersEquity" scale="3" format="ixt:numdotdecimal" decimals="-3">19,197</ix:nonFraction></b></span></td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; padding: 0px 0px 3px; margin: 0px;">&#xa0;</td>
     </tr>

    </tbody>
   </table>
  </div>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&#xa0;</p>
  <table border="0" cellpadding="0" cellspacing="0" style="width:100%;text-indent:0;font-family:'Times New Roman', Times, serif;font-size:10pt;">
   <tbody>
    <tr>
     <td style="vertical-align:bottom;width:100%;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><span style="color:#333333;"><i>See notes to condensed consolidated financial statements</i></span></p> </td>
    </tr>

   </tbody>
  </table>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&#xa0;</p>
  <div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
   <div class="PGFTR" style="text-align: center; width: 100%">
    <div class="hf-row">
     <div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">
       6
     </div>
    </div>
   </div>
   <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000" />
   <div class="PGHDR" style="text-align: left; width: 100%">
    <div class="hf-row">
     <div class="hf-cell TOCLink" style="display: inline-block; text-align: left;">
      <a href="#toc" style="font-weight: initial; font-style: initial; font-variant: initial; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif;">Table of Contents</a>
     </div>
     <div class="hf-cell TOCLink" style="display: inline-block; text-align: left;">
       &#xa0;
     </div>
     <div class="hf-cell TOCLink" style="display: inline-block; text-align: left;">
       &#xa0;
     </div>
     <div class="hf-cell TOCLink" style="display: inline-block; text-align: left;">
       &#xa0;
     </div>
     <div class="hf-cell TOCLink" style="display: inline-block; text-align: left;">
       &#xa0;
     </div>
    </div>
   </div>
  </div>
  <div>
    &#xa0;
  </div>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&#xa0;</p>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><span style="color:#333333;"><b><a id="CashFlows" title="CashFlows" href="#"></a>WINDTREE THERAPEUTICS, INC. AND SUBSIDIARIES</b></span></p>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><span style="color:#333333;"><b>Condensed Consolidated Statements of Cash Flows </b></span></p>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><span style="color:#333333;">(Unaudited)</span></p>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&#xa0;</p>
  <table border="0" cellpadding="0" cellspacing="0" style="width:100%;text-indent:0;font-family:'Times New Roman', Times, serif;font-size:10pt;">
   <tbody>
    <tr>
     <td style="vertical-align:bottom;width:100%;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><span style="color:#333333;"><i>(in thousands)</i></span></p> </td>
    </tr>

   </tbody>
  </table>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&#xa0;</p>
  <div>
   <table class="finTable" style="width: 100%; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; text-indent: 0px;" cellspacing="0" cellpadding="0" border="0"><tbody><tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td colspan="6" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><span style="color:#333333;"><b><em style="font: inherit;"><em style="font: inherit;">Six Months Ended</em></em></b></span></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td colspan="6" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><span style="color:#333333;"><b><em style="font: inherit;"><em style="font: inherit;">June 30,</em></em></b></span></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><span style="color:#333333;"><b><em style="font: inherit;">2022</em></b></span></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#xa0;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><span style="color:#333333;"><b><em style="font: inherit;">2021</em></b></span></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#xa0;</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 70%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><span style="color:#333333;"><b>Cash flows from operating activities:</b></span></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><span style="color:#333333;"><b>&#xa0;</b></span></td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><span style="color:#333333;"><b>&#xa0;</b></span></td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 18pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 18pt;"><span style="color:#333333;">Net loss</span></p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><span style="color:#333333;">$</span></td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><span style="color:#333333;">(<ix:nonFraction id="c86424994" contextRef="d_2022-01-01_2022-06-30" unitRef="USD" name="us-gaap:NetIncomeLoss" scale="3" format="ixt:numdotdecimal" decimals="-4" sign="-">25,460</ix:nonFraction></span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><span style="color:#333333;">)</span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><span style="color:#333333;">$</span></td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><span style="color:#333333;">(<ix:nonFraction id="c86424995" contextRef="d_2021-01-01_2021-06-30" unitRef="USD" name="us-gaap:NetIncomeLoss" scale="3" format="ixt:numdotdecimal" decimals="-4" sign="-">46,350</ix:nonFraction></span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><span style="color:#333333;">)</span></td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 18pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 18pt;"><span style="color:#333333;">Adjustments to reconcile net loss to net cash used in operating activities:</span></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom" class="GFJY4-DFU-com-rdg-thunderdome-client-resources-CssResource-html-lineItem-v2v-addition"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 36pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 36pt;"><span style="color:#333333;">Depreciation and amortization</span></p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><span style="color:#333333;"><ix:nonFraction id="c86424997" contextRef="d_2022-01-01_2022-06-30" unitRef="USD" name="us-gaap:Depreciation" scale="3" format="ixt:numdotdecimal" decimals="-3">488</ix:nonFraction></span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><span style="color:#333333;"><ix:nonFraction id="c86424998" contextRef="d_2021-01-01_2021-06-30" unitRef="USD" name="us-gaap:Depreciation" scale="3" format="ixt:numdotdecimal" decimals="-3">93</ix:nonFraction></span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#xa0;</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 36pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 36pt;"><span style="color:#333333;">Stock-based compensation</span></p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><span style="color:#333333;"><ix:nonFraction id="c86424999" contextRef="d_2022-01-01_2022-06-30" unitRef="USD" name="us-gaap:EmployeeBenefitsAndShareBasedCompensation" scale="3" format="ixt:numdotdecimal" decimals="-3">1,551</ix:nonFraction></span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><span style="color:#333333;"><ix:nonFraction id="c86425000" contextRef="d_2021-01-01_2021-06-30" unitRef="USD" name="us-gaap:EmployeeBenefitsAndShareBasedCompensation" scale="3" format="ixt:numdotdecimal" decimals="-3">3,987</ix:nonFraction></span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#xa0;</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 36pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 36pt;"><span style="color:#333333;">Non-cash lease expense</span></p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><span style="color:#333333;"><ix:nonFraction id="c86425001" contextRef="d_2022-01-01_2022-06-30" unitRef="USD" name="us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense" scale="3" format="ixt:numdotdecimal" decimals="-3">307</ix:nonFraction></span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><span style="color:#333333;"><ix:nonFraction id="c86425002" contextRef="d_2021-01-01_2021-06-30" unitRef="USD" name="us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense" scale="3" format="ixt:numdotdecimal" decimals="-3">336</ix:nonFraction></span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#xa0;</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 36pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 36pt;"><span style="color:#333333;">Non-cash expense related to equity consideration for a service agreement</span></p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><span style="color:#333333;"><ix:nonFraction id="c86425003" contextRef="d_2022-01-01_2022-06-30" unitRef="USD" name="wint:NonCashExpenseRelatedToEquityConsiderationForAServiceAgreement" scale="3" format="ixt:zerodash" decimals="-3">-</ix:nonFraction></span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><span style="color:#333333;"><ix:nonFraction id="c86425004" contextRef="d_2021-01-01_2021-06-30" unitRef="USD" name="wint:NonCashExpenseRelatedToEquityConsiderationForAServiceAgreement" scale="3" format="ixt:numdotdecimal" decimals="-3">494</ix:nonFraction></span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#xa0;</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0"> <p style="margin-top: 0pt; margin-bottom: 0pt; text-indent: 36pt;"><span style="color:#333333;">Loss on impairment of goodwill</span></p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&#xa0;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0"><span style="color:#333333;"><ix:nonFraction id="c86425005" contextRef="d_2022-01-01_2022-06-30" unitRef="USD" name="us-gaap:GoodwillImpairmentLoss" scale="3" format="ixt:numdotdecimal" decimals="-3">11,636</ix:nonFraction></span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&#xa0;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0"><span style="color:#333333;"><ix:nonFraction id="c86425006" contextRef="d_2021-01-01_2021-06-30" unitRef="USD" name="us-gaap:GoodwillImpairmentLoss" scale="3" format="ixt:zerodash" decimals="-3">-</ix:nonFraction></span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&#xa0;</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0"> <p style="margin-top: 0pt; margin-bottom: 0pt; text-indent: 36pt;"><span style="color:#333333;">Loss on impairment of intangible assets</span></p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&#xa0;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0"><span style="color:#333333;"><ix:nonFraction id="c86425007" contextRef="d_2022-01-01_2022-06-30" unitRef="USD" name="us-gaap:ImpairmentOfIntangibleAssetsExcludingGoodwill" scale="3" format="ixt:zerodash" decimals="-3">-</ix:nonFraction></span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&#xa0;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0"><span style="color:#333333;"><ix:nonFraction id="c86425008" contextRef="d_2021-01-01_2021-06-30" unitRef="USD" name="us-gaap:ImpairmentOfIntangibleAssetsExcludingGoodwill" scale="3" format="ixt:numdotdecimal" decimals="-4">37,770</ix:nonFraction></span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&#xa0;</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom" class="GFJY4-DFU-com-rdg-thunderdome-client-resources-CssResource-html-lineItem-v2v-addition"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0"> <p style="margin-top: 0pt; margin-bottom: 0pt; text-indent: 36pt;"><span style="color:#333333;">Loss on sale and disposal of property and equipment</span></p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&#xa0;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0"><span style="color:#333333;"><ix:nonFraction id="c86425842" contextRef="d_2022-01-01_2022-06-30" unitRef="USD" name="us-gaap:GainLossOnDispositionOfAssets" scale="3" format="ixt:numdotdecimal" decimals="-3" sign="-">19</ix:nonFraction></span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&#xa0;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0"><span style="color:#333333;"><ix:nonFraction id="c86425843" contextRef="d_2021-01-01_2021-06-30" unitRef="USD" name="us-gaap:GainLossOnDispositionOfAssets" scale="3" format="ixt:zerodash" decimals="-3" sign="-">-</ix:nonFraction></span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&#xa0;</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0"> <p style="margin-top: 0pt; margin-bottom: 0pt; text-indent: 36pt;"><span style="color:#333333;">Deferred income tax benefit</span></p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&#xa0;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0"><span style="color:#333333;"><ix:nonFraction id="c86425009" contextRef="d_2022-01-01_2022-06-30" unitRef="USD" name="us-gaap:DeferredIncomeTaxExpenseBenefit" scale="3" format="ixt:zerodash" decimals="-3">-</ix:nonFraction></span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&#xa0;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0"><span style="color:#333333;">(<ix:nonFraction id="c86425010" contextRef="d_2021-01-01_2021-06-30" unitRef="USD" name="us-gaap:DeferredIncomeTaxExpenseBenefit" scale="3" format="ixt:numdotdecimal" decimals="-3" sign="-">8,332</ix:nonFraction></span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0"><span style="color:#333333;">)</span></td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 36pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 36pt;"><span style="color:#333333;">Unrealized (gain) loss on foreign exchange rate changes</span></p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><span style="color:#333333;">(<ix:nonFraction id="c86425011" contextRef="d_2022-01-01_2022-06-30" unitRef="USD" name="us-gaap:ForeignCurrencyTransactionGainLossBeforeTax" scale="3" format="ixt:numdotdecimal" decimals="-3">485</ix:nonFraction></span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><span style="color:#333333;">)</span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><span style="color:#333333;"><ix:nonFraction id="c86425012" contextRef="d_2021-01-01_2021-06-30" unitRef="USD" name="us-gaap:ForeignCurrencyTransactionGainLossBeforeTax" scale="3" format="ixt:numdotdecimal" decimals="-5" sign="-">300</ix:nonFraction></span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#xa0;</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 36pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 36pt;"><span style="color:#333333;">Changes in assets and liabilities:</span></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 45pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 45pt;"><span style="color:#333333;">Prepaid expenses and other current assets</span></p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><span style="color:#333333;"><ix:nonFraction id="c86425014" contextRef="d_2022-01-01_2022-06-30" unitRef="USD" name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" scale="3" format="ixt:numdotdecimal" decimals="-3" sign="-">496</ix:nonFraction></span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><span style="color:#333333;"><ix:nonFraction id="c86425015" contextRef="d_2021-01-01_2021-06-30" unitRef="USD" name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" scale="3" format="ixt:numdotdecimal" decimals="-3" sign="-">179</ix:nonFraction></span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#xa0;</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 45pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 45pt;"><span style="color:#333333;">Accounts payable</span></p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><span style="color:#333333;"><ix:nonFraction id="c86425016" contextRef="d_2022-01-01_2022-06-30" unitRef="USD" name="us-gaap:IncreaseDecreaseInAccountsPayable" scale="3" format="ixt:numdotdecimal" decimals="-3">379</ix:nonFraction></span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><span style="color:#333333;">(<ix:nonFraction id="c86425017" contextRef="d_2021-01-01_2021-06-30" unitRef="USD" name="us-gaap:IncreaseDecreaseInAccountsPayable" scale="3" format="ixt:numdotdecimal" decimals="-3" sign="-">873</ix:nonFraction></span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><span style="color:#333333;">)</span></td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 45pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 45pt;"><span style="color:#333333;">Accrued expenses</span></p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><span style="color:#333333;">(<ix:nonFraction id="c86425018" contextRef="d_2022-01-01_2022-06-30" unitRef="USD" name="us-gaap:IncreaseDecreaseInAccruedLiabilities" scale="3" format="ixt:numdotdecimal" decimals="-3" sign="-">576</ix:nonFraction></span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><span style="color:#333333;">)</span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><span style="color:#333333;">(<ix:nonFraction id="c86425019" contextRef="d_2021-01-01_2021-06-30" unitRef="USD" name="us-gaap:IncreaseDecreaseInAccruedLiabilities" scale="3" format="ixt:numdotdecimal" decimals="-3" sign="-">703</ix:nonFraction></span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><span style="color:#333333;">)</span></td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 45pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 45pt;"><span style="color:#333333;">Operating lease liabilities</span></p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><span style="color:#333333;">(<ix:nonFraction id="c86425020" contextRef="d_2022-01-01_2022-06-30" unitRef="USD" name="wint:IncreaseDecreaseOperatingLeaseLiability" scale="3" format="ixt:numdotdecimal" decimals="-3" sign="-">328</ix:nonFraction></span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"><span style="color:#333333;">)</span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><span style="color:#333333;">(<ix:nonFraction id="c86425021" contextRef="d_2021-01-01_2021-06-30" unitRef="USD" name="wint:IncreaseDecreaseOperatingLeaseLiability" scale="3" format="ixt:numdotdecimal" decimals="-3" sign="-">352</ix:nonFraction></span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"><span style="color:#333333;">)</span></td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom" class="GFJY4-DFU-com-rdg-thunderdome-client-resources-CssResource-html-lineItem-v2v-addition"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 45pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 45pt;"><span style="color:#333333;">Net cash used in operating activities</span></p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><span style="color:#333333;">(<ix:nonFraction id="c86425022" contextRef="d_2022-01-01_2022-06-30" unitRef="USD" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" scale="3" format="ixt:numdotdecimal" decimals="-3" sign="-">11,973</ix:nonFraction></span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"><span style="color:#333333;">)</span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><span style="color:#333333;">(<ix:nonFraction id="c86425023" contextRef="d_2021-01-01_2021-06-30" unitRef="USD" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" scale="3" format="ixt:numdotdecimal" decimals="-3" sign="-">13,451</ix:nonFraction></span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"><span style="color:#333333;">)</span></td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td>&#xa0;</td><td>&#xa0;</td><td>&#xa0;</td><td>&#xa0;</td><td>&#xa0;</td><td>&#xa0;</td><td>&#xa0;</td><td>&#xa0;</td><td>&#xa0;</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="margin-top: 0pt; margin-bottom: 0pt"><span style="color:#333333;"><b>Cash flows from investing activities:</b></span></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><span style="color:#333333;"><b>&#xa0;</b></span></td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><span style="color:#333333;"><b>&#xa0;</b></span></td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom" class="GFJY4-DFU-com-rdg-thunderdome-client-resources-CssResource-html-lineItem-v2v-addition"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0"> <p style="margin-top: 0pt; margin-bottom: 0pt; text-indent: 18pt;"><span style="color:#333333;">Proceeds from sale of property and equipment</span></p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&#xa0;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0"><span style="color:#333333;"><ix:nonFraction id="c86425858" contextRef="d_2022-01-01_2022-06-30" unitRef="USD" name="us-gaap:ProceedsFromSaleOfPropertyPlantAndEquipment" scale="3" format="ixt:numdotdecimal" decimals="-4">210</ix:nonFraction></span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&#xa0;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0"><span style="color:#333333;"><ix:nonFraction id="c86425859" contextRef="d_2021-01-01_2021-06-30" unitRef="USD" name="us-gaap:ProceedsFromSaleOfPropertyPlantAndEquipment" scale="3" format="ixt:zerodash" decimals="-3">-</ix:nonFraction></span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&#xa0;</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="padding-left: 18pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="margin-top: 0pt; margin-bottom: 0pt"><span style="color:#333333;">Purchase of property and equipment</span></p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"><span style="color:#333333;">(<ix:nonFraction id="c86425025" contextRef="d_2022-01-01_2022-06-30" unitRef="USD" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" scale="3" format="ixt:numdotdecimal" decimals="-3">13</ix:nonFraction></span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"><span style="color:#333333;">)</span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"><span style="color:#333333;">(<ix:nonFraction id="c86425026" contextRef="d_2021-01-01_2021-06-30" unitRef="USD" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" scale="3" format="ixt:numdotdecimal" decimals="-3">3</ix:nonFraction></span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"><span style="color:#333333;">)</span></td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom" class="GFJY4-DFU-com-rdg-thunderdome-client-resources-CssResource-html-lineItem-v2v-addition"><td style="padding-left: 45pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="margin-top: 0pt; margin-bottom: 0pt"><span style="color:#333333;">Net cash provided by (used in) investing activities</span></p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"><span style="color:#333333;"><ix:nonFraction id="c86425027" contextRef="d_2022-01-01_2022-06-30" unitRef="USD" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" scale="3" format="ixt:numdotdecimal" decimals="-3">197</ix:nonFraction></span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"><span style="color:#333333;">(<ix:nonFraction id="c86425028" contextRef="d_2021-01-01_2021-06-30" unitRef="USD" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" scale="3" format="ixt:numdotdecimal" decimals="-3" sign="-">3</ix:nonFraction></span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"><span style="color:#333333;">)</span></td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td>&#xa0;</td><td>&#xa0;</td><td>&#xa0;</td><td>&#xa0;</td><td>&#xa0;</td><td>&#xa0;</td><td>&#xa0;</td><td>&#xa0;</td><td>&#xa0;</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><span style="color:#333333;"><b>Cash flows from financing activities:</b></span></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><span style="color:#333333;"><b>&#xa0;</b></span></td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><span style="color:#333333;"><b>&#xa0;</b></span></td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="padding-left: 18pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="margin-top: 0pt; margin-bottom: 0pt"><span style="color:#333333;">Proceeds from ATM Program, net of issuance costs</span></p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><span style="color:#333333;"><ix:nonFraction id="c86425030" contextRef="d_2022-01-01_2022-06-30" unitRef="USD" name="us-gaap:ProceedsFromIssuanceOfCommonStock" scale="3" format="ixt:numdotdecimal" decimals="-3">1,225</ix:nonFraction></span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><span style="color:#333333;"><ix:nonFraction id="c86425031" contextRef="d_2021-01-01_2021-06-30" unitRef="USD" name="us-gaap:ProceedsFromIssuanceOfCommonStock" scale="3" format="ixt:numdotdecimal" decimals="-4">1,690</ix:nonFraction></span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#xa0;</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 18pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 18pt;"><span style="color:#333333;">Principal payments on loans payable</span></p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><span style="color:#333333;">(<ix:nonFraction id="c86425032" contextRef="d_2022-01-01_2022-06-30" unitRef="USD" name="us-gaap:RepaymentsOfShortTermDebt" scale="3" format="ixt:numdotdecimal" decimals="-3">419</ix:nonFraction></span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><span style="color:#333333;">)</span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><span style="color:#333333;">(<ix:nonFraction id="c86425033" contextRef="d_2021-01-01_2021-06-30" unitRef="USD" name="us-gaap:RepaymentsOfShortTermDebt" scale="3" format="ixt:numdotdecimal" decimals="-3">2,991</ix:nonFraction></span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><span style="color:#333333;">)</span></td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 18pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 18pt;"><span style="color:#333333;">Proceeds from issuance of common stock and warrants, net of issuance costs</span></p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><span style="color:#333333;"><ix:nonFraction id="c86425034" contextRef="d_2022-01-01_2022-06-30" unitRef="USD" name="wint:ProceedsFromIssuanceOfCommonStockAndWarrants" scale="3" format="ixt:zerodash" decimals="-3">-</ix:nonFraction></span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><span style="color:#333333;"><ix:nonFraction id="c86425035" contextRef="d_2021-01-01_2021-06-30" unitRef="USD" name="wint:ProceedsFromIssuanceOfCommonStockAndWarrants" scale="3" format="ixt:numdotdecimal" decimals="-4">27,390</ix:nonFraction></span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#xa0;</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-top: 0px; padding-right: 0px; padding-left: 0px; margin: 0px;"> <p style="margin-top: 0pt; margin-bottom: 0pt; text-indent: 18pt;"><span style="color:#333333;">Proceeds from research and development funding arrangement</span></p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0px 0px 1px; margin: 0px;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-top: 0px; padding-right: 0px; padding-left: 0px; margin: 0px; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-top: 0px; padding-right: 0px; padding-left: 0px; margin: 0px; border-bottom: 1px solid rgb(0, 0, 0);"><span style="color:#333333;"><ix:nonFraction id="c86425036" contextRef="d_2022-01-01_2022-06-30" unitRef="USD" name="wint:ProceedsFromResearchAndDevelopmentFundingArrangement" scale="3" format="ixt:zerodash" decimals="-3">-</ix:nonFraction></span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0px 0px 1px; margin: 0px;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0px 0px 1px; margin: 0px;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-top: 0px; padding-right: 0px; padding-left: 0px; margin: 0px; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-top: 0px; padding-right: 0px; padding-left: 0px; margin: 0px; border-bottom: 1px solid rgb(0, 0, 0);"><span style="color:#333333;"><ix:nonFraction id="c86425037" contextRef="d_2021-01-01_2021-06-30" unitRef="USD" name="wint:ProceedsFromResearchAndDevelopmentFundingArrangement" scale="3" format="ixt:numdotdecimal" decimals="-5">400</ix:nonFraction></span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0px 0px 1px; margin: 0px;">&#xa0;</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 45pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 45pt;"><span style="color:#333333;">Net cash provided by financing activities</span></p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><span style="color:#333333;"><ix:nonFraction id="c86425038" contextRef="d_2022-01-01_2022-06-30" unitRef="USD" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" scale="3" format="ixt:numdotdecimal" decimals="-3">806</ix:nonFraction></span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><span style="color:#333333;"><ix:nonFraction id="c86425039" contextRef="d_2021-01-01_2021-06-30" unitRef="USD" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" scale="3" format="ixt:numdotdecimal" decimals="-3">26,489</ix:nonFraction></span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#xa0;</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 18pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 18pt;"><span style="color:#333333;">Net (decrease) increase in cash, cash equivalents, and restricted cash</span></p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><span style="color:#333333;">(<ix:nonFraction id="c86425040" contextRef="d_2022-01-01_2022-06-30" unitRef="USD" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" scale="3" format="ixt:numdotdecimal" decimals="-4" sign="-">10,970</ix:nonFraction></span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><span style="color:#333333;">)</span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><span style="color:#333333;"><ix:nonFraction id="c86425041" contextRef="d_2021-01-01_2021-06-30" unitRef="USD" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" scale="3" format="ixt:numdotdecimal" decimals="-3">13,035</ix:nonFraction></span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#xa0;</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 18pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 18pt;"><span style="color:#333333;">Cash, cash equivalents, and restricted cash - beginning of period</span></p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><span style="color:#333333;"><ix:nonFraction id="c86425042" contextRef="i_2021-12-31" unitRef="USD" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" scale="3" format="ixt:numdotdecimal" decimals="-3">22,502</ix:nonFraction></span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><span style="color:#333333;"><ix:nonFraction id="c86425043" contextRef="i_2020-12-31" unitRef="USD" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" scale="3" format="ixt:numdotdecimal" decimals="-3">17,084</ix:nonFraction></span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#xa0;</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 45pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 45pt;"><span style="color:#333333;">Cash, cash equivalents, and restricted cash - end of period</span></p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><span style="color:#333333;">$</span></td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><span style="color:#333333;"><ix:nonFraction id="c86425044" contextRef="i_2022-06-30" unitRef="USD" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" scale="3" format="ixt:numdotdecimal" decimals="-3">11,532</ix:nonFraction></span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><span style="color:#333333;">$</span></td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><span style="color:#333333;"><ix:nonFraction id="c86425045" contextRef="i_2021-06-30" unitRef="USD" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" scale="3" format="ixt:numdotdecimal" decimals="-3">30,119</ix:nonFraction></span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&#xa0;</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td>&#xa0;</td><td>&#xa0;</td><td>&#xa0;</td><td>&#xa0;</td><td>&#xa0;</td><td>&#xa0;</td><td>&#xa0;</td><td>&#xa0;</td><td>&#xa0;</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0"> <p style="margin-top: 0pt; margin-bottom: 0pt"><span style="color:#333333;"><b>Supplementary disclosure of non-cash activity:</b></span></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&#xa0;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&#xa0;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&#xa0;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&#xa0;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&#xa0;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&#xa0;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&#xa0;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&#xa0;</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0"> <p style="margin-top: 0pt; margin-bottom: 0pt; text-indent: 18pt;"><span style="color:#333333;">Prepayment of insurance through third-party financing</span></p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0"><span style="color:#333333;">$</span></td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0"><span style="color:#333333;"><ix:nonFraction id="c86425047" contextRef="d_2022-01-01_2022-06-30" unitRef="USD" name="wint:PrepaymentOfDirectorAndOfficerInsuranceThroughThirdPartyFinancing" scale="3" format="ixt:numdotdecimal" decimals="-3">1,132</ix:nonFraction></span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0"><span style="color:#333333;">$</span></td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0"><span style="color:#333333;"><ix:nonFraction id="c86425048" contextRef="d_2021-01-01_2021-06-30" unitRef="USD" name="wint:PrepaymentOfDirectorAndOfficerInsuranceThroughThirdPartyFinancing" scale="3" format="ixt:numdotdecimal" decimals="-3">1,321</ix:nonFraction></span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&#xa0;</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="padding-left: 18pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="margin-top: 0pt; margin-bottom: 0pt"><span style="color:#333333;">Operating lease liabilities arising from obtaining right-of-use assets</span></p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><span style="color:#333333;"><ix:nonFraction id="c86425049" contextRef="d_2022-01-01_2022-06-30" unitRef="USD" name="us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" scale="3" format="ixt:zerodash" decimals="-3">-</ix:nonFraction></span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><span style="color:#333333;"><ix:nonFraction id="c86425050" contextRef="d_2021-01-01_2021-06-30" unitRef="USD" name="us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" scale="3" format="ixt:numdotdecimal" decimals="-6">2,000</ix:nonFraction></span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#xa0;</td></tr>
</tbody></table>
  </div>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&#xa0;</p>
  <table border="0" cellpadding="0" cellspacing="0" style="width:100%;text-indent:0;font-family:'Times New Roman', Times, serif;font-size:10pt;">
   <tbody>
    <tr>
     <td style="vertical-align:bottom;width:100%;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><span style="color:#333333;"><i>See notes to condensed consolidated financial statements</i></span></p> </td>
    </tr>

   </tbody>
  </table>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&#xa0;</p>
  <div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
   <div class="PGFTR" style="text-align: center; width: 100%">
    <div class="hf-row">
     <div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">
       7
     </div>
    </div>
   </div>
   <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000" />
   <div class="PGHDR" style="text-align: left; width: 100%">
    <div class="hf-row">
     <div class="hf-cell TOCLink" style="display: inline-block; text-align: left;">
      <a href="#toc" style="font-weight: initial; font-style: initial; font-variant: initial; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif;">Table of Contents</a>
     </div>
     <div class="hf-cell TOCLink" style="display: inline-block; text-align: left;">
       &#xa0;
     </div>
     <div class="hf-cell TOCLink" style="display: inline-block; text-align: left;">
       &#xa0;
     </div>
     <div class="hf-cell TOCLink" style="display: inline-block; text-align: left;">
       &#xa0;
     </div>
     <div class="hf-cell TOCLink" style="display: inline-block; text-align: left;">
       &#xa0;
     </div>
    </div>
   </div>
  </div>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&#xa0;</p>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><span style="color:#333333;"><span style="text-decoration: underline; font-size: 10pt;"><b><a id="Notes" title="Notes" href="#"></a>Notes to Condensed Consolidated Financial Statements (unaudited)</b></span></span></p>
  <div>
    &#xa0;
  </div>
  <ix:nonNumeric contextRef="d_2022-01-01_2022-06-30" name="us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" id="c2175897" escape="true">
   <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><span style="color:#333333;"><b>Note <em style="font: inherit;">1</em> &#x2013; The Company and Description of Business</b></span></p>
   <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&#xa0;</p>
   <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><span style="color:#333333;">We are a clinical-stage&#xa0;biopharmaceutical company focused on the development of novel therapeutics intended to address significant unmet medical needs in important acute care markets. Our development programs are primarily focused on the treatment of acute cardiovascular diseases and secondarily on acute pulmonary diseases. Our lead product candidate, istaroxime, is a <em style="font: inherit;">first</em>-in-class, dual-acting agent being developed to improve cardiac function in patients with acute heart failure, or AHF, with a potentially differentiated safety profile from existing treatments. Istaroxime demonstrated significant improvement in both diastolic and systolic aspects of cardiac function and was generally well tolerated in <em style="font: inherit;">three</em> Phase <em style="font: inherit;">2</em> clinical trials.&#xa0;Istaroxime has been granted Fast Track designation for the treatment of AHF by the U.S. Food and Drug Administration, or FDA.&#xa0;Based on the profile observed in our Phase <em style="font: inherit;">2</em> clinical studies in AHF, where istaroxime significantly improved cardiac function and systolic blood pressure in acute decompensated heart failure patients, we initiated a Phase <em style="font: inherit;">2</em> global clinical study to evaluate istaroxime for the treatment of early cardiogenic shock (Society for Cardiovascular Angiography and Interventions&#xa0;Stage B shock),&#xa0;a severe form of AHF characterized by very low blood pressure and risk for hypoperfusion to critical organs. We completed this Phase <em style="font: inherit;">2</em> global clinical study and, in <em style="font: inherit;"> April 2022, </em>announced positive topline results with istaroxime in raising systolic blood pressure.&#xa0;In <em style="font: inherit;"> May 2022, </em>we presented the study results at the European Society of Cardiology Heart Failure Meeting in Madrid, Spain.</span></p>
   <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&#xa0;</p>
   <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><span style="color:#333333;">Our heart failure cardiovascular portfolio also includes sarco endoplasmic reticulum <em style="font: inherit;">Ca2</em>+ -ATPase <em style="font: inherit;">2a,</em> or <em style="font: inherit;">SERCA2a,</em> activators which activate <em style="font: inherit;">SERCA2a.</em> This research program is evaluating these preclinical product candidates, including oral and intravenous <em style="font: inherit;">SERCA2a</em> activator heart failure compounds. As potential oral agents, these candidates would be developed for chronic heart failure. In addition, our cardiovascular drug product candidates include rostafuroxin, a novel product&#xa0;candidate&#xa0;for the treatment of hypertension in patients with a specific genetic profile. We are pursuing potential licensing arrangements and/or other strategic partnerships and do <em style="font: inherit;">not</em> intend to advance this product&#xa0;candidate&#xa0;without securing such an arrangement or partnership.</span></p>
   <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&#xa0;</p>
   <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><span style="color:#333333;">Our pulmonary product candidate portfolio consists of a <em style="font: inherit;">KL4</em> surfactant platform&#xa0;to address a range of serious respiratory conditions in children and adults. In <em style="font: inherit;"> January 2022, </em>we completed enrollment of <em style="font: inherit;">20</em> patients in our Phase <em style="font: inherit;">2</em> study of lucinactant (<em style="font: inherit;">KL4</em> surfactant) for patients with severe novel coronavirus, or COVID-<em style="font: inherit;">19,</em> associated acute respiratory distress syndrome, or ARDS. The study demonstrated that intratracheal administration of reconstituted lyophilized lucinactant was generally safe and well tolerated. Oxygenation and other physiological parameters were stable to improved after dosing, supporting the feasibility of this treatment approach to develop a potential treatment for critically ill patients with ARDS due to COVID-<em style="font: inherit;">19</em> or other causes.</span></p>
   <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&#xa0;</p>
   <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><span style="color:#333333;">Previously, we were also developing AEROSURF (lucinactant for inhalation), a novel drug/medical device combination product for noninvasive delivery of aerosolized <em style="font: inherit;">KL4</em> surfactant using our aerosol delivery system, or ADS, technology for the treatment of respiratory distress syndrome in premature infants. In order to focus our resources on the&#xa0;development of our istaroxime pipeline, we suspended all internal AEROSURF clinical activities in <em style="font: inherit;"> November 2020, </em>and in <em style="font: inherit;"> January 2022 </em>we began to reduce all other costs related to the <em style="font: inherit;">KL4</em> surfactant platform that were <em style="font: inherit;">not</em> already transferred to our licensee in Asia, Lee&#x2019;s Pharmaceutical (HK) Ltd., or Lee&#x2019;s (HK), under the terms of our License, Development and Commercialization Agreement between us and Lee&#x2019;s (HK) dated as of <em style="font: inherit;"> June 12, 2017, </em>as amended, or the Asia License Agreement. To support the future development of our <em style="font: inherit;">KL4</em> surfactant platform in markets outside of Asia, including the U.S., we are pursuing a potential licensing transaction.</span></p>
   <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&#xa0;</p>
   <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><span style="color:#333333;">Our ability to advance our development programs is dependent upon our ability to secure additional capital in both the near and long-term, through public or private securities offerings; convertible debt financings; and/or potential strategic opportunities, including licensing agreements, drug product development, and marketing collaboration arrangements, pharmaceutical research cooperation arrangements, and/or other similar transactions in geographic markets, including the U.S., and/or through potential grants and other funding commitments from U.S. government agencies, in each case, if available. We have engaged with potential counterparties in various markets and will continue to pursue non-dilutive sources of capital as well as potential private and public securities offerings. There can be <em style="font: inherit;">no</em> assurance, however, that we will be able to identify and enter into public or private securities offerings on acceptable terms and in amounts sufficient to meet our needs or qualify for non-dilutive funding opportunities under any grant programs sponsored by U.S. government agencies, private foundations, and/or leading academic institutions, or identify and enter into any strategic transactions that will provide the additional capital that we will require. If <em style="font: inherit;">none</em> of these alternatives is available, or if available and&#xa0;we are unable to raise sufficient capital through such transactions, we potentially could be forced to limit or cease our development activities, which would have a material adverse effect on our business, financial condition, and results of operations.</span></p>
   <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&#xa0;</p>
   <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><span style="color:#333333;">The reader is referred to, and encouraged to read in its entirety, &#x201c;Item <em style="font: inherit;">1</em> &#x2013; Business&#x201d; in our Annual Report on Form <em style="font: inherit;">10</em>-K for the year ended </span><span style="color:#333333;"><em style="font: inherit;"> December 31, 2021</em></span><span style="color:#333333;"> that we filed with the Securities and Exchange Commission, or the SEC, on </span><span style="color:#333333;"><em style="font: inherit;"> March 31, 2022</em></span><span style="color:#333333;">, which contains a discussion of our business and business plans, as well as information concerning our proprietary technologies and our current and planned development programs.</span></p>
  </ix:nonNumeric>
  <div>
    &#xa0;
  </div>
  <ix:nonNumeric contextRef="d_2022-01-01_2022-06-30" name="us-gaap:BasisOfAccounting" id="c2175898" escape="true">
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">&#xa0;</p>
   <ix:exclude>
    <div class="PGFTR" style="text-align: center; width: 100%">
     <div class="hf-row">
      <div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">
       <em style="font: inherit;">8</em>
      </div>
     </div>
    </div>
    <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000" />
    <div class="PGHDR" style="text-align: left; width: 100%">
     <div class="hf-row">
      <div class="hf-cell TOCLink" style="display: inline-block; text-align: left;">
       <a href="#toc" style="font-weight: initial; font-style: initial; font-variant: initial; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif;">Table of Contents</a>
      </div>
     </div>
    </div>
   </ix:exclude>
   <ix:exclude>&#xa0;</ix:exclude>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;"><span style="color:#333333;"><b>Note <em style="font: inherit;">2</em> &#x2013; Basis of Presentation</b></span></p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin: 0pt; text-align: left;">&#xa0;</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin: 0pt; text-align: left;"><span style="color:#333333;">The&#xa0;interim unaudited condensed consolidated financial statements are prepared in accordance with accounting principles generally accepted in the U.S., or US GAAP, for interim financial information in accordance with the instructions to Form <em style="font: inherit;">10</em>-Q and include accounts of Windtree Therapeutics, Inc. and its wholly owned subsidiaries. Accordingly, they do <em style="font: inherit;">not</em> include all of the information and footnotes required by US GAAP for complete consolidated financial statements. Intercompany balances and transactions have been eliminated in consolidation. All adjustments (consisting of normally recurring accruals) considered for fair presentation have been included.&#xa0;Operating results for the </span><span style="color:#333333;"><em style="font: inherit;">three</em> and <em style="font: inherit;">six</em> months ended <em style="font: inherit;"> June 30, 2022</em></span><span style="color:#333333;"> are <em style="font: inherit;">not</em> necessarily indicative of the results that <em style="font: inherit;"> may </em>be expected for the year ending </span><span style="color:#333333;"><em style="font: inherit;"> December 31, 2022</em></span><span style="color:#333333;">. The consolidated balance sheet at </span><span style="color:#333333;"><em style="font: inherit;"> December 31, 2021</em></span><span style="color:#333333;"> has been derived from the Company&#x2019;s audited consolidated financial statements.&#xa0;There have been <em style="font: inherit;">no</em> changes to our significant accounting policies since </span><span style="color:#333333;"><em style="font: inherit;"> December 31, 2021</em></span><span style="color:#333333;">.&#xa0;The accompanying interim unaudited condensed consolidated financial statements should be read in conjunction with our annual audited consolidated financial statements and related notes as of and for the year ended </span><span style="color:#333333;"><em style="font: inherit;"> December 31, 2021</em></span><span style="color:#333333;"> contained in our Annual Report on Form <em style="font: inherit;">10</em>-K for the year ended </span><span style="color:#333333;"><em style="font: inherit;"> December 31, 2021</em></span><span style="color:#333333;">.</span></p>
  </ix:nonNumeric>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin: 0pt; text-align: left;">&#xa0;</p>
  <div>
    &#xa0;
  </div>
  <ix:nonNumeric contextRef="d_2022-01-01_2022-06-30" name="wint:LiquidityDisclosuresTextBlock" id="c2175899" escape="true">
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;"><span style="color:#333333;"><b>Note <em style="font: inherit;">3</em> &#x2013; Going Concern and Management&#x2019;s Plans</b></span></p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">&#xa0;</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin: 0pt; text-align: left;"><span style="color:#333333;">We are subject to risks common to companies in the biotechnology industry, including but <em style="font: inherit;">not</em> limited to, the need for additional capital, risks of failure of preclinical and clinical studies, the need to obtain marketing approval and reimbursement for any drug product candidate that we <em style="font: inherit;"> may </em>identify and develop, the need to successfully commercialize and gain market acceptance of our product candidates, dependence on key personnel, protection of proprietary technology, compliance with government regulations, development of technological innovations by competitors, and&#xa0;risks associated with our international locations and activities abroad, including but <em style="font: inherit;">not</em> limited to having foreign suppliers, manufacturers, and clinical sites in support of our development activities.</span></p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin: 0pt; text-align: left;">&#xa0;</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin: 0pt; text-align: left;"><span style="color:#333333;">We have incurred net losses since inception. Our net loss was </span><span style="color:#333333;">$<ix:nonFraction id="c86425090" contextRef="d_2022-04-01_2022-06-30" unitRef="USD" name="us-gaap:NetIncomeLoss" scale="6" format="ixt:numdotdecimal" decimals="-5" sign="-">17.3</ix:nonFraction></span><span style="color:#333333;">&#xa0;million and </span><span style="color:#333333;">$<ix:nonFraction id="c86425091" contextRef="d_2021-04-01_2021-06-30" unitRef="USD" name="us-gaap:NetIncomeLoss" scale="6" format="ixt:numdotdecimal" decimals="-5" sign="-">37.4</ix:nonFraction></span><span style="color:#333333;">&#xa0;million, respectively, for the <em style="font: inherit;">three</em>-month periods ended </span><span style="color:#333333;"><em style="font: inherit;"> June 30, 2022 </em>and <em style="font: inherit;">2021</em></span><span style="color:#333333;">. Our net loss was&#xa0;</span><span style="color:#333333;">$<ix:nonFraction id="c86425094" contextRef="d_2022-01-01_2022-06-30" unitRef="USD" name="us-gaap:NetIncomeLoss" scale="6" format="ixt:numdotdecimal" decimals="-5" sign="-">25.5</ix:nonFraction></span><span style="color:#333333;"> million and&#xa0;</span><span style="color:#333333;">$<ix:nonFraction id="c86425095" contextRef="d_2021-01-01_2021-06-30" unitRef="USD" name="us-gaap:NetIncomeLoss" scale="6" format="ixt:numdotdecimal" decimals="-5" sign="-">46.4</ix:nonFraction></span><span style="color:#333333;">&#xa0;million, respectively, for the&#xa0;</span><span style="color:#333333;"><em style="font: inherit;">six</em></span><span style="color:#333333;">-month periods ended </span><span style="color:#333333;"><em style="font: inherit;"> June 30, 2022 </em>and <em style="font: inherit;">2021</em></span><span style="color:#333333;">.&#xa0;Included in our net loss for the&#xa0;<em style="font: inherit;">three</em>&#xa0;and&#xa0;</span><span style="color:#333333;"><em style="font: inherit;">six</em> months ended <em style="font: inherit;"> June 30, 2022</em></span><span style="color:#333333;">&#xa0;is an&#xa0;</span><span style="color:#333333;">$<ix:nonFraction id="c86425100" contextRef="d_2022-04-01_2022-06-30" unitRef="USD" name="us-gaap:GoodwillImpairmentLoss" scale="6" format="ixt:numdotdecimal" decimals="-5">11.6</ix:nonFraction></span><span style="color:#333333;"> million loss on impairment of goodwill, and included in our net loss for the <em style="font: inherit;">three</em> and <em style="font: inherit;">six</em> months ended&#xa0;</span><span style="color:#333333;"><em style="font: inherit;"> June 30, 2021</em></span><span style="color:#333333;"> is a&#xa0;</span><span style="color:#333333;">$<ix:nonFraction id="c86425105" contextRef="d_2021-04-01_2021-06-30" unitRef="USD" name="us-gaap:ImpairmentOfIntangibleAssetsExcludingGoodwill" scale="6" format="ixt:numdotdecimal" decimals="-5">37.8</ix:nonFraction></span><span style="color:#333333;"> million loss on impairment of intangible assets&#xa0;related to rostafuroxin&#xa0;and a related&#xa0;</span><span style="color:#333333;">$<ix:nonFraction id="c86425107" contextRef="d_2021-04-01_2021-06-30" unitRef="USD" name="us-gaap:DeferredIncomeTaxExpenseBenefit" scale="6" format="ixt:numdotdecimal" decimals="-5" sign="-">8.3</ix:nonFraction></span><span style="color:#333333;"> million deferred income tax benefit (<i>see</i>,&#xa0;</span><span style="color:#333333;">Note <em style="font: inherit;">4</em> &#x2013; Summary of Significant Accounting Policies</span><span style="color:#333333;">).&#xa0;We expect to continue to incur operating losses for at least the next several years. As of </span><span style="color:#333333;"><em style="font: inherit;"> June 30, 2022</em></span><span style="color:#333333;">, we had an accumulated deficit of </span><span style="color:#333333;">$<ix:nonFraction id="c86425110" contextRef="i_2022-06-30" unitRef="USD" name="us-gaap:RetainedEarningsAccumulatedDeficit" scale="6" format="ixt:numdotdecimal" decimals="-5" sign="-">810.8</ix:nonFraction></span><span style="color:#333333;">&#xa0;million. Our future success is dependent on our ability to fund and develop our product candidates, and ultimately upon our ability to attain profitable operations. We have devoted substantially all of our financial resources and efforts to research and development and general and administrative expense to support such research and development. Net losses and negative cash flows have had, and will continue to have, an adverse effect on our stockholders&#x2019;&#xa0;equity and working capital, and accordingly, our ability to execute our future operating plans.</span></p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin: 0pt; text-align: left;">&#xa0;</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin: 0pt; text-align: left;"><span style="color:#333333;">We are party to an At-The-Market Offering Agreement&#xa0;with Ladenburg Thalmann &amp; Co. Inc., or Ladenburg,&#xa0;pursuant to which we <em style="font: inherit;"> may </em>offer and sell, from time to time at our sole discretion, up to a maximum of&#xa0;</span><span style="color:#333333;">$<ix:nonFraction id="c86425111" contextRef="i_2020-09-17_SubsidiarySaleOfStockAxis-ATMProgramMember" unitRef="USD" name="wint:SharesAuthorizedToBeOfferedAndSoldUnderOfferingAgreementValue" scale="6" format="ixt:numdotdecimal" decimals="-7">10.0</ix:nonFraction></span><span style="color:#333333;"> million of shares of our common stock through Ladenburg as agent and/or principal through an at-the-market program, or the ATM Program. For the&#xa0;</span><span style="color:#333333;"><em style="font: inherit;">six</em> months ended <em style="font: inherit;"> June 30, 2022</em></span><span style="color:#333333;">, we sold&#xa0;</span><span style="color:#333333;"><ix:nonFraction id="c86425113" contextRef="d_2022-01-01_2022-06-30_SubsidiarySaleOfStockAxis-ATMProgramMember" unitRef="Share" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" scale="0" format="ixt:numdotdecimal" decimals="INF">1,137,246</ix:nonFraction></span><span style="color:#333333;">&#xa0;shares&#xa0;of our common stock under the ATM Program&#xa0;resulting in aggregate gross proceeds to us of approximately&#xa0;</span><span style="color:#333333;">$<ix:nonFraction id="c86425114" contextRef="d_2022-01-01_2022-06-30_SubsidiarySaleOfStockAxis-ATMProgramMember" unitRef="USD" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="6" format="ixt:numdotdecimal" decimals="-5">1.3</ix:nonFraction></span><span style="color:#333333;">&#xa0;million and net proceeds of approximately&#xa0;</span><span style="color:#333333;">$<ix:nonFraction id="c86425115" contextRef="d_2022-01-01_2022-06-30_SubsidiarySaleOfStockAxis-ATMProgramMember" unitRef="USD" name="us-gaap:ProceedsFromIssuanceOfCommonStock" scale="6" format="ixt:numdotdecimal" decimals="-5">1.2</ix:nonFraction></span><span style="color:#333333;">&#xa0;million.&#xa0;During <em style="font: inherit;"> July </em>and <em style="font: inherit;"> August 2022,&#xa0;</em>we sold&#xa0;</span><span style="color:#333333;"><ix:nonFraction id="c86425116" contextRef="d_2022-07-01_2022-08-31_SubsequentEventTypeAxis-SubsequentEventMember_SubsidiarySaleOfStockAxis-ATMProgramMember" unitRef="Share" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" scale="0" format="ixt:numdotdecimal" decimals="INF">1,221,706</ix:nonFraction></span><span style="color:#333333;"> shares of our common stock under the ATM Program&#xa0;resulting in aggregate gross and net proceeds to us of approximately&#xa0;</span><span style="color:#333333;">$<ix:nonFraction id="c86425117" contextRef="d_2022-07-01_2022-08-31_SubsequentEventTypeAxis-SubsequentEventMember_SubsidiarySaleOfStockAxis-ATMProgramMember" unitRef="USD" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="6" format="ixt:numdotdecimal" decimals="-5">0.6</ix:nonFraction></span><span style="color:#333333;"> million&#xa0;(<i>see</i>,&#xa0;</span><span style="color:#333333;">Note <em style="font: inherit;">8</em> &#x2013; Stockholders&#x2019; Equity</span><span style="color:#333333;">).</span></p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin: 0pt; text-align: left;">&#xa0;</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin: 0pt; text-align: left;"><span style="color:#333333;">The shares of common stock issued and sold under the ATM Program are registered under our Registration Statement on Form S-<em style="font: inherit;">3</em> (File <em style="font: inherit;">No.</em> <em style="font: inherit;">333</em>-<em style="font: inherit;">248874</em>), which was declared effective by the SEC on <em style="font: inherit;"> September 29, 2020. </em>We are currently subject to the limitations contained in General Instruction <em style="font: inherit;">I.B.6</em> of Form S-<em style="font: inherit;">3.</em> As a result, we are limited in selling <em style="font: inherit;">no</em> more than <em style="font: inherit;">one</em>-<em style="font: inherit;">third</em> of the aggregate market value of the equity held by non-affiliates, or the public float, during any <em style="font: inherit;">12</em>-month period. If our public float increases to $<ix:nonFraction id="c86425129" contextRef="i_2022-06-30_SubsidiarySaleOfStockAxis-ATMProgramMember" unitRef="USD" name="wint:StockOfferingAgreementPublicFloatLimitationAmount" scale="6" format="ixt:numdotdecimal" decimals="-6">75</ix:nonFraction> million or more, we will <em style="font: inherit;">no</em> longer be subject to such limitations.</span></p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin: 0pt; text-align: left;">&#xa0;</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin: 0pt; text-align: left;"><span style="color:#333333;">As of&#xa0;</span><span style="color:#333333;"><em style="font: inherit;"> June 30, 2022</em></span><span style="color:#333333;">,&#xa0;we had cash and cash equivalents of&#xa0;</span><span style="color:#333333;">$<ix:nonFraction id="c86425131" contextRef="i_2022-06-30" unitRef="USD" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" scale="6" format="ixt:numdotdecimal" decimals="-5">11.4</ix:nonFraction></span><span style="color:#333333;"> million and current liabilities of&#xa0;</span><span style="color:#333333;">$<ix:nonFraction id="c86425132" contextRef="i_2022-06-30" unitRef="USD" name="us-gaap:LiabilitiesCurrent" scale="6" format="ixt:numdotdecimal" decimals="-5">5.3</ix:nonFraction></span><span style="color:#333333;"> million. We believe that we have sufficient resources available to support our development activities and fund our business operations&#xa0;into the <em style="font: inherit;">first</em> quarter of <em style="font: inherit;">2023.</em> However, we do <em style="font: inherit;">not</em> have sufficient cash and cash equivalents as of the date of this Quarterly Report on Form <em style="font: inherit;">10</em>-Q to support our operations for at least the <em style="font: inherit;">12</em> months following the date that the financial statements are issued. These conditions raise substantial doubt about our ability to continue as a going concern through <em style="font: inherit;">12</em> months after the date that the financial statements are issued.</span></p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin: 0pt; text-align: left;">&#xa0;</p>
   <ix:exclude>
    <div class="PGFTR" style="text-align:center; width:100%">
     <div class="hf-row">
      <div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: &quot;Times New Roman&quot;;">
       <em style="font: inherit;">9</em>
      </div>
     </div>
    </div>
    <hr style="PAGE-BREAK-AFTER:always; border:none; width:100%; height:2px; color:#000000; background-color:#000000" />
    <div class="PGHDR" style="text-align:left; width:100%">
     <div class="hf-row">
      <div class="hf-cell TOCLink" style="text-align: left; display: inline-block;">
       <a href="#toc" style="font-weight: initial; font-style: initial; font-variant: initial; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif;">Table of Contents</a>
      </div>
     </div>
    </div>
   </ix:exclude> &#xa0;
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin: 0pt; text-align: left;"><span style="color:#333333;">To alleviate the conditions that raise substantial doubt about our ability to continue as a going concern, management plans&#xa0;to secure additional capital, potentially through a combination of public or private securities&#xa0;offerings, convertible debt financings, and/or strategic transactions, including potential licensing arrangements, alliances, and drug product collaborations focused on specified geographic markets; however, <em style="font: inherit;">none</em> of these alternatives are committed at this time. There can be <em style="font: inherit;">no</em> assurance that we will be successful in obtaining sufficient funding on terms acceptable to us to fund continuing operations, if at all, or identify and enter into any strategic transactions that will provide the capital that we will require. Further, on <em style="font: inherit;"> June 3, 2022, </em>we received a deficiency letter from the Nasdaq Stock Market LLC, or Nasdaq, notifying us that the closing bid price of our common stock had been below the minimum <em style="font: inherit;">$1.00</em> per share for <em style="font: inherit;">30</em> consecutive business days, we are out of compliance with the&#xa0;requirements for continued listing on Nasdaq, and are subject to potential delisting.&#xa0;If we are unable to re-achieve compliance with the Nasdaq listing requirements within <em style="font: inherit;">180</em> days, or <em style="font: inherit;"> November 30, 2022, </em>after receipt of a delisting notice,&#xa0;and if we are unable to obtain an extension therefore, we would be subject to delisting, which likely would further impair the liquidity and value of our common stock.&#xa0;The failure to obtain sufficient capital on acceptable terms when needed would have a material adverse effect on our business, results of operations, and financial condition.</span></p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin: 0pt; text-align: left;">&#xa0;</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin: 0pt; text-align: left;"><span style="color:#333333;">The accompanying condensed consolidated financial statements have been prepared on a going concern basis, which contemplates the realization of assets and satisfaction of liabilities in the normal course of business, and do <em style="font: inherit;">not</em> include any adjustments relating to recoverability and classification of recorded asset amounts or the amounts and classification of liabilities that might be necessary should we be unable to continue as a going concern.</span></p>
  </ix:nonNumeric>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin: 0pt; text-align: left;">&#xa0;</p>
  <div>
    &#xa0;
  </div>
  <ix:nonNumeric contextRef="d_2022-01-01_2022-06-30" name="us-gaap:SignificantAccountingPoliciesTextBlock" id="c2175900" escape="true">
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;"><span style="color:#333333;"><b>Note <em style="font: inherit;">4</em> &#x2013; Summary of Significant Accounting Policies</b></span></p>
   <p style="margin: 0px; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin: 0pt; text-align: left;"></p><ix:nonNumeric contextRef="d_2022-01-01_2022-06-30" name="us-gaap:ConsolidationPolicyTextBlock" id="c86426299" escape="true"><p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin: 0pt; text-align: left;"><span style="color:#333333;"><b>Principles of Consolidation</b></span></p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin: 0pt; text-align: left;">&#xa0;</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin: 0pt; text-align: left;"><span style="color:#333333;">The interim unaudited condensed consolidated financial statements are prepared in accordance with US GAAP&#xa0;and include accounts of Windtree Therapeutics, Inc. and its wholly owned subsidiaries, CVie Investments Limited and its wholly owned subsidiary, CVie Therapeutics Limited; and a presently inactive subsidiary, Discovery Laboratories, Inc. (formerly known as Acute Therapeutics, Inc.).</span></p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin: 0pt; text-align: left;">&#xa0;</p></ix:nonNumeric><p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin: 0pt; text-align: left;"></p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin: 0pt; text-align: left;"></p><ix:nonNumeric contextRef="d_2022-01-01_2022-06-30" name="us-gaap:GoodwillAndIntangibleAssetsGoodwillPolicy" id="c86426300" escape="true"><p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin: 0pt; text-align: left;"><span style="color:#333333;"><b>Goodwill and Intangible Assets</b></span></p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin: 0pt; text-align: left;">&#xa0;</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin: 0pt; text-align: left;"><span style="color:#333333;">We record acquired identified intangibles, which includes intangible assets (such as goodwill and other intangibles), based on estimated fair value. The acquired in-process research and development, or IPR&amp;D, assets are considered indefinite-lived intangible assets until completion or abandonment of the associated research and development efforts. IPR&amp;D is <em style="font: inherit;">not</em> amortized but reviewed for impairment at least annually, or when events or changes in the business environment indicate the carrying value <em style="font: inherit;"> may </em>be impaired. During the&#xa0;</span><span style="color:#333333;"><em style="font: inherit;">three</em> and <em style="font: inherit;">six</em> months ended <em style="font: inherit;"> June 30, 2022</em></span><span style="color:#333333;">, <em style="font: inherit;">no</em> events or changes in circumstances occurred indicating that our IPR&amp;D intangible assets were more likely than <em style="font: inherit;">not</em> impaired.</span></p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin: 0pt; text-align: left;">&#xa0;</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin: 0pt; text-align: left;"><span style="color:#333333;">During the&#xa0;<em style="font: inherit;">second</em>&#xa0;quarter of <em style="font: inherit;">2021,</em> we determined that the fair value of the IPR&amp;D related to our rostafuroxin drug candidate was more likely than&#xa0;<em style="font: inherit;">not</em> impaired and we&#xa0;performed the required quantitative impairment assessment of the related intangible asset. We recorded a loss on impairment of intangible assets of&#xa0;</span><span style="color:#333333;">$<ix:nonFraction id="c86425170" contextRef="d_2021-04-01_2021-06-30" unitRef="USD" name="us-gaap:ImpairmentOfIntangibleAssetsExcludingGoodwill" scale="6" format="ixt:numdotdecimal" decimals="-5">37.8</ix:nonFraction></span><span style="color:#333333;">&#xa0;million, recognized within operating expenses in our condensed consolidated statements of operations&#xa0;for the&#xa0;<em style="font: inherit;">three</em>&#xa0;and&#xa0;<em style="font: inherit;">six</em>&#xa0;months ended&#xa0;<em style="font: inherit;"> June 30, 2021.&#xa0;</em><em style="font: inherit;">No</em>&#xa0;events or changes in the business environment occurred during the&#xa0;<em style="font: inherit;">six</em>&#xa0;months ended&#xa0;<em style="font: inherit;"> June 30, 2021&#xa0;</em>to indicate that the fair value of the IPR&amp;D related to our istaroxime drug candidate was impaired.</span></p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin: 0pt; text-align: left;">&#xa0;</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin: 0pt; text-align: left;"><span style="color:#333333;">Goodwill represents the excess of the purchase price over the fair value of assets acquired and liabilities assumed in a business combination and is <em style="font: inherit;">not</em> amortized. It is reviewed for impairment at least annually or when events or changes in the business environment indicate that its carrying value <em style="font: inherit;"> may </em>be impaired. Our company consists of <ix:nonFraction id="c86425180" contextRef="d_2022-01-01_2022-03-31" unitRef="Pure" name="us-gaap:NumberOfReportingUnits" scale="0" format="ixt-sec:numwordsen" decimals="INF">one</ix:nonFraction> reporting unit. In order to perform the quantitative goodwill impairment test, we compare the estimated fair value of our reporting unit to its carrying value. If the fair value exceeds the carrying value, <em style="font: inherit;">no</em> further evaluation is required, and <em style="font: inherit;">no</em> impairment exists. If the carrying value exceeds the fair value, the difference between the carrying value and the fair value is recorded as an impairment loss, the amount of which <em style="font: inherit;"> may </em><em style="font: inherit;">not</em> exceed the total amount of goodwill. When performing our annual goodwill impairment assessment as of <em style="font: inherit;"> December 1, 2021, </em>we estimated the fair value of our reporting unit based upon the quoted market price and related market capitalization of our common stock, adjusted for an estimated control premium. Based on the quantitative test performed, we determined that the fair value of our reporting unit exceeded its carrying value and <em style="font: inherit;">no</em> impairment loss was recognized as of </span><span style="color:#333333;"><em style="font: inherit;"> December 31, 2021</em></span><span style="color:#333333;">.</span></p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin: 0pt; text-align: left;">&#xa0;</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin: 0pt; text-align: left;"><span style="color:#333333;">Throughout the year, we consider whether any events or changes in the business environment have occurred which indicate that goodwill <em style="font: inherit;"> may </em>be impaired. For example, a significant decline in the closing share price of our common stock and market capitalization <em style="font: inherit;"> may </em>suggest that the fair value of our reporting unit has fallen below its carrying amount, indicating that an interim goodwill impairment test is required. Accordingly, we monitor changes in our share price during interim periods between annual impairment tests and consider overall stock market conditions, the underlying reasons for the decline in our share price, the significance of the decline, and the duration of time that our securities have been trading at a lower value. We have experienced a declining trend in the&#xa0;closing share price of our common stock following the announcement in <em style="font: inherit;"> April 2022 </em>of positive topline results in our Phase <em style="font: inherit;">2</em> global clinical study of istaroxime for the treatment of early cardiogenic shock.</span></p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin: 0pt; text-align: left;">&#xa0;</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin: 0pt; text-align: left;"><span style="color:#333333;">During the <em style="font: inherit;">second</em> quarter of <em style="font: inherit;">2022,</em> the continued declining trend in the closing share price of our common stock suggested that the fair value of our reporting unit was more likely than <em style="font: inherit;">not</em> less than its carrying value.&#xa0;As a result, we&#xa0;performed the required interim goodwill impairment test consistent with the methodology that we use when performing our annual goodwill impairment assessment, including the use of the quoted market price and related market capitalization of our common stock, adjusted for an estimated control premium based on transactions completed by comparable companies.&#xa0;Based on the quantitative test performed, we recorded a loss on impairment of goodwill of&#xa0;</span><span style="color:#333333;">$<ix:nonFraction id="c86425189" contextRef="d_2022-04-01_2022-06-30" unitRef="USD" name="us-gaap:GoodwillImpairmentLoss" scale="6" format="ixt:numdotdecimal" decimals="-5">11.6</ix:nonFraction></span><span style="color:#333333;"> million, recognized within operating expenses in our condensed consolidated statements of operations&#xa0;for the&#xa0;<em style="font: inherit;">three</em>&#xa0;and&#xa0;<em style="font: inherit;">six</em>&#xa0;months ended&#xa0;<em style="font: inherit;"> June 30, 2022.</em></span></p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin: 0pt; text-align: left;">&#xa0;</p>
   <ix:exclude>
    <div class="PGFTR" style="text-align: center; width: 100%">
     <div class="hf-row">
      <div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">
       <em style="font: inherit;">10</em>
      </div>
     </div>
    </div>
    <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000" />
    <div class="PGHDR" style="text-align: left; width: 100%">
     <div class="hf-row">
      <div class="hf-cell TOCLink" style="display: inline-block; text-align: left;">
       <a href="#toc" style="font-weight: initial; font-style: initial; font-variant: initial; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif;">Table of Contents</a>
      </div>
     </div>
    </div>
   </ix:exclude>
   <ix:exclude>&#xa0;</ix:exclude>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin: 0pt; text-align: left;"><span style="color:#333333;">The closing share price of our common stock has continued to decline during <em style="font: inherit;"> July </em>and <em style="font: inherit;"> August 2022. </em>If our share price continues to decline during the remainder of the <em style="font: inherit;">third</em> quarter of <em style="font: inherit;">2022,</em> we <em style="font: inherit;"> may </em>be at risk for future impairment to goodwill in the near term.</span></p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin: 0pt; text-align: left;">&#xa0;</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;"><span style="color:#333333;">The following table represents identifiable intangible assets and goodwill as of </span><span style="color:#333333;"><em style="font: inherit;"> June 30, 2022</em></span><span style="color:#333333;"> and </span><span style="color:#333333;"><em style="font: inherit;"> December 31, 2021</em></span><span style="color:#333333;">:</span></p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">&#xa0;</p>
   <ix:nonNumeric contextRef="d_2022-01-01_2022-06-30" name="us-gaap:ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock" id="c2175901" escape="true">
    <table class="finTable" style="margin-right: 5%; margin-left: 5%; width: 90%; font-size: 10pt; font-family: &quot;Times New Roman&quot;; text-indent: 0px;" cellspacing="0" cellpadding="0" border="0"><tbody><tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td colspan="2" rowspan="1" style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; text-align: center;"><span style="color:#333333;"><b><em style="font: inherit;">June 30,</em></b></span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; text-align: center;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; text-align: center;">&#xa0;</td><td colspan="2" rowspan="1" style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; text-align: center;"><span style="color:#333333;"><b><em style="font: inherit;">December 31,</em></b></span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 66%;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;"><span style="color:#333333;"><i>(in thousands)</i></span></p> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><span style="color:#333333;"><b><em style="font: inherit;">2022</em></b></span></p> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px;">&#xa0;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><span style="color:#333333;"><b><em style="font: inherit;">2021</em></b></span></p> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px;">&#xa0;</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;"><span style="color:#333333;">Istaroxime drug candidate</span></p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"><span style="color:#333333;">$</span></td><td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"><span style="color:#333333;"><ix:nonFraction id="c86425285" contextRef="i_2022-06-30_IndefiniteLivedIntangibleAssetsByMajorClassAxis-IstaroximeDrugCandidateMember" unitRef="USD" name="us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill" scale="3" format="ixt:numdotdecimal" decimals="-4">22,340</ix:nonFraction></span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"><span style="color:#333333;">$</span></td><td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"><span style="color:#333333;"><ix:nonFraction id="c86425286" contextRef="i_2021-12-31_IndefiniteLivedIntangibleAssetsByMajorClassAxis-IstaroximeDrugCandidateMember" unitRef="USD" name="us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill" scale="3" format="ixt:numdotdecimal" decimals="-4">22,340</ix:nonFraction></span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#xa0;</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;"><span style="color:#333333;">Rostafuroxin drug candidate</span></p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td><td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><span style="color:#333333;"><ix:nonFraction id="c86425287" contextRef="i_2022-06-30_IndefiniteLivedIntangibleAssetsByMajorClassAxis-RostafuroxinDrugCandidateMember" unitRef="USD" name="us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill" scale="3" format="ixt:numdotdecimal" decimals="-4">9,730</ix:nonFraction></span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td><td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><span style="color:#333333;"><ix:nonFraction id="c86425288" contextRef="i_2021-12-31_IndefiniteLivedIntangibleAssetsByMajorClassAxis-RostafuroxinDrugCandidateMember" unitRef="USD" name="us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill" scale="3" format="ixt:numdotdecimal" decimals="-4">9,730</ix:nonFraction></span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">&#xa0;</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;"><span style="color:#333333;">Intangible assets</span></p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);">&#xa0;</td><td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><span style="color:#333333;"><ix:nonFraction id="c86425289" contextRef="i_2022-06-30" unitRef="USD" name="us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill" scale="3" format="ixt:numdotdecimal" decimals="-4">32,070</ix:nonFraction></span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);">&#xa0;</td><td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><span style="color:#333333;"><ix:nonFraction id="c86425290" contextRef="i_2021-12-31" unitRef="USD" name="us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill" scale="3" format="ixt:numdotdecimal" decimals="-4">32,070</ix:nonFraction></span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&#xa0;</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;"><span style="color:#333333;">Goodwill</span></p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"><span style="color:#333333;">$</span></td><td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"><span style="color:#333333;"><ix:nonFraction id="c86425291" contextRef="i_2022-06-30" unitRef="USD" name="us-gaap:Goodwill" scale="3" format="ixt:numdotdecimal" decimals="-3">4,046</ix:nonFraction></span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"><span style="color:#333333;">$</span></td><td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"><span style="color:#333333;"><ix:nonFraction id="c86425292" contextRef="i_2021-12-31" unitRef="USD" name="us-gaap:Goodwill" scale="3" format="ixt:numdotdecimal" decimals="-3">15,682</ix:nonFraction></span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#xa0;</td></tr>
</tbody></table>
   </ix:nonNumeric>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin: 0pt; text-align: left;">&#xa0;</p></ix:nonNumeric><p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin: 0pt; text-align: left;"></p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin: 0pt; text-align: left;"></p><ix:nonNumeric contextRef="d_2022-01-01_2022-06-30" name="us-gaap:ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" id="c86426301" escape="true"><p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin: 0pt; text-align: left;"><span style="color:#333333;"><b>Foreign Currency Transactions</b></span></p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin: 0pt; text-align: left;">&#xa0;</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin: 0pt; text-align: left;"><span style="color:#333333;">The functional currency for our foreign subsidiaries is U.S. Dollars. We remeasure monetary assets and liabilities that are <em style="font: inherit;">not</em> denominated in the functional currency at exchange rates in effect at the end of each period. Gains and losses from the remeasurement of foreign currency transactions are recognized in </span><span style="color:#333333;">other income (expense), net</span><span style="color:#333333;">. Foreign currency transactions resulted in </span><span style="color:#333333;">gains</span><span style="color:#333333;">&#xa0;of approximately&#xa0;</span><span style="color:#333333;">$<ix:nonFraction id="c86425197" contextRef="d_2022-04-01_2022-06-30" unitRef="USD" name="us-gaap:ForeignCurrencyTransactionGainBeforeTax" scale="6" format="ixt:numdotdecimal" decimals="-5">0.2</ix:nonFraction></span><span style="color:#333333;"> million and losses of approximately&#xa0;</span><span style="color:#333333;">$<ix:nonFraction id="c86425198" contextRef="d_2021-04-01_2021-06-30" unitRef="USD" name="us-gaap:ForeignCurrencyTransactionLossBeforeTax" scale="6" format="ixt:numdotdecimal" decimals="-5">0.3</ix:nonFraction></span><span style="color:#333333;"> million for the <em style="font: inherit;">three</em>-month periods ended </span><span style="color:#333333;"><em style="font: inherit;"> June 30, 2022 </em>and <em style="font: inherit;">2021</em></span><span style="color:#333333;">, respectively.&#xa0;Foreign currency transactions resulted in </span><span style="color:#333333;">gains</span><span style="color:#333333;">&#xa0;of approximately&#xa0;</span><span style="color:#333333;">$<ix:nonFraction id="c86425201" contextRef="d_2021-01-01_2021-06-30" unitRef="USD" name="us-gaap:ForeignCurrencyTransactionGainBeforeTax" scale="6" format="ixt:numdotdecimal" decimals="-5">0.4</ix:nonFraction></span><span style="color:#333333;">&#xa0;million and losses of approximately&#xa0;</span><span style="color:#333333;">$<ix:nonFraction id="c86425202" contextRef="d_2021-01-01_2021-06-30" unitRef="USD" name="us-gaap:ForeignCurrencyTransactionLossBeforeTax" scale="6" format="ixt:numdotdecimal" decimals="-5">0.2</ix:nonFraction></span><span style="color:#333333;">&#xa0;million for the </span><span style="color:#333333;"><em style="font: inherit;">six</em></span><span style="color:#333333;">-month periods ended </span><span style="color:#333333;"><em style="font: inherit;"> June 30, 2022 </em>and <em style="font: inherit;">2021</em></span><span style="color:#333333;">, respectively.&#xa0;</span></p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin: 0pt; text-align: left;">&#xa0;</p></ix:nonNumeric><p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin: 0pt; text-align: left;"></p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin: 0pt; text-align: left;"></p><ix:nonNumeric contextRef="d_2022-01-01_2022-06-30" name="us-gaap:UseOfEstimates" id="c86426302" escape="true"><p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin: 0pt; text-align: left;"><span style="color:#333333;"><b>Use of Estimates</b></span></p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin: 0pt; text-align: left;"><br /> <span style="color:#333333;">The preparation of financial statements in conformity with US GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, including intangible assets and goodwill,&#xa0;at the date of the financial statements and the reported amounts of expenses during the reporting period. Actual results could differ from those estimates.</span></p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin: 0pt; text-align: left;">&#xa0;</p></ix:nonNumeric><p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin: 0pt; text-align: left;"></p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin: 0pt; text-align: left;"></p><ix:nonNumeric contextRef="d_2022-01-01_2022-06-30" name="us-gaap:CashAndCashEquivalentsPolicyTextBlock" id="c86426303" escape="true"><p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin: 0pt; text-align: left;"><span style="color:#333333;"><b>Cash and Cash Equivalents</b></span></p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin: 0pt; text-align: left;">&#xa0;</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin: 0pt; text-align: left;"><span style="color:#333333;">Cash and cash equivalents are held at domestic and foreign financial institutions and consist of liquid investments, money market funds, and U.S. Treasury notes with a maturity from date of purchase of <em style="font: inherit;">90</em> days or less that are readily convertible into cash.</span></p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin: 0pt; text-align: left;">&#xa0;</p></ix:nonNumeric><p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin: 0pt; text-align: left;"></p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin: 0pt; text-align: left;"></p><ix:nonNumeric contextRef="d_2022-01-01_2022-06-30" name="us-gaap:FairValueOfFinancialInstrumentsPolicy" id="c86426304" escape="true"><p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin: 0pt; text-align: left;"><span style="color:#333333;"><b>Severance</b></span></p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin: 0pt; text-align: left;">&#xa0;</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin: 0pt; text-align: left;"><span style="color:#333333;">In <em style="font: inherit;"> January 2022,&#xa0;</em>in order to focus our resources on the&#xa0;development of our istaroxime pipeline, we began to reduce costs related to <em style="font: inherit;">KL4</em> surfactant that were <em style="font: inherit;">not</em> already transferred to our licensee in Asia, Lee&#x2019;s (HK), under the terms of the Asia License Agreement. These costs include certain reductions in headcount dedicated to <em style="font: inherit;">KL4</em> surfactant and the decommissioning of both our analytical and technical support laboratory, which previously conducted release testing of active pharmaceutical ingredients&#xa0;and supportive research for our lyophilized and aerosolized <em style="font: inherit;">KL4</em> surfactant, and our medical device development laboratory, which was previously used to conduct development activities and testing for our ADS technologies. In <em style="font: inherit;"> February 2022, </em>management communicated&#xa0;its commitment to provide severance payments&#xa0;to impacted employees, provided that they remain employed with us through their expected termination dates. The total severance cost for impacted employees is approximately&#xa0;</span><span style="color:#333333;">$<ix:nonFraction id="c86425210" contextRef="d_2022-01-01_2022-06-30" unitRef="USD" name="us-gaap:SeveranceCosts1" scale="6" format="ixt:numdotdecimal" decimals="-5">0.4</ix:nonFraction></span><span style="color:#333333;">&#xa0;million, which was ratably accrued over the service periods of the employees, and to be paid through <em style="font: inherit;"> September 30, 2022. </em>We incurred </span><span style="color:#333333;">$<ix:nonFraction id="c86425211" contextRef="d_2022-04-01_2022-06-30" unitRef="USD" name="wint:SeveranceAccrual" scale="6" format="ixt:numdotdecimal" decimals="-5">0.1</ix:nonFraction></span><span style="color:#333333;"> million and&#xa0;</span><span style="color:#333333;">$<ix:nonFraction id="c86425212" contextRef="d_2022-01-01_2022-06-30" unitRef="USD" name="wint:SeveranceAccrual" scale="6" format="ixt:numdotdecimal" decimals="-5">0.4</ix:nonFraction></span><span style="color:#333333;"> million of expense&#xa0;related to these severance arrangements during the <em style="font: inherit;">three</em> and&#xa0;</span><span style="color:#333333;"><em style="font: inherit;">six</em> months ended <em style="font: inherit;"> June 30, 2022</em></span><span style="color:#333333;">, respectively,&#xa0;which is included in research and development expense.&#xa0;During the <em style="font: inherit;">three</em> and&#xa0;</span><span style="color:#333333;"><em style="font: inherit;">six</em> months ended <em style="font: inherit;"> June 30, 2022</em></span><span style="color:#333333;">,&#xa0;</span><span style="color:#333333;">$<ix:nonFraction id="c86425217" contextRef="d_2022-04-01_2022-06-30" unitRef="USD" name="wint:PaymentsForSeveranceCosts" scale="6" format="ixt:numdotdecimal" decimals="-5">0.2</ix:nonFraction></span><span style="color:#333333;">&#xa0;million was paid.&#xa0;The related liability as of </span><span style="color:#333333;"><em style="font: inherit;"> June 30, 2022</em></span><span style="color:#333333;"> is $<ix:nonFraction id="c86425219" contextRef="i_2022-06-30" unitRef="USD" name="us-gaap:SupplementalUnemploymentBenefitsSeveranceBenefits" scale="6" format="ixt:numdotdecimal" decimals="-5">0.2</ix:nonFraction>&#xa0;million and is included in accrued expenses. </span></p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin: 0pt; text-align: left;">&#xa0;</p></ix:nonNumeric><p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin: 0pt; text-align: left;"></p>
   <div style="font-size:10pt">
    <div style="font-family:&quot;Times New Roman&quot;">
     </div></div><ix:nonNumeric contextRef="d_2022-01-01_2022-06-30" name="us-gaap:PropertyPlantAndEquipmentImpairment" id="c86426305" escape="true"><div style="font-size:10pt"><div style="font-family:&quot;Times New Roman&quot;"><span style="color:#333333;"><b>Property and Equipment</b></span>
    </div>
    <div style="font-family:&quot;Times New Roman&quot;">
      &#xa0;
    </div>
   </div>
   <div style="font-size:10pt">
    <div style="font-family:'Times New Roman'">
     <div style="font-variant:normal">
      <span style="color:#333333;">Property and equipment are recorded at cost and depreciated using the straight-line method over the estimated useful lives of the assets (generally&#xa0;<em style="font: inherit;">three</em>&#xa0;to&#xa0;<em style="font: inherit;">ten</em>&#xa0;years). Leasehold improvements are amortized over the shorter of the estimated useful lives or the remaining term of the lease. Repairs and maintenance costs are charged to expense as incurred.</span>
     </div>
     <div style="font-variant:normal">
       &#xa0;
     </div>
    </div>
   </div>
   <div style="font-size:10pt">
    <div style="font-family:'Times New Roman'">
     <div style="font-variant:normal">
      <span style="color:#333333;">During the <em style="font: inherit;">first</em> quarter of <em style="font: inherit;">2022,</em> we determined that&#xa0;certain&#xa0;manufacturing and laboratory equipment assets related to the <em style="font: inherit;">KL4</em> surfactant platform would be abandoned by <em style="font: inherit;"> March 31, 2022. </em>We accelerated depreciation of these assets during the <em style="font: inherit;">first</em> quarter of <em style="font: inherit;">2022,</em> resulting in $<ix:nonFraction id="c86425227" contextRef="d_2022-01-01_2022-03-31_PropertyPlantAndEquipmentByTypeAxis-ManufacturingAndLaboratoryEquipmentMember" unitRef="USD" name="us-gaap:Depreciation" scale="6" format="ixt:numdotdecimal" decimals="-5">0.4</ix:nonFraction> million of additional depreciation expense for the <em style="font: inherit;">three</em> months ended <em style="font: inherit;"> March 31, 2022.&#xa0;</em>During the <em style="font: inherit;">second</em> quarter of <em style="font: inherit;">2022,</em> the abandoned assets and certain other <em style="font: inherit;">KL4</em> surfactant platform assets were disposed.</span>
     </div>
     <div style="font-variant:normal">
       &#xa0;
     </div></div></div></ix:nonNumeric><div style="font-size:10pt"><div style="font-family:'Times New Roman'"><div style="font-variant:normal"></div>
    </div>
   </div>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin: 0pt; text-align: left;"></p><ix:nonNumeric contextRef="d_2022-01-01_2022-06-30" name="wint:RestructuredDebtLiabilityContingentMilestonePaymentPolicyPolicyTextBlock" id="c86426306" escape="true"><p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin: 0pt; text-align: left;"><span style="color:#333333;"><b>Restructured Debt Liability &#x2013; Contingent Milestone Payment</b></span></p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin: 0pt; text-align: left;">&#xa0;</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin: 0pt; text-align: left;"><span style="color:#333333;">In conjunction with the <em style="font: inherit;"> November 2017 </em>restructuring and retirement of long-term debt (<i>see</i>, </span><span style="color:#333333;">Note <em style="font: inherit;">7</em> &#x2013; Restructured Debt Liability</span><span style="color:#333333;">), we have established a </span><span style="color:#333333;">$<ix:nonFraction id="c86425233" contextRef="i_2017-11-01_LineOfCreditFacilityAxis-DeerfieldManagementLPMember_LongtermDebtTypeAxis-DeerfieldLoanMember_TypeOfArrangementAxis-ExchangeAndTerminationAgreementMember" unitRef="USD" name="wint:LiabilityforContingentMilestonePaymentNoncurrent" scale="6" format="ixt:numdotdecimal" decimals="-6">15.0</ix:nonFraction></span><span style="color:#333333;">&#xa0;million long-term liability for contingent milestone payments potentially due under the Exchange and Termination Agreement dated as of <em style="font: inherit;"> October 27, 2017, </em>or the Exchange and Termination Agreement, between ourselves and affiliates of Deerfield Management Company L.P., or Deerfield. The liability has been recorded at full value of the contingent milestones and will continue to be carried at full value until the milestones are achieved and paid or milestones are <em style="font: inherit;">not</em> achieved and the liability is written off as a gain on debt restructuring.</span></p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin: 0pt; text-align: left;">&#xa0;</p></ix:nonNumeric><p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin: 0pt; text-align: left;"></p>
   <ix:exclude>
    <div class="PGFTR" style="text-align: center; width: 100%">
     <div class="hf-row">
      <div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">
       <em style="font: inherit;">11</em>
      </div>
     </div>
    </div>
    <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000" />
    <div class="PGHDR" style="text-align: left; width: 100%">
     <div class="hf-row">
      <div class="hf-cell TOCLink" style="display: inline-block; text-align: left;">
       <a href="#toc" style="font-weight: initial; font-style: initial; font-variant: initial; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif;">Table of Contents</a>
      </div>
     </div>
    </div>
   </ix:exclude>
   <ix:exclude>&#xa0;</ix:exclude>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin: 0pt; text-align: left;"></p><ix:nonNumeric contextRef="d_2022-01-01_2022-06-30" name="us-gaap:ResearchAndDevelopmentExpensePolicy" id="c86426307" escape="true"><p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin: 0pt; text-align: left;"><span style="color:#333333;"><b>Research and Development</b></span></p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin: 0pt; text-align: left;">&#xa0;</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin: 0pt; text-align: left;"><span style="color:#333333;">We track direct research and development expenses by preclinical and clinical programs, which include <em style="font: inherit;">third</em>-party costs such as contract research organization, consulting, and clinical trial costs. We do <em style="font: inherit;">not</em> allocate indirect research and development expenses, which include product development and manufacturing expenses and clinical, medical, and regulatory operations expenses, to specific programs. Indirect research and development expenses include personnel, facilities, manufacturing and quality operations, pharmaceutical and device development, research, regulatory, and medical affairs. Research and development costs are charged to operations as incurred in accordance with Financial Accounting Standards Board, or FASB, Accounting Standards Codification, or ASC, Topic <em style="font: inherit;">730,</em> Research and Development.</span></p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin: 0pt; text-align: left;">&#xa0;</p></ix:nonNumeric><p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin: 0pt; text-align: left;"></p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin: 0pt; text-align: left;"></p><ix:nonNumeric contextRef="d_2022-01-01_2022-06-30" name="us-gaap:IncomeTaxPolicyTextBlock" id="c86426308" escape="true"><p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin: 0pt; text-align: left;"><span style="color:#333333;"><b>Income Taxes</b></span></p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin: 0pt; text-align: left;">&#xa0;</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin: 0pt; text-align: left;"><span style="color:#333333;">We account for income taxes in accordance with ASC Topic <em style="font: inherit;">740,</em> Accounting for Income Taxes, which requires the recognition of deferred tax liabilities and assets for the expected future tax consequences of temporary differences between financial statement carrying amounts and the tax basis of assets and liabilities.</span></p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin: 0pt; text-align: left;">&#xa0;</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin: 0pt; text-align: left;"><span style="color:#333333;">We use a recognition threshold and measurement attribute for the financial statement recognition and measurement of a tax position taken or expected to be taken in a tax return. Because we have never realized a profit, management has fully reserved the net deferred tax asset since realization is <em style="font: inherit;">not</em> assured.</span></p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin: 0pt; text-align: left;">&#xa0;</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin: 0pt; text-align: left;"><span style="color:#333333;">For the&#xa0;<em style="font: inherit;">three</em>&#xa0;and&#xa0;<em style="font: inherit;">six</em>&#xa0;months ended&#xa0;</span><span style="color:#333333;"><em style="font: inherit;"> June 30, 2021</em></span><span style="color:#333333;">, we recorded a deferred&#xa0;income tax benefit of&#xa0;</span><span style="color:#333333;">$<ix:nonFraction id="c86425243" contextRef="d_2021-01-01_2021-06-30" unitRef="USD" name="us-gaap:DeferredIncomeTaxExpenseBenefit" scale="6" format="ixt:numdotdecimal" decimals="-5" sign="-">8.3</ix:nonFraction></span><span style="color:#333333;">&#xa0;million. The deferred tax benefit recorded for these periods relates solely to the reduction of the deferred tax liability as a result of the loss on impairment of intangible assets related to&#xa0;rostafuroxin.</span></p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin: 0pt; text-align: left;">&#xa0;</p></ix:nonNumeric><p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin: 0pt; text-align: left;"></p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin: 0pt; text-align: left;"></p><ix:nonNumeric contextRef="d_2022-01-01_2022-06-30" name="us-gaap:EarningsPerSharePolicyTextBlock" id="c86426309" escape="true"><p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin: 0pt; text-align: left;"><span style="color:#333333;"><b>Net Loss per Common Share</b></span></p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin: 0pt; text-align: left;">&#xa0;</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin: 0pt; text-align: left;"><span style="color:#333333;">Basic net loss per common share is computed by dividing net loss by the weighted average number of common shares outstanding for the period. Diluted net loss per common share is computed by giving effect to all potentially dilutive securities outstanding for the period. As of </span><span style="color:#333333;"><em style="font: inherit;"> June 30, 2022 </em>and <em style="font: inherit;">2021</em></span><span style="color:#333333;">, the number of shares of common stock potentially issuable upon the exercise of certain stock options and warrants, as well as the vesting of&#xa0;restricted stock units, was&#xa0;</span><span style="color:#333333;"><ix:nonFraction id="c86425246" contextRef="d_2022-01-01_2022-06-30" unitRef="Share" name="wint:NumberOfSharesOfCommonStockPotentiallyIssuableUponTheExerciseOfStockOptionsAndWarrants" scale="6" format="ixt:numdotdecimal" decimals="-5">21.2</ix:nonFraction></span><span style="color:#333333;"> million and&#xa0;</span><span style="color:#333333;"><ix:nonFraction id="c86425247" contextRef="d_2021-01-01_2021-06-30" unitRef="Share" name="wint:NumberOfSharesOfCommonStockPotentiallyIssuableUponTheExerciseOfStockOptionsAndWarrants" scale="6" format="ixt:numdotdecimal" decimals="-5">19.9</ix:nonFraction></span><span style="color:#333333;"> million shares, respectively. For the </span><span style="color:#333333;"><em style="font: inherit;">three</em> and <em style="font: inherit;">six</em> months ended <em style="font: inherit;"> June 30, 2022 </em>and <em style="font: inherit;">2021</em></span><span style="color:#333333;">, all potentially dilutive securities were anti-dilutive and therefore have been excluded from the computation of diluted net loss per share.</span></p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin: 0pt; text-align: left;">&#xa0;</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin: 0pt; text-align: left;"><span style="color:#333333;">We do <em style="font: inherit;">not</em> have any components of other comprehensive (loss) income.</span></p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin: 0pt; text-align: left;">&#xa0;</p></ix:nonNumeric><p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin: 0pt; text-align: left;"></p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin: 0pt; text-align: left;"></p><ix:nonNumeric contextRef="d_2022-01-01_2022-06-30" name="wint:EffectOfCOVID19PandemicPolicyTextBlock" id="c86426310" escape="true"><p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin: 0pt; text-align: left;"><span style="color:#333333;"><b>COVID-<em style="font: inherit;">19</em></b></span></p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin: 0pt; text-align: left;">&#xa0;</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin: 0pt; text-align: left;"><span style="color:#333333;">The COVID-<em style="font: inherit;">19</em> pandemic continues to evolve, and we continue to closely monitor its impact on our business and&#xa0;operations, including its continued&#xa0;impact on our clinical development plans and timelines, and financial condition. There has been intermittent impact of the pandemic in differing geographies,&#xa0;and there <em style="font: inherit;"> may </em>be continued impact, particularly in light of the surge of new COVID-<em style="font: inherit;">19</em> cases relating to new variants. As of the date of the issuance of this Quarterly Report on Form <em style="font: inherit;">10</em>-Q, our operations, capital&#xa0;and financial resources, and overall liquidity position and outlook have been impacted by COVID-<em style="font: inherit;">19,</em> primarily due to delays experienced in our operations, including&#xa0;in clinical study initiation and enrollment. The extended timelines have required us to expend more of our capital resources than planned to achieve our projected milestones. For example, our Phase <em style="font: inherit;">2</em> study of istaroxime for early cardiogenic shock in heart failure patients&#xa0;experienced delays in trial initiation and enrollment in <em style="font: inherit;">2021.</em>&#xa0;Although many countries have re-opened, rises in new cases, including as the result of newly identified COVID-<em style="font: inherit;">19</em> variants, have caused certain countries, states, and localities to re-initiate restrictions.&#xa0;The full extent, duration, or impact that the COVID-<em style="font: inherit;">19</em> pandemic will have, directly or indirectly, on our financial condition and operations, including ongoing and planned clinical trials, will depend on future developments that are highly uncertain and cannot be accurately predicted. These potential future developments include the severity and transmissibility of new variants of the virus, information about any resurgences&#xa0;in <em style="font: inherit;">one</em> or more geographic locations where our current or intended clinical trial sites, our&#xa0;principal executive offices, research and development laboratories, or manufacturing facilities are located, and the actions taken to contain it or treat its impact. In addition, regional impact and responses to the COVID-<em style="font: inherit;">19</em> pandemic have affected where a clinical trial could be executed and how various elements of the clinical trial are performed. Going forward, the pandemic could also impact how monitoring/auditing of clinical trial&#xa0;sites and data occur. The maintenance, or strategic re-implementation, of mitigating COVID-<em style="font: inherit;">19</em> measures in <em style="font: inherit;">one</em> or more geographic locations where our clinical trial sites, principal executive offices, research and development laboratories, or other facilities are located remains possible and if realized, we believe there could be further impact on the clinical development of our product candidates, which <em style="font: inherit;"> may </em>include potential delays, halts, or modifications to our ongoing and planned trials in </span><span style="color:#333333;"><em style="font: inherit;">2022</em></span><span style="color:#333333;"> and beyond.</span></p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin: 0pt; text-align: left;">&#xa0;</p>
   <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left"><span style="color:#333333;">We are <em style="font: inherit;">not</em> aware of any specific event or circumstance that would require us to further update our estimates, judgments, or revise the carrying value of our assets or liabilities as of the date of issuance of these interim unaudited condensed consolidated financial statements. These estimates <em style="font: inherit;"> may </em>change&#xa0;as new events occur and additional information is obtained.</span></p></ix:nonNumeric><p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left"></p>
  </ix:nonNumeric>
  <div>
    &#xa0;
  </div>
  <p style="margin: 0pt; text-align: left;">&#xa0;</p>
  <div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
   <div class="PGFTR" style="text-align: center; width: 100%">
    <div class="hf-row">
     <div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">
       12
     </div>
    </div>
   </div>
   <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000" />
   <div class="PGHDR" style="text-align: left; width: 100%">
    <div class="hf-row">
     <div class="hf-cell TOCLink" style="display: inline-block; text-align: left;">
      <a href="#toc" style="font-weight: initial; font-style: initial; font-variant: initial; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif;">Table of Contents</a>
     </div>
    </div>
   </div>
  </div>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin: 0pt; text-align: left;">&#xa0;</p>
  <ix:nonNumeric contextRef="d_2022-01-01_2022-06-30" name="us-gaap:FairValueDisclosuresTextBlock" id="c2175902" escape="true">
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;"><span style="color:#333333;"><b>Note <em style="font: inherit;">5</em> &#x2013; Fair Value Measurements</b></span></p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin: 0pt; text-align: left;">&#xa0;</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin: 0pt; text-align: left;"><span style="color:#333333;">Fair value is defined as the exchange price that would be received for an asset or paid to transfer a liability in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date.</span></p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin: 0pt; text-align: justify;">&#xa0;</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin: 0pt; text-align: left;"><span style="color:#333333;">Valuation techniques used to measure fair value must maximize the use of observable inputs and minimize the use of unobservable inputs. The fair value hierarchy is based on <em style="font: inherit;">three</em> levels of inputs, of which the <em style="font: inherit;">first</em> <em style="font: inherit;">two</em> are considered observable and the last unobservable, as follows:</span></p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin: 0pt; text-align: left;">&#xa0;</p>
   <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">
    <tbody>
     <tr style="vertical-align: top; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">
      <td style="width: 36pt; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td>
      <td style="width: 36pt; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin: 0pt; text-align: left;"><span style="color:#333333;">&#x25cf;</span></p> </td>
      <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin: 0pt; text-align: left;"><span style="color:#333333;">Level <em style="font: inherit;">1</em> &#x2013; Quoted prices in active markets for identical assets and liabilities.</span></p> </td>
     </tr>

     <tr style="vertical-align: top; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">
      <td style="width: 36pt; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td>
      <td style="width: 36pt; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin: 0pt; text-align: left;"><span style="color:#333333;">&#x25cf;</span></p> </td>
      <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin: 0pt; text-align: left;"><span style="color:#333333;">Level <em style="font: inherit;">2</em> &#x2013; Inputs other than Level <em style="font: inherit;">1</em> that are observable, either directly or indirectly, such as quoted prices for similar assets or liabilities, quoted prices in markets that are <em style="font: inherit;">not</em> active, or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities.</span></p> </td>
     </tr>

     <tr style="vertical-align: top; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">
      <td style="width: 36pt; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td>
      <td style="width: 36pt; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin: 0pt; text-align: left;"><span style="color:#333333;">&#x25cf;</span></p> </td>
      <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin: 0pt; text-align: left;"><span style="color:#333333;">Level <em style="font: inherit;">3</em> &#x2013; Unobservable inputs that are supported by little or <em style="font: inherit;">no</em> market activity and that are significant to the fair value of the assets or liabilities.</span></p> </td>
     </tr>

    </tbody>
   </table>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin: 0pt; text-align: justify;">&#xa0;</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin: 0pt; text-align: left;"><span style="color:#333333;"><b>Fair Value on a Recurring Basis</b></span></p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin: 0pt; text-align: left;">&#xa0;</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin: 0pt; text-align: left;"><span style="color:#333333;">The tables below categorize assets measured at fair value on a recurring basis for the periods presented:</span></p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin: 0pt; text-align: left;">&#xa0;</p>
   <ix:nonNumeric contextRef="d_2022-01-01_2022-06-30" name="us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" id="c8C9C4250-C246-4F41-882E-3B4F714C542E" escape="true" continuedAt="C51B6D85-C2B5-477D-9AA7-67B2D0B99F1A">
    <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="margin-right: 10%; width: 90%; font-size: 10pt; font-family: &quot;Times New Roman&quot;; text-indent: 0px;">
     <tbody>
      <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom">
       <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td>
       <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td>
       <td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin: 0pt; text-align: center;"><span style="color:#333333;"><b><em style="font: inherit;">Fair Value</em></b></span></p> </td>
       <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px;">&#xa0;</td>
       <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td>
       <td colspan="10" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin: 0pt; text-align: center;"><span style="color:#333333;"><b><em style="font: inherit;"><em style="font: inherit;"><em style="font: inherit;">Fair value measurement using</em></em></em></b></span></p> </td>
       <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px;">&#xa0;</td>
      </tr>

      <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom">
       <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td>
       <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td>
       <td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin: 0pt; text-align: center;"><span style="color:#333333;"><b><em style="font: inherit;">June 30,</em></b></span></p> </td>
       <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td>
       <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td>
       <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td>
       <td style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"><em style="font: inherit;">&#xa0;</em></td>
       <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"><span style="color:#333333;"><b>&#xa0;</b></span></td>
       <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td>
       <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td>
       <td style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"><em style="font: inherit;">&#xa0;</em></td>
       <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"><span style="color:#333333;"><b>&#xa0;</b></span></td>
       <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td>
       <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td>
       <td style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"><em style="font: inherit;">&#xa0;</em></td>
       <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"><span style="color:#333333;"><b>&#xa0;</b></span></td>
      </tr>

      <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom">
       <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 44%;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><span style="color:#333333;"><i>(in thousands)</i></span></p> </td>
       <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td>
       <td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin: 0pt; text-align: center;"><span style="color:#333333;"><b><em style="font: inherit;">2022</em></b></span></p> </td>
       <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px;">&#xa0;</td>
       <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td>
       <td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin: 0pt; text-align: center;"><span style="color:#333333;"><b><em style="font: inherit;">Level 1</em></b></span></p> </td>
       <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px;">&#xa0;</td>
       <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td>
       <td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin: 0pt; text-align: center;"><span style="color:#333333;"><b><em style="font: inherit;">Level 2</em></b></span></p> </td>
       <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px;">&#xa0;</td>
       <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td>
       <td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin: 0pt; text-align: center;"><span style="color:#333333;"><b><em style="font: inherit;">Level 3</em></b></span></p> </td>
       <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px;">&#xa0;</td>
      </tr>

      <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom">
       <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td>
       <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td>
       <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td>
       <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td>
       <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td>
       <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td>
       <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td>
       <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td>
       <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td>
       <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td>
       <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td>
       <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td>
       <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td>
       <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td>
       <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td>
       <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td>
       <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td>
      </tr>

      <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom">
       <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><span style="color:#333333;">Cash equivalents:</span></p> </td>
       <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td>
       <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td>
       <td style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td>
       <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td>
       <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td>
       <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td>
       <td style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td>
       <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td>
       <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td>
       <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td>
       <td style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td>
       <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td>
       <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td>
       <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td>
       <td style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td>
       <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td>
      </tr>

      <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom">
       <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><span style="color:#333333;">Money market funds</span></p> </td>
       <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px;">&#xa0;</td>
       <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><span style="color:#333333;">$</span></td>
       <td style="width: 11%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><span style="color:#333333;"><ix:nonFraction id="c86425317" contextRef="i_2022-06-30_CashAndCashEquivalentsAxis-MoneyMarketFundsMember_FairValueByMeasurementFrequencyAxis-FairValueMeasurementsRecurringMember" unitRef="USD" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" scale="3" format="ixt:numdotdecimal" decimals="-3">10,121</ix:nonFraction></span></td>
       <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">&#xa0;</td>
       <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px;">&#xa0;</td>
       <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><span style="color:#333333;">$</span></td>
       <td style="width: 11%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><span style="color:#333333;"><ix:nonFraction id="c86425318" contextRef="i_2022-06-30_CashAndCashEquivalentsAxis-MoneyMarketFundsMember_FairValueByFairValueHierarchyLevelAxis-FairValueInputsLevel1Member_FairValueByMeasurementFrequencyAxis-FairValueMeasurementsRecurringMember" unitRef="USD" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" scale="3" format="ixt:numdotdecimal" decimals="-3">10,121</ix:nonFraction></span></td>
       <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">&#xa0;</td>
       <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px;">&#xa0;</td>
       <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><span style="color:#333333;">$</span></td>
       <td style="width: 11%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><span style="color:#333333;"><em style="font: inherit;">-</em></span></td>
       <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">&#xa0;</td>
       <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px;">&#xa0;</td>
       <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><span style="color:#333333;">$</span></td>
       <td style="width: 11%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><span style="color:#333333;"><em style="font: inherit;">-</em></span></td>
       <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">&#xa0;</td>
      </tr>

      <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom">
       <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 18pt;"><span style="color:#333333;">Total Assets</span></p> </td>
       <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td>
       <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><span style="color:#333333;">$</span></td>
       <td style="width: 11%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><span style="color:#333333;"><ix:nonFraction id="c86425321" contextRef="i_2022-06-30_FairValueByMeasurementFrequencyAxis-FairValueMeasurementsRecurringMember" unitRef="USD" name="us-gaap:AssetsFairValueDisclosure" scale="3" format="ixt:numdotdecimal" decimals="-3">10,121</ix:nonFraction></span></td>
       <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&#xa0;</td>
       <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td>
       <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><span style="color:#333333;">$</span></td>
       <td style="width: 11%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><span style="color:#333333;"><ix:nonFraction id="c86425322" contextRef="i_2022-06-30_FairValueByFairValueHierarchyLevelAxis-FairValueInputsLevel1Member_FairValueByMeasurementFrequencyAxis-FairValueMeasurementsRecurringMember" unitRef="USD" name="us-gaap:AssetsFairValueDisclosure" scale="3" format="ixt:numdotdecimal" decimals="-3">10,121</ix:nonFraction></span></td>
       <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&#xa0;</td>
       <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td>
       <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><span style="color:#333333;">$</span></td>
       <td style="width: 11%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><span style="color:#333333;"><em style="font: inherit;">-</em></span></td>
       <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&#xa0;</td>
       <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td>
       <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><span style="color:#333333;">$</span></td>
       <td style="width: 11%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><span style="color:#333333;"><em style="font: inherit;">-</em></span></td>
       <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&#xa0;</td>
      </tr>

     </tbody>
    </table>
   </ix:nonNumeric>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin: 0pt; text-align: left;">&#xa0;</p>
   <ix:continuation id="C51B6D85-C2B5-477D-9AA7-67B2D0B99F1A">
    <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="margin-right: 10%; width: 90%; font-size: 10pt; font-family: &quot;Times New Roman&quot;; text-indent: 0px;">
     <tbody>
      <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom">
       <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td>
       <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td>
       <td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin: 0pt; text-align: center;"><span style="color:#333333;"><b><em style="font: inherit;">Fair Value</em></b></span></p> </td>
       <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px;">&#xa0;</td>
       <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td>
       <td colspan="10" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin: 0pt; text-align: center;"><span style="color:#333333;"><b><em style="font: inherit;"><em style="font: inherit;"><em style="font: inherit;">Fair value measurement using</em></em></em></b></span></p> </td>
       <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px;">&#xa0;</td>
      </tr>

      <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom">
       <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td>
       <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td>
       <td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin: 0pt; text-align: center;"><span style="color:#333333;"><b><em style="font: inherit;">December 31,</em></b></span></p> </td>
       <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td>
       <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td>
       <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td>
       <td style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"><em style="font: inherit;">&#xa0;</em></td>
       <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"><span style="color:#333333;"><b>&#xa0;</b></span></td>
       <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td>
       <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td>
       <td style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"><em style="font: inherit;">&#xa0;</em></td>
       <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"><span style="color:#333333;"><b>&#xa0;</b></span></td>
       <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td>
       <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td>
       <td style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"><em style="font: inherit;">&#xa0;</em></td>
       <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"><span style="color:#333333;"><b>&#xa0;</b></span></td>
      </tr>

      <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom">
       <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 44%;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><span style="color:#333333;"><i>(in thousands)</i></span></p> </td>
       <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td>
       <td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin: 0pt; text-align: center;"><span style="color:#333333;"><b><em style="font: inherit;">2021</em></b></span></p> </td>
       <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px;">&#xa0;</td>
       <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td>
       <td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin: 0pt; text-align: center;"><span style="color:#333333;"><b><em style="font: inherit;">Level 1</em></b></span></p> </td>
       <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px;">&#xa0;</td>
       <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td>
       <td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin: 0pt; text-align: center;"><span style="color:#333333;"><b><em style="font: inherit;">Level 2</em></b></span></p> </td>
       <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px;">&#xa0;</td>
       <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td>
       <td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin: 0pt; text-align: center;"><span style="color:#333333;"><b><em style="font: inherit;">Level 3</em></b></span></p> </td>
       <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px;">&#xa0;</td>
      </tr>

      <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom">
       <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td>
       <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td>
       <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td>
       <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td>
       <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td>
       <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td>
       <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td>
       <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td>
       <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td>
       <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td>
       <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td>
       <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td>
       <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td>
       <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td>
       <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td>
       <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td>
       <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td>
      </tr>

      <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom">
       <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><span style="color:#333333;">Cash equivalents:</span></p> </td>
       <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td>
       <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td>
       <td style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td>
       <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td>
       <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td>
       <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td>
       <td style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td>
       <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td>
       <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td>
       <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td>
       <td style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td>
       <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td>
       <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td>
       <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td>
       <td style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td>
       <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td>
      </tr>

      <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom">
       <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><span style="color:#333333;">Money market funds</span></p> </td>
       <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px;">&#xa0;</td>
       <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><span style="color:#333333;">$</span></td>
       <td style="width: 11%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><span style="color:#333333;"><ix:nonFraction id="c86425338" contextRef="i_2021-12-31_CashAndCashEquivalentsAxis-MoneyMarketFundsMember_FairValueByMeasurementFrequencyAxis-FairValueMeasurementsRecurringMember" unitRef="USD" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" scale="3" format="ixt:numdotdecimal" decimals="-3">21,104</ix:nonFraction></span></td>
       <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">&#xa0;</td>
       <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px;">&#xa0;</td>
       <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><span style="color:#333333;">$</span></td>
       <td style="width: 11%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><span style="color:#333333;"><ix:nonFraction id="c86425339" contextRef="i_2021-12-31_CashAndCashEquivalentsAxis-MoneyMarketFundsMember_FairValueByFairValueHierarchyLevelAxis-FairValueInputsLevel1Member_FairValueByMeasurementFrequencyAxis-FairValueMeasurementsRecurringMember" unitRef="USD" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" scale="3" format="ixt:numdotdecimal" decimals="-3">21,104</ix:nonFraction></span></td>
       <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">&#xa0;</td>
       <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px;">&#xa0;</td>
       <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><span style="color:#333333;">$</span></td>
       <td style="width: 11%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><span style="color:#333333;"><em style="font: inherit;">-</em></span></td>
       <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">&#xa0;</td>
       <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px;">&#xa0;</td>
       <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><span style="color:#333333;">$</span></td>
       <td style="width: 11%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><span style="color:#333333;"><em style="font: inherit;">-</em></span></td>
       <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">&#xa0;</td>
      </tr>

      <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom">
       <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-top: 0px; padding-right: 0px; padding-left: 0px; margin: 0px;"> <p style="margin-top: 0pt; margin-bottom: 0pt; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 18pt;"><span style="color:#333333;">Total Assets</span></p> </td>
       <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding: 0px 0px 3px; margin: 0px;">&#xa0;</td>
       <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-top: 0px; padding-right: 0px; padding-left: 0px; margin: 0px; border-bottom: 3px double rgb(0, 0, 0);"><span style="color:#333333;">$</span></td>
       <td style="width: 11%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-top: 0px; padding-right: 0px; padding-left: 0px; margin: 0px; border-bottom: 3px double rgb(0, 0, 0);"><span style="color:#333333;"><ix:nonFraction id="c86425342" contextRef="i_2021-12-31_FairValueByMeasurementFrequencyAxis-FairValueMeasurementsRecurringMember" unitRef="USD" name="us-gaap:AssetsFairValueDisclosure" scale="3" format="ixt:numdotdecimal" decimals="-3">21,104</ix:nonFraction></span></td>
       <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding: 0px 0px 3px; margin: 0px;">&#xa0;</td>
       <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding: 0px 0px 3px; margin: 0px;">&#xa0;</td>
       <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-top: 0px; padding-right: 0px; padding-left: 0px; margin: 0px; border-bottom: 3px double rgb(0, 0, 0);"><span style="color:#333333;">$</span></td>
       <td style="width: 11%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-top: 0px; padding-right: 0px; padding-left: 0px; margin: 0px; border-bottom: 3px double rgb(0, 0, 0);"><span style="color:#333333;"><ix:nonFraction id="c86425343" contextRef="i_2021-12-31_FairValueByFairValueHierarchyLevelAxis-FairValueInputsLevel1Member_FairValueByMeasurementFrequencyAxis-FairValueMeasurementsRecurringMember" unitRef="USD" name="us-gaap:AssetsFairValueDisclosure" scale="3" format="ixt:numdotdecimal" decimals="-3">21,104</ix:nonFraction></span></td>
       <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding: 0px 0px 3px; margin: 0px;">&#xa0;</td>
       <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding: 0px 0px 3px; margin: 0px;">&#xa0;</td>
       <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-top: 0px; padding-right: 0px; padding-left: 0px; margin: 0px; border-bottom: 3px double rgb(0, 0, 0);"><span style="color:#333333;">$</span></td>
       <td style="width: 11%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-top: 0px; padding-right: 0px; padding-left: 0px; margin: 0px; border-bottom: 3px double rgb(0, 0, 0);"><span style="color:#333333;"><em style="font: inherit;">-</em></span></td>
       <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding: 0px 0px 3px; margin: 0px;">&#xa0;</td>
       <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding: 0px 0px 3px; margin: 0px;">&#xa0;</td>
       <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-top: 0px; padding-right: 0px; padding-left: 0px; margin: 0px; border-bottom: 3px double rgb(0, 0, 0);"><span style="color:#333333;">$</span></td>
       <td style="width: 11%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-top: 0px; padding-right: 0px; padding-left: 0px; margin: 0px; border-bottom: 3px double rgb(0, 0, 0);"><span style="color:#333333;"><em style="font: inherit;">-</em></span></td>
       <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding: 0px 0px 3px; margin: 0px;">&#xa0;</td>
      </tr>

     </tbody>
    </table>
   </ix:continuation>
  </ix:nonNumeric>
  <p style="margin: 0pt; text-align: left;">&#xa0;</p>
  <div>
    &#xa0;
  </div>
  <ix:nonNumeric contextRef="d_2022-01-01_2022-06-30" name="us-gaap:ShortTermDebtTextBlock" id="c2175905" escape="true">
   <p style="margin: 0pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><span style="color:#333333;"><b>Note <em style="font: inherit;">6</em> &#x2013; Loans Payable</b></span></p>
   <p style="margin: 0pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin: 0pt; text-align: left;"><span style="color:#333333;">In <em style="font: inherit;"> June 2022, </em>we entered into an insurance premium financing and security agreement with Bank Direct. Under the agreement, we financed&#xa0;</span><span style="color:#333333;">$<ix:nonFraction id="c86425347" contextRef="i_2022-06-30_DebtInstrumentAxis-LoanPayableToBankDirectCapitalFinanceMember_ShortTermDebtTypeAxis-LoansPayableMember" unitRef="USD" name="us-gaap:DebtInstrumentFaceAmount" scale="6" format="ixt:numdotdecimal" decimals="-5">1.1</ix:nonFraction></span><span style="color:#333333;">&#xa0;million of certain premiums at a&#xa0;</span><span style="color:#333333;"><ix:nonFraction id="c86425348" contextRef="i_2022-06-30_DebtInstrumentAxis-LoanPayableToBankDirectCapitalFinanceMember_ShortTermDebtTypeAxis-LoansPayableMember" unitRef="Pure" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" format="ixt:numdotdecimal" decimals="3">3.90</ix:nonFraction>%</span><span style="color:#333333;">&#xa0;annual interest rate. Payments of approximately&#xa0;</span><span style="color:#333333;">$<ix:nonFraction id="c86425349" contextRef="d_2022-06-30_2022-06-30_DebtInstrumentAxis-LoanPayableToBankDirectCapitalFinanceMember_ShortTermDebtTypeAxis-LoansPayableMember" unitRef="USD" name="us-gaap:DebtInstrumentPeriodicPayment" scale="0" format="ixt:numdotdecimal" decimals="INF">126,000</ix:nonFraction></span><span style="color:#333333;">&#xa0;are due monthly from <em style="font: inherit;"> July 2022 </em>through <em style="font: inherit;"> March 2023.&#xa0;</em>As of&#xa0;</span><span style="color:#333333;"><em style="font: inherit;"> June 30, 2022</em></span><span style="color:#333333;">, the outstanding principal of the loan was&#xa0;</span><span style="color:#333333;">$<ix:nonFraction id="c86425350" contextRef="i_2022-06-30_DebtInstrumentAxis-LoanPayableToBankDirectCapitalFinanceMember_ShortTermDebtTypeAxis-LoansPayableMember" unitRef="USD" name="us-gaap:LoansPayableToBank" scale="6" format="ixt:numdotdecimal" decimals="-6">1.0</ix:nonFraction></span><span style="color:#333333;"> million.</span></p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin: 0pt; text-align: left;">&#xa0;</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;"><span style="color:#333333;">In <em style="font: inherit;"> June 2021, </em>we entered into an insurance premium financing and security agreement with Bank Direct. Under the agreement, we financed&#xa0;</span><span style="color:#333333;">$<ix:nonFraction id="c86425351" contextRef="i_2021-06-30_DebtInstrumentAxis-LoanPayableToBankDirectCapitalFinanceMember_ShortTermDebtTypeAxis-LoansPayableMember" unitRef="USD" name="us-gaap:DebtInstrumentFaceAmount" scale="6" format="ixt:numdotdecimal" decimals="-5">1.3</ix:nonFraction></span><span style="color:#333333;"> million of certain premiums at a&#xa0;</span><span style="color:#333333;"><ix:nonFraction id="c86425352" contextRef="i_2021-06-30_DebtInstrumentAxis-LoanPayableToBankDirectCapitalFinanceMember_ShortTermDebtTypeAxis-LoansPayableMember" unitRef="Pure" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" format="ixt:numdotdecimal" decimals="4">3.37</ix:nonFraction>%</span><span style="color:#333333;"> annual interest rate. Payments of approximately&#xa0;</span><span style="color:#333333;">$<ix:nonFraction id="c86425353" contextRef="d_2021-06-01_2021-06-30_DebtInstrumentAxis-LoanPayableToBankDirectCapitalFinanceMember_ShortTermDebtTypeAxis-LoansPayableMember" unitRef="USD" name="us-gaap:DebtInstrumentPeriodicPayment" scale="0" format="ixt:numdotdecimal" decimals="INF">147,000</ix:nonFraction></span><span style="color:#333333;"> are due monthly from <em style="font: inherit;"> July 2021 </em>through <em style="font: inherit;"> March 2022.&#xa0;</em>As of&#xa0;</span><span style="color:#333333;"><em style="font: inherit;"> December 31, 2021</em></span><span style="color:#333333;">, the outstanding principal of the loan was $<ix:nonFraction id="c86425354" contextRef="i_2021-12-31_DebtInstrumentAxis-LoanPayableToBankDirectCapitalFinanceMember_ShortTermDebtTypeAxis-LoansPayableMember" unitRef="USD" name="us-gaap:LoansPayableToBank" scale="6" format="ixt:numdotdecimal" decimals="-5">0.3</ix:nonFraction>&#xa0;million.&#xa0;The balance of the loan was repaid during the <em style="font: inherit;">first</em> quarter of <em style="font: inherit;">2022.</em></span></p>
  </ix:nonNumeric>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">&#xa0;</p>
  <div>
    &#xa0;
  </div>
  <ix:nonNumeric contextRef="d_2022-01-01_2022-06-30" name="us-gaap:LongTermDebtTextBlock" id="c2175906" escape="true">
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin: 0pt; text-align: left;"><span style="color:#333333;"><b>Note <em style="font: inherit;">7</em> &#x2013; Restructured Debt Liability</b></span></p>
   <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&#xa0;</p>
   <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><span style="color:#333333;">On <em style="font: inherit;"> October 27, 2017, </em>we and Deerfield entered into an Exchange and Termination Agreement pursuant to which (i) promissory notes evidencing a loan with affiliates of Deerfield Management Company L.P., or the Deerfield Loan,&#xa0;in the aggregate principal amount of $<ix:nonFraction id="c86425363" contextRef="d_2017-10-27_2017-10-27_CounterpartyNameAxis-DeerfieldManagementLPMember_LongtermDebtTypeAxis-DeerfieldLoanMember_TypeOfArrangementAxis-ExchangeAndTerminationAgreementMember" unitRef="USD" name="us-gaap:ExtinguishmentOfDebtAmount" scale="6" format="ixt:numdotdecimal" decimals="-6">25.0</ix:nonFraction> million and (ii) warrants to purchase up to <ix:nonFraction id="c86425364" contextRef="d_2017-10-27_2017-10-27_CounterpartyNameAxis-DeerfieldManagementLPMember_LongtermDebtTypeAxis-DeerfieldLoanMember_TypeOfArrangementAxis-ExchangeAndTerminationAgreementMember" unitRef="Share" name="wint:ClassOfWarrantOrRightNumberOfWarrantsCancelled" scale="0" format="ixt:numdotdecimal" decimals="INF">8,333</ix:nonFraction> shares of our common stock at an exercise price of $<ix:nonFraction id="c86425365" contextRef="i_2017-10-27_CounterpartyNameAxis-DeerfieldManagementLPMember_LongtermDebtTypeAxis-DeerfieldLoanMember_TypeOfArrangementAxis-ExchangeAndTerminationAgreementMember" unitRef="USDPerShare" name="wint:ClassOfWarrantOrRightExercisePriceOfCancelledWarrants" scale="0" format="ixt:numdotdecimal" decimals="INF">2,360.40</ix:nonFraction> per share held by Deerfield were cancelled in consideration for (i) a cash payment in the aggregate amount of $<ix:nonFraction id="c86425366" contextRef="d_2017-10-27_2017-10-27_CounterpartyNameAxis-DeerfieldManagementLPMember_LongtermDebtTypeAxis-DeerfieldLoanMember_TypeOfArrangementAxis-ExchangeAndTerminationAgreementMember" unitRef="USD" name="us-gaap:RepaymentsOfLongTermDebt" scale="6" format="ixt:numdotdecimal" decimals="-5">2.5</ix:nonFraction> million, (ii) <ix:nonFraction id="c86425367" contextRef="d_2017-10-27_2017-10-27_CounterpartyNameAxis-DeerfieldManagementLPMember_LongtermDebtTypeAxis-DeerfieldLoanMember_TypeOfArrangementAxis-ExchangeAndTerminationAgreementMember" unitRef="Share" name="wint:StockIssuedDuringPeriodSharesCancellationOfDebtAndWarrantObligations" scale="0" format="ixt:numdotdecimal" decimals="INF">23,703</ix:nonFraction> shares of common stock, representing <ix:nonFraction id="c86425368" contextRef="d_2017-10-27_2017-10-27_CounterpartyNameAxis-DeerfieldManagementLPMember_LongtermDebtTypeAxis-DeerfieldLoanMember_TypeOfArrangementAxis-ExchangeAndTerminationAgreementMember" unitRef="Pure" name="wint:StockIssuedDuringPeriodSharesCancellationOfDebtAndWarrantObligationsPercentageOfFullyDilutedSharesOutstanding" scale="-2" format="ixt:numdotdecimal" decimals="2">2</ix:nonFraction>% of fully-diluted shares outstanding (as defined in the Exchange and Termination Agreement) on the closing date, and (iii) the right to receive certain milestone payments based on achievement of specified AEROSURF development and commercial milestones, which, if achieved, could potentially total up to </span><span style="color:#333333;"><em style="font: inherit;">$15.0</em></span><span style="color:#333333;">&#xa0;million. In addition, a related security agreement, pursuant to which Deerfield held a security interest in substantially all of our assets, was terminated. We established a </span><span style="color:#333333;">$<ix:nonFraction id="c86425370" contextRef="i_2017-10-27_CounterpartyNameAxis-DeerfieldManagementLPMember_LongtermDebtTypeAxis-DeerfieldLoanMember_TypeOfArrangementAxis-ExchangeAndTerminationAgreementMember" unitRef="USD" name="wint:LiabilityforContingentMilestonePaymentNoncurrent" scale="6" format="ixt:numdotdecimal" decimals="-6">15.0</ix:nonFraction></span><span style="color:#333333;">&#xa0;million long-term liability for the contingent milestone payments potentially due to Deerfield under the Exchange and Termination Agreement (<i>see</i>,&#xa0;</span><span style="color:#333333;">Note <em style="font: inherit;">4</em> &#x2013; Summary of Significant Accounting Policies</span><span style="color:#333333;">). The liability has been recorded at full value of the contingent milestones and will continue to be carried at full value until the milestones are achieved and paid or milestones are <em style="font: inherit;">not</em> achieved and the liability is written off as a gain on debt restructuring.</span></p>
   <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&#xa0;</p>
   <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><span style="color:#333333;">As of </span><span style="color:#333333;"><em style="font: inherit;"> June 30, 2022</em></span><span style="color:#333333;"> and </span><span style="color:#333333;"><em style="font: inherit;"> December 31, 2021</em></span><span style="color:#333333;">, the restructured debt liability balance was&#xa0;</span><span style="color:#333333;">$<ix:nonFraction id="c86425373" contextRef="i_2022-03-31_CounterpartyNameAxis-DeerfieldManagementLPMember_LongtermDebtTypeAxis-DeerfieldLoanMember_TypeOfArrangementAxis-ExchangeAndTerminationAgreementMember" unitRef="USD" name="wint:LiabilityforContingentMilestonePaymentNoncurrent" scale="6" format="ixt:numdotdecimal" decimals="-6">15.0</ix:nonFraction></span><span style="color:#333333;">&#xa0;million.</span></p>
  </ix:nonNumeric>
  <div>
    &#xa0;
  </div>
  <ix:nonNumeric contextRef="d_2022-01-01_2022-06-30" name="us-gaap:StockholdersEquityNoteDisclosureTextBlock" id="c2175907" escape="true">
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin: 0pt; text-align: left;">&#xa0;</p>
   <ix:exclude>
    <div class="PGFTR" style="text-align:center; width:100%">
     <div class="hf-row">
      <div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: &quot;Times New Roman&quot;;">
       <em style="font: inherit;">13</em>
      </div>
     </div>
    </div>
    <hr style="PAGE-BREAK-AFTER:always; border:none; width:100%; height:2px; color:#000000; background-color:#000000" />
    <div class="PGHDR" style="text-align:left; width:100%">
     <div class="hf-row">
      <div class="hf-cell TOCLink" style="text-align: left; display: inline-block;">
       <a href="#toc" style="font-weight: initial; font-style: initial; font-variant: initial; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif;">Table of Contents</a>
      </div>
     </div>
    </div>
   </ix:exclude>
   <ix:exclude>&#xa0;</ix:exclude>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin: 0pt; text-align: left;"><span style="color:#333333;"><b>Note <em style="font: inherit;">8</em> &#x2013; Stockholders&#x2019; Equity</b></span></p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin: 0pt; text-align: left;">&#xa0;</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin: 0pt; text-align: left;"><span style="color:#333333;"><b>At-The-Market Program</b></span></p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin: 0pt; text-align: left;">&#xa0;</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin: 0pt; text-align: left;"><span style="color:#333333;">On <em style="font: inherit;"> September 17, 2020, </em>we entered into an At-The-Market Offering Agreement&#xa0;with Ladenburg, pursuant to which we <em style="font: inherit;"> may </em>offer and sell, from time to time at our sole discretion, up to a maximum of </span><span style="color:#333333;">$<ix:nonFraction id="c86425378" contextRef="i_2020-09-17_SubsidiarySaleOfStockAxis-ATMProgramMember" unitRef="USD" name="wint:SharesAuthorizedToBeOfferedAndSoldUnderOfferingAgreementValue" scale="6" format="ixt:numdotdecimal" decimals="-7">10.0</ix:nonFraction></span><span style="color:#333333;">&#xa0;million of shares of our common stock through Ladenburg as agent and/or principal through the ATM Program. When we issue sales notices to Ladenburg, we designate the maximum amount of&#xa0;shares to be sold by Ladenburg daily and the minimum price per share at which shares <em style="font: inherit;"> may </em>be sold. Ladenburg <em style="font: inherit;"> may </em>sell shares by any method permitted by law deemed to be an &#x201c;at-the-market offering&#x201d; as defined in Rule <em style="font: inherit;">415</em>(a)(<em style="font: inherit;">4</em>) under the Securities Act of <em style="font: inherit;">1933,</em> as amended, or in privately negotiated transactions.</span></p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin: 0pt; text-align: left;">&#xa0;</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin: 0pt; text-align: left;"><span style="color:#333333;">We agreed to pay Ladenburg a commission of </span><span style="color:#333333;"><ix:nonFraction id="c86425382" contextRef="d_2020-09-17_2020-09-17_SubsidiarySaleOfStockAxis-ATMProgramMember" unitRef="Pure" name="wint:CommissionFeePercentFee" scale="-2" format="ixt:numdotdecimal" decimals="2">3</ix:nonFraction>%</span><span style="color:#333333;">&#xa0;of the gross sales price of any shares sold pursuant to the ATM Program. The rate of compensation will <em style="font: inherit;">not</em> apply when Ladenburg acts as principal.</span></p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin: 0pt; text-align: left;">&#xa0;</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin: 0pt; text-align: left;"><span style="color:#333333;">For the&#xa0;</span><span style="color:#333333;"><em style="font: inherit;">six</em> months ended <em style="font: inherit;"> June 30, 2022</em></span><span style="color:#333333;">, we sold&#xa0;</span><span style="color:#333333;"><ix:nonFraction id="c86425385" contextRef="d_2022-01-01_2022-06-30_SubsidiarySaleOfStockAxis-ATMProgramMember" unitRef="Share" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" scale="0" format="ixt:numdotdecimal" decimals="INF">1,137,246</ix:nonFraction></span><span style="color:#333333;">&#xa0;shares&#xa0;of our common stock under the ATM Program&#xa0;resulting in aggregate gross proceeds to us of approximately&#xa0;</span><span style="color:#333333;">$<ix:nonFraction id="c86425386" contextRef="d_2022-01-01_2022-06-30_SubsidiarySaleOfStockAxis-ATMProgramMember" unitRef="USD" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="6" format="ixt:numdotdecimal" decimals="-5">1.3</ix:nonFraction></span><span style="color:#333333;">&#xa0;million and net proceeds of approximately&#xa0;</span><span style="color:#333333;">$<ix:nonFraction id="c86425387" contextRef="d_2022-01-01_2022-06-30_SubsidiarySaleOfStockAxis-ATMProgramMember" unitRef="USD" name="us-gaap:ProceedsFromIssuanceOfCommonStock" scale="6" format="ixt:numdotdecimal" decimals="-5">1.2</ix:nonFraction></span><span style="color:#333333;">&#xa0;million. For the&#xa0;</span><span style="color:#333333;"><em style="font: inherit;">six</em> months ended <em style="font: inherit;"> June 30, 2021</em></span><span style="color:#333333;">, we sold&#xa0;</span><span style="color:#333333;"><ix:nonFraction id="c86425389" contextRef="d_2021-01-01_2021-06-30_SubsidiarySaleOfStockAxis-ATMProgramMember" unitRef="Share" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" scale="0" format="ixt:numdotdecimal" decimals="INF">552,474</ix:nonFraction></span><span style="color:#333333;"> shares of&#xa0;our common stock under the ATM Program&#xa0;resulting in aggregate gross and net proceeds to us of approximately&#xa0;</span><span style="color:#333333;">$<ix:nonFraction id="c86425390" contextRef="d_2021-01-01_2021-06-30_SubsidiarySaleOfStockAxis-ATMProgramMember" unitRef="USD" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="6" format="ixt:numdotdecimal" decimals="-5">1.7</ix:nonFraction></span><span style="color:#333333;"> million.</span></p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin: 0pt; text-align: left;">&#xa0;</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin: 0pt; text-align: left;"><span style="color:#333333;">During <em style="font: inherit;"> July </em>and <em style="font: inherit;"> August 2022,&#xa0;</em>we sold&#xa0;</span><span style="color:#333333;"><ix:nonFraction id="c86425391" contextRef="d_2022-07-01_2022-08-11_SubsequentEventTypeAxis-SubsequentEventMember_SubsidiarySaleOfStockAxis-ATMProgramMember" unitRef="Share" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" scale="0" format="ixt:numdotdecimal" decimals="INF">1,221,706</ix:nonFraction></span><span style="color:#333333;"> shares of our common stock under the ATM Program&#xa0;resulting in aggregate gross and net proceeds to us of approximately&#xa0;</span><span style="color:#333333;">$<ix:nonFraction id="c86425392" contextRef="d_2022-07-01_2022-08-11_SubsequentEventTypeAxis-SubsequentEventMember_SubsidiarySaleOfStockAxis-ATMProgramMember" unitRef="USD" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="6" format="ixt:numdotdecimal" decimals="-5">0.6</ix:nonFraction></span><span style="color:#333333;"> million.&#xa0;</span></p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin: 0pt; text-align: left;">&#xa0;</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin: 0pt; text-align: left;"><span style="color:#333333;">The shares of common stock issued and sold under the ATM Program are registered under our Registration Statement on Form S-<em style="font: inherit;">3</em> (File <em style="font: inherit;">No.</em> <em style="font: inherit;">333</em>-<em style="font: inherit;">248874</em>), which was declared effective by the SEC on <em style="font: inherit;"> September 29, 2020. </em>As of </span><span style="color:#333333;"><em style="font: inherit;"> August 11, 2022</em></span><span style="color:#333333;">, approximately&#xa0;</span><span style="color:#333333;">$<ix:nonFraction id="c86425397" contextRef="i_2022-08-11_SubsequentEventTypeAxis-SubsequentEventMember_SubsidiarySaleOfStockAxis-ATMProgramMember" unitRef="USD" name="wint:StockOfferingAgreementRemainingAmountAvailable" scale="6" format="ixt:numdotdecimal" decimals="-5">3.2</ix:nonFraction></span><span style="color:#333333;"> million remains&#xa0;available under the ATM Program.&#xa0;However, we are currently subject to the limitations contained in General Instruction <em style="font: inherit;">I.B.6</em> of Form S-<em style="font: inherit;">3.</em> As a result, we are limited in selling <em style="font: inherit;">no</em> more than <em style="font: inherit;">one</em>-<em style="font: inherit;">third</em> of our public float during any <em style="font: inherit;">12</em>-month period. If our public float increases to $<ix:nonFraction id="c86425404" contextRef="i_2022-08-11_SubsequentEventTypeAxis-SubsequentEventMember_SubsidiarySaleOfStockAxis-ATMProgramMember" unitRef="USD" name="wint:StockOfferingAgreementPublicFloatLimitationAmount" scale="6" format="ixt:numdotdecimal" decimals="-6">75</ix:nonFraction> million or more, we will <em style="font: inherit;">no</em> longer be subject to such limitations.</span></p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin: 0pt; text-align: left;">&#xa0;</p>
   <div style="font-size:10pt">
    <div style="font-family:&quot;Times New Roman&quot;">
     <span style="color:#333333;"><b><em style="font: inherit;"> March 2021 </em>Public Offering</b></span>
    </div>
   </div>
   <p style="text-align: left; margin: 0pt;">&#xa0;</p>
   <div style="font-size:10pt">
    <div style="font-family:&quot;Times New Roman&quot;">
     <span style="color:#333333;">On <em style="font: inherit;"> March 23, 2021, </em>we entered into an underwriting agreement with Oppenheimer &amp; Co. Inc. as representative for the several underwriters named therein, relating to a public offering, or the <em style="font: inherit;"> March 2021 </em>Offering, of an aggregate of </span>
     <span style="color:#333333;"><ix:nonFraction id="c86425406" contextRef="d_2021-03-23_2021-03-23_SubsidiarySaleOfStockAxis-March2021PublicOfferingMember" unitRef="Share" name="wint:EquityIssuedDuringPeriodUnitsNewIssues" scale="0" format="ixt:numdotdecimal" decimals="INF">9,230,500</ix:nonFraction></span>
     <span style="color:#333333;">&#xa0;units with each unit consisting of <span style="-sec-ix-hidden:c86425407">one</span> share of common stock and a warrant, or the <em style="font: inherit;"> March 2021 </em>Warrants. The <em style="font: inherit;"> March 2021 </em>Warrants are immediately exercisable for shares of common stock at a price of </span>
     <span style="color:#333333;">$<ix:nonFraction id="c86425408" contextRef="i_2021-03-23_ClassOfWarrantOrRightAxis-March2021WarrantsMember" unitRef="USDPerShare" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" format="ixt:numdotdecimal" decimals="INF">3.60</ix:nonFraction></span>
     <span style="color:#333333;"> per share and expire <span style="-sec-ix-hidden:c86425409">five</span> years from the date of issuance. The shares of common stock and the <em style="font: inherit;"> March 2021 </em>Warrants were immediately separable and were issued separately in the <em style="font: inherit;"> March 2021 </em>Offering.</span>
    </div>
    <div style="font-family:&quot;Times New Roman&quot;">
      &#xa0;
    </div>
    <div style="font-family:&quot;Times New Roman&quot;">
     <span style="color:#333333;">The closing of the <em style="font: inherit;"> March 2021 </em>Offering occurred on <em style="font: inherit;"> March 25, 2021. </em>The offering price to the public was </span>
     <span style="color:#333333;">$<ix:nonFraction id="c86425410" contextRef="i_2021-03-25_SubsidiarySaleOfStockAxis-March2021PublicOfferingMember" unitRef="USDPerShare" name="wint:StockAndWarrantsIssuedPricePerShare" scale="0" format="ixt:numdotdecimal" decimals="INF">3.25</ix:nonFraction></span>
     <span style="color:#333333;">&#xa0;per unit resulting in gross proceeds to us of&#xa0;</span>
     <span style="color:#333333;">$<ix:nonFraction id="c86425411" contextRef="d_2021-03-25_2021-03-25_SubsidiarySaleOfStockAxis-March2021PublicOfferingMember" unitRef="USD" name="wint:ProceedsFromIssuanceOrSaleOfEquityGrossAmount" scale="6" format="ixt:numdotdecimal" decimals="-7">30.0</ix:nonFraction></span>
     <span style="color:#333333;"> million. After deducting underwriting discounts and commissions and estimated offering expenses payable by us, and excluding the proceeds, if any, from the exercise of the <em style="font: inherit;"> March 2021 </em>Warrants issued pursuant to the <em style="font: inherit;"> March 2021 </em>Offering, the net proceeds to us were approximately </span>
     <span style="color:#333333;">$<ix:nonFraction id="c86425412" contextRef="d_2021-03-25_2021-03-25_SubsidiarySaleOfStockAxis-March2021PublicOfferingMember" unitRef="USD" name="us-gaap:ProceedsFromIssuanceOrSaleOfEquity" scale="6" format="ixt:numdotdecimal" decimals="-5">27.4</ix:nonFraction></span>
     <span style="color:#333333;"> million.</span>
    </div>
    <div style="font-family:&quot;Times New Roman&quot;">
      &#xa0;
    </div>
    <div style="font-family:&quot;Times New Roman&quot;">
     <span style="color:#333333;">We have determined that the appropriate accounting treatment under ASC <em style="font: inherit;">480,</em> Distinguishing Liabilities from Equity, or ASC <em style="font: inherit;">480,</em> is to classify the common stock and the <em style="font: inherit;"> March 2021 </em>Warrants issued in the <em style="font: inherit;"> March 2021 </em>Offering as equity.&#xa0;We have also determined that the <em style="font: inherit;"> March 2021 </em>Warrants are <em style="font: inherit;">not</em> in their entirety a derivative under the scope of ASC <em style="font: inherit;">815,</em> Derivatives and Hedging, or ASC <em style="font: inherit;">815,</em> due to the scope exception under ASC <em style="font: inherit;">815</em>-<em style="font: inherit;">10</em>-<em style="font: inherit;">15</em>-<em style="font: inherit;">74,</em> nor are there any material embedded derivatives that require separate accounting.&#xa0;We allocated the net proceeds from the <em style="font: inherit;"> March 2021 </em>Offering based on the relative fair value of the common stock and the <em style="font: inherit;"> March 2021 </em>Warrants.</span>
    </div>
   </div>
  </ix:nonNumeric>
  <div style="font-size:10pt">
   <div style="font-family:&quot;Times New Roman&quot;">
     &#xa0;
   </div>
  </div>
  <div>
    &#xa0;
  </div>
  <ix:nonNumeric contextRef="d_2022-01-01_2022-06-30" name="us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" id="c2175908" escape="true">
   <p style="font-family: Times New Roman; font-size: 10pt; margin: 0pt; text-align: left;"><span style="color:#333333;"><span style="font-size: 10pt;"><b>Note <em style="font: inherit;">9</em>&#xa0;&#x2013; Stock-Based Compensation</b></span></span></p>
   <p style="font-family: Times New Roman; font-size: 10pt; margin: 0pt; text-align: left;">&#xa0;</p>
   <p style="font-family: Times New Roman; font-size: 10pt; margin: 0pt; text-align: left;"><span style="color:#333333;"><span style="font-size: 10pt;">We recognize expense in our condensed consolidated financial statements related to all stock-based awards granted to employees and non-employee directors based on their fair value on the date of grant.&#xa0;Compensation expense related to stock options is calculated using the Black-Scholes option-pricing model and is recognized ratably over the vesting period, which is typically <span style="-sec-ix-hidden:c86425425">three</span> years. Compensation expense related to restricted stock unit, or RSU, awards is also recognized ratably over the vesting period, which typically has been between approximately <span style="-sec-ix-hidden:c86425426">one</span> to <span style="-sec-ix-hidden:c86425427">three</span> years.</span></span></p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin: 0pt; text-align: left;">&#xa0;</p>
   <ix:exclude>
    <div class="PGFTR" style="text-align:center; width:100%">
     <div class="hf-row">
      <div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: &quot;Times New Roman&quot;;">
       <em style="font: inherit;">14</em>
      </div>
     </div>
    </div>
    <hr style="PAGE-BREAK-AFTER:always; border:none; width:100%; height:2px; color:#000000; background-color:#000000" />
    <div class="PGHDR" style="text-align:left; width:100%">
     <div class="hf-row">
      <div class="hf-cell TOCLink" style="text-align: left; display: inline-block;">
       <a href="#toc" style="font-weight: initial; font-style: initial; font-variant: initial; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif;">Table of Contents</a>
      </div>
     </div>
    </div>
   </ix:exclude>
   <ix:exclude>&#xa0;</ix:exclude>
   <p style="text-align: left; margin: 0pt; font-size: 10pt;"><span style="color:#333333;">A summary of activity under our long-term incentive plans is presented below:</span></p>
   <p style="text-align: left; margin: 0pt; font-size: 10pt;">&#xa0;</p>
   <ix:nonNumeric contextRef="d_2022-01-01_2022-06-30" name="us-gaap:DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock" id="c2175909" escape="true">
    <table cellpadding="0" cellspacing="0" class="finTable" style="margin-right: auto; width: 80%; font-size: 10pt; font-family: Times New Roman; text-indent: 0px;">
     <tbody>
      <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom">
       <td style="font-family: Times New Roman; font-size: 10pt; padding: 0px; margin: 0px; width: 49%;"> <p style="margin-top: 0pt; margin-bottom: 0pt; font-family: Times New Roman; font-size: 10pt;"><span style="color:#333333;">(in thousands, except for weighted-average data)</span></p> </td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0px; margin: 0px;">&#xa0;</td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0px; margin: 0px;">&#xa0;</td>
       <td style="width: 14%; text-align: right; font-family: Times New Roman; font-size: 10pt; padding: 0px; margin: 0px;">&#xa0;</td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0px; margin: 0px;">&#xa0;</td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0px; margin: 0px;">&#xa0;</td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0px; margin: 0px;">&#xa0;</td>
       <td style="width: 14%; text-align: right; font-family: Times New Roman; font-size: 10pt; padding: 0px; margin: 0px;">&#xa0;</td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0px; margin: 0px;">&#xa0;</td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0px; margin: 0px;">&#xa0;</td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0px; margin: 0px;">&#xa0;</td>
       <td style="width: 14%; text-align: right; font-family: Times New Roman; font-size: 10pt; padding: 0px; margin: 0px;">&#xa0;</td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0px; margin: 0px;">&#xa0;</td>
      </tr>

      <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom">
       <td style="font-family: Times New Roman; font-size: 10pt; width: 49%; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; text-align: center;"><span style="color:#333333;"><b>Stock Options</b></span></p> </td>
       <td style="font-family: Times New Roman; font-size: 10pt; width: 1%;">&#xa0;</td>
       <td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); width: 1%;"> <p style="font-family: Times New Roman; font-size: 10pt; margin: 0pt; text-align: center;"><span style="color:#333333;"><b><em style="font: inherit;">Shares</em></b></span></p> </td>
       <td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; width: 1%;">&#xa0;</td>
       <td style="font-family: Times New Roman; font-size: 10pt; width: 1%;">&#xa0;</td>
       <td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); width: 1%;"> <p style="font-family: Times New Roman; font-size: 10pt; margin: 0pt; text-align: center;"><span style="color:#333333;"><b><em style="font: inherit;">Weighted- Average Exercise Price</em></b></span></p> </td>
       <td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; width: 1%;">&#xa0;</td>
       <td style="font-family: Times New Roman; font-size: 10pt; width: 1%;">&#xa0;</td>
       <td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); width: 1%;"> <p style="font-family: Times New Roman; font-size: 10pt; margin: 0pt; text-align: center;"><span style="color:#333333;"><b><em style="font: inherit;">Weighted- Average Remaining Contractual Term (In Yrs)</em></b></span></p> </td>
       <td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; width: 1%;">&#xa0;</td>
      </tr>

      <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom">
       <td style="font-family: Times New Roman; font-size: 10pt; width: 49%;">&#xa0;</td>
       <td style="font-family: Times New Roman; font-size: 10pt; width: 1%;">&#xa0;</td>
       <td style="font-family: Times New Roman; font-size: 10pt; width: 1%;">&#xa0;</td>
       <td style="font-family: Times New Roman; font-size: 10pt; width: 14%;">&#xa0;</td>
       <td style="font-family: Times New Roman; font-size: 10pt; width: 1%;">&#xa0;</td>
       <td style="font-family: Times New Roman; font-size: 10pt; width: 1%;">&#xa0;</td>
       <td style="font-family: Times New Roman; font-size: 10pt; width: 1%;">&#xa0;</td>
       <td style="font-family: Times New Roman; font-size: 10pt; width: 14%;">&#xa0;</td>
       <td style="font-family: Times New Roman; font-size: 10pt; width: 1%;">&#xa0;</td>
       <td style="font-family: Times New Roman; font-size: 10pt; width: 1%;">&#xa0;</td>
       <td style="font-family: Times New Roman; font-size: 10pt; width: 1%;">&#xa0;</td>
       <td style="font-family: Times New Roman; font-size: 10pt; width: 14%;">&#xa0;</td>
       <td style="font-family: Times New Roman; font-size: 10pt; width: 1%;">&#xa0;</td>
      </tr>

      <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom">
       <td style="font-family: Times New Roman; font-size: 10pt; width: 49%;"> <p style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><span style="color:#333333;">Outstanding at January 1, 2022</span></p> </td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
       <td style="width: 14%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><span style="color:#333333;"><ix:nonFraction id="c86425439" contextRef="i_2021-12-31" unitRef="Share" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" scale="3" format="ixt:numdotdecimal" decimals="-3">3,387</ix:nonFraction></span></td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#xa0;</td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><span style="color:#333333;">$</span></td>
       <td style="width: 14%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><span style="color:#333333;"><ix:nonFraction id="c86425440" contextRef="i_2021-12-31" unitRef="USDPerShare" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" scale="0" format="ixt:numdotdecimal" decimals="INF">9.74</ix:nonFraction></span></td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#xa0;</td>
       <td style="font-family: Times New Roman; font-size: 10pt; width: 1%;">&#xa0;</td>
       <td style="font-family: Times New Roman; font-size: 10pt; width: 1%;">&#xa0;</td>
       <td style="text-align: right; font-family: Times New Roman; font-size: 10pt; width: 14%;"><em style="font: inherit;">&#xa0;</em></td>
       <td style="font-family: Times New Roman; font-size: 10pt; width: 1%;">&#xa0;</td>
      </tr>

      <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom">
       <td style="font-family: Times New Roman; font-size: 10pt; width: 49%;"> <p style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 9pt;"><span style="color:#333333;">Granted</span></p> </td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
       <td style="width: 14%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><span style="color:#333333;"><ix:nonFraction id="c86425442" contextRef="d_2022-01-01_2022-06-30" unitRef="Share" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" scale="3" format="ixt:numdotdecimal" decimals="-4">880</ix:nonFraction></span></td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#xa0;</td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
       <td style="width: 14%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><span style="color:#333333;"><ix:nonFraction id="c86425443" contextRef="d_2022-01-01_2022-06-30" unitRef="USDPerShare" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" scale="0" format="ixt:numdotdecimal" decimals="INF">0.99</ix:nonFraction></span></td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#xa0;</td>
       <td style="font-family: Times New Roman; font-size: 10pt; width: 1%;">&#xa0;</td>
       <td style="font-family: Times New Roman; font-size: 10pt; width: 1%;">&#xa0;</td>
       <td style="text-align: right; font-family: Times New Roman; font-size: 10pt; width: 14%;"><em style="font: inherit;">&#xa0;</em></td>
       <td style="font-family: Times New Roman; font-size: 10pt; width: 1%;">&#xa0;</td>
      </tr>

      <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom">
       <td style="font-family: Times New Roman; font-size: 10pt; width: 49%;"> <p style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 9pt;"><span style="color:#333333;">Forfeited or expired</span></p> </td>
       <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px;">&#xa0;</td>
       <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td>
       <td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><span style="color:#333333;">(<ix:nonFraction id="c86425445" contextRef="d_2022-01-01_2022-06-30" unitRef="Share" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" scale="3" format="ixt:numdotdecimal" decimals="-4">220</ix:nonFraction></span></td>
       <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"><span style="color:#333333;">)</span></td>
       <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px;">&#xa0;</td>
       <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td>
       <td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><span style="color:#333333;"><ix:nonFraction id="c86425446" contextRef="d_2022-01-01_2022-06-30" unitRef="USDPerShare" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" scale="0" format="ixt:numdotdecimal" decimals="INF">9.72</ix:nonFraction></span></td>
       <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">&#xa0;</td>
       <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 1%; padding-bottom: 1px;">&#xa0;</td>
       <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 1%; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td>
       <td style="text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 14%; border-bottom: 1px solid rgb(0, 0, 0);"><em style="font: inherit;">&#xa0;</em></td>
       <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 1%; padding-bottom: 1px;">&#xa0;</td>
      </tr>

      <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom">
       <td style="font-family: Times New Roman; font-size: 10pt; width: 49%;"> <p style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><span style="color:#333333;">Outstanding at June 30, 2022</span></p> </td>
       <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 3px;">&#xa0;</td>
       <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);">&#xa0;</td>
       <td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><span style="color:#333333;"><ix:nonFraction id="c86425448" contextRef="i_2022-06-30" unitRef="Share" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" scale="3" format="ixt:numdotdecimal" decimals="-3">4,047</ix:nonFraction></span></td>
       <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;">&#xa0;</td>
       <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 3px;">&#xa0;</td>
       <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><span style="color:#333333;">$</span></td>
       <td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><span style="color:#333333;"><ix:nonFraction id="c86425449" contextRef="i_2022-06-30" unitRef="USDPerShare" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" scale="0" format="ixt:numdotdecimal" decimals="INF">7.84</ix:nonFraction></span></td>
       <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;">&#xa0;</td>
       <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 3px;">&#xa0;</td>
       <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);">&#xa0;</td>
       <td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><span style="color:#333333;"><ix:nonNumeric contextRef="d_2022-01-01_2022-06-30" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" id="c86425450" format="ixt-sec:duryear">7.8</ix:nonNumeric></span></td>
       <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;">&#xa0;</td>
      </tr>

      <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom">
       <td style="font-family: Times New Roman; font-size: 10pt; width: 49%;">&#xa0;</td>
       <td style="font-family: Times New Roman; font-size: 10pt; width: 1%;">&#xa0;</td>
       <td style="font-family: Times New Roman; font-size: 10pt; width: 1%;">&#xa0;</td>
       <td style="font-family: Times New Roman; font-size: 10pt; width: 14%;">&#xa0;</td>
       <td style="font-family: Times New Roman; font-size: 10pt; width: 1%;">&#xa0;</td>
       <td style="font-family: Times New Roman; font-size: 10pt; width: 1%;">&#xa0;</td>
       <td style="font-family: Times New Roman; font-size: 10pt; width: 1%;">&#xa0;</td>
       <td style="font-family: Times New Roman; font-size: 10pt; width: 14%;">&#xa0;</td>
       <td style="font-family: Times New Roman; font-size: 10pt; width: 1%;">&#xa0;</td>
       <td style="font-family: Times New Roman; font-size: 10pt; width: 1%;">&#xa0;</td>
       <td style="font-family: Times New Roman; font-size: 10pt; width: 1%;">&#xa0;</td>
       <td style="font-family: Times New Roman; font-size: 10pt; width: 14%;">&#xa0;</td>
       <td style="font-family: Times New Roman; font-size: 10pt; width: 1%;">&#xa0;</td>
      </tr>

      <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom">
       <td style="font-family: Times New Roman; font-size: 10pt; width: 49%;"> <p style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><span style="color:#333333;">Vested and exercisable at June 30, 2022</span></p> </td>
       <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td>
       <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td>
       <td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"><span style="color:#333333;"><ix:nonFraction id="c86425451" contextRef="i_2022-06-30" unitRef="Share" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" scale="3" format="ixt:numdotdecimal" decimals="-3">2,229</ix:nonFraction></span></td>
       <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#xa0;</td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><span style="color:#333333;">$</span></td>
       <td style="width: 14%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><span style="color:#333333;"><ix:nonFraction id="c86425452" contextRef="i_2022-06-30" unitRef="USDPerShare" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" scale="0" format="ixt:numdotdecimal" decimals="INF">11.35</ix:nonFraction></span></td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#xa0;</td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
       <td style="width: 14%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><span style="color:#333333;"><ix:nonNumeric contextRef="d_2022-01-01_2022-06-30" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" id="c86425453" format="ixt-sec:duryear">6.8</ix:nonNumeric></span></td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#xa0;</td>
      </tr>

      <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom">
       <td style="padding: 0px; margin: 0px; font-family: Times New Roman; font-size: 10pt; width: 49%;">&#xa0;</td>
       <td style="padding: 0px; margin: 0px; font-family: Times New Roman; font-size: 10pt; width: 1%;">&#xa0;</td>
       <td style="padding: 0px; margin: 0px; font-family: Times New Roman; font-size: 10pt; width: 1%;">&#xa0;</td>
       <td style="padding: 0px; margin: 0px; font-family: Times New Roman; font-size: 10pt; width: 14%;">&#xa0;</td>
       <td style="padding: 0px; margin: 0px; font-family: Times New Roman; font-size: 10pt; width: 1%;">&#xa0;</td>
       <td style="padding: 0px; margin: 0px; font-family: Times New Roman; font-size: 10pt; width: 1%;">&#xa0;</td>
       <td style="padding: 0px; margin: 0px; font-family: Times New Roman; font-size: 10pt; width: 1%;">&#xa0;</td>
       <td style="padding: 0px; margin: 0px; font-family: Times New Roman; font-size: 10pt; width: 14%;">&#xa0;</td>
       <td style="padding: 0px; margin: 0px; font-family: Times New Roman; font-size: 10pt; width: 1%;">&#xa0;</td>
       <td style="padding: 0px; margin: 0px; font-family: Times New Roman; font-size: 10pt; width: 1%;">&#xa0;</td>
       <td style="padding: 0px; margin: 0px; font-family: Times New Roman; font-size: 10pt; width: 1%;">&#xa0;</td>
       <td style="padding: 0px; margin: 0px; font-family: Times New Roman; font-size: 10pt; width: 14%;">&#xa0;</td>
       <td style="padding: 0px; margin: 0px; font-family: Times New Roman; font-size: 10pt; width: 1%;">&#xa0;</td>
      </tr>

      <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom">
       <td style="font-family: Times New Roman; font-size: 10pt; width: 49%;"> <p style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><span style="color:#333333;">Vested and expected to vest at June 30, 2022</span></p> </td>
       <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td>
       <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td>
       <td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"><span style="color:#333333;"><ix:nonFraction id="c86425454" contextRef="i_2022-06-30" unitRef="Share" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" scale="3" format="ixt:numdotdecimal" decimals="-3">3,821</ix:nonFraction></span></td>
       <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#xa0;</td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><span style="color:#333333;">$</span></td>
       <td style="width: 14%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><span style="color:#333333;"><ix:nonFraction id="c86425455" contextRef="i_2022-06-30" unitRef="USDPerShare" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" scale="0" format="ixt:numdotdecimal" decimals="INF">7.85</ix:nonFraction></span></td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#xa0;</td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
       <td style="width: 14%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><span style="color:#333333;"><ix:nonNumeric contextRef="d_2022-01-01_2022-06-30" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" id="c86425456" format="ixt-sec:duryear">7.8</ix:nonNumeric></span></td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#xa0;</td>
      </tr>

     </tbody>
    </table>
   </ix:nonNumeric>
   <p style="margin: 0pt; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</p>
   <ix:nonNumeric contextRef="d_2022-01-01_2022-06-30" name="us-gaap:ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock" id="c2175910" escape="true">
    <table cellpadding="0" cellspacing="0" class="finTable" style="width: 80%; font-size: 10pt; font-family: &quot;Times New Roman&quot;; text-indent: 0px; margin-left: 0pt; margin-right: auto;">
     <tbody>
      <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom">
       <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 58%;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;"><span style="color:#333333;">(in thousands, except for weighted-average data)</span></p> </td>
       <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 1%;">&#xa0;</td>
       <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 1%;">&#xa0;</td>
       <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 16%;">&#xa0;</td>
       <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 1%;">&#xa0;</td>
       <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 1%;">&#xa0;</td>
       <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 1%;">&#xa0;</td>
       <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 20%;">&#xa0;</td>
       <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 1%;">&#xa0;</td>
      </tr>

      <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom">
       <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 58%; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; text-align: center;"><span style="color:#333333;"><b>Restricted Stock Units</b></span></p> </td>
       <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 1%;">&#xa0;</td>
       <td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); width: 1%;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><span style="color:#333333;"><b><em style="font: inherit;">Shares</em></b></span></p> </td>
       <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px; width: 1%;">&#xa0;</td>
       <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 1%;">&#xa0;</td>
       <td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); width: 1%;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><span style="color:#333333;"><b><em style="font: inherit;">Weighted- Average Grant Date Fair Value</em></b></span></p> </td>
       <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px; width: 1%;">&#xa0;</td>
      </tr>

      <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom">
       <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 58%;">&#xa0;</td>
       <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 1%;">&#xa0;</td>
       <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 1%;">&#xa0;</td>
       <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 16%;">&#xa0;</td>
       <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 1%;">&#xa0;</td>
       <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 1%;">&#xa0;</td>
       <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 1%;">&#xa0;</td>
       <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 20%;">&#xa0;</td>
       <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 1%;">&#xa0;</td>
      </tr>

      <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom">
       <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 58%;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;"><span style="color:#333333;">Outstanding at January 1, 2022</span></p> </td>
       <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td>
       <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td>
       <td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"><span style="color:#333333;"><ix:nonFraction id="c86425459" contextRef="i_2021-12-31_AwardTypeAxis-RestrictedStockUnitsRSUMember" unitRef="Share" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" scale="3" format="ixt:zerodash" decimals="-3">-</ix:nonFraction></span></td>
       <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#xa0;</td>
       <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td>
       <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"><span style="color:#333333;">$</span></td>
       <td style="width: 20%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"><span style="color:#333333;"><ix:nonFraction id="c86425460" contextRef="i_2021-12-31_AwardTypeAxis-RestrictedStockUnitsRSUMember" unitRef="USDPerShare" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" scale="0" format="ixt:zerodash" decimals="INF">-</ix:nonFraction></span></td>
       <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#xa0;</td>
      </tr>

      <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom">
       <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 58%;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; text-indent: 9pt;"><span style="color:#333333;">Awarded</span></p> </td>
       <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td>
       <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td>
       <td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"><span style="color:#333333;"><ix:nonFraction id="c86425461" contextRef="d_2022-01-01_2022-06-30_AwardTypeAxis-RestrictedStockUnitsRSUMember" unitRef="Share" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" scale="3" format="ixt:numdotdecimal" decimals="-3">582</ix:nonFraction></span></td>
       <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#xa0;</td>
       <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td>
       <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td>
       <td style="width: 20%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"><span style="color:#333333;"><ix:nonFraction id="c86425462" contextRef="d_2022-01-01_2022-06-30_AwardTypeAxis-RestrictedStockUnitsRSUMember" unitRef="USDPerShare" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" format="ixt:numdotdecimal" decimals="INF">0.99</ix:nonFraction></span></td>
       <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#xa0;</td>
      </tr>

      <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom">
       <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 58%; padding-top: 0px; padding-right: 0px; padding-left: 0px; margin: 0px;"> <p style="margin-top: 0pt; margin-bottom: 0pt; text-indent: 9pt;"><span style="color:#333333;">Cancelled</span></p> </td>
       <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding: 0px 0px 1px; margin: 0px;">&#xa0;</td>
       <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-top: 0px; padding-right: 0px; padding-left: 0px; margin: 0px; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td>
       <td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-top: 0px; padding-right: 0px; padding-left: 0px; margin: 0px; border-bottom: 1px solid rgb(0, 0, 0);"><span style="color:#333333;">(<ix:nonFraction id="c86425463" contextRef="d_2022-01-01_2022-06-30_AwardTypeAxis-RestrictedStockUnitsRSUMember" unitRef="Share" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" scale="0" format="ixt:numdotdecimal" decimals="INF">21</ix:nonFraction></span></td>
       <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding: 0px 0px 1px; margin: 0px;"><span style="color:#333333;">)</span></td>
       <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding: 0px 0px 1px; margin: 0px;">&#xa0;</td>
       <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-top: 0px; padding-right: 0px; padding-left: 0px; margin: 0px; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td>
       <td style="width: 20%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-top: 0px; padding-right: 0px; padding-left: 0px; margin: 0px; border-bottom: 1px solid rgb(0, 0, 0);"><span style="color:#333333;"><ix:nonFraction id="c86425464" contextRef="d_2022-01-01_2022-06-30_AwardTypeAxis-RestrictedStockUnitsRSUMember" unitRef="USDPerShare" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" scale="0" format="ixt:numdotdecimal" decimals="INF">1.02</ix:nonFraction></span></td>
       <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding: 0px 0px 1px; margin: 0px;">&#xa0;</td>
      </tr>

      <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom">
       <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 58%;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;"><span style="color:#333333;">Outstanding at June 30, 2022</span></p> </td>
       <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 3px;">&#xa0;</td>
       <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);">&#xa0;</td>
       <td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><span style="color:#333333;"><ix:nonFraction id="c86425465" contextRef="i_2022-06-30_AwardTypeAxis-RestrictedStockUnitsRSUMember" unitRef="Share" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" scale="3" format="ixt:numdotdecimal" decimals="-3">561</ix:nonFraction></span></td>
       <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;">&#xa0;</td>
       <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 3px;">&#xa0;</td>
       <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><span style="color:#333333;">$</span></td>
       <td style="width: 20%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><span style="color:#333333;"><ix:nonFraction id="c86425466" contextRef="i_2022-06-30_AwardTypeAxis-RestrictedStockUnitsRSUMember" unitRef="USDPerShare" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" scale="0" format="ixt:numdotdecimal" decimals="INF">0.99</ix:nonFraction></span></td>
       <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;">&#xa0;</td>
      </tr>

      <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom">
       <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 58%; padding: 0; margin: 0">&#xa0;</td>
       <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 1%; padding: 0; margin: 0">&#xa0;</td>
       <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 1%; padding: 0; margin: 0">&#xa0;</td>
       <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 16%; padding: 0; margin: 0">&#xa0;</td>
       <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 1%; padding: 0; margin: 0">&#xa0;</td>
       <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 1%; padding: 0; margin: 0">&#xa0;</td>
       <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 1%; padding: 0; margin: 0">&#xa0;</td>
       <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 20%; padding: 0; margin: 0">&#xa0;</td>
       <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 1%; padding: 0; margin: 0">&#xa0;</td>
      </tr>

      <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom">
       <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 58%; padding: 0; margin: 0"> <p style="margin-top: 0pt; margin-bottom: 0pt"><span style="color:#333333;">Vested and exercisable at June 30, 2022</span></p> </td>
       <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding: 0; margin: 0">&#xa0;</td>
       <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding: 0; margin: 0">&#xa0;</td>
       <td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding: 0; margin: 0"><span style="color:#333333;"><ix:nonFraction id="c86425467" contextRef="i_2022-06-30_AwardTypeAxis-RestrictedStockUnitsRSUMember" unitRef="Share" name="wint:SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndExercisable" scale="3" format="ixt:zerodash" decimals="-3">-</ix:nonFraction></span></td>
       <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding: 0; margin: 0">&#xa0;</td>
       <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding: 0; margin: 0">&#xa0;</td>
       <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding: 0; margin: 0"><span style="color:#333333;">$</span></td>
       <td style="width: 20%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding: 0; margin: 0"><span style="color:#333333;"><ix:nonFraction id="c86425468" contextRef="i_2022-06-30_AwardTypeAxis-RestrictedStockUnitsRSUMember" unitRef="USDPerShare" name="wint:SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndExercisableWeightedAverageGrantDateFairValueEndingBalance" scale="0" format="ixt:zerodash" decimals="INF">-</ix:nonFraction></span></td>
       <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding: 0; margin: 0">&#xa0;</td>
      </tr>

      <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom">
       <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 58%; padding: 0; margin: 0">&#xa0;</td>
       <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 1%; padding: 0; margin: 0">&#xa0;</td>
       <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 1%; padding: 0; margin: 0">&#xa0;</td>
       <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 16%; padding: 0; margin: 0">&#xa0;</td>
       <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 1%; padding: 0; margin: 0">&#xa0;</td>
       <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 1%; padding: 0; margin: 0">&#xa0;</td>
       <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 1%; padding: 0; margin: 0">&#xa0;</td>
       <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 20%; padding: 0; margin: 0">&#xa0;</td>
       <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 1%; padding: 0; margin: 0">&#xa0;</td>
      </tr>

      <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom">
       <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 58%; padding: 0; margin: 0"> <p style="margin-top: 0pt; margin-bottom: 0pt"><span style="color:#333333;">Vested and expected to vest at June 30, 2022</span></p> </td>
       <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding: 0; margin: 0">&#xa0;</td>
       <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding: 0; margin: 0">&#xa0;</td>
       <td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding: 0; margin: 0"><span style="color:#333333;"><ix:nonFraction id="c86425469" contextRef="i_2022-06-30_AwardTypeAxis-RestrictedStockUnitsRSUMember" unitRef="Share" name="wint:SharebasedCompensationArrangementBySharebasedPaymentAwardEquityOtherThanOptionsVestedAndExpectedToVestOutstandingNumber" scale="3" format="ixt:numdotdecimal" decimals="-3">561</ix:nonFraction></span></td>
       <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding: 0; margin: 0">&#xa0;</td>
       <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding: 0; margin: 0">&#xa0;</td>
       <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding: 0; margin: 0"><span style="color:#333333;">$</span></td>
       <td style="width: 20%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding: 0; margin: 0"><span style="color:#333333;"><ix:nonFraction id="c86425470" contextRef="i_2022-06-30_AwardTypeAxis-RestrictedStockUnitsRSUMember" unitRef="USDPerShare" name="wint:SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndExpectedToVestWeightedAverageGrantDateFairValueEndingBalance" scale="0" format="ixt:numdotdecimal" decimals="INF">0.99</ix:nonFraction></span></td>
       <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding: 0; margin: 0">&#xa0;</td>
      </tr>

     </tbody>
    </table>
   </ix:nonNumeric>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin: 0pt; text-align: left;">&#xa0;</p>
   <p style="font-family: Times New Roman; font-size: 10pt; margin: 0pt; text-align: left;"><span style="color:#333333;">The table below summarizes the total stock-based compensation expense included in the interim unaudited condensed consolidated statements of operations for the periods presented:</span></p>
   <p style="font-family: Times New Roman; font-size: 10pt; margin: 0pt; text-align: left;">&#xa0;</p>
   <ix:nonNumeric contextRef="d_2022-01-01_2022-06-30" name="us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" id="c2175911" escape="true">
    <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="margin-right: 20%; width: 80%; font-size: 10pt; font-family: Times New Roman; text-indent: 0px;">
     <tbody>
      <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom">
       <td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
       <td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
       <td colspan="6" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><span style="color:#333333;"><b><em style="font: inherit;"><em style="font: inherit;">Three Months Ended June 30,</em></em></b></span></p> </td>
       <td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
       <td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
       <td colspan="6" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><span style="color:#333333;"><b><em style="font: inherit;"><em style="font: inherit;">Six Months Ended June 30,</em></em></b></span></p> </td>
       <td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
      </tr>

      <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom">
       <td style="font-family: Times New Roman; font-size: 10pt; width: 36%;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;"><span style="color:#333333;"><i>(in thousands)</i></span></p> </td>
       <td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
       <td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><span style="color:#333333;"><b><em style="font: inherit;">2022</em></b></span></p> </td>
       <td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&#xa0;</td>
       <td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
       <td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><span style="color:#333333;"><b><em style="font: inherit;">2021</em></b></span></p> </td>
       <td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&#xa0;</td>
       <td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
       <td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><span style="color:#333333;"><b><em style="font: inherit;">2022</em></b></span></p> </td>
       <td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&#xa0;</td>
       <td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
       <td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><span style="color:#333333;"><b><em style="font: inherit;">2021</em></b></span></p> </td>
       <td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&#xa0;</td>
      </tr>

      <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom">
       <td>&#xa0;</td>
       <td>&#xa0;</td>
       <td>&#xa0;</td>
       <td>&#xa0;</td>
       <td>&#xa0;</td>
       <td>&#xa0;</td>
       <td>&#xa0;</td>
       <td>&#xa0;</td>
       <td>&#xa0;</td>
       <td>&#xa0;</td>
       <td>&#xa0;</td>
       <td>&#xa0;</td>
       <td>&#xa0;</td>
       <td>&#xa0;</td>
       <td>&#xa0;</td>
       <td>&#xa0;</td>
       <td>&#xa0;</td>
      </tr>

      <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom">
       <td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;"><span style="color:#333333;">Research and development</span></p> </td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><span style="color:#333333;">$</span></td>
       <td style="width: 13%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><span style="color:#333333;"><ix:nonFraction id="c86425479" contextRef="d_2022-04-01_2022-06-30_IncomeStatementLocationAxis-ResearchAndDevelopmentExpenseMember" unitRef="USD" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" format="ixt:numdotdecimal" decimals="-3">147</ix:nonFraction></span></td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#xa0;</td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><span style="color:#333333;">$</span></td>
       <td style="width: 13%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><span style="color:#333333;"><ix:nonFraction id="c86425480" contextRef="d_2021-04-01_2021-06-30_IncomeStatementLocationAxis-ResearchAndDevelopmentExpenseMember" unitRef="USD" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" format="ixt:numdotdecimal" decimals="-4">630</ix:nonFraction></span></td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#xa0;</td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><span style="color:#333333;">$</span></td>
       <td style="width: 13%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><span style="color:#333333;"><ix:nonFraction id="c86425481" contextRef="d_2022-01-01_2022-06-30_IncomeStatementLocationAxis-ResearchAndDevelopmentExpenseMember" unitRef="USD" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" format="ixt:numdotdecimal" decimals="-3">382</ix:nonFraction></span></td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#xa0;</td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><span style="color:#333333;">$</span></td>
       <td style="width: 13%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><span style="color:#333333;"><ix:nonFraction id="c86425482" contextRef="d_2021-01-01_2021-06-30_IncomeStatementLocationAxis-ResearchAndDevelopmentExpenseMember" unitRef="USD" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" format="ixt:numdotdecimal" decimals="-3">1,569</ix:nonFraction></span></td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#xa0;</td>
      </tr>

      <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom">
       <td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;"><span style="color:#333333;">General and administrative</span></p> </td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td>
       <td style="width: 13%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><span style="color:#333333;"><ix:nonFraction id="c86425483" contextRef="d_2022-04-01_2022-06-30_IncomeStatementLocationAxis-SellingGeneralAndAdministrativeExpensesMember" unitRef="USD" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" format="ixt:numdotdecimal" decimals="-3">634</ix:nonFraction></span></td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#xa0;</td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td>
       <td style="width: 13%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><span style="color:#333333;"><ix:nonFraction id="c86425484" contextRef="d_2021-04-01_2021-06-30_IncomeStatementLocationAxis-SellingGeneralAndAdministrativeExpensesMember" unitRef="USD" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" format="ixt:numdotdecimal" decimals="-3">914</ix:nonFraction></span></td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#xa0;</td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td>
       <td style="width: 13%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><span style="color:#333333;"><ix:nonFraction id="c86425485" contextRef="d_2022-01-01_2022-06-30_IncomeStatementLocationAxis-SellingGeneralAndAdministrativeExpensesMember" unitRef="USD" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" format="ixt:numdotdecimal" decimals="-3">1,169</ix:nonFraction></span></td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#xa0;</td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td>
       <td style="width: 13%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><span style="color:#333333;"><ix:nonFraction id="c86425486" contextRef="d_2021-01-01_2021-06-30_IncomeStatementLocationAxis-SellingGeneralAndAdministrativeExpensesMember" unitRef="USD" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" format="ixt:numdotdecimal" decimals="-3">2,418</ix:nonFraction></span></td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#xa0;</td>
      </tr>

      <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom">
       <td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 18pt;"><span style="color:#333333;">Total</span></p> </td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><span style="color:#333333;">$</span></td>
       <td style="width: 13%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><span style="color:#333333;"><ix:nonFraction id="c86425487" contextRef="d_2022-04-01_2022-06-30" unitRef="USD" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" format="ixt:numdotdecimal" decimals="-3">781</ix:nonFraction></span></td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&#xa0;</td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><span style="color:#333333;">$</span></td>
       <td style="width: 13%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><span style="color:#333333;"><ix:nonFraction id="c86425488" contextRef="d_2021-04-01_2021-06-30" unitRef="USD" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" format="ixt:numdotdecimal" decimals="-3">1,544</ix:nonFraction></span></td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&#xa0;</td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><span style="color:#333333;">$</span></td>
       <td style="width: 13%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><span style="color:#333333;"><ix:nonFraction id="c86425489" contextRef="d_2022-01-01_2022-06-30" unitRef="USD" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" format="ixt:numdotdecimal" decimals="-3">1,551</ix:nonFraction></span></td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&#xa0;</td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><span style="color:#333333;">$</span></td>
       <td style="width: 13%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><span style="color:#333333;"><ix:nonFraction id="c86425490" contextRef="d_2021-01-01_2021-06-30" unitRef="USD" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" format="ixt:numdotdecimal" decimals="-3">3,987</ix:nonFraction></span></td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&#xa0;</td>
      </tr>

     </tbody>
    </table>
   </ix:nonNumeric>
   <p style="font-family: Times New Roman; font-size: 10pt; margin: 0pt; text-align: left;">&#xa0;</p>
   <p style="font-family: Times New Roman; font-size: 10pt; margin: 0pt; text-align: left;"><span style="color:#333333;">The fair value of each option award is estimated on the date of grant using the Black-Scholes option-pricing formula that uses assumptions noted in the following table. Expected volatilities are based upon the historical volatility of our common stock and other factors. We also use historical data and other factors to estimate option exercises, employee terminations and forfeiture rates. The risk-free interest rates are based upon the U.S. Treasury yield curve in effect at the time of the grant.</span></p>
   <p style="font-family: Times New Roman; font-size: 10pt; margin: 0pt; text-align: left;">&#xa0;</p>
   <ix:nonNumeric contextRef="d_2022-01-01_2022-06-30" name="us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" id="c2175912" escape="true">
    <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="margin-right: 20%; width: 80%; font-size: 10pt; font-family: Times New Roman; text-indent: 0px;">
     <tbody>
      <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom">
       <td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
       <td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
       <td colspan="6" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><span style="color:#333333;"><b><em style="font: inherit;"><em style="font: inherit;">Six Months Ended June 30,</em></em></b></span></p> </td>
       <td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
      </tr>

      <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom">
       <td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
       <td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
       <td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><span style="color:#333333;"><b><em style="font: inherit;">2022</em></b></span></p> </td>
       <td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&#xa0;</td>
       <td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
       <td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><span style="color:#333333;"><b><em style="font: inherit;">2021</em></b></span></p> </td>
       <td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&#xa0;</td>
      </tr>

      <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom">
       <td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
       <td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
       <td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
       <td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
       <td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
       <td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
       <td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
       <td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
       <td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
      </tr>

      <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom">
       <td style="font-family: Times New Roman; font-size: 10pt; width: 62%;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;"><span style="color:#333333;">Weighted average expected volatility</span></p> </td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
       <td style="width: 16%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: center;"> <p style="margin-top: 0pt; margin-bottom: 0pt; font-family: Times New Roman; font-size: 10pt;"><span style="color:#333333;"><ix:nonFraction id="c86425495" contextRef="d_2022-01-01_2022-06-30" unitRef="Pure" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate" scale="-2" format="ixt:numdotdecimal" decimals="2">106</ix:nonFraction>%</span></p> </td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#xa0;</td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
       <td style="width: 16%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: center;"> <p style="margin-top: 0pt; margin-bottom: 0pt; font-family: Times New Roman; font-size: 10pt;"><span style="color:#333333;"><ix:nonFraction id="c86425496" contextRef="d_2021-01-01_2021-06-30" unitRef="Pure" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate" scale="-2" format="ixt:numdotdecimal" decimals="2">105</ix:nonFraction>%</span></p> </td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#xa0;</td>
      </tr>

      <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom">
       <td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;"><span style="color:#333333;">Weighted average expected term (in years)</span></p> </td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
       <td style="width: 16%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: center;"> <p style="margin-top: 0pt; margin-bottom: 0pt; font-family: Times New Roman; font-size: 10pt;"><span style="color:#333333;"><ix:nonNumeric contextRef="d_2022-01-01_2022-06-30" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" id="c86425497" format="ixt-sec:duryear">6.9</ix:nonNumeric></span></p> </td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#xa0;</td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
       <td style="width: 16%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: center;"> <p style="margin-top: 0pt; margin-bottom: 0pt; font-family: Times New Roman; font-size: 10pt;"><span style="color:#333333;"><ix:nonNumeric contextRef="d_2021-01-01_2021-06-30" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" id="c86425498" format="ixt-sec:duryear">6.7</ix:nonNumeric></span></p> </td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#xa0;</td>
      </tr>

      <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom">
       <td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;"><span style="color:#333333;">Weighted average risk-free interest rate</span></p> </td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
       <td style="width: 16%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: center;"> <p style="margin-top: 0pt; margin-bottom: 0pt; font-family: Times New Roman; font-size: 10pt;"><span style="color:#333333;"><ix:nonFraction id="c86425499" contextRef="d_2022-01-01_2022-06-30" unitRef="Pure" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" scale="-2" format="ixt:numdotdecimal" decimals="3">1.70</ix:nonFraction>%</span></p> </td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#xa0;</td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
       <td style="width: 16%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: center;"> <p style="margin-top: 0pt; margin-bottom: 0pt; font-family: Times New Roman; font-size: 10pt;"><span style="color:#333333;"><ix:nonFraction id="c86425500" contextRef="d_2021-01-01_2021-06-30" unitRef="Pure" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" scale="-2" format="ixt:numdotdecimal" decimals="4">0.48</ix:nonFraction>%</span></p> </td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#xa0;</td>
      </tr>

      <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom">
       <td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;"><span style="color:#333333;">Expected dividends</span></p> </td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
       <td style="width: 16%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: center;"><em style="font: inherit;"> </em><p style="margin-top: 0pt; margin-bottom: 0pt; font-family: Times New Roman; font-size: 10pt;"><span style="color:#333333;">-</span></p> </td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#xa0;</td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
       <td style="width: 16%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: center;"><em style="font: inherit;"> </em><p style="margin-top: 0pt; margin-bottom: 0pt; font-family: Times New Roman; font-size: 10pt;"><span style="color:#333333;">-</span></p> </td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#xa0;</td>
      </tr>

     </tbody>
    </table>
   </ix:nonNumeric>
  </ix:nonNumeric>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&#xa0;</p>
  <div>
    &#xa0;
  </div>
  <ix:nonNumeric contextRef="d_2022-01-01_2022-06-30" name="wint:CorporatePartnershipLicensingAndResearchFundingAgreementsTextBlock" id="c2175913" escape="true">
   <ix:exclude>
    <div class="PGFTR" style="text-align:center; width:100%">
     <div class="hf-row">
      <div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: &quot;Times New Roman&quot;;">
       <em style="font: inherit;">15</em>
      </div>
     </div>
    </div>
    <hr style="PAGE-BREAK-AFTER:always; border:none; width:100%; height:2px; color:#000000; background-color:#000000" />
    <div class="PGHDR" style="text-align:left; width:100%">
     <div class="hf-row">
      <div class="hf-cell TOCLink" style="text-align: left; display: inline-block;">
       <a href="#toc" style="font-weight: initial; font-style: initial; font-variant: initial; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif;">Table of Contents</a>
      </div>
     </div>
    </div>
   </ix:exclude>
   <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&#xa0;</p>
   <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><span style="color:#333333;"><b>Note <em style="font: inherit;">10</em> &#x2013; Licensing&#xa0;and Research Funding Agreements</b></span></p>
   <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&#xa0;</p>
   <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><span style="color:#333333;">In <em style="font: inherit;"> March 2020, </em>we entered into a Term Sheet with Lee&#x2019;s (HK), pursuant to which Lee&#x2019;s (HK) provided financing for the development of AEROSURF. In <em style="font: inherit;"> August 2020,&#xa0;</em>we entered into a Project Financing Agreement with&#xa0;Lee&#x2019;s (HK), or the&#xa0;PF Agreement, formalizing the terms of the Term Sheet, and&#xa0;under which we received payments totaling&#xa0;$<ix:nonFraction id="c86425505" contextRef="d_2020-08-01_2020-10-31_CounterpartyNameAxis-LeesPharmaceuticalHoldingsLimitedMember_TypeOfArrangementAxis-AerosurfFundingTermSheetMember" unitRef="USD" name="wint:NonrefundablePayments" scale="6" format="ixt:numdotdecimal" decimals="-5">2.8</ix:nonFraction>&#xa0;million&#xa0;through <em style="font: inherit;"> October 2020.&#xa0;</em>In <em style="font: inherit;"> November 2020, </em>Lee&#x2019;s (HK) provided notice of termination of&#xa0;additional funding under&#xa0;the PF Agreement, and we and Lee&#x2019;s (HK) revised our plans for the continued development of AEROSURF. Lee&#x2019;s (HK) agreed to continue the development of AEROSURF in Asia at its cost. Lee&#x2019;s (HK) agreed to&#xa0;fund an additional&#xa0;</span><span style="color:#333333;">$<ix:nonFraction id="c86425506" contextRef="d_2021-01-01_2021-12-31_TypeOfArrangementAxis-TermSheetWithLeeMember" unitRef="USD" name="wint:ProceedsForPaymentsToDevelopProduct" scale="6" format="ixt:numdotdecimal" decimals="-6">1.0</ix:nonFraction></span><span style="color:#333333;"> million to us&#xa0;in <em style="font: inherit;">2021</em> for certain transition and analytical services to be provided by us with respect to the development of AEROSURF, which will be considered &#x201c;Project Expenses&#x201d; under the terms of the PF Agreement.&#xa0;In&#xa0;<em style="font: inherit;">2021,</em>&#xa0;we received payments totaling&#xa0;$<ix:nonFraction id="c86425509" contextRef="d_2021-01-01_2021-12-31_TypeOfArrangementAxis-TermSheetWithLeeMember" unitRef="USD" name="wint:ProceedsForPaymentsToDevelopProduct" scale="6" format="ixt:numdotdecimal" decimals="-6">1.0</ix:nonFraction>&#xa0;million from&#xa0;Lee&#x2019;s (HK) and&#xa0;<em style="font: inherit;">no</em>&#xa0;further amounts are due under the PF Agreement.</span></p>
   <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&#xa0;</p>
   <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><span style="color:#333333;">To repay the funds provided under the terms of the PF Agreement, until such time as we have repaid </span><span style="color:#333333;"><ix:nonFraction id="c86425511" contextRef="i_2020-03-18_TypeOfArrangementAxis-TermSheetWithLeeMember" unitRef="Pure" name="wint:FinancingOfProductPercentOfFinancingThatMustBeRepaidToDiscontinueRevenueSharing" scale="-2" format="ixt:numdotdecimal" decimals="2">125</ix:nonFraction>%</span><span style="color:#333333;">&#xa0;of the amounts funded by Lee&#x2019;s (HK) for the development of AEROSURF, we will pay to Lee&#x2019;s (HK)&#xa0;</span><span style="color:#333333;"><ix:nonFraction id="c86425512" contextRef="i_2020-03-18_TypeOfArrangementAxis-TermSheetWithLeeMember" unitRef="Pure" name="wint:FinancingOfProductPercentOfRevenueSharedWithFinancer" scale="-2" format="ixt:numdotdecimal" decimals="1">50</ix:nonFraction>%</span><span style="color:#333333;"> of all revenue amounts and payments received by us for any sale, divestiture, license or other development and/or commercialization of the <em style="font: inherit;">KL4/AEROSURF</em> patent portfolio, excluding (i) payments for bona fide research and development services; (ii) reimbursement of patent expenses and (iii) all amounts paid to us under the Asia License Agreement, minus certain deductions and certain reductions for any payments made by us with respect to <em style="font: inherit;">third</em> party intellectual property <em style="font: inherit;">not</em> previously funded by Lee&#x2019;s (HK).</span></p>
   <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&#xa0;</p>
   <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><span style="color:#333333;">As of </span><span style="color:#333333;"><em style="font: inherit;"> June 30, 2022</em></span><span style="color:#333333;">, the liability balance related to the payments under the PF Agreement was&#xa0;</span><span style="color:#333333;">$<ix:nonFraction id="c86425516" contextRef="i_2022-03-31_TypeOfArrangementAxis-TermSheetWithLeeMember" unitRef="USD" name="us-gaap:ContractualObligation" scale="6" format="ixt:numdotdecimal" decimals="-5">3.8</ix:nonFraction></span><span style="color:#333333;">&#xa0;million and is recorded in other liabilities.</span></p>
  </ix:nonNumeric>
  <div>
    &#xa0;
  </div>
  <p style="margin: 0pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</p>
  <p style="margin: 0pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><span style="color:#333333;"><b><a id="Item2_MDA" title="Item2_MDA" href="#"></a>Item 2.&#xa0; &#xa0; &#xa0; Management&#x2019;s Discussion and Analysis of Financial Condition and Results of Operations</b></span></p>
  <p style="margin: 0pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</p>
  <p style="margin: 0pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; text-align: left;"><i><span style="color:#333333;">Some of the information contained in this discussion and analysis or set forth elsewhere in this Quarterly Report on Form 10-Q, including information with respect to our plans and strategy for our business and related financing activities, includes forward-looking statements that involve risks, uncertainties and assumptions. These statements are based on our beliefs and expectations about future outcomes and are subject to risks and uncertainties that could cause our actual results to differ materially from anticipated results. We undertake no obligation to publicly update these forward-looking statements, whether as a result of new information, future events or otherwise. The reader should review the section titled "Forward-Looking Statements" and any risk factors discussed elsewhere in this Quarterly Report on Form 10-Q, which are in addition to and supplement the risk factors discussed in our Annual Report on Form 10-K for the year ended </span><span style="color:#333333;">December 31, 2021</span><span style="color:#333333;"> that we filed with the Securities and Exchange Commission, or SEC, on </span><span style="color:#333333;">March 31, 2022</span><span style="color:#333333;">, as supplemented by&#xa0;</span><span style="color:#333333;">our Quarterly Report on Form 10-Q for the three months ended March 31, 2022 filed thereafter, and our other filings with the SEC,</span><span style="color:#333333;">&#xa0;and any amendments thereto, for a discussion of important factors that could cause actual results to differ materially from the results described in or implied by the forward-looking statements contained in the following discussion and analysis or elsewhere in this Quarterly Report on Form 10-Q.</span></i></p>
  <p style="margin: 0pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; text-align: left;">&#xa0;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin: 0pt; text-align: left;"><span style="color:#333333;">This Management&#x2019;s Discussion and Analysis, or MD&amp;A, is provided as a supplement to the accompanying interim unaudited Condensed Consolidated Financial Statements (including the notes thereto) to help provide an understanding of our financial condition and changes in our financial condition and our results of operations. This item should be read in connection with our accompanying interim unaudited Condensed Consolidated Financial Statements (including the notes thereto) and our Annual Report on Form 10-K for the year ended </span><span style="color:#333333;">December 31, 2021</span><span style="color:#333333;">. Unless otherwise specified, references to Notes in this MD&amp;A&#xa0;refer to the Notes to Condensed Consolidated Financial Statements (unaudited) in this Quarterly Report on Form 10-Q.</span></p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin: 0pt; text-align: left;">&#xa0;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin: 0pt; text-align: center;"><span style="color:#333333;"><b>OVERVIEW</b></span></p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin: 0pt; text-align: left;">&#xa0;</p>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><span style="color:#333333;">We are a clinical-stage&#xa0;biopharmaceutical company focused on the development of novel therapeutics intended to address significant unmet medical needs in important acute care markets. Our development programs are primarily focused on the treatment of acute cardiovascular diseases and secondarily on acute pulmonary diseases. Our lead product candidate, istaroxime, is a first-in-class, dual-acting agent being developed to improve cardiac function in patients with acute heart failure, or AHF, with a potentially differentiated safety profile from existing treatments. Istaroxime demonstrated significant improvement in both diastolic and systolic aspects of cardiac function and was generally well tolerated in three Phase 2 clinical trials.&#xa0;Istaroxime has been granted Fast Track designation for the treatment of AHF by the U.S. Food and Drug Administration, or FDA.&#xa0;Based on the profile observed in our Phase 2 clinical studies in AHF, where istaroxime significantly improved cardiac function and systolic blood pressure in acute decompensated heart failure patients, we initiated a Phase 2 global clinical study to evaluate istaroxime for the treatment of early cardiogenic shock (Society for Cardiovascular Angiography and Interventions&#xa0;Stage B shock),&#xa0;a severe form of AHF characterized by very low blood pressure and risk for hypoperfusion to critical organs. We completed this Phase 2 global clinical study and, in April 2022, announced positive topline results with istaroxime in raising systolic blood pressure.&#xa0;In May 2022, we presented the study results at the European Society of Cardiology Heart Failure Meeting in Madrid, Spain.&#xa0;We believe that istaroxime has the potential to fulfill an unmet need in early cardiogenic shock. We further believe that the data from our recently completed Phase 2 global clinical study in early cardiogenic shock will not only support that&#xa0;program&#x2019;s continued development but will also support the continued development of our AHF program as well.</span></p>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&#xa0;</p>
  <div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
   <div class="PGFTR" style="text-align: center; width: 100%">
    <div class="hf-row">
     <div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">
       16
     </div>
    </div>
   </div>
   <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000" />
   <div class="PGHDR" style="text-align: left; width: 100%">
    <div class="hf-row">
     <div class="hf-cell TOCLink" style="display: inline-block; text-align: left;">
      <a href="#toc" style="font-weight: initial; font-style: initial; font-variant: initial; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif;">Table of Contents</a>
     </div>
    </div>
   </div>
  </div>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin: 0pt; text-align: left;">&#xa0;</p>
  <div style="font-size:10pt">
   <div style="font-family:'Times New Roman', Times, serif">
    <span style="color:#333333;">Our heart failure cardiovascular portfolio also includes sarco endoplasmic reticulum Ca2+ -ATPase 2a, or SERCA2a, activators which activate SERCA2a. This research program is evaluating these preclinical product candidates, including oral and intravenous SERCA2a activator heart failure compounds. As potential oral agents, these candidates would be developed for chronic heart failure. In addition, our cardiovascular drug product candidates include rostafuroxin, a novel product&#xa0;candidate&#xa0;for the treatment of hypertension in patients with a specific genetic profile. We are pursuing potential licensing arrangements and/or other strategic partnerships and do not intend to advance this product&#xa0;candidate&#xa0;without securing such an arrangement or partnership.</span>
   </div>
   <div style="font-family:'Times New Roman', Times, serif">
     &#xa0;
   </div>
   <div style="font-family:'Times New Roman', Times, serif">
    <span style="color:#333333;">Our pulmonary product candidate portfolio consists of a KL4 surfactant platform&#xa0;to address a range of serious respiratory conditions in children and adults. In January 2022, we completed enrollment of 20 patients in our Phase 2 study of lucinactant (KL4 surfactant) for patients with severe novel coronavirus, or COVID-19, associated acute respiratory distress syndrome, or ARDS. The study demonstrated that intratracheal administration of reconstituted lyophilized lucinactant was generally safe and well tolerated. Oxygenation and other physiological parameters were stable to improved after dosing, supporting the feasibility of this treatment approach to develop a potential treatment for critically ill patients with ARDS due to COVID-19 or other causes.</span>
   </div>
   <div style="font-family:'Times New Roman', Times, serif">
     &#xa0;
   </div>
   <div style="font-family:'Times New Roman', Times, serif">
    <span style="color:#333333;">Previously, we were also developing AEROSURF (lucinactant for inhalation), a novel drug/medical device combination product for noninvasive delivery of aerosolized KL4 surfactant using our aerosol delivery system, or ADS, technology for the treatment of respiratory distress syndrome in premature infants. In order to focus our resources on the&#xa0;development of our istaroxime pipeline, we suspended all internal AEROSURF clinical activities in November 2020, and in January 2022 we began to reduce all other costs related to the KL4 surfactant platform that were not already transferred to our licensee in Asia, Lee&#x2019;s Pharmaceutical (HK) Ltd., or Lee&#x2019;s (HK), under the terms of our License, Development and Commercialization Agreement between us and Lee&#x2019;s (HK) dated as of June 12, 2017, as amended, or the Asia License Agreement. To support the future development of our KL4 surfactant platform in markets outside of Asia, including the U.S., we are pursuing a potential licensing transaction.</span>
   </div>
   <div style="font-family:'Times New Roman', Times, serif">
     &#xa0;
   </div>
   <div style="font-family:'Times New Roman', Times, serif">
    <span style="color:#333333;">Our ability to advance our development programs is dependent upon our ability to secure additional capital in both the near and long-term, through public or private securities offerings; convertible debt financings; and/or potential strategic opportunities, including licensing agreements, drug product development, and marketing collaboration arrangements, pharmaceutical research cooperation arrangements, and/or other similar transactions in geographic markets, including the U.S., and/or through potential grants and other funding commitments from U.S. government agencies, in each case, if available. We have engaged with potential counterparties in various markets and will continue to pursue non-dilutive sources of capital as well as potential private and public securities offerings. There can be no assurance, however, that we will be able to identify and enter into public or private securities offerings on acceptable terms and in amounts sufficient to meet our needs or qualify for non-dilutive funding opportunities under any grant programs sponsored by U.S. government agencies, private foundations, and/or leading academic institutions, or identify and enter into any strategic transactions that will provide the additional capital that we will require. If none of these alternatives is available, or if available and&#xa0;we are unable to raise sufficient capital through such transactions, we potentially could be forced to limit or cease our development activities, which would have a material adverse effect on our business, financial condition, and results of operations.</span>
   </div>
   <div style="font-family:'Times New Roman', Times, serif">
     &#xa0;
   </div>
   <div style="font-family:'Times New Roman', Times, serif">
    <span style="color:#333333;">We have incurred operating losses since our incorporation on November 6, 1992. For the three-month periods ended&#xa0;</span>
    <span style="color:#333333;">June 30, 2022 and 2021</span>
    <span style="color:#333333;">, we had operating losses of </span>
    <span style="color:#333333;">$17.5</span>
    <span style="color:#333333;">&#xa0;million and&#xa0;</span>
    <span style="color:#333333;">$45.4</span>
    <span style="color:#333333;">&#xa0;million, respectively. For the&#xa0;</span>
    <span style="color:#333333;">six</span>
    <span style="color:#333333;">-month periods ended </span>
    <span style="color:#333333;">June 30, 2022 and 2021</span>
    <span style="color:#333333;">, we had operating losses of&#xa0;</span>
    <span style="color:#333333;">$25.9</span>
    <span style="color:#333333;"> million and&#xa0;</span>
    <span style="color:#333333;">$54.4</span>
    <span style="color:#333333;"> million, respectively.&#xa0;Included in our operating loss for the&#xa0;three&#xa0;and&#xa0;</span>
    <span style="color:#333333;">six months ended June 30, 2022</span>
    <span style="color:#333333;">&#xa0;is an&#xa0;</span>
    <span style="color:#333333;">$11.6</span>
    <span style="color:#333333;"> million loss on impairment of goodwill, and included in our operating&#xa0;loss for the&#xa0;three&#xa0;and&#xa0;six&#xa0;months ended&#xa0;</span>
    <span style="color:#333333;">June 30, 2021</span>
    <span style="color:#333333;"> is a&#xa0;</span>
    <span style="color:#333333;">$37.8</span>
    <span style="color:#333333;"> million loss on impairment of intangible assets&#xa0;related to rostafuroxin&#xa0;(<i>see</i>,&#xa0;</span>
    <span style="color:#333333;">Note 4 &#x2013; Summary of Significant Accounting Policies</span>
    <span style="color:#333333;">).&#xa0;As of&#xa0;</span>
    <span style="color:#333333;">June 30, 2022</span>
    <span style="color:#333333;">, we had an accumulated deficit of&#xa0;</span>
    <span style="color:#333333;">$810.8</span>
    <span style="color:#333333;">&#xa0;million. To date, we have financed our operations primarily through private placements and public offerings of our common and preferred stock and borrowings from investors and financial institutions.</span>
   </div>
  </div>
  <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin: 0pt; text-align: left;">&#xa0;</p>
  </div>
  <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">
   <span style="color:#333333;">We expect to continue to incur significant research and clinical development, regulatory, and other expenses as we (i) continue to develop our product candidates;&#xa0;(ii) seek regulatory clearances or approvals for our product candidates; (iii) conduct clinical trials on our product candidates; and (iv) manufacture, market, and sell any product candidates&#xa0;for which we may obtain regulatory approval.</span>
  </div>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin: 0px;">&#xa0;</p>
  <div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
   <div class="PGFTR" style="text-align: center; width: 100%">
    <div class="hf-row">
     <div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">
       17
     </div>
    </div>
   </div>
   <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000" />
   <div class="PGHDR" style="text-align: left; width: 100%">
    <div class="hf-row">
     <div class="hf-cell TOCLink" style="display: inline-block; text-align: left;">
      <a href="#toc" style="font-weight: initial; font-style: initial; font-variant: initial; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif;">Table of Contents</a>
     </div>
    </div>
   </div>
  </div>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin: 0pt; text-align: left;">&#xa0;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin: 0pt; text-align: left;"><span style="color:#333333;"><b>Business and Program Updates</b></span></p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin: 0pt; text-align: left;">&#xa0;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin: 0pt; text-align: left;"><span style="color:#333333;"><span style="font-size: 10pt;">The reader is referred to, and encouraged to read in its entirety, &#x201c;Item 1 &#x2013; Business&#x201d; in our Annual Report on Form 10-K for the year ended </span></span><span style="color:#333333;">December 31, 2021</span><span style="color:#333333;"><span style="font-size: 10pt;"> that we filed with the SEC on </span></span><span style="color:#333333;">March 31, 2022</span><span style="color:#333333;"><span style="font-size: 10pt;">, which contains a discussion of our business and business plans, as well as information concerning our proprietary technologies and our current and planned development programs.&#xa0;</span></span></p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin: 0pt; text-align: left;">&#xa0;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin: 0pt; text-align: left;"><span style="color:#333333;"><span style="font-size: 10pt;"><i>Istaroxime (Early Cardiogenic Shock)</i></span></span></p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin: 0pt; text-align: left;">&#xa0;</p>
  <p style="margin: 0pt; text-align: left; font-size: 10pt;"><span style="color:#333333;">In September&#xa0;2020, we initiated a small Phase 2 clinical study of istaroxime for the acute treatment of&#xa0;early cardiogenic shock&#xa0;in heart failure patients with a more severe case of heart failure to evaluate the potential to improve blood pressure.&#xa0;The study also evaluated&#xa0;the safety and side effect profile of istaroxime in this patient population. In April 2022, we announced&#xa0;positive topline results with istaroxime in raising systolic blood pressure, the critical clinical objective in treating patients in cardiogenic shock. In May 2022, we presented data from our positive Phase 2 study of istaroxime in early cardiogenic shock in a late-breaker presentation at the European Society of Cardiology Heart Failure Meeting in Madrid,&#xa0;Spain. There&#xa0;is a significant unmet medical need in the area of early cardiogenic shock and severe heart failure.&#xa0;Istaroxime demonstrated a meaningful improvement in blood pressure in clinical trials of this condition, and we believe there may be an opportunity to apply for a Breakthrough Therapy designation that could provide beneficial opportunities for the development program.&#xa0;In order to continue our development of istaroxime for the acute treatment of early cardiogenic shock, subject to adequate resources,&#xa0;we are planning to extend enrollment in this clinical trial by up to 30 patients. We believe that this extension will advance the characterization of the physiology associated with longer dosing as well as evaluate a dose titration. We also believe that this&#xa0;extension will further characterize the effects and potential benefits associated with SERCA2a activation and will support our clinical regulatory strategy for istaroxime.&#xa0;We currently do not have sufficient capital to fully execute the extension of this clinical trial.</span></p>
  <p style="margin: 0pt; text-align: left; font-size: 10pt;">&#xa0;</p>
  <p style="margin: 0pt; text-align: left; font-size: 10pt;"><span style="color:#333333;"><span style="font-size: 10pt;"><i>Istaroxime (AHF)</i></span></span></p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin: 0pt; text-align: left;">&#xa0;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin: 0pt; text-align: left;"><span style="color:#333333;">To advance istaroxime for the treatment of AHF potentially through the Phase 2 clinical program and be in a Phase 3-ready position,&#xa0;our strategy includes, subject to adequate resources,&#xa0;planning an additional Phase 2&#xa0;clinical trial that will enroll approximately 300 patients in approximately 60 clinical sites globally.&#xa0;This trial will focus on treating heart failure patients with low blood pressure, who also tend to be diuretic resistant, as a patient population that we believe could particularly benefit from the unique profile and&#xa0;potential ability of istaroxime to increase cardiac function and increase blood pressure while maintaining or improving renal function.&#xa0;This trial will also collect data on measures that may serve as primary endpoints in a Phase 3 clinical trial, and will include an optimized dosing regimen, potentially extending the infusion time beyond 24 hours.&#xa0;We currently do not have sufficient capital to execute this clinical trial.</span></p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin: 0pt; text-align: left;">&#xa0;</p>
  <div style="font-size:10pt">
   <div style="font-family:&quot;Times New Roman&quot;">
    <div style="font-variant:normal">
     <span style="color:#333333;"><i>Rostafuroxin</i></span>
    </div>
    <div style="font-variant:normal">
      &#xa0;
    </div>
   </div>
  </div>
  <div style="font-size:10pt">
   <div style="font-family:&quot;Times New Roman&quot;">
    <div style="font-variant:normal">
     <span style="color:#333333;">Rostafuroxin has demonstrated efficacy in Caucasian patients in treatment na&#xef;ve&#xa0;hypertension in a Phase 2b trial. During the second quarter of 2021, we concluded an initial process to test the industry&#x2019;s interest in investing in our drug product candidate. We currently have not been able to secure a licensing transaction or other strategic opportunity. As a result, we recorded an impairment of the related intangible asset during the year ended December 31, 2021.&#xa0;Based on feedback received from potential licensing partners, we have determined that there is a need for an additional Phase 2 clinical trial to demonstrate efficacy in non-Caucasian and Caucasian patients in treatment resistant hypertension. We are continuing to pursue licensing arrangements, other strategic partnerships, and/or grant funding for rostafuroxin. We do not intend to conduct the additional Phase 2 clinical trial without securing such an arrangement, partnership, or grant funding.</span>
    </div>
    <div style="font-variant:normal">
      &#xa0;
    </div>
   </div>
  </div>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;"><span style="color:#333333;"><i>SERCA2a Activators &#x2013; Preclinical Oral, Chronic, and Acute Heart Failure Product Candidates</i></span></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin: 0pt; text-align: left;"><span style="color:#333333;">We are pursuing several early exploratory research programs to assess potential product candidates, including oral and intravenous&#xa0;SERCA2a activator heart failure compounds, and believe that we can add value to our cardiovascular portfolio by advancing these SERCA2a activator candidates through preclinical studies. To further advance these product candidates, we are actively exploring potential licensing transactions, research partnership arrangements, or other strategic opportunities.</span></p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin: 0pt; text-align: left;">&#xa0;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin: 0pt; text-align: left;"><span style="color:#333333;"><i>KL4 Surfactant Platform</i>&#xa0;</span></p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin: 0pt; text-align: left;">&#xa0;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin: 0pt; text-align: left;"><span style="color:#333333;">Our pulmonary product candidate portfolio consists of a KL4 surfactant platform&#xa0;to address a range of serious respiratory conditions in children and adults. In January 2022, we completed enrollment of 20 patients in our study of lucinactant (KL4 surfactant) for patients with severe COVID-19 associated ARDS and lung injury. The Phase 2 trial was designed to assess feasibility, safety, and tolerability of administration of reconstituted lyophilized lucinactant in these critically ill patients. The multicenter, single-arm study enrolled 20 critically ill patients in the U.S. and Argentina who were intubated and on mechanical ventilation due to severe COVID-19 associated ARDS. The study demonstrated that intratracheal administration of reconstituted lyophilized lucinactant was generally safe and well tolerated. Lucinactant was safely administered to critically ill, mechanically ventilated patients with severe COVID-19 associated ARDS. Oxygenation and other physiological parameters were stable to improved after dosing, supporting the feasibility of this treatment approach to develop a potential treatment for critically ill patients with ARDS due to COVID-19 or other causes.</span></p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin: 0pt; text-align: left;">&#xa0;</p>
  <div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
   <div class="PGFTR" style="text-align: center; width: 100%">
    <div class="hf-row">
     <div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">
       18
     </div>
    </div>
   </div>
   <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000" />
   <div class="PGHDR" style="text-align: left; width: 100%">
    <div class="hf-row">
     <div class="hf-cell TOCLink" style="display: inline-block; text-align: left;">
      <a href="#toc" style="font-weight: initial; font-style: initial; font-variant: initial; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif;">Table of Contents</a>
     </div>
    </div>
   </div>
  </div>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin: 0pt; text-align: left;">&#xa0;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin: 0pt; text-align: left;"><span style="color:#333333;">Previously, we were also developing AEROSURF (lucinactant for inhalation), a novel drug/medical device combination product for noninvasive delivery of aerosolized KL4 surfactant using our ADS technology for the treatment of respiratory distress syndrome in premature infants. In order to focus our resources on the&#xa0;development of our istaroxime pipeline, we suspended all internal AEROSURF clinical activities in November 2020, and in January 2022 we began to reduce all other costs related to the KL4 surfactant platform that were not already transferred to our licensee in Asia, Lee&#x2019;s (HK), under the terms of the Asia License Agreement.&#xa0;More specifically, since the termination of the Project Financing Agreement in November 2020, we ceased enrollment in our Phase 2b bridging study at the European Union clinical sites, reduced headcount dedicated to KL4 surfactant, and decommissioned both our analytical and technical support laboratory, which previously conducted release testing of active pharmaceutical ingredients&#xa0;and supportive research for our lyophilized and aerosolized KL4 surfactant, and our medical device development laboratory, which was previously used to conduct development activities and testing for our ADS technologies. While we have no direct insight into such, we are continuing to support Lee&#x2019;s (HK) independent development efforts to advance AEROSURF to a Phase 2 bridging study and Phase 3 clinical trial in Asia. To support the future development of our KL4 surfactant platform in markets outside of Asia, including the U.S., we are pursuing a potential licensing transaction.</span></p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin: 0pt; text-align: left;">&#xa0;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin: 0pt; text-align: left;"><span style="color:#333333;"><i>Impact of COVID-19</i></span></p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin: 0pt; text-align: left;">&#xa0;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;"><span style="color:#333333;">The COVID-19 pandemic continues to evolve, and we continue to closely monitor its impact on our business and&#xa0;operations, including its continued&#xa0;impact on our clinical development plans and timelines, and financial condition. There has been intermittent impact of the pandemic in differing geographies,&#xa0;and there may be continued impact, particularly in light of the surge of new COVID-19 cases relating to new variants. As of the date of the issuance of this Quarterly Report on Form 10-Q, our operations, capital&#xa0;and financial resources, and overall liquidity position and outlook have been impacted by COVID-19, primarily due to delays experienced in our operations, including&#xa0;in clinical study initiation and enrollment. The extended timelines have required us to expend more of our capital resources than planned to achieve our projected milestones. For example, our Phase 2 study of istaroxime for early cardiogenic shock in heart failure patients&#xa0;experienced delays in trial initiation and enrollment in 2021.&#xa0;Although many countries have re-opened, rises in new cases, including as the result of newly identified COVID-19 variants, have caused certain countries, states, and localities to re-initiate restrictions.&#xa0;The full extent, duration, or impact that the COVID-19 pandemic will have, directly or indirectly, on our financial condition and operations, including ongoing and planned clinical trials, will depend on future developments that are highly uncertain and cannot be accurately predicted. These potential future developments include the severity and transmissibility of new variants of the virus, information about any resurgences&#xa0;in one or more geographic locations where our current or intended clinical trial sites, our&#xa0;principal executive offices, research and development laboratories, or manufacturing facilities are located, and the actions taken to contain it or treat its impact. In addition, regional impact and responses to the COVID-19 pandemic have affected where a clinical trial could be executed and how various elements of the clinical trial are performed. Going forward, the pandemic could also impact how monitoring/auditing of clinical trial&#xa0;sites and data occur. The maintenance, or strategic re-implementation, of mitigating COVID-19 measures in one or more geographic locations where our clinical trial sites, principal executive offices, research and development laboratories, or other facilities are located remains possible and if realized, we believe there could be further impact on the clinical development of our product candidates, which may include potential delays, halts, or modifications to our ongoing and planned trials in </span><span style="color:#333333;">2022</span><span style="color:#333333;"> and beyond.</span></p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">&#xa0;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin: 0pt; text-align: center;"><span style="color:#333333;"><b>CRITICAL ACCOUNTING POLICIES</b></span></p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin: 0pt; text-align: left;">&#xa0;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin: 0pt; text-align: left;"><span style="color:#333333;">There have been no changes to our critical accounting policies since </span><span style="color:#333333;">December 31, 2021</span><span style="color:#333333;">.&#xa0;For a discussion of our accounting policies, <i>see</i>, </span><span style="color:#333333;">Note 4 &#x2013; Summary of Significant Accounting Policies</span><span style="color:#333333;"> and, in the Notes to Consolidated Financial Statements&#xa0;in our Annual Report on Form 10-K for the year ended </span><span style="color:#333333;">December 31, 2021</span><span style="color:#333333;">, Note 4 &#x2013;&#xa0;Accounting Policies and Recent Accounting Pronouncements.&#xa0;Readers are encouraged to review those disclosures in conjunction with this Quarterly Report on Form 10-Q.</span></p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin: 0pt; text-align: left;">&#xa0;</p>
  <div style="font-size:10pt">
   <div style="font-family:&quot;Times New Roman&quot;">
    <span style="color:#333333;"><b>Goodwill and Intangible Assets</b></span>
   </div>
   <div style="font-family:&quot;Times New Roman&quot;">
     &#xa0;
   </div>
   <div style="font-family:&quot;Times New Roman&quot;">
    <div style="font-size:10pt">
     <div style="font-family:&quot;Times New Roman&quot;">
      <span style="color:#333333;">We record acquired identified intangibles, which includes intangible assets (such as goodwill and other intangibles), based on estimated fair value. The acquired in-process research and development, or IPR&amp;D, assets are considered indefinite-lived intangible assets until completion or abandonment of the associated research and development efforts. IPR&amp;D is not amortized but reviewed for impairment at least annually, or when events or changes in the business environment indicate the carrying value may be impaired.&#xa0;<span style="font-size: 10pt;">During the&#xa0;</span></span>
      <span style="color:#333333;">three and six months ended June 30, 2022</span>
      <span style="color:#333333;"><span style="font-size: 10pt;">,&#xa0;</span>no events or changes in circumstances occurred indicating that our IPR&amp;D intangible assets were more likely than not impaired.</span>
     </div>
    </div>
   </div>
   <div style="font-family:&quot;Times New Roman&quot;">
     &#xa0;
   </div>
   <div style="font-family:&quot;Times New Roman&quot;">
    <div style="font-size:10pt">
     <div style="font-family:&quot;Times New Roman&quot;">
      <span style="color:#333333;">During the&#xa0;second&#xa0;quarter of 2021, we determined that the fair value of the IPR&amp;D related to our rostafuroxin drug candidate was more likely than&#xa0;not impaired and we&#xa0;performed the required quantitative impairment assessment of the related intangible asset. We recorded a loss on impairment of intangible assets of&#xa0;</span>
      <span style="color:#333333;">$37.8</span>
      <span style="color:#333333;">&#xa0;million, recognized within operating expenses in our condensed consolidated statements of operations&#xa0;for the&#xa0;three&#xa0;and&#xa0;six&#xa0;months ended&#xa0;June 30, 2021.&#xa0;No&#xa0;events or changes in the business environment occurred during the&#xa0;six&#xa0;months ended&#xa0;June 30, 2021&#xa0;to indicate that the fair value of the IPR&amp;D related to our istaroxime drug candidate was impaired.</span>
     </div>
    </div>
   </div>
   <div style="font-family:&quot;Times New Roman&quot;">
     &#xa0;
   </div>
   <div style="font-family:&quot;Times New Roman&quot;">
    <div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
     <div class="PGFTR" style="text-align: center; width: 100%">
      <div class="hf-row">
       <div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">
         19
       </div>
      </div>
     </div>
     <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000" />
     <div class="PGHDR" style="text-align: left; width: 100%">
      <div class="hf-row">
       <div class="hf-cell TOCLink" style="display: inline-block; text-align: left;">
        <a href="#toc" style="font-weight: initial; font-style: initial; font-variant: initial; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif;">Table of Contents</a>
       </div>
      </div>
     </div>
    </div>
    <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin: 0pt; text-align: left;">&#xa0;</p>
   </div>
   <div style="font-family:&quot;Times New Roman&quot;">
    <span style="color:#333333;">Throughout the year, we consider whether any events or changes in the business environment have occurred which indicate that goodwill may be impaired. For example, a significant decline in the closing share price of our common stock and market capitalization may suggest that the fair value of our reporting unit has fallen below its carrying amount, indicating that an interim goodwill impairment test is required. Accordingly, we monitor changes in our share price during interim periods between annual impairment tests and consider overall stock market conditions, the underlying reasons for the decline in our share price, the significance of the decline, and the duration of time that our securities have been trading at a lower value. We have experienced a declining trend in the&#xa0;closing share price of our common stock following the announcement in April 2022 of positive topline results in our Phase 2 global clinical study of istaroxime for the treatment of early cardiogenic shock.</span>
   </div>
   <div style="font-family:&quot;Times New Roman&quot;">
     &#xa0;
   </div>
   <div style="font-family:&quot;Times New Roman&quot;">
    <span style="color:#333333;">During the second quarter of 2022, the continued declining trend in the closing share price of our common stock suggested that the fair value of our reporting unit was more likely than not less than its carrying value.&#xa0;As a result, we&#xa0;performed the required interim goodwill impairment test consistent with the methodology that we use when performing our annual goodwill impairment assessment, including the use of the quoted market price and related market capitalization of our common stock, adjusted for an estimated control premium based on transactions completed by comparable companies.&#xa0;Based on the quantitative test performed, we recorded a loss on impairment of goodwill of&#xa0;</span>
    <span style="color:#333333;">$11.6</span>
    <span style="color:#333333;"> million, recognized within operating expenses in our condensed consolidated statements of operations&#xa0;for the&#xa0;three&#xa0;and&#xa0;six&#xa0;months ended&#xa0;June 30, 2022.</span>
   </div>
   <div style="font-family:&quot;Times New Roman&quot;">
     &#xa0;
   </div>
   <div style="font-family:&quot;Times New Roman&quot;">
    <div style="font-size:10pt">
     <div style="font-family:&quot;Times New Roman&quot;">
      <span style="color:#333333;">The closing share price of our common stock has continued to decline during July and August 2022. If our share price continues to decline during the remainder of the third quarter of 2022, we may be at risk for future impairment to goodwill in the near term.</span>
     </div>
    </div>
   </div>
   <div style="font-family:&quot;Times New Roman&quot;">
     &#xa0;
   </div>
   <div style="font-family:&quot;Times New Roman&quot;">
    <span style="color:#333333;">The following table represents identifiable intangible assets and goodwill as of </span>
    <span style="color:#333333;">June 30, 2022</span>
    <span style="color:#333333;"> and </span>
    <span style="color:#333333;">December 31, 2021</span>
    <span style="color:#333333;">:</span>
   </div>
  </div>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="margin-right: 5%; margin-left: 5%; width: 90%; font-size: 10pt; font-family: Times New Roman; text-indent: 0px;">
   <tbody>
    <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom">
     <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td>
     <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td>
     <td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"><span style="color:#333333;"><b>June 30,</b></span></td>
     <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td>
     <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td>
     <td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"><span style="color:#333333;"><b>December 31,</b></span></td>
     <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td>
    </tr>

    <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom">
     <td style="font-family: Times New Roman; font-size: 10pt; width: 66%;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;"><span style="color:#333333;"><i>(in thousands)</i></span></p> </td>
     <td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
     <td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><span style="color:#333333;"><b>2022</b></span></p> </td>
     <td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&#xa0;</td>
     <td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
     <td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><span style="color:#333333;"><b>2021</b></span></p> </td>
     <td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&#xa0;</td>
    </tr>

    <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom">
     <td>&#xa0;</td>
     <td>&#xa0;</td>
     <td>&#xa0;</td>
     <td>&#xa0;</td>
     <td>&#xa0;</td>
     <td>&#xa0;</td>
     <td>&#xa0;</td>
     <td>&#xa0;</td>
     <td>&#xa0;</td>
    </tr>

    <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom">
     <td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;"><span style="color:#333333;">Istaroxime drug candidate</span></p> </td>
     <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
     <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"><span style="color:#333333;">$</span></td>
     <td style="width: 14%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><span style="color:#333333;">22,340</span></td>
     <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#xa0;</td>
     <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
     <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"><span style="color:#333333;">$</span></td>
     <td style="width: 14%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><span style="color:#333333;">22,340</span></td>
     <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#xa0;</td>
    </tr>

    <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom">
     <td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;"><span style="color:#333333;">Rostafuroxin drug candidate</span></p> </td>
     <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&#xa0;</td>
     <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td>
     <td style="width: 14%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><span style="color:#333333;">9,730</span></td>
     <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">&#xa0;</td>
     <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&#xa0;</td>
     <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td>
     <td style="width: 14%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><span style="color:#333333;">9,730</span></td>
     <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">&#xa0;</td>
    </tr>

    <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom">
     <td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;"><span style="color:#333333;">Intangible assets</span></p> </td>
     <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
     <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);">&#xa0;</td>
     <td style="width: 14%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><span style="color:#333333;">32,070</span></td>
     <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&#xa0;</td>
     <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
     <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);">&#xa0;</td>
     <td style="width: 14%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><span style="color:#333333;">32,070</span></td>
     <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&#xa0;</td>
    </tr>

    <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom">
     <td>&#xa0;</td>
     <td>&#xa0;</td>
     <td>&#xa0;</td>
     <td>&#xa0;</td>
     <td>&#xa0;</td>
     <td>&#xa0;</td>
     <td>&#xa0;</td>
     <td>&#xa0;</td>
     <td>&#xa0;</td>
    </tr>

    <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom">
     <td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;"><span style="color:#333333;">Goodwill</span></p> </td>
     <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
     <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><span style="color:#333333;">$</span></td>
     <td style="width: 14%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><span style="color:#333333;">4,046</span></td>
     <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#xa0;</td>
     <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
     <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><span style="color:#333333;">$</span></td>
     <td style="width: 14%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><span style="color:#333333;">15,682</span></td>
     <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#xa0;</td>
    </tr>

   </tbody>
  </table>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin: 0pt; text-align: left;">&#xa0;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin: 0pt; text-align: center;"><span style="color:#333333;"><b>RESULTS OF OPERATIONS</b></span></p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin: 0pt; text-align: left;">&#xa0;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin: 0pt; text-align: left;"><span style="color:#333333;"><b>Operating Loss and Net Loss</b></span></p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin: 0pt; text-align: left;">&#xa0;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin: 0pt; text-align: left;"><span style="color:#333333;">The operating loss for the three months ended </span><span style="color:#333333;">June 30, 2022 and 2021</span><span style="color:#333333;"> was&#xa0;</span><span style="color:#333333;">$17.5</span><span style="color:#333333;"> million and&#xa0;</span><span style="color:#333333;">$45.4</span><span style="color:#333333;"> million, respectively. The&#xa0;</span><span style="color:#333333;">decrease</span><span style="color:#333333;">&#xa0;in operating loss from </span><span style="color:#333333;">2021</span><span style="color:#333333;"> to </span><span style="color:#333333;">2022</span><span style="color:#333333;"> was due to a&#xa0;</span><span style="color:#333333;">$37.8</span><span style="color:#333333;"> million loss on impairment of intangible assets&#xa0;related to rostafuroxin in&#xa0;</span><span style="color:#333333;">2021</span><span style="color:#333333;"> (<i>see</i>,&#xa0;</span><span style="color:#333333;">Note 4 &#x2013; Summary of Significant Accounting Policies</span><span style="color:#333333;">) and a&#xa0;</span><span style="color:#333333;">$1.7</span><span style="color:#333333;"> million&#xa0;</span><span style="color:#333333;">decrease</span><span style="color:#333333;">&#xa0;in&#xa0;operating expenses in </span><span style="color:#333333;">2022</span><span style="color:#333333;">, partially offset by an&#xa0;</span><span style="color:#333333;">$11.6</span><span style="color:#333333;"> million loss on impairment of goodwill in </span><span style="color:#333333;">2022</span><span style="color:#333333;">.</span></p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin: 0pt; text-align: left;">&#xa0;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin: 0pt; text-align: left;"><span style="color:#333333;">The operating loss for the </span><span style="color:#333333;">six</span><span style="color:#333333;"> months ended </span><span style="color:#333333;">June 30, 2022 and 2021</span><span style="color:#333333;"> was&#xa0;</span><span style="color:#333333;">$25.9</span><span style="color:#333333;"> million and&#xa0;</span><span style="color:#333333;">$54.4</span><span style="color:#333333;"> million, respectively.&#xa0;The&#xa0;</span><span style="color:#333333;">decrease</span><span style="color:#333333;">&#xa0;in operating loss from </span><span style="color:#333333;">2021</span><span style="color:#333333;"> to </span><span style="color:#333333;">2022</span><span style="color:#333333;"> was due to a&#xa0;</span><span style="color:#333333;">$37.8</span><span style="color:#333333;"> million loss on impairment of intangible assets&#xa0;related to rostafuroxin&#xa0;in&#xa0;</span><span style="color:#333333;">2021</span><span style="color:#333333;"> and a&#xa0;</span><span style="color:#333333;">$2.4</span><span style="color:#333333;"> million&#xa0;</span><span style="color:#333333;">decrease</span><span style="color:#333333;"> in operating expenses in </span><span style="color:#333333;">2022</span><span style="color:#333333;">, partially offset by an&#xa0;</span><span style="color:#333333;">$11.6</span><span style="color:#333333;"> million loss on impairment of goodwill in&#xa0;</span><span style="color:#333333;">2022</span><span style="color:#333333;">.</span></p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin: 0pt; text-align: left;">&#xa0;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin: 0pt; text-align: left;"><span style="color:#333333;">The net loss for the three months ended </span><span style="color:#333333;">June 30, 2022 and 2021</span><span style="color:#333333;"> was </span><span style="color:#333333;">$17.3</span><span style="color:#333333;">&#xa0;million and </span><span style="color:#333333;">$37.4</span><span style="color:#333333;">&#xa0;million, respectively. The&#xa0;</span><span style="color:#333333;">decrease</span><span style="color:#333333;"> in net loss&#xa0;from </span><span style="color:#333333;">2021</span><span style="color:#333333;"> to </span><span style="color:#333333;">2022</span><span style="color:#333333;"> was due to a&#xa0;</span><span style="color:#333333;">$37.8</span><span style="color:#333333;"> million loss on impairment of intangible assets&#xa0;related to rostafuroxin in&#xa0;</span><span style="color:#333333;">2021</span><span style="color:#333333;"> and a&#xa0;</span><span style="color:#333333;">$1.7</span><span style="color:#333333;"> million&#xa0;</span><span style="color:#333333;">decrease</span><span style="color:#333333;">&#xa0;in&#xa0;operating expenses in </span><span style="color:#333333;">2022</span><span style="color:#333333;">, partially offset by an&#xa0;</span><span style="color:#333333;">$11.6</span><span style="color:#333333;"> million loss on impairment of goodwill in </span><span style="color:#333333;">2022</span><span style="color:#333333;">, an&#xa0;</span><span style="color:#333333;">$8.3</span><span style="color:#333333;"> million deferred income tax benefit related to the reduction of the deferred tax liability in&#xa0;</span><span style="color:#333333;">2021</span><span style="color:#333333;">, and an increase of $0.5 million in other income.</span></p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin: 0pt; text-align: left;">&#xa0;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin: 0pt; text-align: left;"><span style="color:#333333;">The net loss for the </span><span style="color:#333333;">six</span><span style="color:#333333;"> months ended </span><span style="color:#333333;">June 30, 2022 and 2021</span><span style="color:#333333;"> was&#xa0;</span><span style="color:#333333;">$25.5</span><span style="color:#333333;"> million and&#xa0;</span><span style="color:#333333;">$46.4</span><span style="color:#333333;"> million, respectively. The decrease in net loss from </span><span style="color:#333333;">2021</span><span style="color:#333333;"> to </span><span style="color:#333333;">2022</span><span style="color:#333333;"> was due to a&#xa0;</span><span style="color:#333333;">$37.8</span><span style="color:#333333;"> million loss on impairment of intangible assets&#xa0;related to rostafuroxin&#xa0;in&#xa0;</span><span style="color:#333333;">2021</span><span style="color:#333333;"> and a&#xa0;</span><span style="color:#333333;">$2.4</span><span style="color:#333333;"> million&#xa0;</span><span style="color:#333333;">decrease</span><span style="color:#333333;"> in operating expenses in </span><span style="color:#333333;">2022</span><span style="color:#333333;">, partially offset by an&#xa0;</span><span style="color:#333333;">$11.6</span><span style="color:#333333;"> million loss on impairment of goodwill in&#xa0;</span><span style="color:#333333;">2022</span><span style="color:#333333;">, an&#xa0;</span><span style="color:#333333;">$8.3</span><span style="color:#333333;"> million deferred income tax benefit related to the reduction of the deferred tax liability in&#xa0;</span><span style="color:#333333;">2021</span><span style="color:#333333;">, and an increase of $0.6 million in other income.&#xa0;</span></p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin: 0pt; text-align: left;">&#xa0;</p>
  <div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
   <div class="PGFTR" style="text-align: center; width: 100%">
    <div class="hf-row">
     <div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">
       20
     </div>
    </div>
   </div>
   <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000" />
   <div class="PGHDR" style="text-align: left; width: 100%">
    <div class="hf-row">
     <div class="hf-cell TOCLink" style="display: inline-block; text-align: left;">
      <a href="#toc" style="font-weight: initial; font-style: initial; font-variant: initial; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif;">Table of Contents</a>
     </div>
    </div>
   </div>
  </div>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin: 0pt; text-align: left;">&#xa0;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin: 0pt; text-align: left;"><span style="color:#333333;"><b>Research and Development Expenses</b></span></p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin: 0pt; text-align: left;">&#xa0;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;"><span style="color:#333333;">Our research and development expenses are charged to operations as incurred and we incur both direct and indirect expenses for each of our programs. We track direct research and development expenses by preclinical and clinical programs, which include third-party costs such as contract research organization, consulting and clinical trial costs. We do not allocate indirect research and development expenses, which include product development and manufacturing expenses and clinical, medical and regulatory operations expenses, to specific programs. We also account for research and development and report annually by major expense category as follows:&#xa0;(i) contracted services; (ii) salaries and benefits; (iii) stock-based compensation; (iv) raw materials, aerosol devices and supplies; (v) royalties; (vi) rents and utilities; (vii) depreciation; (viii) travel; and (ix) other.&#xa0;We currently have sufficient capital to execute limited clinical trial work on the extension of our trial of istaroxime for early cardiogenic shock.&#xa0;We expect that our research and development expenses will decrease unless and until we secure additional capital.&#xa0;At this time, we cannot reasonably estimate or know the nature, timing, and estimated costs of the efforts that will be necessary to complete the development of our product candidates. We are also unable to predict when, if ever, material net cash inflows will commence from sales of our product candidates.</span></p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">&#xa0;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin: 0pt; text-align: left;"><span style="color:#333333;">Research and development expenses&#xa0;are as follows:&#xa0;</span></p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin: 0pt; text-align: left;">&#xa0;</p>
  <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="margin-right: 5%; width: 95%; font-size: 10pt; font-family: Times New Roman; text-indent: 0px;">
   <tbody>
    <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom">
     <td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
     <td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
     <td colspan="6" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><span style="color:#333333;"><b>Three Months Ended June 30,</b></span></p> </td>
     <td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
     <td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
     <td colspan="6" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><span style="color:#333333;"><b>Six Months Ended June 30,</b></span></p> </td>
     <td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
    </tr>

    <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom">
     <td style="font-family: Times New Roman; font-size: 10pt; width: 48%;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;"><span style="color:#333333;"><i>(in thousands)</i></span></p> </td>
     <td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
     <td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><span style="color:#333333;"><b>2022</b></span></p> </td>
     <td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&#xa0;</td>
     <td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
     <td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><span style="color:#333333;"><b>2021</b></span></p> </td>
     <td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&#xa0;</td>
     <td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
     <td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><span style="color:#333333;"><b>2022</b></span></p> </td>
     <td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&#xa0;</td>
     <td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
     <td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><span style="color:#333333;"><b>2021</b></span></p> </td>
     <td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&#xa0;</td>
    </tr>

    <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom">
     <td>&#xa0;</td>
     <td>&#xa0;</td>
     <td>&#xa0;</td>
     <td>&#xa0;</td>
     <td>&#xa0;</td>
     <td>&#xa0;</td>
     <td>&#xa0;</td>
     <td>&#xa0;</td>
     <td>&#xa0;</td>
     <td>&#xa0;</td>
     <td>&#xa0;</td>
     <td>&#xa0;</td>
     <td>&#xa0;</td>
     <td>&#xa0;</td>
     <td>&#xa0;</td>
     <td>&#xa0;</td>
     <td>&#xa0;</td>
    </tr>

    <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom">
     <td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;"><span style="color:#333333;">Istaroxime - early cardiogenic shock</span></p> </td>
     <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
     <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><span style="color:#333333;">$</span></td>
     <td style="width: 10%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><span style="color:#333333;">974</span></td>
     <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#xa0;</td>
     <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
     <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><span style="color:#333333;">$</span></td>
     <td style="width: 10%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><span style="color:#333333;">840</span></td>
     <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#xa0;</td>
     <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
     <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><span style="color:#333333;">$</span></td>
     <td style="width: 10%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><span style="color:#333333;">2,174</span></td>
     <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#xa0;</td>
     <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
     <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"><span style="color:#333333;">$</span></td>
     <td style="width: 10%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><span style="color:#333333;">1,346</span></td>
     <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#xa0;</td>
    </tr>

    <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom">
     <td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;"><span style="color:#333333;">Istaroxime - AHF</span></p> </td>
     <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
     <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
     <td style="width: 10%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><span style="color:#333333;">111</span></td>
     <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#xa0;</td>
     <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
     <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
     <td style="width: 10%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><span style="color:#333333;">155</span></td>
     <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#xa0;</td>
     <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
     <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
     <td style="width: 10%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><span style="color:#333333;">656</span></td>
     <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#xa0;</td>
     <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
     <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
     <td style="width: 10%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><span style="color:#333333;">654</span></td>
     <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#xa0;</td>
    </tr>

    <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom">
     <td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;"><span style="color:#333333;">KL4 surfactant</span></p> </td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px;">&#xa0;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td>
     <td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><span style="color:#333333;">78</span></td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">&#xa0;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px;">&#xa0;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td>
     <td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><span style="color:#333333;">263</span></td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">&#xa0;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px;">&#xa0;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td>
     <td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><span style="color:#333333;">291</span></td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">&#xa0;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px;">&#xa0;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td>
     <td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><span style="color:#333333;">507</span></td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">&#xa0;</td>
    </tr>

    <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom">
     <td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;"><span style="color:#333333;">Total direct clinical and preclinical programs</span></p> </td>
     <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
     <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
     <td style="width: 10%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><span style="color:#333333;">1,163</span></td>
     <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#xa0;</td>
     <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
     <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
     <td style="width: 10%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><span style="color:#333333;">1,258</span></td>
     <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#xa0;</td>
     <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
     <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
     <td style="width: 10%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><span style="color:#333333;">3,121</span></td>
     <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#xa0;</td>
     <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
     <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
     <td style="width: 10%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><span style="color:#333333;">2,507</span></td>
     <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#xa0;</td>
    </tr>

    <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom">
     <td>&#xa0;</td>
     <td>&#xa0;</td>
     <td>&#xa0;</td>
     <td>&#xa0;</td>
     <td>&#xa0;</td>
     <td>&#xa0;</td>
     <td>&#xa0;</td>
     <td>&#xa0;</td>
     <td>&#xa0;</td>
     <td>&#xa0;</td>
     <td>&#xa0;</td>
     <td>&#xa0;</td>
     <td>&#xa0;</td>
     <td>&#xa0;</td>
     <td>&#xa0;</td>
     <td>&#xa0;</td>
     <td>&#xa0;</td>
    </tr>

    <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom">
     <td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;"><span style="color:#333333;">Product development and manufacturing</span></p> </td>
     <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
     <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
     <td style="width: 10%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><span style="color:#333333;">420</span></td>
     <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#xa0;</td>
     <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
     <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
     <td style="width: 10%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><span style="color:#333333;">1,085</span></td>
     <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#xa0;</td>
     <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
     <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
     <td style="width: 10%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><span style="color:#333333;">2,042</span></td>
     <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#xa0;</td>
     <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
     <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
     <td style="width: 10%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><span style="color:#333333;">2,172</span></td>
     <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#xa0;</td>
    </tr>

    <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom">
     <td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;"><span style="color:#333333;">Clinical, medical, and regulatory operations</span></p> </td>
     <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
     <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td>
     <td style="width: 10%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><span style="color:#333333;">1,412</span></td>
     <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#xa0;</td>
     <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
     <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td>
     <td style="width: 10%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><span style="color:#333333;">1,878</span></td>
     <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#xa0;</td>
     <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
     <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td>
     <td style="width: 10%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><span style="color:#333333;">3,177</span></td>
     <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#xa0;</td>
     <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
     <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td>
     <td style="width: 10%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><span style="color:#333333;">3,952</span></td>
     <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#xa0;</td>
    </tr>

    <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom">
     <td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;"><span style="color:#333333;">Total research and development expenses</span></p> </td>
     <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
     <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><span style="color:#333333;">$</span></td>
     <td style="width: 10%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><span style="color:#333333;">2,995</span></td>
     <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&#xa0;</td>
     <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
     <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><span style="color:#333333;">$</span></td>
     <td style="width: 10%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><span style="color:#333333;">4,221</span></td>
     <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&#xa0;</td>
     <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
     <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><span style="color:#333333;">$</span></td>
     <td style="width: 10%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><span style="color:#333333;">8,340</span></td>
     <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&#xa0;</td>
     <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
     <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><span style="color:#333333;">$</span></td>
     <td style="width: 10%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><span style="color:#333333;">8,631</span></td>
     <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&#xa0;</td>
    </tr>

   </tbody>
  </table>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin: 0pt; text-align: left;">&#xa0;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin: 0pt; text-align: left;"><span style="color:#333333;">Research and development expenses include non-cash charges associated with stock-based compensation and depreciation of&#xa0;</span><span style="color:#333333;">$0.3</span><span style="color:#333333;"> million and </span><span style="color:#333333;">$0.7</span><span style="color:#333333;">&#xa0;million, respectively, for the&#xa0;three months ended&#xa0;</span><span style="color:#333333;">June 30, 2022 and 2021</span><span style="color:#333333;">, and&#xa0;</span><span style="color:#333333;">$1.0</span><span style="color:#333333;"> million and&#xa0;</span><span style="color:#333333;">$1.6</span><span style="color:#333333;"> million, respectively, for the </span><span style="color:#333333;">six</span><span style="color:#333333;"> months&#xa0;ended&#xa0;</span><span style="color:#333333;">June 30, 2022 and 2021</span><span style="color:#333333;">.</span></p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin: 0px;">&#xa0;</p>
  <div style="font-size:10pt">
   <div style="font-family:'Times New Roman', Times, serif">
    <span style="color:#333333;"><i>Direct Clinical and Preclinical Programs</i></span>
   </div>
   <div style="font-family:'Times New Roman', Times, serif">
     &#xa0;
   </div>
   <div style="font-family:'Times New Roman', Times, serif">
    <span style="color:#333333;">Direct clinical and preclinical programs include: (i)&#xa0;activities associated with conducting clinical trials, including patient enrollment costs, clinical site costs, clinical drug supply, and related external costs, such as consultant fees and expenses; and (ii)&#xa0;development activities, toxicology studies, and other preclinical studies.</span>
   </div>
   <div style="font-family:'Times New Roman', Times, serif">
     &#xa0;
   </div>
   <div style="font-family:'Times New Roman', Times, serif">
    <span style="color:#333333;">Istaroxime - early cardiogenic shock increased </span>
    <span style="color:#333333;">$0.1</span>
    <span style="color:#333333;">&#xa0;million and </span>
    <span style="color:#333333;">$0.8</span>
    <span style="color:#333333;"> million, respectively, for the three&#xa0;and&#xa0;</span>
    <span style="color:#333333;">six months ended June 30, 2022</span>
    <span style="color:#333333;"> compared to the same periods in </span>
    <span style="color:#333333;">2021</span>
    <span style="color:#333333;"> due to our Phase 2 global clinical study of istaroxime for the treatment of early cardiogenic shock and our ongoing extension of this trial following the announcement of positive topline results in April 2022.</span>
   </div>
   <div style="font-family:'Times New Roman', Times, serif">
     &#xa0;
   </div>
   <div style="font-family:'Times New Roman', Times, serif">
    <span style="color:#333333;">Istaroxime - AHF costs relate to limited ongoing clinical and preclinical development activities, including toxicology studies and drug lot production.&#xa0;</span>
   </div>
   <div style="font-family:'Times New Roman', Times, serif">
     &#xa0;
   </div>
   <div style="font-family:'Times New Roman', Times, serif">
    <span style="color:#333333;">KL4 surfactant decreased&#xa0;</span>
    <span style="color:#333333;">$0.2</span>
    <span style="color:#333333;"> million for both the three and </span>
    <span style="color:#333333;">six months ended June 30, 2022</span>
    <span style="color:#333333;"> compared to the same periods in </span>
    <span style="color:#333333;">2021</span>
    <span style="color:#333333;"> following the completion of enrollment in January 2022 of our Phase 2b study of lucinactant for patients with severe COVID-19 associated ARDS.</span>
   </div>
   <div style="font-family:'Times New Roman', Times, serif">
    <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin: 0pt; text-align: left;">&#xa0;</p>
   </div>
   <div style="font-family:'Times New Roman', Times, serif">
    <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin: 0pt; text-align: left;"><span style="color:#333333;"><i>Product Development and Manufacturing</i></span></p>
   </div>
  </div>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin: 0pt; text-align: left;">&#xa0;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin: 0pt; text-align: left;"><span style="color:#333333;">Product development and manufacturing includes (i) manufacturing operations, with our contract manufacturing organization, validation activities, quality assurance; and (ii) pharmaceutical and manufacturing development activities of our drug product candidates, including development of istaroxime. These costs include employee expenses, facility-related costs, depreciation, costs of drug substances (including raw materials), supplies, quality assurance activities, and expert consultants and outside services to support pharmaceutical development activities.</span></p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin: 0pt; text-align: left;">&#xa0;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin: 0pt; text-align: left;"><span style="color:#333333;">Product development and manufacturing expenses&#xa0;</span><span style="color:#333333;">decreased</span><span style="color:#333333;">&#xa0;</span><span style="color:#333333;">$0.7</span><span style="color:#333333;"> million for the three months ended&#xa0;</span><span style="color:#333333;">June 30, 2022</span><span style="color:#333333;">&#xa0;compared to the same period in&#xa0;</span><span style="color:#333333;">2021</span><span style="color:#333333;">&#xa0;due to (i) a decrease of $0.4 million related to our decision in January 2022 to begin to reduce costs related to the development of the KL4 surfactant platform that were not already transferred to Lee&#x2019;s (HK);&#xa0;a decrease of $0.1 million related to reductions in headcount for the KL4 surfactant platform; and (iii) a $0.1 million decrease in non-cash stock-based compensation expense.</span></p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin: 0pt; text-align: left;">&#xa0;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin: 0pt; text-align: left;"><span style="color:#333333;">Product development and manufacturing expenses&#xa0;</span><span style="color:#333333;">decreased</span><span style="color:#333333;">$0.1</span><span style="color:#333333;">&#xa0;million for the </span><span style="color:#333333;">six</span><span style="color:#333333;"> months ended&#xa0;</span><span style="color:#333333;">June 30, 2022</span><span style="color:#333333;">&#xa0;compared to the same period in&#xa0;</span><span style="color:#333333;">2021</span><span style="color:#333333;">&#xa0;due to&#xa0;(i) a decrease of $0.4 million related to our decision in January 2022 to begin to reduce costs related to the KL4 surfactant platform that were not already transferred to Lee&#x2019;s (HK); and (ii) a $0.1 million decrease in non-cash stock-based compensation expense; partially offset by (iii) $0.4 million in accelerated depreciation during the first quarter of 2022 following&#xa0;the abandonment and decommissioning of certain&#xa0;manufacturing and laboratory equipment assets related to the KL4 surfactant platform.</span></p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin: 0pt; text-align: left;">&#xa0;</p>
  <div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
   <div class="PGFTR" style="text-align: center; width: 100%">
    <div class="hf-row">
     <div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">
       21
     </div>
    </div>
   </div>
   <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000" />
   <div class="PGHDR" style="text-align: left; width: 100%">
    <div class="hf-row">
     <div class="hf-cell TOCLink" style="display: inline-block; text-align: left;">
      <a href="#toc" style="font-weight: initial; font-style: initial; font-variant: initial; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif;">Table of Contents</a>
     </div>
    </div>
   </div>
  </div>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin: 0pt; text-align: left;">&#xa0;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin: 0pt; text-align: left;"><span style="color:#333333;"><i>Clinical, Medical, and Regulatory Operations</i></span></p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin: 0pt; text-align: left;">&#xa0;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin: 0pt; text-align: left;"><span style="color:#333333;">Clinical, medical, and regulatory operations include medical, scientific, preclinical and clinical, regulatory, data management, and biostatistics activities in support of our research and development programs. These costs include personnel, expert consultants, outside services to support regulatory and data management, symposiums at key medical meetings, facilities-related costs, and other costs for the management of clinical trials.</span></p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin: 0pt; text-align: left;">&#xa0;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin: 0pt; text-align: left;"><span style="color:#333333;">Clinical, medical, and regulatory operations expenses </span><span style="color:#333333;">decreased</span><span style="color:#333333;">&#xa0;</span><span style="color:#333333;">$0.5</span><span style="color:#333333;"> million for the three months ended&#xa0;</span><span style="color:#333333;">June 30, 2022</span><span style="color:#333333;">&#xa0;compared to the same period in&#xa0;</span><span style="color:#333333;">2021</span><span style="color:#333333;">&#xa0;due to&#xa0;</span><span style="color:#333333;">a decrease</span><span style="color:#333333;">&#xa0;of&#xa0;</span><span style="color:#333333;">$0.4</span><span style="color:#333333;"> million in&#xa0;non-cash&#xa0;stock-based compensation expense and&#xa0;</span><span style="color:#333333;">a decrease</span><span style="color:#333333;"> of&#xa0;</span><span style="color:#333333;">$0.1</span><span style="color:#333333;"> million in&#xa0;personnel costs.&#xa0;Clinical, medical, and regulatory operations expenses&#xa0;</span><span style="color:#333333;">decreased</span><span style="color:#333333;">$0.8</span><span style="color:#333333;">&#xa0;million for the </span><span style="color:#333333;">six</span><span style="color:#333333;"> months ended&#xa0;</span><span style="color:#333333;">June 30, 2022</span><span style="color:#333333;">&#xa0;compared to the same period in&#xa0;</span><span style="color:#333333;">2021</span><span style="color:#333333;">&#xa0;due to&#xa0;</span><span style="color:#333333;">a decrease</span><span style="color:#333333;">&#xa0;of&#xa0;</span><span style="color:#333333;">$0.9</span><span style="color:#333333;"> million&#xa0;in&#xa0;non-cash&#xa0;stock-based compensation expense, partially offset by&#xa0;</span><span style="color:#333333;">an increase</span><span style="color:#333333;">&#xa0;of&#xa0;</span><span style="color:#333333;">$0.1</span><span style="color:#333333;">&#xa0;million in&#xa0;personnel costs.</span></p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin: 0pt; text-align: left;">&#xa0;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin: 0pt; text-align: left;"><span style="color:#333333;"><b>General and Administrative Expenses</b></span></p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin: 0pt; text-align: left;">&#xa0;</p>
  <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="margin-right: 5%; width: 95%; font-size: 10pt; font-family: Times New Roman; text-indent: 0px;">
   <tbody>
    <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom">
     <td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
     <td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
     <td colspan="6" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><span style="color:#333333;"><b>Three Months Ended June 30,</b></span></p> </td>
     <td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
     <td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
     <td colspan="6" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><span style="color:#333333;"><b>Six Months Ended June 30,</b></span></p> </td>
     <td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
    </tr>

    <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom">
     <td style="font-family: Times New Roman; font-size: 10pt; width: 48%;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;"><span style="color:#333333;"><i>(in thousands)</i></span></p> </td>
     <td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
     <td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><span style="color:#333333;"><b>2022</b></span></p> </td>
     <td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&#xa0;</td>
     <td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
     <td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><span style="color:#333333;"><b>2021</b></span></p> </td>
     <td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&#xa0;</td>
     <td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
     <td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><span style="color:#333333;"><b>2022</b></span></p> </td>
     <td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&#xa0;</td>
     <td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
     <td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><span style="color:#333333;"><b>2021</b></span></p> </td>
     <td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&#xa0;</td>
    </tr>

    <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom">
     <td>&#xa0;</td>
     <td>&#xa0;</td>
     <td>&#xa0;</td>
     <td>&#xa0;</td>
     <td>&#xa0;</td>
     <td>&#xa0;</td>
     <td>&#xa0;</td>
     <td>&#xa0;</td>
     <td>&#xa0;</td>
     <td>&#xa0;</td>
     <td>&#xa0;</td>
     <td>&#xa0;</td>
     <td>&#xa0;</td>
     <td>&#xa0;</td>
     <td>&#xa0;</td>
     <td>&#xa0;</td>
     <td>&#xa0;</td>
    </tr>

    <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom">
     <td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;"><span style="color:#333333;">General and administrative expenses</span></p> </td>
     <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
     <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><span style="color:#333333;">$</span></td>
     <td style="width: 10%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><span style="color:#333333;">2,907</span></td>
     <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&#xa0;</td>
     <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
     <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><span style="color:#333333;">$</span></td>
     <td style="width: 10%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><span style="color:#333333;">3,371</span></td>
     <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&#xa0;</td>
     <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
     <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><span style="color:#333333;">$</span></td>
     <td style="width: 10%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><span style="color:#333333;">5,895</span></td>
     <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&#xa0;</td>
     <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
     <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><span style="color:#333333;">$</span></td>
     <td style="width: 10%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><span style="color:#333333;">8,040</span></td>
     <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&#xa0;</td>
    </tr>

   </tbody>
  </table>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin: 0pt; text-align: left;">&#xa0;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin: 0pt; text-align: left;"><span style="color:#333333;">General and administrative expenses consist of costs for executive management, business development, intellectual property, finance and accounting, legal, human resources, information technology, facility, and other administrative costs.</span></p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin: 0pt; text-align: left;">&#xa0;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin: 0pt; text-align: left;"><span style="color:#333333;">General and administrative expenses </span><span style="color:#333333;">decreased</span><span style="color:#333333;">&#xa0;</span><span style="color:#333333;">$0.5</span><span style="color:#333333;"> million for the&#xa0;three months ended&#xa0;</span><span style="color:#333333;">June 30, 2022</span><span style="color:#333333;">&#xa0;compared to the same period in&#xa0;</span><span style="color:#333333;">2021</span><span style="color:#333333;">&#xa0;due to (i)&#xa0;</span><span style="color:#333333;">a decrease</span><span style="color:#333333;"> of&#xa0;</span><span style="color:#333333;">$0.3</span><span style="color:#333333;"> million in&#xa0;non-cash&#xa0;stock-based compensation expense and&#xa0;(ii)&#xa0;</span><span style="color:#333333;">a decrease</span><span style="color:#333333;"> of&#xa0;</span><span style="color:#333333;">$0.3</span><span style="color:#333333;"> million&#xa0;in professional fees, partially offset by (iii)&#xa0;</span><span style="color:#333333;">an increase</span><span style="color:#333333;"> of&#xa0;</span><span style="color:#333333;">$0.1</span><span style="color:#333333;"> million in personnel costs.</span></p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin: 0pt; text-align: left;">&#xa0;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin: 0pt; text-align: left;"><span style="color:#333333;">General and administrative expenses </span><span style="color:#333333;">decreased</span><span style="color:#333333;">&#xa0;</span><span style="color:#333333;">$2.1</span><span style="color:#333333;"> million for the&#xa0;</span><span style="color:#333333;">six</span><span style="color:#333333;"> months ended&#xa0;</span><span style="color:#333333;">June 30, 2022</span><span style="color:#333333;">&#xa0;compared to the same period in&#xa0;</span><span style="color:#333333;">2021</span><span style="color:#333333;">&#xa0;due to (i)&#xa0;</span><span style="color:#333333;">a decrease</span><span style="color:#333333;">&#xa0;of&#xa0;</span><span style="color:#333333;">$1.2</span><span style="color:#333333;">&#xa0;million in&#xa0;non-cash&#xa0;stock-based compensation expense and&#xa0;(ii)&#xa0;</span><span style="color:#333333;">a decrease</span><span style="color:#333333;">&#xa0;of&#xa0;</span><span style="color:#333333;">$1.2</span><span style="color:#333333;">&#xa0;million&#xa0;in professional fees, partially offset by (iii)&#xa0;</span><span style="color:#333333;">an increase</span><span style="color:#333333;">&#xa0;of&#xa0;</span><span style="color:#333333;">$0.3</span><span style="color:#333333;">&#xa0;million in personnel costs.</span></p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin: 0pt; text-align: left;">&#xa0;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin: 0pt; text-align: left;"><span style="color:#333333;"><b>Other&#xa0;Income (Expense), Net</b></span></p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin: 0pt; text-align: left;">&#xa0;</p>
  <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="margin-right: 5%; width: 95%; font-size: 10pt; font-family: Times New Roman; text-indent: 0px;">
   <tbody>
    <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom">
     <td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
     <td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
     <td colspan="6" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><span style="color:#333333;"><b>Three Months Ended June 30,</b></span></p> </td>
     <td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&#xa0;</td>
     <td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
     <td colspan="6" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><span style="color:#333333;"><b>Six Months Ended June 30,</b></span></p> </td>
     <td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&#xa0;</td>
    </tr>

    <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom">
     <td style="font-family: Times New Roman; font-size: 10pt; width: 48%;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;"><span style="color:#333333;"><i>(in thousands)</i></span></p> </td>
     <td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
     <td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><span style="color:#333333;"><b>2022</b></span></p> </td>
     <td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&#xa0;</td>
     <td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
     <td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><span style="color:#333333;"><b>2021</b></span></p> </td>
     <td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&#xa0;</td>
     <td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
     <td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><span style="color:#333333;"><b>2022</b></span></p> </td>
     <td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&#xa0;</td>
     <td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
     <td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><span style="color:#333333;"><b>2021</b></span></p> </td>
     <td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&#xa0;</td>
    </tr>

    <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom">
     <td>&#xa0;</td>
     <td>&#xa0;</td>
     <td>&#xa0;</td>
     <td>&#xa0;</td>
     <td>&#xa0;</td>
     <td>&#xa0;</td>
     <td>&#xa0;</td>
     <td>&#xa0;</td>
     <td>&#xa0;</td>
     <td>&#xa0;</td>
     <td>&#xa0;</td>
     <td>&#xa0;</td>
     <td>&#xa0;</td>
     <td>&#xa0;</td>
     <td>&#xa0;</td>
     <td>&#xa0;</td>
     <td>&#xa0;</td>
    </tr>

    <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom">
     <td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;"><span style="color:#333333;">Interest income</span></p> </td>
     <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
     <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
     <td style="width: 10%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><span style="color:#333333;">17</span></td>
     <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#xa0;</td>
     <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
     <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
     <td style="width: 10%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><span style="color:#333333;">39</span></td>
     <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#xa0;</td>
     <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
     <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
     <td style="width: 10%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><span style="color:#333333;">18</span></td>
     <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#xa0;</td>
     <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
     <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
     <td style="width: 10%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><span style="color:#333333;">89</span></td>
     <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#xa0;</td>
    </tr>

    <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom">
     <td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;"><span style="color:#333333;">Interest expense</span></p> </td>
     <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
     <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
     <td style="width: 10%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><span style="color:#333333;">(13</span></td>
     <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><span style="color:#333333;">)</span></td>
     <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
     <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
     <td style="width: 10%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><span style="color:#333333;">(46</span></td>
     <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><span style="color:#333333;">)</span></td>
     <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
     <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
     <td style="width: 10%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><span style="color:#333333;">(26</span></td>
     <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><span style="color:#333333;">)</span></td>
     <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
     <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
     <td style="width: 10%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><span style="color:#333333;">(87</span></td>
     <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><span style="color:#333333;">)</span></td>
    </tr>

    <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom">
     <td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;"><span style="color:#333333;">Other income (expense), net</span></p> </td>
     <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
     <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td>
     <td style="width: 10%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><span style="color:#333333;">201</span></td>
     <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#xa0;</td>
     <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
     <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td>
     <td style="width: 10%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><span style="color:#333333;">(352</span></td>
     <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"><span style="color:#333333;">)</span></td>
     <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
     <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td>
     <td style="width: 10%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><span style="color:#333333;">419</span></td>
     <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#xa0;</td>
     <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
     <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td>
     <td style="width: 10%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><span style="color:#333333;">(243</span></td>
     <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"><span style="color:#333333;">)</span></td>
    </tr>

    <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom">
     <td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 18pt;"><span style="color:#333333;">Total other income (expense), net</span></p> </td>
     <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
     <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><span style="color:#333333;">$</span></td>
     <td style="width: 10%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><span style="color:#333333;">205</span></td>
     <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&#xa0;</td>
     <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
     <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><span style="color:#333333;">$</span></td>
     <td style="width: 10%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><span style="color:#333333;">(359</span></td>
     <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"><span style="color:#333333;">)</span></td>
     <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
     <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><span style="color:#333333;">$</span></td>
     <td style="width: 10%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><span style="color:#333333;">411</span></td>
     <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&#xa0;</td>
     <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
     <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><span style="color:#333333;">$</span></td>
     <td style="width: 10%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><span style="color:#333333;">(241</span></td>
     <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"><span style="color:#333333;">)</span></td>
    </tr>

   </tbody>
  </table>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin: 0pt; text-align: left;">&#xa0;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin: 0pt; text-align: left;"><span style="color:#333333;">Interest income relates to interest on our money market account for the </span><span style="color:#333333;">three and six months ended June 30, 2022 and 2021</span><span style="color:#333333;">, and relates to interest on our&#xa0;U.S. Treasury notes for the&#xa0;</span><span style="color:#333333;">three and six months ended June 30, 2021</span><span style="color:#333333;">.</span></p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin: 0pt; text-align: left;">&#xa0;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin: 0pt; text-align: left;"><span style="color:#333333;">For the </span><span style="color:#333333;">three and six months ended June 30, 2022 and 2021</span><span style="color:#333333;">, interest expense consists of interest expense associated with loans payable.</span></p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin: 0pt; text-align: left;">&#xa0;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin: 0pt; text-align: left;"><span style="color:#333333;">For the </span><span style="color:#333333;">three and six months ended June 30, 2022 and 2021</span><span style="color:#333333;">, other income (expense), net primarily consists of gains and losses on foreign currency translation.</span></p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin: 0pt; text-align: left;">&#xa0;</p>
  <div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
   <div class="PGFTR" style="text-align: center; width: 100%">
    <div class="hf-row">
     <div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">
       22
     </div>
    </div>
   </div>
   <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000" />
   <div class="PGHDR" style="text-align: left; width: 100%">
    <div class="hf-row">
     <div class="hf-cell TOCLink" style="display: inline-block; text-align: left;">
      <a href="#toc" style="font-weight: initial; font-style: initial; font-variant: initial; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif;">Table of Contents</a>
     </div>
    </div>
   </div>
  </div>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin: 0pt; text-align: left;">&#xa0;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin: 0pt; text-align: center;"><span style="color:#333333;"><b>LIQUIDITY AND CAPITAL RESOURCES</b></span></p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin: 0pt; text-align: center;">&#xa0;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin: 0pt; text-align: left;"><span style="color:#333333;">We are subject to risks common to companies in the biotechnology industry, including but not limited to, the need for additional capital, risks of failure of preclinical and clinical studies, the need to obtain marketing approval and reimbursement for any drug product candidate that we may identify and develop, the need to successfully commercialize and gain market acceptance of our product candidates, dependence on key personnel, protection of proprietary technology, compliance with government regulations, development of technological innovations by competitors, and&#xa0;risks associated with our international locations and activities abroad, including but not limited to having foreign suppliers, manufacturers, and clinical sites in support of our development activities.</span></p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin: 0pt;">&#xa0;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin: 0pt;"><span style="color:#333333;">We have incurred net losses since inception. Our net loss was </span><span style="color:#333333;">$17.3</span><span style="color:#333333;">&#xa0;million and </span><span style="color:#333333;">$37.4</span><span style="color:#333333;">&#xa0;million, respectively, for the three-month periods ended </span><span style="color:#333333;">June 30, 2022 and 2021</span><span style="color:#333333;">. Our net loss was&#xa0;</span><span style="color:#333333;">$25.5</span><span style="color:#333333;"> million and&#xa0;</span><span style="color:#333333;">$46.4</span><span style="color:#333333;">&#xa0;million, respectively, for the&#xa0;</span><span style="color:#333333;">six</span><span style="color:#333333;">-month periods ended </span><span style="color:#333333;">June 30, 2022 and 2021</span><span style="color:#333333;">.&#xa0;Included in our net loss for the&#xa0;three&#xa0;and&#xa0;</span><span style="color:#333333;">six months ended June 30, 2022</span><span style="color:#333333;">&#xa0;is an&#xa0;</span><span style="color:#333333;">$11.6</span><span style="color:#333333;"> million loss on impairment of goodwill, and included in our net loss for the&#xa0;three&#xa0;and&#xa0;six&#xa0;months ended&#xa0;</span><span style="color:#333333;">June 30, 2021</span><span style="color:#333333;"> is a&#xa0;</span><span style="color:#333333;">$37.8</span><span style="color:#333333;"> million loss on impairment of intangible assets&#xa0;related to rostafuroxin&#xa0;and a related&#xa0;</span><span style="color:#333333;">$8.3</span><span style="color:#333333;"> million deferred income tax benefit (<i>see</i>,&#xa0;</span><span style="color:#333333;">Note 4 &#x2013; Summary of Significant Accounting Policies</span><span style="color:#333333;">).&#xa0;We expect to continue to incur operating losses for at least the next several years. As of </span><span style="color:#333333;">June 30, 2022</span><span style="color:#333333;">, we had an accumulated deficit of </span><span style="color:#333333;">$810.8</span><span style="color:#333333;">&#xa0;million. Our future success is dependent on our ability to fund and develop our product candidates, and ultimately upon our ability to attain profitable operations. We have devoted substantially all of our financial resources and efforts to research and development and general and administrative expense to support such research and development. Net losses and negative cash flows have had, and will continue to have, an adverse effect on our stockholders&#x2019;&#xa0;equity and working capital, and accordingly, our ability to execute our future operating plans.</span></p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin: 0pt;">&#xa0;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin: 0pt;"><span style="color:#333333;">We are party to an At-The-Market Offering Agreement&#xa0;with Ladenburg Thalmann &amp; Co. Inc., or Ladenburg,&#xa0;pursuant to which we may offer and sell, from time to time at our sole discretion, up to a maximum of&#xa0;</span><span style="color:#333333;">$10.0</span><span style="color:#333333;"> million of shares of our common stock through Ladenburg as agent and/or principal through an at-the-market program, or the ATM Program. For the&#xa0;</span><span style="color:#333333;">six months ended June 30, 2022</span><span style="color:#333333;">, we sold&#xa0;</span><span style="color:#333333;">1,137,246</span><span style="color:#333333;">&#xa0;shares&#xa0;of our common stock under the ATM Program&#xa0;resulting in aggregate gross proceeds to us of approximately&#xa0;</span><span style="color:#333333;">$1.3</span><span style="color:#333333;">&#xa0;million and net proceeds of approximately&#xa0;</span><span style="color:#333333;">$1.2</span><span style="color:#333333;">&#xa0;million.&#xa0;During July and August 2022,&#xa0;we sold&#xa0;</span><span style="color:#333333;">1,221,706</span><span style="color:#333333;"> shares of our common stock under the ATM Program&#xa0;resulting in aggregate gross and net proceeds to us of approximately&#xa0;</span><span style="color:#333333;">$0.6</span><span style="color:#333333;"> million (<i>see</i>,&#xa0;</span><span style="color:#333333;">Note 8 &#x2013; Stockholders&#x2019; Equity</span><span style="color:#333333;">).</span></p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin: 0pt;">&#xa0;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin: 0pt;"><span style="color:#333333;">The shares of common stock issued and sold under the ATM Program are registered under our Registration Statement on Form S-3 (File No. 333-248874), which was declared effective by the SEC on September 29, 2020. We are currently subject to the limitations contained in General Instruction I.B.6 of Form S-3. As a result, we are limited in selling no more than one-third of the aggregate market value of the equity held by non-affiliates, or the public float, during any 12-month period. If our public float increases to $75 million or more, we will no longer be subject to such limitations.</span></p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin: 0pt;">&#xa0;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin: 0pt;"><span style="color:#333333;">As of&#xa0;</span><span style="color:#333333;">June 30, 2022</span><span style="color:#333333;">,&#xa0;we had cash and cash equivalents of&#xa0;</span><span style="color:#333333;">$11.4</span><span style="color:#333333;"> million and current liabilities of&#xa0;</span><span style="color:#333333;">$5.3</span><span style="color:#333333;"> million. We believe that we have sufficient resources available to support our development activities and fund our business operations&#xa0;into the first quarter of 2023. However, we do not have sufficient cash and cash equivalents as of the date of this Quarterly Report on Form 10-Q to support our operations for at least the 12 months following the date that the financial statements are issued. These conditions raise substantial doubt about our ability to continue as a going concern through 12 months after the date that the financial statements are issued.</span></p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin: 0pt;">&#xa0;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin: 0pt;"><span style="color:#333333;">To alleviate the conditions that raise substantial doubt about our ability to continue as a going concern, management plans&#xa0;to secure additional capital, potentially through a combination of public or private securities&#xa0;offerings, convertible debt financings, and/or strategic transactions, including potential licensing arrangements, alliances, and drug product collaborations focused on specified geographic markets; however, none of these alternatives are committed at this time. There can be no assurance that we will be successful in obtaining sufficient funding on terms acceptable to us to fund continuing operations, if at all, or identify and enter into any strategic transactions that will provide the capital that we will require. Further, on June 3, 2022, we received a deficiency letter from the Nasdaq Stock Market LLC, or Nasdaq, notifying us that the closing bid price of our common stock had been below the minimum $1.00 per share for 30 consecutive business days, we are out of compliance with the&#xa0;requirements for continued listing on Nasdaq, and are subject to potential delisting.&#xa0;If we are unable to re-achieve compliance with the Nasdaq listing requirements within 180 days, or November 30, 2022, after receipt of a delisting notice,&#xa0;and if we are unable to obtain an extension therefore, we would be subject to delisting, which likely would further impair the liquidity and value of our common stock.&#xa0;The failure to obtain sufficient capital on acceptable terms when needed would have a material adverse effect on our business, results of operations, and financial condition.</span></p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin: 0pt; text-align: left;">&#xa0;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin: 0pt;"><span style="color:#333333;">The accompanying condensed consolidated financial statements have been prepared on a going concern basis, which contemplates the realization of assets and satisfaction of liabilities in the normal course of business, and do not include any adjustments relating to recoverability and classification of recorded asset amounts or the amounts and classification of liabilities that might be necessary should we be unable to continue as a going concern.</span></p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin: 0pt;">&#xa0;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin: 0pt; text-align: left;"><span style="color:#333333;"><b>Cash Flows</b></span></p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin: 0pt; text-align: left;">&#xa0;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin: 0pt; text-align: left;"><span style="color:#333333;">Cash flows for the </span><span style="color:#333333;">six months ended June 30, 2022</span><span style="color:#333333;">&#xa0;primarily consist&#xa0;of&#xa0;</span><span style="color:#333333;">$12.0</span><span style="color:#333333;"> million of&#xa0;</span><span style="color:#333333;">net cash used in operating activities</span><span style="color:#333333;">,&#xa0;</span><span style="color:#333333;">$0.2</span><span style="color:#333333;"> million of </span><span style="color:#333333;">net cash provided by investing activities</span><span style="color:#333333;">, and&#xa0;</span><span style="color:#333333;">$0.8</span><span style="color:#333333;"> million of&#xa0;</span><span style="color:#333333;">net cash provided by financing activities</span><span style="color:#333333;">.&#xa0;Cash flows for the </span><span style="color:#333333;">six months ended June 30, 2021</span><span style="color:#333333;">&#xa0;consist of&#xa0;</span><span style="color:#333333;">$13.5</span><span style="color:#333333;"> million of </span><span style="color:#333333;">net cash used in operating activities</span><span style="color:#333333;">&#xa0;and&#xa0;</span><span style="color:#333333;">$26.5</span><span style="color:#333333;"> million of&#xa0;</span><span style="color:#333333;">net cash provided by financing activities</span><span style="color:#333333;">.</span></p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin: 0pt; text-align: left;">&#xa0;</p>
  <div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
   <div class="PGFTR" style="text-align: center; width: 100%">
    <div class="hf-row">
     <div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">
       23
     </div>
    </div>
   </div>
   <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000" />
   <div class="PGHDR" style="text-align: left; width: 100%">
    <div class="hf-row">
     <div class="hf-cell TOCLink" style="display: inline-block; text-align: left;">
      <a href="#toc" style="font-weight: initial; font-style: initial; font-variant: initial; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif;">Table of Contents</a>
     </div>
    </div>
   </div>
  </div>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin: 0pt; text-align: left;">&#xa0;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin: 0pt; text-align: left;"><span style="color:#333333;"><i>Operating Activities</i></span></p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin: 0pt; text-align: left;">&#xa0;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin: 0pt; text-align: left;"><span style="color:#333333;">Net cash used in operating activities</span><span style="color:#333333;"> was </span><span style="color:#333333;">$12.0</span><span style="color:#333333;"> million for the </span><span style="color:#333333;">six months ended June 30, 2022</span><span style="color:#333333;"> and consisted primarily of (i) a net loss of </span><span style="color:#333333;">$25.5</span><span style="color:#333333;"> million;&#xa0;and (ii)&#xa0;an unrealized gain on foreign exchange rate changes of&#xa0;</span><span style="color:#333333;">$0.5</span><span style="color:#333333;"> million;&#xa0;partially offset by (iii) a non-cash loss on impairment of goodwill of </span><span style="color:#333333;">$11.6</span><span style="color:#333333;"> million;&#xa0;(iv)&#xa0;non-cash stock-based compensation of&#xa0;</span><span style="color:#333333;">$1.6</span><span style="color:#333333;"> million;&#xa0;(v)&#xa0;depreciation and amortization of&#xa0;</span><span style="color:#333333;">$0.5</span><span style="color:#333333;"> million;&#xa0;and (vi)&#xa0;non-cash lease expense of&#xa0;</span><span style="color:#333333;">$0.3</span><span style="color:#333333;"> million. Changes in prepaid expenses and other current assets, accounts payable, accrued expenses, and operating lease liabilities result from timing differences between the receipt and payment of cash and when the transactions are recognized in our results of operations.</span></p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin: 0pt; text-align: left;">&#xa0;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin: 0pt; text-align: left;"><span style="color:#333333;">Net cash used in operating activities</span><span style="color:#333333;"> was </span><span style="color:#333333;">$13.5</span><span style="color:#333333;"> million for the </span><span style="color:#333333;">six months ended June 30, 2021</span><span style="color:#333333;"> and consisted primarily of (i) a net loss of </span><span style="color:#333333;">$46.4</span><span style="color:#333333;">&#xa0;million;&#xa0;(ii) a non-cash deferred income tax benefit of </span><span style="color:#333333;">$8.3</span><span style="color:#333333;"> million; and (iii) changes in operating assets and liabilities of&#xa0;</span><span style="color:#333333;">$1.7</span><span style="color:#333333;"> million;&#xa0;partially offset by (iv)&#xa0;a non-cash loss on impairment of intangible assets of </span><span style="color:#333333;">$37.8</span><span style="color:#333333;"> million;&#xa0;(v)&#xa0;non-cash stock-based compensation of&#xa0;</span><span style="color:#333333;">$4.0</span><span style="color:#333333;"> million;&#xa0;(vi)&#xa0;non-cash expense related to equity consideration for a financial advisory service agreement of </span><span style="color:#333333;">$0.5</span><span style="color:#333333;"> million;&#xa0;(vii)&#xa0;non-cash lease expense of&#xa0;</span><span style="color:#333333;">$0.3</span><span style="color:#333333;"> million;&#xa0;(viii)&#xa0;an unrealized loss on foreign exchange rate changes of&#xa0;</span><span style="color:#333333;">$0.3</span><span style="color:#333333;">&#xa0;million;&#xa0;and (ix)&#xa0;depreciation and amortization of&#xa0;$0.1 million. Changes in prepaid expenses and other current assets, accounts payable, accrued expenses, and operating lease liabilities result from timing differences between the receipt and payment of cash and when the transactions are recognized in our results of operations.</span></p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin: 0pt; text-align: left;">&#xa0;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin: 0pt; text-align: left;"><span style="color:#333333;"><i>Investing Activities</i></span></p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin: 0pt; text-align: left;">&#xa0;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin: 0pt; text-align: left;"><span style="color:#333333;">Net cash provided by investing activities</span><span style="color:#333333;">&#xa0;was&#xa0;</span><span style="color:#333333;">$0.2</span><span style="color:#333333;"> million for the&#xa0;</span><span style="color:#333333;">six months ended June 30, 2022</span><span style="color:#333333;"> and primarily includes&#xa0;proceeds from sale of property and equipment related to the decommissioning and sale of certain&#xa0;manufacturing and laboratory equipment assets previously used for the KL4 surfactant platform.</span></p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin: 0pt; text-align: left;">&#xa0;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin: 0pt; text-align: left;"><span style="color:#333333;"><i>Financing Activities</i></span></p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin: 0pt; text-align: left;">&#xa0;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin: 0pt; text-align: left;"><span style="color:#333333;">Net cash provided by financing activities</span><span style="color:#333333;">&#xa0;for the </span><span style="color:#333333;">six months ended June 30, 2022</span><span style="color:#333333;"> was </span><span style="color:#333333;">$0.8</span><span style="color:#333333;"> million and includes (i)&#xa0;</span><span style="color:#333333;">$1.2</span><span style="color:#333333;">&#xa0;million in net proceeds from the ATM Program; partially offset by (ii)&#xa0;</span><span style="color:#333333;">$0.4</span><span style="color:#333333;">&#xa0;million of principal payments on loans payable.</span></p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin: 0pt; text-align: left;">&#xa0;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin: 0pt; text-align: left;"><span style="color:#333333;">Net cash provided by financing activities</span><span style="color:#333333;">&#xa0;for the </span><span style="color:#333333;">six months ended June 30, 2021</span><span style="color:#333333;"> was </span><span style="color:#333333;">$26.5</span><span style="color:#333333;"> million&#xa0;and includes (i)&#xa0;$27.4&#xa0;million in net proceeds from the March 2021 public offering;&#xa0;(ii)&#xa0;$1.7 million in net proceeds from the ATM Program;&#xa0;and (iii) </span><span style="color:#333333;">$0.4</span><span style="color:#333333;">&#xa0;million in proceeds from our research and development&#xa0;funding arrangement with Lee&#x2019;s (HK);&#xa0;partially offset by (iv)&#xa0;</span><span style="color:#333333;">$3.0</span><span style="color:#333333;"> million of principal payments on loans payable.</span></p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin: 0pt; text-align: left;">&#xa0;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin: 0pt; text-align: left;"><span style="color:#333333;">The following sections provide a more detailed discussion of our available financing facilities.</span></p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin: 0pt; text-align: left;">&#xa0;</p>
  <div style="font-family:'Times New Roman', Times, serif">
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;"><span style="color:#333333;"><span style="text-decoration: underline; ">Loan Payable to Bank Direct Capital Finance</span></span></p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"><span style="color:#333333;">In June 2022, we entered into an insurance premium financing and security agreement with Bank Direct. Under the agreement, we financed&#xa0;</span><span style="color:#333333;">$1.1</span><span style="color:#333333;">&#xa0;million of certain premiums at a&#xa0;</span><span style="color:#333333;">3.90%</span><span style="color:#333333;">&#xa0;annual interest rate. Payments of approximately&#xa0;</span><span style="color:#333333;">$126,000</span><span style="color:#333333;">&#xa0;are due monthly from July 2022 through March 2023.&#xa0;As of&#xa0;</span><span style="color:#333333;">June 30, 2022</span><span style="color:#333333;">, the outstanding principal of the loan was&#xa0;</span><span style="color:#333333;">$1.0</span><span style="color:#333333;"> million.</span></p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin: 0pt; text-align: left;"><span style="color:#333333;">In June 2021, we entered into an insurance premium financing and security agreement with Bank Direct. Under the agreement, we financed&#xa0;</span><span style="color:#333333;">$1.3</span><span style="color:#333333;"> million of certain premiums at a&#xa0;</span><span style="color:#333333;">3.37%</span><span style="color:#333333;"> annual interest rate. Payments of approximately&#xa0;</span><span style="color:#333333;">$147,000</span><span style="color:#333333;"> are due monthly from July 2021 through March 2022.&#xa0;As of&#xa0;</span><span style="color:#333333;">December 31, 2021</span><span style="color:#333333;">, the outstanding principal of the loan was $0.3&#xa0;million.&#xa0;The balance of the loan was repaid during the first quarter of 2022.</span></p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin: 0pt; text-align: left;">&#xa0;</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin: 0pt; text-align: left;"><span style="color:#333333;"><span style="text-decoration: underline; ">Common Stock Offerings</span></span></p>
  </div>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin: 0pt; text-align: left;">&#xa0;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin: 0pt; text-align: left;"><span style="color:#333333;">Historically, we have funded, and expect that we will continue to fund, our business operations through various sources, including financings in the form of common stock offerings.</span></p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">&#xa0;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin: 0pt; text-align: left;"><span style="color:#333333;"><span style="text-decoration: underline; ">At-The-Market Program</span></span></p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin: 0pt; text-align: left;">&#xa0;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin: 0pt; text-align: left;"><span style="color:#333333;">On September 17, 2020, we entered into an At-The-Market Offering Agreement&#xa0;with Ladenburg, pursuant to which we may offer and sell, from time to time at our sole discretion, up to a maximum of </span><span style="color:#333333;">$10.0</span><span style="color:#333333;">&#xa0;million of shares of our common stock through Ladenburg as agent and/or principal under the ATM Program. When we issue sales notices to Ladenburg, we designate the maximum amount of&#xa0;shares to be sold by Ladenburg daily and the minimum price per share at which shares may be sold. Ladenburg may sell shares by any method permitted by law deemed to be an &#x201c;at-the-market offering&#x201d; as defined in Rule 415(a)(4) under the Securities Act of 1933, as amended, or in privately negotiated transactions.</span></p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin: 0pt; text-align: left;">&#xa0;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin: 0pt; text-align: left;"><span style="color:#333333;">For the&#xa0;</span><span style="color:#333333;">six months ended June 30, 2022</span><span style="color:#333333;">, we sold&#xa0;</span><span style="color:#333333;">1,137,246</span><span style="color:#333333;">&#xa0;shares&#xa0;of our common stock under the ATM Program&#xa0;resulting in aggregate gross proceeds to us of approximately&#xa0;</span><span style="color:#333333;">$1.3</span><span style="color:#333333;">&#xa0;million and net proceeds of approximately&#xa0;</span><span style="color:#333333;">$1.2</span><span style="color:#333333;">&#xa0;million. For the&#xa0;</span><span style="color:#333333;">six months ended June 30, 2021</span><span style="color:#333333;">, we sold&#xa0;</span><span style="color:#333333;">552,474</span><span style="color:#333333;"> shares of&#xa0;our common stock under the ATM Program&#xa0;resulting in aggregate gross and net proceeds to us of approximately&#xa0;</span><span style="color:#333333;">$1.7</span><span style="color:#333333;"> million&#xa0;(<i>see</i>,&#xa0;</span><span style="color:#333333;">Note 8 &#x2013; Stockholders&#x2019; Equity</span><span style="color:#333333;">).</span></p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin: 0pt; text-align: left;">&#xa0;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin: 0pt; text-align: left;"><span style="color:#333333;">During July and August 2022,&#xa0;we sold&#xa0;</span><span style="color:#333333;">1,221,706</span><span style="color:#333333;"> shares of our common stock under the ATM Program&#xa0;resulting in aggregate gross and net proceeds to us of approximately&#xa0;</span><span style="color:#333333;">$0.6</span><span style="color:#333333;"> million.</span></p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin: 0pt; text-align: left;">&#xa0;</p>
  <div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
   <div class="PGFTR" style="text-align: center; width: 100%">
    <div class="hf-row">
     <div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">
       24
     </div>
    </div>
   </div>
   <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000" />
   <div class="PGHDR" style="text-align: left; width: 100%">
    <div class="hf-row">
     <div class="hf-cell TOCLink" style="display: inline-block; text-align: left;">
      <a href="#toc" style="font-weight: initial; font-style: initial; font-variant: initial; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif;">Table of Contents</a>
     </div>
    </div>
   </div>
  </div>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin: 0pt; text-align: left;">&#xa0;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin: 0pt; text-align: left;"><span style="color:#333333;">The shares of common stock issued and sold under the ATM Program are registered under our Registration Statement on Form S-3 (File No. 333-248874), which was declared effective by the SEC on September 29, 2020. As of </span><span style="color:#333333;">August 11, 2022</span><span style="color:#333333;">, approximately&#xa0;</span><span style="color:#333333;">$3.2</span><span style="color:#333333;"> million remains&#xa0;available under the ATM Program.&#xa0;However, we are currently subject to the limitations contained in General Instruction I.B.6 of Form S-3. As a result, we are limited in selling no more than one-third of our public float during any 12-month period. If our public float increases to $75 million or more, we will no longer be subject to such limitations.</span></p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin: 0pt; text-align: left;">&#xa0;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin: 0pt; text-align: left;"><span style="color:#333333;"><span style="text-decoration: underline; ">March 2021 Public Offering</span></span></p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin: 0pt; text-align: left;">&#xa0;</p>
  <div style="font-size:10pt">
   <div style="font-family:&quot;Times New Roman&quot;">
    <span style="color:#333333;">On March 23, 2021, we entered into an underwriting agreement with Oppenheimer &amp; Co. Inc. as representative for the several underwriters named therein, relating to a public offering, or the March 2021 Offering, of an aggregate of </span>
    <span style="color:#333333;">9,230,500</span>
    <span style="color:#333333;">&#xa0;units with each unit consisting of one share of common stock and a warrant, or the March 2021 Warrants. The March 2021 Warrants are immediately exercisable for shares of common stock at a price of </span>
    <span style="color:#333333;">$3.60</span>
    <span style="color:#333333;"> per share and expire five years from the date of issuance. The shares of common stock and the March 2021 Warrants were immediately separable and were issued separately in the March 2021 Offering.</span>
   </div>
  </div>
  <div style="font-size:10pt">
   <div style="font-family:&quot;Times New Roman&quot;">
     &#xa0;
   </div>
  </div>
  <p style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin: 0px;"><span style="color:#333333;">The closing of the March 2021 Offering occurred on March 25, 2021. The offering price to the public was </span><span style="color:#333333;">$3.25</span><span style="color:#333333;">&#xa0;per unit resulting in gross proceeds to us of&#xa0;</span><span style="color:#333333;">$30.0</span><span style="color:#333333;"> million. After deducting underwriting discounts and commissions and estimated offering expenses payable by us, and excluding the proceeds, if any, from the exercise of the March 2021 Warrants issued pursuant to the March 2021 Offering, the net proceeds to us were approximately </span><span style="color:#333333;">$27.4</span><span style="color:#333333;"> million.</span></p>
  <p style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin: 0px;">&#xa0;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin: 0pt; text-align: left;"><span style="color:#333333;"><b>Off-Balance Sheet Arrangements</b></span></p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin: 0pt; text-align: left;">&#xa0;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin: 0pt; text-align: left;"><span style="color:#333333;">We did not have any material off-balance sheet arrangements at </span><span style="color:#333333;">June 30, 2022 and 2021</span><span style="color:#333333;"> or during the periods then ended.</span></p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin: 0pt; text-align: left;">&#xa0;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin: 0pt; text-align: left; text-transform: uppercase;"><span style="color:#333333;"><b><a id="Item3_QQ" title="Item3_QQ" href="#"></a>ITEM 3.&#xa0;&#xa0;&#xa0;&#xa0;&#xa0; QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK</b></span></p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin: 0pt; text-align: left;">&#xa0;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin: 0pt; text-align: left;"><span style="color:#333333;">Not applicable.</span></p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin: 0pt; text-align: left; text-transform: uppercase;">&#xa0;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin: 0pt; text-align: left; text-transform: uppercase;"><span style="color:#333333;"><b><a id="Item4_Controls" title="Item4_Controls" href="#"></a>Item 4.&#xa0; &#xa0; &#xa0; Controls and Procedures </b></span></p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin: 0pt; text-align: left;">&#xa0;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin: 0pt; text-align: left;"><span style="color:#333333;"><b>Evaluation of disclosure controls and procedures&#xa0;</b></span></p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin: 0pt; text-align: left;">&#xa0;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin: 0pt; text-align: left;"><span style="color:#333333;">Our management, including our President and Chief Executive Officer (principal executive officer) and our Senior Vice President and Chief Financial Officer and Treasurer (principal financial and accounting officer), do&#xa0;not expect that our disclosure controls or our internal control over financial reporting will prevent all error and all fraud. Because of the inherent limitations in all control systems, no evaluation of controls can provide absolute assurance that all control issues and instances of fraud, if any, have been detected. These inherent limitations include the realities that judgments in decision-making can be faulty and that breakdowns can occur because of simple error or mistake. Controls can also be circumvented by the individual acts of some persons, by collusion of two or more people, or by management override of the controls. The design of any system of controls is based in part on certain assumptions about the likelihood of future events, and there can be no assurance that any design will succeed in achieving its stated goals under all potential future conditions. Over time, controls may become inadequate because of changes in conditions or deterioration in the degree of compliance with policies or procedures. Because of the inherent limitations in a cost-effective control system, misstatements due to error or fraud may occur and not be detected. In designing and evaluating the disclosure controls and procedures, our management recognized that any controls and procedures, no matter how well designed and operated, can provide only reasonable assurance of achieving the desired control objectives and our management necessarily was required to apply its judgment in evaluating the cost-benefit relationship of possible controls and procedures.</span></p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin: 0pt; text-align: left;">&#xa0;</p>
  <div style="font-family:'Times New Roman', Times, serif">
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin: 0pt; text-align: left;"><span style="color:#333333;">Our President and Chief Executive Officer and our Senior Vice President and Chief Financial Officer and Treasurer have evaluated the effectiveness of the design and operation of our disclosure controls and procedures (as defined in Rule 13a-15(e) and Rule 15d-15(e) of the Exchange Act) as of the end of the period covered by this Quarterly Report on Form 10-Q. Based on this evaluation, our President and Chief Executive Officer and our Senior Vice President and Chief Financial Officer and Treasurer concluded&#xa0;that, as of the end of the period covered by this report, our disclosure controls and procedures were effective to ensure that information required to be disclosed by us in the reports that we file or submit under the Exchange Act is accumulated and communicated to our management, including our President and Chief Executive Officer and our Senior Vice President and Chief Financial Officer and Treasurer, to allow for timely decisions regarding required disclosures, and recorded, processed, summarized, and reported within the time periods specified in the SEC&#x2019;s rules and forms.</span></p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin: 0pt; text-align: left;">&#xa0;</p>
  </div>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin: 0pt; text-align: left;"><span style="color:#333333;"><b>Changes in internal control</b></span></p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin: 0pt; text-align: left;">&#xa0;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin: 0pt; text-align: left;"><span style="color:#333333;">There were no changes in our internal control over financial reporting identified in connection with the evaluation described above that occurred during the quarter ended </span><span style="color:#333333;">June 30, 2022</span><span style="color:#333333;"> that has materially affected, or is reasonably likely to materially affect, our internal control over financial reporting.</span></p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin: 0pt; text-align: left;">&#xa0;</p>
  <div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
   <div class="PGFTR" style="text-align: center; width: 100%">
    <div class="hf-row">
     <div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">
       25
     </div>
    </div>
   </div>
   <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000" />
   <div class="PGHDR" style="text-align: left; width: 100%">
    <div class="hf-row">
     <div class="hf-cell TOCLink" style="display: inline-block; text-align: left;">
      <a href="#toc" style="font-weight: initial; font-style: initial; font-variant: initial; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif;">Table of Contents</a>
     </div>
    </div>
   </div>
  </div>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin: 0pt; text-align: left;">&#xa0;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin: 0pt; text-align: center;"><span style="color:#333333;"><b>PART II &#x2013; OTHER INFORMATION</b></span></p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin: 0pt; text-align: left;">&#xa0;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin: 0pt; text-align: left;"><span style="color:#333333;"><b><a id="legal" title="legal" href="#"></a>ITEM 1.&#xa0; &#xa0; &#xa0; LEGAL PROCEEDINGS</b></span></p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin: 0pt; text-align: left;">&#xa0;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin: 0pt; text-align: left;"><span style="color:#333333;">We are not aware of any pending legal actions that would, if determined adversely to us, have a material adverse effect on our business and operations.</span></p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin: 0pt; text-align: left;">&#xa0;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin: 0pt; text-align: left;"><span style="color:#333333;">We have from time to time been involved in disputes and proceedings arising in the ordinary course of business, including in connection with the conduct of our clinical trials. In addition, as a public company, we are also potentially susceptible to litigation, such as claims asserting violations of securities laws. Any such claims, with or without merit, if not resolved, could be time-consuming and result in costly litigation. There can be no assurance that an adverse result in any future proceeding would not have a potentially material adverse effect on our business, results of operations and financial condition.</span></p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin: 0pt; text-align: left;">&#xa0;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin: 0pt; text-align: left;"><span style="color:#333333;"><b><a id="risk" title="risk" href="#"></a>ITEM 1A.&#xa0; &#xa0; &#xa0; RISK FACTORS</b></span></p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin: 0pt; text-align: left;">&#xa0;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin: 0pt; text-align: left;"><span style="color:#333333;">Investing in our securities involves certain risks. In addition to any risks and uncertainties described elsewhere in this Quarterly Report&#xa0;on Form 10-Q, investors should carefully consider the risks and&#xa0;</span><span style="color:#333333;">uncertainties discussed in Part I, Item 1A. "Risk Factors" in our Annual Report on Form 10-K for the year ended December 31, 2021, as supplemented by risk factors included in our Quarterly Report on Form 10-Q filed thereafter.</span><span style="color:#333333;">&#xa0;These risks are not the only risks that could materialize. Other than as set forth below, there have been no material changes in our risk factors from those </span><span style="color:#333333;">previously disclosed in our Annual Report on Form 10-K for the year ended December 31, 2021 or our Quarterly Report on Form 10-Q filed thereafter.</span><span style="color:#333333;"> Additional risks and uncertainties not presently known to us or that we currently consider to be immaterial may also impair our business operations and development activities.&#xa0;Should any of the risks and uncertainties described in our Annual Report on Form 10-K for the year ended December 31, 2021, as supplemented by our subsequent filings with the SEC,&#xa0;actually materialize,&#xa0;our business, financial condition, and/or results of operations could be materially adversely affected, the trading price of our common stock could decline, and an investor could lose all or part of his or her investment. In particular, the reader&#x2019;s attention is drawn to the discussion in <i>Part I, Item 2 &#x2013; Management&#x2019;s Discussion and Analysis of Financial Condition and Results of Operations &#x2013; Liquidity and Capital Resources</i>.</span></p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin: 0pt; text-align: left;">&#xa0;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin: 0pt; text-align: left;"><span style="color:#333333;"><i><b>Our common stock is listed on the Nasdaq Capital Market. We can provide no assurance that we will be able to comply with the continued listing requirements over time and that our common stock will continue to be listed on the Nasdaq Capital Market. </b></i></span></p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin: 0pt; text-align: left;">&#xa0;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin: 0pt; text-align: left;"><span style="color:#333333;">On June 3, 2022, we received a deficiency letter from the Nasdaq Listing Qualifications Department, or the Staff, of Nasdaq notifying us that, for the last 30 consecutive business days, the closing bid price for our common stock has been below the minimum $1.00 per share required for continued listing on the Nasdaq Capital Market pursuant to Nasdaq Listing Rule 5550(a)(2), or Rule 5550(a)(2). The Nasdaq deficiency letter has no immediate effect on the listing of our&#xa0;common stock, and our&#xa0;common stock will continue to trade on the Nasdaq Capital Market under the symbol &#x201c;WINT&#x201d; at this time. We have been given 180 calendar days, or until November 30, 2022, to regain compliance with Rule 5550(a)(2).&#xa0;If at any time before November 30, 2022, the bid price of our common stock closes at $1.00 per share or more for a minimum of 10 consecutive business days, the Staff will provide written confirmation that we have achieved compliance.&#xa0;If we&#xa0;do&#xa0;not regain compliance with Rule 5550(a)(2) by November 30, 2022, we may be afforded a second 180 calendar day period to regain compliance, if we meet certain other conditions.&#xa0;If we fail to maintain compliance, Nasdaq may take steps to de-list our common stock. If such delisting should occur, it would likely have a negative effect on the price of our common stock and would impair an investor&#x2019;s ability to sell or purchase our common stock when desired. In the event of a delisting, we can provide no assurance that any action taken by us to restore compliance with listing requirements would allow our common stock to become listed again, stabilize the market price or improve the liquidity of our common stock, prevent our common stock from dropping below the Nasdaq minimum bid price requirement, or prevent future non-compliance with Nasdaq&#x2019;s listing requirements.</span></p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin: 0pt; text-align: left;">&#xa0;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin: 0pt; text-align: left;"><span style="color:#333333;"><i><b>We have a significant amount of intangible assets, including goodwill, recorded on our condensed consolidated balance sheets which may lead to potentially significant impairment charges.</b></i></span></p>
  <div style="font-family:'Times New Roman', Times, serif">
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin: 0pt; text-align: left;">&#xa0;</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin: 0pt; text-align: left;"><span style="color:#333333;">We have recorded significant goodwill and intangible assets on our condensed consolidated balance sheets as a result of a previous acquisition, which could become impaired and lead to material charges in the future. The amount of identifiable intangible assets and goodwill in our condensed consolidated balance sheets is significant due to the acquisition of CVie Therapeutics Ltd., or CVie Therapeutics, in December 2018. The identifiable intangible assets resulting from the CVie Therapeutics acquisition relate to in-process research and development, or IPR&amp;D, of istaroxime and rostafuroxin, which, as of </span><span style="color:#333333;">June 30, 2022</span><span style="color:#333333;">, are&#xa0;</span><span style="color:#333333;">$22.3</span><span style="color:#333333;"> million and&#xa0;</span><span style="color:#333333;">$9.7</span><span style="color:#333333;"> million, respectively, recorded in aggregate on our condensed consolidated balance sheets as intangible assets of&#xa0;</span><span style="color:#333333;">$32.1</span><span style="color:#333333;"> million. At </span><span style="color:#333333;">June 30, 2022</span><span style="color:#333333;">, goodwill recorded on our condensed consolidated balance sheets was&#xa0;</span><span style="color:#333333;">$4.0</span><span style="color:#333333;"> million.</span></p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin: 0pt; text-align: left;">&#xa0;</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin: 0pt; text-align: left;"><span style="color:#333333;">Throughout the year, we consider whether any events or changes in the business environment have occurred which indicate that intangible assets or goodwill may be impaired. If an impairment exists, we would be required to take an impairment charge with respect to the impaired asset. Events giving rise to impairment are difficult to predict, including the uncertainties associated with the development of product candidates and the success of business development activities, and are an inherent risk in the pharmaceutical industry.</span></p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin: 0pt; text-align: left;">&#xa0;</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin: 0pt; text-align: left;"><span style="color:#333333;">We have experienced a declining trend in the&#xa0;closing share price of our common stock following the announcement in April 2022 of positive topline results in our Phase 2 global clinical study of istaroxime for the treatment of early cardiogenic shock due to, we believe, both market conditions and our need to secure additional capital in the near term to advance our development programs.</span></p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin: 0pt; text-align: left;">&#xa0;</p>
   <div class="PGBK" style="width:100%">
    <div class="PGFTR" style="text-align:center; width:100%">
     <div class="hf-row">
      <div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: &quot;Times New Roman&quot;;">
        26
      </div>
     </div>
    </div>
    <hr style="PAGE-BREAK-AFTER:always; border:none; width:100%; height:2px; color:#000000; background-color:#000000" />
    <div class="PGHDR" style="text-align:left; width:100%">
     <div class="hf-row">
      <div class="hf-cell TOCLink" style="text-align: left; display: inline-block;">
       <a href="#toc" style="font-weight: initial; font-style: initial; font-variant: initial; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif;">Table of Contents</a>
      </div>
     </div>
    </div>
   </div>
   <p style="margin: 0pt; font-size: 10pt;">&#xa0;</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin: 0pt; text-align: left;"><span style="color:#333333;">During the second quarter of 2022, the continued declining trend in the closing share price of our common stock suggested that the fair value of our reporting unit was more likely than not less than its carrying value.&#xa0;As a result, we&#xa0;performed the required interim goodwill impairment test consistent with the methodology that we use when performing our annual goodwill impairment assessment, including the use of the quoted market price and related market capitalization of our common stock, adjusted for an estimated control premium based on transactions completed by comparable companies.&#xa0;Based on the quantitative test performed, we recorded a loss on impairment of goodwill of&#xa0;</span><span style="color:#333333;">$11.6</span><span style="color:#333333;"> million, recognized within operating expenses in our condensed consolidated statements of operations&#xa0;for the&#xa0;three&#xa0;and&#xa0;six&#xa0;months ended&#xa0;June 30, 2022.</span></p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin: 0pt; text-align: left;">&#xa0;</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin: 0pt; text-align: left;"><span style="color:#333333;">The closing share price of our common stock has continued to decline during July and August 2022. If our share price continues to decline during the remainder of the third quarter of 2022, we may be at risk for future impairment to goodwill in the near term.</span></p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin: 0pt; text-align: left;">&#xa0;</p>
  </div>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin: 0pt; text-align: left;"><span style="color:#333333;"><b><a id="unreg" title="unreg" href="#"></a>ITEM 2.&#xa0; &#xa0; &#xa0; UNREGISTERED SALES OF EQUITY SECURITIES AND USE OF PROCEEDS</b></span></p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin: 0pt; text-align: left;">&#xa0;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;"><span style="color:#333333;">None.</span></p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">&#xa0;</p>
  <p style="margin: 0pt; font-size: 10pt;"><span style="color:#333333;"><span style="font-size: 10pt;"><b style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"><a id="default" title="default" href="#"></a>ITEM 3.&#xa0; &#xa0; &#xa0; DEFAULTS UPON SENIOR SECURITIES</b></span></span></p>
  <p style="margin: 0pt; font-size: 10pt;">&#xa0;</p>
  <div style="font-size:10pt">
   <div style="font-family:Times New Roman">
    <span style="color:#333333;"><span style="font-size: 10pt;"><span style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">None.</span></span></span>
   </div>
   <div style="font-family:Times New Roman">
     &#xa0;
   </div>
  </div>
  <p style="margin: 0pt; font-size: 10pt;"><span style="color:#333333;"><span style="font-size: 10pt;"><b><a id="mine" title="mine" href="#"></a>ITEM 4.&#xa0; &#xa0; &#xa0; MINE SAFETY DISCLOSURES</b></span></span></p>
  <p style="margin: 0pt; font-size: 10pt;">&#xa0;</p>
  <p style="margin: 0pt; font-size: 10pt;"><span style="color:#333333;"><span style="font-size: 10pt;">Not applicable.</span></span></p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin: 0pt; text-align: left;">&#xa0;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin: 0pt; text-align: left;"><span style="color:#333333;"><span style="font-size: 10pt;"><span style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"><b><a id="other" title="other" href="#"></a>ITEM 5.&#xa0; &#xa0; &#xa0; OTHER INFORMATION</b></span></span></span></p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin: 0pt; text-align: left;">&#xa0;</p>
  <p style="font-size: 10pt; margin: 0pt; font-family: &quot;Times New Roman&quot;;"><span style="color:#333333;"><span style="font-size: 10pt;"><span style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">None.</span></span></span></p>
  <p style="font-size: 10pt; margin: 0pt; font-family: Times New Roman;">&#xa0;</p>
  <div class="PGBK" style="width:100%">
   <div class="PGFTR" style="text-align:center; width:100%">
    <div class="hf-row">
     <div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: &quot;Times New Roman&quot;;">
       27
     </div>
    </div>
   </div>
   <hr style="PAGE-BREAK-AFTER:always; border:none; width:100%; height:2px; color:#000000; background-color:#000000" />
   <div class="PGHDR" style="text-align:left; width:100%">
    <div class="hf-row">
     <div class="hf-cell TOCLink" style="text-align: left; display: inline-block;">
      <a href="#toc" style="font-weight: initial; font-style: initial; font-variant: initial; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif;">Table of Contents</a>
     </div>
    </div>
   </div>
  </div>
  <p style="margin: 0pt;">&#xa0;</p>
  <p style="font-family: Times New Roman; margin: 0pt; font-size: 10pt;"><span style="color:#333333;"><span style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"><b><a id="exs" title="exs" href="#"></a>ITEM 6.&#xa0; &#xa0; &#xa0; EXHIBITS</b></span></span></p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin: 0pt; text-align: left;">&#xa0;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin: 0pt; text-align: left;"><span style="color:#333333;">Exhibits are listed on the Index to Exhibits at the end of this Quarterly Report on Form 10-Q. The exhibits required by Item 601 of Regulation S-K, listed on such Index in response to this Item, are incorporated herein by reference.</span></p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin: 0pt; text-align: left;">&#xa0;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin: 0pt; text-align: center;"><span style="color:#333333;"><b>INDEX TO EXHIBITS</b></span></p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin: 0pt; text-align: left;">&#xa0;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin: 0pt; text-align: left;"><span style="color:#333333;">The following exhibits are included with this Quarterly Report on Form 10-Q.</span></p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin: 0pt; text-align: left;">&#xa0;</p>
  <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">
   <tbody>
    <tr style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">
     <td style="vertical-align: top; width: 8%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin: 0pt; text-align: left;"><span style="text-decoration: underline; ">Exhibit</span></p> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin: 0pt; text-align: left;"><span style="text-decoration: underline; ">No.</span></p> </td>
     <td style="vertical-align: top; width: 44%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin: 0pt; text-align: left;"><span style="text-decoration: underline; ">Description</span></p> </td>
     <td style="vertical-align: top; width: 8%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin: 0pt; text-align: left;">&#xa0;</p> </td>
     <td style="vertical-align: top; width: 40%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin: 0pt; text-align: left; text-indent: 9pt;"><span style="text-decoration: underline; ">Method of Filing</span></p> </td>
    </tr>

    <tr style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">
     <td style="vertical-align: top; width: 8%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin: 0pt; text-align: left;">&#xa0;</p> </td>
     <td style="vertical-align: top; width: 44%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin: 0pt; text-align: left;">&#xa0;</p> </td>
     <td style="vertical-align: top; width: 8%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin: 0pt; text-align: left;">&#xa0;</p> </td>
     <td style="vertical-align: top; width: 40%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin: 0pt; text-align: left;">&#xa0;</p> </td>
    </tr>

    <tr>
     <td style="vertical-align: top; width: 8%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">3.1</td>
     <td style="vertical-align: top; width: 44%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"><a href="ex_409319.htm" style="-sec-extract:exhibit;">Amended and Restated By-laws of Windtree Therapeutics, Inc., as amended.</a></td>
     <td style="vertical-align: top; width: 8%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td>
     <td style="vertical-align: top; width: 40%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; text-indent: 9pt;">Filed herewith.</td>
    </tr>

    <tr>
     <td style="vertical-align: top; width: 8%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td>
     <td style="vertical-align: top; width: 44%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td>
     <td style="vertical-align: top; width: 8%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td>
     <td style="vertical-align: top; width: 40%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td>
    </tr>

    <tr style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">
     <td style="vertical-align: top; width: 8%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin: 0pt; text-align: left;">31.1</p> </td>
     <td style="vertical-align: top; width: 44%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin: 0pt; text-align: left;"><a href="ex_378191.htm" style="-sec-extract:exhibit;">Certification of Chief Executive Officer pursuant to Rule 13a-14(a) of the Exchange Act.</a></p> </td>
     <td style="vertical-align: top; width: 8%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin: 0pt; text-align: left;">&#xa0;</p> </td>
     <td style="vertical-align: top; width: 40%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin: 0pt; text-align: left; text-indent: 9pt;">Filed herewith.</p> </td>
    </tr>

    <tr style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">
     <td style="vertical-align: top; width: 8%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin: 0pt; text-align: left;">&#xa0;</p> </td>
     <td style="vertical-align: top; width: 44%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin: 0pt; text-align: left;">&#xa0;</p> </td>
     <td style="vertical-align: top; width: 8%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin: 0pt; text-align: left;">&#xa0;</p> </td>
     <td style="vertical-align: top; width: 40%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin: 0pt; text-align: left;">&#xa0;</p> </td>
    </tr>

    <tr style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">
     <td style="vertical-align: top; width: 8%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin: 0pt; text-align: left;">31.2</p> </td>
     <td style="vertical-align: top; width: 44%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin: 0pt; text-align: left;"><a href="ex_378192.htm" style="-sec-extract:exhibit;">Certification of Chief Financial Officer pursuant to Rule 13a-14(a) of the Exchange Act.</a></p> </td>
     <td style="vertical-align: top; width: 8%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin: 0pt; text-align: left;">&#xa0;</p> </td>
     <td style="vertical-align: top; width: 40%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin: 0pt; text-align: left; text-indent: 9pt;">Filed herewith.</p> </td>
    </tr>

    <tr style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">
     <td style="vertical-align: top; width: 8%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin: 0pt; text-align: left;">&#xa0;</p> </td>
     <td style="vertical-align: top; width: 44%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin: 0pt; text-align: left;">&#xa0;</p> </td>
     <td style="vertical-align: top; width: 8%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin: 0pt; text-align: left;">&#xa0;</p> </td>
     <td style="vertical-align: top; width: 40%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin: 0pt; text-align: left;">&#xa0;</p> </td>
    </tr>

    <tr style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">
     <td style="vertical-align: top; width: 8%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin: 0pt; text-align: left;">32.1</p> </td>
     <td style="vertical-align: top; width: 44%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin: 0pt; text-align: left;"><a href="ex_378193.htm" style="-sec-extract:exhibit;">Certification of Chief Executive Officer and Chief Financial Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.</a></p> </td>
     <td style="vertical-align: top; width: 8%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin: 0pt; text-align: left;">&#xa0;</p> </td>
     <td style="vertical-align: top; width: 40%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin: 0pt; text-align: left; text-indent: 9pt;">Furnished herewith.</p> </td>
    </tr>

   </tbody>
  </table>
  <p style="margin: 0pt;">&#xa0;</p>
  <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">
   <tbody>
    <tr>
     <td style="vertical-align: top; width: 8%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="margin: 0pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">101.1</p> </td>
     <td style="vertical-align: top; width: 44%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">The following condensed consolidated financial statements from Windtree Therapeutics, Inc. Quarterly Report on Form 10-Q for the quarter ended June 30, 2022, formatted in Inline Extensive Business Reporting Language (XBRL): (i) Balance Sheets as of June 30, 2022&#xa0;(unaudited) and December 31, 2021, (ii) Statements of Operations (unaudited) for the three and six months ended June 30, 2022 and June 30, 2021, (iii) Statements of Cash Flows (unaudited) for the six months ended June 30, 2022 and June 30, 2021, and (iv) Notes to Condensed Consolidated Financial Statements.</td>
     <td style="vertical-align: top; width: 8%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td>
     <td style="vertical-align: top; width: 40%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td>
    </tr>

   </tbody>
  </table>
  <p style="margin: 0pt;">&#xa0;</p>
  <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">
   <tbody>
    <tr>
     <td style="vertical-align: top; width: 8%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-size: 10pt; margin: 0px; font-family: &quot;Times New Roman&quot;;"><span style="color:#333333;">101.INS</span></p> </td>
     <td style="vertical-align: top; width: 44%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-size: 10pt; margin: 0px; font-family: &quot;Times New Roman&quot;;"><span style="color:#333333;">Inline XBRL Instance Document (the Instance Document does not appear in the Interactive Data File because its&#xa0;XBRL&#xa0;tags are embedded within the Inline XBRL document) (1).</span></p> </td>
     <td style="vertical-align: top; width: 8%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-size: 10pt; margin: 0px; font-family: &quot;Times New Roman&quot;;">&#xa0;</p> </td>
     <td style="vertical-align: top; width: 40%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-size: 10pt; margin: 0px; text-indent: 9pt; font-family: &quot;Times New Roman&quot;;"><span style="color:#333333;">Filed herewith.</span></p> </td>
    </tr>

    <tr>
     <td style="vertical-align: top; width: 8%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-size: 10pt; margin: 0px; font-family: &quot;Times New Roman&quot;;">&#xa0;</p> </td>
     <td style="vertical-align: top; width: 44%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-size: 10pt; margin: 0px; font-family: &quot;Times New Roman&quot;;">&#xa0;</p> </td>
     <td style="vertical-align: top; width: 8%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-size: 10pt; margin: 0px; font-family: &quot;Times New Roman&quot;;">&#xa0;</p> </td>
     <td style="vertical-align: top; width: 40%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-size: 10pt; margin: 0px; font-family: &quot;Times New Roman&quot;;">&#xa0;</p> </td>
    </tr>

    <tr>
     <td style="vertical-align: top; width: 8%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-size: 10pt; margin: 0px; font-family: &quot;Times New Roman&quot;;"><span style="color:#333333;">101.SCH</span></p> </td>
     <td style="vertical-align: top; width: 44%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-size: 10pt; margin: 0px; font-family: &quot;Times New Roman&quot;;"><span style="color:#333333;">Inline XBRL Taxonomy Extension Schema Document (1).</span></p> </td>
     <td style="vertical-align: top; width: 8%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-size: 10pt; margin: 0px; font-family: &quot;Times New Roman&quot;;">&#xa0;</p> </td>
     <td style="vertical-align: top; width: 40%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-size: 10pt; margin: 0px; text-indent: 9pt; font-family: &quot;Times New Roman&quot;;"><span style="color:#333333;">Filed herewith.</span></p> </td>
    </tr>

    <tr>
     <td style="vertical-align: top; width: 8%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-size: 10pt; margin: 0px; font-family: &quot;Times New Roman&quot;;">&#xa0;</p> </td>
     <td style="vertical-align: top; width: 44%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-size: 10pt; margin: 0px; font-family: &quot;Times New Roman&quot;;">&#xa0;</p> </td>
     <td style="vertical-align: top; width: 8%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-size: 10pt; margin: 0px; font-family: &quot;Times New Roman&quot;;">&#xa0;</p> </td>
     <td style="vertical-align: top; width: 40%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-size: 10pt; margin: 0px; font-family: &quot;Times New Roman&quot;;">&#xa0;</p> </td>
    </tr>

    <tr>
     <td style="vertical-align: top; width: 8%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-size: 10pt; margin: 0px; font-family: &quot;Times New Roman&quot;;"><span style="color:#333333;">101.CAL</span></p> </td>
     <td style="vertical-align: top; width: 44%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-size: 10pt; margin: 0px; font-family: &quot;Times New Roman&quot;;"><span style="color:#333333;">Inline XBRL Taxonomy Extension Calculation Linkbase Document (1).</span></p> </td>
     <td style="vertical-align: top; width: 8%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-size: 10pt; margin: 0px; font-family: &quot;Times New Roman&quot;;">&#xa0;</p> </td>
     <td style="vertical-align: top; width: 40%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-size: 10pt; margin: 0px; text-indent: 9pt; font-family: &quot;Times New Roman&quot;;"><span style="color:#333333;">Filed herewith.</span></p> </td>
    </tr>

    <tr>
     <td style="vertical-align: top; width: 8%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td>
     <td style="vertical-align: top; width: 44%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td>
     <td style="vertical-align: top; width: 8%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td>
     <td style="vertical-align: top; width: 40%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td>
    </tr>

    <tr>
     <td style="vertical-align: top; width: 8%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-size: 10pt; margin: 0px; font-family: &quot;Times New Roman&quot;;"><span style="color:#333333;">101.DEF</span></p> </td>
     <td style="vertical-align: top; width: 44%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-size: 10pt; margin: 0px; font-family: &quot;Times New Roman&quot;;"><span style="color:#333333;">Inline XBRL Taxonomy Extension Definition Linkbase Document (1).</span></p> </td>
     <td style="vertical-align: top; width: 8%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-size: 10pt; margin: 0px; font-family: &quot;Times New Roman&quot;;">&#xa0;</p> </td>
     <td style="vertical-align: top; width: 40%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-size: 10pt; margin: 0px; text-indent: 9pt; font-family: &quot;Times New Roman&quot;;"><span style="color:#333333;">Filed herewith.</span></p> </td>
    </tr>

    <tr>
     <td style="vertical-align: top; width: 8%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-size: 10pt; margin: 0px; font-family: &quot;Times New Roman&quot;;">&#xa0;</p> </td>
     <td style="vertical-align: top; width: 44%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-size: 10pt; margin: 0px; font-family: &quot;Times New Roman&quot;;">&#xa0;</p> </td>
     <td style="vertical-align: top; width: 8%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-size: 10pt; margin: 0px; font-family: &quot;Times New Roman&quot;;">&#xa0;</p> </td>
     <td style="vertical-align: top; width: 40%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-size: 10pt; margin: 0px; font-family: &quot;Times New Roman&quot;;">&#xa0;</p> </td>
    </tr>

    <tr>
     <td style="vertical-align: top; width: 8%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-size: 10pt; margin: 0px; font-family: &quot;Times New Roman&quot;;"><span style="color:#333333;">101.LAB</span></p> </td>
     <td style="vertical-align: top; width: 44%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-size: 10pt; margin: 0px; font-family: &quot;Times New Roman&quot;;"><span style="color:#333333;">Inline XBRL Taxonomy Extension Label Linkbase Document (1).</span></p> </td>
     <td style="vertical-align: top; width: 8%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-size: 10pt; margin: 0px; font-family: &quot;Times New Roman&quot;;">&#xa0;</p> </td>
     <td style="vertical-align: top; width: 40%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-size: 10pt; margin: 0px; text-indent: 9pt; font-family: &quot;Times New Roman&quot;;"><span style="color:#333333;">Filed herewith.</span></p> </td>
    </tr>

    <tr>
     <td style="vertical-align: top; width: 8%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-size: 10pt; margin: 0px; font-family: &quot;Times New Roman&quot;;">&#xa0;</p> </td>
     <td style="vertical-align: top; width: 44%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-size: 10pt; margin: 0px; font-family: &quot;Times New Roman&quot;;">&#xa0;</p> </td>
     <td style="vertical-align: top; width: 8%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-size: 10pt; margin: 0px; font-family: &quot;Times New Roman&quot;;">&#xa0;</p> </td>
     <td style="vertical-align: top; width: 40%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-size: 10pt; margin: 0px; font-family: &quot;Times New Roman&quot;;">&#xa0;</p> </td>
    </tr>

    <tr>
     <td style="vertical-align: top; width: 8%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-size: 10pt; margin: 0px; font-family: &quot;Times New Roman&quot;;"><span style="color:#333333;">101.PRE</span></p> </td>
     <td style="vertical-align: top; width: 44%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-size: 10pt; margin: 0px; font-family: &quot;Times New Roman&quot;;"><span style="color:#333333;">Inline XBRL Taxonomy Extension Presentation Linkbase Document (1).</span></p> </td>
     <td style="vertical-align: top; width: 8%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-size: 10pt; margin: 0px; font-family: &quot;Times New Roman&quot;;">&#xa0;</p> </td>
     <td style="vertical-align: top; width: 40%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-size: 10pt; margin: 0px; text-indent: 9pt; font-family: &quot;Times New Roman&quot;;"><span style="color:#333333;">Filed herewith.</span></p> </td>
    </tr>

    <tr>
     <td style="vertical-align: top; width: 8%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td>
     <td style="vertical-align: top; width: 44%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td>
     <td style="vertical-align: top; width: 8%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td>
     <td style="vertical-align: top; width: 40%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td>
    </tr>

    <tr>
     <td style="vertical-align: top; width: 8%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"><span style="color:#333333;">104</span></td>
     <td style="vertical-align: top; width: 44%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"><span style="color:#333333;">Cover Page Interactive Data File (formatted as Inline XBRL and combined in Exhibit 101.1)</span></td>
     <td style="vertical-align: top; width: 8%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td>
     <td style="vertical-align: top; width: 40%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; text-indent: 9pt;"><span style="color:#333333;">Filed herewith.</span></td>
    </tr>

   </tbody>
  </table>
  <p style="margin: 0px; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><span style="color:#333333;">(1) These Interactive Data Files shall not be deemed filed for purposes of Section 11 or 12 of the Securities Act of 1933, as amended, or Section 18 of the Securities Act of 1934, as amended, or otherwise subject to liability under those sections.</span></p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin: 0pt; text-align: left;">&#xa0;</p>
  <div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
   <div class="PGFTR" style="text-align: center; width: 100%">
    <div class="hf-row">
     <div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">
       28
     </div>
    </div>
   </div>
   <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000" />
   <div class="PGHDR" style="text-align: left; width: 100%">
    <div class="hf-row">
     <div class="hf-cell TOCLink" style="display: inline-block; text-align: left;">
      <a href="#toc" style="font-weight: initial; font-style: initial; font-variant: initial; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif;">Table of Contents</a>
     </div>
    </div>
   </div>
  </div>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin: 0pt; text-align: left;">&#xa0;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin: 0pt; text-align: center;"><span style="color:#333333;"><b><a id="Signatures" title="Signatures" href="#"></a>SIGNATURES</b></span></p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin: 0pt; text-align: left;">&#xa0;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin: 0pt; text-align: left;"><span style="color:#333333;">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.</span></p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin: 0pt; text-align: left;">&#xa0;</p>
  <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">
   <tbody>
    <tr style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">
     <td style="vertical-align: middle; width: 50%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin: 0pt; text-align: left;">&#xa0;</p> </td>
     <td style="vertical-align: middle; width: 10%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin: 0pt; text-align: left;">&#xa0;</p> </td>
     <td style="vertical-align: middle; width: 40%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin: 0pt; text-align: left;"><span style="color:#333333;"><b>Windtree Therapeutics, Inc.</b></span></p> </td>
    </tr>

    <tr style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">
     <td style="vertical-align: middle; width: 50%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin: 0pt; text-align: left;">&#xa0;</p> </td>
     <td style="vertical-align: middle; width: 10%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin: 0pt; text-align: left;">&#xa0;</p> </td>
     <td style="vertical-align: middle; width: 40%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin: 0pt; text-align: left;"><span style="color:#333333;">(Registrant)</span></p> </td>
    </tr>

    <tr style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">
     <td style="vertical-align: middle; width: 50%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin: 0pt; text-align: left;">&#xa0;</p> </td>
     <td style="vertical-align: middle; width: 10%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin: 0pt; text-align: left;">&#xa0;</p> </td>
     <td style="vertical-align: middle; width: 40%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin: 0pt; text-align: left;">&#xa0;</p> </td>
    </tr>

    <tr style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">
     <td style="vertical-align: middle; width: 50%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin: 0pt; text-align: left;"><span style="color:#333333;">Date: </span><span style="color:#333333;">August 11, 2022</span></p> </td>
     <td style="vertical-align: middle; width: 10%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin: 0pt; text-align: left;">&#xa0;</p> </td>
     <td style="vertical-align: middle; width: 40%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin: 0pt; text-align: left;"><span style="color:#333333;">By: <span style="text-decoration: underline; ">/s/ Craig E. Fraser</span></span></p> </td>
    </tr>

    <tr style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">
     <td style="vertical-align: middle; width: 50%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin: 0pt; text-align: left;">&#xa0;</p> </td>
     <td style="vertical-align: middle; width: 10%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin: 0pt; text-align: left;">&#xa0;</p> </td>
     <td style="vertical-align: middle; width: 40%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin: 0pt; text-align: left;"><span style="color:#333333;">Craig E. Fraser</span></p> </td>
    </tr>

    <tr style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">
     <td style="vertical-align: middle; width: 50%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin: 0pt; text-align: left;">&#xa0;</p> </td>
     <td style="vertical-align: middle; width: 10%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin: 0pt; text-align: left;">&#xa0;</p> </td>
     <td style="vertical-align: middle; width: 40%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin: 0pt; text-align: left;"><span style="color:#333333;">President and Chief Executive Officer</span></p> </td>
    </tr>

    <tr style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">
     <td style="vertical-align: middle; width: 50%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin: 0pt; text-align: left;">&#xa0;</p> </td>
     <td style="vertical-align: middle; width: 10%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin: 0pt; text-align: left;">&#xa0;</p> </td>
     <td style="vertical-align: middle; width: 40%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin: 0pt; text-align: left;">&#xa0;</p> </td>
    </tr>

    <tr style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">
     <td style="vertical-align: middle; width: 50%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin: 0pt; text-align: left;">&#xa0;</p> </td>
     <td style="vertical-align: middle; width: 10%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin: 0pt; text-align: left;">&#xa0;</p> </td>
     <td style="vertical-align: middle; width: 40%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin: 0pt; text-align: left;">&#xa0;</p> </td>
    </tr>

    <tr style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">
     <td style="vertical-align: middle; width: 50%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin: 0pt; text-align: left;"><span style="color:#333333;">Date: </span><span style="color:#333333;">August 11, 2022</span></p> </td>
     <td style="vertical-align: middle; width: 10%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin: 0pt; text-align: left;">&#xa0;</p> </td>
     <td style="vertical-align: middle; width: 40%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin: 0pt; text-align: left;"><span style="color:#333333;">By: <span style="text-decoration: underline; ">/s/ John P. Hamill</span></span></p> </td>
    </tr>

    <tr style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">
     <td style="vertical-align: middle; width: 50%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin: 0pt; text-align: left;">&#xa0;</p> </td>
     <td style="vertical-align: middle; width: 10%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin: 0pt; text-align: left;">&#xa0;</p> </td>
     <td style="vertical-align: middle; width: 40%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin: 0pt; text-align: left;"><span style="color:#333333;">John P. Hamill</span></p> </td>
    </tr>

    <tr style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">
     <td style="vertical-align: middle; width: 50%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin: 0pt; text-align: left;">&#xa0;</p> </td>
     <td style="vertical-align: middle; width: 10%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin: 0pt; text-align: left;">&#xa0;</p> </td>
     <td style="vertical-align: middle; width: 40%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin: 0pt; text-align: left;"><span style="color:#333333;">Senior Vice President and Chief Financial Officer</span></p> </td>
    </tr>

   </tbody>
  </table>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin: 0pt; text-align: left;">&#xa0;</p>
  <div class="LAST-PAGE-BREAK">
   <div class="PGFTR">
    <div class="hf-row">
     <div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">
       29
     </div>
    </div>
   </div>
  </div>
 </body>
</html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-3.1
<SEQUENCE>2
<FILENAME>ex_409319.htm
<DESCRIPTION>EXHIBIT 3.1
<TEXT>
<html><head>
	<title>ex_409319.htm</title>

	<!-- Generated by ThunderDome Portal - 8/9/2022 6:21:55 PM --><meta charset="utf-8"><meta name="format-detection" content="telephone=no">
</head>
<body style="font-size:10pt;font-family:'Times New Roman';padding:0in .1in;">
<div contenteditable="false" data-applyto="t" data-auto-pgnum="start" data-displaynum="1" data-fontname="Times New Roman" data-fontsize="10pt" data-numstyle="a" data-prefix="" data-startnum="1" data-suffix="" data-textalign="center">&nbsp;</div>

<p style="margin-bottom: 0px; text-align: right; margin-top: 0px"><font style="font-family: 'Times New Roman', Times, serif; font-size: 10pt"><b>Exhibit 3.1</b></font></p>

<p style="margin-bottom: 0px; text-align: left; margin-top: 0px"><font style="font-family: 'Times New Roman', Times, serif; font-size: 10pt">&nbsp;</font></p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>AMENDED AND RESTATED</b></p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>BY-LAWS OF</b></p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>WINDTREE THERAPEUTICS, INC.</b></p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>(A Delaware Corporation)</b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">(Effective: April 19, 2016)</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">(Amended: June 3, 2022)</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>ARTICLE I</b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>Meetings of Stockholders</b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>Section 1.</b>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<b><u>Annual Meeting.</u></b>&nbsp; The annual meeting of the stockholders of&nbsp;Windtree Therapeutics, Inc. (the "Corporation"), for the election of directors and for the transaction of such other business as may come before the meeting shall&nbsp;be held at such date and time as shall be designated by the Board of Directors (the &#8220;Board&#8221;), the Chairman of the Board or the President.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>Section 2.</b>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<b><u>Special Meeting.</u></b>&nbsp;&nbsp;Special meetings of the stockholders, unless otherwise prescribed by statute, may be called at any time by the Board, the Chairman of the Board or the Chief Executive Officer.&nbsp; Business transacted at any special meeting of stockholders shall be limited to matters relating to the purpose or purposes stated in the notice of meeting.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>Section 3.</b>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<b><u>Notice of Meetings.</u></b>&nbsp;&nbsp;Notice of the place, date and time of the holding of each annual and special meeting of the stockholders and, in the case of a special meeting, the purpose or purposes thereof shall be given personally or by mail in a postage prepaid envelope to each stockholder entitled to vote at such meeting, not less than 10 nor more than 60 days before the date of such meeting, and, if mailed, it shall be directed to such stockholder at his or her address as it appears on the records of the Corporation, unless such stockholder shall have filed with the Secretary of the Corporation a written request that notices to such stockholder be mailed to some other address, in which case it shall be directed to the stockholder at such other address.&nbsp; If mailed, such notice shall be deemed to be delivered when deposited in United States mail so addressed with postage thereon prepaid.&nbsp; Notice of any meeting of stockholders shall not be required to be given to any stockholder who shall attend such meeting in person or by proxy and shall not, at the beginning of such meeting, object to the transaction of any business because the meeting is not lawfully called or convened, or who shall, either before or after the meeting, submit a signed waiver of notice, in person or by proxy.&nbsp; Unless the Board shall fix after the adjournment a new record date for an adjourned meeting, notice of such adjourned meeting need not be given if the time and place to which the meeting shall be adjourned were announced at the meeting at which the adjournment is taken.&nbsp; At the adjourned meeting, the Corporation may transact any business which may have been transacted at the original meeting.&nbsp; If the adjournment is for more than 30 days, or if after the adjournment a new record date is fixed for the adjourned meeting, a notice of the adjourned meeting shall be given to each stockholder of record entitled to vote at the meeting.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>Section 4.</b>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<b><u>Place of Meetings.</u></b>&nbsp; Meetings of the stockholders my be held at such place, within or without the State of Delaware, as the Board or other officer calling the same shall specify in the notice of such meeting, or in a duly executed waiver of notice thereof.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>Section 5.</b>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<b><u>Quorum.</u></b>&nbsp;&nbsp;At all meetings of the stockholders, the holders of one third of the votes of the shares of stock of the Corporation issued and outstanding and entitled to vote shall be present in person or by proxy to constitute a quorum for the transaction of any business, except when stockholders are required to vote by class, in which event a majority of the issued and outstanding shares of the appropriate class shall be present in person or by proxy, or except as otherwise provided by statute or in the Corporation&#8217;s Amended and Restated Certificate of Incorporation (the &#8220;Certificate of Incorporation&#8221;). In the absence of a quorum, the holders of a majority of the votes of the shares of stock present in person or by proxy and entitled to vote, or if no stockholder entitled to vote is present, then the chairman of the meeting, as set forth in Section 6 below, may adjourn the meeting from time to time. At any such adjourned meeting at which a quorum may be present, any business may be transacted which might have been transacted at the meeting as originally called.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM" data-number="1" data-prefix="" data-suffix="" style="text-align: center; font-size: 10pt; font-family: &quot;Times New Roman&quot;;">1</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&nbsp;</div>
</div>
</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>Section 6.</b>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<b><u>Organization.</u></b>&nbsp;&nbsp;At each meeting of the stockholders, the Chairman of the Board, or in his absence or inability to act, the President, or in the absence or inability to act of the Chairman of the Board and the President or an Executive Vice President, or in the absence of all the foregoing, any person chosen by a majority of those stockholders present shall act as chairman of the meeting.&nbsp; The Secretary, or, in his absence or inability to act, the Assistant Secretary or any person appointed by the chairman of the meeting shall act as secretary of the meeting and keep the minutes thereof.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>Section 7.</b>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<b><u>Order of Business.</u></b>&nbsp;&nbsp;The order of business at all meetings of the stockholders shall be as determined by the chairman of the meeting.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>Section 8.</b>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<b><u>Voting.</u></b>&nbsp;&nbsp;Except as otherwise provided by statute, the Certificate of Incorporation or any certificate duly filed in the office of the Secretary of State of the State of Delaware, each holder of record of shares of stock of the Corporation having voting power shall be entitled at each meeting of the stockholders to one vote for every share of such stock standing in his name on the record of stockholders of the Corporation on the date fixed by the Board as the record date for the determination of the stockholders who shall be entitled to notice of and to vote at such meeting; or if such record date shall not have been so fixed, then at the close of business on the day next preceding the day on which the meeting is held; or each stockholder entitled to vote at any meeting of stockholders may authorize another person or persons to act for him by a proxy signed by such stockholder or his attorney-in-fact.&nbsp; Any such proxy shall be delivered to the secretary of such meeting at or prior to the time designated in the order of business for so delivering such proxies.&nbsp; No proxy shall be valid after the expiration of three years from the date thereof, unless otherwise provided in the proxy.&nbsp; Every proxy shall be revocable at the pleasure of the stockholder executing it, except in those cases where an irrevocable proxy is permitted by law.&nbsp; Except as otherwise provided by statute, these Amended and Restated By-Laws (the &#8220;By-Laws&#8221;), or the Certificate of Incorporation, any corporate action to be taken by vote of the stockholders shall be authorized by a majority of the total votes, or when stockholders are required to vote by class by a majority of the votes of the appropriate class, cast at a meeting of stockholders by the holders of shares present in person or represented by proxy and entitled to vote on such action.&nbsp; Unless required by statute, or determined by the chairman of the meeting to be advisable, the vote on any question need not be by written ballot.&nbsp; On a vote by written ballot, each ballot shall be signed by the stockholder voting, or by his proxy, if there be such proxy, and shall state the number of shares voted.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>Section 9.</b>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<b><u>Nominations.</u></b>&nbsp;&nbsp;The&nbsp;procedures governing stockholder nominees of candidates to elections of the Board of Directors or to fill vacancies, as applicable, shall be administered by the Corporation&#8217;s Nomination Committee.&nbsp;&nbsp;This Section 9 shall be the exclusive means by which a stockholder may make such nominations before any meeting of stockholders (other than matters properly brought under Rule 14a-8 under the Securities Exchange Act of 1934, as amended (the &#8220;Exchange Act&#8221;) and included in the Corporation&#8217;s notice of meeting).&nbsp;For nominations for election to the Board or for other business to be properly brought by a stockholder before a meeting of stockholders, the stockholder must first have given timely written notice thereof to the Secretary of the Corporation.&nbsp; In addition to other applicable requirements,&nbsp;to be timely, a notice of nominations or other business to be brought before an annual meeting of stockholders must be substantially in the form set forth below and delivered to the Secretary not later than the date set forth in the &#8220;Stockholder Proposals&#8221; section of the Proxy Statement delivered by the Corporation to its stockholders, and filed with the Securities and Exchange Commission, in connection with the preceding year's annual meeting.&nbsp; If the Corporation did not deliver a Proxy Statement in connection with the preceding year's annual meeting, such notice must be delivered not less than 120 nor more than 150 days prior to the first anniversary of the preceding year's annual meeting; provided, that if the date of an annual meeting is more than 30 days before or more than 60 days after such anniversary, all notices must be delivered not earlier than 90 days prior to such annual meeting and not later than the later of (i) 60 days prior to the annual meeting or (ii) 10 days following the date on which public announcement of the date of such annual meeting is first made by the Corporation.&nbsp; With respect to special meetings of stockholders, such notice must be delivered to the Secretary not more than 90 days prior to such meeting and not later than the later of (i) 60 days prior to such meeting or (ii) 10 days following the date on which public announcement of the date of such meeting is first made by the Corporation.&nbsp; Any stockholder delivering notice to the Secretary under this Section 9, Article I must be a stockholder of record on the date such notice is delivered.&nbsp; The Secretary shall deliver the notice to the Nomination Committee.&nbsp; No stockholder nominee may be a candidate for election at any meeting of stockholders or otherwise elected to fill a vacancy in the Board unless such person has been approved by the Nomination Committee and&nbsp;was nominated in accordance with the procedures set forth in this Section 9, Article I.&nbsp; If the facts warrant, the Board, or the chairman of a stockholders meeting at which Directors are to be elected may determine and declare that a nomination was not made in accordance with the foregoing procedure and, if it is so determined, no election may be made with respect to such nominee.&nbsp; The right of stockholders to make nominations pursuant to the foregoing procedure is subject to the superior rights, if any, of the holders of any class or series of stock having a preference over the common stock.&nbsp; The procedures set forth in this Section 9 of Article I for nomination for the election of Directors by stockholders are in addition to, and not in limitation of, any procedures now in effect or hereafter adopted by or at the direction of the Board or any committee thereof.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM" data-number="2" data-prefix="" data-suffix="" style="text-align: center; font-size: 10pt; font-family: &quot;Times New Roman&quot;;">2</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&nbsp;</div>
</div>
</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">If a stockholder attempts to nominate a candidate to the Board and complies with the procedure set forth in this Section 9, Article I but the Nomination Committee rejects such stockholder&#8217;s nomination, such stockholder may nominate such candidate notwithstanding the decision of the Nomination Committee at the next election of Directors after such candidate was rejected by the Nomination Committee if such stockholder delivers to the Secretary written requests that such person be nominated to the Board from stockholders holding at least 50% of the eligible votes as of the record date of such election.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">To be in proper written form, each such notice to the Secretary delivered in connection with a stockholder nomination must set forth as to each person whom the stockholder proposes to nominate for election as a director:</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">(i) the name, age, business address and residence address of the person;</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">(ii) the principal occupation or employment of the person;</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">(iii) the class or series and number of shares of capital stock of the Corporation that are owned beneficially or of record by the person;</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">(iv) a representation that the person does not have, nor will not have, any undisclosed voting commitments or other arrangements with respect to such person&#8217;s actions as a director; and</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">(v) any other information relating to the person that would be required to be disclosed in a proxy statement or other filings required to be made in connection with solicitations of proxies for election of Directors pursuant to Section 14 of the Exchange Act and the rules and regulations promulgated thereunder;</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Each such notice to the Secretary must also set forth as to the stockholder giving the notice:</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">(i) the name and record address of such stockholder;</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">(ii) the class or series and number of shares of capital stock of the Corporation that are owned beneficially or of record by such stockholder;</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">(iii) a description of all arrangements, material relationships, or understandings between such stockholder and each proposed nominee and any other person or persons (including their names) pursuant to which the nomination(s) are to be made by such stockholder;</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">(iv) a representation that such stockholder intends to appear in person or by proxy at the meeting to nominate the persons named in its notice;</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">(v) any option, warrant, convertible security, stock appreciation right, or similar right with an exercise or conversion privilege or a settlement payment or mechanism at a price related to any class or series of shares of the Corporation or with a value derived in whole or in part from the value of any class or series of shares of the Corporation, whether or not such instrument or right shall be subject to settlement in the underlying class or series of capital stock of the Corporation or otherwise (a &#8220;Derivative Instrument&#8221;) directly or indirectly owned beneficially by such stockholder and any other director indirect opportunity to profit or share in any profit derived from any increase or decrease in the value of shares of the Corporation;</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">(vi) any proxy, contract, arrangement, understanding, or relationship pursuant to which such stockholder has a right to vote any shares of any security of the Corporation;</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM" data-number="3" data-prefix="" data-suffix="" style="text-align: center; font-size: 10pt; font-family: &quot;Times New Roman&quot;;">3</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&nbsp;</div>
</div>
</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">(vii) any short interest in any security of the Corporation (for purposes of this By-Law a person shall be deemed to have a short interest in a security if such person directly or indirectly, through any contract, arrangement, understanding, relationship or otherwise, has the opportunity to profit or share in any profit derived from any decrease in the value of the subject security);</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">(viii) any rights to dividends on the shares of the Corporation owned beneficially by such stockholder that are separated or separable from the underlying shares of the Corporation;</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">(ix) any proportionate interest in shares of the Corporation or Derivative Instruments held, directly or indirectly, by a general or limited partnership in which such stockholder is a general partner or, directly or indirectly, beneficially owns an interest in a general partner;</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">(x) any performance-related fees (other than an asset-based fee) that such stockholder is entitled to based on any increase or decrease in the value of shares of the Corporation or Derivative Instruments, if any, as of the date of such notice, including without limitation any such interests held by members of such stockholder&#8217;s immediate family sharing the same household (which information shall be supplemented by such stockholder and beneficial owner, if any, not later than 10 days after the record date for the meeting to disclose such ownership as of the record date; and</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">(xi) any other information relating to such stockholder that would be required to be disclosed in a proxy statement or other filings required to be made in connection with solicitations of proxies for election of Directors pursuant to Section 14 of the Exchange Act and the rules and regulations promulgated thereunder.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">All notices delivered to the Secretary in connections must be accompanied by a written consent of each proposed nominee to being named as a nominee and to serve as a Director if elected.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>Section 10.</b>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<b><u>Stockholder Proposals</u></b><b><i><u>.</u></i></b>&nbsp;&nbsp;The&nbsp;procedures governing stockholder proposals, other than the nomination of a director or directors by a stockholder, (&#8220;Other Business&#8221;)&nbsp; of business to be conducted at meetings of stockholders shall be administered by the Corporation&#8217;s Nomination Committee. This Section 10 shall be the exclusive means by which a stockholder may submit any Other Business that the stockholder proposes to bring before an any meeting of stockholders (other than matters properly brought under Rule 14a-8 under the Securities Exchange Act of 1934, as amended (the &#8220;Exchange Act&#8221;) and included in the Company&#8217;s notice of meeting).&nbsp; At any meeting of the stockholders, only such Other Business shall be conducted as shall have been properly brought before such meeting.&nbsp; To be properly brought before a meeting, Other Business must be: (a) as specified in the notice of meeting (or any supplement thereto) given by or at the direction of the Board; (b) otherwise properly brought before the meeting by or at the direction of the Board; or (c) otherwise properly brought before the meeting by a stockholder.&nbsp;&nbsp;For Other Business to be properly brought by a stockholder before a meeting of stockholders, the stockholder must first have given timely written notice thereof to the Secretary of the Corporation.&nbsp; In addition to other applicable requirements set forth in the&nbsp;Exchange Act,&nbsp;to be timely, a notice of other Other Business to be brought before an annual meeting of stockholders must be substantially in the form set forth below and delivered to the Secretary not later than the date set forth in the &#8220;Stockholder Proposals&#8221; section of the Proxy Statement delivered by the Corporation to its stockholders, and filed with the Securities and Exchange Commission, in connection with the preceding year's annual meeting.&nbsp; If the Corporation did not deliver a Proxy Statement in connection with the preceding year's annual meeting, such notice must be delivered not less than 120 nor more than 150 days prior to the first anniversary of the date of the Corporation's proxy statement delivered to stockholders in connection with the preceding year's annual meeting; provided, that if (A) the date of an annual meeting is more than 30 days before or more than 60 days after such anniversary, or (B) no proxy statement was delivered to stockholders by the Corporation in connection with the preceding year's annual meeting, all notices must be delivered not earlier than 90 days prior to such annual meeting and not later than the later of (i) 60 days prior to the annual meeting or (ii) 10 days following the date on which public announcement of the date of such annual meeting is first made by the Corporation.&nbsp; With respect to special meetings of stockholders, such notice must be delivered to the Secretary not more than 90 days prior to such meeting and not later than the later of (i) 60 days prior to such meeting or (ii) 10 days following the date on which public announcement of the date of such meeting is first made by the Corporation.&nbsp; Any stockholder delivering notice to the Secretary under this Section 10 of Article I must be a stockholder of record on the date such notice is delivered.&nbsp; The Nomination Committee must approve each stockholder proposal of other business before such proposal may be voted on at any meeting of stockholders or otherwise.&nbsp;&nbsp;No&nbsp;stockholder proposal of other business before such proposal may be voted on at any meeting of stockholders or otherwise&nbsp;unless such proposal was approved in accordance with the procedures set forth in this Section 10 of Article I.&nbsp; The procedures set forth in this Section 10 of Article I for submission of any Other Business that the stockholder proposes to bring before any meeting of stockholders are in addition to, and not in limitation of, any procedures now in effect or hereafter adopted by or at the direction of the Board or any committee thereof.&nbsp; If the chairman of a meeting of stockholders determines that Other Business was not properly brought before the meeting in&nbsp;accordance with the foregoing procedures, the chairman shall declare to the&nbsp;meeting that the Other Business was not properly brought before the meeting and such Other Business shall not be transacted.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM" data-number="4" data-prefix="" data-suffix="" style="text-align: center; font-size: 10pt; font-family: &quot;Times New Roman&quot;;">4</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&nbsp;</div>
</div>
</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">To be in proper written form, a stockholder's notice to the Secretary must set forth as to each matter such stockholder proposes to bring before the meeting:</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">(i) a brief description of the Other Business desired to be brought before the meeting and the reasons for conducting such Other Business at the meeting;</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">(ii) the name and record address of such stockholder;</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">(iii) the class or series and number of shares of capital stock of the Corporation that are owned beneficially or of record by such stockholder;</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">(iv) a description of all arrangements or understandings between such stockholder and any other person or persons (including their names) in connection with the proposal of such Other Business by such stockholder and any material interest of such stockholder in such business;</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">(v) a representation that such stockholder intends to appear in person or by proxy at the meeting to bring such business before the meeting;</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">(vi) any option, warrant, convertible security, stock appreciation right, or similar right with an exercise or conversion privilege or a settlement payment or mechanism at a price related to any class or series of shares of the Corporation or with a value derived in whole or in part from the value of any class or series of shares of the Corporation, whether or not such instrument or right shall be subject to settlement in the underlying class or series of capital stock of the Corporation or otherwise (a &#8220;Derivative Instrument&#8221;) directly or indirectly owned beneficially by such stockholder and any other director indirect opportunity to profit or share in any profit derived from any increase or decrease in the value of shares of the Corporation;</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">(vii) any proxy, contract, arrangement, understanding, or relationship pursuant to which such stockholder has a right to vote any shares of any security of the Corporation;</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">(viii) any short interest in any security of the Corporation (for purposes of this By-Law a person shall be deemed to have a short interest in a security if such person directly or indirectly, through any contract, arrangement, understanding, relationship or otherwise, has the opportunity to profit or share in any profit derived from any decrease in the value of the subject security);</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">(ix) any rights to dividends on the shares of the Corporation owned beneficially by such stockholder that are separated or separable from the underlying shares of the Corporation;</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">(x) any proportionate interest in shares of the Corporation or Derivative Instruments held, directly or indirectly, by a general or limited partnership in which such stockholder is a general partner or, directly or indirectly, beneficially owns an interest in a general partner;</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">(xi)&nbsp; any performance-related fees (other than an asset-based fee) that such stockholder is entitled to based on any increase or decrease in the value of shares of the Corporation or Derivative Instruments, if any, as of the date of such notice, including without limitation any such interests held by members of such stockholder&#8217;s immediate family sharing the same household (which information shall be supplemented by such stockholder and beneficial owner, if any, not later than 10 days after the record date for the meeting to disclose such ownership as of the record date); and</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">(xii) any other information that is required by law to be provided by the stockholder in his capacity as proponent of a stockholder proposal.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>Section 11.</b>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<b><u>List of Stockholders.</u></b>&nbsp;&nbsp;The officer who has charge of the stock ledger of the Corporation, or the transfer agent of the Corporation's stock, if there be one then acting, shall prepare and make, at least 10 days before every meeting of stockholders, a complete list of the stockholders entitled to vote at the meeting arranged in alphabetical order, and showing the address of each stockholder and the number of shares registered in the name of each stockholder.&nbsp; Such list shall be open to the examination of any stockholder, for any purpose germane to the meeting, during ordinary business hours, for a period of at least 10 days prior to the meeting, either at a place within the city where the meeting is to be held, at the place where the meeting is to be held or at the office of the transfer agent.&nbsp; The list shall also be produced and kept at the time and place of the meeting during the whole time thereof, and may be inspected by any stockholder who is present.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM" data-number="5" data-prefix="" data-suffix="" style="text-align: center; font-size: 10pt; font-family: &quot;Times New Roman&quot;;">5</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&nbsp;</div>
</div>
</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>Section 12.</b>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<b><u>Inspectors.</u></b>&nbsp;&nbsp;The Board may, in advance of any meeting of stockholders, appoint one or more inspectors to act at such meeting or any adjournment thereof.&nbsp; If the inspectors shall not be so appointed or if any of them shall fail to appear or act, the chairman of the meeting may, and on the request of any stockholder entitled to vote thereat shall, appoint inspectors.&nbsp; Each inspector, before entering upon the discharge of his duties, shall take and sign an oath faithfully to execute the duties of inspector at such meeting with strict impartiality and according to the best of his ability.&nbsp; The inspectors shall determine the number of shares outstanding and the voting power of each, the number of shares represented at the meeting, the existence of a quorum, the validity and effect of proxies, and shall receive votes, ballots or consents, hear and determine all challenges and questions arising in connection with the right to vote, count and tabulate all votes, ballots or consents, determine the result, and do such acts as are proper to conduct the election or vote with fairness to all stockholders.&nbsp; Upon the request of the chairman of the meeting or any stockholder entitled to vote thereat, the inspectors shall make a report in writing of any challenge, request or matter determined by them and shall execute a certificate of any fact found by them.&nbsp; No director or candidate for the office of director shall act as inspector of an election of directors.&nbsp; Inspectors need not be stockholders.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>Section 13.</b>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<b><u>Consent of Stockholders in Lieu of Meeting.</u></b>&nbsp;&nbsp;Unless otherwise provided in the Certificate of Incorporation, any action required by Subchapter VII of the General Corporation Law of the State of Delaware, to be taken at any annual or special meeting of such stockholders, may be taken without a meeting, without prior notice and without a vote, if a consent or consents in writing, setting forth the action so taken, shall be signed by the holders of outstanding stock having not less than the minimum number of votes that would be necessary to authorize or take such action at a meeting at which all shares entitled to vote thereon were present and voted and shall be delivered to the corporation by delivery to its registered office in this State, its principal place of business, or an officer or agent of the corporation having custody of the book in which proceedings of meetings of stockholders are recorded.&nbsp; Delivery made to a corporation's registered office shall be by hand or by certified or registered mail, return receipt requested.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>ARTICLE II</b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>Board Of Directors</b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>Section 1.</b>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<b><u>General Powers.</u></b>&nbsp;&nbsp;The business and affairs of the Corporation shall be managed by the Board.&nbsp; The Board may exercise all such authority and powers of the Corporation and do all such lawful acts and things as are not by statute or the Certificate of Incorporation or by these By-Laws directed or required to be exercised or done by the stockholders.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>Section 2.</b>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<b><u>Number, Qualifications, Elections and Term of Office.</u></b>&nbsp;&nbsp;The number of directors of the Corporation (&#8220;Directors&#8221;) shall be fixed from time to time by the vote of a majority of the entire Board then in office and the number thereof may thereafter by like vote be increased or decreased to such greater or lesser number (not less than three) as may be so provided, subject to the provisions of Section 11 of this Article II.&nbsp; All of the Directors shall be of full age and need not be stockholders.&nbsp; Except as otherwise provided by statute or these By-Laws, the Directors shall be elected at the annual meeting of the Stockholders for the election of Directors at which a quorum is present, and the persons receiving a plurality of the votes cast at such meeting shall be elected.&nbsp; Each Director shall hold office until the next annual meeting of the stockholders and until his successors shall have been duly elected and qualified, or until such Director&#8217;s death, or until such Director shall have resigned, or have been removed, as hereinafter provided in these By-Laws, or as otherwise provided by statute or the Certificate of Incorporation.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM" data-number="6" data-prefix="" data-suffix="" style="text-align: center; font-size: 10pt; font-family: &quot;Times New Roman&quot;;">6</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&nbsp;</div>
</div>
</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>Section 3.</b>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<b><u>Place of Meetings.</u></b>&nbsp;&nbsp;Meetings of the Board may be held at such place, within or without the State of Delaware, as the Board may from time to time determine or as shall be specified in the notice or waiver of notice of such meeting.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>Section 4.</b>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<b><u>Annual Meeting.</u></b>&nbsp;&nbsp;The Board shall meet for the purpose of organization, the election or appointment of officers and the transaction of other business, as soon as practicable after each annual meeting of the stockholders, on the same day and at the same place where such annual meeting shall be held.&nbsp; Notice of such meeting need not be given.&nbsp; Such meeting may be held at any other time or place (within or without the State of Delaware) which shall be specified in a notice thereof given as hereinafter provided in Section 7 of this Article II.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>Section 5.</b>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<b><u>Regular Meetings.</u></b>&nbsp;&nbsp;Regular meetings of the Board shall be held at such time and place as the Board may from time to time determine.&nbsp; If any day fixed for a regular meeting shall be a legal holiday at the place where the meeting is to be held, then the meeting which would otherwise be held on that day shall be held at the same hour on the next succeeding business day.&nbsp; Notice of regular meetings of the Board need not be given except as otherwise required by statute or these By-Laws.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>Section 6.</b>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<b><u>Special Meetings.</u></b>&nbsp;&nbsp;Special meetings of the Board may be called by the Chairman of the Board, two or more directors or the President of the Corporation.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>Section 7.</b>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<b><u>Notice of Meetings.</u></b>&nbsp;&nbsp;Notice of each special meeting of the Board (and of each regular meeting for which notice shall be required) shall be given by the Secretary as hereinafter provided in this Section 7 of Article II, in which notice shall be stated the time and place (within or without the State of Delaware) of the meeting.&nbsp; Notice of each such meeting shall be delivered to each Director either personally or by telephone, telegraph, cable or wireless, at least 24 hours before the time at which such meeting is to be held or by first-class mail, postage prepaid, addressed to him at his residence, or usual place of business, at least three days before the day on which such meeting is to be held.&nbsp; If mailed, such notice shall be deemed to be delivered when deposited in the United States mail.&nbsp; Notice of any such meeting need not be given to any director who shall, either before or after the meeting, submit a signed waiver of notice or who shall attend such meeting without protesting, prior to or at its commencement, the lack of notice to him.&nbsp; Except as otherwise specifically required by these By-Laws, a notice or waiver of notice of any regular or special meeting need not state the purposes of such meeting.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>Section 8.</b>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<b><u>Quorum and Manner of Acting.</u></b>&nbsp;&nbsp;A majority of the entire Board shall be present in person at any meeting of the Board in order to constitute a quorum for the transaction of business at such meeting, and, except as otherwise expressly required by statute or the Certificate of Incorporation, the act of a majority of the Directors present at any meeting at which a quorum is present shall be the act of the Board.&nbsp; Any one or more members of the Board or any committee thereof may participate in a meeting of the Board or such committee by means of a conference telephone or similar communications equipment allowing all participants in the meeting to hear each other at the same time and participation by such means shall constitute presence in person at a meeting.&nbsp; In the absence of a quorum at any meeting of the Board, a majority of the directors present thereat, or if no director be present, the Secretary, may adjourn such meeting to another time and place, or such meeting, unless it be the annual meeting of the Board, need not be held.&nbsp; At any adjourned meeting at which a quorum is present, any business may be transacted which might have been transacted at the meeting as originally called.&nbsp; Except as provided in Article III of these By-Laws, the directors shall act only as a Board and the individual directors shall have no power as such.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>Section 9.</b>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<b><u>Organization.</u></b>&nbsp;&nbsp;At each meeting of the Board, the Chairman of the Board (or, in his or her absence or inability to act, the President, or, in his or her absence or inability to act, another Director chosen by a majority of the Directors present) shall act as chairman of the meeting and preside thereat.&nbsp; The Secretary (or, in his or her absence or inability to act, any person appointed by the chairman of the meeting) shall act as secretary of the meeting and keep the minutes thereof.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM" data-number="7" data-prefix="" data-suffix="" style="text-align: center; font-size: 10pt; font-family: &quot;Times New Roman&quot;;">7</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&nbsp;</div>
</div>
</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>Section 10.</b>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<b><u>Resignations.</u></b>&nbsp;&nbsp;Any Director may resign at any time by giving written notice of his resignation to the Board, the Chairman of the Board, the President or the Secretary.&nbsp; Any such resignation shall take effect at the time specified therein or, if the time when it shall become effective shall not be specified therein, immediately upon its receipt; and unless otherwise specified therein, the acceptance of such resignation shall not be necessary to make it effective.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>Section 11.</b>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<b><u>Vacancies.</u></b>&nbsp;&nbsp;Vacancies, including newly created directorships, may be filled by the decision of majority of the Directors then in office, including those who have so resigned, shall have power to fill such vacancy or vacancies, the vote thereon to take effect when such resignation or resignations shall become effective, and each director so chosen shall hold office as provided in this Section for the filling of other vacancies.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>Section 12.</b>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<b><u>Removal of Directors.</u></b>&nbsp;&nbsp;Except as otherwise provided in the Certificate of Incorporation or in these By-Laws, any Director may be removed, either with or without cause, at any time, by the affirmative vote of a majority of the votes of the issued and outstanding shares of stock entitled to vote for the election of the stockholders called and held for that purpose, or by a majority vote of the Board at a meeting called for such purpose, and the vacancy in the Board caused by any such removal may be filled by such stockholders or Directors, as the case may be, at such meeting, and if the stockholders shall fail to fill such vacancy, such vacancy shall be filled in the manner as provided by these By-Laws.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>Section 13.</b>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<b><u>Compensation.</u></b>&nbsp;&nbsp;The Board shall have authority to fix the compensation, including fees and reimbursement of expenses, of Directors for services to the Corporation in any capacity, provided no such payment shall preclude any director from serving the Corporation in any other capacity and receiving compensation therefor.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>Section 14.</b>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<b><u>Action by the Board.</u></b>&nbsp;&nbsp;To the extent permitted under the laws of the State of Delaware, any action required or permitted to be taken at any meeting of the Board or of any committee thereof may be taken without a meeting if all members of the Board or committee, as the case may be, consent thereto in writing, and the writing or writings are filed with the minutes of the proceedings of the Board or committee.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>ARTICLE III</b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>Executive and Other Committees</b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>Section 1.</b>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<b><u>Executive and Other Committees.</u></b>&nbsp;&nbsp;The Board may, by resolution passed by a majority of the whole Board, designate one or more committees, each committee to consist of two or more of the directors of the Corporation.&nbsp; The Board may designate one or more directors as alternate members of any committee, who may replace any absent or disqualified member at any meeting of the Committee.&nbsp; Any such committee, to the extent provided in the resolution, shall have and may exercise the powers of the Board in the management of the business and affairs of the Corporation, and may authorize the seal of the Corporation to be affixed to all papers which may require it, provided, however, that in the absence or disqualification of any member of such committee or committees, the member or members thereof present at any meeting and not disqualified from voting, whether or not he or they constitute a quorum, may unanimously appoint another member of the Board to act at the meeting in the place of any such absent or disqualified member.&nbsp; Each committee shall keep minutes of its proceedings and shall, report such minutes to the Board when required.&nbsp; All such proceedings shall be subject to revision or alteration by the Board;&nbsp;<u>provided</u>,&nbsp;<u>however</u>, that third parties shall not be prejudiced by such revision or alteration.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>Section 2.</b>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<b><u>General.</u></b>&nbsp;&nbsp;A majority of any committee may determine its action and fix the time and place of its meetings, unless the Board shall otherwise provide.&nbsp; Notice of such meetings shall be given to each member of the committee in the manner provided for in Article II, Section 7.&nbsp; The Board shall have the power at any time to fill vacancies in, to change the membership of, or to dissolve any such committee.&nbsp; Nothing herein shall be deemed to prevent the Board from appointing one or more committees consisting in whole or in part of persons who are directors of the Corporation;&nbsp;<u>provided</u>,&nbsp;<u>however</u>, that no such committee shall have or may exercise any authority of the Board.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM" data-number="8" data-prefix="" data-suffix="" style="text-align: center; font-size: 10pt; font-family: &quot;Times New Roman&quot;;">8</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&nbsp;</div>
</div>
</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>ARTICLE IV</b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>Officers</b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>Section 1.</b>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<b><u>Number and Qualifications.</u></b>&nbsp;&nbsp;The officers of the Corporation shall include the Chairman of the Board, the President, one or more Vice Presidents (one or more of whom may be designated an Executive Vice President or a Senior Vice President), the Treasurer and the Secretary.&nbsp; Any two or more offices may be held by the same person.&nbsp; Such officers shall be elected or appointed from time to time by the Board, each to hold office until the meeting of the Board following the next annual meeting of the stockholders, or until his or her successor shall have been duly elected or appointed and shall have qualified, or until such Officer&#8217;s death, or until such Officer shall have resigned, or have been removed, as hereinafter provided in these By-Laws.&nbsp; The Board may from time to time elect a Vice Chairman of the Board, and the Board may from time to time elect, or the Chairman of the Board, or the President may appoint, such other officers (including one or more Assistant Vice Presidents, Assistant Secretaries and Assistant Treasurers), as may be necessary or desirable for the business of the Corporation.&nbsp; Such other officers and agents shall have such duties and shall hold their offices for such terms as may be prescribed by the Board or by the appointing.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>Section 2.</b>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<b><u>Resignation.</u></b>&nbsp;&nbsp;Any officer of the Corporation may resign at any time by giving written notice of his resignation to the Board, the Chairman of the Board, the President or the Secretary.&nbsp; Any such resignation shall take effect at the time specified therein or, if the time when it shall become effective shall not be specified therein, immediately upon its receipt; and unless otherwise specified therein, the acceptance of such resignation shall not be necessary to make it effective.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>Section 3.</b>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<b><u>Removal.</u></b>&nbsp;&nbsp;Any officer or agent of the Corporation may be removed, either with or without cause, at any time, by the vote of the majority of the entire Board at any meeting of the Board or, except in the case of an officer or agent elected or appointed by the Board, by the Chairman of the Board or the President.&nbsp; Such removal shall be without prejudice to the contractual rights, if any, of the person so removed.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>Section 4.</b>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<b><u>Vacancies.</u></b>&nbsp;&nbsp;A vacancy in any office, whether arising from death, disability, resignation, removal or any other cause, may be filled for the unexpired portion of the term of the office which shall be vacant, in the manner prescribed in these By-Laws for the regular election or appointment to such office.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>Section 5.</b>&nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;<b>a.</b>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<b><u>The Chairman of the Board.</u></b>&nbsp;&nbsp;The Chairman of the Board, if one be elected, shall, if present, preside at each meeting of the stockholders and of the Board and shall be an ex officio member of all committees of the Board.&nbsp; He shall perform all duties incident to the office of Chairman of the Board and such other duties as may from time to time be assigned to him by the Board.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 81pt;"><b>b.</b>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<b><u>The Vice Chairman of the Board.</u></b>&nbsp;&nbsp;The Vice Chairman of the Board, if one be elected, shall have such powers and perform all such duties as from time to time may be assigned to him by the Board or the Chairman of the Board and, unless otherwise provided by the Board, shall in the case of the absence or inability to act of the Chairman of the Board, perform the duties of the Chairman of the Board and when so acting shall have all the powers of, and be subject to all the restrictions upon, the Chairman of the Board.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>Section 6.</b>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<b><u>The President.</u></b>&nbsp;&nbsp;The President shall be the chief executive officer of the Corporation and shall have general and active supervision and direction over the business and affairs of the Corporation and over its several officers, subject, however, to the direction of the Chairman of the Board and the control of the Board.&nbsp; If no Chairman of the Board is elected or at the request of the Chairman of the Board, or in the case of his absence or inability to act, unless there be a Vice Chairman of the Board so designated to act, the President shall perform the duties of the Chairman of the Board and when so acting shall have all the powers of, and be subject to all the restrictions upon, the Chairman of the Board.&nbsp; He shall perform all duties incident to the office of President and such other duties as from time to time may be assigned to him by the Board or the Chairman of the Board.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM" data-number="9" data-prefix="" data-suffix="" style="text-align: center; font-size: 10pt; font-family: &quot;Times New Roman&quot;;">9</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&nbsp;</div>
</div>
</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>Section 7.</b>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<b><u>Vice Presidents.</u></b>&nbsp;&nbsp;Each Executive Vice President, each Senior Vice President and each Vice President shall have such powers and perform all such duties as from time to time may be assigned to such person by the Board, the Chairman of the Board or the President.&nbsp; They shall in the order of their seniority, have the power and may perform the duties of the Chairman of the Board and the President.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>Section 8.</b>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<b><u>The Treasurer.</u></b>&nbsp;&nbsp;The Treasurer shall exercise general supervision over the receipt, custody and disbursement of corporate funds.&nbsp; He or she shall have such further powers and duties as may be conferred upon him from time to time by the President or the Board of Directors.&nbsp; He or she shall perform the duties of controller if no one is elected to that office.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>Section 9.</b>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<b><u>The Secretary.</u></b>&nbsp;&nbsp;The Secretary shall:</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:27pt;"><b>(a)</b>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;keep or cause to be kept in one or more books provided for the purpose, the minutes of all meetings of the Board, the committees of the Board and the stockholders;</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:27pt;"><b>(b)</b>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;see that all notices are duly given in accordance with the provisions of these By-Laws and as required by law;</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:27pt;"><b>(c)</b>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;be custodian of the records and the seal of the Corporation and affix and attest the seal to all stock certificates of the Corporation (unless the seal be a facsimile, as hereinafter provided) and affix and attest the seal to all other documents to be executed on behalf of the Corporation under its seal;</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:27pt;"><b>(d)</b>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;see that the books, reports, statements, certificates and other documents and records required by law to be kept and filed are properly kept and filed; and</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:27pt;"><b>(e)</b>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;in general, perform all the duties incident to the office of Secretary and such other duties as from time to time may be assigned to him by the Board, the Chairman of the Board, or the President.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>Section 10.</b>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<b><u>Officer's Bonds or Other Security.</u></b>&nbsp;&nbsp;If required by the Board, any officer of the Corporation may be required to give a bond or other security for the faithful performance of his duties, in such amount and with such surety or sureties as the Board may require.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>Section 11.</b>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<b><u>Compensation.</u></b>&nbsp;&nbsp;The compensation of the officers of the Corporation for their services as such officers shall be fixed from time to time by the Board;&nbsp;<u>provided</u>,&nbsp;<u>however</u>, that the Board may delegate to the Chairman of the Board or the President the power to fix the compensation of officers and agents appointed by the Chairman of the Board or the President, as the case may be.&nbsp; An officer of the Corporation shall not be prevented from receiving compensation by reason of the fact that he is also a director of the Corporation, but any such officer who shall also be a Director shall not have any vote in the determination of the amount of compensation paid to him.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM" data-number="10" data-prefix="" data-suffix="" style="text-align: center; font-size: 10pt; font-family: &quot;Times New Roman&quot;;">10</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&nbsp;</div>
</div>
</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>ARTICLE V</b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>Indemnification</b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:63pt;">The Corporation shall, to the fullest extent permitted by the laws of the state of Delaware, indemnify any and all persons whom it shall have power to indemnify against any and all of the costs, expenses, liabilities or other matters incurred by them by reason of having been officers or Directors of the Corporation, any subsidiary of the Corporation or of any other corporation for which such person acted as officer or director at the request of the Corporation.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>ARTICLE VI</b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>Contracts, Checks, Drafts, Bank Account, Etc.</b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>Section 1.</b>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<b><u>Execution of Contracts.</u></b>&nbsp;&nbsp;Except as otherwise required by statute, the Certificate of Incorporation or these By-Laws, any contracts or other instruments may be executed and delivered in the name and on behalf of the Corporation by such officer or officers (including any assistant officer) of the Corporation as the Board may, from time to time, direct.&nbsp; Such authority may be general or confined to specific instances as the Board may determine.&nbsp; Unless authorized by the Board or expressly permitted by these By-Laws, an officer or agent or employee shall not have any power or authority to bind the Corporation by any contract or engagement or to pledge its credit or to render it pecuniarily liable for any purpose or to any amount.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>Section 2.</b>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<b><u>Loans.</u></b>&nbsp;&nbsp;Unless the Board shall otherwise determine, either (a) the Chairman of the Board, the Vice Chairman of the Board or the President, singly, or (b) a Vice President, together with the Treasurer, may effect loans and advances at any time for the Corporation or guarantee any loans and advances to any subsidiary of the Corporation, from any bank, trust company or other institution, or from any firm, corporation or individual, and for such loans and advances way make, execute and deliver promissory notes, bonds or other certificates or evidences of indebtedness of the Corporation, or guarantee of indebtedness of subsidiaries of the Corporation, but no officer or officers shall mortgage, pledge, hypothecate or transfer any securities or other property of the Corporation, except when authorized by the Board.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>Section 3.</b>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<b><u>Checks, Drafts, Etc.</u></b>&nbsp;&nbsp;All checks, drafts, bills of exchange or other orders for the payment of money out of the funds of the Corporation, and all notes or other evidences of indebtedness of the Corporation, shall be signed in the name and on behalf of the Corporation by such persons and in such manner as shall from time to time be authorized by the Board.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>Section 4.</b>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<b><u>Deposits.</u></b>&nbsp;&nbsp;All funds of the Corporation not otherwise employed shall be deposited from time to time to the credit of the Corporation in such banks, trust companies or other depositories as the Board may from time to time designate or as may be designated by any officer or officers of the Corporation to whom such power of designation may from time to time be delegated by the Board.&nbsp; For the purpose of deposit and for the purpose of collection for the account of the Corporation, checks, drafts and other orders for the payment of money which are payable to the order of the Corporation my be endorsed, assigned and delivered by any officer or agent of the Corporation, or in such manner as the Board may determine by resolution.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>Section 5.</b>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<b><u>General and Special Bank Accounts.</u></b>&nbsp;&nbsp;The Board may, from time to time, authorize the opening and keeping of general and special bank accounts with such banks, trust companies or other depositories as the Board may designate or as may be designated by any officer or officers of the Corporation to whom such power of designation may from time to time be delegated by the Board.&nbsp; The Board may make such special rules and regulations with respect to such bank accounts, not inconsistent with the provisions of these By-Laws, as it may deem expedient.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM" data-number="11" data-prefix="" data-suffix="" style="text-align: center; font-size: 10pt; font-family: &quot;Times New Roman&quot;;">11</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&nbsp;</div>
</div>
</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>Section 6.</b>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<b><u>Proxies in Respect of Securities of Other Corporations.</u></b>&nbsp;&nbsp;Unless otherwise provided by resolution adopted by the Board, the Chairman of the Board, the President or a Vice President may from time to time appoint an attorney or attorneys or agent or agents of the Corporation, in the name and on behalf of the Corporation, to cast the votes which the Corporation may be entitled to cast as the holder of stock or other securities in any other corporation, any of whose stock or other securities may be held by the Corporation, at meetings of the holders of the stock or other securities of such other corporation, or to consent in writing, in the name of the Corporation as such holder, to any action by such other corporation, and may instruct the person or persons so appointed as to the manner of casting such votes or giving such consent, and may execute or cause to be executed, in the name and on behalf of the Corporation, and under its corporate seal, or otherwise, all such written proxies or other instruments as he or she may deem necessary or proper in the premises.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>ARTICLE VII</b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>Shares, Etc.</b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>Section 1.</b>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<b><u>Stock Certificates.</u></b>&nbsp;&nbsp;Shares of stock of the Corporation shall be represented by certificates, or shall be uncertificated shares that may be evidenced by a book-entry system maintained by the registrar of such stock, or a combination of both. To the extent that shares are represented by certificates, such certificates shall be in a form approved by the Board. Each certificate shall be signed in the name of the Corporation by (A) the Chairman or Vice Chairman of the Board or the President or a Vice President, and (B) the Secretary or an Assistant Secretary or the Treasurer or an Assistant Treasurer, and sealed with the seal of the Corporation (which seal may be a facsimile, engraved or printed);&nbsp;<u>provided</u>,&nbsp;<u>however</u>, that where any such certificate is countersigned by a transfer agent other than the Corporation or one of its employees, or is registered by a registrar other than the Corporation or one of its employees, the signature of the officers of the Corporation upon such certificates may be facsimiles, engraved or printed. In case any officer who shall have signed or whose facsimile signature has been placed upon such certificates shall have ceased to be such officer before such certificates shall be issued, they may nevertheless be issued by the Corporation with the same effect as if such officer were still in office at the date of their issue.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>Section 2.</b>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<b><u>Books of Account and Record of Shareholders.</u></b>&nbsp;&nbsp;The books and records of the Corporation may be kept at such places within or without the state of incorporation as the Board of Directors may from time to time determine.&nbsp; The stock record books and the blank stock certificate books shall be kept by the Secretary or by any other officer or agent designated by the Board of Directors.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>Section 3.</b>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<b><u>Transfer of Shares.</u></b>&nbsp;&nbsp;Subject to any restrictions on transfer and unless otherwise provided by the Board, shares of stock may be transferred only on the books of the Corporation by the surrender to the Corporation or its transfer agent of the shares in certificated form, properly endorsed or accompanied by a written assignment or power of attorney properly executed, with transfer stamps (if necessary) affixed, or upon proper instructions from the holder of uncertificated shares, in each case with such proof of the authenticity of signature as the Corporation or its transfer agent may reasonably require.&nbsp;&nbsp;Except as otherwise provided by applicable law, the Corporation shall be entitled to recognize the exclusive right of a person in whose name any share or shares stand on the record of stockholders as the owner of such share or shares for all purposes, including, without limitation, the rights to receive dividends or other distributions and to vote as such owner, and the Corporation may hold any such stockholder of record liable for calls and assessments and the Corporation shall not be bound to recognize any equitable or legal claim to or interest in any such share or shares on the part of any other person whether or not it shall have express or other notice thereof.&nbsp; Whenever any transfers of shares shall be made for collateral security and not absolutely, and both the transferor and transferee request the Corporation to do so, such fact shall be stated in the entry of the transfer.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>Section 4.</b>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<b><u>Regulations.</u></b>&nbsp;&nbsp;The Board may make such additional rules and regulations, not inconsistent with these By-Laws, as it may deem expedient concerning the issue, transfer and registration of certificates for shares of stock of the Corporation.&nbsp; It may appoint, or authorize any officer or officers to appoint, one or more transfer agents or one or more transfer clerks and one or more registrars and may require all certificates for shares of stock to bear the signature or signatures of any of them.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM" data-number="12" data-prefix="" data-suffix="" style="text-align: center; font-size: 10pt; font-family: &quot;Times New Roman&quot;;">12</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&nbsp;</div>
</div>
</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>Section 5.</b>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<b><u>Lost, Destroyed or Mutilated Certificates.</u></b>&nbsp;&nbsp;The holder of any certificate representing shares of stock of the Corporation shall immediately notify the Corporation of any loss, destruction or mutilation of such certificate, and the Corporation may issue a new certificate of stock in the place of any certificate theretofore issued by it which the owner thereof shall allege to have been lost, stolen or destroyed or which shall have been mutilated, and the Board may, in its discretion, require such owner or his legal representative to give the Corporation a bond in such sum, limited or unlimited, and in such form and with such surety or sureties as the Board in its absolute discretion shall determine, to indemnify the Corporation against any claim that way be made against it on account of the alleged loss, theft or destruction of any such certificate, or the issuance of a new certificate.&nbsp; Anything herein to the contrary notwithstanding, the Board, in its absolute discretion, may refuse to issue any such new certificate, except pursuant to legal proceedings under the laws of the State of Delaware.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>Section 6.</b>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<b><u>Fixing of Record Date.</u></b>&nbsp;&nbsp;In order that the Corporation may determine the stockholders entitled to notice of, or to vote at, any meeting of stockholders or any adjournment thereof, or to express consent to corporate action in writing without a meeting, or entitled to receive payment of any dividend or other distribution or allotment of any rights, or entitled to exercise any rights in respect of any change, conversion or exchange of stock or for the purpose of any other lawful action, the Board may fix in advance a record date, which shall not be more than 60 nor less than 10 days before the date of such meeting, nor more than 60 days prior to any other action.&nbsp; A determination of stockholders of record entitled to notice of, or to vote at, a meeting of stockholders shall apply to any adjournment of the meeting;&nbsp;<u>provided</u>,&nbsp;<u>however</u>, that the Board may fix a new record date for the adjourned meeting.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>ARTICLE VIII</b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>Offices</b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>Section 1.</b>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<b><u>Principal or Registered Office.</u></b>&nbsp;&nbsp;The principal registered office of the Corporation shall be at such place as may be specified in the Certificate of Incorporation or other certificate filed pursuant to law, or if none be so specified, at such place as may from time to time be fixed by the Board.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>Section 2.</b>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<b><u>Other Offices.</u></b>&nbsp;&nbsp;The Corporation also may have an office or offices other than said principal or registered office, at such place or places either within or without the State of Delaware.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>ARTICLE IX</b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>Fiscal Year</b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">The fiscal year of the Corporation shall be determined by the Board.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>ARTICLE X</b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>Seal</b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">The Board shall provide a corporate seal which shall contain the name of the Corporation, the words "Corporate Seal" and the year and State of Delaware.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM" data-number="13" data-prefix="" data-suffix="" style="text-align: center; font-size: 10pt; font-family: &quot;Times New Roman&quot;;">13</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&nbsp;</div>
</div>
</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>ARTICLE XI</b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>Amendments</b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>Section 1.</b>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<b><u>Stockholders.</u></b>&nbsp;&nbsp;These By-Laws may be amended or repealed, or new By-Laws may be adopted, at any annual or special meeting of the stockholders, by a majority of the total votes of the stockholders or when stockholders are required to vote by class by a majority of the appropriate class, in person or represented by proxy and entitled to vote on such action;&nbsp;<u>provided</u>,&nbsp;<u>however</u>, that the notice of such meeting shall have been given as provided in these By-Laws, which notice shall mention that amendment or repeal of these By-Laws, or the adoption of new By-Laws, is one of the purposes of such meeting.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>Section 2.</b>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<b><u>Board of Directors.</u></b>&nbsp;&nbsp;These By-Laws may also be amended or repealed or new By-Laws may be adopted by the Board at any meeting of the Board;&nbsp;<u>provided</u>,&nbsp;<u>however</u>, that notice of such meeting shall have been given as provided in these By-Laws, which notice shall mention that amendment or repeal of the By-Laws, or the adoption of new By-Laws, is one of the purposes of such meetings.&nbsp; By-Laws adopted by the Board may be amended or repealed by the stockholders as provided in Section 1 of this Article XI.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>ARTICLE XII</b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>Miscellaneous</b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>Section 1.</b>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<b><u>Interested Directors.</u></b>&nbsp;&nbsp;No contract or other transaction between the Corporation and any other corporation shall be affected and invalidated solely by the fact that any one or more of the Directors of the Corporation is or are interested in or is a director or officer or are directors or officers of such other corporation, and any Director or Directors, individually or jointly, may be a party or parties to or may be interested in any contract or transaction of the Corporation or in which the Corporation is interested; and no contract, act or transaction of the Corporation with any person or persons, firm or corporation shall be affected or invalidated by the fact that any Director of the Corporation is a party or are parties to or interested in such contract, act or transaction, or in any way connected with such person or persons, firms or associations, and each and every person who may become a Director of the Corporation is hereby relieved from any liability that might otherwise exist from contracting with the Corporation for the benefit of himself or herself, any firm, association or corporation in which such Director may be in any way interested.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>Section 2.</b>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<b><u>Ratification</u></b><b><i>.</i></b>&nbsp;&nbsp;Any transaction questioned in any stockholders derivative suit on the grounds of lack of authority, defective or irregular execution, adverse interest of director, officer or stockholder, nondisclosure, miscomputation, or the application of improper principles or practices of accounting, may be ratified before or after judgment, by the Board or, by the stockholders in case less than a quorum of Directors are qualified, and, if so ratified, shall have the same force and effect as if the questioned transaction had been originally duly authorized, and said ratification shall be binding upon the Corporation and its stockholders, and shall constitute a bar to any claim or execution of any judgment, in respect of such questioned transaction.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<div class="LAST-PAGE-BREAK">
<div class="PGFTR">
<div class="hf-row">
<div class="hf-cell PGNUM" data-number="14" data-prefix="" data-suffix="" style="text-align: center; font-size: 10pt; font-family: &quot;Times New Roman&quot;;">14</div>
</div>
</div>
</div>


</body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.1
<SEQUENCE>3
<FILENAME>ex_378191.htm
<DESCRIPTION>EXHIBIT 31.1
<TEXT>
<html><head><meta charset="utf-8"><meta name="format-detection" content="telephone=no"><!--Created on 5/17/2021 9:54:52 AM --><meta name="generator" content="RDG HTML Converter 3.4.3.0">
	<title>ex_378191.htm</title>


</head>
<body style="font-size: 10pt; font-family: &quot;Times New Roman&quot;; padding: 0in 0.1in; cursor: auto;">
<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: right; margin: 0pt;"><b>Exhibit 31.1</b></p>

<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;">&nbsp;</p>

<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>CERTIFICATION</b></p>

<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;">&nbsp;</p>

<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt;">I, Craig E. Fraser, certify that:</p>

<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px; font-family: Times New Roman; font-size: 10pt;">

		<tr style="vertical-align: top; font-family: Times New Roman; font-size: 10pt;">
			<td style="width: 27pt; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td>
			<td style="width: 27pt; font-family: Times New Roman; font-size: 10pt;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">1.</p>
			</td>
			<td style="font-family: Times New Roman; font-size: 10pt;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">I have reviewed this Quarterly Report on Form 10-Q of Windtree Therapeutics, Inc.;</p>
			</td>
		</tr>

</table>

<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px; font-family: Times New Roman; font-size: 10pt;">

		<tr style="vertical-align: top; font-family: Times New Roman; font-size: 10pt;">
			<td style="width: 27pt; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td>
			<td style="width: 27pt; font-family: Times New Roman; font-size: 10pt;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">2.</p>
			</td>
			<td style="font-family: Times New Roman; font-size: 10pt;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;</p>
			</td>
		</tr>

</table>

<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px; font-family: Times New Roman; font-size: 10pt;">

		<tr style="vertical-align: top; font-family: Times New Roman; font-size: 10pt;">
			<td style="width: 27pt; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td>
			<td style="width: 27pt; font-family: Times New Roman; font-size: 10pt;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">3.</p>
			</td>
			<td style="font-family: Times New Roman; font-size: 10pt;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;</p>
			</td>
		</tr>

</table>

<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px; font-family: Times New Roman; font-size: 10pt;">

		<tr style="vertical-align: top; font-family: Times New Roman; font-size: 10pt;">
			<td style="width: 27pt; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td>
			<td style="width: 27pt; font-family: Times New Roman; font-size: 10pt;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">4.</p>
			</td>
			<td style="font-family: Times New Roman; font-size: 10pt;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">The registrant&#8217;s other certifying officers and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reports (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f) for the registrant and have:</p>
			</td>
		</tr>

</table>

<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px; font-family: Times New Roman; font-size: 10pt;">

		<tr style="vertical-align: top; font-family: Times New Roman; font-size: 10pt;">
			<td style="width: 72pt; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td>
			<td style="width: 27pt; font-family: Times New Roman; font-size: 10pt;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">(a)</p>
			</td>
			<td style="font-family: Times New Roman; font-size: 10pt;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;</p>
			</td>
		</tr>

</table>

<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px; font-family: Times New Roman; font-size: 10pt;">

		<tr style="vertical-align: top; font-family: Times New Roman; font-size: 10pt;">
			<td style="width: 72pt; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td>
			<td style="width: 27pt; font-family: Times New Roman; font-size: 10pt;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">(b)</p>
			</td>
			<td style="font-family: Times New Roman; font-size: 10pt;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;</p>
			</td>
		</tr>

</table>

<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px; font-family: Times New Roman; font-size: 10pt;">

		<tr style="vertical-align: top; font-family: Times New Roman; font-size: 10pt;">
			<td style="width: 72pt; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td>
			<td style="width: 27pt; font-family: Times New Roman; font-size: 10pt;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">(c)</p>
			</td>
			<td style="font-family: Times New Roman; font-size: 10pt;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">evaluated the effectiveness of the registrant&#8217;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and</p>
			</td>
		</tr>

</table>

<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px; font-family: Times New Roman; font-size: 10pt;">

		<tr style="vertical-align: top; font-family: Times New Roman; font-size: 10pt;">
			<td style="width: 72pt; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td>
			<td style="width: 27pt; font-family: Times New Roman; font-size: 10pt;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">(d)</p>
			</td>
			<td style="font-family: Times New Roman; font-size: 10pt;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">disclosed in this report any change in the registrant&#8217;s internal control over financial reporting that occurred during the registrant&#8217;s most recent fiscal quarter (the registrant&#8217;s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant&#8217;s internal control over financial reporting; and</p>
			</td>
		</tr>

</table>

<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px; font-family: Times New Roman; font-size: 10pt;">

		<tr style="vertical-align: top; font-family: Times New Roman; font-size: 10pt;">
			<td style="width: 27pt; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td>
			<td style="width: 27pt; font-family: Times New Roman; font-size: 10pt;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">5.</p>
			</td>
			<td style="font-family: Times New Roman; font-size: 10pt;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">The registrant&#8217;s other certifying officers and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant&#8217;s auditors and the audit committee of the registrant&#8217;s board of directors (or persons performing the equivalent function):</p>
			</td>
		</tr>

</table>

<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px; font-family: Times New Roman; font-size: 10pt;">

		<tr style="vertical-align: top; font-family: Times New Roman; font-size: 10pt;">
			<td style="width: 72pt; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td>
			<td style="width: 27pt; font-family: Times New Roman; font-size: 10pt;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">(a)</p>
			</td>
			<td style="font-family: Times New Roman; font-size: 10pt;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">all significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant&#8217;s ability to record, process, summarize and report financial information; and</p>
			</td>
		</tr>

</table>

<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px; font-family: Times New Roman; font-size: 10pt;">

		<tr style="vertical-align: top; font-family: Times New Roman; font-size: 10pt;">
			<td style="width: 72pt; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td>
			<td style="width: 27pt; font-family: Times New Roman; font-size: 10pt;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">(b)</p>
			</td>
			<td style="font-family: Times New Roman; font-size: 10pt;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&#8217;s internal control over financial reporting.</p>
			</td>
		</tr>

</table>

<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;">&nbsp;</p>

<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;">Date: <a data-tblloc="20x1" data-tblname="82667" data-tblv="20" id="led82667F20214171621271403474">August 11, 2022</a></p>

<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;">&nbsp;</p>

<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;margin-left:auto;margin-right:auto;">

		<tr style="font-family: Times New Roman; font-size: 10pt;">
			<td style="vertical-align: top; width: 29.7%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td>
			<td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: top; width: 16%; font-family: Times New Roman; font-size: 10pt;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">/s/ Craig E. Fraser</p>
			</td>
		</tr>
		<tr style="font-family: Times New Roman; font-size: 10pt;">
			<td style="vertical-align: top; width: 29.7%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td>
			<td style="vertical-align: top; width: 16%; font-family: Times New Roman; font-size: 10pt;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Craig E. Fraser</p>
			</td>
		</tr>
		<tr style="font-family: Times New Roman; font-size: 10pt;">
			<td style="vertical-align: top; width: 29.7%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td>
			<td style="vertical-align: top; width: 16%; font-family: Times New Roman; font-size: 10pt;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">President and Chief Executive Officer</p>
			</td>
		</tr>
		<tr style="font-family: Times New Roman; font-size: 10pt;">
			<td style="vertical-align: top; width: 29.7%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td>
			<td style="vertical-align: top; width: 16%; font-family: Times New Roman; font-size: 10pt;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">(Principal Executive Officer)</p>
			</td>
		</tr>

</table>

<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;">&nbsp;</p>

<div class="LAST-PAGE-BREAK">
<div class="PGFTR">
<div class="hf-row">
<div class="hf-cell PGNUM">&nbsp;</div>
</div>
</div>
</div>


</body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.2
<SEQUENCE>4
<FILENAME>ex_378192.htm
<DESCRIPTION>EXHIBIT 31.2
<TEXT>
<html><head><meta charset="utf-8"><meta name="format-detection" content="telephone=no"><!--Created on 5/17/2021 9:58:06 AM --><meta name="generator" content="RDG HTML Converter 3.4.3.0">
	<title>ex_378192.htm</title>


</head>
<body style="font-size: 10pt; font-family: &quot;Times New Roman&quot;; padding: 0in 0.1in; cursor: auto;">
<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: right; margin: 0pt;"><b>Exhibit 31.2</b></p>

<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;">&nbsp;</p>

<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>CERTIFICATION</b></p>

<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;">&nbsp;</p>

<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;">I, John P. Hamill, certify that:</p>

<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px; font-family: Times New Roman; font-size: 10pt;">

		<tr style="vertical-align: top; font-family: Times New Roman; font-size: 10pt;">
			<td style="width: 27pt; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td>
			<td style="width: 27pt; font-family: Times New Roman; font-size: 10pt;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">1.</p>
			</td>
			<td style="font-family: Times New Roman; font-size: 10pt;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">I have reviewed this Quarterly Report on Form 10-Q of Windtree Therapeutics, Inc.;</p>
			</td>
		</tr>

</table>

<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px; font-family: Times New Roman; font-size: 10pt;">

		<tr style="vertical-align: top; font-family: Times New Roman; font-size: 10pt;">
			<td style="width: 27pt; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td>
			<td style="width: 27pt; font-family: Times New Roman; font-size: 10pt;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">2.</p>
			</td>
			<td style="font-family: Times New Roman; font-size: 10pt;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;</p>
			</td>
		</tr>

</table>

<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px; font-family: Times New Roman; font-size: 10pt;">

		<tr style="vertical-align: top; font-family: Times New Roman; font-size: 10pt;">
			<td style="width: 27pt; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td>
			<td style="width: 27pt; font-family: Times New Roman; font-size: 10pt;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">3.</p>
			</td>
			<td style="font-family: Times New Roman; font-size: 10pt;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;</p>
			</td>
		</tr>

</table>

<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px; font-family: Times New Roman; font-size: 10pt;">

		<tr style="vertical-align: top; font-family: Times New Roman; font-size: 10pt;">
			<td style="width: 27pt; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td>
			<td style="width: 27pt; font-family: Times New Roman; font-size: 10pt;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">4.</p>
			</td>
			<td style="font-family: Times New Roman; font-size: 10pt;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">The registrant&#8217;s other certifying officers and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting<br>
			(as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:</p>
			</td>
		</tr>

</table>

<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px; font-family: Times New Roman; font-size: 10pt;">

		<tr style="vertical-align: top; font-family: Times New Roman; font-size: 10pt;">
			<td style="width: 72pt; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td>
			<td style="width: 27pt; font-family: Times New Roman; font-size: 10pt;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">(a)</p>
			</td>
			<td style="font-family: Times New Roman; font-size: 10pt;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;</p>
			</td>
		</tr>

</table>

<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px; font-family: Times New Roman; font-size: 10pt;">

		<tr style="vertical-align: top; font-family: Times New Roman; font-size: 10pt;">
			<td style="width: 72pt; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td>
			<td style="width: 27pt; font-family: Times New Roman; font-size: 10pt;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">(b)</p>
			</td>
			<td style="font-family: Times New Roman; font-size: 10pt;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;</p>
			</td>
		</tr>

</table>

<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px; font-family: Times New Roman; font-size: 10pt;">

		<tr style="vertical-align: top; font-family: Times New Roman; font-size: 10pt;">
			<td style="width: 72pt; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td>
			<td style="width: 27pt; font-family: Times New Roman; font-size: 10pt;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">(c)</p>
			</td>
			<td style="font-family: Times New Roman; font-size: 10pt;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">evaluated the effectiveness of the registrant&#8217;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and</p>
			</td>
		</tr>

</table>

<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px; font-family: Times New Roman; font-size: 10pt;">

		<tr style="vertical-align: top; font-family: Times New Roman; font-size: 10pt;">
			<td style="width: 72pt; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td>
			<td style="width: 27pt; font-family: Times New Roman; font-size: 10pt;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">(d)</p>
			</td>
			<td style="font-family: Times New Roman; font-size: 10pt;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">disclosed in this report any change in the registrant&#8217;s internal control over financial reporting that occurred during the registrant&#8217;s most recent fiscal quarter (the registrant&#8217;s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant&#8217;s internal control over financial reporting; and</p>
			</td>
		</tr>

</table>

<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px; font-family: Times New Roman; font-size: 10pt;">

		<tr style="vertical-align: top; font-family: Times New Roman; font-size: 10pt;">
			<td style="width: 27pt; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td>
			<td style="width: 27pt; font-family: Times New Roman; font-size: 10pt;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">5.</p>
			</td>
			<td style="font-family: Times New Roman; font-size: 10pt;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">The registrant&#8217;s other certifying officers and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant&#8217;s auditors and the audit committee of the registrant&#8217;s board of directors (or persons performing the equivalent function):</p>
			</td>
		</tr>

</table>

<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px; font-family: Times New Roman; font-size: 10pt;">

		<tr style="vertical-align: top; font-family: Times New Roman; font-size: 10pt;">
			<td style="width: 72pt; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td>
			<td style="width: 27pt; font-family: Times New Roman; font-size: 10pt;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">(a)</p>
			</td>
			<td style="font-family: Times New Roman; font-size: 10pt;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">all significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant&#8217;s ability to record, process, summarize and report financial information; and</p>
			</td>
		</tr>

</table>

<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px; font-family: Times New Roman; font-size: 10pt;">

		<tr style="vertical-align: top; font-family: Times New Roman; font-size: 10pt;">
			<td style="width: 72pt; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td>
			<td style="width: 27pt; font-family: Times New Roman; font-size: 10pt;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">(b)</p>
			</td>
			<td style="font-family: Times New Roman; font-size: 10pt;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&#8217;s internal control over financial reporting.</p>
			</td>
		</tr>

</table>

<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;">&nbsp;</p>

<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;">Date: <a data-tblloc="20x1" data-tblname="82667" data-tblv="20" id="led82667F20214171621271421240">August 11, 2022</a></p>

<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;margin-left:auto;margin-right:auto;">

		<tr style="font-family: Times New Roman; font-size: 10pt;">
			<td style="vertical-align: top; width: 29.7%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td>
			<td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: top; width: 16%; font-family: Times New Roman; font-size: 10pt;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">/s/ John P. Hamill</p>
			</td>
		</tr>
		<tr style="font-family: Times New Roman; font-size: 10pt;">
			<td style="vertical-align: top; width: 29.7%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td>
			<td style="vertical-align: top; width: 16%; font-family: Times New Roman; font-size: 10pt;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">John P. Hamill</p>
			</td>
		</tr>
		<tr style="font-family: Times New Roman; font-size: 10pt;">
			<td style="vertical-align: top; width: 29.7%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td>
			<td style="vertical-align: top; width: 16%; font-family: Times New Roman; font-size: 10pt;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Senior Vice President and Chief Financial Officer</p>

			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">(Principal Financial&nbsp;Officer)</p>
			</td>
		</tr>

</table>

<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;">&nbsp;</p>

<div class="LAST-PAGE-BREAK">
<div class="PGFTR">
<div class="hf-row">
<div class="hf-cell PGNUM">&nbsp;</div>
</div>
</div>
</div>


</body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.1
<SEQUENCE>5
<FILENAME>ex_378193.htm
<DESCRIPTION>EXHIBIT 32.1
<TEXT>
<html><head><meta charset="utf-8"><meta name="format-detection" content="telephone=no"><!--Created on 5/17/2021 10:00:18 AM --><meta name="generator" content="RDG HTML Converter 3.4.3.0">
	<title>ex_378193.htm</title>

</head>
<body style="font-size:10pt;font-family:'Times New Roman';padding:0in .1in;">
<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: right; margin: 0pt;"><b>Exhibit 32.1</b></p>

<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;">&nbsp;</p>

<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Certification Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002</b></p>

<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>(Subsections (a) and (b) of Section 1350, Chapter 63 of Title 18, United States Code)</b></p>

<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;">&nbsp;</p>

<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 27pt;">In connection with the Quarterly Report of Windtree Therapeutics, Inc. (the &#8220;Company&#8221;) on Form 10-Q for the quarter ended <a data-tblloc="5x1" data-tblname="82667" data-tblv="20" id="led82667F20214171621271436477">June 30, 2022</a>, as filed with the Securities and Exchange Commission on the date hereof (the &#8220;Report&#8221;), each of the undersigned officers of the Company certifies, pursuant to 18 U.S.C. Section&nbsp;1350, as adopted pursuant to Section&nbsp;906 of the Sarbanes-Oxley Act of 2002, that to such officer&#8217;s knowledge:</p>

<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px; font-family: Times New Roman; font-size: 10pt;">

		<tr style="vertical-align: top; font-family: Times New Roman; font-size: 10pt;">
			<td style="width: 27pt; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td>
			<td style="width: 27pt; font-family: Times New Roman; font-size: 10pt;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">(1)</p>
			</td>
			<td style="font-family: Times New Roman; font-size: 10pt;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">The Report fully complies with the requirements of Section13(a) or 15(d) of the Securities Exchange Act of 1934; and</p>
			</td>
		</tr>

</table>

<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px; font-family: Times New Roman; font-size: 10pt;">

		<tr style="vertical-align: top; font-family: Times New Roman; font-size: 10pt;">
			<td style="width: 27pt; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td>
			<td style="width: 27pt; font-family: Times New Roman; font-size: 10pt;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">(2)</p>
			</td>
			<td style="font-family: Times New Roman; font-size: 10pt;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.</p>
			</td>
		</tr>

</table>

<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;">&nbsp;</p>

<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;">Date: <a data-tblloc="20x1" data-tblname="82667" data-tblv="20" id="led82667F20214171621271449131">August 11, 2022</a></p>

<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;margin-left:auto;margin-right:auto;">

		<tr style="font-family: Times New Roman; font-size: 10pt;">
			<td style="vertical-align: top; width: 29.7%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td>
			<td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: top; width: 16%; font-family: Times New Roman; font-size: 10pt;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">/s/ Craig E. Fraser</p>
			</td>
		</tr>
		<tr style="font-family: Times New Roman; font-size: 10pt;">
			<td style="vertical-align: top; width: 29.7%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td>
			<td style="vertical-align: top; width: 16%; font-family: Times New Roman; font-size: 10pt;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Craig E. Fraser</p>
			</td>
		</tr>
		<tr style="font-family: Times New Roman; font-size: 10pt;">
			<td style="vertical-align: top; width: 29.7%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td>
			<td style="vertical-align: top; width: 16%; font-family: Times New Roman; font-size: 10pt;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">President and Chief Executive Officer</p>
			</td>
		</tr>
		<tr style="font-family: Times New Roman; font-size: 10pt;">
			<td style="vertical-align: top; width: 29.7%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td>
			<td style="vertical-align: top; width: 16%; font-family: Times New Roman; font-size: 10pt;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">(Principal Executive Officer)</p>
			</td>
		</tr>
		<tr style="font-family: Times New Roman; font-size: 10pt;">
			<td style="vertical-align: middle; width: 29.7%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td>
			<td style="vertical-align: middle; width: 16%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td>
		</tr>
		<tr style="font-family: Times New Roman; font-size: 10pt;">
			<td style="vertical-align: top; width: 29.7%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td>
			<td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: top; width: 16%; font-family: Times New Roman; font-size: 10pt;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">/s/ John P. Hamill</p>
			</td>
		</tr>
		<tr style="font-family: Times New Roman; font-size: 10pt;">
			<td style="vertical-align: top; width: 29.7%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td>
			<td style="vertical-align: top; width: 16%; font-family: Times New Roman; font-size: 10pt;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">John P. Hamill</p>

			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Senior Vice President and Chief Financial Officer</p>

			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">(Principal Financial Officer)</p>
			</td>
		</tr>

</table>

<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;">&nbsp;</p>

<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;">&nbsp;</p>

<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;">&nbsp;</p>

<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;">A signed original of this written statement required by Section 906 has been provided to the Company and will be retained by the Company and furnished to the Securities and Exchange Commission or its staff upon request. This certification &#8220;accompanies&#8221; the Form 10-Q to which it relates, is not deemed filed with the SEC and is not to be incorporated by reference into any filing of the Company under the Securities Act of 1933, as amended, or the Securities Exchange Act of 1934, as amended (whether made before or after the date of the Form 10-Q), irrespective of any general incorporation language contained in such filing.</p>

<div class="LAST-PAGE-BREAK">
<div class="PGFTR">
<div class="hf-row">
<div class="hf-cell PGNUM">&nbsp;</div>
</div>
</div>
</div>


</body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>6
<FILENAME>wint-20220630.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" standalone="no"?>
<!--Generated by ThunderDome XBRL - 05:34AM UTC 2022-08-11--><xsd:schema xmlns:xsd="http://www.w3.org/2001/XMLSchema" xmlns:country="http://xbrl.sec.gov/country/2022" xmlns:currency="http://xbrl.sec.gov/currency/2022" xmlns:dei="http://xbrl.sec.gov/dei/2022" xmlns:dtr-types="http://www.xbrl.org/dtr/type/2020-01-21" xmlns:exch="http://xbrl.sec.gov/exch/2022" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:naics="http://xbrl.sec.gov/naics/2022" xmlns:sic="http://xbrl.sec.gov/sic/2022" xmlns:srt="http://fasb.org/srt/2022" xmlns:srt-types="http://fasb.org/srt-types/2022" xmlns:stpr="http://xbrl.sec.gov/stpr/2022" xmlns:us-gaap="http://fasb.org/us-gaap/2022" xmlns:us-types="http://fasb.org/us-types/2022" xmlns:wint="http://www.windtreetx.com/20220630" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xlink="http://www.w3.org/1999/xlink" attributeFormDefault="unqualified" elementFormDefault="qualified" targetNamespace="http://www.windtreetx.com/20220630">
  <xsd:import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd"/>
  <xsd:import namespace="http://xbrl.sec.gov/naics/2022" schemaLocation="https://xbrl.sec.gov/naics/2022/naics-2022.xsd"/>
  <xsd:import namespace="http://xbrl.sec.gov/country/2022" schemaLocation="https://xbrl.sec.gov/country/2022/country-2022.xsd"/>
  <xsd:import namespace="http://fasb.org/srt/2022" schemaLocation="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd"/>
  <xsd:import namespace="http://xbrl.sec.gov/dei/2022" schemaLocation="https://xbrl.sec.gov/dei/2022/dei-2022.xsd"/>
  <xsd:import namespace="http://xbrl.sec.gov/sic/2022" schemaLocation="https://xbrl.sec.gov/sic/2022/sic-2022.xsd"/>
  <xsd:import namespace="http://fasb.org/us-types/2022" schemaLocation="https://xbrl.fasb.org/us-gaap/2022/elts/us-types-2022.xsd"/>
  <xsd:import namespace="http://xbrl.org/2005/xbrldt" schemaLocation="http://www.xbrl.org/2005/xbrldt-2005.xsd"/>
  <xsd:import namespace="http://xbrl.sec.gov/stpr/2022" schemaLocation="https://xbrl.sec.gov/stpr/2022/stpr-2022.xsd"/>
  <xsd:import namespace="http://xbrl.sec.gov/exch/2022" schemaLocation="https://xbrl.sec.gov/exch/2022/exch-2022.xsd"/>
  <xsd:import namespace="http://xbrl.sec.gov/currency/2022" schemaLocation="https://xbrl.sec.gov/currency/2022/currency-2022.xsd"/>
  <xsd:import namespace="http://www.xbrl.org/dtr/type/2020-01-21" schemaLocation="https://www.xbrl.org/dtr/type/2020-01-21/types.xsd"/>
  <xsd:import namespace="http://fasb.org/srt-types/2022" schemaLocation="https://xbrl.fasb.org/srt/2022/elts/srt-types-2022.xsd"/>
  <xsd:import namespace="http://fasb.org/us-gaap/2022" schemaLocation="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd"/>
  <xsd:import namespace="http://www.xbrl.org/2009/role/negated" schemaLocation="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd"/>
  <xsd:annotation>
    <xsd:appinfo>
      <link:linkbaseRef xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="wint-20220630_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="wint-20220630_cal.xml" xlink:role="http://www.xbrl.org/2003/role/calculationLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="wint-20220630_def.xml" xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="wint-20220630_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:type="simple"/>
      <link:roleType id="statement-document-and-entity-information" roleURI="http://www.windtreetx.com/20220630/role/statement-document-and-entity-information">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">000 - Document - Document And Entity Information</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-condensed-consolidated-balance-sheets-current-period-unaudited" roleURI="http://www.windtreetx.com/20220630/role/statement-condensed-consolidated-balance-sheets-current-period-unaudited">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">001 - Statement - Condensed Consolidated Balance Sheets (Current Period Unaudited)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-condensed-consolidated-balance-sheets-current-period-unaudited-parentheticals" roleURI="http://www.windtreetx.com/20220630/role/statement-condensed-consolidated-balance-sheets-current-period-unaudited-parentheticals">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">002 - Statement - Condensed Consolidated Balance Sheets (Current Period Unaudited) (Parentheticals)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-condensed-consolidated-statements-of-operations-unaudited" roleURI="http://www.windtreetx.com/20220630/role/statement-condensed-consolidated-statements-of-operations-unaudited">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">003 - Statement - Condensed Consolidated Statements of Operations (Unaudited)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-condensed-consolidated-statements-of-changes-in-stockholders-equity-unaudited-" roleURI="http://www.windtreetx.com/20220630/role/statement-condensed-consolidated-statements-of-changes-in-stockholders-equity-unaudited-">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">004 - Statement - Condensed Consolidated Statements of Changes in Stockholders' Equity (Unaudited)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-condensed-consolidated-statements-of-cash-flows-unaudited-" roleURI="http://www.windtreetx.com/20220630/role/statement-condensed-consolidated-statements-of-cash-flows-unaudited-">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">005 - Statement - Condensed Consolidated Statements of Cash Flows (Unaudited)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-1-the-company-and-description-of-business" roleURI="http://www.windtreetx.com/20220630/role/statement-note-1-the-company-and-description-of-business">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">006 - Disclosure - Note 1 - The Company and Description of Business</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-2-basis-of-presentation" roleURI="http://www.windtreetx.com/20220630/role/statement-note-2-basis-of-presentation">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">007 - Disclosure - Note 2 - Basis of Presentation</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-3-going-concern-and-managements-plans" roleURI="http://www.windtreetx.com/20220630/role/statement-note-3-going-concern-and-managements-plans">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">008 - Disclosure - Note 3 - Going Concern and Management's Plans</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-4-summary-of-significant-accounting-policies" roleURI="http://www.windtreetx.com/20220630/role/statement-note-4-summary-of-significant-accounting-policies">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">009 - Disclosure - Note 4 - Summary of Significant Accounting Policies</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-5-fair-value-measurements" roleURI="http://www.windtreetx.com/20220630/role/statement-note-5-fair-value-measurements">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">010 - Disclosure - Note 5 - Fair Value Measurements</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-6-loans-payable" roleURI="http://www.windtreetx.com/20220630/role/statement-note-6-loans-payable">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">011 - Disclosure - Note 6 - Loans Payable</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-7-restructured-debt-liability" roleURI="http://www.windtreetx.com/20220630/role/statement-note-7-restructured-debt-liability">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">012 - Disclosure - Note 7 - Restructured Debt Liability</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-8-stockholders-equity" roleURI="http://www.windtreetx.com/20220630/role/statement-note-8-stockholders-equity">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">013 - Disclosure - Note 8 - Stockholders' Equity</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-9-stockbased-compensation" roleURI="http://www.windtreetx.com/20220630/role/statement-note-9-stockbased-compensation">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">014 - Disclosure - Note 9 - Stock-Based Compensation</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-10-licensing-and-research-funding-agreements" roleURI="http://www.windtreetx.com/20220630/role/statement-note-10-licensing-and-research-funding-agreements">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">015 - Disclosure - Note 10 - Licensing and Research Funding Agreements</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-significant-accounting-policies-policies" roleURI="http://www.windtreetx.com/20220630/role/statement-significant-accounting-policies-policies">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">016 - Disclosure - Significant Accounting Policies (Policies)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-4-summary-of-significant-accounting-policies-tables" roleURI="http://www.windtreetx.com/20220630/role/statement-note-4-summary-of-significant-accounting-policies-tables">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">017 - Disclosure - Note 4 - Summary of Significant Accounting Policies (Tables)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-5-fair-value-measurements-tables" roleURI="http://www.windtreetx.com/20220630/role/statement-note-5-fair-value-measurements-tables">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">018 - Disclosure - Note 5 - Fair Value Measurements (Tables)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-9-stockbased-compensation-tables" roleURI="http://www.windtreetx.com/20220630/role/statement-note-9-stockbased-compensation-tables">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">019 - Disclosure - Note 9 - Stock-Based Compensation (Tables)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-3-going-concern-and-managements-plans-details-textual" roleURI="http://www.windtreetx.com/20220630/role/statement-note-3-going-concern-and-managements-plans-details-textual">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">020 - Disclosure - Note 3 - Going Concern and Management's Plans (Details Textual)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-4-summary-of-significant-accounting-policies-details-textual" roleURI="http://www.windtreetx.com/20220630/role/statement-note-4-summary-of-significant-accounting-policies-details-textual">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">021 - Disclosure - Note 4 - Summary of Significant Accounting Policies (Details Textual)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-4-summary-of-significant-accounting-policies-intangible-assets-details" roleURI="http://www.windtreetx.com/20220630/role/statement-note-4-summary-of-significant-accounting-policies-intangible-assets-details">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">022 - Disclosure - Note 4 - Summary of Significant Accounting Policies - Intangible Assets (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-5-fair-value-measurements-assets-and-liabilities-measured-at-fair-value-on-a-recurring-basis-details" roleURI="http://www.windtreetx.com/20220630/role/statement-note-5-fair-value-measurements-assets-and-liabilities-measured-at-fair-value-on-a-recurring-basis-details">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">023 - Disclosure - Note 5 - Fair Value Measurements - Assets and Liabilities Measured at Fair Value on a Recurring Basis (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-6-loans-payable-details-textual" roleURI="http://www.windtreetx.com/20220630/role/statement-note-6-loans-payable-details-textual">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">024 - Disclosure - Note 6 - Loans Payable (Details Textual)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-7-restructured-debt-liability-details-textual" roleURI="http://www.windtreetx.com/20220630/role/statement-note-7-restructured-debt-liability-details-textual">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">025 - Disclosure - Note 7 - Restructured Debt Liability (Details Textual)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-8-stockholders-equity-details-textual" roleURI="http://www.windtreetx.com/20220630/role/statement-note-8-stockholders-equity-details-textual">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">026 - Disclosure - Note 8 - Stockholders' Equity (Details Textual)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-9-stockbased-compensation-details-textual" roleURI="http://www.windtreetx.com/20220630/role/statement-note-9-stockbased-compensation-details-textual">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">027 - Disclosure - Note 9 - Stock-Based Compensation (Details Textual)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-9-stockbased-compensation-summary-of-stock-option-activity-details" roleURI="http://www.windtreetx.com/20220630/role/statement-note-9-stockbased-compensation-summary-of-stock-option-activity-details">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">028 - Disclosure - Note 9 - Stock-Based Compensation - Summary of Stock Option Activity (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-9-stockbased-compensation-restricted-stock-units-details" roleURI="http://www.windtreetx.com/20220630/role/statement-note-9-stockbased-compensation-restricted-stock-units-details">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">029 - Disclosure - Note 9 - Stock-Based Compensation - Restricted Stock Units (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-9-stockbased-compensation-stockbased-compensation-expense-details" roleURI="http://www.windtreetx.com/20220630/role/statement-note-9-stockbased-compensation-stockbased-compensation-expense-details">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">030 - Disclosure - Note 9 - Stock-Based Compensation - Stock-Based Compensation Expense (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-9-stockbased-compensation-stock-options-valuation-assumptions-details" roleURI="http://www.windtreetx.com/20220630/role/statement-note-9-stockbased-compensation-stock-options-valuation-assumptions-details">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">031 - Disclosure - Note 9 - Stock-Based Compensation - Stock Options Valuation Assumptions (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-10-licensing-and-research-funding-agreements-details-textual" roleURI="http://www.windtreetx.com/20220630/role/statement-note-10-licensing-and-research-funding-agreements-details-textual">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">032 - Disclosure - Note 10 - Licensing and Research Funding Agreements (Details Textual)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
    </xsd:appinfo>
  </xsd:annotation>
  <xsd:element abstract="true" id="wint_ATMProgramMember" name="ATMProgramMember" nillable="true" substitutionGroup="xbrli:item" type="dtr-types:domainItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="wint_AerosurfFundingTermSheetMember" name="AerosurfFundingTermSheetMember" nillable="true" substitutionGroup="xbrli:item" type="dtr-types:domainItemType" xbrli:periodType="duration"/>
  <xsd:element id="wint_ClassOfWarrantOrRightExercisePriceOfCancelledWarrants" name="ClassOfWarrantOrRightExercisePriceOfCancelledWarrants" nillable="true" substitutionGroup="xbrli:item" type="dtr-types:perShareItemType" xbrli:periodType="instant"/>
  <xsd:element id="wint_ClassOfWarrantOrRightNumberOfWarrantsCancelled" name="ClassOfWarrantOrRightNumberOfWarrantsCancelled" nillable="true" substitutionGroup="xbrli:item" type="xbrli:sharesItemType" xbrli:periodType="duration"/>
  <xsd:element id="wint_CommissionFeePercentFee" name="CommissionFeePercentFee" nillable="true" substitutionGroup="xbrli:item" type="dtr-types:percentItemType" xbrli:periodType="duration"/>
  <xsd:element id="wint_CorporatePartnershipLicensingAndResearchFundingAgreementsTextBlock" name="CorporatePartnershipLicensingAndResearchFundingAgreementsTextBlock" nillable="true" substitutionGroup="xbrli:item" type="dtr-types:textBlockItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="wint_DeerfieldLoanMember" name="DeerfieldLoanMember" nillable="true" substitutionGroup="xbrli:item" type="dtr-types:domainItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="wint_DeerfieldManagementLPMember" name="DeerfieldManagementLPMember" nillable="true" substitutionGroup="xbrli:item" type="dtr-types:domainItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="wint_DocumentAndEntityInformation" name="DocumentAndEntityInformation" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration"/>
  <xsd:element id="wint_EffectOfCOVID19PandemicPolicyTextBlock" name="EffectOfCOVID19PandemicPolicyTextBlock" nillable="true" substitutionGroup="xbrli:item" type="dtr-types:textBlockItemType" xbrli:periodType="duration"/>
  <xsd:element id="wint_EquityIssuedDuringPeriodUnitsNewIssues" name="EquityIssuedDuringPeriodUnitsNewIssues" nillable="true" substitutionGroup="xbrli:item" type="xbrli:sharesItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="wint_ExchangeAndTerminationAgreementMember" name="ExchangeAndTerminationAgreementMember" nillable="true" substitutionGroup="xbrli:item" type="dtr-types:domainItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="wint_ExecutiveOfficersAndEmployeesMember" name="ExecutiveOfficersAndEmployeesMember" nillable="true" substitutionGroup="xbrli:item" type="dtr-types:domainItemType" xbrli:periodType="duration"/>
  <xsd:element id="wint_FinancingOfProductPercentOfFinancingThatMustBeRepaidToDiscontinueRevenueSharing" name="FinancingOfProductPercentOfFinancingThatMustBeRepaidToDiscontinueRevenueSharing" nillable="true" substitutionGroup="xbrli:item" type="dtr-types:percentItemType" xbrli:periodType="instant"/>
  <xsd:element id="wint_FinancingOfProductPercentOfRevenueSharedWithFinancer" name="FinancingOfProductPercentOfRevenueSharedWithFinancer" nillable="true" substitutionGroup="xbrli:item" type="dtr-types:percentItemType" xbrli:periodType="instant"/>
  <xsd:element id="wint_IncreaseDecreaseOperatingLeaseLiability" name="IncreaseDecreaseOperatingLeaseLiability" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="duration"/>
  <xsd:element id="wint_IssuanceOfCommonStockAndCommonStockWarrantsNetOfIssuanceCostsShares" name="IssuanceOfCommonStockAndCommonStockWarrantsNetOfIssuanceCostsShares" nillable="true" substitutionGroup="xbrli:item" type="xbrli:sharesItemType" xbrli:periodType="duration"/>
  <xsd:element id="wint_IssuanceOfCommonStockAndCommonStockWarrantsNetOfIssuanceCostsValue" name="IssuanceOfCommonStockAndCommonStockWarrantsNetOfIssuanceCostsValue" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="wint_IstaroximeDrugCandidateMember" name="IstaroximeDrugCandidateMember" nillable="true" substitutionGroup="xbrli:item" type="dtr-types:domainItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="wint_LeesPharmaceuticalHoldingsLimitedMember" name="LeesPharmaceuticalHoldingsLimitedMember" nillable="true" substitutionGroup="xbrli:item" type="dtr-types:domainItemType" xbrli:periodType="duration"/>
  <xsd:element id="wint_LiabilityforContingentMilestonePaymentNoncurrent" name="LiabilityforContingentMilestonePaymentNoncurrent" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="instant"/>
  <xsd:element id="wint_LiquidityDisclosuresTextBlock" name="LiquidityDisclosuresTextBlock" nillable="true" substitutionGroup="xbrli:item" type="dtr-types:textBlockItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="wint_LoanPayableToBankDirectCapitalFinanceMember" name="LoanPayableToBankDirectCapitalFinanceMember" nillable="true" substitutionGroup="xbrli:item" type="dtr-types:domainItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="wint_ManufacturingAndLaboratoryEquipmentMember" name="ManufacturingAndLaboratoryEquipmentMember" nillable="true" substitutionGroup="xbrli:item" type="dtr-types:domainItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="wint_March2021PublicOfferingMember" name="March2021PublicOfferingMember" nillable="true" substitutionGroup="xbrli:item" type="dtr-types:domainItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="wint_March2021WarrantsMember" name="March2021WarrantsMember" nillable="true" substitutionGroup="xbrli:item" type="dtr-types:domainItemType" xbrli:periodType="duration"/>
  <xsd:element id="wint_NonCashExpenseRelatedToEquityConsiderationForAServiceAgreement" name="NonCashExpenseRelatedToEquityConsiderationForAServiceAgreement" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="wint_NonplanStockOptionsMember" name="NonplanStockOptionsMember" nillable="true" substitutionGroup="xbrli:item" type="dtr-types:domainItemType" xbrli:periodType="duration"/>
  <xsd:element id="wint_NonrefundablePayments" name="NonrefundablePayments" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="wint_NoteToFinancialStatementDetailsTextual" name="NoteToFinancialStatementDetailsTextual" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="wint_NotesToFinancialStatements" name="NotesToFinancialStatements" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="wint_NotesToFinancialStatementsAbstract" name="NotesToFinancialStatementsAbstract" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration"/>
  <xsd:element id="wint_NumberOfSharesOfCommonStockPotentiallyIssuableUponTheExerciseOfStockOptionsAndWarrants" name="NumberOfSharesOfCommonStockPotentiallyIssuableUponTheExerciseOfStockOptionsAndWarrants" nillable="true" substitutionGroup="xbrli:item" type="xbrli:sharesItemType" xbrli:periodType="duration"/>
  <xsd:element id="wint_PaymentsForSeveranceCosts" name="PaymentsForSeveranceCosts" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="duration"/>
  <xsd:element id="wint_PrepaymentOfDirectorAndOfficerInsuranceThroughThirdPartyFinancing" name="PrepaymentOfDirectorAndOfficerInsuranceThroughThirdPartyFinancing" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="duration"/>
  <xsd:element id="wint_ProceedsForPaymentsToDevelopProduct" name="ProceedsForPaymentsToDevelopProduct" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="duration"/>
  <xsd:element id="wint_ProceedsFromIssuanceOfCommonStockAndWarrants" name="ProceedsFromIssuanceOfCommonStockAndWarrants" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="duration"/>
  <xsd:element id="wint_ProceedsFromIssuanceOrSaleOfEquityGrossAmount" name="ProceedsFromIssuanceOrSaleOfEquityGrossAmount" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="duration"/>
  <xsd:element id="wint_ProceedsFromResearchAndDevelopmentFundingArrangement" name="ProceedsFromResearchAndDevelopmentFundingArrangement" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="duration"/>
  <xsd:element id="wint_RestructuredDebtLiabilityContingentMilestonePaymentPolicyPolicyTextBlock" name="RestructuredDebtLiabilityContingentMilestonePaymentPolicyPolicyTextBlock" nillable="true" substitutionGroup="xbrli:item" type="dtr-types:textBlockItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="wint_RostafuroxinDrugCandidateMember" name="RostafuroxinDrugCandidateMember" nillable="true" substitutionGroup="xbrli:item" type="dtr-types:domainItemType" xbrli:periodType="duration"/>
  <xsd:element id="wint_SeveranceAccrual" name="SeveranceAccrual" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="wint_SharePurchaseAgreementDecember2019Member" name="SharePurchaseAgreementDecember2019Member" nillable="true" substitutionGroup="xbrli:item" type="dtr-types:domainItemType" xbrli:periodType="duration"/>
  <xsd:element id="wint_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndExercisable" name="SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndExercisable" nillable="true" substitutionGroup="xbrli:item" type="xbrli:sharesItemType" xbrli:periodType="instant"/>
  <xsd:element id="wint_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndExercisableWeightedAverageGrantDateFairValueEndingBalance" name="SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndExercisableWeightedAverageGrantDateFairValueEndingBalance" nillable="true" substitutionGroup="xbrli:item" type="dtr-types:perShareItemType" xbrli:periodType="instant"/>
  <xsd:element id="wint_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndExpectedToVestWeightedAverageGrantDateFairValueEndingBalance" name="SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndExpectedToVestWeightedAverageGrantDateFairValueEndingBalance" nillable="true" substitutionGroup="xbrli:item" type="dtr-types:perShareItemType" xbrli:periodType="instant"/>
  <xsd:element id="wint_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityOtherThanOptionsVestedAndExpectedToVestOutstandingNumber" name="SharebasedCompensationArrangementBySharebasedPaymentAwardEquityOtherThanOptionsVestedAndExpectedToVestOutstandingNumber" nillable="true" substitutionGroup="xbrli:item" type="xbrli:sharesItemType" xbrli:periodType="instant"/>
  <xsd:element id="wint_SharesAuthorizedToBeOfferedAndSoldUnderOfferingAgreementValue" name="SharesAuthorizedToBeOfferedAndSoldUnderOfferingAgreementValue" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="instant"/>
  <xsd:element id="wint_StockAndWarrantsIssuedPricePerShare" name="StockAndWarrantsIssuedPricePerShare" nillable="true" substitutionGroup="xbrli:item" type="dtr-types:perShareItemType" xbrli:periodType="instant"/>
  <xsd:element id="wint_StockIssuedDuringPeriodSharesCancellationOfDebtAndWarrantObligations" name="StockIssuedDuringPeriodSharesCancellationOfDebtAndWarrantObligations" nillable="true" substitutionGroup="xbrli:item" type="xbrli:sharesItemType" xbrli:periodType="duration"/>
  <xsd:element id="wint_StockIssuedDuringPeriodSharesCancellationOfDebtAndWarrantObligationsPercentageOfFullyDilutedSharesOutstanding" name="StockIssuedDuringPeriodSharesCancellationOfDebtAndWarrantObligationsPercentageOfFullyDilutedSharesOutstanding" nillable="true" substitutionGroup="xbrli:item" type="dtr-types:percentItemType" xbrli:periodType="duration"/>
  <xsd:element id="wint_StockOfferingAgreementPublicFloatLimitationAmount" name="StockOfferingAgreementPublicFloatLimitationAmount" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="instant"/>
  <xsd:element id="wint_StockOfferingAgreementRemainingAmountAvailable" name="StockOfferingAgreementRemainingAmountAvailable" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="instant"/>
  <xsd:element abstract="true" id="wint_TermSheetWithLeeMember" name="TermSheetWithLeeMember" nillable="true" substitutionGroup="xbrli:item" type="dtr-types:domainItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="wint_The2020EquityIncentivePlanMember" name="The2020EquityIncentivePlanMember" nillable="true" substitutionGroup="xbrli:item" type="dtr-types:domainItemType" xbrli:periodType="duration"/>
  <xsd:element id="wint_UnitsNumberOfSecuritiesCalledByEachUnit" name="UnitsNumberOfSecuritiesCalledByEachUnit" nillable="true" substitutionGroup="xbrli:item" type="xbrli:sharesItemType" xbrli:periodType="instant"/>
  <xsd:element abstract="true" id="wint_statement-statement-note-4-summary-of-significant-accounting-policies-intangible-assets-details" name="statement-statement-note-4-summary-of-significant-accounting-policies-intangible-assets-details" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="wint_statement-statement-note-4-summary-of-significant-accounting-policies-tables" name="statement-statement-note-4-summary-of-significant-accounting-policies-tables" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="wint_statement-statement-note-5-fair-value-measurements-assets-and-liabilities-measured-at-fair-value-on-a-recurring-basis-details" name="statement-statement-note-5-fair-value-measurements-assets-and-liabilities-measured-at-fair-value-on-a-recurring-basis-details" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="wint_statement-statement-note-5-fair-value-measurements-tables" name="statement-statement-note-5-fair-value-measurements-tables" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="wint_statement-statement-note-9-stockbased-compensation-restricted-stock-units-details" name="statement-statement-note-9-stockbased-compensation-restricted-stock-units-details" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="wint_statement-statement-note-9-stockbased-compensation-stock-options-valuation-assumptions-details" name="statement-statement-note-9-stockbased-compensation-stock-options-valuation-assumptions-details" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="wint_statement-statement-note-9-stockbased-compensation-stockbased-compensation-expense-details" name="statement-statement-note-9-stockbased-compensation-stockbased-compensation-expense-details" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="wint_statement-statement-note-9-stockbased-compensation-summary-of-stock-option-activity-details" name="statement-statement-note-9-stockbased-compensation-summary-of-stock-option-activity-details" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="wint_statement-statement-note-9-stockbased-compensation-tables" name="statement-statement-note-9-stockbased-compensation-tables" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="wint_statement-statement-significant-accounting-policies-policies" name="statement-statement-significant-accounting-policies-policies" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration"/>
</xsd:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.CAL
<SEQUENCE>7
<FILENAME>wint-20220630_cal.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION CALCULATION LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" standalone="no"?>
<!--Generated by ThunderDome XBRL - 05:34AM UTC 2022-08-11--><link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.windtreetx.com/20220630/role/statement-condensed-consolidated-balance-sheets-current-period-unaudited" xlink:href="wint-20220630.xsd#statement-condensed-consolidated-balance-sheets-current-period-unaudited" xlink:type="simple"/>
  <link:calculationLink xlink:role="http://www.windtreetx.com/20220630/role/statement-condensed-consolidated-balance-sheets-current-period-unaudited" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsPayableCurrent" xlink:label="us-gaap_AccountsPayableCurrent" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="us-gaap_AccruedLiabilitiesCurrent" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapital" xlink:label="us-gaap_AdditionalPaidInCapital" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Assets" xlink:label="us-gaap_Assets" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsCurrent" xlink:label="us-gaap_AssetsCurrent" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockValue" xlink:label="us-gaap_CommonStockValue" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredIncomeTaxLiabilitiesNet" xlink:label="us-gaap_DeferredIncomeTaxLiabilitiesNet" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Goodwill" xlink:label="us-gaap_Goodwill" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill" xlink:label="us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Liabilities" xlink:label="us-gaap_Liabilities" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesCurrent" xlink:label="us-gaap_LiabilitiesCurrent" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LoansPayableCurrent" xlink:label="us-gaap_LoansPayableCurrent" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherLiabilitiesNoncurrent" xlink:label="us-gaap_OtherLiabilitiesNoncurrent" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockValue" xlink:label="us-gaap_PreferredStockValue" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="us-gaap_PropertyPlantAndEquipmentNet" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedCashAndCashEquivalentsNoncurrent" xlink:label="us-gaap_RestrictedCashAndCashEquivalentsNoncurrent" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TreasuryStockValue" xlink:label="us-gaap_TreasuryStockValue" xlink:type="locator"/>
    <link:loc xlink:href="wint-20220630.xsd#wint_LiabilityforContingentMilestonePaymentNoncurrent" xlink:label="wint_LiabilityforContingentMilestonePaymentNoncurrent" xlink:type="locator"/>
    <link:calculationArc order="0" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:type="arc"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:type="arc"/>
    <link:calculationArc order="0" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_RestrictedCashAndCashEquivalentsNoncurrent" xlink:type="arc"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_PropertyPlantAndEquipmentNet" xlink:type="arc"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_AssetsCurrent" xlink:type="arc"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_Goodwill" xlink:type="arc"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill" xlink:type="arc"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset" xlink:type="arc"/>
    <link:calculationArc order="0" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_OperatingLeaseLiabilityCurrent" xlink:type="arc"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_AccruedLiabilitiesCurrent" xlink:type="arc"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_AccountsPayableCurrent" xlink:type="arc"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_LoansPayableCurrent" xlink:type="arc"/>
    <link:calculationArc order="0" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Liabilities" xlink:to="us-gaap_DeferredIncomeTaxLiabilitiesNet" xlink:type="arc"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Liabilities" xlink:to="us-gaap_OtherLiabilitiesNoncurrent" xlink:type="arc"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Liabilities" xlink:to="wint_LiabilityforContingentMilestonePaymentNoncurrent" xlink:type="arc"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Liabilities" xlink:to="us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:type="arc"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Liabilities" xlink:to="us-gaap_LiabilitiesCurrent" xlink:type="arc"/>
    <link:calculationArc order="0" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_PreferredStockValue" xlink:type="arc"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_CommonStockValue" xlink:type="arc"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_TreasuryStockValue" xlink:type="arc"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit" xlink:type="arc"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_AdditionalPaidInCapital" xlink:type="arc"/>
    <link:calculationArc order="0" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_Liabilities" xlink:type="arc"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_StockholdersEquity" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.windtreetx.com/20220630/role/statement-condensed-consolidated-statements-of-cash-flows-unaudited-" xlink:href="wint-20220630.xsd#statement-condensed-consolidated-statements-of-cash-flows-unaudited-" xlink:type="simple"/>
  <link:calculationLink xlink:role="http://www.windtreetx.com/20220630/role/statement-condensed-consolidated-statements-of-cash-flows-unaudited-" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:label="us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Depreciation" xlink:label="us-gaap_Depreciation" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeBenefitsAndShareBasedCompensation" xlink:label="us-gaap_EmployeeBenefitsAndShareBasedCompensation" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ForeignCurrencyTransactionGainLossBeforeTax" xlink:label="us-gaap_ForeignCurrencyTransactionGainLossBeforeTax" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GainLossOnDispositionOfAssets" xlink:label="us-gaap_GainLossOnDispositionOfAssets" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillImpairmentLoss" xlink:label="us-gaap_GoodwillImpairmentLoss" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill" xlink:label="us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccountsPayable" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:label="us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense" xlink:label="us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment" xlink:label="us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RepaymentsOfShortTermDebt" xlink:label="us-gaap_RepaymentsOfShortTermDebt" xlink:type="locator"/>
    <link:loc xlink:href="wint-20220630.xsd#wint_IncreaseDecreaseOperatingLeaseLiability" xlink:label="wint_IncreaseDecreaseOperatingLeaseLiability" xlink:type="locator"/>
    <link:loc xlink:href="wint-20220630.xsd#wint_NonCashExpenseRelatedToEquityConsiderationForAServiceAgreement" xlink:label="wint_NonCashExpenseRelatedToEquityConsiderationForAServiceAgreement" xlink:type="locator"/>
    <link:loc xlink:href="wint-20220630.xsd#wint_ProceedsFromIssuanceOfCommonStockAndWarrants" xlink:label="wint_ProceedsFromIssuanceOfCommonStockAndWarrants" xlink:type="locator"/>
    <link:loc xlink:href="wint-20220630.xsd#wint_ProceedsFromResearchAndDevelopmentFundingArrangement" xlink:label="wint_ProceedsFromResearchAndDevelopmentFundingArrangement" xlink:type="locator"/>
    <link:calculationArc order="0" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_EmployeeBenefitsAndShareBasedCompensation" xlink:type="arc"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_Depreciation" xlink:type="arc"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_NetIncomeLoss" xlink:type="arc"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill" xlink:type="arc"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_GoodwillImpairmentLoss" xlink:type="arc"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="wint_NonCashExpenseRelatedToEquityConsiderationForAServiceAgreement" xlink:type="arc"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense" xlink:type="arc"/>
    <link:calculationArc order="7" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:type="arc"/>
    <link:calculationArc order="8" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_GainLossOnDispositionOfAssets" xlink:type="arc"/>
    <link:calculationArc order="9" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_ForeignCurrencyTransactionGainLossBeforeTax" xlink:type="arc"/>
    <link:calculationArc order="10" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:type="arc"/>
    <link:calculationArc order="11" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="wint_IncreaseDecreaseOperatingLeaseLiability" xlink:type="arc"/>
    <link:calculationArc order="12" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:type="arc"/>
    <link:calculationArc order="13" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayable" xlink:type="arc"/>
    <link:calculationArc order="0" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment" xlink:type="arc"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:type="arc"/>
    <link:calculationArc order="0" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:type="arc"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="wint_ProceedsFromResearchAndDevelopmentFundingArrangement" xlink:type="arc"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="wint_ProceedsFromIssuanceOfCommonStockAndWarrants" xlink:type="arc"/>
    <link:calculationArc order="3" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_RepaymentsOfShortTermDebt" xlink:type="arc"/>
    <link:calculationArc order="0" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:type="arc"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:type="arc"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.windtreetx.com/20220630/role/statement-condensed-consolidated-statements-of-operations-unaudited" xlink:href="wint-20220630.xsd#statement-condensed-consolidated-statements-of-operations-unaudited" xlink:type="simple"/>
  <link:calculationLink xlink:role="http://www.windtreetx.com/20220630/role/statement-condensed-consolidated-statements-of-operations-unaudited" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillImpairmentLoss" xlink:label="us-gaap_GoodwillImpairmentLoss" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill" xlink:label="us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="us-gaap_IncomeTaxExpenseBenefit" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestExpense" xlink:label="us-gaap_InterestExpense" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentIncomeInterest" xlink:label="us-gaap_InvestmentIncomeInterest" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NonoperatingIncomeExpense" xlink:label="us-gaap_NonoperatingIncomeExpense" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingExpenses" xlink:label="us-gaap_OperatingExpenses" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingIncomeLoss" xlink:label="us-gaap_OperatingIncomeLoss" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherNonoperatingIncomeExpense" xlink:label="us-gaap_OtherNonoperatingIncomeExpense" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="us-gaap_ResearchAndDevelopmentExpense" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SellingGeneralAndAdministrativeExpense" xlink:label="us-gaap_SellingGeneralAndAdministrativeExpense" xlink:type="locator"/>
    <link:calculationArc order="0" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingExpenses" xlink:to="us-gaap_ResearchAndDevelopmentExpense" xlink:type="arc"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingExpenses" xlink:to="us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill" xlink:type="arc"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingExpenses" xlink:to="us-gaap_GoodwillImpairmentLoss" xlink:type="arc"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingExpenses" xlink:to="us-gaap_SellingGeneralAndAdministrativeExpense" xlink:type="arc"/>
    <link:calculationArc order="0" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingIncomeLoss" xlink:to="us-gaap_OperatingExpenses" xlink:type="arc"/>
    <link:calculationArc order="0" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NonoperatingIncomeExpense" xlink:to="us-gaap_OtherNonoperatingIncomeExpense" xlink:type="arc"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NonoperatingIncomeExpense" xlink:to="us-gaap_InterestExpense" xlink:type="arc"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NonoperatingIncomeExpense" xlink:to="us-gaap_InvestmentIncomeInterest" xlink:type="arc"/>
    <link:calculationArc order="0" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:to="us-gaap_OperatingIncomeLoss" xlink:type="arc"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:to="us-gaap_NonoperatingIncomeExpense" xlink:type="arc"/>
    <link:calculationArc order="0" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_IncomeTaxExpenseBenefit" xlink:type="arc"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:type="arc"/>
  </link:calculationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.DEF
<SEQUENCE>8
<FILENAME>wint-20220630_def.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION DEFINITION LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" standalone="no"?>
<!--Generated by ThunderDome XBRL - 05:34AM UTC 2022-08-11--><link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/all" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all" xlink:type="simple"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member" xlink:type="simple"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain" xlink:type="simple"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension" xlink:type="simple"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.windtreetx.com/20220630/role/statement-note-5-fair-value-measurements" xlink:href="wint-20220630.xsd#statement-note-5-fair-value-measurements" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.windtreetx.com/20220630/role/statement-note-5-fair-value-measurements" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueDisclosuresTextBlock" xlink:label="us-gaap_FairValueDisclosuresTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DisclosureTextBlockAbstract" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DisclosureTextBlockAbstract" xlink:to="us-gaap_FairValueDisclosuresTextBlock" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.windtreetx.com/20220630/role/statement-note-2-basis-of-presentation" xlink:href="wint-20220630.xsd#statement-note-2-basis-of-presentation" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.windtreetx.com/20220630/role/statement-note-2-basis-of-presentation" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BasisOfAccounting" xlink:label="us-gaap_BasisOfAccounting" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DisclosureTextBlockAbstract" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DisclosureTextBlockAbstract" xlink:to="us-gaap_BasisOfAccounting" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.windtreetx.com/20220630/role/statement-note-1-the-company-and-description-of-business" xlink:href="wint-20220630.xsd#statement-note-1-the-company-and-description-of-business" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.windtreetx.com/20220630/role/statement-note-1-the-company-and-description-of-business" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DisclosureTextBlockAbstract" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DisclosureTextBlockAbstract" xlink:to="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.windtreetx.com/20220630/role/statement-document-and-entity-information" xlink:href="wint-20220630.xsd#statement-document-and-entity-information" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.windtreetx.com/20220630/role/statement-document-and-entity-information" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AmendmentFlag" xlink:label="dei_AmendmentFlag" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CityAreaCode" xlink:label="dei_CityAreaCode" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CurrentFiscalYearEndDate" xlink:label="dei_CurrentFiscalYearEndDate" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="dei_DocumentFiscalPeriodFocus" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentFiscalYearFocus" xlink:label="dei_DocumentFiscalYearFocus" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentInformationLineItems" xlink:label="dei_DocumentInformationLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentInformationTable" xlink:label="dei_DocumentInformationTable" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentPeriodEndDate" xlink:label="dei_DocumentPeriodEndDate" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentQuarterlyReport" xlink:label="dei_DocumentQuarterlyReport" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentTransitionReport" xlink:label="dei_DocumentTransitionReport" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentType" xlink:label="dei_DocumentType" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressAddressLine1" xlink:label="dei_EntityAddressAddressLine1" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressCityOrTown" xlink:label="dei_EntityAddressCityOrTown" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressPostalZipCode" xlink:label="dei_EntityAddressPostalZipCode" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressStateOrProvince" xlink:label="dei_EntityAddressStateOrProvince" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCentralIndexKey" xlink:label="dei_EntityCentralIndexKey" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="dei_EntityCommonStockSharesOutstanding" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCurrentReportingStatus" xlink:label="dei_EntityCurrentReportingStatus" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityEmergingGrowthCompany" xlink:label="dei_EntityEmergingGrowthCompany" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityFileNumber" xlink:label="dei_EntityFileNumber" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityFilerCategory" xlink:label="dei_EntityFilerCategory" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="dei_EntityIncorporationStateCountryCode" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityInteractiveDataCurrent" xlink:label="dei_EntityInteractiveDataCurrent" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityRegistrantName" xlink:label="dei_EntityRegistrantName" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityShellCompany" xlink:label="dei_EntityShellCompany" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntitySmallBusiness" xlink:label="dei_EntitySmallBusiness" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityTaxIdentificationNumber" xlink:label="dei_EntityTaxIdentificationNumber" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LocalPhoneNumber" xlink:label="dei_LocalPhoneNumber" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_Security12bTitle" xlink:label="dei_Security12bTitle" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_SecurityExchangeName" xlink:label="dei_SecurityExchangeName" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_TradingSymbol" xlink:label="dei_TradingSymbol" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="dei_DocumentInformationTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentInformationTable" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityCentralIndexKey" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityRegistrantName" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_AmendmentFlag" xlink:type="arc"/>
    <link:definitionArc order="4" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_CurrentFiscalYearEndDate" xlink:type="arc"/>
    <link:definitionArc order="5" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentFiscalPeriodFocus" xlink:type="arc"/>
    <link:definitionArc order="6" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentFiscalYearFocus" xlink:type="arc"/>
    <link:definitionArc order="7" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentType" xlink:type="arc"/>
    <link:definitionArc order="8" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentQuarterlyReport" xlink:type="arc"/>
    <link:definitionArc order="9" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentPeriodEndDate" xlink:type="arc"/>
    <link:definitionArc order="10" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentTransitionReport" xlink:type="arc"/>
    <link:definitionArc order="11" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityFileNumber" xlink:type="arc"/>
    <link:definitionArc order="12" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityIncorporationStateCountryCode" xlink:type="arc"/>
    <link:definitionArc order="13" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityTaxIdentificationNumber" xlink:type="arc"/>
    <link:definitionArc order="14" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityAddressAddressLine1" xlink:type="arc"/>
    <link:definitionArc order="15" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityAddressCityOrTown" xlink:type="arc"/>
    <link:definitionArc order="16" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityAddressStateOrProvince" xlink:type="arc"/>
    <link:definitionArc order="17" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityAddressPostalZipCode" xlink:type="arc"/>
    <link:definitionArc order="18" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_CityAreaCode" xlink:type="arc"/>
    <link:definitionArc order="19" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_LocalPhoneNumber" xlink:type="arc"/>
    <link:definitionArc order="20" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_Security12bTitle" xlink:type="arc"/>
    <link:definitionArc order="21" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_TradingSymbol" xlink:type="arc"/>
    <link:definitionArc order="22" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_SecurityExchangeName" xlink:type="arc"/>
    <link:definitionArc order="23" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityCurrentReportingStatus" xlink:type="arc"/>
    <link:definitionArc order="24" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityInteractiveDataCurrent" xlink:type="arc"/>
    <link:definitionArc order="25" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityFilerCategory" xlink:type="arc"/>
    <link:definitionArc order="26" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntitySmallBusiness" xlink:type="arc"/>
    <link:definitionArc order="27" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityEmergingGrowthCompany" xlink:type="arc"/>
    <link:definitionArc order="28" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityShellCompany" xlink:type="arc"/>
    <link:definitionArc order="29" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityCommonStockSharesOutstanding" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.windtreetx.com/20220630/role/statement-condensed-consolidated-balance-sheets-current-period-unaudited-parentheticals" xlink:href="wint-20220630.xsd#statement-condensed-consolidated-balance-sheets-current-period-unaudited-parentheticals" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.windtreetx.com/20220630/role/statement-condensed-consolidated-balance-sheets-current-period-unaudited-parentheticals" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="us-gaap_CommonStockSharesAuthorized" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesIssued" xlink:label="us-gaap_CommonStockSharesIssued" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="us-gaap_CommonStockSharesOutstanding" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="us-gaap_PreferredStockSharesAuthorized" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockSharesIssued" xlink:label="us-gaap_PreferredStockSharesIssued" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:label="us-gaap_PreferredStockSharesOutstanding" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TreasuryStockShares" xlink:label="us-gaap_TreasuryStockShares" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PreferredStockParOrStatedValuePerShare" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PreferredStockSharesAuthorized" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PreferredStockSharesIssued" xlink:type="arc"/>
    <link:definitionArc order="4" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PreferredStockSharesOutstanding" xlink:type="arc"/>
    <link:definitionArc order="5" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare" xlink:type="arc"/>
    <link:definitionArc order="6" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommonStockSharesAuthorized" xlink:type="arc"/>
    <link:definitionArc order="7" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommonStockSharesIssued" xlink:type="arc"/>
    <link:definitionArc order="8" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommonStockSharesOutstanding" xlink:type="arc"/>
    <link:definitionArc order="9" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_TreasuryStockShares" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.windtreetx.com/20220630/role/statement-note-3-going-concern-and-managements-plans" xlink:href="wint-20220630.xsd#statement-note-3-going-concern-and-managements-plans" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.windtreetx.com/20220630/role/statement-note-3-going-concern-and-managements-plans" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventMember" xlink:label="us-gaap_SubsequentEventMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="us-gaap_SubsequentEventTypeAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="us-gaap_SubsequentEventTypeDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="us-gaap_SubsequentEventTypeDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis" xlink:type="locator"/>
    <link:loc xlink:href="wint-20220630.xsd#wint_ATMProgramMember" xlink:label="wint_ATMProgramMember" xlink:type="locator"/>
    <link:loc xlink:href="wint-20220630.xsd#wint_LiquidityDisclosuresTextBlock" xlink:label="wint_LiquidityDisclosuresTextBlock" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DisclosureTextBlockAbstract" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="wint_ATMProgramMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_SubsequentEventTypeAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsequentEventTypeDomain" xlink:to="us-gaap_SubsequentEventMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeDomain-default" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DisclosureTextBlockAbstract" xlink:to="wint_LiquidityDisclosuresTextBlock" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.windtreetx.com/20220630/role/statement-note-4-summary-of-significant-accounting-policies" xlink:href="wint-20220630.xsd#statement-note-4-summary-of-significant-accounting-policies" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.windtreetx.com/20220630/role/statement-note-4-summary-of-significant-accounting-policies" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LineOfCreditFacilityAxis" xlink:label="us-gaap_LineOfCreditFacilityAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LineOfCreditFacilityLenderDomain" xlink:label="us-gaap_LineOfCreditFacilityLenderDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LineOfCreditFacilityLenderDomain" xlink:label="us-gaap_LineOfCreditFacilityLenderDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongtermDebtTypeAxis" xlink:label="us-gaap_LongtermDebtTypeAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongtermDebtTypeDomain" xlink:label="us-gaap_LongtermDebtTypeDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongtermDebtTypeDomain" xlink:label="us-gaap_LongtermDebtTypeDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SignificantAccountingPoliciesTextBlock" xlink:label="us-gaap_SignificantAccountingPoliciesTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis" xlink:type="locator"/>
    <link:loc xlink:href="wint-20220630.xsd#wint_DeerfieldLoanMember" xlink:label="wint_DeerfieldLoanMember" xlink:type="locator"/>
    <link:loc xlink:href="wint-20220630.xsd#wint_DeerfieldManagementLPMember" xlink:label="wint_DeerfieldManagementLPMember" xlink:type="locator"/>
    <link:loc xlink:href="wint-20220630.xsd#wint_ExchangeAndTerminationAgreementMember" xlink:label="wint_ExchangeAndTerminationAgreementMember" xlink:type="locator"/>
    <link:loc xlink:href="wint-20220630.xsd#wint_ManufacturingAndLaboratoryEquipmentMember" xlink:label="wint_ManufacturingAndLaboratoryEquipmentMember" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DisclosureTextBlockAbstract" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_LongtermDebtTypeAxis" xlink:to="us-gaap_LongtermDebtTypeDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_LineOfCreditFacilityAxis" xlink:to="us-gaap_LineOfCreditFacilityLenderDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="wint_ManufacturingAndLaboratoryEquipmentMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_LongtermDebtTypeAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LongtermDebtTypeDomain" xlink:to="wint_DeerfieldLoanMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_LongtermDebtTypeAxis" xlink:to="us-gaap_LongtermDebtTypeDomain-default" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_TypeOfArrangementAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="wint_ExchangeAndTerminationAgreementMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember-default" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_LineOfCreditFacilityAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LineOfCreditFacilityLenderDomain" xlink:to="wint_DeerfieldManagementLPMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_LineOfCreditFacilityAxis" xlink:to="us-gaap_LineOfCreditFacilityLenderDomain-default" xlink:type="arc"/>
    <link:definitionArc order="4" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DisclosureTextBlockAbstract" xlink:to="us-gaap_SignificantAccountingPoliciesTextBlock" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.windtreetx.com/20220630/role/statement-note-6-loans-payable" xlink:href="wint-20220630.xsd#statement-note-6-loans-payable" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.windtreetx.com/20220630/role/statement-note-6-loans-payable" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentAxis" xlink:label="us-gaap_DebtInstrumentAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="us-gaap_DebtInstrumentNameDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="us-gaap_DebtInstrumentNameDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LoansPayableMember" xlink:label="us-gaap_LoansPayableMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShortTermDebtTextBlock" xlink:label="us-gaap_ShortTermDebtTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShortTermDebtTypeAxis" xlink:label="us-gaap_ShortTermDebtTypeAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShortTermDebtTypeDomain" xlink:label="us-gaap_ShortTermDebtTypeDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShortTermDebtTypeDomain" xlink:label="us-gaap_ShortTermDebtTypeDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="wint-20220630.xsd#wint_LoanPayableToBankDirectCapitalFinanceMember" xlink:label="wint_LoanPayableToBankDirectCapitalFinanceMember" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DisclosureTextBlockAbstract" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_ShortTermDebtTypeAxis" xlink:to="us-gaap_ShortTermDebtTypeDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_DebtInstrumentAxis" xlink:to="us-gaap_DebtInstrumentNameDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_DebtInstrumentAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentNameDomain" xlink:to="wint_LoanPayableToBankDirectCapitalFinanceMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_DebtInstrumentAxis" xlink:to="us-gaap_DebtInstrumentNameDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_ShortTermDebtTypeAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShortTermDebtTypeDomain" xlink:to="us-gaap_LoansPayableMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_ShortTermDebtTypeAxis" xlink:to="us-gaap_ShortTermDebtTypeDomain-default" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DisclosureTextBlockAbstract" xlink:to="us-gaap_ShortTermDebtTextBlock" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.windtreetx.com/20220630/role/statement-note-7-restructured-debt-liability" xlink:href="wint-20220630.xsd#statement-note-7-restructured-debt-liability" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.windtreetx.com/20220630/role/statement-note-7-restructured-debt-liability" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_CounterpartyNameAxis" xlink:label="srt_CounterpartyNameAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebtTextBlock" xlink:label="us-gaap_LongTermDebtTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongtermDebtTypeAxis" xlink:label="us-gaap_LongtermDebtTypeAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongtermDebtTypeDomain" xlink:label="us-gaap_LongtermDebtTypeDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongtermDebtTypeDomain" xlink:label="us-gaap_LongtermDebtTypeDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis" xlink:type="locator"/>
    <link:loc xlink:href="wint-20220630.xsd#wint_DeerfieldLoanMember" xlink:label="wint_DeerfieldLoanMember" xlink:type="locator"/>
    <link:loc xlink:href="wint-20220630.xsd#wint_DeerfieldManagementLPMember" xlink:label="wint_DeerfieldManagementLPMember" xlink:type="locator"/>
    <link:loc xlink:href="wint-20220630.xsd#wint_ExchangeAndTerminationAgreementMember" xlink:label="wint_ExchangeAndTerminationAgreementMember" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DisclosureTextBlockAbstract" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_CounterpartyNameAxis" xlink:to="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_LongtermDebtTypeAxis" xlink:to="us-gaap_LongtermDebtTypeDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_LongtermDebtTypeAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LongtermDebtTypeDomain" xlink:to="wint_DeerfieldLoanMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_LongtermDebtTypeAxis" xlink:to="us-gaap_LongtermDebtTypeDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_TypeOfArrangementAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="wint_ExchangeAndTerminationAgreementMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember-default" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="srt_CounterpartyNameAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="wint_DeerfieldManagementLPMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_CounterpartyNameAxis" xlink:to="srt_RepurchaseAgreementCounterpartyNameDomain-default" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DisclosureTextBlockAbstract" xlink:to="us-gaap_LongTermDebtTextBlock" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.windtreetx.com/20220630/role/statement-note-8-stockholders-equity" xlink:href="wint-20220630.xsd#statement-note-8-stockholders-equity" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.windtreetx.com/20220630/role/statement-note-8-stockholders-equity" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="us-gaap_ClassOfWarrantOrRightAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="us-gaap_ClassOfWarrantOrRightDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="us-gaap_ClassOfWarrantOrRightDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventMember" xlink:label="us-gaap_SubsequentEventMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="us-gaap_SubsequentEventTypeAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="us-gaap_SubsequentEventTypeDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="us-gaap_SubsequentEventTypeDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis" xlink:type="locator"/>
    <link:loc xlink:href="wint-20220630.xsd#wint_ATMProgramMember" xlink:label="wint_ATMProgramMember" xlink:type="locator"/>
    <link:loc xlink:href="wint-20220630.xsd#wint_March2021PublicOfferingMember" xlink:label="wint_March2021PublicOfferingMember" xlink:type="locator"/>
    <link:loc xlink:href="wint-20220630.xsd#wint_March2021WarrantsMember" xlink:label="wint_March2021WarrantsMember" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DisclosureTextBlockAbstract" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="us-gaap_ClassOfWarrantOrRightDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="wint_ATMProgramMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_SubsequentEventTypeAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsequentEventTypeDomain" xlink:to="us-gaap_SubsequentEventMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="wint_March2021PublicOfferingMember" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_ClassOfWarrantOrRightAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="wint_March2021WarrantsMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="us-gaap_ClassOfWarrantOrRightDomain-default" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DisclosureTextBlockAbstract" xlink:to="us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.windtreetx.com/20220630/role/statement-note-9-stockbased-compensation" xlink:href="wint-20220630.xsd#statement-note-9-stockbased-compensation" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.windtreetx.com/20220630/role/statement-note-9-stockbased-compensation" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember" xlink:label="srt_RangeMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember" xlink:label="srt_RangeMember-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_TitleOfIndividualAxis" xlink:label="srt_TitleOfIndividualAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="srt_TitleOfIndividualWithRelationshipToEntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameAxis" xlink:label="us-gaap_PlanNameAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:label="us-gaap_RestrictedStockUnitsRSUMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="wint-20220630.xsd#wint_ExecutiveOfficersAndEmployeesMember" xlink:label="wint_ExecutiveOfficersAndEmployeesMember" xlink:type="locator"/>
    <link:loc xlink:href="wint-20220630.xsd#wint_NonplanStockOptionsMember" xlink:label="wint_NonplanStockOptionsMember" xlink:type="locator"/>
    <link:loc xlink:href="wint-20220630.xsd#wint_The2020EquityIncentivePlanMember" xlink:label="wint_The2020EquityIncentivePlanMember" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DisclosureTextBlockAbstract" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_TitleOfIndividualAxis" xlink:to="srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_PlanNameAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PlanNameDomain" xlink:to="wint_The2020EquityIncentivePlanMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_AwardTypeAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_RestrictedStockUnitsRSUMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain-default" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="srt_RangeAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PlanNameDomain" xlink:to="wint_NonplanStockOptionsMember" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="srt_TitleOfIndividualAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:to="wint_ExecutiveOfficersAndEmployeesMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_TitleOfIndividualAxis" xlink:to="srt_TitleOfIndividualWithRelationshipToEntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="4" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DisclosureTextBlockAbstract" xlink:to="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.windtreetx.com/20220630/role/statement-note-10-licensing-and-research-funding-agreements" xlink:href="wint-20220630.xsd#statement-note-10-licensing-and-research-funding-agreements" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.windtreetx.com/20220630/role/statement-note-10-licensing-and-research-funding-agreements" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_CounterpartyNameAxis" xlink:label="srt_CounterpartyNameAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis" xlink:type="locator"/>
    <link:loc xlink:href="wint-20220630.xsd#wint_AerosurfFundingTermSheetMember" xlink:label="wint_AerosurfFundingTermSheetMember" xlink:type="locator"/>
    <link:loc xlink:href="wint-20220630.xsd#wint_CorporatePartnershipLicensingAndResearchFundingAgreementsTextBlock" xlink:label="wint_CorporatePartnershipLicensingAndResearchFundingAgreementsTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="wint-20220630.xsd#wint_LeesPharmaceuticalHoldingsLimitedMember" xlink:label="wint_LeesPharmaceuticalHoldingsLimitedMember" xlink:type="locator"/>
    <link:loc xlink:href="wint-20220630.xsd#wint_TermSheetWithLeeMember" xlink:label="wint_TermSheetWithLeeMember" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DisclosureTextBlockAbstract" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_CounterpartyNameAxis" xlink:to="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_TypeOfArrangementAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="wint_AerosurfFundingTermSheetMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="srt_CounterpartyNameAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="wint_LeesPharmaceuticalHoldingsLimitedMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_CounterpartyNameAxis" xlink:to="srt_RepurchaseAgreementCounterpartyNameDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="wint_TermSheetWithLeeMember" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DisclosureTextBlockAbstract" xlink:to="wint_CorporatePartnershipLicensingAndResearchFundingAgreementsTextBlock" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.windtreetx.com/20220630/role/statement-significant-accounting-policies-policies" xlink:href="wint-20220630.xsd#statement-significant-accounting-policies-policies" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.windtreetx.com/20220630/role/statement-significant-accounting-policies-policies" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="us-gaap_AccountingPoliciesAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:label="us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConsolidationPolicyTextBlock" xlink:label="us-gaap_ConsolidationPolicyTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerSharePolicyTextBlock" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:label="us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" xlink:label="us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy" xlink:label="us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxPolicyTextBlock" xlink:label="us-gaap_IncomeTaxPolicyTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PolicyTextBlockAbstract" xlink:label="us-gaap_PolicyTextBlockAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentImpairment" xlink:label="us-gaap_PropertyPlantAndEquipmentImpairment" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:label="us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UseOfEstimates" xlink:label="us-gaap_UseOfEstimates" xlink:type="locator"/>
    <link:loc xlink:href="wint-20220630.xsd#wint_EffectOfCOVID19PandemicPolicyTextBlock" xlink:label="wint_EffectOfCOVID19PandemicPolicyTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="wint-20220630.xsd#wint_RestructuredDebtLiabilityContingentMilestonePaymentPolicyPolicyTextBlock" xlink:label="wint_RestructuredDebtLiabilityContingentMilestonePaymentPolicyPolicyTextBlock" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PolicyTextBlockAbstract" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PolicyTextBlockAbstract" xlink:to="us-gaap_AccountingPoliciesAbstract" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ConsolidationPolicyTextBlock" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_UseOfEstimates" xlink:type="arc"/>
    <link:definitionArc order="4" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:type="arc"/>
    <link:definitionArc order="5" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:type="arc"/>
    <link:definitionArc order="6" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentImpairment" xlink:type="arc"/>
    <link:definitionArc order="7" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="wint_RestructuredDebtLiabilityContingentMilestonePaymentPolicyPolicyTextBlock" xlink:type="arc"/>
    <link:definitionArc order="8" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:type="arc"/>
    <link:definitionArc order="9" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_IncomeTaxPolicyTextBlock" xlink:type="arc"/>
    <link:definitionArc order="10" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_EarningsPerSharePolicyTextBlock" xlink:type="arc"/>
    <link:definitionArc order="11" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="wint_EffectOfCOVID19PandemicPolicyTextBlock" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.windtreetx.com/20220630/role/statement-note-4-summary-of-significant-accounting-policies-tables" xlink:href="wint-20220630.xsd#statement-note-4-summary-of-significant-accounting-policies-tables" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.windtreetx.com/20220630/role/statement-note-4-summary-of-significant-accounting-policies-tables" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock" xlink:label="us-gaap_ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TableTextBlock" xlink:label="us-gaap_TableTextBlock" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_TableTextBlock" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TableTextBlock" xlink:to="us-gaap_ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.windtreetx.com/20220630/role/statement-note-5-fair-value-measurements-tables" xlink:href="wint-20220630.xsd#statement-note-5-fair-value-measurements-tables" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.windtreetx.com/20220630/role/statement-note-5-fair-value-measurements-tables" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:label="us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TableTextBlock" xlink:label="us-gaap_TableTextBlock" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_TableTextBlock" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TableTextBlock" xlink:to="us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.windtreetx.com/20220630/role/statement-note-9-stockbased-compensation-tables" xlink:href="wint-20220630.xsd#statement-note-9-stockbased-compensation-tables" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.windtreetx.com/20220630/role/statement-note-9-stockbased-compensation-tables" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock" xlink:label="us-gaap_DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TableTextBlock" xlink:label="us-gaap_TableTextBlock" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_TableTextBlock" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TableTextBlock" xlink:to="us-gaap_DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TableTextBlock" xlink:to="us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TableTextBlock" xlink:to="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TableTextBlock" xlink:to="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.windtreetx.com/20220630/role/statement-note-3-going-concern-and-managements-plans-details-textual" xlink:href="wint-20220630.xsd#statement-note-3-going-concern-and-managements-plans-details-textual" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.windtreetx.com/20220630/role/statement-note-3-going-concern-and-managements-plans-details-textual" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:label="us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillImpairmentLoss" xlink:label="us-gaap_GoodwillImpairmentLoss" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill" xlink:label="us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesCurrent" xlink:label="us-gaap_LiabilitiesCurrent" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventMember" xlink:label="us-gaap_SubsequentEventMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="us-gaap_SubsequentEventTypeAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="us-gaap_SubsequentEventTypeDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="us-gaap_SubsequentEventTypeDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis" xlink:type="locator"/>
    <link:loc xlink:href="wint-20220630.xsd#wint_ATMProgramMember" xlink:label="wint_ATMProgramMember" xlink:type="locator"/>
    <link:loc xlink:href="wint-20220630.xsd#wint_SharesAuthorizedToBeOfferedAndSoldUnderOfferingAgreementValue" xlink:label="wint_SharesAuthorizedToBeOfferedAndSoldUnderOfferingAgreementValue" xlink:type="locator"/>
    <link:loc xlink:href="wint-20220630.xsd#wint_StockOfferingAgreementPublicFloatLimitationAmount" xlink:label="wint_StockOfferingAgreementPublicFloatLimitationAmount" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="wint_ATMProgramMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_SubsequentEventTypeAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsequentEventTypeDomain" xlink:to="us-gaap_SubsequentEventMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeDomain-default" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NetIncomeLoss" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_GoodwillImpairmentLoss" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill" xlink:type="arc"/>
    <link:definitionArc order="4" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:type="arc"/>
    <link:definitionArc order="5" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit" xlink:type="arc"/>
    <link:definitionArc order="6" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="wint_SharesAuthorizedToBeOfferedAndSoldUnderOfferingAgreementValue" xlink:type="arc"/>
    <link:definitionArc order="7" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:type="arc"/>
    <link:definitionArc order="8" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:type="arc"/>
    <link:definitionArc order="9" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:type="arc"/>
    <link:definitionArc order="10" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="wint_StockOfferingAgreementPublicFloatLimitationAmount" xlink:type="arc"/>
    <link:definitionArc order="11" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:type="arc"/>
    <link:definitionArc order="12" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_LiabilitiesCurrent" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.windtreetx.com/20220630/role/statement-note-4-summary-of-significant-accounting-policies-details-textual" xlink:href="wint-20220630.xsd#statement-note-4-summary-of-significant-accounting-policies-details-textual" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.windtreetx.com/20220630/role/statement-note-4-summary-of-significant-accounting-policies-details-textual" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:label="us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Depreciation" xlink:label="us-gaap_Depreciation" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ForeignCurrencyTransactionGainBeforeTax" xlink:label="us-gaap_ForeignCurrencyTransactionGainBeforeTax" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ForeignCurrencyTransactionLossBeforeTax" xlink:label="us-gaap_ForeignCurrencyTransactionLossBeforeTax" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillImpairmentLoss" xlink:label="us-gaap_GoodwillImpairmentLoss" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill" xlink:label="us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LineOfCreditFacilityAxis" xlink:label="us-gaap_LineOfCreditFacilityAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LineOfCreditFacilityLenderDomain" xlink:label="us-gaap_LineOfCreditFacilityLenderDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LineOfCreditFacilityLenderDomain" xlink:label="us-gaap_LineOfCreditFacilityLenderDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongtermDebtTypeAxis" xlink:label="us-gaap_LongtermDebtTypeAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongtermDebtTypeDomain" xlink:label="us-gaap_LongtermDebtTypeDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongtermDebtTypeDomain" xlink:label="us-gaap_LongtermDebtTypeDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NumberOfReportingUnits" xlink:label="us-gaap_NumberOfReportingUnits" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SeveranceCosts1" xlink:label="us-gaap_SeveranceCosts1" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SupplementalUnemploymentBenefitsSeveranceBenefits" xlink:label="us-gaap_SupplementalUnemploymentBenefitsSeveranceBenefits" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis" xlink:type="locator"/>
    <link:loc xlink:href="wint-20220630.xsd#wint_DeerfieldLoanMember" xlink:label="wint_DeerfieldLoanMember" xlink:type="locator"/>
    <link:loc xlink:href="wint-20220630.xsd#wint_DeerfieldManagementLPMember" xlink:label="wint_DeerfieldManagementLPMember" xlink:type="locator"/>
    <link:loc xlink:href="wint-20220630.xsd#wint_ExchangeAndTerminationAgreementMember" xlink:label="wint_ExchangeAndTerminationAgreementMember" xlink:type="locator"/>
    <link:loc xlink:href="wint-20220630.xsd#wint_LiabilityforContingentMilestonePaymentNoncurrent" xlink:label="wint_LiabilityforContingentMilestonePaymentNoncurrent" xlink:type="locator"/>
    <link:loc xlink:href="wint-20220630.xsd#wint_ManufacturingAndLaboratoryEquipmentMember" xlink:label="wint_ManufacturingAndLaboratoryEquipmentMember" xlink:type="locator"/>
    <link:loc xlink:href="wint-20220630.xsd#wint_NumberOfSharesOfCommonStockPotentiallyIssuableUponTheExerciseOfStockOptionsAndWarrants" xlink:label="wint_NumberOfSharesOfCommonStockPotentiallyIssuableUponTheExerciseOfStockOptionsAndWarrants" xlink:type="locator"/>
    <link:loc xlink:href="wint-20220630.xsd#wint_PaymentsForSeveranceCosts" xlink:label="wint_PaymentsForSeveranceCosts" xlink:type="locator"/>
    <link:loc xlink:href="wint-20220630.xsd#wint_SeveranceAccrual" xlink:label="wint_SeveranceAccrual" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_LongtermDebtTypeAxis" xlink:to="us-gaap_LongtermDebtTypeDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_LineOfCreditFacilityAxis" xlink:to="us-gaap_LineOfCreditFacilityLenderDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="wint_ManufacturingAndLaboratoryEquipmentMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_LongtermDebtTypeAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LongtermDebtTypeDomain" xlink:to="wint_DeerfieldLoanMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_LongtermDebtTypeAxis" xlink:to="us-gaap_LongtermDebtTypeDomain-default" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_TypeOfArrangementAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="wint_ExchangeAndTerminationAgreementMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember-default" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_LineOfCreditFacilityAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LineOfCreditFacilityLenderDomain" xlink:to="wint_DeerfieldManagementLPMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_LineOfCreditFacilityAxis" xlink:to="us-gaap_LineOfCreditFacilityLenderDomain-default" xlink:type="arc"/>
    <link:definitionArc order="4" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NumberOfReportingUnits" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_GoodwillImpairmentLoss" xlink:type="arc"/>
    <link:definitionArc order="4" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ForeignCurrencyTransactionGainBeforeTax" xlink:type="arc"/>
    <link:definitionArc order="5" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ForeignCurrencyTransactionLossBeforeTax" xlink:type="arc"/>
    <link:definitionArc order="6" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SeveranceCosts1" xlink:type="arc"/>
    <link:definitionArc order="7" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="wint_SeveranceAccrual" xlink:type="arc"/>
    <link:definitionArc order="8" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="wint_PaymentsForSeveranceCosts" xlink:type="arc"/>
    <link:definitionArc order="9" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SupplementalUnemploymentBenefitsSeveranceBenefits" xlink:type="arc"/>
    <link:definitionArc order="10" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_Depreciation" xlink:type="arc"/>
    <link:definitionArc order="11" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="wint_LiabilityforContingentMilestonePaymentNoncurrent" xlink:type="arc"/>
    <link:definitionArc order="12" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:type="arc"/>
    <link:definitionArc order="13" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="wint_NumberOfSharesOfCommonStockPotentiallyIssuableUponTheExerciseOfStockOptionsAndWarrants" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.windtreetx.com/20220630/role/statement-note-6-loans-payable-details-textual" xlink:href="wint-20220630.xsd#statement-note-6-loans-payable-details-textual" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.windtreetx.com/20220630/role/statement-note-6-loans-payable-details-textual" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentAxis" xlink:label="us-gaap_DebtInstrumentAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentFaceAmount" xlink:label="us-gaap_DebtInstrumentFaceAmount" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:label="us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="us-gaap_DebtInstrumentNameDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="us-gaap_DebtInstrumentNameDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentPeriodicPayment" xlink:label="us-gaap_DebtInstrumentPeriodicPayment" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LoansPayableMember" xlink:label="us-gaap_LoansPayableMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LoansPayableToBank" xlink:label="us-gaap_LoansPayableToBank" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShortTermDebtTypeAxis" xlink:label="us-gaap_ShortTermDebtTypeAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShortTermDebtTypeDomain" xlink:label="us-gaap_ShortTermDebtTypeDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShortTermDebtTypeDomain" xlink:label="us-gaap_ShortTermDebtTypeDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="wint-20220630.xsd#wint_LoanPayableToBankDirectCapitalFinanceMember" xlink:label="wint_LoanPayableToBankDirectCapitalFinanceMember" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_ShortTermDebtTypeAxis" xlink:to="us-gaap_ShortTermDebtTypeDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_DebtInstrumentAxis" xlink:to="us-gaap_DebtInstrumentNameDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_DebtInstrumentAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentNameDomain" xlink:to="wint_LoanPayableToBankDirectCapitalFinanceMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_DebtInstrumentAxis" xlink:to="us-gaap_DebtInstrumentNameDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_ShortTermDebtTypeAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShortTermDebtTypeDomain" xlink:to="us-gaap_LoansPayableMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_ShortTermDebtTypeAxis" xlink:to="us-gaap_ShortTermDebtTypeDomain-default" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DebtInstrumentFaceAmount" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DebtInstrumentPeriodicPayment" xlink:type="arc"/>
    <link:definitionArc order="4" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_LoansPayableToBank" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.windtreetx.com/20220630/role/statement-note-7-restructured-debt-liability-details-textual" xlink:href="wint-20220630.xsd#statement-note-7-restructured-debt-liability-details-textual" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.windtreetx.com/20220630/role/statement-note-7-restructured-debt-liability-details-textual" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_CounterpartyNameAxis" xlink:label="srt_CounterpartyNameAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ExtinguishmentOfDebtAmount" xlink:label="us-gaap_ExtinguishmentOfDebtAmount" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongtermDebtTypeAxis" xlink:label="us-gaap_LongtermDebtTypeAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongtermDebtTypeDomain" xlink:label="us-gaap_LongtermDebtTypeDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongtermDebtTypeDomain" xlink:label="us-gaap_LongtermDebtTypeDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RepaymentsOfLongTermDebt" xlink:label="us-gaap_RepaymentsOfLongTermDebt" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis" xlink:type="locator"/>
    <link:loc xlink:href="wint-20220630.xsd#wint_ClassOfWarrantOrRightExercisePriceOfCancelledWarrants" xlink:label="wint_ClassOfWarrantOrRightExercisePriceOfCancelledWarrants" xlink:type="locator"/>
    <link:loc xlink:href="wint-20220630.xsd#wint_ClassOfWarrantOrRightNumberOfWarrantsCancelled" xlink:label="wint_ClassOfWarrantOrRightNumberOfWarrantsCancelled" xlink:type="locator"/>
    <link:loc xlink:href="wint-20220630.xsd#wint_DeerfieldLoanMember" xlink:label="wint_DeerfieldLoanMember" xlink:type="locator"/>
    <link:loc xlink:href="wint-20220630.xsd#wint_DeerfieldManagementLPMember" xlink:label="wint_DeerfieldManagementLPMember" xlink:type="locator"/>
    <link:loc xlink:href="wint-20220630.xsd#wint_ExchangeAndTerminationAgreementMember" xlink:label="wint_ExchangeAndTerminationAgreementMember" xlink:type="locator"/>
    <link:loc xlink:href="wint-20220630.xsd#wint_LiabilityforContingentMilestonePaymentNoncurrent" xlink:label="wint_LiabilityforContingentMilestonePaymentNoncurrent" xlink:type="locator"/>
    <link:loc xlink:href="wint-20220630.xsd#wint_StockIssuedDuringPeriodSharesCancellationOfDebtAndWarrantObligations" xlink:label="wint_StockIssuedDuringPeriodSharesCancellationOfDebtAndWarrantObligations" xlink:type="locator"/>
    <link:loc xlink:href="wint-20220630.xsd#wint_StockIssuedDuringPeriodSharesCancellationOfDebtAndWarrantObligationsPercentageOfFullyDilutedSharesOutstanding" xlink:label="wint_StockIssuedDuringPeriodSharesCancellationOfDebtAndWarrantObligationsPercentageOfFullyDilutedSharesOutstanding" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_CounterpartyNameAxis" xlink:to="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_LongtermDebtTypeAxis" xlink:to="us-gaap_LongtermDebtTypeDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_LongtermDebtTypeAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LongtermDebtTypeDomain" xlink:to="wint_DeerfieldLoanMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_LongtermDebtTypeAxis" xlink:to="us-gaap_LongtermDebtTypeDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_TypeOfArrangementAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="wint_ExchangeAndTerminationAgreementMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember-default" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="srt_CounterpartyNameAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="wint_DeerfieldManagementLPMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_CounterpartyNameAxis" xlink:to="srt_RepurchaseAgreementCounterpartyNameDomain-default" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ExtinguishmentOfDebtAmount" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="wint_ClassOfWarrantOrRightNumberOfWarrantsCancelled" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="wint_ClassOfWarrantOrRightExercisePriceOfCancelledWarrants" xlink:type="arc"/>
    <link:definitionArc order="4" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_RepaymentsOfLongTermDebt" xlink:type="arc"/>
    <link:definitionArc order="5" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="wint_StockIssuedDuringPeriodSharesCancellationOfDebtAndWarrantObligations" xlink:type="arc"/>
    <link:definitionArc order="6" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="wint_StockIssuedDuringPeriodSharesCancellationOfDebtAndWarrantObligationsPercentageOfFullyDilutedSharesOutstanding" xlink:type="arc"/>
    <link:definitionArc order="7" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="wint_LiabilityforContingentMilestonePaymentNoncurrent" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.windtreetx.com/20220630/role/statement-note-8-stockholders-equity-details-textual" xlink:href="wint-20220630.xsd#statement-note-8-stockholders-equity-details-textual" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.windtreetx.com/20220630/role/statement-note-8-stockholders-equity-details-textual" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="us-gaap_ClassOfWarrantOrRightAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="us-gaap_ClassOfWarrantOrRightDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="us-gaap_ClassOfWarrantOrRightDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceOrSaleOfEquity" xlink:label="us-gaap_ProceedsFromIssuanceOrSaleOfEquity" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventMember" xlink:label="us-gaap_SubsequentEventMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="us-gaap_SubsequentEventTypeAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="us-gaap_SubsequentEventTypeDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="us-gaap_SubsequentEventTypeDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WarrantsAndRightsOutstandingTerm" xlink:label="us-gaap_WarrantsAndRightsOutstandingTerm" xlink:type="locator"/>
    <link:loc xlink:href="wint-20220630.xsd#wint_ATMProgramMember" xlink:label="wint_ATMProgramMember" xlink:type="locator"/>
    <link:loc xlink:href="wint-20220630.xsd#wint_CommissionFeePercentFee" xlink:label="wint_CommissionFeePercentFee" xlink:type="locator"/>
    <link:loc xlink:href="wint-20220630.xsd#wint_EquityIssuedDuringPeriodUnitsNewIssues" xlink:label="wint_EquityIssuedDuringPeriodUnitsNewIssues" xlink:type="locator"/>
    <link:loc xlink:href="wint-20220630.xsd#wint_March2021PublicOfferingMember" xlink:label="wint_March2021PublicOfferingMember" xlink:type="locator"/>
    <link:loc xlink:href="wint-20220630.xsd#wint_March2021WarrantsMember" xlink:label="wint_March2021WarrantsMember" xlink:type="locator"/>
    <link:loc xlink:href="wint-20220630.xsd#wint_ProceedsFromIssuanceOrSaleOfEquityGrossAmount" xlink:label="wint_ProceedsFromIssuanceOrSaleOfEquityGrossAmount" xlink:type="locator"/>
    <link:loc xlink:href="wint-20220630.xsd#wint_SharesAuthorizedToBeOfferedAndSoldUnderOfferingAgreementValue" xlink:label="wint_SharesAuthorizedToBeOfferedAndSoldUnderOfferingAgreementValue" xlink:type="locator"/>
    <link:loc xlink:href="wint-20220630.xsd#wint_StockAndWarrantsIssuedPricePerShare" xlink:label="wint_StockAndWarrantsIssuedPricePerShare" xlink:type="locator"/>
    <link:loc xlink:href="wint-20220630.xsd#wint_StockOfferingAgreementPublicFloatLimitationAmount" xlink:label="wint_StockOfferingAgreementPublicFloatLimitationAmount" xlink:type="locator"/>
    <link:loc xlink:href="wint-20220630.xsd#wint_StockOfferingAgreementRemainingAmountAvailable" xlink:label="wint_StockOfferingAgreementRemainingAmountAvailable" xlink:type="locator"/>
    <link:loc xlink:href="wint-20220630.xsd#wint_UnitsNumberOfSecuritiesCalledByEachUnit" xlink:label="wint_UnitsNumberOfSecuritiesCalledByEachUnit" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="us-gaap_ClassOfWarrantOrRightDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="wint_ATMProgramMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_SubsequentEventTypeAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsequentEventTypeDomain" xlink:to="us-gaap_SubsequentEventMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="wint_March2021PublicOfferingMember" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_ClassOfWarrantOrRightAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="wint_March2021WarrantsMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="us-gaap_ClassOfWarrantOrRightDomain-default" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="wint_SharesAuthorizedToBeOfferedAndSoldUnderOfferingAgreementValue" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="wint_CommissionFeePercentFee" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:type="arc"/>
    <link:definitionArc order="4" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:type="arc"/>
    <link:definitionArc order="5" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:type="arc"/>
    <link:definitionArc order="6" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="wint_StockOfferingAgreementRemainingAmountAvailable" xlink:type="arc"/>
    <link:definitionArc order="7" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="wint_StockOfferingAgreementPublicFloatLimitationAmount" xlink:type="arc"/>
    <link:definitionArc order="8" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="wint_EquityIssuedDuringPeriodUnitsNewIssues" xlink:type="arc"/>
    <link:definitionArc order="9" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="wint_UnitsNumberOfSecuritiesCalledByEachUnit" xlink:type="arc"/>
    <link:definitionArc order="10" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:type="arc"/>
    <link:definitionArc order="11" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_WarrantsAndRightsOutstandingTerm" xlink:type="arc"/>
    <link:definitionArc order="12" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="wint_StockAndWarrantsIssuedPricePerShare" xlink:type="arc"/>
    <link:definitionArc order="13" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="wint_ProceedsFromIssuanceOrSaleOfEquityGrossAmount" xlink:type="arc"/>
    <link:definitionArc order="14" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ProceedsFromIssuanceOrSaleOfEquity" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.windtreetx.com/20220630/role/statement-note-9-stockbased-compensation-details-textual" xlink:href="wint-20220630.xsd#statement-note-9-stockbased-compensation-details-textual" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.windtreetx.com/20220630/role/statement-note-9-stockbased-compensation-details-textual" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember" xlink:label="srt_RangeMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember" xlink:label="srt_RangeMember-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_TitleOfIndividualAxis" xlink:label="srt_TitleOfIndividualAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="srt_TitleOfIndividualWithRelationshipToEntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameAxis" xlink:label="us-gaap_PlanNameAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:label="us-gaap_RestrictedStockUnitsRSUMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="wint-20220630.xsd#wint_ExecutiveOfficersAndEmployeesMember" xlink:label="wint_ExecutiveOfficersAndEmployeesMember" xlink:type="locator"/>
    <link:loc xlink:href="wint-20220630.xsd#wint_NonplanStockOptionsMember" xlink:label="wint_NonplanStockOptionsMember" xlink:type="locator"/>
    <link:loc xlink:href="wint-20220630.xsd#wint_The2020EquityIncentivePlanMember" xlink:label="wint_The2020EquityIncentivePlanMember" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_TitleOfIndividualAxis" xlink:to="srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_PlanNameAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PlanNameDomain" xlink:to="wint_The2020EquityIncentivePlanMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_AwardTypeAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_RestrictedStockUnitsRSUMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain-default" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="srt_RangeAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PlanNameDomain" xlink:to="wint_NonplanStockOptionsMember" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="srt_TitleOfIndividualAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:to="wint_ExecutiveOfficersAndEmployeesMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_TitleOfIndividualAxis" xlink:to="srt_TitleOfIndividualWithRelationshipToEntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="4" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.windtreetx.com/20220630/role/statement-note-10-licensing-and-research-funding-agreements-details-textual" xlink:href="wint-20220630.xsd#statement-note-10-licensing-and-research-funding-agreements-details-textual" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.windtreetx.com/20220630/role/statement-note-10-licensing-and-research-funding-agreements-details-textual" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_CounterpartyNameAxis" xlink:label="srt_CounterpartyNameAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractualObligation" xlink:label="us-gaap_ContractualObligation" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis" xlink:type="locator"/>
    <link:loc xlink:href="wint-20220630.xsd#wint_AerosurfFundingTermSheetMember" xlink:label="wint_AerosurfFundingTermSheetMember" xlink:type="locator"/>
    <link:loc xlink:href="wint-20220630.xsd#wint_FinancingOfProductPercentOfFinancingThatMustBeRepaidToDiscontinueRevenueSharing" xlink:label="wint_FinancingOfProductPercentOfFinancingThatMustBeRepaidToDiscontinueRevenueSharing" xlink:type="locator"/>
    <link:loc xlink:href="wint-20220630.xsd#wint_FinancingOfProductPercentOfRevenueSharedWithFinancer" xlink:label="wint_FinancingOfProductPercentOfRevenueSharedWithFinancer" xlink:type="locator"/>
    <link:loc xlink:href="wint-20220630.xsd#wint_LeesPharmaceuticalHoldingsLimitedMember" xlink:label="wint_LeesPharmaceuticalHoldingsLimitedMember" xlink:type="locator"/>
    <link:loc xlink:href="wint-20220630.xsd#wint_NonrefundablePayments" xlink:label="wint_NonrefundablePayments" xlink:type="locator"/>
    <link:loc xlink:href="wint-20220630.xsd#wint_ProceedsForPaymentsToDevelopProduct" xlink:label="wint_ProceedsForPaymentsToDevelopProduct" xlink:type="locator"/>
    <link:loc xlink:href="wint-20220630.xsd#wint_TermSheetWithLeeMember" xlink:label="wint_TermSheetWithLeeMember" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_CounterpartyNameAxis" xlink:to="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_TypeOfArrangementAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="wint_AerosurfFundingTermSheetMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="srt_CounterpartyNameAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="wint_LeesPharmaceuticalHoldingsLimitedMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_CounterpartyNameAxis" xlink:to="srt_RepurchaseAgreementCounterpartyNameDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="wint_TermSheetWithLeeMember" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="wint_NonrefundablePayments" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="wint_ProceedsForPaymentsToDevelopProduct" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="wint_FinancingOfProductPercentOfFinancingThatMustBeRepaidToDiscontinueRevenueSharing" xlink:type="arc"/>
    <link:definitionArc order="4" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="wint_FinancingOfProductPercentOfRevenueSharedWithFinancer" xlink:type="arc"/>
    <link:definitionArc order="5" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ContractualObligation" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.windtreetx.com/20220630/role/statement-condensed-consolidated-balance-sheets-current-period-unaudited" xlink:href="wint-20220630.xsd#statement-condensed-consolidated-balance-sheets-current-period-unaudited" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.windtreetx.com/20220630/role/statement-condensed-consolidated-balance-sheets-current-period-unaudited" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsPayableCurrent" xlink:label="us-gaap_AccountsPayableCurrent" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="us-gaap_AccruedLiabilitiesCurrent" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapital" xlink:label="us-gaap_AdditionalPaidInCapital" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Assets" xlink:label="us-gaap_Assets" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsCurrent" xlink:label="us-gaap_AssetsCurrent" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsCurrentAbstract" xlink:label="us-gaap_AssetsCurrentAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockValue" xlink:label="us-gaap_CommonStockValue" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredIncomeTaxLiabilitiesNet" xlink:label="us-gaap_DeferredIncomeTaxLiabilitiesNet" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Goodwill" xlink:label="us-gaap_Goodwill" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill" xlink:label="us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Liabilities" xlink:label="us-gaap_Liabilities" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesCurrent" xlink:label="us-gaap_LiabilitiesCurrent" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="us-gaap_LiabilitiesCurrentAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LoansPayableCurrent" xlink:label="us-gaap_LoansPayableCurrent" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherLiabilitiesNoncurrent" xlink:label="us-gaap_OtherLiabilitiesNoncurrent" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockValue" xlink:label="us-gaap_PreferredStockValue" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="us-gaap_PropertyPlantAndEquipmentNet" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedCashAndCashEquivalentsNoncurrent" xlink:label="us-gaap_RestrictedCashAndCashEquivalentsNoncurrent" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityAbstract" xlink:label="us-gaap_StockholdersEquityAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TreasuryStockValue" xlink:label="us-gaap_TreasuryStockValue" xlink:type="locator"/>
    <link:loc xlink:href="wint-20220630.xsd#wint_LiabilityforContingentMilestonePaymentNoncurrent" xlink:label="wint_LiabilityforContingentMilestonePaymentNoncurrent" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AssetsCurrentAbstract" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_AssetsCurrent" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentNet" xlink:type="arc"/>
    <link:definitionArc order="4" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_RestrictedCashAndCashEquivalentsNoncurrent" xlink:type="arc"/>
    <link:definitionArc order="5" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset" xlink:type="arc"/>
    <link:definitionArc order="6" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill" xlink:type="arc"/>
    <link:definitionArc order="7" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_Goodwill" xlink:type="arc"/>
    <link:definitionArc order="8" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_Assets" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_LiabilitiesCurrentAbstract" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_AccountsPayableCurrent" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_AccruedLiabilitiesCurrent" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_OperatingLeaseLiabilityCurrent" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_LoansPayableCurrent" xlink:type="arc"/>
    <link:definitionArc order="4" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_LiabilitiesCurrent" xlink:type="arc"/>
    <link:definitionArc order="5" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:type="arc"/>
    <link:definitionArc order="6" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="wint_LiabilityforContingentMilestonePaymentNoncurrent" xlink:type="arc"/>
    <link:definitionArc order="7" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_OtherLiabilitiesNoncurrent" xlink:type="arc"/>
    <link:definitionArc order="8" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_DeferredIncomeTaxLiabilitiesNet" xlink:type="arc"/>
    <link:definitionArc order="9" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_Liabilities" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockholdersEquityAbstract" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_PreferredStockValue" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_CommonStockValue" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_AdditionalPaidInCapital" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit" xlink:type="arc"/>
    <link:definitionArc order="4" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_TreasuryStockValue" xlink:type="arc"/>
    <link:definitionArc order="5" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_StockholdersEquity" xlink:type="arc"/>
    <link:definitionArc order="6" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_LiabilitiesAndStockholdersEquity" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.windtreetx.com/20220630/role/statement-condensed-consolidated-statements-of-cash-flows-unaudited-" xlink:href="wint-20220630.xsd#statement-condensed-consolidated-statements-of-cash-flows-unaudited-" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.windtreetx.com/20220630/role/statement-condensed-consolidated-statements-of-cash-flows-unaudited-" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:label="us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Depreciation" xlink:label="us-gaap_Depreciation" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeBenefitsAndShareBasedCompensation" xlink:label="us-gaap_EmployeeBenefitsAndShareBasedCompensation" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ForeignCurrencyTransactionGainLossBeforeTax" xlink:label="us-gaap_ForeignCurrencyTransactionGainLossBeforeTax" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GainLossOnDispositionOfAssets" xlink:label="us-gaap_GainLossOnDispositionOfAssets" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillImpairmentLoss" xlink:label="us-gaap_GoodwillImpairmentLoss" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill" xlink:label="us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccountsPayable" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:label="us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:label="us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense" xlink:label="us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment" xlink:label="us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RepaymentsOfShortTermDebt" xlink:label="us-gaap_RepaymentsOfShortTermDebt" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:label="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="wint-20220630.xsd#wint_IncreaseDecreaseOperatingLeaseLiability" xlink:label="wint_IncreaseDecreaseOperatingLeaseLiability" xlink:type="locator"/>
    <link:loc xlink:href="wint-20220630.xsd#wint_NonCashExpenseRelatedToEquityConsiderationForAServiceAgreement" xlink:label="wint_NonCashExpenseRelatedToEquityConsiderationForAServiceAgreement" xlink:type="locator"/>
    <link:loc xlink:href="wint-20220630.xsd#wint_PrepaymentOfDirectorAndOfficerInsuranceThroughThirdPartyFinancing" xlink:label="wint_PrepaymentOfDirectorAndOfficerInsuranceThroughThirdPartyFinancing" xlink:type="locator"/>
    <link:loc xlink:href="wint-20220630.xsd#wint_ProceedsFromIssuanceOfCommonStockAndWarrants" xlink:label="wint_ProceedsFromIssuanceOfCommonStockAndWarrants" xlink:type="locator"/>
    <link:loc xlink:href="wint-20220630.xsd#wint_ProceedsFromResearchAndDevelopmentFundingArrangement" xlink:label="wint_ProceedsFromResearchAndDevelopmentFundingArrangement" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_NetIncomeLoss" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_Depreciation" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_EmployeeBenefitsAndShareBasedCompensation" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="wint_NonCashExpenseRelatedToEquityConsiderationForAServiceAgreement" xlink:type="arc"/>
    <link:definitionArc order="4" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_GoodwillImpairmentLoss" xlink:type="arc"/>
    <link:definitionArc order="5" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill" xlink:type="arc"/>
    <link:definitionArc order="6" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_GainLossOnDispositionOfAssets" xlink:type="arc"/>
    <link:definitionArc order="7" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:type="arc"/>
    <link:definitionArc order="8" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_ForeignCurrencyTransactionGainLossBeforeTax" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayable" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="wint_IncreaseDecreaseOperatingLeaseLiability" xlink:type="arc"/>
    <link:definitionArc order="4" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:type="arc"/>
    <link:definitionArc order="4" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:type="arc"/>
    <link:definitionArc order="5" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_RepaymentsOfShortTermDebt" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="wint_ProceedsFromIssuanceOfCommonStockAndWarrants" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="wint_ProceedsFromResearchAndDevelopmentFundingArrangement" xlink:type="arc"/>
    <link:definitionArc order="4" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:type="arc"/>
    <link:definitionArc order="5" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:type="arc"/>
    <link:definitionArc order="6" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:type="arc"/>
    <link:definitionArc order="6" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:to="wint_PrepaymentOfDirectorAndOfficerInsuranceThroughThirdPartyFinancing" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:to="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.windtreetx.com/20220630/role/statement-condensed-consolidated-statements-of-changes-in-stockholders-equity-unaudited-" xlink:href="wint-20220630.xsd#statement-condensed-consolidated-statements-of-changes-in-stockholders-equity-unaudited-" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.windtreetx.com/20220630/role/statement-condensed-consolidated-statements-of-changes-in-stockholders-equity-unaudited-" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="us-gaap_AdditionalPaidInCapitalMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsMember" xlink:label="us-gaap_RetainedEarningsMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharesOutstanding" xlink:label="us-gaap_SharesOutstanding" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueIssuedForServices" xlink:label="us-gaap_StockIssuedDuringPeriodValueIssuedForServices" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TreasuryStockMember" xlink:label="us-gaap_TreasuryStockMember" xlink:type="locator"/>
    <link:loc xlink:href="wint-20220630.xsd#wint_ATMProgramMember" xlink:label="wint_ATMProgramMember" xlink:type="locator"/>
    <link:loc xlink:href="wint-20220630.xsd#wint_IssuanceOfCommonStockAndCommonStockWarrantsNetOfIssuanceCostsShares" xlink:label="wint_IssuanceOfCommonStockAndCommonStockWarrantsNetOfIssuanceCostsShares" xlink:type="locator"/>
    <link:loc xlink:href="wint-20220630.xsd#wint_IssuanceOfCommonStockAndCommonStockWarrantsNetOfIssuanceCostsValue" xlink:label="wint_IssuanceOfCommonStockAndCommonStockWarrantsNetOfIssuanceCostsValue" xlink:type="locator"/>
    <link:loc xlink:href="wint-20220630.xsd#wint_SharePurchaseAgreementDecember2019Member" xlink:label="wint_SharePurchaseAgreementDecember2019Member" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementClassOfStockAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="wint_ATMProgramMember" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="wint_SharePurchaseAgreementDecember2019Member" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain-default" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementEquityComponentsAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_CommonStockMember" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_AdditionalPaidInCapitalMember" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_RetainedEarningsMember" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_TreasuryStockMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SharesOutstanding" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockholdersEquity" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NetIncomeLoss" xlink:type="arc"/>
    <link:definitionArc order="4" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="wint_IssuanceOfCommonStockAndCommonStockWarrantsNetOfIssuanceCostsShares" xlink:type="arc"/>
    <link:definitionArc order="5" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="wint_IssuanceOfCommonStockAndCommonStockWarrantsNetOfIssuanceCostsValue" xlink:type="arc"/>
    <link:definitionArc order="6" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:type="arc"/>
    <link:definitionArc order="7" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:type="arc"/>
    <link:definitionArc order="8" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:type="arc"/>
    <link:definitionArc order="9" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueIssuedForServices" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.windtreetx.com/20220630/role/statement-note-4-summary-of-significant-accounting-policies-intangible-assets-details" xlink:href="wint-20220630.xsd#statement-note-4-summary-of-significant-accounting-policies-intangible-assets-details" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.windtreetx.com/20220630/role/statement-note-4-summary-of-significant-accounting-policies-intangible-assets-details" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Goodwill" xlink:label="us-gaap_Goodwill" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis" xlink:label="us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill" xlink:label="us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="wint-20220630.xsd#wint_IstaroximeDrugCandidateMember" xlink:label="wint_IstaroximeDrugCandidateMember" xlink:type="locator"/>
    <link:loc xlink:href="wint-20220630.xsd#wint_RostafuroxinDrugCandidateMember" xlink:label="wint_RostafuroxinDrugCandidateMember" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="wint_IstaroximeDrugCandidateMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="wint_RostafuroxinDrugCandidateMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_Goodwill" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.windtreetx.com/20220630/role/statement-note-9-stockbased-compensation-summary-of-stock-option-activity-details" xlink:href="wint-20220630.xsd#statement-note-9-stockbased-compensation-summary-of-stock-option-activity-details" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.windtreetx.com/20220630/role/statement-note-9-stockbased-compensation-summary-of-stock-option-activity-details" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:type="arc"/>
    <link:definitionArc order="4" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:type="arc"/>
    <link:definitionArc order="5" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" xlink:type="arc"/>
    <link:definitionArc order="6" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" xlink:type="arc"/>
    <link:definitionArc order="7" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:type="arc"/>
    <link:definitionArc order="8" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:type="arc"/>
    <link:definitionArc order="9" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:type="arc"/>
    <link:definitionArc order="10" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:type="arc"/>
    <link:definitionArc order="11" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:type="arc"/>
    <link:definitionArc order="12" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:type="arc"/>
    <link:definitionArc order="13" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.windtreetx.com/20220630/role/statement-note-9-stockbased-compensation-restricted-stock-units-details" xlink:href="wint-20220630.xsd#statement-note-9-stockbased-compensation-restricted-stock-units-details" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.windtreetx.com/20220630/role/statement-note-9-stockbased-compensation-restricted-stock-units-details" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:label="us-gaap_RestrictedStockUnitsRSUMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="wint-20220630.xsd#wint_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndExercisable" xlink:label="wint_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndExercisable" xlink:type="locator"/>
    <link:loc xlink:href="wint-20220630.xsd#wint_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndExercisableWeightedAverageGrantDateFairValueEndingBalance" xlink:label="wint_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndExercisableWeightedAverageGrantDateFairValueEndingBalance" xlink:type="locator"/>
    <link:loc xlink:href="wint-20220630.xsd#wint_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndExpectedToVestWeightedAverageGrantDateFairValueEndingBalance" xlink:label="wint_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndExpectedToVestWeightedAverageGrantDateFairValueEndingBalance" xlink:type="locator"/>
    <link:loc xlink:href="wint-20220630.xsd#wint_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityOtherThanOptionsVestedAndExpectedToVestOutstandingNumber" xlink:label="wint_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityOtherThanOptionsVestedAndExpectedToVestOutstandingNumber" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_AwardTypeAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_RestrictedStockUnitsRSUMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:type="arc"/>
    <link:definitionArc order="4" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:type="arc"/>
    <link:definitionArc order="5" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:type="arc"/>
    <link:definitionArc order="6" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:type="arc"/>
    <link:definitionArc order="7" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="wint_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndExercisable" xlink:type="arc"/>
    <link:definitionArc order="8" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="wint_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndExercisableWeightedAverageGrantDateFairValueEndingBalance" xlink:type="arc"/>
    <link:definitionArc order="9" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="wint_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityOtherThanOptionsVestedAndExpectedToVestOutstandingNumber" xlink:type="arc"/>
    <link:definitionArc order="10" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="wint_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndExpectedToVestWeightedAverageGrantDateFairValueEndingBalance" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.windtreetx.com/20220630/role/statement-note-9-stockbased-compensation-stockbased-compensation-expense-details" xlink:href="wint-20220630.xsd#statement-note-9-stockbased-compensation-stockbased-compensation-expense-details" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.windtreetx.com/20220630/role/statement-note-9-stockbased-compensation-stockbased-compensation-expense-details" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="us-gaap_IncomeStatementLocationAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="us-gaap_IncomeStatementLocationDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="us-gaap_IncomeStatementLocationDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SellingGeneralAndAdministrativeExpensesMember" xlink:label="us-gaap_SellingGeneralAndAdministrativeExpensesMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_IncomeStatementLocationAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_ResearchAndDevelopmentExpenseMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_SellingGeneralAndAdministrativeExpensesMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.windtreetx.com/20220630/role/statement-note-9-stockbased-compensation-stock-options-valuation-assumptions-details" xlink:href="wint-20220630.xsd#statement-note-9-stockbased-compensation-stock-options-valuation-assumptions-details" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.windtreetx.com/20220630/role/statement-note-9-stockbased-compensation-stock-options-valuation-assumptions-details" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.windtreetx.com/20220630/role/statement-condensed-consolidated-statements-of-operations-unaudited" xlink:href="wint-20220630.xsd#statement-condensed-consolidated-statements-of-operations-unaudited" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.windtreetx.com/20220630/role/statement-condensed-consolidated-statements-of-operations-unaudited" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="us-gaap_EarningsPerShareAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareBasic" xlink:label="us-gaap_EarningsPerShareBasic" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareBasicAbstract" xlink:label="us-gaap_EarningsPerShareBasicAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillImpairmentLoss" xlink:label="us-gaap_GoodwillImpairmentLoss" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill" xlink:label="us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="us-gaap_IncomeTaxExpenseBenefit" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestExpense" xlink:label="us-gaap_InterestExpense" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentIncomeInterest" xlink:label="us-gaap_InvestmentIncomeInterest" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NonoperatingIncomeExpense" xlink:label="us-gaap_NonoperatingIncomeExpense" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingExpenses" xlink:label="us-gaap_OperatingExpenses" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingExpensesAbstract" xlink:label="us-gaap_OperatingExpensesAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingIncomeLoss" xlink:label="us-gaap_OperatingIncomeLoss" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherNonoperatingIncomeExpense" xlink:label="us-gaap_OtherNonoperatingIncomeExpense" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="us-gaap_ResearchAndDevelopmentExpense" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SellingGeneralAndAdministrativeExpense" xlink:label="us-gaap_SellingGeneralAndAdministrativeExpense" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_OperatingExpensesAbstract" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_ResearchAndDevelopmentExpense" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_SellingGeneralAndAdministrativeExpense" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_GoodwillImpairmentLoss" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill" xlink:type="arc"/>
    <link:definitionArc order="4" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_OperatingExpenses" xlink:type="arc"/>
    <link:definitionArc order="5" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_OperatingIncomeLoss" xlink:type="arc"/>
    <link:definitionArc order="6" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_InvestmentIncomeInterest" xlink:type="arc"/>
    <link:definitionArc order="7" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_InterestExpense" xlink:type="arc"/>
    <link:definitionArc order="8" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_OtherNonoperatingIncomeExpense" xlink:type="arc"/>
    <link:definitionArc order="9" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_NonoperatingIncomeExpense" xlink:type="arc"/>
    <link:definitionArc order="10" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:type="arc"/>
    <link:definitionArc order="11" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_IncomeTaxExpenseBenefit" xlink:type="arc"/>
    <link:definitionArc order="12" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_NetIncomeLoss" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_EarningsPerShareAbstract" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_EarningsPerShareBasic" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_EarningsPerShareBasicAbstract" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EarningsPerShareBasicAbstract" xlink:to="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.windtreetx.com/20220630/role/statement-note-5-fair-value-measurements-assets-and-liabilities-measured-at-fair-value-on-a-recurring-basis-details" xlink:href="wint-20220630.xsd#statement-note-5-fair-value-measurements-assets-and-liabilities-measured-at-fair-value-on-a-recurring-basis-details" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.windtreetx.com/20220630/role/statement-note-5-fair-value-measurements-assets-and-liabilities-measured-at-fair-value-on-a-recurring-basis-details" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsFairValueDisclosure" xlink:label="us-gaap_AssetsFairValueDisclosure" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsAxis" xlink:label="us-gaap_CashAndCashEquivalentsAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:label="us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByMeasurementFrequencyAxis" xlink:label="us-gaap_FairValueByMeasurementFrequencyAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel1Member" xlink:label="us-gaap_FairValueInputsLevel1Member" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementFrequencyDomain" xlink:label="us-gaap_FairValueMeasurementFrequencyDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementFrequencyDomain" xlink:label="us-gaap_FairValueMeasurementFrequencyDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsRecurringMember" xlink:label="us-gaap_FairValueMeasurementsRecurringMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MoneyMarketFundsMember" xlink:label="us-gaap_MoneyMarketFundsMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:label="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:label="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_CashAndCashEquivalentsAxis" xlink:to="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_FairValueByMeasurementFrequencyAxis" xlink:to="us-gaap_FairValueMeasurementFrequencyDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_FairValueByMeasurementFrequencyAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueMeasurementFrequencyDomain" xlink:to="us-gaap_FairValueMeasurementsRecurringMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_FairValueByMeasurementFrequencyAxis" xlink:to="us-gaap_FairValueMeasurementFrequencyDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_CashAndCashEquivalentsAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:to="us-gaap_MoneyMarketFundsMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_CashAndCashEquivalentsAxis" xlink:to="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember-default" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueInputsLevel1Member" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="us-gaap_FairValueMeasurementsFairValueHierarchyDomain-default" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AssetsFairValueDisclosure" xlink:type="arc"/>
  </link:definitionLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>9
<FILENAME>wint-20220630_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABEL LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" standalone="no"?>
<!--Generated by ThunderDome XBRL - 05:34AM UTC 2022-08-11--><link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/netLabel" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel" xlink:type="simple"/>
  <link:labelLink xlink:role="http://www.xbrl.org/2003/role/link" xlink:type="extended">
    <link:loc xlink:href="wint-20220630.xsd#wint_DocumentAndEntityInformation" xlink:label="wint_DocumentAndEntityInformation" xlink:type="locator"/>
    <link:label xlink:label="wint_DocumentAndEntityInformation-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document And Entity Information</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="wint_DocumentAndEntityInformation" xlink:to="wint_DocumentAndEntityInformation-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:label="us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_FairValueOfFinancialInstrumentsPolicy-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value of Financial Instruments, Policy [Policy Text Block]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:to="us-gaap_FairValueOfFinancialInstrumentsPolicy-label" xlink:type="arc"/>
    <link:loc xlink:href="wint-20220630.xsd#wint_NoteToFinancialStatementDetailsTextual" xlink:label="wint_NoteToFinancialStatementDetailsTextual" xlink:type="locator"/>
    <link:label xlink:label="wint_NoteToFinancialStatementDetailsTextual-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Note To Financial Statement Details Textual</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="wint_NoteToFinancialStatementDetailsTextual" xlink:to="wint_NoteToFinancialStatementDetailsTextual-label" xlink:type="arc"/>
    <link:loc xlink:href="wint-20220630.xsd#wint_statement-statement-significant-accounting-policies-policies" xlink:label="wint_statement-statement-significant-accounting-policies-policies" xlink:type="locator"/>
    <link:label xlink:label="wint_statement-statement-significant-accounting-policies-policies-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Significant Accounting Policies</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="wint_statement-statement-significant-accounting-policies-policies" xlink:to="wint_statement-statement-significant-accounting-policies-policies-label" xlink:type="arc"/>
    <link:loc xlink:href="wint-20220630.xsd#wint_statement-statement-note-4-summary-of-significant-accounting-policies-tables" xlink:label="wint_statement-statement-note-4-summary-of-significant-accounting-policies-tables" xlink:type="locator"/>
    <link:label xlink:label="wint_statement-statement-note-4-summary-of-significant-accounting-policies-tables-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Note 4 - Summary of Significant Accounting Policies</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="wint_statement-statement-note-4-summary-of-significant-accounting-policies-tables" xlink:to="wint_statement-statement-note-4-summary-of-significant-accounting-policies-tables-label" xlink:type="arc"/>
    <link:loc xlink:href="wint-20220630.xsd#wint_statement-statement-note-5-fair-value-measurements-tables" xlink:label="wint_statement-statement-note-5-fair-value-measurements-tables" xlink:type="locator"/>
    <link:label xlink:label="wint_statement-statement-note-5-fair-value-measurements-tables-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Note 5 - Fair Value Measurements</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="wint_statement-statement-note-5-fair-value-measurements-tables" xlink:to="wint_statement-statement-note-5-fair-value-measurements-tables-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate</link:label>
    <link:label xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Weighted average risk-free interest rate</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate-label" xlink:type="arc"/>
    <link:loc xlink:href="wint-20220630.xsd#wint_statement-statement-note-9-stockbased-compensation-tables" xlink:label="wint_statement-statement-note-9-stockbased-compensation-tables" xlink:type="locator"/>
    <link:label xlink:label="wint_statement-statement-note-9-stockbased-compensation-tables-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Note 9 - Stock-Based Compensation</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="wint_statement-statement-note-9-stockbased-compensation-tables" xlink:to="wint_statement-statement-note-9-stockbased-compensation-tables-label" xlink:type="arc"/>
    <link:loc xlink:href="wint-20220630.xsd#wint_statement-statement-note-4-summary-of-significant-accounting-policies-intangible-assets-details" xlink:label="wint_statement-statement-note-4-summary-of-significant-accounting-policies-intangible-assets-details" xlink:type="locator"/>
    <link:label xlink:label="wint_statement-statement-note-4-summary-of-significant-accounting-policies-intangible-assets-details-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Note 4 - Summary of Significant Accounting Policies - Intangible Assets (Details)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="wint_statement-statement-note-4-summary-of-significant-accounting-policies-intangible-assets-details" xlink:to="wint_statement-statement-note-4-summary-of-significant-accounting-policies-intangible-assets-details-label" xlink:type="arc"/>
    <link:loc xlink:href="wint-20220630.xsd#wint_statement-statement-note-5-fair-value-measurements-assets-and-liabilities-measured-at-fair-value-on-a-recurring-basis-details" xlink:label="wint_statement-statement-note-5-fair-value-measurements-assets-and-liabilities-measured-at-fair-value-on-a-recurring-basis-details" xlink:type="locator"/>
    <link:label xlink:label="wint_statement-statement-note-5-fair-value-measurements-assets-and-liabilities-measured-at-fair-value-on-a-recurring-basis-details-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Note 5 - Fair Value Measurements - Assets and Liabilities Measured at Fair Value on a Recurring Basis (Details)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="wint_statement-statement-note-5-fair-value-measurements-assets-and-liabilities-measured-at-fair-value-on-a-recurring-basis-details" xlink:to="wint_statement-statement-note-5-fair-value-measurements-assets-and-liabilities-measured-at-fair-value-on-a-recurring-basis-details-label" xlink:type="arc"/>
    <link:loc xlink:href="wint-20220630.xsd#wint_statement-statement-note-9-stockbased-compensation-summary-of-stock-option-activity-details" xlink:label="wint_statement-statement-note-9-stockbased-compensation-summary-of-stock-option-activity-details" xlink:type="locator"/>
    <link:label xlink:label="wint_statement-statement-note-9-stockbased-compensation-summary-of-stock-option-activity-details-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Note 9 - Stock-Based Compensation - Summary of Stock Option Activity (Details)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="wint_statement-statement-note-9-stockbased-compensation-summary-of-stock-option-activity-details" xlink:to="wint_statement-statement-note-9-stockbased-compensation-summary-of-stock-option-activity-details-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate</link:label>
    <link:label xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Weighted average expected volatility</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate-label" xlink:type="arc"/>
    <link:loc xlink:href="wint-20220630.xsd#wint_statement-statement-note-9-stockbased-compensation-restricted-stock-units-details" xlink:label="wint_statement-statement-note-9-stockbased-compensation-restricted-stock-units-details" xlink:type="locator"/>
    <link:label xlink:label="wint_statement-statement-note-9-stockbased-compensation-restricted-stock-units-details-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Note 9 - Stock-Based Compensation - Restricted Stock Units (Details)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="wint_statement-statement-note-9-stockbased-compensation-restricted-stock-units-details" xlink:to="wint_statement-statement-note-9-stockbased-compensation-restricted-stock-units-details-label" xlink:type="arc"/>
    <link:loc xlink:href="wint-20220630.xsd#wint_statement-statement-note-9-stockbased-compensation-stockbased-compensation-expense-details" xlink:label="wint_statement-statement-note-9-stockbased-compensation-stockbased-compensation-expense-details" xlink:type="locator"/>
    <link:label xlink:label="wint_statement-statement-note-9-stockbased-compensation-stockbased-compensation-expense-details-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Note 9 - Stock-Based Compensation - Stock-Based Compensation Expense (Details)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="wint_statement-statement-note-9-stockbased-compensation-stockbased-compensation-expense-details" xlink:to="wint_statement-statement-note-9-stockbased-compensation-stockbased-compensation-expense-details-label" xlink:type="arc"/>
    <link:loc xlink:href="wint-20220630.xsd#wint_statement-statement-note-9-stockbased-compensation-stock-options-valuation-assumptions-details" xlink:label="wint_statement-statement-note-9-stockbased-compensation-stock-options-valuation-assumptions-details" xlink:type="locator"/>
    <link:label xlink:label="wint_statement-statement-note-9-stockbased-compensation-stock-options-valuation-assumptions-details-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Note 9 - Stock-Based Compensation - Stock Options Valuation Assumptions (Details)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="wint_statement-statement-note-9-stockbased-compensation-stock-options-valuation-assumptions-details" xlink:to="wint_statement-statement-note-9-stockbased-compensation-stock-options-valuation-assumptions-details-label" xlink:type="arc"/>
    <link:loc xlink:href="wint-20220630.xsd#wint_NotesToFinancialStatements" xlink:label="wint_NotesToFinancialStatements" xlink:type="locator"/>
    <link:label xlink:label="wint_NotesToFinancialStatements-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Notes To Financial Statements</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="wint_NotesToFinancialStatements" xlink:to="wint_NotesToFinancialStatements-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" xlink:label="us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Foreign Currency Transactions and Translations Policy [Policy Text Block]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" xlink:to="us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock-label" xlink:type="arc"/>
    <link:loc xlink:href="wint-20220630.xsd#wint_NotesToFinancialStatementsAbstract" xlink:label="wint_NotesToFinancialStatementsAbstract" xlink:type="locator"/>
    <link:label xlink:label="wint_NotesToFinancialStatementsAbstract-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Notes To Financial Statements [Abstract]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="wint_NotesToFinancialStatementsAbstract" xlink:to="wint_NotesToFinancialStatementsAbstract-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesCurrent" xlink:label="us-gaap_LiabilitiesCurrent" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_LiabilitiesCurrent-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_LiabilitiesCurrent</link:label>
    <link:label xlink:label="us-gaap_LiabilitiesCurrent-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Liabilities, Current, Total</link:label>
    <link:label xlink:label="us-gaap_LiabilitiesCurrent-label" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total current liabilities</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_LiabilitiesCurrent-label" xlink:type="arc"/>
    <link:loc xlink:href="wint-20220630.xsd#wint_LeesPharmaceuticalHoldingsLimitedMember" xlink:label="wint_LeesPharmaceuticalHoldingsLimitedMember" xlink:type="locator"/>
    <link:label xlink:label="wint_LeesPharmaceuticalHoldingsLimitedMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lee&#8217;s Pharmaceutical Holdings Limited [Member]</link:label>
    <link:label xlink:label="wint_LeesPharmaceuticalHoldingsLimitedMember-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents Lee&#8217;s Pharmaceutical Holdings Limited.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="wint_LeesPharmaceuticalHoldingsLimitedMember" xlink:to="wint_LeesPharmaceuticalHoldingsLimitedMember-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1</link:label>
    <link:label xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Weighted average expected term (Year)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerSharePolicyTextBlock" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_EarningsPerSharePolicyTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Earnings Per Share, Policy [Policy Text Block]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerSharePolicyTextBlock" xlink:to="us-gaap_EarningsPerSharePolicyTextBlock-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Share-Based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:to="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingExpensesAbstract" xlink:label="us-gaap_OperatingExpensesAbstract" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_OperatingExpensesAbstract-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Expenses:</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_OperatingExpensesAbstract-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxPolicyTextBlock" xlink:label="us-gaap_IncomeTaxPolicyTextBlock" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_IncomeTaxPolicyTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income Tax, Policy [Policy Text Block]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxPolicyTextBlock" xlink:to="us-gaap_IncomeTaxPolicyTextBlock-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsFairValueDisclosure" xlink:label="us-gaap_AssetsFairValueDisclosure" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_AssetsFairValueDisclosure-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_AssetsFairValueDisclosure</link:label>
    <link:label xlink:label="us-gaap_AssetsFairValueDisclosure-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Total Assets</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsFairValueDisclosure" xlink:to="us-gaap_AssetsFairValueDisclosure-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Awarded, Weighted- Average Grant Date Fair Value, Outstanding (in dollars per share)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Payment Arrangement, Restricted Stock Unit, Activity [Table Text Block]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock" xlink:to="us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cancelled, Weighted- Average Grant Date Fair Value, Outstanding (in dollars per share)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue</link:label>
    <link:label xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue-label" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Weighted- Average Grant Date Fair Value, Outstanding, Beginning Balance (in dollars per share)</link:label>
    <link:label xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue-label" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Weighted- Average Grant Date Fair Value, Outstanding (in dollars per share)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod</link:label>
    <link:label xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod-label" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Cancelled (in shares)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber</link:label>
    <link:label xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber-label" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Shares Outstanding, Beginning Balance (in shares)</link:label>
    <link:label xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber-label" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Outstanding at June 30, 2022 (in shares)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:label="us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ResearchAndDevelopmentExpensePolicy-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Research and Development Expense, Policy [Policy Text Block]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:to="us-gaap_ResearchAndDevelopmentExpensePolicy-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Depreciation" xlink:label="us-gaap_Depreciation" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_Depreciation-label" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Depreciation and amortization</link:label>
    <link:label xlink:label="us-gaap_Depreciation-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_Depreciation</link:label>
    <link:label xlink:label="us-gaap_Depreciation-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Depreciation, Total</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Depreciation" xlink:to="us-gaap_Depreciation-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Awarded (in shares)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Weighted Average Remaining Contractual Life, Vested and Expected to Vest (Year)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Vested and expected to vest (in shares)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LoansPayableCurrent" xlink:label="us-gaap_LoansPayableCurrent" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_LoansPayableCurrent-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Loans payable - current portion</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LoansPayableCurrent" xlink:to="us-gaap_LoansPayableCurrent-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Weighted Average Exercise Price, Vested and Expected to Vest (in dollars per share)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsCurrent" xlink:label="us-gaap_AssetsCurrent" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_AssetsCurrent-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_AssetsCurrent</link:label>
    <link:label xlink:label="us-gaap_AssetsCurrent-label" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total current assets</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_AssetsCurrent-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice</link:label>
    <link:label xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Weighted Average Exercise Price, Vested and Exercisable (in dollars per share)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1</link:label>
    <link:label xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Weighted Average Remaining Contractual Life, Vested and Exercisable (Year)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:label="us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_CashAndCashEquivalentsFairValueDisclosure-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_CashAndCashEquivalentsFairValueDisclosure</link:label>
    <link:label xlink:label="us-gaap_CashAndCashEquivalentsFairValueDisclosure-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cash equivalents</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:to="us-gaap_CashAndCashEquivalentsFairValueDisclosure-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stockholders' Equity Note Disclosure [Text Block]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:to="us-gaap_StockholdersEquityNoteDisclosureTextBlock-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber</link:label>
    <link:label xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Shares Vested and Exercisable (in shares)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber-label" xlink:type="arc"/>
    <link:loc xlink:href="wint-20220630.xsd#wint_IstaroximeDrugCandidateMember" xlink:label="wint_IstaroximeDrugCandidateMember" xlink:type="locator"/>
    <link:label xlink:label="wint_IstaroximeDrugCandidateMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Istaroxime Drug Candidate [Member]</link:label>
    <link:label xlink:label="wint_IstaroximeDrugCandidateMember-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Related to Istaroxime drug candidate.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="wint_IstaroximeDrugCandidateMember" xlink:to="wint_IstaroximeDrugCandidateMember-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2</link:label>
    <link:label xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Weighted Average Remaining Contractual Life, Outstanding (Year)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill" xlink:label="us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Loss on impairment of intangible assets</link:label>
    <link:label xlink:label="us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Impairment of Intangible Assets (Excluding Goodwill), Total</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill" xlink:to="us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TreasuryStockShares" xlink:label="us-gaap_TreasuryStockShares" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_TreasuryStockShares-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Treasury stock, shares (in shares)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TreasuryStockShares" xlink:to="us-gaap_TreasuryStockShares-label" xlink:type="arc"/>
    <link:loc xlink:href="wint-20220630.xsd#wint_RostafuroxinDrugCandidateMember" xlink:label="wint_RostafuroxinDrugCandidateMember" xlink:type="locator"/>
    <link:label xlink:label="wint_RostafuroxinDrugCandidateMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Rostafuroxin Drug Candidate [Member]</link:label>
    <link:label xlink:label="wint_RostafuroxinDrugCandidateMember-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Related to Rostafuroxin drug candidate.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="wint_RostafuroxinDrugCandidateMember" xlink:to="wint_RostafuroxinDrugCandidateMember-label" xlink:type="arc"/>
    <link:loc xlink:href="wint-20220630.xsd#wint_NonrefundablePayments" xlink:label="wint_NonrefundablePayments" xlink:type="locator"/>
    <link:label xlink:label="wint_NonrefundablePayments-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">wint_NonrefundablePayments</link:label>
    <link:label xlink:label="wint_NonrefundablePayments-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Nonrefundable Payments</link:label>
    <link:label xlink:label="wint_NonrefundablePayments-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">The amount of nonrefundable payments pursuant to the agreement.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="wint_NonrefundablePayments" xlink:to="wint_NonrefundablePayments-label" xlink:type="arc"/>
    <link:loc xlink:href="wint-20220630.xsd#wint_The2020EquityIncentivePlanMember" xlink:label="wint_The2020EquityIncentivePlanMember" xlink:type="locator"/>
    <link:label xlink:label="wint_The2020EquityIncentivePlanMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">The 2020 Equity Incentive Plan [Member]</link:label>
    <link:label xlink:label="wint_The2020EquityIncentivePlanMember-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Information related to the 2020 Equity Incentive Plan, or the 2020 Plan.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="wint_The2020EquityIncentivePlanMember" xlink:to="wint_The2020EquityIncentivePlanMember-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockValue" xlink:label="us-gaap_CommonStockValue" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_CommonStockValue-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Common stock, $0.001 par value; 120,000,000 shares authorized at June 30, 2022 and December 31, 2021; 29,406,196 and 28,268,950 shares issued at June 30, 2022 and December 31, 2021, respectively; 29,406,172 and 28,268,926 shares outstanding at June 30, 2022 and December 31, 2021, respectively</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockValue" xlink:to="us-gaap_CommonStockValue-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Adjustments to reconcile net loss to net cash used in operating activities:</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByMeasurementFrequencyAxis" xlink:label="us-gaap_FairValueByMeasurementFrequencyAxis" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_FairValueByMeasurementFrequencyAxis-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Measurement Frequency [Axis]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueByMeasurementFrequencyAxis" xlink:to="us-gaap_FairValueByMeasurementFrequencyAxis-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice</link:label>
    <link:label xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice-label" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Weighted Average Exercise Price, Outstanding, at Beginning Period (in dollars per share)</link:label>
    <link:label xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice-label" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Weighted Average Exercise Price, Outstanding, at Ending Period (in dollars per share)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice-label" xlink:type="arc"/>
    <link:loc xlink:href="wint-20220630.xsd#wint_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndExercisable" xlink:label="wint_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndExercisable" xlink:type="locator"/>
    <link:label xlink:label="wint_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndExercisable-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Vested and exercisable at June 30, 2022 (in shares)</link:label>
    <link:label xlink:label="wint_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndExercisable-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are vested and exercisable as of the balance sheet date.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="wint_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndExercisable" xlink:to="wint_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndExercisable-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementFrequencyDomain" xlink:label="us-gaap_FairValueMeasurementFrequencyDomain" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_FairValueMeasurementFrequencyDomain-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Measurement Frequency [Domain]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueMeasurementFrequencyDomain" xlink:to="us-gaap_FairValueMeasurementFrequencyDomain-label" xlink:type="arc"/>
    <link:loc xlink:href="wint-20220630.xsd#wint_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityOtherThanOptionsVestedAndExpectedToVestOutstandingNumber" xlink:label="wint_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityOtherThanOptionsVestedAndExpectedToVestOutstandingNumber" xlink:type="locator"/>
    <link:label xlink:label="wint_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityOtherThanOptionsVestedAndExpectedToVestOutstandingNumber-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Vested and expected to vest at June 30, 2022 (in shares)</link:label>
    <link:label xlink:label="wint_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityOtherThanOptionsVestedAndExpectedToVestOutstandingNumber-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are vested and expected to vest as of the balance sheet date.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="wint_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityOtherThanOptionsVestedAndExpectedToVestOutstandingNumber" xlink:to="wint_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityOtherThanOptionsVestedAndExpectedToVestOutstandingNumber-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsRecurringMember" xlink:label="us-gaap_FairValueMeasurementsRecurringMember" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_FairValueMeasurementsRecurringMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value, Recurring [Member]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueMeasurementsRecurringMember" xlink:to="us-gaap_FairValueMeasurementsRecurringMember-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="us-gaap_CommonStockSharesAuthorized" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_CommonStockSharesAuthorized-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Common stock, shares authorize (in shares)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesAuthorized" xlink:to="us-gaap_CommonStockSharesAuthorized-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesIssued" xlink:label="us-gaap_CommonStockSharesIssued" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_CommonStockSharesIssued-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Common stock, shares issued (in shares)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesIssued" xlink:to="us-gaap_CommonStockSharesIssued-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice</link:label>
    <link:label xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Weighted Average Exercise Price, Forfeited or Expired (in dollars per share)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_CommonStockParOrStatedValuePerShare-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Common stock, par value (in dollars per share)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockParOrStatedValuePerShare" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Weighted Average Exercise Price, Granted (in dollars per share)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="us-gaap_AccruedLiabilitiesCurrent" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_AccruedLiabilitiesCurrent-label" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Accrued expenses</link:label>
    <link:label xlink:label="us-gaap_AccruedLiabilitiesCurrent-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_AccruedLiabilitiesCurrent</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccruedLiabilitiesCurrent" xlink:to="us-gaap_AccruedLiabilitiesCurrent-label" xlink:type="arc"/>
    <link:loc xlink:href="wint-20220630.xsd#wint_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndExercisableWeightedAverageGrantDateFairValueEndingBalance" xlink:label="wint_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndExercisableWeightedAverageGrantDateFairValueEndingBalance" xlink:type="locator"/>
    <link:label xlink:label="wint_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndExercisableWeightedAverageGrantDateFairValueEndingBalance-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Vested and exercisable Weighted- Average Grant Date Fair Value (in dollars per share)</link:label>
    <link:label xlink:label="wint_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndExercisableWeightedAverageGrantDateFairValueEndingBalance-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Weighted average exercise price of vested and exercisable for equity instruments other than option.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="wint_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndExercisableWeightedAverageGrantDateFairValueEndingBalance" xlink:to="wint_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndExercisableWeightedAverageGrantDateFairValueEndingBalance-label" xlink:type="arc"/>
    <link:loc xlink:href="wint-20220630.xsd#wint_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndExpectedToVestWeightedAverageGrantDateFairValueEndingBalance" xlink:label="wint_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndExpectedToVestWeightedAverageGrantDateFairValueEndingBalance" xlink:type="locator"/>
    <link:label xlink:label="wint_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndExpectedToVestWeightedAverageGrantDateFairValueEndingBalance-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Vested and expected to vest Weighted- Average Grant Date Fair Value (in dollars per share)</link:label>
    <link:label xlink:label="wint_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndExpectedToVestWeightedAverageGrantDateFairValueEndingBalance-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Weighted average grant date fair value for vested and expected to vest for equity instrument other than options of share based compensation.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="wint_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndExpectedToVestWeightedAverageGrantDateFairValueEndingBalance" xlink:to="wint_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndExpectedToVestWeightedAverageGrantDateFairValueEndingBalance-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember" xlink:label="srt_RangeMember" xlink:type="locator"/>
    <link:label xlink:label="srt_RangeMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statistical Measurement [Domain]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_RangeMember" xlink:to="srt_RangeMember-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember" xlink:type="locator"/>
    <link:label xlink:label="srt_MinimumMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Minimum [Member]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_MinimumMember" xlink:to="srt_MinimumMember-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsPayableCurrent" xlink:label="us-gaap_AccountsPayableCurrent" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_AccountsPayableCurrent-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accounts payable</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsPayableCurrent" xlink:to="us-gaap_AccountsPayableCurrent-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber</link:label>
    <link:label xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber-label" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Shares Outstanding, Beginning Balance (in shares)</link:label>
    <link:label xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber-label" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Shares Outstanding, Ending Balance (in shares)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis" xlink:type="locator"/>
    <link:label xlink:label="srt_RangeAxis-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statistical Measurement [Axis]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_RangeAxis" xlink:to="srt_RangeAxis-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod</link:label>
    <link:label xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod-label" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Shares Forfeited or Expired (in shares)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment" xlink:label="us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Proceeds from sale of property and equipment</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment" xlink:to="us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockValue" xlink:label="us-gaap_PreferredStockValue" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_PreferredStockValue-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Preferred stock, $0.001 par value; 5,000,000 shares authorized; 0 shares issued and outstanding at June 30, 2022 and December 31, 2021</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockValue" xlink:to="us-gaap_PreferredStockValue-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NumberOfReportingUnits" xlink:label="us-gaap_NumberOfReportingUnits" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_NumberOfReportingUnits-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_NumberOfReportingUnits</link:label>
    <link:label xlink:label="us-gaap_NumberOfReportingUnits-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Number of Reporting Units</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NumberOfReportingUnits" xlink:to="us-gaap_NumberOfReportingUnits-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockSharesIssued" xlink:label="us-gaap_PreferredStockSharesIssued" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_PreferredStockSharesIssued-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Preferred stock, shares issued (in shares)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockSharesIssued" xlink:to="us-gaap_PreferredStockSharesIssued-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PolicyTextBlockAbstract" xlink:label="us-gaap_PolicyTextBlockAbstract" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_PolicyTextBlockAbstract-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_PolicyTextBlockAbstract</link:label>
    <link:label xlink:label="us-gaap_PolicyTextBlockAbstract-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accounting Policies</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PolicyTextBlockAbstract" xlink:to="us-gaap_PolicyTextBlockAbstract-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="us-gaap_PreferredStockSharesAuthorized" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_PreferredStockSharesAuthorized-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Preferred stock, shares authorized (in shares)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockSharesAuthorized" xlink:to="us-gaap_PreferredStockSharesAuthorized-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy" xlink:label="us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Goodwill and Intangible Assets, Goodwill, Policy [Policy Text Block]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy" xlink:to="us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentImpairment" xlink:label="us-gaap_PropertyPlantAndEquipmentImpairment" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_PropertyPlantAndEquipmentImpairment-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment, Impairment [Policy Text Block]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentImpairment" xlink:to="us-gaap_PropertyPlantAndEquipmentImpairment-label" xlink:type="arc"/>
    <link:loc xlink:href="wint-20220630.xsd#wint_March2021WarrantsMember" xlink:label="wint_March2021WarrantsMember" xlink:type="locator"/>
    <link:label xlink:label="wint_March2021WarrantsMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">March 2021 Warrants [Member]</link:label>
    <link:label xlink:label="wint_March2021WarrantsMember-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Information related to the March 2021 Offering Warrants.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="wint_March2021WarrantsMember" xlink:to="wint_March2021WarrantsMember-label" xlink:type="arc"/>
    <link:loc xlink:href="wint-20220630.xsd#wint_March2021PublicOfferingMember" xlink:label="wint_March2021PublicOfferingMember" xlink:type="locator"/>
    <link:label xlink:label="wint_March2021PublicOfferingMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">March 2021 Public Offering [Member]</link:label>
    <link:label xlink:label="wint_March2021PublicOfferingMember-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Information related to the March 2021 Public Offering.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="wint_March2021PublicOfferingMember" xlink:to="wint_March2021PublicOfferingMember-label" xlink:type="arc"/>
    <link:loc xlink:href="wint-20220630.xsd#wint_ProceedsFromIssuanceOfCommonStockAndWarrants" xlink:label="wint_ProceedsFromIssuanceOfCommonStockAndWarrants" xlink:type="locator"/>
    <link:label xlink:label="wint_ProceedsFromIssuanceOfCommonStockAndWarrants-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Proceeds from issuance of common stock and warrants, net of issuance costs</link:label>
    <link:label xlink:label="wint_ProceedsFromIssuanceOfCommonStockAndWarrants-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">The cash inflow from the additional capital contribution to the entity and from issuance of rights to purchase common shares at predetermined price.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="wint_ProceedsFromIssuanceOfCommonStockAndWarrants" xlink:to="wint_ProceedsFromIssuanceOfCommonStockAndWarrants-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Preferred stock, par value (in dollars per share)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockParOrStatedValuePerShare" xlink:to="us-gaap_PreferredStockParOrStatedValuePerShare-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis" xlink:label="us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Indefinite-Lived Intangible Assets [Axis]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Indefinite-Lived Intangible Assets, Major Class Name [Domain]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_PaymentsToAcquirePropertyPlantAndEquipment</link:label>
    <link:label xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment-label" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Purchase of property and equipment</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:to="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ForeignCurrencyTransactionGainLossBeforeTax" xlink:label="us-gaap_ForeignCurrencyTransactionGainLossBeforeTax" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ForeignCurrencyTransactionGainLossBeforeTax-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_ForeignCurrencyTransactionGainLossBeforeTax</link:label>
    <link:label xlink:label="us-gaap_ForeignCurrencyTransactionGainLossBeforeTax-label" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Unrealized (gain) loss on foreign exchange rate changes</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ForeignCurrencyTransactionGainLossBeforeTax" xlink:to="us-gaap_ForeignCurrencyTransactionGainLossBeforeTax-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:label="us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_NoncashInvestingAndFinancingItemsAbstract-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Supplementary disclosure of non-cash activity:</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:to="us-gaap_NoncashInvestingAndFinancingItemsAbstract-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value Hierarchy and NAV [Domain]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueMeasurementsFairValueHierarchyDomain-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel1Member" xlink:label="us-gaap_FairValueInputsLevel1Member" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_FairValueInputsLevel1Member-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value, Inputs, Level 1 [Member]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueInputsLevel1Member" xlink:to="us-gaap_FairValueInputsLevel1Member-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1</link:label>
    <link:label xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Award Requisite Service Period (Year)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value Hierarchy and NAV [Axis]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="us-gaap_FairValueByFairValueHierarchyLevelAxis-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="us-gaap_LiabilitiesCurrentAbstract" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_LiabilitiesCurrentAbstract-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Current Liabilities:</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_LiabilitiesCurrentAbstract-label" xlink:type="arc"/>
    <link:loc xlink:href="wint-20220630.xsd#wint_NonCashExpenseRelatedToEquityConsiderationForAServiceAgreement" xlink:label="wint_NonCashExpenseRelatedToEquityConsiderationForAServiceAgreement" xlink:type="locator"/>
    <link:label xlink:label="wint_NonCashExpenseRelatedToEquityConsiderationForAServiceAgreement-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Non-cash expense related to equity consideration for a service agreement</link:label>
    <link:label xlink:label="wint_NonCashExpenseRelatedToEquityConsiderationForAServiceAgreement-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents non-cash expense related to equity consideration for a service agreement.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="wint_NonCashExpenseRelatedToEquityConsiderationForAServiceAgreement" xlink:to="wint_NonCashExpenseRelatedToEquityConsiderationForAServiceAgreement-label" xlink:type="arc"/>
    <link:loc xlink:href="wint-20220630.xsd#wint_LoanPayableToBankDirectCapitalFinanceMember" xlink:label="wint_LoanPayableToBankDirectCapitalFinanceMember" xlink:type="locator"/>
    <link:label xlink:label="wint_LoanPayableToBankDirectCapitalFinanceMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Loan payable to Bank Direct Capital Finance [Member]</link:label>
    <link:label xlink:label="wint_LoanPayableToBankDirectCapitalFinanceMember-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Information pertaining to loan payable to Bank Direct Capital Finance.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="wint_LoanPayableToBankDirectCapitalFinanceMember" xlink:to="wint_LoanPayableToBankDirectCapitalFinanceMember-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Assets" xlink:label="us-gaap_Assets" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_Assets-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_Assets</link:label>
    <link:label xlink:label="us-gaap_Assets-label" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total assets</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Assets" xlink:to="us-gaap_Assets-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock" xlink:label="us-gaap_DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of Share-Based Compensation Arrangements by Share-Based Payment Award [Table Text Block]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock" xlink:to="us-gaap_DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameAxis" xlink:label="us-gaap_PlanNameAxis" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_PlanNameAxis-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Plan Name [Axis]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameAxis-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_PlanNameDomain-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Plan Name [Domain]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PlanNameDomain" xlink:to="us-gaap_PlanNameDomain-label" xlink:type="arc"/>
    <link:loc xlink:href="wint-20220630.xsd#wint_SeveranceAccrual" xlink:label="wint_SeveranceAccrual" xlink:type="locator"/>
    <link:label xlink:label="wint_SeveranceAccrual-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">wint_SeveranceAccrual</link:label>
    <link:label xlink:label="wint_SeveranceAccrual-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Severance Accrual</link:label>
    <link:label xlink:label="wint_SeveranceAccrual-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents amount of severance accrual.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="wint_SeveranceAccrual" xlink:to="wint_SeveranceAccrual-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash flows from operating activities:</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract-label" xlink:type="arc"/>
    <link:loc xlink:href="wint-20220630.xsd#wint_IssuanceOfCommonStockAndCommonStockWarrantsNetOfIssuanceCostsValue" xlink:label="wint_IssuanceOfCommonStockAndCommonStockWarrantsNetOfIssuanceCostsValue" xlink:type="locator"/>
    <link:label xlink:label="wint_IssuanceOfCommonStockAndCommonStockWarrantsNetOfIssuanceCostsValue-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Issuance of common stock and common stock warrants, net of issuance costs</link:label>
    <link:label xlink:label="wint_IssuanceOfCommonStockAndCommonStockWarrantsNetOfIssuanceCostsValue-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents value of common stock and common stock warrants issued net of issuance costs.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="wint_IssuanceOfCommonStockAndCommonStockWarrantsNetOfIssuanceCostsValue" xlink:to="wint_IssuanceOfCommonStockAndCommonStockWarrantsNetOfIssuanceCostsValue-label" xlink:type="arc"/>
    <link:loc xlink:href="wint-20220630.xsd#wint_IssuanceOfCommonStockAndCommonStockWarrantsNetOfIssuanceCostsShares" xlink:label="wint_IssuanceOfCommonStockAndCommonStockWarrantsNetOfIssuanceCostsShares" xlink:type="locator"/>
    <link:label xlink:label="wint_IssuanceOfCommonStockAndCommonStockWarrantsNetOfIssuanceCostsShares-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Issuance of common stock and common stock warrants, net of issuance costs (in shares)</link:label>
    <link:label xlink:label="wint_IssuanceOfCommonStockAndCommonStockWarrantsNetOfIssuanceCostsShares-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents number of shares of common stock and common stock warrants issued net of issuance costs.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="wint_IssuanceOfCommonStockAndCommonStockWarrantsNetOfIssuanceCostsShares" xlink:to="wint_IssuanceOfCommonStockAndCommonStockWarrantsNetOfIssuanceCostsShares-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_StatementLineItems-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statement [Line Items]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementLineItems-label" xlink:type="arc"/>
    <link:loc xlink:href="wint-20220630.xsd#wint_LiquidityDisclosuresTextBlock" xlink:label="wint_LiquidityDisclosuresTextBlock" xlink:type="locator"/>
    <link:label xlink:label="wint_LiquidityDisclosuresTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Liquidity Disclosures [Text Block]</link:label>
    <link:label xlink:label="wint_LiquidityDisclosuresTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Disclosure of historical and expected sources of liquidity, available cash and cash equivalents as of the balance sheet date, and management's plans to maintain sufficient working capital through one or more of the following, if available: public and private securities offerings, equity financing facilities, capital equipment and debt facilities, and strategic alliances, as well as sales revenue from products approved for marketing, if and when approved.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="wint_LiquidityDisclosuresTextBlock" xlink:to="wint_LiquidityDisclosuresTextBlock-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapital" xlink:label="us-gaap_AdditionalPaidInCapital" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_AdditionalPaidInCapital-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Additional paid-in capital</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdditionalPaidInCapital" xlink:to="us-gaap_AdditionalPaidInCapital-label" xlink:type="arc"/>
    <link:loc xlink:href="wint-20220630.xsd#wint_ProceedsFromResearchAndDevelopmentFundingArrangement" xlink:label="wint_ProceedsFromResearchAndDevelopmentFundingArrangement" xlink:type="locator"/>
    <link:label xlink:label="wint_ProceedsFromResearchAndDevelopmentFundingArrangement-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Proceeds from research and development funding arrangement</link:label>
    <link:label xlink:label="wint_ProceedsFromResearchAndDevelopmentFundingArrangement-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">The cash inflow from research and development funding arrangement.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="wint_ProceedsFromResearchAndDevelopmentFundingArrangement" xlink:to="wint_ProceedsFromResearchAndDevelopmentFundingArrangement-label" xlink:type="arc"/>
    <link:loc xlink:href="wint-20220630.xsd#wint_DeerfieldLoanMember" xlink:label="wint_DeerfieldLoanMember" xlink:type="locator"/>
    <link:label xlink:label="wint_DeerfieldLoanMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deerfield Loan [Member]</link:label>
    <link:label xlink:label="wint_DeerfieldLoanMember-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents the long-term debt under a secure loan - "Deerfield Loan."</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="wint_DeerfieldLoanMember" xlink:to="wint_DeerfieldLoanMember-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Payment Arrangement [Text Block]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:to="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock-label" xlink:type="arc"/>
    <link:loc xlink:href="wint-20220630.xsd#wint_DeerfieldManagementLPMember" xlink:label="wint_DeerfieldManagementLPMember" xlink:type="locator"/>
    <link:label xlink:label="wint_DeerfieldManagementLPMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deerfield Management, L.P. [Member]</link:label>
    <link:label xlink:label="wint_DeerfieldManagementLPMember-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents the affiliates of Deerfield Management, L.P.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="wint_DeerfieldManagementLPMember" xlink:to="wint_DeerfieldManagementLPMember-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:to="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityAbstract" xlink:label="us-gaap_StockholdersEquityAbstract" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_StockholdersEquityAbstract-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stockholders&#8217; Equity:</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_StockholdersEquityAbstract-label" xlink:type="arc"/>
    <link:loc xlink:href="wint-20220630.xsd#wint_ATMProgramMember" xlink:label="wint_ATMProgramMember" xlink:type="locator"/>
    <link:label xlink:label="wint_ATMProgramMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">ATM Program [Member]</link:label>
    <link:label xlink:label="wint_ATMProgramMember-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents the "at-the-market" program (ATM Program) by which the reporting entity secures capital.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="wint_ATMProgramMember" xlink:to="wint_ATMProgramMember-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherNonoperatingIncomeExpense" xlink:label="us-gaap_OtherNonoperatingIncomeExpense" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_OtherNonoperatingIncomeExpense-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other income (expense), net</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherNonoperatingIncomeExpense" xlink:to="us-gaap_OtherNonoperatingIncomeExpense-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Long-Lived Tangible Asset [Axis]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentByTypeAxis-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NonoperatingIncomeExpense" xlink:label="us-gaap_NonoperatingIncomeExpense" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_NonoperatingIncomeExpense-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_NonoperatingIncomeExpense</link:label>
    <link:label xlink:label="us-gaap_NonoperatingIncomeExpense-label" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total other income (expense), net</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NonoperatingIncomeExpense" xlink:to="us-gaap_NonoperatingIncomeExpense-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Long-Lived Tangible Asset [Domain]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Award Type [Domain]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsCurrentAbstract" xlink:label="us-gaap_AssetsCurrentAbstract" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_AssetsCurrentAbstract-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Current Assets:</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_AssetsCurrentAbstract-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueDisclosuresTextBlock" xlink:label="us-gaap_FairValueDisclosuresTextBlock" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_FairValueDisclosuresTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value Disclosures [Text Block]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueDisclosuresTextBlock" xlink:to="us-gaap_FairValueDisclosuresTextBlock-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_NetIncomeLoss-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net loss</link:label>
    <link:label xlink:label="us-gaap_NetIncomeLoss-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Net Income (Loss) Attributable to Parent, Total</link:label>
    <link:label xlink:label="us-gaap_NetIncomeLoss-label" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Net loss</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_NetIncomeLoss-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_AwardTypeAxis-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Award Type [Axis]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_AwardTypeAxis-label" xlink:type="arc"/>
    <link:loc xlink:href="wint-20220630.xsd#wint_EquityIssuedDuringPeriodUnitsNewIssues" xlink:label="wint_EquityIssuedDuringPeriodUnitsNewIssues" xlink:type="locator"/>
    <link:label xlink:label="wint_EquityIssuedDuringPeriodUnitsNewIssues-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">wint_EquityIssuedDuringPeriodUnitsNewIssues</link:label>
    <link:label xlink:label="wint_EquityIssuedDuringPeriodUnitsNewIssues-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Equity Issued During Period, Units, New Issues (in shares)</link:label>
    <link:label xlink:label="wint_EquityIssuedDuringPeriodUnitsNewIssues-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Number of new units issued during the period.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="wint_EquityIssuedDuringPeriodUnitsNewIssues" xlink:to="wint_EquityIssuedDuringPeriodUnitsNewIssues-label" xlink:type="arc"/>
    <link:loc xlink:href="wint-20220630.xsd#wint_UnitsNumberOfSecuritiesCalledByEachUnit" xlink:label="wint_UnitsNumberOfSecuritiesCalledByEachUnit" xlink:type="locator"/>
    <link:label xlink:label="wint_UnitsNumberOfSecuritiesCalledByEachUnit-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">wint_UnitsNumberOfSecuritiesCalledByEachUnit</link:label>
    <link:label xlink:label="wint_UnitsNumberOfSecuritiesCalledByEachUnit-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Units, Number of Securities Called by Each Unit (in shares)</link:label>
    <link:label xlink:label="wint_UnitsNumberOfSecuritiesCalledByEachUnit-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Number of securities into which each unit may be converted. For example, but not limited to, each unit may be converted into two shares.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="wint_UnitsNumberOfSecuritiesCalledByEachUnit" xlink:to="wint_UnitsNumberOfSecuritiesCalledByEachUnit-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations</link:label>
    <link:label xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations-label" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Cash, cash equivalents, and restricted cash - beginning of period</link:label>
    <link:label xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations-label" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Cash, cash equivalents, and restricted cash - end of period</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentIncomeInterest" xlink:label="us-gaap_InvestmentIncomeInterest" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_InvestmentIncomeInterest-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Interest income</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InvestmentIncomeInterest" xlink:to="us-gaap_InvestmentIncomeInterest-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:label="us-gaap_RestrictedStockUnitsRSUMember" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_RestrictedStockUnitsRSUMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Restricted Stock Units (RSUs) [Member]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestrictedStockUnitsRSUMember" xlink:to="us-gaap_RestrictedStockUnitsRSUMember-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect</link:label>
    <link:label xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect-label" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Net (decrease) increase in cash, cash equivalents, and restricted cash</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect-label" xlink:type="arc"/>
    <link:loc xlink:href="wint-20220630.xsd#wint_StockAndWarrantsIssuedPricePerShare" xlink:label="wint_StockAndWarrantsIssuedPricePerShare" xlink:type="locator"/>
    <link:label xlink:label="wint_StockAndWarrantsIssuedPricePerShare-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">wint_StockAndWarrantsIssuedPricePerShare</link:label>
    <link:label xlink:label="wint_StockAndWarrantsIssuedPricePerShare-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Stock and Warrants Issued, Price Per Share (in dollars per share)</link:label>
    <link:label xlink:label="wint_StockAndWarrantsIssuedPricePerShare-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">The stock and warrants issued price per share.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="wint_StockAndWarrantsIssuedPricePerShare" xlink:to="wint_StockAndWarrantsIssuedPricePerShare-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Liabilities" xlink:label="us-gaap_Liabilities" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_Liabilities-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_Liabilities</link:label>
    <link:label xlink:label="us-gaap_Liabilities-label" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total liabilities</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Liabilities" xlink:to="us-gaap_Liabilities-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_NetCashProvidedByUsedInFinancingActivities</link:label>
    <link:label xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities-label" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Net cash provided by financing activities</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_SubsidiarySaleOfStockAxis-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Sale of Stock [Axis]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SubsidiarySaleOfStockAxis-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SupplementalUnemploymentBenefitsSeveranceBenefits" xlink:label="us-gaap_SupplementalUnemploymentBenefitsSeveranceBenefits" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_SupplementalUnemploymentBenefitsSeveranceBenefits-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_SupplementalUnemploymentBenefitsSeveranceBenefits</link:label>
    <link:label xlink:label="us-gaap_SupplementalUnemploymentBenefitsSeveranceBenefits-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Supplemental Unemployment Benefits, Severance Benefits</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SupplementalUnemploymentBenefitsSeveranceBenefits" xlink:to="us-gaap_SupplementalUnemploymentBenefitsSeveranceBenefits-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Sale of Stock [Domain]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingIncomeLoss" xlink:label="us-gaap_OperatingIncomeLoss" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_OperatingIncomeLoss-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_OperatingIncomeLoss</link:label>
    <link:label xlink:label="us-gaap_OperatingIncomeLoss-label" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Operating loss</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingIncomeLoss" xlink:to="us-gaap_OperatingIncomeLoss-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_NetCashProvidedByUsedInOperatingActivities</link:label>
    <link:label xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities-label" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Net cash used in operating activities</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Prepaid expenses and other current assets</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:to="us-gaap_PrepaidExpenseAndOtherAssetsCurrent-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_NetCashProvidedByUsedInInvestingActivities</link:label>
    <link:label xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities-label" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Net cash provided by (used in) investing activities</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_CounterpartyNameAxis" xlink:label="srt_CounterpartyNameAxis" xlink:type="locator"/>
    <link:label xlink:label="srt_CounterpartyNameAxis-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Counterparty Name [Axis]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_CounterpartyNameAxis" xlink:to="srt_CounterpartyNameAxis-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:type="locator"/>
    <link:label xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Counterparty Name [Domain]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="srt_RepurchaseAgreementCounterpartyNameDomain-label" xlink:type="arc"/>
    <link:loc xlink:href="wint-20220630.xsd#wint_NumberOfSharesOfCommonStockPotentiallyIssuableUponTheExerciseOfStockOptionsAndWarrants" xlink:label="wint_NumberOfSharesOfCommonStockPotentiallyIssuableUponTheExerciseOfStockOptionsAndWarrants" xlink:type="locator"/>
    <link:label xlink:label="wint_NumberOfSharesOfCommonStockPotentiallyIssuableUponTheExerciseOfStockOptionsAndWarrants-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">wint_NumberOfSharesOfCommonStockPotentiallyIssuableUponTheExerciseOfStockOptionsAndWarrants</link:label>
    <link:label xlink:label="wint_NumberOfSharesOfCommonStockPotentiallyIssuableUponTheExerciseOfStockOptionsAndWarrants-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Number of Shares of Common Stock Potentially Issuable upon the Exercise of Stock Options and Warrants (in shares)</link:label>
    <link:label xlink:label="wint_NumberOfSharesOfCommonStockPotentiallyIssuableUponTheExerciseOfStockOptionsAndWarrants-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents number of shares of common stock potentially issuable exercise of certain stock options and warrants during the period.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="wint_NumberOfSharesOfCommonStockPotentiallyIssuableUponTheExerciseOfStockOptionsAndWarrants" xlink:to="wint_NumberOfSharesOfCommonStockPotentiallyIssuableUponTheExerciseOfStockOptionsAndWarrants-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill" xlink:label="us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill</link:label>
    <link:label xlink:label="us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Intangible assets</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill" xlink:to="us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredIncomeTaxLiabilitiesNet" xlink:label="us-gaap_DeferredIncomeTaxLiabilitiesNet" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_DeferredIncomeTaxLiabilitiesNet-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred tax liabilities</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredIncomeTaxLiabilitiesNet" xlink:to="us-gaap_DeferredIncomeTaxLiabilitiesNet-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="us-gaap_PropertyPlantAndEquipmentNet" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_PropertyPlantAndEquipmentNet-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Property and equipment, net</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentNet" xlink:to="us-gaap_PropertyPlantAndEquipmentNet-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Goodwill" xlink:label="us-gaap_Goodwill" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_Goodwill-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Goodwill</link:label>
    <link:label xlink:label="us-gaap_Goodwill-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Goodwill</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Goodwill" xlink:to="us-gaap_Goodwill-label" xlink:type="arc"/>
    <link:loc xlink:href="wint-20220630.xsd#wint_CorporatePartnershipLicensingAndResearchFundingAgreementsTextBlock" xlink:label="wint_CorporatePartnershipLicensingAndResearchFundingAgreementsTextBlock" xlink:type="locator"/>
    <link:label xlink:label="wint_CorporatePartnershipLicensingAndResearchFundingAgreementsTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Corporate Partnership, Licensing and Research Funding Agreements [Text Block]</link:label>
    <link:label xlink:label="wint_CorporatePartnershipLicensingAndResearchFundingAgreementsTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">The entire disclosure for corporate partnerships, licensing and research funding agreements.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="wint_CorporatePartnershipLicensingAndResearchFundingAgreementsTextBlock" xlink:to="wint_CorporatePartnershipLicensingAndResearchFundingAgreementsTextBlock-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongtermDebtTypeAxis" xlink:label="us-gaap_LongtermDebtTypeAxis" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_LongtermDebtTypeAxis-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Long-Term Debt, Type [Axis]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LongtermDebtTypeAxis" xlink:to="us-gaap_LongtermDebtTypeAxis-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongtermDebtTypeDomain" xlink:label="us-gaap_LongtermDebtTypeDomain" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_LongtermDebtTypeDomain-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Long-Term Debt, Type [Domain]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LongtermDebtTypeDomain" xlink:to="us-gaap_LongtermDebtTypeDomain-label" xlink:type="arc"/>
    <link:loc xlink:href="wint-20220630.xsd#wint_IncreaseDecreaseOperatingLeaseLiability" xlink:label="wint_IncreaseDecreaseOperatingLeaseLiability" xlink:type="locator"/>
    <link:label xlink:label="wint_IncreaseDecreaseOperatingLeaseLiability-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating lease liabilities</link:label>
    <link:label xlink:label="wint_IncreaseDecreaseOperatingLeaseLiability-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">The increase (decrease) during the reporting period in the operating lease liability.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="wint_IncreaseDecreaseOperatingLeaseLiability" xlink:to="wint_IncreaseDecreaseOperatingLeaseLiability-label" xlink:type="arc"/>
    <link:loc xlink:href="wint-20220630.xsd#wint_PrepaymentOfDirectorAndOfficerInsuranceThroughThirdPartyFinancing" xlink:label="wint_PrepaymentOfDirectorAndOfficerInsuranceThroughThirdPartyFinancing" xlink:type="locator"/>
    <link:label xlink:label="wint_PrepaymentOfDirectorAndOfficerInsuranceThroughThirdPartyFinancing-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Prepayment of insurance through third-party financing</link:label>
    <link:label xlink:label="wint_PrepaymentOfDirectorAndOfficerInsuranceThroughThirdPartyFinancing-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Amount of prepayment of director and officer insurance through third party financing.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="wint_PrepaymentOfDirectorAndOfficerInsuranceThroughThirdPartyFinancing" xlink:to="wint_PrepaymentOfDirectorAndOfficerInsuranceThroughThirdPartyFinancing-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceOrSaleOfEquity" xlink:label="us-gaap_ProceedsFromIssuanceOrSaleOfEquity" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ProceedsFromIssuanceOrSaleOfEquity-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_ProceedsFromIssuanceOrSaleOfEquity</link:label>
    <link:label xlink:label="us-gaap_ProceedsFromIssuanceOrSaleOfEquity-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Proceeds from Issuance or Sale of Equity, Total</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceOrSaleOfEquity" xlink:to="us-gaap_ProceedsFromIssuanceOrSaleOfEquity-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash flows from investing activities:</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsMember" xlink:label="us-gaap_RetainedEarningsMember" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_RetainedEarningsMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Retained Earnings [Member]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RetainedEarningsMember" xlink:to="us-gaap_RetainedEarningsMember-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="us-gaap_EarningsPerShareAbstract" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_EarningsPerShareAbstract-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net loss per common share</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_EarningsPerShareAbstract-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ExtinguishmentOfDebtAmount" xlink:label="us-gaap_ExtinguishmentOfDebtAmount" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ExtinguishmentOfDebtAmount-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_ExtinguishmentOfDebtAmount</link:label>
    <link:label xlink:label="us-gaap_ExtinguishmentOfDebtAmount-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Extinguishment of Debt, Amount</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ExtinguishmentOfDebtAmount" xlink:to="us-gaap_ExtinguishmentOfDebtAmount-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Proceeds from ATM Program, net of issuance costs</link:label>
    <link:label xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Proceeds from Issuance of Common Stock</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:type="locator"/>
    <link:label xlink:label="srt_TitleOfIndividualWithRelationshipToEntityDomain-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Title of Individual [Domain]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:to="srt_TitleOfIndividualWithRelationshipToEntityDomain-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_TitleOfIndividualAxis" xlink:label="srt_TitleOfIndividualAxis" xlink:type="locator"/>
    <link:label xlink:label="srt_TitleOfIndividualAxis-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Title of Individual [Axis]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_TitleOfIndividualAxis" xlink:to="srt_TitleOfIndividualAxis-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TreasuryStockMember" xlink:label="us-gaap_TreasuryStockMember" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_TreasuryStockMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Treasury Stock [Member]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TreasuryStockMember" xlink:to="us-gaap_TreasuryStockMember-label" xlink:type="arc"/>
    <link:loc xlink:href="wint-20220630.xsd#wint_StockIssuedDuringPeriodSharesCancellationOfDebtAndWarrantObligationsPercentageOfFullyDilutedSharesOutstanding" xlink:label="wint_StockIssuedDuringPeriodSharesCancellationOfDebtAndWarrantObligationsPercentageOfFullyDilutedSharesOutstanding" xlink:type="locator"/>
    <link:label xlink:label="wint_StockIssuedDuringPeriodSharesCancellationOfDebtAndWarrantObligationsPercentageOfFullyDilutedSharesOutstanding-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">wint_StockIssuedDuringPeriodSharesCancellationOfDebtAndWarrantObligationsPercentageOfFullyDilutedSharesOutstanding</link:label>
    <link:label xlink:label="wint_StockIssuedDuringPeriodSharesCancellationOfDebtAndWarrantObligationsPercentageOfFullyDilutedSharesOutstanding-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Stock Issued During Period, Shares, Cancellation of Debt and Warrant Obligations, Percentage of Fully-diluted Shares Outstanding</link:label>
    <link:label xlink:label="wint_StockIssuedDuringPeriodSharesCancellationOfDebtAndWarrantObligationsPercentageOfFullyDilutedSharesOutstanding-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">The percentage of the shares of stock issued attributable to transactions for the purpose of being granted forgiveness of debt and warrant obligations represent as all of the reporting entity's fully-diluted shares outstanding.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="wint_StockIssuedDuringPeriodSharesCancellationOfDebtAndWarrantObligationsPercentageOfFullyDilutedSharesOutstanding" xlink:to="wint_StockIssuedDuringPeriodSharesCancellationOfDebtAndWarrantObligationsPercentageOfFullyDilutedSharesOutstanding-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="us-gaap_AdditionalPaidInCapitalMember" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_AdditionalPaidInCapitalMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Additional Paid-in Capital [Member]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdditionalPaidInCapitalMember" xlink:to="us-gaap_AdditionalPaidInCapitalMember-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_CommonStockMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Common Stock [Member]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockMember" xlink:to="us-gaap_CommonStockMember-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LoansPayableMember" xlink:label="us-gaap_LoansPayableMember" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_LoansPayableMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Loans Payable [Member]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LoansPayableMember" xlink:to="us-gaap_LoansPayableMember-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:label="us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_IncreaseDecreaseInAccruedLiabilities-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_IncreaseDecreaseInAccruedLiabilities</link:label>
    <link:label xlink:label="us-gaap_IncreaseDecreaseInAccruedLiabilities-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accrued expenses</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:to="us-gaap_IncreaseDecreaseInAccruedLiabilities-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="us-gaap_IncomeTaxExpenseBenefit" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_IncomeTaxExpenseBenefit-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_IncomeTaxExpenseBenefit</link:label>
    <link:label xlink:label="us-gaap_IncomeTaxExpenseBenefit-label" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Deferred income tax benefit</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxExpenseBenefit" xlink:to="us-gaap_IncomeTaxExpenseBenefit-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShortTermDebtTypeAxis" xlink:label="us-gaap_ShortTermDebtTypeAxis" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ShortTermDebtTypeAxis-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Short-Term Debt, Type [Axis]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShortTermDebtTypeAxis" xlink:to="us-gaap_ShortTermDebtTypeAxis-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_StatementEquityComponentsAxis-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity Components [Axis]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_StatementEquityComponentsAxis-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShortTermDebtTypeDomain" xlink:label="us-gaap_ShortTermDebtTypeDomain" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ShortTermDebtTypeDomain-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Short-Term Debt, Type [Domain]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShortTermDebtTypeDomain" xlink:to="us-gaap_ShortTermDebtTypeDomain-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_EquityComponentDomain-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity Component [Domain]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_EquityComponentDomain-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccountsPayable" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_IncreaseDecreaseInAccountsPayable</link:label>
    <link:label xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accounts payable</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccountsPayable" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayable-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1</link:label>
    <link:label xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:to="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="us-gaap_ClassOfWarrantOrRightAxis" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ClassOfWarrantOrRightAxis-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Class of Warrant or Right [Axis]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="us-gaap_ClassOfWarrantOrRightAxis-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="us-gaap_ClassOfWarrantOrRightDomain" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ClassOfWarrantOrRightDomain-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Class of Warrant or Right [Domain]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="us-gaap_ClassOfWarrantOrRightDomain-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LoansPayableToBank" xlink:label="us-gaap_LoansPayableToBank" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_LoansPayableToBank-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_LoansPayableToBank</link:label>
    <link:label xlink:label="us-gaap_LoansPayableToBank-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Loans Payable to Bank, Total</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LoansPayableToBank" xlink:to="us-gaap_LoansPayableToBank-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest</link:label>
    <link:label xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest-label" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Loss before income taxes</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingExpenses" xlink:label="us-gaap_OperatingExpenses" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_OperatingExpenses-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_OperatingExpenses</link:label>
    <link:label xlink:label="us-gaap_OperatingExpenses-label" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total operating expenses</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingExpenses" xlink:to="us-gaap_OperatingExpenses-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedCashAndCashEquivalentsNoncurrent" xlink:label="us-gaap_RestrictedCashAndCashEquivalentsNoncurrent" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_RestrictedCashAndCashEquivalentsNoncurrent-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Restricted cash</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestrictedCashAndCashEquivalentsNoncurrent" xlink:to="us-gaap_RestrictedCashAndCashEquivalentsNoncurrent-label" xlink:type="arc"/>
    <link:loc xlink:href="wint-20220630.xsd#wint_StockOfferingAgreementRemainingAmountAvailable" xlink:label="wint_StockOfferingAgreementRemainingAmountAvailable" xlink:type="locator"/>
    <link:label xlink:label="wint_StockOfferingAgreementRemainingAmountAvailable-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">wint_StockOfferingAgreementRemainingAmountAvailable</link:label>
    <link:label xlink:label="wint_StockOfferingAgreementRemainingAmountAvailable-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Stock Offering Agreement, Remaining Amount Available</link:label>
    <link:label xlink:label="wint_StockOfferingAgreementRemainingAmountAvailable-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">The amount of remaining amount available under a stock offering agreement.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="wint_StockOfferingAgreementRemainingAmountAvailable" xlink:to="wint_StockOfferingAgreementRemainingAmountAvailable-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash and cash equivalents</link:label>
    <link:label xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cash and Cash Equivalents, at Carrying Value, Total</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_AllocatedShareBasedCompensationExpense-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_AllocatedShareBasedCompensationExpense</link:label>
    <link:label xlink:label="us-gaap_AllocatedShareBasedCompensationExpense-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Stock-based compensation expense</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AllocatedShareBasedCompensationExpense" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RepaymentsOfLongTermDebt" xlink:label="us-gaap_RepaymentsOfLongTermDebt" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_RepaymentsOfLongTermDebt-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_RepaymentsOfLongTermDebt</link:label>
    <link:label xlink:label="us-gaap_RepaymentsOfLongTermDebt-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Repayments of Long-term Debt, Total</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RepaymentsOfLongTermDebt" xlink:to="us-gaap_RepaymentsOfLongTermDebt-label" xlink:type="arc"/>
    <link:loc xlink:href="wint-20220630.xsd#wint_ProceedsFromIssuanceOrSaleOfEquityGrossAmount" xlink:label="wint_ProceedsFromIssuanceOrSaleOfEquityGrossAmount" xlink:type="locator"/>
    <link:label xlink:label="wint_ProceedsFromIssuanceOrSaleOfEquityGrossAmount-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">wint_ProceedsFromIssuanceOrSaleOfEquityGrossAmount</link:label>
    <link:label xlink:label="wint_ProceedsFromIssuanceOrSaleOfEquityGrossAmount-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Proceeds from Issuance or Sale of Equity, Gross Amount</link:label>
    <link:label xlink:label="wint_ProceedsFromIssuanceOrSaleOfEquityGrossAmount-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">The gross proceeds from the issuance of common stock, preferred stock, treasury stock, stock options, and other types of equity.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="wint_ProceedsFromIssuanceOrSaleOfEquityGrossAmount" xlink:to="wint_ProceedsFromIssuanceOrSaleOfEquityGrossAmount-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:label="us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_CashAndCashEquivalentsPolicyTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash and Cash Equivalents, Policy [Policy Text Block]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:to="us-gaap_CashAndCashEquivalentsPolicyTextBlock-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentQuarterlyReport" xlink:label="dei_DocumentQuarterlyReport" xlink:type="locator"/>
    <link:label xlink:label="dei_DocumentQuarterlyReport-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Quarterly Report</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentQuarterlyReport" xlink:to="dei_DocumentQuarterlyReport-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AmendmentFlag" xlink:label="dei_AmendmentFlag" xlink:type="locator"/>
    <link:label xlink:label="dei_AmendmentFlag-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Amendment Flag</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentFlag" xlink:to="dei_AmendmentFlag-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="dei_EntityIncorporationStateCountryCode" xlink:type="locator"/>
    <link:label xlink:label="dei_EntityIncorporationStateCountryCode-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityIncorporationStateCountryCode" xlink:to="dei_EntityIncorporationStateCountryCode-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="us-gaap_AccountingPoliciesAbstract" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_AccountingPoliciesAbstract-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accounting Policies [Abstract]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_AccountingPoliciesAbstract-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SignificantAccountingPoliciesTextBlock" xlink:label="us-gaap_SignificantAccountingPoliciesTextBlock" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_SignificantAccountingPoliciesTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Significant Accounting Policies [Text Block]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SignificantAccountingPoliciesTextBlock" xlink:to="us-gaap_SignificantAccountingPoliciesTextBlock-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentTransitionReport" xlink:label="dei_DocumentTransitionReport" xlink:type="locator"/>
    <link:label xlink:label="dei_DocumentTransitionReport-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Transition Report</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentTransitionReport" xlink:to="dei_DocumentTransitionReport-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CityAreaCode" xlink:label="dei_CityAreaCode" xlink:type="locator"/>
    <link:label xlink:label="dei_CityAreaCode-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">City Area Code</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CityAreaCode" xlink:to="dei_CityAreaCode-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UseOfEstimates" xlink:label="us-gaap_UseOfEstimates" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_UseOfEstimates-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Use of Estimates, Policy [Policy Text Block]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_UseOfEstimates" xlink:to="us-gaap_UseOfEstimates-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentPeriodicPayment" xlink:label="us-gaap_DebtInstrumentPeriodicPayment" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_DebtInstrumentPeriodicPayment-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_DebtInstrumentPeriodicPayment</link:label>
    <link:label xlink:label="us-gaap_DebtInstrumentPeriodicPayment-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Debt Instrument, Periodic Payment, Total</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentPeriodicPayment" xlink:to="us-gaap_DebtInstrumentPeriodicPayment-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SellingGeneralAndAdministrativeExpensesMember" xlink:label="us-gaap_SellingGeneralAndAdministrativeExpensesMember" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_SellingGeneralAndAdministrativeExpensesMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Selling, General and Administrative Expenses [Member]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SellingGeneralAndAdministrativeExpensesMember" xlink:to="us-gaap_SellingGeneralAndAdministrativeExpensesMember-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityInteractiveDataCurrent" xlink:label="dei_EntityInteractiveDataCurrent" xlink:type="locator"/>
    <link:label xlink:label="dei_EntityInteractiveDataCurrent-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Interactive Data Current</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityInteractiveDataCurrent" xlink:to="dei_EntityInteractiveDataCurrent-label" xlink:type="arc"/>
    <link:loc xlink:href="wint-20220630.xsd#wint_NonplanStockOptionsMember" xlink:label="wint_NonplanStockOptionsMember" xlink:type="locator"/>
    <link:label xlink:label="wint_NonplanStockOptionsMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Non-plan Stock Options [Member]</link:label>
    <link:label xlink:label="wint_NonplanStockOptionsMember-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Related to non-plan options awarded.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="wint_NonplanStockOptionsMember" xlink:to="wint_NonplanStockOptionsMember-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharesOutstanding" xlink:label="us-gaap_SharesOutstanding" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_SharesOutstanding-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_SharesOutstanding</link:label>
    <link:label xlink:label="us-gaap_SharesOutstanding-label" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Balance (in shares)</link:label>
    <link:label xlink:label="us-gaap_SharesOutstanding-label" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Balance (in shares)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharesOutstanding" xlink:to="us-gaap_SharesOutstanding-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_SecurityExchangeName" xlink:label="dei_SecurityExchangeName" xlink:type="locator"/>
    <link:label xlink:label="dei_SecurityExchangeName-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Security Exchange Name</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SecurityExchangeName" xlink:to="dei_SecurityExchangeName-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="us-gaap_CommonStockSharesOutstanding" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_CommonStockSharesOutstanding-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Common stock, shares outstanding (in shares)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesOutstanding" xlink:to="us-gaap_CommonStockSharesOutstanding-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:label="us-gaap_PreferredStockSharesOutstanding" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_PreferredStockSharesOutstanding-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Preferred stock, shares outstanding (in shares)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockSharesOutstanding" xlink:to="us-gaap_PreferredStockSharesOutstanding-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_Security12bTitle" xlink:label="dei_Security12bTitle" xlink:type="locator"/>
    <link:label xlink:label="dei_Security12bTitle-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Title of 12(b) Security</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Security12bTitle" xlink:to="dei_Security12bTitle-label" xlink:type="arc"/>
    <link:loc xlink:href="wint-20220630.xsd#wint_CommissionFeePercentFee" xlink:label="wint_CommissionFeePercentFee" xlink:type="locator"/>
    <link:label xlink:label="wint_CommissionFeePercentFee-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">wint_CommissionFeePercentFee</link:label>
    <link:label xlink:label="wint_CommissionFeePercentFee-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Commission Fee, Percent Fee</link:label>
    <link:label xlink:label="wint_CommissionFeePercentFee-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">The percentage charged for commission.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="wint_CommissionFeePercentFee" xlink:to="wint_CommissionFeePercentFee-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CurrentFiscalYearEndDate" xlink:label="dei_CurrentFiscalYearEndDate" xlink:type="locator"/>
    <link:label xlink:label="dei_CurrentFiscalYearEndDate-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Current Fiscal Year End Date</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CurrentFiscalYearEndDate" xlink:to="dei_CurrentFiscalYearEndDate-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:label="us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_DebtInstrumentInterestRateStatedPercentage-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_DebtInstrumentInterestRateStatedPercentage</link:label>
    <link:label xlink:label="us-gaap_DebtInstrumentInterestRateStatedPercentage-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Debt Instrument, Interest Rate, Stated Percentage</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:to="us-gaap_DebtInstrumentInterestRateStatedPercentage-label" xlink:type="arc"/>
    <link:loc xlink:href="wint-20220630.xsd#wint_PaymentsForSeveranceCosts" xlink:label="wint_PaymentsForSeveranceCosts" xlink:type="locator"/>
    <link:label xlink:label="wint_PaymentsForSeveranceCosts-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">wint_PaymentsForSeveranceCosts</link:label>
    <link:label xlink:label="wint_PaymentsForSeveranceCosts-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Payments for Severance Costs</link:label>
    <link:label xlink:label="wint_PaymentsForSeveranceCosts-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Amount of cash outflow to satisfy severance cost obligation.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="wint_PaymentsForSeveranceCosts" xlink:to="wint_PaymentsForSeveranceCosts-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets</link:label>
    <link:label xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets-label" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Prepaid expenses and other current assets</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:to="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BasisOfAccounting" xlink:label="us-gaap_BasisOfAccounting" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_BasisOfAccounting-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Basis of Accounting [Text Block]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BasisOfAccounting" xlink:to="us-gaap_BasisOfAccounting-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Research and Development Expense [Member]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpenseMember" xlink:to="us-gaap_ResearchAndDevelopmentExpenseMember-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="dei_DocumentFiscalPeriodFocus" xlink:type="locator"/>
    <link:label xlink:label="dei_DocumentFiscalPeriodFocus-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Fiscal Period Focus</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalPeriodFocus" xlink:to="dei_DocumentFiscalPeriodFocus-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentFiscalYearFocus" xlink:label="dei_DocumentFiscalYearFocus" xlink:type="locator"/>
    <link:label xlink:label="dei_DocumentFiscalYearFocus-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Fiscal Year Focus</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalYearFocus" xlink:to="dei_DocumentFiscalYearFocus-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConsolidationPolicyTextBlock" xlink:label="us-gaap_ConsolidationPolicyTextBlock" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ConsolidationPolicyTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Consolidation, Policy [Policy Text Block]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConsolidationPolicyTextBlock" xlink:to="us-gaap_ConsolidationPolicyTextBlock-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentPeriodEndDate" xlink:label="dei_DocumentPeriodEndDate" xlink:type="locator"/>
    <link:label xlink:label="dei_DocumentPeriodEndDate-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Period End Date</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodEndDate" xlink:to="dei_DocumentPeriodEndDate-label" xlink:type="arc"/>
    <link:loc xlink:href="wint-20220630.xsd#wint_StockOfferingAgreementPublicFloatLimitationAmount" xlink:label="wint_StockOfferingAgreementPublicFloatLimitationAmount" xlink:type="locator"/>
    <link:label xlink:label="wint_StockOfferingAgreementPublicFloatLimitationAmount-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">wint_StockOfferingAgreementPublicFloatLimitationAmount</link:label>
    <link:label xlink:label="wint_StockOfferingAgreementPublicFloatLimitationAmount-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Stock Offering Agreement, Public Float Limitation Amount</link:label>
    <link:label xlink:label="wint_StockOfferingAgreementPublicFloatLimitationAmount-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">The amount of public float required to remove limitations on a stock offering agreement.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="wint_StockOfferingAgreementPublicFloatLimitationAmount" xlink:to="wint_StockOfferingAgreementPublicFloatLimitationAmount-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:label="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating lease liabilities arising from obtaining right-of-use assets</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:to="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="us-gaap_IncomeStatementLocationAxis" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_IncomeStatementLocationAxis-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income Statement Location [Axis]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationAxis-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="us-gaap_IncomeStatementLocationDomain" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_IncomeStatementLocationDomain-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income Statement Location [Domain]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_IncomeStatementLocationDomain-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityFileNumber" xlink:label="dei_EntityFileNumber" xlink:type="locator"/>
    <link:label xlink:label="dei_EntityFileNumber-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity File Number</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFileNumber" xlink:to="dei_EntityFileNumber-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_TypeOfArrangementAxis-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Axis]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_TypeOfArrangementAxis-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityEmergingGrowthCompany" xlink:label="dei_EntityEmergingGrowthCompany" xlink:type="locator"/>
    <link:label xlink:label="dei_EntityEmergingGrowthCompany-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityEmergingGrowthCompany" xlink:to="dei_EntityEmergingGrowthCompany-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentFaceAmount" xlink:label="us-gaap_DebtInstrumentFaceAmount" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_DebtInstrumentFaceAmount-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_DebtInstrumentFaceAmount</link:label>
    <link:label xlink:label="us-gaap_DebtInstrumentFaceAmount-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Debt Instrument, Face Amount</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentFaceAmount" xlink:to="us-gaap_DebtInstrumentFaceAmount-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentType" xlink:label="dei_DocumentType" xlink:type="locator"/>
    <link:label xlink:label="dei_DocumentType-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Type</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentType" xlink:to="dei_DocumentType-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntitySmallBusiness" xlink:label="dei_EntitySmallBusiness" xlink:type="locator"/>
    <link:label xlink:label="dei_EntitySmallBusiness-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Small Business</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntitySmallBusiness" xlink:to="dei_EntitySmallBusiness-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityShellCompany" xlink:label="dei_EntityShellCompany" xlink:type="locator"/>
    <link:label xlink:label="dei_EntityShellCompany-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Shell Company</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityShellCompany" xlink:to="dei_EntityShellCompany-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentInformationLineItems" xlink:label="dei_DocumentInformationLineItems" xlink:type="locator"/>
    <link:label xlink:label="dei_DocumentInformationLineItems-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Information [Line Items]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentInformationLineItems-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentInformationTable" xlink:label="dei_DocumentInformationTable" xlink:type="locator"/>
    <link:label xlink:label="dei_DocumentInformationTable-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Information [Table]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentInformationTable" xlink:to="dei_DocumentInformationTable-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SeveranceCosts1" xlink:label="us-gaap_SeveranceCosts1" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_SeveranceCosts1-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_SeveranceCosts1</link:label>
    <link:label xlink:label="us-gaap_SeveranceCosts1-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Severance Costs</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SeveranceCosts1" xlink:to="us-gaap_SeveranceCosts1-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityFilerCategory" xlink:label="dei_EntityFilerCategory" xlink:type="locator"/>
    <link:label xlink:label="dei_EntityFilerCategory-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Filer Category</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFilerCategory" xlink:to="dei_EntityFilerCategory-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentAxis" xlink:label="us-gaap_DebtInstrumentAxis" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_DebtInstrumentAxis-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Instrument [Axis]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentAxis" xlink:to="us-gaap_DebtInstrumentAxis-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCurrentReportingStatus" xlink:label="dei_EntityCurrentReportingStatus" xlink:type="locator"/>
    <link:label xlink:label="dei_EntityCurrentReportingStatus-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Current Reporting Status</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCurrentReportingStatus" xlink:to="dei_EntityCurrentReportingStatus-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="us-gaap_DebtInstrumentNameDomain" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_DebtInstrumentNameDomain-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Instrument, Name [Domain]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentNameDomain" xlink:to="us-gaap_DebtInstrumentNameDomain-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RepaymentsOfShortTermDebt" xlink:label="us-gaap_RepaymentsOfShortTermDebt" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_RepaymentsOfShortTermDebt-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_RepaymentsOfShortTermDebt</link:label>
    <link:label xlink:label="us-gaap_RepaymentsOfShortTermDebt-label" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Principal payments on loans payable</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RepaymentsOfShortTermDebt" xlink:to="us-gaap_RepaymentsOfShortTermDebt-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractualObligation" xlink:label="us-gaap_ContractualObligation" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ContractualObligation-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_ContractualObligation</link:label>
    <link:label xlink:label="us-gaap_ContractualObligation-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Contractual Obligation, Total</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ContractualObligation" xlink:to="us-gaap_ContractualObligation-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillImpairmentLoss" xlink:label="us-gaap_GoodwillImpairmentLoss" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_GoodwillImpairmentLoss-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Loss on impairment of goodwill</link:label>
    <link:label xlink:label="us-gaap_GoodwillImpairmentLoss-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Goodwill, Impairment Loss</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GoodwillImpairmentLoss" xlink:to="us-gaap_GoodwillImpairmentLoss-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stock-based compensation expense</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityTaxIdentificationNumber" xlink:label="dei_EntityTaxIdentificationNumber" xlink:type="locator"/>
    <link:label xlink:label="dei_EntityTaxIdentificationNumber-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Tax Identification Number</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityTaxIdentificationNumber" xlink:to="dei_EntityTaxIdentificationNumber-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCentralIndexKey" xlink:label="dei_EntityCentralIndexKey" xlink:type="locator"/>
    <link:label xlink:label="dei_EntityCentralIndexKey-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCentralIndexKey" xlink:to="dei_EntityCentralIndexKey-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityRegistrantName" xlink:label="dei_EntityRegistrantName" xlink:type="locator"/>
    <link:label xlink:label="dei_EntityRegistrantName-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityRegistrantName" xlink:to="dei_EntityRegistrantName-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:label xlink:label="dei_EntityDomain-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity [Domain]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityDomain" xlink:to="dei_EntityDomain-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:label xlink:label="dei_LegalEntityAxis-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Legal Entity [Axis]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_LegalEntityAxis" xlink:to="dei_LegalEntityAxis-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_StatementTable-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statement [Table]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementTable-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressAddressLine1" xlink:label="dei_EntityAddressAddressLine1" xlink:type="locator"/>
    <link:label xlink:label="dei_EntityAddressAddressLine1-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Address, Address Line One</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine1" xlink:to="dei_EntityAddressAddressLine1-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="us-gaap_StatementOfFinancialPositionAbstract" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_StatementOfFinancialPositionAbstract-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statement of Financial Position [Abstract]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_StatementOfFinancialPositionAbstract-label" xlink:type="arc"/>
    <link:loc xlink:href="wint-20220630.xsd#wint_AerosurfFundingTermSheetMember" xlink:label="wint_AerosurfFundingTermSheetMember" xlink:type="locator"/>
    <link:label xlink:label="wint_AerosurfFundingTermSheetMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">AEROSURF Funding Term Sheet [Member]</link:label>
    <link:label xlink:label="wint_AerosurfFundingTermSheetMember-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents the information pertaining to the AEROSURF Funding Term Sheet.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="wint_AerosurfFundingTermSheetMember" xlink:to="wint_AerosurfFundingTermSheetMember-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_WeightedAverageNumberOfSharesOutstandingBasic</link:label>
    <link:label xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Basic and diluted (in shares)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:to="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressCityOrTown" xlink:label="dei_EntityAddressCityOrTown" xlink:type="locator"/>
    <link:label xlink:label="dei_EntityAddressCityOrTown-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Address, City or Town</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressCityOrTown" xlink:to="dei_EntityAddressCityOrTown-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressPostalZipCode" xlink:label="dei_EntityAddressPostalZipCode" xlink:type="locator"/>
    <link:label xlink:label="dei_EntityAddressPostalZipCode-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressPostalZipCode" xlink:to="dei_EntityAddressPostalZipCode-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareBasic" xlink:label="us-gaap_EarningsPerShareBasic" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_EarningsPerShareBasic-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_EarningsPerShareBasic</link:label>
    <link:label xlink:label="us-gaap_EarningsPerShareBasic-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Basic and diluted (in dollars per share)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareBasic" xlink:to="us-gaap_EarningsPerShareBasic-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressStateOrProvince" xlink:label="dei_EntityAddressStateOrProvince" xlink:type="locator"/>
    <link:label xlink:label="dei_EntityAddressStateOrProvince-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Address, State or Province</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressStateOrProvince" xlink:to="dei_EntityAddressStateOrProvince-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TreasuryStockValue" xlink:label="us-gaap_TreasuryStockValue" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_TreasuryStockValue-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_TreasuryStockValue</link:label>
    <link:label xlink:label="us-gaap_TreasuryStockValue-label" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Treasury stock (at cost); 24 shares</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TreasuryStockValue" xlink:to="us-gaap_TreasuryStockValue-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareBasicAbstract" xlink:label="us-gaap_EarningsPerShareBasicAbstract" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_EarningsPerShareBasicAbstract-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Weighted average number of common shares outstanding</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareBasicAbstract" xlink:to="us-gaap_EarningsPerShareBasicAbstract-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:label="us-gaap_StatementOfCashFlowsAbstract" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_StatementOfCashFlowsAbstract-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statement of Cash Flows [Abstract]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_StatementOfCashFlowsAbstract-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="dei_EntityCommonStockSharesOutstanding" xlink:type="locator"/>
    <link:label xlink:label="dei_EntityCommonStockSharesOutstanding-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Common Stock, Shares Outstanding</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCommonStockSharesOutstanding" xlink:to="dei_EntityCommonStockSharesOutstanding-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfStockholdersEquityAbstract" xlink:label="us-gaap_StatementOfStockholdersEquityAbstract" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_StatementOfStockholdersEquityAbstract-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statement of Stockholders' Equity [Abstract]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfStockholdersEquityAbstract" xlink:to="us-gaap_StatementOfStockholdersEquityAbstract-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementAbstract" xlink:label="us-gaap_IncomeStatementAbstract" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_IncomeStatementAbstract-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income Statement [Abstract]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_IncomeStatementAbstract-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebtTextBlock" xlink:label="us-gaap_LongTermDebtTextBlock" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_LongTermDebtTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Long-Term Debt [Text Block]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LongTermDebtTextBlock" xlink:to="us-gaap_LongTermDebtTextBlock-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_TradingSymbol" xlink:label="dei_TradingSymbol" xlink:type="locator"/>
    <link:label xlink:label="dei_TradingSymbol-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Trading Symbol</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_TradingSymbol" xlink:to="dei_TradingSymbol-label" xlink:type="arc"/>
    <link:loc xlink:href="wint-20220630.xsd#wint_ExchangeAndTerminationAgreementMember" xlink:label="wint_ExchangeAndTerminationAgreementMember" xlink:type="locator"/>
    <link:label xlink:label="wint_ExchangeAndTerminationAgreementMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Exchange and Termination Agreement [Member]</link:label>
    <link:label xlink:label="wint_ExchangeAndTerminationAgreementMember-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents information pertaining to an Exchange and Termination Agreement, under which debt and warrant obligations are cancelled in exchange for payments in cash, stock, and milestone payments.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="wint_ExchangeAndTerminationAgreementMember" xlink:to="wint_ExchangeAndTerminationAgreementMember-label" xlink:type="arc"/>
    <link:loc xlink:href="wint-20220630.xsd#wint_ManufacturingAndLaboratoryEquipmentMember" xlink:label="wint_ManufacturingAndLaboratoryEquipmentMember" xlink:type="locator"/>
    <link:label xlink:label="wint_ManufacturingAndLaboratoryEquipmentMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Manufacturing and Laboratory Equipment [Member]</link:label>
    <link:label xlink:label="wint_ManufacturingAndLaboratoryEquipmentMember-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Related to manufacturing and laboratory equipment.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="wint_ManufacturingAndLaboratoryEquipmentMember" xlink:to="wint_ManufacturingAndLaboratoryEquipmentMember-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:to="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock-label" xlink:type="arc"/>
    <link:loc xlink:href="wint-20220630.xsd#wint_ExecutiveOfficersAndEmployeesMember" xlink:label="wint_ExecutiveOfficersAndEmployeesMember" xlink:type="locator"/>
    <link:label xlink:label="wint_ExecutiveOfficersAndEmployeesMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Executive Officers and Employees [Member]</link:label>
    <link:label xlink:label="wint_ExecutiveOfficersAndEmployeesMember-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents information regarding executive officers and employees.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="wint_ExecutiveOfficersAndEmployeesMember" xlink:to="wint_ExecutiveOfficersAndEmployeesMember-label" xlink:type="arc"/>
    <link:loc xlink:href="wint-20220630.xsd#wint_StockIssuedDuringPeriodSharesCancellationOfDebtAndWarrantObligations" xlink:label="wint_StockIssuedDuringPeriodSharesCancellationOfDebtAndWarrantObligations" xlink:type="locator"/>
    <link:label xlink:label="wint_StockIssuedDuringPeriodSharesCancellationOfDebtAndWarrantObligations-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">wint_StockIssuedDuringPeriodSharesCancellationOfDebtAndWarrantObligations</link:label>
    <link:label xlink:label="wint_StockIssuedDuringPeriodSharesCancellationOfDebtAndWarrantObligations-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Stock Issued During Period, Shares, Cancellation of Debt and Warrant Obligations (in shares)</link:label>
    <link:label xlink:label="wint_StockIssuedDuringPeriodSharesCancellationOfDebtAndWarrantObligations-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Number of shares of stock issued attributable to transactions for the purpose of being granted forgiveness of debt and warrant obligations.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="wint_StockIssuedDuringPeriodSharesCancellationOfDebtAndWarrantObligations" xlink:to="wint_StockIssuedDuringPeriodSharesCancellationOfDebtAndWarrantObligations-label" xlink:type="arc"/>
    <link:loc xlink:href="wint-20220630.xsd#wint_ProceedsForPaymentsToDevelopProduct" xlink:label="wint_ProceedsForPaymentsToDevelopProduct" xlink:type="locator"/>
    <link:label xlink:label="wint_ProceedsForPaymentsToDevelopProduct-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">wint_ProceedsForPaymentsToDevelopProduct</link:label>
    <link:label xlink:label="wint_ProceedsForPaymentsToDevelopProduct-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Proceeds for Payments to Develop Product</link:label>
    <link:label xlink:label="wint_ProceedsForPaymentsToDevelopProduct-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">The amount of cash inflow from payments from a third party to develop a product.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="wint_ProceedsForPaymentsToDevelopProduct" xlink:to="wint_ProceedsForPaymentsToDevelopProduct-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LocalPhoneNumber" xlink:label="dei_LocalPhoneNumber" xlink:type="locator"/>
    <link:label xlink:label="dei_LocalPhoneNumber-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Local Phone Number</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_LocalPhoneNumber" xlink:to="dei_LocalPhoneNumber-label" xlink:type="arc"/>
    <link:loc xlink:href="wint-20220630.xsd#wint_EffectOfCOVID19PandemicPolicyTextBlock" xlink:label="wint_EffectOfCOVID19PandemicPolicyTextBlock" xlink:type="locator"/>
    <link:label xlink:label="wint_EffectOfCOVID19PandemicPolicyTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Effect of COVID-19 Pandemic [Policy Text Block]</link:label>
    <link:label xlink:label="wint_EffectOfCOVID19PandemicPolicyTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">The disclosure for the accounting policy related to the effect of the COVID-19 pandemic.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="wint_EffectOfCOVID19PandemicPolicyTextBlock" xlink:to="wint_EffectOfCOVID19PandemicPolicyTextBlock-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GainLossOnDispositionOfAssets" xlink:label="us-gaap_GainLossOnDispositionOfAssets" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_GainLossOnDispositionOfAssets-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_GainLossOnDispositionOfAssets</link:label>
    <link:label xlink:label="us-gaap_GainLossOnDispositionOfAssets-label" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Loss on sale and disposal of property and equipment</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GainLossOnDispositionOfAssets" xlink:to="us-gaap_GainLossOnDispositionOfAssets-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TableTextBlock" xlink:label="us-gaap_TableTextBlock" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_TableTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_TableTextBlock</link:label>
    <link:label xlink:label="us-gaap_TableTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Notes Tables</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TableTextBlock" xlink:to="us-gaap_TableTextBlock-label" xlink:type="arc"/>
    <link:loc xlink:href="wint-20220630.xsd#wint_TermSheetWithLeeMember" xlink:label="wint_TermSheetWithLeeMember" xlink:type="locator"/>
    <link:label xlink:label="wint_TermSheetWithLeeMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Term Sheet With Lee [Member]</link:label>
    <link:label xlink:label="wint_TermSheetWithLeeMember-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Related to a term sheet with Lee.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="wint_TermSheetWithLeeMember" xlink:to="wint_TermSheetWithLeeMember-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock" xlink:label="us-gaap_ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Intangible Assets and Goodwill [Table Text Block]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock" xlink:to="us-gaap_ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock-label" xlink:type="arc"/>
    <link:loc xlink:href="wint-20220630.xsd#wint_FinancingOfProductPercentOfFinancingThatMustBeRepaidToDiscontinueRevenueSharing" xlink:label="wint_FinancingOfProductPercentOfFinancingThatMustBeRepaidToDiscontinueRevenueSharing" xlink:type="locator"/>
    <link:label xlink:label="wint_FinancingOfProductPercentOfFinancingThatMustBeRepaidToDiscontinueRevenueSharing-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">wint_FinancingOfProductPercentOfFinancingThatMustBeRepaidToDiscontinueRevenueSharing</link:label>
    <link:label xlink:label="wint_FinancingOfProductPercentOfFinancingThatMustBeRepaidToDiscontinueRevenueSharing-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Financing of Product, Percent of Financing That Must be Repaid to Discontinue Revenue Sharing</link:label>
    <link:label xlink:label="wint_FinancingOfProductPercentOfFinancingThatMustBeRepaidToDiscontinueRevenueSharing-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">The percent of financing that must be repaid to discontinue the revenue sharing provisions of product financing.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="wint_FinancingOfProductPercentOfFinancingThatMustBeRepaidToDiscontinueRevenueSharing" xlink:to="wint_FinancingOfProductPercentOfFinancingThatMustBeRepaidToDiscontinueRevenueSharing-label" xlink:type="arc"/>
    <link:loc xlink:href="wint-20220630.xsd#wint_SharePurchaseAgreementDecember2019Member" xlink:label="wint_SharePurchaseAgreementDecember2019Member" xlink:type="locator"/>
    <link:label xlink:label="wint_SharePurchaseAgreementDecember2019Member-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share Purchase Agreement, December 2019 [Member]</link:label>
    <link:label xlink:label="wint_SharePurchaseAgreementDecember2019Member-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents information regarding Share Purchase Agreement, December 2019.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="wint_SharePurchaseAgreementDecember2019Member" xlink:to="wint_SharePurchaseAgreementDecember2019Member-label" xlink:type="arc"/>
    <link:loc xlink:href="wint-20220630.xsd#wint_ClassOfWarrantOrRightExercisePriceOfCancelledWarrants" xlink:label="wint_ClassOfWarrantOrRightExercisePriceOfCancelledWarrants" xlink:type="locator"/>
    <link:label xlink:label="wint_ClassOfWarrantOrRightExercisePriceOfCancelledWarrants-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">wint_ClassOfWarrantOrRightExercisePriceOfCancelledWarrants</link:label>
    <link:label xlink:label="wint_ClassOfWarrantOrRightExercisePriceOfCancelledWarrants-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Class of Warrant or Right, Exercise Price of Cancelled Warrants (in dollars per share)</link:label>
    <link:label xlink:label="wint_ClassOfWarrantOrRightExercisePriceOfCancelledWarrants-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents the exercise price per share of cancelled warrants.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="wint_ClassOfWarrantOrRightExercisePriceOfCancelledWarrants" xlink:to="wint_ClassOfWarrantOrRightExercisePriceOfCancelledWarrants-label" xlink:type="arc"/>
    <link:loc xlink:href="wint-20220630.xsd#wint_ClassOfWarrantOrRightNumberOfWarrantsCancelled" xlink:label="wint_ClassOfWarrantOrRightNumberOfWarrantsCancelled" xlink:type="locator"/>
    <link:label xlink:label="wint_ClassOfWarrantOrRightNumberOfWarrantsCancelled-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">wint_ClassOfWarrantOrRightNumberOfWarrantsCancelled</link:label>
    <link:label xlink:label="wint_ClassOfWarrantOrRightNumberOfWarrantsCancelled-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Class of Warrant or Right, Number of Warrants Cancelled (in shares)</link:label>
    <link:label xlink:label="wint_ClassOfWarrantOrRightNumberOfWarrantsCancelled-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents the number of warrants or rights cancelled during the period.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="wint_ClassOfWarrantOrRightNumberOfWarrantsCancelled" xlink:to="wint_ClassOfWarrantOrRightNumberOfWarrantsCancelled-label" xlink:type="arc"/>
    <link:loc xlink:href="wint-20220630.xsd#wint_FinancingOfProductPercentOfRevenueSharedWithFinancer" xlink:label="wint_FinancingOfProductPercentOfRevenueSharedWithFinancer" xlink:type="locator"/>
    <link:label xlink:label="wint_FinancingOfProductPercentOfRevenueSharedWithFinancer-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">wint_FinancingOfProductPercentOfRevenueSharedWithFinancer</link:label>
    <link:label xlink:label="wint_FinancingOfProductPercentOfRevenueSharedWithFinancer-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Financing of Product, Percent of Revenue Shared With Financer</link:label>
    <link:label xlink:label="wint_FinancingOfProductPercentOfRevenueSharedWithFinancer-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">The percent of revenue shared with financer for the financing of a product.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="wint_FinancingOfProductPercentOfRevenueSharedWithFinancer" xlink:to="wint_FinancingOfProductPercentOfRevenueSharedWithFinancer-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SellingGeneralAndAdministrativeExpense" xlink:label="us-gaap_SellingGeneralAndAdministrativeExpense" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_SellingGeneralAndAdministrativeExpense-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">General and administrative</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SellingGeneralAndAdministrativeExpense" xlink:to="us-gaap_SellingGeneralAndAdministrativeExpense-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash flows from financing activities:</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Shares Granted (in shares)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WarrantsAndRightsOutstandingTerm" xlink:label="us-gaap_WarrantsAndRightsOutstandingTerm" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_WarrantsAndRightsOutstandingTerm-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_WarrantsAndRightsOutstandingTerm</link:label>
    <link:label xlink:label="us-gaap_WarrantsAndRightsOutstandingTerm-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Warrants and Rights Outstanding, Term (Year)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WarrantsAndRightsOutstandingTerm" xlink:to="us-gaap_WarrantsAndRightsOutstandingTerm-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:label="us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis [Table Text Block]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:to="us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherLiabilitiesNoncurrent" xlink:label="us-gaap_OtherLiabilitiesNoncurrent" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_OtherLiabilitiesNoncurrent-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other liabilities</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherLiabilitiesNoncurrent" xlink:to="us-gaap_OtherLiabilitiesNoncurrent-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LineOfCreditFacilityLenderDomain" xlink:label="us-gaap_LineOfCreditFacilityLenderDomain" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_LineOfCreditFacilityLenderDomain-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Line of Credit Facility, Lender [Domain]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LineOfCreditFacilityLenderDomain" xlink:to="us-gaap_LineOfCreditFacilityLenderDomain-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Domain]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Issuance of common stock, ATM Program, net of issuance costs (in shares)</link:label>
    <link:label xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Stock Issued During Period, Shares, New Issues (in shares)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues-label" xlink:type="arc"/>
    <link:loc xlink:href="wint-20220630.xsd#wint_SharesAuthorizedToBeOfferedAndSoldUnderOfferingAgreementValue" xlink:label="wint_SharesAuthorizedToBeOfferedAndSoldUnderOfferingAgreementValue" xlink:type="locator"/>
    <link:label xlink:label="wint_SharesAuthorizedToBeOfferedAndSoldUnderOfferingAgreementValue-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">wint_SharesAuthorizedToBeOfferedAndSoldUnderOfferingAgreementValue</link:label>
    <link:label xlink:label="wint_SharesAuthorizedToBeOfferedAndSoldUnderOfferingAgreementValue-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Shares Authorized to Be Offered and Sold Under Offering Agreement, Value</link:label>
    <link:label xlink:label="wint_SharesAuthorizedToBeOfferedAndSoldUnderOfferingAgreementValue-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents the dollar amount of stock authorized to be offered and sold under an offering agreement.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="wint_SharesAuthorizedToBeOfferedAndSoldUnderOfferingAgreementValue" xlink:to="wint_SharesAuthorizedToBeOfferedAndSoldUnderOfferingAgreementValue-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueIssuedForServices" xlink:label="us-gaap_StockIssuedDuringPeriodValueIssuedForServices" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_StockIssuedDuringPeriodValueIssuedForServices-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Issuance of common stock warrants, equity consideration for service agreement</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueIssuedForServices" xlink:to="us-gaap_StockIssuedDuringPeriodValueIssuedForServices-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LineOfCreditFacilityAxis" xlink:label="us-gaap_LineOfCreditFacilityAxis" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_LineOfCreditFacilityAxis-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lender Name [Axis]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LineOfCreditFacilityAxis" xlink:to="us-gaap_LineOfCreditFacilityAxis-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_LiabilitiesAndStockholdersEquity-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_LiabilitiesAndStockholdersEquity</link:label>
    <link:label xlink:label="us-gaap_LiabilitiesAndStockholdersEquity-label" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total liabilities &amp; stockholders&#8217; equity</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_LiabilitiesAndStockholdersEquity-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Issuance of common stock, ATM Program, net of issuance costs</link:label>
    <link:label xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Stock Issued During Period, Value, New Issues</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:to="us-gaap_StockIssuedDuringPeriodValueNewIssues-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accumulated deficit</link:label>
    <link:label xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Retained Earnings (Accumulated Deficit), Total</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RetainedEarningsAccumulatedDeficit" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="us-gaap_ResearchAndDevelopmentExpense" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ResearchAndDevelopmentExpense-label" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Research and development</link:label>
    <link:label xlink:label="us-gaap_ResearchAndDevelopmentExpense-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_ResearchAndDevelopmentExpense</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpense" xlink:to="us-gaap_ResearchAndDevelopmentExpense-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MoneyMarketFundsMember" xlink:label="us-gaap_MoneyMarketFundsMember" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_MoneyMarketFundsMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Money Market Funds [Member]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MoneyMarketFundsMember" xlink:to="us-gaap_MoneyMarketFundsMember-label" xlink:type="arc"/>
    <link:loc xlink:href="wint-20220630.xsd#wint_LiabilityforContingentMilestonePaymentNoncurrent" xlink:label="wint_LiabilityforContingentMilestonePaymentNoncurrent" xlink:type="locator"/>
    <link:label xlink:label="wint_LiabilityforContingentMilestonePaymentNoncurrent-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Restructured debt liability - contingent milestone payments</link:label>
    <link:label xlink:label="wint_LiabilityforContingentMilestonePaymentNoncurrent-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Liability for Contingent Milestone Payment, Noncurrent</link:label>
    <link:label xlink:label="wint_LiabilityforContingentMilestonePaymentNoncurrent-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Amount of restructured debt liability for contingent milestone payments, due after one year or the normal operating cycle, if longer.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="wint_LiabilityforContingentMilestonePaymentNoncurrent" xlink:to="wint_LiabilityforContingentMilestonePaymentNoncurrent-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsAxis" xlink:label="us-gaap_CashAndCashEquivalentsAxis" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_CashAndCashEquivalentsAxis-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash and Cash Equivalents [Axis]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsAxis" xlink:to="us-gaap_CashAndCashEquivalentsAxis-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShortTermDebtTextBlock" xlink:label="us-gaap_ShortTermDebtTextBlock" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ShortTermDebtTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Short-Term Debt [Text Block]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShortTermDebtTextBlock" xlink:to="us-gaap_ShortTermDebtTextBlock-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestExpense" xlink:label="us-gaap_InterestExpense" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_InterestExpense-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_InterestExpense</link:label>
    <link:label xlink:label="us-gaap_InterestExpense-label" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Interest expense</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestExpense" xlink:to="us-gaap_InterestExpense-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:label="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash and Cash Equivalents [Domain]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:to="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Changes in assets and liabilities:</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_StockholdersEquity-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_StockholdersEquity</link:label>
    <link:label xlink:label="us-gaap_StockholdersEquity-label" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total stockholders&#8217; equity</link:label>
    <link:label xlink:label="us-gaap_StockholdersEquity-label" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Balance</link:label>
    <link:label xlink:label="us-gaap_StockholdersEquity-label" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Balance</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_StockholdersEquity-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense" xlink:label="us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Non-cash lease expense</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense" xlink:to="us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_DisclosureTextBlockAbstract-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_DisclosureTextBlockAbstract</link:label>
    <link:label xlink:label="us-gaap_DisclosureTextBlockAbstract-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Notes to Financial Statements</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DisclosureTextBlockAbstract" xlink:to="us-gaap_DisclosureTextBlockAbstract-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventMember" xlink:label="us-gaap_SubsequentEventMember" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_SubsequentEventMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Subsequent Event [Member]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventMember" xlink:to="us-gaap_SubsequentEventMember-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating lease liabilities - non-current portion</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:to="us-gaap_OperatingLeaseLiabilityNoncurrent-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ForeignCurrencyTransactionGainBeforeTax" xlink:label="us-gaap_ForeignCurrencyTransactionGainBeforeTax" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ForeignCurrencyTransactionGainBeforeTax-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_ForeignCurrencyTransactionGainBeforeTax</link:label>
    <link:label xlink:label="us-gaap_ForeignCurrencyTransactionGainBeforeTax-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Foreign Currency Transaction Gain, before Tax</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ForeignCurrencyTransactionGainBeforeTax" xlink:to="us-gaap_ForeignCurrencyTransactionGainBeforeTax-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_StatementClassOfStockAxis-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Class of Stock [Axis]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_StatementClassOfStockAxis-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ForeignCurrencyTransactionLossBeforeTax" xlink:label="us-gaap_ForeignCurrencyTransactionLossBeforeTax" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ForeignCurrencyTransactionLossBeforeTax-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_ForeignCurrencyTransactionLossBeforeTax</link:label>
    <link:label xlink:label="us-gaap_ForeignCurrencyTransactionLossBeforeTax-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Foreign Currency Transaction Loss, before Tax</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ForeignCurrencyTransactionLossBeforeTax" xlink:to="us-gaap_ForeignCurrencyTransactionLossBeforeTax-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ClassOfStockDomain-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Class of Stock [Domain]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_ClassOfStockDomain-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="us-gaap_SubsequentEventTypeAxis" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_SubsequentEventTypeAxis-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Subsequent Event Type [Axis]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeAxis-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_OperatingLeaseLiabilityCurrent-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating lease liabilities - current portion</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiabilityCurrent" xlink:to="us-gaap_OperatingLeaseLiabilityCurrent-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="us-gaap_SubsequentEventTypeDomain" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_SubsequentEventTypeDomain-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Subsequent Event Type [Domain]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventTypeDomain" xlink:to="us-gaap_SubsequentEventTypeDomain-label" xlink:type="arc"/>
    <link:loc xlink:href="wint-20220630.xsd#wint_RestructuredDebtLiabilityContingentMilestonePaymentPolicyPolicyTextBlock" xlink:label="wint_RestructuredDebtLiabilityContingentMilestonePaymentPolicyPolicyTextBlock" xlink:type="locator"/>
    <link:label xlink:label="wint_RestructuredDebtLiabilityContingentMilestonePaymentPolicyPolicyTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Restructured Debt Liability, Contingent Milestone Payment, Policy [Policy Text Block]</link:label>
    <link:label xlink:label="wint_RestructuredDebtLiabilityContingentMilestonePaymentPolicyPolicyTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Disclosure of accounting policy regarding restructured debt liability contingent milestone payment.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="wint_RestructuredDebtLiabilityContingentMilestonePaymentPolicyPolicyTextBlock" xlink:to="wint_RestructuredDebtLiabilityContingentMilestonePaymentPolicyPolicyTextBlock-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_OperatingLeaseRightOfUseAsset-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating lease right-of-use assets</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseRightOfUseAsset" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:label="us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_DeferredIncomeTaxExpenseBenefit-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred income tax benefit</link:label>
    <link:label xlink:label="us-gaap_DeferredIncomeTaxExpenseBenefit-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Deferred Income Tax Expense (Benefit), Total</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:to="us-gaap_DeferredIncomeTaxExpenseBenefit-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeBenefitsAndShareBasedCompensation" xlink:label="us-gaap_EmployeeBenefitsAndShareBasedCompensation" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_EmployeeBenefitsAndShareBasedCompensation-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stock-based compensation</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeBenefitsAndShareBasedCompensation" xlink:to="us-gaap_EmployeeBenefitsAndShareBasedCompensation-label" xlink:type="arc"/>
  </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>10
<FILENAME>wint-20220630_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" standalone="no"?>
<!--Generated by ThunderDome XBRL - 05:34AM UTC 2022-08-11--><link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.windtreetx.com/20220630/role/statement-note-5-fair-value-measurements" xlink:href="wint-20220630.xsd#statement-note-5-fair-value-measurements" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.windtreetx.com/20220630/role/statement-note-5-fair-value-measurements" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueDisclosuresTextBlock" xlink:label="us-gaap_FairValueDisclosuresTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="wint-20220630.xsd#wint_NotesToFinancialStatementsAbstract" xlink:label="wint_NotesToFinancialStatementsAbstract" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="wint_NotesToFinancialStatementsAbstract" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DisclosureTextBlockAbstract-2" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureTextBlockAbstract" xlink:to="us-gaap_FairValueDisclosuresTextBlock" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.windtreetx.com/20220630/role/statement-note-2-basis-of-presentation" xlink:href="wint-20220630.xsd#statement-note-2-basis-of-presentation" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.windtreetx.com/20220630/role/statement-note-2-basis-of-presentation" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BasisOfAccounting" xlink:label="us-gaap_BasisOfAccounting" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="wint-20220630.xsd#wint_NotesToFinancialStatementsAbstract" xlink:label="wint_NotesToFinancialStatementsAbstract" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="wint_NotesToFinancialStatementsAbstract" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DisclosureTextBlockAbstract-2" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureTextBlockAbstract" xlink:to="us-gaap_BasisOfAccounting" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.windtreetx.com/20220630/role/statement-note-1-the-company-and-description-of-business" xlink:href="wint-20220630.xsd#statement-note-1-the-company-and-description-of-business" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.windtreetx.com/20220630/role/statement-note-1-the-company-and-description-of-business" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="wint-20220630.xsd#wint_NotesToFinancialStatementsAbstract" xlink:label="wint_NotesToFinancialStatementsAbstract" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="wint_NotesToFinancialStatementsAbstract" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DisclosureTextBlockAbstract-2" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureTextBlockAbstract" xlink:to="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.windtreetx.com/20220630/role/statement-document-and-entity-information" xlink:href="wint-20220630.xsd#statement-document-and-entity-information" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.windtreetx.com/20220630/role/statement-document-and-entity-information" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AmendmentFlag" xlink:label="dei_AmendmentFlag" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CityAreaCode" xlink:label="dei_CityAreaCode" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CurrentFiscalYearEndDate" xlink:label="dei_CurrentFiscalYearEndDate" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="dei_DocumentFiscalPeriodFocus" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentFiscalYearFocus" xlink:label="dei_DocumentFiscalYearFocus" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentInformationLineItems" xlink:label="dei_DocumentInformationLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentInformationTable" xlink:label="dei_DocumentInformationTable" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentPeriodEndDate" xlink:label="dei_DocumentPeriodEndDate" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentQuarterlyReport" xlink:label="dei_DocumentQuarterlyReport" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentTransitionReport" xlink:label="dei_DocumentTransitionReport" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentType" xlink:label="dei_DocumentType" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressAddressLine1" xlink:label="dei_EntityAddressAddressLine1" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressCityOrTown" xlink:label="dei_EntityAddressCityOrTown" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressPostalZipCode" xlink:label="dei_EntityAddressPostalZipCode" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressStateOrProvince" xlink:label="dei_EntityAddressStateOrProvince" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCentralIndexKey" xlink:label="dei_EntityCentralIndexKey" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="dei_EntityCommonStockSharesOutstanding" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCurrentReportingStatus" xlink:label="dei_EntityCurrentReportingStatus" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityEmergingGrowthCompany" xlink:label="dei_EntityEmergingGrowthCompany" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityFileNumber" xlink:label="dei_EntityFileNumber" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityFilerCategory" xlink:label="dei_EntityFilerCategory" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="dei_EntityIncorporationStateCountryCode" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityInteractiveDataCurrent" xlink:label="dei_EntityInteractiveDataCurrent" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityRegistrantName" xlink:label="dei_EntityRegistrantName" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityShellCompany" xlink:label="dei_EntityShellCompany" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntitySmallBusiness" xlink:label="dei_EntitySmallBusiness" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityTaxIdentificationNumber" xlink:label="dei_EntityTaxIdentificationNumber" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LocalPhoneNumber" xlink:label="dei_LocalPhoneNumber" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_Security12bTitle" xlink:label="dei_Security12bTitle" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_SecurityExchangeName" xlink:label="dei_SecurityExchangeName" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_TradingSymbol" xlink:label="dei_TradingSymbol" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationTable" xlink:to="dei_DocumentInformationLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityCentralIndexKey" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityRegistrantName" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_AmendmentFlag" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_CurrentFiscalYearEndDate" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentFiscalPeriodFocus" xlink:type="arc"/>
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentFiscalYearFocus" xlink:type="arc"/>
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentType" xlink:type="arc"/>
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentQuarterlyReport" xlink:type="arc"/>
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentPeriodEndDate" xlink:type="arc"/>
    <link:presentationArc order="9" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentTransitionReport" xlink:type="arc"/>
    <link:presentationArc order="10" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityFileNumber" xlink:type="arc"/>
    <link:presentationArc order="11" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityIncorporationStateCountryCode" xlink:type="arc"/>
    <link:presentationArc order="12" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityTaxIdentificationNumber" xlink:type="arc"/>
    <link:presentationArc order="13" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityAddressAddressLine1" xlink:type="arc"/>
    <link:presentationArc order="14" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityAddressCityOrTown" xlink:type="arc"/>
    <link:presentationArc order="15" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityAddressStateOrProvince" xlink:type="arc"/>
    <link:presentationArc order="16" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityAddressPostalZipCode" xlink:type="arc"/>
    <link:presentationArc order="17" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_CityAreaCode" xlink:type="arc"/>
    <link:presentationArc order="18" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_LocalPhoneNumber" xlink:type="arc"/>
    <link:presentationArc order="19" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_Security12bTitle" xlink:type="arc"/>
    <link:presentationArc order="20" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_TradingSymbol" xlink:type="arc"/>
    <link:presentationArc order="21" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_SecurityExchangeName" xlink:type="arc"/>
    <link:presentationArc order="22" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityCurrentReportingStatus" xlink:type="arc"/>
    <link:presentationArc order="23" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityInteractiveDataCurrent" xlink:type="arc"/>
    <link:presentationArc order="24" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityFilerCategory" xlink:type="arc"/>
    <link:presentationArc order="25" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntitySmallBusiness" xlink:type="arc"/>
    <link:presentationArc order="26" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityEmergingGrowthCompany" xlink:type="arc"/>
    <link:presentationArc order="27" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityShellCompany" xlink:type="arc"/>
    <link:presentationArc order="28" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityCommonStockSharesOutstanding" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.windtreetx.com/20220630/role/statement-condensed-consolidated-balance-sheets-current-period-unaudited-parentheticals" xlink:href="wint-20220630.xsd#statement-condensed-consolidated-balance-sheets-current-period-unaudited-parentheticals" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.windtreetx.com/20220630/role/statement-condensed-consolidated-balance-sheets-current-period-unaudited-parentheticals" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="us-gaap_CommonStockSharesAuthorized" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesIssued" xlink:label="us-gaap_CommonStockSharesIssued" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="us-gaap_CommonStockSharesOutstanding" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="us-gaap_PreferredStockSharesAuthorized" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockSharesIssued" xlink:label="us-gaap_PreferredStockSharesIssued" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:label="us-gaap_PreferredStockSharesOutstanding" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="us-gaap_StatementOfFinancialPositionAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TreasuryStockShares" xlink:label="us-gaap_TreasuryStockShares" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PreferredStockParOrStatedValuePerShare" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PreferredStockSharesAuthorized" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PreferredStockSharesIssued" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PreferredStockSharesOutstanding" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare" xlink:type="arc"/>
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommonStockSharesAuthorized" xlink:type="arc"/>
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommonStockSharesIssued" xlink:type="arc"/>
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommonStockSharesOutstanding" xlink:type="arc"/>
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_TreasuryStockShares" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.windtreetx.com/20220630/role/statement-note-3-going-concern-and-managements-plans" xlink:href="wint-20220630.xsd#statement-note-3-going-concern-and-managements-plans" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.windtreetx.com/20220630/role/statement-note-3-going-concern-and-managements-plans" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventMember" xlink:label="us-gaap_SubsequentEventMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="us-gaap_SubsequentEventTypeAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="us-gaap_SubsequentEventTypeDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis" xlink:type="locator"/>
    <link:loc xlink:href="wint-20220630.xsd#wint_ATMProgramMember" xlink:label="wint_ATMProgramMember" xlink:type="locator"/>
    <link:loc xlink:href="wint-20220630.xsd#wint_LiquidityDisclosuresTextBlock" xlink:label="wint_LiquidityDisclosuresTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="wint-20220630.xsd#wint_NotesToFinancialStatementsAbstract" xlink:label="wint_NotesToFinancialStatementsAbstract" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="wint_NotesToFinancialStatementsAbstract" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DisclosureTextBlockAbstract-2" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="wint_ATMProgramMember" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_SubsequentEventTypeAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureTextBlockAbstract" xlink:to="wint_LiquidityDisclosuresTextBlock" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.windtreetx.com/20220630/role/statement-note-4-summary-of-significant-accounting-policies" xlink:href="wint-20220630.xsd#statement-note-4-summary-of-significant-accounting-policies" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.windtreetx.com/20220630/role/statement-note-4-summary-of-significant-accounting-policies" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LineOfCreditFacilityAxis" xlink:label="us-gaap_LineOfCreditFacilityAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LineOfCreditFacilityLenderDomain" xlink:label="us-gaap_LineOfCreditFacilityLenderDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongtermDebtTypeAxis" xlink:label="us-gaap_LongtermDebtTypeAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongtermDebtTypeDomain" xlink:label="us-gaap_LongtermDebtTypeDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SignificantAccountingPoliciesTextBlock" xlink:label="us-gaap_SignificantAccountingPoliciesTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis" xlink:type="locator"/>
    <link:loc xlink:href="wint-20220630.xsd#wint_DeerfieldLoanMember" xlink:label="wint_DeerfieldLoanMember" xlink:type="locator"/>
    <link:loc xlink:href="wint-20220630.xsd#wint_DeerfieldManagementLPMember" xlink:label="wint_DeerfieldManagementLPMember" xlink:type="locator"/>
    <link:loc xlink:href="wint-20220630.xsd#wint_ExchangeAndTerminationAgreementMember" xlink:label="wint_ExchangeAndTerminationAgreementMember" xlink:type="locator"/>
    <link:loc xlink:href="wint-20220630.xsd#wint_ManufacturingAndLaboratoryEquipmentMember" xlink:label="wint_ManufacturingAndLaboratoryEquipmentMember" xlink:type="locator"/>
    <link:loc xlink:href="wint-20220630.xsd#wint_NotesToFinancialStatementsAbstract" xlink:label="wint_NotesToFinancialStatementsAbstract" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="wint_NotesToFinancialStatementsAbstract" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DisclosureTextBlockAbstract-2" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LongtermDebtTypeAxis" xlink:to="us-gaap_LongtermDebtTypeDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LineOfCreditFacilityAxis" xlink:to="us-gaap_LineOfCreditFacilityLenderDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="wint_ManufacturingAndLaboratoryEquipmentMember" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_LongtermDebtTypeAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LongtermDebtTypeAxis" xlink:to="wint_DeerfieldLoanMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_TypeOfArrangementAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="wint_ExchangeAndTerminationAgreementMember" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_LineOfCreditFacilityAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LineOfCreditFacilityAxis" xlink:to="wint_DeerfieldManagementLPMember" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureTextBlockAbstract" xlink:to="us-gaap_SignificantAccountingPoliciesTextBlock" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.windtreetx.com/20220630/role/statement-note-6-loans-payable" xlink:href="wint-20220630.xsd#statement-note-6-loans-payable" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.windtreetx.com/20220630/role/statement-note-6-loans-payable" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentAxis" xlink:label="us-gaap_DebtInstrumentAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="us-gaap_DebtInstrumentNameDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LoansPayableMember" xlink:label="us-gaap_LoansPayableMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShortTermDebtTextBlock" xlink:label="us-gaap_ShortTermDebtTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShortTermDebtTypeAxis" xlink:label="us-gaap_ShortTermDebtTypeAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShortTermDebtTypeDomain" xlink:label="us-gaap_ShortTermDebtTypeDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="wint-20220630.xsd#wint_LoanPayableToBankDirectCapitalFinanceMember" xlink:label="wint_LoanPayableToBankDirectCapitalFinanceMember" xlink:type="locator"/>
    <link:loc xlink:href="wint-20220630.xsd#wint_NotesToFinancialStatementsAbstract" xlink:label="wint_NotesToFinancialStatementsAbstract" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="wint_NotesToFinancialStatementsAbstract" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DisclosureTextBlockAbstract-2" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShortTermDebtTypeAxis" xlink:to="us-gaap_ShortTermDebtTypeDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentAxis" xlink:to="us-gaap_DebtInstrumentNameDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_DebtInstrumentAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentAxis" xlink:to="wint_LoanPayableToBankDirectCapitalFinanceMember" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_ShortTermDebtTypeAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShortTermDebtTypeAxis" xlink:to="us-gaap_LoansPayableMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureTextBlockAbstract" xlink:to="us-gaap_ShortTermDebtTextBlock" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.windtreetx.com/20220630/role/statement-note-7-restructured-debt-liability" xlink:href="wint-20220630.xsd#statement-note-7-restructured-debt-liability" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.windtreetx.com/20220630/role/statement-note-7-restructured-debt-liability" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_CounterpartyNameAxis" xlink:label="srt_CounterpartyNameAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebtTextBlock" xlink:label="us-gaap_LongTermDebtTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongtermDebtTypeAxis" xlink:label="us-gaap_LongtermDebtTypeAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongtermDebtTypeDomain" xlink:label="us-gaap_LongtermDebtTypeDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis" xlink:type="locator"/>
    <link:loc xlink:href="wint-20220630.xsd#wint_DeerfieldLoanMember" xlink:label="wint_DeerfieldLoanMember" xlink:type="locator"/>
    <link:loc xlink:href="wint-20220630.xsd#wint_DeerfieldManagementLPMember" xlink:label="wint_DeerfieldManagementLPMember" xlink:type="locator"/>
    <link:loc xlink:href="wint-20220630.xsd#wint_ExchangeAndTerminationAgreementMember" xlink:label="wint_ExchangeAndTerminationAgreementMember" xlink:type="locator"/>
    <link:loc xlink:href="wint-20220630.xsd#wint_NotesToFinancialStatementsAbstract" xlink:label="wint_NotesToFinancialStatementsAbstract" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="wint_NotesToFinancialStatementsAbstract" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DisclosureTextBlockAbstract-2" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_CounterpartyNameAxis" xlink:to="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LongtermDebtTypeAxis" xlink:to="us-gaap_LongtermDebtTypeDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_LongtermDebtTypeAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LongtermDebtTypeAxis" xlink:to="wint_DeerfieldLoanMember" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_TypeOfArrangementAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="wint_ExchangeAndTerminationAgreementMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="srt_CounterpartyNameAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_CounterpartyNameAxis" xlink:to="wint_DeerfieldManagementLPMember" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureTextBlockAbstract" xlink:to="us-gaap_LongTermDebtTextBlock" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.windtreetx.com/20220630/role/statement-note-8-stockholders-equity" xlink:href="wint-20220630.xsd#statement-note-8-stockholders-equity" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.windtreetx.com/20220630/role/statement-note-8-stockholders-equity" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="us-gaap_ClassOfWarrantOrRightAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="us-gaap_ClassOfWarrantOrRightDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventMember" xlink:label="us-gaap_SubsequentEventMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="us-gaap_SubsequentEventTypeAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="us-gaap_SubsequentEventTypeDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis" xlink:type="locator"/>
    <link:loc xlink:href="wint-20220630.xsd#wint_ATMProgramMember" xlink:label="wint_ATMProgramMember" xlink:type="locator"/>
    <link:loc xlink:href="wint-20220630.xsd#wint_March2021PublicOfferingMember" xlink:label="wint_March2021PublicOfferingMember" xlink:type="locator"/>
    <link:loc xlink:href="wint-20220630.xsd#wint_March2021WarrantsMember" xlink:label="wint_March2021WarrantsMember" xlink:type="locator"/>
    <link:loc xlink:href="wint-20220630.xsd#wint_NotesToFinancialStatementsAbstract" xlink:label="wint_NotesToFinancialStatementsAbstract" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="wint_NotesToFinancialStatementsAbstract" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DisclosureTextBlockAbstract-2" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="us-gaap_ClassOfWarrantOrRightDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="wint_ATMProgramMember" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_SubsequentEventTypeAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="wint_March2021PublicOfferingMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_ClassOfWarrantOrRightAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="wint_March2021WarrantsMember" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureTextBlockAbstract" xlink:to="us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.windtreetx.com/20220630/role/statement-note-9-stockbased-compensation" xlink:href="wint-20220630.xsd#statement-note-9-stockbased-compensation" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.windtreetx.com/20220630/role/statement-note-9-stockbased-compensation" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember" xlink:label="srt_RangeMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_TitleOfIndividualAxis" xlink:label="srt_TitleOfIndividualAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameAxis" xlink:label="us-gaap_PlanNameAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:label="us-gaap_RestrictedStockUnitsRSUMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="wint-20220630.xsd#wint_ExecutiveOfficersAndEmployeesMember" xlink:label="wint_ExecutiveOfficersAndEmployeesMember" xlink:type="locator"/>
    <link:loc xlink:href="wint-20220630.xsd#wint_NonplanStockOptionsMember" xlink:label="wint_NonplanStockOptionsMember" xlink:type="locator"/>
    <link:loc xlink:href="wint-20220630.xsd#wint_NotesToFinancialStatementsAbstract" xlink:label="wint_NotesToFinancialStatementsAbstract" xlink:type="locator"/>
    <link:loc xlink:href="wint-20220630.xsd#wint_The2020EquityIncentivePlanMember" xlink:label="wint_The2020EquityIncentivePlanMember" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="wint_NotesToFinancialStatementsAbstract" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DisclosureTextBlockAbstract-2" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_TitleOfIndividualAxis" xlink:to="srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_PlanNameAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameAxis" xlink:to="wint_The2020EquityIncentivePlanMember" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_AwardTypeAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_RestrictedStockUnitsRSUMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="srt_RangeAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_MinimumMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameAxis" xlink:to="wint_NonplanStockOptionsMember" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="srt_TitleOfIndividualAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_TitleOfIndividualAxis" xlink:to="wint_ExecutiveOfficersAndEmployeesMember" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureTextBlockAbstract" xlink:to="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.windtreetx.com/20220630/role/statement-note-10-licensing-and-research-funding-agreements" xlink:href="wint-20220630.xsd#statement-note-10-licensing-and-research-funding-agreements" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.windtreetx.com/20220630/role/statement-note-10-licensing-and-research-funding-agreements" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_CounterpartyNameAxis" xlink:label="srt_CounterpartyNameAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis" xlink:type="locator"/>
    <link:loc xlink:href="wint-20220630.xsd#wint_AerosurfFundingTermSheetMember" xlink:label="wint_AerosurfFundingTermSheetMember" xlink:type="locator"/>
    <link:loc xlink:href="wint-20220630.xsd#wint_CorporatePartnershipLicensingAndResearchFundingAgreementsTextBlock" xlink:label="wint_CorporatePartnershipLicensingAndResearchFundingAgreementsTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="wint-20220630.xsd#wint_LeesPharmaceuticalHoldingsLimitedMember" xlink:label="wint_LeesPharmaceuticalHoldingsLimitedMember" xlink:type="locator"/>
    <link:loc xlink:href="wint-20220630.xsd#wint_NotesToFinancialStatementsAbstract" xlink:label="wint_NotesToFinancialStatementsAbstract" xlink:type="locator"/>
    <link:loc xlink:href="wint-20220630.xsd#wint_TermSheetWithLeeMember" xlink:label="wint_TermSheetWithLeeMember" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="wint_NotesToFinancialStatementsAbstract" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DisclosureTextBlockAbstract-2" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_CounterpartyNameAxis" xlink:to="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_TypeOfArrangementAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="wint_AerosurfFundingTermSheetMember" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="srt_CounterpartyNameAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_CounterpartyNameAxis" xlink:to="wint_LeesPharmaceuticalHoldingsLimitedMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="wint_TermSheetWithLeeMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureTextBlockAbstract" xlink:to="wint_CorporatePartnershipLicensingAndResearchFundingAgreementsTextBlock" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.windtreetx.com/20220630/role/statement-significant-accounting-policies-policies" xlink:href="wint-20220630.xsd#statement-significant-accounting-policies-policies" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.windtreetx.com/20220630/role/statement-significant-accounting-policies-policies" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="us-gaap_AccountingPoliciesAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:label="us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConsolidationPolicyTextBlock" xlink:label="us-gaap_ConsolidationPolicyTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerSharePolicyTextBlock" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:label="us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" xlink:label="us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy" xlink:label="us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxPolicyTextBlock" xlink:label="us-gaap_IncomeTaxPolicyTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PolicyTextBlockAbstract" xlink:label="us-gaap_PolicyTextBlockAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PolicyTextBlockAbstract" xlink:label="us-gaap_PolicyTextBlockAbstract-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentImpairment" xlink:label="us-gaap_PropertyPlantAndEquipmentImpairment" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:label="us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UseOfEstimates" xlink:label="us-gaap_UseOfEstimates" xlink:type="locator"/>
    <link:loc xlink:href="wint-20220630.xsd#wint_EffectOfCOVID19PandemicPolicyTextBlock" xlink:label="wint_EffectOfCOVID19PandemicPolicyTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="wint-20220630.xsd#wint_RestructuredDebtLiabilityContingentMilestonePaymentPolicyPolicyTextBlock" xlink:label="wint_RestructuredDebtLiabilityContingentMilestonePaymentPolicyPolicyTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="wint-20220630.xsd#wint_statement-statement-significant-accounting-policies-policies" xlink:label="wint_statement-statement-significant-accounting-policies-policies" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="wint_statement-statement-significant-accounting-policies-policies" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PolicyTextBlockAbstract-2" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PolicyTextBlockAbstract" xlink:to="us-gaap_AccountingPoliciesAbstract" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ConsolidationPolicyTextBlock" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_UseOfEstimates" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:type="arc"/>
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:type="arc"/>
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentImpairment" xlink:type="arc"/>
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="wint_RestructuredDebtLiabilityContingentMilestonePaymentPolicyPolicyTextBlock" xlink:type="arc"/>
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:type="arc"/>
    <link:presentationArc order="9" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_IncomeTaxPolicyTextBlock" xlink:type="arc"/>
    <link:presentationArc order="10" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_EarningsPerSharePolicyTextBlock" xlink:type="arc"/>
    <link:presentationArc order="11" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="wint_EffectOfCOVID19PandemicPolicyTextBlock" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.windtreetx.com/20220630/role/statement-note-4-summary-of-significant-accounting-policies-tables" xlink:href="wint-20220630.xsd#statement-note-4-summary-of-significant-accounting-policies-tables" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.windtreetx.com/20220630/role/statement-note-4-summary-of-significant-accounting-policies-tables" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock" xlink:label="us-gaap_ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TableTextBlock" xlink:label="us-gaap_TableTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TableTextBlock" xlink:label="us-gaap_TableTextBlock-2" xlink:type="locator"/>
    <link:loc xlink:href="wint-20220630.xsd#wint_statement-statement-note-4-summary-of-significant-accounting-policies-tables" xlink:label="wint_statement-statement-note-4-summary-of-significant-accounting-policies-tables" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="wint_statement-statement-note-4-summary-of-significant-accounting-policies-tables" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_TableTextBlock-2" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TableTextBlock" xlink:to="us-gaap_ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.windtreetx.com/20220630/role/statement-note-5-fair-value-measurements-tables" xlink:href="wint-20220630.xsd#statement-note-5-fair-value-measurements-tables" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.windtreetx.com/20220630/role/statement-note-5-fair-value-measurements-tables" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:label="us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TableTextBlock" xlink:label="us-gaap_TableTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TableTextBlock" xlink:label="us-gaap_TableTextBlock-2" xlink:type="locator"/>
    <link:loc xlink:href="wint-20220630.xsd#wint_statement-statement-note-5-fair-value-measurements-tables" xlink:label="wint_statement-statement-note-5-fair-value-measurements-tables" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="wint_statement-statement-note-5-fair-value-measurements-tables" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_TableTextBlock-2" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TableTextBlock" xlink:to="us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.windtreetx.com/20220630/role/statement-note-9-stockbased-compensation-tables" xlink:href="wint-20220630.xsd#statement-note-9-stockbased-compensation-tables" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.windtreetx.com/20220630/role/statement-note-9-stockbased-compensation-tables" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock" xlink:label="us-gaap_DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TableTextBlock" xlink:label="us-gaap_TableTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TableTextBlock" xlink:label="us-gaap_TableTextBlock-2" xlink:type="locator"/>
    <link:loc xlink:href="wint-20220630.xsd#wint_statement-statement-note-9-stockbased-compensation-tables" xlink:label="wint_statement-statement-note-9-stockbased-compensation-tables" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="wint_statement-statement-note-9-stockbased-compensation-tables" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_TableTextBlock-2" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TableTextBlock" xlink:to="us-gaap_DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TableTextBlock" xlink:to="us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TableTextBlock" xlink:to="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TableTextBlock" xlink:to="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.windtreetx.com/20220630/role/statement-note-3-going-concern-and-managements-plans-details-textual" xlink:href="wint-20220630.xsd#statement-note-3-going-concern-and-managements-plans-details-textual" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.windtreetx.com/20220630/role/statement-note-3-going-concern-and-managements-plans-details-textual" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:label="us-gaap_DeferredIncomeTaxExpenseBenefit-n2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillImpairmentLoss" xlink:label="us-gaap_GoodwillImpairmentLoss-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill" xlink:label="us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesCurrent" xlink:label="us-gaap_LiabilitiesCurrent-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss-n2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit-n2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventMember" xlink:label="us-gaap_SubsequentEventMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="us-gaap_SubsequentEventTypeAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="us-gaap_SubsequentEventTypeDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis" xlink:type="locator"/>
    <link:loc xlink:href="wint-20220630.xsd#wint_ATMProgramMember" xlink:label="wint_ATMProgramMember" xlink:type="locator"/>
    <link:loc xlink:href="wint-20220630.xsd#wint_NoteToFinancialStatementDetailsTextual" xlink:label="wint_NoteToFinancialStatementDetailsTextual" xlink:type="locator"/>
    <link:loc xlink:href="wint-20220630.xsd#wint_SharesAuthorizedToBeOfferedAndSoldUnderOfferingAgreementValue" xlink:label="wint_SharesAuthorizedToBeOfferedAndSoldUnderOfferingAgreementValue-2" xlink:type="locator"/>
    <link:loc xlink:href="wint-20220630.xsd#wint_StockOfferingAgreementPublicFloatLimitationAmount" xlink:label="wint_StockOfferingAgreementPublicFloatLimitationAmount-2" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="wint_NoteToFinancialStatementDetailsTextual" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="wint_ATMProgramMember" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_SubsequentEventTypeAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NetIncomeLoss-n2" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_GoodwillImpairmentLoss-2" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill-2" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DeferredIncomeTaxExpenseBenefit-n2" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit-n2" xlink:type="arc"/>
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="wint_SharesAuthorizedToBeOfferedAndSoldUnderOfferingAgreementValue-2" xlink:type="arc"/>
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues-2" xlink:type="arc"/>
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueNewIssues-2" xlink:type="arc"/>
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock-2" xlink:type="arc"/>
    <link:presentationArc order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="wint_StockOfferingAgreementPublicFloatLimitationAmount-2" xlink:type="arc"/>
    <link:presentationArc order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue-2" xlink:type="arc"/>
    <link:presentationArc order="11" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_LiabilitiesCurrent-2" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.windtreetx.com/20220630/role/statement-note-4-summary-of-significant-accounting-policies-details-textual" xlink:href="wint-20220630.xsd#statement-note-4-summary-of-significant-accounting-policies-details-textual" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.windtreetx.com/20220630/role/statement-note-4-summary-of-significant-accounting-policies-details-textual" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:label="us-gaap_DeferredIncomeTaxExpenseBenefit-n2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Depreciation" xlink:label="us-gaap_Depreciation-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ForeignCurrencyTransactionGainBeforeTax" xlink:label="us-gaap_ForeignCurrencyTransactionGainBeforeTax-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ForeignCurrencyTransactionLossBeforeTax" xlink:label="us-gaap_ForeignCurrencyTransactionLossBeforeTax-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillImpairmentLoss" xlink:label="us-gaap_GoodwillImpairmentLoss-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill" xlink:label="us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LineOfCreditFacilityAxis" xlink:label="us-gaap_LineOfCreditFacilityAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LineOfCreditFacilityLenderDomain" xlink:label="us-gaap_LineOfCreditFacilityLenderDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongtermDebtTypeAxis" xlink:label="us-gaap_LongtermDebtTypeAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongtermDebtTypeDomain" xlink:label="us-gaap_LongtermDebtTypeDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NumberOfReportingUnits" xlink:label="us-gaap_NumberOfReportingUnits-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SeveranceCosts1" xlink:label="us-gaap_SeveranceCosts1-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SupplementalUnemploymentBenefitsSeveranceBenefits" xlink:label="us-gaap_SupplementalUnemploymentBenefitsSeveranceBenefits-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis" xlink:type="locator"/>
    <link:loc xlink:href="wint-20220630.xsd#wint_DeerfieldLoanMember" xlink:label="wint_DeerfieldLoanMember" xlink:type="locator"/>
    <link:loc xlink:href="wint-20220630.xsd#wint_DeerfieldManagementLPMember" xlink:label="wint_DeerfieldManagementLPMember" xlink:type="locator"/>
    <link:loc xlink:href="wint-20220630.xsd#wint_ExchangeAndTerminationAgreementMember" xlink:label="wint_ExchangeAndTerminationAgreementMember" xlink:type="locator"/>
    <link:loc xlink:href="wint-20220630.xsd#wint_LiabilityforContingentMilestonePaymentNoncurrent" xlink:label="wint_LiabilityforContingentMilestonePaymentNoncurrent-2" xlink:type="locator"/>
    <link:loc xlink:href="wint-20220630.xsd#wint_ManufacturingAndLaboratoryEquipmentMember" xlink:label="wint_ManufacturingAndLaboratoryEquipmentMember" xlink:type="locator"/>
    <link:loc xlink:href="wint-20220630.xsd#wint_NoteToFinancialStatementDetailsTextual" xlink:label="wint_NoteToFinancialStatementDetailsTextual" xlink:type="locator"/>
    <link:loc xlink:href="wint-20220630.xsd#wint_NumberOfSharesOfCommonStockPotentiallyIssuableUponTheExerciseOfStockOptionsAndWarrants" xlink:label="wint_NumberOfSharesOfCommonStockPotentiallyIssuableUponTheExerciseOfStockOptionsAndWarrants-2" xlink:type="locator"/>
    <link:loc xlink:href="wint-20220630.xsd#wint_PaymentsForSeveranceCosts" xlink:label="wint_PaymentsForSeveranceCosts-2" xlink:type="locator"/>
    <link:loc xlink:href="wint-20220630.xsd#wint_SeveranceAccrual" xlink:label="wint_SeveranceAccrual-2" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="wint_NoteToFinancialStatementDetailsTextual" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LongtermDebtTypeAxis" xlink:to="us-gaap_LongtermDebtTypeDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LineOfCreditFacilityAxis" xlink:to="us-gaap_LineOfCreditFacilityLenderDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="wint_ManufacturingAndLaboratoryEquipmentMember" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_LongtermDebtTypeAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LongtermDebtTypeAxis" xlink:to="wint_DeerfieldLoanMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_TypeOfArrangementAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="wint_ExchangeAndTerminationAgreementMember" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_LineOfCreditFacilityAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LineOfCreditFacilityAxis" xlink:to="wint_DeerfieldManagementLPMember" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill-2" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NumberOfReportingUnits-2" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_GoodwillImpairmentLoss-2" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ForeignCurrencyTransactionGainBeforeTax-2" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ForeignCurrencyTransactionLossBeforeTax-2" xlink:type="arc"/>
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SeveranceCosts1-2" xlink:type="arc"/>
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="wint_SeveranceAccrual-2" xlink:type="arc"/>
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="wint_PaymentsForSeveranceCosts-2" xlink:type="arc"/>
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SupplementalUnemploymentBenefitsSeveranceBenefits-2" xlink:type="arc"/>
    <link:presentationArc order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_Depreciation-2" xlink:type="arc"/>
    <link:presentationArc order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="wint_LiabilityforContingentMilestonePaymentNoncurrent-2" xlink:type="arc"/>
    <link:presentationArc order="11" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DeferredIncomeTaxExpenseBenefit-n2" xlink:type="arc"/>
    <link:presentationArc order="12" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="wint_NumberOfSharesOfCommonStockPotentiallyIssuableUponTheExerciseOfStockOptionsAndWarrants-2" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.windtreetx.com/20220630/role/statement-note-6-loans-payable-details-textual" xlink:href="wint-20220630.xsd#statement-note-6-loans-payable-details-textual" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.windtreetx.com/20220630/role/statement-note-6-loans-payable-details-textual" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentAxis" xlink:label="us-gaap_DebtInstrumentAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentFaceAmount" xlink:label="us-gaap_DebtInstrumentFaceAmount-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:label="us-gaap_DebtInstrumentInterestRateStatedPercentage-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="us-gaap_DebtInstrumentNameDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentPeriodicPayment" xlink:label="us-gaap_DebtInstrumentPeriodicPayment-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LoansPayableMember" xlink:label="us-gaap_LoansPayableMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LoansPayableToBank" xlink:label="us-gaap_LoansPayableToBank-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShortTermDebtTypeAxis" xlink:label="us-gaap_ShortTermDebtTypeAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShortTermDebtTypeDomain" xlink:label="us-gaap_ShortTermDebtTypeDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="wint-20220630.xsd#wint_LoanPayableToBankDirectCapitalFinanceMember" xlink:label="wint_LoanPayableToBankDirectCapitalFinanceMember" xlink:type="locator"/>
    <link:loc xlink:href="wint-20220630.xsd#wint_NoteToFinancialStatementDetailsTextual" xlink:label="wint_NoteToFinancialStatementDetailsTextual" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="wint_NoteToFinancialStatementDetailsTextual" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShortTermDebtTypeAxis" xlink:to="us-gaap_ShortTermDebtTypeDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentAxis" xlink:to="us-gaap_DebtInstrumentNameDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_DebtInstrumentAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentAxis" xlink:to="wint_LoanPayableToBankDirectCapitalFinanceMember" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_ShortTermDebtTypeAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShortTermDebtTypeAxis" xlink:to="us-gaap_LoansPayableMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DebtInstrumentFaceAmount-2" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DebtInstrumentInterestRateStatedPercentage-2" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DebtInstrumentPeriodicPayment-2" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_LoansPayableToBank-2" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.windtreetx.com/20220630/role/statement-note-7-restructured-debt-liability-details-textual" xlink:href="wint-20220630.xsd#statement-note-7-restructured-debt-liability-details-textual" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.windtreetx.com/20220630/role/statement-note-7-restructured-debt-liability-details-textual" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_CounterpartyNameAxis" xlink:label="srt_CounterpartyNameAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ExtinguishmentOfDebtAmount" xlink:label="us-gaap_ExtinguishmentOfDebtAmount-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongtermDebtTypeAxis" xlink:label="us-gaap_LongtermDebtTypeAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongtermDebtTypeDomain" xlink:label="us-gaap_LongtermDebtTypeDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RepaymentsOfLongTermDebt" xlink:label="us-gaap_RepaymentsOfLongTermDebt-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis" xlink:type="locator"/>
    <link:loc xlink:href="wint-20220630.xsd#wint_ClassOfWarrantOrRightExercisePriceOfCancelledWarrants" xlink:label="wint_ClassOfWarrantOrRightExercisePriceOfCancelledWarrants-2" xlink:type="locator"/>
    <link:loc xlink:href="wint-20220630.xsd#wint_ClassOfWarrantOrRightNumberOfWarrantsCancelled" xlink:label="wint_ClassOfWarrantOrRightNumberOfWarrantsCancelled-2" xlink:type="locator"/>
    <link:loc xlink:href="wint-20220630.xsd#wint_DeerfieldLoanMember" xlink:label="wint_DeerfieldLoanMember" xlink:type="locator"/>
    <link:loc xlink:href="wint-20220630.xsd#wint_DeerfieldManagementLPMember" xlink:label="wint_DeerfieldManagementLPMember" xlink:type="locator"/>
    <link:loc xlink:href="wint-20220630.xsd#wint_ExchangeAndTerminationAgreementMember" xlink:label="wint_ExchangeAndTerminationAgreementMember" xlink:type="locator"/>
    <link:loc xlink:href="wint-20220630.xsd#wint_LiabilityforContingentMilestonePaymentNoncurrent" xlink:label="wint_LiabilityforContingentMilestonePaymentNoncurrent-2" xlink:type="locator"/>
    <link:loc xlink:href="wint-20220630.xsd#wint_NoteToFinancialStatementDetailsTextual" xlink:label="wint_NoteToFinancialStatementDetailsTextual" xlink:type="locator"/>
    <link:loc xlink:href="wint-20220630.xsd#wint_StockIssuedDuringPeriodSharesCancellationOfDebtAndWarrantObligations" xlink:label="wint_StockIssuedDuringPeriodSharesCancellationOfDebtAndWarrantObligations-2" xlink:type="locator"/>
    <link:loc xlink:href="wint-20220630.xsd#wint_StockIssuedDuringPeriodSharesCancellationOfDebtAndWarrantObligationsPercentageOfFullyDilutedSharesOutstanding" xlink:label="wint_StockIssuedDuringPeriodSharesCancellationOfDebtAndWarrantObligationsPercentageOfFullyDilutedSharesOutstanding-2" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="wint_NoteToFinancialStatementDetailsTextual" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_CounterpartyNameAxis" xlink:to="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LongtermDebtTypeAxis" xlink:to="us-gaap_LongtermDebtTypeDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_LongtermDebtTypeAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LongtermDebtTypeAxis" xlink:to="wint_DeerfieldLoanMember" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_TypeOfArrangementAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="wint_ExchangeAndTerminationAgreementMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="srt_CounterpartyNameAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_CounterpartyNameAxis" xlink:to="wint_DeerfieldManagementLPMember" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ExtinguishmentOfDebtAmount-2" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="wint_ClassOfWarrantOrRightNumberOfWarrantsCancelled-2" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="wint_ClassOfWarrantOrRightExercisePriceOfCancelledWarrants-2" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_RepaymentsOfLongTermDebt-2" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="wint_StockIssuedDuringPeriodSharesCancellationOfDebtAndWarrantObligations-2" xlink:type="arc"/>
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="wint_StockIssuedDuringPeriodSharesCancellationOfDebtAndWarrantObligationsPercentageOfFullyDilutedSharesOutstanding-2" xlink:type="arc"/>
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="wint_LiabilityforContingentMilestonePaymentNoncurrent-2" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.windtreetx.com/20220630/role/statement-note-8-stockholders-equity-details-textual" xlink:href="wint-20220630.xsd#statement-note-8-stockholders-equity-details-textual" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.windtreetx.com/20220630/role/statement-note-8-stockholders-equity-details-textual" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="us-gaap_ClassOfWarrantOrRightAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="us-gaap_ClassOfWarrantOrRightDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceOrSaleOfEquity" xlink:label="us-gaap_ProceedsFromIssuanceOrSaleOfEquity-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventMember" xlink:label="us-gaap_SubsequentEventMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="us-gaap_SubsequentEventTypeAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="us-gaap_SubsequentEventTypeDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WarrantsAndRightsOutstandingTerm" xlink:label="us-gaap_WarrantsAndRightsOutstandingTerm-2" xlink:type="locator"/>
    <link:loc xlink:href="wint-20220630.xsd#wint_ATMProgramMember" xlink:label="wint_ATMProgramMember" xlink:type="locator"/>
    <link:loc xlink:href="wint-20220630.xsd#wint_CommissionFeePercentFee" xlink:label="wint_CommissionFeePercentFee-2" xlink:type="locator"/>
    <link:loc xlink:href="wint-20220630.xsd#wint_EquityIssuedDuringPeriodUnitsNewIssues" xlink:label="wint_EquityIssuedDuringPeriodUnitsNewIssues-2" xlink:type="locator"/>
    <link:loc xlink:href="wint-20220630.xsd#wint_March2021PublicOfferingMember" xlink:label="wint_March2021PublicOfferingMember" xlink:type="locator"/>
    <link:loc xlink:href="wint-20220630.xsd#wint_March2021WarrantsMember" xlink:label="wint_March2021WarrantsMember" xlink:type="locator"/>
    <link:loc xlink:href="wint-20220630.xsd#wint_NoteToFinancialStatementDetailsTextual" xlink:label="wint_NoteToFinancialStatementDetailsTextual" xlink:type="locator"/>
    <link:loc xlink:href="wint-20220630.xsd#wint_ProceedsFromIssuanceOrSaleOfEquityGrossAmount" xlink:label="wint_ProceedsFromIssuanceOrSaleOfEquityGrossAmount-2" xlink:type="locator"/>
    <link:loc xlink:href="wint-20220630.xsd#wint_SharesAuthorizedToBeOfferedAndSoldUnderOfferingAgreementValue" xlink:label="wint_SharesAuthorizedToBeOfferedAndSoldUnderOfferingAgreementValue-2" xlink:type="locator"/>
    <link:loc xlink:href="wint-20220630.xsd#wint_StockAndWarrantsIssuedPricePerShare" xlink:label="wint_StockAndWarrantsIssuedPricePerShare-2" xlink:type="locator"/>
    <link:loc xlink:href="wint-20220630.xsd#wint_StockOfferingAgreementPublicFloatLimitationAmount" xlink:label="wint_StockOfferingAgreementPublicFloatLimitationAmount-2" xlink:type="locator"/>
    <link:loc xlink:href="wint-20220630.xsd#wint_StockOfferingAgreementRemainingAmountAvailable" xlink:label="wint_StockOfferingAgreementRemainingAmountAvailable-2" xlink:type="locator"/>
    <link:loc xlink:href="wint-20220630.xsd#wint_UnitsNumberOfSecuritiesCalledByEachUnit" xlink:label="wint_UnitsNumberOfSecuritiesCalledByEachUnit-2" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="wint_NoteToFinancialStatementDetailsTextual" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="us-gaap_ClassOfWarrantOrRightDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="wint_ATMProgramMember" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_SubsequentEventTypeAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="wint_March2021PublicOfferingMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_ClassOfWarrantOrRightAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="wint_March2021WarrantsMember" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="wint_SharesAuthorizedToBeOfferedAndSoldUnderOfferingAgreementValue-2" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="wint_CommissionFeePercentFee-2" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues-2" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueNewIssues-2" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock-2" xlink:type="arc"/>
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="wint_StockOfferingAgreementRemainingAmountAvailable-2" xlink:type="arc"/>
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="wint_StockOfferingAgreementPublicFloatLimitationAmount-2" xlink:type="arc"/>
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="wint_EquityIssuedDuringPeriodUnitsNewIssues-2" xlink:type="arc"/>
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="wint_UnitsNumberOfSecuritiesCalledByEachUnit-2" xlink:type="arc"/>
    <link:presentationArc order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1-2" xlink:type="arc"/>
    <link:presentationArc order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_WarrantsAndRightsOutstandingTerm-2" xlink:type="arc"/>
    <link:presentationArc order="11" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="wint_StockAndWarrantsIssuedPricePerShare-2" xlink:type="arc"/>
    <link:presentationArc order="12" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="wint_ProceedsFromIssuanceOrSaleOfEquityGrossAmount-2" xlink:type="arc"/>
    <link:presentationArc order="13" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ProceedsFromIssuanceOrSaleOfEquity-2" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.windtreetx.com/20220630/role/statement-note-9-stockbased-compensation-details-textual" xlink:href="wint-20220630.xsd#statement-note-9-stockbased-compensation-details-textual" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.windtreetx.com/20220630/role/statement-note-9-stockbased-compensation-details-textual" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember" xlink:label="srt_RangeMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_TitleOfIndividualAxis" xlink:label="srt_TitleOfIndividualAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameAxis" xlink:label="us-gaap_PlanNameAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:label="us-gaap_RestrictedStockUnitsRSUMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="wint-20220630.xsd#wint_ExecutiveOfficersAndEmployeesMember" xlink:label="wint_ExecutiveOfficersAndEmployeesMember" xlink:type="locator"/>
    <link:loc xlink:href="wint-20220630.xsd#wint_NonplanStockOptionsMember" xlink:label="wint_NonplanStockOptionsMember" xlink:type="locator"/>
    <link:loc xlink:href="wint-20220630.xsd#wint_NoteToFinancialStatementDetailsTextual" xlink:label="wint_NoteToFinancialStatementDetailsTextual" xlink:type="locator"/>
    <link:loc xlink:href="wint-20220630.xsd#wint_The2020EquityIncentivePlanMember" xlink:label="wint_The2020EquityIncentivePlanMember" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="wint_NoteToFinancialStatementDetailsTextual" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_TitleOfIndividualAxis" xlink:to="srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_PlanNameAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameAxis" xlink:to="wint_The2020EquityIncentivePlanMember" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_AwardTypeAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_RestrictedStockUnitsRSUMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="srt_RangeAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_MinimumMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameAxis" xlink:to="wint_NonplanStockOptionsMember" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="srt_TitleOfIndividualAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_TitleOfIndividualAxis" xlink:to="wint_ExecutiveOfficersAndEmployeesMember" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1-2" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.windtreetx.com/20220630/role/statement-note-10-licensing-and-research-funding-agreements-details-textual" xlink:href="wint-20220630.xsd#statement-note-10-licensing-and-research-funding-agreements-details-textual" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.windtreetx.com/20220630/role/statement-note-10-licensing-and-research-funding-agreements-details-textual" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_CounterpartyNameAxis" xlink:label="srt_CounterpartyNameAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractualObligation" xlink:label="us-gaap_ContractualObligation-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis" xlink:type="locator"/>
    <link:loc xlink:href="wint-20220630.xsd#wint_AerosurfFundingTermSheetMember" xlink:label="wint_AerosurfFundingTermSheetMember" xlink:type="locator"/>
    <link:loc xlink:href="wint-20220630.xsd#wint_FinancingOfProductPercentOfFinancingThatMustBeRepaidToDiscontinueRevenueSharing" xlink:label="wint_FinancingOfProductPercentOfFinancingThatMustBeRepaidToDiscontinueRevenueSharing-2" xlink:type="locator"/>
    <link:loc xlink:href="wint-20220630.xsd#wint_FinancingOfProductPercentOfRevenueSharedWithFinancer" xlink:label="wint_FinancingOfProductPercentOfRevenueSharedWithFinancer-2" xlink:type="locator"/>
    <link:loc xlink:href="wint-20220630.xsd#wint_LeesPharmaceuticalHoldingsLimitedMember" xlink:label="wint_LeesPharmaceuticalHoldingsLimitedMember" xlink:type="locator"/>
    <link:loc xlink:href="wint-20220630.xsd#wint_NonrefundablePayments" xlink:label="wint_NonrefundablePayments-2" xlink:type="locator"/>
    <link:loc xlink:href="wint-20220630.xsd#wint_NoteToFinancialStatementDetailsTextual" xlink:label="wint_NoteToFinancialStatementDetailsTextual" xlink:type="locator"/>
    <link:loc xlink:href="wint-20220630.xsd#wint_ProceedsForPaymentsToDevelopProduct" xlink:label="wint_ProceedsForPaymentsToDevelopProduct-2" xlink:type="locator"/>
    <link:loc xlink:href="wint-20220630.xsd#wint_TermSheetWithLeeMember" xlink:label="wint_TermSheetWithLeeMember" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="wint_NoteToFinancialStatementDetailsTextual" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_CounterpartyNameAxis" xlink:to="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_TypeOfArrangementAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="wint_AerosurfFundingTermSheetMember" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="srt_CounterpartyNameAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_CounterpartyNameAxis" xlink:to="wint_LeesPharmaceuticalHoldingsLimitedMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="wint_TermSheetWithLeeMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="wint_NonrefundablePayments-2" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="wint_ProceedsForPaymentsToDevelopProduct-2" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="wint_FinancingOfProductPercentOfFinancingThatMustBeRepaidToDiscontinueRevenueSharing-2" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="wint_FinancingOfProductPercentOfRevenueSharedWithFinancer-2" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ContractualObligation-2" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.windtreetx.com/20220630/role/statement-condensed-consolidated-balance-sheets-current-period-unaudited" xlink:href="wint-20220630.xsd#statement-condensed-consolidated-balance-sheets-current-period-unaudited" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.windtreetx.com/20220630/role/statement-condensed-consolidated-balance-sheets-current-period-unaudited" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsPayableCurrent" xlink:label="us-gaap_AccountsPayableCurrent" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="us-gaap_AccruedLiabilitiesCurrent-1" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapital" xlink:label="us-gaap_AdditionalPaidInCapital" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Assets" xlink:label="us-gaap_Assets-3" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsCurrent" xlink:label="us-gaap_AssetsCurrent-3" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsCurrentAbstract" xlink:label="us-gaap_AssetsCurrentAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockValue" xlink:label="us-gaap_CommonStockValue" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredIncomeTaxLiabilitiesNet" xlink:label="us-gaap_DeferredIncomeTaxLiabilitiesNet" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Goodwill" xlink:label="us-gaap_Goodwill" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill" xlink:label="us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Liabilities" xlink:label="us-gaap_Liabilities-3" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity-3" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesCurrent" xlink:label="us-gaap_LiabilitiesCurrent-3" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="us-gaap_LiabilitiesCurrentAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LoansPayableCurrent" xlink:label="us-gaap_LoansPayableCurrent" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherLiabilitiesNoncurrent" xlink:label="us-gaap_OtherLiabilitiesNoncurrent" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockValue" xlink:label="us-gaap_PreferredStockValue" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="us-gaap_PropertyPlantAndEquipmentNet" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedCashAndCashEquivalentsNoncurrent" xlink:label="us-gaap_RestrictedCashAndCashEquivalentsNoncurrent" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="us-gaap_StatementOfFinancialPositionAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity-3" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityAbstract" xlink:label="us-gaap_StockholdersEquityAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TreasuryStockValue" xlink:label="us-gaap_TreasuryStockValue-n8" xlink:type="locator"/>
    <link:loc xlink:href="wint-20220630.xsd#wint_LiabilityforContingentMilestonePaymentNoncurrent" xlink:label="wint_LiabilityforContingentMilestonePaymentNoncurrent" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AssetsCurrentAbstract" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_AssetsCurrent-3" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentNet" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_RestrictedCashAndCashEquivalentsNoncurrent" xlink:type="arc"/>
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset" xlink:type="arc"/>
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill-2" xlink:type="arc"/>
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_Goodwill" xlink:type="arc"/>
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_Assets-3" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_LiabilitiesCurrentAbstract" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_AccountsPayableCurrent" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_AccruedLiabilitiesCurrent-1" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_OperatingLeaseLiabilityCurrent" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_LoansPayableCurrent" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_LiabilitiesCurrent-3" xlink:type="arc"/>
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:type="arc"/>
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="wint_LiabilityforContingentMilestonePaymentNoncurrent" xlink:type="arc"/>
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_OtherLiabilitiesNoncurrent" xlink:type="arc"/>
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_DeferredIncomeTaxLiabilitiesNet" xlink:type="arc"/>
    <link:presentationArc order="9" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_Liabilities-3" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockholdersEquityAbstract" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_PreferredStockValue" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_CommonStockValue" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_AdditionalPaidInCapital" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_TreasuryStockValue-n8" xlink:type="arc"/>
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_StockholdersEquity-3" xlink:type="arc"/>
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_LiabilitiesAndStockholdersEquity-3" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.windtreetx.com/20220630/role/statement-condensed-consolidated-statements-of-cash-flows-unaudited-" xlink:href="wint-20220630.xsd#statement-condensed-consolidated-statements-of-cash-flows-unaudited-" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.windtreetx.com/20220630/role/statement-condensed-consolidated-statements-of-cash-flows-unaudited-" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations-4" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations-5" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect-3" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:label="us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Depreciation" xlink:label="us-gaap_Depreciation-1" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeBenefitsAndShareBasedCompensation" xlink:label="us-gaap_EmployeeBenefitsAndShareBasedCompensation" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ForeignCurrencyTransactionGainLossBeforeTax" xlink:label="us-gaap_ForeignCurrencyTransactionGainLossBeforeTax-n8" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GainLossOnDispositionOfAssets" xlink:label="us-gaap_GainLossOnDispositionOfAssets-n8" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillImpairmentLoss" xlink:label="us-gaap_GoodwillImpairmentLoss" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill" xlink:label="us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccountsPayable" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:label="us-gaap_IncreaseDecreaseInAccruedLiabilities-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets-n9" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities-3" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities-3" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities-3" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:label="us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense" xlink:label="us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment-n8" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment" xlink:label="us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RepaymentsOfShortTermDebt" xlink:label="us-gaap_RepaymentsOfShortTermDebt-n8" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:label="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:label="us-gaap_StatementOfCashFlowsAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="wint-20220630.xsd#wint_IncreaseDecreaseOperatingLeaseLiability" xlink:label="wint_IncreaseDecreaseOperatingLeaseLiability" xlink:type="locator"/>
    <link:loc xlink:href="wint-20220630.xsd#wint_NonCashExpenseRelatedToEquityConsiderationForAServiceAgreement" xlink:label="wint_NonCashExpenseRelatedToEquityConsiderationForAServiceAgreement" xlink:type="locator"/>
    <link:loc xlink:href="wint-20220630.xsd#wint_PrepaymentOfDirectorAndOfficerInsuranceThroughThirdPartyFinancing" xlink:label="wint_PrepaymentOfDirectorAndOfficerInsuranceThroughThirdPartyFinancing" xlink:type="locator"/>
    <link:loc xlink:href="wint-20220630.xsd#wint_ProceedsFromIssuanceOfCommonStockAndWarrants" xlink:label="wint_ProceedsFromIssuanceOfCommonStockAndWarrants" xlink:type="locator"/>
    <link:loc xlink:href="wint-20220630.xsd#wint_ProceedsFromResearchAndDevelopmentFundingArrangement" xlink:label="wint_ProceedsFromResearchAndDevelopmentFundingArrangement" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_NetIncomeLoss" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_Depreciation-1" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_EmployeeBenefitsAndShareBasedCompensation" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="wint_NonCashExpenseRelatedToEquityConsiderationForAServiceAgreement" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_GoodwillImpairmentLoss" xlink:type="arc"/>
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill" xlink:type="arc"/>
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_GainLossOnDispositionOfAssets-n8" xlink:type="arc"/>
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:type="arc"/>
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_ForeignCurrencyTransactionGainLossBeforeTax-n8" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets-n9" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayable-2" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInAccruedLiabilities-2" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="wint_IncreaseDecreaseOperatingLeaseLiability" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities-3" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment-n8" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities-3" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_RepaymentsOfShortTermDebt-n8" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="wint_ProceedsFromIssuanceOfCommonStockAndWarrants" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="wint_ProceedsFromResearchAndDevelopmentFundingArrangement" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities-3" xlink:type="arc"/>
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect-3" xlink:type="arc"/>
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations-4" xlink:type="arc"/>
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations-5" xlink:type="arc"/>
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:to="wint_PrepaymentOfDirectorAndOfficerInsuranceThroughThirdPartyFinancing" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:to="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.windtreetx.com/20220630/role/statement-condensed-consolidated-statements-of-changes-in-stockholders-equity-unaudited-" xlink:href="wint-20220630.xsd#statement-condensed-consolidated-statements-of-changes-in-stockholders-equity-unaudited-" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.windtreetx.com/20220630/role/statement-condensed-consolidated-statements-of-changes-in-stockholders-equity-unaudited-" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="us-gaap_AdditionalPaidInCapitalMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsMember" xlink:label="us-gaap_RetainedEarningsMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharesOutstanding" xlink:label="us-gaap_SharesOutstanding-4" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharesOutstanding" xlink:label="us-gaap_SharesOutstanding-5" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfStockholdersEquityAbstract" xlink:label="us-gaap_StatementOfStockholdersEquityAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueIssuedForServices" xlink:label="us-gaap_StockIssuedDuringPeriodValueIssuedForServices" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity-4" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity-5" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TreasuryStockMember" xlink:label="us-gaap_TreasuryStockMember" xlink:type="locator"/>
    <link:loc xlink:href="wint-20220630.xsd#wint_ATMProgramMember" xlink:label="wint_ATMProgramMember" xlink:type="locator"/>
    <link:loc xlink:href="wint-20220630.xsd#wint_IssuanceOfCommonStockAndCommonStockWarrantsNetOfIssuanceCostsShares" xlink:label="wint_IssuanceOfCommonStockAndCommonStockWarrantsNetOfIssuanceCostsShares" xlink:type="locator"/>
    <link:loc xlink:href="wint-20220630.xsd#wint_IssuanceOfCommonStockAndCommonStockWarrantsNetOfIssuanceCostsValue" xlink:label="wint_IssuanceOfCommonStockAndCommonStockWarrantsNetOfIssuanceCostsValue" xlink:type="locator"/>
    <link:loc xlink:href="wint-20220630.xsd#wint_SharePurchaseAgreementDecember2019Member" xlink:label="wint_SharePurchaseAgreementDecember2019Member" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfStockholdersEquityAbstract" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementClassOfStockAxis" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="wint_ATMProgramMember" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="wint_SharePurchaseAgreementDecember2019Member" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementEquityComponentsAxis" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_CommonStockMember" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_AdditionalPaidInCapitalMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_RetainedEarningsMember" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_TreasuryStockMember" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SharesOutstanding-4" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockholdersEquity-4" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NetIncomeLoss" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="wint_IssuanceOfCommonStockAndCommonStockWarrantsNetOfIssuanceCostsShares" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="wint_IssuanceOfCommonStockAndCommonStockWarrantsNetOfIssuanceCostsValue" xlink:type="arc"/>
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:type="arc"/>
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:type="arc"/>
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:type="arc"/>
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueIssuedForServices" xlink:type="arc"/>
    <link:presentationArc order="9" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SharesOutstanding-5" xlink:type="arc"/>
    <link:presentationArc order="10" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockholdersEquity-5" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.windtreetx.com/20220630/role/statement-note-4-summary-of-significant-accounting-policies-intangible-assets-details" xlink:href="wint-20220630.xsd#statement-note-4-summary-of-significant-accounting-policies-intangible-assets-details" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.windtreetx.com/20220630/role/statement-note-4-summary-of-significant-accounting-policies-intangible-assets-details" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Goodwill" xlink:label="us-gaap_Goodwill-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis" xlink:label="us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill" xlink:label="us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="wint-20220630.xsd#wint_IstaroximeDrugCandidateMember" xlink:label="wint_IstaroximeDrugCandidateMember" xlink:type="locator"/>
    <link:loc xlink:href="wint-20220630.xsd#wint_RostafuroxinDrugCandidateMember" xlink:label="wint_RostafuroxinDrugCandidateMember" xlink:type="locator"/>
    <link:loc xlink:href="wint-20220630.xsd#wint_statement-statement-note-4-summary-of-significant-accounting-policies-intangible-assets-details" xlink:label="wint_statement-statement-note-4-summary-of-significant-accounting-policies-intangible-assets-details" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="wint_statement-statement-note-4-summary-of-significant-accounting-policies-intangible-assets-details" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="wint_IstaroximeDrugCandidateMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="wint_RostafuroxinDrugCandidateMember" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill-2" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_Goodwill-2" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.windtreetx.com/20220630/role/statement-note-9-stockbased-compensation-summary-of-stock-option-activity-details" xlink:href="wint-20220630.xsd#statement-note-9-stockbased-compensation-summary-of-stock-option-activity-details" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.windtreetx.com/20220630/role/statement-note-9-stockbased-compensation-summary-of-stock-option-activity-details" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod-n9" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber-4" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber-5" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice-4" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice-5" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="wint-20220630.xsd#wint_statement-statement-note-9-stockbased-compensation-summary-of-stock-option-activity-details" xlink:label="wint_statement-statement-note-9-stockbased-compensation-summary-of-stock-option-activity-details" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="wint_statement-statement-note-9-stockbased-compensation-summary-of-stock-option-activity-details" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber-4" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice-4" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod-n9" xlink:type="arc"/>
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice-2" xlink:type="arc"/>
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber-5" xlink:type="arc"/>
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice-5" xlink:type="arc"/>
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2-2" xlink:type="arc"/>
    <link:presentationArc order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber-2" xlink:type="arc"/>
    <link:presentationArc order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice-2" xlink:type="arc"/>
    <link:presentationArc order="11" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1-2" xlink:type="arc"/>
    <link:presentationArc order="12" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:type="arc"/>
    <link:presentationArc order="13" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:type="arc"/>
    <link:presentationArc order="14" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.windtreetx.com/20220630/role/statement-note-9-stockbased-compensation-restricted-stock-units-details" xlink:href="wint-20220630.xsd#statement-note-9-stockbased-compensation-restricted-stock-units-details" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.windtreetx.com/20220630/role/statement-note-9-stockbased-compensation-restricted-stock-units-details" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:label="us-gaap_RestrictedStockUnitsRSUMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod-n9" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber-4" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber-5" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue-4" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue-5" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="wint-20220630.xsd#wint_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndExercisable" xlink:label="wint_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndExercisable" xlink:type="locator"/>
    <link:loc xlink:href="wint-20220630.xsd#wint_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndExercisableWeightedAverageGrantDateFairValueEndingBalance" xlink:label="wint_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndExercisableWeightedAverageGrantDateFairValueEndingBalance" xlink:type="locator"/>
    <link:loc xlink:href="wint-20220630.xsd#wint_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndExpectedToVestWeightedAverageGrantDateFairValueEndingBalance" xlink:label="wint_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndExpectedToVestWeightedAverageGrantDateFairValueEndingBalance" xlink:type="locator"/>
    <link:loc xlink:href="wint-20220630.xsd#wint_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityOtherThanOptionsVestedAndExpectedToVestOutstandingNumber" xlink:label="wint_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityOtherThanOptionsVestedAndExpectedToVestOutstandingNumber" xlink:type="locator"/>
    <link:loc xlink:href="wint-20220630.xsd#wint_statement-statement-note-9-stockbased-compensation-restricted-stock-units-details" xlink:label="wint_statement-statement-note-9-stockbased-compensation-restricted-stock-units-details" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="wint_statement-statement-note-9-stockbased-compensation-restricted-stock-units-details" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_AwardTypeAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_RestrictedStockUnitsRSUMember" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber-4" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue-4" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod-n9" xlink:type="arc"/>
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:type="arc"/>
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber-5" xlink:type="arc"/>
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue-5" xlink:type="arc"/>
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="wint_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndExercisable" xlink:type="arc"/>
    <link:presentationArc order="9" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="wint_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndExercisableWeightedAverageGrantDateFairValueEndingBalance" xlink:type="arc"/>
    <link:presentationArc order="10" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="wint_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityOtherThanOptionsVestedAndExpectedToVestOutstandingNumber" xlink:type="arc"/>
    <link:presentationArc order="11" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="wint_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndExpectedToVestWeightedAverageGrantDateFairValueEndingBalance" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.windtreetx.com/20220630/role/statement-note-9-stockbased-compensation-stockbased-compensation-expense-details" xlink:href="wint-20220630.xsd#statement-note-9-stockbased-compensation-stockbased-compensation-expense-details" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.windtreetx.com/20220630/role/statement-note-9-stockbased-compensation-stockbased-compensation-expense-details" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="us-gaap_IncomeStatementLocationAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="us-gaap_IncomeStatementLocationDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SellingGeneralAndAdministrativeExpensesMember" xlink:label="us-gaap_SellingGeneralAndAdministrativeExpensesMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="wint-20220630.xsd#wint_statement-statement-note-9-stockbased-compensation-stockbased-compensation-expense-details" xlink:label="wint_statement-statement-note-9-stockbased-compensation-stockbased-compensation-expense-details" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="wint_statement-statement-note-9-stockbased-compensation-stockbased-compensation-expense-details" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_IncomeStatementLocationAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_ResearchAndDevelopmentExpenseMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_SellingGeneralAndAdministrativeExpensesMember" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense-2" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.windtreetx.com/20220630/role/statement-note-9-stockbased-compensation-stock-options-valuation-assumptions-details" xlink:href="wint-20220630.xsd#statement-note-9-stockbased-compensation-stock-options-valuation-assumptions-details" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.windtreetx.com/20220630/role/statement-note-9-stockbased-compensation-stock-options-valuation-assumptions-details" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="wint-20220630.xsd#wint_statement-statement-note-9-stockbased-compensation-stock-options-valuation-assumptions-details" xlink:label="wint_statement-statement-note-9-stockbased-compensation-stock-options-valuation-assumptions-details" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="wint_statement-statement-note-9-stockbased-compensation-stock-options-valuation-assumptions-details" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate-2" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1-2" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate-2" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.windtreetx.com/20220630/role/statement-condensed-consolidated-statements-of-operations-unaudited" xlink:href="wint-20220630.xsd#statement-condensed-consolidated-statements-of-operations-unaudited" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.windtreetx.com/20220630/role/statement-condensed-consolidated-statements-of-operations-unaudited" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="us-gaap_EarningsPerShareAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareBasic" xlink:label="us-gaap_EarningsPerShareBasic-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareBasicAbstract" xlink:label="us-gaap_EarningsPerShareBasicAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillImpairmentLoss" xlink:label="us-gaap_GoodwillImpairmentLoss" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill" xlink:label="us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest-3" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementAbstract" xlink:label="us-gaap_IncomeStatementAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="us-gaap_IncomeTaxExpenseBenefit-n8" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestExpense" xlink:label="us-gaap_InterestExpense-n8" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentIncomeInterest" xlink:label="us-gaap_InvestmentIncomeInterest" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss-3" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NonoperatingIncomeExpense" xlink:label="us-gaap_NonoperatingIncomeExpense-3" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingExpenses" xlink:label="us-gaap_OperatingExpenses-3" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingExpensesAbstract" xlink:label="us-gaap_OperatingExpensesAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingIncomeLoss" xlink:label="us-gaap_OperatingIncomeLoss-3" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherNonoperatingIncomeExpense" xlink:label="us-gaap_OtherNonoperatingIncomeExpense" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="us-gaap_ResearchAndDevelopmentExpense-1" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SellingGeneralAndAdministrativeExpense" xlink:label="us-gaap_SellingGeneralAndAdministrativeExpense" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic-2" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_OperatingExpensesAbstract" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_ResearchAndDevelopmentExpense-1" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_SellingGeneralAndAdministrativeExpense" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_GoodwillImpairmentLoss" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_OperatingExpenses-3" xlink:type="arc"/>
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_OperatingIncomeLoss-3" xlink:type="arc"/>
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_InvestmentIncomeInterest" xlink:type="arc"/>
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_InterestExpense-n8" xlink:type="arc"/>
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_OtherNonoperatingIncomeExpense" xlink:type="arc"/>
    <link:presentationArc order="9" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_NonoperatingIncomeExpense-3" xlink:type="arc"/>
    <link:presentationArc order="10" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest-3" xlink:type="arc"/>
    <link:presentationArc order="11" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_IncomeTaxExpenseBenefit-n8" xlink:type="arc"/>
    <link:presentationArc order="12" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_NetIncomeLoss-3" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_EarningsPerShareAbstract" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_EarningsPerShareBasic-2" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_EarningsPerShareBasicAbstract" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareBasicAbstract" xlink:to="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic-2" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.windtreetx.com/20220630/role/statement-note-5-fair-value-measurements-assets-and-liabilities-measured-at-fair-value-on-a-recurring-basis-details" xlink:href="wint-20220630.xsd#statement-note-5-fair-value-measurements-assets-and-liabilities-measured-at-fair-value-on-a-recurring-basis-details" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.windtreetx.com/20220630/role/statement-note-5-fair-value-measurements-assets-and-liabilities-measured-at-fair-value-on-a-recurring-basis-details" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsFairValueDisclosure" xlink:label="us-gaap_AssetsFairValueDisclosure-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsAxis" xlink:label="us-gaap_CashAndCashEquivalentsAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:label="us-gaap_CashAndCashEquivalentsFairValueDisclosure-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByMeasurementFrequencyAxis" xlink:label="us-gaap_FairValueByMeasurementFrequencyAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel1Member" xlink:label="us-gaap_FairValueInputsLevel1Member" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementFrequencyDomain" xlink:label="us-gaap_FairValueMeasurementFrequencyDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsRecurringMember" xlink:label="us-gaap_FairValueMeasurementsRecurringMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MoneyMarketFundsMember" xlink:label="us-gaap_MoneyMarketFundsMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:label="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="wint-20220630.xsd#wint_statement-statement-note-5-fair-value-measurements-assets-and-liabilities-measured-at-fair-value-on-a-recurring-basis-details" xlink:label="wint_statement-statement-note-5-fair-value-measurements-assets-and-liabilities-measured-at-fair-value-on-a-recurring-basis-details" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="wint_statement-statement-note-5-fair-value-measurements-assets-and-liabilities-measured-at-fair-value-on-a-recurring-basis-details" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CashAndCashEquivalentsAxis" xlink:to="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueByMeasurementFrequencyAxis" xlink:to="us-gaap_FairValueMeasurementFrequencyDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_FairValueByMeasurementFrequencyAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueByMeasurementFrequencyAxis" xlink:to="us-gaap_FairValueMeasurementsRecurringMember" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_CashAndCashEquivalentsAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CashAndCashEquivalentsAxis" xlink:to="us-gaap_MoneyMarketFundsMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="us-gaap_FairValueInputsLevel1Member" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CashAndCashEquivalentsFairValueDisclosure-2" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AssetsFairValueDisclosure-2" xlink:type="arc"/>
  </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>11
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm139823961219776">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Document And Entity Information - shares<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Aug. 11, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentInformationLineItems', window );"><strong>Document Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0000946486<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">WINDTREE THERAPEUTICS INC /DE/<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CurrentFiscalYearEndDate', window );">Current Fiscal Year End Date</a></td>
<td class="text">--12-31<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentFiscalPeriodFocus', window );">Document Fiscal Period Focus</a></td>
<td class="text">Q2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentFiscalYearFocus', window );">Document Fiscal Year Focus</a></td>
<td class="text">2022<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">10-Q<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentQuarterlyReport', window );">Document Quarterly Report</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Jun. 30,  2022<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentTransitionReport', window );">Document Transition Report</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">000-26422<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">DE<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">94-3171943<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">2600 Kelly Road, Suite 100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">Warrington<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">PA<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">18976-3622<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">215<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">488-9300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Common Stock, $0.001 par value<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">WINT<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCurrentReportingStatus', window );">Entity Current Reporting Status</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityInteractiveDataCurrent', window );">Entity Interactive Data Current</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityFilerCategory', window );">Entity Filer Category</a></td>
<td class="text">Non-accelerated Filer<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntitySmallBusiness', window );">Entity Small Business</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityShellCompany', window );">Entity Shell Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCommonStockSharesOutstanding', window );">Entity Common Stock, Shares Outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">30,627,878<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CurrentFiscalYearEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>End date of current fiscal year in the format --MM-DD.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CurrentFiscalYearEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gMonthDayItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalPeriodFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalPeriodFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fiscalPeriodItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalYearFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalYearFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentInformationLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentInformationLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentQuarterlyReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as an quarterly report.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-Q<br> -Number 240<br> -Section 308<br> -Subsection a<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentQuarterlyReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentTransitionReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as a transition report.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Forms 10-K, 10-Q, 20-F<br> -Number 240<br> -Section 13<br> -Subsection a-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentTransitionReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCurrentReportingStatus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCurrentReportingStatus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFilerCategory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFilerCategory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:filerCategoryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityInteractiveDataCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-T<br> -Number 232<br> -Section 405<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityInteractiveDataCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityShellCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityShellCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntitySmallBusiness">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicates that the company is a Smaller Reporting Company (SRC).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntitySmallBusiness</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>12
<FILENAME>R2.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm139823962153856">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Condensed Consolidated Balance Sheets (Current Period Unaudited) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsCurrentAbstract', window );"><strong>Current Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 11,378<span></span>
</td>
<td class="nump">$ 22,348<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent', window );">Prepaid expenses and other current assets</a></td>
<td class="nump">1,784<span></span>
</td>
<td class="nump">1,143<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsCurrent', window );">Total current assets</a></td>
<td class="nump">13,162<span></span>
</td>
<td class="nump">23,491<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property and equipment, net</a></td>
<td class="nump">307<span></span>
</td>
<td class="nump">1,011<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestrictedCashAndCashEquivalentsNoncurrent', window );">Restricted cash</a></td>
<td class="nump">154<span></span>
</td>
<td class="nump">154<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Operating lease right-of-use assets</a></td>
<td class="nump">2,074<span></span>
</td>
<td class="nump">2,381<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill', window );">Intangible assets</a></td>
<td class="nump">32,070<span></span>
</td>
<td class="nump">32,070<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Goodwill</a></td>
<td class="nump">4,046<span></span>
</td>
<td class="nump">15,682<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Assets', window );">Total assets</a></td>
<td class="nump">51,813<span></span>
</td>
<td class="nump">74,789<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrentAbstract', window );"><strong>Current Liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsPayableCurrent', window );">Accounts payable</a></td>
<td class="nump">1,072<span></span>
</td>
<td class="nump">693<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrent', window );">Accrued expenses</a></td>
<td class="nump">2,823<span></span>
</td>
<td class="nump">3,408<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityCurrent', window );">Operating lease liabilities - current portion</a></td>
<td class="nump">432<span></span>
</td>
<td class="nump">528<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LoansPayableCurrent', window );">Loans payable - current portion</a></td>
<td class="nump">1,007<span></span>
</td>
<td class="nump">294<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrent', window );">Total current liabilities</a></td>
<td class="nump">5,334<span></span>
</td>
<td class="nump">4,923<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityNoncurrent', window );">Operating lease liabilities - non-current portion</a></td>
<td class="nump">1,839<span></span>
</td>
<td class="nump">2,071<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_wint_LiabilityforContingentMilestonePaymentNoncurrent', window );">Restructured debt liability - contingent milestone payments</a></td>
<td class="nump">15,000<span></span>
</td>
<td class="nump">15,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesNoncurrent', window );">Other liabilities</a></td>
<td class="nump">3,800<span></span>
</td>
<td class="nump">3,800<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredIncomeTaxLiabilitiesNet', window );">Deferred tax liabilities</a></td>
<td class="nump">6,643<span></span>
</td>
<td class="nump">7,114<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Liabilities', window );">Total liabilities</a></td>
<td class="nump">32,616<span></span>
</td>
<td class="nump">32,908<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityAbstract', window );"><strong>Stockholders&#8217; Equity:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockValue', window );">Preferred stock, $0.001 par value; 5,000,000 shares authorized; 0 shares issued and outstanding at June 30, 2022 and December 31, 2021</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockValue', window );">Common stock, $0.001 par value; 120,000,000 shares authorized at June 30, 2022 and December 31, 2021; 29,406,196 and 28,268,950 shares issued at June 30, 2022 and December 31, 2021, respectively; 29,406,172 and 28,268,926 shares outstanding at June 30, 2022 and December 31, 2021, respectively</a></td>
<td class="nump">29<span></span>
</td>
<td class="nump">28<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdditionalPaidInCapital', window );">Additional paid-in capital</a></td>
<td class="nump">833,006<span></span>
</td>
<td class="nump">830,231<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
<td class="num">(810,784)<span></span>
</td>
<td class="num">(785,324)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TreasuryStockValue', window );">Treasury stock (at cost); 24 shares</a></td>
<td class="num">(3,054)<span></span>
</td>
<td class="num">(3,054)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Total stockholders&#8217; equity</a></td>
<td class="nump">19,197<span></span>
</td>
<td class="nump">41,881<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesAndStockholdersEquity', window );">Total liabilities &amp; stockholders&#8217; equity</a></td>
<td class="nump">$ 51,813<span></span>
</td>
<td class="nump">$ 74,789<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(a))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdditionalPaidInCapital">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of excess of issue price over par or stated value of stock and from other transaction involving stock or stockholder. Includes, but is not limited to, additional paid-in capital (APIC) for common and preferred stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdditionalPaidInCapital</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Assets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(11))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(12))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(18))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Assets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(9))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3044-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredIncomeTaxLiabilitiesNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after deferred tax asset, of deferred tax liability attributable to taxable differences with jurisdictional netting.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=123427490&amp;loc=d3e31931-109318<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=123427490&amp;loc=d3e31917-109318<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredIncomeTaxLiabilitiesNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Goodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(10)(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (h)<br> -URI https://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 55<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=122137925&amp;loc=d3e14258-109268<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=99380562&amp;loc=d3e13770-109266<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(15))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Goodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of assets, excluding financial assets and goodwill, lacking physical substance and having a projected indefinite period of benefit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Liabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19-26)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Liabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesAndStockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(23))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(25))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(32))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesAndStockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6904-107765<br><br>Reference 21: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.21)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LoansPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of portion of long-term loans payable due within one year or the operating cycle if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LoansPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's right to use underlying asset under operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLiabilitiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.24)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLiabilitiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(9))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseAndOtherAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 360<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124429447&amp;loc=SL124453093-239630<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedCashAndCashEquivalentsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents restricted as to withdrawal or usage, classified as noncurrent. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=SL98516268-108586<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3044-108585<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 954<br> -SubTopic 210<br> -Section 45<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=120413173&amp;loc=SL116631458-115580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedCashAndCashEquivalentsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cumulative amount of the reporting entity's undistributed earnings or deficit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -URI https://asc.fasb.org/extlink&amp;oid=122038336&amp;loc=d3e74512-122707<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TreasuryStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount allocated to treasury stock. Treasury stock is common and preferred shares of an entity that were issued, repurchased by the entity, and are held in its treasury.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 30<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=6405834&amp;loc=d3e23315-112656<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29,30)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6405813&amp;loc=d3e23239-112655<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TreasuryStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_wint_LiabilityforContingentMilestonePaymentNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of restructured debt liability for contingent milestone payments, due after one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">wint_LiabilityforContingentMilestonePaymentNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>wint_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>13
<FILENAME>R3.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm139823961194128">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Condensed Consolidated Balance Sheets (Current Period Unaudited) (Parentheticals) - $ / shares<br></strong></div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Preferred stock, par value (in dollars per share)</a></td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred stock, shares authorized (in shares)</a></td>
<td class="nump">5,000,000<span></span>
</td>
<td class="nump">5,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesIssued', window );">Preferred stock, shares issued (in shares)</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesOutstanding', window );">Preferred stock, shares outstanding (in shares)</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value (in dollars per share)</a></td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, shares authorize (in shares)</a></td>
<td class="nump">120,000,000<span></span>
</td>
<td class="nump">120,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock, shares issued (in shares)</a></td>
<td class="nump">29,406,196<span></span>
</td>
<td class="nump">28,268,950<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common stock, shares outstanding (in shares)</a></td>
<td class="nump">29,406,172<span></span>
</td>
<td class="nump">28,268,926<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TreasuryStockShares', window );">Treasury stock, shares (in shares)</a></td>
<td class="nump">24<span></span>
</td>
<td class="nump">24<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496158-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496158-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TreasuryStockShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of common and preferred shares that were previously issued and that were repurchased by the issuing entity and held in treasury on the financial statement date. This stock has no voting rights and receives no dividends.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29,30)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6405813&amp;loc=d3e23239-112655<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TreasuryStockShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>14
<FILENAME>R4.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm139823961749232">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Condensed Consolidated Statements of Operations (Unaudited) - USD ($)<br> shares in Thousands, $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingExpensesAbstract', window );"><strong>Expenses:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development</a></td>
<td class="nump">$ 2,995<span></span>
</td>
<td class="nump">$ 4,221<span></span>
</td>
<td class="nump">$ 8,340<span></span>
</td>
<td class="nump">$ 8,631<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SellingGeneralAndAdministrativeExpense', window );">General and administrative</a></td>
<td class="nump">2,907<span></span>
</td>
<td class="nump">3,371<span></span>
</td>
<td class="nump">5,895<span></span>
</td>
<td class="nump">8,040<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillImpairmentLoss', window );">Loss on impairment of goodwill</a></td>
<td class="nump">11,636<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">11,636<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill', window );">Loss on impairment of intangible assets</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">37,770<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">37,770<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingExpenses', window );">Total operating expenses</a></td>
<td class="nump">17,538<span></span>
</td>
<td class="nump">45,362<span></span>
</td>
<td class="nump">25,871<span></span>
</td>
<td class="nump">54,441<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Operating loss</a></td>
<td class="num">(17,538)<span></span>
</td>
<td class="num">(45,362)<span></span>
</td>
<td class="num">(25,871)<span></span>
</td>
<td class="num">(54,441)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentIncomeInterest', window );">Interest income</a></td>
<td class="nump">17<span></span>
</td>
<td class="nump">39<span></span>
</td>
<td class="nump">18<span></span>
</td>
<td class="nump">89<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestExpense', window );">Interest expense</a></td>
<td class="num">(13)<span></span>
</td>
<td class="num">(46)<span></span>
</td>
<td class="num">(26)<span></span>
</td>
<td class="num">(87)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherNonoperatingIncomeExpense', window );">Other income (expense), net</a></td>
<td class="nump">201<span></span>
</td>
<td class="num">(352)<span></span>
</td>
<td class="nump">419<span></span>
</td>
<td class="num">(243)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NonoperatingIncomeExpense', window );">Total other income (expense), net</a></td>
<td class="nump">205<span></span>
</td>
<td class="num">(359)<span></span>
</td>
<td class="nump">411<span></span>
</td>
<td class="num">(241)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest', window );">Loss before income taxes</a></td>
<td class="num">(17,333)<span></span>
</td>
<td class="num">(45,721)<span></span>
</td>
<td class="num">(25,460)<span></span>
</td>
<td class="num">(54,682)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Deferred income tax benefit</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">8,332<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">8,332<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">$ (17,333)<span></span>
</td>
<td class="num">$ (37,389)<span></span>
</td>
<td class="num">$ (25,460)<span></span>
</td>
<td class="num">$ (46,350)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Net loss per common share</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasic', window );">Basic and diluted (in dollars per share)</a></td>
<td class="num">$ (0.59)<span></span>
</td>
<td class="num">$ (1.42)<span></span>
</td>
<td class="num">$ (0.87)<span></span>
</td>
<td class="num">$ (2.10)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasicAbstract', window );"><strong>Weighted average number of common shares outstanding</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">Basic and diluted (in shares)</a></td>
<td class="nump">29,200<span></span>
</td>
<td class="nump">26,350<span></span>
</td>
<td class="nump">29,236<span></span>
</td>
<td class="nump">22,047<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1448-109256<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1337-109256<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI https://asc.fasb.org/extlink&amp;oid=128363288&amp;loc=d3e4984-109258<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI https://asc.fasb.org/extlink&amp;oid=128363288&amp;loc=d3e3842-109258<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22644-107794<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1252-109256<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasicAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasicAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillImpairmentLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of loss from the write-down of an asset representing the future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13854-109267<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=99380562&amp;loc=d3e13777-109266<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 55<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=122137925&amp;loc=d3e14258-109268<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillImpairmentLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of impairment loss recognized in the period resulting from the write-down of the carrying amount of an intangible asset (excluding goodwill) to fair value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16373-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 940<br> -SubTopic 20<br> -Section 25<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=126941158&amp;loc=d3e41242-110953<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(10))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(8))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(15))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.7)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32672-109319<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (h)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123586238&amp;loc=d3e38679-109324<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(9))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of the cost of borrowed funds accounted for as interest expense.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=6450988&amp;loc=d3e26243-108391<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124435984&amp;loc=d3e28555-108399<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (210.5-03(11))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04.9)<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentIncomeInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before accretion (amortization) of purchase discount (premium) of interest income on nonoperating securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.7(b))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentIncomeInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669619-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669625-108580<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NonoperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.7)<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NonoperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpensesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpensesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The net result for the period of deducting operating expenses from operating revenues.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherNonoperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of income (expense) related to nonoperating activities, classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.9)<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherNonoperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 912<br> -SubTopic 730<br> -Section 25<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6472174&amp;loc=d3e58812-109433<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 985<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6501960&amp;loc=d3e128462-111756<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SellingGeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate total costs related to selling a firm's product and services, as well as all other general and administrative expenses. Direct selling expenses (for example, credit, warranty, and advertising) are expenses that can be directly linked to the sale of specific products. Indirect selling expenses are expenses that cannot be directly linked to the sale of specific products, for example telephone expenses, Internet, and postal charges. General and administrative expenses include salaries of non-sales personnel, rent, utilities, communication, etc.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.4)<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SellingGeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1448-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>15
<FILENAME>R5.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm139823956477568">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Condensed Consolidated Statements of Changes in Stockholders' Equity (Unaudited) - USD ($)<br> shares in Thousands, $ in Thousands</strong></div></th>
<th class="th">
<div>ATM Program [Member] </div>
<div>Common Stock [Member]</div>
</th>
<th class="th">
<div>ATM Program [Member] </div>
<div>Additional Paid-in Capital [Member]</div>
</th>
<th class="th">
<div>ATM Program [Member] </div>
<div>Retained Earnings [Member]</div>
</th>
<th class="th">
<div>ATM Program [Member] </div>
<div>Treasury Stock [Member]</div>
</th>
<th class="th"><div>ATM Program [Member]</div></th>
<th class="th">
<div>Share Purchase Agreement, December 2019 [Member] </div>
<div>Common Stock [Member]</div>
</th>
<th class="th">
<div>Share Purchase Agreement, December 2019 [Member] </div>
<div>Additional Paid-in Capital [Member]</div>
</th>
<th class="th">
<div>Share Purchase Agreement, December 2019 [Member] </div>
<div>Retained Earnings [Member]</div>
</th>
<th class="th">
<div>Share Purchase Agreement, December 2019 [Member] </div>
<div>Treasury Stock [Member]</div>
</th>
<th class="th"><div>Share Purchase Agreement, December 2019 [Member]</div></th>
<th class="th"><div>Common Stock [Member]</div></th>
<th class="th"><div>Additional Paid-in Capital [Member]</div></th>
<th class="th"><div>Retained Earnings [Member]</div></th>
<th class="th"><div>Treasury Stock [Member]</div></th>
<th class="th"><div>Total</div></th>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance (in shares) at Dec. 31, 2020</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">16,922<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at Dec. 31, 2020</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 17<span></span>
</td>
<td class="nump">$ 790,277<span></span>
</td>
<td class="num">$ (717,688)<span></span>
</td>
<td class="num">$ (3,054)<span></span>
</td>
<td class="nump">$ 69,552<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(8,961)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(8,961)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_wint_IssuanceOfCommonStockAndCommonStockWarrantsNetOfIssuanceCostsShares', window );">Issuance of common stock and common stock warrants, net of issuance costs (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9,230<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_wint_IssuanceOfCommonStockAndCommonStockWarrantsNetOfIssuanceCostsValue', window );">Issuance of common stock and common stock warrants, net of issuance costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 9<span></span>
</td>
<td class="nump">27,381<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">27,390<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based compensation expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,443<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,443<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Issuance of common stock, ATM Program, net of issuance costs (in shares)</a></td>
<td class="nump">105<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Issuance of common stock, ATM Program, net of issuance costs</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 570<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 570<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueIssuedForServices', window );">Issuance of common stock warrants, equity consideration for service agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 494<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 494<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance (in shares) at Mar. 31, 2021</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">26,257<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at Mar. 31, 2021</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 26<span></span>
</td>
<td class="nump">821,165<span></span>
</td>
<td class="num">(726,649)<span></span>
</td>
<td class="num">(3,054)<span></span>
</td>
<td class="nump">91,488<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance (in shares) at Dec. 31, 2020</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">16,922<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at Dec. 31, 2020</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 17<span></span>
</td>
<td class="nump">790,277<span></span>
</td>
<td class="num">(717,688)<span></span>
</td>
<td class="num">$ (3,054)<span></span>
</td>
<td class="nump">69,552<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(46,350)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance (in shares) at Jun. 30, 2021</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">26,704<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at Jun. 30, 2021</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 27<span></span>
</td>
<td class="nump">823,828<span></span>
</td>
<td class="num">(764,038)<span></span>
</td>
<td class="num">$ (3,054)<span></span>
</td>
<td class="nump">56,763<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance (in shares) at Mar. 31, 2021</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">26,257<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at Mar. 31, 2021</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 26<span></span>
</td>
<td class="nump">821,165<span></span>
</td>
<td class="num">(726,649)<span></span>
</td>
<td class="num">(3,054)<span></span>
</td>
<td class="nump">91,488<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="num">(37,389)<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="num">(37,389)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based compensation expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">1,544<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">1,544<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Issuance of common stock, ATM Program, net of issuance costs (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">447<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Issuance of common stock, ATM Program, net of issuance costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1<span></span>
</td>
<td class="nump">1,119<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">1,120<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance (in shares) at Jun. 30, 2021</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">26,704<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at Jun. 30, 2021</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 27<span></span>
</td>
<td class="nump">823,828<span></span>
</td>
<td class="num">(764,038)<span></span>
</td>
<td class="num">$ (3,054)<span></span>
</td>
<td class="nump">56,763<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance (in shares) at Dec. 31, 2021</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">28,269<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at Dec. 31, 2021</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 28<span></span>
</td>
<td class="nump">830,231<span></span>
</td>
<td class="num">(785,324)<span></span>
</td>
<td class="num">(3,054)<span></span>
</td>
<td class="nump">41,881<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(8,127)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(8,127)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based compensation expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">770<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">770<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Issuance of common stock, ATM Program, net of issuance costs (in shares)</a></td>
<td class="nump">200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Issuance of common stock, ATM Program, net of issuance costs</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 205<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 205<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance (in shares) at Mar. 31, 2022</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">28,469<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at Mar. 31, 2022</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 28<span></span>
</td>
<td class="nump">831,206<span></span>
</td>
<td class="num">(793,451)<span></span>
</td>
<td class="num">(3,054)<span></span>
</td>
<td class="nump">34,729<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance (in shares) at Dec. 31, 2021</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">28,269<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at Dec. 31, 2021</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 28<span></span>
</td>
<td class="nump">830,231<span></span>
</td>
<td class="num">(785,324)<span></span>
</td>
<td class="num">$ (3,054)<span></span>
</td>
<td class="nump">41,881<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(25,460)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance (in shares) at Jun. 30, 2022</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">29,406<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at Jun. 30, 2022</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 29<span></span>
</td>
<td class="nump">833,006<span></span>
</td>
<td class="num">(810,784)<span></span>
</td>
<td class="num">$ (3,054)<span></span>
</td>
<td class="nump">19,197<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance (in shares) at Mar. 31, 2022</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">28,469<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at Mar. 31, 2022</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 28<span></span>
</td>
<td class="nump">831,206<span></span>
</td>
<td class="num">(793,451)<span></span>
</td>
<td class="num">(3,054)<span></span>
</td>
<td class="nump">34,729<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="num">(17,333)<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="num">(17,333)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based compensation expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">781<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">781<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Issuance of common stock, ATM Program, net of issuance costs (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">937<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Issuance of common stock, ATM Program, net of issuance costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1<span></span>
</td>
<td class="nump">1,019<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">1,020<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance (in shares) at Jun. 30, 2022</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">29,406<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at Jun. 30, 2022</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 29<span></span>
</td>
<td class="nump">$ 833,006<span></span>
</td>
<td class="num">$ (810,784)<span></span>
</td>
<td class="num">$ (3,054)<span></span>
</td>
<td class="nump">$ 19,197<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 20<br> -Section 55<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=126964447&amp;loc=d3e11149-113907<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 20<br> -Section 55<br> -Paragraph 13<br> -URI https://asc.fasb.org/extlink&amp;oid=126964447&amp;loc=d3e11178-113907<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 35<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126961718&amp;loc=d3e4534-113899<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669619-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669625-108580<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued which are neither cancelled nor held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueIssuedForServices">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value of stock issued in lieu of cash for services contributed to the entity. Value of the stock issued includes, but is not limited to, services contributed by vendors and founders.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueIssuedForServices</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -URI https://asc.fasb.org/extlink&amp;oid=122038336&amp;loc=d3e74512-122707<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_wint_IssuanceOfCommonStockAndCommonStockWarrantsNetOfIssuanceCostsShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents number of shares of common stock and common stock warrants issued net of issuance costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">wint_IssuanceOfCommonStockAndCommonStockWarrantsNetOfIssuanceCostsShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>wint_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_wint_IssuanceOfCommonStockAndCommonStockWarrantsNetOfIssuanceCostsValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents value of common stock and common stock warrants issued net of issuance costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">wint_IssuanceOfCommonStockAndCommonStockWarrantsNetOfIssuanceCostsValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>wint_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>16
<FILENAME>R6.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm139823962291264">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Condensed Consolidated Statements of Cash Flows (Unaudited) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Cash flows from operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">$ (25,460)<span></span>
</td>
<td class="num">$ (46,350)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Adjustments to reconcile net loss to net cash used in operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Depreciation', window );">Depreciation and amortization</a></td>
<td class="nump">488<span></span>
</td>
<td class="nump">93<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeBenefitsAndShareBasedCompensation', window );">Stock-based compensation</a></td>
<td class="nump">1,551<span></span>
</td>
<td class="nump">3,987<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense', window );">Non-cash lease expense</a></td>
<td class="nump">307<span></span>
</td>
<td class="nump">336<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_wint_NonCashExpenseRelatedToEquityConsiderationForAServiceAgreement', window );">Non-cash expense related to equity consideration for a service agreement</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">494<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillImpairmentLoss', window );">Loss on impairment of goodwill</a></td>
<td class="nump">11,636<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill', window );">Loss on impairment of intangible assets</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">37,770<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GainLossOnDispositionOfAssets', window );">Loss on sale and disposal of property and equipment</a></td>
<td class="nump">19<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredIncomeTaxExpenseBenefit', window );">Deferred income tax benefit</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(8,332)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax', window );">Unrealized (gain) loss on foreign exchange rate changes</a></td>
<td class="num">(485)<span></span>
</td>
<td class="nump">300<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract', window );"><strong>Changes in assets and liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets', window );">Prepaid expenses and other current assets</a></td>
<td class="nump">496<span></span>
</td>
<td class="nump">179<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsPayable', window );">Accounts payable</a></td>
<td class="nump">379<span></span>
</td>
<td class="num">(873)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccruedLiabilities', window );">Accrued expenses</a></td>
<td class="num">(576)<span></span>
</td>
<td class="num">(703)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_wint_IncreaseDecreaseOperatingLeaseLiability', window );">Operating lease liabilities</a></td>
<td class="num">(328)<span></span>
</td>
<td class="num">(352)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivities', window );">Net cash used in operating activities</a></td>
<td class="num">(11,973)<span></span>
</td>
<td class="num">(13,451)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract', window );"><strong>Cash flows from investing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment', window );">Proceeds from sale of property and equipment</a></td>
<td class="nump">210<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment', window );">Purchase of property and equipment</a></td>
<td class="num">(13)<span></span>
</td>
<td class="num">(3)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivities', window );">Net cash provided by (used in) investing activities</a></td>
<td class="nump">197<span></span>
</td>
<td class="num">(3)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract', window );"><strong>Cash flows from financing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Proceeds from ATM Program, net of issuance costs</a></td>
<td class="nump">1,225<span></span>
</td>
<td class="nump">1,690<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RepaymentsOfShortTermDebt', window );">Principal payments on loans payable</a></td>
<td class="num">(419)<span></span>
</td>
<td class="num">(2,991)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_wint_ProceedsFromIssuanceOfCommonStockAndWarrants', window );">Proceeds from issuance of common stock and warrants, net of issuance costs</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">27,390<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_wint_ProceedsFromResearchAndDevelopmentFundingArrangement', window );">Proceeds from research and development funding arrangement</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">400<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivities', window );">Net cash provided by financing activities</a></td>
<td class="nump">806<span></span>
</td>
<td class="nump">26,489<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect', window );">Net (decrease) increase in cash, cash equivalents, and restricted cash</a></td>
<td class="num">(10,970)<span></span>
</td>
<td class="nump">13,035<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations', window );">Cash, cash equivalents, and restricted cash - beginning of period</a></td>
<td class="nump">22,502<span></span>
</td>
<td class="nump">17,084<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations', window );">Cash, cash equivalents, and restricted cash - end of period</a></td>
<td class="nump">11,532<span></span>
</td>
<td class="nump">30,119<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NoncashInvestingAndFinancingItemsAbstract', window );"><strong>Supplementary disclosure of non-cash activity:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_wint_PrepaymentOfDirectorAndOfficerInsuranceThroughThirdPartyFinancing', window );">Prepayment of insurance through third-party financing</a></td>
<td class="nump">1,132<span></span>
</td>
<td class="nump">1,321<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability', window );">Operating lease liabilities arising from obtaining right-of-use assets</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 2,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including, but not limited to, disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=SL98516268-108586<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3521-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3044-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 230<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=123444420&amp;loc=d3e33268-110906<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredIncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred income tax expense (benefit) pertaining to income (loss) from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.1)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.2)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32639-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredIncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Depreciation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Depreciation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeBenefitsAndShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for employee benefit and equity-based compensation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeBenefitsAndShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before tax of foreign currency transaction realized and unrealized gain (loss) recognized in the income statement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=125521441&amp;loc=d3e30690-110894<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 20<br> -Section 35<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=123602790&amp;loc=d3e30226-110892<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 10<br> -Section 45<br> -Paragraph 17<br> -URI https://asc.fasb.org/extlink&amp;oid=126980362&amp;loc=d3e28228-110885<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124440516&amp;loc=d3e30840-110895<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ForeignCurrencyTransactionGainLossBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainLossOnDispositionOfAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of gain (loss) on sale or disposal of property, plant and equipment assets, excluding oil and gas property and timber property.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=126905981&amp;loc=d3e2443-110228<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=109226691&amp;loc=d3e2941-110230<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainLossOnDispositionOfAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillImpairmentLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of loss from the write-down of an asset representing the future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13854-109267<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=99380562&amp;loc=d3e13777-109266<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 55<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=122137925&amp;loc=d3e14258-109268<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillImpairmentLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of impairment loss recognized in the period resulting from the write-down of the carrying amount of an intangible asset (excluding goodwill) to fair value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16373-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccruedLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate amount of expenses incurred but not yet paid.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccruedLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOperatingCapitalAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in prepaid expenses, and assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3536-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3521-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669619-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669625-108580<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NoncashInvestingAndFinancingItemsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NoncashInvestingAndFinancingItemsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization expense for right-of-use asset from operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquirePropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the additional capital contribution to the entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the sale of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3179-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RepaymentsOfShortTermDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for a borrowing having initial term of repayment within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RepaymentsOfShortTermDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in right-of-use asset obtained in exchange for operating lease liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI https://asc.fasb.org/extlink&amp;oid=123414884&amp;loc=SL77918982-209971<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_wint_IncreaseDecreaseOperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the operating lease liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">wint_IncreaseDecreaseOperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>wint_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_wint_NonCashExpenseRelatedToEquityConsiderationForAServiceAgreement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents non-cash expense related to equity consideration for a service agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">wint_NonCashExpenseRelatedToEquityConsiderationForAServiceAgreement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>wint_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_wint_PrepaymentOfDirectorAndOfficerInsuranceThroughThirdPartyFinancing">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of prepayment of director and officer insurance through third party financing.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">wint_PrepaymentOfDirectorAndOfficerInsuranceThroughThirdPartyFinancing</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>wint_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_wint_ProceedsFromIssuanceOfCommonStockAndWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the additional capital contribution to the entity and from issuance of rights to purchase common shares at predetermined price.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">wint_ProceedsFromIssuanceOfCommonStockAndWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>wint_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_wint_ProceedsFromResearchAndDevelopmentFundingArrangement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from research and development funding arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">wint_ProceedsFromResearchAndDevelopmentFundingArrangement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>wint_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>17
<FILENAME>R7.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm139823961216976">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note 1 - The Company and Description of Business<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureTextBlockAbstract', window );"><strong>Notes to Financial Statements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock', window );">Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block]</a></td>
<td class="text">
   <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><span style="color:#333333;"><b>Note <em style="font: inherit;">1</em> &#8211; The Company and Description of Business</b></span></p>
   <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&#160;</p>
   <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><span style="color:#333333;">We are a clinical-stage&#160;biopharmaceutical company focused on the development of novel therapeutics intended to address significant unmet medical needs in important acute care markets. Our development programs are primarily focused on the treatment of acute cardiovascular diseases and secondarily on acute pulmonary diseases. Our lead product candidate, istaroxime, is a <em style="font: inherit;">first</em>-in-class, dual-acting agent being developed to improve cardiac function in patients with acute heart failure, or AHF, with a potentially differentiated safety profile from existing treatments. Istaroxime demonstrated significant improvement in both diastolic and systolic aspects of cardiac function and was generally well tolerated in <em style="font: inherit;">three</em> Phase <em style="font: inherit;">2</em> clinical trials.&#160;Istaroxime has been granted Fast Track designation for the treatment of AHF by the U.S. Food and Drug Administration, or FDA.&#160;Based on the profile observed in our Phase <em style="font: inherit;">2</em> clinical studies in AHF, where istaroxime significantly improved cardiac function and systolic blood pressure in acute decompensated heart failure patients, we initiated a Phase <em style="font: inherit;">2</em> global clinical study to evaluate istaroxime for the treatment of early cardiogenic shock (Society for Cardiovascular Angiography and Interventions&#160;Stage B shock),&#160;a severe form of AHF characterized by very low blood pressure and risk for hypoperfusion to critical organs. We completed this Phase <em style="font: inherit;">2</em> global clinical study and, in <em style="font: inherit;"> April 2022, </em>announced positive topline results with istaroxime in raising systolic blood pressure.&#160;In <em style="font: inherit;"> May 2022, </em>we presented the study results at the European Society of Cardiology Heart Failure Meeting in Madrid, Spain.</span></p>
   <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&#160;</p>
   <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><span style="color:#333333;">Our heart failure cardiovascular portfolio also includes sarco endoplasmic reticulum <em style="font: inherit;">Ca2</em>+ -ATPase <em style="font: inherit;">2a,</em> or <em style="font: inherit;">SERCA2a,</em> activators which activate <em style="font: inherit;">SERCA2a.</em> This research program is evaluating these preclinical product candidates, including oral and intravenous <em style="font: inherit;">SERCA2a</em> activator heart failure compounds. As potential oral agents, these candidates would be developed for chronic heart failure. In addition, our cardiovascular drug product candidates include rostafuroxin, a novel product&#160;candidate&#160;for the treatment of hypertension in patients with a specific genetic profile. We are pursuing potential licensing arrangements and/or other strategic partnerships and do <em style="font: inherit;">not</em> intend to advance this product&#160;candidate&#160;without securing such an arrangement or partnership.</span></p>
   <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&#160;</p>
   <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><span style="color:#333333;">Our pulmonary product candidate portfolio consists of a <em style="font: inherit;">KL4</em> surfactant platform&#160;to address a range of serious respiratory conditions in children and adults. In <em style="font: inherit;"> January 2022, </em>we completed enrollment of <em style="font: inherit;">20</em> patients in our Phase <em style="font: inherit;">2</em> study of lucinactant (<em style="font: inherit;">KL4</em> surfactant) for patients with severe novel coronavirus, or COVID-<em style="font: inherit;">19,</em> associated acute respiratory distress syndrome, or ARDS. The study demonstrated that intratracheal administration of reconstituted lyophilized lucinactant was generally safe and well tolerated. Oxygenation and other physiological parameters were stable to improved after dosing, supporting the feasibility of this treatment approach to develop a potential treatment for critically ill patients with ARDS due to COVID-<em style="font: inherit;">19</em> or other causes.</span></p>
   <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&#160;</p>
   <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><span style="color:#333333;">Previously, we were also developing AEROSURF (lucinactant for inhalation), a novel drug/medical device combination product for noninvasive delivery of aerosolized <em style="font: inherit;">KL4</em> surfactant using our aerosol delivery system, or ADS, technology for the treatment of respiratory distress syndrome in premature infants. In order to focus our resources on the&#160;development of our istaroxime pipeline, we suspended all internal AEROSURF clinical activities in <em style="font: inherit;"> November 2020, </em>and in <em style="font: inherit;"> January 2022 </em>we began to reduce all other costs related to the <em style="font: inherit;">KL4</em> surfactant platform that were <em style="font: inherit;">not</em> already transferred to our licensee in Asia, Lee&#8217;s Pharmaceutical (HK) Ltd., or Lee&#8217;s (HK), under the terms of our License, Development and Commercialization Agreement between us and Lee&#8217;s (HK) dated as of <em style="font: inherit;"> June 12, 2017, </em>as amended, or the Asia License Agreement. To support the future development of our <em style="font: inherit;">KL4</em> surfactant platform in markets outside of Asia, including the U.S., we are pursuing a potential licensing transaction.</span></p>
   <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&#160;</p>
   <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><span style="color:#333333;">Our ability to advance our development programs is dependent upon our ability to secure additional capital in both the near and long-term, through public or private securities offerings; convertible debt financings; and/or potential strategic opportunities, including licensing agreements, drug product development, and marketing collaboration arrangements, pharmaceutical research cooperation arrangements, and/or other similar transactions in geographic markets, including the U.S., and/or through potential grants and other funding commitments from U.S. government agencies, in each case, if available. We have engaged with potential counterparties in various markets and will continue to pursue non-dilutive sources of capital as well as potential private and public securities offerings. There can be <em style="font: inherit;">no</em> assurance, however, that we will be able to identify and enter into public or private securities offerings on acceptable terms and in amounts sufficient to meet our needs or qualify for non-dilutive funding opportunities under any grant programs sponsored by U.S. government agencies, private foundations, and/or leading academic institutions, or identify and enter into any strategic transactions that will provide the additional capital that we will require. If <em style="font: inherit;">none</em> of these alternatives is available, or if available and&#160;we are unable to raise sufficient capital through such transactions, we potentially could be forced to limit or cease our development activities, which would have a material adverse effect on our business, financial condition, and results of operations.</span></p>
   <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&#160;</p>
   <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><span style="color:#333333;">The reader is referred to, and encouraged to read in its entirety, &#8220;Item <em style="font: inherit;">1</em> &#8211; Business&#8221; in our Annual Report on Form <em style="font: inherit;">10</em>-K for the year ended </span><span style="color:#333333;"><em style="font: inherit;"> December 31, 2021</em></span><span style="color:#333333;"> that we filed with the Securities and Exchange Commission, or the SEC, on </span><span style="color:#333333;"><em style="font: inherit;"> March 31, 2022</em></span><span style="color:#333333;">, which contains a discussion of our business and business plans, as well as information concerning our proprietary technologies and our current and planned development programs.</span></p>
  <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureTextBlockAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureTextBlockAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for organization, consolidation and basis of presentation of financial statements disclosure.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -URI https://asc.fasb.org/topic&amp;trid=2122149<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -URI https://asc.fasb.org/topic&amp;trid=2197479<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>18
<FILENAME>R8.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm139823965568736">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note 2 - Basis of Presentation<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureTextBlockAbstract', window );"><strong>Notes to Financial Statements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BasisOfAccounting', window );">Basis of Accounting [Text Block]</a></td>
<td class="text">
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">&#160;</p>


   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;"><span style="color:#333333;"><b>Note <em style="font: inherit;">2</em> &#8211; Basis of Presentation</b></span></p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin: 0pt; text-align: left;">&#160;</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin: 0pt; text-align: left;"><span style="color:#333333;">The&#160;interim unaudited condensed consolidated financial statements are prepared in accordance with accounting principles generally accepted in the U.S., or US GAAP, for interim financial information in accordance with the instructions to Form <em style="font: inherit;">10</em>-Q and include accounts of Windtree Therapeutics, Inc. and its wholly owned subsidiaries. Accordingly, they do <em style="font: inherit;">not</em> include all of the information and footnotes required by US GAAP for complete consolidated financial statements. Intercompany balances and transactions have been eliminated in consolidation. All adjustments (consisting of normally recurring accruals) considered for fair presentation have been included.&#160;Operating results for the </span><span style="color:#333333;"><em style="font: inherit;">three</em> and <em style="font: inherit;">six</em> months ended <em style="font: inherit;"> June 30, 2022</em></span><span style="color:#333333;"> are <em style="font: inherit;">not</em> necessarily indicative of the results that <em style="font: inherit;"> may </em>be expected for the year ending </span><span style="color:#333333;"><em style="font: inherit;"> December 31, 2022</em></span><span style="color:#333333;">. The consolidated balance sheet at </span><span style="color:#333333;"><em style="font: inherit;"> December 31, 2021</em></span><span style="color:#333333;"> has been derived from the Company&#8217;s audited consolidated financial statements.&#160;There have been <em style="font: inherit;">no</em> changes to our significant accounting policies since </span><span style="color:#333333;"><em style="font: inherit;"> December 31, 2021</em></span><span style="color:#333333;">.&#160;The accompanying interim unaudited condensed consolidated financial statements should be read in conjunction with our annual audited consolidated financial statements and related notes as of and for the year ended </span><span style="color:#333333;"><em style="font: inherit;"> December 31, 2021</em></span><span style="color:#333333;"> contained in our Annual Report on Form <em style="font: inherit;">10</em>-K for the year ended </span><span style="color:#333333;"><em style="font: inherit;"> December 31, 2021</em></span><span style="color:#333333;">.</span></p>
  <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BasisOfAccounting">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -URI https://asc.fasb.org/topic&amp;trid=2122369<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BasisOfAccounting</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureTextBlockAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureTextBlockAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>19
<FILENAME>R9.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm139824052659424">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note 3 - Going Concern and Management's Plans<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureTextBlockAbstract', window );"><strong>Notes to Financial Statements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_wint_LiquidityDisclosuresTextBlock', window );">Liquidity Disclosures [Text Block]</a></td>
<td class="text">
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;"><span style="color:#333333;"><b>Note <em style="font: inherit;">3</em> &#8211; Going Concern and Management&#8217;s Plans</b></span></p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">&#160;</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin: 0pt; text-align: left;"><span style="color:#333333;">We are subject to risks common to companies in the biotechnology industry, including but <em style="font: inherit;">not</em> limited to, the need for additional capital, risks of failure of preclinical and clinical studies, the need to obtain marketing approval and reimbursement for any drug product candidate that we <em style="font: inherit;"> may </em>identify and develop, the need to successfully commercialize and gain market acceptance of our product candidates, dependence on key personnel, protection of proprietary technology, compliance with government regulations, development of technological innovations by competitors, and&#160;risks associated with our international locations and activities abroad, including but <em style="font: inherit;">not</em> limited to having foreign suppliers, manufacturers, and clinical sites in support of our development activities.</span></p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin: 0pt; text-align: left;">&#160;</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin: 0pt; text-align: left;"><span style="color:#333333;">We have incurred net losses since inception. Our net loss was </span><span style="color:#333333;">$17.3</span><span style="color:#333333;">&#160;million and </span><span style="color:#333333;">$37.4</span><span style="color:#333333;">&#160;million, respectively, for the <em style="font: inherit;">three</em>-month periods ended </span><span style="color:#333333;"><em style="font: inherit;"> June 30, 2022 </em>and <em style="font: inherit;">2021</em></span><span style="color:#333333;">. Our net loss was&#160;</span><span style="color:#333333;">$25.5</span><span style="color:#333333;"> million and&#160;</span><span style="color:#333333;">$46.4</span><span style="color:#333333;">&#160;million, respectively, for the&#160;</span><span style="color:#333333;"><em style="font: inherit;">six</em></span><span style="color:#333333;">-month periods ended </span><span style="color:#333333;"><em style="font: inherit;"> June 30, 2022 </em>and <em style="font: inherit;">2021</em></span><span style="color:#333333;">.&#160;Included in our net loss for the&#160;<em style="font: inherit;">three</em>&#160;and&#160;</span><span style="color:#333333;"><em style="font: inherit;">six</em> months ended <em style="font: inherit;"> June 30, 2022</em></span><span style="color:#333333;">&#160;is an&#160;</span><span style="color:#333333;">$11.6</span><span style="color:#333333;"> million loss on impairment of goodwill, and included in our net loss for the <em style="font: inherit;">three</em> and <em style="font: inherit;">six</em> months ended&#160;</span><span style="color:#333333;"><em style="font: inherit;"> June 30, 2021</em></span><span style="color:#333333;"> is a&#160;</span><span style="color:#333333;">$37.8</span><span style="color:#333333;"> million loss on impairment of intangible assets&#160;related to rostafuroxin&#160;and a related&#160;</span><span style="color:#333333;">$8.3</span><span style="color:#333333;"> million deferred income tax benefit (<i>see</i>,&#160;</span><span style="color:#333333;">Note <em style="font: inherit;">4</em> &#8211; Summary of Significant Accounting Policies</span><span style="color:#333333;">).&#160;We expect to continue to incur operating losses for at least the next several years. As of </span><span style="color:#333333;"><em style="font: inherit;"> June 30, 2022</em></span><span style="color:#333333;">, we had an accumulated deficit of </span><span style="color:#333333;">$810.8</span><span style="color:#333333;">&#160;million. Our future success is dependent on our ability to fund and develop our product candidates, and ultimately upon our ability to attain profitable operations. We have devoted substantially all of our financial resources and efforts to research and development and general and administrative expense to support such research and development. Net losses and negative cash flows have had, and will continue to have, an adverse effect on our stockholders&#8217;&#160;equity and working capital, and accordingly, our ability to execute our future operating plans.</span></p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin: 0pt; text-align: left;">&#160;</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin: 0pt; text-align: left;"><span style="color:#333333;">We are party to an At-The-Market Offering Agreement&#160;with Ladenburg Thalmann &amp; Co. Inc., or Ladenburg,&#160;pursuant to which we <em style="font: inherit;"> may </em>offer and sell, from time to time at our sole discretion, up to a maximum of&#160;</span><span style="color:#333333;">$10.0</span><span style="color:#333333;"> million of shares of our common stock through Ladenburg as agent and/or principal through an at-the-market program, or the ATM Program. For the&#160;</span><span style="color:#333333;"><em style="font: inherit;">six</em> months ended <em style="font: inherit;"> June 30, 2022</em></span><span style="color:#333333;">, we sold&#160;</span><span style="color:#333333;">1,137,246</span><span style="color:#333333;">&#160;shares&#160;of our common stock under the ATM Program&#160;resulting in aggregate gross proceeds to us of approximately&#160;</span><span style="color:#333333;">$1.3</span><span style="color:#333333;">&#160;million and net proceeds of approximately&#160;</span><span style="color:#333333;">$1.2</span><span style="color:#333333;">&#160;million.&#160;During <em style="font: inherit;"> July </em>and <em style="font: inherit;"> August 2022,&#160;</em>we sold&#160;</span><span style="color:#333333;">1,221,706</span><span style="color:#333333;"> shares of our common stock under the ATM Program&#160;resulting in aggregate gross and net proceeds to us of approximately&#160;</span><span style="color:#333333;">$0.6</span><span style="color:#333333;"> million&#160;(<i>see</i>,&#160;</span><span style="color:#333333;">Note <em style="font: inherit;">8</em> &#8211; Stockholders&#8217; Equity</span><span style="color:#333333;">).</span></p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin: 0pt; text-align: left;">&#160;</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin: 0pt; text-align: left;"><span style="color:#333333;">The shares of common stock issued and sold under the ATM Program are registered under our Registration Statement on Form S-<em style="font: inherit;">3</em> (File <em style="font: inherit;">No.</em> <em style="font: inherit;">333</em>-<em style="font: inherit;">248874</em>), which was declared effective by the SEC on <em style="font: inherit;"> September 29, 2020. </em>We are currently subject to the limitations contained in General Instruction <em style="font: inherit;">I.B.6</em> of Form S-<em style="font: inherit;">3.</em> As a result, we are limited in selling <em style="font: inherit;">no</em> more than <em style="font: inherit;">one</em>-<em style="font: inherit;">third</em> of the aggregate market value of the equity held by non-affiliates, or the public float, during any <em style="font: inherit;">12</em>-month period. If our public float increases to $75 million or more, we will <em style="font: inherit;">no</em> longer be subject to such limitations.</span></p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin: 0pt; text-align: left;">&#160;</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin: 0pt; text-align: left;"><span style="color:#333333;">As of&#160;</span><span style="color:#333333;"><em style="font: inherit;"> June 30, 2022</em></span><span style="color:#333333;">,&#160;we had cash and cash equivalents of&#160;</span><span style="color:#333333;">$11.4</span><span style="color:#333333;"> million and current liabilities of&#160;</span><span style="color:#333333;">$5.3</span><span style="color:#333333;"> million. We believe that we have sufficient resources available to support our development activities and fund our business operations&#160;into the <em style="font: inherit;">first</em> quarter of <em style="font: inherit;">2023.</em> However, we do <em style="font: inherit;">not</em> have sufficient cash and cash equivalents as of the date of this Quarterly Report on Form <em style="font: inherit;">10</em>-Q to support our operations for at least the <em style="font: inherit;">12</em> months following the date that the financial statements are issued. These conditions raise substantial doubt about our ability to continue as a going concern through <em style="font: inherit;">12</em> months after the date that the financial statements are issued.</span></p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin: 0pt; text-align: left;">&#160;</p>
    &#160;
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin: 0pt; text-align: left;"><span style="color:#333333;">To alleviate the conditions that raise substantial doubt about our ability to continue as a going concern, management plans&#160;to secure additional capital, potentially through a combination of public or private securities&#160;offerings, convertible debt financings, and/or strategic transactions, including potential licensing arrangements, alliances, and drug product collaborations focused on specified geographic markets; however, <em style="font: inherit;">none</em> of these alternatives are committed at this time. There can be <em style="font: inherit;">no</em> assurance that we will be successful in obtaining sufficient funding on terms acceptable to us to fund continuing operations, if at all, or identify and enter into any strategic transactions that will provide the capital that we will require. Further, on <em style="font: inherit;"> June 3, 2022, </em>we received a deficiency letter from the Nasdaq Stock Market LLC, or Nasdaq, notifying us that the closing bid price of our common stock had been below the minimum <em style="font: inherit;">$1.00</em> per share for <em style="font: inherit;">30</em> consecutive business days, we are out of compliance with the&#160;requirements for continued listing on Nasdaq, and are subject to potential delisting.&#160;If we are unable to re-achieve compliance with the Nasdaq listing requirements within <em style="font: inherit;">180</em> days, or <em style="font: inherit;"> November 30, 2022, </em>after receipt of a delisting notice,&#160;and if we are unable to obtain an extension therefore, we would be subject to delisting, which likely would further impair the liquidity and value of our common stock.&#160;The failure to obtain sufficient capital on acceptable terms when needed would have a material adverse effect on our business, results of operations, and financial condition.</span></p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin: 0pt; text-align: left;">&#160;</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin: 0pt; text-align: left;"><span style="color:#333333;">The accompanying condensed consolidated financial statements have been prepared on a going concern basis, which contemplates the realization of assets and satisfaction of liabilities in the normal course of business, and do <em style="font: inherit;">not</em> include any adjustments relating to recoverability and classification of recorded asset amounts or the amounts and classification of liabilities that might be necessary should we be unable to continue as a going concern.</span></p>
  <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureTextBlockAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureTextBlockAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_wint_LiquidityDisclosuresTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of historical and expected sources of liquidity, available cash and cash equivalents as of the balance sheet date, and management's plans to maintain sufficient working capital through one or more of the following, if available: public and private securities offerings, equity financing facilities, capital equipment and debt facilities, and strategic alliances, as well as sales revenue from products approved for marketing, if and when approved.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">wint_LiquidityDisclosuresTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>wint_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>20
<FILENAME>R10.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm139823965488224">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note 4 - Summary of Significant Accounting Policies<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureTextBlockAbstract', window );"><strong>Notes to Financial Statements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SignificantAccountingPoliciesTextBlock', window );">Significant Accounting Policies [Text Block]</a></td>
<td class="text">
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;"><span style="color:#333333;"><b>Note <em style="font: inherit;">4</em> &#8211; Summary of Significant Accounting Policies</b></span></p>
   <p style="margin: 0px; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin: 0pt; text-align: left;"/><p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin: 0pt; text-align: left;"><span style="color:#333333;"><b>Principles of Consolidation</b></span></p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin: 0pt; text-align: left;">&#160;</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin: 0pt; text-align: left;"><span style="color:#333333;">The interim unaudited condensed consolidated financial statements are prepared in accordance with US GAAP&#160;and include accounts of Windtree Therapeutics, Inc. and its wholly owned subsidiaries, CVie Investments Limited and its wholly owned subsidiary, CVie Therapeutics Limited; and a presently inactive subsidiary, Discovery Laboratories, Inc. (formerly known as Acute Therapeutics, Inc.).</span></p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin: 0pt; text-align: left;">&#160;</p><p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin: 0pt; text-align: left;"/>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin: 0pt; text-align: left;"/><p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin: 0pt; text-align: left;"><span style="color:#333333;"><b>Goodwill and Intangible Assets</b></span></p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin: 0pt; text-align: left;">&#160;</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin: 0pt; text-align: left;"><span style="color:#333333;">We record acquired identified intangibles, which includes intangible assets (such as goodwill and other intangibles), based on estimated fair value. The acquired in-process research and development, or IPR&amp;D, assets are considered indefinite-lived intangible assets until completion or abandonment of the associated research and development efforts. IPR&amp;D is <em style="font: inherit;">not</em> amortized but reviewed for impairment at least annually, or when events or changes in the business environment indicate the carrying value <em style="font: inherit;"> may </em>be impaired. During the&#160;</span><span style="color:#333333;"><em style="font: inherit;">three</em> and <em style="font: inherit;">six</em> months ended <em style="font: inherit;"> June 30, 2022</em></span><span style="color:#333333;">, <em style="font: inherit;">no</em> events or changes in circumstances occurred indicating that our IPR&amp;D intangible assets were more likely than <em style="font: inherit;">not</em> impaired.</span></p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin: 0pt; text-align: left;">&#160;</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin: 0pt; text-align: left;"><span style="color:#333333;">During the&#160;<em style="font: inherit;">second</em>&#160;quarter of <em style="font: inherit;">2021,</em> we determined that the fair value of the IPR&amp;D related to our rostafuroxin drug candidate was more likely than&#160;<em style="font: inherit;">not</em> impaired and we&#160;performed the required quantitative impairment assessment of the related intangible asset. We recorded a loss on impairment of intangible assets of&#160;</span><span style="color:#333333;">$37.8</span><span style="color:#333333;">&#160;million, recognized within operating expenses in our condensed consolidated statements of operations&#160;for the&#160;<em style="font: inherit;">three</em>&#160;and&#160;<em style="font: inherit;">six</em>&#160;months ended&#160;<em style="font: inherit;"> June 30, 2021.&#160;</em><em style="font: inherit;">No</em>&#160;events or changes in the business environment occurred during the&#160;<em style="font: inherit;">six</em>&#160;months ended&#160;<em style="font: inherit;"> June 30, 2021&#160;</em>to indicate that the fair value of the IPR&amp;D related to our istaroxime drug candidate was impaired.</span></p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin: 0pt; text-align: left;">&#160;</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin: 0pt; text-align: left;"><span style="color:#333333;">Goodwill represents the excess of the purchase price over the fair value of assets acquired and liabilities assumed in a business combination and is <em style="font: inherit;">not</em> amortized. It is reviewed for impairment at least annually or when events or changes in the business environment indicate that its carrying value <em style="font: inherit;"> may </em>be impaired. Our company consists of one reporting unit. In order to perform the quantitative goodwill impairment test, we compare the estimated fair value of our reporting unit to its carrying value. If the fair value exceeds the carrying value, <em style="font: inherit;">no</em> further evaluation is required, and <em style="font: inherit;">no</em> impairment exists. If the carrying value exceeds the fair value, the difference between the carrying value and the fair value is recorded as an impairment loss, the amount of which <em style="font: inherit;"> may </em><em style="font: inherit;">not</em> exceed the total amount of goodwill. When performing our annual goodwill impairment assessment as of <em style="font: inherit;"> December 1, 2021, </em>we estimated the fair value of our reporting unit based upon the quoted market price and related market capitalization of our common stock, adjusted for an estimated control premium. Based on the quantitative test performed, we determined that the fair value of our reporting unit exceeded its carrying value and <em style="font: inherit;">no</em> impairment loss was recognized as of </span><span style="color:#333333;"><em style="font: inherit;"> December 31, 2021</em></span><span style="color:#333333;">.</span></p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin: 0pt; text-align: left;">&#160;</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin: 0pt; text-align: left;"><span style="color:#333333;">Throughout the year, we consider whether any events or changes in the business environment have occurred which indicate that goodwill <em style="font: inherit;"> may </em>be impaired. For example, a significant decline in the closing share price of our common stock and market capitalization <em style="font: inherit;"> may </em>suggest that the fair value of our reporting unit has fallen below its carrying amount, indicating that an interim goodwill impairment test is required. Accordingly, we monitor changes in our share price during interim periods between annual impairment tests and consider overall stock market conditions, the underlying reasons for the decline in our share price, the significance of the decline, and the duration of time that our securities have been trading at a lower value. We have experienced a declining trend in the&#160;closing share price of our common stock following the announcement in <em style="font: inherit;"> April 2022 </em>of positive topline results in our Phase <em style="font: inherit;">2</em> global clinical study of istaroxime for the treatment of early cardiogenic shock.</span></p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin: 0pt; text-align: left;">&#160;</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin: 0pt; text-align: left;"><span style="color:#333333;">During the <em style="font: inherit;">second</em> quarter of <em style="font: inherit;">2022,</em> the continued declining trend in the closing share price of our common stock suggested that the fair value of our reporting unit was more likely than <em style="font: inherit;">not</em> less than its carrying value.&#160;As a result, we&#160;performed the required interim goodwill impairment test consistent with the methodology that we use when performing our annual goodwill impairment assessment, including the use of the quoted market price and related market capitalization of our common stock, adjusted for an estimated control premium based on transactions completed by comparable companies.&#160;Based on the quantitative test performed, we recorded a loss on impairment of goodwill of&#160;</span><span style="color:#333333;">$11.6</span><span style="color:#333333;"> million, recognized within operating expenses in our condensed consolidated statements of operations&#160;for the&#160;<em style="font: inherit;">three</em>&#160;and&#160;<em style="font: inherit;">six</em>&#160;months ended&#160;<em style="font: inherit;"> June 30, 2022.</em></span></p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin: 0pt; text-align: left;">&#160;</p>


   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin: 0pt; text-align: left;"><span style="color:#333333;">The closing share price of our common stock has continued to decline during <em style="font: inherit;"> July </em>and <em style="font: inherit;"> August 2022. </em>If our share price continues to decline during the remainder of the <em style="font: inherit;">third</em> quarter of <em style="font: inherit;">2022,</em> we <em style="font: inherit;"> may </em>be at risk for future impairment to goodwill in the near term.</span></p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin: 0pt; text-align: left;">&#160;</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;"><span style="color:#333333;">The following table represents identifiable intangible assets and goodwill as of </span><span style="color:#333333;"><em style="font: inherit;"> June 30, 2022</em></span><span style="color:#333333;"> and </span><span style="color:#333333;"><em style="font: inherit;"> December 31, 2021</em></span><span style="color:#333333;">:</span></p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">&#160;</p>

    <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="margin-right: 5%; margin-left: 5%; width: 90%; font-size: 10pt; font-family: &quot;Times New Roman&quot;; text-indent: 0px;"><tbody><tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td colspan="2" rowspan="1" style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; text-align: center;"><span style="color:#333333;"><b><em style="font: inherit;">June 30,</em></b></span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; text-align: center;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; text-align: center;">&#160;</td><td colspan="2" rowspan="1" style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; text-align: center;"><span style="color:#333333;"><b><em style="font: inherit;">December 31,</em></b></span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 66%;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;"><span style="color:#333333;"><i>(in thousands)</i></span></p> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><span style="color:#333333;"><b><em style="font: inherit;">2022</em></b></span></p> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><span style="color:#333333;"><b><em style="font: inherit;">2021</em></b></span></p> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px;">&#160;</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;"><span style="color:#333333;">Istaroxime drug candidate</span></p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"><span style="color:#333333;">$</span></td><td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"><span style="color:#333333;">22,340</span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"><span style="color:#333333;">$</span></td><td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"><span style="color:#333333;">22,340</span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;"><span style="color:#333333;">Rostafuroxin drug candidate</span></p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><span style="color:#333333;">9,730</span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><span style="color:#333333;">9,730</span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">&#160;</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;"><span style="color:#333333;">Intangible assets</span></p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);">&#160;</td><td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><span style="color:#333333;">32,070</span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);">&#160;</td><td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><span style="color:#333333;">32,070</span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&#160;</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;"><span style="color:#333333;">Goodwill</span></p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"><span style="color:#333333;">$</span></td><td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"><span style="color:#333333;">4,046</span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"><span style="color:#333333;">$</span></td><td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"><span style="color:#333333;">15,682</span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
</tbody></table>

   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin: 0pt; text-align: left;">&#160;</p><p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin: 0pt; text-align: left;"/>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin: 0pt; text-align: left;"/><p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin: 0pt; text-align: left;"><span style="color:#333333;"><b>Foreign Currency Transactions</b></span></p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin: 0pt; text-align: left;">&#160;</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin: 0pt; text-align: left;"><span style="color:#333333;">The functional currency for our foreign subsidiaries is U.S. Dollars. We remeasure monetary assets and liabilities that are <em style="font: inherit;">not</em> denominated in the functional currency at exchange rates in effect at the end of each period. Gains and losses from the remeasurement of foreign currency transactions are recognized in </span><span style="color:#333333;">other income (expense), net</span><span style="color:#333333;">. Foreign currency transactions resulted in </span><span style="color:#333333;">gains</span><span style="color:#333333;">&#160;of approximately&#160;</span><span style="color:#333333;">$0.2</span><span style="color:#333333;"> million and losses of approximately&#160;</span><span style="color:#333333;">$0.3</span><span style="color:#333333;"> million for the <em style="font: inherit;">three</em>-month periods ended </span><span style="color:#333333;"><em style="font: inherit;"> June 30, 2022 </em>and <em style="font: inherit;">2021</em></span><span style="color:#333333;">, respectively.&#160;Foreign currency transactions resulted in </span><span style="color:#333333;">gains</span><span style="color:#333333;">&#160;of approximately&#160;</span><span style="color:#333333;">$0.4</span><span style="color:#333333;">&#160;million and losses of approximately&#160;</span><span style="color:#333333;">$0.2</span><span style="color:#333333;">&#160;million for the </span><span style="color:#333333;"><em style="font: inherit;">six</em></span><span style="color:#333333;">-month periods ended </span><span style="color:#333333;"><em style="font: inherit;"> June 30, 2022 </em>and <em style="font: inherit;">2021</em></span><span style="color:#333333;">, respectively.&#160;</span></p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin: 0pt; text-align: left;">&#160;</p><p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin: 0pt; text-align: left;"/>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin: 0pt; text-align: left;"/><p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin: 0pt; text-align: left;"><span style="color:#333333;"><b>Use of Estimates</b></span></p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin: 0pt; text-align: left;"><br/> <span style="color:#333333;">The preparation of financial statements in conformity with US GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, including intangible assets and goodwill,&#160;at the date of the financial statements and the reported amounts of expenses during the reporting period. Actual results could differ from those estimates.</span></p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin: 0pt; text-align: left;">&#160;</p><p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin: 0pt; text-align: left;"/>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin: 0pt; text-align: left;"/><p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin: 0pt; text-align: left;"><span style="color:#333333;"><b>Cash and Cash Equivalents</b></span></p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin: 0pt; text-align: left;">&#160;</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin: 0pt; text-align: left;"><span style="color:#333333;">Cash and cash equivalents are held at domestic and foreign financial institutions and consist of liquid investments, money market funds, and U.S. Treasury notes with a maturity from date of purchase of <em style="font: inherit;">90</em> days or less that are readily convertible into cash.</span></p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin: 0pt; text-align: left;">&#160;</p><p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin: 0pt; text-align: left;"/>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin: 0pt; text-align: left;"/><p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin: 0pt; text-align: left;"><span style="color:#333333;"><b>Severance</b></span></p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin: 0pt; text-align: left;">&#160;</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin: 0pt; text-align: left;"><span style="color:#333333;">In <em style="font: inherit;"> January 2022,&#160;</em>in order to focus our resources on the&#160;development of our istaroxime pipeline, we began to reduce costs related to <em style="font: inherit;">KL4</em> surfactant that were <em style="font: inherit;">not</em> already transferred to our licensee in Asia, Lee&#8217;s (HK), under the terms of the Asia License Agreement. These costs include certain reductions in headcount dedicated to <em style="font: inherit;">KL4</em> surfactant and the decommissioning of both our analytical and technical support laboratory, which previously conducted release testing of active pharmaceutical ingredients&#160;and supportive research for our lyophilized and aerosolized <em style="font: inherit;">KL4</em> surfactant, and our medical device development laboratory, which was previously used to conduct development activities and testing for our ADS technologies. In <em style="font: inherit;"> February 2022, </em>management communicated&#160;its commitment to provide severance payments&#160;to impacted employees, provided that they remain employed with us through their expected termination dates. The total severance cost for impacted employees is approximately&#160;</span><span style="color:#333333;">$0.4</span><span style="color:#333333;">&#160;million, which was ratably accrued over the service periods of the employees, and to be paid through <em style="font: inherit;"> September 30, 2022. </em>We incurred </span><span style="color:#333333;">$0.1</span><span style="color:#333333;"> million and&#160;</span><span style="color:#333333;">$0.4</span><span style="color:#333333;"> million of expense&#160;related to these severance arrangements during the <em style="font: inherit;">three</em> and&#160;</span><span style="color:#333333;"><em style="font: inherit;">six</em> months ended <em style="font: inherit;"> June 30, 2022</em></span><span style="color:#333333;">, respectively,&#160;which is included in research and development expense.&#160;During the <em style="font: inherit;">three</em> and&#160;</span><span style="color:#333333;"><em style="font: inherit;">six</em> months ended <em style="font: inherit;"> June 30, 2022</em></span><span style="color:#333333;">,&#160;</span><span style="color:#333333;">$0.2</span><span style="color:#333333;">&#160;million was paid.&#160;The related liability as of </span><span style="color:#333333;"><em style="font: inherit;"> June 30, 2022</em></span><span style="color:#333333;"> is $0.2&#160;million and is included in accrued expenses. </span></p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin: 0pt; text-align: left;">&#160;</p><p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin: 0pt; text-align: left;"/>
   <div style="font-size:10pt">
    <div style="font-family:&quot;Times New Roman&quot;">
     </div></div><div style="font-size:10pt"><div style="font-family:&quot;Times New Roman&quot;"><span style="color:#333333;"><b>Property and Equipment</b></span>
    </div>
    <div style="font-family:&quot;Times New Roman&quot;">
      &#160;
    </div>
   </div>
   <div style="font-size:10pt">
    <div style="font-family:'Times New Roman'">
     <div style="font-variant:normal">
      <span style="color:#333333;">Property and equipment are recorded at cost and depreciated using the straight-line method over the estimated useful lives of the assets (generally&#160;<em style="font: inherit;">three</em>&#160;to&#160;<em style="font: inherit;">ten</em>&#160;years). Leasehold improvements are amortized over the shorter of the estimated useful lives or the remaining term of the lease. Repairs and maintenance costs are charged to expense as incurred.</span>
     </div>
     <div style="font-variant:normal">
       &#160;
     </div>
    </div>
   </div>
   <div style="font-size:10pt">
    <div style="font-family:'Times New Roman'">
     <div style="font-variant:normal">
      <span style="color:#333333;">During the <em style="font: inherit;">first</em> quarter of <em style="font: inherit;">2022,</em> we determined that&#160;certain&#160;manufacturing and laboratory equipment assets related to the <em style="font: inherit;">KL4</em> surfactant platform would be abandoned by <em style="font: inherit;"> March 31, 2022. </em>We accelerated depreciation of these assets during the <em style="font: inherit;">first</em> quarter of <em style="font: inherit;">2022,</em> resulting in $0.4 million of additional depreciation expense for the <em style="font: inherit;">three</em> months ended <em style="font: inherit;"> March 31, 2022.&#160;</em>During the <em style="font: inherit;">second</em> quarter of <em style="font: inherit;">2022,</em> the abandoned assets and certain other <em style="font: inherit;">KL4</em> surfactant platform assets were disposed.</span>
     </div>
     <div style="font-variant:normal">
       &#160;
     </div></div></div><div style="font-size:10pt"><div style="font-family:'Times New Roman'"><div style="font-variant:normal"/>
    </div>
   </div>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin: 0pt; text-align: left;"/><p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin: 0pt; text-align: left;"><span style="color:#333333;"><b>Restructured Debt Liability &#8211; Contingent Milestone Payment</b></span></p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin: 0pt; text-align: left;">&#160;</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin: 0pt; text-align: left;"><span style="color:#333333;">In conjunction with the <em style="font: inherit;"> November 2017 </em>restructuring and retirement of long-term debt (<i>see</i>, </span><span style="color:#333333;">Note <em style="font: inherit;">7</em> &#8211; Restructured Debt Liability</span><span style="color:#333333;">), we have established a </span><span style="color:#333333;">$15.0</span><span style="color:#333333;">&#160;million long-term liability for contingent milestone payments potentially due under the Exchange and Termination Agreement dated as of <em style="font: inherit;"> October 27, 2017, </em>or the Exchange and Termination Agreement, between ourselves and affiliates of Deerfield Management Company L.P., or Deerfield. The liability has been recorded at full value of the contingent milestones and will continue to be carried at full value until the milestones are achieved and paid or milestones are <em style="font: inherit;">not</em> achieved and the liability is written off as a gain on debt restructuring.</span></p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin: 0pt; text-align: left;">&#160;</p><p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin: 0pt; text-align: left;"/>


   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin: 0pt; text-align: left;"/><p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin: 0pt; text-align: left;"><span style="color:#333333;"><b>Research and Development</b></span></p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin: 0pt; text-align: left;">&#160;</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin: 0pt; text-align: left;"><span style="color:#333333;">We track direct research and development expenses by preclinical and clinical programs, which include <em style="font: inherit;">third</em>-party costs such as contract research organization, consulting, and clinical trial costs. We do <em style="font: inherit;">not</em> allocate indirect research and development expenses, which include product development and manufacturing expenses and clinical, medical, and regulatory operations expenses, to specific programs. Indirect research and development expenses include personnel, facilities, manufacturing and quality operations, pharmaceutical and device development, research, regulatory, and medical affairs. Research and development costs are charged to operations as incurred in accordance with Financial Accounting Standards Board, or FASB, Accounting Standards Codification, or ASC, Topic <em style="font: inherit;">730,</em> Research and Development.</span></p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin: 0pt; text-align: left;">&#160;</p><p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin: 0pt; text-align: left;"/>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin: 0pt; text-align: left;"/><p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin: 0pt; text-align: left;"><span style="color:#333333;"><b>Income Taxes</b></span></p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin: 0pt; text-align: left;">&#160;</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin: 0pt; text-align: left;"><span style="color:#333333;">We account for income taxes in accordance with ASC Topic <em style="font: inherit;">740,</em> Accounting for Income Taxes, which requires the recognition of deferred tax liabilities and assets for the expected future tax consequences of temporary differences between financial statement carrying amounts and the tax basis of assets and liabilities.</span></p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin: 0pt; text-align: left;">&#160;</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin: 0pt; text-align: left;"><span style="color:#333333;">We use a recognition threshold and measurement attribute for the financial statement recognition and measurement of a tax position taken or expected to be taken in a tax return. Because we have never realized a profit, management has fully reserved the net deferred tax asset since realization is <em style="font: inherit;">not</em> assured.</span></p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin: 0pt; text-align: left;">&#160;</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin: 0pt; text-align: left;"><span style="color:#333333;">For the&#160;<em style="font: inherit;">three</em>&#160;and&#160;<em style="font: inherit;">six</em>&#160;months ended&#160;</span><span style="color:#333333;"><em style="font: inherit;"> June 30, 2021</em></span><span style="color:#333333;">, we recorded a deferred&#160;income tax benefit of&#160;</span><span style="color:#333333;">$8.3</span><span style="color:#333333;">&#160;million. The deferred tax benefit recorded for these periods relates solely to the reduction of the deferred tax liability as a result of the loss on impairment of intangible assets related to&#160;rostafuroxin.</span></p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin: 0pt; text-align: left;">&#160;</p><p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin: 0pt; text-align: left;"/>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin: 0pt; text-align: left;"/><p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin: 0pt; text-align: left;"><span style="color:#333333;"><b>Net Loss per Common Share</b></span></p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin: 0pt; text-align: left;">&#160;</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin: 0pt; text-align: left;"><span style="color:#333333;">Basic net loss per common share is computed by dividing net loss by the weighted average number of common shares outstanding for the period. Diluted net loss per common share is computed by giving effect to all potentially dilutive securities outstanding for the period. As of </span><span style="color:#333333;"><em style="font: inherit;"> June 30, 2022 </em>and <em style="font: inherit;">2021</em></span><span style="color:#333333;">, the number of shares of common stock potentially issuable upon the exercise of certain stock options and warrants, as well as the vesting of&#160;restricted stock units, was&#160;</span><span style="color:#333333;">21.2</span><span style="color:#333333;"> million and&#160;</span><span style="color:#333333;">19.9</span><span style="color:#333333;"> million shares, respectively. For the </span><span style="color:#333333;"><em style="font: inherit;">three</em> and <em style="font: inherit;">six</em> months ended <em style="font: inherit;"> June 30, 2022 </em>and <em style="font: inherit;">2021</em></span><span style="color:#333333;">, all potentially dilutive securities were anti-dilutive and therefore have been excluded from the computation of diluted net loss per share.</span></p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin: 0pt; text-align: left;">&#160;</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin: 0pt; text-align: left;"><span style="color:#333333;">We do <em style="font: inherit;">not</em> have any components of other comprehensive (loss) income.</span></p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin: 0pt; text-align: left;">&#160;</p><p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin: 0pt; text-align: left;"/>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin: 0pt; text-align: left;"/><p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin: 0pt; text-align: left;"><span style="color:#333333;"><b>COVID-<em style="font: inherit;">19</em></b></span></p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin: 0pt; text-align: left;">&#160;</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin: 0pt; text-align: left;"><span style="color:#333333;">The COVID-<em style="font: inherit;">19</em> pandemic continues to evolve, and we continue to closely monitor its impact on our business and&#160;operations, including its continued&#160;impact on our clinical development plans and timelines, and financial condition. There has been intermittent impact of the pandemic in differing geographies,&#160;and there <em style="font: inherit;"> may </em>be continued impact, particularly in light of the surge of new COVID-<em style="font: inherit;">19</em> cases relating to new variants. As of the date of the issuance of this Quarterly Report on Form <em style="font: inherit;">10</em>-Q, our operations, capital&#160;and financial resources, and overall liquidity position and outlook have been impacted by COVID-<em style="font: inherit;">19,</em> primarily due to delays experienced in our operations, including&#160;in clinical study initiation and enrollment. The extended timelines have required us to expend more of our capital resources than planned to achieve our projected milestones. For example, our Phase <em style="font: inherit;">2</em> study of istaroxime for early cardiogenic shock in heart failure patients&#160;experienced delays in trial initiation and enrollment in <em style="font: inherit;">2021.</em>&#160;Although many countries have re-opened, rises in new cases, including as the result of newly identified COVID-<em style="font: inherit;">19</em> variants, have caused certain countries, states, and localities to re-initiate restrictions.&#160;The full extent, duration, or impact that the COVID-<em style="font: inherit;">19</em> pandemic will have, directly or indirectly, on our financial condition and operations, including ongoing and planned clinical trials, will depend on future developments that are highly uncertain and cannot be accurately predicted. These potential future developments include the severity and transmissibility of new variants of the virus, information about any resurgences&#160;in <em style="font: inherit;">one</em> or more geographic locations where our current or intended clinical trial sites, our&#160;principal executive offices, research and development laboratories, or manufacturing facilities are located, and the actions taken to contain it or treat its impact. In addition, regional impact and responses to the COVID-<em style="font: inherit;">19</em> pandemic have affected where a clinical trial could be executed and how various elements of the clinical trial are performed. Going forward, the pandemic could also impact how monitoring/auditing of clinical trial&#160;sites and data occur. The maintenance, or strategic re-implementation, of mitigating COVID-<em style="font: inherit;">19</em> measures in <em style="font: inherit;">one</em> or more geographic locations where our clinical trial sites, principal executive offices, research and development laboratories, or other facilities are located remains possible and if realized, we believe there could be further impact on the clinical development of our product candidates, which <em style="font: inherit;"> may </em>include potential delays, halts, or modifications to our ongoing and planned trials in </span><span style="color:#333333;"><em style="font: inherit;">2022</em></span><span style="color:#333333;"> and beyond.</span></p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin: 0pt; text-align: left;">&#160;</p>
   <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left"><span style="color:#333333;">We are <em style="font: inherit;">not</em> aware of any specific event or circumstance that would require us to further update our estimates, judgments, or revise the carrying value of our assets or liabilities as of the date of issuance of these interim unaudited condensed consolidated financial statements. These estimates <em style="font: inherit;"> may </em>change&#160;as new events occur and additional information is obtained.</span></p><p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left"/>
  <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureTextBlockAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureTextBlockAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SignificantAccountingPoliciesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for all significant accounting policies of the reporting entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=126899994&amp;loc=d3e18726-107790<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -URI https://asc.fasb.org/topic&amp;trid=2122369<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SignificantAccountingPoliciesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>21
<FILENAME>R11.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm139823965488224">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note 5 - Fair Value Measurements<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureTextBlockAbstract', window );"><strong>Notes to Financial Statements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresTextBlock', window );">Fair Value Disclosures [Text Block]</a></td>
<td class="text">
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;"><span style="color:#333333;"><b>Note <em style="font: inherit;">5</em> &#8211; Fair Value Measurements</b></span></p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin: 0pt; text-align: left;">&#160;</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin: 0pt; text-align: left;"><span style="color:#333333;">Fair value is defined as the exchange price that would be received for an asset or paid to transfer a liability in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date.</span></p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin: 0pt; text-align: justify;">&#160;</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin: 0pt; text-align: left;"><span style="color:#333333;">Valuation techniques used to measure fair value must maximize the use of observable inputs and minimize the use of unobservable inputs. The fair value hierarchy is based on <em style="font: inherit;">three</em> levels of inputs, of which the <em style="font: inherit;">first</em> <em style="font: inherit;">two</em> are considered observable and the last unobservable, as follows:</span></p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin: 0pt; text-align: left;">&#160;</p>
   <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">
    <tbody>
     <tr style="vertical-align: top; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">
      <td style="width: 36pt; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td>
      <td style="width: 36pt; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin: 0pt; text-align: left;"><span style="color:#333333;">&#9679;</span></p> </td>
      <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin: 0pt; text-align: left;"><span style="color:#333333;">Level <em style="font: inherit;">1</em> &#8211; Quoted prices in active markets for identical assets and liabilities.</span></p> </td>
     </tr>

     <tr style="vertical-align: top; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">
      <td style="width: 36pt; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td>
      <td style="width: 36pt; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin: 0pt; text-align: left;"><span style="color:#333333;">&#9679;</span></p> </td>
      <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin: 0pt; text-align: left;"><span style="color:#333333;">Level <em style="font: inherit;">2</em> &#8211; Inputs other than Level <em style="font: inherit;">1</em> that are observable, either directly or indirectly, such as quoted prices for similar assets or liabilities, quoted prices in markets that are <em style="font: inherit;">not</em> active, or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities.</span></p> </td>
     </tr>

     <tr style="vertical-align: top; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">
      <td style="width: 36pt; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td>
      <td style="width: 36pt; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin: 0pt; text-align: left;"><span style="color:#333333;">&#9679;</span></p> </td>
      <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin: 0pt; text-align: left;"><span style="color:#333333;">Level <em style="font: inherit;">3</em> &#8211; Unobservable inputs that are supported by little or <em style="font: inherit;">no</em> market activity and that are significant to the fair value of the assets or liabilities.</span></p> </td>
     </tr>

    </tbody>
   </table>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin: 0pt; text-align: justify;">&#160;</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin: 0pt; text-align: left;"><span style="color:#333333;"><b>Fair Value on a Recurring Basis</b></span></p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin: 0pt; text-align: left;">&#160;</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin: 0pt; text-align: left;"><span style="color:#333333;">The tables below categorize assets measured at fair value on a recurring basis for the periods presented:</span></p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin: 0pt; text-align: left;">&#160;</p>

    <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="margin-right: 10%; width: 90%; font-size: 10pt; font-family: &quot;Times New Roman&quot;; text-indent: 0px;">
     <tbody>
      <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom">
       <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td>
       <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td>
       <td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin: 0pt; text-align: center;"><span style="color:#333333;"><b><em style="font: inherit;">Fair Value</em></b></span></p> </td>
       <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px;">&#160;</td>
       <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td>
       <td colspan="10" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin: 0pt; text-align: center;"><span style="color:#333333;"><b><em style="font: inherit;"><em style="font: inherit;"><em style="font: inherit;">Fair value measurement using</em></em></em></b></span></p> </td>
       <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px;">&#160;</td>
      </tr>

      <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom">
       <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td>
       <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td>
       <td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin: 0pt; text-align: center;"><span style="color:#333333;"><b><em style="font: inherit;">June 30,</em></b></span></p> </td>
       <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td>
       <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td>
       <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td>
       <td style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"><em style="font: inherit;">&#160;</em></td>
       <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"><span style="color:#333333;"><b>&#160;</b></span></td>
       <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td>
       <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td>
       <td style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"><em style="font: inherit;">&#160;</em></td>
       <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"><span style="color:#333333;"><b>&#160;</b></span></td>
       <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td>
       <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td>
       <td style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"><em style="font: inherit;">&#160;</em></td>
       <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"><span style="color:#333333;"><b>&#160;</b></span></td>
      </tr>

      <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom">
       <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 44%;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><span style="color:#333333;"><i>(in thousands)</i></span></p> </td>
       <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td>
       <td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin: 0pt; text-align: center;"><span style="color:#333333;"><b><em style="font: inherit;">2022</em></b></span></p> </td>
       <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px;">&#160;</td>
       <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td>
       <td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin: 0pt; text-align: center;"><span style="color:#333333;"><b><em style="font: inherit;">Level 1</em></b></span></p> </td>
       <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px;">&#160;</td>
       <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td>
       <td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin: 0pt; text-align: center;"><span style="color:#333333;"><b><em style="font: inherit;">Level 2</em></b></span></p> </td>
       <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px;">&#160;</td>
       <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td>
       <td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin: 0pt; text-align: center;"><span style="color:#333333;"><b><em style="font: inherit;">Level 3</em></b></span></p> </td>
       <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px;">&#160;</td>
      </tr>

      <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom">
       <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td>
       <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td>
       <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td>
       <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td>
       <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td>
       <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td>
       <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td>
       <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td>
       <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td>
       <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td>
       <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td>
       <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td>
       <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td>
       <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td>
       <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td>
       <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td>
       <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td>
      </tr>

      <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom">
       <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><span style="color:#333333;">Cash equivalents:</span></p> </td>
       <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td>
       <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td>
       <td style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td>
       <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td>
       <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td>
       <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td>
       <td style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td>
       <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td>
       <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td>
       <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td>
       <td style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td>
       <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td>
       <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td>
       <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td>
       <td style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td>
       <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td>
      </tr>

      <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom">
       <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><span style="color:#333333;">Money market funds</span></p> </td>
       <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px;">&#160;</td>
       <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><span style="color:#333333;">$</span></td>
       <td style="width: 11%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><span style="color:#333333;">10,121</span></td>
       <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">&#160;</td>
       <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px;">&#160;</td>
       <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><span style="color:#333333;">$</span></td>
       <td style="width: 11%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><span style="color:#333333;">10,121</span></td>
       <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">&#160;</td>
       <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px;">&#160;</td>
       <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><span style="color:#333333;">$</span></td>
       <td style="width: 11%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><span style="color:#333333;"><em style="font: inherit;">-</em></span></td>
       <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">&#160;</td>
       <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px;">&#160;</td>
       <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><span style="color:#333333;">$</span></td>
       <td style="width: 11%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><span style="color:#333333;"><em style="font: inherit;">-</em></span></td>
       <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">&#160;</td>
      </tr>

      <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom">
       <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 18pt;"><span style="color:#333333;">Total Assets</span></p> </td>
       <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td>
       <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><span style="color:#333333;">$</span></td>
       <td style="width: 11%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><span style="color:#333333;">10,121</span></td>
       <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&#160;</td>
       <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td>
       <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><span style="color:#333333;">$</span></td>
       <td style="width: 11%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><span style="color:#333333;">10,121</span></td>
       <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&#160;</td>
       <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td>
       <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><span style="color:#333333;">$</span></td>
       <td style="width: 11%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><span style="color:#333333;"><em style="font: inherit;">-</em></span></td>
       <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&#160;</td>
       <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td>
       <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><span style="color:#333333;">$</span></td>
       <td style="width: 11%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><span style="color:#333333;"><em style="font: inherit;">-</em></span></td>
       <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&#160;</td>
      </tr>

     </tbody>
    </table>

   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin: 0pt; text-align: left;">&#160;</p>

    <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="margin-right: 10%; width: 90%; font-size: 10pt; font-family: &quot;Times New Roman&quot;; text-indent: 0px;">
     <tbody>
      <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom">
       <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td>
       <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td>
       <td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin: 0pt; text-align: center;"><span style="color:#333333;"><b><em style="font: inherit;">Fair Value</em></b></span></p> </td>
       <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px;">&#160;</td>
       <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td>
       <td colspan="10" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin: 0pt; text-align: center;"><span style="color:#333333;"><b><em style="font: inherit;"><em style="font: inherit;"><em style="font: inherit;">Fair value measurement using</em></em></em></b></span></p> </td>
       <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px;">&#160;</td>
      </tr>

      <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom">
       <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td>
       <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td>
       <td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin: 0pt; text-align: center;"><span style="color:#333333;"><b><em style="font: inherit;">December 31,</em></b></span></p> </td>
       <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td>
       <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td>
       <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td>
       <td style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"><em style="font: inherit;">&#160;</em></td>
       <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"><span style="color:#333333;"><b>&#160;</b></span></td>
       <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td>
       <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td>
       <td style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"><em style="font: inherit;">&#160;</em></td>
       <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"><span style="color:#333333;"><b>&#160;</b></span></td>
       <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td>
       <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td>
       <td style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"><em style="font: inherit;">&#160;</em></td>
       <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"><span style="color:#333333;"><b>&#160;</b></span></td>
      </tr>

      <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom">
       <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 44%;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><span style="color:#333333;"><i>(in thousands)</i></span></p> </td>
       <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td>
       <td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin: 0pt; text-align: center;"><span style="color:#333333;"><b><em style="font: inherit;">2021</em></b></span></p> </td>
       <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px;">&#160;</td>
       <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td>
       <td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin: 0pt; text-align: center;"><span style="color:#333333;"><b><em style="font: inherit;">Level 1</em></b></span></p> </td>
       <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px;">&#160;</td>
       <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td>
       <td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin: 0pt; text-align: center;"><span style="color:#333333;"><b><em style="font: inherit;">Level 2</em></b></span></p> </td>
       <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px;">&#160;</td>
       <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td>
       <td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin: 0pt; text-align: center;"><span style="color:#333333;"><b><em style="font: inherit;">Level 3</em></b></span></p> </td>
       <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px;">&#160;</td>
      </tr>

      <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom">
       <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td>
       <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td>
       <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td>
       <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td>
       <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td>
       <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td>
       <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td>
       <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td>
       <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td>
       <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td>
       <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td>
       <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td>
       <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td>
       <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td>
       <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td>
       <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td>
       <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td>
      </tr>

      <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom">
       <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><span style="color:#333333;">Cash equivalents:</span></p> </td>
       <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td>
       <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td>
       <td style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td>
       <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td>
       <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td>
       <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td>
       <td style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td>
       <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td>
       <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td>
       <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td>
       <td style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td>
       <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td>
       <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td>
       <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td>
       <td style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td>
       <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td>
      </tr>

      <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom">
       <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><span style="color:#333333;">Money market funds</span></p> </td>
       <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px;">&#160;</td>
       <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><span style="color:#333333;">$</span></td>
       <td style="width: 11%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><span style="color:#333333;">21,104</span></td>
       <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">&#160;</td>
       <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px;">&#160;</td>
       <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><span style="color:#333333;">$</span></td>
       <td style="width: 11%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><span style="color:#333333;">21,104</span></td>
       <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">&#160;</td>
       <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px;">&#160;</td>
       <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><span style="color:#333333;">$</span></td>
       <td style="width: 11%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><span style="color:#333333;"><em style="font: inherit;">-</em></span></td>
       <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">&#160;</td>
       <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px;">&#160;</td>
       <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><span style="color:#333333;">$</span></td>
       <td style="width: 11%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><span style="color:#333333;"><em style="font: inherit;">-</em></span></td>
       <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">&#160;</td>
      </tr>

      <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom">
       <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-top: 0px; padding-right: 0px; padding-left: 0px; margin: 0px;"> <p style="margin-top: 0pt; margin-bottom: 0pt; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 18pt;"><span style="color:#333333;">Total Assets</span></p> </td>
       <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding: 0px 0px 3px; margin: 0px;">&#160;</td>
       <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-top: 0px; padding-right: 0px; padding-left: 0px; margin: 0px; border-bottom: 3px double rgb(0, 0, 0);"><span style="color:#333333;">$</span></td>
       <td style="width: 11%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-top: 0px; padding-right: 0px; padding-left: 0px; margin: 0px; border-bottom: 3px double rgb(0, 0, 0);"><span style="color:#333333;">21,104</span></td>
       <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding: 0px 0px 3px; margin: 0px;">&#160;</td>
       <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding: 0px 0px 3px; margin: 0px;">&#160;</td>
       <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-top: 0px; padding-right: 0px; padding-left: 0px; margin: 0px; border-bottom: 3px double rgb(0, 0, 0);"><span style="color:#333333;">$</span></td>
       <td style="width: 11%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-top: 0px; padding-right: 0px; padding-left: 0px; margin: 0px; border-bottom: 3px double rgb(0, 0, 0);"><span style="color:#333333;">21,104</span></td>
       <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding: 0px 0px 3px; margin: 0px;">&#160;</td>
       <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding: 0px 0px 3px; margin: 0px;">&#160;</td>
       <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-top: 0px; padding-right: 0px; padding-left: 0px; margin: 0px; border-bottom: 3px double rgb(0, 0, 0);"><span style="color:#333333;">$</span></td>
       <td style="width: 11%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-top: 0px; padding-right: 0px; padding-left: 0px; margin: 0px; border-bottom: 3px double rgb(0, 0, 0);"><span style="color:#333333;"><em style="font: inherit;">-</em></span></td>
       <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding: 0px 0px 3px; margin: 0px;">&#160;</td>
       <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding: 0px 0px 3px; margin: 0px;">&#160;</td>
       <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-top: 0px; padding-right: 0px; padding-left: 0px; margin: 0px; border-bottom: 3px double rgb(0, 0, 0);"><span style="color:#333333;">$</span></td>
       <td style="width: 11%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-top: 0px; padding-right: 0px; padding-left: 0px; margin: 0px; border-bottom: 3px double rgb(0, 0, 0);"><span style="color:#333333;"><em style="font: inherit;">-</em></span></td>
       <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding: 0px 0px 3px; margin: 0px;">&#160;</td>
      </tr>

     </tbody>
    </table>

  <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureTextBlockAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureTextBlockAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126976982&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>22
<FILENAME>R12.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm139824052384976">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note 6 - Loans Payable<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureTextBlockAbstract', window );"><strong>Notes to Financial Statements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShortTermDebtTextBlock', window );">Short-Term Debt [Text Block]</a></td>
<td class="text">
   <p style="margin: 0pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><span style="color:#333333;"><b>Note <em style="font: inherit;">6</em> &#8211; Loans Payable</b></span></p>
   <p style="margin: 0pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin: 0pt; text-align: left;"><span style="color:#333333;">In <em style="font: inherit;"> June 2022, </em>we entered into an insurance premium financing and security agreement with Bank Direct. Under the agreement, we financed&#160;</span><span style="color:#333333;">$1.1</span><span style="color:#333333;">&#160;million of certain premiums at a&#160;</span><span style="color:#333333;">3.90%</span><span style="color:#333333;">&#160;annual interest rate. Payments of approximately&#160;</span><span style="color:#333333;">$126,000</span><span style="color:#333333;">&#160;are due monthly from <em style="font: inherit;"> July 2022 </em>through <em style="font: inherit;"> March 2023.&#160;</em>As of&#160;</span><span style="color:#333333;"><em style="font: inherit;"> June 30, 2022</em></span><span style="color:#333333;">, the outstanding principal of the loan was&#160;</span><span style="color:#333333;">$1.0</span><span style="color:#333333;"> million.</span></p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin: 0pt; text-align: left;">&#160;</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;"><span style="color:#333333;">In <em style="font: inherit;"> June 2021, </em>we entered into an insurance premium financing and security agreement with Bank Direct. Under the agreement, we financed&#160;</span><span style="color:#333333;">$1.3</span><span style="color:#333333;"> million of certain premiums at a&#160;</span><span style="color:#333333;">3.37%</span><span style="color:#333333;"> annual interest rate. Payments of approximately&#160;</span><span style="color:#333333;">$147,000</span><span style="color:#333333;"> are due monthly from <em style="font: inherit;"> July 2021 </em>through <em style="font: inherit;"> March 2022.&#160;</em>As of&#160;</span><span style="color:#333333;"><em style="font: inherit;"> December 31, 2021</em></span><span style="color:#333333;">, the outstanding principal of the loan was $0.3&#160;million.&#160;The balance of the loan was repaid during the <em style="font: inherit;">first</em> quarter of <em style="font: inherit;">2022.</em></span></p>
  <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureTextBlockAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureTextBlockAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShortTermDebtTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for short-term debt.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -URI https://asc.fasb.org/topic&amp;trid=2208564<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShortTermDebtTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>23
<FILENAME>R13.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm139823966619776">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note 7 - Restructured Debt Liability<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureTextBlockAbstract', window );"><strong>Notes to Financial Statements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtTextBlock', window );">Long-Term Debt [Text Block]</a></td>
<td class="text">
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin: 0pt; text-align: left;"><span style="color:#333333;"><b>Note <em style="font: inherit;">7</em> &#8211; Restructured Debt Liability</b></span></p>
   <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&#160;</p>
   <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><span style="color:#333333;">On <em style="font: inherit;"> October 27, 2017, </em>we and Deerfield entered into an Exchange and Termination Agreement pursuant to which (i) promissory notes evidencing a loan with affiliates of Deerfield Management Company L.P., or the Deerfield Loan,&#160;in the aggregate principal amount of $25.0 million and (ii) warrants to purchase up to 8,333 shares of our common stock at an exercise price of $2,360.40 per share held by Deerfield were cancelled in consideration for (i) a cash payment in the aggregate amount of $2.5 million, (ii) 23,703 shares of common stock, representing 2% of fully-diluted shares outstanding (as defined in the Exchange and Termination Agreement) on the closing date, and (iii) the right to receive certain milestone payments based on achievement of specified AEROSURF development and commercial milestones, which, if achieved, could potentially total up to </span><span style="color:#333333;"><em style="font: inherit;">$15.0</em></span><span style="color:#333333;">&#160;million. In addition, a related security agreement, pursuant to which Deerfield held a security interest in substantially all of our assets, was terminated. We established a </span><span style="color:#333333;">$15.0</span><span style="color:#333333;">&#160;million long-term liability for the contingent milestone payments potentially due to Deerfield under the Exchange and Termination Agreement (<i>see</i>,&#160;</span><span style="color:#333333;">Note <em style="font: inherit;">4</em> &#8211; Summary of Significant Accounting Policies</span><span style="color:#333333;">). The liability has been recorded at full value of the contingent milestones and will continue to be carried at full value until the milestones are achieved and paid or milestones are <em style="font: inherit;">not</em> achieved and the liability is written off as a gain on debt restructuring.</span></p>
   <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&#160;</p>
   <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><span style="color:#333333;">As of </span><span style="color:#333333;"><em style="font: inherit;"> June 30, 2022</em></span><span style="color:#333333;"> and </span><span style="color:#333333;"><em style="font: inherit;"> December 31, 2021</em></span><span style="color:#333333;">, the restructured debt liability balance was&#160;</span><span style="color:#333333;">$15.0</span><span style="color:#333333;">&#160;million.</span></p>
  <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureTextBlockAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureTextBlockAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for long-term debt.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -URI https://asc.fasb.org/topic&amp;trid=2208564<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>24
<FILENAME>R14.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm139823956454368">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note 8 - Stockholders' Equity<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureTextBlockAbstract', window );"><strong>Notes to Financial Statements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock', window );">Stockholders' Equity Note Disclosure [Text Block]</a></td>
<td class="text">
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin: 0pt; text-align: left;">&#160;</p>


   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin: 0pt; text-align: left;"><span style="color:#333333;"><b>Note <em style="font: inherit;">8</em> &#8211; Stockholders&#8217; Equity</b></span></p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin: 0pt; text-align: left;">&#160;</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin: 0pt; text-align: left;"><span style="color:#333333;"><b>At-The-Market Program</b></span></p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin: 0pt; text-align: left;">&#160;</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin: 0pt; text-align: left;"><span style="color:#333333;">On <em style="font: inherit;"> September 17, 2020, </em>we entered into an At-The-Market Offering Agreement&#160;with Ladenburg, pursuant to which we <em style="font: inherit;"> may </em>offer and sell, from time to time at our sole discretion, up to a maximum of </span><span style="color:#333333;">$10.0</span><span style="color:#333333;">&#160;million of shares of our common stock through Ladenburg as agent and/or principal through the ATM Program. When we issue sales notices to Ladenburg, we designate the maximum amount of&#160;shares to be sold by Ladenburg daily and the minimum price per share at which shares <em style="font: inherit;"> may </em>be sold. Ladenburg <em style="font: inherit;"> may </em>sell shares by any method permitted by law deemed to be an &#8220;at-the-market offering&#8221; as defined in Rule <em style="font: inherit;">415</em>(a)(<em style="font: inherit;">4</em>) under the Securities Act of <em style="font: inherit;">1933,</em> as amended, or in privately negotiated transactions.</span></p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin: 0pt; text-align: left;">&#160;</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin: 0pt; text-align: left;"><span style="color:#333333;">We agreed to pay Ladenburg a commission of </span><span style="color:#333333;">3%</span><span style="color:#333333;">&#160;of the gross sales price of any shares sold pursuant to the ATM Program. The rate of compensation will <em style="font: inherit;">not</em> apply when Ladenburg acts as principal.</span></p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin: 0pt; text-align: left;">&#160;</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin: 0pt; text-align: left;"><span style="color:#333333;">For the&#160;</span><span style="color:#333333;"><em style="font: inherit;">six</em> months ended <em style="font: inherit;"> June 30, 2022</em></span><span style="color:#333333;">, we sold&#160;</span><span style="color:#333333;">1,137,246</span><span style="color:#333333;">&#160;shares&#160;of our common stock under the ATM Program&#160;resulting in aggregate gross proceeds to us of approximately&#160;</span><span style="color:#333333;">$1.3</span><span style="color:#333333;">&#160;million and net proceeds of approximately&#160;</span><span style="color:#333333;">$1.2</span><span style="color:#333333;">&#160;million. For the&#160;</span><span style="color:#333333;"><em style="font: inherit;">six</em> months ended <em style="font: inherit;"> June 30, 2021</em></span><span style="color:#333333;">, we sold&#160;</span><span style="color:#333333;">552,474</span><span style="color:#333333;"> shares of&#160;our common stock under the ATM Program&#160;resulting in aggregate gross and net proceeds to us of approximately&#160;</span><span style="color:#333333;">$1.7</span><span style="color:#333333;"> million.</span></p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin: 0pt; text-align: left;">&#160;</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin: 0pt; text-align: left;"><span style="color:#333333;">During <em style="font: inherit;"> July </em>and <em style="font: inherit;"> August 2022,&#160;</em>we sold&#160;</span><span style="color:#333333;">1,221,706</span><span style="color:#333333;"> shares of our common stock under the ATM Program&#160;resulting in aggregate gross and net proceeds to us of approximately&#160;</span><span style="color:#333333;">$0.6</span><span style="color:#333333;"> million.&#160;</span></p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin: 0pt; text-align: left;">&#160;</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin: 0pt; text-align: left;"><span style="color:#333333;">The shares of common stock issued and sold under the ATM Program are registered under our Registration Statement on Form S-<em style="font: inherit;">3</em> (File <em style="font: inherit;">No.</em> <em style="font: inherit;">333</em>-<em style="font: inherit;">248874</em>), which was declared effective by the SEC on <em style="font: inherit;"> September 29, 2020. </em>As of </span><span style="color:#333333;"><em style="font: inherit;"> August 11, 2022</em></span><span style="color:#333333;">, approximately&#160;</span><span style="color:#333333;">$3.2</span><span style="color:#333333;"> million remains&#160;available under the ATM Program.&#160;However, we are currently subject to the limitations contained in General Instruction <em style="font: inherit;">I.B.6</em> of Form S-<em style="font: inherit;">3.</em> As a result, we are limited in selling <em style="font: inherit;">no</em> more than <em style="font: inherit;">one</em>-<em style="font: inherit;">third</em> of our public float during any <em style="font: inherit;">12</em>-month period. If our public float increases to $75 million or more, we will <em style="font: inherit;">no</em> longer be subject to such limitations.</span></p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin: 0pt; text-align: left;">&#160;</p>
   <div style="font-size:10pt">
    <div style="font-family:&quot;Times New Roman&quot;">
     <span style="color:#333333;"><b><em style="font: inherit;"> March 2021 </em>Public Offering</b></span>
    </div>
   </div>
   <p style="text-align: left; margin: 0pt;">&#160;</p>
   <div style="font-size:10pt">
    <div style="font-family:&quot;Times New Roman&quot;">
     <span style="color:#333333;">On <em style="font: inherit;"> March 23, 2021, </em>we entered into an underwriting agreement with Oppenheimer &amp; Co. Inc. as representative for the several underwriters named therein, relating to a public offering, or the <em style="font: inherit;"> March 2021 </em>Offering, of an aggregate of </span>
     <span style="color:#333333;">9,230,500</span>
     <span style="color:#333333;">&#160;units with each unit consisting of <span style="-sec-ix-hidden:c86425407">one</span> share of common stock and a warrant, or the <em style="font: inherit;"> March 2021 </em>Warrants. The <em style="font: inherit;"> March 2021 </em>Warrants are immediately exercisable for shares of common stock at a price of </span>
     <span style="color:#333333;">$3.60</span>
     <span style="color:#333333;"> per share and expire <span style="-sec-ix-hidden:c86425409">five</span> years from the date of issuance. The shares of common stock and the <em style="font: inherit;"> March 2021 </em>Warrants were immediately separable and were issued separately in the <em style="font: inherit;"> March 2021 </em>Offering.</span>
    </div>
    <div style="font-family:&quot;Times New Roman&quot;">
      &#160;
    </div>
    <div style="font-family:&quot;Times New Roman&quot;">
     <span style="color:#333333;">The closing of the <em style="font: inherit;"> March 2021 </em>Offering occurred on <em style="font: inherit;"> March 25, 2021. </em>The offering price to the public was </span>
     <span style="color:#333333;">$3.25</span>
     <span style="color:#333333;">&#160;per unit resulting in gross proceeds to us of&#160;</span>
     <span style="color:#333333;">$30.0</span>
     <span style="color:#333333;"> million. After deducting underwriting discounts and commissions and estimated offering expenses payable by us, and excluding the proceeds, if any, from the exercise of the <em style="font: inherit;"> March 2021 </em>Warrants issued pursuant to the <em style="font: inherit;"> March 2021 </em>Offering, the net proceeds to us were approximately </span>
     <span style="color:#333333;">$27.4</span>
     <span style="color:#333333;"> million.</span>
    </div>
    <div style="font-family:&quot;Times New Roman&quot;">
      &#160;
    </div>
    <div style="font-family:&quot;Times New Roman&quot;">
     <span style="color:#333333;">We have determined that the appropriate accounting treatment under ASC <em style="font: inherit;">480,</em> Distinguishing Liabilities from Equity, or ASC <em style="font: inherit;">480,</em> is to classify the common stock and the <em style="font: inherit;"> March 2021 </em>Warrants issued in the <em style="font: inherit;"> March 2021 </em>Offering as equity.&#160;We have also determined that the <em style="font: inherit;"> March 2021 </em>Warrants are <em style="font: inherit;">not</em> in their entirety a derivative under the scope of ASC <em style="font: inherit;">815,</em> Derivatives and Hedging, or ASC <em style="font: inherit;">815,</em> due to the scope exception under ASC <em style="font: inherit;">815</em>-<em style="font: inherit;">10</em>-<em style="font: inherit;">15</em>-<em style="font: inherit;">74,</em> nor are there any material embedded derivatives that require separate accounting.&#160;We allocated the net proceeds from the <em style="font: inherit;"> March 2021 </em>Offering based on the relative fair value of the common stock and the <em style="font: inherit;"> March 2021 </em>Warrants.</span>
    </div>
   </div>
  <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureTextBlockAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureTextBlockAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -URI https://asc.fasb.org/topic&amp;trid=2208762<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496158-112644<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496158-112644<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496171-112644<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496171-112644<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496189-112644<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (g)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496158-112644<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496189-112644<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (h)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496158-112644<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496171-112644<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496189-112644<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 16<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496180-112644<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (i)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496158-112644<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(e)(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126731327&amp;loc=SL126733271-114008<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>25
<FILENAME>R15.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm139823964046080">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note 9 - Stock-Based Compensation<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureTextBlockAbstract', window );"><strong>Notes to Financial Statements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock', window );">Share-Based Payment Arrangement [Text Block]</a></td>
<td class="text">
   <p style="font-family: Times New Roman; font-size: 10pt; margin: 0pt; text-align: left;"><span style="color:#333333;"><span style="font-size: 10pt;"><b>Note <em style="font: inherit;">9</em>&#160;&#8211; Stock-Based Compensation</b></span></span></p>
   <p style="font-family: Times New Roman; font-size: 10pt; margin: 0pt; text-align: left;">&#160;</p>
   <p style="font-family: Times New Roman; font-size: 10pt; margin: 0pt; text-align: left;"><span style="color:#333333;"><span style="font-size: 10pt;">We recognize expense in our condensed consolidated financial statements related to all stock-based awards granted to employees and non-employee directors based on their fair value on the date of grant.&#160;Compensation expense related to stock options is calculated using the Black-Scholes option-pricing model and is recognized ratably over the vesting period, which is typically <span style="-sec-ix-hidden:c86425425">three</span> years. Compensation expense related to restricted stock unit, or RSU, awards is also recognized ratably over the vesting period, which typically has been between approximately <span style="-sec-ix-hidden:c86425426">one</span> to <span style="-sec-ix-hidden:c86425427">three</span> years.</span></span></p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin: 0pt; text-align: left;">&#160;</p>


   <p style="text-align: left; margin: 0pt; font-size: 10pt;"><span style="color:#333333;">A summary of activity under our long-term incentive plans is presented below:</span></p>
   <p style="text-align: left; margin: 0pt; font-size: 10pt;">&#160;</p>

    <table cellpadding="0" cellspacing="0" class="finTable" style="margin-right: auto; width: 80%; font-size: 10pt; font-family: Times New Roman; text-indent: 0px;">
     <tbody>
      <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom">
       <td style="font-family: Times New Roman; font-size: 10pt; padding: 0px; margin: 0px; width: 49%;"> <p style="margin-top: 0pt; margin-bottom: 0pt; font-family: Times New Roman; font-size: 10pt;"><span style="color:#333333;">(in thousands, except for weighted-average data)</span></p> </td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0px; margin: 0px;">&#160;</td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0px; margin: 0px;">&#160;</td>
       <td style="width: 14%; text-align: right; font-family: Times New Roman; font-size: 10pt; padding: 0px; margin: 0px;">&#160;</td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0px; margin: 0px;">&#160;</td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0px; margin: 0px;">&#160;</td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0px; margin: 0px;">&#160;</td>
       <td style="width: 14%; text-align: right; font-family: Times New Roman; font-size: 10pt; padding: 0px; margin: 0px;">&#160;</td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0px; margin: 0px;">&#160;</td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0px; margin: 0px;">&#160;</td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0px; margin: 0px;">&#160;</td>
       <td style="width: 14%; text-align: right; font-family: Times New Roman; font-size: 10pt; padding: 0px; margin: 0px;">&#160;</td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0px; margin: 0px;">&#160;</td>
      </tr>

      <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom">
       <td style="font-family: Times New Roman; font-size: 10pt; width: 49%; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; text-align: center;"><span style="color:#333333;"><b>Stock Options</b></span></p> </td>
       <td style="font-family: Times New Roman; font-size: 10pt; width: 1%;">&#160;</td>
       <td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); width: 1%;"> <p style="font-family: Times New Roman; font-size: 10pt; margin: 0pt; text-align: center;"><span style="color:#333333;"><b><em style="font: inherit;">Shares</em></b></span></p> </td>
       <td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; width: 1%;">&#160;</td>
       <td style="font-family: Times New Roman; font-size: 10pt; width: 1%;">&#160;</td>
       <td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); width: 1%;"> <p style="font-family: Times New Roman; font-size: 10pt; margin: 0pt; text-align: center;"><span style="color:#333333;"><b><em style="font: inherit;">Weighted- Average Exercise Price</em></b></span></p> </td>
       <td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; width: 1%;">&#160;</td>
       <td style="font-family: Times New Roman; font-size: 10pt; width: 1%;">&#160;</td>
       <td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); width: 1%;"> <p style="font-family: Times New Roman; font-size: 10pt; margin: 0pt; text-align: center;"><span style="color:#333333;"><b><em style="font: inherit;">Weighted- Average Remaining Contractual Term (In Yrs)</em></b></span></p> </td>
       <td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; width: 1%;">&#160;</td>
      </tr>

      <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom">
       <td style="font-family: Times New Roman; font-size: 10pt; width: 49%;">&#160;</td>
       <td style="font-family: Times New Roman; font-size: 10pt; width: 1%;">&#160;</td>
       <td style="font-family: Times New Roman; font-size: 10pt; width: 1%;">&#160;</td>
       <td style="font-family: Times New Roman; font-size: 10pt; width: 14%;">&#160;</td>
       <td style="font-family: Times New Roman; font-size: 10pt; width: 1%;">&#160;</td>
       <td style="font-family: Times New Roman; font-size: 10pt; width: 1%;">&#160;</td>
       <td style="font-family: Times New Roman; font-size: 10pt; width: 1%;">&#160;</td>
       <td style="font-family: Times New Roman; font-size: 10pt; width: 14%;">&#160;</td>
       <td style="font-family: Times New Roman; font-size: 10pt; width: 1%;">&#160;</td>
       <td style="font-family: Times New Roman; font-size: 10pt; width: 1%;">&#160;</td>
       <td style="font-family: Times New Roman; font-size: 10pt; width: 1%;">&#160;</td>
       <td style="font-family: Times New Roman; font-size: 10pt; width: 14%;">&#160;</td>
       <td style="font-family: Times New Roman; font-size: 10pt; width: 1%;">&#160;</td>
      </tr>

      <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom">
       <td style="font-family: Times New Roman; font-size: 10pt; width: 49%;"> <p style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><span style="color:#333333;">Outstanding at January 1, 2022</span></p> </td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td>
       <td style="width: 14%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><span style="color:#333333;">3,387</span></td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><span style="color:#333333;">$</span></td>
       <td style="width: 14%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><span style="color:#333333;">9.74</span></td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td>
       <td style="font-family: Times New Roman; font-size: 10pt; width: 1%;">&#160;</td>
       <td style="font-family: Times New Roman; font-size: 10pt; width: 1%;">&#160;</td>
       <td style="text-align: right; font-family: Times New Roman; font-size: 10pt; width: 14%;"><em style="font: inherit;">&#160;</em></td>
       <td style="font-family: Times New Roman; font-size: 10pt; width: 1%;">&#160;</td>
      </tr>

      <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom">
       <td style="font-family: Times New Roman; font-size: 10pt; width: 49%;"> <p style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 9pt;"><span style="color:#333333;">Granted</span></p> </td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td>
       <td style="width: 14%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><span style="color:#333333;">880</span></td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td>
       <td style="width: 14%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><span style="color:#333333;">0.99</span></td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td>
       <td style="font-family: Times New Roman; font-size: 10pt; width: 1%;">&#160;</td>
       <td style="font-family: Times New Roman; font-size: 10pt; width: 1%;">&#160;</td>
       <td style="text-align: right; font-family: Times New Roman; font-size: 10pt; width: 14%;"><em style="font: inherit;">&#160;</em></td>
       <td style="font-family: Times New Roman; font-size: 10pt; width: 1%;">&#160;</td>
      </tr>

      <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom">
       <td style="font-family: Times New Roman; font-size: 10pt; width: 49%;"> <p style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 9pt;"><span style="color:#333333;">Forfeited or expired</span></p> </td>
       <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px;">&#160;</td>
       <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
       <td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><span style="color:#333333;">(220</span></td>
       <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"><span style="color:#333333;">)</span></td>
       <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px;">&#160;</td>
       <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
       <td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><span style="color:#333333;">9.72</span></td>
       <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">&#160;</td>
       <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 1%; padding-bottom: 1px;">&#160;</td>
       <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 1%; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
       <td style="text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 14%; border-bottom: 1px solid rgb(0, 0, 0);"><em style="font: inherit;">&#160;</em></td>
       <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 1%; padding-bottom: 1px;">&#160;</td>
      </tr>

      <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom">
       <td style="font-family: Times New Roman; font-size: 10pt; width: 49%;"> <p style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><span style="color:#333333;">Outstanding at June 30, 2022</span></p> </td>
       <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 3px;">&#160;</td>
       <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);">&#160;</td>
       <td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><span style="color:#333333;">4,047</span></td>
       <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;">&#160;</td>
       <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 3px;">&#160;</td>
       <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><span style="color:#333333;">$</span></td>
       <td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><span style="color:#333333;">7.84</span></td>
       <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;">&#160;</td>
       <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 3px;">&#160;</td>
       <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);">&#160;</td>
       <td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><span style="color:#333333;">7.8</span></td>
       <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;">&#160;</td>
      </tr>

      <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom">
       <td style="font-family: Times New Roman; font-size: 10pt; width: 49%;">&#160;</td>
       <td style="font-family: Times New Roman; font-size: 10pt; width: 1%;">&#160;</td>
       <td style="font-family: Times New Roman; font-size: 10pt; width: 1%;">&#160;</td>
       <td style="font-family: Times New Roman; font-size: 10pt; width: 14%;">&#160;</td>
       <td style="font-family: Times New Roman; font-size: 10pt; width: 1%;">&#160;</td>
       <td style="font-family: Times New Roman; font-size: 10pt; width: 1%;">&#160;</td>
       <td style="font-family: Times New Roman; font-size: 10pt; width: 1%;">&#160;</td>
       <td style="font-family: Times New Roman; font-size: 10pt; width: 14%;">&#160;</td>
       <td style="font-family: Times New Roman; font-size: 10pt; width: 1%;">&#160;</td>
       <td style="font-family: Times New Roman; font-size: 10pt; width: 1%;">&#160;</td>
       <td style="font-family: Times New Roman; font-size: 10pt; width: 1%;">&#160;</td>
       <td style="font-family: Times New Roman; font-size: 10pt; width: 14%;">&#160;</td>
       <td style="font-family: Times New Roman; font-size: 10pt; width: 1%;">&#160;</td>
      </tr>

      <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom">
       <td style="font-family: Times New Roman; font-size: 10pt; width: 49%;"> <p style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><span style="color:#333333;">Vested and exercisable at June 30, 2022</span></p> </td>
       <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td>
       <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td>
       <td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"><span style="color:#333333;">2,229</span></td>
       <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#160;</td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><span style="color:#333333;">$</span></td>
       <td style="width: 14%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><span style="color:#333333;">11.35</span></td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td>
       <td style="width: 14%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><span style="color:#333333;">6.8</span></td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td>
      </tr>

      <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom">
       <td style="padding: 0px; margin: 0px; font-family: Times New Roman; font-size: 10pt; width: 49%;">&#160;</td>
       <td style="padding: 0px; margin: 0px; font-family: Times New Roman; font-size: 10pt; width: 1%;">&#160;</td>
       <td style="padding: 0px; margin: 0px; font-family: Times New Roman; font-size: 10pt; width: 1%;">&#160;</td>
       <td style="padding: 0px; margin: 0px; font-family: Times New Roman; font-size: 10pt; width: 14%;">&#160;</td>
       <td style="padding: 0px; margin: 0px; font-family: Times New Roman; font-size: 10pt; width: 1%;">&#160;</td>
       <td style="padding: 0px; margin: 0px; font-family: Times New Roman; font-size: 10pt; width: 1%;">&#160;</td>
       <td style="padding: 0px; margin: 0px; font-family: Times New Roman; font-size: 10pt; width: 1%;">&#160;</td>
       <td style="padding: 0px; margin: 0px; font-family: Times New Roman; font-size: 10pt; width: 14%;">&#160;</td>
       <td style="padding: 0px; margin: 0px; font-family: Times New Roman; font-size: 10pt; width: 1%;">&#160;</td>
       <td style="padding: 0px; margin: 0px; font-family: Times New Roman; font-size: 10pt; width: 1%;">&#160;</td>
       <td style="padding: 0px; margin: 0px; font-family: Times New Roman; font-size: 10pt; width: 1%;">&#160;</td>
       <td style="padding: 0px; margin: 0px; font-family: Times New Roman; font-size: 10pt; width: 14%;">&#160;</td>
       <td style="padding: 0px; margin: 0px; font-family: Times New Roman; font-size: 10pt; width: 1%;">&#160;</td>
      </tr>

      <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom">
       <td style="font-family: Times New Roman; font-size: 10pt; width: 49%;"> <p style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><span style="color:#333333;">Vested and expected to vest at June 30, 2022</span></p> </td>
       <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td>
       <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td>
       <td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"><span style="color:#333333;">3,821</span></td>
       <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#160;</td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><span style="color:#333333;">$</span></td>
       <td style="width: 14%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><span style="color:#333333;">7.85</span></td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td>
       <td style="width: 14%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><span style="color:#333333;">7.8</span></td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td>
      </tr>

     </tbody>
    </table>

   <p style="margin: 0pt; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</p>

    <table cellpadding="0" cellspacing="0" class="finTable" style="width: 80%; font-size: 10pt; font-family: &quot;Times New Roman&quot;; text-indent: 0px; margin-left: 0pt; margin-right: auto;">
     <tbody>
      <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom">
       <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 58%;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;"><span style="color:#333333;">(in thousands, except for weighted-average data)</span></p> </td>
       <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 1%;">&#160;</td>
       <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 1%;">&#160;</td>
       <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 16%;">&#160;</td>
       <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 1%;">&#160;</td>
       <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 1%;">&#160;</td>
       <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 1%;">&#160;</td>
       <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 20%;">&#160;</td>
       <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 1%;">&#160;</td>
      </tr>

      <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom">
       <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 58%; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; text-align: center;"><span style="color:#333333;"><b>Restricted Stock Units</b></span></p> </td>
       <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 1%;">&#160;</td>
       <td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); width: 1%;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><span style="color:#333333;"><b><em style="font: inherit;">Shares</em></b></span></p> </td>
       <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px; width: 1%;">&#160;</td>
       <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 1%;">&#160;</td>
       <td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); width: 1%;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><span style="color:#333333;"><b><em style="font: inherit;">Weighted- Average Grant Date Fair Value</em></b></span></p> </td>
       <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px; width: 1%;">&#160;</td>
      </tr>

      <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom">
       <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 58%;">&#160;</td>
       <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 1%;">&#160;</td>
       <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 1%;">&#160;</td>
       <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 16%;">&#160;</td>
       <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 1%;">&#160;</td>
       <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 1%;">&#160;</td>
       <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 1%;">&#160;</td>
       <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 20%;">&#160;</td>
       <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 1%;">&#160;</td>
      </tr>

      <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom">
       <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 58%;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;"><span style="color:#333333;">Outstanding at January 1, 2022</span></p> </td>
       <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td>
       <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td>
       <td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"><span style="color:#333333;">-</span></td>
       <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#160;</td>
       <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td>
       <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"><span style="color:#333333;">$</span></td>
       <td style="width: 20%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"><span style="color:#333333;">-</span></td>
       <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#160;</td>
      </tr>

      <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom">
       <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 58%;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; text-indent: 9pt;"><span style="color:#333333;">Awarded</span></p> </td>
       <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td>
       <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td>
       <td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"><span style="color:#333333;">582</span></td>
       <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#160;</td>
       <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td>
       <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td>
       <td style="width: 20%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"><span style="color:#333333;">0.99</span></td>
       <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#160;</td>
      </tr>

      <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom">
       <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 58%; padding-top: 0px; padding-right: 0px; padding-left: 0px; margin: 0px;"> <p style="margin-top: 0pt; margin-bottom: 0pt; text-indent: 9pt;"><span style="color:#333333;">Cancelled</span></p> </td>
       <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding: 0px 0px 1px; margin: 0px;">&#160;</td>
       <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-top: 0px; padding-right: 0px; padding-left: 0px; margin: 0px; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
       <td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-top: 0px; padding-right: 0px; padding-left: 0px; margin: 0px; border-bottom: 1px solid rgb(0, 0, 0);"><span style="color:#333333;">(21</span></td>
       <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding: 0px 0px 1px; margin: 0px;"><span style="color:#333333;">)</span></td>
       <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding: 0px 0px 1px; margin: 0px;">&#160;</td>
       <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-top: 0px; padding-right: 0px; padding-left: 0px; margin: 0px; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
       <td style="width: 20%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-top: 0px; padding-right: 0px; padding-left: 0px; margin: 0px; border-bottom: 1px solid rgb(0, 0, 0);"><span style="color:#333333;">1.02</span></td>
       <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding: 0px 0px 1px; margin: 0px;">&#160;</td>
      </tr>

      <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom">
       <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 58%;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;"><span style="color:#333333;">Outstanding at June 30, 2022</span></p> </td>
       <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 3px;">&#160;</td>
       <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);">&#160;</td>
       <td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><span style="color:#333333;">561</span></td>
       <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;">&#160;</td>
       <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 3px;">&#160;</td>
       <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><span style="color:#333333;">$</span></td>
       <td style="width: 20%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><span style="color:#333333;">0.99</span></td>
       <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;">&#160;</td>
      </tr>

      <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom">
       <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 58%; padding: 0; margin: 0">&#160;</td>
       <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 1%; padding: 0; margin: 0">&#160;</td>
       <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 1%; padding: 0; margin: 0">&#160;</td>
       <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 16%; padding: 0; margin: 0">&#160;</td>
       <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 1%; padding: 0; margin: 0">&#160;</td>
       <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 1%; padding: 0; margin: 0">&#160;</td>
       <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 1%; padding: 0; margin: 0">&#160;</td>
       <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 20%; padding: 0; margin: 0">&#160;</td>
       <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 1%; padding: 0; margin: 0">&#160;</td>
      </tr>

      <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom">
       <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 58%; padding: 0; margin: 0"> <p style="margin-top: 0pt; margin-bottom: 0pt"><span style="color:#333333;">Vested and exercisable at June 30, 2022</span></p> </td>
       <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding: 0; margin: 0">&#160;</td>
       <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding: 0; margin: 0">&#160;</td>
       <td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding: 0; margin: 0"><span style="color:#333333;">-</span></td>
       <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding: 0; margin: 0">&#160;</td>
       <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding: 0; margin: 0">&#160;</td>
       <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding: 0; margin: 0"><span style="color:#333333;">$</span></td>
       <td style="width: 20%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding: 0; margin: 0"><span style="color:#333333;">-</span></td>
       <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding: 0; margin: 0">&#160;</td>
      </tr>

      <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom">
       <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 58%; padding: 0; margin: 0">&#160;</td>
       <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 1%; padding: 0; margin: 0">&#160;</td>
       <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 1%; padding: 0; margin: 0">&#160;</td>
       <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 16%; padding: 0; margin: 0">&#160;</td>
       <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 1%; padding: 0; margin: 0">&#160;</td>
       <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 1%; padding: 0; margin: 0">&#160;</td>
       <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 1%; padding: 0; margin: 0">&#160;</td>
       <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 20%; padding: 0; margin: 0">&#160;</td>
       <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 1%; padding: 0; margin: 0">&#160;</td>
      </tr>

      <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom">
       <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 58%; padding: 0; margin: 0"> <p style="margin-top: 0pt; margin-bottom: 0pt"><span style="color:#333333;">Vested and expected to vest at June 30, 2022</span></p> </td>
       <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding: 0; margin: 0">&#160;</td>
       <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding: 0; margin: 0">&#160;</td>
       <td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding: 0; margin: 0"><span style="color:#333333;">561</span></td>
       <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding: 0; margin: 0">&#160;</td>
       <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding: 0; margin: 0">&#160;</td>
       <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding: 0; margin: 0"><span style="color:#333333;">$</span></td>
       <td style="width: 20%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding: 0; margin: 0"><span style="color:#333333;">0.99</span></td>
       <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding: 0; margin: 0">&#160;</td>
      </tr>

     </tbody>
    </table>

   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin: 0pt; text-align: left;">&#160;</p>
   <p style="font-family: Times New Roman; font-size: 10pt; margin: 0pt; text-align: left;"><span style="color:#333333;">The table below summarizes the total stock-based compensation expense included in the interim unaudited condensed consolidated statements of operations for the periods presented:</span></p>
   <p style="font-family: Times New Roman; font-size: 10pt; margin: 0pt; text-align: left;">&#160;</p>

    <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="margin-right: 20%; width: 80%; font-size: 10pt; font-family: Times New Roman; text-indent: 0px;">
     <tbody>
      <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom">
       <td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td>
       <td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td>
       <td colspan="6" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><span style="color:#333333;"><b><em style="font: inherit;"><em style="font: inherit;">Three Months Ended June 30,</em></em></b></span></p> </td>
       <td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td>
       <td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td>
       <td colspan="6" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><span style="color:#333333;"><b><em style="font: inherit;"><em style="font: inherit;">Six Months Ended June 30,</em></em></b></span></p> </td>
       <td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td>
      </tr>

      <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom">
       <td style="font-family: Times New Roman; font-size: 10pt; width: 36%;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;"><span style="color:#333333;"><i>(in thousands)</i></span></p> </td>
       <td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td>
       <td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><span style="color:#333333;"><b><em style="font: inherit;">2022</em></b></span></p> </td>
       <td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&#160;</td>
       <td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td>
       <td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><span style="color:#333333;"><b><em style="font: inherit;">2021</em></b></span></p> </td>
       <td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&#160;</td>
       <td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td>
       <td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><span style="color:#333333;"><b><em style="font: inherit;">2022</em></b></span></p> </td>
       <td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&#160;</td>
       <td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td>
       <td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><span style="color:#333333;"><b><em style="font: inherit;">2021</em></b></span></p> </td>
       <td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&#160;</td>
      </tr>

      <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom">
       <td>&#160;</td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td>&#160;</td>
      </tr>

      <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom">
       <td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;"><span style="color:#333333;">Research and development</span></p> </td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><span style="color:#333333;">$</span></td>
       <td style="width: 13%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><span style="color:#333333;">147</span></td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><span style="color:#333333;">$</span></td>
       <td style="width: 13%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><span style="color:#333333;">630</span></td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><span style="color:#333333;">$</span></td>
       <td style="width: 13%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><span style="color:#333333;">382</span></td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><span style="color:#333333;">$</span></td>
       <td style="width: 13%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><span style="color:#333333;">1,569</span></td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td>
      </tr>

      <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom">
       <td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;"><span style="color:#333333;">General and administrative</span></p> </td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
       <td style="width: 13%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><span style="color:#333333;">634</span></td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
       <td style="width: 13%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><span style="color:#333333;">914</span></td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
       <td style="width: 13%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><span style="color:#333333;">1,169</span></td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
       <td style="width: 13%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><span style="color:#333333;">2,418</span></td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td>
      </tr>

      <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom">
       <td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 18pt;"><span style="color:#333333;">Total</span></p> </td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><span style="color:#333333;">$</span></td>
       <td style="width: 13%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><span style="color:#333333;">781</span></td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&#160;</td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><span style="color:#333333;">$</span></td>
       <td style="width: 13%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><span style="color:#333333;">1,544</span></td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&#160;</td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><span style="color:#333333;">$</span></td>
       <td style="width: 13%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><span style="color:#333333;">1,551</span></td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&#160;</td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><span style="color:#333333;">$</span></td>
       <td style="width: 13%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><span style="color:#333333;">3,987</span></td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&#160;</td>
      </tr>

     </tbody>
    </table>

   <p style="font-family: Times New Roman; font-size: 10pt; margin: 0pt; text-align: left;">&#160;</p>
   <p style="font-family: Times New Roman; font-size: 10pt; margin: 0pt; text-align: left;"><span style="color:#333333;">The fair value of each option award is estimated on the date of grant using the Black-Scholes option-pricing formula that uses assumptions noted in the following table. Expected volatilities are based upon the historical volatility of our common stock and other factors. We also use historical data and other factors to estimate option exercises, employee terminations and forfeiture rates. The risk-free interest rates are based upon the U.S. Treasury yield curve in effect at the time of the grant.</span></p>
   <p style="font-family: Times New Roman; font-size: 10pt; margin: 0pt; text-align: left;">&#160;</p>

    <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="margin-right: 20%; width: 80%; font-size: 10pt; font-family: Times New Roman; text-indent: 0px;">
     <tbody>
      <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom">
       <td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td>
       <td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td>
       <td colspan="6" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><span style="color:#333333;"><b><em style="font: inherit;"><em style="font: inherit;">Six Months Ended June 30,</em></em></b></span></p> </td>
       <td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td>
      </tr>

      <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom">
       <td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td>
       <td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td>
       <td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><span style="color:#333333;"><b><em style="font: inherit;">2022</em></b></span></p> </td>
       <td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&#160;</td>
       <td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td>
       <td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><span style="color:#333333;"><b><em style="font: inherit;">2021</em></b></span></p> </td>
       <td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&#160;</td>
      </tr>

      <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom">
       <td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td>
       <td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td>
       <td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td>
       <td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td>
       <td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td>
       <td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td>
       <td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td>
       <td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td>
       <td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td>
      </tr>

      <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom">
       <td style="font-family: Times New Roman; font-size: 10pt; width: 62%;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;"><span style="color:#333333;">Weighted average expected volatility</span></p> </td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td>
       <td style="width: 16%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: center;"> <p style="margin-top: 0pt; margin-bottom: 0pt; font-family: Times New Roman; font-size: 10pt;"><span style="color:#333333;">106%</span></p> </td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td>
       <td style="width: 16%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: center;"> <p style="margin-top: 0pt; margin-bottom: 0pt; font-family: Times New Roman; font-size: 10pt;"><span style="color:#333333;">105%</span></p> </td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td>
      </tr>

      <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom">
       <td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;"><span style="color:#333333;">Weighted average expected term (in years)</span></p> </td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td>
       <td style="width: 16%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: center;"> <p style="margin-top: 0pt; margin-bottom: 0pt; font-family: Times New Roman; font-size: 10pt;"><span style="color:#333333;">6.9</span></p> </td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td>
       <td style="width: 16%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: center;"> <p style="margin-top: 0pt; margin-bottom: 0pt; font-family: Times New Roman; font-size: 10pt;"><span style="color:#333333;">6.7</span></p> </td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td>
      </tr>

      <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom">
       <td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;"><span style="color:#333333;">Weighted average risk-free interest rate</span></p> </td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td>
       <td style="width: 16%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: center;"> <p style="margin-top: 0pt; margin-bottom: 0pt; font-family: Times New Roman; font-size: 10pt;"><span style="color:#333333;">1.70%</span></p> </td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td>
       <td style="width: 16%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: center;"> <p style="margin-top: 0pt; margin-bottom: 0pt; font-family: Times New Roman; font-size: 10pt;"><span style="color:#333333;">0.48%</span></p> </td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td>
      </tr>

      <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom">
       <td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;"><span style="color:#333333;">Expected dividends</span></p> </td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td>
       <td style="width: 16%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: center;"><em style="font: inherit;"> </em><p style="margin-top: 0pt; margin-bottom: 0pt; font-family: Times New Roman; font-size: 10pt;"><span style="color:#333333;">-</span></p> </td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td>
       <td style="width: 16%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: center;"><em style="font: inherit;"> </em><p style="margin-top: 0pt; margin-bottom: 0pt; font-family: Times New Roman; font-size: 10pt;"><span style="color:#333333;">-</span></p> </td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td>
      </tr>

     </tbody>
    </table>

  <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -URI https://asc.fasb.org/topic&amp;trid=2228938<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (l)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(2)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureTextBlockAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureTextBlockAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>26
<FILENAME>R16.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm139823964104576">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note 10 - Licensing and Research Funding Agreements<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureTextBlockAbstract', window );"><strong>Notes to Financial Statements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_wint_CorporatePartnershipLicensingAndResearchFundingAgreementsTextBlock', window );">Corporate Partnership, Licensing and Research Funding Agreements [Text Block]</a></td>
<td class="text">

   <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&#160;</p>
   <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><span style="color:#333333;"><b>Note <em style="font: inherit;">10</em> &#8211; Licensing&#160;and Research Funding Agreements</b></span></p>
   <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&#160;</p>
   <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><span style="color:#333333;">In <em style="font: inherit;"> March 2020, </em>we entered into a Term Sheet with Lee&#8217;s (HK), pursuant to which Lee&#8217;s (HK) provided financing for the development of AEROSURF. In <em style="font: inherit;"> August 2020,&#160;</em>we entered into a Project Financing Agreement with&#160;Lee&#8217;s (HK), or the&#160;PF Agreement, formalizing the terms of the Term Sheet, and&#160;under which we received payments totaling&#160;$2.8&#160;million&#160;through <em style="font: inherit;"> October 2020.&#160;</em>In <em style="font: inherit;"> November 2020, </em>Lee&#8217;s (HK) provided notice of termination of&#160;additional funding under&#160;the PF Agreement, and we and Lee&#8217;s (HK) revised our plans for the continued development of AEROSURF. Lee&#8217;s (HK) agreed to continue the development of AEROSURF in Asia at its cost. Lee&#8217;s (HK) agreed to&#160;fund an additional&#160;</span><span style="color:#333333;">$1.0</span><span style="color:#333333;"> million to us&#160;in <em style="font: inherit;">2021</em> for certain transition and analytical services to be provided by us with respect to the development of AEROSURF, which will be considered &#8220;Project Expenses&#8221; under the terms of the PF Agreement.&#160;In&#160;<em style="font: inherit;">2021,</em>&#160;we received payments totaling&#160;$1.0&#160;million from&#160;Lee&#8217;s (HK) and&#160;<em style="font: inherit;">no</em>&#160;further amounts are due under the PF Agreement.</span></p>
   <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&#160;</p>
   <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><span style="color:#333333;">To repay the funds provided under the terms of the PF Agreement, until such time as we have repaid </span><span style="color:#333333;">125%</span><span style="color:#333333;">&#160;of the amounts funded by Lee&#8217;s (HK) for the development of AEROSURF, we will pay to Lee&#8217;s (HK)&#160;</span><span style="color:#333333;">50%</span><span style="color:#333333;"> of all revenue amounts and payments received by us for any sale, divestiture, license or other development and/or commercialization of the <em style="font: inherit;">KL4/AEROSURF</em> patent portfolio, excluding (i) payments for bona fide research and development services; (ii) reimbursement of patent expenses and (iii) all amounts paid to us under the Asia License Agreement, minus certain deductions and certain reductions for any payments made by us with respect to <em style="font: inherit;">third</em> party intellectual property <em style="font: inherit;">not</em> previously funded by Lee&#8217;s (HK).</span></p>
   <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&#160;</p>
   <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><span style="color:#333333;">As of </span><span style="color:#333333;"><em style="font: inherit;"> June 30, 2022</em></span><span style="color:#333333;">, the liability balance related to the payments under the PF Agreement was&#160;</span><span style="color:#333333;">$3.8</span><span style="color:#333333;">&#160;million and is recorded in other liabilities.</span></p>
  <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureTextBlockAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureTextBlockAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_wint_CorporatePartnershipLicensingAndResearchFundingAgreementsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for corporate partnerships, licensing and research funding agreements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">wint_CorporatePartnershipLicensingAndResearchFundingAgreementsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>wint_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>27
<FILENAME>R17.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm139823956439008">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Significant Accounting Policies (Policies)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConsolidationPolicyTextBlock', window );">Consolidation, Policy [Policy Text Block]</a></td>
<td class="text"><p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin: 0pt; text-align: left;"><span style="color:#333333;"><b>Principles of Consolidation</b></span></p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin: 0pt; text-align: left;">&#160;</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin: 0pt; text-align: left;"><span style="color:#333333;">The interim unaudited condensed consolidated financial statements are prepared in accordance with US GAAP&#160;and include accounts of Windtree Therapeutics, Inc. and its wholly owned subsidiaries, CVie Investments Limited and its wholly owned subsidiary, CVie Therapeutics Limited; and a presently inactive subsidiary, Discovery Laboratories, Inc. (formerly known as Acute Therapeutics, Inc.).</span></p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin: 0pt; text-align: left;">&#160;</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy', window );">Goodwill and Intangible Assets, Goodwill, Policy [Policy Text Block]</a></td>
<td class="text"><p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin: 0pt; text-align: left;"><span style="color:#333333;"><b>Goodwill and Intangible Assets</b></span></p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin: 0pt; text-align: left;">&#160;</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin: 0pt; text-align: left;"><span style="color:#333333;">We record acquired identified intangibles, which includes intangible assets (such as goodwill and other intangibles), based on estimated fair value. The acquired in-process research and development, or IPR&amp;D, assets are considered indefinite-lived intangible assets until completion or abandonment of the associated research and development efforts. IPR&amp;D is <em style="font: inherit;">not</em> amortized but reviewed for impairment at least annually, or when events or changes in the business environment indicate the carrying value <em style="font: inherit;"> may </em>be impaired. During the&#160;</span><span style="color:#333333;"><em style="font: inherit;">three</em> and <em style="font: inherit;">six</em> months ended <em style="font: inherit;"> June 30, 2022</em></span><span style="color:#333333;">, <em style="font: inherit;">no</em> events or changes in circumstances occurred indicating that our IPR&amp;D intangible assets were more likely than <em style="font: inherit;">not</em> impaired.</span></p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin: 0pt; text-align: left;">&#160;</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin: 0pt; text-align: left;"><span style="color:#333333;">During the&#160;<em style="font: inherit;">second</em>&#160;quarter of <em style="font: inherit;">2021,</em> we determined that the fair value of the IPR&amp;D related to our rostafuroxin drug candidate was more likely than&#160;<em style="font: inherit;">not</em> impaired and we&#160;performed the required quantitative impairment assessment of the related intangible asset. We recorded a loss on impairment of intangible assets of&#160;</span><span style="color:#333333;">$37.8</span><span style="color:#333333;">&#160;million, recognized within operating expenses in our condensed consolidated statements of operations&#160;for the&#160;<em style="font: inherit;">three</em>&#160;and&#160;<em style="font: inherit;">six</em>&#160;months ended&#160;<em style="font: inherit;"> June 30, 2021.&#160;</em><em style="font: inherit;">No</em>&#160;events or changes in the business environment occurred during the&#160;<em style="font: inherit;">six</em>&#160;months ended&#160;<em style="font: inherit;"> June 30, 2021&#160;</em>to indicate that the fair value of the IPR&amp;D related to our istaroxime drug candidate was impaired.</span></p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin: 0pt; text-align: left;">&#160;</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin: 0pt; text-align: left;"><span style="color:#333333;">Goodwill represents the excess of the purchase price over the fair value of assets acquired and liabilities assumed in a business combination and is <em style="font: inherit;">not</em> amortized. It is reviewed for impairment at least annually or when events or changes in the business environment indicate that its carrying value <em style="font: inherit;"> may </em>be impaired. Our company consists of one reporting unit. In order to perform the quantitative goodwill impairment test, we compare the estimated fair value of our reporting unit to its carrying value. If the fair value exceeds the carrying value, <em style="font: inherit;">no</em> further evaluation is required, and <em style="font: inherit;">no</em> impairment exists. If the carrying value exceeds the fair value, the difference between the carrying value and the fair value is recorded as an impairment loss, the amount of which <em style="font: inherit;"> may </em><em style="font: inherit;">not</em> exceed the total amount of goodwill. When performing our annual goodwill impairment assessment as of <em style="font: inherit;"> December 1, 2021, </em>we estimated the fair value of our reporting unit based upon the quoted market price and related market capitalization of our common stock, adjusted for an estimated control premium. Based on the quantitative test performed, we determined that the fair value of our reporting unit exceeded its carrying value and <em style="font: inherit;">no</em> impairment loss was recognized as of </span><span style="color:#333333;"><em style="font: inherit;"> December 31, 2021</em></span><span style="color:#333333;">.</span></p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin: 0pt; text-align: left;">&#160;</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin: 0pt; text-align: left;"><span style="color:#333333;">Throughout the year, we consider whether any events or changes in the business environment have occurred which indicate that goodwill <em style="font: inherit;"> may </em>be impaired. For example, a significant decline in the closing share price of our common stock and market capitalization <em style="font: inherit;"> may </em>suggest that the fair value of our reporting unit has fallen below its carrying amount, indicating that an interim goodwill impairment test is required. Accordingly, we monitor changes in our share price during interim periods between annual impairment tests and consider overall stock market conditions, the underlying reasons for the decline in our share price, the significance of the decline, and the duration of time that our securities have been trading at a lower value. We have experienced a declining trend in the&#160;closing share price of our common stock following the announcement in <em style="font: inherit;"> April 2022 </em>of positive topline results in our Phase <em style="font: inherit;">2</em> global clinical study of istaroxime for the treatment of early cardiogenic shock.</span></p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin: 0pt; text-align: left;">&#160;</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin: 0pt; text-align: left;"><span style="color:#333333;">During the <em style="font: inherit;">second</em> quarter of <em style="font: inherit;">2022,</em> the continued declining trend in the closing share price of our common stock suggested that the fair value of our reporting unit was more likely than <em style="font: inherit;">not</em> less than its carrying value.&#160;As a result, we&#160;performed the required interim goodwill impairment test consistent with the methodology that we use when performing our annual goodwill impairment assessment, including the use of the quoted market price and related market capitalization of our common stock, adjusted for an estimated control premium based on transactions completed by comparable companies.&#160;Based on the quantitative test performed, we recorded a loss on impairment of goodwill of&#160;</span><span style="color:#333333;">$11.6</span><span style="color:#333333;"> million, recognized within operating expenses in our condensed consolidated statements of operations&#160;for the&#160;<em style="font: inherit;">three</em>&#160;and&#160;<em style="font: inherit;">six</em>&#160;months ended&#160;<em style="font: inherit;"> June 30, 2022.</em></span></p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin: 0pt; text-align: left;">&#160;</p>


   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin: 0pt; text-align: left;"><span style="color:#333333;">The closing share price of our common stock has continued to decline during <em style="font: inherit;"> July </em>and <em style="font: inherit;"> August 2022. </em>If our share price continues to decline during the remainder of the <em style="font: inherit;">third</em> quarter of <em style="font: inherit;">2022,</em> we <em style="font: inherit;"> may </em>be at risk for future impairment to goodwill in the near term.</span></p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin: 0pt; text-align: left;">&#160;</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;"><span style="color:#333333;">The following table represents identifiable intangible assets and goodwill as of </span><span style="color:#333333;"><em style="font: inherit;"> June 30, 2022</em></span><span style="color:#333333;"> and </span><span style="color:#333333;"><em style="font: inherit;"> December 31, 2021</em></span><span style="color:#333333;">:</span></p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">&#160;</p>

    <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="margin-right: 5%; margin-left: 5%; width: 90%; font-size: 10pt; font-family: &quot;Times New Roman&quot;; text-indent: 0px;"><tbody><tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td colspan="2" rowspan="1" style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; text-align: center;"><span style="color:#333333;"><b><em style="font: inherit;">June 30,</em></b></span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; text-align: center;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; text-align: center;">&#160;</td><td colspan="2" rowspan="1" style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; text-align: center;"><span style="color:#333333;"><b><em style="font: inherit;">December 31,</em></b></span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 66%;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;"><span style="color:#333333;"><i>(in thousands)</i></span></p> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><span style="color:#333333;"><b><em style="font: inherit;">2022</em></b></span></p> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><span style="color:#333333;"><b><em style="font: inherit;">2021</em></b></span></p> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px;">&#160;</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;"><span style="color:#333333;">Istaroxime drug candidate</span></p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"><span style="color:#333333;">$</span></td><td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"><span style="color:#333333;">22,340</span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"><span style="color:#333333;">$</span></td><td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"><span style="color:#333333;">22,340</span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;"><span style="color:#333333;">Rostafuroxin drug candidate</span></p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><span style="color:#333333;">9,730</span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><span style="color:#333333;">9,730</span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">&#160;</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;"><span style="color:#333333;">Intangible assets</span></p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);">&#160;</td><td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><span style="color:#333333;">32,070</span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);">&#160;</td><td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><span style="color:#333333;">32,070</span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&#160;</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;"><span style="color:#333333;">Goodwill</span></p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"><span style="color:#333333;">$</span></td><td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"><span style="color:#333333;">4,046</span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"><span style="color:#333333;">$</span></td><td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"><span style="color:#333333;">15,682</span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
</tbody></table>

   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin: 0pt; text-align: left;">&#160;</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock', window );">Foreign Currency Transactions and Translations Policy [Policy Text Block]</a></td>
<td class="text"><p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin: 0pt; text-align: left;"><span style="color:#333333;"><b>Foreign Currency Transactions</b></span></p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin: 0pt; text-align: left;">&#160;</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin: 0pt; text-align: left;"><span style="color:#333333;">The functional currency for our foreign subsidiaries is U.S. Dollars. We remeasure monetary assets and liabilities that are <em style="font: inherit;">not</em> denominated in the functional currency at exchange rates in effect at the end of each period. Gains and losses from the remeasurement of foreign currency transactions are recognized in </span><span style="color:#333333;">other income (expense), net</span><span style="color:#333333;">. Foreign currency transactions resulted in </span><span style="color:#333333;">gains</span><span style="color:#333333;">&#160;of approximately&#160;</span><span style="color:#333333;">$0.2</span><span style="color:#333333;"> million and losses of approximately&#160;</span><span style="color:#333333;">$0.3</span><span style="color:#333333;"> million for the <em style="font: inherit;">three</em>-month periods ended </span><span style="color:#333333;"><em style="font: inherit;"> June 30, 2022 </em>and <em style="font: inherit;">2021</em></span><span style="color:#333333;">, respectively.&#160;Foreign currency transactions resulted in </span><span style="color:#333333;">gains</span><span style="color:#333333;">&#160;of approximately&#160;</span><span style="color:#333333;">$0.4</span><span style="color:#333333;">&#160;million and losses of approximately&#160;</span><span style="color:#333333;">$0.2</span><span style="color:#333333;">&#160;million for the </span><span style="color:#333333;"><em style="font: inherit;">six</em></span><span style="color:#333333;">-month periods ended </span><span style="color:#333333;"><em style="font: inherit;"> June 30, 2022 </em>and <em style="font: inherit;">2021</em></span><span style="color:#333333;">, respectively.&#160;</span></p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin: 0pt; text-align: left;">&#160;</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UseOfEstimates', window );">Use of Estimates, Policy [Policy Text Block]</a></td>
<td class="text"><p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin: 0pt; text-align: left;"><span style="color:#333333;"><b>Use of Estimates</b></span></p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin: 0pt; text-align: left;"><br/> <span style="color:#333333;">The preparation of financial statements in conformity with US GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, including intangible assets and goodwill,&#160;at the date of the financial statements and the reported amounts of expenses during the reporting period. Actual results could differ from those estimates.</span></p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin: 0pt; text-align: left;">&#160;</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsPolicyTextBlock', window );">Cash and Cash Equivalents, Policy [Policy Text Block]</a></td>
<td class="text"><p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin: 0pt; text-align: left;"><span style="color:#333333;"><b>Cash and Cash Equivalents</b></span></p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin: 0pt; text-align: left;">&#160;</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin: 0pt; text-align: left;"><span style="color:#333333;">Cash and cash equivalents are held at domestic and foreign financial institutions and consist of liquid investments, money market funds, and U.S. Treasury notes with a maturity from date of purchase of <em style="font: inherit;">90</em> days or less that are readily convertible into cash.</span></p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin: 0pt; text-align: left;">&#160;</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueOfFinancialInstrumentsPolicy', window );">Fair Value of Financial Instruments, Policy [Policy Text Block]</a></td>
<td class="text"><p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin: 0pt; text-align: left;"><span style="color:#333333;"><b>Severance</b></span></p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin: 0pt; text-align: left;">&#160;</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin: 0pt; text-align: left;"><span style="color:#333333;">In <em style="font: inherit;"> January 2022,&#160;</em>in order to focus our resources on the&#160;development of our istaroxime pipeline, we began to reduce costs related to <em style="font: inherit;">KL4</em> surfactant that were <em style="font: inherit;">not</em> already transferred to our licensee in Asia, Lee&#8217;s (HK), under the terms of the Asia License Agreement. These costs include certain reductions in headcount dedicated to <em style="font: inherit;">KL4</em> surfactant and the decommissioning of both our analytical and technical support laboratory, which previously conducted release testing of active pharmaceutical ingredients&#160;and supportive research for our lyophilized and aerosolized <em style="font: inherit;">KL4</em> surfactant, and our medical device development laboratory, which was previously used to conduct development activities and testing for our ADS technologies. In <em style="font: inherit;"> February 2022, </em>management communicated&#160;its commitment to provide severance payments&#160;to impacted employees, provided that they remain employed with us through their expected termination dates. The total severance cost for impacted employees is approximately&#160;</span><span style="color:#333333;">$0.4</span><span style="color:#333333;">&#160;million, which was ratably accrued over the service periods of the employees, and to be paid through <em style="font: inherit;"> September 30, 2022. </em>We incurred </span><span style="color:#333333;">$0.1</span><span style="color:#333333;"> million and&#160;</span><span style="color:#333333;">$0.4</span><span style="color:#333333;"> million of expense&#160;related to these severance arrangements during the <em style="font: inherit;">three</em> and&#160;</span><span style="color:#333333;"><em style="font: inherit;">six</em> months ended <em style="font: inherit;"> June 30, 2022</em></span><span style="color:#333333;">, respectively,&#160;which is included in research and development expense.&#160;During the <em style="font: inherit;">three</em> and&#160;</span><span style="color:#333333;"><em style="font: inherit;">six</em> months ended <em style="font: inherit;"> June 30, 2022</em></span><span style="color:#333333;">,&#160;</span><span style="color:#333333;">$0.2</span><span style="color:#333333;">&#160;million was paid.&#160;The related liability as of </span><span style="color:#333333;"><em style="font: inherit;"> June 30, 2022</em></span><span style="color:#333333;"> is $0.2&#160;million and is included in accrued expenses. </span></p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin: 0pt; text-align: left;">&#160;</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentImpairment', window );">Property, Plant and Equipment, Impairment [Policy Text Block]</a></td>
<td class="text"><div style="font-size:10pt"><div style="font-family:&quot;Times New Roman&quot;"><span style="color:#333333;"><b>Property and Equipment</b></span>
    </div>
    <div style="font-family:&quot;Times New Roman&quot;">
      &#160;
    </div>
   </div>
   <div style="font-size:10pt">
    <div style="font-family:'Times New Roman'">
     <div style="font-variant:normal">
      <span style="color:#333333;">Property and equipment are recorded at cost and depreciated using the straight-line method over the estimated useful lives of the assets (generally&#160;<em style="font: inherit;">three</em>&#160;to&#160;<em style="font: inherit;">ten</em>&#160;years). Leasehold improvements are amortized over the shorter of the estimated useful lives or the remaining term of the lease. Repairs and maintenance costs are charged to expense as incurred.</span>
     </div>
     <div style="font-variant:normal">
       &#160;
     </div>
    </div>
   </div>
   <div style="font-size:10pt">
    <div style="font-family:'Times New Roman'">
     <div style="font-variant:normal">
      <span style="color:#333333;">During the <em style="font: inherit;">first</em> quarter of <em style="font: inherit;">2022,</em> we determined that&#160;certain&#160;manufacturing and laboratory equipment assets related to the <em style="font: inherit;">KL4</em> surfactant platform would be abandoned by <em style="font: inherit;"> March 31, 2022. </em>We accelerated depreciation of these assets during the <em style="font: inherit;">first</em> quarter of <em style="font: inherit;">2022,</em> resulting in $0.4 million of additional depreciation expense for the <em style="font: inherit;">three</em> months ended <em style="font: inherit;"> March 31, 2022.&#160;</em>During the <em style="font: inherit;">second</em> quarter of <em style="font: inherit;">2022,</em> the abandoned assets and certain other <em style="font: inherit;">KL4</em> surfactant platform assets were disposed.</span>
     </div>
     <div style="font-variant:normal">
       &#160;
     </div></div></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_wint_RestructuredDebtLiabilityContingentMilestonePaymentPolicyPolicyTextBlock', window );">Restructured Debt Liability, Contingent Milestone Payment, Policy [Policy Text Block]</a></td>
<td class="text"><p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin: 0pt; text-align: left;"><span style="color:#333333;"><b>Restructured Debt Liability &#8211; Contingent Milestone Payment</b></span></p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin: 0pt; text-align: left;">&#160;</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin: 0pt; text-align: left;"><span style="color:#333333;">In conjunction with the <em style="font: inherit;"> November 2017 </em>restructuring and retirement of long-term debt (<i>see</i>, </span><span style="color:#333333;">Note <em style="font: inherit;">7</em> &#8211; Restructured Debt Liability</span><span style="color:#333333;">), we have established a </span><span style="color:#333333;">$15.0</span><span style="color:#333333;">&#160;million long-term liability for contingent milestone payments potentially due under the Exchange and Termination Agreement dated as of <em style="font: inherit;"> October 27, 2017, </em>or the Exchange and Termination Agreement, between ourselves and affiliates of Deerfield Management Company L.P., or Deerfield. The liability has been recorded at full value of the contingent milestones and will continue to be carried at full value until the milestones are achieved and paid or milestones are <em style="font: inherit;">not</em> achieved and the liability is written off as a gain on debt restructuring.</span></p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin: 0pt; text-align: left;">&#160;</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpensePolicy', window );">Research and Development Expense, Policy [Policy Text Block]</a></td>
<td class="text"><p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin: 0pt; text-align: left;"><span style="color:#333333;"><b>Research and Development</b></span></p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin: 0pt; text-align: left;">&#160;</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin: 0pt; text-align: left;"><span style="color:#333333;">We track direct research and development expenses by preclinical and clinical programs, which include <em style="font: inherit;">third</em>-party costs such as contract research organization, consulting, and clinical trial costs. We do <em style="font: inherit;">not</em> allocate indirect research and development expenses, which include product development and manufacturing expenses and clinical, medical, and regulatory operations expenses, to specific programs. Indirect research and development expenses include personnel, facilities, manufacturing and quality operations, pharmaceutical and device development, research, regulatory, and medical affairs. Research and development costs are charged to operations as incurred in accordance with Financial Accounting Standards Board, or FASB, Accounting Standards Codification, or ASC, Topic <em style="font: inherit;">730,</em> Research and Development.</span></p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin: 0pt; text-align: left;">&#160;</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxPolicyTextBlock', window );">Income Tax, Policy [Policy Text Block]</a></td>
<td class="text"><p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin: 0pt; text-align: left;"><span style="color:#333333;"><b>Income Taxes</b></span></p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin: 0pt; text-align: left;">&#160;</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin: 0pt; text-align: left;"><span style="color:#333333;">We account for income taxes in accordance with ASC Topic <em style="font: inherit;">740,</em> Accounting for Income Taxes, which requires the recognition of deferred tax liabilities and assets for the expected future tax consequences of temporary differences between financial statement carrying amounts and the tax basis of assets and liabilities.</span></p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin: 0pt; text-align: left;">&#160;</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin: 0pt; text-align: left;"><span style="color:#333333;">We use a recognition threshold and measurement attribute for the financial statement recognition and measurement of a tax position taken or expected to be taken in a tax return. Because we have never realized a profit, management has fully reserved the net deferred tax asset since realization is <em style="font: inherit;">not</em> assured.</span></p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin: 0pt; text-align: left;">&#160;</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin: 0pt; text-align: left;"><span style="color:#333333;">For the&#160;<em style="font: inherit;">three</em>&#160;and&#160;<em style="font: inherit;">six</em>&#160;months ended&#160;</span><span style="color:#333333;"><em style="font: inherit;"> June 30, 2021</em></span><span style="color:#333333;">, we recorded a deferred&#160;income tax benefit of&#160;</span><span style="color:#333333;">$8.3</span><span style="color:#333333;">&#160;million. The deferred tax benefit recorded for these periods relates solely to the reduction of the deferred tax liability as a result of the loss on impairment of intangible assets related to&#160;rostafuroxin.</span></p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin: 0pt; text-align: left;">&#160;</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerSharePolicyTextBlock', window );">Earnings Per Share, Policy [Policy Text Block]</a></td>
<td class="text"><p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin: 0pt; text-align: left;"><span style="color:#333333;"><b>Net Loss per Common Share</b></span></p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin: 0pt; text-align: left;">&#160;</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin: 0pt; text-align: left;"><span style="color:#333333;">Basic net loss per common share is computed by dividing net loss by the weighted average number of common shares outstanding for the period. Diluted net loss per common share is computed by giving effect to all potentially dilutive securities outstanding for the period. As of </span><span style="color:#333333;"><em style="font: inherit;"> June 30, 2022 </em>and <em style="font: inherit;">2021</em></span><span style="color:#333333;">, the number of shares of common stock potentially issuable upon the exercise of certain stock options and warrants, as well as the vesting of&#160;restricted stock units, was&#160;</span><span style="color:#333333;">21.2</span><span style="color:#333333;"> million and&#160;</span><span style="color:#333333;">19.9</span><span style="color:#333333;"> million shares, respectively. For the </span><span style="color:#333333;"><em style="font: inherit;">three</em> and <em style="font: inherit;">six</em> months ended <em style="font: inherit;"> June 30, 2022 </em>and <em style="font: inherit;">2021</em></span><span style="color:#333333;">, all potentially dilutive securities were anti-dilutive and therefore have been excluded from the computation of diluted net loss per share.</span></p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin: 0pt; text-align: left;">&#160;</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin: 0pt; text-align: left;"><span style="color:#333333;">We do <em style="font: inherit;">not</em> have any components of other comprehensive (loss) income.</span></p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin: 0pt; text-align: left;">&#160;</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_wint_EffectOfCOVID19PandemicPolicyTextBlock', window );">Effect of COVID-19 Pandemic [Policy Text Block]</a></td>
<td class="text"><p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin: 0pt; text-align: left;"><span style="color:#333333;"><b>COVID-<em style="font: inherit;">19</em></b></span></p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin: 0pt; text-align: left;">&#160;</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin: 0pt; text-align: left;"><span style="color:#333333;">The COVID-<em style="font: inherit;">19</em> pandemic continues to evolve, and we continue to closely monitor its impact on our business and&#160;operations, including its continued&#160;impact on our clinical development plans and timelines, and financial condition. There has been intermittent impact of the pandemic in differing geographies,&#160;and there <em style="font: inherit;"> may </em>be continued impact, particularly in light of the surge of new COVID-<em style="font: inherit;">19</em> cases relating to new variants. As of the date of the issuance of this Quarterly Report on Form <em style="font: inherit;">10</em>-Q, our operations, capital&#160;and financial resources, and overall liquidity position and outlook have been impacted by COVID-<em style="font: inherit;">19,</em> primarily due to delays experienced in our operations, including&#160;in clinical study initiation and enrollment. The extended timelines have required us to expend more of our capital resources than planned to achieve our projected milestones. For example, our Phase <em style="font: inherit;">2</em> study of istaroxime for early cardiogenic shock in heart failure patients&#160;experienced delays in trial initiation and enrollment in <em style="font: inherit;">2021.</em>&#160;Although many countries have re-opened, rises in new cases, including as the result of newly identified COVID-<em style="font: inherit;">19</em> variants, have caused certain countries, states, and localities to re-initiate restrictions.&#160;The full extent, duration, or impact that the COVID-<em style="font: inherit;">19</em> pandemic will have, directly or indirectly, on our financial condition and operations, including ongoing and planned clinical trials, will depend on future developments that are highly uncertain and cannot be accurately predicted. These potential future developments include the severity and transmissibility of new variants of the virus, information about any resurgences&#160;in <em style="font: inherit;">one</em> or more geographic locations where our current or intended clinical trial sites, our&#160;principal executive offices, research and development laboratories, or manufacturing facilities are located, and the actions taken to contain it or treat its impact. In addition, regional impact and responses to the COVID-<em style="font: inherit;">19</em> pandemic have affected where a clinical trial could be executed and how various elements of the clinical trial are performed. Going forward, the pandemic could also impact how monitoring/auditing of clinical trial&#160;sites and data occur. The maintenance, or strategic re-implementation, of mitigating COVID-<em style="font: inherit;">19</em> measures in <em style="font: inherit;">one</em> or more geographic locations where our clinical trial sites, principal executive offices, research and development laboratories, or other facilities are located remains possible and if realized, we believe there could be further impact on the clinical development of our product candidates, which <em style="font: inherit;"> may </em>include potential delays, halts, or modifications to our ongoing and planned trials in </span><span style="color:#333333;"><em style="font: inherit;">2022</em></span><span style="color:#333333;"> and beyond.</span></p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin: 0pt; text-align: left;">&#160;</p>
   <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left"><span style="color:#333333;">We are <em style="font: inherit;">not</em> aware of any specific event or circumstance that would require us to further update our estimates, judgments, or revise the carrying value of our assets or liabilities as of the date of issuance of these interim unaudited condensed consolidated financial statements. These estimates <em style="font: inherit;"> may </em>change&#160;as new events occur and additional information is obtained.</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=d3e4273-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConsolidationPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy regarding (1) the principles it follows in consolidating or combining the separate financial statements, including the principles followed in determining the inclusion or exclusion of subsidiaries or other entities in the consolidated or combined financial statements and (2) its treatment of interests (for example, common stock, a partnership interest or other means of exerting influence) in other entities, for example consolidation or use of the equity or cost methods of accounting. The accounting policy may also address the accounting treatment for intercompany accounts and transactions, noncontrolling interest, and the income statement treatment in consolidation for issuances of stock by a subsidiary.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126899994&amp;loc=d3e18823-107790<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=d3e5614-111684<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConsolidationPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerSharePolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3630-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerSharePolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueOfFinancialInstrumentsPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for determining the fair value of financial instruments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 60<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=7493716&amp;loc=d3e21868-110260<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=123594938&amp;loc=d3e13279-108611<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueOfFinancialInstrumentsPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for (1) transactions denominated in a currency other than the reporting enterprise's functional currency, (2) translating foreign currency financial statements that are incorporated into the financial statements of the reporting enterprise by consolidation, combination, or the equity method of accounting, and (3) remeasurement of the financial statements of a foreign reporting enterprise in a hyperinflationary economy.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -URI https://asc.fasb.org/topic&amp;trid=2175825<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for goodwill. This accounting policy also may address how an entity assesses and measures impairment of goodwill, how reporting units are determined, how goodwill is allocated to such units, and how the fair values of the reporting units are determined.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13854-109267<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -URI https://asc.fasb.org/subtopic&amp;trid=2144439<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 55<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=122137925&amp;loc=d3e14258-109268<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -URI https://asc.fasb.org/extlink&amp;oid=123427490&amp;loc=d3e32247-109318<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32847-109319<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 19<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32840-109319<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL116659661-227067<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32639-109319<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI https://asc.fasb.org/extlink&amp;oid=123427490&amp;loc=d3e32280-109318<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 17<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32809-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentImpairment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for assessing and recognizing impairments of its property, plant and equipment.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=109226691&amp;loc=d3e2921-110230<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentImpairment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpensePolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpensePolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UseOfEstimates">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6191-108592<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6161-108592<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6143-108592<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6061-108592<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6132-108592<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UseOfEstimates</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_wint_EffectOfCOVID19PandemicPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The disclosure for the accounting policy related to the effect of the COVID-19 pandemic.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">wint_EffectOfCOVID19PandemicPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>wint_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_wint_RestructuredDebtLiabilityContingentMilestonePaymentPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy regarding restructured debt liability contingent milestone payment.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">wint_RestructuredDebtLiabilityContingentMilestonePaymentPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>wint_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>28
<FILENAME>R18.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm139823964721216">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note 4 - Summary of Significant Accounting Policies (Tables)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TableTextBlock', window );"><strong>Notes Tables</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock', window );">Schedule of Intangible Assets and Goodwill [Table Text Block]</a></td>
<td class="text">
    <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="margin-right: 5%; margin-left: 5%; width: 90%; font-size: 10pt; font-family: &quot;Times New Roman&quot;; text-indent: 0px;"><tbody><tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td colspan="2" rowspan="1" style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; text-align: center;"><span style="color:#333333;"><b><em style="font: inherit;">June 30,</em></b></span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; text-align: center;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; text-align: center;">&#160;</td><td colspan="2" rowspan="1" style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; text-align: center;"><span style="color:#333333;"><b><em style="font: inherit;">December 31,</em></b></span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 66%;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;"><span style="color:#333333;"><i>(in thousands)</i></span></p> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><span style="color:#333333;"><b><em style="font: inherit;">2022</em></b></span></p> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><span style="color:#333333;"><b><em style="font: inherit;">2021</em></b></span></p> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px;">&#160;</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;"><span style="color:#333333;">Istaroxime drug candidate</span></p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"><span style="color:#333333;">$</span></td><td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"><span style="color:#333333;">22,340</span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"><span style="color:#333333;">$</span></td><td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"><span style="color:#333333;">22,340</span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;"><span style="color:#333333;">Rostafuroxin drug candidate</span></p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><span style="color:#333333;">9,730</span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><span style="color:#333333;">9,730</span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">&#160;</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;"><span style="color:#333333;">Intangible assets</span></p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);">&#160;</td><td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><span style="color:#333333;">32,070</span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);">&#160;</td><td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><span style="color:#333333;">32,070</span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&#160;</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;"><span style="color:#333333;">Goodwill</span></p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"><span style="color:#333333;">$</span></td><td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"><span style="color:#333333;">4,046</span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"><span style="color:#333333;">$</span></td><td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"><span style="color:#333333;">15,682</span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
</tbody></table>
   <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of goodwill and intangible assets, which may be broken down by segment or major class.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>29
<FILENAME>R19.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm139823964033920">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note 5 - Fair Value Measurements (Tables)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TableTextBlock', window );"><strong>Notes Tables</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock', window );">Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis [Table Text Block]</a></td>
<td class="text">
    <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="margin-right: 10%; width: 90%; font-size: 10pt; font-family: &quot;Times New Roman&quot;; text-indent: 0px;">
     <tbody>
      <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom">
       <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td>
       <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td>
       <td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin: 0pt; text-align: center;"><span style="color:#333333;"><b><em style="font: inherit;">Fair Value</em></b></span></p> </td>
       <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px;">&#160;</td>
       <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td>
       <td colspan="10" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin: 0pt; text-align: center;"><span style="color:#333333;"><b><em style="font: inherit;"><em style="font: inherit;"><em style="font: inherit;">Fair value measurement using</em></em></em></b></span></p> </td>
       <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px;">&#160;</td>
      </tr>

      <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom">
       <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td>
       <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td>
       <td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin: 0pt; text-align: center;"><span style="color:#333333;"><b><em style="font: inherit;">June 30,</em></b></span></p> </td>
       <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td>
       <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td>
       <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td>
       <td style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"><em style="font: inherit;">&#160;</em></td>
       <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"><span style="color:#333333;"><b>&#160;</b></span></td>
       <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td>
       <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td>
       <td style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"><em style="font: inherit;">&#160;</em></td>
       <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"><span style="color:#333333;"><b>&#160;</b></span></td>
       <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td>
       <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td>
       <td style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"><em style="font: inherit;">&#160;</em></td>
       <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"><span style="color:#333333;"><b>&#160;</b></span></td>
      </tr>

      <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom">
       <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 44%;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><span style="color:#333333;"><i>(in thousands)</i></span></p> </td>
       <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td>
       <td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin: 0pt; text-align: center;"><span style="color:#333333;"><b><em style="font: inherit;">2022</em></b></span></p> </td>
       <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px;">&#160;</td>
       <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td>
       <td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin: 0pt; text-align: center;"><span style="color:#333333;"><b><em style="font: inherit;">Level 1</em></b></span></p> </td>
       <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px;">&#160;</td>
       <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td>
       <td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin: 0pt; text-align: center;"><span style="color:#333333;"><b><em style="font: inherit;">Level 2</em></b></span></p> </td>
       <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px;">&#160;</td>
       <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td>
       <td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin: 0pt; text-align: center;"><span style="color:#333333;"><b><em style="font: inherit;">Level 3</em></b></span></p> </td>
       <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px;">&#160;</td>
      </tr>

      <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom">
       <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td>
       <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td>
       <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td>
       <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td>
       <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td>
       <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td>
       <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td>
       <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td>
       <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td>
       <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td>
       <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td>
       <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td>
       <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td>
       <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td>
       <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td>
       <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td>
       <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td>
      </tr>

      <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom">
       <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><span style="color:#333333;">Cash equivalents:</span></p> </td>
       <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td>
       <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td>
       <td style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td>
       <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td>
       <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td>
       <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td>
       <td style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td>
       <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td>
       <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td>
       <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td>
       <td style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td>
       <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td>
       <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td>
       <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td>
       <td style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td>
       <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td>
      </tr>

      <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom">
       <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><span style="color:#333333;">Money market funds</span></p> </td>
       <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px;">&#160;</td>
       <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><span style="color:#333333;">$</span></td>
       <td style="width: 11%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><span style="color:#333333;">10,121</span></td>
       <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">&#160;</td>
       <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px;">&#160;</td>
       <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><span style="color:#333333;">$</span></td>
       <td style="width: 11%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><span style="color:#333333;">10,121</span></td>
       <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">&#160;</td>
       <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px;">&#160;</td>
       <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><span style="color:#333333;">$</span></td>
       <td style="width: 11%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><span style="color:#333333;"><em style="font: inherit;">-</em></span></td>
       <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">&#160;</td>
       <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px;">&#160;</td>
       <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><span style="color:#333333;">$</span></td>
       <td style="width: 11%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><span style="color:#333333;"><em style="font: inherit;">-</em></span></td>
       <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">&#160;</td>
      </tr>

      <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom">
       <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 18pt;"><span style="color:#333333;">Total Assets</span></p> </td>
       <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td>
       <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><span style="color:#333333;">$</span></td>
       <td style="width: 11%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><span style="color:#333333;">10,121</span></td>
       <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&#160;</td>
       <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td>
       <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><span style="color:#333333;">$</span></td>
       <td style="width: 11%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><span style="color:#333333;">10,121</span></td>
       <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&#160;</td>
       <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td>
       <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><span style="color:#333333;">$</span></td>
       <td style="width: 11%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><span style="color:#333333;"><em style="font: inherit;">-</em></span></td>
       <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&#160;</td>
       <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td>
       <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><span style="color:#333333;">$</span></td>
       <td style="width: 11%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><span style="color:#333333;"><em style="font: inherit;">-</em></span></td>
       <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&#160;</td>
      </tr>

     </tbody>
    </table>

    <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="margin-right: 10%; width: 90%; font-size: 10pt; font-family: &quot;Times New Roman&quot;; text-indent: 0px;">
     <tbody>
      <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom">
       <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td>
       <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td>
       <td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin: 0pt; text-align: center;"><span style="color:#333333;"><b><em style="font: inherit;">Fair Value</em></b></span></p> </td>
       <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px;">&#160;</td>
       <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td>
       <td colspan="10" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin: 0pt; text-align: center;"><span style="color:#333333;"><b><em style="font: inherit;"><em style="font: inherit;"><em style="font: inherit;">Fair value measurement using</em></em></em></b></span></p> </td>
       <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px;">&#160;</td>
      </tr>

      <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom">
       <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td>
       <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td>
       <td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin: 0pt; text-align: center;"><span style="color:#333333;"><b><em style="font: inherit;">December 31,</em></b></span></p> </td>
       <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td>
       <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td>
       <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td>
       <td style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"><em style="font: inherit;">&#160;</em></td>
       <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"><span style="color:#333333;"><b>&#160;</b></span></td>
       <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td>
       <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td>
       <td style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"><em style="font: inherit;">&#160;</em></td>
       <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"><span style="color:#333333;"><b>&#160;</b></span></td>
       <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td>
       <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td>
       <td style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"><em style="font: inherit;">&#160;</em></td>
       <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"><span style="color:#333333;"><b>&#160;</b></span></td>
      </tr>

      <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom">
       <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 44%;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><span style="color:#333333;"><i>(in thousands)</i></span></p> </td>
       <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td>
       <td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin: 0pt; text-align: center;"><span style="color:#333333;"><b><em style="font: inherit;">2021</em></b></span></p> </td>
       <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px;">&#160;</td>
       <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td>
       <td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin: 0pt; text-align: center;"><span style="color:#333333;"><b><em style="font: inherit;">Level 1</em></b></span></p> </td>
       <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px;">&#160;</td>
       <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td>
       <td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin: 0pt; text-align: center;"><span style="color:#333333;"><b><em style="font: inherit;">Level 2</em></b></span></p> </td>
       <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px;">&#160;</td>
       <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td>
       <td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin: 0pt; text-align: center;"><span style="color:#333333;"><b><em style="font: inherit;">Level 3</em></b></span></p> </td>
       <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px;">&#160;</td>
      </tr>

      <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom">
       <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td>
       <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td>
       <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td>
       <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td>
       <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td>
       <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td>
       <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td>
       <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td>
       <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td>
       <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td>
       <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td>
       <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td>
       <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td>
       <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td>
       <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td>
       <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td>
       <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td>
      </tr>

      <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom">
       <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><span style="color:#333333;">Cash equivalents:</span></p> </td>
       <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td>
       <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td>
       <td style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td>
       <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td>
       <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td>
       <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td>
       <td style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td>
       <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td>
       <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td>
       <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td>
       <td style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td>
       <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td>
       <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td>
       <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td>
       <td style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td>
       <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td>
      </tr>

      <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom">
       <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><span style="color:#333333;">Money market funds</span></p> </td>
       <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px;">&#160;</td>
       <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><span style="color:#333333;">$</span></td>
       <td style="width: 11%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><span style="color:#333333;">21,104</span></td>
       <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">&#160;</td>
       <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px;">&#160;</td>
       <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><span style="color:#333333;">$</span></td>
       <td style="width: 11%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><span style="color:#333333;">21,104</span></td>
       <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">&#160;</td>
       <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px;">&#160;</td>
       <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><span style="color:#333333;">$</span></td>
       <td style="width: 11%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><span style="color:#333333;"><em style="font: inherit;">-</em></span></td>
       <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">&#160;</td>
       <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px;">&#160;</td>
       <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><span style="color:#333333;">$</span></td>
       <td style="width: 11%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><span style="color:#333333;"><em style="font: inherit;">-</em></span></td>
       <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">&#160;</td>
      </tr>

      <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom">
       <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-top: 0px; padding-right: 0px; padding-left: 0px; margin: 0px;"> <p style="margin-top: 0pt; margin-bottom: 0pt; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 18pt;"><span style="color:#333333;">Total Assets</span></p> </td>
       <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding: 0px 0px 3px; margin: 0px;">&#160;</td>
       <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-top: 0px; padding-right: 0px; padding-left: 0px; margin: 0px; border-bottom: 3px double rgb(0, 0, 0);"><span style="color:#333333;">$</span></td>
       <td style="width: 11%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-top: 0px; padding-right: 0px; padding-left: 0px; margin: 0px; border-bottom: 3px double rgb(0, 0, 0);"><span style="color:#333333;">21,104</span></td>
       <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding: 0px 0px 3px; margin: 0px;">&#160;</td>
       <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding: 0px 0px 3px; margin: 0px;">&#160;</td>
       <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-top: 0px; padding-right: 0px; padding-left: 0px; margin: 0px; border-bottom: 3px double rgb(0, 0, 0);"><span style="color:#333333;">$</span></td>
       <td style="width: 11%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-top: 0px; padding-right: 0px; padding-left: 0px; margin: 0px; border-bottom: 3px double rgb(0, 0, 0);"><span style="color:#333333;">21,104</span></td>
       <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding: 0px 0px 3px; margin: 0px;">&#160;</td>
       <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding: 0px 0px 3px; margin: 0px;">&#160;</td>
       <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-top: 0px; padding-right: 0px; padding-left: 0px; margin: 0px; border-bottom: 3px double rgb(0, 0, 0);"><span style="color:#333333;">$</span></td>
       <td style="width: 11%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-top: 0px; padding-right: 0px; padding-left: 0px; margin: 0px; border-bottom: 3px double rgb(0, 0, 0);"><span style="color:#333333;"><em style="font: inherit;">-</em></span></td>
       <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding: 0px 0px 3px; margin: 0px;">&#160;</td>
       <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding: 0px 0px 3px; margin: 0px;">&#160;</td>
       <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-top: 0px; padding-right: 0px; padding-left: 0px; margin: 0px; border-bottom: 3px double rgb(0, 0, 0);"><span style="color:#333333;">$</span></td>
       <td style="width: 11%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-top: 0px; padding-right: 0px; padding-left: 0px; margin: 0px; border-bottom: 3px double rgb(0, 0, 0);"><span style="color:#333333;"><em style="font: inherit;">-</em></span></td>
       <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding: 0px 0px 3px; margin: 0px;">&#160;</td>
      </tr>

     </tbody>
    </table>
   <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of assets and liabilities, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126976982&amp;loc=d3e19207-110258<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126976982&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>30
<FILENAME>R20.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm139823956323168">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note 9 - Stock-Based Compensation (Tables)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TableTextBlock', window );"><strong>Notes Tables</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock', window );">Disclosure of Share-Based Compensation Arrangements by Share-Based Payment Award [Table Text Block]</a></td>
<td class="text">
    <table cellpadding="0" cellspacing="0" class="finTable" style="margin-right: auto; width: 80%; font-size: 10pt; font-family: Times New Roman; text-indent: 0px;">
     <tbody>
      <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom">
       <td style="font-family: Times New Roman; font-size: 10pt; padding: 0px; margin: 0px; width: 49%;"> <p style="margin-top: 0pt; margin-bottom: 0pt; font-family: Times New Roman; font-size: 10pt;"><span style="color:#333333;">(in thousands, except for weighted-average data)</span></p> </td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0px; margin: 0px;">&#160;</td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0px; margin: 0px;">&#160;</td>
       <td style="width: 14%; text-align: right; font-family: Times New Roman; font-size: 10pt; padding: 0px; margin: 0px;">&#160;</td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0px; margin: 0px;">&#160;</td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0px; margin: 0px;">&#160;</td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0px; margin: 0px;">&#160;</td>
       <td style="width: 14%; text-align: right; font-family: Times New Roman; font-size: 10pt; padding: 0px; margin: 0px;">&#160;</td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0px; margin: 0px;">&#160;</td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0px; margin: 0px;">&#160;</td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0px; margin: 0px;">&#160;</td>
       <td style="width: 14%; text-align: right; font-family: Times New Roman; font-size: 10pt; padding: 0px; margin: 0px;">&#160;</td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0px; margin: 0px;">&#160;</td>
      </tr>

      <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom">
       <td style="font-family: Times New Roman; font-size: 10pt; width: 49%; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; text-align: center;"><span style="color:#333333;"><b>Stock Options</b></span></p> </td>
       <td style="font-family: Times New Roman; font-size: 10pt; width: 1%;">&#160;</td>
       <td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); width: 1%;"> <p style="font-family: Times New Roman; font-size: 10pt; margin: 0pt; text-align: center;"><span style="color:#333333;"><b><em style="font: inherit;">Shares</em></b></span></p> </td>
       <td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; width: 1%;">&#160;</td>
       <td style="font-family: Times New Roman; font-size: 10pt; width: 1%;">&#160;</td>
       <td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); width: 1%;"> <p style="font-family: Times New Roman; font-size: 10pt; margin: 0pt; text-align: center;"><span style="color:#333333;"><b><em style="font: inherit;">Weighted- Average Exercise Price</em></b></span></p> </td>
       <td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; width: 1%;">&#160;</td>
       <td style="font-family: Times New Roman; font-size: 10pt; width: 1%;">&#160;</td>
       <td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); width: 1%;"> <p style="font-family: Times New Roman; font-size: 10pt; margin: 0pt; text-align: center;"><span style="color:#333333;"><b><em style="font: inherit;">Weighted- Average Remaining Contractual Term (In Yrs)</em></b></span></p> </td>
       <td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; width: 1%;">&#160;</td>
      </tr>

      <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom">
       <td style="font-family: Times New Roman; font-size: 10pt; width: 49%;">&#160;</td>
       <td style="font-family: Times New Roman; font-size: 10pt; width: 1%;">&#160;</td>
       <td style="font-family: Times New Roman; font-size: 10pt; width: 1%;">&#160;</td>
       <td style="font-family: Times New Roman; font-size: 10pt; width: 14%;">&#160;</td>
       <td style="font-family: Times New Roman; font-size: 10pt; width: 1%;">&#160;</td>
       <td style="font-family: Times New Roman; font-size: 10pt; width: 1%;">&#160;</td>
       <td style="font-family: Times New Roman; font-size: 10pt; width: 1%;">&#160;</td>
       <td style="font-family: Times New Roman; font-size: 10pt; width: 14%;">&#160;</td>
       <td style="font-family: Times New Roman; font-size: 10pt; width: 1%;">&#160;</td>
       <td style="font-family: Times New Roman; font-size: 10pt; width: 1%;">&#160;</td>
       <td style="font-family: Times New Roman; font-size: 10pt; width: 1%;">&#160;</td>
       <td style="font-family: Times New Roman; font-size: 10pt; width: 14%;">&#160;</td>
       <td style="font-family: Times New Roman; font-size: 10pt; width: 1%;">&#160;</td>
      </tr>

      <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom">
       <td style="font-family: Times New Roman; font-size: 10pt; width: 49%;"> <p style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><span style="color:#333333;">Outstanding at January 1, 2022</span></p> </td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td>
       <td style="width: 14%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><span style="color:#333333;">3,387</span></td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><span style="color:#333333;">$</span></td>
       <td style="width: 14%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><span style="color:#333333;">9.74</span></td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td>
       <td style="font-family: Times New Roman; font-size: 10pt; width: 1%;">&#160;</td>
       <td style="font-family: Times New Roman; font-size: 10pt; width: 1%;">&#160;</td>
       <td style="text-align: right; font-family: Times New Roman; font-size: 10pt; width: 14%;"><em style="font: inherit;">&#160;</em></td>
       <td style="font-family: Times New Roman; font-size: 10pt; width: 1%;">&#160;</td>
      </tr>

      <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom">
       <td style="font-family: Times New Roman; font-size: 10pt; width: 49%;"> <p style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 9pt;"><span style="color:#333333;">Granted</span></p> </td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td>
       <td style="width: 14%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><span style="color:#333333;">880</span></td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td>
       <td style="width: 14%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><span style="color:#333333;">0.99</span></td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td>
       <td style="font-family: Times New Roman; font-size: 10pt; width: 1%;">&#160;</td>
       <td style="font-family: Times New Roman; font-size: 10pt; width: 1%;">&#160;</td>
       <td style="text-align: right; font-family: Times New Roman; font-size: 10pt; width: 14%;"><em style="font: inherit;">&#160;</em></td>
       <td style="font-family: Times New Roman; font-size: 10pt; width: 1%;">&#160;</td>
      </tr>

      <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom">
       <td style="font-family: Times New Roman; font-size: 10pt; width: 49%;"> <p style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 9pt;"><span style="color:#333333;">Forfeited or expired</span></p> </td>
       <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px;">&#160;</td>
       <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
       <td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><span style="color:#333333;">(220</span></td>
       <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"><span style="color:#333333;">)</span></td>
       <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px;">&#160;</td>
       <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
       <td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><span style="color:#333333;">9.72</span></td>
       <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">&#160;</td>
       <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 1%; padding-bottom: 1px;">&#160;</td>
       <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 1%; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
       <td style="text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 14%; border-bottom: 1px solid rgb(0, 0, 0);"><em style="font: inherit;">&#160;</em></td>
       <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 1%; padding-bottom: 1px;">&#160;</td>
      </tr>

      <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom">
       <td style="font-family: Times New Roman; font-size: 10pt; width: 49%;"> <p style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><span style="color:#333333;">Outstanding at June 30, 2022</span></p> </td>
       <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 3px;">&#160;</td>
       <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);">&#160;</td>
       <td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><span style="color:#333333;">4,047</span></td>
       <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;">&#160;</td>
       <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 3px;">&#160;</td>
       <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><span style="color:#333333;">$</span></td>
       <td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><span style="color:#333333;">7.84</span></td>
       <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;">&#160;</td>
       <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 3px;">&#160;</td>
       <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);">&#160;</td>
       <td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><span style="color:#333333;">7.8</span></td>
       <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;">&#160;</td>
      </tr>

      <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom">
       <td style="font-family: Times New Roman; font-size: 10pt; width: 49%;">&#160;</td>
       <td style="font-family: Times New Roman; font-size: 10pt; width: 1%;">&#160;</td>
       <td style="font-family: Times New Roman; font-size: 10pt; width: 1%;">&#160;</td>
       <td style="font-family: Times New Roman; font-size: 10pt; width: 14%;">&#160;</td>
       <td style="font-family: Times New Roman; font-size: 10pt; width: 1%;">&#160;</td>
       <td style="font-family: Times New Roman; font-size: 10pt; width: 1%;">&#160;</td>
       <td style="font-family: Times New Roman; font-size: 10pt; width: 1%;">&#160;</td>
       <td style="font-family: Times New Roman; font-size: 10pt; width: 14%;">&#160;</td>
       <td style="font-family: Times New Roman; font-size: 10pt; width: 1%;">&#160;</td>
       <td style="font-family: Times New Roman; font-size: 10pt; width: 1%;">&#160;</td>
       <td style="font-family: Times New Roman; font-size: 10pt; width: 1%;">&#160;</td>
       <td style="font-family: Times New Roman; font-size: 10pt; width: 14%;">&#160;</td>
       <td style="font-family: Times New Roman; font-size: 10pt; width: 1%;">&#160;</td>
      </tr>

      <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom">
       <td style="font-family: Times New Roman; font-size: 10pt; width: 49%;"> <p style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><span style="color:#333333;">Vested and exercisable at June 30, 2022</span></p> </td>
       <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td>
       <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td>
       <td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"><span style="color:#333333;">2,229</span></td>
       <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#160;</td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><span style="color:#333333;">$</span></td>
       <td style="width: 14%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><span style="color:#333333;">11.35</span></td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td>
       <td style="width: 14%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><span style="color:#333333;">6.8</span></td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td>
      </tr>

      <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom">
       <td style="padding: 0px; margin: 0px; font-family: Times New Roman; font-size: 10pt; width: 49%;">&#160;</td>
       <td style="padding: 0px; margin: 0px; font-family: Times New Roman; font-size: 10pt; width: 1%;">&#160;</td>
       <td style="padding: 0px; margin: 0px; font-family: Times New Roman; font-size: 10pt; width: 1%;">&#160;</td>
       <td style="padding: 0px; margin: 0px; font-family: Times New Roman; font-size: 10pt; width: 14%;">&#160;</td>
       <td style="padding: 0px; margin: 0px; font-family: Times New Roman; font-size: 10pt; width: 1%;">&#160;</td>
       <td style="padding: 0px; margin: 0px; font-family: Times New Roman; font-size: 10pt; width: 1%;">&#160;</td>
       <td style="padding: 0px; margin: 0px; font-family: Times New Roman; font-size: 10pt; width: 1%;">&#160;</td>
       <td style="padding: 0px; margin: 0px; font-family: Times New Roman; font-size: 10pt; width: 14%;">&#160;</td>
       <td style="padding: 0px; margin: 0px; font-family: Times New Roman; font-size: 10pt; width: 1%;">&#160;</td>
       <td style="padding: 0px; margin: 0px; font-family: Times New Roman; font-size: 10pt; width: 1%;">&#160;</td>
       <td style="padding: 0px; margin: 0px; font-family: Times New Roman; font-size: 10pt; width: 1%;">&#160;</td>
       <td style="padding: 0px; margin: 0px; font-family: Times New Roman; font-size: 10pt; width: 14%;">&#160;</td>
       <td style="padding: 0px; margin: 0px; font-family: Times New Roman; font-size: 10pt; width: 1%;">&#160;</td>
      </tr>

      <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom">
       <td style="font-family: Times New Roman; font-size: 10pt; width: 49%;"> <p style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><span style="color:#333333;">Vested and expected to vest at June 30, 2022</span></p> </td>
       <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td>
       <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td>
       <td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"><span style="color:#333333;">3,821</span></td>
       <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#160;</td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><span style="color:#333333;">$</span></td>
       <td style="width: 14%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><span style="color:#333333;">7.85</span></td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td>
       <td style="width: 14%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><span style="color:#333333;">7.8</span></td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td>
      </tr>

     </tbody>
    </table>
   <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock', window );">Share-Based Payment Arrangement, Restricted Stock Unit, Activity [Table Text Block]</a></td>
<td class="text">
    <table cellpadding="0" cellspacing="0" class="finTable" style="width: 80%; font-size: 10pt; font-family: &quot;Times New Roman&quot;; text-indent: 0px; margin-left: 0pt; margin-right: auto;">
     <tbody>
      <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom">
       <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 58%;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;"><span style="color:#333333;">(in thousands, except for weighted-average data)</span></p> </td>
       <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 1%;">&#160;</td>
       <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 1%;">&#160;</td>
       <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 16%;">&#160;</td>
       <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 1%;">&#160;</td>
       <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 1%;">&#160;</td>
       <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 1%;">&#160;</td>
       <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 20%;">&#160;</td>
       <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 1%;">&#160;</td>
      </tr>

      <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom">
       <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 58%; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; text-align: center;"><span style="color:#333333;"><b>Restricted Stock Units</b></span></p> </td>
       <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 1%;">&#160;</td>
       <td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); width: 1%;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><span style="color:#333333;"><b><em style="font: inherit;">Shares</em></b></span></p> </td>
       <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px; width: 1%;">&#160;</td>
       <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 1%;">&#160;</td>
       <td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); width: 1%;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><span style="color:#333333;"><b><em style="font: inherit;">Weighted- Average Grant Date Fair Value</em></b></span></p> </td>
       <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px; width: 1%;">&#160;</td>
      </tr>

      <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom">
       <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 58%;">&#160;</td>
       <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 1%;">&#160;</td>
       <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 1%;">&#160;</td>
       <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 16%;">&#160;</td>
       <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 1%;">&#160;</td>
       <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 1%;">&#160;</td>
       <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 1%;">&#160;</td>
       <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 20%;">&#160;</td>
       <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 1%;">&#160;</td>
      </tr>

      <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom">
       <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 58%;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;"><span style="color:#333333;">Outstanding at January 1, 2022</span></p> </td>
       <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td>
       <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td>
       <td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"><span style="color:#333333;">-</span></td>
       <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#160;</td>
       <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td>
       <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"><span style="color:#333333;">$</span></td>
       <td style="width: 20%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"><span style="color:#333333;">-</span></td>
       <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#160;</td>
      </tr>

      <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom">
       <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 58%;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; text-indent: 9pt;"><span style="color:#333333;">Awarded</span></p> </td>
       <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td>
       <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td>
       <td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"><span style="color:#333333;">582</span></td>
       <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#160;</td>
       <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td>
       <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td>
       <td style="width: 20%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"><span style="color:#333333;">0.99</span></td>
       <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#160;</td>
      </tr>

      <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom">
       <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 58%; padding-top: 0px; padding-right: 0px; padding-left: 0px; margin: 0px;"> <p style="margin-top: 0pt; margin-bottom: 0pt; text-indent: 9pt;"><span style="color:#333333;">Cancelled</span></p> </td>
       <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding: 0px 0px 1px; margin: 0px;">&#160;</td>
       <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-top: 0px; padding-right: 0px; padding-left: 0px; margin: 0px; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
       <td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-top: 0px; padding-right: 0px; padding-left: 0px; margin: 0px; border-bottom: 1px solid rgb(0, 0, 0);"><span style="color:#333333;">(21</span></td>
       <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding: 0px 0px 1px; margin: 0px;"><span style="color:#333333;">)</span></td>
       <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding: 0px 0px 1px; margin: 0px;">&#160;</td>
       <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-top: 0px; padding-right: 0px; padding-left: 0px; margin: 0px; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
       <td style="width: 20%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-top: 0px; padding-right: 0px; padding-left: 0px; margin: 0px; border-bottom: 1px solid rgb(0, 0, 0);"><span style="color:#333333;">1.02</span></td>
       <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding: 0px 0px 1px; margin: 0px;">&#160;</td>
      </tr>

      <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom">
       <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 58%;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;"><span style="color:#333333;">Outstanding at June 30, 2022</span></p> </td>
       <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 3px;">&#160;</td>
       <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);">&#160;</td>
       <td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><span style="color:#333333;">561</span></td>
       <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;">&#160;</td>
       <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 3px;">&#160;</td>
       <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><span style="color:#333333;">$</span></td>
       <td style="width: 20%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><span style="color:#333333;">0.99</span></td>
       <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;">&#160;</td>
      </tr>

      <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom">
       <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 58%; padding: 0; margin: 0">&#160;</td>
       <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 1%; padding: 0; margin: 0">&#160;</td>
       <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 1%; padding: 0; margin: 0">&#160;</td>
       <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 16%; padding: 0; margin: 0">&#160;</td>
       <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 1%; padding: 0; margin: 0">&#160;</td>
       <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 1%; padding: 0; margin: 0">&#160;</td>
       <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 1%; padding: 0; margin: 0">&#160;</td>
       <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 20%; padding: 0; margin: 0">&#160;</td>
       <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 1%; padding: 0; margin: 0">&#160;</td>
      </tr>

      <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom">
       <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 58%; padding: 0; margin: 0"> <p style="margin-top: 0pt; margin-bottom: 0pt"><span style="color:#333333;">Vested and exercisable at June 30, 2022</span></p> </td>
       <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding: 0; margin: 0">&#160;</td>
       <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding: 0; margin: 0">&#160;</td>
       <td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding: 0; margin: 0"><span style="color:#333333;">-</span></td>
       <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding: 0; margin: 0">&#160;</td>
       <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding: 0; margin: 0">&#160;</td>
       <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding: 0; margin: 0"><span style="color:#333333;">$</span></td>
       <td style="width: 20%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding: 0; margin: 0"><span style="color:#333333;">-</span></td>
       <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding: 0; margin: 0">&#160;</td>
      </tr>

      <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom">
       <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 58%; padding: 0; margin: 0">&#160;</td>
       <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 1%; padding: 0; margin: 0">&#160;</td>
       <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 1%; padding: 0; margin: 0">&#160;</td>
       <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 16%; padding: 0; margin: 0">&#160;</td>
       <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 1%; padding: 0; margin: 0">&#160;</td>
       <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 1%; padding: 0; margin: 0">&#160;</td>
       <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 1%; padding: 0; margin: 0">&#160;</td>
       <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 20%; padding: 0; margin: 0">&#160;</td>
       <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 1%; padding: 0; margin: 0">&#160;</td>
      </tr>

      <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom">
       <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 58%; padding: 0; margin: 0"> <p style="margin-top: 0pt; margin-bottom: 0pt"><span style="color:#333333;">Vested and expected to vest at June 30, 2022</span></p> </td>
       <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding: 0; margin: 0">&#160;</td>
       <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding: 0; margin: 0">&#160;</td>
       <td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding: 0; margin: 0"><span style="color:#333333;">561</span></td>
       <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding: 0; margin: 0">&#160;</td>
       <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding: 0; margin: 0">&#160;</td>
       <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding: 0; margin: 0"><span style="color:#333333;">$</span></td>
       <td style="width: 20%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding: 0; margin: 0"><span style="color:#333333;">0.99</span></td>
       <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding: 0; margin: 0">&#160;</td>
      </tr>

     </tbody>
    </table>
   <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock', window );">Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block]</a></td>
<td class="text">
    <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="margin-right: 20%; width: 80%; font-size: 10pt; font-family: Times New Roman; text-indent: 0px;">
     <tbody>
      <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom">
       <td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td>
       <td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td>
       <td colspan="6" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><span style="color:#333333;"><b><em style="font: inherit;"><em style="font: inherit;">Three Months Ended June 30,</em></em></b></span></p> </td>
       <td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td>
       <td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td>
       <td colspan="6" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><span style="color:#333333;"><b><em style="font: inherit;"><em style="font: inherit;">Six Months Ended June 30,</em></em></b></span></p> </td>
       <td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td>
      </tr>

      <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom">
       <td style="font-family: Times New Roman; font-size: 10pt; width: 36%;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;"><span style="color:#333333;"><i>(in thousands)</i></span></p> </td>
       <td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td>
       <td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><span style="color:#333333;"><b><em style="font: inherit;">2022</em></b></span></p> </td>
       <td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&#160;</td>
       <td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td>
       <td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><span style="color:#333333;"><b><em style="font: inherit;">2021</em></b></span></p> </td>
       <td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&#160;</td>
       <td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td>
       <td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><span style="color:#333333;"><b><em style="font: inherit;">2022</em></b></span></p> </td>
       <td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&#160;</td>
       <td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td>
       <td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><span style="color:#333333;"><b><em style="font: inherit;">2021</em></b></span></p> </td>
       <td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&#160;</td>
      </tr>

      <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom">
       <td>&#160;</td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td>&#160;</td>
      </tr>

      <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom">
       <td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;"><span style="color:#333333;">Research and development</span></p> </td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><span style="color:#333333;">$</span></td>
       <td style="width: 13%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><span style="color:#333333;">147</span></td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><span style="color:#333333;">$</span></td>
       <td style="width: 13%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><span style="color:#333333;">630</span></td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><span style="color:#333333;">$</span></td>
       <td style="width: 13%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><span style="color:#333333;">382</span></td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><span style="color:#333333;">$</span></td>
       <td style="width: 13%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><span style="color:#333333;">1,569</span></td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td>
      </tr>

      <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom">
       <td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;"><span style="color:#333333;">General and administrative</span></p> </td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
       <td style="width: 13%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><span style="color:#333333;">634</span></td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
       <td style="width: 13%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><span style="color:#333333;">914</span></td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
       <td style="width: 13%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><span style="color:#333333;">1,169</span></td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
       <td style="width: 13%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><span style="color:#333333;">2,418</span></td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td>
      </tr>

      <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom">
       <td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 18pt;"><span style="color:#333333;">Total</span></p> </td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><span style="color:#333333;">$</span></td>
       <td style="width: 13%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><span style="color:#333333;">781</span></td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&#160;</td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><span style="color:#333333;">$</span></td>
       <td style="width: 13%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><span style="color:#333333;">1,544</span></td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&#160;</td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><span style="color:#333333;">$</span></td>
       <td style="width: 13%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><span style="color:#333333;">1,551</span></td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&#160;</td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><span style="color:#333333;">$</span></td>
       <td style="width: 13%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><span style="color:#333333;">3,987</span></td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&#160;</td>
      </tr>

     </tbody>
    </table>
   <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock', window );">Schedule of Share-Based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]</a></td>
<td class="text">
    <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="margin-right: 20%; width: 80%; font-size: 10pt; font-family: Times New Roman; text-indent: 0px;">
     <tbody>
      <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom">
       <td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td>
       <td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td>
       <td colspan="6" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><span style="color:#333333;"><b><em style="font: inherit;"><em style="font: inherit;">Six Months Ended June 30,</em></em></b></span></p> </td>
       <td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td>
      </tr>

      <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom">
       <td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td>
       <td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td>
       <td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><span style="color:#333333;"><b><em style="font: inherit;">2022</em></b></span></p> </td>
       <td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&#160;</td>
       <td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td>
       <td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><span style="color:#333333;"><b><em style="font: inherit;">2021</em></b></span></p> </td>
       <td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&#160;</td>
      </tr>

      <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom">
       <td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td>
       <td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td>
       <td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td>
       <td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td>
       <td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td>
       <td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td>
       <td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td>
       <td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td>
       <td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td>
      </tr>

      <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom">
       <td style="font-family: Times New Roman; font-size: 10pt; width: 62%;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;"><span style="color:#333333;">Weighted average expected volatility</span></p> </td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td>
       <td style="width: 16%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: center;"> <p style="margin-top: 0pt; margin-bottom: 0pt; font-family: Times New Roman; font-size: 10pt;"><span style="color:#333333;">106%</span></p> </td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td>
       <td style="width: 16%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: center;"> <p style="margin-top: 0pt; margin-bottom: 0pt; font-family: Times New Roman; font-size: 10pt;"><span style="color:#333333;">105%</span></p> </td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td>
      </tr>

      <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom">
       <td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;"><span style="color:#333333;">Weighted average expected term (in years)</span></p> </td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td>
       <td style="width: 16%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: center;"> <p style="margin-top: 0pt; margin-bottom: 0pt; font-family: Times New Roman; font-size: 10pt;"><span style="color:#333333;">6.9</span></p> </td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td>
       <td style="width: 16%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: center;"> <p style="margin-top: 0pt; margin-bottom: 0pt; font-family: Times New Roman; font-size: 10pt;"><span style="color:#333333;">6.7</span></p> </td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td>
      </tr>

      <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom">
       <td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;"><span style="color:#333333;">Weighted average risk-free interest rate</span></p> </td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td>
       <td style="width: 16%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: center;"> <p style="margin-top: 0pt; margin-bottom: 0pt; font-family: Times New Roman; font-size: 10pt;"><span style="color:#333333;">1.70%</span></p> </td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td>
       <td style="width: 16%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: center;"> <p style="margin-top: 0pt; margin-bottom: 0pt; font-family: Times New Roman; font-size: 10pt;"><span style="color:#333333;">0.48%</span></p> </td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td>
      </tr>

      <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom">
       <td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;"><span style="color:#333333;">Expected dividends</span></p> </td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td>
       <td style="width: 16%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: center;"><em style="font: inherit;"> </em><p style="margin-top: 0pt; margin-bottom: 0pt; font-family: Times New Roman; font-size: 10pt;"><span style="color:#333333;">-</span></p> </td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td>
       <td style="width: 16%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: center;"><em style="font: inherit;"> </em><p style="margin-top: 0pt; margin-bottom: 0pt; font-family: Times New Roman; font-size: 10pt;"><span style="color:#333333;">-</span></p> </td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td>
      </tr>

     </tbody>
    </table>
   <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5047-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of allocation of amount expensed and capitalized for award under share-based payment arrangement to statement of income or comprehensive income and statement of financial position. Includes, but is not limited to, corresponding line item in financial statement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the number and weighted-average grant date fair value for restricted stock units that were outstanding at the beginning and end of the year, and the number of restricted stock units that were granted, vested, or forfeited during the year.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>31
<FILENAME>R21.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm139823961282208">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note 3 - Going Concern and Management's Plans (Details Textual) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="1">2 Months Ended</th>
<th class="th" colspan="4">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Aug. 11, 2022</div></th>
<th class="th"><div>Aug. 31, 2022</div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Mar. 31, 2021</div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Sep. 17, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net Income (Loss) Attributable to Parent, Total</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (17,333)<span></span>
</td>
<td class="num">$ (8,127)<span></span>
</td>
<td class="num">$ (37,389)<span></span>
</td>
<td class="num">$ (8,961)<span></span>
</td>
<td class="num">$ (25,460)<span></span>
</td>
<td class="num">$ (46,350)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillImpairmentLoss', window );">Goodwill, Impairment Loss</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">11,636<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">11,636<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill', window );">Impairment of Intangible Assets (Excluding Goodwill), Total</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">37,770<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">37,770<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredIncomeTaxExpenseBenefit', window );">Deferred Income Tax Expense (Benefit), Total</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(8,300)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="num">(8,332)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Retained Earnings (Accumulated Deficit), Total</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(810,784)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(810,784)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (785,324)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Stock Issued During Period, Value, New Issues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,020<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,120<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Proceeds from Issuance of Common Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,225<span></span>
</td>
<td class="nump">$ 1,690<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and Cash Equivalents, at Carrying Value, Total</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">11,378<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">11,378<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">22,348<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrent', window );">Liabilities, Current, Total</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,334<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,334<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4,923<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=wint_ATMProgramMember', window );">ATM Program [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_wint_SharesAuthorizedToBeOfferedAndSoldUnderOfferingAgreementValue', window );">Shares Authorized to Be Offered and Sold Under Offering Agreement, Value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Stock Issued During Period, Shares, New Issues (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,137,246<span></span>
</td>
<td class="nump">552,474<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Stock Issued During Period, Value, New Issues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,300<span></span>
</td>
<td class="nump">$ 1,700<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Proceeds from Issuance of Common Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_wint_StockOfferingAgreementPublicFloatLimitationAmount', window );">Stock Offering Agreement, Public Float Limitation Amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 75,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 75,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=wint_ATMProgramMember', window );">ATM Program [Member] | Subsequent Event [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Stock Issued During Period, Shares, New Issues (in shares)</a></td>
<td class="nump">1,221,706<span></span>
</td>
<td class="nump">1,221,706<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Stock Issued During Period, Value, New Issues</a></td>
<td class="nump">$ 600<span></span>
</td>
<td class="nump">$ 600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_wint_StockOfferingAgreementPublicFloatLimitationAmount', window );">Stock Offering Agreement, Public Float Limitation Amount</a></td>
<td class="nump">$ 75,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3044-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredIncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred income tax expense (benefit) pertaining to income (loss) from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.1)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.2)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32639-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredIncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillImpairmentLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of loss from the write-down of an asset representing the future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13854-109267<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=99380562&amp;loc=d3e13777-109266<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 55<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=122137925&amp;loc=d3e14258-109268<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillImpairmentLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of impairment loss recognized in the period resulting from the write-down of the carrying amount of an intangible asset (excluding goodwill) to fair value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16373-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6904-107765<br><br>Reference 21: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.21)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669619-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669625-108580<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the additional capital contribution to the entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cumulative amount of the reporting entity's undistributed earnings or deficit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_wint_SharesAuthorizedToBeOfferedAndSoldUnderOfferingAgreementValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the dollar amount of stock authorized to be offered and sold under an offering agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">wint_SharesAuthorizedToBeOfferedAndSoldUnderOfferingAgreementValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>wint_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_wint_StockOfferingAgreementPublicFloatLimitationAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of public float required to remove limitations on a stock offering agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">wint_StockOfferingAgreementPublicFloatLimitationAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>wint_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=wint_ATMProgramMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=wint_ATMProgramMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>32
<FILENAME>R22.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm139823962351168">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note 4 - Summary of Significant Accounting Policies (Details Textual)<br> $ in Thousands, shares in Millions</strong></div></th>
<th class="th" colspan="3">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Jun. 30, 2022 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Mar. 31, 2022 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jun. 30, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jun. 30, 2022 </div>
<div>USD ($) </div>
<div>shares</div>
</th>
<th class="th">
<div>Jun. 30, 2021 </div>
<div>USD ($) </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Nov. 01, 2017 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill', window );">Impairment of Intangible Assets (Excluding Goodwill), Total</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 37,770<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 37,770<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NumberOfReportingUnits', window );">Number of Reporting Units</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillImpairmentLoss', window );">Goodwill, Impairment Loss</a></td>
<td class="nump">11,636<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">11,636<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ForeignCurrencyTransactionGainBeforeTax', window );">Foreign Currency Transaction Gain, before Tax</a></td>
<td class="nump">200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ForeignCurrencyTransactionLossBeforeTax', window );">Foreign Currency Transaction Loss, before Tax</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SeveranceCosts1', window );">Severance Costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_wint_SeveranceAccrual', window );">Severance Accrual</a></td>
<td class="nump">100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_wint_PaymentsForSeveranceCosts', window );">Payments for Severance Costs</a></td>
<td class="nump">200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SupplementalUnemploymentBenefitsSeveranceBenefits', window );">Supplemental Unemployment Benefits, Severance Benefits</a></td>
<td class="nump">200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Depreciation', window );">Depreciation, Total</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">488<span></span>
</td>
<td class="nump">93<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_wint_LiabilityforContingentMilestonePaymentNoncurrent', window );">Liability for Contingent Milestone Payment, Noncurrent</a></td>
<td class="nump">$ 15,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">15,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 15,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredIncomeTaxExpenseBenefit', window );">Deferred Income Tax Expense (Benefit), Total</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (8,300)<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="num">$ (8,332)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_wint_NumberOfSharesOfCommonStockPotentiallyIssuableUponTheExerciseOfStockOptionsAndWarrants', window );">Number of Shares of Common Stock Potentially Issuable upon the Exercise of Stock Options and Warrants (in shares) | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">21.2<span></span>
</td>
<td class="nump">19.9<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=wint_DeerfieldLoanMember', window );">Deerfield Loan [Member] | Exchange and Termination Agreement [Member] | Deerfield Management, L.P. [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_wint_LiabilityforContingentMilestonePaymentNoncurrent', window );">Liability for Contingent Milestone Payment, Noncurrent</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 15,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=wint_ManufacturingAndLaboratoryEquipmentMember', window );">Manufacturing and Laboratory Equipment [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Depreciation', window );">Depreciation, Total</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredIncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred income tax expense (benefit) pertaining to income (loss) from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.1)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.2)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32639-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredIncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Depreciation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Depreciation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ForeignCurrencyTransactionGainBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before tax of foreign currency transaction realized and unrealized gain recognized in the income statement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=125521441&amp;loc=d3e30690-110894<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124440516&amp;loc=d3e30840-110895<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ForeignCurrencyTransactionGainBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ForeignCurrencyTransactionLossBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before tax of foreign currency transaction realized and unrealized loss recognized in the income statement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124440516&amp;loc=d3e30840-110895<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=125521441&amp;loc=d3e30690-110894<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ForeignCurrencyTransactionLossBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillImpairmentLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of loss from the write-down of an asset representing the future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13854-109267<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=99380562&amp;loc=d3e13777-109266<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 55<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=122137925&amp;loc=d3e14258-109268<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillImpairmentLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of impairment loss recognized in the period resulting from the write-down of the carrying amount of an intangible asset (excluding goodwill) to fair value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16373-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NumberOfReportingUnits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of reporting units tested for impairment of goodwill. A reporting unit is an operating segment or one level below an operating segment.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NumberOfReportingUnits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SeveranceCosts1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expenses for special or contractual termination benefits provided to current employees involuntarily terminated under a benefit arrangement associated exit or disposal activities pursuant to an authorized plan. Excludes expenses related to one-time termination benefits, a discontinued operation or an asset retirement obligation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SeveranceCosts1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SupplementalUnemploymentBenefitsSeveranceBenefits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Liability for amount due employees, in addition to wages and any other money that employers owe employees, when their employment ends through a layoff or other termination. For example, a company may provide involuntarily terminated employees with a lump sum payment equal to one week's salary for every year of employment.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SupplementalUnemploymentBenefitsSeveranceBenefits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_wint_LiabilityforContingentMilestonePaymentNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of restructured debt liability for contingent milestone payments, due after one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">wint_LiabilityforContingentMilestonePaymentNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>wint_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_wint_NumberOfSharesOfCommonStockPotentiallyIssuableUponTheExerciseOfStockOptionsAndWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents number of shares of common stock potentially issuable exercise of certain stock options and warrants during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">wint_NumberOfSharesOfCommonStockPotentiallyIssuableUponTheExerciseOfStockOptionsAndWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>wint_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_wint_PaymentsForSeveranceCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow to satisfy severance cost obligation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">wint_PaymentsForSeveranceCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>wint_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_wint_SeveranceAccrual">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents amount of severance accrual.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">wint_SeveranceAccrual</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>wint_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=wint_DeerfieldLoanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=wint_DeerfieldLoanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=wint_ExchangeAndTerminationAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=wint_ExchangeAndTerminationAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LineOfCreditFacilityAxis=wint_DeerfieldManagementLPMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LineOfCreditFacilityAxis=wint_DeerfieldManagementLPMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=wint_ManufacturingAndLaboratoryEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=wint_ManufacturingAndLaboratoryEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>33
<FILENAME>R23.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm139823962329664">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Note 4 - Summary of Significant Accounting Policies - Intangible Assets (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill', window );">Intangible assets</a></td>
<td class="nump">$ 32,070<span></span>
</td>
<td class="nump">$ 32,070<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Goodwill</a></td>
<td class="nump">4,046<span></span>
</td>
<td class="nump">15,682<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis=wint_IstaroximeDrugCandidateMember', window );">Istaroxime Drug Candidate [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill', window );">Intangible assets</a></td>
<td class="nump">22,340<span></span>
</td>
<td class="nump">22,340<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis=wint_RostafuroxinDrugCandidateMember', window );">Rostafuroxin Drug Candidate [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill', window );">Intangible assets</a></td>
<td class="nump">$ 9,730<span></span>
</td>
<td class="nump">$ 9,730<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Goodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(10)(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (h)<br> -URI https://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 55<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=122137925&amp;loc=d3e14258-109268<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=99380562&amp;loc=d3e13770-109266<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(15))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Goodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of assets, excluding financial assets and goodwill, lacking physical substance and having a projected indefinite period of benefit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis=wint_IstaroximeDrugCandidateMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis=wint_IstaroximeDrugCandidateMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis=wint_RostafuroxinDrugCandidateMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis=wint_RostafuroxinDrugCandidateMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>34
<FILENAME>R24.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm139823962495296">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Note 5 - Fair Value Measurements - Assets and Liabilities Measured at Fair Value on a Recurring Basis (Details) - Fair Value, Recurring [Member] - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total Assets</a></td>
<td class="nump">$ 10,121<span></span>
</td>
<td class="nump">$ 21,104<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Inputs, Level 1 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total Assets</a></td>
<td class="nump">10,121<span></span>
</td>
<td class="nump">21,104<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Money Market Funds [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Cash equivalents</a></td>
<td class="nump">10,121<span></span>
</td>
<td class="nump">21,104<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Money Market Funds [Member] | Fair Value, Inputs, Level 1 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Cash equivalents</a></td>
<td class="nump">$ 10,121<span></span>
</td>
<td class="nump">$ 21,104<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126976982&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAxis=us-gaap_MoneyMarketFundsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAxis=us-gaap_MoneyMarketFundsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>35
<FILENAME>R25.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm139823962259712">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note 6 - Loans Payable (Details Textual) - Loan payable to Bank Direct Capital Finance [Member] - Loans Payable [Member] - USD ($)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Debt Instrument, Face Amount</a></td>
<td class="nump">$ 1,100,000<span></span>
</td>
<td class="nump">$ 1,300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Debt Instrument, Interest Rate, Stated Percentage</a></td>
<td class="nump">3.90%<span></span>
</td>
<td class="nump">3.37%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentPeriodicPayment', window );">Debt Instrument, Periodic Payment, Total</a></td>
<td class="nump">$ 126,000<span></span>
</td>
<td class="nump">$ 147,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LoansPayableToBank', window );">Loans Payable to Bank, Total</a></td>
<td class="nump">$ 1,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 300,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentFaceAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face (par) amount of debt instrument at time of issuance.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=124435984&amp;loc=d3e28551-108399<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 55<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=114775985&amp;loc=d3e28878-108400<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124429444&amp;loc=SL124452920-239629<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69C<br> -URI https://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495737-112612<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69B<br> -URI https://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495735-112612<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentFaceAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentInterestRateStatedPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Contractual interest rate for funds borrowed, under the debt agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22(a)(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentInterestRateStatedPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentPeriodicPayment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of the required periodic payments including both interest and principal payments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 470<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=123599511&amp;loc=d3e64711-112823<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentPeriodicPayment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LoansPayableToBank">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Including the current and noncurrent portions, carrying value as of the balance sheet date of loans from a bank with maturities initially due after one year or beyond the normal operating cycle if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(16)(a))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LoansPayableToBank</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=wint_LoanPayableToBankDirectCapitalFinanceMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=wint_LoanPayableToBankDirectCapitalFinanceMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShortTermDebtTypeAxis=us-gaap_LoansPayableMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShortTermDebtTypeAxis=us-gaap_LoansPayableMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>36
<FILENAME>R26.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm139823961481312">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Note 7 - Restructured Debt Liability (Details Textual) - USD ($)<br> $ / shares in Units, $ in Millions</strong></div></th>
<th class="th"><div>Oct. 27, 2017</div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_wint_LiabilityforContingentMilestonePaymentNoncurrent', window );">Liability for Contingent Milestone Payment, Noncurrent</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 15.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 15.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=wint_DeerfieldLoanMember', window );">Deerfield Loan [Member] | Exchange and Termination Agreement [Member] | Deerfield Management, L.P. [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ExtinguishmentOfDebtAmount', window );">Extinguishment of Debt, Amount</a></td>
<td class="nump">$ 25.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_wint_ClassOfWarrantOrRightNumberOfWarrantsCancelled', window );">Class of Warrant or Right, Number of Warrants Cancelled (in shares)</a></td>
<td class="nump">8,333<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_wint_ClassOfWarrantOrRightExercisePriceOfCancelledWarrants', window );">Class of Warrant or Right, Exercise Price of Cancelled Warrants (in dollars per share)</a></td>
<td class="nump">$ 2,360.40<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RepaymentsOfLongTermDebt', window );">Repayments of Long-term Debt, Total</a></td>
<td class="nump">$ 2.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_wint_StockIssuedDuringPeriodSharesCancellationOfDebtAndWarrantObligations', window );">Stock Issued During Period, Shares, Cancellation of Debt and Warrant Obligations (in shares)</a></td>
<td class="nump">23,703<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_wint_StockIssuedDuringPeriodSharesCancellationOfDebtAndWarrantObligationsPercentageOfFullyDilutedSharesOutstanding', window );">Stock Issued During Period, Shares, Cancellation of Debt and Warrant Obligations, Percentage of Fully-diluted Shares Outstanding</a></td>
<td class="nump">2.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_wint_LiabilityforContingentMilestonePaymentNoncurrent', window );">Liability for Contingent Milestone Payment, Noncurrent</a></td>
<td class="nump">$ 15.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 15.0<span></span>
</td>
<td class="nump">$ 15.0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ExtinguishmentOfDebtAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Gross amount of debt extinguished.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ExtinguishmentOfDebtAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RepaymentsOfLongTermDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for debt initially having maturity due after one year or beyond the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RepaymentsOfLongTermDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_wint_ClassOfWarrantOrRightExercisePriceOfCancelledWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the exercise price per share of cancelled warrants.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">wint_ClassOfWarrantOrRightExercisePriceOfCancelledWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>wint_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_wint_ClassOfWarrantOrRightNumberOfWarrantsCancelled">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the number of warrants or rights cancelled during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">wint_ClassOfWarrantOrRightNumberOfWarrantsCancelled</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>wint_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_wint_LiabilityforContingentMilestonePaymentNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of restructured debt liability for contingent milestone payments, due after one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">wint_LiabilityforContingentMilestonePaymentNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>wint_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_wint_StockIssuedDuringPeriodSharesCancellationOfDebtAndWarrantObligations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares of stock issued attributable to transactions for the purpose of being granted forgiveness of debt and warrant obligations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">wint_StockIssuedDuringPeriodSharesCancellationOfDebtAndWarrantObligations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>wint_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_wint_StockIssuedDuringPeriodSharesCancellationOfDebtAndWarrantObligationsPercentageOfFullyDilutedSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The percentage of the shares of stock issued attributable to transactions for the purpose of being granted forgiveness of debt and warrant obligations represent as all of the reporting entity's fully-diluted shares outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">wint_StockIssuedDuringPeriodSharesCancellationOfDebtAndWarrantObligationsPercentageOfFullyDilutedSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>wint_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=wint_DeerfieldLoanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=wint_DeerfieldLoanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=wint_ExchangeAndTerminationAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=wint_ExchangeAndTerminationAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=wint_DeerfieldManagementLPMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=wint_DeerfieldManagementLPMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>37
<FILENAME>R27.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm139823960806496">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note 8 - Stockholders' Equity (Details Textual) - USD ($)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="1">2 Months Ended</th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 25, 2021</div></th>
<th class="th"><div>Mar. 23, 2021</div></th>
<th class="th"><div>Sep. 17, 2020</div></th>
<th class="th"><div>Aug. 11, 2022</div></th>
<th class="th"><div>Aug. 31, 2022</div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Stock Issued During Period, Value, New Issues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,020<span></span>
</td>
<td class="nump">$ 1,120<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Proceeds from Issuance of Common Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,225<span></span>
</td>
<td class="nump">$ 1,690<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=wint_March2021WarrantsMember', window );">March 2021 Warrants [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3.60<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingTerm', window );">Warrants and Rights Outstanding, Term (Year)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=wint_ATMProgramMember', window );">ATM Program [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_wint_SharesAuthorizedToBeOfferedAndSoldUnderOfferingAgreementValue', window );">Shares Authorized to Be Offered and Sold Under Offering Agreement, Value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_wint_CommissionFeePercentFee', window );">Commission Fee, Percent Fee</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Stock Issued During Period, Shares, New Issues (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,137,246<span></span>
</td>
<td class="nump">552,474<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Stock Issued During Period, Value, New Issues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,300<span></span>
</td>
<td class="nump">$ 1,700<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Proceeds from Issuance of Common Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_wint_StockOfferingAgreementPublicFloatLimitationAmount', window );">Stock Offering Agreement, Public Float Limitation Amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 75,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 75,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=wint_ATMProgramMember', window );">ATM Program [Member] | Subsequent Event [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Stock Issued During Period, Shares, New Issues (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,221,706<span></span>
</td>
<td class="nump">1,221,706<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Stock Issued During Period, Value, New Issues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 600<span></span>
</td>
<td class="nump">$ 600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_wint_StockOfferingAgreementRemainingAmountAvailable', window );">Stock Offering Agreement, Remaining Amount Available</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_wint_StockOfferingAgreementPublicFloatLimitationAmount', window );">Stock Offering Agreement, Public Float Limitation Amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 75,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=wint_March2021PublicOfferingMember', window );">March 2021 Public Offering [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_wint_EquityIssuedDuringPeriodUnitsNewIssues', window );">Equity Issued During Period, Units, New Issues (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9,230,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_wint_UnitsNumberOfSecuritiesCalledByEachUnit', window );">Units, Number of Securities Called by Each Unit (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_wint_StockAndWarrantsIssuedPricePerShare', window );">Stock and Warrants Issued, Price Per Share (in dollars per share)</a></td>
<td class="nump">$ 3.25<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_wint_ProceedsFromIssuanceOrSaleOfEquityGrossAmount', window );">Proceeds from Issuance or Sale of Equity, Gross Amount</a></td>
<td class="nump">$ 30,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOrSaleOfEquity', window );">Proceeds from Issuance or Sale of Equity, Total</a></td>
<td class="nump">$ 27,400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Exercise price per share or per unit of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21475-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the additional capital contribution to the entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOrSaleOfEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the issuance of common stock, preferred stock, treasury stock, stock options, and other types of equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOrSaleOfEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WarrantsAndRightsOutstandingTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Period between issuance and expiration of outstanding warrant and right embodying unconditional obligation requiring redemption by transferring asset at specified or determinable date or upon event certain to occur, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=126976982&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WarrantsAndRightsOutstandingTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_wint_CommissionFeePercentFee">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The percentage charged for commission.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">wint_CommissionFeePercentFee</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>wint_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_wint_EquityIssuedDuringPeriodUnitsNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of new units issued during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">wint_EquityIssuedDuringPeriodUnitsNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>wint_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_wint_ProceedsFromIssuanceOrSaleOfEquityGrossAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The gross proceeds from the issuance of common stock, preferred stock, treasury stock, stock options, and other types of equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">wint_ProceedsFromIssuanceOrSaleOfEquityGrossAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>wint_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_wint_SharesAuthorizedToBeOfferedAndSoldUnderOfferingAgreementValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the dollar amount of stock authorized to be offered and sold under an offering agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">wint_SharesAuthorizedToBeOfferedAndSoldUnderOfferingAgreementValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>wint_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_wint_StockAndWarrantsIssuedPricePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The stock and warrants issued price per share.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">wint_StockAndWarrantsIssuedPricePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>wint_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_wint_StockOfferingAgreementPublicFloatLimitationAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of public float required to remove limitations on a stock offering agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">wint_StockOfferingAgreementPublicFloatLimitationAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>wint_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_wint_StockOfferingAgreementRemainingAmountAvailable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of remaining amount available under a stock offering agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">wint_StockOfferingAgreementRemainingAmountAvailable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>wint_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_wint_UnitsNumberOfSecuritiesCalledByEachUnit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of securities into which each unit may be converted. For example, but not limited to, each unit may be converted into two shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">wint_UnitsNumberOfSecuritiesCalledByEachUnit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>wint_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=wint_March2021WarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=wint_March2021WarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=wint_ATMProgramMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=wint_ATMProgramMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=wint_March2021PublicOfferingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=wint_March2021PublicOfferingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>38
<FILENAME>R28.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm139823965865824">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note 9 - Stock-Based Compensation (Details Textual)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2022</div></th></tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember', window );">Restricted Stock Units (RSUs) [Member] | Minimum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1', window );">Share-based Compensation Arrangement by Share-based Payment Award, Award Requisite Service Period (Year)</a></td>
<td class="text">1 year<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=wint_The2020EquityIncentivePlanMember', window );">The 2020 Equity Incentive Plan [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1', window );">Share-based Compensation Arrangement by Share-based Payment Award, Award Requisite Service Period (Year)</a></td>
<td class="text">3 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=wint_NonplanStockOptionsMember', window );">Non-plan Stock Options [Member] | Executive Officers and Employees [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1', window );">Share-based Compensation Arrangement by Share-based Payment Award, Award Requisite Service Period (Year)</a></td>
<td class="text">3 years<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Estimated period over which an employee is required to provide service in exchange for the equity-based payment award, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=wint_The2020EquityIncentivePlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=wint_The2020EquityIncentivePlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=wint_NonplanStockOptionsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=wint_NonplanStockOptionsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_TitleOfIndividualAxis=wint_ExecutiveOfficersAndEmployeesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_TitleOfIndividualAxis=wint_ExecutiveOfficersAndEmployeesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>39
<FILENAME>R29.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm139823961487920">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note 9 - Stock-Based Compensation - Summary of Stock Option Activity (Details)<br> shares in Thousands</strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th">
<div>Jun. 30, 2022 </div>
<div>$ / shares </div>
<div>shares</div>
</th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Shares Outstanding, Beginning Balance (in shares) | shares</a></td>
<td class="nump">3,387<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Weighted Average Exercise Price, Outstanding, at Beginning Period (in dollars per share) | $ / shares</a></td>
<td class="nump">$ 9.74<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Shares Granted (in shares) | shares</a></td>
<td class="nump">880<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice', window );">Weighted Average Exercise Price, Granted (in dollars per share) | $ / shares</a></td>
<td class="nump">$ 0.99<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod', window );">Shares Forfeited or Expired (in shares) | shares</a></td>
<td class="num">(220)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice', window );">Weighted Average Exercise Price, Forfeited or Expired (in dollars per share) | $ / shares</a></td>
<td class="nump">$ 9.72<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Shares Outstanding, Ending Balance (in shares) | shares</a></td>
<td class="nump">4,047<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Weighted Average Exercise Price, Outstanding, at Ending Period (in dollars per share) | $ / shares</a></td>
<td class="nump">$ 7.84<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2', window );">Weighted Average Remaining Contractual Life, Outstanding (Year)</a></td>
<td class="text">7 years 9 months 18 days<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber', window );">Shares Vested and Exercisable (in shares) | shares</a></td>
<td class="nump">2,229<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice', window );">Weighted Average Exercise Price, Vested and Exercisable (in dollars per share) | $ / shares</a></td>
<td class="nump">$ 11.35<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1', window );">Weighted Average Remaining Contractual Life, Vested and Exercisable (Year)</a></td>
<td class="text">6 years 9 months 18 days<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber', window );">Vested and expected to vest (in shares) | shares</a></td>
<td class="nump">3,821<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice', window );">Weighted Average Exercise Price, Vested and Expected to Vest (in dollars per share) | $ / shares</a></td>
<td class="nump">$ 7.85<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1', window );">Weighted Average Remaining Contractual Life, Vested and Expected to Vest (Year)</a></td>
<td class="text">7 years 9 months 18 days<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>For presentations that combine terminations, the number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan or that expired.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price of options that were either forfeited or expired.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Gross number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of options outstanding, including both vested and non-vested options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of fully vested and expected to vest options outstanding that can be converted into shares under option plan. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted-average exercise price, at which grantee can acquire shares reserved for issuance, for fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for fully vested and expected to vest options outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>40
<FILENAME>R30.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm139823960960640">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note 9 - Stock-Based Compensation - Restricted Stock Units (Details) - Restricted Stock Units (RSUs) [Member]<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th">
<div>Jun. 30, 2022 </div>
<div>$ / shares </div>
<div>shares</div>
</th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Shares Outstanding, Beginning Balance (in shares) | shares</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue', window );">Weighted- Average Grant Date Fair Value, Outstanding, Beginning Balance (in dollars per share) | $ / shares</a></td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod', window );">Awarded (in shares) | shares</a></td>
<td class="nump">582,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Awarded, Weighted- Average Grant Date Fair Value, Outstanding (in dollars per share) | $ / shares</a></td>
<td class="nump">$ 0.99<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod', window );">Cancelled (in shares) | shares</a></td>
<td class="num">(21)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue', window );">Cancelled, Weighted- Average Grant Date Fair Value, Outstanding (in dollars per share) | $ / shares</a></td>
<td class="nump">$ 1.02<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Outstanding at June 30, 2022 (in shares) | shares</a></td>
<td class="nump">561,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue', window );">Weighted- Average Grant Date Fair Value, Outstanding (in dollars per share) | $ / shares</a></td>
<td class="nump">$ 0.99<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_wint_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndExercisable', window );">Vested and exercisable at June 30, 2022 (in shares) | shares</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_wint_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndExercisableWeightedAverageGrantDateFairValueEndingBalance', window );">Vested and exercisable Weighted- Average Grant Date Fair Value (in dollars per share) | $ / shares</a></td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_wint_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityOtherThanOptionsVestedAndExpectedToVestOutstandingNumber', window );">Vested and expected to vest at June 30, 2022 (in shares) | shares</a></td>
<td class="nump">561,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_wint_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndExpectedToVestWeightedAverageGrantDateFairValueEndingBalance', window );">Vested and expected to vest Weighted- Average Grant Date Fair Value (in dollars per share) | $ / shares</a></td>
<td class="nump">$ 0.99<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of equity-based payment instruments, excluding stock (or unit) options, that were forfeited during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(03)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average fair value as of the grant date of equity-based award plans other than stock (unit) option plans that were not exercised or put into effect as a result of the occurrence of a terminating event.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(03)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Per share or unit weighted-average fair value of nonvested award under share-based payment arrangement. Excludes share and unit options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_wint_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndExercisable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are vested and exercisable as of the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">wint_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndExercisable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>wint_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_wint_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndExercisableWeightedAverageGrantDateFairValueEndingBalance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average exercise price of vested and exercisable for equity instruments other than option.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">wint_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndExercisableWeightedAverageGrantDateFairValueEndingBalance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>wint_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_wint_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndExpectedToVestWeightedAverageGrantDateFairValueEndingBalance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average grant date fair value for vested and expected to vest for equity instrument other than options of share based compensation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">wint_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndExpectedToVestWeightedAverageGrantDateFairValueEndingBalance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>wint_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_wint_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityOtherThanOptionsVestedAndExpectedToVestOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are vested and expected to vest as of the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">wint_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityOtherThanOptionsVestedAndExpectedToVestOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>wint_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>41
<FILENAME>R31.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm139823962127120">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note 9 - Stock-Based Compensation - Stock-Based Compensation Expense (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Stock-based compensation expense</a></td>
<td class="nump">$ 781<span></span>
</td>
<td class="nump">$ 1,544<span></span>
</td>
<td class="nump">$ 1,551<span></span>
</td>
<td class="nump">$ 3,987<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember', window );">Research and Development Expense [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Stock-based compensation expense</a></td>
<td class="nump">147<span></span>
</td>
<td class="nump">630<span></span>
</td>
<td class="nump">382<span></span>
</td>
<td class="nump">1,569<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_SellingGeneralAndAdministrativeExpensesMember', window );">Selling, General and Administrative Expenses [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Stock-based compensation expense</a></td>
<td class="nump">$ 634<span></span>
</td>
<td class="nump">$ 914<span></span>
</td>
<td class="nump">$ 1,169<span></span>
</td>
<td class="nump">$ 2,418<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllocatedShareBasedCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllocatedShareBasedCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_SellingGeneralAndAdministrativeExpensesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_SellingGeneralAndAdministrativeExpensesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>42
<FILENAME>R32.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm139823962408032">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note 9 - Stock-Based Compensation - Stock Options Valuation Assumptions (Details)<br></strong></div></th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate', window );">Weighted average expected volatility</a></td>
<td class="nump">106.00%<span></span>
</td>
<td class="nump">105.00%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Weighted average expected term (Year)</a></td>
<td class="text">6 years 10 months 24 days<span></span>
</td>
<td class="text">6 years 8 months 12 days<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate', window );">Weighted average risk-free interest rate</a></td>
<td class="nump">1.70%<span></span>
</td>
<td class="nump">0.48%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The risk-free interest rate assumption that is used in valuing an option on its own shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Rate of weighted-average expected volatility for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>43
<FILENAME>R33.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm139823956399504">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note 10 - Licensing and Research Funding Agreements (Details Textual) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Oct. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Mar. 18, 2020</div></th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=wint_AerosurfFundingTermSheetMember', window );">AEROSURF Funding Term Sheet [Member] | Lee&#8217;s Pharmaceutical Holdings Limited [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_wint_NonrefundablePayments', window );">Nonrefundable Payments</a></td>
<td class="nump">$ 2.8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=wint_TermSheetWithLeeMember', window );">Term Sheet With Lee [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_wint_ProceedsForPaymentsToDevelopProduct', window );">Proceeds for Payments to Develop Product</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_wint_FinancingOfProductPercentOfFinancingThatMustBeRepaidToDiscontinueRevenueSharing', window );">Financing of Product, Percent of Financing That Must be Repaid to Discontinue Revenue Sharing</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">125.00%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_wint_FinancingOfProductPercentOfRevenueSharedWithFinancer', window );">Financing of Product, Percent of Revenue Shared With Financer</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">50.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractualObligation', window );">Contractual Obligation, Total</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3.8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractualObligation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of contractual obligation, including but not limited to, long-term debt, capital lease obligations, operating lease obligations, purchase obligations, and other commitments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractualObligation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_wint_FinancingOfProductPercentOfFinancingThatMustBeRepaidToDiscontinueRevenueSharing">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The percent of financing that must be repaid to discontinue the revenue sharing provisions of product financing.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">wint_FinancingOfProductPercentOfFinancingThatMustBeRepaidToDiscontinueRevenueSharing</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>wint_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_wint_FinancingOfProductPercentOfRevenueSharedWithFinancer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The percent of revenue shared with financer for the financing of a product.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">wint_FinancingOfProductPercentOfRevenueSharedWithFinancer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>wint_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_wint_NonrefundablePayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of nonrefundable payments pursuant to the agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">wint_NonrefundablePayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>wint_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_wint_ProceedsForPaymentsToDevelopProduct">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of cash inflow from payments from a third party to develop a product.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">wint_ProceedsForPaymentsToDevelopProduct</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>wint_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=wint_AerosurfFundingTermSheetMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=wint_AerosurfFundingTermSheetMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=wint_LeesPharmaceuticalHoldingsLimitedMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=wint_LeesPharmaceuticalHoldingsLimitedMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=wint_TermSheetWithLeeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=wint_TermSheetWithLeeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>44
<FILENAME>wint20220630_10q_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:dei="http://xbrl.sec.gov/dei/2022"
  xmlns:iso4217="http://www.xbrl.org/2003/iso4217"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:srt="http://fasb.org/srt/2022"
  xmlns:thunderdome="http://www.RDGFilings.com"
  xmlns:us-gaap="http://fasb.org/us-gaap/2022"
  xmlns:utr="http://www.xbrl.org/2009/utr"
  xmlns:wint="http://www.windtreetx.com/20220630"
  xmlns:xbrldi="http://xbrl.org/2006/xbrldi"
  xmlns:xlink="http://www.w3.org/1999/xlink">
    <link:schemaRef xlink:href="wint-20220630.xsd" xlink:type="simple"/>
    <context id="d_2022-01-01_2022-06-30">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000946486</identifier>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="i_2022-08-11">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000946486</identifier>
        </entity>
        <period>
            <instant>2022-08-11</instant>
        </period>
    </context>
    <context id="i_2022-06-30">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000946486</identifier>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="i_2021-12-31">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000946486</identifier>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="d_2022-04-01_2022-06-30">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000946486</identifier>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="d_2021-04-01_2021-06-30">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000946486</identifier>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="d_2021-01-01_2021-06-30">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000946486</identifier>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i_2020-12-31_StatementEquityComponentsAxis-CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000946486</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i_2020-12-31_StatementEquityComponentsAxis-AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000946486</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i_2020-12-31_StatementEquityComponentsAxis-RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000946486</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i_2020-12-31_StatementEquityComponentsAxis-TreasuryStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000946486</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i_2020-12-31">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000946486</identifier>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="d_2021-01-01_2021-03-31_StatementEquityComponentsAxis-RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000946486</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="d_2021-01-01_2021-03-31">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000946486</identifier>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="d_2021-01-01_2021-03-31_StatementEquityComponentsAxis-CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000946486</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="d_2021-01-01_2021-03-31_StatementEquityComponentsAxis-AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000946486</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="d_2021-01-01_2021-03-31_StatementClassOfStockAxis-ATMProgramMember_StatementEquityComponentsAxis-CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000946486</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">wint:ATMProgramMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="d_2021-01-01_2021-03-31_StatementClassOfStockAxis-ATMProgramMember_StatementEquityComponentsAxis-AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000946486</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">wint:ATMProgramMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="d_2021-01-01_2021-03-31_StatementClassOfStockAxis-ATMProgramMember_StatementEquityComponentsAxis-RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000946486</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">wint:ATMProgramMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="d_2021-01-01_2021-03-31_StatementClassOfStockAxis-ATMProgramMember_StatementEquityComponentsAxis-TreasuryStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000946486</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">wint:ATMProgramMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="d_2021-01-01_2021-03-31_StatementClassOfStockAxis-ATMProgramMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000946486</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">wint:ATMProgramMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="d_2021-01-01_2021-03-31_StatementEquityComponentsAxis-CommonStockMember_SubsidiarySaleOfStockAxis-SharePurchaseAgreementDecember2019Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000946486</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">wint:SharePurchaseAgreementDecember2019Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="d_2021-01-01_2021-03-31_StatementEquityComponentsAxis-AdditionalPaidInCapitalMember_SubsidiarySaleOfStockAxis-SharePurchaseAgreementDecember2019Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000946486</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">wint:SharePurchaseAgreementDecember2019Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="d_2021-01-01_2021-03-31_StatementEquityComponentsAxis-RetainedEarningsMember_SubsidiarySaleOfStockAxis-SharePurchaseAgreementDecember2019Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000946486</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">wint:SharePurchaseAgreementDecember2019Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="d_2021-01-01_2021-03-31_StatementEquityComponentsAxis-TreasuryStockMember_SubsidiarySaleOfStockAxis-SharePurchaseAgreementDecember2019Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000946486</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">wint:SharePurchaseAgreementDecember2019Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="d_2021-01-01_2021-03-31_SubsidiarySaleOfStockAxis-SharePurchaseAgreementDecember2019Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000946486</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">wint:SharePurchaseAgreementDecember2019Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="i_2021-03-31_StatementEquityComponentsAxis-CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000946486</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="i_2021-03-31_StatementEquityComponentsAxis-AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000946486</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="i_2021-03-31_StatementEquityComponentsAxis-RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000946486</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="i_2021-03-31_StatementEquityComponentsAxis-TreasuryStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000946486</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="i_2021-03-31">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000946486</identifier>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="d_2021-04-01_2021-06-30_StatementEquityComponentsAxis-CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000946486</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="d_2021-04-01_2021-06-30_StatementEquityComponentsAxis-AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000946486</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="d_2021-04-01_2021-06-30_StatementEquityComponentsAxis-RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000946486</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="d_2021-04-01_2021-06-30_StatementEquityComponentsAxis-TreasuryStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000946486</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i_2021-06-30_StatementEquityComponentsAxis-CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000946486</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="i_2021-06-30_StatementEquityComponentsAxis-AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000946486</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="i_2021-06-30_StatementEquityComponentsAxis-RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000946486</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="i_2021-06-30_StatementEquityComponentsAxis-TreasuryStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000946486</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="i_2021-06-30">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000946486</identifier>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="i_2021-12-31_StatementEquityComponentsAxis-CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000946486</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i_2021-12-31_StatementEquityComponentsAxis-AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000946486</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i_2021-12-31_StatementEquityComponentsAxis-RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000946486</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i_2021-12-31_StatementEquityComponentsAxis-TreasuryStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000946486</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="d_2022-01-01_2022-03-31_StatementEquityComponentsAxis-RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000946486</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="d_2022-01-01_2022-03-31">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000946486</identifier>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="d_2022-01-01_2022-03-31_StatementEquityComponentsAxis-AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000946486</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="d_2022-01-01_2022-03-31_StatementClassOfStockAxis-ATMProgramMember_StatementEquityComponentsAxis-CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000946486</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">wint:ATMProgramMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="d_2022-01-01_2022-03-31_StatementClassOfStockAxis-ATMProgramMember_StatementEquityComponentsAxis-AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000946486</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">wint:ATMProgramMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="d_2022-01-01_2022-03-31_StatementClassOfStockAxis-ATMProgramMember_StatementEquityComponentsAxis-RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000946486</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">wint:ATMProgramMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="d_2022-01-01_2022-03-31_StatementClassOfStockAxis-ATMProgramMember_StatementEquityComponentsAxis-TreasuryStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000946486</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">wint:ATMProgramMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="d_2022-01-01_2022-03-31_StatementClassOfStockAxis-ATMProgramMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000946486</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">wint:ATMProgramMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i_2022-03-31_StatementEquityComponentsAxis-CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000946486</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="i_2022-03-31_StatementEquityComponentsAxis-AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000946486</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="i_2022-03-31_StatementEquityComponentsAxis-RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000946486</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="i_2022-03-31_StatementEquityComponentsAxis-TreasuryStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000946486</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="i_2022-03-31">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000946486</identifier>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="d_2022-04-01_2022-06-30_StatementEquityComponentsAxis-CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000946486</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="d_2022-04-01_2022-06-30_StatementEquityComponentsAxis-AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000946486</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="d_2022-04-01_2022-06-30_StatementEquityComponentsAxis-RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000946486</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="d_2022-04-01_2022-06-30_StatementEquityComponentsAxis-TreasuryStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000946486</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="i_2022-06-30_StatementEquityComponentsAxis-CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000946486</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="i_2022-06-30_StatementEquityComponentsAxis-AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000946486</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="i_2022-06-30_StatementEquityComponentsAxis-RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000946486</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="i_2022-06-30_StatementEquityComponentsAxis-TreasuryStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000946486</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="i_2020-09-17_SubsidiarySaleOfStockAxis-ATMProgramMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000946486</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">wint:ATMProgramMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-17</instant>
        </period>
    </context>
    <context id="d_2022-01-01_2022-06-30_SubsidiarySaleOfStockAxis-ATMProgramMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000946486</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">wint:ATMProgramMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="d_2022-07-01_2022-08-31_SubsequentEventTypeAxis-SubsequentEventMember_SubsidiarySaleOfStockAxis-ATMProgramMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000946486</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">wint:ATMProgramMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-08-31</endDate>
        </period>
    </context>
    <context id="i_2022-06-30_SubsidiarySaleOfStockAxis-ATMProgramMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000946486</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">wint:ATMProgramMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="i_2022-06-30_IndefiniteLivedIntangibleAssetsByMajorClassAxis-IstaroximeDrugCandidateMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000946486</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis">wint:IstaroximeDrugCandidateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="i_2021-12-31_IndefiniteLivedIntangibleAssetsByMajorClassAxis-IstaroximeDrugCandidateMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000946486</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis">wint:IstaroximeDrugCandidateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i_2022-06-30_IndefiniteLivedIntangibleAssetsByMajorClassAxis-RostafuroxinDrugCandidateMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000946486</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis">wint:RostafuroxinDrugCandidateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="i_2021-12-31_IndefiniteLivedIntangibleAssetsByMajorClassAxis-RostafuroxinDrugCandidateMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000946486</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis">wint:RostafuroxinDrugCandidateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="d_2022-01-01_2022-03-31_PropertyPlantAndEquipmentByTypeAxis-ManufacturingAndLaboratoryEquipmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000946486</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">wint:ManufacturingAndLaboratoryEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i_2017-11-01_LineOfCreditFacilityAxis-DeerfieldManagementLPMember_LongtermDebtTypeAxis-DeerfieldLoanMember_TypeOfArrangementAxis-ExchangeAndTerminationAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000946486</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">wint:DeerfieldManagementLPMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">wint:DeerfieldLoanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">wint:ExchangeAndTerminationAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2017-11-01</instant>
        </period>
    </context>
    <context id="i_2022-06-30_CashAndCashEquivalentsAxis-MoneyMarketFundsMember_FairValueByMeasurementFrequencyAxis-FairValueMeasurementsRecurringMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000946486</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="i_2022-06-30_CashAndCashEquivalentsAxis-MoneyMarketFundsMember_FairValueByFairValueHierarchyLevelAxis-FairValueInputsLevel1Member_FairValueByMeasurementFrequencyAxis-FairValueMeasurementsRecurringMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000946486</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="i_2022-06-30_FairValueByMeasurementFrequencyAxis-FairValueMeasurementsRecurringMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000946486</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="i_2022-06-30_FairValueByFairValueHierarchyLevelAxis-FairValueInputsLevel1Member_FairValueByMeasurementFrequencyAxis-FairValueMeasurementsRecurringMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000946486</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="i_2021-12-31_CashAndCashEquivalentsAxis-MoneyMarketFundsMember_FairValueByMeasurementFrequencyAxis-FairValueMeasurementsRecurringMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000946486</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i_2021-12-31_CashAndCashEquivalentsAxis-MoneyMarketFundsMember_FairValueByFairValueHierarchyLevelAxis-FairValueInputsLevel1Member_FairValueByMeasurementFrequencyAxis-FairValueMeasurementsRecurringMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000946486</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i_2021-12-31_FairValueByMeasurementFrequencyAxis-FairValueMeasurementsRecurringMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000946486</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i_2021-12-31_FairValueByFairValueHierarchyLevelAxis-FairValueInputsLevel1Member_FairValueByMeasurementFrequencyAxis-FairValueMeasurementsRecurringMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000946486</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i_2022-06-30_DebtInstrumentAxis-LoanPayableToBankDirectCapitalFinanceMember_ShortTermDebtTypeAxis-LoansPayableMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000946486</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">wint:LoanPayableToBankDirectCapitalFinanceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">us-gaap:LoansPayableMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="d_2022-06-30_2022-06-30_DebtInstrumentAxis-LoanPayableToBankDirectCapitalFinanceMember_ShortTermDebtTypeAxis-LoansPayableMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000946486</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">wint:LoanPayableToBankDirectCapitalFinanceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">us-gaap:LoansPayableMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-06-30</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="i_2021-06-30_DebtInstrumentAxis-LoanPayableToBankDirectCapitalFinanceMember_ShortTermDebtTypeAxis-LoansPayableMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000946486</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">wint:LoanPayableToBankDirectCapitalFinanceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">us-gaap:LoansPayableMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="d_2021-06-01_2021-06-30_DebtInstrumentAxis-LoanPayableToBankDirectCapitalFinanceMember_ShortTermDebtTypeAxis-LoansPayableMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000946486</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">wint:LoanPayableToBankDirectCapitalFinanceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">us-gaap:LoansPayableMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-06-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i_2021-12-31_DebtInstrumentAxis-LoanPayableToBankDirectCapitalFinanceMember_ShortTermDebtTypeAxis-LoansPayableMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000946486</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">wint:LoanPayableToBankDirectCapitalFinanceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">us-gaap:LoansPayableMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="d_2017-10-27_2017-10-27_CounterpartyNameAxis-DeerfieldManagementLPMember_LongtermDebtTypeAxis-DeerfieldLoanMember_TypeOfArrangementAxis-ExchangeAndTerminationAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000946486</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">wint:DeerfieldManagementLPMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">wint:DeerfieldLoanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">wint:ExchangeAndTerminationAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-10-27</startDate>
            <endDate>2017-10-27</endDate>
        </period>
    </context>
    <context id="i_2017-10-27_CounterpartyNameAxis-DeerfieldManagementLPMember_LongtermDebtTypeAxis-DeerfieldLoanMember_TypeOfArrangementAxis-ExchangeAndTerminationAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000946486</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">wint:DeerfieldManagementLPMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">wint:DeerfieldLoanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">wint:ExchangeAndTerminationAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2017-10-27</instant>
        </period>
    </context>
    <context id="i_2022-03-31_CounterpartyNameAxis-DeerfieldManagementLPMember_LongtermDebtTypeAxis-DeerfieldLoanMember_TypeOfArrangementAxis-ExchangeAndTerminationAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000946486</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">wint:DeerfieldManagementLPMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">wint:DeerfieldLoanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">wint:ExchangeAndTerminationAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="i_2021-12-31_CounterpartyNameAxis-DeerfieldManagementLPMember_LongtermDebtTypeAxis-DeerfieldLoanMember_TypeOfArrangementAxis-ExchangeAndTerminationAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000946486</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">wint:DeerfieldManagementLPMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">wint:DeerfieldLoanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">wint:ExchangeAndTerminationAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="d_2020-09-17_2020-09-17_SubsidiarySaleOfStockAxis-ATMProgramMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000946486</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">wint:ATMProgramMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-09-17</startDate>
            <endDate>2020-09-17</endDate>
        </period>
    </context>
    <context id="d_2021-01-01_2021-06-30_SubsidiarySaleOfStockAxis-ATMProgramMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000946486</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">wint:ATMProgramMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="d_2022-07-01_2022-08-11_SubsequentEventTypeAxis-SubsequentEventMember_SubsidiarySaleOfStockAxis-ATMProgramMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000946486</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">wint:ATMProgramMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-08-11</endDate>
        </period>
    </context>
    <context id="i_2022-08-11_SubsequentEventTypeAxis-SubsequentEventMember_SubsidiarySaleOfStockAxis-ATMProgramMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000946486</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">wint:ATMProgramMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-08-11</instant>
        </period>
    </context>
    <context id="d_2021-03-23_2021-03-23_SubsidiarySaleOfStockAxis-March2021PublicOfferingMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000946486</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">wint:March2021PublicOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-03-23</startDate>
            <endDate>2021-03-23</endDate>
        </period>
    </context>
    <context id="i_2021-03-23_SubsidiarySaleOfStockAxis-March2021PublicOfferingMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000946486</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">wint:March2021PublicOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-23</instant>
        </period>
    </context>
    <context id="i_2021-03-23_ClassOfWarrantOrRightAxis-March2021WarrantsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000946486</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">wint:March2021WarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-23</instant>
        </period>
    </context>
    <context id="i_2021-03-25_SubsidiarySaleOfStockAxis-March2021PublicOfferingMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000946486</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">wint:March2021PublicOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-25</instant>
        </period>
    </context>
    <context id="d_2021-03-25_2021-03-25_SubsidiarySaleOfStockAxis-March2021PublicOfferingMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000946486</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">wint:March2021PublicOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-03-25</startDate>
            <endDate>2021-03-25</endDate>
        </period>
    </context>
    <context id="d_2022-01-01_2022-06-30_PlanNameAxis-The2020EquityIncentivePlanMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000946486</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">wint:The2020EquityIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="d_2022-01-01_2022-06-30_AwardTypeAxis-RestrictedStockUnitsRSUMember_RangeAxis-MinimumMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000946486</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="d_2022-01-01_2022-06-30_PlanNameAxis-NonplanStockOptionsMember_TitleOfIndividualAxis-ExecutiveOfficersAndEmployeesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000946486</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">wint:ExecutiveOfficersAndEmployeesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">wint:NonplanStockOptionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="i_2021-12-31_AwardTypeAxis-RestrictedStockUnitsRSUMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000946486</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="d_2022-01-01_2022-06-30_AwardTypeAxis-RestrictedStockUnitsRSUMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000946486</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="i_2022-06-30_AwardTypeAxis-RestrictedStockUnitsRSUMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000946486</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="d_2022-04-01_2022-06-30_IncomeStatementLocationAxis-ResearchAndDevelopmentExpenseMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000946486</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="d_2021-04-01_2021-06-30_IncomeStatementLocationAxis-ResearchAndDevelopmentExpenseMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000946486</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="d_2022-01-01_2022-06-30_IncomeStatementLocationAxis-ResearchAndDevelopmentExpenseMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000946486</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="d_2021-01-01_2021-06-30_IncomeStatementLocationAxis-ResearchAndDevelopmentExpenseMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000946486</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="d_2022-04-01_2022-06-30_IncomeStatementLocationAxis-SellingGeneralAndAdministrativeExpensesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000946486</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="d_2021-04-01_2021-06-30_IncomeStatementLocationAxis-SellingGeneralAndAdministrativeExpensesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000946486</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="d_2022-01-01_2022-06-30_IncomeStatementLocationAxis-SellingGeneralAndAdministrativeExpensesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000946486</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="d_2021-01-01_2021-06-30_IncomeStatementLocationAxis-SellingGeneralAndAdministrativeExpensesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000946486</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="d_2020-08-01_2020-10-31_CounterpartyNameAxis-LeesPharmaceuticalHoldingsLimitedMember_TypeOfArrangementAxis-AerosurfFundingTermSheetMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000946486</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">wint:LeesPharmaceuticalHoldingsLimitedMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">wint:AerosurfFundingTermSheetMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-08-01</startDate>
            <endDate>2020-10-31</endDate>
        </period>
    </context>
    <context id="d_2021-01-01_2021-12-31_TypeOfArrangementAxis-TermSheetWithLeeMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000946486</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">wint:TermSheetWithLeeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i_2020-03-18_TypeOfArrangementAxis-TermSheetWithLeeMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000946486</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">wint:TermSheetWithLeeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-03-18</instant>
        </period>
    </context>
    <context id="i_2022-03-31_TypeOfArrangementAxis-TermSheetWithLeeMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000946486</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">wint:TermSheetWithLeeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <unit id="Share">
        <measure>shares</measure>
    </unit>
    <unit id="NonApplicable">
        <measure>thunderdome:item</measure>
    </unit>
    <unit id="USD">
        <measure>iso4217:USD</measure>
    </unit>
    <unit id="USDPerShare">
        <divide>
            <unitNumerator>
                <measure>iso4217:USD</measure>
            </unitNumerator>
            <unitDenominator>
                <measure>shares</measure>
            </unitDenominator>
        </divide>
    </unit>
    <unit id="Pure">
        <measure>pure</measure>
    </unit>
    <unit id="Year">
        <measure>utr:Y</measure>
    </unit>
    <dei:EntityCentralIndexKey
      contextRef="d_2022-01-01_2022-06-30"
      id="thunderdome-EntityCentralIndexKey">0000946486</dei:EntityCentralIndexKey>
    <dei:EntityRegistrantName
      contextRef="d_2022-01-01_2022-06-30"
      id="thunderdome-EntityRegistrantName">WINDTREE THERAPEUTICS INC /DE/</dei:EntityRegistrantName>
    <dei:AmendmentFlag contextRef="d_2022-01-01_2022-06-30">false</dei:AmendmentFlag>
    <dei:CurrentFiscalYearEndDate contextRef="d_2022-01-01_2022-06-30">--12-31</dei:CurrentFiscalYearEndDate>
    <dei:DocumentFiscalPeriodFocus contextRef="d_2022-01-01_2022-06-30">Q2</dei:DocumentFiscalPeriodFocus>
    <dei:DocumentFiscalYearFocus contextRef="d_2022-01-01_2022-06-30">2022</dei:DocumentFiscalYearFocus>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="i_2022-06-30"
      decimals="INF"
      id="c86424713"
      unitRef="USDPerShare">0.001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="i_2021-12-31"
      decimals="INF"
      id="c86424714"
      unitRef="USDPerShare">0.001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="i_2022-06-30"
      decimals="INF"
      id="c86424715"
      unitRef="Share">5000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="i_2021-12-31"
      decimals="INF"
      id="c86424716"
      unitRef="Share">5000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesIssued
      contextRef="i_2022-06-30"
      decimals="-3"
      id="c86424717"
      unitRef="Share">0</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="i_2022-06-30"
      decimals="-3"
      id="c86424719"
      unitRef="Share">0</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PreferredStockSharesIssued
      contextRef="i_2021-12-31"
      decimals="-3"
      id="c86424718"
      unitRef="Share">0</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="i_2021-12-31"
      decimals="-3"
      id="c86424720"
      unitRef="Share">0</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="i_2022-06-30"
      decimals="INF"
      id="c86424723"
      unitRef="USDPerShare">0.001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="i_2021-12-31"
      decimals="INF"
      id="c86424724"
      unitRef="USDPerShare">0.001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="i_2022-06-30"
      decimals="INF"
      id="c86424725"
      unitRef="Share">120000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="i_2021-12-31"
      decimals="INF"
      id="c86424726"
      unitRef="Share">120000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesIssued
      contextRef="i_2022-06-30"
      decimals="INF"
      id="c86424727"
      unitRef="Share">29406196</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesIssued
      contextRef="i_2021-12-31"
      decimals="INF"
      id="c86424728"
      unitRef="Share">28268950</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="i_2022-06-30"
      decimals="INF"
      id="c86424729"
      unitRef="Share">29406172</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="i_2021-12-31"
      decimals="INF"
      id="c86424730"
      unitRef="Share">28268926</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:TreasuryStockShares
      contextRef="i_2022-06-30"
      decimals="INF"
      id="c86424737"
      unitRef="Share">24</us-gaap:TreasuryStockShares>
    <us-gaap:TreasuryStockShares
      contextRef="i_2021-12-31"
      decimals="INF"
      id="c86424738"
      unitRef="Share">24</us-gaap:TreasuryStockShares>
    <us-gaap:GoodwillImpairmentLoss
      contextRef="d_2022-01-01_2022-06-30"
      decimals="-5"
      id="c86425101"
      unitRef="USD">11600000</us-gaap:GoodwillImpairmentLoss>
    <us-gaap:ImpairmentOfIntangibleAssetsExcludingGoodwill
      contextRef="d_2021-01-01_2021-06-30"
      decimals="-5"
      id="c86425106"
      unitRef="USD">37800000</us-gaap:ImpairmentOfIntangibleAssetsExcludingGoodwill>
    <us-gaap:DeferredIncomeTaxExpenseBenefit
      contextRef="d_2021-01-01_2021-06-30"
      decimals="-5"
      id="c86425108"
      unitRef="USD">-8300000</us-gaap:DeferredIncomeTaxExpenseBenefit>
    <us-gaap:ImpairmentOfIntangibleAssetsExcludingGoodwill
      contextRef="d_2021-01-01_2021-06-30"
      decimals="-5"
      id="c86425173"
      unitRef="USD">37800000</us-gaap:ImpairmentOfIntangibleAssetsExcludingGoodwill>
    <us-gaap:GoodwillImpairmentLoss
      contextRef="d_2022-01-01_2022-06-30"
      decimals="-5"
      id="c86425190"
      unitRef="USD">11600000</us-gaap:GoodwillImpairmentLoss>
    <wint:PaymentsForSeveranceCosts
      contextRef="d_2022-01-01_2022-06-30"
      decimals="-5"
      id="c86425218"
      unitRef="USD">200000</wint:PaymentsForSeveranceCosts>
    <us-gaap:DeferredIncomeTaxExpenseBenefit
      contextRef="d_2021-04-01_2021-06-30"
      decimals="-5"
      id="c86425244"
      unitRef="USD">-8300000</us-gaap:DeferredIncomeTaxExpenseBenefit>
    <wint:LiabilityforContingentMilestonePaymentNoncurrent
      contextRef="i_2021-12-31_CounterpartyNameAxis-DeerfieldManagementLPMember_LongtermDebtTypeAxis-DeerfieldLoanMember_TypeOfArrangementAxis-ExchangeAndTerminationAgreementMember"
      decimals="-6"
      id="c86425374"
      unitRef="USD">15000000.0</wint:LiabilityforContingentMilestonePaymentNoncurrent>
    <wint:UnitsNumberOfSecuritiesCalledByEachUnit
      contextRef="i_2021-03-23_SubsidiarySaleOfStockAxis-March2021PublicOfferingMember"
      decimals="INF"
      id="c86425407"
      unitRef="Share">1</wint:UnitsNumberOfSecuritiesCalledByEachUnit>
    <us-gaap:WarrantsAndRightsOutstandingTerm
      contextRef="i_2021-03-23_ClassOfWarrantOrRightAxis-March2021WarrantsMember"
      id="c86425409">P5Y</us-gaap:WarrantsAndRightsOutstandingTerm>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1
      contextRef="d_2022-01-01_2022-06-30_PlanNameAxis-The2020EquityIncentivePlanMember"
      id="c86425425">P3Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1
      contextRef="d_2022-01-01_2022-06-30_AwardTypeAxis-RestrictedStockUnitsRSUMember_RangeAxis-MinimumMember"
      id="c86425426">P1Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1
      contextRef="d_2022-01-01_2022-06-30_PlanNameAxis-NonplanStockOptionsMember_TitleOfIndividualAxis-ExecutiveOfficersAndEmployeesMember"
      id="c86425427">P3Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1>
    <dei:DocumentType contextRef="d_2022-01-01_2022-06-30">10-Q</dei:DocumentType>
    <dei:DocumentQuarterlyReport contextRef="d_2022-01-01_2022-06-30">true</dei:DocumentQuarterlyReport>
    <dei:DocumentPeriodEndDate contextRef="d_2022-01-01_2022-06-30">2022-06-30</dei:DocumentPeriodEndDate>
    <dei:DocumentTransitionReport contextRef="d_2022-01-01_2022-06-30">false</dei:DocumentTransitionReport>
    <dei:EntityFileNumber contextRef="d_2022-01-01_2022-06-30">000-26422</dei:EntityFileNumber>
    <dei:EntityIncorporationStateCountryCode contextRef="d_2022-01-01_2022-06-30">DE</dei:EntityIncorporationStateCountryCode>
    <dei:EntityTaxIdentificationNumber contextRef="d_2022-01-01_2022-06-30">94-3171943</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1 contextRef="d_2022-01-01_2022-06-30">2600 Kelly Road, Suite 100</dei:EntityAddressAddressLine1>
    <dei:EntityAddressCityOrTown contextRef="d_2022-01-01_2022-06-30">Warrington</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince contextRef="d_2022-01-01_2022-06-30">PA</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode contextRef="d_2022-01-01_2022-06-30">18976-3622</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode contextRef="d_2022-01-01_2022-06-30">215</dei:CityAreaCode>
    <dei:LocalPhoneNumber contextRef="d_2022-01-01_2022-06-30">488-9300</dei:LocalPhoneNumber>
    <dei:Security12bTitle contextRef="d_2022-01-01_2022-06-30">Common Stock, $0.001 par value</dei:Security12bTitle>
    <dei:TradingSymbol contextRef="d_2022-01-01_2022-06-30">WINT</dei:TradingSymbol>
    <dei:SecurityExchangeName contextRef="d_2022-01-01_2022-06-30">NASDAQ</dei:SecurityExchangeName>
    <dei:EntityCurrentReportingStatus contextRef="d_2022-01-01_2022-06-30">Yes</dei:EntityCurrentReportingStatus>
    <dei:EntityInteractiveDataCurrent contextRef="d_2022-01-01_2022-06-30">Yes</dei:EntityInteractiveDataCurrent>
    <dei:EntityFilerCategory contextRef="d_2022-01-01_2022-06-30">Non-accelerated Filer</dei:EntityFilerCategory>
    <dei:EntitySmallBusiness contextRef="d_2022-01-01_2022-06-30">true</dei:EntitySmallBusiness>
    <dei:EntityEmergingGrowthCompany contextRef="d_2022-01-01_2022-06-30">false</dei:EntityEmergingGrowthCompany>
    <dei:EntityShellCompany contextRef="d_2022-01-01_2022-06-30">false</dei:EntityShellCompany>
    <dei:EntityCommonStockSharesOutstanding contextRef="i_2022-08-11" decimals="INF" unitRef="Share">30627878</dei:EntityCommonStockSharesOutstanding>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="i_2022-06-30"
      decimals="-3"
      id="c86424670"
      unitRef="USD">11378000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="i_2021-12-31"
      decimals="-3"
      id="c86424671"
      unitRef="USD">22348000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent
      contextRef="i_2022-06-30"
      decimals="-3"
      id="c86424672"
      unitRef="USD">1784000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent
      contextRef="i_2021-12-31"
      decimals="-3"
      id="c86424673"
      unitRef="USD">1143000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:AssetsCurrent
      contextRef="i_2022-06-30"
      decimals="-3"
      id="c86424674"
      unitRef="USD">13162000</us-gaap:AssetsCurrent>
    <us-gaap:AssetsCurrent
      contextRef="i_2021-12-31"
      decimals="-3"
      id="c86424675"
      unitRef="USD">23491000</us-gaap:AssetsCurrent>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="i_2022-06-30"
      decimals="-3"
      id="c86424676"
      unitRef="USD">307000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="i_2021-12-31"
      decimals="-3"
      id="c86424677"
      unitRef="USD">1011000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:RestrictedCashAndCashEquivalentsNoncurrent
      contextRef="i_2022-06-30"
      decimals="-3"
      id="c86424678"
      unitRef="USD">154000</us-gaap:RestrictedCashAndCashEquivalentsNoncurrent>
    <us-gaap:RestrictedCashAndCashEquivalentsNoncurrent
      contextRef="i_2021-12-31"
      decimals="-3"
      id="c86424679"
      unitRef="USD">154000</us-gaap:RestrictedCashAndCashEquivalentsNoncurrent>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="i_2022-06-30"
      decimals="-3"
      id="c86424680"
      unitRef="USD">2074000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="i_2021-12-31"
      decimals="-3"
      id="c86424681"
      unitRef="USD">2381000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill
      contextRef="i_2022-06-30"
      decimals="-4"
      id="c86424682"
      unitRef="USD">32070000</us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill>
    <us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill
      contextRef="i_2021-12-31"
      decimals="-4"
      id="c86424683"
      unitRef="USD">32070000</us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill>
    <us-gaap:Goodwill
      contextRef="i_2022-06-30"
      decimals="-3"
      id="c86424684"
      unitRef="USD">4046000</us-gaap:Goodwill>
    <us-gaap:Goodwill
      contextRef="i_2021-12-31"
      decimals="-3"
      id="c86424685"
      unitRef="USD">15682000</us-gaap:Goodwill>
    <us-gaap:Assets
      contextRef="i_2022-06-30"
      decimals="-3"
      id="c86424686"
      unitRef="USD">51813000</us-gaap:Assets>
    <us-gaap:Assets
      contextRef="i_2021-12-31"
      decimals="-3"
      id="c86424687"
      unitRef="USD">74789000</us-gaap:Assets>
    <us-gaap:AccountsPayableCurrent
      contextRef="i_2022-06-30"
      decimals="-3"
      id="c86424690"
      unitRef="USD">1072000</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccountsPayableCurrent
      contextRef="i_2021-12-31"
      decimals="-3"
      id="c86424691"
      unitRef="USD">693000</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="i_2022-06-30"
      decimals="-3"
      id="c86424692"
      unitRef="USD">2823000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="i_2021-12-31"
      decimals="-3"
      id="c86424693"
      unitRef="USD">3408000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="i_2022-06-30"
      decimals="-3"
      id="c86424694"
      unitRef="USD">432000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="i_2021-12-31"
      decimals="-3"
      id="c86424695"
      unitRef="USD">528000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:LoansPayableCurrent
      contextRef="i_2022-06-30"
      decimals="-3"
      id="c86424696"
      unitRef="USD">1007000</us-gaap:LoansPayableCurrent>
    <us-gaap:LoansPayableCurrent
      contextRef="i_2021-12-31"
      decimals="-3"
      id="c86424697"
      unitRef="USD">294000</us-gaap:LoansPayableCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="i_2022-06-30"
      decimals="-3"
      id="c86424698"
      unitRef="USD">5334000</us-gaap:LiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="i_2021-12-31"
      decimals="-3"
      id="c86424699"
      unitRef="USD">4923000</us-gaap:LiabilitiesCurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="i_2022-06-30"
      decimals="-3"
      id="c86424700"
      unitRef="USD">1839000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="i_2021-12-31"
      decimals="-3"
      id="c86424701"
      unitRef="USD">2071000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <wint:LiabilityforContingentMilestonePaymentNoncurrent
      contextRef="i_2022-06-30"
      decimals="-6"
      id="c86424702"
      unitRef="USD">15000000</wint:LiabilityforContingentMilestonePaymentNoncurrent>
    <wint:LiabilityforContingentMilestonePaymentNoncurrent
      contextRef="i_2021-12-31"
      decimals="-6"
      id="c86424703"
      unitRef="USD">15000000</wint:LiabilityforContingentMilestonePaymentNoncurrent>
    <us-gaap:OtherLiabilitiesNoncurrent
      contextRef="i_2022-06-30"
      decimals="-5"
      id="c86424704"
      unitRef="USD">3800000</us-gaap:OtherLiabilitiesNoncurrent>
    <us-gaap:OtherLiabilitiesNoncurrent
      contextRef="i_2021-12-31"
      decimals="-5"
      id="c86424705"
      unitRef="USD">3800000</us-gaap:OtherLiabilitiesNoncurrent>
    <us-gaap:DeferredIncomeTaxLiabilitiesNet
      contextRef="i_2022-06-30"
      decimals="-3"
      id="c86424706"
      unitRef="USD">6643000</us-gaap:DeferredIncomeTaxLiabilitiesNet>
    <us-gaap:DeferredIncomeTaxLiabilitiesNet
      contextRef="i_2021-12-31"
      decimals="-3"
      id="c86424707"
      unitRef="USD">7114000</us-gaap:DeferredIncomeTaxLiabilitiesNet>
    <us-gaap:Liabilities
      contextRef="i_2022-06-30"
      decimals="-3"
      id="c86424708"
      unitRef="USD">32616000</us-gaap:Liabilities>
    <us-gaap:Liabilities
      contextRef="i_2021-12-31"
      decimals="-3"
      id="c86424709"
      unitRef="USD">32908000</us-gaap:Liabilities>
    <us-gaap:PreferredStockValue
      contextRef="i_2022-06-30"
      decimals="-3"
      id="c86424711"
      unitRef="USD">0</us-gaap:PreferredStockValue>
    <us-gaap:PreferredStockValue
      contextRef="i_2021-12-31"
      decimals="-3"
      id="c86424712"
      unitRef="USD">0</us-gaap:PreferredStockValue>
    <us-gaap:CommonStockValue
      contextRef="i_2022-06-30"
      decimals="-3"
      id="c86424721"
      unitRef="USD">29000</us-gaap:CommonStockValue>
    <us-gaap:CommonStockValue
      contextRef="i_2021-12-31"
      decimals="-3"
      id="c86424722"
      unitRef="USD">28000</us-gaap:CommonStockValue>
    <us-gaap:AdditionalPaidInCapital
      contextRef="i_2022-06-30"
      decimals="-3"
      id="c86424731"
      unitRef="USD">833006000</us-gaap:AdditionalPaidInCapital>
    <us-gaap:AdditionalPaidInCapital
      contextRef="i_2021-12-31"
      decimals="-3"
      id="c86424732"
      unitRef="USD">830231000</us-gaap:AdditionalPaidInCapital>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="i_2022-06-30"
      decimals="-3"
      id="c86424733"
      unitRef="USD">-810784000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="i_2021-12-31"
      decimals="-3"
      id="c86424734"
      unitRef="USD">-785324000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:TreasuryStockValue
      contextRef="i_2022-06-30"
      decimals="-3"
      id="c86424735"
      unitRef="USD">3054000</us-gaap:TreasuryStockValue>
    <us-gaap:TreasuryStockValue
      contextRef="i_2021-12-31"
      decimals="-3"
      id="c86424736"
      unitRef="USD">3054000</us-gaap:TreasuryStockValue>
    <us-gaap:StockholdersEquity
      contextRef="i_2022-06-30"
      decimals="-3"
      id="c86424739"
      unitRef="USD">19197000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i_2021-12-31"
      decimals="-3"
      id="c86424740"
      unitRef="USD">41881000</us-gaap:StockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="i_2022-06-30"
      decimals="-3"
      id="c86424741"
      unitRef="USD">51813000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="i_2021-12-31"
      decimals="-3"
      id="c86424742"
      unitRef="USD">74789000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="d_2022-04-01_2022-06-30"
      decimals="-3"
      id="c86424756"
      unitRef="USD">2995000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="d_2021-04-01_2021-06-30"
      decimals="-3"
      id="c86424757"
      unitRef="USD">4221000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="d_2022-01-01_2022-06-30"
      decimals="-4"
      id="c86424758"
      unitRef="USD">8340000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="d_2021-01-01_2021-06-30"
      decimals="-3"
      id="c86424759"
      unitRef="USD">8631000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:SellingGeneralAndAdministrativeExpense
      contextRef="d_2022-04-01_2022-06-30"
      decimals="-3"
      id="c86424760"
      unitRef="USD">2907000</us-gaap:SellingGeneralAndAdministrativeExpense>
    <us-gaap:SellingGeneralAndAdministrativeExpense
      contextRef="d_2021-04-01_2021-06-30"
      decimals="-3"
      id="c86424761"
      unitRef="USD">3371000</us-gaap:SellingGeneralAndAdministrativeExpense>
    <us-gaap:SellingGeneralAndAdministrativeExpense
      contextRef="d_2022-01-01_2022-06-30"
      decimals="-3"
      id="c86424762"
      unitRef="USD">5895000</us-gaap:SellingGeneralAndAdministrativeExpense>
    <us-gaap:SellingGeneralAndAdministrativeExpense
      contextRef="d_2021-01-01_2021-06-30"
      decimals="-4"
      id="c86424763"
      unitRef="USD">8040000</us-gaap:SellingGeneralAndAdministrativeExpense>
    <us-gaap:GoodwillImpairmentLoss
      contextRef="d_2022-04-01_2022-06-30"
      decimals="-3"
      id="c86424764"
      unitRef="USD">11636000</us-gaap:GoodwillImpairmentLoss>
    <us-gaap:GoodwillImpairmentLoss
      contextRef="d_2021-04-01_2021-06-30"
      decimals="-3"
      id="c86424765"
      unitRef="USD">0</us-gaap:GoodwillImpairmentLoss>
    <us-gaap:GoodwillImpairmentLoss
      contextRef="d_2022-01-01_2022-06-30"
      decimals="-3"
      id="c86424766"
      unitRef="USD">11636000</us-gaap:GoodwillImpairmentLoss>
    <us-gaap:GoodwillImpairmentLoss
      contextRef="d_2021-01-01_2021-06-30"
      decimals="-3"
      id="c86424767"
      unitRef="USD">0</us-gaap:GoodwillImpairmentLoss>
    <us-gaap:ImpairmentOfIntangibleAssetsExcludingGoodwill
      contextRef="d_2022-04-01_2022-06-30"
      decimals="-3"
      id="c86424768"
      unitRef="USD">0</us-gaap:ImpairmentOfIntangibleAssetsExcludingGoodwill>
    <us-gaap:ImpairmentOfIntangibleAssetsExcludingGoodwill
      contextRef="d_2021-04-01_2021-06-30"
      decimals="-4"
      id="c86424769"
      unitRef="USD">37770000</us-gaap:ImpairmentOfIntangibleAssetsExcludingGoodwill>
    <us-gaap:ImpairmentOfIntangibleAssetsExcludingGoodwill
      contextRef="d_2022-01-01_2022-06-30"
      decimals="-3"
      id="c86424770"
      unitRef="USD">0</us-gaap:ImpairmentOfIntangibleAssetsExcludingGoodwill>
    <us-gaap:ImpairmentOfIntangibleAssetsExcludingGoodwill
      contextRef="d_2021-01-01_2021-06-30"
      decimals="-4"
      id="c86424771"
      unitRef="USD">37770000</us-gaap:ImpairmentOfIntangibleAssetsExcludingGoodwill>
    <us-gaap:OperatingExpenses
      contextRef="d_2022-04-01_2022-06-30"
      decimals="-3"
      id="c86424772"
      unitRef="USD">17538000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses
      contextRef="d_2021-04-01_2021-06-30"
      decimals="-3"
      id="c86424773"
      unitRef="USD">45362000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses
      contextRef="d_2022-01-01_2022-06-30"
      decimals="-3"
      id="c86424774"
      unitRef="USD">25871000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses
      contextRef="d_2021-01-01_2021-06-30"
      decimals="-3"
      id="c86424775"
      unitRef="USD">54441000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingIncomeLoss
      contextRef="d_2022-04-01_2022-06-30"
      decimals="-3"
      id="c86424776"
      unitRef="USD">-17538000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="d_2021-04-01_2021-06-30"
      decimals="-3"
      id="c86424777"
      unitRef="USD">-45362000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="d_2022-01-01_2022-06-30"
      decimals="-3"
      id="c86424778"
      unitRef="USD">-25871000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="d_2021-01-01_2021-06-30"
      decimals="-3"
      id="c86424779"
      unitRef="USD">-54441000</us-gaap:OperatingIncomeLoss>
    <us-gaap:InvestmentIncomeInterest
      contextRef="d_2022-04-01_2022-06-30"
      decimals="-3"
      id="c86424781"
      unitRef="USD">17000</us-gaap:InvestmentIncomeInterest>
    <us-gaap:InvestmentIncomeInterest
      contextRef="d_2021-04-01_2021-06-30"
      decimals="-3"
      id="c86424782"
      unitRef="USD">39000</us-gaap:InvestmentIncomeInterest>
    <us-gaap:InvestmentIncomeInterest
      contextRef="d_2022-01-01_2022-06-30"
      decimals="-3"
      id="c86424783"
      unitRef="USD">18000</us-gaap:InvestmentIncomeInterest>
    <us-gaap:InvestmentIncomeInterest
      contextRef="d_2021-01-01_2021-06-30"
      decimals="-3"
      id="c86424784"
      unitRef="USD">89000</us-gaap:InvestmentIncomeInterest>
    <us-gaap:InterestExpense
      contextRef="d_2022-04-01_2022-06-30"
      decimals="-3"
      id="c86424785"
      unitRef="USD">13000</us-gaap:InterestExpense>
    <us-gaap:InterestExpense
      contextRef="d_2021-04-01_2021-06-30"
      decimals="-3"
      id="c86424786"
      unitRef="USD">46000</us-gaap:InterestExpense>
    <us-gaap:InterestExpense
      contextRef="d_2022-01-01_2022-06-30"
      decimals="-3"
      id="c86424787"
      unitRef="USD">26000</us-gaap:InterestExpense>
    <us-gaap:InterestExpense
      contextRef="d_2021-01-01_2021-06-30"
      decimals="-3"
      id="c86424788"
      unitRef="USD">87000</us-gaap:InterestExpense>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="d_2022-04-01_2022-06-30"
      decimals="-3"
      id="c86424789"
      unitRef="USD">201000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="d_2021-04-01_2021-06-30"
      decimals="-3"
      id="c86424790"
      unitRef="USD">-352000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="d_2022-01-01_2022-06-30"
      decimals="-3"
      id="c86424791"
      unitRef="USD">419000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="d_2021-01-01_2021-06-30"
      decimals="-3"
      id="c86424792"
      unitRef="USD">-243000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:NonoperatingIncomeExpense
      contextRef="d_2022-04-01_2022-06-30"
      decimals="-3"
      id="c86424793"
      unitRef="USD">205000</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:NonoperatingIncomeExpense
      contextRef="d_2021-04-01_2021-06-30"
      decimals="-3"
      id="c86424794"
      unitRef="USD">-359000</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:NonoperatingIncomeExpense
      contextRef="d_2022-01-01_2022-06-30"
      decimals="-3"
      id="c86424795"
      unitRef="USD">411000</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:NonoperatingIncomeExpense
      contextRef="d_2021-01-01_2021-06-30"
      decimals="-3"
      id="c86424796"
      unitRef="USD">-241000</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="d_2022-04-01_2022-06-30"
      decimals="-3"
      id="c86424797"
      unitRef="USD">-17333000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="d_2021-04-01_2021-06-30"
      decimals="-3"
      id="c86424798"
      unitRef="USD">-45721000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="d_2022-01-01_2022-06-30"
      decimals="-4"
      id="c86424799"
      unitRef="USD">-25460000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="d_2021-01-01_2021-06-30"
      decimals="-3"
      id="c86424800"
      unitRef="USD">-54682000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="d_2022-04-01_2022-06-30"
      decimals="-3"
      id="c86424801"
      unitRef="USD">-0</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="d_2021-04-01_2021-06-30"
      decimals="-3"
      id="c86424802"
      unitRef="USD">-8332000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="d_2022-01-01_2022-06-30"
      decimals="-3"
      id="c86424803"
      unitRef="USD">-0</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="d_2021-01-01_2021-06-30"
      decimals="-3"
      id="c86424804"
      unitRef="USD">-8332000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:NetIncomeLoss
      contextRef="d_2022-04-01_2022-06-30"
      decimals="-3"
      id="c86424805"
      unitRef="USD">-17333000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="d_2021-04-01_2021-06-30"
      decimals="-3"
      id="c86424806"
      unitRef="USD">-37389000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="d_2022-01-01_2022-06-30"
      decimals="-4"
      id="c86424807"
      unitRef="USD">-25460000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="d_2021-01-01_2021-06-30"
      decimals="-4"
      id="c86424808"
      unitRef="USD">-46350000</us-gaap:NetIncomeLoss>
    <us-gaap:EarningsPerShareBasic
      contextRef="d_2022-04-01_2022-06-30"
      decimals="INF"
      id="c86424810"
      unitRef="USDPerShare">-0.59</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="d_2021-04-01_2021-06-30"
      decimals="INF"
      id="c86424811"
      unitRef="USDPerShare">-1.42</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="d_2022-01-01_2022-06-30"
      decimals="INF"
      id="c86424812"
      unitRef="USDPerShare">-0.87</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="d_2021-01-01_2021-06-30"
      decimals="INF"
      id="c86424813"
      unitRef="USDPerShare">-2.10</us-gaap:EarningsPerShareBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="d_2022-04-01_2022-06-30"
      decimals="-5"
      id="c86424815"
      unitRef="Share">29200000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="d_2021-04-01_2021-06-30"
      decimals="-4"
      id="c86424816"
      unitRef="Share">26350000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="d_2022-01-01_2022-06-30"
      decimals="-3"
      id="c86424817"
      unitRef="Share">29236000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="d_2021-01-01_2021-06-30"
      decimals="-3"
      id="c86424818"
      unitRef="Share">22047000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:SharesOutstanding
      contextRef="i_2020-12-31_StatementEquityComponentsAxis-CommonStockMember"
      decimals="-3"
      id="c86424833"
      unitRef="Share">16922000</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="i_2020-12-31_StatementEquityComponentsAxis-CommonStockMember"
      decimals="-3"
      id="c86424834"
      unitRef="USD">17000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i_2020-12-31_StatementEquityComponentsAxis-AdditionalPaidInCapitalMember"
      decimals="-3"
      id="c86424835"
      unitRef="USD">790277000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i_2020-12-31_StatementEquityComponentsAxis-RetainedEarningsMember"
      decimals="-3"
      id="c86424836"
      unitRef="USD">-717688000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i_2020-12-31_StatementEquityComponentsAxis-TreasuryStockMember"
      decimals="-3"
      id="c86424838"
      unitRef="USD">-3054000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i_2020-12-31"
      decimals="-3"
      id="c86424839"
      unitRef="USD">69552000</us-gaap:StockholdersEquity>
    <us-gaap:NetIncomeLoss
      contextRef="d_2021-01-01_2021-03-31_StatementEquityComponentsAxis-RetainedEarningsMember"
      decimals="-3"
      id="c86424843"
      unitRef="USD">-8961000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="d_2021-01-01_2021-03-31"
      decimals="-3"
      id="c86424846"
      unitRef="USD">-8961000</us-gaap:NetIncomeLoss>
    <wint:IssuanceOfCommonStockAndCommonStockWarrantsNetOfIssuanceCostsShares
      contextRef="d_2021-01-01_2021-03-31_StatementEquityComponentsAxis-CommonStockMember"
      decimals="-4"
      id="c86424847"
      unitRef="Share">9230000</wint:IssuanceOfCommonStockAndCommonStockWarrantsNetOfIssuanceCostsShares>
    <wint:IssuanceOfCommonStockAndCommonStockWarrantsNetOfIssuanceCostsValue
      contextRef="d_2021-01-01_2021-03-31_StatementEquityComponentsAxis-CommonStockMember"
      decimals="-3"
      id="c86424848"
      unitRef="USD">9000</wint:IssuanceOfCommonStockAndCommonStockWarrantsNetOfIssuanceCostsValue>
    <wint:IssuanceOfCommonStockAndCommonStockWarrantsNetOfIssuanceCostsValue
      contextRef="d_2021-01-01_2021-03-31_StatementEquityComponentsAxis-AdditionalPaidInCapitalMember"
      decimals="-3"
      id="c86424849"
      unitRef="USD">27381000</wint:IssuanceOfCommonStockAndCommonStockWarrantsNetOfIssuanceCostsValue>
    <wint:IssuanceOfCommonStockAndCommonStockWarrantsNetOfIssuanceCostsValue
      contextRef="d_2021-01-01_2021-03-31"
      decimals="-4"
      id="c86424853"
      unitRef="USD">27390000</wint:IssuanceOfCommonStockAndCommonStockWarrantsNetOfIssuanceCostsValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="d_2021-01-01_2021-03-31_StatementEquityComponentsAxis-AdditionalPaidInCapitalMember"
      decimals="-3"
      id="c86424856"
      unitRef="USD">2443000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="d_2021-01-01_2021-03-31"
      decimals="-3"
      id="c86424860"
      unitRef="USD">2443000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="d_2021-01-01_2021-03-31_StatementClassOfStockAxis-ATMProgramMember_StatementEquityComponentsAxis-CommonStockMember"
      decimals="-3"
      id="c86424861"
      unitRef="Share">105000</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="d_2021-01-01_2021-03-31_StatementClassOfStockAxis-ATMProgramMember_StatementEquityComponentsAxis-CommonStockMember"
      decimals="-3"
      id="c86424862"
      unitRef="USD">0</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="d_2021-01-01_2021-03-31_StatementClassOfStockAxis-ATMProgramMember_StatementEquityComponentsAxis-AdditionalPaidInCapitalMember"
      decimals="-4"
      id="c86424863"
      unitRef="USD">570000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="d_2021-01-01_2021-03-31_StatementClassOfStockAxis-ATMProgramMember_StatementEquityComponentsAxis-RetainedEarningsMember"
      decimals="-3"
      id="c86424864"
      unitRef="USD">0</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="d_2021-01-01_2021-03-31_StatementClassOfStockAxis-ATMProgramMember_StatementEquityComponentsAxis-TreasuryStockMember"
      decimals="-3"
      id="c86424865"
      unitRef="Share">0</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="d_2021-01-01_2021-03-31_StatementClassOfStockAxis-ATMProgramMember_StatementEquityComponentsAxis-TreasuryStockMember"
      decimals="-3"
      id="c86424866"
      unitRef="USD">0</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="d_2021-01-01_2021-03-31_StatementClassOfStockAxis-ATMProgramMember"
      decimals="-4"
      id="c86424867"
      unitRef="USD">570000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueIssuedForServices
      contextRef="d_2021-01-01_2021-03-31_StatementEquityComponentsAxis-CommonStockMember_SubsidiarySaleOfStockAxis-SharePurchaseAgreementDecember2019Member"
      decimals="-3"
      id="c86424869"
      unitRef="USD">0</us-gaap:StockIssuedDuringPeriodValueIssuedForServices>
    <us-gaap:StockIssuedDuringPeriodValueIssuedForServices
      contextRef="d_2021-01-01_2021-03-31_StatementEquityComponentsAxis-AdditionalPaidInCapitalMember_SubsidiarySaleOfStockAxis-SharePurchaseAgreementDecember2019Member"
      decimals="-3"
      id="c86424870"
      unitRef="USD">494000</us-gaap:StockIssuedDuringPeriodValueIssuedForServices>
    <us-gaap:StockIssuedDuringPeriodValueIssuedForServices
      contextRef="d_2021-01-01_2021-03-31_StatementEquityComponentsAxis-RetainedEarningsMember_SubsidiarySaleOfStockAxis-SharePurchaseAgreementDecember2019Member"
      decimals="-3"
      id="c86424871"
      unitRef="USD">0</us-gaap:StockIssuedDuringPeriodValueIssuedForServices>
    <us-gaap:StockIssuedDuringPeriodValueIssuedForServices
      contextRef="d_2021-01-01_2021-03-31_StatementEquityComponentsAxis-TreasuryStockMember_SubsidiarySaleOfStockAxis-SharePurchaseAgreementDecember2019Member"
      decimals="-3"
      id="c86424873"
      unitRef="USD">0</us-gaap:StockIssuedDuringPeriodValueIssuedForServices>
    <us-gaap:StockIssuedDuringPeriodValueIssuedForServices
      contextRef="d_2021-01-01_2021-03-31_SubsidiarySaleOfStockAxis-SharePurchaseAgreementDecember2019Member"
      decimals="-3"
      id="c86424874"
      unitRef="USD">494000</us-gaap:StockIssuedDuringPeriodValueIssuedForServices>
    <us-gaap:SharesOutstanding
      contextRef="i_2021-03-31_StatementEquityComponentsAxis-CommonStockMember"
      decimals="-3"
      id="c86424875"
      unitRef="Share">26257000</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="i_2021-03-31_StatementEquityComponentsAxis-CommonStockMember"
      decimals="-3"
      id="c86424876"
      unitRef="USD">26000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i_2021-03-31_StatementEquityComponentsAxis-AdditionalPaidInCapitalMember"
      decimals="-3"
      id="c86424877"
      unitRef="USD">821165000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i_2021-03-31_StatementEquityComponentsAxis-RetainedEarningsMember"
      decimals="-3"
      id="c86424878"
      unitRef="USD">-726649000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i_2021-03-31_StatementEquityComponentsAxis-TreasuryStockMember"
      decimals="-3"
      id="c86424880"
      unitRef="USD">-3054000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i_2021-03-31"
      decimals="-3"
      id="c86424881"
      unitRef="USD">91488000</us-gaap:StockholdersEquity>
    <us-gaap:NetIncomeLoss
      contextRef="d_2021-04-01_2021-06-30_StatementEquityComponentsAxis-CommonStockMember"
      decimals="-3"
      id="c86424883"
      unitRef="USD">0</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="d_2021-04-01_2021-06-30_StatementEquityComponentsAxis-AdditionalPaidInCapitalMember"
      decimals="-3"
      id="c86424884"
      unitRef="USD">0</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="d_2021-04-01_2021-06-30_StatementEquityComponentsAxis-RetainedEarningsMember"
      decimals="-3"
      id="c86424885"
      unitRef="USD">-37389000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="d_2021-04-01_2021-06-30_StatementEquityComponentsAxis-TreasuryStockMember"
      decimals="-3"
      id="c86424887"
      unitRef="USD">0</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="d_2021-04-01_2021-06-30"
      decimals="-3"
      id="c86424888"
      unitRef="USD">-37389000</us-gaap:NetIncomeLoss>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="d_2021-04-01_2021-06-30_StatementEquityComponentsAxis-CommonStockMember"
      decimals="-3"
      id="c86424890"
      unitRef="USD">0</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="d_2021-04-01_2021-06-30_StatementEquityComponentsAxis-AdditionalPaidInCapitalMember"
      decimals="-3"
      id="c86424891"
      unitRef="USD">1544000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="d_2021-04-01_2021-06-30_StatementEquityComponentsAxis-RetainedEarningsMember"
      decimals="-3"
      id="c86424892"
      unitRef="USD">0</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="d_2021-04-01_2021-06-30_StatementEquityComponentsAxis-TreasuryStockMember"
      decimals="-3"
      id="c86424894"
      unitRef="USD">0</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="d_2021-04-01_2021-06-30"
      decimals="-3"
      id="c86424895"
      unitRef="USD">1544000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="d_2021-04-01_2021-06-30_StatementEquityComponentsAxis-CommonStockMember"
      decimals="-3"
      id="c86424896"
      unitRef="Share">447000</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="d_2021-04-01_2021-06-30_StatementEquityComponentsAxis-CommonStockMember"
      decimals="-3"
      id="c86424897"
      unitRef="USD">1000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="d_2021-04-01_2021-06-30_StatementEquityComponentsAxis-AdditionalPaidInCapitalMember"
      decimals="-3"
      id="c86424898"
      unitRef="USD">1119000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="d_2021-04-01_2021-06-30_StatementEquityComponentsAxis-RetainedEarningsMember"
      decimals="-3"
      id="c86424899"
      unitRef="USD">0</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="d_2021-04-01_2021-06-30_StatementEquityComponentsAxis-TreasuryStockMember"
      decimals="-3"
      id="c86424900"
      unitRef="Share">0</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="d_2021-04-01_2021-06-30_StatementEquityComponentsAxis-TreasuryStockMember"
      decimals="-3"
      id="c86424901"
      unitRef="USD">0</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="d_2021-04-01_2021-06-30"
      decimals="-4"
      id="c86424902"
      unitRef="USD">1120000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:SharesOutstanding
      contextRef="i_2021-06-30_StatementEquityComponentsAxis-CommonStockMember"
      decimals="-3"
      id="c86424903"
      unitRef="Share">26704000</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="i_2021-06-30_StatementEquityComponentsAxis-CommonStockMember"
      decimals="-3"
      id="c86424904"
      unitRef="USD">27000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i_2021-06-30_StatementEquityComponentsAxis-AdditionalPaidInCapitalMember"
      decimals="-3"
      id="c86424905"
      unitRef="USD">823828000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i_2021-06-30_StatementEquityComponentsAxis-RetainedEarningsMember"
      decimals="-3"
      id="c86424906"
      unitRef="USD">-764038000</us-gaap:StockholdersEquity>
    <us-gaap:SharesOutstanding
      contextRef="i_2021-06-30_StatementEquityComponentsAxis-TreasuryStockMember"
      decimals="-3"
      id="c86424907"
      unitRef="Share">0</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="i_2021-06-30_StatementEquityComponentsAxis-TreasuryStockMember"
      decimals="-3"
      id="c86424908"
      unitRef="USD">-3054000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i_2021-06-30"
      decimals="-3"
      id="c86424909"
      unitRef="USD">56763000</us-gaap:StockholdersEquity>
    <us-gaap:SharesOutstanding
      contextRef="i_2021-12-31_StatementEquityComponentsAxis-CommonStockMember"
      decimals="-3"
      id="c86424924"
      unitRef="Share">28269000</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="i_2021-12-31_StatementEquityComponentsAxis-CommonStockMember"
      decimals="-3"
      id="c86424925"
      unitRef="USD">28000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i_2021-12-31_StatementEquityComponentsAxis-AdditionalPaidInCapitalMember"
      decimals="-3"
      id="c86424926"
      unitRef="USD">830231000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i_2021-12-31_StatementEquityComponentsAxis-RetainedEarningsMember"
      decimals="-3"
      id="c86424927"
      unitRef="USD">-785324000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i_2021-12-31_StatementEquityComponentsAxis-TreasuryStockMember"
      decimals="-3"
      id="c86424929"
      unitRef="USD">-3054000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i_2021-12-31"
      decimals="-3"
      id="c86424930"
      unitRef="USD">41881000</us-gaap:StockholdersEquity>
    <us-gaap:NetIncomeLoss
      contextRef="d_2022-01-01_2022-03-31_StatementEquityComponentsAxis-RetainedEarningsMember"
      decimals="-3"
      id="c86424934"
      unitRef="USD">-8127000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="d_2022-01-01_2022-03-31"
      decimals="-3"
      id="c86424937"
      unitRef="USD">-8127000</us-gaap:NetIncomeLoss>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="d_2022-01-01_2022-03-31_StatementEquityComponentsAxis-AdditionalPaidInCapitalMember"
      decimals="-4"
      id="c86424940"
      unitRef="USD">770000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="d_2022-01-01_2022-03-31"
      decimals="-4"
      id="c86424944"
      unitRef="USD">770000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="d_2022-01-01_2022-03-31_StatementClassOfStockAxis-ATMProgramMember_StatementEquityComponentsAxis-CommonStockMember"
      decimals="-5"
      id="c86424945"
      unitRef="Share">200000</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="d_2022-01-01_2022-03-31_StatementClassOfStockAxis-ATMProgramMember_StatementEquityComponentsAxis-CommonStockMember"
      decimals="-3"
      id="c86424946"
      unitRef="USD">0</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="d_2022-01-01_2022-03-31_StatementClassOfStockAxis-ATMProgramMember_StatementEquityComponentsAxis-AdditionalPaidInCapitalMember"
      decimals="-3"
      id="c86424947"
      unitRef="USD">205000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="d_2022-01-01_2022-03-31_StatementClassOfStockAxis-ATMProgramMember_StatementEquityComponentsAxis-RetainedEarningsMember"
      decimals="-3"
      id="c86424948"
      unitRef="USD">0</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="d_2022-01-01_2022-03-31_StatementClassOfStockAxis-ATMProgramMember_StatementEquityComponentsAxis-TreasuryStockMember"
      decimals="-3"
      id="c86424949"
      unitRef="Share">0</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="d_2022-01-01_2022-03-31_StatementClassOfStockAxis-ATMProgramMember_StatementEquityComponentsAxis-TreasuryStockMember"
      decimals="-3"
      id="c86424950"
      unitRef="USD">0</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="d_2022-01-01_2022-03-31_StatementClassOfStockAxis-ATMProgramMember"
      decimals="-3"
      id="c86424951"
      unitRef="USD">205000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:SharesOutstanding
      contextRef="i_2022-03-31_StatementEquityComponentsAxis-CommonStockMember"
      decimals="-3"
      id="c86424952"
      unitRef="Share">28469000</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="i_2022-03-31_StatementEquityComponentsAxis-CommonStockMember"
      decimals="-3"
      id="c86424953"
      unitRef="USD">28000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i_2022-03-31_StatementEquityComponentsAxis-AdditionalPaidInCapitalMember"
      decimals="-3"
      id="c86424954"
      unitRef="USD">831206000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i_2022-03-31_StatementEquityComponentsAxis-RetainedEarningsMember"
      decimals="-3"
      id="c86424955"
      unitRef="USD">-793451000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i_2022-03-31_StatementEquityComponentsAxis-TreasuryStockMember"
      decimals="-3"
      id="c86424957"
      unitRef="USD">-3054000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i_2022-03-31"
      decimals="-3"
      id="c86424958"
      unitRef="USD">34729000</us-gaap:StockholdersEquity>
    <us-gaap:NetIncomeLoss
      contextRef="d_2022-04-01_2022-06-30_StatementEquityComponentsAxis-CommonStockMember"
      decimals="-3"
      id="c86424960"
      unitRef="USD">0</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="d_2022-04-01_2022-06-30_StatementEquityComponentsAxis-AdditionalPaidInCapitalMember"
      decimals="-3"
      id="c86424961"
      unitRef="USD">0</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="d_2022-04-01_2022-06-30_StatementEquityComponentsAxis-RetainedEarningsMember"
      decimals="-3"
      id="c86424962"
      unitRef="USD">-17333000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="d_2022-04-01_2022-06-30_StatementEquityComponentsAxis-TreasuryStockMember"
      decimals="-3"
      id="c86424964"
      unitRef="USD">0</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="d_2022-04-01_2022-06-30"
      decimals="-3"
      id="c86424965"
      unitRef="USD">-17333000</us-gaap:NetIncomeLoss>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="d_2022-04-01_2022-06-30_StatementEquityComponentsAxis-CommonStockMember"
      decimals="-3"
      id="c86424967"
      unitRef="USD">0</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="d_2022-04-01_2022-06-30_StatementEquityComponentsAxis-AdditionalPaidInCapitalMember"
      decimals="-3"
      id="c86424968"
      unitRef="USD">781000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="d_2022-04-01_2022-06-30_StatementEquityComponentsAxis-RetainedEarningsMember"
      decimals="-3"
      id="c86424969"
      unitRef="USD">0</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="d_2022-04-01_2022-06-30_StatementEquityComponentsAxis-TreasuryStockMember"
      decimals="-3"
      id="c86424971"
      unitRef="USD">0</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="d_2022-04-01_2022-06-30"
      decimals="-3"
      id="c86424972"
      unitRef="USD">781000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="d_2022-04-01_2022-06-30_StatementEquityComponentsAxis-CommonStockMember"
      decimals="-3"
      id="c86424973"
      unitRef="Share">937000</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="d_2022-04-01_2022-06-30_StatementEquityComponentsAxis-CommonStockMember"
      decimals="-3"
      id="c86424974"
      unitRef="USD">1000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="d_2022-04-01_2022-06-30_StatementEquityComponentsAxis-AdditionalPaidInCapitalMember"
      decimals="-3"
      id="c86424975"
      unitRef="USD">1019000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="d_2022-04-01_2022-06-30_StatementEquityComponentsAxis-RetainedEarningsMember"
      decimals="-3"
      id="c86424976"
      unitRef="USD">0</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="d_2022-04-01_2022-06-30_StatementEquityComponentsAxis-TreasuryStockMember"
      decimals="-3"
      id="c86424977"
      unitRef="Share">0</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="d_2022-04-01_2022-06-30_StatementEquityComponentsAxis-TreasuryStockMember"
      decimals="-3"
      id="c86424978"
      unitRef="USD">0</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="d_2022-04-01_2022-06-30"
      decimals="-4"
      id="c86424979"
      unitRef="USD">1020000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:SharesOutstanding
      contextRef="i_2022-06-30_StatementEquityComponentsAxis-CommonStockMember"
      decimals="-3"
      id="c86424980"
      unitRef="Share">29406000</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="i_2022-06-30_StatementEquityComponentsAxis-CommonStockMember"
      decimals="-3"
      id="c86424981"
      unitRef="USD">29000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i_2022-06-30_StatementEquityComponentsAxis-AdditionalPaidInCapitalMember"
      decimals="-3"
      id="c86424982"
      unitRef="USD">833006000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i_2022-06-30_StatementEquityComponentsAxis-RetainedEarningsMember"
      decimals="-3"
      id="c86424983"
      unitRef="USD">-810784000</us-gaap:StockholdersEquity>
    <us-gaap:SharesOutstanding
      contextRef="i_2022-06-30_StatementEquityComponentsAxis-TreasuryStockMember"
      decimals="-3"
      id="c86424984"
      unitRef="Share">0</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="i_2022-06-30_StatementEquityComponentsAxis-TreasuryStockMember"
      decimals="-3"
      id="c86424985"
      unitRef="USD">-3054000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i_2022-06-30"
      decimals="-3"
      id="c86424986"
      unitRef="USD">19197000</us-gaap:StockholdersEquity>
    <us-gaap:NetIncomeLoss
      contextRef="d_2022-01-01_2022-06-30"
      decimals="-4"
      id="c86424994"
      unitRef="USD">-25460000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="d_2021-01-01_2021-06-30"
      decimals="-4"
      id="c86424995"
      unitRef="USD">-46350000</us-gaap:NetIncomeLoss>
    <us-gaap:Depreciation
      contextRef="d_2022-01-01_2022-06-30"
      decimals="-3"
      id="c86424997"
      unitRef="USD">488000</us-gaap:Depreciation>
    <us-gaap:Depreciation
      contextRef="d_2021-01-01_2021-06-30"
      decimals="-3"
      id="c86424998"
      unitRef="USD">93000</us-gaap:Depreciation>
    <us-gaap:EmployeeBenefitsAndShareBasedCompensation
      contextRef="d_2022-01-01_2022-06-30"
      decimals="-3"
      id="c86424999"
      unitRef="USD">1551000</us-gaap:EmployeeBenefitsAndShareBasedCompensation>
    <us-gaap:EmployeeBenefitsAndShareBasedCompensation
      contextRef="d_2021-01-01_2021-06-30"
      decimals="-3"
      id="c86425000"
      unitRef="USD">3987000</us-gaap:EmployeeBenefitsAndShareBasedCompensation>
    <us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense
      contextRef="d_2022-01-01_2022-06-30"
      decimals="-3"
      id="c86425001"
      unitRef="USD">307000</us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense>
    <us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense
      contextRef="d_2021-01-01_2021-06-30"
      decimals="-3"
      id="c86425002"
      unitRef="USD">336000</us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense>
    <wint:NonCashExpenseRelatedToEquityConsiderationForAServiceAgreement
      contextRef="d_2022-01-01_2022-06-30"
      decimals="-3"
      id="c86425003"
      unitRef="USD">0</wint:NonCashExpenseRelatedToEquityConsiderationForAServiceAgreement>
    <wint:NonCashExpenseRelatedToEquityConsiderationForAServiceAgreement
      contextRef="d_2021-01-01_2021-06-30"
      decimals="-3"
      id="c86425004"
      unitRef="USD">494000</wint:NonCashExpenseRelatedToEquityConsiderationForAServiceAgreement>
    <us-gaap:GoodwillImpairmentLoss
      contextRef="d_2022-01-01_2022-06-30"
      decimals="-3"
      id="c86425005"
      unitRef="USD">11636000</us-gaap:GoodwillImpairmentLoss>
    <us-gaap:GoodwillImpairmentLoss
      contextRef="d_2021-01-01_2021-06-30"
      decimals="-3"
      id="c86425006"
      unitRef="USD">0</us-gaap:GoodwillImpairmentLoss>
    <us-gaap:ImpairmentOfIntangibleAssetsExcludingGoodwill
      contextRef="d_2022-01-01_2022-06-30"
      decimals="-3"
      id="c86425007"
      unitRef="USD">0</us-gaap:ImpairmentOfIntangibleAssetsExcludingGoodwill>
    <us-gaap:ImpairmentOfIntangibleAssetsExcludingGoodwill
      contextRef="d_2021-01-01_2021-06-30"
      decimals="-4"
      id="c86425008"
      unitRef="USD">37770000</us-gaap:ImpairmentOfIntangibleAssetsExcludingGoodwill>
    <us-gaap:GainLossOnDispositionOfAssets
      contextRef="d_2022-01-01_2022-06-30"
      decimals="-3"
      id="c86425842"
      unitRef="USD">-19000</us-gaap:GainLossOnDispositionOfAssets>
    <us-gaap:GainLossOnDispositionOfAssets
      contextRef="d_2021-01-01_2021-06-30"
      decimals="-3"
      id="c86425843"
      unitRef="USD">-0</us-gaap:GainLossOnDispositionOfAssets>
    <us-gaap:DeferredIncomeTaxExpenseBenefit
      contextRef="d_2022-01-01_2022-06-30"
      decimals="-3"
      id="c86425009"
      unitRef="USD">0</us-gaap:DeferredIncomeTaxExpenseBenefit>
    <us-gaap:DeferredIncomeTaxExpenseBenefit
      contextRef="d_2021-01-01_2021-06-30"
      decimals="-3"
      id="c86425010"
      unitRef="USD">-8332000</us-gaap:DeferredIncomeTaxExpenseBenefit>
    <us-gaap:ForeignCurrencyTransactionGainLossBeforeTax
      contextRef="d_2022-01-01_2022-06-30"
      decimals="-3"
      id="c86425011"
      unitRef="USD">485000</us-gaap:ForeignCurrencyTransactionGainLossBeforeTax>
    <us-gaap:ForeignCurrencyTransactionGainLossBeforeTax
      contextRef="d_2021-01-01_2021-06-30"
      decimals="-5"
      id="c86425012"
      unitRef="USD">-300000</us-gaap:ForeignCurrencyTransactionGainLossBeforeTax>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
      contextRef="d_2022-01-01_2022-06-30"
      decimals="-3"
      id="c86425014"
      unitRef="USD">-496000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
      contextRef="d_2021-01-01_2021-06-30"
      decimals="-3"
      id="c86425015"
      unitRef="USD">-179000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <us-gaap:IncreaseDecreaseInAccountsPayable
      contextRef="d_2022-01-01_2022-06-30"
      decimals="-3"
      id="c86425016"
      unitRef="USD">379000</us-gaap:IncreaseDecreaseInAccountsPayable>
    <us-gaap:IncreaseDecreaseInAccountsPayable
      contextRef="d_2021-01-01_2021-06-30"
      decimals="-3"
      id="c86425017"
      unitRef="USD">-873000</us-gaap:IncreaseDecreaseInAccountsPayable>
    <us-gaap:IncreaseDecreaseInAccruedLiabilities
      contextRef="d_2022-01-01_2022-06-30"
      decimals="-3"
      id="c86425018"
      unitRef="USD">-576000</us-gaap:IncreaseDecreaseInAccruedLiabilities>
    <us-gaap:IncreaseDecreaseInAccruedLiabilities
      contextRef="d_2021-01-01_2021-06-30"
      decimals="-3"
      id="c86425019"
      unitRef="USD">-703000</us-gaap:IncreaseDecreaseInAccruedLiabilities>
    <wint:IncreaseDecreaseOperatingLeaseLiability
      contextRef="d_2022-01-01_2022-06-30"
      decimals="-3"
      id="c86425020"
      unitRef="USD">-328000</wint:IncreaseDecreaseOperatingLeaseLiability>
    <wint:IncreaseDecreaseOperatingLeaseLiability
      contextRef="d_2021-01-01_2021-06-30"
      decimals="-3"
      id="c86425021"
      unitRef="USD">-352000</wint:IncreaseDecreaseOperatingLeaseLiability>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="d_2022-01-01_2022-06-30"
      decimals="-3"
      id="c86425022"
      unitRef="USD">-11973000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="d_2021-01-01_2021-06-30"
      decimals="-3"
      id="c86425023"
      unitRef="USD">-13451000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:ProceedsFromSaleOfPropertyPlantAndEquipment
      contextRef="d_2022-01-01_2022-06-30"
      decimals="-4"
      id="c86425858"
      unitRef="USD">210000</us-gaap:ProceedsFromSaleOfPropertyPlantAndEquipment>
    <us-gaap:ProceedsFromSaleOfPropertyPlantAndEquipment
      contextRef="d_2021-01-01_2021-06-30"
      decimals="-3"
      id="c86425859"
      unitRef="USD">0</us-gaap:ProceedsFromSaleOfPropertyPlantAndEquipment>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="d_2022-01-01_2022-06-30"
      decimals="-3"
      id="c86425025"
      unitRef="USD">13000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="d_2021-01-01_2021-06-30"
      decimals="-3"
      id="c86425026"
      unitRef="USD">3000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="d_2022-01-01_2022-06-30"
      decimals="-3"
      id="c86425027"
      unitRef="USD">197000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="d_2021-01-01_2021-06-30"
      decimals="-3"
      id="c86425028"
      unitRef="USD">-3000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="d_2022-01-01_2022-06-30"
      decimals="-3"
      id="c86425030"
      unitRef="USD">1225000</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="d_2021-01-01_2021-06-30"
      decimals="-4"
      id="c86425031"
      unitRef="USD">1690000</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:RepaymentsOfShortTermDebt
      contextRef="d_2022-01-01_2022-06-30"
      decimals="-3"
      id="c86425032"
      unitRef="USD">419000</us-gaap:RepaymentsOfShortTermDebt>
    <us-gaap:RepaymentsOfShortTermDebt
      contextRef="d_2021-01-01_2021-06-30"
      decimals="-3"
      id="c86425033"
      unitRef="USD">2991000</us-gaap:RepaymentsOfShortTermDebt>
    <wint:ProceedsFromIssuanceOfCommonStockAndWarrants
      contextRef="d_2022-01-01_2022-06-30"
      decimals="-3"
      id="c86425034"
      unitRef="USD">0</wint:ProceedsFromIssuanceOfCommonStockAndWarrants>
    <wint:ProceedsFromIssuanceOfCommonStockAndWarrants
      contextRef="d_2021-01-01_2021-06-30"
      decimals="-4"
      id="c86425035"
      unitRef="USD">27390000</wint:ProceedsFromIssuanceOfCommonStockAndWarrants>
    <wint:ProceedsFromResearchAndDevelopmentFundingArrangement
      contextRef="d_2022-01-01_2022-06-30"
      decimals="-3"
      id="c86425036"
      unitRef="USD">0</wint:ProceedsFromResearchAndDevelopmentFundingArrangement>
    <wint:ProceedsFromResearchAndDevelopmentFundingArrangement
      contextRef="d_2021-01-01_2021-06-30"
      decimals="-5"
      id="c86425037"
      unitRef="USD">400000</wint:ProceedsFromResearchAndDevelopmentFundingArrangement>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="d_2022-01-01_2022-06-30"
      decimals="-3"
      id="c86425038"
      unitRef="USD">806000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="d_2021-01-01_2021-06-30"
      decimals="-3"
      id="c86425039"
      unitRef="USD">26489000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="d_2022-01-01_2022-06-30"
      decimals="-4"
      id="c86425040"
      unitRef="USD">-10970000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="d_2021-01-01_2021-06-30"
      decimals="-3"
      id="c86425041"
      unitRef="USD">13035000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
      contextRef="i_2021-12-31"
      decimals="-3"
      id="c86425042"
      unitRef="USD">22502000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
      contextRef="i_2020-12-31"
      decimals="-3"
      id="c86425043"
      unitRef="USD">17084000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
      contextRef="i_2022-06-30"
      decimals="-3"
      id="c86425044"
      unitRef="USD">11532000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
      contextRef="i_2021-06-30"
      decimals="-3"
      id="c86425045"
      unitRef="USD">30119000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations>
    <wint:PrepaymentOfDirectorAndOfficerInsuranceThroughThirdPartyFinancing
      contextRef="d_2022-01-01_2022-06-30"
      decimals="-3"
      id="c86425047"
      unitRef="USD">1132000</wint:PrepaymentOfDirectorAndOfficerInsuranceThroughThirdPartyFinancing>
    <wint:PrepaymentOfDirectorAndOfficerInsuranceThroughThirdPartyFinancing
      contextRef="d_2021-01-01_2021-06-30"
      decimals="-3"
      id="c86425048"
      unitRef="USD">1321000</wint:PrepaymentOfDirectorAndOfficerInsuranceThroughThirdPartyFinancing>
    <us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
      contextRef="d_2022-01-01_2022-06-30"
      decimals="-3"
      id="c86425049"
      unitRef="USD">0</us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability>
    <us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
      contextRef="d_2021-01-01_2021-06-30"
      decimals="-6"
      id="c86425050"
      unitRef="USD">2000000</us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability>
    <us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock contextRef="d_2022-01-01_2022-06-30" id="c2175897">
   &lt;p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"&gt;&lt;span style="color:#333333;"&gt;&lt;b&gt;Note &lt;em style="font: inherit;"&gt;1&lt;/em&gt; &#x2013; The Company and Description of Business&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"&gt;&lt;span style="color:#333333;"&gt;We are a clinical-stage&#160;biopharmaceutical company focused on the development of novel therapeutics intended to address significant unmet medical needs in important acute care markets. Our development programs are primarily focused on the treatment of acute cardiovascular diseases and secondarily on acute pulmonary diseases. Our lead product candidate, istaroxime, is a &lt;em style="font: inherit;"&gt;first&lt;/em&gt;-in-class, dual-acting agent being developed to improve cardiac function in patients with acute heart failure, or AHF, with a potentially differentiated safety profile from existing treatments. Istaroxime demonstrated significant improvement in both diastolic and systolic aspects of cardiac function and was generally well tolerated in &lt;em style="font: inherit;"&gt;three&lt;/em&gt; Phase &lt;em style="font: inherit;"&gt;2&lt;/em&gt; clinical trials.&#160;Istaroxime has been granted Fast Track designation for the treatment of AHF by the U.S. Food and Drug Administration, or FDA.&#160;Based on the profile observed in our Phase &lt;em style="font: inherit;"&gt;2&lt;/em&gt; clinical studies in AHF, where istaroxime significantly improved cardiac function and systolic blood pressure in acute decompensated heart failure patients, we initiated a Phase &lt;em style="font: inherit;"&gt;2&lt;/em&gt; global clinical study to evaluate istaroxime for the treatment of early cardiogenic shock (Society for Cardiovascular Angiography and Interventions&#160;Stage B shock),&#160;a severe form of AHF characterized by very low blood pressure and risk for hypoperfusion to critical organs. We completed this Phase &lt;em style="font: inherit;"&gt;2&lt;/em&gt; global clinical study and, in &lt;em style="font: inherit;"&gt; April 2022, &lt;/em&gt;announced positive topline results with istaroxime in raising systolic blood pressure.&#160;In &lt;em style="font: inherit;"&gt; May 2022, &lt;/em&gt;we presented the study results at the European Society of Cardiology Heart Failure Meeting in Madrid, Spain.&lt;/span&gt;&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"&gt;&lt;span style="color:#333333;"&gt;Our heart failure cardiovascular portfolio also includes sarco endoplasmic reticulum &lt;em style="font: inherit;"&gt;Ca2&lt;/em&gt;+ -ATPase &lt;em style="font: inherit;"&gt;2a,&lt;/em&gt; or &lt;em style="font: inherit;"&gt;SERCA2a,&lt;/em&gt; activators which activate &lt;em style="font: inherit;"&gt;SERCA2a.&lt;/em&gt; This research program is evaluating these preclinical product candidates, including oral and intravenous &lt;em style="font: inherit;"&gt;SERCA2a&lt;/em&gt; activator heart failure compounds. As potential oral agents, these candidates would be developed for chronic heart failure. In addition, our cardiovascular drug product candidates include rostafuroxin, a novel product&#160;candidate&#160;for the treatment of hypertension in patients with a specific genetic profile. We are pursuing potential licensing arrangements and/or other strategic partnerships and do &lt;em style="font: inherit;"&gt;not&lt;/em&gt; intend to advance this product&#160;candidate&#160;without securing such an arrangement or partnership.&lt;/span&gt;&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"&gt;&lt;span style="color:#333333;"&gt;Our pulmonary product candidate portfolio consists of a &lt;em style="font: inherit;"&gt;KL4&lt;/em&gt; surfactant platform&#160;to address a range of serious respiratory conditions in children and adults. In &lt;em style="font: inherit;"&gt; January 2022, &lt;/em&gt;we completed enrollment of &lt;em style="font: inherit;"&gt;20&lt;/em&gt; patients in our Phase &lt;em style="font: inherit;"&gt;2&lt;/em&gt; study of lucinactant (&lt;em style="font: inherit;"&gt;KL4&lt;/em&gt; surfactant) for patients with severe novel coronavirus, or COVID-&lt;em style="font: inherit;"&gt;19,&lt;/em&gt; associated acute respiratory distress syndrome, or ARDS. The study demonstrated that intratracheal administration of reconstituted lyophilized lucinactant was generally safe and well tolerated. Oxygenation and other physiological parameters were stable to improved after dosing, supporting the feasibility of this treatment approach to develop a potential treatment for critically ill patients with ARDS due to COVID-&lt;em style="font: inherit;"&gt;19&lt;/em&gt; or other causes.&lt;/span&gt;&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"&gt;&lt;span style="color:#333333;"&gt;Previously, we were also developing AEROSURF (lucinactant for inhalation), a novel drug/medical device combination product for noninvasive delivery of aerosolized &lt;em style="font: inherit;"&gt;KL4&lt;/em&gt; surfactant using our aerosol delivery system, or ADS, technology for the treatment of respiratory distress syndrome in premature infants. In order to focus our resources on the&#160;development of our istaroxime pipeline, we suspended all internal AEROSURF clinical activities in &lt;em style="font: inherit;"&gt; November 2020, &lt;/em&gt;and in &lt;em style="font: inherit;"&gt; January 2022 &lt;/em&gt;we began to reduce all other costs related to the &lt;em style="font: inherit;"&gt;KL4&lt;/em&gt; surfactant platform that were &lt;em style="font: inherit;"&gt;not&lt;/em&gt; already transferred to our licensee in Asia, Lee&#x2019;s Pharmaceutical (HK) Ltd., or Lee&#x2019;s (HK), under the terms of our License, Development and Commercialization Agreement between us and Lee&#x2019;s (HK) dated as of &lt;em style="font: inherit;"&gt; June 12, 2017, &lt;/em&gt;as amended, or the Asia License Agreement. To support the future development of our &lt;em style="font: inherit;"&gt;KL4&lt;/em&gt; surfactant platform in markets outside of Asia, including the U.S., we are pursuing a potential licensing transaction.&lt;/span&gt;&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"&gt;&lt;span style="color:#333333;"&gt;Our ability to advance our development programs is dependent upon our ability to secure additional capital in both the near and long-term, through public or private securities offerings; convertible debt financings; and/or potential strategic opportunities, including licensing agreements, drug product development, and marketing collaboration arrangements, pharmaceutical research cooperation arrangements, and/or other similar transactions in geographic markets, including the U.S., and/or through potential grants and other funding commitments from U.S. government agencies, in each case, if available. We have engaged with potential counterparties in various markets and will continue to pursue non-dilutive sources of capital as well as potential private and public securities offerings. There can be &lt;em style="font: inherit;"&gt;no&lt;/em&gt; assurance, however, that we will be able to identify and enter into public or private securities offerings on acceptable terms and in amounts sufficient to meet our needs or qualify for non-dilutive funding opportunities under any grant programs sponsored by U.S. government agencies, private foundations, and/or leading academic institutions, or identify and enter into any strategic transactions that will provide the additional capital that we will require. If &lt;em style="font: inherit;"&gt;none&lt;/em&gt; of these alternatives is available, or if available and&#160;we are unable to raise sufficient capital through such transactions, we potentially could be forced to limit or cease our development activities, which would have a material adverse effect on our business, financial condition, and results of operations.&lt;/span&gt;&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"&gt;&lt;span style="color:#333333;"&gt;The reader is referred to, and encouraged to read in its entirety, &#x201c;Item &lt;em style="font: inherit;"&gt;1&lt;/em&gt; &#x2013; Business&#x201d; in our Annual Report on Form &lt;em style="font: inherit;"&gt;10&lt;/em&gt;-K for the year ended &lt;/span&gt;&lt;span style="color:#333333;"&gt;&lt;em style="font: inherit;"&gt; December 31, 2021&lt;/em&gt;&lt;/span&gt;&lt;span style="color:#333333;"&gt; that we filed with the Securities and Exchange Commission, or the SEC, on &lt;/span&gt;&lt;span style="color:#333333;"&gt;&lt;em style="font: inherit;"&gt; March 31, 2022&lt;/em&gt;&lt;/span&gt;&lt;span style="color:#333333;"&gt;, which contains a discussion of our business and business plans, as well as information concerning our proprietary technologies and our current and planned development programs.&lt;/span&gt;&lt;/p&gt;
  </us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock>
    <us-gaap:BasisOfAccounting contextRef="d_2022-01-01_2022-06-30" id="c2175898">
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;&#160;&lt;/p&gt;


   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;&lt;span style="color:#333333;"&gt;&lt;b&gt;Note &lt;em style="font: inherit;"&gt;2&lt;/em&gt; &#x2013; Basis of Presentation&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin: 0pt; text-align: left;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin: 0pt; text-align: left;"&gt;&lt;span style="color:#333333;"&gt;The&#160;interim unaudited condensed consolidated financial statements are prepared in accordance with accounting principles generally accepted in the U.S., or US GAAP, for interim financial information in accordance with the instructions to Form &lt;em style="font: inherit;"&gt;10&lt;/em&gt;-Q and include accounts of Windtree Therapeutics, Inc. and its wholly owned subsidiaries. Accordingly, they do &lt;em style="font: inherit;"&gt;not&lt;/em&gt; include all of the information and footnotes required by US GAAP for complete consolidated financial statements. Intercompany balances and transactions have been eliminated in consolidation. All adjustments (consisting of normally recurring accruals) considered for fair presentation have been included.&#160;Operating results for the &lt;/span&gt;&lt;span style="color:#333333;"&gt;&lt;em style="font: inherit;"&gt;three&lt;/em&gt; and &lt;em style="font: inherit;"&gt;six&lt;/em&gt; months ended &lt;em style="font: inherit;"&gt; June 30, 2022&lt;/em&gt;&lt;/span&gt;&lt;span style="color:#333333;"&gt; are &lt;em style="font: inherit;"&gt;not&lt;/em&gt; necessarily indicative of the results that &lt;em style="font: inherit;"&gt; may &lt;/em&gt;be expected for the year ending &lt;/span&gt;&lt;span style="color:#333333;"&gt;&lt;em style="font: inherit;"&gt; December 31, 2022&lt;/em&gt;&lt;/span&gt;&lt;span style="color:#333333;"&gt;. The consolidated balance sheet at &lt;/span&gt;&lt;span style="color:#333333;"&gt;&lt;em style="font: inherit;"&gt; December 31, 2021&lt;/em&gt;&lt;/span&gt;&lt;span style="color:#333333;"&gt; has been derived from the Company&#x2019;s audited consolidated financial statements.&#160;There have been &lt;em style="font: inherit;"&gt;no&lt;/em&gt; changes to our significant accounting policies since &lt;/span&gt;&lt;span style="color:#333333;"&gt;&lt;em style="font: inherit;"&gt; December 31, 2021&lt;/em&gt;&lt;/span&gt;&lt;span style="color:#333333;"&gt;.&#160;The accompanying interim unaudited condensed consolidated financial statements should be read in conjunction with our annual audited consolidated financial statements and related notes as of and for the year ended &lt;/span&gt;&lt;span style="color:#333333;"&gt;&lt;em style="font: inherit;"&gt; December 31, 2021&lt;/em&gt;&lt;/span&gt;&lt;span style="color:#333333;"&gt; contained in our Annual Report on Form &lt;em style="font: inherit;"&gt;10&lt;/em&gt;-K for the year ended &lt;/span&gt;&lt;span style="color:#333333;"&gt;&lt;em style="font: inherit;"&gt; December 31, 2021&lt;/em&gt;&lt;/span&gt;&lt;span style="color:#333333;"&gt;.&lt;/span&gt;&lt;/p&gt;
  </us-gaap:BasisOfAccounting>
    <wint:LiquidityDisclosuresTextBlock contextRef="d_2022-01-01_2022-06-30" id="c2175899">
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;&lt;span style="color:#333333;"&gt;&lt;b&gt;Note &lt;em style="font: inherit;"&gt;3&lt;/em&gt; &#x2013; Going Concern and Management&#x2019;s Plans&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin: 0pt; text-align: left;"&gt;&lt;span style="color:#333333;"&gt;We are subject to risks common to companies in the biotechnology industry, including but &lt;em style="font: inherit;"&gt;not&lt;/em&gt; limited to, the need for additional capital, risks of failure of preclinical and clinical studies, the need to obtain marketing approval and reimbursement for any drug product candidate that we &lt;em style="font: inherit;"&gt; may &lt;/em&gt;identify and develop, the need to successfully commercialize and gain market acceptance of our product candidates, dependence on key personnel, protection of proprietary technology, compliance with government regulations, development of technological innovations by competitors, and&#160;risks associated with our international locations and activities abroad, including but &lt;em style="font: inherit;"&gt;not&lt;/em&gt; limited to having foreign suppliers, manufacturers, and clinical sites in support of our development activities.&lt;/span&gt;&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin: 0pt; text-align: left;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin: 0pt; text-align: left;"&gt;&lt;span style="color:#333333;"&gt;We have incurred net losses since inception. Our net loss was &lt;/span&gt;&lt;span style="color:#333333;"&gt;$17.3&lt;/span&gt;&lt;span style="color:#333333;"&gt;&#160;million and &lt;/span&gt;&lt;span style="color:#333333;"&gt;$37.4&lt;/span&gt;&lt;span style="color:#333333;"&gt;&#160;million, respectively, for the &lt;em style="font: inherit;"&gt;three&lt;/em&gt;-month periods ended &lt;/span&gt;&lt;span style="color:#333333;"&gt;&lt;em style="font: inherit;"&gt; June 30, 2022 &lt;/em&gt;and &lt;em style="font: inherit;"&gt;2021&lt;/em&gt;&lt;/span&gt;&lt;span style="color:#333333;"&gt;. Our net loss was&#160;&lt;/span&gt;&lt;span style="color:#333333;"&gt;$25.5&lt;/span&gt;&lt;span style="color:#333333;"&gt; million and&#160;&lt;/span&gt;&lt;span style="color:#333333;"&gt;$46.4&lt;/span&gt;&lt;span style="color:#333333;"&gt;&#160;million, respectively, for the&#160;&lt;/span&gt;&lt;span style="color:#333333;"&gt;&lt;em style="font: inherit;"&gt;six&lt;/em&gt;&lt;/span&gt;&lt;span style="color:#333333;"&gt;-month periods ended &lt;/span&gt;&lt;span style="color:#333333;"&gt;&lt;em style="font: inherit;"&gt; June 30, 2022 &lt;/em&gt;and &lt;em style="font: inherit;"&gt;2021&lt;/em&gt;&lt;/span&gt;&lt;span style="color:#333333;"&gt;.&#160;Included in our net loss for the&#160;&lt;em style="font: inherit;"&gt;three&lt;/em&gt;&#160;and&#160;&lt;/span&gt;&lt;span style="color:#333333;"&gt;&lt;em style="font: inherit;"&gt;six&lt;/em&gt; months ended &lt;em style="font: inherit;"&gt; June 30, 2022&lt;/em&gt;&lt;/span&gt;&lt;span style="color:#333333;"&gt;&#160;is an&#160;&lt;/span&gt;&lt;span style="color:#333333;"&gt;$11.6&lt;/span&gt;&lt;span style="color:#333333;"&gt; million loss on impairment of goodwill, and included in our net loss for the &lt;em style="font: inherit;"&gt;three&lt;/em&gt; and &lt;em style="font: inherit;"&gt;six&lt;/em&gt; months ended&#160;&lt;/span&gt;&lt;span style="color:#333333;"&gt;&lt;em style="font: inherit;"&gt; June 30, 2021&lt;/em&gt;&lt;/span&gt;&lt;span style="color:#333333;"&gt; is a&#160;&lt;/span&gt;&lt;span style="color:#333333;"&gt;$37.8&lt;/span&gt;&lt;span style="color:#333333;"&gt; million loss on impairment of intangible assets&#160;related to rostafuroxin&#160;and a related&#160;&lt;/span&gt;&lt;span style="color:#333333;"&gt;$8.3&lt;/span&gt;&lt;span style="color:#333333;"&gt; million deferred income tax benefit (&lt;i&gt;see&lt;/i&gt;,&#160;&lt;/span&gt;&lt;span style="color:#333333;"&gt;Note &lt;em style="font: inherit;"&gt;4&lt;/em&gt; &#x2013; Summary of Significant Accounting Policies&lt;/span&gt;&lt;span style="color:#333333;"&gt;).&#160;We expect to continue to incur operating losses for at least the next several years. As of &lt;/span&gt;&lt;span style="color:#333333;"&gt;&lt;em style="font: inherit;"&gt; June 30, 2022&lt;/em&gt;&lt;/span&gt;&lt;span style="color:#333333;"&gt;, we had an accumulated deficit of &lt;/span&gt;&lt;span style="color:#333333;"&gt;$810.8&lt;/span&gt;&lt;span style="color:#333333;"&gt;&#160;million. Our future success is dependent on our ability to fund and develop our product candidates, and ultimately upon our ability to attain profitable operations. We have devoted substantially all of our financial resources and efforts to research and development and general and administrative expense to support such research and development. Net losses and negative cash flows have had, and will continue to have, an adverse effect on our stockholders&#x2019;&#160;equity and working capital, and accordingly, our ability to execute our future operating plans.&lt;/span&gt;&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin: 0pt; text-align: left;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin: 0pt; text-align: left;"&gt;&lt;span style="color:#333333;"&gt;We are party to an At-The-Market Offering Agreement&#160;with Ladenburg Thalmann &amp;amp; Co. Inc., or Ladenburg,&#160;pursuant to which we &lt;em style="font: inherit;"&gt; may &lt;/em&gt;offer and sell, from time to time at our sole discretion, up to a maximum of&#160;&lt;/span&gt;&lt;span style="color:#333333;"&gt;$10.0&lt;/span&gt;&lt;span style="color:#333333;"&gt; million of shares of our common stock through Ladenburg as agent and/or principal through an at-the-market program, or the ATM Program. For the&#160;&lt;/span&gt;&lt;span style="color:#333333;"&gt;&lt;em style="font: inherit;"&gt;six&lt;/em&gt; months ended &lt;em style="font: inherit;"&gt; June 30, 2022&lt;/em&gt;&lt;/span&gt;&lt;span style="color:#333333;"&gt;, we sold&#160;&lt;/span&gt;&lt;span style="color:#333333;"&gt;1,137,246&lt;/span&gt;&lt;span style="color:#333333;"&gt;&#160;shares&#160;of our common stock under the ATM Program&#160;resulting in aggregate gross proceeds to us of approximately&#160;&lt;/span&gt;&lt;span style="color:#333333;"&gt;$1.3&lt;/span&gt;&lt;span style="color:#333333;"&gt;&#160;million and net proceeds of approximately&#160;&lt;/span&gt;&lt;span style="color:#333333;"&gt;$1.2&lt;/span&gt;&lt;span style="color:#333333;"&gt;&#160;million.&#160;During &lt;em style="font: inherit;"&gt; July &lt;/em&gt;and &lt;em style="font: inherit;"&gt; August 2022,&#160;&lt;/em&gt;we sold&#160;&lt;/span&gt;&lt;span style="color:#333333;"&gt;1,221,706&lt;/span&gt;&lt;span style="color:#333333;"&gt; shares of our common stock under the ATM Program&#160;resulting in aggregate gross and net proceeds to us of approximately&#160;&lt;/span&gt;&lt;span style="color:#333333;"&gt;$0.6&lt;/span&gt;&lt;span style="color:#333333;"&gt; million&#160;(&lt;i&gt;see&lt;/i&gt;,&#160;&lt;/span&gt;&lt;span style="color:#333333;"&gt;Note &lt;em style="font: inherit;"&gt;8&lt;/em&gt; &#x2013; Stockholders&#x2019; Equity&lt;/span&gt;&lt;span style="color:#333333;"&gt;).&lt;/span&gt;&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin: 0pt; text-align: left;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin: 0pt; text-align: left;"&gt;&lt;span style="color:#333333;"&gt;The shares of common stock issued and sold under the ATM Program are registered under our Registration Statement on Form S-&lt;em style="font: inherit;"&gt;3&lt;/em&gt; (File &lt;em style="font: inherit;"&gt;No.&lt;/em&gt; &lt;em style="font: inherit;"&gt;333&lt;/em&gt;-&lt;em style="font: inherit;"&gt;248874&lt;/em&gt;), which was declared effective by the SEC on &lt;em style="font: inherit;"&gt; September 29, 2020. &lt;/em&gt;We are currently subject to the limitations contained in General Instruction &lt;em style="font: inherit;"&gt;I.B.6&lt;/em&gt; of Form S-&lt;em style="font: inherit;"&gt;3.&lt;/em&gt; As a result, we are limited in selling &lt;em style="font: inherit;"&gt;no&lt;/em&gt; more than &lt;em style="font: inherit;"&gt;one&lt;/em&gt;-&lt;em style="font: inherit;"&gt;third&lt;/em&gt; of the aggregate market value of the equity held by non-affiliates, or the public float, during any &lt;em style="font: inherit;"&gt;12&lt;/em&gt;-month period. If our public float increases to $75 million or more, we will &lt;em style="font: inherit;"&gt;no&lt;/em&gt; longer be subject to such limitations.&lt;/span&gt;&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin: 0pt; text-align: left;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin: 0pt; text-align: left;"&gt;&lt;span style="color:#333333;"&gt;As of&#160;&lt;/span&gt;&lt;span style="color:#333333;"&gt;&lt;em style="font: inherit;"&gt; June 30, 2022&lt;/em&gt;&lt;/span&gt;&lt;span style="color:#333333;"&gt;,&#160;we had cash and cash equivalents of&#160;&lt;/span&gt;&lt;span style="color:#333333;"&gt;$11.4&lt;/span&gt;&lt;span style="color:#333333;"&gt; million and current liabilities of&#160;&lt;/span&gt;&lt;span style="color:#333333;"&gt;$5.3&lt;/span&gt;&lt;span style="color:#333333;"&gt; million. We believe that we have sufficient resources available to support our development activities and fund our business operations&#160;into the &lt;em style="font: inherit;"&gt;first&lt;/em&gt; quarter of &lt;em style="font: inherit;"&gt;2023.&lt;/em&gt; However, we do &lt;em style="font: inherit;"&gt;not&lt;/em&gt; have sufficient cash and cash equivalents as of the date of this Quarterly Report on Form &lt;em style="font: inherit;"&gt;10&lt;/em&gt;-Q to support our operations for at least the &lt;em style="font: inherit;"&gt;12&lt;/em&gt; months following the date that the financial statements are issued. These conditions raise substantial doubt about our ability to continue as a going concern through &lt;em style="font: inherit;"&gt;12&lt;/em&gt; months after the date that the financial statements are issued.&lt;/span&gt;&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin: 0pt; text-align: left;"&gt;&#160;&lt;/p&gt;
    &#160;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin: 0pt; text-align: left;"&gt;&lt;span style="color:#333333;"&gt;To alleviate the conditions that raise substantial doubt about our ability to continue as a going concern, management plans&#160;to secure additional capital, potentially through a combination of public or private securities&#160;offerings, convertible debt financings, and/or strategic transactions, including potential licensing arrangements, alliances, and drug product collaborations focused on specified geographic markets; however, &lt;em style="font: inherit;"&gt;none&lt;/em&gt; of these alternatives are committed at this time. There can be &lt;em style="font: inherit;"&gt;no&lt;/em&gt; assurance that we will be successful in obtaining sufficient funding on terms acceptable to us to fund continuing operations, if at all, or identify and enter into any strategic transactions that will provide the capital that we will require. Further, on &lt;em style="font: inherit;"&gt; June 3, 2022, &lt;/em&gt;we received a deficiency letter from the Nasdaq Stock Market LLC, or Nasdaq, notifying us that the closing bid price of our common stock had been below the minimum &lt;em style="font: inherit;"&gt;$1.00&lt;/em&gt; per share for &lt;em style="font: inherit;"&gt;30&lt;/em&gt; consecutive business days, we are out of compliance with the&#160;requirements for continued listing on Nasdaq, and are subject to potential delisting.&#160;If we are unable to re-achieve compliance with the Nasdaq listing requirements within &lt;em style="font: inherit;"&gt;180&lt;/em&gt; days, or &lt;em style="font: inherit;"&gt; November 30, 2022, &lt;/em&gt;after receipt of a delisting notice,&#160;and if we are unable to obtain an extension therefore, we would be subject to delisting, which likely would further impair the liquidity and value of our common stock.&#160;The failure to obtain sufficient capital on acceptable terms when needed would have a material adverse effect on our business, results of operations, and financial condition.&lt;/span&gt;&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin: 0pt; text-align: left;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin: 0pt; text-align: left;"&gt;&lt;span style="color:#333333;"&gt;The accompanying condensed consolidated financial statements have been prepared on a going concern basis, which contemplates the realization of assets and satisfaction of liabilities in the normal course of business, and do &lt;em style="font: inherit;"&gt;not&lt;/em&gt; include any adjustments relating to recoverability and classification of recorded asset amounts or the amounts and classification of liabilities that might be necessary should we be unable to continue as a going concern.&lt;/span&gt;&lt;/p&gt;
  </wint:LiquidityDisclosuresTextBlock>
    <us-gaap:NetIncomeLoss
      contextRef="d_2022-04-01_2022-06-30"
      decimals="-5"
      id="c86425090"
      unitRef="USD">-17300000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="d_2021-04-01_2021-06-30"
      decimals="-5"
      id="c86425091"
      unitRef="USD">-37400000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="d_2022-01-01_2022-06-30"
      decimals="-5"
      id="c86425094"
      unitRef="USD">-25500000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="d_2021-01-01_2021-06-30"
      decimals="-5"
      id="c86425095"
      unitRef="USD">-46400000</us-gaap:NetIncomeLoss>
    <us-gaap:GoodwillImpairmentLoss
      contextRef="d_2022-04-01_2022-06-30"
      decimals="-5"
      id="c86425100"
      unitRef="USD">11600000</us-gaap:GoodwillImpairmentLoss>
    <us-gaap:ImpairmentOfIntangibleAssetsExcludingGoodwill
      contextRef="d_2021-04-01_2021-06-30"
      decimals="-5"
      id="c86425105"
      unitRef="USD">37800000</us-gaap:ImpairmentOfIntangibleAssetsExcludingGoodwill>
    <us-gaap:DeferredIncomeTaxExpenseBenefit
      contextRef="d_2021-04-01_2021-06-30"
      decimals="-5"
      id="c86425107"
      unitRef="USD">-8300000</us-gaap:DeferredIncomeTaxExpenseBenefit>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="i_2022-06-30"
      decimals="-5"
      id="c86425110"
      unitRef="USD">-810800000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <wint:SharesAuthorizedToBeOfferedAndSoldUnderOfferingAgreementValue
      contextRef="i_2020-09-17_SubsidiarySaleOfStockAxis-ATMProgramMember"
      decimals="-7"
      id="c86425111"
      unitRef="USD">10000000.0</wint:SharesAuthorizedToBeOfferedAndSoldUnderOfferingAgreementValue>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="d_2022-01-01_2022-06-30_SubsidiarySaleOfStockAxis-ATMProgramMember"
      decimals="INF"
      id="c86425113"
      unitRef="Share">1137246</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="d_2022-01-01_2022-06-30_SubsidiarySaleOfStockAxis-ATMProgramMember"
      decimals="-5"
      id="c86425114"
      unitRef="USD">1300000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="d_2022-01-01_2022-06-30_SubsidiarySaleOfStockAxis-ATMProgramMember"
      decimals="-5"
      id="c86425115"
      unitRef="USD">1200000</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="d_2022-07-01_2022-08-31_SubsequentEventTypeAxis-SubsequentEventMember_SubsidiarySaleOfStockAxis-ATMProgramMember"
      decimals="INF"
      id="c86425116"
      unitRef="Share">1221706</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="d_2022-07-01_2022-08-31_SubsequentEventTypeAxis-SubsequentEventMember_SubsidiarySaleOfStockAxis-ATMProgramMember"
      decimals="-5"
      id="c86425117"
      unitRef="USD">600000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <wint:StockOfferingAgreementPublicFloatLimitationAmount
      contextRef="i_2022-06-30_SubsidiarySaleOfStockAxis-ATMProgramMember"
      decimals="-6"
      id="c86425129"
      unitRef="USD">75000000</wint:StockOfferingAgreementPublicFloatLimitationAmount>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="i_2022-06-30"
      decimals="-5"
      id="c86425131"
      unitRef="USD">11400000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:LiabilitiesCurrent
      contextRef="i_2022-06-30"
      decimals="-5"
      id="c86425132"
      unitRef="USD">5300000</us-gaap:LiabilitiesCurrent>
    <us-gaap:SignificantAccountingPoliciesTextBlock contextRef="d_2022-01-01_2022-06-30" id="c2175900">
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;&lt;span style="color:#333333;"&gt;&lt;b&gt;Note &lt;em style="font: inherit;"&gt;4&lt;/em&gt; &#x2013; Summary of Significant Accounting Policies&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;
   &lt;p style="margin: 0px; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin: 0pt; text-align: left;"/&gt;&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin: 0pt; text-align: left;"&gt;&lt;span style="color:#333333;"&gt;&lt;b&gt;Principles of Consolidation&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin: 0pt; text-align: left;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin: 0pt; text-align: left;"&gt;&lt;span style="color:#333333;"&gt;The interim unaudited condensed consolidated financial statements are prepared in accordance with US GAAP&#160;and include accounts of Windtree Therapeutics, Inc. and its wholly owned subsidiaries, CVie Investments Limited and its wholly owned subsidiary, CVie Therapeutics Limited; and a presently inactive subsidiary, Discovery Laboratories, Inc. (formerly known as Acute Therapeutics, Inc.).&lt;/span&gt;&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin: 0pt; text-align: left;"&gt;&#160;&lt;/p&gt;&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin: 0pt; text-align: left;"/&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin: 0pt; text-align: left;"/&gt;&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin: 0pt; text-align: left;"&gt;&lt;span style="color:#333333;"&gt;&lt;b&gt;Goodwill and Intangible Assets&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin: 0pt; text-align: left;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin: 0pt; text-align: left;"&gt;&lt;span style="color:#333333;"&gt;We record acquired identified intangibles, which includes intangible assets (such as goodwill and other intangibles), based on estimated fair value. The acquired in-process research and development, or IPR&amp;amp;D, assets are considered indefinite-lived intangible assets until completion or abandonment of the associated research and development efforts. IPR&amp;amp;D is &lt;em style="font: inherit;"&gt;not&lt;/em&gt; amortized but reviewed for impairment at least annually, or when events or changes in the business environment indicate the carrying value &lt;em style="font: inherit;"&gt; may &lt;/em&gt;be impaired. During the&#160;&lt;/span&gt;&lt;span style="color:#333333;"&gt;&lt;em style="font: inherit;"&gt;three&lt;/em&gt; and &lt;em style="font: inherit;"&gt;six&lt;/em&gt; months ended &lt;em style="font: inherit;"&gt; June 30, 2022&lt;/em&gt;&lt;/span&gt;&lt;span style="color:#333333;"&gt;, &lt;em style="font: inherit;"&gt;no&lt;/em&gt; events or changes in circumstances occurred indicating that our IPR&amp;amp;D intangible assets were more likely than &lt;em style="font: inherit;"&gt;not&lt;/em&gt; impaired.&lt;/span&gt;&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin: 0pt; text-align: left;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin: 0pt; text-align: left;"&gt;&lt;span style="color:#333333;"&gt;During the&#160;&lt;em style="font: inherit;"&gt;second&lt;/em&gt;&#160;quarter of &lt;em style="font: inherit;"&gt;2021,&lt;/em&gt; we determined that the fair value of the IPR&amp;amp;D related to our rostafuroxin drug candidate was more likely than&#160;&lt;em style="font: inherit;"&gt;not&lt;/em&gt; impaired and we&#160;performed the required quantitative impairment assessment of the related intangible asset. We recorded a loss on impairment of intangible assets of&#160;&lt;/span&gt;&lt;span style="color:#333333;"&gt;$37.8&lt;/span&gt;&lt;span style="color:#333333;"&gt;&#160;million, recognized within operating expenses in our condensed consolidated statements of operations&#160;for the&#160;&lt;em style="font: inherit;"&gt;three&lt;/em&gt;&#160;and&#160;&lt;em style="font: inherit;"&gt;six&lt;/em&gt;&#160;months ended&#160;&lt;em style="font: inherit;"&gt; June 30, 2021.&#160;&lt;/em&gt;&lt;em style="font: inherit;"&gt;No&lt;/em&gt;&#160;events or changes in the business environment occurred during the&#160;&lt;em style="font: inherit;"&gt;six&lt;/em&gt;&#160;months ended&#160;&lt;em style="font: inherit;"&gt; June 30, 2021&#160;&lt;/em&gt;to indicate that the fair value of the IPR&amp;amp;D related to our istaroxime drug candidate was impaired.&lt;/span&gt;&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin: 0pt; text-align: left;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin: 0pt; text-align: left;"&gt;&lt;span style="color:#333333;"&gt;Goodwill represents the excess of the purchase price over the fair value of assets acquired and liabilities assumed in a business combination and is &lt;em style="font: inherit;"&gt;not&lt;/em&gt; amortized. It is reviewed for impairment at least annually or when events or changes in the business environment indicate that its carrying value &lt;em style="font: inherit;"&gt; may &lt;/em&gt;be impaired. Our company consists of one reporting unit. In order to perform the quantitative goodwill impairment test, we compare the estimated fair value of our reporting unit to its carrying value. If the fair value exceeds the carrying value, &lt;em style="font: inherit;"&gt;no&lt;/em&gt; further evaluation is required, and &lt;em style="font: inherit;"&gt;no&lt;/em&gt; impairment exists. If the carrying value exceeds the fair value, the difference between the carrying value and the fair value is recorded as an impairment loss, the amount of which &lt;em style="font: inherit;"&gt; may &lt;/em&gt;&lt;em style="font: inherit;"&gt;not&lt;/em&gt; exceed the total amount of goodwill. When performing our annual goodwill impairment assessment as of &lt;em style="font: inherit;"&gt; December 1, 2021, &lt;/em&gt;we estimated the fair value of our reporting unit based upon the quoted market price and related market capitalization of our common stock, adjusted for an estimated control premium. Based on the quantitative test performed, we determined that the fair value of our reporting unit exceeded its carrying value and &lt;em style="font: inherit;"&gt;no&lt;/em&gt; impairment loss was recognized as of &lt;/span&gt;&lt;span style="color:#333333;"&gt;&lt;em style="font: inherit;"&gt; December 31, 2021&lt;/em&gt;&lt;/span&gt;&lt;span style="color:#333333;"&gt;.&lt;/span&gt;&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin: 0pt; text-align: left;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin: 0pt; text-align: left;"&gt;&lt;span style="color:#333333;"&gt;Throughout the year, we consider whether any events or changes in the business environment have occurred which indicate that goodwill &lt;em style="font: inherit;"&gt; may &lt;/em&gt;be impaired. For example, a significant decline in the closing share price of our common stock and market capitalization &lt;em style="font: inherit;"&gt; may &lt;/em&gt;suggest that the fair value of our reporting unit has fallen below its carrying amount, indicating that an interim goodwill impairment test is required. Accordingly, we monitor changes in our share price during interim periods between annual impairment tests and consider overall stock market conditions, the underlying reasons for the decline in our share price, the significance of the decline, and the duration of time that our securities have been trading at a lower value. We have experienced a declining trend in the&#160;closing share price of our common stock following the announcement in &lt;em style="font: inherit;"&gt; April 2022 &lt;/em&gt;of positive topline results in our Phase &lt;em style="font: inherit;"&gt;2&lt;/em&gt; global clinical study of istaroxime for the treatment of early cardiogenic shock.&lt;/span&gt;&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin: 0pt; text-align: left;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin: 0pt; text-align: left;"&gt;&lt;span style="color:#333333;"&gt;During the &lt;em style="font: inherit;"&gt;second&lt;/em&gt; quarter of &lt;em style="font: inherit;"&gt;2022,&lt;/em&gt; the continued declining trend in the closing share price of our common stock suggested that the fair value of our reporting unit was more likely than &lt;em style="font: inherit;"&gt;not&lt;/em&gt; less than its carrying value.&#160;As a result, we&#160;performed the required interim goodwill impairment test consistent with the methodology that we use when performing our annual goodwill impairment assessment, including the use of the quoted market price and related market capitalization of our common stock, adjusted for an estimated control premium based on transactions completed by comparable companies.&#160;Based on the quantitative test performed, we recorded a loss on impairment of goodwill of&#160;&lt;/span&gt;&lt;span style="color:#333333;"&gt;$11.6&lt;/span&gt;&lt;span style="color:#333333;"&gt; million, recognized within operating expenses in our condensed consolidated statements of operations&#160;for the&#160;&lt;em style="font: inherit;"&gt;three&lt;/em&gt;&#160;and&#160;&lt;em style="font: inherit;"&gt;six&lt;/em&gt;&#160;months ended&#160;&lt;em style="font: inherit;"&gt; June 30, 2022.&lt;/em&gt;&lt;/span&gt;&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin: 0pt; text-align: left;"&gt;&#160;&lt;/p&gt;


   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin: 0pt; text-align: left;"&gt;&lt;span style="color:#333333;"&gt;The closing share price of our common stock has continued to decline during &lt;em style="font: inherit;"&gt; July &lt;/em&gt;and &lt;em style="font: inherit;"&gt; August 2022. &lt;/em&gt;If our share price continues to decline during the remainder of the &lt;em style="font: inherit;"&gt;third&lt;/em&gt; quarter of &lt;em style="font: inherit;"&gt;2022,&lt;/em&gt; we &lt;em style="font: inherit;"&gt; may &lt;/em&gt;be at risk for future impairment to goodwill in the near term.&lt;/span&gt;&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin: 0pt; text-align: left;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;&lt;span style="color:#333333;"&gt;The following table represents identifiable intangible assets and goodwill as of &lt;/span&gt;&lt;span style="color:#333333;"&gt;&lt;em style="font: inherit;"&gt; June 30, 2022&lt;/em&gt;&lt;/span&gt;&lt;span style="color:#333333;"&gt; and &lt;/span&gt;&lt;span style="color:#333333;"&gt;&lt;em style="font: inherit;"&gt; December 31, 2021&lt;/em&gt;&lt;/span&gt;&lt;span style="color:#333333;"&gt;:&lt;/span&gt;&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;&#160;&lt;/p&gt;

    &lt;table border="0" cellpadding="0" cellspacing="0" class="finTable" style="margin-right: 5%; margin-left: 5%; width: 90%; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; text-indent: 0px;"&gt;&lt;tbody&gt;&lt;tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" rowspan="1" style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; text-align: center;"&gt;&lt;span style="color:#333333;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;June 30,&lt;/em&gt;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; text-align: center;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; text-align: center;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" rowspan="1" style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; text-align: center;"&gt;&lt;span style="color:#333333;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;December 31,&lt;/em&gt;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; width: 66%;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;span style="color:#333333;"&gt;&lt;i&gt;(in thousands)&lt;/i&gt;&lt;/span&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;span style="color:#333333;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;2022&lt;/em&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;span style="color:#333333;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;2021&lt;/em&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;span style="color:#333333;"&gt;Istaroxime drug candidate&lt;/span&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&lt;span style="color:#333333;"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 14%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt;&lt;span style="color:#333333;"&gt;22,340&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&lt;span style="color:#333333;"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 14%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt;&lt;span style="color:#333333;"&gt;22,340&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;span style="color:#333333;"&gt;Rostafuroxin drug candidate&lt;/span&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 14%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&lt;span style="color:#333333;"&gt;9,730&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 14%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&lt;span style="color:#333333;"&gt;9,730&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;span style="color:#333333;"&gt;Intangible assets&lt;/span&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 14%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;&lt;span style="color:#333333;"&gt;32,070&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 14%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;&lt;span style="color:#333333;"&gt;32,070&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;span style="color:#333333;"&gt;Goodwill&lt;/span&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt;&lt;span style="color:#333333;"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 14%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt;&lt;span style="color:#333333;"&gt;4,046&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt;&lt;span style="color:#333333;"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 14%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt;&lt;span style="color:#333333;"&gt;15,682&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;/tbody&gt;&lt;/table&gt;

   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin: 0pt; text-align: left;"&gt;&#160;&lt;/p&gt;&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin: 0pt; text-align: left;"/&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin: 0pt; text-align: left;"/&gt;&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin: 0pt; text-align: left;"&gt;&lt;span style="color:#333333;"&gt;&lt;b&gt;Foreign Currency Transactions&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin: 0pt; text-align: left;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin: 0pt; text-align: left;"&gt;&lt;span style="color:#333333;"&gt;The functional currency for our foreign subsidiaries is U.S. Dollars. We remeasure monetary assets and liabilities that are &lt;em style="font: inherit;"&gt;not&lt;/em&gt; denominated in the functional currency at exchange rates in effect at the end of each period. Gains and losses from the remeasurement of foreign currency transactions are recognized in &lt;/span&gt;&lt;span style="color:#333333;"&gt;other income (expense), net&lt;/span&gt;&lt;span style="color:#333333;"&gt;. Foreign currency transactions resulted in &lt;/span&gt;&lt;span style="color:#333333;"&gt;gains&lt;/span&gt;&lt;span style="color:#333333;"&gt;&#160;of approximately&#160;&lt;/span&gt;&lt;span style="color:#333333;"&gt;$0.2&lt;/span&gt;&lt;span style="color:#333333;"&gt; million and losses of approximately&#160;&lt;/span&gt;&lt;span style="color:#333333;"&gt;$0.3&lt;/span&gt;&lt;span style="color:#333333;"&gt; million for the &lt;em style="font: inherit;"&gt;three&lt;/em&gt;-month periods ended &lt;/span&gt;&lt;span style="color:#333333;"&gt;&lt;em style="font: inherit;"&gt; June 30, 2022 &lt;/em&gt;and &lt;em style="font: inherit;"&gt;2021&lt;/em&gt;&lt;/span&gt;&lt;span style="color:#333333;"&gt;, respectively.&#160;Foreign currency transactions resulted in &lt;/span&gt;&lt;span style="color:#333333;"&gt;gains&lt;/span&gt;&lt;span style="color:#333333;"&gt;&#160;of approximately&#160;&lt;/span&gt;&lt;span style="color:#333333;"&gt;$0.4&lt;/span&gt;&lt;span style="color:#333333;"&gt;&#160;million and losses of approximately&#160;&lt;/span&gt;&lt;span style="color:#333333;"&gt;$0.2&lt;/span&gt;&lt;span style="color:#333333;"&gt;&#160;million for the &lt;/span&gt;&lt;span style="color:#333333;"&gt;&lt;em style="font: inherit;"&gt;six&lt;/em&gt;&lt;/span&gt;&lt;span style="color:#333333;"&gt;-month periods ended &lt;/span&gt;&lt;span style="color:#333333;"&gt;&lt;em style="font: inherit;"&gt; June 30, 2022 &lt;/em&gt;and &lt;em style="font: inherit;"&gt;2021&lt;/em&gt;&lt;/span&gt;&lt;span style="color:#333333;"&gt;, respectively.&#160;&lt;/span&gt;&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin: 0pt; text-align: left;"&gt;&#160;&lt;/p&gt;&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin: 0pt; text-align: left;"/&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin: 0pt; text-align: left;"/&gt;&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin: 0pt; text-align: left;"&gt;&lt;span style="color:#333333;"&gt;&lt;b&gt;Use of Estimates&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin: 0pt; text-align: left;"&gt;&lt;br/&gt; &lt;span style="color:#333333;"&gt;The preparation of financial statements in conformity with US GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, including intangible assets and goodwill,&#160;at the date of the financial statements and the reported amounts of expenses during the reporting period. Actual results could differ from those estimates.&lt;/span&gt;&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin: 0pt; text-align: left;"&gt;&#160;&lt;/p&gt;&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin: 0pt; text-align: left;"/&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin: 0pt; text-align: left;"/&gt;&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin: 0pt; text-align: left;"&gt;&lt;span style="color:#333333;"&gt;&lt;b&gt;Cash and Cash Equivalents&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin: 0pt; text-align: left;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin: 0pt; text-align: left;"&gt;&lt;span style="color:#333333;"&gt;Cash and cash equivalents are held at domestic and foreign financial institutions and consist of liquid investments, money market funds, and U.S. Treasury notes with a maturity from date of purchase of &lt;em style="font: inherit;"&gt;90&lt;/em&gt; days or less that are readily convertible into cash.&lt;/span&gt;&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin: 0pt; text-align: left;"&gt;&#160;&lt;/p&gt;&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin: 0pt; text-align: left;"/&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin: 0pt; text-align: left;"/&gt;&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin: 0pt; text-align: left;"&gt;&lt;span style="color:#333333;"&gt;&lt;b&gt;Severance&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin: 0pt; text-align: left;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin: 0pt; text-align: left;"&gt;&lt;span style="color:#333333;"&gt;In &lt;em style="font: inherit;"&gt; January 2022,&#160;&lt;/em&gt;in order to focus our resources on the&#160;development of our istaroxime pipeline, we began to reduce costs related to &lt;em style="font: inherit;"&gt;KL4&lt;/em&gt; surfactant that were &lt;em style="font: inherit;"&gt;not&lt;/em&gt; already transferred to our licensee in Asia, Lee&#x2019;s (HK), under the terms of the Asia License Agreement. These costs include certain reductions in headcount dedicated to &lt;em style="font: inherit;"&gt;KL4&lt;/em&gt; surfactant and the decommissioning of both our analytical and technical support laboratory, which previously conducted release testing of active pharmaceutical ingredients&#160;and supportive research for our lyophilized and aerosolized &lt;em style="font: inherit;"&gt;KL4&lt;/em&gt; surfactant, and our medical device development laboratory, which was previously used to conduct development activities and testing for our ADS technologies. In &lt;em style="font: inherit;"&gt; February 2022, &lt;/em&gt;management communicated&#160;its commitment to provide severance payments&#160;to impacted employees, provided that they remain employed with us through their expected termination dates. The total severance cost for impacted employees is approximately&#160;&lt;/span&gt;&lt;span style="color:#333333;"&gt;$0.4&lt;/span&gt;&lt;span style="color:#333333;"&gt;&#160;million, which was ratably accrued over the service periods of the employees, and to be paid through &lt;em style="font: inherit;"&gt; September 30, 2022. &lt;/em&gt;We incurred &lt;/span&gt;&lt;span style="color:#333333;"&gt;$0.1&lt;/span&gt;&lt;span style="color:#333333;"&gt; million and&#160;&lt;/span&gt;&lt;span style="color:#333333;"&gt;$0.4&lt;/span&gt;&lt;span style="color:#333333;"&gt; million of expense&#160;related to these severance arrangements during the &lt;em style="font: inherit;"&gt;three&lt;/em&gt; and&#160;&lt;/span&gt;&lt;span style="color:#333333;"&gt;&lt;em style="font: inherit;"&gt;six&lt;/em&gt; months ended &lt;em style="font: inherit;"&gt; June 30, 2022&lt;/em&gt;&lt;/span&gt;&lt;span style="color:#333333;"&gt;, respectively,&#160;which is included in research and development expense.&#160;During the &lt;em style="font: inherit;"&gt;three&lt;/em&gt; and&#160;&lt;/span&gt;&lt;span style="color:#333333;"&gt;&lt;em style="font: inherit;"&gt;six&lt;/em&gt; months ended &lt;em style="font: inherit;"&gt; June 30, 2022&lt;/em&gt;&lt;/span&gt;&lt;span style="color:#333333;"&gt;,&#160;&lt;/span&gt;&lt;span style="color:#333333;"&gt;$0.2&lt;/span&gt;&lt;span style="color:#333333;"&gt;&#160;million was paid.&#160;The related liability as of &lt;/span&gt;&lt;span style="color:#333333;"&gt;&lt;em style="font: inherit;"&gt; June 30, 2022&lt;/em&gt;&lt;/span&gt;&lt;span style="color:#333333;"&gt; is $0.2&#160;million and is included in accrued expenses. &lt;/span&gt;&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin: 0pt; text-align: left;"&gt;&#160;&lt;/p&gt;&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin: 0pt; text-align: left;"/&gt;
   &lt;div style="font-size:10pt"&gt;
    &lt;div style="font-family:&amp;quot;Times New Roman&amp;quot;"&gt;
     &lt;/div&gt;&lt;/div&gt;&lt;div style="font-size:10pt"&gt;&lt;div style="font-family:&amp;quot;Times New Roman&amp;quot;"&gt;&lt;span style="color:#333333;"&gt;&lt;b&gt;Property and Equipment&lt;/b&gt;&lt;/span&gt;
    &lt;/div&gt;
    &lt;div style="font-family:&amp;quot;Times New Roman&amp;quot;"&gt;
      &#160;
    &lt;/div&gt;
   &lt;/div&gt;
   &lt;div style="font-size:10pt"&gt;
    &lt;div style="font-family:'Times New Roman'"&gt;
     &lt;div style="font-variant:normal"&gt;
      &lt;span style="color:#333333;"&gt;Property and equipment are recorded at cost and depreciated using the straight-line method over the estimated useful lives of the assets (generally&#160;&lt;em style="font: inherit;"&gt;three&lt;/em&gt;&#160;to&#160;&lt;em style="font: inherit;"&gt;ten&lt;/em&gt;&#160;years). Leasehold improvements are amortized over the shorter of the estimated useful lives or the remaining term of the lease. Repairs and maintenance costs are charged to expense as incurred.&lt;/span&gt;
     &lt;/div&gt;
     &lt;div style="font-variant:normal"&gt;
       &#160;
     &lt;/div&gt;
    &lt;/div&gt;
   &lt;/div&gt;
   &lt;div style="font-size:10pt"&gt;
    &lt;div style="font-family:'Times New Roman'"&gt;
     &lt;div style="font-variant:normal"&gt;
      &lt;span style="color:#333333;"&gt;During the &lt;em style="font: inherit;"&gt;first&lt;/em&gt; quarter of &lt;em style="font: inherit;"&gt;2022,&lt;/em&gt; we determined that&#160;certain&#160;manufacturing and laboratory equipment assets related to the &lt;em style="font: inherit;"&gt;KL4&lt;/em&gt; surfactant platform would be abandoned by &lt;em style="font: inherit;"&gt; March 31, 2022. &lt;/em&gt;We accelerated depreciation of these assets during the &lt;em style="font: inherit;"&gt;first&lt;/em&gt; quarter of &lt;em style="font: inherit;"&gt;2022,&lt;/em&gt; resulting in $0.4 million of additional depreciation expense for the &lt;em style="font: inherit;"&gt;three&lt;/em&gt; months ended &lt;em style="font: inherit;"&gt; March 31, 2022.&#160;&lt;/em&gt;During the &lt;em style="font: inherit;"&gt;second&lt;/em&gt; quarter of &lt;em style="font: inherit;"&gt;2022,&lt;/em&gt; the abandoned assets and certain other &lt;em style="font: inherit;"&gt;KL4&lt;/em&gt; surfactant platform assets were disposed.&lt;/span&gt;
     &lt;/div&gt;
     &lt;div style="font-variant:normal"&gt;
       &#160;
     &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="font-size:10pt"&gt;&lt;div style="font-family:'Times New Roman'"&gt;&lt;div style="font-variant:normal"/&gt;
    &lt;/div&gt;
   &lt;/div&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin: 0pt; text-align: left;"/&gt;&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin: 0pt; text-align: left;"&gt;&lt;span style="color:#333333;"&gt;&lt;b&gt;Restructured Debt Liability &#x2013; Contingent Milestone Payment&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin: 0pt; text-align: left;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin: 0pt; text-align: left;"&gt;&lt;span style="color:#333333;"&gt;In conjunction with the &lt;em style="font: inherit;"&gt; November 2017 &lt;/em&gt;restructuring and retirement of long-term debt (&lt;i&gt;see&lt;/i&gt;, &lt;/span&gt;&lt;span style="color:#333333;"&gt;Note &lt;em style="font: inherit;"&gt;7&lt;/em&gt; &#x2013; Restructured Debt Liability&lt;/span&gt;&lt;span style="color:#333333;"&gt;), we have established a &lt;/span&gt;&lt;span style="color:#333333;"&gt;$15.0&lt;/span&gt;&lt;span style="color:#333333;"&gt;&#160;million long-term liability for contingent milestone payments potentially due under the Exchange and Termination Agreement dated as of &lt;em style="font: inherit;"&gt; October 27, 2017, &lt;/em&gt;or the Exchange and Termination Agreement, between ourselves and affiliates of Deerfield Management Company L.P., or Deerfield. The liability has been recorded at full value of the contingent milestones and will continue to be carried at full value until the milestones are achieved and paid or milestones are &lt;em style="font: inherit;"&gt;not&lt;/em&gt; achieved and the liability is written off as a gain on debt restructuring.&lt;/span&gt;&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin: 0pt; text-align: left;"&gt;&#160;&lt;/p&gt;&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin: 0pt; text-align: left;"/&gt;


   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin: 0pt; text-align: left;"/&gt;&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin: 0pt; text-align: left;"&gt;&lt;span style="color:#333333;"&gt;&lt;b&gt;Research and Development&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin: 0pt; text-align: left;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin: 0pt; text-align: left;"&gt;&lt;span style="color:#333333;"&gt;We track direct research and development expenses by preclinical and clinical programs, which include &lt;em style="font: inherit;"&gt;third&lt;/em&gt;-party costs such as contract research organization, consulting, and clinical trial costs. We do &lt;em style="font: inherit;"&gt;not&lt;/em&gt; allocate indirect research and development expenses, which include product development and manufacturing expenses and clinical, medical, and regulatory operations expenses, to specific programs. Indirect research and development expenses include personnel, facilities, manufacturing and quality operations, pharmaceutical and device development, research, regulatory, and medical affairs. Research and development costs are charged to operations as incurred in accordance with Financial Accounting Standards Board, or FASB, Accounting Standards Codification, or ASC, Topic &lt;em style="font: inherit;"&gt;730,&lt;/em&gt; Research and Development.&lt;/span&gt;&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin: 0pt; text-align: left;"&gt;&#160;&lt;/p&gt;&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin: 0pt; text-align: left;"/&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin: 0pt; text-align: left;"/&gt;&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin: 0pt; text-align: left;"&gt;&lt;span style="color:#333333;"&gt;&lt;b&gt;Income Taxes&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin: 0pt; text-align: left;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin: 0pt; text-align: left;"&gt;&lt;span style="color:#333333;"&gt;We account for income taxes in accordance with ASC Topic &lt;em style="font: inherit;"&gt;740,&lt;/em&gt; Accounting for Income Taxes, which requires the recognition of deferred tax liabilities and assets for the expected future tax consequences of temporary differences between financial statement carrying amounts and the tax basis of assets and liabilities.&lt;/span&gt;&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin: 0pt; text-align: left;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin: 0pt; text-align: left;"&gt;&lt;span style="color:#333333;"&gt;We use a recognition threshold and measurement attribute for the financial statement recognition and measurement of a tax position taken or expected to be taken in a tax return. Because we have never realized a profit, management has fully reserved the net deferred tax asset since realization is &lt;em style="font: inherit;"&gt;not&lt;/em&gt; assured.&lt;/span&gt;&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin: 0pt; text-align: left;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin: 0pt; text-align: left;"&gt;&lt;span style="color:#333333;"&gt;For the&#160;&lt;em style="font: inherit;"&gt;three&lt;/em&gt;&#160;and&#160;&lt;em style="font: inherit;"&gt;six&lt;/em&gt;&#160;months ended&#160;&lt;/span&gt;&lt;span style="color:#333333;"&gt;&lt;em style="font: inherit;"&gt; June 30, 2021&lt;/em&gt;&lt;/span&gt;&lt;span style="color:#333333;"&gt;, we recorded a deferred&#160;income tax benefit of&#160;&lt;/span&gt;&lt;span style="color:#333333;"&gt;$8.3&lt;/span&gt;&lt;span style="color:#333333;"&gt;&#160;million. The deferred tax benefit recorded for these periods relates solely to the reduction of the deferred tax liability as a result of the loss on impairment of intangible assets related to&#160;rostafuroxin.&lt;/span&gt;&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin: 0pt; text-align: left;"&gt;&#160;&lt;/p&gt;&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin: 0pt; text-align: left;"/&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin: 0pt; text-align: left;"/&gt;&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin: 0pt; text-align: left;"&gt;&lt;span style="color:#333333;"&gt;&lt;b&gt;Net Loss per Common Share&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin: 0pt; text-align: left;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin: 0pt; text-align: left;"&gt;&lt;span style="color:#333333;"&gt;Basic net loss per common share is computed by dividing net loss by the weighted average number of common shares outstanding for the period. Diluted net loss per common share is computed by giving effect to all potentially dilutive securities outstanding for the period. As of &lt;/span&gt;&lt;span style="color:#333333;"&gt;&lt;em style="font: inherit;"&gt; June 30, 2022 &lt;/em&gt;and &lt;em style="font: inherit;"&gt;2021&lt;/em&gt;&lt;/span&gt;&lt;span style="color:#333333;"&gt;, the number of shares of common stock potentially issuable upon the exercise of certain stock options and warrants, as well as the vesting of&#160;restricted stock units, was&#160;&lt;/span&gt;&lt;span style="color:#333333;"&gt;21.2&lt;/span&gt;&lt;span style="color:#333333;"&gt; million and&#160;&lt;/span&gt;&lt;span style="color:#333333;"&gt;19.9&lt;/span&gt;&lt;span style="color:#333333;"&gt; million shares, respectively. For the &lt;/span&gt;&lt;span style="color:#333333;"&gt;&lt;em style="font: inherit;"&gt;three&lt;/em&gt; and &lt;em style="font: inherit;"&gt;six&lt;/em&gt; months ended &lt;em style="font: inherit;"&gt; June 30, 2022 &lt;/em&gt;and &lt;em style="font: inherit;"&gt;2021&lt;/em&gt;&lt;/span&gt;&lt;span style="color:#333333;"&gt;, all potentially dilutive securities were anti-dilutive and therefore have been excluded from the computation of diluted net loss per share.&lt;/span&gt;&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin: 0pt; text-align: left;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin: 0pt; text-align: left;"&gt;&lt;span style="color:#333333;"&gt;We do &lt;em style="font: inherit;"&gt;not&lt;/em&gt; have any components of other comprehensive (loss) income.&lt;/span&gt;&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin: 0pt; text-align: left;"&gt;&#160;&lt;/p&gt;&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin: 0pt; text-align: left;"/&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin: 0pt; text-align: left;"/&gt;&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin: 0pt; text-align: left;"&gt;&lt;span style="color:#333333;"&gt;&lt;b&gt;COVID-&lt;em style="font: inherit;"&gt;19&lt;/em&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin: 0pt; text-align: left;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin: 0pt; text-align: left;"&gt;&lt;span style="color:#333333;"&gt;The COVID-&lt;em style="font: inherit;"&gt;19&lt;/em&gt; pandemic continues to evolve, and we continue to closely monitor its impact on our business and&#160;operations, including its continued&#160;impact on our clinical development plans and timelines, and financial condition. There has been intermittent impact of the pandemic in differing geographies,&#160;and there &lt;em style="font: inherit;"&gt; may &lt;/em&gt;be continued impact, particularly in light of the surge of new COVID-&lt;em style="font: inherit;"&gt;19&lt;/em&gt; cases relating to new variants. As of the date of the issuance of this Quarterly Report on Form &lt;em style="font: inherit;"&gt;10&lt;/em&gt;-Q, our operations, capital&#160;and financial resources, and overall liquidity position and outlook have been impacted by COVID-&lt;em style="font: inherit;"&gt;19,&lt;/em&gt; primarily due to delays experienced in our operations, including&#160;in clinical study initiation and enrollment. The extended timelines have required us to expend more of our capital resources than planned to achieve our projected milestones. For example, our Phase &lt;em style="font: inherit;"&gt;2&lt;/em&gt; study of istaroxime for early cardiogenic shock in heart failure patients&#160;experienced delays in trial initiation and enrollment in &lt;em style="font: inherit;"&gt;2021.&lt;/em&gt;&#160;Although many countries have re-opened, rises in new cases, including as the result of newly identified COVID-&lt;em style="font: inherit;"&gt;19&lt;/em&gt; variants, have caused certain countries, states, and localities to re-initiate restrictions.&#160;The full extent, duration, or impact that the COVID-&lt;em style="font: inherit;"&gt;19&lt;/em&gt; pandemic will have, directly or indirectly, on our financial condition and operations, including ongoing and planned clinical trials, will depend on future developments that are highly uncertain and cannot be accurately predicted. These potential future developments include the severity and transmissibility of new variants of the virus, information about any resurgences&#160;in &lt;em style="font: inherit;"&gt;one&lt;/em&gt; or more geographic locations where our current or intended clinical trial sites, our&#160;principal executive offices, research and development laboratories, or manufacturing facilities are located, and the actions taken to contain it or treat its impact. In addition, regional impact and responses to the COVID-&lt;em style="font: inherit;"&gt;19&lt;/em&gt; pandemic have affected where a clinical trial could be executed and how various elements of the clinical trial are performed. Going forward, the pandemic could also impact how monitoring/auditing of clinical trial&#160;sites and data occur. The maintenance, or strategic re-implementation, of mitigating COVID-&lt;em style="font: inherit;"&gt;19&lt;/em&gt; measures in &lt;em style="font: inherit;"&gt;one&lt;/em&gt; or more geographic locations where our clinical trial sites, principal executive offices, research and development laboratories, or other facilities are located remains possible and if realized, we believe there could be further impact on the clinical development of our product candidates, which &lt;em style="font: inherit;"&gt; may &lt;/em&gt;include potential delays, halts, or modifications to our ongoing and planned trials in &lt;/span&gt;&lt;span style="color:#333333;"&gt;&lt;em style="font: inherit;"&gt;2022&lt;/em&gt;&lt;/span&gt;&lt;span style="color:#333333;"&gt; and beyond.&lt;/span&gt;&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin: 0pt; text-align: left;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left"&gt;&lt;span style="color:#333333;"&gt;We are &lt;em style="font: inherit;"&gt;not&lt;/em&gt; aware of any specific event or circumstance that would require us to further update our estimates, judgments, or revise the carrying value of our assets or liabilities as of the date of issuance of these interim unaudited condensed consolidated financial statements. These estimates &lt;em style="font: inherit;"&gt; may &lt;/em&gt;change&#160;as new events occur and additional information is obtained.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left"/&gt;
  </us-gaap:SignificantAccountingPoliciesTextBlock>
    <us-gaap:ConsolidationPolicyTextBlock contextRef="d_2022-01-01_2022-06-30" id="c86426299">&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin: 0pt; text-align: left;"&gt;&lt;span style="color:#333333;"&gt;&lt;b&gt;Principles of Consolidation&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin: 0pt; text-align: left;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin: 0pt; text-align: left;"&gt;&lt;span style="color:#333333;"&gt;The interim unaudited condensed consolidated financial statements are prepared in accordance with US GAAP&#160;and include accounts of Windtree Therapeutics, Inc. and its wholly owned subsidiaries, CVie Investments Limited and its wholly owned subsidiary, CVie Therapeutics Limited; and a presently inactive subsidiary, Discovery Laboratories, Inc. (formerly known as Acute Therapeutics, Inc.).&lt;/span&gt;&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin: 0pt; text-align: left;"&gt;&#160;&lt;/p&gt;</us-gaap:ConsolidationPolicyTextBlock>
    <us-gaap:GoodwillAndIntangibleAssetsGoodwillPolicy contextRef="d_2022-01-01_2022-06-30" id="c86426300">&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin: 0pt; text-align: left;"&gt;&lt;span style="color:#333333;"&gt;&lt;b&gt;Goodwill and Intangible Assets&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin: 0pt; text-align: left;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin: 0pt; text-align: left;"&gt;&lt;span style="color:#333333;"&gt;We record acquired identified intangibles, which includes intangible assets (such as goodwill and other intangibles), based on estimated fair value. The acquired in-process research and development, or IPR&amp;amp;D, assets are considered indefinite-lived intangible assets until completion or abandonment of the associated research and development efforts. IPR&amp;amp;D is &lt;em style="font: inherit;"&gt;not&lt;/em&gt; amortized but reviewed for impairment at least annually, or when events or changes in the business environment indicate the carrying value &lt;em style="font: inherit;"&gt; may &lt;/em&gt;be impaired. During the&#160;&lt;/span&gt;&lt;span style="color:#333333;"&gt;&lt;em style="font: inherit;"&gt;three&lt;/em&gt; and &lt;em style="font: inherit;"&gt;six&lt;/em&gt; months ended &lt;em style="font: inherit;"&gt; June 30, 2022&lt;/em&gt;&lt;/span&gt;&lt;span style="color:#333333;"&gt;, &lt;em style="font: inherit;"&gt;no&lt;/em&gt; events or changes in circumstances occurred indicating that our IPR&amp;amp;D intangible assets were more likely than &lt;em style="font: inherit;"&gt;not&lt;/em&gt; impaired.&lt;/span&gt;&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin: 0pt; text-align: left;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin: 0pt; text-align: left;"&gt;&lt;span style="color:#333333;"&gt;During the&#160;&lt;em style="font: inherit;"&gt;second&lt;/em&gt;&#160;quarter of &lt;em style="font: inherit;"&gt;2021,&lt;/em&gt; we determined that the fair value of the IPR&amp;amp;D related to our rostafuroxin drug candidate was more likely than&#160;&lt;em style="font: inherit;"&gt;not&lt;/em&gt; impaired and we&#160;performed the required quantitative impairment assessment of the related intangible asset. We recorded a loss on impairment of intangible assets of&#160;&lt;/span&gt;&lt;span style="color:#333333;"&gt;$37.8&lt;/span&gt;&lt;span style="color:#333333;"&gt;&#160;million, recognized within operating expenses in our condensed consolidated statements of operations&#160;for the&#160;&lt;em style="font: inherit;"&gt;three&lt;/em&gt;&#160;and&#160;&lt;em style="font: inherit;"&gt;six&lt;/em&gt;&#160;months ended&#160;&lt;em style="font: inherit;"&gt; June 30, 2021.&#160;&lt;/em&gt;&lt;em style="font: inherit;"&gt;No&lt;/em&gt;&#160;events or changes in the business environment occurred during the&#160;&lt;em style="font: inherit;"&gt;six&lt;/em&gt;&#160;months ended&#160;&lt;em style="font: inherit;"&gt; June 30, 2021&#160;&lt;/em&gt;to indicate that the fair value of the IPR&amp;amp;D related to our istaroxime drug candidate was impaired.&lt;/span&gt;&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin: 0pt; text-align: left;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin: 0pt; text-align: left;"&gt;&lt;span style="color:#333333;"&gt;Goodwill represents the excess of the purchase price over the fair value of assets acquired and liabilities assumed in a business combination and is &lt;em style="font: inherit;"&gt;not&lt;/em&gt; amortized. It is reviewed for impairment at least annually or when events or changes in the business environment indicate that its carrying value &lt;em style="font: inherit;"&gt; may &lt;/em&gt;be impaired. Our company consists of one reporting unit. In order to perform the quantitative goodwill impairment test, we compare the estimated fair value of our reporting unit to its carrying value. If the fair value exceeds the carrying value, &lt;em style="font: inherit;"&gt;no&lt;/em&gt; further evaluation is required, and &lt;em style="font: inherit;"&gt;no&lt;/em&gt; impairment exists. If the carrying value exceeds the fair value, the difference between the carrying value and the fair value is recorded as an impairment loss, the amount of which &lt;em style="font: inherit;"&gt; may &lt;/em&gt;&lt;em style="font: inherit;"&gt;not&lt;/em&gt; exceed the total amount of goodwill. When performing our annual goodwill impairment assessment as of &lt;em style="font: inherit;"&gt; December 1, 2021, &lt;/em&gt;we estimated the fair value of our reporting unit based upon the quoted market price and related market capitalization of our common stock, adjusted for an estimated control premium. Based on the quantitative test performed, we determined that the fair value of our reporting unit exceeded its carrying value and &lt;em style="font: inherit;"&gt;no&lt;/em&gt; impairment loss was recognized as of &lt;/span&gt;&lt;span style="color:#333333;"&gt;&lt;em style="font: inherit;"&gt; December 31, 2021&lt;/em&gt;&lt;/span&gt;&lt;span style="color:#333333;"&gt;.&lt;/span&gt;&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin: 0pt; text-align: left;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin: 0pt; text-align: left;"&gt;&lt;span style="color:#333333;"&gt;Throughout the year, we consider whether any events or changes in the business environment have occurred which indicate that goodwill &lt;em style="font: inherit;"&gt; may &lt;/em&gt;be impaired. For example, a significant decline in the closing share price of our common stock and market capitalization &lt;em style="font: inherit;"&gt; may &lt;/em&gt;suggest that the fair value of our reporting unit has fallen below its carrying amount, indicating that an interim goodwill impairment test is required. Accordingly, we monitor changes in our share price during interim periods between annual impairment tests and consider overall stock market conditions, the underlying reasons for the decline in our share price, the significance of the decline, and the duration of time that our securities have been trading at a lower value. We have experienced a declining trend in the&#160;closing share price of our common stock following the announcement in &lt;em style="font: inherit;"&gt; April 2022 &lt;/em&gt;of positive topline results in our Phase &lt;em style="font: inherit;"&gt;2&lt;/em&gt; global clinical study of istaroxime for the treatment of early cardiogenic shock.&lt;/span&gt;&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin: 0pt; text-align: left;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin: 0pt; text-align: left;"&gt;&lt;span style="color:#333333;"&gt;During the &lt;em style="font: inherit;"&gt;second&lt;/em&gt; quarter of &lt;em style="font: inherit;"&gt;2022,&lt;/em&gt; the continued declining trend in the closing share price of our common stock suggested that the fair value of our reporting unit was more likely than &lt;em style="font: inherit;"&gt;not&lt;/em&gt; less than its carrying value.&#160;As a result, we&#160;performed the required interim goodwill impairment test consistent with the methodology that we use when performing our annual goodwill impairment assessment, including the use of the quoted market price and related market capitalization of our common stock, adjusted for an estimated control premium based on transactions completed by comparable companies.&#160;Based on the quantitative test performed, we recorded a loss on impairment of goodwill of&#160;&lt;/span&gt;&lt;span style="color:#333333;"&gt;$11.6&lt;/span&gt;&lt;span style="color:#333333;"&gt; million, recognized within operating expenses in our condensed consolidated statements of operations&#160;for the&#160;&lt;em style="font: inherit;"&gt;three&lt;/em&gt;&#160;and&#160;&lt;em style="font: inherit;"&gt;six&lt;/em&gt;&#160;months ended&#160;&lt;em style="font: inherit;"&gt; June 30, 2022.&lt;/em&gt;&lt;/span&gt;&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin: 0pt; text-align: left;"&gt;&#160;&lt;/p&gt;


   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin: 0pt; text-align: left;"&gt;&lt;span style="color:#333333;"&gt;The closing share price of our common stock has continued to decline during &lt;em style="font: inherit;"&gt; July &lt;/em&gt;and &lt;em style="font: inherit;"&gt; August 2022. &lt;/em&gt;If our share price continues to decline during the remainder of the &lt;em style="font: inherit;"&gt;third&lt;/em&gt; quarter of &lt;em style="font: inherit;"&gt;2022,&lt;/em&gt; we &lt;em style="font: inherit;"&gt; may &lt;/em&gt;be at risk for future impairment to goodwill in the near term.&lt;/span&gt;&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin: 0pt; text-align: left;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;&lt;span style="color:#333333;"&gt;The following table represents identifiable intangible assets and goodwill as of &lt;/span&gt;&lt;span style="color:#333333;"&gt;&lt;em style="font: inherit;"&gt; June 30, 2022&lt;/em&gt;&lt;/span&gt;&lt;span style="color:#333333;"&gt; and &lt;/span&gt;&lt;span style="color:#333333;"&gt;&lt;em style="font: inherit;"&gt; December 31, 2021&lt;/em&gt;&lt;/span&gt;&lt;span style="color:#333333;"&gt;:&lt;/span&gt;&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;&#160;&lt;/p&gt;

    &lt;table border="0" cellpadding="0" cellspacing="0" class="finTable" style="margin-right: 5%; margin-left: 5%; width: 90%; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; text-indent: 0px;"&gt;&lt;tbody&gt;&lt;tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" rowspan="1" style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; text-align: center;"&gt;&lt;span style="color:#333333;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;June 30,&lt;/em&gt;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; text-align: center;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; text-align: center;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" rowspan="1" style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; text-align: center;"&gt;&lt;span style="color:#333333;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;December 31,&lt;/em&gt;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; width: 66%;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;span style="color:#333333;"&gt;&lt;i&gt;(in thousands)&lt;/i&gt;&lt;/span&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;span style="color:#333333;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;2022&lt;/em&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;span style="color:#333333;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;2021&lt;/em&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;span style="color:#333333;"&gt;Istaroxime drug candidate&lt;/span&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&lt;span style="color:#333333;"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 14%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt;&lt;span style="color:#333333;"&gt;22,340&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&lt;span style="color:#333333;"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 14%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt;&lt;span style="color:#333333;"&gt;22,340&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;span style="color:#333333;"&gt;Rostafuroxin drug candidate&lt;/span&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 14%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&lt;span style="color:#333333;"&gt;9,730&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 14%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&lt;span style="color:#333333;"&gt;9,730&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;span style="color:#333333;"&gt;Intangible assets&lt;/span&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 14%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;&lt;span style="color:#333333;"&gt;32,070&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 14%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;&lt;span style="color:#333333;"&gt;32,070&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;span style="color:#333333;"&gt;Goodwill&lt;/span&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt;&lt;span style="color:#333333;"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 14%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt;&lt;span style="color:#333333;"&gt;4,046&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt;&lt;span style="color:#333333;"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 14%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt;&lt;span style="color:#333333;"&gt;15,682&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;/tbody&gt;&lt;/table&gt;

   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin: 0pt; text-align: left;"&gt;&#160;&lt;/p&gt;</us-gaap:GoodwillAndIntangibleAssetsGoodwillPolicy>
    <us-gaap:ImpairmentOfIntangibleAssetsExcludingGoodwill
      contextRef="d_2021-04-01_2021-06-30"
      decimals="-5"
      id="c86425170"
      unitRef="USD">37800000</us-gaap:ImpairmentOfIntangibleAssetsExcludingGoodwill>
    <us-gaap:NumberOfReportingUnits
      contextRef="d_2022-01-01_2022-03-31"
      decimals="INF"
      id="c86425180"
      unitRef="Pure">1</us-gaap:NumberOfReportingUnits>
    <us-gaap:GoodwillImpairmentLoss
      contextRef="d_2022-04-01_2022-06-30"
      decimals="-5"
      id="c86425189"
      unitRef="USD">11600000</us-gaap:GoodwillImpairmentLoss>
    <us-gaap:ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock contextRef="d_2022-01-01_2022-06-30" id="c2175901">
    &lt;table border="0" cellpadding="0" cellspacing="0" class="finTable" style="margin-right: 5%; margin-left: 5%; width: 90%; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; text-indent: 0px;"&gt;&lt;tbody&gt;&lt;tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" rowspan="1" style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; text-align: center;"&gt;&lt;span style="color:#333333;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;June 30,&lt;/em&gt;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; text-align: center;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; text-align: center;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" rowspan="1" style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; text-align: center;"&gt;&lt;span style="color:#333333;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;December 31,&lt;/em&gt;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; width: 66%;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;span style="color:#333333;"&gt;&lt;i&gt;(in thousands)&lt;/i&gt;&lt;/span&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;span style="color:#333333;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;2022&lt;/em&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;span style="color:#333333;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;2021&lt;/em&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;span style="color:#333333;"&gt;Istaroxime drug candidate&lt;/span&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&lt;span style="color:#333333;"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 14%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt;&lt;span style="color:#333333;"&gt;22,340&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&lt;span style="color:#333333;"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 14%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt;&lt;span style="color:#333333;"&gt;22,340&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;span style="color:#333333;"&gt;Rostafuroxin drug candidate&lt;/span&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 14%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&lt;span style="color:#333333;"&gt;9,730&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 14%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&lt;span style="color:#333333;"&gt;9,730&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;span style="color:#333333;"&gt;Intangible assets&lt;/span&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 14%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;&lt;span style="color:#333333;"&gt;32,070&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 14%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;&lt;span style="color:#333333;"&gt;32,070&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;span style="color:#333333;"&gt;Goodwill&lt;/span&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt;&lt;span style="color:#333333;"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 14%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt;&lt;span style="color:#333333;"&gt;4,046&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt;&lt;span style="color:#333333;"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 14%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt;&lt;span style="color:#333333;"&gt;15,682&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;/tbody&gt;&lt;/table&gt;
   </us-gaap:ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock>
    <us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill
      contextRef="i_2022-06-30_IndefiniteLivedIntangibleAssetsByMajorClassAxis-IstaroximeDrugCandidateMember"
      decimals="-4"
      id="c86425285"
      unitRef="USD">22340000</us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill>
    <us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill
      contextRef="i_2021-12-31_IndefiniteLivedIntangibleAssetsByMajorClassAxis-IstaroximeDrugCandidateMember"
      decimals="-4"
      id="c86425286"
      unitRef="USD">22340000</us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill>
    <us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill
      contextRef="i_2022-06-30_IndefiniteLivedIntangibleAssetsByMajorClassAxis-RostafuroxinDrugCandidateMember"
      decimals="-4"
      id="c86425287"
      unitRef="USD">9730000</us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill>
    <us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill
      contextRef="i_2021-12-31_IndefiniteLivedIntangibleAssetsByMajorClassAxis-RostafuroxinDrugCandidateMember"
      decimals="-4"
      id="c86425288"
      unitRef="USD">9730000</us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill>
    <us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill
      contextRef="i_2022-06-30"
      decimals="-4"
      id="c86425289"
      unitRef="USD">32070000</us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill>
    <us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill
      contextRef="i_2021-12-31"
      decimals="-4"
      id="c86425290"
      unitRef="USD">32070000</us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill>
    <us-gaap:Goodwill
      contextRef="i_2022-06-30"
      decimals="-3"
      id="c86425291"
      unitRef="USD">4046000</us-gaap:Goodwill>
    <us-gaap:Goodwill
      contextRef="i_2021-12-31"
      decimals="-3"
      id="c86425292"
      unitRef="USD">15682000</us-gaap:Goodwill>
    <us-gaap:ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock contextRef="d_2022-01-01_2022-06-30" id="c86426301">&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin: 0pt; text-align: left;"&gt;&lt;span style="color:#333333;"&gt;&lt;b&gt;Foreign Currency Transactions&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin: 0pt; text-align: left;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin: 0pt; text-align: left;"&gt;&lt;span style="color:#333333;"&gt;The functional currency for our foreign subsidiaries is U.S. Dollars. We remeasure monetary assets and liabilities that are &lt;em style="font: inherit;"&gt;not&lt;/em&gt; denominated in the functional currency at exchange rates in effect at the end of each period. Gains and losses from the remeasurement of foreign currency transactions are recognized in &lt;/span&gt;&lt;span style="color:#333333;"&gt;other income (expense), net&lt;/span&gt;&lt;span style="color:#333333;"&gt;. Foreign currency transactions resulted in &lt;/span&gt;&lt;span style="color:#333333;"&gt;gains&lt;/span&gt;&lt;span style="color:#333333;"&gt;&#160;of approximately&#160;&lt;/span&gt;&lt;span style="color:#333333;"&gt;$0.2&lt;/span&gt;&lt;span style="color:#333333;"&gt; million and losses of approximately&#160;&lt;/span&gt;&lt;span style="color:#333333;"&gt;$0.3&lt;/span&gt;&lt;span style="color:#333333;"&gt; million for the &lt;em style="font: inherit;"&gt;three&lt;/em&gt;-month periods ended &lt;/span&gt;&lt;span style="color:#333333;"&gt;&lt;em style="font: inherit;"&gt; June 30, 2022 &lt;/em&gt;and &lt;em style="font: inherit;"&gt;2021&lt;/em&gt;&lt;/span&gt;&lt;span style="color:#333333;"&gt;, respectively.&#160;Foreign currency transactions resulted in &lt;/span&gt;&lt;span style="color:#333333;"&gt;gains&lt;/span&gt;&lt;span style="color:#333333;"&gt;&#160;of approximately&#160;&lt;/span&gt;&lt;span style="color:#333333;"&gt;$0.4&lt;/span&gt;&lt;span style="color:#333333;"&gt;&#160;million and losses of approximately&#160;&lt;/span&gt;&lt;span style="color:#333333;"&gt;$0.2&lt;/span&gt;&lt;span style="color:#333333;"&gt;&#160;million for the &lt;/span&gt;&lt;span style="color:#333333;"&gt;&lt;em style="font: inherit;"&gt;six&lt;/em&gt;&lt;/span&gt;&lt;span style="color:#333333;"&gt;-month periods ended &lt;/span&gt;&lt;span style="color:#333333;"&gt;&lt;em style="font: inherit;"&gt; June 30, 2022 &lt;/em&gt;and &lt;em style="font: inherit;"&gt;2021&lt;/em&gt;&lt;/span&gt;&lt;span style="color:#333333;"&gt;, respectively.&#160;&lt;/span&gt;&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin: 0pt; text-align: left;"&gt;&#160;&lt;/p&gt;</us-gaap:ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock>
    <us-gaap:ForeignCurrencyTransactionGainBeforeTax
      contextRef="d_2022-04-01_2022-06-30"
      decimals="-5"
      id="c86425197"
      unitRef="USD">200000</us-gaap:ForeignCurrencyTransactionGainBeforeTax>
    <us-gaap:ForeignCurrencyTransactionLossBeforeTax
      contextRef="d_2021-04-01_2021-06-30"
      decimals="-5"
      id="c86425198"
      unitRef="USD">300000</us-gaap:ForeignCurrencyTransactionLossBeforeTax>
    <us-gaap:ForeignCurrencyTransactionGainBeforeTax
      contextRef="d_2021-01-01_2021-06-30"
      decimals="-5"
      id="c86425201"
      unitRef="USD">400000</us-gaap:ForeignCurrencyTransactionGainBeforeTax>
    <us-gaap:ForeignCurrencyTransactionLossBeforeTax
      contextRef="d_2021-01-01_2021-06-30"
      decimals="-5"
      id="c86425202"
      unitRef="USD">200000</us-gaap:ForeignCurrencyTransactionLossBeforeTax>
    <us-gaap:UseOfEstimates contextRef="d_2022-01-01_2022-06-30" id="c86426302">&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin: 0pt; text-align: left;"&gt;&lt;span style="color:#333333;"&gt;&lt;b&gt;Use of Estimates&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin: 0pt; text-align: left;"&gt;&lt;br/&gt; &lt;span style="color:#333333;"&gt;The preparation of financial statements in conformity with US GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, including intangible assets and goodwill,&#160;at the date of the financial statements and the reported amounts of expenses during the reporting period. Actual results could differ from those estimates.&lt;/span&gt;&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin: 0pt; text-align: left;"&gt;&#160;&lt;/p&gt;</us-gaap:UseOfEstimates>
    <us-gaap:CashAndCashEquivalentsPolicyTextBlock contextRef="d_2022-01-01_2022-06-30" id="c86426303">&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin: 0pt; text-align: left;"&gt;&lt;span style="color:#333333;"&gt;&lt;b&gt;Cash and Cash Equivalents&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin: 0pt; text-align: left;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin: 0pt; text-align: left;"&gt;&lt;span style="color:#333333;"&gt;Cash and cash equivalents are held at domestic and foreign financial institutions and consist of liquid investments, money market funds, and U.S. Treasury notes with a maturity from date of purchase of &lt;em style="font: inherit;"&gt;90&lt;/em&gt; days or less that are readily convertible into cash.&lt;/span&gt;&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin: 0pt; text-align: left;"&gt;&#160;&lt;/p&gt;</us-gaap:CashAndCashEquivalentsPolicyTextBlock>
    <us-gaap:FairValueOfFinancialInstrumentsPolicy contextRef="d_2022-01-01_2022-06-30" id="c86426304">&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin: 0pt; text-align: left;"&gt;&lt;span style="color:#333333;"&gt;&lt;b&gt;Severance&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin: 0pt; text-align: left;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin: 0pt; text-align: left;"&gt;&lt;span style="color:#333333;"&gt;In &lt;em style="font: inherit;"&gt; January 2022,&#160;&lt;/em&gt;in order to focus our resources on the&#160;development of our istaroxime pipeline, we began to reduce costs related to &lt;em style="font: inherit;"&gt;KL4&lt;/em&gt; surfactant that were &lt;em style="font: inherit;"&gt;not&lt;/em&gt; already transferred to our licensee in Asia, Lee&#x2019;s (HK), under the terms of the Asia License Agreement. These costs include certain reductions in headcount dedicated to &lt;em style="font: inherit;"&gt;KL4&lt;/em&gt; surfactant and the decommissioning of both our analytical and technical support laboratory, which previously conducted release testing of active pharmaceutical ingredients&#160;and supportive research for our lyophilized and aerosolized &lt;em style="font: inherit;"&gt;KL4&lt;/em&gt; surfactant, and our medical device development laboratory, which was previously used to conduct development activities and testing for our ADS technologies. In &lt;em style="font: inherit;"&gt; February 2022, &lt;/em&gt;management communicated&#160;its commitment to provide severance payments&#160;to impacted employees, provided that they remain employed with us through their expected termination dates. The total severance cost for impacted employees is approximately&#160;&lt;/span&gt;&lt;span style="color:#333333;"&gt;$0.4&lt;/span&gt;&lt;span style="color:#333333;"&gt;&#160;million, which was ratably accrued over the service periods of the employees, and to be paid through &lt;em style="font: inherit;"&gt; September 30, 2022. &lt;/em&gt;We incurred &lt;/span&gt;&lt;span style="color:#333333;"&gt;$0.1&lt;/span&gt;&lt;span style="color:#333333;"&gt; million and&#160;&lt;/span&gt;&lt;span style="color:#333333;"&gt;$0.4&lt;/span&gt;&lt;span style="color:#333333;"&gt; million of expense&#160;related to these severance arrangements during the &lt;em style="font: inherit;"&gt;three&lt;/em&gt; and&#160;&lt;/span&gt;&lt;span style="color:#333333;"&gt;&lt;em style="font: inherit;"&gt;six&lt;/em&gt; months ended &lt;em style="font: inherit;"&gt; June 30, 2022&lt;/em&gt;&lt;/span&gt;&lt;span style="color:#333333;"&gt;, respectively,&#160;which is included in research and development expense.&#160;During the &lt;em style="font: inherit;"&gt;three&lt;/em&gt; and&#160;&lt;/span&gt;&lt;span style="color:#333333;"&gt;&lt;em style="font: inherit;"&gt;six&lt;/em&gt; months ended &lt;em style="font: inherit;"&gt; June 30, 2022&lt;/em&gt;&lt;/span&gt;&lt;span style="color:#333333;"&gt;,&#160;&lt;/span&gt;&lt;span style="color:#333333;"&gt;$0.2&lt;/span&gt;&lt;span style="color:#333333;"&gt;&#160;million was paid.&#160;The related liability as of &lt;/span&gt;&lt;span style="color:#333333;"&gt;&lt;em style="font: inherit;"&gt; June 30, 2022&lt;/em&gt;&lt;/span&gt;&lt;span style="color:#333333;"&gt; is $0.2&#160;million and is included in accrued expenses. &lt;/span&gt;&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin: 0pt; text-align: left;"&gt;&#160;&lt;/p&gt;</us-gaap:FairValueOfFinancialInstrumentsPolicy>
    <us-gaap:SeveranceCosts1
      contextRef="d_2022-01-01_2022-06-30"
      decimals="-5"
      id="c86425210"
      unitRef="USD">400000</us-gaap:SeveranceCosts1>
    <wint:SeveranceAccrual
      contextRef="d_2022-04-01_2022-06-30"
      decimals="-5"
      id="c86425211"
      unitRef="USD">100000</wint:SeveranceAccrual>
    <wint:SeveranceAccrual
      contextRef="d_2022-01-01_2022-06-30"
      decimals="-5"
      id="c86425212"
      unitRef="USD">400000</wint:SeveranceAccrual>
    <wint:PaymentsForSeveranceCosts
      contextRef="d_2022-04-01_2022-06-30"
      decimals="-5"
      id="c86425217"
      unitRef="USD">200000</wint:PaymentsForSeveranceCosts>
    <us-gaap:SupplementalUnemploymentBenefitsSeveranceBenefits
      contextRef="i_2022-06-30"
      decimals="-5"
      id="c86425219"
      unitRef="USD">200000</us-gaap:SupplementalUnemploymentBenefitsSeveranceBenefits>
    <us-gaap:PropertyPlantAndEquipmentImpairment contextRef="d_2022-01-01_2022-06-30" id="c86426305">&lt;div style="font-size:10pt"&gt;&lt;div style="font-family:&amp;quot;Times New Roman&amp;quot;"&gt;&lt;span style="color:#333333;"&gt;&lt;b&gt;Property and Equipment&lt;/b&gt;&lt;/span&gt;
    &lt;/div&gt;
    &lt;div style="font-family:&amp;quot;Times New Roman&amp;quot;"&gt;
      &#160;
    &lt;/div&gt;
   &lt;/div&gt;
   &lt;div style="font-size:10pt"&gt;
    &lt;div style="font-family:'Times New Roman'"&gt;
     &lt;div style="font-variant:normal"&gt;
      &lt;span style="color:#333333;"&gt;Property and equipment are recorded at cost and depreciated using the straight-line method over the estimated useful lives of the assets (generally&#160;&lt;em style="font: inherit;"&gt;three&lt;/em&gt;&#160;to&#160;&lt;em style="font: inherit;"&gt;ten&lt;/em&gt;&#160;years). Leasehold improvements are amortized over the shorter of the estimated useful lives or the remaining term of the lease. Repairs and maintenance costs are charged to expense as incurred.&lt;/span&gt;
     &lt;/div&gt;
     &lt;div style="font-variant:normal"&gt;
       &#160;
     &lt;/div&gt;
    &lt;/div&gt;
   &lt;/div&gt;
   &lt;div style="font-size:10pt"&gt;
    &lt;div style="font-family:'Times New Roman'"&gt;
     &lt;div style="font-variant:normal"&gt;
      &lt;span style="color:#333333;"&gt;During the &lt;em style="font: inherit;"&gt;first&lt;/em&gt; quarter of &lt;em style="font: inherit;"&gt;2022,&lt;/em&gt; we determined that&#160;certain&#160;manufacturing and laboratory equipment assets related to the &lt;em style="font: inherit;"&gt;KL4&lt;/em&gt; surfactant platform would be abandoned by &lt;em style="font: inherit;"&gt; March 31, 2022. &lt;/em&gt;We accelerated depreciation of these assets during the &lt;em style="font: inherit;"&gt;first&lt;/em&gt; quarter of &lt;em style="font: inherit;"&gt;2022,&lt;/em&gt; resulting in $0.4 million of additional depreciation expense for the &lt;em style="font: inherit;"&gt;three&lt;/em&gt; months ended &lt;em style="font: inherit;"&gt; March 31, 2022.&#160;&lt;/em&gt;During the &lt;em style="font: inherit;"&gt;second&lt;/em&gt; quarter of &lt;em style="font: inherit;"&gt;2022,&lt;/em&gt; the abandoned assets and certain other &lt;em style="font: inherit;"&gt;KL4&lt;/em&gt; surfactant platform assets were disposed.&lt;/span&gt;
     &lt;/div&gt;
     &lt;div style="font-variant:normal"&gt;
       &#160;
     &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:PropertyPlantAndEquipmentImpairment>
    <us-gaap:Depreciation
      contextRef="d_2022-01-01_2022-03-31_PropertyPlantAndEquipmentByTypeAxis-ManufacturingAndLaboratoryEquipmentMember"
      decimals="-5"
      id="c86425227"
      unitRef="USD">400000</us-gaap:Depreciation>
    <wint:RestructuredDebtLiabilityContingentMilestonePaymentPolicyPolicyTextBlock contextRef="d_2022-01-01_2022-06-30" id="c86426306">&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin: 0pt; text-align: left;"&gt;&lt;span style="color:#333333;"&gt;&lt;b&gt;Restructured Debt Liability &#x2013; Contingent Milestone Payment&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin: 0pt; text-align: left;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin: 0pt; text-align: left;"&gt;&lt;span style="color:#333333;"&gt;In conjunction with the &lt;em style="font: inherit;"&gt; November 2017 &lt;/em&gt;restructuring and retirement of long-term debt (&lt;i&gt;see&lt;/i&gt;, &lt;/span&gt;&lt;span style="color:#333333;"&gt;Note &lt;em style="font: inherit;"&gt;7&lt;/em&gt; &#x2013; Restructured Debt Liability&lt;/span&gt;&lt;span style="color:#333333;"&gt;), we have established a &lt;/span&gt;&lt;span style="color:#333333;"&gt;$15.0&lt;/span&gt;&lt;span style="color:#333333;"&gt;&#160;million long-term liability for contingent milestone payments potentially due under the Exchange and Termination Agreement dated as of &lt;em style="font: inherit;"&gt; October 27, 2017, &lt;/em&gt;or the Exchange and Termination Agreement, between ourselves and affiliates of Deerfield Management Company L.P., or Deerfield. The liability has been recorded at full value of the contingent milestones and will continue to be carried at full value until the milestones are achieved and paid or milestones are &lt;em style="font: inherit;"&gt;not&lt;/em&gt; achieved and the liability is written off as a gain on debt restructuring.&lt;/span&gt;&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin: 0pt; text-align: left;"&gt;&#160;&lt;/p&gt;</wint:RestructuredDebtLiabilityContingentMilestonePaymentPolicyPolicyTextBlock>
    <wint:LiabilityforContingentMilestonePaymentNoncurrent
      contextRef="i_2017-11-01_LineOfCreditFacilityAxis-DeerfieldManagementLPMember_LongtermDebtTypeAxis-DeerfieldLoanMember_TypeOfArrangementAxis-ExchangeAndTerminationAgreementMember"
      decimals="-6"
      id="c86425233"
      unitRef="USD">15000000.0</wint:LiabilityforContingentMilestonePaymentNoncurrent>
    <us-gaap:ResearchAndDevelopmentExpensePolicy contextRef="d_2022-01-01_2022-06-30" id="c86426307">&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin: 0pt; text-align: left;"&gt;&lt;span style="color:#333333;"&gt;&lt;b&gt;Research and Development&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin: 0pt; text-align: left;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin: 0pt; text-align: left;"&gt;&lt;span style="color:#333333;"&gt;We track direct research and development expenses by preclinical and clinical programs, which include &lt;em style="font: inherit;"&gt;third&lt;/em&gt;-party costs such as contract research organization, consulting, and clinical trial costs. We do &lt;em style="font: inherit;"&gt;not&lt;/em&gt; allocate indirect research and development expenses, which include product development and manufacturing expenses and clinical, medical, and regulatory operations expenses, to specific programs. Indirect research and development expenses include personnel, facilities, manufacturing and quality operations, pharmaceutical and device development, research, regulatory, and medical affairs. Research and development costs are charged to operations as incurred in accordance with Financial Accounting Standards Board, or FASB, Accounting Standards Codification, or ASC, Topic &lt;em style="font: inherit;"&gt;730,&lt;/em&gt; Research and Development.&lt;/span&gt;&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin: 0pt; text-align: left;"&gt;&#160;&lt;/p&gt;</us-gaap:ResearchAndDevelopmentExpensePolicy>
    <us-gaap:IncomeTaxPolicyTextBlock contextRef="d_2022-01-01_2022-06-30" id="c86426308">&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin: 0pt; text-align: left;"&gt;&lt;span style="color:#333333;"&gt;&lt;b&gt;Income Taxes&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin: 0pt; text-align: left;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin: 0pt; text-align: left;"&gt;&lt;span style="color:#333333;"&gt;We account for income taxes in accordance with ASC Topic &lt;em style="font: inherit;"&gt;740,&lt;/em&gt; Accounting for Income Taxes, which requires the recognition of deferred tax liabilities and assets for the expected future tax consequences of temporary differences between financial statement carrying amounts and the tax basis of assets and liabilities.&lt;/span&gt;&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin: 0pt; text-align: left;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin: 0pt; text-align: left;"&gt;&lt;span style="color:#333333;"&gt;We use a recognition threshold and measurement attribute for the financial statement recognition and measurement of a tax position taken or expected to be taken in a tax return. Because we have never realized a profit, management has fully reserved the net deferred tax asset since realization is &lt;em style="font: inherit;"&gt;not&lt;/em&gt; assured.&lt;/span&gt;&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin: 0pt; text-align: left;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin: 0pt; text-align: left;"&gt;&lt;span style="color:#333333;"&gt;For the&#160;&lt;em style="font: inherit;"&gt;three&lt;/em&gt;&#160;and&#160;&lt;em style="font: inherit;"&gt;six&lt;/em&gt;&#160;months ended&#160;&lt;/span&gt;&lt;span style="color:#333333;"&gt;&lt;em style="font: inherit;"&gt; June 30, 2021&lt;/em&gt;&lt;/span&gt;&lt;span style="color:#333333;"&gt;, we recorded a deferred&#160;income tax benefit of&#160;&lt;/span&gt;&lt;span style="color:#333333;"&gt;$8.3&lt;/span&gt;&lt;span style="color:#333333;"&gt;&#160;million. The deferred tax benefit recorded for these periods relates solely to the reduction of the deferred tax liability as a result of the loss on impairment of intangible assets related to&#160;rostafuroxin.&lt;/span&gt;&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin: 0pt; text-align: left;"&gt;&#160;&lt;/p&gt;</us-gaap:IncomeTaxPolicyTextBlock>
    <us-gaap:DeferredIncomeTaxExpenseBenefit
      contextRef="d_2021-01-01_2021-06-30"
      decimals="-5"
      id="c86425243"
      unitRef="USD">-8300000</us-gaap:DeferredIncomeTaxExpenseBenefit>
    <us-gaap:EarningsPerSharePolicyTextBlock contextRef="d_2022-01-01_2022-06-30" id="c86426309">&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin: 0pt; text-align: left;"&gt;&lt;span style="color:#333333;"&gt;&lt;b&gt;Net Loss per Common Share&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin: 0pt; text-align: left;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin: 0pt; text-align: left;"&gt;&lt;span style="color:#333333;"&gt;Basic net loss per common share is computed by dividing net loss by the weighted average number of common shares outstanding for the period. Diluted net loss per common share is computed by giving effect to all potentially dilutive securities outstanding for the period. As of &lt;/span&gt;&lt;span style="color:#333333;"&gt;&lt;em style="font: inherit;"&gt; June 30, 2022 &lt;/em&gt;and &lt;em style="font: inherit;"&gt;2021&lt;/em&gt;&lt;/span&gt;&lt;span style="color:#333333;"&gt;, the number of shares of common stock potentially issuable upon the exercise of certain stock options and warrants, as well as the vesting of&#160;restricted stock units, was&#160;&lt;/span&gt;&lt;span style="color:#333333;"&gt;21.2&lt;/span&gt;&lt;span style="color:#333333;"&gt; million and&#160;&lt;/span&gt;&lt;span style="color:#333333;"&gt;19.9&lt;/span&gt;&lt;span style="color:#333333;"&gt; million shares, respectively. For the &lt;/span&gt;&lt;span style="color:#333333;"&gt;&lt;em style="font: inherit;"&gt;three&lt;/em&gt; and &lt;em style="font: inherit;"&gt;six&lt;/em&gt; months ended &lt;em style="font: inherit;"&gt; June 30, 2022 &lt;/em&gt;and &lt;em style="font: inherit;"&gt;2021&lt;/em&gt;&lt;/span&gt;&lt;span style="color:#333333;"&gt;, all potentially dilutive securities were anti-dilutive and therefore have been excluded from the computation of diluted net loss per share.&lt;/span&gt;&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin: 0pt; text-align: left;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin: 0pt; text-align: left;"&gt;&lt;span style="color:#333333;"&gt;We do &lt;em style="font: inherit;"&gt;not&lt;/em&gt; have any components of other comprehensive (loss) income.&lt;/span&gt;&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin: 0pt; text-align: left;"&gt;&#160;&lt;/p&gt;</us-gaap:EarningsPerSharePolicyTextBlock>
    <wint:NumberOfSharesOfCommonStockPotentiallyIssuableUponTheExerciseOfStockOptionsAndWarrants
      contextRef="d_2022-01-01_2022-06-30"
      decimals="-5"
      id="c86425246"
      unitRef="Share">21200000</wint:NumberOfSharesOfCommonStockPotentiallyIssuableUponTheExerciseOfStockOptionsAndWarrants>
    <wint:NumberOfSharesOfCommonStockPotentiallyIssuableUponTheExerciseOfStockOptionsAndWarrants
      contextRef="d_2021-01-01_2021-06-30"
      decimals="-5"
      id="c86425247"
      unitRef="Share">19900000</wint:NumberOfSharesOfCommonStockPotentiallyIssuableUponTheExerciseOfStockOptionsAndWarrants>
    <wint:EffectOfCOVID19PandemicPolicyTextBlock contextRef="d_2022-01-01_2022-06-30" id="c86426310">&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin: 0pt; text-align: left;"&gt;&lt;span style="color:#333333;"&gt;&lt;b&gt;COVID-&lt;em style="font: inherit;"&gt;19&lt;/em&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin: 0pt; text-align: left;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin: 0pt; text-align: left;"&gt;&lt;span style="color:#333333;"&gt;The COVID-&lt;em style="font: inherit;"&gt;19&lt;/em&gt; pandemic continues to evolve, and we continue to closely monitor its impact on our business and&#160;operations, including its continued&#160;impact on our clinical development plans and timelines, and financial condition. There has been intermittent impact of the pandemic in differing geographies,&#160;and there &lt;em style="font: inherit;"&gt; may &lt;/em&gt;be continued impact, particularly in light of the surge of new COVID-&lt;em style="font: inherit;"&gt;19&lt;/em&gt; cases relating to new variants. As of the date of the issuance of this Quarterly Report on Form &lt;em style="font: inherit;"&gt;10&lt;/em&gt;-Q, our operations, capital&#160;and financial resources, and overall liquidity position and outlook have been impacted by COVID-&lt;em style="font: inherit;"&gt;19,&lt;/em&gt; primarily due to delays experienced in our operations, including&#160;in clinical study initiation and enrollment. The extended timelines have required us to expend more of our capital resources than planned to achieve our projected milestones. For example, our Phase &lt;em style="font: inherit;"&gt;2&lt;/em&gt; study of istaroxime for early cardiogenic shock in heart failure patients&#160;experienced delays in trial initiation and enrollment in &lt;em style="font: inherit;"&gt;2021.&lt;/em&gt;&#160;Although many countries have re-opened, rises in new cases, including as the result of newly identified COVID-&lt;em style="font: inherit;"&gt;19&lt;/em&gt; variants, have caused certain countries, states, and localities to re-initiate restrictions.&#160;The full extent, duration, or impact that the COVID-&lt;em style="font: inherit;"&gt;19&lt;/em&gt; pandemic will have, directly or indirectly, on our financial condition and operations, including ongoing and planned clinical trials, will depend on future developments that are highly uncertain and cannot be accurately predicted. These potential future developments include the severity and transmissibility of new variants of the virus, information about any resurgences&#160;in &lt;em style="font: inherit;"&gt;one&lt;/em&gt; or more geographic locations where our current or intended clinical trial sites, our&#160;principal executive offices, research and development laboratories, or manufacturing facilities are located, and the actions taken to contain it or treat its impact. In addition, regional impact and responses to the COVID-&lt;em style="font: inherit;"&gt;19&lt;/em&gt; pandemic have affected where a clinical trial could be executed and how various elements of the clinical trial are performed. Going forward, the pandemic could also impact how monitoring/auditing of clinical trial&#160;sites and data occur. The maintenance, or strategic re-implementation, of mitigating COVID-&lt;em style="font: inherit;"&gt;19&lt;/em&gt; measures in &lt;em style="font: inherit;"&gt;one&lt;/em&gt; or more geographic locations where our clinical trial sites, principal executive offices, research and development laboratories, or other facilities are located remains possible and if realized, we believe there could be further impact on the clinical development of our product candidates, which &lt;em style="font: inherit;"&gt; may &lt;/em&gt;include potential delays, halts, or modifications to our ongoing and planned trials in &lt;/span&gt;&lt;span style="color:#333333;"&gt;&lt;em style="font: inherit;"&gt;2022&lt;/em&gt;&lt;/span&gt;&lt;span style="color:#333333;"&gt; and beyond.&lt;/span&gt;&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin: 0pt; text-align: left;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left"&gt;&lt;span style="color:#333333;"&gt;We are &lt;em style="font: inherit;"&gt;not&lt;/em&gt; aware of any specific event or circumstance that would require us to further update our estimates, judgments, or revise the carrying value of our assets or liabilities as of the date of issuance of these interim unaudited condensed consolidated financial statements. These estimates &lt;em style="font: inherit;"&gt; may &lt;/em&gt;change&#160;as new events occur and additional information is obtained.&lt;/span&gt;&lt;/p&gt;</wint:EffectOfCOVID19PandemicPolicyTextBlock>
    <us-gaap:FairValueDisclosuresTextBlock contextRef="d_2022-01-01_2022-06-30" id="c2175902">
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;&lt;span style="color:#333333;"&gt;&lt;b&gt;Note &lt;em style="font: inherit;"&gt;5&lt;/em&gt; &#x2013; Fair Value Measurements&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin: 0pt; text-align: left;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin: 0pt; text-align: left;"&gt;&lt;span style="color:#333333;"&gt;Fair value is defined as the exchange price that would be received for an asset or paid to transfer a liability in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date.&lt;/span&gt;&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin: 0pt; text-align: justify;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin: 0pt; text-align: left;"&gt;&lt;span style="color:#333333;"&gt;Valuation techniques used to measure fair value must maximize the use of observable inputs and minimize the use of unobservable inputs. The fair value hierarchy is based on &lt;em style="font: inherit;"&gt;three&lt;/em&gt; levels of inputs, of which the &lt;em style="font: inherit;"&gt;first&lt;/em&gt; &lt;em style="font: inherit;"&gt;two&lt;/em&gt; are considered observable and the last unobservable, as follows:&lt;/span&gt;&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin: 0pt; text-align: left;"&gt;&#160;&lt;/p&gt;
   &lt;table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;
    &lt;tbody&gt;
     &lt;tr style="vertical-align: top; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;
      &lt;td style="width: 36pt; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
      &lt;td style="width: 36pt; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin: 0pt; text-align: left;"&gt;&lt;span style="color:#333333;"&gt;&#x25cf;&lt;/span&gt;&lt;/p&gt; &lt;/td&gt;
      &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin: 0pt; text-align: left;"&gt;&lt;span style="color:#333333;"&gt;Level &lt;em style="font: inherit;"&gt;1&lt;/em&gt; &#x2013; Quoted prices in active markets for identical assets and liabilities.&lt;/span&gt;&lt;/p&gt; &lt;/td&gt;
     &lt;/tr&gt;

     &lt;tr style="vertical-align: top; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;
      &lt;td style="width: 36pt; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
      &lt;td style="width: 36pt; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin: 0pt; text-align: left;"&gt;&lt;span style="color:#333333;"&gt;&#x25cf;&lt;/span&gt;&lt;/p&gt; &lt;/td&gt;
      &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin: 0pt; text-align: left;"&gt;&lt;span style="color:#333333;"&gt;Level &lt;em style="font: inherit;"&gt;2&lt;/em&gt; &#x2013; Inputs other than Level &lt;em style="font: inherit;"&gt;1&lt;/em&gt; that are observable, either directly or indirectly, such as quoted prices for similar assets or liabilities, quoted prices in markets that are &lt;em style="font: inherit;"&gt;not&lt;/em&gt; active, or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities.&lt;/span&gt;&lt;/p&gt; &lt;/td&gt;
     &lt;/tr&gt;

     &lt;tr style="vertical-align: top; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;
      &lt;td style="width: 36pt; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
      &lt;td style="width: 36pt; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin: 0pt; text-align: left;"&gt;&lt;span style="color:#333333;"&gt;&#x25cf;&lt;/span&gt;&lt;/p&gt; &lt;/td&gt;
      &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin: 0pt; text-align: left;"&gt;&lt;span style="color:#333333;"&gt;Level &lt;em style="font: inherit;"&gt;3&lt;/em&gt; &#x2013; Unobservable inputs that are supported by little or &lt;em style="font: inherit;"&gt;no&lt;/em&gt; market activity and that are significant to the fair value of the assets or liabilities.&lt;/span&gt;&lt;/p&gt; &lt;/td&gt;
     &lt;/tr&gt;

    &lt;/tbody&gt;
   &lt;/table&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin: 0pt; text-align: justify;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin: 0pt; text-align: left;"&gt;&lt;span style="color:#333333;"&gt;&lt;b&gt;Fair Value on a Recurring Basis&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin: 0pt; text-align: left;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin: 0pt; text-align: left;"&gt;&lt;span style="color:#333333;"&gt;The tables below categorize assets measured at fair value on a recurring basis for the periods presented:&lt;/span&gt;&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin: 0pt; text-align: left;"&gt;&#160;&lt;/p&gt;

    &lt;table border="0" cellpadding="0" cellspacing="0" class="finTable" style="margin-right: 10%; width: 90%; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; text-indent: 0px;"&gt;
     &lt;tbody&gt;
      &lt;tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;
       &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
       &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
       &lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin: 0pt; text-align: center;"&gt;&lt;span style="color:#333333;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;Fair Value&lt;/em&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt; &lt;/td&gt;
       &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;
       &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
       &lt;td colspan="10" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin: 0pt; text-align: center;"&gt;&lt;span style="color:#333333;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;&lt;em style="font: inherit;"&gt;&lt;em style="font: inherit;"&gt;Fair value measurement using&lt;/em&gt;&lt;/em&gt;&lt;/em&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt; &lt;/td&gt;
       &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;
      &lt;/tr&gt;

      &lt;tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;
       &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
       &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
       &lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin: 0pt; text-align: center;"&gt;&lt;span style="color:#333333;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;June 30,&lt;/em&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt; &lt;/td&gt;
       &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
       &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
       &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
       &lt;td style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&lt;em style="font: inherit;"&gt;&#160;&lt;/em&gt;&lt;/td&gt;
       &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&lt;span style="color:#333333;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
       &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
       &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
       &lt;td style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&lt;em style="font: inherit;"&gt;&#160;&lt;/em&gt;&lt;/td&gt;
       &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&lt;span style="color:#333333;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
       &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
       &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
       &lt;td style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&lt;em style="font: inherit;"&gt;&#160;&lt;/em&gt;&lt;/td&gt;
       &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&lt;span style="color:#333333;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
      &lt;/tr&gt;

      &lt;tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;
       &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; width: 44%;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;span style="color:#333333;"&gt;&lt;i&gt;(in thousands)&lt;/i&gt;&lt;/span&gt;&lt;/p&gt; &lt;/td&gt;
       &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
       &lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin: 0pt; text-align: center;"&gt;&lt;span style="color:#333333;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;2022&lt;/em&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt; &lt;/td&gt;
       &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;
       &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
       &lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin: 0pt; text-align: center;"&gt;&lt;span style="color:#333333;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;Level 1&lt;/em&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt; &lt;/td&gt;
       &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;
       &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
       &lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin: 0pt; text-align: center;"&gt;&lt;span style="color:#333333;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;Level 2&lt;/em&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt; &lt;/td&gt;
       &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;
       &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
       &lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin: 0pt; text-align: center;"&gt;&lt;span style="color:#333333;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;Level 3&lt;/em&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt; &lt;/td&gt;
       &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;
      &lt;/tr&gt;

      &lt;tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;
       &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
       &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
       &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
       &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
       &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
       &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
       &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
       &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
       &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
       &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
       &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
       &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
       &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
       &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
       &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
       &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
       &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
      &lt;/tr&gt;

      &lt;tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"&gt;
       &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;span style="color:#333333;"&gt;Cash equivalents:&lt;/span&gt;&lt;/p&gt; &lt;/td&gt;
       &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
       &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
       &lt;td style="text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
       &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
       &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
       &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
       &lt;td style="text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
       &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
       &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
       &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
       &lt;td style="text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
       &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
       &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
       &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
       &lt;td style="text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
       &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
      &lt;/tr&gt;

      &lt;tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;
       &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;span style="color:#333333;"&gt;Money market funds&lt;/span&gt;&lt;/p&gt; &lt;/td&gt;
       &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;
       &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&lt;span style="color:#333333;"&gt;$&lt;/span&gt;&lt;/td&gt;
       &lt;td style="width: 11%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&lt;span style="color:#333333;"&gt;10,121&lt;/span&gt;&lt;/td&gt;
       &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;
       &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;
       &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&lt;span style="color:#333333;"&gt;$&lt;/span&gt;&lt;/td&gt;
       &lt;td style="width: 11%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&lt;span style="color:#333333;"&gt;10,121&lt;/span&gt;&lt;/td&gt;
       &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;
       &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;
       &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&lt;span style="color:#333333;"&gt;$&lt;/span&gt;&lt;/td&gt;
       &lt;td style="width: 11%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&lt;span style="color:#333333;"&gt;&lt;em style="font: inherit;"&gt;-&lt;/em&gt;&lt;/span&gt;&lt;/td&gt;
       &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;
       &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;
       &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&lt;span style="color:#333333;"&gt;$&lt;/span&gt;&lt;/td&gt;
       &lt;td style="width: 11%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&lt;span style="color:#333333;"&gt;&lt;em style="font: inherit;"&gt;-&lt;/em&gt;&lt;/span&gt;&lt;/td&gt;
       &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;
      &lt;/tr&gt;

      &lt;tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"&gt;
       &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 18pt;"&gt;&lt;span style="color:#333333;"&gt;Total Assets&lt;/span&gt;&lt;/p&gt; &lt;/td&gt;
       &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
       &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;&lt;span style="color:#333333;"&gt;$&lt;/span&gt;&lt;/td&gt;
       &lt;td style="width: 11%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;&lt;span style="color:#333333;"&gt;10,121&lt;/span&gt;&lt;/td&gt;
       &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
       &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
       &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;&lt;span style="color:#333333;"&gt;$&lt;/span&gt;&lt;/td&gt;
       &lt;td style="width: 11%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;&lt;span style="color:#333333;"&gt;10,121&lt;/span&gt;&lt;/td&gt;
       &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
       &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
       &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;&lt;span style="color:#333333;"&gt;$&lt;/span&gt;&lt;/td&gt;
       &lt;td style="width: 11%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;&lt;span style="color:#333333;"&gt;&lt;em style="font: inherit;"&gt;-&lt;/em&gt;&lt;/span&gt;&lt;/td&gt;
       &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
       &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
       &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;&lt;span style="color:#333333;"&gt;$&lt;/span&gt;&lt;/td&gt;
       &lt;td style="width: 11%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;&lt;span style="color:#333333;"&gt;&lt;em style="font: inherit;"&gt;-&lt;/em&gt;&lt;/span&gt;&lt;/td&gt;
       &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
      &lt;/tr&gt;

     &lt;/tbody&gt;
    &lt;/table&gt;

   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin: 0pt; text-align: left;"&gt;&#160;&lt;/p&gt;

    &lt;table border="0" cellpadding="0" cellspacing="0" class="finTable" style="margin-right: 10%; width: 90%; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; text-indent: 0px;"&gt;
     &lt;tbody&gt;
      &lt;tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;
       &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
       &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
       &lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin: 0pt; text-align: center;"&gt;&lt;span style="color:#333333;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;Fair Value&lt;/em&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt; &lt;/td&gt;
       &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;
       &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
       &lt;td colspan="10" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin: 0pt; text-align: center;"&gt;&lt;span style="color:#333333;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;&lt;em style="font: inherit;"&gt;&lt;em style="font: inherit;"&gt;Fair value measurement using&lt;/em&gt;&lt;/em&gt;&lt;/em&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt; &lt;/td&gt;
       &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;
      &lt;/tr&gt;

      &lt;tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;
       &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
       &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
       &lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin: 0pt; text-align: center;"&gt;&lt;span style="color:#333333;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;December 31,&lt;/em&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt; &lt;/td&gt;
       &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
       &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
       &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
       &lt;td style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&lt;em style="font: inherit;"&gt;&#160;&lt;/em&gt;&lt;/td&gt;
       &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&lt;span style="color:#333333;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
       &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
       &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
       &lt;td style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&lt;em style="font: inherit;"&gt;&#160;&lt;/em&gt;&lt;/td&gt;
       &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&lt;span style="color:#333333;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
       &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
       &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
       &lt;td style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&lt;em style="font: inherit;"&gt;&#160;&lt;/em&gt;&lt;/td&gt;
       &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&lt;span style="color:#333333;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
      &lt;/tr&gt;

      &lt;tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;
       &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; width: 44%;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;span style="color:#333333;"&gt;&lt;i&gt;(in thousands)&lt;/i&gt;&lt;/span&gt;&lt;/p&gt; &lt;/td&gt;
       &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
       &lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin: 0pt; text-align: center;"&gt;&lt;span style="color:#333333;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;2021&lt;/em&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt; &lt;/td&gt;
       &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;
       &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
       &lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin: 0pt; text-align: center;"&gt;&lt;span style="color:#333333;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;Level 1&lt;/em&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt; &lt;/td&gt;
       &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;
       &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
       &lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin: 0pt; text-align: center;"&gt;&lt;span style="color:#333333;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;Level 2&lt;/em&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt; &lt;/td&gt;
       &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;
       &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
       &lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin: 0pt; text-align: center;"&gt;&lt;span style="color:#333333;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;Level 3&lt;/em&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt; &lt;/td&gt;
       &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;
      &lt;/tr&gt;

      &lt;tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;
       &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
       &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
       &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
       &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
       &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
       &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
       &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
       &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
       &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
       &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
       &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
       &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
       &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
       &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
       &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
       &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
       &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
      &lt;/tr&gt;

      &lt;tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"&gt;
       &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;span style="color:#333333;"&gt;Cash equivalents:&lt;/span&gt;&lt;/p&gt; &lt;/td&gt;
       &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
       &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
       &lt;td style="text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
       &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
       &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
       &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
       &lt;td style="text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
       &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
       &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
       &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
       &lt;td style="text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
       &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
       &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
       &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
       &lt;td style="text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
       &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
      &lt;/tr&gt;

      &lt;tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;
       &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;span style="color:#333333;"&gt;Money market funds&lt;/span&gt;&lt;/p&gt; &lt;/td&gt;
       &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;
       &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&lt;span style="color:#333333;"&gt;$&lt;/span&gt;&lt;/td&gt;
       &lt;td style="width: 11%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&lt;span style="color:#333333;"&gt;21,104&lt;/span&gt;&lt;/td&gt;
       &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;
       &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;
       &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&lt;span style="color:#333333;"&gt;$&lt;/span&gt;&lt;/td&gt;
       &lt;td style="width: 11%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&lt;span style="color:#333333;"&gt;21,104&lt;/span&gt;&lt;/td&gt;
       &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;
       &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;
       &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&lt;span style="color:#333333;"&gt;$&lt;/span&gt;&lt;/td&gt;
       &lt;td style="width: 11%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&lt;span style="color:#333333;"&gt;&lt;em style="font: inherit;"&gt;-&lt;/em&gt;&lt;/span&gt;&lt;/td&gt;
       &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;
       &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;
       &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&lt;span style="color:#333333;"&gt;$&lt;/span&gt;&lt;/td&gt;
       &lt;td style="width: 11%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&lt;span style="color:#333333;"&gt;&lt;em style="font: inherit;"&gt;-&lt;/em&gt;&lt;/span&gt;&lt;/td&gt;
       &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;
      &lt;/tr&gt;

      &lt;tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"&gt;
       &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; padding-top: 0px; padding-right: 0px; padding-left: 0px; margin: 0px;"&gt; &lt;p style="margin-top: 0pt; margin-bottom: 0pt; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 18pt;"&gt;&lt;span style="color:#333333;"&gt;Total Assets&lt;/span&gt;&lt;/p&gt; &lt;/td&gt;
       &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; padding: 0px 0px 3px; margin: 0px;"&gt;&#160;&lt;/td&gt;
       &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; padding-top: 0px; padding-right: 0px; padding-left: 0px; margin: 0px; border-bottom: 3px double rgb(0, 0, 0);"&gt;&lt;span style="color:#333333;"&gt;$&lt;/span&gt;&lt;/td&gt;
       &lt;td style="width: 11%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; padding-top: 0px; padding-right: 0px; padding-left: 0px; margin: 0px; border-bottom: 3px double rgb(0, 0, 0);"&gt;&lt;span style="color:#333333;"&gt;21,104&lt;/span&gt;&lt;/td&gt;
       &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; padding: 0px 0px 3px; margin: 0px;"&gt;&#160;&lt;/td&gt;
       &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; padding: 0px 0px 3px; margin: 0px;"&gt;&#160;&lt;/td&gt;
       &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; padding-top: 0px; padding-right: 0px; padding-left: 0px; margin: 0px; border-bottom: 3px double rgb(0, 0, 0);"&gt;&lt;span style="color:#333333;"&gt;$&lt;/span&gt;&lt;/td&gt;
       &lt;td style="width: 11%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; padding-top: 0px; padding-right: 0px; padding-left: 0px; margin: 0px; border-bottom: 3px double rgb(0, 0, 0);"&gt;&lt;span style="color:#333333;"&gt;21,104&lt;/span&gt;&lt;/td&gt;
       &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; padding: 0px 0px 3px; margin: 0px;"&gt;&#160;&lt;/td&gt;
       &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; padding: 0px 0px 3px; margin: 0px;"&gt;&#160;&lt;/td&gt;
       &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; padding-top: 0px; padding-right: 0px; padding-left: 0px; margin: 0px; border-bottom: 3px double rgb(0, 0, 0);"&gt;&lt;span style="color:#333333;"&gt;$&lt;/span&gt;&lt;/td&gt;
       &lt;td style="width: 11%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; padding-top: 0px; padding-right: 0px; padding-left: 0px; margin: 0px; border-bottom: 3px double rgb(0, 0, 0);"&gt;&lt;span style="color:#333333;"&gt;&lt;em style="font: inherit;"&gt;-&lt;/em&gt;&lt;/span&gt;&lt;/td&gt;
       &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; padding: 0px 0px 3px; margin: 0px;"&gt;&#160;&lt;/td&gt;
       &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; padding: 0px 0px 3px; margin: 0px;"&gt;&#160;&lt;/td&gt;
       &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; padding-top: 0px; padding-right: 0px; padding-left: 0px; margin: 0px; border-bottom: 3px double rgb(0, 0, 0);"&gt;&lt;span style="color:#333333;"&gt;$&lt;/span&gt;&lt;/td&gt;
       &lt;td style="width: 11%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; padding-top: 0px; padding-right: 0px; padding-left: 0px; margin: 0px; border-bottom: 3px double rgb(0, 0, 0);"&gt;&lt;span style="color:#333333;"&gt;&lt;em style="font: inherit;"&gt;-&lt;/em&gt;&lt;/span&gt;&lt;/td&gt;
       &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; padding: 0px 0px 3px; margin: 0px;"&gt;&#160;&lt;/td&gt;
      &lt;/tr&gt;

     &lt;/tbody&gt;
    &lt;/table&gt;

  </us-gaap:FairValueDisclosuresTextBlock>
    <us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock
      contextRef="d_2022-01-01_2022-06-30"
      id="c8C9C4250-C246-4F41-882E-3B4F714C542E">
    &lt;table border="0" cellpadding="0" cellspacing="0" class="finTable" style="margin-right: 10%; width: 90%; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; text-indent: 0px;"&gt;
     &lt;tbody&gt;
      &lt;tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;
       &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
       &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
       &lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin: 0pt; text-align: center;"&gt;&lt;span style="color:#333333;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;Fair Value&lt;/em&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt; &lt;/td&gt;
       &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;
       &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
       &lt;td colspan="10" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin: 0pt; text-align: center;"&gt;&lt;span style="color:#333333;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;&lt;em style="font: inherit;"&gt;&lt;em style="font: inherit;"&gt;Fair value measurement using&lt;/em&gt;&lt;/em&gt;&lt;/em&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt; &lt;/td&gt;
       &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;
      &lt;/tr&gt;

      &lt;tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;
       &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
       &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
       &lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin: 0pt; text-align: center;"&gt;&lt;span style="color:#333333;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;June 30,&lt;/em&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt; &lt;/td&gt;
       &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
       &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
       &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
       &lt;td style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&lt;em style="font: inherit;"&gt;&#160;&lt;/em&gt;&lt;/td&gt;
       &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&lt;span style="color:#333333;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
       &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
       &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
       &lt;td style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&lt;em style="font: inherit;"&gt;&#160;&lt;/em&gt;&lt;/td&gt;
       &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&lt;span style="color:#333333;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
       &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
       &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
       &lt;td style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&lt;em style="font: inherit;"&gt;&#160;&lt;/em&gt;&lt;/td&gt;
       &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&lt;span style="color:#333333;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
      &lt;/tr&gt;

      &lt;tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;
       &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; width: 44%;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;span style="color:#333333;"&gt;&lt;i&gt;(in thousands)&lt;/i&gt;&lt;/span&gt;&lt;/p&gt; &lt;/td&gt;
       &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
       &lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin: 0pt; text-align: center;"&gt;&lt;span style="color:#333333;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;2022&lt;/em&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt; &lt;/td&gt;
       &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;
       &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
       &lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin: 0pt; text-align: center;"&gt;&lt;span style="color:#333333;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;Level 1&lt;/em&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt; &lt;/td&gt;
       &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;
       &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
       &lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin: 0pt; text-align: center;"&gt;&lt;span style="color:#333333;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;Level 2&lt;/em&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt; &lt;/td&gt;
       &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;
       &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
       &lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin: 0pt; text-align: center;"&gt;&lt;span style="color:#333333;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;Level 3&lt;/em&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt; &lt;/td&gt;
       &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;
      &lt;/tr&gt;

      &lt;tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;
       &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
       &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
       &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
       &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
       &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
       &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
       &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
       &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
       &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
       &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
       &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
       &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
       &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
       &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
       &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
       &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
       &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
      &lt;/tr&gt;

      &lt;tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"&gt;
       &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;span style="color:#333333;"&gt;Cash equivalents:&lt;/span&gt;&lt;/p&gt; &lt;/td&gt;
       &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
       &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
       &lt;td style="text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
       &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
       &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
       &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
       &lt;td style="text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
       &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
       &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
       &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
       &lt;td style="text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
       &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
       &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
       &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
       &lt;td style="text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
       &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
      &lt;/tr&gt;

      &lt;tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;
       &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;span style="color:#333333;"&gt;Money market funds&lt;/span&gt;&lt;/p&gt; &lt;/td&gt;
       &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;
       &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&lt;span style="color:#333333;"&gt;$&lt;/span&gt;&lt;/td&gt;
       &lt;td style="width: 11%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&lt;span style="color:#333333;"&gt;10,121&lt;/span&gt;&lt;/td&gt;
       &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;
       &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;
       &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&lt;span style="color:#333333;"&gt;$&lt;/span&gt;&lt;/td&gt;
       &lt;td style="width: 11%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&lt;span style="color:#333333;"&gt;10,121&lt;/span&gt;&lt;/td&gt;
       &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;
       &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;
       &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&lt;span style="color:#333333;"&gt;$&lt;/span&gt;&lt;/td&gt;
       &lt;td style="width: 11%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&lt;span style="color:#333333;"&gt;&lt;em style="font: inherit;"&gt;-&lt;/em&gt;&lt;/span&gt;&lt;/td&gt;
       &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;
       &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;
       &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&lt;span style="color:#333333;"&gt;$&lt;/span&gt;&lt;/td&gt;
       &lt;td style="width: 11%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&lt;span style="color:#333333;"&gt;&lt;em style="font: inherit;"&gt;-&lt;/em&gt;&lt;/span&gt;&lt;/td&gt;
       &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;
      &lt;/tr&gt;

      &lt;tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"&gt;
       &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 18pt;"&gt;&lt;span style="color:#333333;"&gt;Total Assets&lt;/span&gt;&lt;/p&gt; &lt;/td&gt;
       &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
       &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;&lt;span style="color:#333333;"&gt;$&lt;/span&gt;&lt;/td&gt;
       &lt;td style="width: 11%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;&lt;span style="color:#333333;"&gt;10,121&lt;/span&gt;&lt;/td&gt;
       &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
       &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
       &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;&lt;span style="color:#333333;"&gt;$&lt;/span&gt;&lt;/td&gt;
       &lt;td style="width: 11%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;&lt;span style="color:#333333;"&gt;10,121&lt;/span&gt;&lt;/td&gt;
       &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
       &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
       &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;&lt;span style="color:#333333;"&gt;$&lt;/span&gt;&lt;/td&gt;
       &lt;td style="width: 11%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;&lt;span style="color:#333333;"&gt;&lt;em style="font: inherit;"&gt;-&lt;/em&gt;&lt;/span&gt;&lt;/td&gt;
       &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
       &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
       &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;&lt;span style="color:#333333;"&gt;$&lt;/span&gt;&lt;/td&gt;
       &lt;td style="width: 11%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;&lt;span style="color:#333333;"&gt;&lt;em style="font: inherit;"&gt;-&lt;/em&gt;&lt;/span&gt;&lt;/td&gt;
       &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
      &lt;/tr&gt;

     &lt;/tbody&gt;
    &lt;/table&gt;

    &lt;table border="0" cellpadding="0" cellspacing="0" class="finTable" style="margin-right: 10%; width: 90%; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; text-indent: 0px;"&gt;
     &lt;tbody&gt;
      &lt;tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;
       &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
       &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
       &lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin: 0pt; text-align: center;"&gt;&lt;span style="color:#333333;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;Fair Value&lt;/em&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt; &lt;/td&gt;
       &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;
       &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
       &lt;td colspan="10" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin: 0pt; text-align: center;"&gt;&lt;span style="color:#333333;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;&lt;em style="font: inherit;"&gt;&lt;em style="font: inherit;"&gt;Fair value measurement using&lt;/em&gt;&lt;/em&gt;&lt;/em&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt; &lt;/td&gt;
       &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;
      &lt;/tr&gt;

      &lt;tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;
       &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
       &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
       &lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin: 0pt; text-align: center;"&gt;&lt;span style="color:#333333;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;December 31,&lt;/em&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt; &lt;/td&gt;
       &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
       &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
       &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
       &lt;td style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&lt;em style="font: inherit;"&gt;&#160;&lt;/em&gt;&lt;/td&gt;
       &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&lt;span style="color:#333333;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
       &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
       &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
       &lt;td style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&lt;em style="font: inherit;"&gt;&#160;&lt;/em&gt;&lt;/td&gt;
       &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&lt;span style="color:#333333;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
       &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
       &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
       &lt;td style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&lt;em style="font: inherit;"&gt;&#160;&lt;/em&gt;&lt;/td&gt;
       &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&lt;span style="color:#333333;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
      &lt;/tr&gt;

      &lt;tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;
       &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; width: 44%;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;span style="color:#333333;"&gt;&lt;i&gt;(in thousands)&lt;/i&gt;&lt;/span&gt;&lt;/p&gt; &lt;/td&gt;
       &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
       &lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin: 0pt; text-align: center;"&gt;&lt;span style="color:#333333;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;2021&lt;/em&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt; &lt;/td&gt;
       &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;
       &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
       &lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin: 0pt; text-align: center;"&gt;&lt;span style="color:#333333;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;Level 1&lt;/em&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt; &lt;/td&gt;
       &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;
       &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
       &lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin: 0pt; text-align: center;"&gt;&lt;span style="color:#333333;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;Level 2&lt;/em&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt; &lt;/td&gt;
       &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;
       &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
       &lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin: 0pt; text-align: center;"&gt;&lt;span style="color:#333333;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;Level 3&lt;/em&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt; &lt;/td&gt;
       &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;
      &lt;/tr&gt;

      &lt;tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;
       &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
       &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
       &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
       &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
       &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
       &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
       &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
       &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
       &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
       &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
       &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
       &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
       &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
       &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
       &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
       &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
       &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
      &lt;/tr&gt;

      &lt;tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"&gt;
       &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;span style="color:#333333;"&gt;Cash equivalents:&lt;/span&gt;&lt;/p&gt; &lt;/td&gt;
       &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
       &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
       &lt;td style="text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
       &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
       &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
       &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
       &lt;td style="text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
       &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
       &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
       &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
       &lt;td style="text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
       &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
       &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
       &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
       &lt;td style="text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
       &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
      &lt;/tr&gt;

      &lt;tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;
       &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;span style="color:#333333;"&gt;Money market funds&lt;/span&gt;&lt;/p&gt; &lt;/td&gt;
       &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;
       &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&lt;span style="color:#333333;"&gt;$&lt;/span&gt;&lt;/td&gt;
       &lt;td style="width: 11%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&lt;span style="color:#333333;"&gt;21,104&lt;/span&gt;&lt;/td&gt;
       &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;
       &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;
       &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&lt;span style="color:#333333;"&gt;$&lt;/span&gt;&lt;/td&gt;
       &lt;td style="width: 11%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&lt;span style="color:#333333;"&gt;21,104&lt;/span&gt;&lt;/td&gt;
       &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;
       &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;
       &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&lt;span style="color:#333333;"&gt;$&lt;/span&gt;&lt;/td&gt;
       &lt;td style="width: 11%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&lt;span style="color:#333333;"&gt;&lt;em style="font: inherit;"&gt;-&lt;/em&gt;&lt;/span&gt;&lt;/td&gt;
       &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;
       &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;
       &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&lt;span style="color:#333333;"&gt;$&lt;/span&gt;&lt;/td&gt;
       &lt;td style="width: 11%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&lt;span style="color:#333333;"&gt;&lt;em style="font: inherit;"&gt;-&lt;/em&gt;&lt;/span&gt;&lt;/td&gt;
       &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;
      &lt;/tr&gt;

      &lt;tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"&gt;
       &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; padding-top: 0px; padding-right: 0px; padding-left: 0px; margin: 0px;"&gt; &lt;p style="margin-top: 0pt; margin-bottom: 0pt; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 18pt;"&gt;&lt;span style="color:#333333;"&gt;Total Assets&lt;/span&gt;&lt;/p&gt; &lt;/td&gt;
       &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; padding: 0px 0px 3px; margin: 0px;"&gt;&#160;&lt;/td&gt;
       &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; padding-top: 0px; padding-right: 0px; padding-left: 0px; margin: 0px; border-bottom: 3px double rgb(0, 0, 0);"&gt;&lt;span style="color:#333333;"&gt;$&lt;/span&gt;&lt;/td&gt;
       &lt;td style="width: 11%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; padding-top: 0px; padding-right: 0px; padding-left: 0px; margin: 0px; border-bottom: 3px double rgb(0, 0, 0);"&gt;&lt;span style="color:#333333;"&gt;21,104&lt;/span&gt;&lt;/td&gt;
       &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; padding: 0px 0px 3px; margin: 0px;"&gt;&#160;&lt;/td&gt;
       &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; padding: 0px 0px 3px; margin: 0px;"&gt;&#160;&lt;/td&gt;
       &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; padding-top: 0px; padding-right: 0px; padding-left: 0px; margin: 0px; border-bottom: 3px double rgb(0, 0, 0);"&gt;&lt;span style="color:#333333;"&gt;$&lt;/span&gt;&lt;/td&gt;
       &lt;td style="width: 11%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; padding-top: 0px; padding-right: 0px; padding-left: 0px; margin: 0px; border-bottom: 3px double rgb(0, 0, 0);"&gt;&lt;span style="color:#333333;"&gt;21,104&lt;/span&gt;&lt;/td&gt;
       &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; padding: 0px 0px 3px; margin: 0px;"&gt;&#160;&lt;/td&gt;
       &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; padding: 0px 0px 3px; margin: 0px;"&gt;&#160;&lt;/td&gt;
       &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; padding-top: 0px; padding-right: 0px; padding-left: 0px; margin: 0px; border-bottom: 3px double rgb(0, 0, 0);"&gt;&lt;span style="color:#333333;"&gt;$&lt;/span&gt;&lt;/td&gt;
       &lt;td style="width: 11%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; padding-top: 0px; padding-right: 0px; padding-left: 0px; margin: 0px; border-bottom: 3px double rgb(0, 0, 0);"&gt;&lt;span style="color:#333333;"&gt;&lt;em style="font: inherit;"&gt;-&lt;/em&gt;&lt;/span&gt;&lt;/td&gt;
       &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; padding: 0px 0px 3px; margin: 0px;"&gt;&#160;&lt;/td&gt;
       &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; padding: 0px 0px 3px; margin: 0px;"&gt;&#160;&lt;/td&gt;
       &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; padding-top: 0px; padding-right: 0px; padding-left: 0px; margin: 0px; border-bottom: 3px double rgb(0, 0, 0);"&gt;&lt;span style="color:#333333;"&gt;$&lt;/span&gt;&lt;/td&gt;
       &lt;td style="width: 11%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; padding-top: 0px; padding-right: 0px; padding-left: 0px; margin: 0px; border-bottom: 3px double rgb(0, 0, 0);"&gt;&lt;span style="color:#333333;"&gt;&lt;em style="font: inherit;"&gt;-&lt;/em&gt;&lt;/span&gt;&lt;/td&gt;
       &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; padding: 0px 0px 3px; margin: 0px;"&gt;&#160;&lt;/td&gt;
      &lt;/tr&gt;

     &lt;/tbody&gt;
    &lt;/table&gt;
   </us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="i_2022-06-30_CashAndCashEquivalentsAxis-MoneyMarketFundsMember_FairValueByMeasurementFrequencyAxis-FairValueMeasurementsRecurringMember"
      decimals="-3"
      id="c86425317"
      unitRef="USD">10121000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="i_2022-06-30_CashAndCashEquivalentsAxis-MoneyMarketFundsMember_FairValueByFairValueHierarchyLevelAxis-FairValueInputsLevel1Member_FairValueByMeasurementFrequencyAxis-FairValueMeasurementsRecurringMember"
      decimals="-3"
      id="c86425318"
      unitRef="USD">10121000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i_2022-06-30_FairValueByMeasurementFrequencyAxis-FairValueMeasurementsRecurringMember"
      decimals="-3"
      id="c86425321"
      unitRef="USD">10121000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i_2022-06-30_FairValueByFairValueHierarchyLevelAxis-FairValueInputsLevel1Member_FairValueByMeasurementFrequencyAxis-FairValueMeasurementsRecurringMember"
      decimals="-3"
      id="c86425322"
      unitRef="USD">10121000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="i_2021-12-31_CashAndCashEquivalentsAxis-MoneyMarketFundsMember_FairValueByMeasurementFrequencyAxis-FairValueMeasurementsRecurringMember"
      decimals="-3"
      id="c86425338"
      unitRef="USD">21104000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="i_2021-12-31_CashAndCashEquivalentsAxis-MoneyMarketFundsMember_FairValueByFairValueHierarchyLevelAxis-FairValueInputsLevel1Member_FairValueByMeasurementFrequencyAxis-FairValueMeasurementsRecurringMember"
      decimals="-3"
      id="c86425339"
      unitRef="USD">21104000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i_2021-12-31_FairValueByMeasurementFrequencyAxis-FairValueMeasurementsRecurringMember"
      decimals="-3"
      id="c86425342"
      unitRef="USD">21104000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i_2021-12-31_FairValueByFairValueHierarchyLevelAxis-FairValueInputsLevel1Member_FairValueByMeasurementFrequencyAxis-FairValueMeasurementsRecurringMember"
      decimals="-3"
      id="c86425343"
      unitRef="USD">21104000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:ShortTermDebtTextBlock contextRef="d_2022-01-01_2022-06-30" id="c2175905">
   &lt;p style="margin: 0pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&lt;span style="color:#333333;"&gt;&lt;b&gt;Note &lt;em style="font: inherit;"&gt;6&lt;/em&gt; &#x2013; Loans Payable&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;
   &lt;p style="margin: 0pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin: 0pt; text-align: left;"&gt;&lt;span style="color:#333333;"&gt;In &lt;em style="font: inherit;"&gt; June 2022, &lt;/em&gt;we entered into an insurance premium financing and security agreement with Bank Direct. Under the agreement, we financed&#160;&lt;/span&gt;&lt;span style="color:#333333;"&gt;$1.1&lt;/span&gt;&lt;span style="color:#333333;"&gt;&#160;million of certain premiums at a&#160;&lt;/span&gt;&lt;span style="color:#333333;"&gt;3.90%&lt;/span&gt;&lt;span style="color:#333333;"&gt;&#160;annual interest rate. Payments of approximately&#160;&lt;/span&gt;&lt;span style="color:#333333;"&gt;$126,000&lt;/span&gt;&lt;span style="color:#333333;"&gt;&#160;are due monthly from &lt;em style="font: inherit;"&gt; July 2022 &lt;/em&gt;through &lt;em style="font: inherit;"&gt; March 2023.&#160;&lt;/em&gt;As of&#160;&lt;/span&gt;&lt;span style="color:#333333;"&gt;&lt;em style="font: inherit;"&gt; June 30, 2022&lt;/em&gt;&lt;/span&gt;&lt;span style="color:#333333;"&gt;, the outstanding principal of the loan was&#160;&lt;/span&gt;&lt;span style="color:#333333;"&gt;$1.0&lt;/span&gt;&lt;span style="color:#333333;"&gt; million.&lt;/span&gt;&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin: 0pt; text-align: left;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;&lt;span style="color:#333333;"&gt;In &lt;em style="font: inherit;"&gt; June 2021, &lt;/em&gt;we entered into an insurance premium financing and security agreement with Bank Direct. Under the agreement, we financed&#160;&lt;/span&gt;&lt;span style="color:#333333;"&gt;$1.3&lt;/span&gt;&lt;span style="color:#333333;"&gt; million of certain premiums at a&#160;&lt;/span&gt;&lt;span style="color:#333333;"&gt;3.37%&lt;/span&gt;&lt;span style="color:#333333;"&gt; annual interest rate. Payments of approximately&#160;&lt;/span&gt;&lt;span style="color:#333333;"&gt;$147,000&lt;/span&gt;&lt;span style="color:#333333;"&gt; are due monthly from &lt;em style="font: inherit;"&gt; July 2021 &lt;/em&gt;through &lt;em style="font: inherit;"&gt; March 2022.&#160;&lt;/em&gt;As of&#160;&lt;/span&gt;&lt;span style="color:#333333;"&gt;&lt;em style="font: inherit;"&gt; December 31, 2021&lt;/em&gt;&lt;/span&gt;&lt;span style="color:#333333;"&gt;, the outstanding principal of the loan was $0.3&#160;million.&#160;The balance of the loan was repaid during the &lt;em style="font: inherit;"&gt;first&lt;/em&gt; quarter of &lt;em style="font: inherit;"&gt;2022.&lt;/em&gt;&lt;/span&gt;&lt;/p&gt;
  </us-gaap:ShortTermDebtTextBlock>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="i_2022-06-30_DebtInstrumentAxis-LoanPayableToBankDirectCapitalFinanceMember_ShortTermDebtTypeAxis-LoansPayableMember"
      decimals="-5"
      id="c86425347"
      unitRef="USD">1100000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="i_2022-06-30_DebtInstrumentAxis-LoanPayableToBankDirectCapitalFinanceMember_ShortTermDebtTypeAxis-LoansPayableMember"
      decimals="3"
      id="c86425348"
      unitRef="Pure">0.0390</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentPeriodicPayment
      contextRef="d_2022-06-30_2022-06-30_DebtInstrumentAxis-LoanPayableToBankDirectCapitalFinanceMember_ShortTermDebtTypeAxis-LoansPayableMember"
      decimals="INF"
      id="c86425349"
      unitRef="USD">126000</us-gaap:DebtInstrumentPeriodicPayment>
    <us-gaap:LoansPayableToBank
      contextRef="i_2022-06-30_DebtInstrumentAxis-LoanPayableToBankDirectCapitalFinanceMember_ShortTermDebtTypeAxis-LoansPayableMember"
      decimals="-6"
      id="c86425350"
      unitRef="USD">1000000.0</us-gaap:LoansPayableToBank>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="i_2021-06-30_DebtInstrumentAxis-LoanPayableToBankDirectCapitalFinanceMember_ShortTermDebtTypeAxis-LoansPayableMember"
      decimals="-5"
      id="c86425351"
      unitRef="USD">1300000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="i_2021-06-30_DebtInstrumentAxis-LoanPayableToBankDirectCapitalFinanceMember_ShortTermDebtTypeAxis-LoansPayableMember"
      decimals="4"
      id="c86425352"
      unitRef="Pure">0.0337</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentPeriodicPayment
      contextRef="d_2021-06-01_2021-06-30_DebtInstrumentAxis-LoanPayableToBankDirectCapitalFinanceMember_ShortTermDebtTypeAxis-LoansPayableMember"
      decimals="INF"
      id="c86425353"
      unitRef="USD">147000</us-gaap:DebtInstrumentPeriodicPayment>
    <us-gaap:LoansPayableToBank
      contextRef="i_2021-12-31_DebtInstrumentAxis-LoanPayableToBankDirectCapitalFinanceMember_ShortTermDebtTypeAxis-LoansPayableMember"
      decimals="-5"
      id="c86425354"
      unitRef="USD">300000</us-gaap:LoansPayableToBank>
    <us-gaap:LongTermDebtTextBlock contextRef="d_2022-01-01_2022-06-30" id="c2175906">
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin: 0pt; text-align: left;"&gt;&lt;span style="color:#333333;"&gt;&lt;b&gt;Note &lt;em style="font: inherit;"&gt;7&lt;/em&gt; &#x2013; Restructured Debt Liability&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"&gt;&lt;span style="color:#333333;"&gt;On &lt;em style="font: inherit;"&gt; October 27, 2017, &lt;/em&gt;we and Deerfield entered into an Exchange and Termination Agreement pursuant to which (i) promissory notes evidencing a loan with affiliates of Deerfield Management Company L.P., or the Deerfield Loan,&#160;in the aggregate principal amount of $25.0 million and (ii) warrants to purchase up to 8,333 shares of our common stock at an exercise price of $2,360.40 per share held by Deerfield were cancelled in consideration for (i) a cash payment in the aggregate amount of $2.5 million, (ii) 23,703 shares of common stock, representing 2% of fully-diluted shares outstanding (as defined in the Exchange and Termination Agreement) on the closing date, and (iii) the right to receive certain milestone payments based on achievement of specified AEROSURF development and commercial milestones, which, if achieved, could potentially total up to &lt;/span&gt;&lt;span style="color:#333333;"&gt;&lt;em style="font: inherit;"&gt;$15.0&lt;/em&gt;&lt;/span&gt;&lt;span style="color:#333333;"&gt;&#160;million. In addition, a related security agreement, pursuant to which Deerfield held a security interest in substantially all of our assets, was terminated. We established a &lt;/span&gt;&lt;span style="color:#333333;"&gt;$15.0&lt;/span&gt;&lt;span style="color:#333333;"&gt;&#160;million long-term liability for the contingent milestone payments potentially due to Deerfield under the Exchange and Termination Agreement (&lt;i&gt;see&lt;/i&gt;,&#160;&lt;/span&gt;&lt;span style="color:#333333;"&gt;Note &lt;em style="font: inherit;"&gt;4&lt;/em&gt; &#x2013; Summary of Significant Accounting Policies&lt;/span&gt;&lt;span style="color:#333333;"&gt;). The liability has been recorded at full value of the contingent milestones and will continue to be carried at full value until the milestones are achieved and paid or milestones are &lt;em style="font: inherit;"&gt;not&lt;/em&gt; achieved and the liability is written off as a gain on debt restructuring.&lt;/span&gt;&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"&gt;&lt;span style="color:#333333;"&gt;As of &lt;/span&gt;&lt;span style="color:#333333;"&gt;&lt;em style="font: inherit;"&gt; June 30, 2022&lt;/em&gt;&lt;/span&gt;&lt;span style="color:#333333;"&gt; and &lt;/span&gt;&lt;span style="color:#333333;"&gt;&lt;em style="font: inherit;"&gt; December 31, 2021&lt;/em&gt;&lt;/span&gt;&lt;span style="color:#333333;"&gt;, the restructured debt liability balance was&#160;&lt;/span&gt;&lt;span style="color:#333333;"&gt;$15.0&lt;/span&gt;&lt;span style="color:#333333;"&gt;&#160;million.&lt;/span&gt;&lt;/p&gt;
  </us-gaap:LongTermDebtTextBlock>
    <us-gaap:ExtinguishmentOfDebtAmount
      contextRef="d_2017-10-27_2017-10-27_CounterpartyNameAxis-DeerfieldManagementLPMember_LongtermDebtTypeAxis-DeerfieldLoanMember_TypeOfArrangementAxis-ExchangeAndTerminationAgreementMember"
      decimals="-6"
      id="c86425363"
      unitRef="USD">25000000.0</us-gaap:ExtinguishmentOfDebtAmount>
    <wint:ClassOfWarrantOrRightNumberOfWarrantsCancelled
      contextRef="d_2017-10-27_2017-10-27_CounterpartyNameAxis-DeerfieldManagementLPMember_LongtermDebtTypeAxis-DeerfieldLoanMember_TypeOfArrangementAxis-ExchangeAndTerminationAgreementMember"
      decimals="INF"
      id="c86425364"
      unitRef="Share">8333</wint:ClassOfWarrantOrRightNumberOfWarrantsCancelled>
    <wint:ClassOfWarrantOrRightExercisePriceOfCancelledWarrants
      contextRef="i_2017-10-27_CounterpartyNameAxis-DeerfieldManagementLPMember_LongtermDebtTypeAxis-DeerfieldLoanMember_TypeOfArrangementAxis-ExchangeAndTerminationAgreementMember"
      decimals="INF"
      id="c86425365"
      unitRef="USDPerShare">2360.40</wint:ClassOfWarrantOrRightExercisePriceOfCancelledWarrants>
    <us-gaap:RepaymentsOfLongTermDebt
      contextRef="d_2017-10-27_2017-10-27_CounterpartyNameAxis-DeerfieldManagementLPMember_LongtermDebtTypeAxis-DeerfieldLoanMember_TypeOfArrangementAxis-ExchangeAndTerminationAgreementMember"
      decimals="-5"
      id="c86425366"
      unitRef="USD">2500000</us-gaap:RepaymentsOfLongTermDebt>
    <wint:StockIssuedDuringPeriodSharesCancellationOfDebtAndWarrantObligations
      contextRef="d_2017-10-27_2017-10-27_CounterpartyNameAxis-DeerfieldManagementLPMember_LongtermDebtTypeAxis-DeerfieldLoanMember_TypeOfArrangementAxis-ExchangeAndTerminationAgreementMember"
      decimals="INF"
      id="c86425367"
      unitRef="Share">23703</wint:StockIssuedDuringPeriodSharesCancellationOfDebtAndWarrantObligations>
    <wint:StockIssuedDuringPeriodSharesCancellationOfDebtAndWarrantObligationsPercentageOfFullyDilutedSharesOutstanding
      contextRef="d_2017-10-27_2017-10-27_CounterpartyNameAxis-DeerfieldManagementLPMember_LongtermDebtTypeAxis-DeerfieldLoanMember_TypeOfArrangementAxis-ExchangeAndTerminationAgreementMember"
      decimals="2"
      id="c86425368"
      unitRef="Pure">0.02</wint:StockIssuedDuringPeriodSharesCancellationOfDebtAndWarrantObligationsPercentageOfFullyDilutedSharesOutstanding>
    <wint:LiabilityforContingentMilestonePaymentNoncurrent
      contextRef="i_2017-10-27_CounterpartyNameAxis-DeerfieldManagementLPMember_LongtermDebtTypeAxis-DeerfieldLoanMember_TypeOfArrangementAxis-ExchangeAndTerminationAgreementMember"
      decimals="-6"
      id="c86425370"
      unitRef="USD">15000000.0</wint:LiabilityforContingentMilestonePaymentNoncurrent>
    <wint:LiabilityforContingentMilestonePaymentNoncurrent
      contextRef="i_2022-03-31_CounterpartyNameAxis-DeerfieldManagementLPMember_LongtermDebtTypeAxis-DeerfieldLoanMember_TypeOfArrangementAxis-ExchangeAndTerminationAgreementMember"
      decimals="-6"
      id="c86425373"
      unitRef="USD">15000000.0</wint:LiabilityforContingentMilestonePaymentNoncurrent>
    <us-gaap:StockholdersEquityNoteDisclosureTextBlock contextRef="d_2022-01-01_2022-06-30" id="c2175907">
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin: 0pt; text-align: left;"&gt;&#160;&lt;/p&gt;


   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin: 0pt; text-align: left;"&gt;&lt;span style="color:#333333;"&gt;&lt;b&gt;Note &lt;em style="font: inherit;"&gt;8&lt;/em&gt; &#x2013; Stockholders&#x2019; Equity&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin: 0pt; text-align: left;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin: 0pt; text-align: left;"&gt;&lt;span style="color:#333333;"&gt;&lt;b&gt;At-The-Market Program&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin: 0pt; text-align: left;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin: 0pt; text-align: left;"&gt;&lt;span style="color:#333333;"&gt;On &lt;em style="font: inherit;"&gt; September 17, 2020, &lt;/em&gt;we entered into an At-The-Market Offering Agreement&#160;with Ladenburg, pursuant to which we &lt;em style="font: inherit;"&gt; may &lt;/em&gt;offer and sell, from time to time at our sole discretion, up to a maximum of &lt;/span&gt;&lt;span style="color:#333333;"&gt;$10.0&lt;/span&gt;&lt;span style="color:#333333;"&gt;&#160;million of shares of our common stock through Ladenburg as agent and/or principal through the ATM Program. When we issue sales notices to Ladenburg, we designate the maximum amount of&#160;shares to be sold by Ladenburg daily and the minimum price per share at which shares &lt;em style="font: inherit;"&gt; may &lt;/em&gt;be sold. Ladenburg &lt;em style="font: inherit;"&gt; may &lt;/em&gt;sell shares by any method permitted by law deemed to be an &#x201c;at-the-market offering&#x201d; as defined in Rule &lt;em style="font: inherit;"&gt;415&lt;/em&gt;(a)(&lt;em style="font: inherit;"&gt;4&lt;/em&gt;) under the Securities Act of &lt;em style="font: inherit;"&gt;1933,&lt;/em&gt; as amended, or in privately negotiated transactions.&lt;/span&gt;&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin: 0pt; text-align: left;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin: 0pt; text-align: left;"&gt;&lt;span style="color:#333333;"&gt;We agreed to pay Ladenburg a commission of &lt;/span&gt;&lt;span style="color:#333333;"&gt;3%&lt;/span&gt;&lt;span style="color:#333333;"&gt;&#160;of the gross sales price of any shares sold pursuant to the ATM Program. The rate of compensation will &lt;em style="font: inherit;"&gt;not&lt;/em&gt; apply when Ladenburg acts as principal.&lt;/span&gt;&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin: 0pt; text-align: left;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin: 0pt; text-align: left;"&gt;&lt;span style="color:#333333;"&gt;For the&#160;&lt;/span&gt;&lt;span style="color:#333333;"&gt;&lt;em style="font: inherit;"&gt;six&lt;/em&gt; months ended &lt;em style="font: inherit;"&gt; June 30, 2022&lt;/em&gt;&lt;/span&gt;&lt;span style="color:#333333;"&gt;, we sold&#160;&lt;/span&gt;&lt;span style="color:#333333;"&gt;1,137,246&lt;/span&gt;&lt;span style="color:#333333;"&gt;&#160;shares&#160;of our common stock under the ATM Program&#160;resulting in aggregate gross proceeds to us of approximately&#160;&lt;/span&gt;&lt;span style="color:#333333;"&gt;$1.3&lt;/span&gt;&lt;span style="color:#333333;"&gt;&#160;million and net proceeds of approximately&#160;&lt;/span&gt;&lt;span style="color:#333333;"&gt;$1.2&lt;/span&gt;&lt;span style="color:#333333;"&gt;&#160;million. For the&#160;&lt;/span&gt;&lt;span style="color:#333333;"&gt;&lt;em style="font: inherit;"&gt;six&lt;/em&gt; months ended &lt;em style="font: inherit;"&gt; June 30, 2021&lt;/em&gt;&lt;/span&gt;&lt;span style="color:#333333;"&gt;, we sold&#160;&lt;/span&gt;&lt;span style="color:#333333;"&gt;552,474&lt;/span&gt;&lt;span style="color:#333333;"&gt; shares of&#160;our common stock under the ATM Program&#160;resulting in aggregate gross and net proceeds to us of approximately&#160;&lt;/span&gt;&lt;span style="color:#333333;"&gt;$1.7&lt;/span&gt;&lt;span style="color:#333333;"&gt; million.&lt;/span&gt;&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin: 0pt; text-align: left;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin: 0pt; text-align: left;"&gt;&lt;span style="color:#333333;"&gt;During &lt;em style="font: inherit;"&gt; July &lt;/em&gt;and &lt;em style="font: inherit;"&gt; August 2022,&#160;&lt;/em&gt;we sold&#160;&lt;/span&gt;&lt;span style="color:#333333;"&gt;1,221,706&lt;/span&gt;&lt;span style="color:#333333;"&gt; shares of our common stock under the ATM Program&#160;resulting in aggregate gross and net proceeds to us of approximately&#160;&lt;/span&gt;&lt;span style="color:#333333;"&gt;$0.6&lt;/span&gt;&lt;span style="color:#333333;"&gt; million.&#160;&lt;/span&gt;&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin: 0pt; text-align: left;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin: 0pt; text-align: left;"&gt;&lt;span style="color:#333333;"&gt;The shares of common stock issued and sold under the ATM Program are registered under our Registration Statement on Form S-&lt;em style="font: inherit;"&gt;3&lt;/em&gt; (File &lt;em style="font: inherit;"&gt;No.&lt;/em&gt; &lt;em style="font: inherit;"&gt;333&lt;/em&gt;-&lt;em style="font: inherit;"&gt;248874&lt;/em&gt;), which was declared effective by the SEC on &lt;em style="font: inherit;"&gt; September 29, 2020. &lt;/em&gt;As of &lt;/span&gt;&lt;span style="color:#333333;"&gt;&lt;em style="font: inherit;"&gt; August 11, 2022&lt;/em&gt;&lt;/span&gt;&lt;span style="color:#333333;"&gt;, approximately&#160;&lt;/span&gt;&lt;span style="color:#333333;"&gt;$3.2&lt;/span&gt;&lt;span style="color:#333333;"&gt; million remains&#160;available under the ATM Program.&#160;However, we are currently subject to the limitations contained in General Instruction &lt;em style="font: inherit;"&gt;I.B.6&lt;/em&gt; of Form S-&lt;em style="font: inherit;"&gt;3.&lt;/em&gt; As a result, we are limited in selling &lt;em style="font: inherit;"&gt;no&lt;/em&gt; more than &lt;em style="font: inherit;"&gt;one&lt;/em&gt;-&lt;em style="font: inherit;"&gt;third&lt;/em&gt; of our public float during any &lt;em style="font: inherit;"&gt;12&lt;/em&gt;-month period. If our public float increases to $75 million or more, we will &lt;em style="font: inherit;"&gt;no&lt;/em&gt; longer be subject to such limitations.&lt;/span&gt;&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin: 0pt; text-align: left;"&gt;&#160;&lt;/p&gt;
   &lt;div style="font-size:10pt"&gt;
    &lt;div style="font-family:&amp;quot;Times New Roman&amp;quot;"&gt;
     &lt;span style="color:#333333;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt; March 2021 &lt;/em&gt;Public Offering&lt;/b&gt;&lt;/span&gt;
    &lt;/div&gt;
   &lt;/div&gt;
   &lt;p style="text-align: left; margin: 0pt;"&gt;&#160;&lt;/p&gt;
   &lt;div style="font-size:10pt"&gt;
    &lt;div style="font-family:&amp;quot;Times New Roman&amp;quot;"&gt;
     &lt;span style="color:#333333;"&gt;On &lt;em style="font: inherit;"&gt; March 23, 2021, &lt;/em&gt;we entered into an underwriting agreement with Oppenheimer &amp;amp; Co. Inc. as representative for the several underwriters named therein, relating to a public offering, or the &lt;em style="font: inherit;"&gt; March 2021 &lt;/em&gt;Offering, of an aggregate of &lt;/span&gt;
     &lt;span style="color:#333333;"&gt;9,230,500&lt;/span&gt;
     &lt;span style="color:#333333;"&gt;&#160;units with each unit consisting of &lt;span style="-sec-ix-hidden:c86425407"&gt;one&lt;/span&gt; share of common stock and a warrant, or the &lt;em style="font: inherit;"&gt; March 2021 &lt;/em&gt;Warrants. The &lt;em style="font: inherit;"&gt; March 2021 &lt;/em&gt;Warrants are immediately exercisable for shares of common stock at a price of &lt;/span&gt;
     &lt;span style="color:#333333;"&gt;$3.60&lt;/span&gt;
     &lt;span style="color:#333333;"&gt; per share and expire &lt;span style="-sec-ix-hidden:c86425409"&gt;five&lt;/span&gt; years from the date of issuance. The shares of common stock and the &lt;em style="font: inherit;"&gt; March 2021 &lt;/em&gt;Warrants were immediately separable and were issued separately in the &lt;em style="font: inherit;"&gt; March 2021 &lt;/em&gt;Offering.&lt;/span&gt;
    &lt;/div&gt;
    &lt;div style="font-family:&amp;quot;Times New Roman&amp;quot;"&gt;
      &#160;
    &lt;/div&gt;
    &lt;div style="font-family:&amp;quot;Times New Roman&amp;quot;"&gt;
     &lt;span style="color:#333333;"&gt;The closing of the &lt;em style="font: inherit;"&gt; March 2021 &lt;/em&gt;Offering occurred on &lt;em style="font: inherit;"&gt; March 25, 2021. &lt;/em&gt;The offering price to the public was &lt;/span&gt;
     &lt;span style="color:#333333;"&gt;$3.25&lt;/span&gt;
     &lt;span style="color:#333333;"&gt;&#160;per unit resulting in gross proceeds to us of&#160;&lt;/span&gt;
     &lt;span style="color:#333333;"&gt;$30.0&lt;/span&gt;
     &lt;span style="color:#333333;"&gt; million. After deducting underwriting discounts and commissions and estimated offering expenses payable by us, and excluding the proceeds, if any, from the exercise of the &lt;em style="font: inherit;"&gt; March 2021 &lt;/em&gt;Warrants issued pursuant to the &lt;em style="font: inherit;"&gt; March 2021 &lt;/em&gt;Offering, the net proceeds to us were approximately &lt;/span&gt;
     &lt;span style="color:#333333;"&gt;$27.4&lt;/span&gt;
     &lt;span style="color:#333333;"&gt; million.&lt;/span&gt;
    &lt;/div&gt;
    &lt;div style="font-family:&amp;quot;Times New Roman&amp;quot;"&gt;
      &#160;
    &lt;/div&gt;
    &lt;div style="font-family:&amp;quot;Times New Roman&amp;quot;"&gt;
     &lt;span style="color:#333333;"&gt;We have determined that the appropriate accounting treatment under ASC &lt;em style="font: inherit;"&gt;480,&lt;/em&gt; Distinguishing Liabilities from Equity, or ASC &lt;em style="font: inherit;"&gt;480,&lt;/em&gt; is to classify the common stock and the &lt;em style="font: inherit;"&gt; March 2021 &lt;/em&gt;Warrants issued in the &lt;em style="font: inherit;"&gt; March 2021 &lt;/em&gt;Offering as equity.&#160;We have also determined that the &lt;em style="font: inherit;"&gt; March 2021 &lt;/em&gt;Warrants are &lt;em style="font: inherit;"&gt;not&lt;/em&gt; in their entirety a derivative under the scope of ASC &lt;em style="font: inherit;"&gt;815,&lt;/em&gt; Derivatives and Hedging, or ASC &lt;em style="font: inherit;"&gt;815,&lt;/em&gt; due to the scope exception under ASC &lt;em style="font: inherit;"&gt;815&lt;/em&gt;-&lt;em style="font: inherit;"&gt;10&lt;/em&gt;-&lt;em style="font: inherit;"&gt;15&lt;/em&gt;-&lt;em style="font: inherit;"&gt;74,&lt;/em&gt; nor are there any material embedded derivatives that require separate accounting.&#160;We allocated the net proceeds from the &lt;em style="font: inherit;"&gt; March 2021 &lt;/em&gt;Offering based on the relative fair value of the common stock and the &lt;em style="font: inherit;"&gt; March 2021 &lt;/em&gt;Warrants.&lt;/span&gt;
    &lt;/div&gt;
   &lt;/div&gt;
  </us-gaap:StockholdersEquityNoteDisclosureTextBlock>
    <wint:SharesAuthorizedToBeOfferedAndSoldUnderOfferingAgreementValue
      contextRef="i_2020-09-17_SubsidiarySaleOfStockAxis-ATMProgramMember"
      decimals="-7"
      id="c86425378"
      unitRef="USD">10000000.0</wint:SharesAuthorizedToBeOfferedAndSoldUnderOfferingAgreementValue>
    <wint:CommissionFeePercentFee
      contextRef="d_2020-09-17_2020-09-17_SubsidiarySaleOfStockAxis-ATMProgramMember"
      decimals="2"
      id="c86425382"
      unitRef="Pure">0.03</wint:CommissionFeePercentFee>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="d_2022-01-01_2022-06-30_SubsidiarySaleOfStockAxis-ATMProgramMember"
      decimals="INF"
      id="c86425385"
      unitRef="Share">1137246</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="d_2022-01-01_2022-06-30_SubsidiarySaleOfStockAxis-ATMProgramMember"
      decimals="-5"
      id="c86425386"
      unitRef="USD">1300000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="d_2022-01-01_2022-06-30_SubsidiarySaleOfStockAxis-ATMProgramMember"
      decimals="-5"
      id="c86425387"
      unitRef="USD">1200000</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="d_2021-01-01_2021-06-30_SubsidiarySaleOfStockAxis-ATMProgramMember"
      decimals="INF"
      id="c86425389"
      unitRef="Share">552474</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="d_2021-01-01_2021-06-30_SubsidiarySaleOfStockAxis-ATMProgramMember"
      decimals="-5"
      id="c86425390"
      unitRef="USD">1700000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="d_2022-07-01_2022-08-11_SubsequentEventTypeAxis-SubsequentEventMember_SubsidiarySaleOfStockAxis-ATMProgramMember"
      decimals="INF"
      id="c86425391"
      unitRef="Share">1221706</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="d_2022-07-01_2022-08-11_SubsequentEventTypeAxis-SubsequentEventMember_SubsidiarySaleOfStockAxis-ATMProgramMember"
      decimals="-5"
      id="c86425392"
      unitRef="USD">600000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <wint:StockOfferingAgreementRemainingAmountAvailable
      contextRef="i_2022-08-11_SubsequentEventTypeAxis-SubsequentEventMember_SubsidiarySaleOfStockAxis-ATMProgramMember"
      decimals="-5"
      id="c86425397"
      unitRef="USD">3200000</wint:StockOfferingAgreementRemainingAmountAvailable>
    <wint:StockOfferingAgreementPublicFloatLimitationAmount
      contextRef="i_2022-08-11_SubsequentEventTypeAxis-SubsequentEventMember_SubsidiarySaleOfStockAxis-ATMProgramMember"
      decimals="-6"
      id="c86425404"
      unitRef="USD">75000000</wint:StockOfferingAgreementPublicFloatLimitationAmount>
    <wint:EquityIssuedDuringPeriodUnitsNewIssues
      contextRef="d_2021-03-23_2021-03-23_SubsidiarySaleOfStockAxis-March2021PublicOfferingMember"
      decimals="INF"
      id="c86425406"
      unitRef="Share">9230500</wint:EquityIssuedDuringPeriodUnitsNewIssues>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="i_2021-03-23_ClassOfWarrantOrRightAxis-March2021WarrantsMember"
      decimals="INF"
      id="c86425408"
      unitRef="USDPerShare">3.60</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <wint:StockAndWarrantsIssuedPricePerShare
      contextRef="i_2021-03-25_SubsidiarySaleOfStockAxis-March2021PublicOfferingMember"
      decimals="INF"
      id="c86425410"
      unitRef="USDPerShare">3.25</wint:StockAndWarrantsIssuedPricePerShare>
    <wint:ProceedsFromIssuanceOrSaleOfEquityGrossAmount
      contextRef="d_2021-03-25_2021-03-25_SubsidiarySaleOfStockAxis-March2021PublicOfferingMember"
      decimals="-7"
      id="c86425411"
      unitRef="USD">30000000.0</wint:ProceedsFromIssuanceOrSaleOfEquityGrossAmount>
    <us-gaap:ProceedsFromIssuanceOrSaleOfEquity
      contextRef="d_2021-03-25_2021-03-25_SubsidiarySaleOfStockAxis-March2021PublicOfferingMember"
      decimals="-5"
      id="c86425412"
      unitRef="USD">27400000</us-gaap:ProceedsFromIssuanceOrSaleOfEquity>
    <us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock contextRef="d_2022-01-01_2022-06-30" id="c2175908">
   &lt;p style="font-family: Times New Roman; font-size: 10pt; margin: 0pt; text-align: left;"&gt;&lt;span style="color:#333333;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;b&gt;Note &lt;em style="font: inherit;"&gt;9&lt;/em&gt;&#160;&#x2013; Stock-Based Compensation&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
   &lt;p style="font-family: Times New Roman; font-size: 10pt; margin: 0pt; text-align: left;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family: Times New Roman; font-size: 10pt; margin: 0pt; text-align: left;"&gt;&lt;span style="color:#333333;"&gt;&lt;span style="font-size: 10pt;"&gt;We recognize expense in our condensed consolidated financial statements related to all stock-based awards granted to employees and non-employee directors based on their fair value on the date of grant.&#160;Compensation expense related to stock options is calculated using the Black-Scholes option-pricing model and is recognized ratably over the vesting period, which is typically &lt;span style="-sec-ix-hidden:c86425425"&gt;three&lt;/span&gt; years. Compensation expense related to restricted stock unit, or RSU, awards is also recognized ratably over the vesting period, which typically has been between approximately &lt;span style="-sec-ix-hidden:c86425426"&gt;one&lt;/span&gt; to &lt;span style="-sec-ix-hidden:c86425427"&gt;three&lt;/span&gt; years.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin: 0pt; text-align: left;"&gt;&#160;&lt;/p&gt;


   &lt;p style="text-align: left; margin: 0pt; font-size: 10pt;"&gt;&lt;span style="color:#333333;"&gt;A summary of activity under our long-term incentive plans is presented below:&lt;/span&gt;&lt;/p&gt;
   &lt;p style="text-align: left; margin: 0pt; font-size: 10pt;"&gt;&#160;&lt;/p&gt;

    &lt;table cellpadding="0" cellspacing="0" class="finTable" style="margin-right: auto; width: 80%; font-size: 10pt; font-family: Times New Roman; text-indent: 0px;"&gt;
     &lt;tbody&gt;
      &lt;tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;
       &lt;td style="font-family: Times New Roman; font-size: 10pt; padding: 0px; margin: 0px; width: 49%;"&gt; &lt;p style="margin-top: 0pt; margin-bottom: 0pt; font-family: Times New Roman; font-size: 10pt;"&gt;&lt;span style="color:#333333;"&gt;(in thousands, except for weighted-average data)&lt;/span&gt;&lt;/p&gt; &lt;/td&gt;
       &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0px; margin: 0px;"&gt;&#160;&lt;/td&gt;
       &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0px; margin: 0px;"&gt;&#160;&lt;/td&gt;
       &lt;td style="width: 14%; text-align: right; font-family: Times New Roman; font-size: 10pt; padding: 0px; margin: 0px;"&gt;&#160;&lt;/td&gt;
       &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0px; margin: 0px;"&gt;&#160;&lt;/td&gt;
       &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0px; margin: 0px;"&gt;&#160;&lt;/td&gt;
       &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0px; margin: 0px;"&gt;&#160;&lt;/td&gt;
       &lt;td style="width: 14%; text-align: right; font-family: Times New Roman; font-size: 10pt; padding: 0px; margin: 0px;"&gt;&#160;&lt;/td&gt;
       &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0px; margin: 0px;"&gt;&#160;&lt;/td&gt;
       &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0px; margin: 0px;"&gt;&#160;&lt;/td&gt;
       &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0px; margin: 0px;"&gt;&#160;&lt;/td&gt;
       &lt;td style="width: 14%; text-align: right; font-family: Times New Roman; font-size: 10pt; padding: 0px; margin: 0px;"&gt;&#160;&lt;/td&gt;
       &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0px; margin: 0px;"&gt;&#160;&lt;/td&gt;
      &lt;/tr&gt;

      &lt;tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;
       &lt;td style="font-family: Times New Roman; font-size: 10pt; width: 49%; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; text-align: center;"&gt;&lt;span style="color:#333333;"&gt;&lt;b&gt;Stock Options&lt;/b&gt;&lt;/span&gt;&lt;/p&gt; &lt;/td&gt;
       &lt;td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"&gt;&#160;&lt;/td&gt;
       &lt;td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); width: 1%;"&gt; &lt;p style="font-family: Times New Roman; font-size: 10pt; margin: 0pt; text-align: center;"&gt;&lt;span style="color:#333333;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;Shares&lt;/em&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt; &lt;/td&gt;
       &lt;td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; width: 1%;"&gt;&#160;&lt;/td&gt;
       &lt;td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"&gt;&#160;&lt;/td&gt;
       &lt;td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); width: 1%;"&gt; &lt;p style="font-family: Times New Roman; font-size: 10pt; margin: 0pt; text-align: center;"&gt;&lt;span style="color:#333333;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;Weighted- Average Exercise Price&lt;/em&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt; &lt;/td&gt;
       &lt;td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; width: 1%;"&gt;&#160;&lt;/td&gt;
       &lt;td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"&gt;&#160;&lt;/td&gt;
       &lt;td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); width: 1%;"&gt; &lt;p style="font-family: Times New Roman; font-size: 10pt; margin: 0pt; text-align: center;"&gt;&lt;span style="color:#333333;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;Weighted- Average Remaining Contractual Term (In Yrs)&lt;/em&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt; &lt;/td&gt;
       &lt;td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; width: 1%;"&gt;&#160;&lt;/td&gt;
      &lt;/tr&gt;

      &lt;tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;
       &lt;td style="font-family: Times New Roman; font-size: 10pt; width: 49%;"&gt;&#160;&lt;/td&gt;
       &lt;td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"&gt;&#160;&lt;/td&gt;
       &lt;td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"&gt;&#160;&lt;/td&gt;
       &lt;td style="font-family: Times New Roman; font-size: 10pt; width: 14%;"&gt;&#160;&lt;/td&gt;
       &lt;td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"&gt;&#160;&lt;/td&gt;
       &lt;td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"&gt;&#160;&lt;/td&gt;
       &lt;td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"&gt;&#160;&lt;/td&gt;
       &lt;td style="font-family: Times New Roman; font-size: 10pt; width: 14%;"&gt;&#160;&lt;/td&gt;
       &lt;td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"&gt;&#160;&lt;/td&gt;
       &lt;td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"&gt;&#160;&lt;/td&gt;
       &lt;td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"&gt;&#160;&lt;/td&gt;
       &lt;td style="font-family: Times New Roman; font-size: 10pt; width: 14%;"&gt;&#160;&lt;/td&gt;
       &lt;td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"&gt;&#160;&lt;/td&gt;
      &lt;/tr&gt;

      &lt;tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"&gt;
       &lt;td style="font-family: Times New Roman; font-size: 10pt; width: 49%;"&gt; &lt;p style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;span style="color:#333333;"&gt;Outstanding at January 1, 2022&lt;/span&gt;&lt;/p&gt; &lt;/td&gt;
       &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
       &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
       &lt;td style="width: 14%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&lt;span style="color:#333333;"&gt;3,387&lt;/span&gt;&lt;/td&gt;
       &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
       &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
       &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&lt;span style="color:#333333;"&gt;$&lt;/span&gt;&lt;/td&gt;
       &lt;td style="width: 14%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&lt;span style="color:#333333;"&gt;9.74&lt;/span&gt;&lt;/td&gt;
       &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
       &lt;td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"&gt;&#160;&lt;/td&gt;
       &lt;td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"&gt;&#160;&lt;/td&gt;
       &lt;td style="text-align: right; font-family: Times New Roman; font-size: 10pt; width: 14%;"&gt;&lt;em style="font: inherit;"&gt;&#160;&lt;/em&gt;&lt;/td&gt;
       &lt;td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"&gt;&#160;&lt;/td&gt;
      &lt;/tr&gt;

      &lt;tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;
       &lt;td style="font-family: Times New Roman; font-size: 10pt; width: 49%;"&gt; &lt;p style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 9pt;"&gt;&lt;span style="color:#333333;"&gt;Granted&lt;/span&gt;&lt;/p&gt; &lt;/td&gt;
       &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
       &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
       &lt;td style="width: 14%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&lt;span style="color:#333333;"&gt;880&lt;/span&gt;&lt;/td&gt;
       &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
       &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
       &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
       &lt;td style="width: 14%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&lt;span style="color:#333333;"&gt;0.99&lt;/span&gt;&lt;/td&gt;
       &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
       &lt;td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"&gt;&#160;&lt;/td&gt;
       &lt;td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"&gt;&#160;&lt;/td&gt;
       &lt;td style="text-align: right; font-family: Times New Roman; font-size: 10pt; width: 14%;"&gt;&lt;em style="font: inherit;"&gt;&#160;&lt;/em&gt;&lt;/td&gt;
       &lt;td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"&gt;&#160;&lt;/td&gt;
      &lt;/tr&gt;

      &lt;tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"&gt;
       &lt;td style="font-family: Times New Roman; font-size: 10pt; width: 49%;"&gt; &lt;p style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 9pt;"&gt;&lt;span style="color:#333333;"&gt;Forfeited or expired&lt;/span&gt;&lt;/p&gt; &lt;/td&gt;
       &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;
       &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;
       &lt;td style="width: 14%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&lt;span style="color:#333333;"&gt;(220&lt;/span&gt;&lt;/td&gt;
       &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"&gt;&lt;span style="color:#333333;"&gt;)&lt;/span&gt;&lt;/td&gt;
       &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;
       &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;
       &lt;td style="width: 14%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&lt;span style="color:#333333;"&gt;9.72&lt;/span&gt;&lt;/td&gt;
       &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;
       &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; width: 1%; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;
       &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; width: 1%; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;
       &lt;td style="text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; width: 14%; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&lt;em style="font: inherit;"&gt;&#160;&lt;/em&gt;&lt;/td&gt;
       &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; width: 1%; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;
      &lt;/tr&gt;

      &lt;tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;
       &lt;td style="font-family: Times New Roman; font-size: 10pt; width: 49%;"&gt; &lt;p style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;span style="color:#333333;"&gt;Outstanding at June 30, 2022&lt;/span&gt;&lt;/p&gt; &lt;/td&gt;
       &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; padding-bottom: 3px;"&gt;&#160;&lt;/td&gt;
       &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;
       &lt;td style="width: 14%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;&lt;span style="color:#333333;"&gt;4,047&lt;/span&gt;&lt;/td&gt;
       &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;"&gt;&#160;&lt;/td&gt;
       &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; padding-bottom: 3px;"&gt;&#160;&lt;/td&gt;
       &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;&lt;span style="color:#333333;"&gt;$&lt;/span&gt;&lt;/td&gt;
       &lt;td style="width: 14%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;&lt;span style="color:#333333;"&gt;7.84&lt;/span&gt;&lt;/td&gt;
       &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;"&gt;&#160;&lt;/td&gt;
       &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; padding-bottom: 3px;"&gt;&#160;&lt;/td&gt;
       &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;
       &lt;td style="width: 14%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;&lt;span style="color:#333333;"&gt;7.8&lt;/span&gt;&lt;/td&gt;
       &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;"&gt;&#160;&lt;/td&gt;
      &lt;/tr&gt;

      &lt;tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"&gt;
       &lt;td style="font-family: Times New Roman; font-size: 10pt; width: 49%;"&gt;&#160;&lt;/td&gt;
       &lt;td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"&gt;&#160;&lt;/td&gt;
       &lt;td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"&gt;&#160;&lt;/td&gt;
       &lt;td style="font-family: Times New Roman; font-size: 10pt; width: 14%;"&gt;&#160;&lt;/td&gt;
       &lt;td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"&gt;&#160;&lt;/td&gt;
       &lt;td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"&gt;&#160;&lt;/td&gt;
       &lt;td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"&gt;&#160;&lt;/td&gt;
       &lt;td style="font-family: Times New Roman; font-size: 10pt; width: 14%;"&gt;&#160;&lt;/td&gt;
       &lt;td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"&gt;&#160;&lt;/td&gt;
       &lt;td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"&gt;&#160;&lt;/td&gt;
       &lt;td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"&gt;&#160;&lt;/td&gt;
       &lt;td style="font-family: Times New Roman; font-size: 10pt; width: 14%;"&gt;&#160;&lt;/td&gt;
       &lt;td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"&gt;&#160;&lt;/td&gt;
      &lt;/tr&gt;

      &lt;tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;
       &lt;td style="font-family: Times New Roman; font-size: 10pt; width: 49%;"&gt; &lt;p style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;span style="color:#333333;"&gt;Vested and exercisable at June 30, 2022&lt;/span&gt;&lt;/p&gt; &lt;/td&gt;
       &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
       &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
       &lt;td style="width: 14%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt;&lt;span style="color:#333333;"&gt;2,229&lt;/span&gt;&lt;/td&gt;
       &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
       &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
       &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&lt;span style="color:#333333;"&gt;$&lt;/span&gt;&lt;/td&gt;
       &lt;td style="width: 14%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&lt;span style="color:#333333;"&gt;11.35&lt;/span&gt;&lt;/td&gt;
       &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
       &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
       &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
       &lt;td style="width: 14%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&lt;span style="color:#333333;"&gt;6.8&lt;/span&gt;&lt;/td&gt;
       &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
      &lt;/tr&gt;

      &lt;tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"&gt;
       &lt;td style="padding: 0px; margin: 0px; font-family: Times New Roman; font-size: 10pt; width: 49%;"&gt;&#160;&lt;/td&gt;
       &lt;td style="padding: 0px; margin: 0px; font-family: Times New Roman; font-size: 10pt; width: 1%;"&gt;&#160;&lt;/td&gt;
       &lt;td style="padding: 0px; margin: 0px; font-family: Times New Roman; font-size: 10pt; width: 1%;"&gt;&#160;&lt;/td&gt;
       &lt;td style="padding: 0px; margin: 0px; font-family: Times New Roman; font-size: 10pt; width: 14%;"&gt;&#160;&lt;/td&gt;
       &lt;td style="padding: 0px; margin: 0px; font-family: Times New Roman; font-size: 10pt; width: 1%;"&gt;&#160;&lt;/td&gt;
       &lt;td style="padding: 0px; margin: 0px; font-family: Times New Roman; font-size: 10pt; width: 1%;"&gt;&#160;&lt;/td&gt;
       &lt;td style="padding: 0px; margin: 0px; font-family: Times New Roman; font-size: 10pt; width: 1%;"&gt;&#160;&lt;/td&gt;
       &lt;td style="padding: 0px; margin: 0px; font-family: Times New Roman; font-size: 10pt; width: 14%;"&gt;&#160;&lt;/td&gt;
       &lt;td style="padding: 0px; margin: 0px; font-family: Times New Roman; font-size: 10pt; width: 1%;"&gt;&#160;&lt;/td&gt;
       &lt;td style="padding: 0px; margin: 0px; font-family: Times New Roman; font-size: 10pt; width: 1%;"&gt;&#160;&lt;/td&gt;
       &lt;td style="padding: 0px; margin: 0px; font-family: Times New Roman; font-size: 10pt; width: 1%;"&gt;&#160;&lt;/td&gt;
       &lt;td style="padding: 0px; margin: 0px; font-family: Times New Roman; font-size: 10pt; width: 14%;"&gt;&#160;&lt;/td&gt;
       &lt;td style="padding: 0px; margin: 0px; font-family: Times New Roman; font-size: 10pt; width: 1%;"&gt;&#160;&lt;/td&gt;
      &lt;/tr&gt;

      &lt;tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;
       &lt;td style="font-family: Times New Roman; font-size: 10pt; width: 49%;"&gt; &lt;p style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;span style="color:#333333;"&gt;Vested and expected to vest at June 30, 2022&lt;/span&gt;&lt;/p&gt; &lt;/td&gt;
       &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
       &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
       &lt;td style="width: 14%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt;&lt;span style="color:#333333;"&gt;3,821&lt;/span&gt;&lt;/td&gt;
       &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
       &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
       &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&lt;span style="color:#333333;"&gt;$&lt;/span&gt;&lt;/td&gt;
       &lt;td style="width: 14%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&lt;span style="color:#333333;"&gt;7.85&lt;/span&gt;&lt;/td&gt;
       &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
       &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
       &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
       &lt;td style="width: 14%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&lt;span style="color:#333333;"&gt;7.8&lt;/span&gt;&lt;/td&gt;
       &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
      &lt;/tr&gt;

     &lt;/tbody&gt;
    &lt;/table&gt;

   &lt;p style="margin: 0pt; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/p&gt;

    &lt;table cellpadding="0" cellspacing="0" class="finTable" style="width: 80%; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; text-indent: 0px; margin-left: 0pt; margin-right: auto;"&gt;
     &lt;tbody&gt;
      &lt;tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;
       &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; width: 58%;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;span style="color:#333333;"&gt;(in thousands, except for weighted-average data)&lt;/span&gt;&lt;/p&gt; &lt;/td&gt;
       &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; width: 1%;"&gt;&#160;&lt;/td&gt;
       &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; width: 1%;"&gt;&#160;&lt;/td&gt;
       &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; width: 16%;"&gt;&#160;&lt;/td&gt;
       &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; width: 1%;"&gt;&#160;&lt;/td&gt;
       &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; width: 1%;"&gt;&#160;&lt;/td&gt;
       &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; width: 1%;"&gt;&#160;&lt;/td&gt;
       &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; width: 20%;"&gt;&#160;&lt;/td&gt;
       &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; width: 1%;"&gt;&#160;&lt;/td&gt;
      &lt;/tr&gt;

      &lt;tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;
       &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; width: 58%; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; text-align: center;"&gt;&lt;span style="color:#333333;"&gt;&lt;b&gt;Restricted Stock Units&lt;/b&gt;&lt;/span&gt;&lt;/p&gt; &lt;/td&gt;
       &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; width: 1%;"&gt;&#160;&lt;/td&gt;
       &lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); width: 1%;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;span style="color:#333333;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;Shares&lt;/em&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt; &lt;/td&gt;
       &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; padding-bottom: 1px; width: 1%;"&gt;&#160;&lt;/td&gt;
       &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; width: 1%;"&gt;&#160;&lt;/td&gt;
       &lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); width: 1%;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;span style="color:#333333;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;Weighted- Average Grant Date Fair Value&lt;/em&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt; &lt;/td&gt;
       &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; padding-bottom: 1px; width: 1%;"&gt;&#160;&lt;/td&gt;
      &lt;/tr&gt;

      &lt;tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;
       &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; width: 58%;"&gt;&#160;&lt;/td&gt;
       &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; width: 1%;"&gt;&#160;&lt;/td&gt;
       &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; width: 1%;"&gt;&#160;&lt;/td&gt;
       &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; width: 16%;"&gt;&#160;&lt;/td&gt;
       &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; width: 1%;"&gt;&#160;&lt;/td&gt;
       &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; width: 1%;"&gt;&#160;&lt;/td&gt;
       &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; width: 1%;"&gt;&#160;&lt;/td&gt;
       &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; width: 20%;"&gt;&#160;&lt;/td&gt;
       &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; width: 1%;"&gt;&#160;&lt;/td&gt;
      &lt;/tr&gt;

      &lt;tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"&gt;
       &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; width: 58%;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;span style="color:#333333;"&gt;Outstanding at January 1, 2022&lt;/span&gt;&lt;/p&gt; &lt;/td&gt;
       &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
       &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
       &lt;td style="width: 16%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt;&lt;span style="color:#333333;"&gt;-&lt;/span&gt;&lt;/td&gt;
       &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
       &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
       &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt;&lt;span style="color:#333333;"&gt;$&lt;/span&gt;&lt;/td&gt;
       &lt;td style="width: 20%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt;&lt;span style="color:#333333;"&gt;-&lt;/span&gt;&lt;/td&gt;
       &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
      &lt;/tr&gt;

      &lt;tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;
       &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; width: 58%;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; text-indent: 9pt;"&gt;&lt;span style="color:#333333;"&gt;Awarded&lt;/span&gt;&lt;/p&gt; &lt;/td&gt;
       &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
       &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
       &lt;td style="width: 16%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt;&lt;span style="color:#333333;"&gt;582&lt;/span&gt;&lt;/td&gt;
       &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
       &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
       &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
       &lt;td style="width: 20%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt;&lt;span style="color:#333333;"&gt;0.99&lt;/span&gt;&lt;/td&gt;
       &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
      &lt;/tr&gt;

      &lt;tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"&gt;
       &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; width: 58%; padding-top: 0px; padding-right: 0px; padding-left: 0px; margin: 0px;"&gt; &lt;p style="margin-top: 0pt; margin-bottom: 0pt; text-indent: 9pt;"&gt;&lt;span style="color:#333333;"&gt;Cancelled&lt;/span&gt;&lt;/p&gt; &lt;/td&gt;
       &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; padding: 0px 0px 1px; margin: 0px;"&gt;&#160;&lt;/td&gt;
       &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; padding-top: 0px; padding-right: 0px; padding-left: 0px; margin: 0px; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;
       &lt;td style="width: 16%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; padding-top: 0px; padding-right: 0px; padding-left: 0px; margin: 0px; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&lt;span style="color:#333333;"&gt;(21&lt;/span&gt;&lt;/td&gt;
       &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; padding: 0px 0px 1px; margin: 0px;"&gt;&lt;span style="color:#333333;"&gt;)&lt;/span&gt;&lt;/td&gt;
       &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; padding: 0px 0px 1px; margin: 0px;"&gt;&#160;&lt;/td&gt;
       &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; padding-top: 0px; padding-right: 0px; padding-left: 0px; margin: 0px; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;
       &lt;td style="width: 20%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; padding-top: 0px; padding-right: 0px; padding-left: 0px; margin: 0px; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&lt;span style="color:#333333;"&gt;1.02&lt;/span&gt;&lt;/td&gt;
       &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; padding: 0px 0px 1px; margin: 0px;"&gt;&#160;&lt;/td&gt;
      &lt;/tr&gt;

      &lt;tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;
       &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; width: 58%;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;span style="color:#333333;"&gt;Outstanding at June 30, 2022&lt;/span&gt;&lt;/p&gt; &lt;/td&gt;
       &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; padding-bottom: 3px;"&gt;&#160;&lt;/td&gt;
       &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;
       &lt;td style="width: 16%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;&lt;span style="color:#333333;"&gt;561&lt;/span&gt;&lt;/td&gt;
       &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;"&gt;&#160;&lt;/td&gt;
       &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; padding-bottom: 3px;"&gt;&#160;&lt;/td&gt;
       &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;&lt;span style="color:#333333;"&gt;$&lt;/span&gt;&lt;/td&gt;
       &lt;td style="width: 20%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;&lt;span style="color:#333333;"&gt;0.99&lt;/span&gt;&lt;/td&gt;
       &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;"&gt;&#160;&lt;/td&gt;
      &lt;/tr&gt;

      &lt;tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"&gt;
       &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; width: 58%; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;
       &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; width: 1%; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;
       &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; width: 1%; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;
       &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; width: 16%; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;
       &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; width: 1%; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;
       &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; width: 1%; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;
       &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; width: 1%; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;
       &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; width: 20%; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;
       &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; width: 1%; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;
      &lt;/tr&gt;

      &lt;tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;
       &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; width: 58%; padding: 0; margin: 0"&gt; &lt;p style="margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;span style="color:#333333;"&gt;Vested and exercisable at June 30, 2022&lt;/span&gt;&lt;/p&gt; &lt;/td&gt;
       &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;
       &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;
       &lt;td style="width: 16%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; padding: 0; margin: 0"&gt;&lt;span style="color:#333333;"&gt;-&lt;/span&gt;&lt;/td&gt;
       &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;
       &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;
       &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; padding: 0; margin: 0"&gt;&lt;span style="color:#333333;"&gt;$&lt;/span&gt;&lt;/td&gt;
       &lt;td style="width: 20%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; padding: 0; margin: 0"&gt;&lt;span style="color:#333333;"&gt;-&lt;/span&gt;&lt;/td&gt;
       &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;
      &lt;/tr&gt;

      &lt;tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"&gt;
       &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; width: 58%; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;
       &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; width: 1%; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;
       &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; width: 1%; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;
       &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; width: 16%; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;
       &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; width: 1%; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;
       &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; width: 1%; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;
       &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; width: 1%; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;
       &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; width: 20%; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;
       &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; width: 1%; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;
      &lt;/tr&gt;

      &lt;tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;
       &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; width: 58%; padding: 0; margin: 0"&gt; &lt;p style="margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;span style="color:#333333;"&gt;Vested and expected to vest at June 30, 2022&lt;/span&gt;&lt;/p&gt; &lt;/td&gt;
       &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;
       &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;
       &lt;td style="width: 16%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; padding: 0; margin: 0"&gt;&lt;span style="color:#333333;"&gt;561&lt;/span&gt;&lt;/td&gt;
       &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;
       &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;
       &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; padding: 0; margin: 0"&gt;&lt;span style="color:#333333;"&gt;$&lt;/span&gt;&lt;/td&gt;
       &lt;td style="width: 20%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; padding: 0; margin: 0"&gt;&lt;span style="color:#333333;"&gt;0.99&lt;/span&gt;&lt;/td&gt;
       &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;
      &lt;/tr&gt;

     &lt;/tbody&gt;
    &lt;/table&gt;

   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin: 0pt; text-align: left;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family: Times New Roman; font-size: 10pt; margin: 0pt; text-align: left;"&gt;&lt;span style="color:#333333;"&gt;The table below summarizes the total stock-based compensation expense included in the interim unaudited condensed consolidated statements of operations for the periods presented:&lt;/span&gt;&lt;/p&gt;
   &lt;p style="font-family: Times New Roman; font-size: 10pt; margin: 0pt; text-align: left;"&gt;&#160;&lt;/p&gt;

    &lt;table border="0" cellpadding="0" cellspacing="0" class="finTable" style="margin-right: 20%; width: 80%; font-size: 10pt; font-family: Times New Roman; text-indent: 0px;"&gt;
     &lt;tbody&gt;
      &lt;tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;
       &lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
       &lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
       &lt;td colspan="6" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;&lt;span style="color:#333333;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;&lt;em style="font: inherit;"&gt;Three Months Ended June 30,&lt;/em&gt;&lt;/em&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt; &lt;/td&gt;
       &lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
       &lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
       &lt;td colspan="6" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;&lt;span style="color:#333333;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;&lt;em style="font: inherit;"&gt;Six Months Ended June 30,&lt;/em&gt;&lt;/em&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt; &lt;/td&gt;
       &lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
      &lt;/tr&gt;

      &lt;tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;
       &lt;td style="font-family: Times New Roman; font-size: 10pt; width: 36%;"&gt; &lt;p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;span style="color:#333333;"&gt;&lt;i&gt;(in thousands)&lt;/i&gt;&lt;/span&gt;&lt;/p&gt; &lt;/td&gt;
       &lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
       &lt;td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;&lt;span style="color:#333333;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;2022&lt;/em&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt; &lt;/td&gt;
       &lt;td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;
       &lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
       &lt;td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;&lt;span style="color:#333333;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;2021&lt;/em&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt; &lt;/td&gt;
       &lt;td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;
       &lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
       &lt;td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;&lt;span style="color:#333333;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;2022&lt;/em&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt; &lt;/td&gt;
       &lt;td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;
       &lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
       &lt;td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;&lt;span style="color:#333333;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;2021&lt;/em&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt; &lt;/td&gt;
       &lt;td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;
      &lt;/tr&gt;

      &lt;tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;
       &lt;td&gt;&#160;&lt;/td&gt;
       &lt;td&gt;&#160;&lt;/td&gt;
       &lt;td&gt;&#160;&lt;/td&gt;
       &lt;td&gt;&#160;&lt;/td&gt;
       &lt;td&gt;&#160;&lt;/td&gt;
       &lt;td&gt;&#160;&lt;/td&gt;
       &lt;td&gt;&#160;&lt;/td&gt;
       &lt;td&gt;&#160;&lt;/td&gt;
       &lt;td&gt;&#160;&lt;/td&gt;
       &lt;td&gt;&#160;&lt;/td&gt;
       &lt;td&gt;&#160;&lt;/td&gt;
       &lt;td&gt;&#160;&lt;/td&gt;
       &lt;td&gt;&#160;&lt;/td&gt;
       &lt;td&gt;&#160;&lt;/td&gt;
       &lt;td&gt;&#160;&lt;/td&gt;
       &lt;td&gt;&#160;&lt;/td&gt;
       &lt;td&gt;&#160;&lt;/td&gt;
      &lt;/tr&gt;

      &lt;tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"&gt;
       &lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt; &lt;p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;span style="color:#333333;"&gt;Research and development&lt;/span&gt;&lt;/p&gt; &lt;/td&gt;
       &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
       &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&lt;span style="color:#333333;"&gt;$&lt;/span&gt;&lt;/td&gt;
       &lt;td style="width: 13%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&lt;span style="color:#333333;"&gt;147&lt;/span&gt;&lt;/td&gt;
       &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
       &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
       &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&lt;span style="color:#333333;"&gt;$&lt;/span&gt;&lt;/td&gt;
       &lt;td style="width: 13%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&lt;span style="color:#333333;"&gt;630&lt;/span&gt;&lt;/td&gt;
       &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
       &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
       &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&lt;span style="color:#333333;"&gt;$&lt;/span&gt;&lt;/td&gt;
       &lt;td style="width: 13%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&lt;span style="color:#333333;"&gt;382&lt;/span&gt;&lt;/td&gt;
       &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
       &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
       &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&lt;span style="color:#333333;"&gt;$&lt;/span&gt;&lt;/td&gt;
       &lt;td style="width: 13%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&lt;span style="color:#333333;"&gt;1,569&lt;/span&gt;&lt;/td&gt;
       &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
      &lt;/tr&gt;

      &lt;tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;
       &lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt; &lt;p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;span style="color:#333333;"&gt;General and administrative&lt;/span&gt;&lt;/p&gt; &lt;/td&gt;
       &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
       &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;
       &lt;td style="width: 13%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&lt;span style="color:#333333;"&gt;634&lt;/span&gt;&lt;/td&gt;
       &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
       &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
       &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;
       &lt;td style="width: 13%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&lt;span style="color:#333333;"&gt;914&lt;/span&gt;&lt;/td&gt;
       &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
       &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
       &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;
       &lt;td style="width: 13%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&lt;span style="color:#333333;"&gt;1,169&lt;/span&gt;&lt;/td&gt;
       &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
       &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
       &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;
       &lt;td style="width: 13%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&lt;span style="color:#333333;"&gt;2,418&lt;/span&gt;&lt;/td&gt;
       &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
      &lt;/tr&gt;

      &lt;tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"&gt;
       &lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt; &lt;p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 18pt;"&gt;&lt;span style="color:#333333;"&gt;Total&lt;/span&gt;&lt;/p&gt; &lt;/td&gt;
       &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
       &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;&lt;span style="color:#333333;"&gt;$&lt;/span&gt;&lt;/td&gt;
       &lt;td style="width: 13%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;&lt;span style="color:#333333;"&gt;781&lt;/span&gt;&lt;/td&gt;
       &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
       &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
       &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;&lt;span style="color:#333333;"&gt;$&lt;/span&gt;&lt;/td&gt;
       &lt;td style="width: 13%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;&lt;span style="color:#333333;"&gt;1,544&lt;/span&gt;&lt;/td&gt;
       &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
       &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
       &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;&lt;span style="color:#333333;"&gt;$&lt;/span&gt;&lt;/td&gt;
       &lt;td style="width: 13%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;&lt;span style="color:#333333;"&gt;1,551&lt;/span&gt;&lt;/td&gt;
       &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
       &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
       &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;&lt;span style="color:#333333;"&gt;$&lt;/span&gt;&lt;/td&gt;
       &lt;td style="width: 13%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;&lt;span style="color:#333333;"&gt;3,987&lt;/span&gt;&lt;/td&gt;
       &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
      &lt;/tr&gt;

     &lt;/tbody&gt;
    &lt;/table&gt;

   &lt;p style="font-family: Times New Roman; font-size: 10pt; margin: 0pt; text-align: left;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family: Times New Roman; font-size: 10pt; margin: 0pt; text-align: left;"&gt;&lt;span style="color:#333333;"&gt;The fair value of each option award is estimated on the date of grant using the Black-Scholes option-pricing formula that uses assumptions noted in the following table. Expected volatilities are based upon the historical volatility of our common stock and other factors. We also use historical data and other factors to estimate option exercises, employee terminations and forfeiture rates. The risk-free interest rates are based upon the U.S. Treasury yield curve in effect at the time of the grant.&lt;/span&gt;&lt;/p&gt;
   &lt;p style="font-family: Times New Roman; font-size: 10pt; margin: 0pt; text-align: left;"&gt;&#160;&lt;/p&gt;

    &lt;table border="0" cellpadding="0" cellspacing="0" class="finTable" style="margin-right: 20%; width: 80%; font-size: 10pt; font-family: Times New Roman; text-indent: 0px;"&gt;
     &lt;tbody&gt;
      &lt;tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;
       &lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
       &lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
       &lt;td colspan="6" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;&lt;span style="color:#333333;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;&lt;em style="font: inherit;"&gt;Six Months Ended June 30,&lt;/em&gt;&lt;/em&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt; &lt;/td&gt;
       &lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
      &lt;/tr&gt;

      &lt;tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;
       &lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
       &lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
       &lt;td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;&lt;span style="color:#333333;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;2022&lt;/em&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt; &lt;/td&gt;
       &lt;td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;
       &lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
       &lt;td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;&lt;span style="color:#333333;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;2021&lt;/em&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt; &lt;/td&gt;
       &lt;td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;
      &lt;/tr&gt;

      &lt;tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;
       &lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
       &lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
       &lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
       &lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
       &lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
       &lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
       &lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
       &lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
       &lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
      &lt;/tr&gt;

      &lt;tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"&gt;
       &lt;td style="font-family: Times New Roman; font-size: 10pt; width: 62%;"&gt; &lt;p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;span style="color:#333333;"&gt;Weighted average expected volatility&lt;/span&gt;&lt;/p&gt; &lt;/td&gt;
       &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
       &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
       &lt;td style="width: 16%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: center;"&gt; &lt;p style="margin-top: 0pt; margin-bottom: 0pt; font-family: Times New Roman; font-size: 10pt;"&gt;&lt;span style="color:#333333;"&gt;106%&lt;/span&gt;&lt;/p&gt; &lt;/td&gt;
       &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
       &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
       &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
       &lt;td style="width: 16%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: center;"&gt; &lt;p style="margin-top: 0pt; margin-bottom: 0pt; font-family: Times New Roman; font-size: 10pt;"&gt;&lt;span style="color:#333333;"&gt;105%&lt;/span&gt;&lt;/p&gt; &lt;/td&gt;
       &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
      &lt;/tr&gt;

      &lt;tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;
       &lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt; &lt;p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;span style="color:#333333;"&gt;Weighted average expected term (in years)&lt;/span&gt;&lt;/p&gt; &lt;/td&gt;
       &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
       &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
       &lt;td style="width: 16%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: center;"&gt; &lt;p style="margin-top: 0pt; margin-bottom: 0pt; font-family: Times New Roman; font-size: 10pt;"&gt;&lt;span style="color:#333333;"&gt;6.9&lt;/span&gt;&lt;/p&gt; &lt;/td&gt;
       &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
       &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
       &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
       &lt;td style="width: 16%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: center;"&gt; &lt;p style="margin-top: 0pt; margin-bottom: 0pt; font-family: Times New Roman; font-size: 10pt;"&gt;&lt;span style="color:#333333;"&gt;6.7&lt;/span&gt;&lt;/p&gt; &lt;/td&gt;
       &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
      &lt;/tr&gt;

      &lt;tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"&gt;
       &lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt; &lt;p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;span style="color:#333333;"&gt;Weighted average risk-free interest rate&lt;/span&gt;&lt;/p&gt; &lt;/td&gt;
       &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
       &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
       &lt;td style="width: 16%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: center;"&gt; &lt;p style="margin-top: 0pt; margin-bottom: 0pt; font-family: Times New Roman; font-size: 10pt;"&gt;&lt;span style="color:#333333;"&gt;1.70%&lt;/span&gt;&lt;/p&gt; &lt;/td&gt;
       &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
       &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
       &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
       &lt;td style="width: 16%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: center;"&gt; &lt;p style="margin-top: 0pt; margin-bottom: 0pt; font-family: Times New Roman; font-size: 10pt;"&gt;&lt;span style="color:#333333;"&gt;0.48%&lt;/span&gt;&lt;/p&gt; &lt;/td&gt;
       &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
      &lt;/tr&gt;

      &lt;tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;
       &lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt; &lt;p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;span style="color:#333333;"&gt;Expected dividends&lt;/span&gt;&lt;/p&gt; &lt;/td&gt;
       &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
       &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
       &lt;td style="width: 16%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: center;"&gt;&lt;em style="font: inherit;"&gt; &lt;/em&gt;&lt;p style="margin-top: 0pt; margin-bottom: 0pt; font-family: Times New Roman; font-size: 10pt;"&gt;&lt;span style="color:#333333;"&gt;-&lt;/span&gt;&lt;/p&gt; &lt;/td&gt;
       &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
       &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
       &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
       &lt;td style="width: 16%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: center;"&gt;&lt;em style="font: inherit;"&gt; &lt;/em&gt;&lt;p style="margin-top: 0pt; margin-bottom: 0pt; font-family: Times New Roman; font-size: 10pt;"&gt;&lt;span style="color:#333333;"&gt;-&lt;/span&gt;&lt;/p&gt; &lt;/td&gt;
       &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
      &lt;/tr&gt;

     &lt;/tbody&gt;
    &lt;/table&gt;

  </us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock>
    <us-gaap:DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock contextRef="d_2022-01-01_2022-06-30" id="c2175909">
    &lt;table cellpadding="0" cellspacing="0" class="finTable" style="margin-right: auto; width: 80%; font-size: 10pt; font-family: Times New Roman; text-indent: 0px;"&gt;
     &lt;tbody&gt;
      &lt;tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;
       &lt;td style="font-family: Times New Roman; font-size: 10pt; padding: 0px; margin: 0px; width: 49%;"&gt; &lt;p style="margin-top: 0pt; margin-bottom: 0pt; font-family: Times New Roman; font-size: 10pt;"&gt;&lt;span style="color:#333333;"&gt;(in thousands, except for weighted-average data)&lt;/span&gt;&lt;/p&gt; &lt;/td&gt;
       &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0px; margin: 0px;"&gt;&#160;&lt;/td&gt;
       &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0px; margin: 0px;"&gt;&#160;&lt;/td&gt;
       &lt;td style="width: 14%; text-align: right; font-family: Times New Roman; font-size: 10pt; padding: 0px; margin: 0px;"&gt;&#160;&lt;/td&gt;
       &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0px; margin: 0px;"&gt;&#160;&lt;/td&gt;
       &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0px; margin: 0px;"&gt;&#160;&lt;/td&gt;
       &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0px; margin: 0px;"&gt;&#160;&lt;/td&gt;
       &lt;td style="width: 14%; text-align: right; font-family: Times New Roman; font-size: 10pt; padding: 0px; margin: 0px;"&gt;&#160;&lt;/td&gt;
       &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0px; margin: 0px;"&gt;&#160;&lt;/td&gt;
       &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0px; margin: 0px;"&gt;&#160;&lt;/td&gt;
       &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0px; margin: 0px;"&gt;&#160;&lt;/td&gt;
       &lt;td style="width: 14%; text-align: right; font-family: Times New Roman; font-size: 10pt; padding: 0px; margin: 0px;"&gt;&#160;&lt;/td&gt;
       &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0px; margin: 0px;"&gt;&#160;&lt;/td&gt;
      &lt;/tr&gt;

      &lt;tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;
       &lt;td style="font-family: Times New Roman; font-size: 10pt; width: 49%; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; text-align: center;"&gt;&lt;span style="color:#333333;"&gt;&lt;b&gt;Stock Options&lt;/b&gt;&lt;/span&gt;&lt;/p&gt; &lt;/td&gt;
       &lt;td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"&gt;&#160;&lt;/td&gt;
       &lt;td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); width: 1%;"&gt; &lt;p style="font-family: Times New Roman; font-size: 10pt; margin: 0pt; text-align: center;"&gt;&lt;span style="color:#333333;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;Shares&lt;/em&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt; &lt;/td&gt;
       &lt;td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; width: 1%;"&gt;&#160;&lt;/td&gt;
       &lt;td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"&gt;&#160;&lt;/td&gt;
       &lt;td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); width: 1%;"&gt; &lt;p style="font-family: Times New Roman; font-size: 10pt; margin: 0pt; text-align: center;"&gt;&lt;span style="color:#333333;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;Weighted- Average Exercise Price&lt;/em&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt; &lt;/td&gt;
       &lt;td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; width: 1%;"&gt;&#160;&lt;/td&gt;
       &lt;td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"&gt;&#160;&lt;/td&gt;
       &lt;td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); width: 1%;"&gt; &lt;p style="font-family: Times New Roman; font-size: 10pt; margin: 0pt; text-align: center;"&gt;&lt;span style="color:#333333;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;Weighted- Average Remaining Contractual Term (In Yrs)&lt;/em&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt; &lt;/td&gt;
       &lt;td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; width: 1%;"&gt;&#160;&lt;/td&gt;
      &lt;/tr&gt;

      &lt;tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;
       &lt;td style="font-family: Times New Roman; font-size: 10pt; width: 49%;"&gt;&#160;&lt;/td&gt;
       &lt;td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"&gt;&#160;&lt;/td&gt;
       &lt;td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"&gt;&#160;&lt;/td&gt;
       &lt;td style="font-family: Times New Roman; font-size: 10pt; width: 14%;"&gt;&#160;&lt;/td&gt;
       &lt;td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"&gt;&#160;&lt;/td&gt;
       &lt;td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"&gt;&#160;&lt;/td&gt;
       &lt;td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"&gt;&#160;&lt;/td&gt;
       &lt;td style="font-family: Times New Roman; font-size: 10pt; width: 14%;"&gt;&#160;&lt;/td&gt;
       &lt;td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"&gt;&#160;&lt;/td&gt;
       &lt;td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"&gt;&#160;&lt;/td&gt;
       &lt;td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"&gt;&#160;&lt;/td&gt;
       &lt;td style="font-family: Times New Roman; font-size: 10pt; width: 14%;"&gt;&#160;&lt;/td&gt;
       &lt;td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"&gt;&#160;&lt;/td&gt;
      &lt;/tr&gt;

      &lt;tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"&gt;
       &lt;td style="font-family: Times New Roman; font-size: 10pt; width: 49%;"&gt; &lt;p style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;span style="color:#333333;"&gt;Outstanding at January 1, 2022&lt;/span&gt;&lt;/p&gt; &lt;/td&gt;
       &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
       &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
       &lt;td style="width: 14%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&lt;span style="color:#333333;"&gt;3,387&lt;/span&gt;&lt;/td&gt;
       &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
       &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
       &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&lt;span style="color:#333333;"&gt;$&lt;/span&gt;&lt;/td&gt;
       &lt;td style="width: 14%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&lt;span style="color:#333333;"&gt;9.74&lt;/span&gt;&lt;/td&gt;
       &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
       &lt;td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"&gt;&#160;&lt;/td&gt;
       &lt;td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"&gt;&#160;&lt;/td&gt;
       &lt;td style="text-align: right; font-family: Times New Roman; font-size: 10pt; width: 14%;"&gt;&lt;em style="font: inherit;"&gt;&#160;&lt;/em&gt;&lt;/td&gt;
       &lt;td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"&gt;&#160;&lt;/td&gt;
      &lt;/tr&gt;

      &lt;tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;
       &lt;td style="font-family: Times New Roman; font-size: 10pt; width: 49%;"&gt; &lt;p style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 9pt;"&gt;&lt;span style="color:#333333;"&gt;Granted&lt;/span&gt;&lt;/p&gt; &lt;/td&gt;
       &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
       &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
       &lt;td style="width: 14%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&lt;span style="color:#333333;"&gt;880&lt;/span&gt;&lt;/td&gt;
       &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
       &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
       &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
       &lt;td style="width: 14%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&lt;span style="color:#333333;"&gt;0.99&lt;/span&gt;&lt;/td&gt;
       &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
       &lt;td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"&gt;&#160;&lt;/td&gt;
       &lt;td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"&gt;&#160;&lt;/td&gt;
       &lt;td style="text-align: right; font-family: Times New Roman; font-size: 10pt; width: 14%;"&gt;&lt;em style="font: inherit;"&gt;&#160;&lt;/em&gt;&lt;/td&gt;
       &lt;td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"&gt;&#160;&lt;/td&gt;
      &lt;/tr&gt;

      &lt;tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"&gt;
       &lt;td style="font-family: Times New Roman; font-size: 10pt; width: 49%;"&gt; &lt;p style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 9pt;"&gt;&lt;span style="color:#333333;"&gt;Forfeited or expired&lt;/span&gt;&lt;/p&gt; &lt;/td&gt;
       &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;
       &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;
       &lt;td style="width: 14%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&lt;span style="color:#333333;"&gt;(220&lt;/span&gt;&lt;/td&gt;
       &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"&gt;&lt;span style="color:#333333;"&gt;)&lt;/span&gt;&lt;/td&gt;
       &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;
       &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;
       &lt;td style="width: 14%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&lt;span style="color:#333333;"&gt;9.72&lt;/span&gt;&lt;/td&gt;
       &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;
       &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; width: 1%; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;
       &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; width: 1%; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;
       &lt;td style="text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; width: 14%; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&lt;em style="font: inherit;"&gt;&#160;&lt;/em&gt;&lt;/td&gt;
       &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; width: 1%; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;
      &lt;/tr&gt;

      &lt;tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;
       &lt;td style="font-family: Times New Roman; font-size: 10pt; width: 49%;"&gt; &lt;p style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;span style="color:#333333;"&gt;Outstanding at June 30, 2022&lt;/span&gt;&lt;/p&gt; &lt;/td&gt;
       &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; padding-bottom: 3px;"&gt;&#160;&lt;/td&gt;
       &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;
       &lt;td style="width: 14%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;&lt;span style="color:#333333;"&gt;4,047&lt;/span&gt;&lt;/td&gt;
       &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;"&gt;&#160;&lt;/td&gt;
       &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; padding-bottom: 3px;"&gt;&#160;&lt;/td&gt;
       &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;&lt;span style="color:#333333;"&gt;$&lt;/span&gt;&lt;/td&gt;
       &lt;td style="width: 14%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;&lt;span style="color:#333333;"&gt;7.84&lt;/span&gt;&lt;/td&gt;
       &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;"&gt;&#160;&lt;/td&gt;
       &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; padding-bottom: 3px;"&gt;&#160;&lt;/td&gt;
       &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;
       &lt;td style="width: 14%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;&lt;span style="color:#333333;"&gt;7.8&lt;/span&gt;&lt;/td&gt;
       &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;"&gt;&#160;&lt;/td&gt;
      &lt;/tr&gt;

      &lt;tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"&gt;
       &lt;td style="font-family: Times New Roman; font-size: 10pt; width: 49%;"&gt;&#160;&lt;/td&gt;
       &lt;td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"&gt;&#160;&lt;/td&gt;
       &lt;td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"&gt;&#160;&lt;/td&gt;
       &lt;td style="font-family: Times New Roman; font-size: 10pt; width: 14%;"&gt;&#160;&lt;/td&gt;
       &lt;td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"&gt;&#160;&lt;/td&gt;
       &lt;td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"&gt;&#160;&lt;/td&gt;
       &lt;td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"&gt;&#160;&lt;/td&gt;
       &lt;td style="font-family: Times New Roman; font-size: 10pt; width: 14%;"&gt;&#160;&lt;/td&gt;
       &lt;td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"&gt;&#160;&lt;/td&gt;
       &lt;td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"&gt;&#160;&lt;/td&gt;
       &lt;td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"&gt;&#160;&lt;/td&gt;
       &lt;td style="font-family: Times New Roman; font-size: 10pt; width: 14%;"&gt;&#160;&lt;/td&gt;
       &lt;td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"&gt;&#160;&lt;/td&gt;
      &lt;/tr&gt;

      &lt;tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;
       &lt;td style="font-family: Times New Roman; font-size: 10pt; width: 49%;"&gt; &lt;p style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;span style="color:#333333;"&gt;Vested and exercisable at June 30, 2022&lt;/span&gt;&lt;/p&gt; &lt;/td&gt;
       &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
       &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
       &lt;td style="width: 14%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt;&lt;span style="color:#333333;"&gt;2,229&lt;/span&gt;&lt;/td&gt;
       &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
       &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
       &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&lt;span style="color:#333333;"&gt;$&lt;/span&gt;&lt;/td&gt;
       &lt;td style="width: 14%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&lt;span style="color:#333333;"&gt;11.35&lt;/span&gt;&lt;/td&gt;
       &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
       &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
       &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
       &lt;td style="width: 14%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&lt;span style="color:#333333;"&gt;6.8&lt;/span&gt;&lt;/td&gt;
       &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
      &lt;/tr&gt;

      &lt;tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"&gt;
       &lt;td style="padding: 0px; margin: 0px; font-family: Times New Roman; font-size: 10pt; width: 49%;"&gt;&#160;&lt;/td&gt;
       &lt;td style="padding: 0px; margin: 0px; font-family: Times New Roman; font-size: 10pt; width: 1%;"&gt;&#160;&lt;/td&gt;
       &lt;td style="padding: 0px; margin: 0px; font-family: Times New Roman; font-size: 10pt; width: 1%;"&gt;&#160;&lt;/td&gt;
       &lt;td style="padding: 0px; margin: 0px; font-family: Times New Roman; font-size: 10pt; width: 14%;"&gt;&#160;&lt;/td&gt;
       &lt;td style="padding: 0px; margin: 0px; font-family: Times New Roman; font-size: 10pt; width: 1%;"&gt;&#160;&lt;/td&gt;
       &lt;td style="padding: 0px; margin: 0px; font-family: Times New Roman; font-size: 10pt; width: 1%;"&gt;&#160;&lt;/td&gt;
       &lt;td style="padding: 0px; margin: 0px; font-family: Times New Roman; font-size: 10pt; width: 1%;"&gt;&#160;&lt;/td&gt;
       &lt;td style="padding: 0px; margin: 0px; font-family: Times New Roman; font-size: 10pt; width: 14%;"&gt;&#160;&lt;/td&gt;
       &lt;td style="padding: 0px; margin: 0px; font-family: Times New Roman; font-size: 10pt; width: 1%;"&gt;&#160;&lt;/td&gt;
       &lt;td style="padding: 0px; margin: 0px; font-family: Times New Roman; font-size: 10pt; width: 1%;"&gt;&#160;&lt;/td&gt;
       &lt;td style="padding: 0px; margin: 0px; font-family: Times New Roman; font-size: 10pt; width: 1%;"&gt;&#160;&lt;/td&gt;
       &lt;td style="padding: 0px; margin: 0px; font-family: Times New Roman; font-size: 10pt; width: 14%;"&gt;&#160;&lt;/td&gt;
       &lt;td style="padding: 0px; margin: 0px; font-family: Times New Roman; font-size: 10pt; width: 1%;"&gt;&#160;&lt;/td&gt;
      &lt;/tr&gt;

      &lt;tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;
       &lt;td style="font-family: Times New Roman; font-size: 10pt; width: 49%;"&gt; &lt;p style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;span style="color:#333333;"&gt;Vested and expected to vest at June 30, 2022&lt;/span&gt;&lt;/p&gt; &lt;/td&gt;
       &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
       &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
       &lt;td style="width: 14%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt;&lt;span style="color:#333333;"&gt;3,821&lt;/span&gt;&lt;/td&gt;
       &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
       &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
       &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&lt;span style="color:#333333;"&gt;$&lt;/span&gt;&lt;/td&gt;
       &lt;td style="width: 14%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&lt;span style="color:#333333;"&gt;7.85&lt;/span&gt;&lt;/td&gt;
       &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
       &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
       &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
       &lt;td style="width: 14%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&lt;span style="color:#333333;"&gt;7.8&lt;/span&gt;&lt;/td&gt;
       &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
      &lt;/tr&gt;

     &lt;/tbody&gt;
    &lt;/table&gt;
   </us-gaap:DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="i_2021-12-31"
      decimals="-3"
      id="c86425439"
      unitRef="Share">3387000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="i_2021-12-31"
      decimals="INF"
      id="c86425440"
      unitRef="USDPerShare">9.74</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="d_2022-01-01_2022-06-30"
      decimals="-4"
      id="c86425442"
      unitRef="Share">880000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
      contextRef="d_2022-01-01_2022-06-30"
      decimals="INF"
      id="c86425443"
      unitRef="USDPerShare">0.99</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod
      contextRef="d_2022-01-01_2022-06-30"
      decimals="-4"
      id="c86425445"
      unitRef="Share">220000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice
      contextRef="d_2022-01-01_2022-06-30"
      decimals="INF"
      id="c86425446"
      unitRef="USDPerShare">9.72</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="i_2022-06-30"
      decimals="-3"
      id="c86425448"
      unitRef="Share">4047000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="i_2022-06-30"
      decimals="INF"
      id="c86425449"
      unitRef="USDPerShare">7.84</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2 contextRef="d_2022-01-01_2022-06-30" id="c86425450">P7Y9M18D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
      contextRef="i_2022-06-30"
      decimals="-3"
      id="c86425451"
      unitRef="Share">2229000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
      contextRef="i_2022-06-30"
      decimals="INF"
      id="c86425452"
      unitRef="USDPerShare">11.35</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1 contextRef="d_2022-01-01_2022-06-30" id="c86425453">P6Y9M18D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber
      contextRef="i_2022-06-30"
      decimals="-3"
      id="c86425454"
      unitRef="Share">3821000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice
      contextRef="i_2022-06-30"
      decimals="INF"
      id="c86425455"
      unitRef="USDPerShare">7.85</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1 contextRef="d_2022-01-01_2022-06-30" id="c86425456">P7Y9M18D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1>
    <us-gaap:ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock contextRef="d_2022-01-01_2022-06-30" id="c2175910">
    &lt;table cellpadding="0" cellspacing="0" class="finTable" style="width: 80%; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; text-indent: 0px; margin-left: 0pt; margin-right: auto;"&gt;
     &lt;tbody&gt;
      &lt;tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;
       &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; width: 58%;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;span style="color:#333333;"&gt;(in thousands, except for weighted-average data)&lt;/span&gt;&lt;/p&gt; &lt;/td&gt;
       &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; width: 1%;"&gt;&#160;&lt;/td&gt;
       &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; width: 1%;"&gt;&#160;&lt;/td&gt;
       &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; width: 16%;"&gt;&#160;&lt;/td&gt;
       &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; width: 1%;"&gt;&#160;&lt;/td&gt;
       &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; width: 1%;"&gt;&#160;&lt;/td&gt;
       &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; width: 1%;"&gt;&#160;&lt;/td&gt;
       &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; width: 20%;"&gt;&#160;&lt;/td&gt;
       &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; width: 1%;"&gt;&#160;&lt;/td&gt;
      &lt;/tr&gt;

      &lt;tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;
       &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; width: 58%; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; text-align: center;"&gt;&lt;span style="color:#333333;"&gt;&lt;b&gt;Restricted Stock Units&lt;/b&gt;&lt;/span&gt;&lt;/p&gt; &lt;/td&gt;
       &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; width: 1%;"&gt;&#160;&lt;/td&gt;
       &lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); width: 1%;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;span style="color:#333333;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;Shares&lt;/em&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt; &lt;/td&gt;
       &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; padding-bottom: 1px; width: 1%;"&gt;&#160;&lt;/td&gt;
       &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; width: 1%;"&gt;&#160;&lt;/td&gt;
       &lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); width: 1%;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;span style="color:#333333;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;Weighted- Average Grant Date Fair Value&lt;/em&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt; &lt;/td&gt;
       &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; padding-bottom: 1px; width: 1%;"&gt;&#160;&lt;/td&gt;
      &lt;/tr&gt;

      &lt;tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;
       &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; width: 58%;"&gt;&#160;&lt;/td&gt;
       &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; width: 1%;"&gt;&#160;&lt;/td&gt;
       &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; width: 1%;"&gt;&#160;&lt;/td&gt;
       &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; width: 16%;"&gt;&#160;&lt;/td&gt;
       &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; width: 1%;"&gt;&#160;&lt;/td&gt;
       &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; width: 1%;"&gt;&#160;&lt;/td&gt;
       &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; width: 1%;"&gt;&#160;&lt;/td&gt;
       &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; width: 20%;"&gt;&#160;&lt;/td&gt;
       &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; width: 1%;"&gt;&#160;&lt;/td&gt;
      &lt;/tr&gt;

      &lt;tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"&gt;
       &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; width: 58%;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;span style="color:#333333;"&gt;Outstanding at January 1, 2022&lt;/span&gt;&lt;/p&gt; &lt;/td&gt;
       &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
       &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
       &lt;td style="width: 16%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt;&lt;span style="color:#333333;"&gt;-&lt;/span&gt;&lt;/td&gt;
       &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
       &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
       &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt;&lt;span style="color:#333333;"&gt;$&lt;/span&gt;&lt;/td&gt;
       &lt;td style="width: 20%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt;&lt;span style="color:#333333;"&gt;-&lt;/span&gt;&lt;/td&gt;
       &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
      &lt;/tr&gt;

      &lt;tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;
       &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; width: 58%;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; text-indent: 9pt;"&gt;&lt;span style="color:#333333;"&gt;Awarded&lt;/span&gt;&lt;/p&gt; &lt;/td&gt;
       &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
       &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
       &lt;td style="width: 16%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt;&lt;span style="color:#333333;"&gt;582&lt;/span&gt;&lt;/td&gt;
       &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
       &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
       &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
       &lt;td style="width: 20%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt;&lt;span style="color:#333333;"&gt;0.99&lt;/span&gt;&lt;/td&gt;
       &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
      &lt;/tr&gt;

      &lt;tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"&gt;
       &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; width: 58%; padding-top: 0px; padding-right: 0px; padding-left: 0px; margin: 0px;"&gt; &lt;p style="margin-top: 0pt; margin-bottom: 0pt; text-indent: 9pt;"&gt;&lt;span style="color:#333333;"&gt;Cancelled&lt;/span&gt;&lt;/p&gt; &lt;/td&gt;
       &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; padding: 0px 0px 1px; margin: 0px;"&gt;&#160;&lt;/td&gt;
       &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; padding-top: 0px; padding-right: 0px; padding-left: 0px; margin: 0px; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;
       &lt;td style="width: 16%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; padding-top: 0px; padding-right: 0px; padding-left: 0px; margin: 0px; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&lt;span style="color:#333333;"&gt;(21&lt;/span&gt;&lt;/td&gt;
       &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; padding: 0px 0px 1px; margin: 0px;"&gt;&lt;span style="color:#333333;"&gt;)&lt;/span&gt;&lt;/td&gt;
       &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; padding: 0px 0px 1px; margin: 0px;"&gt;&#160;&lt;/td&gt;
       &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; padding-top: 0px; padding-right: 0px; padding-left: 0px; margin: 0px; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;
       &lt;td style="width: 20%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; padding-top: 0px; padding-right: 0px; padding-left: 0px; margin: 0px; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&lt;span style="color:#333333;"&gt;1.02&lt;/span&gt;&lt;/td&gt;
       &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; padding: 0px 0px 1px; margin: 0px;"&gt;&#160;&lt;/td&gt;
      &lt;/tr&gt;

      &lt;tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;
       &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; width: 58%;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;span style="color:#333333;"&gt;Outstanding at June 30, 2022&lt;/span&gt;&lt;/p&gt; &lt;/td&gt;
       &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; padding-bottom: 3px;"&gt;&#160;&lt;/td&gt;
       &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;
       &lt;td style="width: 16%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;&lt;span style="color:#333333;"&gt;561&lt;/span&gt;&lt;/td&gt;
       &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;"&gt;&#160;&lt;/td&gt;
       &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; padding-bottom: 3px;"&gt;&#160;&lt;/td&gt;
       &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;&lt;span style="color:#333333;"&gt;$&lt;/span&gt;&lt;/td&gt;
       &lt;td style="width: 20%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;&lt;span style="color:#333333;"&gt;0.99&lt;/span&gt;&lt;/td&gt;
       &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;"&gt;&#160;&lt;/td&gt;
      &lt;/tr&gt;

      &lt;tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"&gt;
       &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; width: 58%; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;
       &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; width: 1%; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;
       &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; width: 1%; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;
       &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; width: 16%; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;
       &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; width: 1%; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;
       &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; width: 1%; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;
       &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; width: 1%; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;
       &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; width: 20%; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;
       &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; width: 1%; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;
      &lt;/tr&gt;

      &lt;tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;
       &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; width: 58%; padding: 0; margin: 0"&gt; &lt;p style="margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;span style="color:#333333;"&gt;Vested and exercisable at June 30, 2022&lt;/span&gt;&lt;/p&gt; &lt;/td&gt;
       &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;
       &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;
       &lt;td style="width: 16%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; padding: 0; margin: 0"&gt;&lt;span style="color:#333333;"&gt;-&lt;/span&gt;&lt;/td&gt;
       &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;
       &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;
       &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; padding: 0; margin: 0"&gt;&lt;span style="color:#333333;"&gt;$&lt;/span&gt;&lt;/td&gt;
       &lt;td style="width: 20%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; padding: 0; margin: 0"&gt;&lt;span style="color:#333333;"&gt;-&lt;/span&gt;&lt;/td&gt;
       &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;
      &lt;/tr&gt;

      &lt;tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"&gt;
       &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; width: 58%; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;
       &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; width: 1%; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;
       &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; width: 1%; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;
       &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; width: 16%; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;
       &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; width: 1%; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;
       &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; width: 1%; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;
       &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; width: 1%; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;
       &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; width: 20%; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;
       &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; width: 1%; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;
      &lt;/tr&gt;

      &lt;tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;
       &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; width: 58%; padding: 0; margin: 0"&gt; &lt;p style="margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;span style="color:#333333;"&gt;Vested and expected to vest at June 30, 2022&lt;/span&gt;&lt;/p&gt; &lt;/td&gt;
       &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;
       &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;
       &lt;td style="width: 16%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; padding: 0; margin: 0"&gt;&lt;span style="color:#333333;"&gt;561&lt;/span&gt;&lt;/td&gt;
       &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;
       &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;
       &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; padding: 0; margin: 0"&gt;&lt;span style="color:#333333;"&gt;$&lt;/span&gt;&lt;/td&gt;
       &lt;td style="width: 20%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; padding: 0; margin: 0"&gt;&lt;span style="color:#333333;"&gt;0.99&lt;/span&gt;&lt;/td&gt;
       &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;
      &lt;/tr&gt;

     &lt;/tbody&gt;
    &lt;/table&gt;
   </us-gaap:ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="i_2021-12-31_AwardTypeAxis-RestrictedStockUnitsRSUMember"
      decimals="-3"
      id="c86425459"
      unitRef="Share">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
      contextRef="i_2021-12-31_AwardTypeAxis-RestrictedStockUnitsRSUMember"
      decimals="INF"
      id="c86425460"
      unitRef="USDPerShare">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
      contextRef="d_2022-01-01_2022-06-30_AwardTypeAxis-RestrictedStockUnitsRSUMember"
      decimals="-3"
      id="c86425461"
      unitRef="Share">582000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="d_2022-01-01_2022-06-30_AwardTypeAxis-RestrictedStockUnitsRSUMember"
      decimals="INF"
      id="c86425462"
      unitRef="USDPerShare">0.99</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod
      contextRef="d_2022-01-01_2022-06-30_AwardTypeAxis-RestrictedStockUnitsRSUMember"
      decimals="INF"
      id="c86425463"
      unitRef="Share">21</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue
      contextRef="d_2022-01-01_2022-06-30_AwardTypeAxis-RestrictedStockUnitsRSUMember"
      decimals="INF"
      id="c86425464"
      unitRef="USDPerShare">1.02</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="i_2022-06-30_AwardTypeAxis-RestrictedStockUnitsRSUMember"
      decimals="-3"
      id="c86425465"
      unitRef="Share">561000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
      contextRef="i_2022-06-30_AwardTypeAxis-RestrictedStockUnitsRSUMember"
      decimals="INF"
      id="c86425466"
      unitRef="USDPerShare">0.99</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue>
    <wint:SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndExercisable
      contextRef="i_2022-06-30_AwardTypeAxis-RestrictedStockUnitsRSUMember"
      decimals="-3"
      id="c86425467"
      unitRef="Share">0</wint:SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndExercisable>
    <wint:SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndExercisableWeightedAverageGrantDateFairValueEndingBalance
      contextRef="i_2022-06-30_AwardTypeAxis-RestrictedStockUnitsRSUMember"
      decimals="INF"
      id="c86425468"
      unitRef="USDPerShare">0</wint:SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndExercisableWeightedAverageGrantDateFairValueEndingBalance>
    <wint:SharebasedCompensationArrangementBySharebasedPaymentAwardEquityOtherThanOptionsVestedAndExpectedToVestOutstandingNumber
      contextRef="i_2022-06-30_AwardTypeAxis-RestrictedStockUnitsRSUMember"
      decimals="-3"
      id="c86425469"
      unitRef="Share">561000</wint:SharebasedCompensationArrangementBySharebasedPaymentAwardEquityOtherThanOptionsVestedAndExpectedToVestOutstandingNumber>
    <wint:SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndExpectedToVestWeightedAverageGrantDateFairValueEndingBalance
      contextRef="i_2022-06-30_AwardTypeAxis-RestrictedStockUnitsRSUMember"
      decimals="INF"
      id="c86425470"
      unitRef="USDPerShare">0.99</wint:SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndExpectedToVestWeightedAverageGrantDateFairValueEndingBalance>
    <us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock contextRef="d_2022-01-01_2022-06-30" id="c2175911">
    &lt;table border="0" cellpadding="0" cellspacing="0" class="finTable" style="margin-right: 20%; width: 80%; font-size: 10pt; font-family: Times New Roman; text-indent: 0px;"&gt;
     &lt;tbody&gt;
      &lt;tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;
       &lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
       &lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
       &lt;td colspan="6" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;&lt;span style="color:#333333;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;&lt;em style="font: inherit;"&gt;Three Months Ended June 30,&lt;/em&gt;&lt;/em&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt; &lt;/td&gt;
       &lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
       &lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
       &lt;td colspan="6" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;&lt;span style="color:#333333;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;&lt;em style="font: inherit;"&gt;Six Months Ended June 30,&lt;/em&gt;&lt;/em&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt; &lt;/td&gt;
       &lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
      &lt;/tr&gt;

      &lt;tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;
       &lt;td style="font-family: Times New Roman; font-size: 10pt; width: 36%;"&gt; &lt;p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;span style="color:#333333;"&gt;&lt;i&gt;(in thousands)&lt;/i&gt;&lt;/span&gt;&lt;/p&gt; &lt;/td&gt;
       &lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
       &lt;td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;&lt;span style="color:#333333;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;2022&lt;/em&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt; &lt;/td&gt;
       &lt;td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;
       &lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
       &lt;td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;&lt;span style="color:#333333;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;2021&lt;/em&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt; &lt;/td&gt;
       &lt;td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;
       &lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
       &lt;td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;&lt;span style="color:#333333;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;2022&lt;/em&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt; &lt;/td&gt;
       &lt;td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;
       &lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
       &lt;td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;&lt;span style="color:#333333;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;2021&lt;/em&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt; &lt;/td&gt;
       &lt;td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;
      &lt;/tr&gt;

      &lt;tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;
       &lt;td&gt;&#160;&lt;/td&gt;
       &lt;td&gt;&#160;&lt;/td&gt;
       &lt;td&gt;&#160;&lt;/td&gt;
       &lt;td&gt;&#160;&lt;/td&gt;
       &lt;td&gt;&#160;&lt;/td&gt;
       &lt;td&gt;&#160;&lt;/td&gt;
       &lt;td&gt;&#160;&lt;/td&gt;
       &lt;td&gt;&#160;&lt;/td&gt;
       &lt;td&gt;&#160;&lt;/td&gt;
       &lt;td&gt;&#160;&lt;/td&gt;
       &lt;td&gt;&#160;&lt;/td&gt;
       &lt;td&gt;&#160;&lt;/td&gt;
       &lt;td&gt;&#160;&lt;/td&gt;
       &lt;td&gt;&#160;&lt;/td&gt;
       &lt;td&gt;&#160;&lt;/td&gt;
       &lt;td&gt;&#160;&lt;/td&gt;
       &lt;td&gt;&#160;&lt;/td&gt;
      &lt;/tr&gt;

      &lt;tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"&gt;
       &lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt; &lt;p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;span style="color:#333333;"&gt;Research and development&lt;/span&gt;&lt;/p&gt; &lt;/td&gt;
       &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
       &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&lt;span style="color:#333333;"&gt;$&lt;/span&gt;&lt;/td&gt;
       &lt;td style="width: 13%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&lt;span style="color:#333333;"&gt;147&lt;/span&gt;&lt;/td&gt;
       &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
       &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
       &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&lt;span style="color:#333333;"&gt;$&lt;/span&gt;&lt;/td&gt;
       &lt;td style="width: 13%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&lt;span style="color:#333333;"&gt;630&lt;/span&gt;&lt;/td&gt;
       &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
       &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
       &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&lt;span style="color:#333333;"&gt;$&lt;/span&gt;&lt;/td&gt;
       &lt;td style="width: 13%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&lt;span style="color:#333333;"&gt;382&lt;/span&gt;&lt;/td&gt;
       &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
       &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
       &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&lt;span style="color:#333333;"&gt;$&lt;/span&gt;&lt;/td&gt;
       &lt;td style="width: 13%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&lt;span style="color:#333333;"&gt;1,569&lt;/span&gt;&lt;/td&gt;
       &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
      &lt;/tr&gt;

      &lt;tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;
       &lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt; &lt;p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;span style="color:#333333;"&gt;General and administrative&lt;/span&gt;&lt;/p&gt; &lt;/td&gt;
       &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
       &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;
       &lt;td style="width: 13%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&lt;span style="color:#333333;"&gt;634&lt;/span&gt;&lt;/td&gt;
       &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
       &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
       &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;
       &lt;td style="width: 13%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&lt;span style="color:#333333;"&gt;914&lt;/span&gt;&lt;/td&gt;
       &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
       &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
       &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;
       &lt;td style="width: 13%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&lt;span style="color:#333333;"&gt;1,169&lt;/span&gt;&lt;/td&gt;
       &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
       &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
       &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;
       &lt;td style="width: 13%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&lt;span style="color:#333333;"&gt;2,418&lt;/span&gt;&lt;/td&gt;
       &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
      &lt;/tr&gt;

      &lt;tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"&gt;
       &lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt; &lt;p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 18pt;"&gt;&lt;span style="color:#333333;"&gt;Total&lt;/span&gt;&lt;/p&gt; &lt;/td&gt;
       &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
       &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;&lt;span style="color:#333333;"&gt;$&lt;/span&gt;&lt;/td&gt;
       &lt;td style="width: 13%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;&lt;span style="color:#333333;"&gt;781&lt;/span&gt;&lt;/td&gt;
       &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
       &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
       &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;&lt;span style="color:#333333;"&gt;$&lt;/span&gt;&lt;/td&gt;
       &lt;td style="width: 13%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;&lt;span style="color:#333333;"&gt;1,544&lt;/span&gt;&lt;/td&gt;
       &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
       &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
       &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;&lt;span style="color:#333333;"&gt;$&lt;/span&gt;&lt;/td&gt;
       &lt;td style="width: 13%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;&lt;span style="color:#333333;"&gt;1,551&lt;/span&gt;&lt;/td&gt;
       &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
       &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
       &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;&lt;span style="color:#333333;"&gt;$&lt;/span&gt;&lt;/td&gt;
       &lt;td style="width: 13%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;&lt;span style="color:#333333;"&gt;3,987&lt;/span&gt;&lt;/td&gt;
       &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
      &lt;/tr&gt;

     &lt;/tbody&gt;
    &lt;/table&gt;
   </us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="d_2022-04-01_2022-06-30_IncomeStatementLocationAxis-ResearchAndDevelopmentExpenseMember"
      decimals="-3"
      id="c86425479"
      unitRef="USD">147000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="d_2021-04-01_2021-06-30_IncomeStatementLocationAxis-ResearchAndDevelopmentExpenseMember"
      decimals="-4"
      id="c86425480"
      unitRef="USD">630000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="d_2022-01-01_2022-06-30_IncomeStatementLocationAxis-ResearchAndDevelopmentExpenseMember"
      decimals="-3"
      id="c86425481"
      unitRef="USD">382000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="d_2021-01-01_2021-06-30_IncomeStatementLocationAxis-ResearchAndDevelopmentExpenseMember"
      decimals="-3"
      id="c86425482"
      unitRef="USD">1569000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="d_2022-04-01_2022-06-30_IncomeStatementLocationAxis-SellingGeneralAndAdministrativeExpensesMember"
      decimals="-3"
      id="c86425483"
      unitRef="USD">634000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="d_2021-04-01_2021-06-30_IncomeStatementLocationAxis-SellingGeneralAndAdministrativeExpensesMember"
      decimals="-3"
      id="c86425484"
      unitRef="USD">914000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="d_2022-01-01_2022-06-30_IncomeStatementLocationAxis-SellingGeneralAndAdministrativeExpensesMember"
      decimals="-3"
      id="c86425485"
      unitRef="USD">1169000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="d_2021-01-01_2021-06-30_IncomeStatementLocationAxis-SellingGeneralAndAdministrativeExpensesMember"
      decimals="-3"
      id="c86425486"
      unitRef="USD">2418000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="d_2022-04-01_2022-06-30"
      decimals="-3"
      id="c86425487"
      unitRef="USD">781000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="d_2021-04-01_2021-06-30"
      decimals="-3"
      id="c86425488"
      unitRef="USD">1544000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="d_2022-01-01_2022-06-30"
      decimals="-3"
      id="c86425489"
      unitRef="USD">1551000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="d_2021-01-01_2021-06-30"
      decimals="-3"
      id="c86425490"
      unitRef="USD">3987000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock contextRef="d_2022-01-01_2022-06-30" id="c2175912">
    &lt;table border="0" cellpadding="0" cellspacing="0" class="finTable" style="margin-right: 20%; width: 80%; font-size: 10pt; font-family: Times New Roman; text-indent: 0px;"&gt;
     &lt;tbody&gt;
      &lt;tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;
       &lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
       &lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
       &lt;td colspan="6" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;&lt;span style="color:#333333;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;&lt;em style="font: inherit;"&gt;Six Months Ended June 30,&lt;/em&gt;&lt;/em&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt; &lt;/td&gt;
       &lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
      &lt;/tr&gt;

      &lt;tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;
       &lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
       &lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
       &lt;td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;&lt;span style="color:#333333;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;2022&lt;/em&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt; &lt;/td&gt;
       &lt;td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;
       &lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
       &lt;td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;&lt;span style="color:#333333;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;2021&lt;/em&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt; &lt;/td&gt;
       &lt;td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;
      &lt;/tr&gt;

      &lt;tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;
       &lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
       &lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
       &lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
       &lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
       &lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
       &lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
       &lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
       &lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
       &lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
      &lt;/tr&gt;

      &lt;tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"&gt;
       &lt;td style="font-family: Times New Roman; font-size: 10pt; width: 62%;"&gt; &lt;p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;span style="color:#333333;"&gt;Weighted average expected volatility&lt;/span&gt;&lt;/p&gt; &lt;/td&gt;
       &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
       &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
       &lt;td style="width: 16%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: center;"&gt; &lt;p style="margin-top: 0pt; margin-bottom: 0pt; font-family: Times New Roman; font-size: 10pt;"&gt;&lt;span style="color:#333333;"&gt;106%&lt;/span&gt;&lt;/p&gt; &lt;/td&gt;
       &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
       &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
       &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
       &lt;td style="width: 16%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: center;"&gt; &lt;p style="margin-top: 0pt; margin-bottom: 0pt; font-family: Times New Roman; font-size: 10pt;"&gt;&lt;span style="color:#333333;"&gt;105%&lt;/span&gt;&lt;/p&gt; &lt;/td&gt;
       &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
      &lt;/tr&gt;

      &lt;tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;
       &lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt; &lt;p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;span style="color:#333333;"&gt;Weighted average expected term (in years)&lt;/span&gt;&lt;/p&gt; &lt;/td&gt;
       &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
       &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
       &lt;td style="width: 16%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: center;"&gt; &lt;p style="margin-top: 0pt; margin-bottom: 0pt; font-family: Times New Roman; font-size: 10pt;"&gt;&lt;span style="color:#333333;"&gt;6.9&lt;/span&gt;&lt;/p&gt; &lt;/td&gt;
       &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
       &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
       &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
       &lt;td style="width: 16%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: center;"&gt; &lt;p style="margin-top: 0pt; margin-bottom: 0pt; font-family: Times New Roman; font-size: 10pt;"&gt;&lt;span style="color:#333333;"&gt;6.7&lt;/span&gt;&lt;/p&gt; &lt;/td&gt;
       &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
      &lt;/tr&gt;

      &lt;tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"&gt;
       &lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt; &lt;p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;span style="color:#333333;"&gt;Weighted average risk-free interest rate&lt;/span&gt;&lt;/p&gt; &lt;/td&gt;
       &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
       &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
       &lt;td style="width: 16%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: center;"&gt; &lt;p style="margin-top: 0pt; margin-bottom: 0pt; font-family: Times New Roman; font-size: 10pt;"&gt;&lt;span style="color:#333333;"&gt;1.70%&lt;/span&gt;&lt;/p&gt; &lt;/td&gt;
       &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
       &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
       &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
       &lt;td style="width: 16%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: center;"&gt; &lt;p style="margin-top: 0pt; margin-bottom: 0pt; font-family: Times New Roman; font-size: 10pt;"&gt;&lt;span style="color:#333333;"&gt;0.48%&lt;/span&gt;&lt;/p&gt; &lt;/td&gt;
       &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
      &lt;/tr&gt;

      &lt;tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;
       &lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt; &lt;p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;span style="color:#333333;"&gt;Expected dividends&lt;/span&gt;&lt;/p&gt; &lt;/td&gt;
       &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
       &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
       &lt;td style="width: 16%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: center;"&gt;&lt;em style="font: inherit;"&gt; &lt;/em&gt;&lt;p style="margin-top: 0pt; margin-bottom: 0pt; font-family: Times New Roman; font-size: 10pt;"&gt;&lt;span style="color:#333333;"&gt;-&lt;/span&gt;&lt;/p&gt; &lt;/td&gt;
       &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
       &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
       &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
       &lt;td style="width: 16%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: center;"&gt;&lt;em style="font: inherit;"&gt; &lt;/em&gt;&lt;p style="margin-top: 0pt; margin-bottom: 0pt; font-family: Times New Roman; font-size: 10pt;"&gt;&lt;span style="color:#333333;"&gt;-&lt;/span&gt;&lt;/p&gt; &lt;/td&gt;
       &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
      &lt;/tr&gt;

     &lt;/tbody&gt;
    &lt;/table&gt;
   </us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate
      contextRef="d_2022-01-01_2022-06-30"
      decimals="2"
      id="c86425495"
      unitRef="Pure">1.06</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate
      contextRef="d_2021-01-01_2021-06-30"
      decimals="2"
      id="c86425496"
      unitRef="Pure">1.05</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 contextRef="d_2022-01-01_2022-06-30" id="c86425497">P6Y10M24D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 contextRef="d_2021-01-01_2021-06-30" id="c86425498">P6Y8M12D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="d_2022-01-01_2022-06-30"
      decimals="3"
      id="c86425499"
      unitRef="Pure">0.0170</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="d_2021-01-01_2021-06-30"
      decimals="4"
      id="c86425500"
      unitRef="Pure">0.0048</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <wint:CorporatePartnershipLicensingAndResearchFundingAgreementsTextBlock contextRef="d_2022-01-01_2022-06-30" id="c2175913">

   &lt;p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"&gt;&lt;span style="color:#333333;"&gt;&lt;b&gt;Note &lt;em style="font: inherit;"&gt;10&lt;/em&gt; &#x2013; Licensing&#160;and Research Funding Agreements&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"&gt;&lt;span style="color:#333333;"&gt;In &lt;em style="font: inherit;"&gt; March 2020, &lt;/em&gt;we entered into a Term Sheet with Lee&#x2019;s (HK), pursuant to which Lee&#x2019;s (HK) provided financing for the development of AEROSURF. In &lt;em style="font: inherit;"&gt; August 2020,&#160;&lt;/em&gt;we entered into a Project Financing Agreement with&#160;Lee&#x2019;s (HK), or the&#160;PF Agreement, formalizing the terms of the Term Sheet, and&#160;under which we received payments totaling&#160;$2.8&#160;million&#160;through &lt;em style="font: inherit;"&gt; October 2020.&#160;&lt;/em&gt;In &lt;em style="font: inherit;"&gt; November 2020, &lt;/em&gt;Lee&#x2019;s (HK) provided notice of termination of&#160;additional funding under&#160;the PF Agreement, and we and Lee&#x2019;s (HK) revised our plans for the continued development of AEROSURF. Lee&#x2019;s (HK) agreed to continue the development of AEROSURF in Asia at its cost. Lee&#x2019;s (HK) agreed to&#160;fund an additional&#160;&lt;/span&gt;&lt;span style="color:#333333;"&gt;$1.0&lt;/span&gt;&lt;span style="color:#333333;"&gt; million to us&#160;in &lt;em style="font: inherit;"&gt;2021&lt;/em&gt; for certain transition and analytical services to be provided by us with respect to the development of AEROSURF, which will be considered &#x201c;Project Expenses&#x201d; under the terms of the PF Agreement.&#160;In&#160;&lt;em style="font: inherit;"&gt;2021,&lt;/em&gt;&#160;we received payments totaling&#160;$1.0&#160;million from&#160;Lee&#x2019;s (HK) and&#160;&lt;em style="font: inherit;"&gt;no&lt;/em&gt;&#160;further amounts are due under the PF Agreement.&lt;/span&gt;&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"&gt;&lt;span style="color:#333333;"&gt;To repay the funds provided under the terms of the PF Agreement, until such time as we have repaid &lt;/span&gt;&lt;span style="color:#333333;"&gt;125%&lt;/span&gt;&lt;span style="color:#333333;"&gt;&#160;of the amounts funded by Lee&#x2019;s (HK) for the development of AEROSURF, we will pay to Lee&#x2019;s (HK)&#160;&lt;/span&gt;&lt;span style="color:#333333;"&gt;50%&lt;/span&gt;&lt;span style="color:#333333;"&gt; of all revenue amounts and payments received by us for any sale, divestiture, license or other development and/or commercialization of the &lt;em style="font: inherit;"&gt;KL4/AEROSURF&lt;/em&gt; patent portfolio, excluding (i) payments for bona fide research and development services; (ii) reimbursement of patent expenses and (iii) all amounts paid to us under the Asia License Agreement, minus certain deductions and certain reductions for any payments made by us with respect to &lt;em style="font: inherit;"&gt;third&lt;/em&gt; party intellectual property &lt;em style="font: inherit;"&gt;not&lt;/em&gt; previously funded by Lee&#x2019;s (HK).&lt;/span&gt;&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"&gt;&lt;span style="color:#333333;"&gt;As of &lt;/span&gt;&lt;span style="color:#333333;"&gt;&lt;em style="font: inherit;"&gt; June 30, 2022&lt;/em&gt;&lt;/span&gt;&lt;span style="color:#333333;"&gt;, the liability balance related to the payments under the PF Agreement was&#160;&lt;/span&gt;&lt;span style="color:#333333;"&gt;$3.8&lt;/span&gt;&lt;span style="color:#333333;"&gt;&#160;million and is recorded in other liabilities.&lt;/span&gt;&lt;/p&gt;
  </wint:CorporatePartnershipLicensingAndResearchFundingAgreementsTextBlock>
    <wint:NonrefundablePayments
      contextRef="d_2020-08-01_2020-10-31_CounterpartyNameAxis-LeesPharmaceuticalHoldingsLimitedMember_TypeOfArrangementAxis-AerosurfFundingTermSheetMember"
      decimals="-5"
      id="c86425505"
      unitRef="USD">2800000</wint:NonrefundablePayments>
    <wint:ProceedsForPaymentsToDevelopProduct
      contextRef="d_2021-01-01_2021-12-31_TypeOfArrangementAxis-TermSheetWithLeeMember"
      decimals="-6"
      id="c86425506"
      unitRef="USD">1000000.0</wint:ProceedsForPaymentsToDevelopProduct>
    <wint:ProceedsForPaymentsToDevelopProduct
      contextRef="d_2021-01-01_2021-12-31_TypeOfArrangementAxis-TermSheetWithLeeMember"
      decimals="-6"
      id="c86425509"
      unitRef="USD">1000000.0</wint:ProceedsForPaymentsToDevelopProduct>
    <wint:FinancingOfProductPercentOfFinancingThatMustBeRepaidToDiscontinueRevenueSharing
      contextRef="i_2020-03-18_TypeOfArrangementAxis-TermSheetWithLeeMember"
      decimals="2"
      id="c86425511"
      unitRef="Pure">1.25</wint:FinancingOfProductPercentOfFinancingThatMustBeRepaidToDiscontinueRevenueSharing>
    <wint:FinancingOfProductPercentOfRevenueSharedWithFinancer
      contextRef="i_2020-03-18_TypeOfArrangementAxis-TermSheetWithLeeMember"
      decimals="1"
      id="c86425512"
      unitRef="Pure">0.50</wint:FinancingOfProductPercentOfRevenueSharedWithFinancer>
    <us-gaap:ContractualObligation
      contextRef="i_2022-03-31_TypeOfArrangementAxis-TermSheetWithLeeMember"
      decimals="-5"
      id="c86425516"
      unitRef="USD">3800000</us-gaap:ContractualObligation>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>45
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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MVS;UFJ&"OV?)*?'<$\)<QBSM&>+A@VQQ2BBUA;]JCE?VG)?K>?MZ;K>[_OX
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M76_:,!2&_XH5[:*5.N($"% !TDHU;9,FH7;=KMW$$*N.G=D.M/OU.W;2C-!
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MW Y<,X4+'%4V .974IK7CKTBU%?"^5]02P,$%     @ -( +5>EFJ$]U!0
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MRBJ'H/ <P966A<B9@9L[ _\@6D8CN4)+IC?H(T1<HXO/%:MS 3)OT!!]OON
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MV1.#AA2$%Z#.U"MD7V@X2WN& -P1+(XS+.!3->_\&L3G$^=PDGK^"TBE21_
MCF!QG&%_VPV0S0RPE_5!K#XG#BDY'J>"4I.>=D,ZZB1QZOSUE.DWA)KXU#C$
M>+X7WG8S%I*CX[U9[!!YQZ,$OVK?):H'KD\9VTF4GU_;9,ZE[= +'2^3."_?
M*IEQGK<^<.S\*D(F/MD2?,QU :$>@B =(Y,X(]_6"JA+OQ9N@'6QEW(!H9ZB
M)ATODY<WN:Y0 .P##,<YNG]"%VW5O EF7]  GVVA:(X-"!!WGP$=(Y,7&/FH
M7E:B8K ;/J%>SDK*Y])VZ(6.E,E+I+Q?+S=_?$+P9*U8^=9]"+"3N-8U. 8F
M*ZG#W$P"M$O(\5P5DIK.^^JF8V<29^=;!2.LV,+@#?3<?L6K8$9D592P28"+
MQ][H'9(B\WE?K^XHF\0I^]#K.P^#MV$:+^VVPF[M7?D_,J486/6:>/@T[G4P
M7X2DM#<:'=63.-4?&F83ED%;:S9(_($7TG4RM*JKW%6:M6W=NWTF+^^? R+C
MOFF==E, /7$*V&]NH081_([I,_PL.1ZU D)D.I[U#*NTFP)H?#=MD5_D/%-V
MTK)MN+FRDXPUZ&UCEN64!^!&EU<V.! IHT1F/WM8@:!9_DYZB)-Y>AR1@!RF
M"9WT6-8Q.XTS^_)T^&@(F]FUJ"H;+,NG7 F9!XT*T#V9).38IL V/4UF/1]J
MZ-ZG\CCIO\XF;O=+46M\HL=X0CUK?#&:8-R7>]U(0,=11KVKM]O"%3-33_:#
M2 9;]5JYOE8]?V5K:^<I? 00G3E>?09P)FV'[N@&#!JE[F:_^]1]T )7N+YM
M-DK6ZPW\%RH?;ID=]':])>B522"L?E0#4I3T4!7M!@0:'Q BFS=HWT+;7YIS
MGGO#A*LX98\3AW(UA&DPLJ5O7SR-=/> "$F\]C[:.Q(LN5J[DU*-W*Z].4;;
M/=V=QMZX,\BCY^_QY;(Y4^W4-$>\GYB"?J+!!RM0F;Q+P<VJ.35M;HS<NH/'
M>VF,+-WEAK.<*RL OZ^D-,\W]@6[L^O%?U!+ P04    "  T@ M56T'/MPH&
M  #M#   &    'AL+W=O<FMS:&5E=',O<VAE970W+GAM;(U7:V_4.!3]*]8@
MH5TIG4=:"@OM2&TI6M@%JA:6#ZO]X'%N$JN.G;6=F99?O^<ZF72 H5J5$COQ
M?9][?'NR<?XVU$11W#7&AM-)'6/[<C8+JJ9&AJEKR>)+Z7PC([:^FH76DRR2
M4&-F^7Q^/&NDMI/E27IWY9<GKHM&6[KR(G1-(_W].1FW.9TL)ML7U[JJ([^8
M+4]:6=$-Q<_ME<=N-FHI=$,V:&>%I_)T<K9X>7[$Y].!OS1MPLY:<"0KYVYY
M\[8XG<S9(3*D(FN0>*SI@HQA17#CWT'G9#3)@KOKK?8W*7;$LI*!+ISYHHM8
MGTY>3$1!I>Q,O':;WVF(YQGK4\Z$]+_8#&?G$Z&Z$%TS",.#1MO^*>^&//P?
M@7P0R)/?O:'DY6L9Y?+$NXWP?!K:>)%"3=)P3ELNRDWT^*HA%Y<?7"2Q$ ?B
M4TWBPC6MM/="VD*\IJ"\;E/J7"G.NP#)$$YF$599=J8&"^>]A?PG%H[%>V=C
M'<2E+:CX5GX&;T>7\ZW+Y_FC"M]U=BH.YYG(YWG^B+[#,06'2=_A(RD((CKQ
M1EMIE99&W$09"="+>^/MU1WM5\==]#*T4M'I!&T2R*]ILGSZ9'$\?_6(LT>C
MLT>/:5]^])6T^JODNF0HF W.Z$+V"$?9KMBDC7);MWTQB=<Z*.-"YTG\_8GN
MHC@W3MW^LR_6Q[T9T/.%A(0N*10.:"7-08CH:+'2KJTE>D=1%_F]4 /"2@=L
M4R'@9 3P"EJ#'EKVCIVV#EO^X&6;)(/0-A+CA^LDBP)1!A%T974)O9#J; ,&
M:ZA(9BQ1P3)"-ZWSD0](U<%7Q7Z"?6X)5"8^=OX;TZUWE9=-2-&T7N.@-C\X
M&T%^<>OJJ+;0;BV#ZHR$3AT(3!%210(I9XM>4Z(A%F@[TS@+%AS/]MX8\"J[
M470J0JLMN+:4"8V$>G<'.N0U,EUJ'R+<\40B'W[.X+))79&)]_)^6+':FJ2/
MHI3:<,V_\Y8S5 )%2*P)#EE3IBO@?)!>.8&LN];(T&@ @E"+SG2-N) P*#-Q
M<WE]<;:SF&X7J&%,IA\B_2&L'<M(44",(:54_/'GD7@G;<=2?1#Y'/'QZ\5O
M&7X9YFOMNF#N,[$A_&/XL?=#.;6MQ-GE]<>;S]=OQ"^F4V@#E7" >PPAUM*D
M%ODU$W* 6^&[:K8%$-1H10S7%213,VW=9P7666V10%PH.&KP@*?L.GG'#?D5
M:&%O/T!SLR+/48"P=F-*WSE)H#/T4(IQ\3Q+KSEO<J6-CO<]WM?H81+N9W %
M(@IJN3^X$UKN_&\U (-<>#2.YEBX$66K(Y[HD96+=0*V!4H29(VSU4$DWV2,
M,-=5-<JX,D  8@?(UER\I!/JB(M6DD?*PRLN))(1]<IP9E9(5T] Z2-TSU@#
M6,-&YJ00/515K+AE,'0V*<P&$'(5895' *QD!; G LM2L<:*[.0D2_[W#<XR
MN!Z-7#D_$*3WTE9;'=]1$Q,G$%]#!B//7HG!?\?,!/9I-+</0K!!IADC44Y%
M7)6V1E #T>R&PWG^/+V9CLK&!(])@323- ?26RH[6_3!-(V./867WC5)D:B
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MX7C_AP#R4W$>#)40G4^?/YL(WP_7_2:Z-@VT("Z,QVE9I_KS 7PO'9 U;-C
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M'Z*LA I18^L4])?7$"KA8(6HN4M8;CTLI#5U8'AAZD;HW<L79_GP]1L6\[$
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M&T9]!N(@QV8@WQ$<N$_7D(<O-H@EKGLZ!.0Q #/D=%K#E5$8D_E-^Z(ZU%P
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M$#$TVT,UIYEO-KK]O348+O>C=65->F.B7*8C&\I0XM 1I'6VZKC9BID"T3!
M8:5BQTK+B:"1TECMJ$[H+';P)*!&8%."PM3IY$XAGKP9O6D?1,6WM#&/4H1D
M@U\Q[THYRNI![[2CB5$[1<PTYH>90A91MXD>)%*LDG/;]B/?!@@^ 7>>>7R[
M=O+G7V>G.S@F1VMW1^\-\#,9XS_.D=YQT9,W@LI4=T4SV_< ,[5&4>8-FEZ5
MQK>]V=_M?9@IE5OPYR<F_";$;S3MT_8+UU'\L---CY_'0 T6U" 6:HZEX]'!
MRX%P\9-3O FVXL\\,QN"+?ERJ23J*4W ^-S",>F&-FB_^QW^%U!+ P04
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MUAOP][7AJ^PW/L#PPUS^#U!+ P04    "  T@ M5Z0"F$E(%  #B#   &0
M 'AL+W=O<FMS:&5E=',O<VAE970Q-"YX;6RM5\MRVS84W?LK[JAINY$EBI0L
M)[4U8^?1.-.TGCAM%ITN(/**1$T2# !:]M_W7%"BE$3V=)&%:8"\CW/N"]#9
MVMA;5S![NJ_*VIT/"N^;%^.Q2PNNE!N9AFM\61E;*8^MS<>NL:RRH%25XSB*
M3L:5TO5@<1;>7=O%F6E]J6N^MN3:JE+VX9)+LSX?3 ;;%Q]T7GAY,5Z<-2KG
M&_9_-M<6NW%O)=,5UTZ;FBROS@<7DQ>74Y$/ G]I7KN]-0F3I3&WLKG*S@>1
M .*24R\6%/[=\4LN2S$$&)\W-@>]2U'<7V^MOPG<P66I'+\TY2>=^>)\<#J@
MC%>J+?T'LW[+&SXSL9>:TH4GK3O9632@M'7>5!ME(*ATW?U7]YLX["F</J80
M;Q3B@+MS%%"^4EXMSJQ9DQ5I6)-%H!JT 4[7DI0;;_%50\\O?C>>Z92.Z<:;
M]+8P9<;6_4RO/[?:/YR-/5R(X#C=F+OLS,6/F#NA]Z;VA:/7=<;9E_IC0.OQ
MQ5M\E_&3!M^U]8B2:$AQ%,=/V$MZODFPESS!UY$W]$;7JDZU*L%<>4:=>7>(
M;V=N>MB<M,P+UZB4SP?H"<?VC@>+GWZ8G$2_/ %VVH.=/F5]<2@G%#+V2KNT
M-*ZU3']_Y'M/ER5$_SE$X$D7APELBN+"'W\L^/B]LK>8#M?6Y%95]$=--]P@
M8DNV-)F'S" _E7J@9Y-H%*%*RU(:SJS(%0I&965:2ZFI*KQWPHI\84V;%_2;
MRKA>MC8GY0ACH/:DZFQL+#56(T$-,K25]073Q<?W6R@C^E1P36LF[5S+Y%0)
M9[7Q.NURW-L>BE#&3N<U<AWLH(=TU5:D*M/"YPXL]):PA:C3\F$/7J9T^2#8
M.G5=!W6 3)D:A"*HD_*T+G1:;*U)6.1O.IG1E";/DV1(GR"66^9,?#5JWXD*
M00*=30"3'^4I#G-KG-M0[)SB@ZH?MHX"X*:UKE6@ \/?! NY)"OTH0@O&.M.
MA<FX1L(D;(0Y%]2<OB<T'O>-1R& P<5D.$GFPWAZ\E1R6W2__1H!9KC#K-1U
M3AKC.$<(<H'3,6NL21&2$/\V6%4-WB%)D"FEMD9)7UJ2A1HUV2L=$H^WXJ-'
MB4WVB,UF\7 ZGWYG6M\@?9S>?(?W56O%WKL67R[:',= 2,,0T8_CR7 >?>_H
M_V^8T>AD!U,J:H?C"PRA([-@-T3W,";I&.#0SK/EK9#P^1!>VJX^^P%-V,A9
M3#?'E& 0XF1($HJGIZ?(VVXHQ<^[H33:QFXRZ<OX*SK)KDH 1"XQB,4=.ETM
M2SX,>D1OS9KOV(;2$09I:RW0P9YKE__BNK%MOU)7V@<.#M&I/<R#)<+_*]=L
M,=BN:I!LN_O)U>@2L4U&Z$3PE"&E+=HMQOX((Q@C10KV".-WLTNZ$A[2[BL]
M'\8H[5D4 ;OV#JWM"V*%S[(7$ YQE2*0PH&7/=V])>)R$NU/-:21[QN-Y0J7
MJ,-:1U(.<BIMS$L$OA6<=:A'(?:SX"- ^Z(\'QL)SY*] P;I7:%N,-<S"2$T
M0[[65H=-AB-21GM7W+NQVNT949 BR&!VQ:';0! C4<:K>@CIQ_AOW7!#/BW;
M3*2$U1;8D'28P4-:65.%3WS/-M6.'P] B&\\'TU['D<X$ IU)R<4^%2A2'R!
MDT0,A(+%P)=>56E@%&#@!NY#3W1%>G'SDJ:GF&KA<=CKWE*F_>D$N=@^:!(1
MGO/I8\J'KC/CO7MGQ38/MVLI=8#LKJ#]V_X"?]'=6W?BW>T?GG)IOI)74(U&
M\]F ;'>C[C;>-.$6NS0>=^*P+/ CA*T(X/O*X-*RV8B#_F?-XC]02P,$%
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MYW5?DI]K[BTO*[((&"G7MYHKV&;&=,W67?&+:X(&):\(!Z;B* 43=^7A!*H
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MVMB08MQ2MY/;P"F-;14(ARX]A\0$6NF.PFGG/6;$L,1JL)CN=D[$9*9)(>$
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MJG+(/RC2X)CC?%.E&ZH/]L\B?L:)F"3GEPAS4<C8G^43I7Z2O#N.DGLY-U1
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MK1D_AWRY*D^8__+"LIQ_=LB )LE!:38HS0&EN: TKZ8U.NN3K*??5<MLUPI
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M")X380KHWQ=<;Y6*&^-@<Q![_#]02P,$%     @ -( +59(N%G:N @  "P@
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MMU^@]S,V?!FGTGY1V\=Z#LH:J7C=@[6"FK#NCV_[/&P 1N$C +\'^/\+"'I
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M-ZL"W_>Z==6:M$XMK=,JK1G)&<]RK?;A I?(P*^#V2:YE=6>/T<J(Q&.''/
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M6-?:!*E"N,X64Z?G^)]W]#A@YI_NZ-&9\1OU&#1Z#%ZG!S)G(F&QN9#5RJW
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MI@,^7PH\QA<7YJM ^9UI\B]02P,$%     @ -( +5>1_3T0;"   DDT  !D
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M-RZQ9;:)VU8WR?_(8_XDV>>\F,"ZS\5OT\JGN8J3DQQJ'D-I+I3F06D^E!9
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MO/O))XIGMN-XXDKW+W:XTATC"K-!OU]PW744$^.@[$&G_P)02P,$%     @
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MURR+]4+L/V$YGX'A"T2L\K^P+_MV+0@RI452@BF"A*?%DSV7.AP B*<>X)8
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MD0>5R(-&D0]6R3>N([,^&O.^D>W<O&^3S&N3S&^)[,B2867)L-&2N10!8JB
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M2VS[J3!I%]L-W.WF\]E?4$L#!!0    ( #2 "U7@/0E7: $  $H4   :
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M#T'[\$$4HXRQ@*0%U@*T)N2:!'A-"#8)$)N0;!)@-B':)$!M0K9)@-N$<),
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M).N'ULN__O76KDDM57/P9]W_S=D74$L! A0#%     @ -( +50=!36*!
ML0   !               ( !     &1O8U!R;W!S+V%P<"YX;6Q02P$"% ,4
M    "  T@ M56"]A$.X    K @  $0              @ &O    9&]C4')O
M<',O8V]R92YX;6Q02P$"% ,4    "  T@ M5F5R<(Q &  "<)P  $P
M        @ ', 0  >&PO=&AE;64O=&AE;64Q+GAM;%!+ 0(4 Q0    ( #2
M"U67MFF$Y@4  /X>   8              " @0T(  !X;"]W;W)K<VAE971S
M+W-H965T,2YX;6Q02P$"% ,4    "  T@ M56."[)B<&  !.&0  &
M        @($I#@  >&PO=V]R:W-H965T<R]S:&5E=#(N>&UL4$L! A0#%
M  @ -( +54F,0./I @  '@H  !@              ("!AA0  'AL+W=O<FMS
M:&5E=',O<VAE970S+GAM;%!+ 0(4 Q0    ( #2 "U7I9JA/=04  (88   8
M              " @:47  !X;"]W;W)K<VAE971S+W-H965T-"YX;6Q02P$"
M% ,4    "  T@ M5\'M-0LT.  ")U   &               @(%0'0  >&PO
M=V]R:W-H965T<R]S:&5E=#4N>&UL4$L! A0#%     @ -( +51'R=L0^!P
MQQX  !@              ("!4RP  'AL+W=O<FMS:&5E=',O<VAE970V+GAM
M;%!+ 0(4 Q0    ( #2 "U5;0<^W"@8  .T,   8              " @<<S
M  !X;"]W;W)K<VAE971S+W-H965T-RYX;6Q02P$"% ,4    "  T@ M5)I>M
M940#  "V!P  &               @($'.@  >&PO=V]R:W-H965T<R]S:&5E
M=#@N>&UL4$L! A0#%     @ -( +5>:C1X"7!P  9A$  !@
M ("!@3T  'AL+W=O<FMS:&5E=',O<VAE970Y+GAM;%!+ 0(4 Q0    ( #2
M"U5 3?R,]0H   ,<   9              " @4Y%  !X;"]W;W)K<VAE971S
M+W-H965T,3 N>&UL4$L! A0#%     @ -( +5?'O_LG% P  VP@  !D
M         ("!>E   'AL+W=O<FMS:&5E=',O<VAE970Q,2YX;6Q02P$"% ,4
M    "  T@ M5BH.)Z>$"  "M!@  &0              @(%V5   >&PO=V]R
M:W-H965T<R]S:&5E=#$R+GAM;%!+ 0(4 Q0    ( #2 "U4(9)B$60,  #P'
M   9              " @8Y7  !X;"]W;W)K<VAE971S+W-H965T,3,N>&UL
M4$L! A0#%     @ -( +5>D IA)2!0  X@P  !D              ("!'EL
M 'AL+W=O<FMS:&5E=',O<VAE970Q-"YX;6Q02P$"% ,4    "  T@ M580N@
MP_(%  #T#0  &0              @(&G8   >&PO=V]R:W-H965T<R]S:&5E
M=#$U+GAM;%!+ 0(4 Q0    ( #2 "U4V5$E[;0,  %H'   9
M  " @=!F  !X;"]W;W)K<VAE971S+W-H965T,38N>&UL4$L! A0#%     @
M-( +5=(2IP85#   6B0  !D              ("!=&H  'AL+W=O<FMS:&5E
M=',O<VAE970Q-RYX;6Q02P$"% ,4    "  T@ M50* >JYD"  "E!0  &0
M            @(' =@  >&PO=V]R:W-H965T<R]S:&5E=#$X+GAM;%!+ 0(4
M Q0    ( #2 "U7/"=B=L0(  '\&   9              " @9!Y  !X;"]W
M;W)K<VAE971S+W-H965T,3DN>&UL4$L! A0#%     @ -( +5<;.CU6*!
M0 P  !D              ("!>'P  'AL+W=O<FMS:&5E=',O<VAE970R,"YX
M;6Q02P$"% ,4    "  T@ M5["/5&^<'   %1   &0              @($Y
M@0  >&PO=V]R:W-H965T<R]S:&5E=#(Q+GAM;%!+ 0(4 Q0    ( #2 "U4K
MJ2:%J@8  )0M   9              " @5>)  !X;"]W;W)K<VAE971S+W-H
M965T,C(N>&UL4$L! A0#%     @ -( +59(N%G:N @  "P@  !D
M     ("!.)   'AL+W=O<FMS:&5E=',O<VAE970R,RYX;6Q02P$"% ,4
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M+GAM;%!+ 0(4 Q0    ( #2 "U7;HP!;T0(  (((   9              "
M@1"F  !X;"]W;W)K<VAE971S+W-H965T,C@N>&UL4$L! A0#%     @ -( +
M5=-='93, P  CPX  !D              ("!&*D  'AL+W=O<FMS:&5E=',O
M<VAE970R.2YX;6Q02P$"% ,4    "  T@ M5IH^<ST,#   C#   &0
M        @($;K0  >&PO=V]R:W-H965T<R]S:&5E=#,P+GAM;%!+ 0(4 Q0
M   ( #2 "U7L:K =)P,  )L+   9              " @96P  !X;"]W;W)K
M<VAE971S+W-H965T,S$N>&UL4$L! A0#%     @ -( +5>*B!"&' @  C 8
M !D              ("!\[,  'AL+W=O<FMS:&5E=',O<VAE970S,BYX;6Q0
M2P$"% ,4    "  T@ M5:W$<#-P#   :$   &0              @(&QM@
M>&PO=V]R:W-H965T<R]S:&5E=#,S+GAM;%!+ 0(4 Q0    ( #2 "U6??W';
M0@,  "84   -              "  <2Z  !X;"]S='EL97,N>&UL4$L! A0#
M%     @ -( +59>*NQS     $P(   L              ( !,;X  %]R96QS
M+RYR96QS4$L! A0#%     @ -( +53.=6!E? P   !<   \
M ( !&K\  'AL+W=O<FMB;V]K+GAM;%!+ 0(4 Q0    ( #2 "U7@/0E7: $
M $H4   :              "  :;"  !X;"]?<F5L<R]W;W)K8F]O:RYX;6PN
M<F5L<U!+ 0(4 Q0    ( #2 "U4<F@E=C $  .<4   3              "
M 4;$  !;0V]N=&5N=%]4>7!E<UTN>&UL4$L%!@     I "D %@L   /&
!  $!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>46
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>47
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>48
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.22.2</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>119</ContextCount>
  <ElementCount>202</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>32</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>6</UnitCount>
  <MyReports>
    <Report instance="wint20220630_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>000 - Document - Document And Entity Information</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.windtreetx.com/20220630/role/statement-document-and-entity-information</Role>
      <ShortName>Document And Entity Information</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report instance="wint20220630_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R2.htm</HtmlFileName>
      <LongName>001 - Statement - Condensed Consolidated Balance Sheets (Current Period Unaudited)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.windtreetx.com/20220630/role/statement-condensed-consolidated-balance-sheets-current-period-unaudited</Role>
      <ShortName>Condensed Consolidated Balance Sheets (Current Period Unaudited)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>2</Position>
    </Report>
    <Report instance="wint20220630_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R3.htm</HtmlFileName>
      <LongName>002 - Statement - Condensed Consolidated Balance Sheets (Current Period Unaudited) (Parentheticals)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.windtreetx.com/20220630/role/statement-condensed-consolidated-balance-sheets-current-period-unaudited-parentheticals</Role>
      <ShortName>Condensed Consolidated Balance Sheets (Current Period Unaudited) (Parentheticals)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>3</Position>
    </Report>
    <Report instance="wint20220630_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R4.htm</HtmlFileName>
      <LongName>003 - Statement - Condensed Consolidated Statements of Operations (Unaudited)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.windtreetx.com/20220630/role/statement-condensed-consolidated-statements-of-operations-unaudited</Role>
      <ShortName>Condensed Consolidated Statements of Operations (Unaudited)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>4</Position>
    </Report>
    <Report instance="wint20220630_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R5.htm</HtmlFileName>
      <LongName>004 - Statement - Condensed Consolidated Statements of Changes in Stockholders' Equity (Unaudited)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.windtreetx.com/20220630/role/statement-condensed-consolidated-statements-of-changes-in-stockholders-equity-unaudited-</Role>
      <ShortName>Condensed Consolidated Statements of Changes in Stockholders' Equity (Unaudited)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>5</Position>
    </Report>
    <Report instance="wint20220630_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R6.htm</HtmlFileName>
      <LongName>005 - Statement - Condensed Consolidated Statements of Cash Flows (Unaudited)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.windtreetx.com/20220630/role/statement-condensed-consolidated-statements-of-cash-flows-unaudited-</Role>
      <ShortName>Condensed Consolidated Statements of Cash Flows (Unaudited)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>6</Position>
    </Report>
    <Report instance="wint20220630_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R7.htm</HtmlFileName>
      <LongName>006 - Disclosure - Note 1 - The Company and Description of Business</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.windtreetx.com/20220630/role/statement-note-1-the-company-and-description-of-business</Role>
      <ShortName>Note 1 - The Company and Description of Business</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>7</Position>
    </Report>
    <Report instance="wint20220630_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R8.htm</HtmlFileName>
      <LongName>007 - Disclosure - Note 2 - Basis of Presentation</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.windtreetx.com/20220630/role/statement-note-2-basis-of-presentation</Role>
      <ShortName>Note 2 - Basis of Presentation</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>8</Position>
    </Report>
    <Report instance="wint20220630_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R9.htm</HtmlFileName>
      <LongName>008 - Disclosure - Note 3 - Going Concern and Management's Plans</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.windtreetx.com/20220630/role/statement-note-3-going-concern-and-managements-plans</Role>
      <ShortName>Note 3 - Going Concern and Management's Plans</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>9</Position>
    </Report>
    <Report instance="wint20220630_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R10.htm</HtmlFileName>
      <LongName>009 - Disclosure - Note 4 - Summary of Significant Accounting Policies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.windtreetx.com/20220630/role/statement-note-4-summary-of-significant-accounting-policies</Role>
      <ShortName>Note 4 - Summary of Significant Accounting Policies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>10</Position>
    </Report>
    <Report instance="wint20220630_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R11.htm</HtmlFileName>
      <LongName>010 - Disclosure - Note 5 - Fair Value Measurements</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.windtreetx.com/20220630/role/statement-note-5-fair-value-measurements</Role>
      <ShortName>Note 5 - Fair Value Measurements</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>11</Position>
    </Report>
    <Report instance="wint20220630_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R12.htm</HtmlFileName>
      <LongName>011 - Disclosure - Note 6 - Loans Payable</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.windtreetx.com/20220630/role/statement-note-6-loans-payable</Role>
      <ShortName>Note 6 - Loans Payable</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>12</Position>
    </Report>
    <Report instance="wint20220630_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R13.htm</HtmlFileName>
      <LongName>012 - Disclosure - Note 7 - Restructured Debt Liability</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.windtreetx.com/20220630/role/statement-note-7-restructured-debt-liability</Role>
      <ShortName>Note 7 - Restructured Debt Liability</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>13</Position>
    </Report>
    <Report instance="wint20220630_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R14.htm</HtmlFileName>
      <LongName>013 - Disclosure - Note 8 - Stockholders' Equity</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.windtreetx.com/20220630/role/statement-note-8-stockholders-equity</Role>
      <ShortName>Note 8 - Stockholders' Equity</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>14</Position>
    </Report>
    <Report instance="wint20220630_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R15.htm</HtmlFileName>
      <LongName>014 - Disclosure - Note 9 - Stock-Based Compensation</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.windtreetx.com/20220630/role/statement-note-9-stockbased-compensation</Role>
      <ShortName>Note 9 - Stock-Based Compensation</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>15</Position>
    </Report>
    <Report instance="wint20220630_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R16.htm</HtmlFileName>
      <LongName>015 - Disclosure - Note 10 - Licensing and Research Funding Agreements</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.windtreetx.com/20220630/role/statement-note-10-licensing-and-research-funding-agreements</Role>
      <ShortName>Note 10 - Licensing and Research Funding Agreements</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>16</Position>
    </Report>
    <Report instance="wint20220630_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R17.htm</HtmlFileName>
      <LongName>016 - Disclosure - Significant Accounting Policies (Policies)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.windtreetx.com/20220630/role/statement-significant-accounting-policies-policies</Role>
      <ShortName>Significant Accounting Policies (Policies)</ShortName>
      <MenuCategory>Policies</MenuCategory>
      <ParentRole>http://www.windtreetx.com/20220630/role/statement-note-4-summary-of-significant-accounting-policies</ParentRole>
      <Position>17</Position>
    </Report>
    <Report instance="wint20220630_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R18.htm</HtmlFileName>
      <LongName>017 - Disclosure - Note 4 - Summary of Significant Accounting Policies (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.windtreetx.com/20220630/role/statement-note-4-summary-of-significant-accounting-policies-tables</Role>
      <ShortName>Note 4 - Summary of Significant Accounting Policies (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.windtreetx.com/20220630/role/statement-note-4-summary-of-significant-accounting-policies</ParentRole>
      <Position>18</Position>
    </Report>
    <Report instance="wint20220630_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R19.htm</HtmlFileName>
      <LongName>018 - Disclosure - Note 5 - Fair Value Measurements (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.windtreetx.com/20220630/role/statement-note-5-fair-value-measurements-tables</Role>
      <ShortName>Note 5 - Fair Value Measurements (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.windtreetx.com/20220630/role/statement-note-5-fair-value-measurements</ParentRole>
      <Position>19</Position>
    </Report>
    <Report instance="wint20220630_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R20.htm</HtmlFileName>
      <LongName>019 - Disclosure - Note 9 - Stock-Based Compensation (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.windtreetx.com/20220630/role/statement-note-9-stockbased-compensation-tables</Role>
      <ShortName>Note 9 - Stock-Based Compensation (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.windtreetx.com/20220630/role/statement-note-9-stockbased-compensation</ParentRole>
      <Position>20</Position>
    </Report>
    <Report instance="wint20220630_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R21.htm</HtmlFileName>
      <LongName>020 - Disclosure - Note 3 - Going Concern and Management's Plans (Details Textual)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.windtreetx.com/20220630/role/statement-note-3-going-concern-and-managements-plans-details-textual</Role>
      <ShortName>Note 3 - Going Concern and Management's Plans (Details Textual)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.windtreetx.com/20220630/role/statement-note-3-going-concern-and-managements-plans</ParentRole>
      <Position>21</Position>
    </Report>
    <Report instance="wint20220630_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R22.htm</HtmlFileName>
      <LongName>021 - Disclosure - Note 4 - Summary of Significant Accounting Policies (Details Textual)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.windtreetx.com/20220630/role/statement-note-4-summary-of-significant-accounting-policies-details-textual</Role>
      <ShortName>Note 4 - Summary of Significant Accounting Policies (Details Textual)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.windtreetx.com/20220630/role/statement-note-4-summary-of-significant-accounting-policies-tables</ParentRole>
      <Position>22</Position>
    </Report>
    <Report instance="wint20220630_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R23.htm</HtmlFileName>
      <LongName>022 - Disclosure - Note 4 - Summary of Significant Accounting Policies - Intangible Assets (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.windtreetx.com/20220630/role/statement-note-4-summary-of-significant-accounting-policies-intangible-assets-details</Role>
      <ShortName>Note 4 - Summary of Significant Accounting Policies - Intangible Assets (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>23</Position>
    </Report>
    <Report instance="wint20220630_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R24.htm</HtmlFileName>
      <LongName>023 - Disclosure - Note 5 - Fair Value Measurements - Assets and Liabilities Measured at Fair Value on a Recurring Basis (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.windtreetx.com/20220630/role/statement-note-5-fair-value-measurements-assets-and-liabilities-measured-at-fair-value-on-a-recurring-basis-details</Role>
      <ShortName>Note 5 - Fair Value Measurements - Assets and Liabilities Measured at Fair Value on a Recurring Basis (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>24</Position>
    </Report>
    <Report instance="wint20220630_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R25.htm</HtmlFileName>
      <LongName>024 - Disclosure - Note 6 - Loans Payable (Details Textual)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.windtreetx.com/20220630/role/statement-note-6-loans-payable-details-textual</Role>
      <ShortName>Note 6 - Loans Payable (Details Textual)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.windtreetx.com/20220630/role/statement-note-6-loans-payable</ParentRole>
      <Position>25</Position>
    </Report>
    <Report instance="wint20220630_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R26.htm</HtmlFileName>
      <LongName>025 - Disclosure - Note 7 - Restructured Debt Liability (Details Textual)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.windtreetx.com/20220630/role/statement-note-7-restructured-debt-liability-details-textual</Role>
      <ShortName>Note 7 - Restructured Debt Liability (Details Textual)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.windtreetx.com/20220630/role/statement-note-7-restructured-debt-liability</ParentRole>
      <Position>26</Position>
    </Report>
    <Report instance="wint20220630_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R27.htm</HtmlFileName>
      <LongName>026 - Disclosure - Note 8 - Stockholders' Equity (Details Textual)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.windtreetx.com/20220630/role/statement-note-8-stockholders-equity-details-textual</Role>
      <ShortName>Note 8 - Stockholders' Equity (Details Textual)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.windtreetx.com/20220630/role/statement-note-8-stockholders-equity</ParentRole>
      <Position>27</Position>
    </Report>
    <Report instance="wint20220630_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R28.htm</HtmlFileName>
      <LongName>027 - Disclosure - Note 9 - Stock-Based Compensation (Details Textual)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.windtreetx.com/20220630/role/statement-note-9-stockbased-compensation-details-textual</Role>
      <ShortName>Note 9 - Stock-Based Compensation (Details Textual)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.windtreetx.com/20220630/role/statement-note-9-stockbased-compensation-tables</ParentRole>
      <Position>28</Position>
    </Report>
    <Report instance="wint20220630_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R29.htm</HtmlFileName>
      <LongName>028 - Disclosure - Note 9 - Stock-Based Compensation - Summary of Stock Option Activity (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.windtreetx.com/20220630/role/statement-note-9-stockbased-compensation-summary-of-stock-option-activity-details</Role>
      <ShortName>Note 9 - Stock-Based Compensation - Summary of Stock Option Activity (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>29</Position>
    </Report>
    <Report instance="wint20220630_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R30.htm</HtmlFileName>
      <LongName>029 - Disclosure - Note 9 - Stock-Based Compensation - Restricted Stock Units (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.windtreetx.com/20220630/role/statement-note-9-stockbased-compensation-restricted-stock-units-details</Role>
      <ShortName>Note 9 - Stock-Based Compensation - Restricted Stock Units (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>30</Position>
    </Report>
    <Report instance="wint20220630_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R31.htm</HtmlFileName>
      <LongName>030 - Disclosure - Note 9 - Stock-Based Compensation - Stock-Based Compensation Expense (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.windtreetx.com/20220630/role/statement-note-9-stockbased-compensation-stockbased-compensation-expense-details</Role>
      <ShortName>Note 9 - Stock-Based Compensation - Stock-Based Compensation Expense (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>31</Position>
    </Report>
    <Report instance="wint20220630_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R32.htm</HtmlFileName>
      <LongName>031 - Disclosure - Note 9 - Stock-Based Compensation - Stock Options Valuation Assumptions (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.windtreetx.com/20220630/role/statement-note-9-stockbased-compensation-stock-options-valuation-assumptions-details</Role>
      <ShortName>Note 9 - Stock-Based Compensation - Stock Options Valuation Assumptions (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>32</Position>
    </Report>
    <Report instance="wint20220630_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R33.htm</HtmlFileName>
      <LongName>032 - Disclosure - Note 10 - Licensing and Research Funding Agreements (Details Textual)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.windtreetx.com/20220630/role/statement-note-10-licensing-and-research-funding-agreements-details-textual</Role>
      <ShortName>Note 10 - Licensing and Research Funding Agreements (Details Textual)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.windtreetx.com/20220630/role/statement-note-10-licensing-and-research-funding-agreements</ParentRole>
      <Position>33</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File doctype="10-Q" original="wint20220630_10q.htm">wint20220630_10q.htm</File>
    <File>ex_378191.htm</File>
    <File>ex_378192.htm</File>
    <File>ex_378193.htm</File>
    <File>ex_409319.htm</File>
    <File>wint-20220630.xsd</File>
    <File>wint-20220630_cal.xml</File>
    <File>wint-20220630_def.xml</File>
    <File>wint-20220630_lab.xml</File>
    <File>wint-20220630_pre.xml</File>
  </InputFiles>
  <SupplementalFiles/>
  <BaseTaxonomies>
    <BaseTaxonomy items="410">http://fasb.org/us-gaap/2022</BaseTaxonomy>
    <BaseTaxonomy items="29">http://xbrl.sec.gov/dei/2022</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>true</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>51
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "instance": {
  "wint20220630_10q.htm": {
   "axisCustom": 0,
   "axisStandard": 21,
   "contextCount": 119,
   "dts": {
    "calculationLink": {
     "local": [
      "wint-20220630_cal.xml"
     ]
    },
    "definitionLink": {
     "local": [
      "wint-20220630_def.xml"
     ]
    },
    "inline": {
     "local": [
      "wint20220630_10q.htm"
     ]
    },
    "labelLink": {
     "local": [
      "wint-20220630_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "wint-20220630_pre.xml"
     ]
    },
    "schema": {
     "local": [
      "wint-20220630.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd",
      "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd",
      "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd",
      "https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd",
      "https://xbrl.fasb.org/srt/2022/elts/srt-roles-2022.xsd",
      "https://xbrl.fasb.org/srt/2022/elts/srt-types-2022.xsd",
      "https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd",
      "https://xbrl.fasb.org/us-gaap/2022/elts/us-roles-2022.xsd",
      "https://xbrl.fasb.org/us-gaap/2022/elts/us-types-2022.xsd",
      "https://xbrl.sec.gov/country/2022/country-2022.xsd",
      "https://xbrl.sec.gov/currency/2022/currency-2022.xsd",
      "https://xbrl.sec.gov/dei/2022/dei-2022.xsd",
      "https://xbrl.sec.gov/exch/2022/exch-2022.xsd",
      "https://xbrl.sec.gov/naics/2022/naics-2022.xsd",
      "https://xbrl.sec.gov/sic/2022/sic-2022.xsd",
      "https://xbrl.sec.gov/stpr/2022/stpr-2022.xsd"
     ]
    }
   },
   "elementCount": 312,
   "entityCount": 1,
   "hidden": {
    "http://fasb.org/us-gaap/2022": 28,
    "http://www.windtreetx.com/20220630": 3,
    "http://xbrl.sec.gov/dei/2022": 6,
    "total": 37
   },
   "keyCustom": 35,
   "keyStandard": 167,
   "memberCustom": 17,
   "memberStandard": 13,
   "nsprefix": "wint",
   "nsuri": "http://www.windtreetx.com/20220630",
   "report": {
    "R1": {
     "firstAnchor": {
      "ancestors": [
       "b",
       "span",
       "p",
       "div",
       "body",
       "html"
      ],
      "baseRef": "wint20220630_10q.htm",
      "contextRef": "d_2022-01-01_2022-06-30",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "document",
     "isDefault": "true",
     "longName": "000 - Document - Document And Entity Information",
     "role": "http://www.windtreetx.com/20220630/role/statement-document-and-entity-information",
     "shortName": "Document And Entity Information",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "b",
       "span",
       "p",
       "div",
       "body",
       "html"
      ],
      "baseRef": "wint20220630_10q.htm",
      "contextRef": "d_2022-01-01_2022-06-30",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R10": {
     "firstAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "wint20220630_10q.htm",
      "contextRef": "d_2022-01-01_2022-06-30",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SignificantAccountingPoliciesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "009 - Disclosure - Note 4 - Summary of Significant Accounting Policies",
     "role": "http://www.windtreetx.com/20220630/role/statement-note-4-summary-of-significant-accounting-policies",
     "shortName": "Note 4 - Summary of Significant Accounting Policies",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "wint20220630_10q.htm",
      "contextRef": "d_2022-01-01_2022-06-30",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SignificantAccountingPoliciesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R11": {
     "firstAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "wint20220630_10q.htm",
      "contextRef": "d_2022-01-01_2022-06-30",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueDisclosuresTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "010 - Disclosure - Note 5 - Fair Value Measurements",
     "role": "http://www.windtreetx.com/20220630/role/statement-note-5-fair-value-measurements",
     "shortName": "Note 5 - Fair Value Measurements",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "wint20220630_10q.htm",
      "contextRef": "d_2022-01-01_2022-06-30",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueDisclosuresTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R12": {
     "firstAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "wint20220630_10q.htm",
      "contextRef": "d_2022-01-01_2022-06-30",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ShortTermDebtTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "011 - Disclosure - Note 6 - Loans Payable",
     "role": "http://www.windtreetx.com/20220630/role/statement-note-6-loans-payable",
     "shortName": "Note 6 - Loans Payable",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "wint20220630_10q.htm",
      "contextRef": "d_2022-01-01_2022-06-30",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ShortTermDebtTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R13": {
     "firstAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "wint20220630_10q.htm",
      "contextRef": "d_2022-01-01_2022-06-30",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LongTermDebtTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "012 - Disclosure - Note 7 - Restructured Debt Liability",
     "role": "http://www.windtreetx.com/20220630/role/statement-note-7-restructured-debt-liability",
     "shortName": "Note 7 - Restructured Debt Liability",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "wint20220630_10q.htm",
      "contextRef": "d_2022-01-01_2022-06-30",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LongTermDebtTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R14": {
     "firstAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "wint20220630_10q.htm",
      "contextRef": "d_2022-01-01_2022-06-30",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "013 - Disclosure - Note 8 - Stockholders' Equity",
     "role": "http://www.windtreetx.com/20220630/role/statement-note-8-stockholders-equity",
     "shortName": "Note 8 - Stockholders' Equity",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "wint20220630_10q.htm",
      "contextRef": "d_2022-01-01_2022-06-30",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R15": {
     "firstAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "wint20220630_10q.htm",
      "contextRef": "d_2022-01-01_2022-06-30",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "014 - Disclosure - Note 9 - Stock-Based Compensation",
     "role": "http://www.windtreetx.com/20220630/role/statement-note-9-stockbased-compensation",
     "shortName": "Note 9 - Stock-Based Compensation",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "wint20220630_10q.htm",
      "contextRef": "d_2022-01-01_2022-06-30",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R16": {
     "firstAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "wint20220630_10q.htm",
      "contextRef": "d_2022-01-01_2022-06-30",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "wint:CorporatePartnershipLicensingAndResearchFundingAgreementsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "015 - Disclosure - Note 10 - Licensing and Research Funding Agreements",
     "role": "http://www.windtreetx.com/20220630/role/statement-note-10-licensing-and-research-funding-agreements",
     "shortName": "Note 10 - Licensing and Research Funding Agreements",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "wint20220630_10q.htm",
      "contextRef": "d_2022-01-01_2022-06-30",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "wint:CorporatePartnershipLicensingAndResearchFundingAgreementsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R17": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "body",
       "html"
      ],
      "baseRef": "wint20220630_10q.htm",
      "contextRef": "d_2022-01-01_2022-06-30",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ConsolidationPolicyTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "016 - Disclosure - Significant Accounting Policies (Policies)",
     "role": "http://www.windtreetx.com/20220630/role/statement-significant-accounting-policies-policies",
     "shortName": "Significant Accounting Policies (Policies)",
     "subGroupType": "policies",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "body",
       "html"
      ],
      "baseRef": "wint20220630_10q.htm",
      "contextRef": "d_2022-01-01_2022-06-30",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ConsolidationPolicyTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R18": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:GoodwillAndIntangibleAssetsGoodwillPolicy",
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "body",
       "html"
      ],
      "baseRef": "wint20220630_10q.htm",
      "contextRef": "d_2022-01-01_2022-06-30",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "017 - Disclosure - Note 4 - Summary of Significant Accounting Policies (Tables)",
     "role": "http://www.windtreetx.com/20220630/role/statement-note-4-summary-of-significant-accounting-policies-tables",
     "shortName": "Note 4 - Summary of Significant Accounting Policies (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:GoodwillAndIntangibleAssetsGoodwillPolicy",
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "body",
       "html"
      ],
      "baseRef": "wint20220630_10q.htm",
      "contextRef": "d_2022-01-01_2022-06-30",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R19": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:FairValueDisclosuresTextBlock",
       "body",
       "html"
      ],
      "baseRef": "wint20220630_10q.htm",
      "contextRef": "d_2022-01-01_2022-06-30",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "018 - Disclosure - Note 5 - Fair Value Measurements (Tables)",
     "role": "http://www.windtreetx.com/20220630/role/statement-note-5-fair-value-measurements-tables",
     "shortName": "Note 5 - Fair Value Measurements (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:FairValueDisclosuresTextBlock",
       "body",
       "html"
      ],
      "baseRef": "wint20220630_10q.htm",
      "contextRef": "d_2022-01-01_2022-06-30",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R2": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "tbody",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "wint20220630_10q.htm",
      "contextRef": "i_2022-06-30",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "reportCount": 1,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "001 - Statement - Condensed Consolidated Balance Sheets (Current Period Unaudited)",
     "role": "http://www.windtreetx.com/20220630/role/statement-condensed-consolidated-balance-sheets-current-period-unaudited",
     "shortName": "Condensed Consolidated Balance Sheets (Current Period Unaudited)",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "tbody",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "wint20220630_10q.htm",
      "contextRef": "i_2022-06-30",
      "decimals": "-3",
      "lang": null,
      "name": "us-gaap:PrepaidExpenseAndOtherAssetsCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     }
    },
    "R20": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "body",
       "html"
      ],
      "baseRef": "wint20220630_10q.htm",
      "contextRef": "d_2022-01-01_2022-06-30",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "019 - Disclosure - Note 9 - Stock-Based Compensation (Tables)",
     "role": "http://www.windtreetx.com/20220630/role/statement-note-9-stockbased-compensation-tables",
     "shortName": "Note 9 - Stock-Based Compensation (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "body",
       "html"
      ],
      "baseRef": "wint20220630_10q.htm",
      "contextRef": "d_2022-01-01_2022-06-30",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R21": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "tbody",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "wint20220630_10q.htm",
      "contextRef": "d_2022-04-01_2022-06-30",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:NetIncomeLoss",
      "reportCount": 1,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "020 - Disclosure - Note 3 - Going Concern and Management's Plans (Details Textual)",
     "role": "http://www.windtreetx.com/20220630/role/statement-note-3-going-concern-and-managements-plans-details-textual",
     "shortName": "Note 3 - Going Concern and Management's Plans (Details Textual)",
     "subGroupType": "details",
     "uniqueAnchor": null
    },
    "R22": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "tbody",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "wint20220630_10q.htm",
      "contextRef": "d_2022-04-01_2022-06-30",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:ImpairmentOfIntangibleAssetsExcludingGoodwill",
      "reportCount": 1,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "021 - Disclosure - Note 4 - Summary of Significant Accounting Policies (Details Textual)",
     "role": "http://www.windtreetx.com/20220630/role/statement-note-4-summary-of-significant-accounting-policies-details-textual",
     "shortName": "Note 4 - Summary of Significant Accounting Policies (Details Textual)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "us-gaap:GoodwillAndIntangibleAssetsGoodwillPolicy",
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "body",
       "html"
      ],
      "baseRef": "wint20220630_10q.htm",
      "contextRef": "d_2022-01-01_2022-03-31",
      "decimals": "INF",
      "lang": null,
      "name": "us-gaap:NumberOfReportingUnits",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Pure",
      "xsiNil": "false"
     }
    },
    "R23": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "tbody",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "wint20220630_10q.htm",
      "contextRef": "i_2022-06-30",
      "decimals": "-4",
      "first": true,
      "lang": null,
      "name": "us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill",
      "reportCount": 1,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "022 - Disclosure - Note 4 - Summary of Significant Accounting Policies - Intangible Assets (Details)",
     "role": "http://www.windtreetx.com/20220630/role/statement-note-4-summary-of-significant-accounting-policies-intangible-assets-details",
     "shortName": "Note 4 - Summary of Significant Accounting Policies - Intangible Assets (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "tbody",
       "table",
       "us-gaap:ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock",
       "us-gaap:GoodwillAndIntangibleAssetsGoodwillPolicy",
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "body",
       "html"
      ],
      "baseRef": "wint20220630_10q.htm",
      "contextRef": "i_2022-06-30_IndefiniteLivedIntangibleAssetsByMajorClassAxis-IstaroximeDrugCandidateMember",
      "decimals": "-4",
      "lang": null,
      "name": "us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     }
    },
    "R24": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "tbody",
       "table",
       "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock",
       "us-gaap:FairValueDisclosuresTextBlock",
       "body",
       "html"
      ],
      "baseRef": "wint20220630_10q.htm",
      "contextRef": "i_2022-06-30_FairValueByMeasurementFrequencyAxis-FairValueMeasurementsRecurringMember",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:AssetsFairValueDisclosure",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "023 - Disclosure - Note 5 - Fair Value Measurements - Assets and Liabilities Measured at Fair Value on a Recurring Basis (Details)",
     "role": "http://www.windtreetx.com/20220630/role/statement-note-5-fair-value-measurements-assets-and-liabilities-measured-at-fair-value-on-a-recurring-basis-details",
     "shortName": "Note 5 - Fair Value Measurements - Assets and Liabilities Measured at Fair Value on a Recurring Basis (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "tbody",
       "table",
       "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock",
       "us-gaap:FairValueDisclosuresTextBlock",
       "body",
       "html"
      ],
      "baseRef": "wint20220630_10q.htm",
      "contextRef": "i_2022-06-30_FairValueByMeasurementFrequencyAxis-FairValueMeasurementsRecurringMember",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:AssetsFairValueDisclosure",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     }
    },
    "R25": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "us-gaap:ShortTermDebtTextBlock",
       "body",
       "html"
      ],
      "baseRef": "wint20220630_10q.htm",
      "contextRef": "i_2022-06-30_DebtInstrumentAxis-LoanPayableToBankDirectCapitalFinanceMember_ShortTermDebtTypeAxis-LoansPayableMember",
      "decimals": "-5",
      "first": true,
      "lang": null,
      "name": "us-gaap:DebtInstrumentFaceAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "024 - Disclosure - Note 6 - Loans Payable (Details Textual)",
     "role": "http://www.windtreetx.com/20220630/role/statement-note-6-loans-payable-details-textual",
     "shortName": "Note 6 - Loans Payable (Details Textual)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "us-gaap:ShortTermDebtTextBlock",
       "body",
       "html"
      ],
      "baseRef": "wint20220630_10q.htm",
      "contextRef": "i_2022-06-30_DebtInstrumentAxis-LoanPayableToBankDirectCapitalFinanceMember_ShortTermDebtTypeAxis-LoansPayableMember",
      "decimals": "-5",
      "first": true,
      "lang": null,
      "name": "us-gaap:DebtInstrumentFaceAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     }
    },
    "R26": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "tbody",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "wint20220630_10q.htm",
      "contextRef": "i_2022-06-30",
      "decimals": "-6",
      "first": true,
      "lang": null,
      "name": "wint:LiabilityforContingentMilestonePaymentNoncurrent",
      "reportCount": 1,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "025 - Disclosure - Note 7 - Restructured Debt Liability (Details Textual)",
     "role": "http://www.windtreetx.com/20220630/role/statement-note-7-restructured-debt-liability-details-textual",
     "shortName": "Note 7 - Restructured Debt Liability (Details Textual)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "us-gaap:LongTermDebtTextBlock",
       "body",
       "html"
      ],
      "baseRef": "wint20220630_10q.htm",
      "contextRef": "d_2017-10-27_2017-10-27_CounterpartyNameAxis-DeerfieldManagementLPMember_LongtermDebtTypeAxis-DeerfieldLoanMember_TypeOfArrangementAxis-ExchangeAndTerminationAgreementMember",
      "decimals": "-6",
      "lang": null,
      "name": "us-gaap:ExtinguishmentOfDebtAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     }
    },
    "R27": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "tbody",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "wint20220630_10q.htm",
      "contextRef": "d_2022-04-01_2022-06-30",
      "decimals": "-4",
      "first": true,
      "lang": null,
      "name": "us-gaap:StockIssuedDuringPeriodValueNewIssues",
      "reportCount": 1,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "026 - Disclosure - Note 8 - Stockholders' Equity (Details Textual)",
     "role": "http://www.windtreetx.com/20220630/role/statement-note-8-stockholders-equity-details-textual",
     "shortName": "Note 8 - Stockholders' Equity (Details Textual)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "div",
       "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "wint20220630_10q.htm",
      "contextRef": "i_2021-03-23_ClassOfWarrantOrRightAxis-March2021WarrantsMember",
      "decimals": "INF",
      "lang": null,
      "name": "us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USDPerShare",
      "xsiNil": "false"
     }
    },
    "R28": {
     "firstAnchor": null,
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "027 - Disclosure - Note 9 - Stock-Based Compensation (Details Textual)",
     "role": "http://www.windtreetx.com/20220630/role/statement-note-9-stockbased-compensation-details-textual",
     "shortName": "Note 9 - Stock-Based Compensation (Details Textual)",
     "subGroupType": "details",
     "uniqueAnchor": null
    },
    "R29": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "tbody",
       "table",
       "us-gaap:DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "body",
       "html"
      ],
      "baseRef": "wint20220630_10q.htm",
      "contextRef": "i_2021-12-31",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Share",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "028 - Disclosure - Note 9 - Stock-Based Compensation - Summary of Stock Option Activity (Details)",
     "role": "http://www.windtreetx.com/20220630/role/statement-note-9-stockbased-compensation-summary-of-stock-option-activity-details",
     "shortName": "Note 9 - Stock-Based Compensation - Summary of Stock Option Activity (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "tbody",
       "table",
       "us-gaap:DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "body",
       "html"
      ],
      "baseRef": "wint20220630_10q.htm",
      "contextRef": "i_2021-12-31",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Share",
      "xsiNil": "false"
     }
    },
    "R3": {
     "firstAnchor": null,
     "groupType": "statement",
     "isDefault": "false",
     "longName": "002 - Statement - Condensed Consolidated Balance Sheets (Current Period Unaudited) (Parentheticals)",
     "role": "http://www.windtreetx.com/20220630/role/statement-condensed-consolidated-balance-sheets-current-period-unaudited-parentheticals",
     "shortName": "Condensed Consolidated Balance Sheets (Current Period Unaudited) (Parentheticals)",
     "subGroupType": "parenthetical",
     "uniqueAnchor": null
    },
    "R30": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "tbody",
       "table",
       "us-gaap:ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "body",
       "html"
      ],
      "baseRef": "wint20220630_10q.htm",
      "contextRef": "i_2021-12-31_AwardTypeAxis-RestrictedStockUnitsRSUMember",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Share",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "029 - Disclosure - Note 9 - Stock-Based Compensation - Restricted Stock Units (Details)",
     "role": "http://www.windtreetx.com/20220630/role/statement-note-9-stockbased-compensation-restricted-stock-units-details",
     "shortName": "Note 9 - Stock-Based Compensation - Restricted Stock Units (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "tbody",
       "table",
       "us-gaap:ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "body",
       "html"
      ],
      "baseRef": "wint20220630_10q.htm",
      "contextRef": "i_2021-12-31_AwardTypeAxis-RestrictedStockUnitsRSUMember",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Share",
      "xsiNil": "false"
     }
    },
    "R31": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "tbody",
       "table",
       "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "body",
       "html"
      ],
      "baseRef": "wint20220630_10q.htm",
      "contextRef": "d_2022-04-01_2022-06-30",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:AllocatedShareBasedCompensationExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "030 - Disclosure - Note 9 - Stock-Based Compensation - Stock-Based Compensation Expense (Details)",
     "role": "http://www.windtreetx.com/20220630/role/statement-note-9-stockbased-compensation-stockbased-compensation-expense-details",
     "shortName": "Note 9 - Stock-Based Compensation - Stock-Based Compensation Expense (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "tbody",
       "table",
       "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "body",
       "html"
      ],
      "baseRef": "wint20220630_10q.htm",
      "contextRef": "d_2022-04-01_2022-06-30",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:AllocatedShareBasedCompensationExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     }
    },
    "R32": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "tbody",
       "table",
       "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "body",
       "html"
      ],
      "baseRef": "wint20220630_10q.htm",
      "contextRef": "d_2022-01-01_2022-06-30",
      "decimals": "2",
      "first": true,
      "lang": null,
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Pure",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "031 - Disclosure - Note 9 - Stock-Based Compensation - Stock Options Valuation Assumptions (Details)",
     "role": "http://www.windtreetx.com/20220630/role/statement-note-9-stockbased-compensation-stock-options-valuation-assumptions-details",
     "shortName": "Note 9 - Stock-Based Compensation - Stock Options Valuation Assumptions (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "tbody",
       "table",
       "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "body",
       "html"
      ],
      "baseRef": "wint20220630_10q.htm",
      "contextRef": "d_2022-01-01_2022-06-30",
      "decimals": "2",
      "first": true,
      "lang": null,
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Pure",
      "xsiNil": "false"
     }
    },
    "R33": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "wint:CorporatePartnershipLicensingAndResearchFundingAgreementsTextBlock",
       "body",
       "html"
      ],
      "baseRef": "wint20220630_10q.htm",
      "contextRef": "d_2020-08-01_2020-10-31_CounterpartyNameAxis-LeesPharmaceuticalHoldingsLimitedMember_TypeOfArrangementAxis-AerosurfFundingTermSheetMember",
      "decimals": "-5",
      "first": true,
      "lang": null,
      "name": "wint:NonrefundablePayments",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "032 - Disclosure - Note 10 - Licensing and Research Funding Agreements (Details Textual)",
     "role": "http://www.windtreetx.com/20220630/role/statement-note-10-licensing-and-research-funding-agreements-details-textual",
     "shortName": "Note 10 - Licensing and Research Funding Agreements (Details Textual)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "wint:CorporatePartnershipLicensingAndResearchFundingAgreementsTextBlock",
       "body",
       "html"
      ],
      "baseRef": "wint20220630_10q.htm",
      "contextRef": "d_2020-08-01_2020-10-31_CounterpartyNameAxis-LeesPharmaceuticalHoldingsLimitedMember_TypeOfArrangementAxis-AerosurfFundingTermSheetMember",
      "decimals": "-5",
      "first": true,
      "lang": null,
      "name": "wint:NonrefundablePayments",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     }
    },
    "R4": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "tbody",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "wint20220630_10q.htm",
      "contextRef": "d_2022-04-01_2022-06-30",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:ResearchAndDevelopmentExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "003 - Statement - Condensed Consolidated Statements of Operations (Unaudited)",
     "role": "http://www.windtreetx.com/20220630/role/statement-condensed-consolidated-statements-of-operations-unaudited",
     "shortName": "Condensed Consolidated Statements of Operations (Unaudited)",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "tbody",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "wint20220630_10q.htm",
      "contextRef": "d_2022-04-01_2022-06-30",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:ResearchAndDevelopmentExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     }
    },
    "R5": {
     "firstAnchor": {
      "ancestors": [
       "b",
       "span",
       "td",
       "tr",
       "tbody",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "wint20220630_10q.htm",
      "contextRef": "i_2020-12-31_StatementEquityComponentsAxis-CommonStockMember",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:SharesOutstanding",
      "reportCount": 1,
      "unitRef": "Share",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "004 - Statement - Condensed Consolidated Statements of Changes in Stockholders' Equity (Unaudited)",
     "role": "http://www.windtreetx.com/20220630/role/statement-condensed-consolidated-statements-of-changes-in-stockholders-equity-unaudited-",
     "shortName": "Condensed Consolidated Statements of Changes in Stockholders' Equity (Unaudited)",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "tbody",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "wint20220630_10q.htm",
      "contextRef": "d_2021-01-01_2021-03-31_StatementEquityComponentsAxis-RetainedEarningsMember",
      "decimals": "-3",
      "lang": null,
      "name": "us-gaap:NetIncomeLoss",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     }
    },
    "R6": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "tbody",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "wint20220630_10q.htm",
      "contextRef": "d_2022-01-01_2022-06-30",
      "decimals": "-4",
      "first": true,
      "lang": null,
      "name": "us-gaap:NetIncomeLoss",
      "reportCount": 1,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "005 - Statement - Condensed Consolidated Statements of Cash Flows (Unaudited)",
     "role": "http://www.windtreetx.com/20220630/role/statement-condensed-consolidated-statements-of-cash-flows-unaudited-",
     "shortName": "Condensed Consolidated Statements of Cash Flows (Unaudited)",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "tbody",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "wint20220630_10q.htm",
      "contextRef": "d_2022-01-01_2022-06-30",
      "decimals": "-3",
      "lang": null,
      "name": "us-gaap:EmployeeBenefitsAndShareBasedCompensation",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     }
    },
    "R7": {
     "firstAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "wint20220630_10q.htm",
      "contextRef": "d_2022-01-01_2022-06-30",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "006 - Disclosure - Note 1 - The Company and Description of Business",
     "role": "http://www.windtreetx.com/20220630/role/statement-note-1-the-company-and-description-of-business",
     "shortName": "Note 1 - The Company and Description of Business",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "wint20220630_10q.htm",
      "contextRef": "d_2022-01-01_2022-06-30",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R8": {
     "firstAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "wint20220630_10q.htm",
      "contextRef": "d_2022-01-01_2022-06-30",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BasisOfAccounting",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "007 - Disclosure - Note 2 - Basis of Presentation",
     "role": "http://www.windtreetx.com/20220630/role/statement-note-2-basis-of-presentation",
     "shortName": "Note 2 - Basis of Presentation",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "wint20220630_10q.htm",
      "contextRef": "d_2022-01-01_2022-06-30",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BasisOfAccounting",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R9": {
     "firstAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "wint20220630_10q.htm",
      "contextRef": "d_2022-01-01_2022-06-30",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "wint:LiquidityDisclosuresTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "008 - Disclosure - Note 3 - Going Concern and Management's Plans",
     "role": "http://www.windtreetx.com/20220630/role/statement-note-3-going-concern-and-managements-plans",
     "shortName": "Note 3 - Going Concern and Management's Plans",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "wint20220630_10q.htm",
      "contextRef": "d_2022-01-01_2022-06-30",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "wint:LiquidityDisclosuresTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    }
   },
   "segmentCount": 32,
   "tag": {
    "dei_AmendmentFlag": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.",
        "label": "Amendment Flag"
       }
      }
     },
     "localname": "AmendmentFlag",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.windtreetx.com/20220630/role/statement-document-and-entity-information"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_CityAreaCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Area code of city",
        "label": "City Area Code"
       }
      }
     },
     "localname": "CityAreaCode",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.windtreetx.com/20220630/role/statement-document-and-entity-information"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_CurrentFiscalYearEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "End date of current fiscal year in the format --MM-DD.",
        "label": "Current Fiscal Year End Date"
       }
      }
     },
     "localname": "CurrentFiscalYearEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.windtreetx.com/20220630/role/statement-document-and-entity-information"
     ],
     "xbrltype": "gMonthDayItemType"
    },
    "dei_DocumentFiscalPeriodFocus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.",
        "label": "Document Fiscal Period Focus"
       }
      }
     },
     "localname": "DocumentFiscalPeriodFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.windtreetx.com/20220630/role/statement-document-and-entity-information"
     ],
     "xbrltype": "fiscalPeriodItemType"
    },
    "dei_DocumentFiscalYearFocus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.",
        "label": "Document Fiscal Year Focus"
       }
      }
     },
     "localname": "DocumentFiscalYearFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.windtreetx.com/20220630/role/statement-document-and-entity-information"
     ],
     "xbrltype": "gYearItemType"
    },
    "dei_DocumentInformationLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Document Information [Line Items]"
       }
      }
     },
     "localname": "DocumentInformationLineItems",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.windtreetx.com/20220630/role/statement-document-and-entity-information"
     ],
     "xbrltype": "stringItemType"
    },
    "dei_DocumentInformationTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Container to support the formal attachment of each official or unofficial, public or private document as part of a submission package.",
        "label": "Document Information [Table]"
       }
      }
     },
     "localname": "DocumentInformationTable",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "xbrltype": "stringItemType"
    },
    "dei_DocumentPeriodEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.",
        "label": "Document Period End Date"
       }
      }
     },
     "localname": "DocumentPeriodEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.windtreetx.com/20220630/role/statement-document-and-entity-information"
     ],
     "xbrltype": "dateItemType"
    },
    "dei_DocumentQuarterlyReport": {
     "auth_ref": [
      "r375"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as an quarterly report.",
        "label": "Document Quarterly Report"
       }
      }
     },
     "localname": "DocumentQuarterlyReport",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.windtreetx.com/20220630/role/statement-document-and-entity-information"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentTransitionReport": {
     "auth_ref": [
      "r376"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as a transition report.",
        "label": "Document Transition Report"
       }
      }
     },
     "localname": "DocumentTransitionReport",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.windtreetx.com/20220630/role/statement-document-and-entity-information"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentType": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.",
        "label": "Document Type"
       }
      }
     },
     "localname": "DocumentType",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.windtreetx.com/20220630/role/statement-document-and-entity-information"
     ],
     "xbrltype": "submissionTypeItemType"
    },
    "dei_EntityAddressAddressLine1": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name",
        "label": "Entity Address, Address Line One"
       }
      }
     },
     "localname": "EntityAddressAddressLine1",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.windtreetx.com/20220630/role/statement-document-and-entity-information"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressCityOrTown": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the City or Town",
        "label": "Entity Address, City or Town"
       }
      }
     },
     "localname": "EntityAddressCityOrTown",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.windtreetx.com/20220630/role/statement-document-and-entity-information"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressPostalZipCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Code for the postal or zip code",
        "label": "Entity Address, Postal Zip Code"
       }
      }
     },
     "localname": "EntityAddressPostalZipCode",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.windtreetx.com/20220630/role/statement-document-and-entity-information"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressStateOrProvince": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the state or province.",
        "label": "Entity Address, State or Province"
       }
      }
     },
     "localname": "EntityAddressStateOrProvince",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.windtreetx.com/20220630/role/statement-document-and-entity-information"
     ],
     "xbrltype": "stateOrProvinceItemType"
    },
    "dei_EntityCentralIndexKey": {
     "auth_ref": [
      "r373"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.",
        "label": "Entity Central Index Key"
       }
      }
     },
     "localname": "EntityCentralIndexKey",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.windtreetx.com/20220630/role/statement-document-and-entity-information"
     ],
     "xbrltype": "centralIndexKeyItemType"
    },
    "dei_EntityCommonStockSharesOutstanding": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.",
        "label": "Entity Common Stock, Shares Outstanding"
       }
      }
     },
     "localname": "EntityCommonStockSharesOutstanding",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.windtreetx.com/20220630/role/statement-document-and-entity-information"
     ],
     "xbrltype": "sharesItemType"
    },
    "dei_EntityCurrentReportingStatus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
        "label": "Entity Current Reporting Status"
       }
      }
     },
     "localname": "EntityCurrentReportingStatus",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.windtreetx.com/20220630/role/statement-document-and-entity-information"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "All the names of the entities being reported upon in a document. Any legal structure used to conduct activities or to hold assets. Some examples of such structures are corporations, partnerships, limited liability companies, grantor trusts, and other trusts. This item does not include business and geographical segments which are included in the geographical or business segments domains.",
        "label": "Entity [Domain]"
       }
      }
     },
     "localname": "EntityDomain",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.windtreetx.com/20220630/role/statement-condensed-consolidated-balance-sheets-current-period-unaudited",
      "http://www.windtreetx.com/20220630/role/statement-condensed-consolidated-balance-sheets-current-period-unaudited-parentheticals",
      "http://www.windtreetx.com/20220630/role/statement-condensed-consolidated-statements-of-cash-flows-unaudited-",
      "http://www.windtreetx.com/20220630/role/statement-condensed-consolidated-statements-of-operations-unaudited",
      "http://www.windtreetx.com/20220630/role/statement-document-and-entity-information",
      "http://www.windtreetx.com/20220630/role/statement-note-1-the-company-and-description-of-business",
      "http://www.windtreetx.com/20220630/role/statement-note-10-licensing-and-research-funding-agreements",
      "http://www.windtreetx.com/20220630/role/statement-note-10-licensing-and-research-funding-agreements-details-textual",
      "http://www.windtreetx.com/20220630/role/statement-note-2-basis-of-presentation",
      "http://www.windtreetx.com/20220630/role/statement-note-3-going-concern-and-managements-plans",
      "http://www.windtreetx.com/20220630/role/statement-note-3-going-concern-and-managements-plans-details-textual",
      "http://www.windtreetx.com/20220630/role/statement-note-4-summary-of-significant-accounting-policies",
      "http://www.windtreetx.com/20220630/role/statement-note-4-summary-of-significant-accounting-policies-details-textual",
      "http://www.windtreetx.com/20220630/role/statement-note-4-summary-of-significant-accounting-policies-intangible-assets-details",
      "http://www.windtreetx.com/20220630/role/statement-note-4-summary-of-significant-accounting-policies-tables",
      "http://www.windtreetx.com/20220630/role/statement-note-5-fair-value-measurements",
      "http://www.windtreetx.com/20220630/role/statement-note-5-fair-value-measurements-assets-and-liabilities-measured-at-fair-value-on-a-recurring-basis-details",
      "http://www.windtreetx.com/20220630/role/statement-note-5-fair-value-measurements-tables",
      "http://www.windtreetx.com/20220630/role/statement-note-6-loans-payable",
      "http://www.windtreetx.com/20220630/role/statement-note-6-loans-payable-details-textual",
      "http://www.windtreetx.com/20220630/role/statement-note-7-restructured-debt-liability",
      "http://www.windtreetx.com/20220630/role/statement-note-7-restructured-debt-liability-details-textual",
      "http://www.windtreetx.com/20220630/role/statement-note-8-stockholders-equity",
      "http://www.windtreetx.com/20220630/role/statement-note-8-stockholders-equity-details-textual",
      "http://www.windtreetx.com/20220630/role/statement-note-9-stockbased-compensation",
      "http://www.windtreetx.com/20220630/role/statement-note-9-stockbased-compensation-details-textual",
      "http://www.windtreetx.com/20220630/role/statement-note-9-stockbased-compensation-restricted-stock-units-details",
      "http://www.windtreetx.com/20220630/role/statement-note-9-stockbased-compensation-stock-options-valuation-assumptions-details",
      "http://www.windtreetx.com/20220630/role/statement-note-9-stockbased-compensation-stockbased-compensation-expense-details",
      "http://www.windtreetx.com/20220630/role/statement-note-9-stockbased-compensation-summary-of-stock-option-activity-details",
      "http://www.windtreetx.com/20220630/role/statement-note-9-stockbased-compensation-tables",
      "http://www.windtreetx.com/20220630/role/statement-significant-accounting-policies-policies"
     ],
     "xbrltype": "domainItemType"
    },
    "dei_EntityEmergingGrowthCompany": {
     "auth_ref": [
      "r373"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate if registrant meets the emerging growth company criteria.",
        "label": "Entity Emerging Growth Company"
       }
      }
     },
     "localname": "EntityEmergingGrowthCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.windtreetx.com/20220630/role/statement-document-and-entity-information"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityFileNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.",
        "label": "Entity File Number"
       }
      }
     },
     "localname": "EntityFileNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.windtreetx.com/20220630/role/statement-document-and-entity-information"
     ],
     "xbrltype": "fileNumberItemType"
    },
    "dei_EntityFilerCategory": {
     "auth_ref": [
      "r373"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
        "label": "Entity Filer Category"
       }
      }
     },
     "localname": "EntityFilerCategory",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.windtreetx.com/20220630/role/statement-document-and-entity-information"
     ],
     "xbrltype": "filerCategoryItemType"
    },
    "dei_EntityIncorporationStateCountryCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Two-character EDGAR code representing the state or country of incorporation.",
        "label": "Entity Incorporation, State or Country Code"
       }
      }
     },
     "localname": "EntityIncorporationStateCountryCode",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.windtreetx.com/20220630/role/statement-document-and-entity-information"
     ],
     "xbrltype": "edgarStateCountryItemType"
    },
    "dei_EntityInteractiveDataCurrent": {
     "auth_ref": [
      "r378"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).",
        "label": "Entity Interactive Data Current"
       }
      }
     },
     "localname": "EntityInteractiveDataCurrent",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.windtreetx.com/20220630/role/statement-document-and-entity-information"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityRegistrantName": {
     "auth_ref": [
      "r373"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.",
        "label": "Entity Registrant Name"
       }
      }
     },
     "localname": "EntityRegistrantName",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.windtreetx.com/20220630/role/statement-document-and-entity-information"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityShellCompany": {
     "auth_ref": [
      "r373"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.",
        "label": "Entity Shell Company"
       }
      }
     },
     "localname": "EntityShellCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.windtreetx.com/20220630/role/statement-document-and-entity-information"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntitySmallBusiness": {
     "auth_ref": [
      "r373"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicates that the company is a Smaller Reporting Company (SRC).",
        "label": "Entity Small Business"
       }
      }
     },
     "localname": "EntitySmallBusiness",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.windtreetx.com/20220630/role/statement-document-and-entity-information"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityTaxIdentificationNumber": {
     "auth_ref": [
      "r373"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.",
        "label": "Entity Tax Identification Number"
       }
      }
     },
     "localname": "EntityTaxIdentificationNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.windtreetx.com/20220630/role/statement-document-and-entity-information"
     ],
     "xbrltype": "employerIdItemType"
    },
    "dei_LegalEntityAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The set of legal entities associated with a report.",
        "label": "Legal Entity [Axis]"
       }
      }
     },
     "localname": "LegalEntityAxis",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.windtreetx.com/20220630/role/statement-condensed-consolidated-balance-sheets-current-period-unaudited",
      "http://www.windtreetx.com/20220630/role/statement-condensed-consolidated-balance-sheets-current-period-unaudited-parentheticals",
      "http://www.windtreetx.com/20220630/role/statement-condensed-consolidated-statements-of-cash-flows-unaudited-",
      "http://www.windtreetx.com/20220630/role/statement-condensed-consolidated-statements-of-operations-unaudited",
      "http://www.windtreetx.com/20220630/role/statement-document-and-entity-information",
      "http://www.windtreetx.com/20220630/role/statement-note-1-the-company-and-description-of-business",
      "http://www.windtreetx.com/20220630/role/statement-note-10-licensing-and-research-funding-agreements",
      "http://www.windtreetx.com/20220630/role/statement-note-10-licensing-and-research-funding-agreements-details-textual",
      "http://www.windtreetx.com/20220630/role/statement-note-2-basis-of-presentation",
      "http://www.windtreetx.com/20220630/role/statement-note-3-going-concern-and-managements-plans",
      "http://www.windtreetx.com/20220630/role/statement-note-3-going-concern-and-managements-plans-details-textual",
      "http://www.windtreetx.com/20220630/role/statement-note-4-summary-of-significant-accounting-policies",
      "http://www.windtreetx.com/20220630/role/statement-note-4-summary-of-significant-accounting-policies-details-textual",
      "http://www.windtreetx.com/20220630/role/statement-note-4-summary-of-significant-accounting-policies-intangible-assets-details",
      "http://www.windtreetx.com/20220630/role/statement-note-4-summary-of-significant-accounting-policies-tables",
      "http://www.windtreetx.com/20220630/role/statement-note-5-fair-value-measurements",
      "http://www.windtreetx.com/20220630/role/statement-note-5-fair-value-measurements-assets-and-liabilities-measured-at-fair-value-on-a-recurring-basis-details",
      "http://www.windtreetx.com/20220630/role/statement-note-5-fair-value-measurements-tables",
      "http://www.windtreetx.com/20220630/role/statement-note-6-loans-payable",
      "http://www.windtreetx.com/20220630/role/statement-note-6-loans-payable-details-textual",
      "http://www.windtreetx.com/20220630/role/statement-note-7-restructured-debt-liability",
      "http://www.windtreetx.com/20220630/role/statement-note-7-restructured-debt-liability-details-textual",
      "http://www.windtreetx.com/20220630/role/statement-note-8-stockholders-equity",
      "http://www.windtreetx.com/20220630/role/statement-note-8-stockholders-equity-details-textual",
      "http://www.windtreetx.com/20220630/role/statement-note-9-stockbased-compensation",
      "http://www.windtreetx.com/20220630/role/statement-note-9-stockbased-compensation-details-textual",
      "http://www.windtreetx.com/20220630/role/statement-note-9-stockbased-compensation-restricted-stock-units-details",
      "http://www.windtreetx.com/20220630/role/statement-note-9-stockbased-compensation-stock-options-valuation-assumptions-details",
      "http://www.windtreetx.com/20220630/role/statement-note-9-stockbased-compensation-stockbased-compensation-expense-details",
      "http://www.windtreetx.com/20220630/role/statement-note-9-stockbased-compensation-summary-of-stock-option-activity-details",
      "http://www.windtreetx.com/20220630/role/statement-note-9-stockbased-compensation-tables",
      "http://www.windtreetx.com/20220630/role/statement-significant-accounting-policies-policies"
     ],
     "xbrltype": "stringItemType"
    },
    "dei_LocalPhoneNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Local phone number for entity.",
        "label": "Local Phone Number"
       }
      }
     },
     "localname": "LocalPhoneNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.windtreetx.com/20220630/role/statement-document-and-entity-information"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_Security12bTitle": {
     "auth_ref": [
      "r372"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Title of a 12(b) registered security.",
        "label": "Title of 12(b) Security"
       }
      }
     },
     "localname": "Security12bTitle",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.windtreetx.com/20220630/role/statement-document-and-entity-information"
     ],
     "xbrltype": "securityTitleItemType"
    },
    "dei_SecurityExchangeName": {
     "auth_ref": [
      "r374"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the Exchange on which a security is registered.",
        "label": "Security Exchange Name"
       }
      }
     },
     "localname": "SecurityExchangeName",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.windtreetx.com/20220630/role/statement-document-and-entity-information"
     ],
     "xbrltype": "edgarExchangeCodeItemType"
    },
    "dei_TradingSymbol": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Trading symbol of an instrument as listed on an exchange.",
        "label": "Trading Symbol"
       }
      }
     },
     "localname": "TradingSymbol",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.windtreetx.com/20220630/role/statement-document-and-entity-information"
     ],
     "xbrltype": "tradingSymbolItemType"
    },
    "srt_CounterpartyNameAxis": {
     "auth_ref": [
      "r32",
      "r34",
      "r69",
      "r70",
      "r165",
      "r186"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Counterparty Name [Axis]"
       }
      }
     },
     "localname": "CounterpartyNameAxis",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.windtreetx.com/20220630/role/statement-note-10-licensing-and-research-funding-agreements",
      "http://www.windtreetx.com/20220630/role/statement-note-10-licensing-and-research-funding-agreements-details-textual",
      "http://www.windtreetx.com/20220630/role/statement-note-7-restructured-debt-liability",
      "http://www.windtreetx.com/20220630/role/statement-note-7-restructured-debt-liability-details-textual"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_MinimumMember": {
     "auth_ref": [
      "r145",
      "r146",
      "r147",
      "r148",
      "r164",
      "r185",
      "r214",
      "r215",
      "r329",
      "r330",
      "r331",
      "r332",
      "r333",
      "r334",
      "r335",
      "r361",
      "r362",
      "r369",
      "r370"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Minimum [Member]"
       }
      }
     },
     "localname": "MinimumMember",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.windtreetx.com/20220630/role/statement-note-9-stockbased-compensation",
      "http://www.windtreetx.com/20220630/role/statement-note-9-stockbased-compensation-details-textual"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_RangeAxis": {
     "auth_ref": [
      "r143",
      "r145",
      "r146",
      "r147",
      "r148",
      "r164",
      "r185",
      "r205",
      "r214",
      "r215",
      "r244",
      "r245",
      "r246",
      "r329",
      "r330",
      "r331",
      "r332",
      "r333",
      "r334",
      "r335",
      "r361",
      "r362",
      "r369",
      "r370"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statistical Measurement [Axis]"
       }
      }
     },
     "localname": "RangeAxis",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.windtreetx.com/20220630/role/statement-note-9-stockbased-compensation",
      "http://www.windtreetx.com/20220630/role/statement-note-9-stockbased-compensation-details-textual"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_RangeMember": {
     "auth_ref": [
      "r143",
      "r145",
      "r146",
      "r147",
      "r148",
      "r164",
      "r185",
      "r205",
      "r214",
      "r215",
      "r244",
      "r245",
      "r246",
      "r329",
      "r330",
      "r331",
      "r332",
      "r333",
      "r334",
      "r335",
      "r361",
      "r362",
      "r369",
      "r370"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statistical Measurement [Domain]"
       }
      }
     },
     "localname": "RangeMember",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.windtreetx.com/20220630/role/statement-note-9-stockbased-compensation",
      "http://www.windtreetx.com/20220630/role/statement-note-9-stockbased-compensation-details-textual"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_RepurchaseAgreementCounterpartyNameDomain": {
     "auth_ref": [
      "r33",
      "r34",
      "r69",
      "r70",
      "r165",
      "r186"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Counterparty Name [Domain]"
       }
      }
     },
     "localname": "RepurchaseAgreementCounterpartyNameDomain",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.windtreetx.com/20220630/role/statement-note-10-licensing-and-research-funding-agreements",
      "http://www.windtreetx.com/20220630/role/statement-note-10-licensing-and-research-funding-agreements-details-textual",
      "http://www.windtreetx.com/20220630/role/statement-note-7-restructured-debt-liability",
      "http://www.windtreetx.com/20220630/role/statement-note-7-restructured-debt-liability-details-textual"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_TitleOfIndividualAxis": {
     "auth_ref": [
      "r120",
      "r321"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Title of Individual [Axis]"
       }
      }
     },
     "localname": "TitleOfIndividualAxis",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.windtreetx.com/20220630/role/statement-note-9-stockbased-compensation",
      "http://www.windtreetx.com/20220630/role/statement-note-9-stockbased-compensation-details-textual"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_TitleOfIndividualWithRelationshipToEntityDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Title of Individual [Domain]"
       }
      }
     },
     "localname": "TitleOfIndividualWithRelationshipToEntityDomain",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.windtreetx.com/20220630/role/statement-note-9-stockbased-compensation",
      "http://www.windtreetx.com/20220630/role/statement-note-9-stockbased-compensation-details-textual"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AccountingPoliciesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accounting Policies [Abstract]"
       }
      }
     },
     "localname": "AccountingPoliciesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.windtreetx.com/20220630/role/statement-significant-accounting-policies-policies"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AccountsPayableCurrent": {
     "auth_ref": [
      "r21",
      "r324"
     ],
     "calculation": {
      "http://www.windtreetx.com/20220630/role/statement-condensed-consolidated-balance-sheets-current-period-unaudited": {
       "order": 2.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accounts payable"
       }
      }
     },
     "localname": "AccountsPayableCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.windtreetx.com/20220630/role/statement-condensed-consolidated-balance-sheets-current-period-unaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccruedLiabilitiesCurrent": {
     "auth_ref": [
      "r25"
     ],
     "calculation": {
      "http://www.windtreetx.com/20220630/role/statement-condensed-consolidated-balance-sheets-current-period-unaudited": {
       "order": 1.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "us-gaap_AccruedLiabilitiesCurrent",
        "verboseLabel": "Accrued expenses"
       }
      }
     },
     "localname": "AccruedLiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.windtreetx.com/20220630/role/statement-condensed-consolidated-balance-sheets-current-period-unaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdditionalPaidInCapital": {
     "auth_ref": [
      "r15",
      "r324"
     ],
     "calculation": {
      "http://www.windtreetx.com/20220630/role/statement-condensed-consolidated-balance-sheets-current-period-unaudited": {
       "order": 4.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of excess of issue price over par or stated value of stock and from other transaction involving stock or stockholder. Includes, but is not limited to, additional paid-in capital (APIC) for common and preferred stock.",
        "label": "Additional paid-in capital"
       }
      }
     },
     "localname": "AdditionalPaidInCapital",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.windtreetx.com/20220630/role/statement-condensed-consolidated-balance-sheets-current-period-unaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdditionalPaidInCapitalMember": {
     "auth_ref": [
      "r73",
      "r74",
      "r75",
      "r254",
      "r255",
      "r256",
      "r286"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders.",
        "label": "Additional Paid-in Capital [Member]"
       }
      }
     },
     "localname": "AdditionalPaidInCapitalMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.windtreetx.com/20220630/role/statement-condensed-consolidated-statements-of-changes-in-stockholders-equity-unaudited-"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue": {
     "auth_ref": [
      "r216",
      "r257",
      "r258"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement.",
        "label": "Stock-based compensation expense"
       }
      }
     },
     "localname": "AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.windtreetx.com/20220630/role/statement-condensed-consolidated-statements-of-changes-in-stockholders-equity-unaudited-"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustments to reconcile net loss to net cash used in operating activities:"
       }
      }
     },
     "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.windtreetx.com/20220630/role/statement-condensed-consolidated-statements-of-cash-flows-unaudited-"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AllocatedShareBasedCompensationExpense": {
     "auth_ref": [
      "r249"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.",
        "label": "us-gaap_AllocatedShareBasedCompensationExpense",
        "terseLabel": "Stock-based compensation expense"
       }
      }
     },
     "localname": "AllocatedShareBasedCompensationExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.windtreetx.com/20220630/role/statement-note-9-stockbased-compensation-stockbased-compensation-expense-details"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ArrangementsAndNonarrangementTransactionsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations.",
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Domain]"
       }
      }
     },
     "localname": "ArrangementsAndNonarrangementTransactionsMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.windtreetx.com/20220630/role/statement-note-10-licensing-and-research-funding-agreements",
      "http://www.windtreetx.com/20220630/role/statement-note-10-licensing-and-research-funding-agreements-details-textual",
      "http://www.windtreetx.com/20220630/role/statement-note-4-summary-of-significant-accounting-policies",
      "http://www.windtreetx.com/20220630/role/statement-note-4-summary-of-significant-accounting-policies-details-textual",
      "http://www.windtreetx.com/20220630/role/statement-note-7-restructured-debt-liability",
      "http://www.windtreetx.com/20220630/role/statement-note-7-restructured-debt-liability-details-textual"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_Assets": {
     "auth_ref": [
      "r8",
      "r66",
      "r112",
      "r114",
      "r118",
      "r122",
      "r150",
      "r151",
      "r152",
      "r153",
      "r154",
      "r155",
      "r156",
      "r157",
      "r158",
      "r159",
      "r160",
      "r279",
      "r282",
      "r297",
      "r322",
      "r324",
      "r340",
      "r353"
     ],
     "calculation": {
      "http://www.windtreetx.com/20220630/role/statement-condensed-consolidated-balance-sheets-current-period-unaudited": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "us-gaap_Assets",
        "totalLabel": "Total assets"
       }
      }
     },
     "localname": "Assets",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.windtreetx.com/20220630/role/statement-condensed-consolidated-balance-sheets-current-period-unaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetsCurrent": {
     "auth_ref": [
      "r4",
      "r20",
      "r66",
      "r122",
      "r150",
      "r151",
      "r152",
      "r153",
      "r154",
      "r155",
      "r156",
      "r157",
      "r158",
      "r159",
      "r160",
      "r279",
      "r282",
      "r297",
      "r322",
      "r324"
     ],
     "calculation": {
      "http://www.windtreetx.com/20220630/role/statement-condensed-consolidated-balance-sheets-current-period-unaudited": {
       "order": 2.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "us-gaap_AssetsCurrent",
        "totalLabel": "Total current assets"
       }
      }
     },
     "localname": "AssetsCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.windtreetx.com/20220630/role/statement-condensed-consolidated-balance-sheets-current-period-unaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetsCurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Current Assets:"
       }
      }
     },
     "localname": "AssetsCurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.windtreetx.com/20220630/role/statement-condensed-consolidated-balance-sheets-current-period-unaudited"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AssetsFairValueDisclosure": {
     "auth_ref": [
      "r289"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value portion of probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "us-gaap_AssetsFairValueDisclosure",
        "terseLabel": "Total Assets"
       }
      }
     },
     "localname": "AssetsFairValueDisclosure",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.windtreetx.com/20220630/role/statement-note-5-fair-value-measurements-assets-and-liabilities-measured-at-fair-value-on-a-recurring-basis-details"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AwardTypeAxis": {
     "auth_ref": [
      "r220",
      "r221",
      "r222",
      "r224",
      "r225",
      "r226",
      "r227",
      "r228",
      "r229",
      "r230",
      "r231",
      "r232",
      "r233",
      "r234",
      "r235",
      "r236",
      "r237",
      "r238",
      "r239",
      "r240",
      "r241",
      "r243",
      "r244",
      "r245",
      "r246",
      "r247"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of award under share-based payment arrangement.",
        "label": "Award Type [Axis]"
       }
      }
     },
     "localname": "AwardTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.windtreetx.com/20220630/role/statement-note-9-stockbased-compensation",
      "http://www.windtreetx.com/20220630/role/statement-note-9-stockbased-compensation-details-textual",
      "http://www.windtreetx.com/20220630/role/statement-note-9-stockbased-compensation-restricted-stock-units-details"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_BasisOfAccounting": {
     "auth_ref": [
      "r72"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for the basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).",
        "label": "Basis of Accounting [Text Block]"
       }
      }
     },
     "localname": "BasisOfAccounting",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.windtreetx.com/20220630/role/statement-note-2-basis-of-presentation"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CashAndCashEquivalentsAtCarryingValue": {
     "auth_ref": [
      "r3",
      "r6",
      "r58"
     ],
     "calculation": {
      "http://www.windtreetx.com/20220630/role/statement-condensed-consolidated-balance-sheets-current-period-unaudited": {
       "order": 1.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.",
        "label": "Cash and cash equivalents",
        "terseLabel": "Cash and Cash Equivalents, at Carrying Value, Total"
       }
      }
     },
     "localname": "CashAndCashEquivalentsAtCarryingValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.windtreetx.com/20220630/role/statement-condensed-consolidated-balance-sheets-current-period-unaudited",
      "http://www.windtreetx.com/20220630/role/statement-note-3-going-concern-and-managements-plans-details-textual"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashAndCashEquivalentsAxis": {
     "auth_ref": [
      "r6"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of cash and cash equivalent balance.",
        "label": "Cash and Cash Equivalents [Axis]"
       }
      }
     },
     "localname": "CashAndCashEquivalentsAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.windtreetx.com/20220630/role/statement-note-5-fair-value-measurements-assets-and-liabilities-measured-at-fair-value-on-a-recurring-basis-details"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_CashAndCashEquivalentsFairValueDisclosure": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value portion of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "us-gaap_CashAndCashEquivalentsFairValueDisclosure",
        "terseLabel": "Cash equivalents"
       }
      }
     },
     "localname": "CashAndCashEquivalentsFairValueDisclosure",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.windtreetx.com/20220630/role/statement-note-5-fair-value-measurements-assets-and-liabilities-measured-at-fair-value-on-a-recurring-basis-details"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashAndCashEquivalentsPolicyTextBlock": {
     "auth_ref": [
      "r59"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value.",
        "label": "Cash and Cash Equivalents, Policy [Policy Text Block]"
       }
      }
     },
     "localname": "CashAndCashEquivalentsPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.windtreetx.com/20220630/role/statement-significant-accounting-policies-policies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations": {
     "auth_ref": [
      "r53",
      "r58",
      "r60"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including, but not limited to, disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations",
        "periodEndLabel": "Cash, cash equivalents, and restricted cash - end of period",
        "periodStartLabel": "Cash, cash equivalents, and restricted cash - beginning of period"
       }
      }
     },
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.windtreetx.com/20220630/role/statement-condensed-consolidated-statements-of-cash-flows-unaudited-"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect": {
     "auth_ref": [
      "r53",
      "r302"
     ],
     "calculation": {
      "http://www.windtreetx.com/20220630/role/statement-condensed-consolidated-statements-of-cash-flows-unaudited-": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
        "totalLabel": "Net (decrease) increase in cash, cash equivalents, and restricted cash"
       }
      }
     },
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.windtreetx.com/20220630/role/statement-condensed-consolidated-statements-of-cash-flows-unaudited-"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ClassOfStockDomain": {
     "auth_ref": [
      "r12",
      "r13",
      "r14",
      "r63",
      "r66",
      "r87",
      "r88",
      "r89",
      "r91",
      "r93",
      "r99",
      "r100",
      "r101",
      "r122",
      "r150",
      "r154",
      "r155",
      "r156",
      "r159",
      "r160",
      "r183",
      "r184",
      "r188",
      "r192",
      "r198",
      "r297",
      "r377"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share of stock differentiated by the voting rights the holder receives. Examples include, but are not limited to, common stock, redeemable preferred stock, nonredeemable preferred stock, and convertible stock.",
        "label": "Class of Stock [Domain]"
       }
      }
     },
     "localname": "ClassOfStockDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.windtreetx.com/20220630/role/statement-condensed-consolidated-statements-of-changes-in-stockholders-equity-unaudited-"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ClassOfWarrantOrRightAxis": {
     "auth_ref": [
      "r203",
      "r217"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of warrant or right issued.",
        "label": "Class of Warrant or Right [Axis]"
       }
      }
     },
     "localname": "ClassOfWarrantOrRightAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.windtreetx.com/20220630/role/statement-note-8-stockholders-equity",
      "http://www.windtreetx.com/20220630/role/statement-note-8-stockholders-equity-details-textual"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ClassOfWarrantOrRightDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the class or type of warrant or right outstanding. Warrants and rights represent derivative securities that give the holder the right to purchase securities (usually equity) from the issuer at a specific price within a certain time frame. Warrants are often included in a new debt issue to entice investors by a higher return potential. The main difference between warrants and call options is that warrants are issued and guaranteed by the company, whereas options are exchange instruments and are not issued by the company. Also, the lifetime of a warrant is often measured in years, while the lifetime of a typical option is measured in months.",
        "label": "Class of Warrant or Right [Domain]"
       }
      }
     },
     "localname": "ClassOfWarrantOrRightDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.windtreetx.com/20220630/role/statement-note-8-stockholders-equity",
      "http://www.windtreetx.com/20220630/role/statement-note-8-stockholders-equity-details-textual"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1": {
     "auth_ref": [
      "r199"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Exercise price per share or per unit of warrants or rights outstanding.",
        "label": "us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1",
        "terseLabel": "Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share)"
       }
      }
     },
     "localname": "ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.windtreetx.com/20220630/role/statement-note-8-stockholders-equity-details-textual"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_CommonStockMember": {
     "auth_ref": [
      "r73",
      "r74",
      "r286"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stock that is subordinate to all other stock of the issuer.",
        "label": "Common Stock [Member]"
       }
      }
     },
     "localname": "CommonStockMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.windtreetx.com/20220630/role/statement-condensed-consolidated-statements-of-changes-in-stockholders-equity-unaudited-"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CommonStockParOrStatedValuePerShare": {
     "auth_ref": [
      "r14"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Face amount or stated value per share of common stock.",
        "label": "Common stock, par value (in dollars per share)"
       }
      }
     },
     "localname": "CommonStockParOrStatedValuePerShare",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.windtreetx.com/20220630/role/statement-condensed-consolidated-balance-sheets-current-period-unaudited-parentheticals"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_CommonStockSharesAuthorized": {
     "auth_ref": [
      "r14"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws.",
        "label": "Common stock, shares authorize (in shares)"
       }
      }
     },
     "localname": "CommonStockSharesAuthorized",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.windtreetx.com/20220630/role/statement-condensed-consolidated-balance-sheets-current-period-unaudited-parentheticals"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockSharesIssued": {
     "auth_ref": [
      "r14"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.",
        "label": "Common stock, shares issued (in shares)"
       }
      }
     },
     "localname": "CommonStockSharesIssued",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.windtreetx.com/20220630/role/statement-condensed-consolidated-balance-sheets-current-period-unaudited-parentheticals"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockSharesOutstanding": {
     "auth_ref": [
      "r14",
      "r198"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.",
        "label": "Common stock, shares outstanding (in shares)"
       }
      }
     },
     "localname": "CommonStockSharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.windtreetx.com/20220630/role/statement-condensed-consolidated-balance-sheets-current-period-unaudited-parentheticals"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockValue": {
     "auth_ref": [
      "r14",
      "r324"
     ],
     "calculation": {
      "http://www.windtreetx.com/20220630/role/statement-condensed-consolidated-balance-sheets-current-period-unaudited": {
       "order": 1.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.",
        "label": "Common stock, $0.001 par value; 120,000,000 shares authorized at June 30, 2022 and December 31, 2021; 29,406,196 and 28,268,950 shares issued at June 30, 2022 and December 31, 2021, respectively; 29,406,172 and 28,268,926 shares outstanding at June 30, 2022 and December 31, 2021, respectively"
       }
      }
     },
     "localname": "CommonStockValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.windtreetx.com/20220630/role/statement-condensed-consolidated-balance-sheets-current-period-unaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ConsolidationPolicyTextBlock": {
     "auth_ref": [
      "r62",
      "r281"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy regarding (1) the principles it follows in consolidating or combining the separate financial statements, including the principles followed in determining the inclusion or exclusion of subsidiaries or other entities in the consolidated or combined financial statements and (2) its treatment of interests (for example, common stock, a partnership interest or other means of exerting influence) in other entities, for example consolidation or use of the equity or cost methods of accounting. The accounting policy may also address the accounting treatment for intercompany accounts and transactions, noncontrolling interest, and the income statement treatment in consolidation for issuances of stock by a subsidiary.",
        "label": "Consolidation, Policy [Policy Text Block]"
       }
      }
     },
     "localname": "ConsolidationPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.windtreetx.com/20220630/role/statement-significant-accounting-policies-policies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ContractualObligation": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of contractual obligation, including but not limited to, long-term debt, capital lease obligations, operating lease obligations, purchase obligations, and other commitments.",
        "label": "us-gaap_ContractualObligation",
        "terseLabel": "Contractual Obligation, Total"
       }
      }
     },
     "localname": "ContractualObligation",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.windtreetx.com/20220630/role/statement-note-10-licensing-and-research-funding-agreements-details-textual"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtInstrumentAxis": {
     "auth_ref": [
      "r9",
      "r10",
      "r11",
      "r65",
      "r71",
      "r161",
      "r162",
      "r163",
      "r164",
      "r165",
      "r166",
      "r167",
      "r168",
      "r169",
      "r170",
      "r171",
      "r172",
      "r173",
      "r174",
      "r175",
      "r176",
      "r177",
      "r178",
      "r179",
      "r180",
      "r181",
      "r314",
      "r341",
      "r342",
      "r352"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of debt instrument, including, but not limited to, draws against credit facilities.",
        "label": "Debt Instrument [Axis]"
       }
      }
     },
     "localname": "DebtInstrumentAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.windtreetx.com/20220630/role/statement-note-6-loans-payable",
      "http://www.windtreetx.com/20220630/role/statement-note-6-loans-payable-details-textual"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtInstrumentFaceAmount": {
     "auth_ref": [
      "r161",
      "r178",
      "r179",
      "r312",
      "r314",
      "r315"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Face (par) amount of debt instrument at time of issuance.",
        "label": "us-gaap_DebtInstrumentFaceAmount",
        "terseLabel": "Debt Instrument, Face Amount"
       }
      }
     },
     "localname": "DebtInstrumentFaceAmount",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.windtreetx.com/20220630/role/statement-note-6-loans-payable-details-textual"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtInstrumentInterestRateStatedPercentage": {
     "auth_ref": [
      "r27",
      "r162"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Contractual interest rate for funds borrowed, under the debt agreement.",
        "label": "us-gaap_DebtInstrumentInterestRateStatedPercentage",
        "terseLabel": "Debt Instrument, Interest Rate, Stated Percentage"
       }
      }
     },
     "localname": "DebtInstrumentInterestRateStatedPercentage",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.windtreetx.com/20220630/role/statement-note-6-loans-payable-details-textual"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_DebtInstrumentNameDomain": {
     "auth_ref": [
      "r28",
      "r65",
      "r71",
      "r161",
      "r162",
      "r163",
      "r164",
      "r165",
      "r166",
      "r167",
      "r168",
      "r169",
      "r170",
      "r171",
      "r172",
      "r173",
      "r174",
      "r175",
      "r176",
      "r177",
      "r178",
      "r179",
      "r180",
      "r181",
      "r314"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The name for the particular debt instrument or borrowing that distinguishes it from other debt instruments or borrowings, including draws against credit facilities.",
        "label": "Debt Instrument, Name [Domain]"
       }
      }
     },
     "localname": "DebtInstrumentNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.windtreetx.com/20220630/role/statement-note-6-loans-payable",
      "http://www.windtreetx.com/20220630/role/statement-note-6-loans-payable-details-textual"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DebtInstrumentPeriodicPayment": {
     "auth_ref": [
      "r28",
      "r350"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of the required periodic payments including both interest and principal payments.",
        "label": "us-gaap_DebtInstrumentPeriodicPayment",
        "terseLabel": "Debt Instrument, Periodic Payment, Total"
       }
      }
     },
     "localname": "DebtInstrumentPeriodicPayment",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.windtreetx.com/20220630/role/statement-note-6-loans-payable-details-textual"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredIncomeTaxExpenseBenefit": {
     "auth_ref": [
      "r56",
      "r67",
      "r269",
      "r274",
      "r275",
      "r276"
     ],
     "calculation": {
      "http://www.windtreetx.com/20220630/role/statement-condensed-consolidated-statements-of-cash-flows-unaudited-": {
       "order": 10.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred income tax expense (benefit) pertaining to income (loss) from continuing operations.",
        "label": "Deferred income tax benefit",
        "terseLabel": "Deferred Income Tax Expense (Benefit), Total"
       }
      }
     },
     "localname": "DeferredIncomeTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.windtreetx.com/20220630/role/statement-condensed-consolidated-statements-of-cash-flows-unaudited-",
      "http://www.windtreetx.com/20220630/role/statement-note-3-going-concern-and-managements-plans-details-textual",
      "http://www.windtreetx.com/20220630/role/statement-note-4-summary-of-significant-accounting-policies-details-textual"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredIncomeTaxLiabilitiesNet": {
     "auth_ref": [
      "r263",
      "r264"
     ],
     "calculation": {
      "http://www.windtreetx.com/20220630/role/statement-condensed-consolidated-balance-sheets-current-period-unaudited": {
       "order": 0.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after deferred tax asset, of deferred tax liability attributable to taxable differences with jurisdictional netting.",
        "label": "Deferred tax liabilities"
       }
      }
     },
     "localname": "DeferredIncomeTaxLiabilitiesNet",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.windtreetx.com/20220630/role/statement-condensed-consolidated-balance-sheets-current-period-unaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_Depreciation": {
     "auth_ref": [
      "r56",
      "r137"
     ],
     "calculation": {
      "http://www.windtreetx.com/20220630/role/statement-condensed-consolidated-statements-of-cash-flows-unaudited-": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.",
        "label": "us-gaap_Depreciation",
        "terseLabel": "Depreciation, Total",
        "verboseLabel": "Depreciation and amortization"
       }
      }
     },
     "localname": "Depreciation",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.windtreetx.com/20220630/role/statement-condensed-consolidated-statements-of-cash-flows-unaudited-",
      "http://www.windtreetx.com/20220630/role/statement-note-4-summary-of-significant-accounting-policies-details-textual"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock": {
     "auth_ref": [
      "r219",
      "r220",
      "r250",
      "r251",
      "r252",
      "r259"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for share-based payment arrangement.",
        "label": "Share-Based Payment Arrangement [Text Block]"
       }
      }
     },
     "localname": "DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.windtreetx.com/20220630/role/statement-note-9-stockbased-compensation"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock": {
     "auth_ref": [
      "r218",
      "r253"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of share-based payment arrangement.",
        "label": "Disclosure of Share-Based Compensation Arrangements by Share-Based Payment Award [Table Text Block]"
       }
      }
     },
     "localname": "DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.windtreetx.com/20220630/role/statement-note-9-stockbased-compensation-tables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_DisclosureTextBlockAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "us-gaap_DisclosureTextBlockAbstract",
        "terseLabel": "Notes to Financial Statements"
       }
      }
     },
     "localname": "DisclosureTextBlockAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.windtreetx.com/20220630/role/statement-note-1-the-company-and-description-of-business",
      "http://www.windtreetx.com/20220630/role/statement-note-10-licensing-and-research-funding-agreements",
      "http://www.windtreetx.com/20220630/role/statement-note-2-basis-of-presentation",
      "http://www.windtreetx.com/20220630/role/statement-note-3-going-concern-and-managements-plans",
      "http://www.windtreetx.com/20220630/role/statement-note-4-summary-of-significant-accounting-policies",
      "http://www.windtreetx.com/20220630/role/statement-note-5-fair-value-measurements",
      "http://www.windtreetx.com/20220630/role/statement-note-6-loans-payable",
      "http://www.windtreetx.com/20220630/role/statement-note-7-restructured-debt-liability",
      "http://www.windtreetx.com/20220630/role/statement-note-8-stockholders-equity",
      "http://www.windtreetx.com/20220630/role/statement-note-9-stockbased-compensation"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_EarningsPerShareAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net loss per common share"
       }
      }
     },
     "localname": "EarningsPerShareAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.windtreetx.com/20220630/role/statement-condensed-consolidated-statements-of-operations-unaudited"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_EarningsPerShareBasic": {
     "auth_ref": [
      "r44",
      "r78",
      "r79",
      "r80",
      "r81",
      "r82",
      "r86",
      "r87",
      "r91",
      "r92",
      "r93",
      "r96",
      "r97",
      "r287",
      "r288",
      "r346",
      "r358"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.",
        "label": "us-gaap_EarningsPerShareBasic",
        "terseLabel": "Basic and diluted (in dollars per share)"
       }
      }
     },
     "localname": "EarningsPerShareBasic",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.windtreetx.com/20220630/role/statement-condensed-consolidated-statements-of-operations-unaudited"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_EarningsPerShareBasicAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Weighted average number of common shares outstanding"
       }
      }
     },
     "localname": "EarningsPerShareBasicAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.windtreetx.com/20220630/role/statement-condensed-consolidated-statements-of-operations-unaudited"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_EarningsPerSharePolicyTextBlock": {
     "auth_ref": [
      "r94",
      "r95"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements.",
        "label": "Earnings Per Share, Policy [Policy Text Block]"
       }
      }
     },
     "localname": "EarningsPerSharePolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.windtreetx.com/20220630/role/statement-significant-accounting-policies-policies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_EmployeeBenefitsAndShareBasedCompensation": {
     "auth_ref": [],
     "calculation": {
      "http://www.windtreetx.com/20220630/role/statement-condensed-consolidated-statements-of-cash-flows-unaudited-": {
       "order": 0.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expense for employee benefit and equity-based compensation.",
        "label": "Stock-based compensation"
       }
      }
     },
     "localname": "EmployeeBenefitsAndShareBasedCompensation",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.windtreetx.com/20220630/role/statement-condensed-consolidated-statements-of-cash-flows-unaudited-"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EquityComponentDomain": {
     "auth_ref": [
      "r0",
      "r38",
      "r39",
      "r40",
      "r73",
      "r74",
      "r75",
      "r77",
      "r83",
      "r85",
      "r98",
      "r123",
      "r198",
      "r200",
      "r254",
      "r255",
      "r256",
      "r271",
      "r272",
      "r286",
      "r303",
      "r304",
      "r305",
      "r306",
      "r307",
      "r308",
      "r320",
      "r363",
      "r364",
      "r365"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc.",
        "label": "Equity Component [Domain]"
       }
      }
     },
     "localname": "EquityComponentDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.windtreetx.com/20220630/role/statement-condensed-consolidated-statements-of-changes-in-stockholders-equity-unaudited-"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ExtinguishmentOfDebtAmount": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Gross amount of debt extinguished.",
        "label": "us-gaap_ExtinguishmentOfDebtAmount",
        "terseLabel": "Extinguishment of Debt, Amount"
       }
      }
     },
     "localname": "ExtinguishmentOfDebtAmount",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.windtreetx.com/20220630/role/statement-note-7-restructured-debt-liability-details-textual"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FairValueByFairValueHierarchyLevelAxis": {
     "auth_ref": [
      "r170",
      "r178",
      "r179",
      "r206",
      "r207",
      "r208",
      "r209",
      "r210",
      "r211",
      "r212",
      "r213",
      "r290",
      "r326",
      "r327",
      "r328"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by level within fair value hierarchy and fair value measured at net asset value per share as practical expedient.",
        "label": "Fair Value Hierarchy and NAV [Axis]"
       }
      }
     },
     "localname": "FairValueByFairValueHierarchyLevelAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.windtreetx.com/20220630/role/statement-note-5-fair-value-measurements-assets-and-liabilities-measured-at-fair-value-on-a-recurring-basis-details"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueByMeasurementFrequencyAxis": {
     "auth_ref": [
      "r289",
      "r290",
      "r291",
      "r292",
      "r294"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by measurement frequency.",
        "label": "Measurement Frequency [Axis]"
       }
      }
     },
     "localname": "FairValueByMeasurementFrequencyAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.windtreetx.com/20220630/role/statement-note-5-fair-value-measurements-assets-and-liabilities-measured-at-fair-value-on-a-recurring-basis-details"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueDisclosuresTextBlock": {
     "auth_ref": [
      "r293"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.",
        "label": "Fair Value Disclosures [Text Block]"
       }
      }
     },
     "localname": "FairValueDisclosuresTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.windtreetx.com/20220630/role/statement-note-5-fair-value-measurements"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FairValueInputsLevel1Member": {
     "auth_ref": [
      "r170",
      "r206",
      "r207",
      "r212",
      "r213",
      "r290",
      "r326"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Quoted prices in active markets for identical assets or liabilities that the reporting entity can access at the measurement date.",
        "label": "Fair Value, Inputs, Level 1 [Member]"
       }
      }
     },
     "localname": "FairValueInputsLevel1Member",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.windtreetx.com/20220630/role/statement-note-5-fair-value-measurements-assets-and-liabilities-measured-at-fair-value-on-a-recurring-basis-details"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueMeasurementFrequencyDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Measurement frequency.",
        "label": "Measurement Frequency [Domain]"
       }
      }
     },
     "localname": "FairValueMeasurementFrequencyDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.windtreetx.com/20220630/role/statement-note-5-fair-value-measurements-assets-and-liabilities-measured-at-fair-value-on-a-recurring-basis-details"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueMeasurementsFairValueHierarchyDomain": {
     "auth_ref": [
      "r170",
      "r178",
      "r179",
      "r206",
      "r207",
      "r208",
      "r209",
      "r210",
      "r211",
      "r212",
      "r213",
      "r326",
      "r327",
      "r328"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Categories used to prioritize the inputs to valuation techniques to measure fair value.",
        "label": "Fair Value Hierarchy and NAV [Domain]"
       }
      }
     },
     "localname": "FairValueMeasurementsFairValueHierarchyDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.windtreetx.com/20220630/role/statement-note-5-fair-value-measurements-assets-and-liabilities-measured-at-fair-value-on-a-recurring-basis-details"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueMeasurementsRecurringMember": {
     "auth_ref": [
      "r293",
      "r294"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Frequent fair value measurement. Includes, but is not limited to, fair value adjustment for impairment of asset, liability or equity, frequently measured at fair value.",
        "label": "Fair Value, Recurring [Member]"
       }
      }
     },
     "localname": "FairValueMeasurementsRecurringMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.windtreetx.com/20220630/role/statement-note-5-fair-value-measurements-assets-and-liabilities-measured-at-fair-value-on-a-recurring-basis-details"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueOfFinancialInstrumentsPolicy": {
     "auth_ref": [
      "r295",
      "r296"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for determining the fair value of financial instruments.",
        "label": "Fair Value of Financial Instruments, Policy [Policy Text Block]"
       }
      }
     },
     "localname": "FairValueOfFinancialInstrumentsPolicy",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.windtreetx.com/20220630/role/statement-significant-accounting-policies-policies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ForeignCurrencyTransactionGainBeforeTax": {
     "auth_ref": [
      "r300",
      "r301"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before tax of foreign currency transaction realized and unrealized gain recognized in the income statement.",
        "label": "us-gaap_ForeignCurrencyTransactionGainBeforeTax",
        "terseLabel": "Foreign Currency Transaction Gain, before Tax"
       }
      }
     },
     "localname": "ForeignCurrencyTransactionGainBeforeTax",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.windtreetx.com/20220630/role/statement-note-4-summary-of-significant-accounting-policies-details-textual"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ForeignCurrencyTransactionGainLossBeforeTax": {
     "auth_ref": [
      "r298",
      "r299",
      "r300",
      "r301"
     ],
     "calculation": {
      "http://www.windtreetx.com/20220630/role/statement-condensed-consolidated-statements-of-cash-flows-unaudited-": {
       "order": 9.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before tax of foreign currency transaction realized and unrealized gain (loss) recognized in the income statement.",
        "label": "us-gaap_ForeignCurrencyTransactionGainLossBeforeTax",
        "negatedLabel": "Unrealized (gain) loss on foreign exchange rate changes"
       }
      }
     },
     "localname": "ForeignCurrencyTransactionGainLossBeforeTax",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.windtreetx.com/20220630/role/statement-condensed-consolidated-statements-of-cash-flows-unaudited-"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ForeignCurrencyTransactionLossBeforeTax": {
     "auth_ref": [
      "r300",
      "r301"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before tax of foreign currency transaction realized and unrealized loss recognized in the income statement.",
        "label": "us-gaap_ForeignCurrencyTransactionLossBeforeTax",
        "terseLabel": "Foreign Currency Transaction Loss, before Tax"
       }
      }
     },
     "localname": "ForeignCurrencyTransactionLossBeforeTax",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.windtreetx.com/20220630/role/statement-note-4-summary-of-significant-accounting-policies-details-textual"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock": {
     "auth_ref": [
      "r310"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for (1) transactions denominated in a currency other than the reporting enterprise's functional currency, (2) translating foreign currency financial statements that are incorporated into the financial statements of the reporting enterprise by consolidation, combination, or the equity method of accounting, and (3) remeasurement of the financial statements of a foreign reporting enterprise in a hyperinflationary economy.",
        "label": "Foreign Currency Transactions and Translations Policy [Policy Text Block]"
       }
      }
     },
     "localname": "ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.windtreetx.com/20220630/role/statement-significant-accounting-policies-policies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_GainLossOnDispositionOfAssets": {
     "auth_ref": [
      "r56",
      "r136",
      "r141"
     ],
     "calculation": {
      "http://www.windtreetx.com/20220630/role/statement-condensed-consolidated-statements-of-cash-flows-unaudited-": {
       "order": 8.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of gain (loss) on sale or disposal of property, plant and equipment assets, excluding oil and gas property and timber property.",
        "label": "us-gaap_GainLossOnDispositionOfAssets",
        "negatedLabel": "Loss on sale and disposal of property and equipment"
       }
      }
     },
     "localname": "GainLossOnDispositionOfAssets",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.windtreetx.com/20220630/role/statement-condensed-consolidated-statements-of-cash-flows-unaudited-"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_Goodwill": {
     "auth_ref": [
      "r7",
      "r124",
      "r126",
      "r128",
      "r131",
      "r324",
      "r339"
     ],
     "calculation": {
      "http://www.windtreetx.com/20220630/role/statement-condensed-consolidated-balance-sheets-current-period-unaudited": {
       "order": 3.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.",
        "label": "Goodwill",
        "terseLabel": "Goodwill"
       }
      }
     },
     "localname": "Goodwill",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.windtreetx.com/20220630/role/statement-condensed-consolidated-balance-sheets-current-period-unaudited",
      "http://www.windtreetx.com/20220630/role/statement-note-4-summary-of-significant-accounting-policies-intangible-assets-details"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy": {
     "auth_ref": [
      "r130",
      "r131",
      "r132"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for goodwill. This accounting policy also may address how an entity assesses and measures impairment of goodwill, how reporting units are determined, how goodwill is allocated to such units, and how the fair values of the reporting units are determined.",
        "label": "Goodwill and Intangible Assets, Goodwill, Policy [Policy Text Block]"
       }
      }
     },
     "localname": "GoodwillAndIntangibleAssetsGoodwillPolicy",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.windtreetx.com/20220630/role/statement-significant-accounting-policies-policies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_GoodwillImpairmentLoss": {
     "auth_ref": [
      "r56",
      "r125",
      "r127",
      "r130",
      "r131"
     ],
     "calculation": {
      "http://www.windtreetx.com/20220630/role/statement-condensed-consolidated-statements-of-cash-flows-unaudited-": {
       "order": 4.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      },
      "http://www.windtreetx.com/20220630/role/statement-condensed-consolidated-statements-of-operations-unaudited": {
       "order": 2.0,
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of loss from the write-down of an asset representing the future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.",
        "label": "Loss on impairment of goodwill",
        "terseLabel": "Goodwill, Impairment Loss"
       }
      }
     },
     "localname": "GoodwillImpairmentLoss",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.windtreetx.com/20220630/role/statement-condensed-consolidated-statements-of-cash-flows-unaudited-",
      "http://www.windtreetx.com/20220630/role/statement-condensed-consolidated-statements-of-operations-unaudited",
      "http://www.windtreetx.com/20220630/role/statement-note-3-going-concern-and-managements-plans-details-textual",
      "http://www.windtreetx.com/20220630/role/statement-note-4-summary-of-significant-accounting-policies-details-textual"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill": {
     "auth_ref": [
      "r56",
      "r135"
     ],
     "calculation": {
      "http://www.windtreetx.com/20220630/role/statement-condensed-consolidated-statements-of-cash-flows-unaudited-": {
       "order": 3.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      },
      "http://www.windtreetx.com/20220630/role/statement-condensed-consolidated-statements-of-operations-unaudited": {
       "order": 1.0,
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of impairment loss recognized in the period resulting from the write-down of the carrying amount of an intangible asset (excluding goodwill) to fair value.",
        "label": "Loss on impairment of intangible assets",
        "terseLabel": "Impairment of Intangible Assets (Excluding Goodwill), Total"
       }
      }
     },
     "localname": "ImpairmentOfIntangibleAssetsExcludingGoodwill",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.windtreetx.com/20220630/role/statement-condensed-consolidated-statements-of-cash-flows-unaudited-",
      "http://www.windtreetx.com/20220630/role/statement-condensed-consolidated-statements-of-operations-unaudited",
      "http://www.windtreetx.com/20220630/role/statement-note-3-going-concern-and-managements-plans-details-textual",
      "http://www.windtreetx.com/20220630/role/statement-note-4-summary-of-significant-accounting-policies-details-textual"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest": {
     "auth_ref": [
      "r42",
      "r112",
      "r113",
      "r116",
      "r117",
      "r119",
      "r338",
      "r344",
      "r348",
      "r359"
     ],
     "calculation": {
      "http://www.windtreetx.com/20220630/role/statement-condensed-consolidated-statements-of-operations-unaudited": {
       "order": 1.0,
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.",
        "label": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
        "totalLabel": "Loss before income taxes"
       }
      }
     },
     "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.windtreetx.com/20220630/role/statement-condensed-consolidated-statements-of-operations-unaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeStatementAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Statement [Abstract]"
       }
      }
     },
     "localname": "IncomeStatementAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeStatementLocationAxis": {
     "auth_ref": [
      "r142",
      "r144"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by location in the income statement.",
        "label": "Income Statement Location [Axis]"
       }
      }
     },
     "localname": "IncomeStatementLocationAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.windtreetx.com/20220630/role/statement-note-9-stockbased-compensation-stockbased-compensation-expense-details"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeStatementLocationDomain": {
     "auth_ref": [
      "r144"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Location in the income statement.",
        "label": "Income Statement Location [Domain]"
       }
      }
     },
     "localname": "IncomeStatementLocationDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.windtreetx.com/20220630/role/statement-note-9-stockbased-compensation-stockbased-compensation-expense-details"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_IncomeTaxExpenseBenefit": {
     "auth_ref": [
      "r68",
      "r84",
      "r85",
      "r111",
      "r265",
      "r273",
      "r277",
      "r360"
     ],
     "calculation": {
      "http://www.windtreetx.com/20220630/role/statement-condensed-consolidated-statements-of-operations-unaudited": {
       "order": 0.0,
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.",
        "label": "us-gaap_IncomeTaxExpenseBenefit",
        "negatedLabel": "Deferred income tax benefit"
       }
      }
     },
     "localname": "IncomeTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.windtreetx.com/20220630/role/statement-condensed-consolidated-statements-of-operations-unaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeTaxPolicyTextBlock": {
     "auth_ref": [
      "r37",
      "r261",
      "r262",
      "r266",
      "r267",
      "r268",
      "r270"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements.",
        "label": "Income Tax, Policy [Policy Text Block]"
       }
      }
     },
     "localname": "IncomeTaxPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.windtreetx.com/20220630/role/statement-significant-accounting-policies-policies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_IncreaseDecreaseInAccountsPayable": {
     "auth_ref": [
      "r55"
     ],
     "calculation": {
      "http://www.windtreetx.com/20220630/role/statement-condensed-consolidated-statements-of-cash-flows-unaudited-": {
       "order": 13.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business.",
        "label": "us-gaap_IncreaseDecreaseInAccountsPayable",
        "terseLabel": "Accounts payable"
       }
      }
     },
     "localname": "IncreaseDecreaseInAccountsPayable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.windtreetx.com/20220630/role/statement-condensed-consolidated-statements-of-cash-flows-unaudited-"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInAccruedLiabilities": {
     "auth_ref": [
      "r55"
     ],
     "calculation": {
      "http://www.windtreetx.com/20220630/role/statement-condensed-consolidated-statements-of-cash-flows-unaudited-": {
       "order": 12.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in the aggregate amount of expenses incurred but not yet paid.",
        "label": "us-gaap_IncreaseDecreaseInAccruedLiabilities",
        "terseLabel": "Accrued expenses"
       }
      }
     },
     "localname": "IncreaseDecreaseInAccruedLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.windtreetx.com/20220630/role/statement-condensed-consolidated-statements-of-cash-flows-unaudited-"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInOperatingCapitalAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Changes in assets and liabilities:"
       }
      }
     },
     "localname": "IncreaseDecreaseInOperatingCapitalAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.windtreetx.com/20220630/role/statement-condensed-consolidated-statements-of-cash-flows-unaudited-"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets": {
     "auth_ref": [
      "r55"
     ],
     "calculation": {
      "http://www.windtreetx.com/20220630/role/statement-condensed-consolidated-statements-of-cash-flows-unaudited-": {
       "order": 7.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in prepaid expenses, and assets classified as other.",
        "label": "us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets",
        "negatedTerseLabel": "Prepaid expenses and other current assets"
       }
      }
     },
     "localname": "IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.windtreetx.com/20220630/role/statement-condensed-consolidated-statements-of-cash-flows-unaudited-"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis": {
     "auth_ref": [
      "r133",
      "r134"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type or class of assets, excluding financial assets and goodwill, lacking physical substance and having a projected indefinite period of benefit.",
        "label": "Indefinite-Lived Intangible Assets [Axis]"
       }
      }
     },
     "localname": "IndefiniteLivedIntangibleAssetsByMajorClassAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.windtreetx.com/20220630/role/statement-note-4-summary-of-significant-accounting-policies-intangible-assets-details"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill": {
     "auth_ref": [
      "r134"
     ],
     "calculation": {
      "http://www.windtreetx.com/20220630/role/statement-condensed-consolidated-balance-sheets-current-period-unaudited": {
       "order": 4.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of assets, excluding financial assets and goodwill, lacking physical substance and having a projected indefinite period of benefit.",
        "label": "us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill",
        "terseLabel": "Intangible assets"
       }
      }
     },
     "localname": "IndefiniteLivedIntangibleAssetsExcludingGoodwill",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.windtreetx.com/20220630/role/statement-condensed-consolidated-balance-sheets-current-period-unaudited",
      "http://www.windtreetx.com/20220630/role/statement-note-4-summary-of-significant-accounting-policies-intangible-assets-details"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain": {
     "auth_ref": [
      "r133",
      "r134"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The major class of indefinite-lived intangible asset (for example, trade names, etc. but not all-inclusive), excluding goodwill. A major class is composed of intangible assets that can be grouped together because they are similar, either by their nature or by their use in the operations of the company.",
        "label": "Indefinite-Lived Intangible Assets, Major Class Name [Domain]"
       }
      }
     },
     "localname": "IndefiniteLivedIntangibleAssetsMajorClassNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.windtreetx.com/20220630/role/statement-note-4-summary-of-significant-accounting-policies-intangible-assets-details"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_InterestExpense": {
     "auth_ref": [
      "r41",
      "r110",
      "r311",
      "r313",
      "r347"
     ],
     "calculation": {
      "http://www.windtreetx.com/20220630/role/statement-condensed-consolidated-statements-of-operations-unaudited": {
       "order": 1.0,
       "parentTag": "us-gaap_NonoperatingIncomeExpense",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of the cost of borrowed funds accounted for as interest expense.",
        "label": "us-gaap_InterestExpense",
        "negatedLabel": "Interest expense"
       }
      }
     },
     "localname": "InterestExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.windtreetx.com/20220630/role/statement-condensed-consolidated-statements-of-operations-unaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InvestmentIncomeInterest": {
     "auth_ref": [
      "r46",
      "r109"
     ],
     "calculation": {
      "http://www.windtreetx.com/20220630/role/statement-condensed-consolidated-statements-of-operations-unaudited": {
       "order": 2.0,
       "parentTag": "us-gaap_NonoperatingIncomeExpense",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before accretion (amortization) of purchase discount (premium) of interest income on nonoperating securities.",
        "label": "Interest income"
       }
      }
     },
     "localname": "InvestmentIncomeInterest",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.windtreetx.com/20220630/role/statement-condensed-consolidated-statements-of-operations-unaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_Liabilities": {
     "auth_ref": [
      "r24",
      "r66",
      "r115",
      "r122",
      "r150",
      "r151",
      "r152",
      "r154",
      "r155",
      "r156",
      "r157",
      "r158",
      "r159",
      "r160",
      "r280",
      "r282",
      "r283",
      "r297",
      "r322",
      "r323"
     ],
     "calculation": {
      "http://www.windtreetx.com/20220630/role/statement-condensed-consolidated-balance-sheets-current-period-unaudited": {
       "order": 0.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.",
        "label": "us-gaap_Liabilities",
        "totalLabel": "Total liabilities"
       }
      }
     },
     "localname": "Liabilities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.windtreetx.com/20220630/role/statement-condensed-consolidated-balance-sheets-current-period-unaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesAndStockholdersEquity": {
     "auth_ref": [
      "r19",
      "r66",
      "r122",
      "r297",
      "r324",
      "r343",
      "r355"
     ],
     "calculation": {
      "http://www.windtreetx.com/20220630/role/statement-condensed-consolidated-balance-sheets-current-period-unaudited": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.",
        "label": "us-gaap_LiabilitiesAndStockholdersEquity",
        "totalLabel": "Total liabilities &amp; stockholders\u2019 equity"
       }
      }
     },
     "localname": "LiabilitiesAndStockholdersEquity",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.windtreetx.com/20220630/role/statement-condensed-consolidated-balance-sheets-current-period-unaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesCurrent": {
     "auth_ref": [
      "r5",
      "r26",
      "r66",
      "r122",
      "r150",
      "r151",
      "r152",
      "r154",
      "r155",
      "r156",
      "r157",
      "r158",
      "r159",
      "r160",
      "r280",
      "r282",
      "r283",
      "r297",
      "r322",
      "r323",
      "r324"
     ],
     "calculation": {
      "http://www.windtreetx.com/20220630/role/statement-condensed-consolidated-balance-sheets-current-period-unaudited": {
       "order": 4.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.",
        "label": "us-gaap_LiabilitiesCurrent",
        "terseLabel": "Liabilities, Current, Total",
        "totalLabel": "Total current liabilities"
       }
      }
     },
     "localname": "LiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.windtreetx.com/20220630/role/statement-condensed-consolidated-balance-sheets-current-period-unaudited",
      "http://www.windtreetx.com/20220630/role/statement-note-3-going-concern-and-managements-plans-details-textual"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesCurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Current Liabilities:"
       }
      }
     },
     "localname": "LiabilitiesCurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.windtreetx.com/20220630/role/statement-condensed-consolidated-balance-sheets-current-period-unaudited"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LineOfCreditFacilityAxis": {
     "auth_ref": [
      "r22",
      "r65"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by name of lender, which may be a single entity (for example, but not limited to, a bank, pension fund, venture capital firm) or a group of entities that participate in the line of credit.",
        "label": "Lender Name [Axis]"
       }
      }
     },
     "localname": "LineOfCreditFacilityAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.windtreetx.com/20220630/role/statement-note-4-summary-of-significant-accounting-policies",
      "http://www.windtreetx.com/20220630/role/statement-note-4-summary-of-significant-accounting-policies-details-textual"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LineOfCreditFacilityLenderDomain": {
     "auth_ref": [
      "r22",
      "r65"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Identification of the lender, which may be a single entity (for example, a bank, pension fund, venture capital firm) or a group of entities that participate in the line of credit, including a letter of credit facility.",
        "label": "Line of Credit Facility, Lender [Domain]"
       }
      }
     },
     "localname": "LineOfCreditFacilityLenderDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.windtreetx.com/20220630/role/statement-note-4-summary-of-significant-accounting-policies",
      "http://www.windtreetx.com/20220630/role/statement-note-4-summary-of-significant-accounting-policies-details-textual"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_LoansPayableCurrent": {
     "auth_ref": [
      "r25"
     ],
     "calculation": {
      "http://www.windtreetx.com/20220630/role/statement-condensed-consolidated-balance-sheets-current-period-unaudited": {
       "order": 3.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of portion of long-term loans payable due within one year or the operating cycle if longer.",
        "label": "Loans payable - current portion"
       }
      }
     },
     "localname": "LoansPayableCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.windtreetx.com/20220630/role/statement-condensed-consolidated-balance-sheets-current-period-unaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LoansPayableMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Borrowing supported by a written promise to pay an obligation.",
        "label": "Loans Payable [Member]"
       }
      }
     },
     "localname": "LoansPayableMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.windtreetx.com/20220630/role/statement-note-6-loans-payable",
      "http://www.windtreetx.com/20220630/role/statement-note-6-loans-payable-details-textual"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_LoansPayableToBank": {
     "auth_ref": [
      "r11",
      "r342",
      "r351"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Including the current and noncurrent portions, carrying value as of the balance sheet date of loans from a bank with maturities initially due after one year or beyond the normal operating cycle if longer.",
        "label": "us-gaap_LoansPayableToBank",
        "terseLabel": "Loans Payable to Bank, Total"
       }
      }
     },
     "localname": "LoansPayableToBank",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.windtreetx.com/20220630/role/statement-note-6-loans-payable-details-textual"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LongTermDebtTextBlock": {
     "auth_ref": [
      "r182"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for long-term debt.",
        "label": "Long-Term Debt [Text Block]"
       }
      }
     },
     "localname": "LongTermDebtTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.windtreetx.com/20220630/role/statement-note-7-restructured-debt-liability"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_LongtermDebtTypeAxis": {
     "auth_ref": [
      "r28"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of long-term debt.",
        "label": "Long-Term Debt, Type [Axis]"
       }
      }
     },
     "localname": "LongtermDebtTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.windtreetx.com/20220630/role/statement-note-4-summary-of-significant-accounting-policies",
      "http://www.windtreetx.com/20220630/role/statement-note-4-summary-of-significant-accounting-policies-details-textual",
      "http://www.windtreetx.com/20220630/role/statement-note-7-restructured-debt-liability",
      "http://www.windtreetx.com/20220630/role/statement-note-7-restructured-debt-liability-details-textual"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LongtermDebtTypeDomain": {
     "auth_ref": [
      "r28",
      "r149"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Type of long-term debt arrangement, such as notes, line of credit, commercial paper, asset-based financing, project financing, letter of credit financing. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the company, if longer.",
        "label": "Long-Term Debt, Type [Domain]"
       }
      }
     },
     "localname": "LongtermDebtTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.windtreetx.com/20220630/role/statement-note-4-summary-of-significant-accounting-policies",
      "http://www.windtreetx.com/20220630/role/statement-note-4-summary-of-significant-accounting-policies-details-textual",
      "http://www.windtreetx.com/20220630/role/statement-note-7-restructured-debt-liability",
      "http://www.windtreetx.com/20220630/role/statement-note-7-restructured-debt-liability-details-textual"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_MoneyMarketFundsMember": {
     "auth_ref": [
      "r206"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fund that invests in short-term money-market instruments, for example, but not limited to, commercial paper, banker's acceptances, repurchase agreements, government securities, certificates of deposit, and other highly liquid securities.",
        "label": "Money Market Funds [Member]"
       }
      }
     },
     "localname": "MoneyMarketFundsMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.windtreetx.com/20220630/role/statement-note-5-fair-value-measurements-assets-and-liabilities-measured-at-fair-value-on-a-recurring-basis-details"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivities": {
     "auth_ref": [
      "r53"
     ],
     "calculation": {
      "http://www.windtreetx.com/20220630/role/statement-condensed-consolidated-statements-of-cash-flows-unaudited-": {
       "order": 2.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.",
        "label": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
        "totalLabel": "Net cash provided by financing activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInFinancingActivities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.windtreetx.com/20220630/role/statement-condensed-consolidated-statements-of-cash-flows-unaudited-"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash flows from financing activities:"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.windtreetx.com/20220630/role/statement-condensed-consolidated-statements-of-cash-flows-unaudited-"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivities": {
     "auth_ref": [
      "r53"
     ],
     "calculation": {
      "http://www.windtreetx.com/20220630/role/statement-condensed-consolidated-statements-of-cash-flows-unaudited-": {
       "order": 0.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.",
        "label": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
        "totalLabel": "Net cash provided by (used in) investing activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInInvestingActivities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.windtreetx.com/20220630/role/statement-condensed-consolidated-statements-of-cash-flows-unaudited-"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash flows from investing activities:"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInInvestingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.windtreetx.com/20220630/role/statement-condensed-consolidated-statements-of-cash-flows-unaudited-"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivities": {
     "auth_ref": [
      "r53",
      "r54",
      "r57"
     ],
     "calculation": {
      "http://www.windtreetx.com/20220630/role/statement-condensed-consolidated-statements-of-cash-flows-unaudited-": {
       "order": 1.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.",
        "label": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
        "totalLabel": "Net cash used in operating activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInOperatingActivities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.windtreetx.com/20220630/role/statement-condensed-consolidated-statements-of-cash-flows-unaudited-"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash flows from operating activities:"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.windtreetx.com/20220630/role/statement-condensed-consolidated-statements-of-cash-flows-unaudited-"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetIncomeLoss": {
     "auth_ref": [
      "r1",
      "r35",
      "r36",
      "r40",
      "r43",
      "r57",
      "r66",
      "r76",
      "r78",
      "r79",
      "r80",
      "r81",
      "r84",
      "r85",
      "r90",
      "r112",
      "r113",
      "r116",
      "r117",
      "r119",
      "r122",
      "r150",
      "r151",
      "r152",
      "r154",
      "r155",
      "r156",
      "r157",
      "r158",
      "r159",
      "r160",
      "r288",
      "r297",
      "r345",
      "r357"
     ],
     "calculation": {
      "http://www.windtreetx.com/20220630/role/statement-condensed-consolidated-statements-of-cash-flows-unaudited-": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      },
      "http://www.windtreetx.com/20220630/role/statement-condensed-consolidated-statements-of-operations-unaudited": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.",
        "label": "Net loss",
        "terseLabel": "Net Income (Loss) Attributable to Parent, Total",
        "totalLabel": "Net loss"
       }
      }
     },
     "localname": "NetIncomeLoss",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.windtreetx.com/20220630/role/statement-condensed-consolidated-statements-of-cash-flows-unaudited-",
      "http://www.windtreetx.com/20220630/role/statement-condensed-consolidated-statements-of-changes-in-stockholders-equity-unaudited-",
      "http://www.windtreetx.com/20220630/role/statement-condensed-consolidated-statements-of-operations-unaudited",
      "http://www.windtreetx.com/20220630/role/statement-note-3-going-concern-and-managements-plans-details-textual"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NoncashInvestingAndFinancingItemsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Supplementary disclosure of non-cash activity:"
       }
      }
     },
     "localname": "NoncashInvestingAndFinancingItemsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.windtreetx.com/20220630/role/statement-condensed-consolidated-statements-of-cash-flows-unaudited-"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NonoperatingIncomeExpense": {
     "auth_ref": [
      "r47"
     ],
     "calculation": {
      "http://www.windtreetx.com/20220630/role/statement-condensed-consolidated-statements-of-operations-unaudited": {
       "order": 1.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business).",
        "label": "us-gaap_NonoperatingIncomeExpense",
        "totalLabel": "Total other income (expense), net"
       }
      }
     },
     "localname": "NonoperatingIncomeExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.windtreetx.com/20220630/role/statement-condensed-consolidated-statements-of-operations-unaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NumberOfReportingUnits": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of reporting units tested for impairment of goodwill. A reporting unit is an operating segment or one level below an operating segment.",
        "label": "us-gaap_NumberOfReportingUnits",
        "terseLabel": "Number of Reporting Units"
       }
      }
     },
     "localname": "NumberOfReportingUnits",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.windtreetx.com/20220630/role/statement-note-4-summary-of-significant-accounting-policies-details-textual"
     ],
     "xbrltype": "integerItemType"
    },
    "us-gaap_OperatingExpenses": {
     "auth_ref": [],
     "calculation": {
      "http://www.windtreetx.com/20220630/role/statement-condensed-consolidated-statements-of-operations-unaudited": {
       "order": 0.0,
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.",
        "label": "us-gaap_OperatingExpenses",
        "totalLabel": "Total operating expenses"
       }
      }
     },
     "localname": "OperatingExpenses",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.windtreetx.com/20220630/role/statement-condensed-consolidated-statements-of-operations-unaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingExpensesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Expenses:"
       }
      }
     },
     "localname": "OperatingExpensesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.windtreetx.com/20220630/role/statement-condensed-consolidated-statements-of-operations-unaudited"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OperatingIncomeLoss": {
     "auth_ref": [
      "r112",
      "r113",
      "r116",
      "r117",
      "r119"
     ],
     "calculation": {
      "http://www.windtreetx.com/20220630/role/statement-condensed-consolidated-statements-of-operations-unaudited": {
       "order": 0.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The net result for the period of deducting operating expenses from operating revenues.",
        "label": "us-gaap_OperatingIncomeLoss",
        "totalLabel": "Operating loss"
       }
      }
     },
     "localname": "OperatingIncomeLoss",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.windtreetx.com/20220630/role/statement-condensed-consolidated-statements-of-operations-unaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseLiabilityCurrent": {
     "auth_ref": [
      "r317"
     ],
     "calculation": {
      "http://www.windtreetx.com/20220630/role/statement-condensed-consolidated-balance-sheets-current-period-unaudited": {
       "order": 0.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.",
        "label": "Operating lease liabilities - current portion"
       }
      }
     },
     "localname": "OperatingLeaseLiabilityCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.windtreetx.com/20220630/role/statement-condensed-consolidated-balance-sheets-current-period-unaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseLiabilityNoncurrent": {
     "auth_ref": [
      "r317"
     ],
     "calculation": {
      "http://www.windtreetx.com/20220630/role/statement-condensed-consolidated-balance-sheets-current-period-unaudited": {
       "order": 3.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.",
        "label": "Operating lease liabilities - non-current portion"
       }
      }
     },
     "localname": "OperatingLeaseLiabilityNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.windtreetx.com/20220630/role/statement-condensed-consolidated-balance-sheets-current-period-unaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseRightOfUseAsset": {
     "auth_ref": [
      "r316"
     ],
     "calculation": {
      "http://www.windtreetx.com/20220630/role/statement-condensed-consolidated-balance-sheets-current-period-unaudited": {
       "order": 5.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's right to use underlying asset under operating lease.",
        "label": "Operating lease right-of-use assets"
       }
      }
     },
     "localname": "OperatingLeaseRightOfUseAsset",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.windtreetx.com/20220630/role/statement-condensed-consolidated-balance-sheets-current-period-unaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense": {
     "auth_ref": [
      "r56"
     ],
     "calculation": {
      "http://www.windtreetx.com/20220630/role/statement-condensed-consolidated-statements-of-cash-flows-unaudited-": {
       "order": 6.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of amortization expense for right-of-use asset from operating lease.",
        "label": "Non-cash lease expense"
       }
      }
     },
     "localname": "OperatingLeaseRightOfUseAssetAmortizationExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.windtreetx.com/20220630/role/statement-condensed-consolidated-statements-of-cash-flows-unaudited-"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock": {
     "auth_ref": [
      "r2",
      "r284"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for organization, consolidation and basis of presentation of financial statements disclosure.",
        "label": "Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block]"
       }
      }
     },
     "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.windtreetx.com/20220630/role/statement-note-1-the-company-and-description-of-business"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_OtherLiabilitiesNoncurrent": {
     "auth_ref": [
      "r29"
     ],
     "calculation": {
      "http://www.windtreetx.com/20220630/role/statement-condensed-consolidated-balance-sheets-current-period-unaudited": {
       "order": 1.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer.",
        "label": "Other liabilities"
       }
      }
     },
     "localname": "OtherLiabilitiesNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.windtreetx.com/20220630/role/statement-condensed-consolidated-balance-sheets-current-period-unaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherNonoperatingIncomeExpense": {
     "auth_ref": [
      "r48"
     ],
     "calculation": {
      "http://www.windtreetx.com/20220630/role/statement-condensed-consolidated-statements-of-operations-unaudited": {
       "order": 0.0,
       "parentTag": "us-gaap_NonoperatingIncomeExpense",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of income (expense) related to nonoperating activities, classified as other.",
        "label": "Other income (expense), net"
       }
      }
     },
     "localname": "OtherNonoperatingIncomeExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.windtreetx.com/20220630/role/statement-condensed-consolidated-statements-of-operations-unaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToAcquirePropertyPlantAndEquipment": {
     "auth_ref": [
      "r50"
     ],
     "calculation": {
      "http://www.windtreetx.com/20220630/role/statement-condensed-consolidated-statements-of-cash-flows-unaudited-": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.",
        "label": "us-gaap_PaymentsToAcquirePropertyPlantAndEquipment",
        "negatedLabel": "Purchase of property and equipment"
       }
      }
     },
     "localname": "PaymentsToAcquirePropertyPlantAndEquipment",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.windtreetx.com/20220630/role/statement-condensed-consolidated-statements-of-cash-flows-unaudited-"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PlanNameAxis": {
     "auth_ref": [
      "r220",
      "r221",
      "r222",
      "r224",
      "r225",
      "r226",
      "r227",
      "r228",
      "r229",
      "r230",
      "r231",
      "r232",
      "r233",
      "r234",
      "r235",
      "r236",
      "r237",
      "r238",
      "r239",
      "r240",
      "r241",
      "r243",
      "r244",
      "r245",
      "r246",
      "r247"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by plan name for share-based payment arrangement.",
        "label": "Plan Name [Axis]"
       }
      }
     },
     "localname": "PlanNameAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.windtreetx.com/20220630/role/statement-note-9-stockbased-compensation",
      "http://www.windtreetx.com/20220630/role/statement-note-9-stockbased-compensation-details-textual"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_PlanNameDomain": {
     "auth_ref": [
      "r220",
      "r221",
      "r222",
      "r224",
      "r225",
      "r226",
      "r227",
      "r228",
      "r229",
      "r230",
      "r231",
      "r232",
      "r233",
      "r234",
      "r235",
      "r236",
      "r237",
      "r238",
      "r239",
      "r240",
      "r241",
      "r243",
      "r244",
      "r245",
      "r246",
      "r247"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Plan name for share-based payment arrangement.",
        "label": "Plan Name [Domain]"
       }
      }
     },
     "localname": "PlanNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.windtreetx.com/20220630/role/statement-note-9-stockbased-compensation",
      "http://www.windtreetx.com/20220630/role/statement-note-9-stockbased-compensation-details-textual"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PolicyTextBlockAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "us-gaap_PolicyTextBlockAbstract",
        "terseLabel": "Accounting Policies"
       }
      }
     },
     "localname": "PolicyTextBlockAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.windtreetx.com/20220630/role/statement-significant-accounting-policies-policies"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_PreferredStockParOrStatedValuePerShare": {
     "auth_ref": [
      "r13",
      "r183"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.",
        "label": "Preferred stock, par value (in dollars per share)"
       }
      }
     },
     "localname": "PreferredStockParOrStatedValuePerShare",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.windtreetx.com/20220630/role/statement-condensed-consolidated-balance-sheets-current-period-unaudited-parentheticals"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_PreferredStockSharesAuthorized": {
     "auth_ref": [
      "r13"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.",
        "label": "Preferred stock, shares authorized (in shares)"
       }
      }
     },
     "localname": "PreferredStockSharesAuthorized",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.windtreetx.com/20220630/role/statement-condensed-consolidated-balance-sheets-current-period-unaudited-parentheticals"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_PreferredStockSharesIssued": {
     "auth_ref": [
      "r13",
      "r183"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.",
        "label": "Preferred stock, shares issued (in shares)"
       }
      }
     },
     "localname": "PreferredStockSharesIssued",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.windtreetx.com/20220630/role/statement-condensed-consolidated-balance-sheets-current-period-unaudited-parentheticals"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_PreferredStockSharesOutstanding": {
     "auth_ref": [
      "r13"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.",
        "label": "Preferred stock, shares outstanding (in shares)"
       }
      }
     },
     "localname": "PreferredStockSharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.windtreetx.com/20220630/role/statement-condensed-consolidated-balance-sheets-current-period-unaudited-parentheticals"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_PreferredStockValue": {
     "auth_ref": [
      "r13",
      "r324"
     ],
     "calculation": {
      "http://www.windtreetx.com/20220630/role/statement-condensed-consolidated-balance-sheets-current-period-unaudited": {
       "order": 0.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.",
        "label": "Preferred stock, $0.001 par value; 5,000,000 shares authorized; 0 shares issued and outstanding at June 30, 2022 and December 31, 2021"
       }
      }
     },
     "localname": "PreferredStockValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.windtreetx.com/20220630/role/statement-condensed-consolidated-balance-sheets-current-period-unaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PrepaidExpenseAndOtherAssetsCurrent": {
     "auth_ref": [
      "r20"
     ],
     "calculation": {
      "http://www.windtreetx.com/20220630/role/statement-condensed-consolidated-balance-sheets-current-period-unaudited": {
       "order": 0.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.",
        "label": "Prepaid expenses and other current assets"
       }
      }
     },
     "localname": "PrepaidExpenseAndOtherAssetsCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.windtreetx.com/20220630/role/statement-condensed-consolidated-balance-sheets-current-period-unaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromIssuanceOfCommonStock": {
     "auth_ref": [
      "r51"
     ],
     "calculation": {
      "http://www.windtreetx.com/20220630/role/statement-condensed-consolidated-statements-of-cash-flows-unaudited-": {
       "order": 0.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow from the additional capital contribution to the entity.",
        "label": "Proceeds from ATM Program, net of issuance costs",
        "terseLabel": "Proceeds from Issuance of Common Stock"
       }
      }
     },
     "localname": "ProceedsFromIssuanceOfCommonStock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.windtreetx.com/20220630/role/statement-condensed-consolidated-statements-of-cash-flows-unaudited-",
      "http://www.windtreetx.com/20220630/role/statement-note-3-going-concern-and-managements-plans-details-textual",
      "http://www.windtreetx.com/20220630/role/statement-note-8-stockholders-equity-details-textual"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromIssuanceOrSaleOfEquity": {
     "auth_ref": [
      "r51"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow from the issuance of common stock, preferred stock, treasury stock, stock options, and other types of equity.",
        "label": "us-gaap_ProceedsFromIssuanceOrSaleOfEquity",
        "terseLabel": "Proceeds from Issuance or Sale of Equity, Total"
       }
      }
     },
     "localname": "ProceedsFromIssuanceOrSaleOfEquity",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.windtreetx.com/20220630/role/statement-note-8-stockholders-equity-details-textual"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment": {
     "auth_ref": [
      "r49"
     ],
     "calculation": {
      "http://www.windtreetx.com/20220630/role/statement-condensed-consolidated-statements-of-cash-flows-unaudited-": {
       "order": 0.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow from the sale of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale.",
        "label": "Proceeds from sale of property and equipment"
       }
      }
     },
     "localname": "ProceedsFromSaleOfPropertyPlantAndEquipment",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.windtreetx.com/20220630/role/statement-condensed-consolidated-statements-of-cash-flows-unaudited-"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentByTypeAxis": {
     "auth_ref": [
      "r139"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of long-lived, physical assets used to produce goods and services and not intended for resale.",
        "label": "Long-Lived Tangible Asset [Axis]"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentByTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.windtreetx.com/20220630/role/statement-note-4-summary-of-significant-accounting-policies",
      "http://www.windtreetx.com/20220630/role/statement-note-4-summary-of-significant-accounting-policies-details-textual"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentImpairment": {
     "auth_ref": [
      "r140"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for assessing and recognizing impairments of its property, plant and equipment.",
        "label": "Property, Plant and Equipment, Impairment [Policy Text Block]"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentImpairment",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.windtreetx.com/20220630/role/statement-significant-accounting-policies-policies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentNet": {
     "auth_ref": [
      "r139",
      "r324",
      "r349",
      "r356"
     ],
     "calculation": {
      "http://www.windtreetx.com/20220630/role/statement-condensed-consolidated-balance-sheets-current-period-unaudited": {
       "order": 1.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.",
        "label": "Property and equipment, net"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentNet",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.windtreetx.com/20220630/role/statement-condensed-consolidated-balance-sheets-current-period-unaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentTypeDomain": {
     "auth_ref": [
      "r138"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Listing of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale. Examples include land, buildings, machinery and equipment, and other types of furniture and equipment including, but not limited to, office equipment, furniture and fixtures, and computer equipment and software.",
        "label": "Long-Lived Tangible Asset [Domain]"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.windtreetx.com/20220630/role/statement-note-4-summary-of-significant-accounting-policies",
      "http://www.windtreetx.com/20220630/role/statement-note-4-summary-of-significant-accounting-policies-details-textual"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RepaymentsOfLongTermDebt": {
     "auth_ref": [
      "r52"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow for debt initially having maturity due after one year or beyond the normal operating cycle, if longer.",
        "label": "us-gaap_RepaymentsOfLongTermDebt",
        "terseLabel": "Repayments of Long-term Debt, Total"
       }
      }
     },
     "localname": "RepaymentsOfLongTermDebt",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.windtreetx.com/20220630/role/statement-note-7-restructured-debt-liability-details-textual"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RepaymentsOfShortTermDebt": {
     "auth_ref": [
      "r52"
     ],
     "calculation": {
      "http://www.windtreetx.com/20220630/role/statement-condensed-consolidated-statements-of-cash-flows-unaudited-": {
       "order": 3.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow for a borrowing having initial term of repayment within one year or the normal operating cycle, if longer.",
        "label": "us-gaap_RepaymentsOfShortTermDebt",
        "negatedLabel": "Principal payments on loans payable"
       }
      }
     },
     "localname": "RepaymentsOfShortTermDebt",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.windtreetx.com/20220630/role/statement-condensed-consolidated-statements-of-cash-flows-unaudited-"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ResearchAndDevelopmentExpense": {
     "auth_ref": [
      "r260",
      "r336",
      "r371"
     ],
     "calculation": {
      "http://www.windtreetx.com/20220630/role/statement-condensed-consolidated-statements-of-operations-unaudited": {
       "order": 0.0,
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.",
        "label": "us-gaap_ResearchAndDevelopmentExpense",
        "verboseLabel": "Research and development"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.windtreetx.com/20220630/role/statement-condensed-consolidated-statements-of-operations-unaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ResearchAndDevelopmentExpenseMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Primary financial statement caption in which the reported facts about research and development expense have been included.",
        "label": "Research and Development Expense [Member]"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpenseMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.windtreetx.com/20220630/role/statement-note-9-stockbased-compensation-stockbased-compensation-expense-details"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ResearchAndDevelopmentExpensePolicy": {
     "auth_ref": [
      "r260"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process.",
        "label": "Research and Development Expense, Policy [Policy Text Block]"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpensePolicy",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.windtreetx.com/20220630/role/statement-significant-accounting-policies-policies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember": {
     "auth_ref": [
      "r6"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Type of cash and cash equivalent. Cash is currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash and Cash Equivalents [Domain]"
       }
      }
     },
     "localname": "RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.windtreetx.com/20220630/role/statement-note-5-fair-value-measurements-assets-and-liabilities-measured-at-fair-value-on-a-recurring-basis-details"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RestrictedCashAndCashEquivalentsNoncurrent": {
     "auth_ref": [
      "r58",
      "r60",
      "r368"
     ],
     "calculation": {
      "http://www.windtreetx.com/20220630/role/statement-condensed-consolidated-balance-sheets-current-period-unaudited": {
       "order": 0.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash and cash equivalents restricted as to withdrawal or usage, classified as noncurrent. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Restricted cash"
       }
      }
     },
     "localname": "RestrictedCashAndCashEquivalentsNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.windtreetx.com/20220630/role/statement-condensed-consolidated-balance-sheets-current-period-unaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RestrictedStockUnitsRSUMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share instrument which is convertible to stock or an equivalent amount of cash, after a specified period of time or when specified performance conditions are met.",
        "label": "Restricted Stock Units (RSUs) [Member]"
       }
      }
     },
     "localname": "RestrictedStockUnitsRSUMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.windtreetx.com/20220630/role/statement-note-9-stockbased-compensation",
      "http://www.windtreetx.com/20220630/role/statement-note-9-stockbased-compensation-details-textual",
      "http://www.windtreetx.com/20220630/role/statement-note-9-stockbased-compensation-restricted-stock-units-details"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RetainedEarningsAccumulatedDeficit": {
     "auth_ref": [
      "r16",
      "r200",
      "r324",
      "r354",
      "r366",
      "r367"
     ],
     "calculation": {
      "http://www.windtreetx.com/20220630/role/statement-condensed-consolidated-balance-sheets-current-period-unaudited": {
       "order": 3.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.",
        "label": "Accumulated deficit",
        "terseLabel": "Retained Earnings (Accumulated Deficit), Total"
       }
      }
     },
     "localname": "RetainedEarningsAccumulatedDeficit",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.windtreetx.com/20220630/role/statement-condensed-consolidated-balance-sheets-current-period-unaudited",
      "http://www.windtreetx.com/20220630/role/statement-note-3-going-concern-and-managements-plans-details-textual"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RetainedEarningsMember": {
     "auth_ref": [
      "r0",
      "r73",
      "r74",
      "r75",
      "r77",
      "r83",
      "r85",
      "r123",
      "r254",
      "r255",
      "r256",
      "r271",
      "r272",
      "r286",
      "r363",
      "r365"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.",
        "label": "Retained Earnings [Member]"
       }
      }
     },
     "localname": "RetainedEarningsMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.windtreetx.com/20220630/role/statement-condensed-consolidated-statements-of-changes-in-stockholders-equity-unaudited-"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability": {
     "auth_ref": [
      "r318",
      "r319"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase in right-of-use asset obtained in exchange for operating lease liability.",
        "label": "Operating lease liabilities arising from obtaining right-of-use assets"
       }
      }
     },
     "localname": "RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.windtreetx.com/20220630/role/statement-condensed-consolidated-statements-of-cash-flows-unaudited-"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SaleOfStockNameOfTransactionDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sale of the entity's stock, including, but not limited to, initial public offering (IPO) and private placement.",
        "label": "Sale of Stock [Domain]"
       }
      }
     },
     "localname": "SaleOfStockNameOfTransactionDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.windtreetx.com/20220630/role/statement-condensed-consolidated-statements-of-changes-in-stockholders-equity-unaudited-",
      "http://www.windtreetx.com/20220630/role/statement-note-3-going-concern-and-managements-plans",
      "http://www.windtreetx.com/20220630/role/statement-note-3-going-concern-and-managements-plans-details-textual",
      "http://www.windtreetx.com/20220630/role/statement-note-8-stockholders-equity",
      "http://www.windtreetx.com/20220630/role/statement-note-8-stockholders-equity-details-textual"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock": {
     "auth_ref": [
      "r248"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of allocation of amount expensed and capitalized for award under share-based payment arrangement to statement of income or comprehensive income and statement of financial position. Includes, but is not limited to, corresponding line item in financial statement.",
        "label": "Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block]"
       }
      }
     },
     "localname": "ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.windtreetx.com/20220630/role/statement-note-9-stockbased-compensation-tables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock": {
     "auth_ref": [
      "r289",
      "r290"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of assets and liabilities, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3).",
        "label": "Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis [Table Text Block]"
       }
      }
     },
     "localname": "ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.windtreetx.com/20220630/role/statement-note-5-fair-value-measurements-tables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock": {
     "auth_ref": [
      "r129"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of goodwill and intangible assets, which may be broken down by segment or major class.",
        "label": "Schedule of Intangible Assets and Goodwill [Table Text Block]"
       }
      }
     },
     "localname": "ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.windtreetx.com/20220630/role/statement-note-4-summary-of-significant-accounting-policies-tables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock": {
     "auth_ref": [
      "r223"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the number and weighted-average grant date fair value for restricted stock units that were outstanding at the beginning and end of the year, and the number of restricted stock units that were granted, vested, or forfeited during the year.",
        "label": "Share-Based Payment Arrangement, Restricted Stock Unit, Activity [Table Text Block]"
       }
      }
     },
     "localname": "ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.windtreetx.com/20220630/role/statement-note-9-stockbased-compensation-tables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock": {
     "auth_ref": [
      "r242"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.",
        "label": "Schedule of Share-Based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]"
       }
      }
     },
     "localname": "ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.windtreetx.com/20220630/role/statement-note-9-stockbased-compensation-tables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SellingGeneralAndAdministrativeExpense": {
     "auth_ref": [
      "r45"
     ],
     "calculation": {
      "http://www.windtreetx.com/20220630/role/statement-condensed-consolidated-statements-of-operations-unaudited": {
       "order": 3.0,
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate total costs related to selling a firm's product and services, as well as all other general and administrative expenses. Direct selling expenses (for example, credit, warranty, and advertising) are expenses that can be directly linked to the sale of specific products. Indirect selling expenses are expenses that cannot be directly linked to the sale of specific products, for example telephone expenses, Internet, and postal charges. General and administrative expenses include salaries of non-sales personnel, rent, utilities, communication, etc.",
        "label": "General and administrative"
       }
      }
     },
     "localname": "SellingGeneralAndAdministrativeExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.windtreetx.com/20220630/role/statement-condensed-consolidated-statements-of-operations-unaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SellingGeneralAndAdministrativeExpensesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Primary financial statement caption encompassing selling, general and administrative expense.",
        "label": "Selling, General and Administrative Expenses [Member]"
       }
      }
     },
     "localname": "SellingGeneralAndAdministrativeExpensesMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.windtreetx.com/20220630/role/statement-note-9-stockbased-compensation-stockbased-compensation-expense-details"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SeveranceCosts1": {
     "auth_ref": [
      "r56"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expenses for special or contractual termination benefits provided to current employees involuntarily terminated under a benefit arrangement associated exit or disposal activities pursuant to an authorized plan. Excludes expenses related to one-time termination benefits, a discontinued operation or an asset retirement obligation.",
        "label": "us-gaap_SeveranceCosts1",
        "terseLabel": "Severance Costs"
       }
      }
     },
     "localname": "SeveranceCosts1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.windtreetx.com/20220630/role/statement-note-4-summary-of-significant-accounting-policies-details-textual"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1": {
     "auth_ref": [
      "r220"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Estimated period over which an employee is required to provide service in exchange for the equity-based payment award, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1",
        "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award, Award Requisite Service Period (Year)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.windtreetx.com/20220630/role/statement-note-9-stockbased-compensation-details-textual"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod": {
     "auth_ref": [
      "r237"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that were forfeited during the reporting period.",
        "label": "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod",
        "negatedTerseLabel": "Cancelled (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.windtreetx.com/20220630/role/statement-note-9-stockbased-compensation-restricted-stock-units-details"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue": {
     "auth_ref": [
      "r237"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average fair value as of the grant date of equity-based award plans other than stock (unit) option plans that were not exercised or put into effect as a result of the occurrence of a terminating event.",
        "label": "Cancelled, Weighted- Average Grant Date Fair Value, Outstanding (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.windtreetx.com/20220630/role/statement-note-9-stockbased-compensation-restricted-stock-units-details"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod": {
     "auth_ref": [
      "r235"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).",
        "label": "Awarded (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.windtreetx.com/20220630/role/statement-note-9-stockbased-compensation-restricted-stock-units-details"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": {
     "auth_ref": [
      "r235"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).",
        "label": "Awarded, Weighted- Average Grant Date Fair Value, Outstanding (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.windtreetx.com/20220630/role/statement-note-9-stockbased-compensation-restricted-stock-units-details"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber": {
     "auth_ref": [
      "r232",
      "r233"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date.",
        "label": "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber",
        "periodEndLabel": "Outstanding at June 30, 2022 (in shares)",
        "periodStartLabel": "Shares Outstanding, Beginning Balance (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.windtreetx.com/20220630/role/statement-note-9-stockbased-compensation-restricted-stock-units-details"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue": {
     "auth_ref": [
      "r232",
      "r233"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Per share or unit weighted-average fair value of nonvested award under share-based payment arrangement. Excludes share and unit options.",
        "label": "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue",
        "periodEndLabel": "Weighted- Average Grant Date Fair Value, Outstanding (in dollars per share)",
        "periodStartLabel": "Weighted- Average Grant Date Fair Value, Outstanding, Beginning Balance (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.windtreetx.com/20220630/role/statement-note-9-stockbased-compensation-restricted-stock-units-details"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate": {
     "auth_ref": [
      "r246"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The risk-free interest rate assumption that is used in valuing an option on its own shares.",
        "label": "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate",
        "terseLabel": "Weighted average risk-free interest rate"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.windtreetx.com/20220630/role/statement-note-9-stockbased-compensation-stock-options-valuation-assumptions-details"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate": {
     "auth_ref": [
      "r244"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Rate of weighted-average expected volatility for award under share-based payment arrangement.",
        "label": "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate",
        "terseLabel": "Weighted average expected volatility"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.windtreetx.com/20220630/role/statement-note-9-stockbased-compensation-stock-options-valuation-assumptions-details"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber": {
     "auth_ref": [
      "r226"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan.",
        "label": "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber",
        "terseLabel": "Shares Vested and Exercisable (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.windtreetx.com/20220630/role/statement-note-9-stockbased-compensation-summary-of-stock-option-activity-details"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice": {
     "auth_ref": [
      "r226"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan.",
        "label": "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice",
        "terseLabel": "Weighted Average Exercise Price, Vested and Exercisable (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.windtreetx.com/20220630/role/statement-note-9-stockbased-compensation-summary-of-stock-option-activity-details"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod": {
     "auth_ref": [
      "r227"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "For presentations that combine terminations, the number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan or that expired.",
        "label": "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod",
        "negatedTerseLabel": "Shares Forfeited or Expired (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.windtreetx.com/20220630/role/statement-note-9-stockbased-compensation-summary-of-stock-option-activity-details"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [
      "r227"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average price of options that were either forfeited or expired.",
        "label": "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice",
        "terseLabel": "Weighted Average Exercise Price, Forfeited or Expired (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.windtreetx.com/20220630/role/statement-note-9-stockbased-compensation-summary-of-stock-option-activity-details"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross": {
     "auth_ref": [
      "r228"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Gross number of share options (or share units) granted during the period.",
        "label": "Shares Granted (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.windtreetx.com/20220630/role/statement-note-9-stockbased-compensation-summary-of-stock-option-activity-details"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber": {
     "auth_ref": [
      "r224",
      "r225"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of options outstanding, including both vested and non-vested options.",
        "label": "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
        "periodEndLabel": "Shares Outstanding, Ending Balance (in shares)",
        "periodStartLabel": "Shares Outstanding, Beginning Balance (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.windtreetx.com/20220630/role/statement-note-9-stockbased-compensation-summary-of-stock-option-activity-details"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice": {
     "auth_ref": [
      "r224",
      "r225"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.",
        "label": "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice",
        "periodEndLabel": "Weighted Average Exercise Price, Outstanding, at Ending Period (in dollars per share)",
        "periodStartLabel": "Weighted Average Exercise Price, Outstanding, at Beginning Period (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.windtreetx.com/20220630/role/statement-note-9-stockbased-compensation-summary-of-stock-option-activity-details"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber": {
     "auth_ref": [
      "r240"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of fully vested and expected to vest options outstanding that can be converted into shares under option plan. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.",
        "label": "Vested and expected to vest (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.windtreetx.com/20220630/role/statement-note-9-stockbased-compensation-summary-of-stock-option-activity-details"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice": {
     "auth_ref": [
      "r240"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted-average exercise price, at which grantee can acquire shares reserved for issuance, for fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.",
        "label": "Weighted Average Exercise Price, Vested and Expected to Vest (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.windtreetx.com/20220630/role/statement-note-9-stockbased-compensation-summary-of-stock-option-activity-details"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain": {
     "auth_ref": [
      "r220",
      "r221",
      "r222",
      "r224",
      "r225",
      "r226",
      "r227",
      "r228",
      "r229",
      "r230",
      "r231",
      "r232",
      "r233",
      "r234",
      "r235",
      "r236",
      "r237",
      "r238",
      "r239",
      "r240",
      "r241",
      "r243",
      "r244",
      "r245",
      "r246",
      "r247"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Award under share-based payment arrangement.",
        "label": "Award Type [Domain]"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.windtreetx.com/20220630/role/statement-note-9-stockbased-compensation",
      "http://www.windtreetx.com/20220630/role/statement-note-9-stockbased-compensation-details-textual",
      "http://www.windtreetx.com/20220630/role/statement-note-9-stockbased-compensation-restricted-stock-units-details"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [
      "r228"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.",
        "label": "Weighted Average Exercise Price, Granted (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.windtreetx.com/20220630/role/statement-note-9-stockbased-compensation-summary-of-stock-option-activity-details"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1": {
     "auth_ref": [
      "r243"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1",
        "terseLabel": "Weighted average expected term (Year)"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.windtreetx.com/20220630/role/statement-note-9-stockbased-compensation-stock-options-valuation-assumptions-details"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1": {
     "auth_ref": [
      "r253"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1",
        "terseLabel": "Weighted Average Remaining Contractual Life, Vested and Exercisable (Year)"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.windtreetx.com/20220630/role/statement-note-9-stockbased-compensation-summary-of-stock-option-activity-details"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2": {
     "auth_ref": [
      "r240"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2",
        "terseLabel": "Weighted Average Remaining Contractual Life, Outstanding (Year)"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.windtreetx.com/20220630/role/statement-note-9-stockbased-compensation-summary-of-stock-option-activity-details"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1": {
     "auth_ref": [
      "r240"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average remaining contractual term for fully vested and expected to vest options outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.",
        "label": "Weighted Average Remaining Contractual Life, Vested and Expected to Vest (Year)"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.windtreetx.com/20220630/role/statement-note-9-stockbased-compensation-summary-of-stock-option-activity-details"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharesOutstanding": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares issued which are neither cancelled nor held in the treasury.",
        "label": "us-gaap_SharesOutstanding",
        "periodEndLabel": "Balance (in shares)",
        "periodStartLabel": "Balance (in shares)"
       }
      }
     },
     "localname": "SharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.windtreetx.com/20220630/role/statement-condensed-consolidated-statements-of-changes-in-stockholders-equity-unaudited-"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShortTermDebtTextBlock": {
     "auth_ref": [
      "r182"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for short-term debt.",
        "label": "Short-Term Debt [Text Block]"
       }
      }
     },
     "localname": "ShortTermDebtTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.windtreetx.com/20220630/role/statement-note-6-loans-payable"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ShortTermDebtTypeAxis": {
     "auth_ref": [
      "r23"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of short-term debt arrangement.",
        "label": "Short-Term Debt, Type [Axis]"
       }
      }
     },
     "localname": "ShortTermDebtTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.windtreetx.com/20220630/role/statement-note-6-loans-payable",
      "http://www.windtreetx.com/20220630/role/statement-note-6-loans-payable-details-textual"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShortTermDebtTypeDomain": {
     "auth_ref": [
      "r21"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Type of short-term debt arrangement, such as notes, line of credit, commercial paper, asset-based financing, project financing, letter of credit financing.",
        "label": "Short-Term Debt, Type [Domain]"
       }
      }
     },
     "localname": "ShortTermDebtTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.windtreetx.com/20220630/role/statement-note-6-loans-payable",
      "http://www.windtreetx.com/20220630/role/statement-note-6-loans-payable-details-textual"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SignificantAccountingPoliciesTextBlock": {
     "auth_ref": [
      "r61",
      "r72"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for all significant accounting policies of the reporting entity.",
        "label": "Significant Accounting Policies [Text Block]"
       }
      }
     },
     "localname": "SignificantAccountingPoliciesTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.windtreetx.com/20220630/role/statement-note-4-summary-of-significant-accounting-policies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_StatementClassOfStockAxis": {
     "auth_ref": [
      "r12",
      "r13",
      "r14",
      "r63",
      "r66",
      "r87",
      "r88",
      "r89",
      "r91",
      "r93",
      "r99",
      "r100",
      "r101",
      "r122",
      "r150",
      "r154",
      "r155",
      "r156",
      "r159",
      "r160",
      "r183",
      "r184",
      "r188",
      "r192",
      "r198",
      "r297",
      "r377"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by the different classes of stock of the entity.",
        "label": "Class of Stock [Axis]"
       }
      }
     },
     "localname": "StatementClassOfStockAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.windtreetx.com/20220630/role/statement-condensed-consolidated-statements-of-changes-in-stockholders-equity-unaudited-"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementEquityComponentsAxis": {
     "auth_ref": [
      "r0",
      "r31",
      "r38",
      "r39",
      "r40",
      "r73",
      "r74",
      "r75",
      "r77",
      "r83",
      "r85",
      "r98",
      "r123",
      "r198",
      "r200",
      "r254",
      "r255",
      "r256",
      "r271",
      "r272",
      "r286",
      "r303",
      "r304",
      "r305",
      "r306",
      "r307",
      "r308",
      "r320",
      "r363",
      "r364",
      "r365"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by component of equity.",
        "label": "Equity Components [Axis]"
       }
      }
     },
     "localname": "StatementEquityComponentsAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.windtreetx.com/20220630/role/statement-condensed-consolidated-statements-of-changes-in-stockholders-equity-unaudited-"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Statement [Line Items]"
       }
      }
     },
     "localname": "StatementLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.windtreetx.com/20220630/role/statement-condensed-consolidated-balance-sheets-current-period-unaudited",
      "http://www.windtreetx.com/20220630/role/statement-condensed-consolidated-balance-sheets-current-period-unaudited-parentheticals",
      "http://www.windtreetx.com/20220630/role/statement-condensed-consolidated-statements-of-cash-flows-unaudited-",
      "http://www.windtreetx.com/20220630/role/statement-condensed-consolidated-statements-of-changes-in-stockholders-equity-unaudited-",
      "http://www.windtreetx.com/20220630/role/statement-condensed-consolidated-statements-of-operations-unaudited",
      "http://www.windtreetx.com/20220630/role/statement-note-1-the-company-and-description-of-business",
      "http://www.windtreetx.com/20220630/role/statement-note-10-licensing-and-research-funding-agreements",
      "http://www.windtreetx.com/20220630/role/statement-note-10-licensing-and-research-funding-agreements-details-textual",
      "http://www.windtreetx.com/20220630/role/statement-note-2-basis-of-presentation",
      "http://www.windtreetx.com/20220630/role/statement-note-3-going-concern-and-managements-plans",
      "http://www.windtreetx.com/20220630/role/statement-note-3-going-concern-and-managements-plans-details-textual",
      "http://www.windtreetx.com/20220630/role/statement-note-4-summary-of-significant-accounting-policies",
      "http://www.windtreetx.com/20220630/role/statement-note-4-summary-of-significant-accounting-policies-details-textual",
      "http://www.windtreetx.com/20220630/role/statement-note-4-summary-of-significant-accounting-policies-intangible-assets-details",
      "http://www.windtreetx.com/20220630/role/statement-note-4-summary-of-significant-accounting-policies-tables",
      "http://www.windtreetx.com/20220630/role/statement-note-5-fair-value-measurements",
      "http://www.windtreetx.com/20220630/role/statement-note-5-fair-value-measurements-assets-and-liabilities-measured-at-fair-value-on-a-recurring-basis-details",
      "http://www.windtreetx.com/20220630/role/statement-note-5-fair-value-measurements-tables",
      "http://www.windtreetx.com/20220630/role/statement-note-6-loans-payable",
      "http://www.windtreetx.com/20220630/role/statement-note-6-loans-payable-details-textual",
      "http://www.windtreetx.com/20220630/role/statement-note-7-restructured-debt-liability",
      "http://www.windtreetx.com/20220630/role/statement-note-7-restructured-debt-liability-details-textual",
      "http://www.windtreetx.com/20220630/role/statement-note-8-stockholders-equity",
      "http://www.windtreetx.com/20220630/role/statement-note-8-stockholders-equity-details-textual",
      "http://www.windtreetx.com/20220630/role/statement-note-9-stockbased-compensation",
      "http://www.windtreetx.com/20220630/role/statement-note-9-stockbased-compensation-details-textual",
      "http://www.windtreetx.com/20220630/role/statement-note-9-stockbased-compensation-restricted-stock-units-details",
      "http://www.windtreetx.com/20220630/role/statement-note-9-stockbased-compensation-stock-options-valuation-assumptions-details",
      "http://www.windtreetx.com/20220630/role/statement-note-9-stockbased-compensation-stockbased-compensation-expense-details",
      "http://www.windtreetx.com/20220630/role/statement-note-9-stockbased-compensation-summary-of-stock-option-activity-details",
      "http://www.windtreetx.com/20220630/role/statement-note-9-stockbased-compensation-tables",
      "http://www.windtreetx.com/20220630/role/statement-significant-accounting-policies-policies"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfCashFlowsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Cash Flows [Abstract]"
       }
      }
     },
     "localname": "StatementOfCashFlowsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfFinancialPositionAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Financial Position [Abstract]"
       }
      }
     },
     "localname": "StatementOfFinancialPositionAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfStockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Stockholders' Equity [Abstract]"
       }
      }
     },
     "localname": "StatementOfStockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementTable": {
     "auth_ref": [
      "r73",
      "r74",
      "r75",
      "r98",
      "r337"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule reflecting a Statement of Income, Statement of Cash Flows, Statement of Financial Position, Statement of Shareholders' Equity and Other Comprehensive Income, or other statement as needed.",
        "label": "Statement [Table]"
       }
      }
     },
     "localname": "StatementTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.windtreetx.com/20220630/role/statement-condensed-consolidated-balance-sheets-current-period-unaudited",
      "http://www.windtreetx.com/20220630/role/statement-condensed-consolidated-balance-sheets-current-period-unaudited-parentheticals",
      "http://www.windtreetx.com/20220630/role/statement-condensed-consolidated-statements-of-cash-flows-unaudited-",
      "http://www.windtreetx.com/20220630/role/statement-condensed-consolidated-statements-of-changes-in-stockholders-equity-unaudited-",
      "http://www.windtreetx.com/20220630/role/statement-condensed-consolidated-statements-of-operations-unaudited",
      "http://www.windtreetx.com/20220630/role/statement-note-1-the-company-and-description-of-business",
      "http://www.windtreetx.com/20220630/role/statement-note-10-licensing-and-research-funding-agreements",
      "http://www.windtreetx.com/20220630/role/statement-note-10-licensing-and-research-funding-agreements-details-textual",
      "http://www.windtreetx.com/20220630/role/statement-note-2-basis-of-presentation",
      "http://www.windtreetx.com/20220630/role/statement-note-3-going-concern-and-managements-plans",
      "http://www.windtreetx.com/20220630/role/statement-note-3-going-concern-and-managements-plans-details-textual",
      "http://www.windtreetx.com/20220630/role/statement-note-4-summary-of-significant-accounting-policies",
      "http://www.windtreetx.com/20220630/role/statement-note-4-summary-of-significant-accounting-policies-details-textual",
      "http://www.windtreetx.com/20220630/role/statement-note-4-summary-of-significant-accounting-policies-intangible-assets-details",
      "http://www.windtreetx.com/20220630/role/statement-note-4-summary-of-significant-accounting-policies-tables",
      "http://www.windtreetx.com/20220630/role/statement-note-5-fair-value-measurements",
      "http://www.windtreetx.com/20220630/role/statement-note-5-fair-value-measurements-assets-and-liabilities-measured-at-fair-value-on-a-recurring-basis-details",
      "http://www.windtreetx.com/20220630/role/statement-note-5-fair-value-measurements-tables",
      "http://www.windtreetx.com/20220630/role/statement-note-6-loans-payable",
      "http://www.windtreetx.com/20220630/role/statement-note-6-loans-payable-details-textual",
      "http://www.windtreetx.com/20220630/role/statement-note-7-restructured-debt-liability",
      "http://www.windtreetx.com/20220630/role/statement-note-7-restructured-debt-liability-details-textual",
      "http://www.windtreetx.com/20220630/role/statement-note-8-stockholders-equity",
      "http://www.windtreetx.com/20220630/role/statement-note-8-stockholders-equity-details-textual",
      "http://www.windtreetx.com/20220630/role/statement-note-9-stockbased-compensation",
      "http://www.windtreetx.com/20220630/role/statement-note-9-stockbased-compensation-details-textual",
      "http://www.windtreetx.com/20220630/role/statement-note-9-stockbased-compensation-restricted-stock-units-details",
      "http://www.windtreetx.com/20220630/role/statement-note-9-stockbased-compensation-stock-options-valuation-assumptions-details",
      "http://www.windtreetx.com/20220630/role/statement-note-9-stockbased-compensation-stockbased-compensation-expense-details",
      "http://www.windtreetx.com/20220630/role/statement-note-9-stockbased-compensation-summary-of-stock-option-activity-details",
      "http://www.windtreetx.com/20220630/role/statement-note-9-stockbased-compensation-tables",
      "http://www.windtreetx.com/20220630/role/statement-significant-accounting-policies-policies"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesNewIssues": {
     "auth_ref": [
      "r13",
      "r14",
      "r198",
      "r200"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of new stock issued during the period.",
        "label": "Issuance of common stock, ATM Program, net of issuance costs (in shares)",
        "terseLabel": "Stock Issued During Period, Shares, New Issues (in shares)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesNewIssues",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.windtreetx.com/20220630/role/statement-condensed-consolidated-statements-of-changes-in-stockholders-equity-unaudited-",
      "http://www.windtreetx.com/20220630/role/statement-note-3-going-concern-and-managements-plans-details-textual",
      "http://www.windtreetx.com/20220630/role/statement-note-8-stockholders-equity-details-textual"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueIssuedForServices": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Value of stock issued in lieu of cash for services contributed to the entity. Value of the stock issued includes, but is not limited to, services contributed by vendors and founders.",
        "label": "Issuance of common stock warrants, equity consideration for service agreement"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueIssuedForServices",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.windtreetx.com/20220630/role/statement-condensed-consolidated-statements-of-changes-in-stockholders-equity-unaudited-"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueNewIssues": {
     "auth_ref": [
      "r13",
      "r14",
      "r198",
      "r200"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.",
        "label": "Issuance of common stock, ATM Program, net of issuance costs",
        "terseLabel": "Stock Issued During Period, Value, New Issues"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueNewIssues",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.windtreetx.com/20220630/role/statement-condensed-consolidated-statements-of-changes-in-stockholders-equity-unaudited-",
      "http://www.windtreetx.com/20220630/role/statement-note-3-going-concern-and-managements-plans-details-textual",
      "http://www.windtreetx.com/20220630/role/statement-note-8-stockholders-equity-details-textual"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockholdersEquity": {
     "auth_ref": [
      "r14",
      "r17",
      "r18",
      "r66",
      "r121",
      "r122",
      "r297",
      "r324"
     ],
     "calculation": {
      "http://www.windtreetx.com/20220630/role/statement-condensed-consolidated-balance-sheets-current-period-unaudited": {
       "order": 1.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.",
        "label": "us-gaap_StockholdersEquity",
        "periodEndLabel": "Balance",
        "periodStartLabel": "Balance",
        "totalLabel": "Total stockholders\u2019 equity"
       }
      }
     },
     "localname": "StockholdersEquity",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.windtreetx.com/20220630/role/statement-condensed-consolidated-balance-sheets-current-period-unaudited",
      "http://www.windtreetx.com/20220630/role/statement-condensed-consolidated-statements-of-changes-in-stockholders-equity-unaudited-"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stockholders\u2019 Equity:"
       }
      }
     },
     "localname": "StockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.windtreetx.com/20220630/role/statement-condensed-consolidated-balance-sheets-current-period-unaudited"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StockholdersEquityNoteDisclosureTextBlock": {
     "auth_ref": [
      "r64",
      "r184",
      "r187",
      "r188",
      "r189",
      "r190",
      "r191",
      "r192",
      "r193",
      "r194",
      "r195",
      "r196",
      "r197",
      "r200",
      "r204",
      "r285"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.",
        "label": "Stockholders' Equity Note Disclosure [Text Block]"
       }
      }
     },
     "localname": "StockholdersEquityNoteDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.windtreetx.com/20220630/role/statement-note-8-stockholders-equity"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SubsequentEventMember": {
     "auth_ref": [
      "r309",
      "r325"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Identifies event that occurred after the balance sheet date but before financial statements are issued or available to be issued.",
        "label": "Subsequent Event [Member]"
       }
      }
     },
     "localname": "SubsequentEventMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.windtreetx.com/20220630/role/statement-note-3-going-concern-and-managements-plans",
      "http://www.windtreetx.com/20220630/role/statement-note-3-going-concern-and-managements-plans-details-textual",
      "http://www.windtreetx.com/20220630/role/statement-note-8-stockholders-equity",
      "http://www.windtreetx.com/20220630/role/statement-note-8-stockholders-equity-details-textual"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SubsequentEventTypeAxis": {
     "auth_ref": [
      "r309",
      "r325"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by event that occurred after the balance sheet date but before financial statements are issued or available to be issued.",
        "label": "Subsequent Event Type [Axis]"
       }
      }
     },
     "localname": "SubsequentEventTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.windtreetx.com/20220630/role/statement-note-3-going-concern-and-managements-plans",
      "http://www.windtreetx.com/20220630/role/statement-note-3-going-concern-and-managements-plans-details-textual",
      "http://www.windtreetx.com/20220630/role/statement-note-8-stockholders-equity",
      "http://www.windtreetx.com/20220630/role/statement-note-8-stockholders-equity-details-textual"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SubsequentEventTypeDomain": {
     "auth_ref": [
      "r309",
      "r325"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Event that occurred after the balance sheet date but before financial statements are issued or available to be issued.",
        "label": "Subsequent Event Type [Domain]"
       }
      }
     },
     "localname": "SubsequentEventTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.windtreetx.com/20220630/role/statement-note-3-going-concern-and-managements-plans",
      "http://www.windtreetx.com/20220630/role/statement-note-3-going-concern-and-managements-plans-details-textual",
      "http://www.windtreetx.com/20220630/role/statement-note-8-stockholders-equity",
      "http://www.windtreetx.com/20220630/role/statement-note-8-stockholders-equity-details-textual"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SubsidiarySaleOfStockAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of sale of the entity's stock.",
        "label": "Sale of Stock [Axis]"
       }
      }
     },
     "localname": "SubsidiarySaleOfStockAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.windtreetx.com/20220630/role/statement-condensed-consolidated-statements-of-changes-in-stockholders-equity-unaudited-",
      "http://www.windtreetx.com/20220630/role/statement-note-3-going-concern-and-managements-plans",
      "http://www.windtreetx.com/20220630/role/statement-note-3-going-concern-and-managements-plans-details-textual",
      "http://www.windtreetx.com/20220630/role/statement-note-8-stockholders-equity",
      "http://www.windtreetx.com/20220630/role/statement-note-8-stockholders-equity-details-textual"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SupplementalUnemploymentBenefitsSeveranceBenefits": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Liability for amount due employees, in addition to wages and any other money that employers owe employees, when their employment ends through a layoff or other termination. For example, a company may provide involuntarily terminated employees with a lump sum payment equal to one week's salary for every year of employment.",
        "label": "us-gaap_SupplementalUnemploymentBenefitsSeveranceBenefits",
        "terseLabel": "Supplemental Unemployment Benefits, Severance Benefits"
       }
      }
     },
     "localname": "SupplementalUnemploymentBenefitsSeveranceBenefits",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.windtreetx.com/20220630/role/statement-note-4-summary-of-significant-accounting-policies-details-textual"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_TableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "us-gaap_TableTextBlock",
        "terseLabel": "Notes Tables"
       }
      }
     },
     "localname": "TableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.windtreetx.com/20220630/role/statement-note-4-summary-of-significant-accounting-policies-tables",
      "http://www.windtreetx.com/20220630/role/statement-note-5-fair-value-measurements-tables",
      "http://www.windtreetx.com/20220630/role/statement-note-9-stockbased-compensation-tables"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_TreasuryStockMember": {
     "auth_ref": [
      "r30",
      "r201"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Shares of an entity that have been repurchased by the entity. This stock has no voting rights and receives no dividends. Note that treasury stock may be recorded at its total cost or separately as par (or stated) value and additional paid in capital. Classified within stockholders' equity if nonredeemable or redeemable solely at the option of the issuer. Classified within temporary equity if redemption is outside the control of the issuer.",
        "label": "Treasury Stock [Member]"
       }
      }
     },
     "localname": "TreasuryStockMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.windtreetx.com/20220630/role/statement-condensed-consolidated-statements-of-changes-in-stockholders-equity-unaudited-"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_TreasuryStockShares": {
     "auth_ref": [
      "r30",
      "r201"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of common and preferred shares that were previously issued and that were repurchased by the issuing entity and held in treasury on the financial statement date. This stock has no voting rights and receives no dividends.",
        "label": "Treasury stock, shares (in shares)"
       }
      }
     },
     "localname": "TreasuryStockShares",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.windtreetx.com/20220630/role/statement-condensed-consolidated-balance-sheets-current-period-unaudited-parentheticals"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_TreasuryStockValue": {
     "auth_ref": [
      "r30",
      "r201",
      "r202"
     ],
     "calculation": {
      "http://www.windtreetx.com/20220630/role/statement-condensed-consolidated-balance-sheets-current-period-unaudited": {
       "order": 2.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount allocated to treasury stock. Treasury stock is common and preferred shares of an entity that were issued, repurchased by the entity, and are held in its treasury.",
        "label": "us-gaap_TreasuryStockValue",
        "negatedLabel": "Treasury stock (at cost); 24 shares"
       }
      }
     },
     "localname": "TreasuryStockValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.windtreetx.com/20220630/role/statement-condensed-consolidated-balance-sheets-current-period-unaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_TypeOfArrangementAxis": {
     "auth_ref": [
      "r278"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations.",
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Axis]"
       }
      }
     },
     "localname": "TypeOfArrangementAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.windtreetx.com/20220630/role/statement-note-10-licensing-and-research-funding-agreements",
      "http://www.windtreetx.com/20220630/role/statement-note-10-licensing-and-research-funding-agreements-details-textual",
      "http://www.windtreetx.com/20220630/role/statement-note-4-summary-of-significant-accounting-policies",
      "http://www.windtreetx.com/20220630/role/statement-note-4-summary-of-significant-accounting-policies-details-textual",
      "http://www.windtreetx.com/20220630/role/statement-note-7-restructured-debt-liability",
      "http://www.windtreetx.com/20220630/role/statement-note-7-restructured-debt-liability-details-textual"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_UseOfEstimates": {
     "auth_ref": [
      "r102",
      "r103",
      "r104",
      "r105",
      "r106",
      "r107",
      "r108"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.",
        "label": "Use of Estimates, Policy [Policy Text Block]"
       }
      }
     },
     "localname": "UseOfEstimates",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.windtreetx.com/20220630/role/statement-significant-accounting-policies-policies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_WarrantsAndRightsOutstandingTerm": {
     "auth_ref": [
      "r292"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Period between issuance and expiration of outstanding warrant and right embodying unconditional obligation requiring redemption by transferring asset at specified or determinable date or upon event certain to occur, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "us-gaap_WarrantsAndRightsOutstandingTerm",
        "terseLabel": "Warrants and Rights Outstanding, Term (Year)"
       }
      }
     },
     "localname": "WarrantsAndRightsOutstandingTerm",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.windtreetx.com/20220630/role/statement-note-8-stockholders-equity-details-textual"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_WeightedAverageNumberOfSharesOutstandingBasic": {
     "auth_ref": [
      "r86",
      "r93"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.",
        "label": "us-gaap_WeightedAverageNumberOfSharesOutstandingBasic",
        "terseLabel": "Basic and diluted (in shares)"
       }
      }
     },
     "localname": "WeightedAverageNumberOfSharesOutstandingBasic",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.windtreetx.com/20220630/role/statement-condensed-consolidated-statements-of-operations-unaudited"
     ],
     "xbrltype": "sharesItemType"
    },
    "wint_ATMProgramMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the \"at-the-market\" program (ATM Program) by which the reporting entity secures capital.",
        "label": "ATM Program [Member]"
       }
      }
     },
     "localname": "ATMProgramMember",
     "nsuri": "http://www.windtreetx.com/20220630",
     "presentation": [
      "http://www.windtreetx.com/20220630/role/statement-condensed-consolidated-statements-of-changes-in-stockholders-equity-unaudited-",
      "http://www.windtreetx.com/20220630/role/statement-note-3-going-concern-and-managements-plans",
      "http://www.windtreetx.com/20220630/role/statement-note-3-going-concern-and-managements-plans-details-textual",
      "http://www.windtreetx.com/20220630/role/statement-note-8-stockholders-equity",
      "http://www.windtreetx.com/20220630/role/statement-note-8-stockholders-equity-details-textual"
     ],
     "xbrltype": "domainItemType"
    },
    "wint_AerosurfFundingTermSheetMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the information pertaining to the AEROSURF Funding Term Sheet.",
        "label": "AEROSURF Funding Term Sheet [Member]"
       }
      }
     },
     "localname": "AerosurfFundingTermSheetMember",
     "nsuri": "http://www.windtreetx.com/20220630",
     "presentation": [
      "http://www.windtreetx.com/20220630/role/statement-note-10-licensing-and-research-funding-agreements",
      "http://www.windtreetx.com/20220630/role/statement-note-10-licensing-and-research-funding-agreements-details-textual"
     ],
     "xbrltype": "domainItemType"
    },
    "wint_ClassOfWarrantOrRightExercisePriceOfCancelledWarrants": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the exercise price per share of cancelled warrants.",
        "label": "wint_ClassOfWarrantOrRightExercisePriceOfCancelledWarrants",
        "terseLabel": "Class of Warrant or Right, Exercise Price of Cancelled Warrants (in dollars per share)"
       }
      }
     },
     "localname": "ClassOfWarrantOrRightExercisePriceOfCancelledWarrants",
     "nsuri": "http://www.windtreetx.com/20220630",
     "presentation": [
      "http://www.windtreetx.com/20220630/role/statement-note-7-restructured-debt-liability-details-textual"
     ],
     "xbrltype": "perShareItemType"
    },
    "wint_ClassOfWarrantOrRightNumberOfWarrantsCancelled": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the number of warrants or rights cancelled during the period.",
        "label": "wint_ClassOfWarrantOrRightNumberOfWarrantsCancelled",
        "terseLabel": "Class of Warrant or Right, Number of Warrants Cancelled (in shares)"
       }
      }
     },
     "localname": "ClassOfWarrantOrRightNumberOfWarrantsCancelled",
     "nsuri": "http://www.windtreetx.com/20220630",
     "presentation": [
      "http://www.windtreetx.com/20220630/role/statement-note-7-restructured-debt-liability-details-textual"
     ],
     "xbrltype": "sharesItemType"
    },
    "wint_CommissionFeePercentFee": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The percentage charged for commission.",
        "label": "wint_CommissionFeePercentFee",
        "terseLabel": "Commission Fee, Percent Fee"
       }
      }
     },
     "localname": "CommissionFeePercentFee",
     "nsuri": "http://www.windtreetx.com/20220630",
     "presentation": [
      "http://www.windtreetx.com/20220630/role/statement-note-8-stockholders-equity-details-textual"
     ],
     "xbrltype": "percentItemType"
    },
    "wint_CorporatePartnershipLicensingAndResearchFundingAgreementsTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for corporate partnerships, licensing and research funding agreements.",
        "label": "Corporate Partnership, Licensing and Research Funding Agreements [Text Block]"
       }
      }
     },
     "localname": "CorporatePartnershipLicensingAndResearchFundingAgreementsTextBlock",
     "nsuri": "http://www.windtreetx.com/20220630",
     "presentation": [
      "http://www.windtreetx.com/20220630/role/statement-note-10-licensing-and-research-funding-agreements"
     ],
     "xbrltype": "textBlockItemType"
    },
    "wint_DeerfieldLoanMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the long-term debt under a secure loan - \"Deerfield Loan.\"",
        "label": "Deerfield Loan [Member]"
       }
      }
     },
     "localname": "DeerfieldLoanMember",
     "nsuri": "http://www.windtreetx.com/20220630",
     "presentation": [
      "http://www.windtreetx.com/20220630/role/statement-note-4-summary-of-significant-accounting-policies",
      "http://www.windtreetx.com/20220630/role/statement-note-4-summary-of-significant-accounting-policies-details-textual",
      "http://www.windtreetx.com/20220630/role/statement-note-7-restructured-debt-liability",
      "http://www.windtreetx.com/20220630/role/statement-note-7-restructured-debt-liability-details-textual"
     ],
     "xbrltype": "domainItemType"
    },
    "wint_DeerfieldManagementLPMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the affiliates of Deerfield Management, L.P.",
        "label": "Deerfield Management, L.P. [Member]"
       }
      }
     },
     "localname": "DeerfieldManagementLPMember",
     "nsuri": "http://www.windtreetx.com/20220630",
     "presentation": [
      "http://www.windtreetx.com/20220630/role/statement-note-4-summary-of-significant-accounting-policies",
      "http://www.windtreetx.com/20220630/role/statement-note-4-summary-of-significant-accounting-policies-details-textual",
      "http://www.windtreetx.com/20220630/role/statement-note-7-restructured-debt-liability",
      "http://www.windtreetx.com/20220630/role/statement-note-7-restructured-debt-liability-details-textual"
     ],
     "xbrltype": "domainItemType"
    },
    "wint_EffectOfCOVID19PandemicPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The disclosure for the accounting policy related to the effect of the COVID-19 pandemic.",
        "label": "Effect of COVID-19 Pandemic [Policy Text Block]"
       }
      }
     },
     "localname": "EffectOfCOVID19PandemicPolicyTextBlock",
     "nsuri": "http://www.windtreetx.com/20220630",
     "presentation": [
      "http://www.windtreetx.com/20220630/role/statement-significant-accounting-policies-policies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "wint_EquityIssuedDuringPeriodUnitsNewIssues": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of new units issued during the period.",
        "label": "wint_EquityIssuedDuringPeriodUnitsNewIssues",
        "terseLabel": "Equity Issued During Period, Units, New Issues (in shares)"
       }
      }
     },
     "localname": "EquityIssuedDuringPeriodUnitsNewIssues",
     "nsuri": "http://www.windtreetx.com/20220630",
     "presentation": [
      "http://www.windtreetx.com/20220630/role/statement-note-8-stockholders-equity-details-textual"
     ],
     "xbrltype": "sharesItemType"
    },
    "wint_ExchangeAndTerminationAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents information pertaining to an Exchange and Termination Agreement, under which debt and warrant obligations are cancelled in exchange for payments in cash, stock, and milestone payments.",
        "label": "Exchange and Termination Agreement [Member]"
       }
      }
     },
     "localname": "ExchangeAndTerminationAgreementMember",
     "nsuri": "http://www.windtreetx.com/20220630",
     "presentation": [
      "http://www.windtreetx.com/20220630/role/statement-note-4-summary-of-significant-accounting-policies",
      "http://www.windtreetx.com/20220630/role/statement-note-4-summary-of-significant-accounting-policies-details-textual",
      "http://www.windtreetx.com/20220630/role/statement-note-7-restructured-debt-liability",
      "http://www.windtreetx.com/20220630/role/statement-note-7-restructured-debt-liability-details-textual"
     ],
     "xbrltype": "domainItemType"
    },
    "wint_ExecutiveOfficersAndEmployeesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents information regarding executive officers and employees.",
        "label": "Executive Officers and Employees [Member]"
       }
      }
     },
     "localname": "ExecutiveOfficersAndEmployeesMember",
     "nsuri": "http://www.windtreetx.com/20220630",
     "presentation": [
      "http://www.windtreetx.com/20220630/role/statement-note-9-stockbased-compensation",
      "http://www.windtreetx.com/20220630/role/statement-note-9-stockbased-compensation-details-textual"
     ],
     "xbrltype": "domainItemType"
    },
    "wint_FinancingOfProductPercentOfFinancingThatMustBeRepaidToDiscontinueRevenueSharing": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The percent of financing that must be repaid to discontinue the revenue sharing provisions of product financing.",
        "label": "wint_FinancingOfProductPercentOfFinancingThatMustBeRepaidToDiscontinueRevenueSharing",
        "terseLabel": "Financing of Product, Percent of Financing That Must be Repaid to Discontinue Revenue Sharing"
       }
      }
     },
     "localname": "FinancingOfProductPercentOfFinancingThatMustBeRepaidToDiscontinueRevenueSharing",
     "nsuri": "http://www.windtreetx.com/20220630",
     "presentation": [
      "http://www.windtreetx.com/20220630/role/statement-note-10-licensing-and-research-funding-agreements-details-textual"
     ],
     "xbrltype": "percentItemType"
    },
    "wint_FinancingOfProductPercentOfRevenueSharedWithFinancer": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The percent of revenue shared with financer for the financing of a product.",
        "label": "wint_FinancingOfProductPercentOfRevenueSharedWithFinancer",
        "terseLabel": "Financing of Product, Percent of Revenue Shared With Financer"
       }
      }
     },
     "localname": "FinancingOfProductPercentOfRevenueSharedWithFinancer",
     "nsuri": "http://www.windtreetx.com/20220630",
     "presentation": [
      "http://www.windtreetx.com/20220630/role/statement-note-10-licensing-and-research-funding-agreements-details-textual"
     ],
     "xbrltype": "percentItemType"
    },
    "wint_IncreaseDecreaseOperatingLeaseLiability": {
     "auth_ref": [],
     "calculation": {
      "http://www.windtreetx.com/20220630/role/statement-condensed-consolidated-statements-of-cash-flows-unaudited-": {
       "order": 11.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in the operating lease liability.",
        "label": "Operating lease liabilities"
       }
      }
     },
     "localname": "IncreaseDecreaseOperatingLeaseLiability",
     "nsuri": "http://www.windtreetx.com/20220630",
     "presentation": [
      "http://www.windtreetx.com/20220630/role/statement-condensed-consolidated-statements-of-cash-flows-unaudited-"
     ],
     "xbrltype": "monetaryItemType"
    },
    "wint_IssuanceOfCommonStockAndCommonStockWarrantsNetOfIssuanceCostsShares": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents number of shares of common stock and common stock warrants issued net of issuance costs.",
        "label": "Issuance of common stock and common stock warrants, net of issuance costs (in shares)"
       }
      }
     },
     "localname": "IssuanceOfCommonStockAndCommonStockWarrantsNetOfIssuanceCostsShares",
     "nsuri": "http://www.windtreetx.com/20220630",
     "presentation": [
      "http://www.windtreetx.com/20220630/role/statement-condensed-consolidated-statements-of-changes-in-stockholders-equity-unaudited-"
     ],
     "xbrltype": "sharesItemType"
    },
    "wint_IssuanceOfCommonStockAndCommonStockWarrantsNetOfIssuanceCostsValue": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents value of common stock and common stock warrants issued net of issuance costs.",
        "label": "Issuance of common stock and common stock warrants, net of issuance costs"
       }
      }
     },
     "localname": "IssuanceOfCommonStockAndCommonStockWarrantsNetOfIssuanceCostsValue",
     "nsuri": "http://www.windtreetx.com/20220630",
     "presentation": [
      "http://www.windtreetx.com/20220630/role/statement-condensed-consolidated-statements-of-changes-in-stockholders-equity-unaudited-"
     ],
     "xbrltype": "monetaryItemType"
    },
    "wint_IstaroximeDrugCandidateMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Related to Istaroxime drug candidate.",
        "label": "Istaroxime Drug Candidate [Member]"
       }
      }
     },
     "localname": "IstaroximeDrugCandidateMember",
     "nsuri": "http://www.windtreetx.com/20220630",
     "presentation": [
      "http://www.windtreetx.com/20220630/role/statement-note-4-summary-of-significant-accounting-policies-intangible-assets-details"
     ],
     "xbrltype": "domainItemType"
    },
    "wint_LeesPharmaceuticalHoldingsLimitedMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents Lee\u2019s Pharmaceutical Holdings Limited.",
        "label": "Lee\u2019s Pharmaceutical Holdings Limited [Member]"
       }
      }
     },
     "localname": "LeesPharmaceuticalHoldingsLimitedMember",
     "nsuri": "http://www.windtreetx.com/20220630",
     "presentation": [
      "http://www.windtreetx.com/20220630/role/statement-note-10-licensing-and-research-funding-agreements",
      "http://www.windtreetx.com/20220630/role/statement-note-10-licensing-and-research-funding-agreements-details-textual"
     ],
     "xbrltype": "domainItemType"
    },
    "wint_LiabilityforContingentMilestonePaymentNoncurrent": {
     "auth_ref": [],
     "calculation": {
      "http://www.windtreetx.com/20220630/role/statement-condensed-consolidated-balance-sheets-current-period-unaudited": {
       "order": 2.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of restructured debt liability for contingent milestone payments, due after one year or the normal operating cycle, if longer.",
        "label": "Restructured debt liability - contingent milestone payments",
        "terseLabel": "Liability for Contingent Milestone Payment, Noncurrent"
       }
      }
     },
     "localname": "LiabilityforContingentMilestonePaymentNoncurrent",
     "nsuri": "http://www.windtreetx.com/20220630",
     "presentation": [
      "http://www.windtreetx.com/20220630/role/statement-condensed-consolidated-balance-sheets-current-period-unaudited",
      "http://www.windtreetx.com/20220630/role/statement-note-4-summary-of-significant-accounting-policies-details-textual",
      "http://www.windtreetx.com/20220630/role/statement-note-7-restructured-debt-liability-details-textual"
     ],
     "xbrltype": "monetaryItemType"
    },
    "wint_LiquidityDisclosuresTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of historical and expected sources of liquidity, available cash and cash equivalents as of the balance sheet date, and management's plans to maintain sufficient working capital through one or more of the following, if available: public and private securities offerings, equity financing facilities, capital equipment and debt facilities, and strategic alliances, as well as sales revenue from products approved for marketing, if and when approved.",
        "label": "Liquidity Disclosures [Text Block]"
       }
      }
     },
     "localname": "LiquidityDisclosuresTextBlock",
     "nsuri": "http://www.windtreetx.com/20220630",
     "presentation": [
      "http://www.windtreetx.com/20220630/role/statement-note-3-going-concern-and-managements-plans"
     ],
     "xbrltype": "textBlockItemType"
    },
    "wint_LoanPayableToBankDirectCapitalFinanceMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information pertaining to loan payable to Bank Direct Capital Finance.",
        "label": "Loan payable to Bank Direct Capital Finance [Member]"
       }
      }
     },
     "localname": "LoanPayableToBankDirectCapitalFinanceMember",
     "nsuri": "http://www.windtreetx.com/20220630",
     "presentation": [
      "http://www.windtreetx.com/20220630/role/statement-note-6-loans-payable",
      "http://www.windtreetx.com/20220630/role/statement-note-6-loans-payable-details-textual"
     ],
     "xbrltype": "domainItemType"
    },
    "wint_ManufacturingAndLaboratoryEquipmentMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Related to manufacturing and laboratory equipment.",
        "label": "Manufacturing and Laboratory Equipment [Member]"
       }
      }
     },
     "localname": "ManufacturingAndLaboratoryEquipmentMember",
     "nsuri": "http://www.windtreetx.com/20220630",
     "presentation": [
      "http://www.windtreetx.com/20220630/role/statement-note-4-summary-of-significant-accounting-policies",
      "http://www.windtreetx.com/20220630/role/statement-note-4-summary-of-significant-accounting-policies-details-textual"
     ],
     "xbrltype": "domainItemType"
    },
    "wint_March2021PublicOfferingMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information related to the March 2021 Public Offering.",
        "label": "March 2021 Public Offering [Member]"
       }
      }
     },
     "localname": "March2021PublicOfferingMember",
     "nsuri": "http://www.windtreetx.com/20220630",
     "presentation": [
      "http://www.windtreetx.com/20220630/role/statement-note-8-stockholders-equity",
      "http://www.windtreetx.com/20220630/role/statement-note-8-stockholders-equity-details-textual"
     ],
     "xbrltype": "domainItemType"
    },
    "wint_March2021WarrantsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information related to the March 2021 Offering Warrants.",
        "label": "March 2021 Warrants [Member]"
       }
      }
     },
     "localname": "March2021WarrantsMember",
     "nsuri": "http://www.windtreetx.com/20220630",
     "presentation": [
      "http://www.windtreetx.com/20220630/role/statement-note-8-stockholders-equity",
      "http://www.windtreetx.com/20220630/role/statement-note-8-stockholders-equity-details-textual"
     ],
     "xbrltype": "domainItemType"
    },
    "wint_NonCashExpenseRelatedToEquityConsiderationForAServiceAgreement": {
     "auth_ref": [],
     "calculation": {
      "http://www.windtreetx.com/20220630/role/statement-condensed-consolidated-statements-of-cash-flows-unaudited-": {
       "order": 5.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents non-cash expense related to equity consideration for a service agreement.",
        "label": "Non-cash expense related to equity consideration for a service agreement"
       }
      }
     },
     "localname": "NonCashExpenseRelatedToEquityConsiderationForAServiceAgreement",
     "nsuri": "http://www.windtreetx.com/20220630",
     "presentation": [
      "http://www.windtreetx.com/20220630/role/statement-condensed-consolidated-statements-of-cash-flows-unaudited-"
     ],
     "xbrltype": "monetaryItemType"
    },
    "wint_NonplanStockOptionsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Related to non-plan options awarded.",
        "label": "Non-plan Stock Options [Member]"
       }
      }
     },
     "localname": "NonplanStockOptionsMember",
     "nsuri": "http://www.windtreetx.com/20220630",
     "presentation": [
      "http://www.windtreetx.com/20220630/role/statement-note-9-stockbased-compensation",
      "http://www.windtreetx.com/20220630/role/statement-note-9-stockbased-compensation-details-textual"
     ],
     "xbrltype": "domainItemType"
    },
    "wint_NonrefundablePayments": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of nonrefundable payments pursuant to the agreement.",
        "label": "wint_NonrefundablePayments",
        "terseLabel": "Nonrefundable Payments"
       }
      }
     },
     "localname": "NonrefundablePayments",
     "nsuri": "http://www.windtreetx.com/20220630",
     "presentation": [
      "http://www.windtreetx.com/20220630/role/statement-note-10-licensing-and-research-funding-agreements-details-textual"
     ],
     "xbrltype": "monetaryItemType"
    },
    "wint_NoteToFinancialStatementDetailsTextual": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Note To Financial Statement Details Textual"
       }
      }
     },
     "localname": "NoteToFinancialStatementDetailsTextual",
     "nsuri": "http://www.windtreetx.com/20220630",
     "xbrltype": "stringItemType"
    },
    "wint_NotesToFinancialStatementsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Notes To Financial Statements [Abstract]"
       }
      }
     },
     "localname": "NotesToFinancialStatementsAbstract",
     "nsuri": "http://www.windtreetx.com/20220630",
     "xbrltype": "stringItemType"
    },
    "wint_NumberOfSharesOfCommonStockPotentiallyIssuableUponTheExerciseOfStockOptionsAndWarrants": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents number of shares of common stock potentially issuable exercise of certain stock options and warrants during the period.",
        "label": "wint_NumberOfSharesOfCommonStockPotentiallyIssuableUponTheExerciseOfStockOptionsAndWarrants",
        "terseLabel": "Number of Shares of Common Stock Potentially Issuable upon the Exercise of Stock Options and Warrants (in shares)"
       }
      }
     },
     "localname": "NumberOfSharesOfCommonStockPotentiallyIssuableUponTheExerciseOfStockOptionsAndWarrants",
     "nsuri": "http://www.windtreetx.com/20220630",
     "presentation": [
      "http://www.windtreetx.com/20220630/role/statement-note-4-summary-of-significant-accounting-policies-details-textual"
     ],
     "xbrltype": "sharesItemType"
    },
    "wint_PaymentsForSeveranceCosts": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash outflow to satisfy severance cost obligation.",
        "label": "wint_PaymentsForSeveranceCosts",
        "terseLabel": "Payments for Severance Costs"
       }
      }
     },
     "localname": "PaymentsForSeveranceCosts",
     "nsuri": "http://www.windtreetx.com/20220630",
     "presentation": [
      "http://www.windtreetx.com/20220630/role/statement-note-4-summary-of-significant-accounting-policies-details-textual"
     ],
     "xbrltype": "monetaryItemType"
    },
    "wint_PrepaymentOfDirectorAndOfficerInsuranceThroughThirdPartyFinancing": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of prepayment of director and officer insurance through third party financing.",
        "label": "Prepayment of insurance through third-party financing"
       }
      }
     },
     "localname": "PrepaymentOfDirectorAndOfficerInsuranceThroughThirdPartyFinancing",
     "nsuri": "http://www.windtreetx.com/20220630",
     "presentation": [
      "http://www.windtreetx.com/20220630/role/statement-condensed-consolidated-statements-of-cash-flows-unaudited-"
     ],
     "xbrltype": "monetaryItemType"
    },
    "wint_ProceedsForPaymentsToDevelopProduct": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of cash inflow from payments from a third party to develop a product.",
        "label": "wint_ProceedsForPaymentsToDevelopProduct",
        "terseLabel": "Proceeds for Payments to Develop Product"
       }
      }
     },
     "localname": "ProceedsForPaymentsToDevelopProduct",
     "nsuri": "http://www.windtreetx.com/20220630",
     "presentation": [
      "http://www.windtreetx.com/20220630/role/statement-note-10-licensing-and-research-funding-agreements-details-textual"
     ],
     "xbrltype": "monetaryItemType"
    },
    "wint_ProceedsFromIssuanceOfCommonStockAndWarrants": {
     "auth_ref": [],
     "calculation": {
      "http://www.windtreetx.com/20220630/role/statement-condensed-consolidated-statements-of-cash-flows-unaudited-": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow from the additional capital contribution to the entity and from issuance of rights to purchase common shares at predetermined price.",
        "label": "Proceeds from issuance of common stock and warrants, net of issuance costs"
       }
      }
     },
     "localname": "ProceedsFromIssuanceOfCommonStockAndWarrants",
     "nsuri": "http://www.windtreetx.com/20220630",
     "presentation": [
      "http://www.windtreetx.com/20220630/role/statement-condensed-consolidated-statements-of-cash-flows-unaudited-"
     ],
     "xbrltype": "monetaryItemType"
    },
    "wint_ProceedsFromIssuanceOrSaleOfEquityGrossAmount": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The gross proceeds from the issuance of common stock, preferred stock, treasury stock, stock options, and other types of equity.",
        "label": "wint_ProceedsFromIssuanceOrSaleOfEquityGrossAmount",
        "terseLabel": "Proceeds from Issuance or Sale of Equity, Gross Amount"
       }
      }
     },
     "localname": "ProceedsFromIssuanceOrSaleOfEquityGrossAmount",
     "nsuri": "http://www.windtreetx.com/20220630",
     "presentation": [
      "http://www.windtreetx.com/20220630/role/statement-note-8-stockholders-equity-details-textual"
     ],
     "xbrltype": "monetaryItemType"
    },
    "wint_ProceedsFromResearchAndDevelopmentFundingArrangement": {
     "auth_ref": [],
     "calculation": {
      "http://www.windtreetx.com/20220630/role/statement-condensed-consolidated-statements-of-cash-flows-unaudited-": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow from research and development funding arrangement.",
        "label": "Proceeds from research and development funding arrangement"
       }
      }
     },
     "localname": "ProceedsFromResearchAndDevelopmentFundingArrangement",
     "nsuri": "http://www.windtreetx.com/20220630",
     "presentation": [
      "http://www.windtreetx.com/20220630/role/statement-condensed-consolidated-statements-of-cash-flows-unaudited-"
     ],
     "xbrltype": "monetaryItemType"
    },
    "wint_RestructuredDebtLiabilityContingentMilestonePaymentPolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy regarding restructured debt liability contingent milestone payment.",
        "label": "Restructured Debt Liability, Contingent Milestone Payment, Policy [Policy Text Block]"
       }
      }
     },
     "localname": "RestructuredDebtLiabilityContingentMilestonePaymentPolicyPolicyTextBlock",
     "nsuri": "http://www.windtreetx.com/20220630",
     "presentation": [
      "http://www.windtreetx.com/20220630/role/statement-significant-accounting-policies-policies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "wint_RostafuroxinDrugCandidateMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Related to Rostafuroxin drug candidate.",
        "label": "Rostafuroxin Drug Candidate [Member]"
       }
      }
     },
     "localname": "RostafuroxinDrugCandidateMember",
     "nsuri": "http://www.windtreetx.com/20220630",
     "presentation": [
      "http://www.windtreetx.com/20220630/role/statement-note-4-summary-of-significant-accounting-policies-intangible-assets-details"
     ],
     "xbrltype": "domainItemType"
    },
    "wint_SeveranceAccrual": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents amount of severance accrual.",
        "label": "wint_SeveranceAccrual",
        "terseLabel": "Severance Accrual"
       }
      }
     },
     "localname": "SeveranceAccrual",
     "nsuri": "http://www.windtreetx.com/20220630",
     "presentation": [
      "http://www.windtreetx.com/20220630/role/statement-note-4-summary-of-significant-accounting-policies-details-textual"
     ],
     "xbrltype": "monetaryItemType"
    },
    "wint_SharePurchaseAgreementDecember2019Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents information regarding Share Purchase Agreement, December 2019.",
        "label": "Share Purchase Agreement, December 2019 [Member]"
       }
      }
     },
     "localname": "SharePurchaseAgreementDecember2019Member",
     "nsuri": "http://www.windtreetx.com/20220630",
     "presentation": [
      "http://www.windtreetx.com/20220630/role/statement-condensed-consolidated-statements-of-changes-in-stockholders-equity-unaudited-"
     ],
     "xbrltype": "domainItemType"
    },
    "wint_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndExercisable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are vested and exercisable as of the balance sheet date.",
        "label": "Vested and exercisable at June 30, 2022 (in shares)"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndExercisable",
     "nsuri": "http://www.windtreetx.com/20220630",
     "presentation": [
      "http://www.windtreetx.com/20220630/role/statement-note-9-stockbased-compensation-restricted-stock-units-details"
     ],
     "xbrltype": "sharesItemType"
    },
    "wint_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndExercisableWeightedAverageGrantDateFairValueEndingBalance": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average exercise price of vested and exercisable for equity instruments other than option.",
        "label": "Vested and exercisable Weighted- Average Grant Date Fair Value (in dollars per share)"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndExercisableWeightedAverageGrantDateFairValueEndingBalance",
     "nsuri": "http://www.windtreetx.com/20220630",
     "presentation": [
      "http://www.windtreetx.com/20220630/role/statement-note-9-stockbased-compensation-restricted-stock-units-details"
     ],
     "xbrltype": "perShareItemType"
    },
    "wint_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndExpectedToVestWeightedAverageGrantDateFairValueEndingBalance": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average grant date fair value for vested and expected to vest for equity instrument other than options of share based compensation.",
        "label": "Vested and expected to vest Weighted- Average Grant Date Fair Value (in dollars per share)"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndExpectedToVestWeightedAverageGrantDateFairValueEndingBalance",
     "nsuri": "http://www.windtreetx.com/20220630",
     "presentation": [
      "http://www.windtreetx.com/20220630/role/statement-note-9-stockbased-compensation-restricted-stock-units-details"
     ],
     "xbrltype": "perShareItemType"
    },
    "wint_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityOtherThanOptionsVestedAndExpectedToVestOutstandingNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are vested and expected to vest as of the balance sheet date.",
        "label": "Vested and expected to vest at June 30, 2022 (in shares)"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardEquityOtherThanOptionsVestedAndExpectedToVestOutstandingNumber",
     "nsuri": "http://www.windtreetx.com/20220630",
     "presentation": [
      "http://www.windtreetx.com/20220630/role/statement-note-9-stockbased-compensation-restricted-stock-units-details"
     ],
     "xbrltype": "sharesItemType"
    },
    "wint_SharesAuthorizedToBeOfferedAndSoldUnderOfferingAgreementValue": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the dollar amount of stock authorized to be offered and sold under an offering agreement.",
        "label": "wint_SharesAuthorizedToBeOfferedAndSoldUnderOfferingAgreementValue",
        "terseLabel": "Shares Authorized to Be Offered and Sold Under Offering Agreement, Value"
       }
      }
     },
     "localname": "SharesAuthorizedToBeOfferedAndSoldUnderOfferingAgreementValue",
     "nsuri": "http://www.windtreetx.com/20220630",
     "presentation": [
      "http://www.windtreetx.com/20220630/role/statement-note-3-going-concern-and-managements-plans-details-textual",
      "http://www.windtreetx.com/20220630/role/statement-note-8-stockholders-equity-details-textual"
     ],
     "xbrltype": "monetaryItemType"
    },
    "wint_StockAndWarrantsIssuedPricePerShare": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The stock and warrants issued price per share.",
        "label": "wint_StockAndWarrantsIssuedPricePerShare",
        "terseLabel": "Stock and Warrants Issued, Price Per Share (in dollars per share)"
       }
      }
     },
     "localname": "StockAndWarrantsIssuedPricePerShare",
     "nsuri": "http://www.windtreetx.com/20220630",
     "presentation": [
      "http://www.windtreetx.com/20220630/role/statement-note-8-stockholders-equity-details-textual"
     ],
     "xbrltype": "perShareItemType"
    },
    "wint_StockIssuedDuringPeriodSharesCancellationOfDebtAndWarrantObligations": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares of stock issued attributable to transactions for the purpose of being granted forgiveness of debt and warrant obligations.",
        "label": "wint_StockIssuedDuringPeriodSharesCancellationOfDebtAndWarrantObligations",
        "terseLabel": "Stock Issued During Period, Shares, Cancellation of Debt and Warrant Obligations (in shares)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesCancellationOfDebtAndWarrantObligations",
     "nsuri": "http://www.windtreetx.com/20220630",
     "presentation": [
      "http://www.windtreetx.com/20220630/role/statement-note-7-restructured-debt-liability-details-textual"
     ],
     "xbrltype": "sharesItemType"
    },
    "wint_StockIssuedDuringPeriodSharesCancellationOfDebtAndWarrantObligationsPercentageOfFullyDilutedSharesOutstanding": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The percentage of the shares of stock issued attributable to transactions for the purpose of being granted forgiveness of debt and warrant obligations represent as all of the reporting entity's fully-diluted shares outstanding.",
        "label": "wint_StockIssuedDuringPeriodSharesCancellationOfDebtAndWarrantObligationsPercentageOfFullyDilutedSharesOutstanding",
        "terseLabel": "Stock Issued During Period, Shares, Cancellation of Debt and Warrant Obligations, Percentage of Fully-diluted Shares Outstanding"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesCancellationOfDebtAndWarrantObligationsPercentageOfFullyDilutedSharesOutstanding",
     "nsuri": "http://www.windtreetx.com/20220630",
     "presentation": [
      "http://www.windtreetx.com/20220630/role/statement-note-7-restructured-debt-liability-details-textual"
     ],
     "xbrltype": "percentItemType"
    },
    "wint_StockOfferingAgreementPublicFloatLimitationAmount": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of public float required to remove limitations on a stock offering agreement.",
        "label": "wint_StockOfferingAgreementPublicFloatLimitationAmount",
        "terseLabel": "Stock Offering Agreement, Public Float Limitation Amount"
       }
      }
     },
     "localname": "StockOfferingAgreementPublicFloatLimitationAmount",
     "nsuri": "http://www.windtreetx.com/20220630",
     "presentation": [
      "http://www.windtreetx.com/20220630/role/statement-note-3-going-concern-and-managements-plans-details-textual",
      "http://www.windtreetx.com/20220630/role/statement-note-8-stockholders-equity-details-textual"
     ],
     "xbrltype": "monetaryItemType"
    },
    "wint_StockOfferingAgreementRemainingAmountAvailable": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of remaining amount available under a stock offering agreement.",
        "label": "wint_StockOfferingAgreementRemainingAmountAvailable",
        "terseLabel": "Stock Offering Agreement, Remaining Amount Available"
       }
      }
     },
     "localname": "StockOfferingAgreementRemainingAmountAvailable",
     "nsuri": "http://www.windtreetx.com/20220630",
     "presentation": [
      "http://www.windtreetx.com/20220630/role/statement-note-8-stockholders-equity-details-textual"
     ],
     "xbrltype": "monetaryItemType"
    },
    "wint_TermSheetWithLeeMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Related to a term sheet with Lee.",
        "label": "Term Sheet With Lee [Member]"
       }
      }
     },
     "localname": "TermSheetWithLeeMember",
     "nsuri": "http://www.windtreetx.com/20220630",
     "presentation": [
      "http://www.windtreetx.com/20220630/role/statement-note-10-licensing-and-research-funding-agreements",
      "http://www.windtreetx.com/20220630/role/statement-note-10-licensing-and-research-funding-agreements-details-textual"
     ],
     "xbrltype": "domainItemType"
    },
    "wint_The2020EquityIncentivePlanMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information related to the 2020 Equity Incentive Plan, or the 2020 Plan.",
        "label": "The 2020 Equity Incentive Plan [Member]"
       }
      }
     },
     "localname": "The2020EquityIncentivePlanMember",
     "nsuri": "http://www.windtreetx.com/20220630",
     "presentation": [
      "http://www.windtreetx.com/20220630/role/statement-note-9-stockbased-compensation",
      "http://www.windtreetx.com/20220630/role/statement-note-9-stockbased-compensation-details-textual"
     ],
     "xbrltype": "domainItemType"
    },
    "wint_UnitsNumberOfSecuritiesCalledByEachUnit": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of securities into which each unit may be converted. For example, but not limited to, each unit may be converted into two shares.",
        "label": "wint_UnitsNumberOfSecuritiesCalledByEachUnit",
        "terseLabel": "Units, Number of Securities Called by Each Unit (in shares)"
       }
      }
     },
     "localname": "UnitsNumberOfSecuritiesCalledByEachUnit",
     "nsuri": "http://www.windtreetx.com/20220630",
     "presentation": [
      "http://www.windtreetx.com/20220630/role/statement-note-8-stockholders-equity-details-textual"
     ],
     "xbrltype": "sharesItemType"
    },
    "wint_statement-statement-note-4-summary-of-significant-accounting-policies-intangible-assets-details": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Note 4 - Summary of Significant Accounting Policies - Intangible Assets (Details)"
       }
      }
     },
     "localname": "statement-statement-note-4-summary-of-significant-accounting-policies-intangible-assets-details",
     "nsuri": "http://www.windtreetx.com/20220630",
     "xbrltype": "stringItemType"
    },
    "wint_statement-statement-note-4-summary-of-significant-accounting-policies-tables": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Note 4 - Summary of Significant Accounting Policies"
       }
      }
     },
     "localname": "statement-statement-note-4-summary-of-significant-accounting-policies-tables",
     "nsuri": "http://www.windtreetx.com/20220630",
     "xbrltype": "stringItemType"
    },
    "wint_statement-statement-note-5-fair-value-measurements-assets-and-liabilities-measured-at-fair-value-on-a-recurring-basis-details": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Note 5 - Fair Value Measurements - Assets and Liabilities Measured at Fair Value on a Recurring Basis (Details)"
       }
      }
     },
     "localname": "statement-statement-note-5-fair-value-measurements-assets-and-liabilities-measured-at-fair-value-on-a-recurring-basis-details",
     "nsuri": "http://www.windtreetx.com/20220630",
     "xbrltype": "stringItemType"
    },
    "wint_statement-statement-note-5-fair-value-measurements-tables": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Note 5 - Fair Value Measurements"
       }
      }
     },
     "localname": "statement-statement-note-5-fair-value-measurements-tables",
     "nsuri": "http://www.windtreetx.com/20220630",
     "xbrltype": "stringItemType"
    },
    "wint_statement-statement-note-9-stockbased-compensation-restricted-stock-units-details": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Note 9 - Stock-Based Compensation - Restricted Stock Units (Details)"
       }
      }
     },
     "localname": "statement-statement-note-9-stockbased-compensation-restricted-stock-units-details",
     "nsuri": "http://www.windtreetx.com/20220630",
     "xbrltype": "stringItemType"
    },
    "wint_statement-statement-note-9-stockbased-compensation-stock-options-valuation-assumptions-details": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Note 9 - Stock-Based Compensation - Stock Options Valuation Assumptions (Details)"
       }
      }
     },
     "localname": "statement-statement-note-9-stockbased-compensation-stock-options-valuation-assumptions-details",
     "nsuri": "http://www.windtreetx.com/20220630",
     "xbrltype": "stringItemType"
    },
    "wint_statement-statement-note-9-stockbased-compensation-stockbased-compensation-expense-details": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Note 9 - Stock-Based Compensation - Stock-Based Compensation Expense (Details)"
       }
      }
     },
     "localname": "statement-statement-note-9-stockbased-compensation-stockbased-compensation-expense-details",
     "nsuri": "http://www.windtreetx.com/20220630",
     "xbrltype": "stringItemType"
    },
    "wint_statement-statement-note-9-stockbased-compensation-summary-of-stock-option-activity-details": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Note 9 - Stock-Based Compensation - Summary of Stock Option Activity (Details)"
       }
      }
     },
     "localname": "statement-statement-note-9-stockbased-compensation-summary-of-stock-option-activity-details",
     "nsuri": "http://www.windtreetx.com/20220630",
     "xbrltype": "stringItemType"
    },
    "wint_statement-statement-note-9-stockbased-compensation-tables": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Note 9 - Stock-Based Compensation"
       }
      }
     },
     "localname": "statement-statement-note-9-stockbased-compensation-tables",
     "nsuri": "http://www.windtreetx.com/20220630",
     "xbrltype": "stringItemType"
    },
    "wint_statement-statement-significant-accounting-policies-policies": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Significant Accounting Policies"
       }
      }
     },
     "localname": "statement-statement-significant-accounting-policies-policies",
     "nsuri": "http://www.windtreetx.com/20220630",
     "xbrltype": "stringItemType"
    }
   },
   "unitCount": 6
  }
 },
 "std_ref": {
  "r0": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "105",
   "URI": "https://asc.fasb.org/extlink&oid=126987489&loc=SL124442142-165695"
  },
  "r1": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "https://asc.fasb.org/extlink&oid=109222650&loc=SL51721683-107760"
  },
  "r10": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(20))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r100": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "272",
   "URI": "https://asc.fasb.org/extlink&oid=6373374&loc=d3e70434-108055"
  },
  "r101": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "272",
   "URI": "https://asc.fasb.org/extlink&oid=6373374&loc=d3e70478-108055"
  },
  "r102": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592"
  },
  "r103": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592"
  },
  "r104": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6161-108592"
  },
  "r105": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6191-108592"
  },
  "r106": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6061-108592"
  },
  "r107": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6132-108592"
  },
  "r108": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6143-108592"
  },
  "r109": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599"
  },
  "r11": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(22))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r110": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599"
  },
  "r111": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599"
  },
  "r112": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599"
  },
  "r113": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599"
  },
  "r114": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599"
  },
  "r115": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599"
  },
  "r116": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "31",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8924-108599"
  },
  "r117": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599"
  },
  "r118": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599"
  },
  "r119": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599"
  },
  "r12": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(27)(b))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r120": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "https://asc.fasb.org/extlink&oid=124259787&loc=d3e4647-111522"
  },
  "r121": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 4.E)",
   "Topic": "310",
   "URI": "https://asc.fasb.org/extlink&oid=122038336&loc=d3e74512-122707"
  },
  "r122": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "323",
   "URI": "https://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571"
  },
  "r123": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437"
  },
  "r124": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=99380562&loc=d3e13770-109266"
  },
  "r125": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=99380562&loc=d3e13777-109266"
  },
  "r126": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267"
  },
  "r127": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(e)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267"
  },
  "r128": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(h)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267"
  },
  "r129": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267"
  },
  "r13": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(28))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r130": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13854-109267"
  },
  "r131": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=122137925&loc=d3e14258-109268"
  },
  "r132": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "SubTopic": "20",
   "Topic": "350",
   "URI": "https://asc.fasb.org/subtopic&trid=2144439"
  },
  "r133": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(b)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275"
  },
  "r134": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(b)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275"
  },
  "r135": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(b)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16373-109275"
  },
  "r136": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "360",
   "URI": "https://asc.fasb.org/extlink&oid=126905981&loc=d3e2443-110228"
  },
  "r137": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "360",
   "URI": "https://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229"
  },
  "r138": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "360",
   "URI": "https://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229"
  },
  "r139": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "360",
   "URI": "https://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229"
  },
  "r14": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(29))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r140": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "360",
   "URI": "https://asc.fasb.org/extlink&oid=109226691&loc=d3e2921-110230"
  },
  "r141": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "360",
   "URI": "https://asc.fasb.org/extlink&oid=109226691&loc=d3e2941-110230"
  },
  "r142": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "360",
   "URI": "https://asc.fasb.org/extlink&oid=109226691&loc=d3e2941-110230"
  },
  "r143": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(c)",
   "Topic": "410",
   "URI": "https://asc.fasb.org/extlink&oid=6393242&loc=d3e13237-110859"
  },
  "r144": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "420",
   "URI": "https://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869"
  },
  "r145": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "450",
   "URI": "https://asc.fasb.org/extlink&oid=121557415&loc=d3e14435-108349"
  },
  "r146": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "450",
   "URI": "https://asc.fasb.org/extlink&oid=121557415&loc=d3e14557-108349"
  },
  "r147": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "20",
   "Subparagraph": "(SAB Topic 5.Y.Q2)",
   "Topic": "450",
   "URI": "https://asc.fasb.org/extlink&oid=27011672&loc=d3e149879-122751"
  },
  "r148": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "20",
   "Subparagraph": "(SAB Topic 5.Y.Q4)",
   "Topic": "450",
   "URI": "https://asc.fasb.org/extlink&oid=27011672&loc=d3e149879-122751"
  },
  "r149": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123465755&loc=SL6230698-112601"
  },
  "r15": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(1))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r150": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(i))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756"
  },
  "r151": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(ii))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756"
  },
  "r152": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii)(A))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756"
  },
  "r153": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756"
  },
  "r154": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iv))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756"
  },
  "r155": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(5))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756"
  },
  "r156": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(i))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756"
  },
  "r157": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(A))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756"
  },
  "r158": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(B))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756"
  },
  "r159": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iv))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756"
  },
  "r16": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(3))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r160": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(5))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756"
  },
  "r161": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r162": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r163": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r164": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r165": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(e)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r166": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(f)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r167": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(h)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r168": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611"
  },
  "r169": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611"
  },
  "r17": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r170": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611"
  },
  "r171": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1E",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611"
  },
  "r172": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1E",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611"
  },
  "r173": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1E",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611"
  },
  "r174": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1F",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611"
  },
  "r175": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1F",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611"
  },
  "r176": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1F",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(1)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611"
  },
  "r177": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1F",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611"
  },
  "r178": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "69B",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466577&loc=SL123495735-112612"
  },
  "r179": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "69C",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466577&loc=SL123495737-112612"
  },
  "r18": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(31))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r180": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "69E",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466577&loc=SL123495743-112612"
  },
  "r181": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "69F",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466577&loc=SL123495745-112612"
  },
  "r182": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "470",
   "URI": "https://asc.fasb.org/topic&trid=2208564"
  },
  "r183": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644"
  },
  "r184": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644"
  },
  "r185": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644"
  },
  "r186": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644"
  },
  "r187": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(g)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644"
  },
  "r188": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644"
  },
  "r189": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(i)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644"
  },
  "r19": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(32))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r190": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644"
  },
  "r191": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496171-112644"
  },
  "r192": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496171-112644"
  },
  "r193": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496171-112644"
  },
  "r194": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496180-112644"
  },
  "r195": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496189-112644"
  },
  "r196": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496189-112644"
  },
  "r197": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496189-112644"
  },
  "r198": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21463-112644"
  },
  "r199": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21475-112644"
  },
  "r2": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "205",
   "URI": "https://asc.fasb.org/topic&trid=2122149"
  },
  "r20": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(9))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r200": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.3-04)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770"
  },
  "r201": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=6405813&loc=d3e23239-112655"
  },
  "r202": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=6405834&loc=d3e23315-112656"
  },
  "r203": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "50",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=6784392&loc=d3e188667-122775"
  },
  "r204": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "505",
   "URI": "https://asc.fasb.org/topic&trid=2208762"
  },
  "r205": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(i)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r206": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(ii)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r207": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(01)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r208": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r209": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)(A)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r21": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19(a))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r210": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)(B)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r211": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)(C)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r212": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(03)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r213": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123450688&loc=d3e4179-114921"
  },
  "r214": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(d)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=65877416&loc=SL14450657-114947"
  },
  "r215": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "80",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=35742348&loc=SL14450788-114948"
  },
  "r216": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=126961718&loc=d3e4534-113899"
  },
  "r217": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5047-113901"
  },
  "r218": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5047-113901"
  },
  "r219": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r22": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19(b),22(b))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r220": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r221": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r222": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(3)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r223": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r224": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r225": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(ii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r226": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r227": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r228": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(01)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r229": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(02)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r23": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r230": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(03)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r231": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(04)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r232": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r233": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(ii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r234": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r235": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(01)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r236": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(02)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r237": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(03)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r238": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r239": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r24": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19-26)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r240": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r241": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r242": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r243": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r244": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(ii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r245": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(iii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r246": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(iv)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r247": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(v)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r248": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r249": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)(1)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r25": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.20)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r250": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r251": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)(2)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r252": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(l)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r253": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r254": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128097895&loc=SL121327923-165333"
  },
  "r255": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(f)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128097895&loc=SL121327923-165333"
  },
  "r256": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128097895&loc=SL121327923-165333"
  },
  "r257": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=126964447&loc=d3e11149-113907"
  },
  "r258": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=126964447&loc=d3e11178-113907"
  },
  "r259": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "718",
   "URI": "https://asc.fasb.org/topic&trid=2228938"
  },
  "r26": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.21)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r260": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "730",
   "URI": "https://asc.fasb.org/extlink&oid=6420194&loc=d3e21568-108373"
  },
  "r261": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=123427490&loc=d3e32247-109318"
  },
  "r262": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=123427490&loc=d3e32280-109318"
  },
  "r263": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=123427490&loc=d3e31917-109318"
  },
  "r264": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=123427490&loc=d3e31931-109318"
  },
  "r265": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32672-109319"
  },
  "r266": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32809-109319"
  },
  "r267": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "19",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32840-109319"
  },
  "r268": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32847-109319"
  },
  "r269": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32639-109319"
  },
  "r27": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.22(a)(1))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r270": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32639-109319"
  },
  "r271": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)(2)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=126983759&loc=SL121830611-158277"
  },
  "r272": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)(3)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=126983759&loc=SL121830611-158277"
  },
  "r273": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB TOPIC 6.I.7)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817"
  },
  "r274": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 6.I.7)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817"
  },
  "r275": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 6.I.Fact.1)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817"
  },
  "r276": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 6.I.Fact.2)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817"
  },
  "r277": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=123586238&loc=d3e38679-109324"
  },
  "r278": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "808",
   "URI": "https://asc.fasb.org/extlink&oid=6931272&loc=SL5834143-161434"
  },
  "r279": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988"
  },
  "r28": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.22)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r280": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988"
  },
  "r281": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=109239629&loc=d3e5614-111684"
  },
  "r282": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bb)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=123419778&loc=d3e5710-111685"
  },
  "r283": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=123419778&loc=d3e5710-111685"
  },
  "r284": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "810",
   "URI": "https://asc.fasb.org/topic&trid=2197479"
  },
  "r285": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Subparagraph": "(a)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126731327&loc=SL126733271-114008"
  },
  "r286": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)(3)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011"
  },
  "r287": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)(4)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011"
  },
  "r288": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011"
  },
  "r289": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258"
  },
  "r29": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.24)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r290": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258"
  },
  "r291": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bbb)(1)",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258"
  },
  "r292": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bbb)(2)",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258"
  },
  "r293": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258"
  },
  "r294": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=SL6742756-110258"
  },
  "r295": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "60",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=7493716&loc=d3e21868-110260"
  },
  "r296": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "825",
   "URI": "https://asc.fasb.org/extlink&oid=123594938&loc=d3e13279-108611"
  },
  "r297": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "825",
   "URI": "https://asc.fasb.org/extlink&oid=123596393&loc=d3e14064-108612"
  },
  "r298": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=126980362&loc=d3e28228-110885"
  },
  "r299": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "20",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=123602790&loc=d3e30226-110892"
  },
  "r3": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765"
  },
  "r30": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.29,30)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r300": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=125521441&loc=d3e30690-110894"
  },
  "r301": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=124440516&loc=d3e30840-110895"
  },
  "r302": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "230",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=123444420&loc=d3e33268-110906"
  },
  "r303": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32136-110900"
  },
  "r304": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r305": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(b)",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r306": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(c)",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r307": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(d)",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r308": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=6450520&loc=d3e32583-110901"
  },
  "r309": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=6450520&loc=d3e32618-110901"
  },
  "r31": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.29-31)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r310": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "830",
   "URI": "https://asc.fasb.org/topic&trid=2175825"
  },
  "r311": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "835",
   "URI": "https://asc.fasb.org/extlink&oid=6450988&loc=d3e26243-108391"
  },
  "r312": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "https://asc.fasb.org/extlink&oid=124435984&loc=d3e28551-108399"
  },
  "r313": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "https://asc.fasb.org/extlink&oid=124435984&loc=d3e28555-108399"
  },
  "r314": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "https://asc.fasb.org/extlink&oid=124429444&loc=SL124452920-239629"
  },
  "r315": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "https://asc.fasb.org/extlink&oid=114775985&loc=d3e28878-108400"
  },
  "r316": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=123391704&loc=SL77918627-209977"
  },
  "r317": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=123391704&loc=SL77918627-209977"
  },
  "r318": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)(2)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918686-209980"
  },
  "r319": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "53",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=123414884&loc=SL77918982-209971"
  },
  "r32": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=99393222&loc=SL20226024-175313"
  },
  "r320": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)(3)(iii)(03)",
   "Topic": "848",
   "URI": "https://asc.fasb.org/extlink&oid=125980421&loc=SL125981372-237846"
  },
  "r321": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "850",
   "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39599-107864"
  },
  "r322": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "852",
   "URI": "https://asc.fasb.org/extlink&oid=124433192&loc=SL2890621-112765"
  },
  "r323": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "852",
   "URI": "https://asc.fasb.org/extlink&oid=124433192&loc=SL2890621-112765"
  },
  "r324": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "852",
   "URI": "https://asc.fasb.org/extlink&oid=84165509&loc=d3e56426-112766"
  },
  "r325": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "855",
   "URI": "https://asc.fasb.org/extlink&oid=6842918&loc=SL6314017-165662"
  },
  "r326": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(1)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r327": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(2)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r328": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(3)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r329": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(1)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r33": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=99393222&loc=SL20226049-175313"
  },
  "r330": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(2)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r331": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(3)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r332": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(1)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719"
  },
  "r333": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719"
  },
  "r334": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(3)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719"
  },
  "r335": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "910",
   "URI": "https://asc.fasb.org/extlink&oid=126937589&loc=SL119991595-234733"
  },
  "r336": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "730",
   "Topic": "912",
   "URI": "https://asc.fasb.org/extlink&oid=6472174&loc=d3e58812-109433"
  },
  "r337": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 11.L)",
   "Topic": "924",
   "URI": "https://asc.fasb.org/extlink&oid=6472922&loc=d3e499488-122856"
  },
  "r338": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "20",
   "Topic": "940",
   "URI": "https://asc.fasb.org/extlink&oid=126941158&loc=d3e41242-110953"
  },
  "r339": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(10)(1))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878"
  },
  "r34": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=99393222&loc=SL20226052-175313"
  },
  "r340": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(11))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878"
  },
  "r341": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(13))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878"
  },
  "r342": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(16))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878"
  },
  "r343": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(23))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878"
  },
  "r344": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(15))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r345": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(22))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r346": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(27))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r347": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04.9)",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r348": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "235",
   "Subparagraph": "(SX 210.9-05(b)(2))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=120399901&loc=d3e537907-122884"
  },
  "r349": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "360",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=124429447&loc=SL124453093-239630"
  },
  "r35": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669619-108580"
  },
  "r350": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "470",
   "Subparagraph": "(c)",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=123599511&loc=d3e64711-112823"
  },
  "r351": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(16)(a))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910"
  },
  "r352": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(16))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910"
  },
  "r353": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(12))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910"
  },
  "r354": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910"
  },
  "r355": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(25))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910"
  },
  "r356": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(8))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910"
  },
  "r357": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(18))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r358": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(23))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r359": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(8))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r36": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669625-108580"
  },
  "r360": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(9))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r361": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Subparagraph": "(d)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124506351&loc=SL117782755-158439"
  },
  "r362": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29F",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "40",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126561865&loc=SL117819544-158441"
  },
  "r363": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r364": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)(1)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r365": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)(2)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r366": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(2)(i)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r367": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(h)(2)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r368": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "210",
   "Topic": "954",
   "URI": "https://asc.fasb.org/extlink&oid=120413173&loc=SL116631458-115580"
  },
  "r369": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "310",
   "Subparagraph": "(c)",
   "Topic": "976",
   "URI": "https://asc.fasb.org/extlink&oid=6497875&loc=d3e22274-108663"
  },
  "r37": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL116659661-227067"
  },
  "r370": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "310",
   "Subparagraph": "(b)",
   "Topic": "978",
   "URI": "https://asc.fasb.org/extlink&oid=126945304&loc=d3e27327-108691"
  },
  "r371": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "985",
   "URI": "https://asc.fasb.org/extlink&oid=6501960&loc=d3e128462-111756"
  },
  "r372": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b"
  },
  "r373": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r374": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r375": {
   "Name": "Form 10-Q",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "308",
   "Subsection": "a"
  },
  "r376": {
   "Name": "Forms 10-K, 10-Q, 20-F",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "13",
   "Subsection": "a-1"
  },
  "r377": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(a)",
   "Publisher": "SEC",
   "Section": "1402"
  },
  "r378": {
   "Name": "Regulation S-T",
   "Number": "232",
   "Publisher": "SEC",
   "Section": "405"
  },
  "r38": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124442407-227067"
  },
  "r39": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124442411-227067"
  },
  "r4": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765"
  },
  "r40": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124452729-227067"
  },
  "r41": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(210.5-03(11))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227"
  },
  "r42": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(10))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227"
  },
  "r43": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(20))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227"
  },
  "r44": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(25))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227"
  },
  "r45": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.4)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227"
  },
  "r46": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.7(b))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227"
  },
  "r47": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.7)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227"
  },
  "r48": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.9)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227"
  },
  "r49": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3179-108585"
  },
  "r5": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6904-107765"
  },
  "r50": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3213-108585"
  },
  "r51": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3255-108585"
  },
  "r52": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3291-108585"
  },
  "r53": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3521-108585"
  },
  "r54": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3536-108585"
  },
  "r55": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585"
  },
  "r56": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585"
  },
  "r57": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585"
  },
  "r58": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3044-108585"
  },
  "r59": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=d3e4273-108586"
  },
  "r6": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(1))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r60": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=SL98516268-108586"
  },
  "r61": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=126899994&loc=d3e18726-107790"
  },
  "r62": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=126899994&loc=d3e18823-107790"
  },
  "r63": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(d))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r64": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(e)(1))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r65": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(f))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r66": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(g)(1)(ii))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r67": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(h)(1)(Note 1))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r68": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(h))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r69": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(m)(1)(iii))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r7": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(15))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r70": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(m)(2)(ii))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r71": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.12-04(a))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e24072-122690"
  },
  "r72": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "235",
   "URI": "https://asc.fasb.org/topic&trid=2122369"
  },
  "r73": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "23",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21914-107793"
  },
  "r74": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21930-107793"
  },
  "r75": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21711-107793"
  },
  "r76": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(2)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794"
  },
  "r77": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(3)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794"
  },
  "r78": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794"
  },
  "r79": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794"
  },
  "r8": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(18))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r80": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22583-107794"
  },
  "r81": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22595-107794"
  },
  "r82": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22644-107794"
  },
  "r83": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22644-107794"
  },
  "r84": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22658-107794"
  },
  "r85": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22663-107794"
  },
  "r86": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1448-109256"
  },
  "r87": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1252-109256"
  },
  "r88": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1278-109256"
  },
  "r89": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "55",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e2626-109256"
  },
  "r9": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(19))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r90": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "60B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=SL5780133-109256"
  },
  "r91": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "60B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=SL5780133-109256"
  },
  "r92": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1337-109256"
  },
  "r93": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257"
  },
  "r94": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257"
  },
  "r95": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3630-109257"
  },
  "r96": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=128363288&loc=d3e3842-109258"
  },
  "r97": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "52",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=128363288&loc=d3e4984-109258"
  },
  "r98": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "272",
   "URI": "https://asc.fasb.org/extlink&oid=125520817&loc=d3e70191-108054"
  },
  "r99": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "272",
   "URI": "https://asc.fasb.org/extlink&oid=125520817&loc=d3e70229-108054"
  }
 },
 "version": "2.1"
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>52
<FILENAME>0001437749-22-020091-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001437749-22-020091-xbrl.zip
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M422IUGC+C;<=6H3'6-'"4HI\DCK50A!6071@R#7+;,QB*F:+#,>+4^0'4TG
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MW:Y?Z$6'OD%&C>._M_X?4$L#!!0    ( #2 "U5J&;D//P@  ,\[   -
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MT@)&.08YP,Z#@^^^^))W4.2"%0'V894#=,.*"A9MA&5L5T?(KSW9TQ_K)M@
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M#'GD*W#)P=)%-_=(<EY2<()YVTU+[29'7C[.BC$."?U5.@Z3H#QRZZ!O_5*
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MF!8F$=]1Z_0-S<<7=24L@T&DU-;<;W.#4' IM\52E+ M%VL*J4,M(R9FD4E
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M8E]'-K8\J5OZZ+-KN\BP*]41K6+H5$%Q_*>NY1BKC&V0J*4YFWFR!([9&EV
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M:@$CL#OG&K+PEU"=5]U,PNA.$<K'K>]UJ<HH00V0 /P1#ZC(&1>FP(D4F8W
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M7<*8R,ZK*T6$+^?=MOV#4'=9COU$\JZR;EOJ8Z]& W%1GKT\-O1336N-)&-
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MATA<77:IE26NY**#.,0!$1XA!AF!DQ<25]9TYOES2N6RGF5(*Q&OW8 1N .
MZXT@5G8#1T5;=F^4- TF1-T%4EW2>SHCS!WXF.OX^,5/ *\>*?R#$120QC-@
M?M@7#Q[*A'AKU$H)#+$I4Y.0=@&*'?M60N];[@@*N6Z'AO]&M[OQ<1?_ZBY^
M#QRJ6IY\=W\V]3FDRV*^K%IT_R), ATRM?.Z0(^+X\"6 _&LSW5!")9QZJ\X
M./]&P80Q_94OE=2&3)R[F:'>/.S?2PW]#961"8E'>D'D &C=[:%3N''<POH2
M_C.;THX(QI#*N?K:L>R6L8FHDEMB%[:S/J!K2AP:Z/M!_^M[F.K(+IOBK6E9
M'<N35V)K3/P4Q,U7>EL:8Y#"/"H50*A/YDC_S>?1':^)FMOW>Q,PEW'\70:1
M*?2?+ZJ;JWGP)J*JIKB8OD8?] W\2\+_ZC !6<85F3%%O&@/7H+P5ETJN6@A
MS0U&!+]5"ZL473+$(H8OYIB%S%:C]FTZ5%1CX4Q:C5:S'PPA7X2@G*(JRUJN
M)ZJV9O%^6:#32G,E'"RX0+QK,SK%O:<>7L8Y\,-D&"_H9&YTB?"-+]H/5#Q"
M,I5DB[&2>X]2M1BTT-J@*?YN30=(T=%DUM[K"*IB<4'Q7 Y%B39"F9(^M_$'
MLH^"72'*\XB7W"H;G>L-XB//6-V2U&]5JENKI\P37:9U*Z3X@?1I1UTVZY6B
M?//2:GQZ%.:.F2RK#PI 1$H\3U<;4<[O,Y\/)C0^9H-N*?<!V_WR(=V+C?[F
M&6[L<V"?>*"/L&G$.6>L^CJ"RN6C"[4$G86"]T9AN K[('>CVN0MAW@=^0PF
M(.9X,I@PX>*!UCPI6"7J&QBH:LX\-4N^0ZF+MHW-// [8&7/GT7UNL4\E"&M
MOJ;"GQ:58I87_99]?BS=Q0/Q0)LP8@3YI&Q/\0>M:Y5?T^F'T#X^G ;#1=!%
MVOBH&BTYSH39._:M[%RD?[*%O]A*JC;%)9OPM+'@A-+@>%6ME]S#5D=& 98I
M^9I2YF:R2N0BR0[>=AR1BLMSWE=N;R\TD0[*^@&L32(726Z'.GKJ6XWF6=96
M6]!7PV@HK_ZP./W!;LKE7,X7)-$R:S\1X48G[!P7J=ZQ>VI"Q6!">!2+_@9+
MD[IX4!N&JN'EQ:E9>DVN+QD*ERG[OJ["OU/\Y@W>XL(;TZ\8173 7^"O[_5Q
MS[7>6*+_L^QMC+*UC-7X)O%5)FE&'5URPU<5MN5>8OX4YBPY.;U H2@X 6&R
M;\A,>["OA$.4[4!-?,'^AY)>4GU$H.5_\#WW.W>Q*A*>&B0[:>;<>]]!*GM*
MN)P!AA^RZ0^V^Q'RDSDH15J1U8:RKGZ4%YHQ^B1;KX#>""/^A5:]H<?&ND5F
M]-Y_K#>OD9G0(_KN"?QN;W03>-Z\P[P EG]445PL?Y.3MPW3:GRH'E9*EYU!
M>#QYX_E$Z:\F0A><J5?LTK':OF5%F7N*Z02^T0JT'PGS,A'[MKVJIG]AAI?\
M[@>_$^S2I=R[L+62Q]>#"6TU6HTXB,-5PQXI7H*YI-5FNDIDI^'GVO'Y"-X5
MIJ\4NR+XTYW+^35Q)D@2JU6>_(W"GT+#I2YT?YDK%<,)>GDVE3N+-*-R?,&R
MR6E,QOQQYNQU+EK<,,FO),3/8)62L"TQP(\S&[O?-K-AEO88^&>8O:UNO-AY
M*K?C\M/,:YE+:_:;TU(<?HKY+'V!V>X36I[%SS"C)7>1$@/\$+-1_O]M*IZ0
M+<9XM3D)+P21S@22=OCS_U!+ P04    "  T@ M5<.LJ1L((  !W;P  %0
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M9%GJ"B]QR-*=]C&A,JD9RD<_*M?AD'GL;/YL$*VP@TLM-E7P#U. NEAF4^/
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MI?6SCQ](WD"8H$5KFF8HGU:KK\RC.4*KFC"<%OGVFT<*-U_\<4;R.*6<=^Z
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M_$<^WG35D-46LMKL9[7YY^P+66TAJ\UJ5IL_SD(]ZZTWW-U.Z1EW2IMU9?!
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M9A?"[,+=-.%NFD.\L>7U( UEFH+;W\/R/]R2Y\O-'<>8<8Z;7=0*$2\B>;L
M[4I2,D2KAP723BE;409OZQHD=@;G?3C[7FW5.5C]-QME;D/(3LX+PRXMCVH!
MXA7&^36<')8HQF5!8I3^BZ;\L?D561(X6XA?@V%7&Q$:VS?-#1+P>$E<AK1E
MB,8(T1CALI+7?EE)N"^ATWT))KNP5Z;3OGG:![]5N"C![**$5KJ,5USMUZ4)
M[MRO7<68CJ8XNFB&X,LR1A1\63W[LGHY^SKU9>5DGI$9; [P&<4QEYK<@[.B
M*8D)SG<?]%U8IB.Z\5RUHRHXK%Z?P\K$_+YCI.L-^RALT>H.3ND_1?D"!!3_
MCP<]WZ.4BZ6*M+4JR]JHKUM4H!@!&4D53: )1J.+4PSGB&5<4[_&K(J!T(.A
MV<LID@M$V&\H+>%8>D$RE,4$I9<9,'VY?&08 1ZCOFY1489A1SDM&<,93/&>
M3L[O6N1_;D++]-Y<Y_&<HO]$:?*-I"F0=ID5<# AH-$=YSDN\NU/TO=JW-\I
MNLL,% E\AQ[T7IVJN=O* 4]I4&Q'BM9N*6<4CHC%FH<>%SP&%3:5%5_FE\L5
MB(']$\MS%/H]75=%J/1^(.D,W^.45D2=/_!(-RQ='P8]@^OZ %S77W/8X<[S
M@BR!%-&<-C>RD5D_F^&XF,Q.)[]=GAU]O$9PXEF26"[]6O2T0&J5S53&!9S+
M$WXKXQ5!4Y+"$0 4.*Y5PUO\3%)H1#.\B1BMB=$ 8WOLT3MDM78'GQQ[(W+&
M!GMHL(>.R1ZJD@74W,;A'48-PFD;DX%_[B4CH"T/:V[]2]916SJ0:\Z"I11(
MZ[,@TSG=)L/97[_F]DM-Q#]ZBKB%-4T3\4^>(C:V#&CB_8=G>'L\OVC.R,^>
MS4AK2XHFWH^>XM4S1NIJ)+[J7D9^#EVPONE?K2TL3N,'JHS0'Z*\7"X16T=T
MIO2T%_RX8YH2V^$)#C-C.U,9X@U"O(',GATO<%+6=2R>GL1@?]L>QBIS@O*N
M\_8C!8_# 7@<M)C$_/V/PJXM@Q7,V<&<'<S9!V_.%H@ :G&#=*^%_QC-$&'1
M/3?Q 'K$HY<KRTX[E5MW.(?ZM1E)09D.RK26,KTSC.X6^-9V1G@)O(K-DDEV
M@^.2\7M^3U!.<D,UV^(S@@(>%/"@@ <%/"C@00%_#0JX]:W3O6HNO(:XG6JN
M.YQ#U=R,I*":!]5<\U[0]O7]3>X)M?B4@0XQVYK=MYC=DQ@+ *457?!I,@-Y
M2><9^1O@8$9H77!7_T#3T_,&FKUF\ILNSZBOCH@+<@\KQ/ 0:/4I@\_4_BK8
MOPJ []7UV\_S<EE_UWJBNC\D')?#<3D<E\-Q.1R7PW'Y<(_+O2JSWF4PF)@/
M>E"ZO,MM,)F/7A5W[_(=VG&*+:W3O:7I^VA.>9@A2-D8LZRZGV.),K19^!&_
MMRL'\5X@DN81%\0EVLE13?-3IV<XM$E9H#,8JH*ARKB TG%QBAA; ^M59FO!
M:<6HKUOS&YYAQG"R2R;8Y$N<X S6J/">!;U>@Q2J><SWN:*YZ$@N;^RV!,V.
MA)?Q1^</<5KR0H);>@5P6HWA%.6>&Z?.LQ2QEKBA4WJ_X*)F;@D3-;9Q74@G
MQCC)+T /N@0U!<'F5]VPMJ3UC9T"RK7[.2ZB [MSAI-MRL]Q')?+LKHA#@0.
MB87B2+^C6X,;JC1-/I^\+/%DMI=9W+@'FW<\%#R#WC,4#+E]T0DOG(L76(8E
M]];79\KJZ)5_P=^JG\1S;=+9!UR5$M<25G-?MZC*:8[_*GG*[#W/'Y;=(B9M
M.R35_$X$R5U0BM9#4RX7HJKVXZ1^6,D/5)&$(+;>VZ(4_"-M;Z'NV?'=9U#/
MY@PM)3>("=I8>'PM8(_+8D$9MP/>T1-^73B&TQZ<8&]IFGS-$LRJK_8KG#<=
M?^T-: -89=M[_I3K<IJ2^"*EJ*ANRJ@M?DN>P=L(INT@@WDF#\6-IW?/DTK
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M<CI$E'B72>",H?1CHKS+(G6G,!C$6'J7A.IJEEI'#'JW'>IIZ&U#A[S3NUL
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MI,M80A_HG,"?GQYNE##?O8(1KU*Z@&VZ#1YIPG$64RPS.F__+LFRO<\ CW>
MQYL_ !Z_:INMV*XY;^3Q:IW0%Z\&8WI/LYA%5^G(*+=/:P7WCT60%3:P/YYX
M9/QGK B2<3$_GG)LG+D(HR/C?#3ER#A_H"/SQ^&$X^&+0+0X1E(3NP1&W?*_
ME0-AP@ZA*N"5(KPQ,?U:4'X?E5*SGIN%>XOX$J> Z-NWK__PV]<"3?C)/RY9
MN%G1M#A+N; HXF)[D\Y9MA+RO0(CT)0S:(V7:"5P2["L7/#>D@WGG29-:FH1
MZ9C\&<W9)@OEI<I!P[5/T^FGCR_^M8)-.' BH9,&^#^_VF%[O):SK*)SD(4]
MN)4C7H6,WZCK8G]=\XRM3(C,C"DG"<&1.-R3 U8!_/-*T9@'^:-8P2:?+H)@
M_0IXZ!5-BKSZB> JP5'E#_YQ'<397X-D0^_FUW'*U8<X2&ZX(I$)1/-[EL3A
M]H"[4-\:<IH1#-M<!T@0@05A<U+C01J(3(A$A7PN_YSQLT[.^7I__K].N1*W
M.6P0Q76Y52'8/K""SE@-C.L2!058E[0(XB0'2FZ"I$W$F7V)$79Z$&PS(&!!
M9JS!>C4BI,2$E*BX%X&&F\ &4'8@H^45C&GC;_$BC>=Q&/"_!V'(-EPPIXOI
M&M@\IGG]ES;V&V,^#%,.@6N;53_N\"!G-1Y2.G+P[MESE$UBHU/> BNG_$1-
M?S?--ZM5D&VG;-Z+6A$\)OJL/73^L5@=BX<3*?T[,B4?)6:@+#R+XS!X8[N.
MQSB[9>NX_'XZY_K.] D4GNF*!ODF$[]%G0W=R48]"'U G7#][SG7-[3D]PTT
M3HC%M?>GEY_-B.[,FONX##)Z'N0TNF"K-4US85J>91G?,('?^78WY#[8"F/T
M2Y!%M=)_EO.#NH:O\H<X__DZH_0F+2C?_^*!4T!A"3J#B[0BK>-G^Y Y6TCW
M:7TVU"T4?M(.$O^-QHLE/!L%3S0+%I1D')/IG*-"XA(7DO52R)(U[^Z ,6_[
M:NN*?\=_P$+Q>!5-P\9*,%>\[F2C7O%]0)U<\>] L04TIF*_29,G3NB.U]Z@
MWCO>C.HG8<_QF?B^Q1R[:9#GE*LCD?2FV#/Q>D'ZL_J4J)V@(<@'W]3HDC.!
M+GE9^L*^.Z'S-3)SC&LY:NZX>V.RQ"9(HVD2!X]Q$A> ;SDFF@9%\U,N8H)I
M1L--EL'RN 2*<2?9)4*.C-KQ$/=M&//?E.><+X;<[A93C>*J:-'\F*4D( _5
M8L@Y+.8D9813MAM@J]OB)?>:;%-&"AV-":V;"\DB?HJ++4IZC ?.D3:LBY9W
M??E -8!1Y$[@RG4#B>M)'NP1.6* ^HW;YN?IA*N\$F?2*?%7EO#9N)S:NO+&
M:2%P"FZY3D2?I7^N<T7>'74CTWL,CQW]NJ8A_."I1N;Y>^OT#J MMYW!+KO7
M>L"/F,6PX^5%L$ECI,]C*!!'&DXW,J>@USS4&)9ZS2? \)EI,YI[/D"',=E(
M#^:$XN<@8-.<CFU-F$%S94SH874*9T[YJRN)ZS,[?:;\,,24P&RRI_-8FCFY
M<$?(GP>[B]K&F32#Z/)<ZF%V,F>S-.YSX<B3OVGH6,_Q>!JRQM CBMGO$:+2
M\[8 Y=8CUC\:&WW>/JL+ULX5(><>0KHTR,L,:>8NQ89EW(A*+S991M-P.^-V
M6 ZN*LZX9VDD_ID(EBYS*R#R722.J-)NALZ'3<7!PK6>GB,1(Q5FI(F:>%QI
M(G=RB3J#MY.-OD?61.?9(S=[.$)F(O3PJW%%:36[5Y%*/E=HN.5"4\KW2]EV
M<CJ3MHUW5'D*#GFM?R!2/AY/Z,KK? P9XQT> W^$%[<!=E**\&)"1'*^MU4H
M*@-TK$+@2T()D31>D[W<*1V\S?1)-? 6N*4TOU\&V2H(Z::(PR#Y=Y9 $9?\
M-E[%!8W>T]4CS=JN L-/,?>!)@C;1YBC\>M?_>GMFS_^R!63/71(A0\I$2*?
M)4H]%X3+M49E0GM+38&.-3_0-?^MN/4,EO^]^WO1E W9$'J[?9]^['\?>M1Y
M'[HJG]QF-%N]Z7J/M@IPR/NS%<2<OC=;60'Z??E$Z#GJ>S*?;$5>_IT&F5L7
MG<,3=/B [& ;G4F\JR!+0?K>TTP@KN=GT?P**7MZ9K<M0"KPA,,G H&3JV"B
M2W^&)*J["S=<TFB3T+MY>]R%>"(H7PCJ!X+&$9I!NDD?M]H!@KU81T7&>LF*
M$EL1BPGXEB\Y)<9$H#S9?\F9*)YR/@O4O9\=2]S W&RQLY-YMX92H5QBE _E
M*O^D]GCD>5'.:_T:*.']X(5+^\G)C&GDC'=NTI"MZ"SXJJ=-] U'<HYJ6MN,
M(^$2#OCD](9>2C-3\CGC*9D/5*O1EW$>)@QR411,U3L>R57*>5W9M4H$,&;I
MB*M!6)72,RQQ\'(>^IF$&=/J]),IKG[9B *;=>'"NV))L]DR2$NEY"<^19'?
MI+* \4&<L_CE95#0FA)=OJU3PL]U*L;8Z[ M8032E*OS%2934N)"!#($L&ED
M74[(W:80I>8AY_)EG)*()4F0Y83K(R0'FGCT"9W"CBE=2*> W F9_$U*[*+D
MA9TD8N3%^JOT/[3-/P*4$8W^ =A8M_K;+/T=@T[:,QDFNP3-$S;UQV""'EM_
MM)W]!E2):Y;-:5QP+>DP7^H$] @,<B>G1)@LPK;@N( F*TGR_W6(T;G.B0*!
M9Z5O0%)]8.D3%];T!.T=<]1.3DKI+^'D\]%'7*O33'6O>[3N[(6D$7E@<H],
MR#E=Q&DJ2P$E<"FAKI9O;P/:6VF-3/[_&M<X0B@[N<2Q3/0-7.&E_D*CR@?B
MRZ(XQN#D+N0C3)__O7NTI-.2[D,HWM<]3]\R$\)9"&3'.;4^#Y]+ZTFUO]^
M?*VOE@^;EO0$;_!/3K8>X/G\)>O!@DY+K@ZF-MHV$0CG.I:'EL!]IH0SMBF:
MID)0D/^Y22GY[>N):#G]#5]/*NGEUBIHVVMG5],#S2D'LSQ+HTOZ1!.V!F3+
MJ+7.AIH&7R*O PT(M@5YA8)(S&\@414K.KEX,I-=80-([8Q!+R'_+HSWDO8.
M^*1M")+EFE.9\Q8WZQ^9J1W0!"G8+%BQK(C_J=&KPL8:<(I.$Z9[G!&!;DV
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M'-T&T3]73XC BPC$"&#FMQ/*D&W3Y_;^O7"G8,AXQGS&SL)?-G%&C6,$C2?
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M^O2EMD%X+FA,YHH) *1GG:B5ADR/,);%_$TZ9]E*N 5N.?_=%'35%?/2-7S
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MZ^D F;", &R_.GH+5=LT=!6I7+ (U\:*(/D_\?J"16H7;M?@H8RR-ZEK7I'
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M02I$FD'I%2X$D,&; _86:BF429,B/A[63?F2#=J#@2?P(@GR_&Y>/<-G#U!
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M]@]&PG6%([ZBM?<CZ?J1!K$&&/8CY726TBD<?_ YC")^<G+?R9(E-*(DWW[
MNX]T1S3E-6I'EW<6C23;^_'VE5VO7Y3"&J[N8)3^TS"?PW' _^, QX<PX8=
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MMSYZ3GTT<F[XU$>C2GVTMW *G&=AWQ<*1F 9*-71WJ),^@/:[&VV)P^T$0(
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M=*[C)GL,'YZG+6^'!QO@LK4I7O?$S?9XR $O8/,G83_<;!]QX(KQK=.)B(Y
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MI%8Y;ISGW]6SU;MZ^]#Y3KX @1JF<>\.H06%&!1YGLJTBQM3X2ERD",=$)_
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M 5$P\^$BJE-T(7JFXYA#/IG>+$^M@S^_M3SG-V@;^A%MF,-@S3MX&>?7HER
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MP[SX!JJ%>CR/_'0D3;[%&:;?MW!Y!I)>A^##K4B)AEEM)$]2,+]3,WOI5RB
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M.,Z2%KXE!=G'07N'N2RF4__0%#3FXEDQU^*&C2=H1G'!!7?PD*@7U:1:[DO
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M@1].=^UD:KH75_]*)-I]J0P60,#6EE8&/48Y7[K.R?8CL(R5<!4/KDOK@_G
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M90C+4QZ.G)ZICO$;5HR\(G\C(-!4[=7[E"BO?Y[JX\]3W9OTCG?.Z\8%?HS
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MS&BS.4(*@ZO0](_$XV;@LC4QN&QJ\/!N,%EO"V(;S#.G^')!>B-ANU'8-H?
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M]8AANXGWP[ 1>[\<G,Q7S'-H_Z-ULEZ2]/N?05ZF9]:><>M)>R??X=K )BU
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M/726R5UYY/1,=8S?,.79%?D; 0ZN:J_>I\0=T9^GNO/S5$\F'>']\*4O?HR
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M]( PT)I'./>6RP)QNF5(]/ARD2]L&.T'TMX 6L+?5[\<L>$5SGBM4JU?DNZ
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M&-L]D8SQH#T/M!3R-HHGC^?^:?@"3#[J<\-. 6)Q$O$"QM7+7=.-P$;!%!O
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MA8F,S6/M#*<!R] ZKIA%<;(",\HP[0%DDYC32V4Y@K%S78<DDQMDL7!6>OK
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MC#G*66I)$LG)PPE9_X]"^WWUW.HG! 9*8,[.H^[H-$%>!&K(%]-X5;3+UR\
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M>DO9WC_=2NZ.I)I,,G?]!3R"?!#_>-/K1!%"70L2=0V=P#4N0=]!%<EP]90
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M^%\6A@+\8Y26JU5":_F^ ^-ME;Z'1*!>U,6]C:VA &1Q<4-#M-GI#+[]"!
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M2SBG#">_OO;*/95?0BZ(+'OFZ(A7*WM?^_C\_$SZ,QLJF$%.4\>W\5BBUQ.
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M8D:226M'),E1X^+\.9.D5B"2391QK[\T>&NEVSW;BZP'K.O'^FEA.P,KI/X
MEHU=!"POMD2<P-5CL77(Q=E8>8U/][$W@)7&.!P!/W_O@PW=O'<&H0_;YF6:
M(P F/H"XE?HV/&CC=^ !.X[3(?<B )LUR8J_>R%@[B.MBO=S8*D.!=9#Z /N
M^E[BX?<C87%)>3J2.QMX<1)&:*!GCXZI,#R-L/!\&"(P0N<[A4=#[(@ $'#@
M._&!]:>P ,%#W)RY$)S6GGX<6^PHP"B(R5:D(FY80M9GPYU$0R^0->FX2D_/
M+;$B^"Z\%Z\A\N+OS1[6H%+E._;NH;\6'?+;P3U\*1)VG$9C:^P)W[6<-'K
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MQ)Z-154>(+03QDGIJGQ$/#4<Q\H H6Z"67=YA6L)E<S-8VFUD4J*$5UC]I_
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MU1S5N8$W2-R4$".<7J&ZB"V[V/9V+]:X,N'B@OPLKK?H[;5>O3LIB0.7"EH
MO V@CG@W&=\*#*&AQ0@+1[P_.QA;,>RR@0$8+)''6O>&Y9.-*]#VX$)Z\XYA
MS9]#KM#'$GJT0)0V2?A0PF/_^'3\L\(/EO(C&UT7UBB,DEX(?+QAL4,"5=#7
MWIML\[C;+BAF8+NYR!2*)U)I?> M?-M#7=0;=L$R% H[Y?OD*'L&$#P)CR+X
M%-B(XY#.8K O4BL_2<@8O NT:7A.J2I +JF3=1!0'T?9QPKN^FA#&TY4K+"4
MP#(9>)&K@ C&%67 ^#Y\,06]"-CO2."GI1(OD=]'E3U,8W]<1O _O)3KD/"J
MQ*]*##=5NFT9];#S5VP0"OJ>W>4V&5W;1RX#N.)3MP^IW&J<*E94K$<[7H]A
MTSHM8+MM9+MKT255^@&Z-O'M@-(W7;@H8C1+6>Q'!19[=;&HE$PD:8\X*7K)
MJ0D*,TAU,YZ()^FD,.13'H*9"+$5A=*J>XI+HHRCYWG=W!)AFU#K8R*&[7]_
M_M!Y!4I@@L\:GTAG/#S_L_T./[?:TJ:R\O]\!NN0L2YC7ZABI7&L;K"#]F/L
M$3E+T0XL$W#-S6S,.Q&G?D*/W  GY:8P!=[<EW57A6V)O/(+O ^SOC5>P 2)
M4$3V *)/M0H"<+OY:[#U-42PGP1I&:2?\&/Q""0E]-?^F8)\$Q%()U"9X1EL
M;03VY1"VW/QG QY3"H/Y]DE)FGFC\-74DUGTQR2,\4]=[(PD8OZK8JJ9FQ@9
MQ@-1MWJ?($&.F4Y-/PR_XT.QZ@H=<^,D+W@(_0=.4HW1QI'* #=$0@!DJ5'4
M60CT"F.-K)L0ZE:X1^%[HL=?Y1(3U:JH&Z8 OI0:%<&/V*):O@$^B-/N7Q((
MM!/Z0WXSM%TG3+$YD8TME?!US'81AD0(\'77Z_6 UV$;I0@H!M4%,+IAO<1S
MO!&!3#Y-#9I(!B7V=V$% '_-OG&E40J_.K! .J(&50D=?C9 T3LCV"*'_<NW
M(-(%@-_&M3<4%% /3F*MP#YZL9#-FX2-DC$>T&E1\8$5$'5CP4*.6(]KO;J6
MF_DD-Z-[?L>O)/:."9ZZR93$;OCNPBC,KB>;OZ!\D @GPM5T-/)9?">R^U3!
M.SW&D4X0X*5-O^4/;:]A0KPE2,VK(@ _@-5 CN:C%NDLK4KV"&$4&( ]#X%)
MQ(COOA=.&GF: *Z>G 'J",![AT./. ,%/.ZO+ANX^2JOXO"1W%R[FBX%2)1!
ME=3=ZEH10KGT.C6@DP$FI@]#ZMO# ,]O5D('$538/5B0/>OX!MF_S$,G7VS
M#P!376M1: HJ5> JQ@3O2L(&6R$F1P9B\H9X& RBZ<9IDXRA,E,@5)5/ ;-T
M(J\KL33"]P G(RN#6\C-Y*,3,L1L-U<B3!:DOTQA\YY+K,]OPC8C5[,L;V16
M/M/2'0<!< MH4T2YGS_\CST<O>TT4$W6/D!BVB8?8VO%=D!2P0[&++P1@88@
M-6R0YDB5J)"AL4T_49,;$C&9QI:Q9"RR5%H KHPM"C6RO\'W#80_4AO"2 \)
M)\ TCG;)KH,]O;234P:92\6*R<YZ#/\697ICJ/5&%#T #P_55BEYNBR*<$E8
M))#"APB=A>\S@4;M>T<$QX'U+?!1#]-BVT(5SNL!OV@ Q(#5B$#&>[[0212)
M*\QC,J(G%9[Q@_#+0F#3T'ZS*!MY1@I^3J:1Y8C.L>=N_G5U]Z^/5W^6FDM;
M!LJS>8VP4RE((MMR0)93:C]PG;Y,Z.AZX2B7!V%)LH=# X\UVKCFG>Q!"+\2
M$=LC^F9,3()H$]5&UXV0B&+8))".0ZU?@R'86$/ATFL"#-(A7F<RWW92T,0=
MW"R<]KM +?XFS?M^@8'V(WO(QLD(>)(=>?[49A/@;(G:JE[6]<('&R2'#UP$
MA+>PE?\5-&^@2UX).2E]893ZH#G9T5@_R[OQD6F.V D/JP+[11I&<9/84?@$
M5TBB!_W$P-Z;7M"DW,"&Y:9850%L%LVY/FZN*TB/X.,QX  :("+D=FT'W:'2
M]16@Z]@CSD!,FG<Y ):(VI+GD]\<&&7G=XQ\T!/6*$1G,RM%K";1K\AR8KLG
MDC$>!'5 5IG$$QR"V+2"'YSYHSX7[!0@PI:KF[M:N6N".&RT"[P3WF?'"7 X
MAT$\5K^004SB:>J,E-4!HKK/ XQ@TX^83 E?%/Q.8H.HT]X.X$*LMD9IV#&<
M,E9![FS+\!R 603<T!99+>S*^AK9SG?4"N$,;!)JE=G$' "E4A&IC>YU&+JT
MR0]1VK?,X4K2;+C^T)%;>&\;Z*B ''8Q.I#92E.GB!-@^"Q2^!I9A\R.8P =
MH"/![A9#4H.\Z^.^1TB0J;3P"'=<X:B2*E@CATD:URB(QKFC5/:J]]SWPRYR
M"W/K%&43#]1.-[?M0NC"^^ ,3)=PX[!1T$S@6E[?AXZ'N(G?NLR3;2?H>\@
M1H,QG9$*N=#21B6'(7^/S,UZSXN]D3EQH/P!E46TDZ&Z6E"JT!$+W/:_; O
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M[&7H&'\#\PB8 '"0G*F+1\$$E(#2]? K_C@< 0#)CC(/F3?FT>4@*S=,J_[
MNGD:PU-VYL8F@@,;+R;[@IDFV&J@_ ODQ@B5F,>M9"X3.#U&L( 8D9 ;2G-6
M7N>>L&.OJT?\$&5F?,4>P1HXS@CC2<P,3?>)\20Q2&GQH0E.Z:7FK2%L*54;
MW;WRDK(\1@IBQ2^&AF]UXAYGV^+-D/B50*0R,U49\]I$#82C%PQLGZ[]3280
M4(S\K+R$L Q6#0'1=57)D&(4N #HNUX  @C-8Q<L/3+@D4E@@5;(^#C!+G@
M%44X^*'LBV@UBR$3R(=[D)?"&01LX!9*HE(Z(]$4B:&=L,^E9P>2I9"N3H8M
M.BU5S ;^P:@">XSX(@NL/,-6'GDC@4HQ 3Y.0>R1\Q6S2"E<@[54&O1:]\CR
M2'"#$S5<K'7D>!XNWA5]FSP=E$,JZ!42F\.8TGIS*8 S^+.*R!-' XKS,?HT
MYLJ:GH@B7@ /*9-_A2JE:N130?-U>YP*_BEQ#^CB"NH7"_+_\2TRD;9A?<BG
M%E,J0#ZO.$M?[(KD$;V):3RC]HSC.3:]A1(M6VV,/;7.*.9/<7",(X5E&;W
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M&C0!1I(F#4"MPOL6( :2WPM#].@,"]36!%%07T"7)\L$]$909%52I/84F-$
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MC\"V_97;MG-S*6E5H&\KX1WAX:1]0F4VE2WEYJ\EBP_QZ1"-=T@!*G<QB9.
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M/,$MMRW "?0PPZ!T7]E4P(#>O812ME]_\OU.1[NM:%)EZ":JD#+D/39Q0A
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M!9]C1!-=%I=RK2N2SID"/[=1KS^,4XQ](1X/,:>*15BAK'<T4<8NY26FI[3
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MZ] +^6*.[A#9U'!4=H,3H2?2<=2!"$? *5XL1M0XA0<Z4# 1D0#ZHP1WY$J
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MI4LU<?0FHI%' M.KQ'W:\O[ ^^Q; >6@>ZY4FK@)9<!92X1+42ELK<:ST"O
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M\_-TW,.2%!^??#S\^NGRPOOZY>PSB.WGT[-S1WH+DCIECQHYM@NC+)>6IA9
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M  !E>%\S-S@Q.3(N:'1M4$L! A0#%     @ -( +5=P_(*I.!@  *R$   T
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M,#(R,#8S,%]D968N>&UL4$L! A0#%     @ -( +59VEYJ #2@  BNH# !4
M             ( !8Z,  '=I;G0M,C R,C V,S!?;&%B+GAM;%!+ 0(4 Q0
M   ( #2 "U520\CQFS0  ']R!  5              "  9GM  !W:6YT+3(P
M,C(P-C,P7W!R92YX;6Q02P$"% ,4    "  T@ M5]O[N#\(G 0 [:0X %
M            @ %G(@$ =VEN=#(P,C(P-C,P7S$P<2YH=&U02P4&      H
,"@!Y @  6TH"

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
